<SEC-DOCUMENT>0001628280-20-012247.txt : 20200810
<SEC-HEADER>0001628280-20-012247.hdr.sgml : 20200810
<ACCEPTANCE-DATETIME>20200810083903
ACCESSION NUMBER:		0001628280-20-012247
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		97
CONFORMED PERIOD OF REPORT:	20200630
FILED AS OF DATE:		20200810
DATE AS OF CHANGE:		20200810

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Apollo Medical Holdings, Inc.
		CENTRAL INDEX KEY:			0001083446
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MANAGEMENT CONSULTING SERVICES [8742]
		IRS NUMBER:				870042699
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37392
		FILM NUMBER:		201087274

	BUSINESS ADDRESS:	
		STREET 1:		1668 S. GARFIELD AVENUE
		STREET 2:		2ND FLOOR
		CITY:			ALHAMBRA
		STATE:			CA
		ZIP:			91801
		BUSINESS PHONE:		(626) 282-0288

	MAIL ADDRESS:	
		STREET 1:		1668 S. GARFIELD AVENUE
		STREET 2:		2ND FLOOR
		CITY:			ALHAMBRA
		STATE:			CA
		ZIP:			91801

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SICLONE INDUSTRIES INC
		DATE OF NAME CHANGE:	19990413
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ameh-20200630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:b88c77a1-c027-414b-9d80-e41583dc701a,g:39bb5244-cfb0-4a0f-b0d7-a52c48426910,d:cc5d6783c1494a1f886c03c93e398cee--><html xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ameh="http://www.apollomed.net/20200630" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ameh-20200630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80L2ZyYWc6NTBlMDIzMTA5NTM3NDBkNmIxYjI2MTViZmIyMzZhMzIvdGFibGU6MTM1MDJhOGZjNjdjNGUzZjg2YzBkY2Q3YzliNWM4ZGEvdGFibGVyYW5nZToxMzUwMmE4ZmM2N2M0ZTNmODZjMGRjZDdjOWI1YzhkYV8zLTEtMS0xLTA_d2822e06-1413-4a74-82fa-af75c6e0bdd1">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80L2ZyYWc6NTBlMDIzMTA5NTM3NDBkNmIxYjI2MTViZmIyMzZhMzIvdGFibGU6MTM1MDJhOGZjNjdjNGUzZjg2YzBkY2Q3YzliNWM4ZGEvdGFibGVyYW5nZToxMzUwMmE4ZmM2N2M0ZTNmODZjMGRjZDdjOWI1YzhkYV80LTEtMS0xLTA_353fccad-d2ad-4a11-833f-12d1f134c1df">2020</ix:nonNumeric><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80L2ZyYWc6NTBlMDIzMTA5NTM3NDBkNmIxYjI2MTViZmIyMzZhMzIvdGFibGU6MTM1MDJhOGZjNjdjNGUzZjg2YzBkY2Q3YzliNWM4ZGEvdGFibGVyYW5nZToxMzUwMmE4ZmM2N2M0ZTNmODZjMGRjZDdjOWI1YzhkYV81LTEtMS0xLTA_1d14d0e7-72c8-41cd-b355-80e56138428c">Q2</ix:nonNumeric><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80L2ZyYWc6NTBlMDIzMTA5NTM3NDBkNmIxYjI2MTViZmIyMzZhMzIvdGFibGU6MTM1MDJhOGZjNjdjNGUzZjg2YzBkY2Q3YzliNWM4ZGEvdGFibGVyYW5nZToxMzUwMmE4ZmM2N2M0ZTNmODZjMGRjZDdjOWI1YzhkYV82LTEtMS0xLTA_99b3c4a3-c78b-443b-be34-05234f2230d3">0001083446</ix:nonNumeric><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80L2ZyYWc6NTBlMDIzMTA5NTM3NDBkNmIxYjI2MTViZmIyMzZhMzIvdGFibGU6MTM1MDJhOGZjNjdjNGUzZjg2YzBkY2Q3YzliNWM4ZGEvdGFibGVyYW5nZToxMzUwMmE4ZmM2N2M0ZTNmODZjMGRjZDdjOWI1YzhkYV83LTEtMS0xLTA_2d5785a8-28cd-41cc-bcd9-0ca31dda9b0d">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="iaf29becc238d412a85e642e1be07a346_I20191231" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMjY0NTk_5c465777-41e6-4d7a-b713-4cd6abec3b70">P2Y</ix:nonNumeric><ix:nonNumeric contextRef="i5cc5a987a5c04cad931ce456ee204243_I20200630" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMjY1MzU_16e36149-7c47-4c0c-bc55-d85a3cf36fbe">P2Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ameh-20200630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="if9ce4b07b09648a8b493eae45f76841f_I20200803"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-08-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i2bce3c5038344323935db8cc2710a157_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i17d58afdf6094c3f9289f4089d3a6678_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6e2f1d8c41a4e708493e14e80f2e50d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3ded1fe24c44729a7d30f51269fad23_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83686cfeea3643b2ab0ba5131ab70154_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie034b8ac717f4e0f821b2e6846cc21da_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:HealthCareCapitationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c020c0256064c2e9f9890db9de73a18_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:HealthCareCapitationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb543017186b41428d7d61876f751a53_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:HealthCareCapitationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibca1f4a0742946218cb28c01d1e69d3a_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:HealthCareCapitationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie935f35786ac43c595cc0e1bdd2bfa7a_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e76ce3a79df48a5b2aef434c3026411_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9a5e5a435384ed9b47445e91f2e5dbe_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfc4299f8823436fac5fd23586298d02_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86ffd806ab8441679dbed516276b4734_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2c681dbab0b446cafe1a39de28bedb6_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic862c6560a614f5abea31e3ad439d0fe_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7276b0b6cad94ed6955187e2affe1b27_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia03e0ac0e02248b881a5720c0b7bcc62_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i352052d598714a3aa1bc0f6be299be80_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a83b91f96d642cb888e655253482c99_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18eff8c461884069b655593a6463d4b2_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17c717d9ab9c4c13925e6d4f409d3e67_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic79fc17a0341400e9e62338ca77a93da_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie229ade0fac144a8a4262469a1176554_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i455aac9cb9b24b88861613f2d5737086_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a40c5284da24efa84bc4df89f4f2705_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4e637eec6484f0786a6ed5c1f6430cb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdd5d78f45b9441eba8b9eacaa9bf76e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11c1b7b9b865434fa9576e7784c2dc13_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia43dbbf6ada5449bacec1ab39ed62847_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f94bdfba2434414a07e834a64442b28_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1f8b99761ef4aa3ad4c66bc1cdef075_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67cb29fa35d447558cebf0c44017ecd8_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib557e6848b8949778b46babd52ad1570_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i691e279196924ed386447cfa2fdb3c0a_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8c91ec953b9448fb223cb4a034a52d3_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic62aa01d15f74e74b86bfdec19d0c108_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5f49e82ee9c46f680d56792f282a687_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i083b9bc8a05048a5840ae066d8501457_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b2a896675d04c7d9830d427157f52b0_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d951dc1190e45e2ac445202aec7daa9_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee021f30ec494988b04ffd293da80842_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab3938dc2790442bbae7aab01097fc8b_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id415104b7a1f4a52af19c2f74be0a88d_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieff7bbd8785d4105a279ebbb1b6569a6_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6205a2691794f12816d94e2384216d4_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f79c810c09544658e32ad8904dcddfb_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i601b184c6fdf4eada4f627de564a12d2_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56db13635c644c7eb66668022d8f8878_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ccf0e9ee2e64a3182ccb11330048327_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb7195fbea754ef3b0e02c161fbcbf6c_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e6a563a26fa49f79fe7e401bb5fec30_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88dd112506904c6cb0c741b6ed17ccaf_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8af5fb33859043a8b3f81453abfe1293_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86cd437dd5a04045874dddd70078b5dd_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10e399c42ec54ff9a466cf51bb20fe33_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0d5534ac5c5479487b6ae9068ef457e_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i009fc823ec144ee3b772b4396d458c88_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadd4f63ba5ae42d4ac92cc9136de9da2_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22c58b4fa0a543509216aa49494d6aba_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3adcf989a11491086e545b6aee38fc5_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a6c0314826740a281244477bbba6dfa_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ee6d5d8a1594010bfbaaec890b48045_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5148fbc9970c485988d70ba64178db69_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4974f1b145d14972a8e0b668e4693f24_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78399cf970d54e8fa6805bb19581eedc_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24b621b2e16049f5821822f6c6b515c8_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i726581c835934409b022b695e21f02c5_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i949449b3a63b462bb5ac492454d52236_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcb813ea894446d389589a68e78f85f8_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95b98be4bbee40bb905948aa3d1b28ea_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71a1516b4672496586bb6ad8954b6d32_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c10cea2d1d546b486e52aae1b79c77a_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id43602e4d3ec401c85cc9e362fcdbb4b_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87ba6bb181b44445a257ca2168e67b6f_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3af73b22faf94113b2f3aeaf70427a31_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bcbf8bc939c4eb8b67d8f9031b07763_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27980f94484946c1a35649f7381b97d6_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic610016f8d084d548913bcfa0f781a33_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf1828c07785428dbc2e0059af0c356e_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2db2c0d074c34657a5d523b0ae1e5784_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d3c15f58ae34e5680acaea7c6ae5cd1_D19990701-19990701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>1999-07-01</xbrli:startDate><xbrli:endDate>1999-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie580169aa3e849ceb22d709b7d624f59_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:APAMHMedicalCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1456ec083d5c410eb2ebf5f48f52fd2d_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:APAMHMedicalCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ia151a285a5884ae0892fe7f6a0836f46_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:APAMHMedicalCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15770f5ee2dc453aafa11b7b82d77e5d_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a7880e80374477ab2037c274813c2fd_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:ApolloMedicalHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8449be3fd6d243ea8e51a64ca55d07be_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:ApolloMedicalHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02112e8965954796a8e1a049bed45005_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:ConcourseDiagnosticSurgeryCenterLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09e180bcec104dbe8bbc280162a1b502_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:MaverickMedicalGroupIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="enrollee"><xbrli:measure>ameh:enrollee</xbrli:measure></xbrli:unit><xbrli:context id="i1291ccf07b4747d5a674402448bcc8b7_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlphaCareMedicalGroupInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="primary_care_physician"><xbrli:measure>ameh:primary_care_physician</xbrli:measure></xbrli:unit><xbrli:context id="if0f1246eac284240868626e2943e4052_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="specialty_care_physician"><xbrli:measure>ameh:specialty_care_physician</xbrli:measure></xbrli:unit><xbrli:unit id="medical_center"><xbrli:measure>ameh:medical_center</xbrli:measure></xbrli:unit><xbrli:unit id="member"><xbrli:measure>ameh:member</xbrli:measure></xbrli:unit><xbrli:unit id="plan"><xbrli:measure>ameh:plan</xbrli:measure></xbrli:unit><xbrli:context id="ib00db7be80b34cfaa597d79cb3128aff_I20190830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26cbf8fca0d84265be9879b3b17db702_D20190830-20190830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:APCAndAPCLSMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:Dr.JayMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-30</xbrli:startDate><xbrli:endDate>2019-08-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="clinic"><xbrli:measure>ameh:clinic</xbrli:measure></xbrli:unit><xbrli:context id="if5945e9c877b4ccea72cbc601bc3a9b6_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AmgIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9f8aa30820f40aaa284eb4906fe92a2_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AmgIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11b99b377a6a43aa865ba7d01fecd1e5_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AmgIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3e410ddfdb74a3daeb61a44c92264d8_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AmgIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d896ebc98ae47969367089670863233_I20140630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4fe11ff13bc463aa7c7d46c9968606e_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a23351d6549453987064b1ed4ccd7a5_D20200430-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-30</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbe089761e214533973bb396d097bec6_D20200430-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:BrightHealthCompanyOfCaliforniaInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-30</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c07037f02c24f758bbadde10f2a6d6b_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>ameh:segment</xbrli:measure></xbrli:unit><xbrli:context id="ib671a237f06845ccacc1a406f5790edd_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6dab3a2b4fba451e82b3256455eeec2b_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcd3d205d526423cbea49810dc2340a8_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0dd8dccc65a74133a54656bd7c8b4677_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:CommercialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a042bfad69542c1b01c261138a48a66_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:CommercialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29b931e0f69a45658584dcdb33cccae8_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5e9ac126c4447a892ae9c1c466ce045_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf70769b3ae24d8bbf5cea51b1569ce3_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a6065f0bcd44f40b22cc3dee9debebc_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d46920109e94a34afa570bab6edc321_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:OtherThirdPartiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd7a28bbb9224f319f70f1a38371eb43_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:OtherThirdPartiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i512f416ef63d4ba3abe4a36d380da0b0_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:CommercialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddb4dfed860740f3a71ee2c530ce3733_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:CommercialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ecfacaa79e54b258148a979b14f66f4_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i947f9298713445cea034b7b41f37b6b7_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ff9e8dbf4b24be7b22e1054c2cdb0fa_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04580df691394c6fb1c265641dc8e4fa_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2fca4eb23c541db83ecd5805b54ba56_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:OtherThirdPartiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b8d4a587e3e4ac684b3f6a5d7d7ffed_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:OtherThirdPartiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66d29491233d435a9781fc3960674175_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fea9adc9dbd4dfcb6c28fcec10b58ca_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba2f1722e182406485b06e7780640a59_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92d5ad54dc7b46a692cb712060a47f6f_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i100279b65cca403299b145ef5c501434_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46aa5cd04c64411ca7afff2e510cebe6_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36fac0be4bce47a8a6f1debf5fb86518_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c897dd4206d414da215cddbc7679657_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf6775dc61fe4ce084d261017e9ef958_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorFMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbe89b583f4b4cac886b6bd1886fc66b_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc08a7c3b8514351988c046d7326f98b_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea3de6234363414c85c4cadd8273d9a4_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fc422ddf26946f9b6595157d37a7e4d_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia98e92f83fb948a4a5b27c9b21933f87_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ad5e28b46a94718807f8ff7283fa384_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id916e080e86746bb89c3cd06f5f75ae6_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71e3a0e877e1403587f03dd1d16e1041_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorFMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11b3d315843d44af8440a243a1ec9346_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84779c02d5604bc6bfe042cc4a70617c_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6e01a159a3e4416b534f097f6b023a9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1dc8d99226664ef48c410daff8c273d8_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb7ca1d55e834afd9682b7e0f9cd250b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaacb62a7ead1402e943c4985b979a303_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65e1f17227cc4de2a22981878af26dee_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34d83ddf3e164119a0619b2f774d028a_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee4970fdbd0c4e57965c08b65849a300_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3be99826872a4e079e77a494a475c430_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5c34ba4f1f24e1e87163828fbf170f9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="unit"><xbrli:measure>ameh:unit</xbrli:measure></xbrli:unit><xbrli:context id="i86d36b0423244dd6a1ef5fb8fed9dc60_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:PerMemberPerMonthManagedCareContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf29becc238d412a85e642e1be07a346_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:NextGenerationACOModelParticipationAgreementMember</xbrldi:explicitMember><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2017-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cc5a987a5c04cad931ce456ee204243_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:NextGenerationACOModelParticipationAgreementMember</xbrldi:explicitMember><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2019-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5fbfd0a0b9b4ab3876be59e23e3f101_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:CMSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8986202564b4172b0aab2302c7971a4_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ameh:OtherReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1e6d8b85f4246bf94ae0b52733c146d_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">ameh:OtherReceivablesFinalSettlement2018PerformanceYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f4243e46d3647e093788a742f11debf_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ameh:AccountsPayableAndAccruedExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab3766c2a60b42849e233d9acb377205_I20190531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AlphaCareMedicalGroupInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:APCAndAPCLSMAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e2f250049ae44589256e0929aad4803_D20190531-20190531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AlphaCareMedicalGroupInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:APCAndAPCLSMAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-31</xbrli:startDate><xbrli:endDate>2019-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9004566cce7c4ef7b4abb21095da7358_I20190830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:APCAndAPCLSMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:Dr.JayMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9efe901318bb4ed08cc6432008f3343c_I20190830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i460f9923ee7347d6aa697c85d63b74e1_I20190830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9519fc3d763e44bba24ad68ede94a1c0_D20190830-20190830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-30</xbrli:startDate><xbrli:endDate>2019-08-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40df6f98654940f690d8f5bfc4d573bc_D20190830-20190830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-30</xbrli:startDate><xbrli:endDate>2019-08-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic772c23a08d84f8da481202e5fe65be4_I20190830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:Dr.JayMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38b436d30e5240e3965b3cb5408fc04b_D20190830-20190830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:Dr.JayMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-30</xbrli:startDate><xbrli:endDate>2019-08-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i226c14d75f674f3aace656903b7c99e1_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AmgIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73be6919be5e46b1a06e1ea222b2fdbe_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia02225d6109046c78a438c6a8b4976e7_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a061ecd0e88428da9167e4c5ef52ac3_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57bb690a343d4f7d8bad8f8f0b00a299_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5588309d1fff48048fb83af0ddcb456b_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7cb7d40948da4beb88d80ee62fb3d330_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic456fd261edf4e6b9386c6e78baefd90_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e1880f00d4d4d1e9e8b42e76237839e_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i200a2160c6bc4775ad07f433b5e95e1a_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7bfc72f47df49e08bf78786c1c3f3a8_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f688ddde99b4f1e907fddc9a3a91b08_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id11fed723b204eccb39c30a6f9bcb4ec_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0041ee30d491407b91c0d34ee0fd8035_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80ad21fe7a3a4d959fdd8ebdbe3e6e65_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf9258f9195d44eebf1af16facb1fb4a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife724f4c09364f2587ef6b1db0ffb506_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id69c143aef794cd8af6e5723d91edb2c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0aef9156d514b559b4f1bc502166379_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fcb4ca5c3c4484fa5efae17077926cd_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04ee375bba5d426fae0a9eb750e81925_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ccf5d499e3e4698884b846f6d3df73d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia58b0f57301940558ebd969a25e55261_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3925100079946168d1204aa44f455d9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fdfa470671c47fdbbc39c5426a4e251_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie050574270bf4bdba21a2294fe288e97_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i723d471168484995a1f33bc20e25ae83_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie984a2ae967749fbb28bc018191f1448_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i509c376a3e0f41cdbfb08128ed5aff20_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d9b625d40984cada77fed26b2662304_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a335fe94da74cc1b74cfe701830c693_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadefc20aa4134071bd9a5346e792b746_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fd06ba095124e0abdcc0d7f91fc1472_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c66cc2214574c8e905c03e9a5ac08d7_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i314c4ccc348b436ba49cb07ab3848d81_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3451c081a11c49aea7b55e24c90e4721_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i357af7bf55294d7b86954b0bf136c8c6_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic39201e9036d43759acb734c62b0b8d4_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4cd0390dd82a461ebe94ea5eebf97a2a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:MWNCommunityHospitalLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied6eb8f6738c4de2bcbeba58131b807b_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:MWNCommunityHospitalLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdc4f73cb093421a92e71951326cfe64_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:MWNCommunityHospitalLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="provider"><xbrli:measure>ameh:provider</xbrli:measure></xbrli:unit><xbrli:unit id="patient"><xbrli:measure>ameh:patient</xbrli:measure></xbrli:unit><xbrli:context id="i82b0e8a55cc14efc8f01a2a693617301_I20121231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2012-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50b118c2801142889220d4c0dfe9842d_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50bd805f807f463da5c172dec611a78f_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16e5d9ad68cf4cacbf2ae6fc6a2646a1_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if450a74f42464ca8ac08b054152aac34_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1f5324dabcd473b8949ece8d5f9bcbc_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i953f113f807a4b629361138a8c340c45_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i475942101d5b4fb6bf5d97d6d803565f_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e6db84cfdcf4e68a45f60ccbfcef795_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7524fa990e04653b73c016dce167669_I20150731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6aa1fa085114394a6e85030a974182f_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ameh:ContractTypeAxis">ameh:AncillaryServiceContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c258e6f71044221a1fb158a0d855efb_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ameh:ContractTypeAxis">ameh:AncillaryServiceContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6610cb295b3947a5b0b3747521ffcc00_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ameh:ContractTypeAxis">ameh:AncillaryServiceContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5aa2f3de1fe244a09059fe1a984dab17_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ameh:ContractTypeAxis">ameh:AncillaryServiceContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b5e25abcace4fa0adbbc4c02841298d_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36438be782f84c0ab30c9128983e63ae_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bec381b83b140e5a9bfeac12bc0b911_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib53dd899d00f4b69a3502812c5cc65dc_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i157f8e47c0564056805baaf2a463ba46_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia85acbdd13224660a5969a4561ebdc1c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5150473a0c7e46868c76e2b4a7a9fc96_I20150831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ameh:VotingCommonStockTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6176328037a345afb5006679c54758ba_D20150801-20150831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ameh:VotingCommonStockTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-08-01</xbrli:startDate><xbrli:endDate>2015-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e93302086af4602804bb434c398a652_I20150831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ameh:ContractTypeAxis">ameh:AncillaryServiceContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ameh:VotingCommonStockTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i170e72202cdd4b73a7b7a48e85b5dd54_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:BrightHealthCompanyOfCaliforniaInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19617cb0db6c48aea309f2c2b2bbd2ca_D20200430-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:BrightHealthCompanyOfCaliforniaInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-30</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e1d4837a47949caa2ce6ff7a21167cc_D20200430-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-30</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d3be425c4e74837aa2e7e572caa5cdc_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:BrightHealthCompanyOfCaliforniaInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ca6abb962c644ebad2d7e2afff211f2_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if482ba97bdb84bda9cf6288b01d207b9_D20200430-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-30</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idcfb848097a34b5a83ecc1ab0b752557_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:BrightHealthCompanyOfCaliforniaInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9beb3a18cbe642a8aa4c713b758e5b41_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1f85d23728f488aa706b6728075d6a6_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i371098e379a64f1ab0452b0340ffdcd8_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icceb687a46d94c0d8314ae9896a926f0_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd24a1722d5b442bba297bcc460eb0c0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e9c10a96719436f9bc86a015712be60_D20200101-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie24c440e5f474a2884cc40d10efab865_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifaefb6ce9ff24e308243a14d1cc7814f_I20160514"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-05-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74f5fd5d4b8a44e882631f206e038bd7_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61394655c4ad4039984a2f0503f8cb4d_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cc11225aa314266a6ef2696d7d4dfad_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id158f4ef37084b119e97ae1e8a41d0c9_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic80c408963dd4f07a4718bf817b59f78_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:CollegeStreetInvestmentLpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib33ce2cceba04d82b64d3b892ada4ad8_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2d9c71932034be7bd4932da0626f712_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id61177debadf4225a858af823bca90d6_D20180601-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idda53a861d504beea7993e7de2f52ee0_I20190423"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74302930c31d45b8a80be7e006522de5_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i051b582accf543bc87134371ea6f7726_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8b7f2e4ee2a4d2c9a3e1fe33363b2d3_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3ac42f4999448a69359a25a83b0f908_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if55f174a731f484e9a8b88ed6a99666e_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbb6a15f7620432bb5505e89f3004b9c_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i703c2ff9263240b296697549156a727f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0af7733faffb48348018de02ffdfff6a_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea1fae3b79a34d86b70cbdfb21ad3dbb_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd12b893ddc54a6ead35cdb2bc89c8bc_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:HealthSourceMSOInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00815df6bd294d36b80661bd7ee807a7_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:Pacific6EnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c9caf98dc0642adba42edbbc942a39e_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:MWNCommunityHospitalLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id084b778b0c0437ca9710b2d345a5e1c_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:Pacific6EnterprisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:MWNCommunityHospitalLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i802f55fac88e49498a6b008731c49198_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:HealthSourceMSOInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:MWNCommunityHospitalLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb3fd4253957445eb4629822911925ed_I20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:MWNCommunityHospitalLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1757e23b7dae4837b5c342d3a54fdb9f_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:MWNCommunityHospitalLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9729bda7911148aea82f02fafc542f1e_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:MWNCommunityHospitalLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21ee88acf5e24e5aa9702c3e569cdb0d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:MWNCommunityHospitalLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc2b7046e5434c1188649346120d70f7_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:MWNCommunityHospitalLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3635f2277d854166953f31769a15549d_I20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:MediPortalLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0bdfa92f0584697bf3e23e968030cd7_D20180501-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:MediPortalLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2fefe9326624bf8a6e101283a7f761f_I20190701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:AchievaMedInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1f0176357034096b162de4acd821801_D20190701-20190701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:AchievaMedInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b00da16353446959bec407e221c7666_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:AchievaMedInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68d3a067d0bf4b79866706938706fb56_I20190628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Dr.ArteagaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7a2683890994e1893345aed93623d96_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Dr.ArteagaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0ac55575d2248d28bbb2cd6f69b2d1b_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Dr.ArteagaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie109929786d34e3893f52ead1a5eb485_I20190628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:APCAndAPCLSMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Dr.ArteagaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i901365bdd3be4af6a404cf5c6e1a6075_I20190628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:Dr.ArteagaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1cce33515e484386a173dc2819744d21_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Dr.ArteagaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2719e7d006164071b43867d77f417602_I20200228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Dr.ArteagaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib85a0e470e8b45179bd029ecf6828423_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Dr.ArteagaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i718197c336244bfaae074a41bf6ba00c_I20151231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i620d8d9b4ce144e39fd90208e9f296c6_I20180629"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica83580f8f45424a8053d06ddb0d6b69_I20181128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99b8494c9ac5475fb455098946c75db9_I20191213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67a0fe9f9fdd46d7b8bf35810922c6aa_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifaa289066f18409dae39bd6fe0b1bf0a_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2219841d151045028ba5da60cd719d17_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:DrJayLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59aea64b29bd441fbc9a872ccf8d6901_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff4cb76a3da64b79b6a83acbf4ac62d5_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ameh:TermLoanAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8692d3a0d3f43509f73c146da09a16f_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91da1a2343864108babfdb0d2e98962a_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f0dc8ddd67e4b4c8a1d5a71831e1067_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ac3810d42dd495ca842271bd91690b0_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89df1d2e4cc246138d52d9f6d8cd6e7f_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ameh:TermLoanAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7490feb65964fa796425290739b321d_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">ameh:PaymentPeriodOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65f643704c1c43d88db131c9dcf5f1c4_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">ameh:PaymentPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d42642f16854ea2855614113b660e84_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">ameh:PaymentPeriodThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15f80bd5e8b04174974b1f69d1519f06_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic96d1c4217de472a84ac6f11bbb720c3_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i663b5171da0843d99423875dfcef6e74_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0e05edf24764d42964dacb1936f8e5f_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fdcc51ad0fd4793ad2145ddf9d3333f_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c4c1dc5b0424494b3aa09efc8137c81_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b7ff140c5b34302b6867e8581216396_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1d8ce42602448a88e6e94a295508d62_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45e40a83e59c4f21b6a684d812a61ca2_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="financial_ratio"><xbrli:measure>ameh:financial_ratio</xbrli:measure></xbrli:unit><xbrli:context id="i1a435515824f4e14934a70bbffa79e42_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44c831b5e48a42e88b05d16f1fdb9240_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cbb20b8a5374294838553f9c534c7e6_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a1baad6dc7444dc9016d658275316ce_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:NMMLineOfCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a8fc30c8bb8493fa605fcaa4207f068_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:NMMLineOfCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8ce6e89d9dc47b7a39dd3dd0614631b_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c34126de2c140689211bd3a59b45b51_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bfbe9abbba34f0183c6540bd57fce10_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2719f73504548bbae721f92df01a971_I20180614"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:NmmBusinessLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibff1604bc099467eb93746f757585546_I20180901"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:NmmBusinessLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16eef96539a54340912379d5350ec95c_D20181231-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:NmmBusinessLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie40c6e5bceac47058b37a4f4c0981530_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:NmmBusinessLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13403ca944e64582bbcaa0105295fb08_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:NmmBusinessLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5266cd1d689d4ec2b6a1329887bfa026_I20180905"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:NMMLineOfCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2cd4816f5eb443c93bc954045c6a0d2_I20190417"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:NMMLineOfCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83420fb7674741a7adf09dd0edce6cb9_I20190729"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:NMMLineOfCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd9d64e834b04bf7b54467b2c29f3db8_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:NMMLineOfCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9253d136d6c409ea392551405cd59a3_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:NMMLineOfCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ceb41120b5c427da8f7a165eb95d2a4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:NMMLineOfCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i889eb6bfb2e4488e843c332fa29a6f88_D20180905-20180905"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:NMMLineOfCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-05</xbrli:startDate><xbrli:endDate>2018-09-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6929d7ef6c724b578ebd614e9aac9b40_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i489c8baa67d6408a868e6bdf3c0b60ea_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d75edd516124fbb828f66a694cd578d_I20180614"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ApcBusinessLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c7162ddeee34091b6e14c1103b27d19_I20190611"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ApcBusinessLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b837318f7d8458cb42d750eb8bbe6ef_I20190801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ApcBusinessLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if65f3f073a4e4926bd996e2b6f3709ca_I20190910"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ApcBusinessLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39925af9c158412d82ae7eac78d51ab3_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ApcBusinessLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadd3b4557abb442c93c1de563072e1bb_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ApcBusinessLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i349ef1b628184659aacbb0718a7d4338_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ApcBusinessLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i256fed6446054355bc000991eae06751_I20181002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApaacoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i180bcd7578544f3fa0a9e820344d67de_D20181002-20181002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApaacoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-02</xbrli:startDate><xbrli:endDate>2018-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65b7438288394c098e39150948dddc7d_I20190814"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApaacoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28f48691115042d086bf50c14043181c_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1cdc831367ff4a8584c4a6fb205fddcd_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fc12c8dd5b743488bb6c1675f17858f_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlphaCareMedicalGroupInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fcdc1d2217741c292117f4a0d9fff3e_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlphaCareMedicalGroupInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i165dffaa08f24a1888f81cae72742649_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7bf1ad2136147739b9d3573b799cfb2_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ameh:ApcStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9147cda570b34114b9da7922c7249550_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ameh:ApcStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0190ef7dee34fbda65c048ee6b393c7_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4688143439664825ac968a174665ba3d_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i394a53913abc46b7840e4b3b601af231_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7f3c7099ea7466e8c0372573a9eb42b_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ec7494ea7af48fda7c1d23e2672ba9d_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c63f7d7fa16447cb33f1cc3ad14ba3f_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c5087d6c84a4583badaea62a58fdd8a_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3ba07d0aaff4c4cbfb30aa71876350e_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5b38446c9f64ce5babcd929b0922482_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id57bfd29aaf44d4d95e8e561bbe67cf2_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i414264e0cb1e499287a23f8ddf6b9498_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id265c5c2e7f34a2bbb064c838d92d806_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0652754b1e534a8089d0c0347af659b7_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1f01a331d6248978588759d09efd270_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i717848bf538848ab855a3a3e35ae4238_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4f9f7ea8c4f4b079f5fc8ba6a915106_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1b7b6fb52d049f38e00e0bc30605358_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b530cfd9afc42f2a4a14a51d941740c_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i228644db04a54aeea81ac55c214613cf_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i070e64c85f6a46f3abd4745871816551_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a07edf9a6d9427cbb8e495a1c38dba1_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58c8b96e915044a5a2285690f262e2f1_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5348fddd2d3647eab57aabde18624e3e_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59b3484b35404c20b3bede5ccbf47667_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4081b94ec67249e5a1d21eae73e8d25e_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if21a86c3eed7480aad7e5a1485553c3f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b03d1915fa54978a6378c9edaa22474_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:AlliedPacificofCaliforniaBrokerageAccountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i255d39881fdb459ba312544c3eb6589e_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82a52038c4164e77a3f6e20b01157134_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf76f2b7860f4f6a97ee09255e45287d_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:CDSCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fa3d2acebea43c3a0c0f3e590d02ad4_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:CDSCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2abd2d27dacd4cf191ac018ca9039a4a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:PreferredBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5bc5df3e2c84bd598e901cd27c8df93_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:PreferredBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43ace250a7394cfe9446cf2a610e1531_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialSupportToNonconsolidatedLegalEntityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaebe0c39b9204bfbbf9445aa9abc70d5_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialSupportToNonconsolidatedLegalEntityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6e276121e9b45228da8ba0bab8f06ba_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlphaCareMedicalGroupInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5904f2bef064b47980c2947e43ad5d1_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlphaCareMedicalGroupInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia04e3870deaf4cb7ae407dafc0ffd53d_D20180323-20180403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-23</xbrli:startDate><xbrli:endDate>2018-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41ded2bb0c6348508704a83b2f25e6bc_I20151116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-11-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47e9a1771bc24da387426527e858cf9b_I20151116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-11-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="agreement"><xbrli:measure>ameh:agreement</xbrli:measure></xbrli:unit><xbrli:context id="iac4018695bd347a1a544a3f52b293cce_I20181128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i122ebc0907a746cd87fa56f04f446654_I20180628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia70ec1e9fb224dbcab815eb4726d1011_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:LmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55654d78599d405eb7c57be43551a331_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:LmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5c167aa7b744e4890c04342962e5ae7_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:LmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72f269c8a584404ba65db62cbf5e0711_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2586f7c4e99c40dabdf57469f68203ca_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08b5e965334b4ac8b0d2c0c36dd50b77_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:PmiocMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d443f60c53b4d9dbf390091cef3b913_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:PmiocMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id80519ef0ba24fdcafbe65246db80663_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:PmiocMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e8fcf6df1fc4d238058ca06726c6b36_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:PmiocMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ac733b67d504bb484f4fb9e53a73cde_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PmiocMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8163cedd4bfb49cba3c59247fab38128_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PmiocMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b7917e163c9464c858059b5c869b1da_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:DmgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7267113c36ba4c0ca445f3971b88da9e_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:DmgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide7ed8079ad649bd9de797dff9e87471_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:DmgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bafd7f9c77a44129ecb7839f0bf7f38_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:DmgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0138e45151034c838711c008d2c84fde_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DmgMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd86a14da8ce4c19b459bfe1b8ee8770_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DmgMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3921017da3f648c8bc7eb46abb24b98e_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AdvanceDiagnosticSurgeryCenterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ce5207c08154b16a3abfc694d36072c_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AdvanceDiagnosticSurgeryCenterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74b45c805f954374b47abc23fa83e224_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26a7e7336a074ec58f3aadf344b86686_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23919fb2bb874604b0836a44a501d87e_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ShareholdersAndOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6966114f283543be9a6c6ecfb91dcb1a_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ShareholdersAndOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i558c42e47d0740c28d1824777489c673_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0238892dfcac44a1ab11666f4229eff6_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73ff4025db084040a797fa1c7d3e1949_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ShareholdersAndOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib304e370b0554caf951b8a9f9f09d259_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ShareholdersAndOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11e982a75af145058c37f804c38acd6b_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:MedicalPropertyPartnersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i974cbc9f20e14ae6bf9611c0590bba01_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:MedicalPropertyPartnersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i232d93f7f5aa4f659c5d32bb1ce43cb7_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:MedicalPropertyPartnersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d7d20d05cc44774b777b10316295823_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:MedicalPropertyPartnersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a9d069f26ee4fcab93f166f59b290ee_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6349dc89b0824f79a96623fb0a3f9237_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i725b298255bc442d989d2da38e506475_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:DrSimAndDrLamMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa7e8193abcb43cabefbe6e0890b995d_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia52b05b7d3c744de85af06e314bf01e0_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:CriticalQualityManagementCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie772acedf7f24e9c9b7eba3a1c2c4b74_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:CriticalQualityManagementCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8b1a37d00a1473aa256f482831880c0_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:NumenLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:SCHCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40cef4f9cb574f67ae5763a10bf872ae_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:NumenLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:SCHCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd17dbf950ae420ba6642ac1f2e76be4_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:NumenLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:SCHCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3889cb5090e84ede9aeaa5cb4970cb04_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:NumenLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:SCHCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7badae2658444d349982f8266469914b_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:NumenLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b1e96ab04c2463f8f4b975abf5cd0e1_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8624e665c0b14f12bb96c8f05d6efefc_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i345a15f206fb4db5b7f79fbbfcd4823d_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i297705914c5f4af994b21ae2e9e0dda8_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5bc423a58e44f17b75caa9dcd78c5d9_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:HSMSOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib978cd0ae3f8463592332de24798e91f_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:HSMSOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e3dd126351d40269ef3b0cff2e2cc12_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:HSMSOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i187e0af77f734ccebbbd27aabf183e43_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:HSMSOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c2ea55436e04e569ef824cc8bf38f62_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AurionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c92e2a8835d47c094fdb6ae01f4010e_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AurionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied3ee0af55294b1c90c71dc22ea57f02_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AurionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07ec194477214462b08c359051ff95f4_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AurionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11c2bb41ca6348fb8713e36fda662dfe_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if379bd0a6704484a92b75bcaee392d54_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83ceffd8ac474d21a39c47ca896605c6_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94a7e25c8cae461cae1b75c5fa5c6e2b_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica6dee6dfddc4d1daed02284b5602d0e_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08491d90fbdd471d983861bcd2288ac8_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e330acfd08c4813a18296547a2a33b7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7d554f31b964866b8df4f6b60c0a919_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i450dc203ab3a40b6a28283cf284bd195_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f7252c42eff45858f156999763bf992_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifced76c7228e456281eecd440fc4200c_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02765d0185984e60929a5d510dd803fe_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d2d3cf0b58a46d1835e2032498d600a_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ba5a4313e034d9c9d26fa5c9c002ef7_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1acd759fc07341a7815dd2541d1fa444_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9d48ee182734c28b3a941a4ea33ad0a_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7bd39987453433c8655b734992caa99_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27599a16780e40908fb6bbc9191294f0_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i954924a949ec4f81b4ccce5827b40713_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife480d762a994b8685aef3f1fd37b377_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a92fa7d1d5341c18bcd43745c8b8460_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f9c10048151448696ea86f0e39c0212_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fe8e8ce30b4463d841ecdce075f4f3d_D20200630-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-30</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1ac92c6e4a04bde94c7027334556000_D20191231-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-31</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="icc5d6783c1494a1f886c03c93e398cee_1"></div><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">UNITED STATES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Washington, D.C. 20549</span></div><div style="text-align:center;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">FORM <ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xL2ZyYWc6Y2QyMDE0YzgzODNmNDA3MWI5YmRlNzU1NzE0YWM3MTMvdGV4dHJlZ2lvbjpjZDIwMTRjODM4M2Y0MDcxYjliZGU3NTU3MTRhYzcxM18yMDg3_3bfab0a4-0446-437b-aa15-1bcc58fbc15e">10-Q</ix:nonNumeric> </span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:1.879%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:94.121%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xL2ZyYWc6Y2QyMDE0YzgzODNmNDA3MWI5YmRlNzU1NzE0YWM3MTMvdGFibGU6MjU2MWU5ZWY1ZmFjNGRkMmFhNWJiMWJjZDM0MzEyNGYvdGFibGVyYW5nZToyNTYxZTllZjVmYWM0ZGQyYWE1YmIxYmNkMzQzMTI0Zl8wLTAtMS0xLTA_d79f059b-3b91-4fbd-abdf-b0a8840243b5">&#9746;</ix:nonNumeric></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the quarterly period ended </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xL2ZyYWc6Y2QyMDE0YzgzODNmNDA3MWI5YmRlNzU1NzE0YWM3MTMvdGV4dHJlZ2lvbjpjZDIwMTRjODM4M2Y0MDcxYjliZGU3NTU3MTRhYzcxM18xMjQ_fb49dd5b-f1f6-44f5-bb5a-2256c8db9e56">June 30, 2020</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="margin-top:8pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:1.879%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:94.121%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xL2ZyYWc6Y2QyMDE0YzgzODNmNDA3MWI5YmRlNzU1NzE0YWM3MTMvdGFibGU6ZmZlZDZmZWM5MWJkNDMzMjlmNGJmOTU1MzdiMzY5NmUvdGFibGVyYW5nZTpmZmVkNmZlYzkxYmQ0MzMyOWY0YmY5NTUzN2IzNjk2ZV8wLTAtMS0xLTA_269e7f87-8f13-4534-ad5c-7f4e0714a9d7">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the transition period from &#160;___&#160;to ___.</span></div><div style="text-align:center;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Commission File No. <ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xL2ZyYWc6Y2QyMDE0YzgzODNmNDA3MWI5YmRlNzU1NzE0YWM3MTMvdGV4dHJlZ2lvbjpjZDIwMTRjODM4M2Y0MDcxYjliZGU3NTU3MTRhYzcxM18yMDk1_62e594ba-72cb-4d67-9d70-3814cf1b2d1e">001-37392</ix:nonNumeric> </span></div><div style="text-align:center;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xL2ZyYWc6Y2QyMDE0YzgzODNmNDA3MWI5YmRlNzU1NzE0YWM3MTMvdGV4dHJlZ2lvbjpjZDIwMTRjODM4M2Y0MDcxYjliZGU3NTU3MTRhYzcxM18yMDk2_ed98d922-fdb5-4bfc-a1ce-507631d0f41f">Apollo Medical Holdings, Inc.</ix:nonNumeric> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center;margin-top:8pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:48.000%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:48.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xL2ZyYWc6Y2QyMDE0YzgzODNmNDA3MWI5YmRlNzU1NzE0YWM3MTMvdGFibGU6ODM5OTM0ZGNmMGQ4NGM0ZWIxOTMxZTNkNTIwMmIzMTIvdGFibGVyYW5nZTo4Mzk5MzRkY2YwZDg0YzRlYjE5MzFlM2Q1MjAyYjMxMl8wLTAtMS0xLTA_4941bf5a-b51e-4ec6-a6bb-6d2a0be13e37">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xL2ZyYWc6Y2QyMDE0YzgzODNmNDA3MWI5YmRlNzU1NzE0YWM3MTMvdGFibGU6ODM5OTM0ZGNmMGQ4NGM0ZWIxOTMxZTNkNTIwMmIzMTIvdGFibGVyYW5nZTo4Mzk5MzRkY2YwZDg0YzRlYjE5MzFlM2Q1MjAyYjMxMl8wLTEtMS0xLTA_4372e628-a24c-4e8c-8e0e-b9d1d3590353">95-4472349</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(State or Other Jurisdiction</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(I.R.S. Employer</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">of Incorporation)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Identification Number)</span></td></tr></table></div><div style="text-align:center;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xL2ZyYWc6Y2QyMDE0YzgzODNmNDA3MWI5YmRlNzU1NzE0YWM3MTMvdGV4dHJlZ2lvbjpjZDIwMTRjODM4M2Y0MDcxYjliZGU3NTU3MTRhYzcxM18yMDg4_0bdef1b2-ecea-4711-b30f-accbf0d38e0a">1668 S. Garfield Avenue</ix:nonNumeric>, <ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xL2ZyYWc6Y2QyMDE0YzgzODNmNDA3MWI5YmRlNzU1NzE0YWM3MTMvdGV4dHJlZ2lvbjpjZDIwMTRjODM4M2Y0MDcxYjliZGU3NTU3MTRhYzcxM18yMDk3_7c6e561e-d862-4ad7-858e-8592c4836921" continuedAt="i8151b9e053f8439b8202fa51e7f3881a">2</ix:nonNumeric></span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;vertical-align:top;"><ix:continuation id="i8151b9e053f8439b8202fa51e7f3881a" continuedAt="id2e957b01d0944158a0bd0ea182e3f58">nd</ix:continuation></sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:continuation id="id2e957b01d0944158a0bd0ea182e3f58"> Floor</ix:continuation>, <ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xL2ZyYWc6Y2QyMDE0YzgzODNmNDA3MWI5YmRlNzU1NzE0YWM3MTMvdGV4dHJlZ2lvbjpjZDIwMTRjODM4M2Y0MDcxYjliZGU3NTU3MTRhYzcxM18yMDk4_3d1f9455-eb75-46ff-bf3b-964267f658cd">Alhambra</ix:nonNumeric>, <ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xL2ZyYWc6Y2QyMDE0YzgzODNmNDA3MWI5YmRlNzU1NzE0YWM3MTMvdGV4dHJlZ2lvbjpjZDIwMTRjODM4M2Y0MDcxYjliZGU3NTU3MTRhYzcxM18yMDg5_d0f6fc75-268a-453d-8fc2-d0c2d736fe79">California</ix:nonNumeric> <ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xL2ZyYWc6Y2QyMDE0YzgzODNmNDA3MWI5YmRlNzU1NzE0YWM3MTMvdGV4dHJlZ2lvbjpjZDIwMTRjODM4M2Y0MDcxYjliZGU3NTU3MTRhYzcxM18yMDkx_b2efc840-260f-4d53-aec4-997078f4c5ee">91801</ix:nonNumeric> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(Address of principal executive offices and zip code)</span></div><div style="text-align:center;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(<ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xL2ZyYWc6Y2QyMDE0YzgzODNmNDA3MWI5YmRlNzU1NzE0YWM3MTMvdGV4dHJlZ2lvbjpjZDIwMTRjODM4M2Y0MDcxYjliZGU3NTU3MTRhYzcxM18yMDky_697e60f8-b799-45a8-bbbf-5567927d3826">626</ix:nonNumeric>) <ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xL2ZyYWc6Y2QyMDE0YzgzODNmNDA3MWI5YmRlNzU1NzE0YWM3MTMvdGV4dHJlZ2lvbjpjZDIwMTRjODM4M2Y0MDcxYjliZGU3NTU3MTRhYzcxM18yMDkz_17fcd365-9d50-43e4-95af-8b4e6252ccb3">282-0288</ix:nonNumeric> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(Registrant&#8217;s telephone number, including area code)&#160;</span></div><div style="margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days:&#160;&#160; </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9746;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">   <ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xL2ZyYWc6Y2QyMDE0YzgzODNmNDA3MWI5YmRlNzU1NzE0YWM3MTMvdGV4dHJlZ2lvbjpjZDIwMTRjODM4M2Y0MDcxYjliZGU3NTU3MTRhYzcxM18yMDk0_fcb1de85-6c39-4c84-bebc-f13f5707f723">Yes</ix:nonNumeric>&#160;&#160;&#160;&#160; </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9744;  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">No</span></div><div style="margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160; </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9746;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> &#160;&#160;<ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xL2ZyYWc6Y2QyMDE0YzgzODNmNDA3MWI5YmRlNzU1NzE0YWM3MTMvdGV4dHJlZ2lvbjpjZDIwMTRjODM4M2Y0MDcxYjliZGU3NTU3MTRhYzcxM18yMDkw_6188b07f-0013-4924-8191-6a94316a6073">Yes</ix:nonNumeric>&#160;&#160;&#160;&#160; </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9744;  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">No</span></div><div style="margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:8pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:45.126%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.673%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:45.126%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.675%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Large accelerated filer</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9744;</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xL2ZyYWc6Y2QyMDE0YzgzODNmNDA3MWI5YmRlNzU1NzE0YWM3MTMvdGFibGU6MDA0YmFjZDg3N2Y4NDBhYzg4Mzc5YjJhMGQ0ZWFiYjcvdGFibGVyYW5nZTowMDRiYWNkODc3Zjg0MGFjODgzNzliMmEwZDRlYWJiN18wLTItMS0xLTA_05a3b6be-b3bb-4844-953b-764a850a3a9b">Accelerated filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9746;</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Non-accelerated filer</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9744;</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Smaller reporting company</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xL2ZyYWc6Y2QyMDE0YzgzODNmNDA3MWI5YmRlNzU1NzE0YWM3MTMvdGFibGU6MDA0YmFjZDg3N2Y4NDBhYzg4Mzc5YjJhMGQ0ZWFiYjcvdGFibGVyYW5nZTowMDRiYWNkODc3Zjg0MGFjODgzNzliMmEwZDRlYWJiN18xLTMtMS0xLTA_1f7ba652-1635-4204-b4c5-5f96f6814f10">&#9744;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Emerging growth company</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xL2ZyYWc6Y2QyMDE0YzgzODNmNDA3MWI5YmRlNzU1NzE0YWM3MTMvdGFibGU6MDA0YmFjZDg3N2Y4NDBhYzg4Mzc5YjJhMGQ0ZWFiYjcvdGFibGVyYW5nZTowMDRiYWNkODc3Zjg0MGFjODgzNzliMmEwZDRlYWJiN18yLTMtMS0xLTA_34eac57f-30f6-463c-94d0-1b381a9a2ce3">&#9744;</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9744;</span></div><div style="margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act):&#160; </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xL2ZyYWc6Y2QyMDE0YzgzODNmNDA3MWI5YmRlNzU1NzE0YWM3MTMvdGV4dHJlZ2lvbjpjZDIwMTRjODM4M2Y0MDcxYjliZGU3NTU3MTRhYzcxM18yMDk5_0a3f851d-1654-4909-b669-38be88d62091">&#9744;</ix:nonNumeric>  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Yes&#160;&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9746;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160; No</span></div><div style="text-align:center;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:32.339%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.093%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:15.097%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.093%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:20.988%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:20.990%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Title of Each Class</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Trading Symbol</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Name of Each Exchange on Which Registered</span></div></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xL2ZyYWc6Y2QyMDE0YzgzODNmNDA3MWI5YmRlNzU1NzE0YWM3MTMvdGFibGU6ODBkMjcxMTg1MDU2NDFkMjkxZTA5MDY2ZjU0ZDMyZjQvdGFibGVyYW5nZTo4MGQyNzExODUwNTY0MWQyOTFlMDkwNjZmNTRkMzJmNF8xLTAtMS0xLTA_fc9f7f51-62d3-40c8-b502-e7051903d3c8">Common Stock, $0.001 par value per share</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xL2ZyYWc6Y2QyMDE0YzgzODNmNDA3MWI5YmRlNzU1NzE0YWM3MTMvdGFibGU6ODBkMjcxMTg1MDU2NDFkMjkxZTA5MDY2ZjU0ZDMyZjQvdGFibGVyYW5nZTo4MGQyNzExODUwNTY0MWQyOTFlMDkwNjZmNTRkMzJmNF8xLTItMS0xLTA_50623908-8c45-48b5-8d11-ea58c1c81146">AMEH</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Nasdaq Capital Market</span></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of August&#160;3, 2020, there were <ix:nonFraction unitRef="shares" contextRef="if9ce4b07b09648a8b493eae45f76841f_I20200803" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xL2ZyYWc6Y2QyMDE0YzgzODNmNDA3MWI5YmRlNzU1NzE0YWM3MTMvdGV4dHJlZ2lvbjpjZDIwMTRjODM4M2Y0MDcxYjliZGU3NTU3MTRhYzcxM18xOTg5_89a2a857-d2f3-43e1-b8a1-2b6336aa788a">53,513,655</ix:nonFraction> shares of common stock of the registrant, $0.001 par value per share, issued and outstanding</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">.</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:2pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div><span><br/></span></div></div></div><div id="icc5d6783c1494a1f886c03c93e398cee_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">APOLLO MEDICAL HOLDINGS, INC.</span></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">INDEX TO FORM 10-Q FILING</span></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">TABLE OF CONTENTS</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:9.730%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:77.912%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:6.358%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PAGE</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_13">Introductory Note</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_13">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_13">Note About Forward-Looking Statements</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_13">4</a></span></div></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_16">PART I</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_16">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_19">Item 1.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_19">Consolidated Financial Statements &#8211; Unaudited</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_19">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_22">Consolidated Balance Sheets as of June 30, 2020 and December 31, 2019</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_22">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_28">Consolidated Statements of Income for the Three and Six Months Ended June 30, 2020 and 2019</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_28">7</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_31">Consolidated Statements of Mezzanine and Stockholders</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_115">&#8217;</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_31"> Equity for the Three and Six Months Ended June 30, 2020 and 2019</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_31">8</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_34">Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2020 and 2019</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_34">9</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_37">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_37">11</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_115">Item 2.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_115">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_115">48</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_151">Item 3.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_151">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_151">62</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_154">Item 4.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_154">Controls and Procedures</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_154">62</a></span></div></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_157">PART II</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_157">OTHER INFORMATION</a></span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_160">Item 1.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_160">Legal Proceedings</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_160">63</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_163">Item 1A.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_163">Risk Factors</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_163">63</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_166">Item 2.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_166">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_166">65</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_169">Item 3.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_169">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_169">65</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_172">Item 4.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_172">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_172">65</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_175">Item 5.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_175">Other Information</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_175">65</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_178">Item 6.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_178">Exhibits</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_178">66</a></span></div></td></tr></table></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span><br/></span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2</span></div></div></div><div id="icc5d6783c1494a1f886c03c93e398cee_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Glossary</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following abbreviations or acronyms that may be used in this document shall have the adjacent meanings set forth below:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.964%;"><tr><td style="width:1.0%;"></td><td style="width:27.761%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:68.239%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accountable Health Care</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accountable Health Care IPA, a Professional Medical Corporation</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">AHMC</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">AHMC Healthcare Inc.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">AIPBP</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">All-Inclusive Population-Based Payments</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Alpha Care</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Alpha Care Medical Group, Inc.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">AMG</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">AMG, a Professional Medical Corporation</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">AMH</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ApolloMed Hospitalists, a Medical Corporation</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">AMM</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Apollo Medical Management, Inc.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">AP-AMH</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">AP-AMH Medical Corporation</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">APAACO</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">APA ACO, Inc.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">APC</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Allied Pacific of California IPA</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">APC-LSMA</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">APC-LSMA Designated Shareholder Medical Corporation</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Apollo Care Connect</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Apollo Care Connect, Inc.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">BAHA</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Bay Area Hospitalist Associates</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Bright</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Bright Health Company of California, Inc.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CDSC</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Concourse Diagnostic Surgery Center, LLC</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CQMC</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Critical Quality Management Corporation</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CSI</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">College Street Investment LP, a California limited partnership</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">DMHC</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">California Department of Managed Healthcare</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">DMG</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Diagnostic Medical Group</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">HSMSO</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Health Source MSO Inc., a California corporation</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ICC</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">AHMC International Cancer Center, a Medical Corporation</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">IPA</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">independent practice association</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">LMA</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">LaSalle Medical Associates</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">MMG</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Maverick Medical Group, Inc.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">MPP</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Medical Property Partners</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">NGACO</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Next Generation Accountable Care Organization</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">NMM</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Network Medical Management, Inc.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">PASC</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pacific Ambulatory Health Care, LLC</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">PMIOC</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pacific Medical Imaging and Oncology Center, Inc.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SCHC</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Southern California Heart Centers</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">UCAP</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Universal Care Acquisition Partners, LLC</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">UCI</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Universal Care, Inc.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">VIE</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Variable Interest Entity</span></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span><br/></span></div><div id="icc5d6783c1494a1f886c03c93e398cee_13"></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">INTRODUCTORY NOTE</span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Unless the context dictates otherwise, references in this Quarterly Report on Form 10-Q to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and similar words are references to Apollo Medical Holdings, Inc., a Delaware corporation, and its consolidated subsidiaries and affiliated entities, as appropriate, including its consolidated variable interest entities (&#8220;VIEs&#8221;) and &#8220;ApolloMed&#8221; refers to Apollo Medical Holdings, Inc.</span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) have not reviewed any statements contained in this Quarterly Report on Form 10-Q describing the participation of APA ACO, Inc. (&#8220;APAACO&#8221;) in the Next Generation Accountable Care Organization (&#8220;NGACO&#8221;) Model.</span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Trade names and trademarks of the Company and its subsidiaries referred to herein and their respective logos, are our property. This Quarterly Report on Form 10-Q may contain additional trade names and/or trademarks of other companies, which are the property of their respective owners. We do not intend our use or display of other companies&#8217; trade names and/or trademarks, if any, to imply an endorsement or sponsorship of us by such companies, or any relationship with any of these companies.</span></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%;">NOTE ABOUT FORWARD-LOOKING STATEMENTS</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This Quarterly Report on Form 10-Q contains &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). All statements other than statements of historical fact are &#8220;forward-looking statements&#8221; for purposes of federal and state securities laws, including, but not limited to, statements about the Company's guidance for the year ending December 31, 2020, any statements about our business (including the impact of the 2019 Novel Coronavirus (COVID-19) pandemic on our business), financial condition, operating results, plans, objectives, expectations and intentions, any guidance on, or projections of, earnings, revenue or other financial items, such as our projected capitation from CMS for the year ending December 31, 2020 or otherwise, and our future liquidity, including cash flows and any payments under the $545.0 million loan we made to our VIE, AP-AMH; any statements of any plans, strategies and objectives of management for future operations such as the material opportunities that we believe exist for our Company; any statements concerning proposed services, developments, mergers or acquisitions; any statements regarding the outlook on our NGACO Model or strategic transactions; any statements regarding management&#8217;s view of future expectations and prospects for us; any statements about prospective adoption of new accounting standards or effects of changes in accounting standards; any statements regarding future economic conditions or performance; any statements of belief; any statements of assumptions underlying any of the foregoing; and other statements that are not historical facts. Forward-looking statements may be identified by the use of forward-looking terms such as &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;can,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;should,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;project,&#8221; &#8220;believe,&#8221; &#8220;think,&#8221; &#8220;plan,&#8221; &#8220;envision,&#8221; &#8220;intend,&#8221; &#8220;continue,&#8221; &#8220;target,&#8221; &#8220;seek,&#8221; &#8220;contemplate,&#8221; &#8220;budgeted,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; and the negative of such terms, other variations on such terms or other similar or comparable words, phrases or terminology. These forward-looking statements present our estimates and assumptions only as of the date of this Quarterly Report on Form 10-Q and are subject to change.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Forward-looking statements involve risks and uncertainties and are based on the current beliefs, expectations and certain assumptions of management. Some or all of such beliefs, expectations and assumptions may not materialize or may vary significantly from actual results. Such statements are qualified by important economic, competitive, governmental and technological factors that could cause our business, strategy, or actual results or events to differ materially from those in our forward-looking statements.  Factors that might cause or contribute to such differences include, but are not limited to, those discussed in our Annual Report on Form 10-K, for the year ended&#160;December 31, 2019, filed with the SEC on March 16, 2020, including, the risk factors discussed under the heading &#8220;Risk Factors&#8221; in Part I, Item IA thereof.  Although we believe that the expectations reflected in our forward-looking statements are reasonable, actual results could differ materially from those projected or assumed in any of our forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to change, and significant risks and uncertainties that could cause actual conditions, outcomes and results to differ materially from those indicated by such statements.</span></div><div id="icc5d6783c1494a1f886c03c93e398cee_16"></div><div style="text-align:center;margin-top:10pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PART I FINANCIAL INFORMATION</span></div><div><span><br/></span></div><div id="icc5d6783c1494a1f886c03c93e398cee_19"></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS - UNAUDITED</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4</span></div></div></div><div id="icc5d6783c1494a1f886c03c93e398cee_22"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">APOLLO MEDICAL HOLDINGS, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(UNAUDITED)</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.684%;"><tr><td style="width:1.0%;"></td><td style="width:70.296%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.481%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.133%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.890%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNS0xLTEtMS0w_6edd72f1-21b8-4997-ba68-58aa8c48f33b">152,441</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNS0zLTEtMS0w_282a81b4-f840-4fcb-bf74-c7d7f8cb30c6">103,189</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNi0xLTEtMS0w_81906b88-8b55-4c0c-a320-b0d8a5e5eec6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNi0zLTEtMS0w_b7682186-6225-41f7-a66c-f30e668be383">75</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investment in marketable securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNy0xLTEtMS0w_3596a548-f6b4-46cd-aff7-23e2e7c9813e">117,656</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNy0zLTEtMS0w_22aefde5-bb33-454a-8d9e-f3a4a9825456">116,539</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Receivables, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfOC0xLTEtMS0w_7e2dadbc-a962-4ca1-bb3b-2f3fa5f49979">17,588</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfOC0zLTEtMS0w_a9d00f15-5868-4068-85e2-c9d8946a81e8">11,004</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Receivables, net &#8211; related parties</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfOS0xLTEtMS0w_ccc7e5af-5075-4f0b-8643-7994419a5580">59,328</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfOS0zLTEtMS0w_9a3608ed-69e3-40cc-b9d7-f43890376bb1">48,136</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other receivables</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMTAtMS0xLTEtMA_48b43d83-47a6-4884-8860-a3a38dc4e216">15,919</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMTAtMy0xLTEtMA_3e577a66-beba-468d-a93e-680f545bc814">16,885</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses and other current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMTEtMS0xLTEtMA_6bd0a703-4094-45ce-8d11-c29194f4ed09">11,188</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMTEtMy0xLTEtMA_8589e04b-f1db-4f19-b367-232c5a616fcb">10,315</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loans receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NotesAndLoansReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMTItMS0xLTEtMA_f08e4fda-464c-4cc4-bf88-becf261adfea">6,425</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NotesAndLoansReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMTItMy0xLTEtMA_9c98caee-1567-4144-9b7c-cf316076ee60">6,425</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loans receivable &#8211; related parties</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:NotesReceivableRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMTMtMS0xLTEtMA_cb4d3ec8-bb2e-4cb5-aeea-1bac37b51aa6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NotesReceivableRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMTMtMy0xLTEtMA_9520bc91-82f4-403b-b861-7232cd4ec01f">16,500</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total current assets</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMTUtMS0xLTEtMA_fd19c10a-319f-43bc-8876-1635d8b8a8da">380,545</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMTUtMy0xLTEtMA_e0191ce2-1244-4e57-bf3e-24ed03460d67">329,068</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMTgtMS0xLTEtNDUwMw_9e1d1a2f-ed4d-451c-8f3a-322b69a346e2">746</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMTgtMy0xLTEtNDUwMw_f2686610-e28f-4541-829c-735879d88cec">746</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Land, property and equipment, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMTgtMS0xLTEtMA_d3a29806-9040-4b86-bdbc-9c177dd760da">11,485</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMTgtMy0xLTEtMA_fb441ddd-d935-416c-a520-3e0e83c98c80">12,130</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intangible assets, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMTktMS0xLTEtMA_e114b01d-b8b8-43cc-97a5-7f315eb0724d">94,790</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMTktMy0xLTEtMA_0192ae55-de1f-4d08-965c-25eae5beff43">103,012</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMjAtMS0xLTEtMA_d0a7c8ae-b688-4b49-9dd7-1654c7df19c0">239,053</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMjAtMy0xLTEtMA_7f33caa2-45b8-4dbc-bea3-36d44b110751">238,505</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investment in other entities &#8211; equity method</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMjEtMS0xLTEtMA_7ce63163-0523-409a-9137-3c675ac305b7">26,817</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMjEtMy0xLTEtMA_1ae9af94-5b98-4c14-a986-2c279f385c17">28,427</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investments in privately held entities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMjItMS0xLTEtMA_46105ccb-ca08-44d7-b66f-cdf7416fe51e">37,075</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" name="ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMjItMy0xLTEtMA_d8dd3b0f-f7a7-47e0-8ee5-056752790476">896</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease right-of-use assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMjQtMS0xLTEtMA_736f5f79-4daf-4dc7-8eb3-3bd9919e2475">20,219</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMjQtMy0xLTEtMA_ba57ac47-927a-4d33-9d78-b7a10df4545f">14,248</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMjUtMS0xLTEtMA_be76bb43-820c-4092-8a2e-3d4b15c82a58">22,487</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMjUtMy0xLTEtMA_f757d017-cbf0-4f08-aaf7-3f70e64f8bbe">1,681</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total noncurrent assets</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMjctMS0xLTEtMA_84749817-da11-4057-b97d-d3a398dcdfc3">452,672</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMjctMy0xLTEtMA_828aa1fb-9616-4f06-a87d-85f10e644c5a">399,645</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Total assets</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMjktMS0xLTEtMA_de607d2e-64b4-4591-afba-8d0cfcaf9a0d">833,217</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMjktMy0xLTEtMA_15cc3f68-2e1d-4ffd-87ac-0a35a7fbe37c">728,713</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Liabilities, mezzanine equity and stockholders&#8217; equity</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Current liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable and accrued expenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMzUtMS0xLTEtMA_cfb1aa39-97f4-4283-b406-527078ea9a4b">24,788</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMzUtMy0xLTEtMA_f28f2bf5-3a5d-4028-981f-c302b17fb248">27,279</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fiduciary accounts payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="ameh:FiduciaryAccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMzYtMS0xLTEtMA_0caeaf10-a402-408b-98ee-157dbed2b8bf">1,853</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="ameh:FiduciaryAccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMzYtMy0xLTEtMA_e2975118-986c-4d1d-8dc1-587acc2e1901">2,027</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Medical liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMzctMS0xLTEtMA_db12b7c6-5f9a-4217-8585-3ebd38064794">70,273</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMzctMy0xLTEtMA_f97f6b9d-2eb9-46c9-a0e7-052ff583e7c5">58,725</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income taxes payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedIncomeTaxesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMzgtMS0xLTEtMA_1d885fa1-08b9-4ad1-9f24-9c9d2cf49073">42,210</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedIncomeTaxesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMzgtMy0xLTEtMA_d940dd9c-4899-4296-9e2a-8d49f24078cd">4,529</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dividend payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" name="us-gaap:DividendsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMzktMS0xLTEtMA_9d64e104-2585-4ee2-8c19-599a3f2a03d5">431</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" name="us-gaap:DividendsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMzktMy0xLTEtMA_8966119f-578a-4882-92a9-0a15478dc3bf">271</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance lease liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNDAtMS0xLTEtMA_3543bac5-b3b4-4edb-8320-006176b9bd90">102</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNDAtMy0xLTEtMA_c27016a3-bb8c-481a-96dd-3562d2d3e31d">102</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNDEtMS0xLTEtMA_b330bd29-c9c5-46da-9c53-c54b6d09f889">3,350</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNDEtMy0xLTEtMA_40fbb7d5-1855-488c-87d9-c8810201921b">2,990</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.684%;"><tr><td style="width:1.0%;"></td><td style="width:70.296%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.481%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.133%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.890%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current portion of long-term debt</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNDItMS0xLTEtMA_e669f042-c0e0-4feb-9d00-590e371bc8cd">9,500</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNDItMy0xLTEtMA_e3723f96-460d-430a-9211-2361b9462d90">9,500</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total current liabilities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNDMtMS0xLTEtMA_ea56551f-0e74-4a8d-a78b-eaf01c5e7a7a">152,507</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNDMtMy0xLTEtMA_a04edb83-130d-4cba-a918-9609ad77eeeb">105,423</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNDYtMS0xLTEtMA_af022b49-12a7-4003-bcd4-c49ff42c3805">13,654</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNDYtMy0xLTEtMA_498a72b3-b7eb-4b8b-a005-73740ba9dfbc">18,269</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance lease liabilities, net of current portion</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNDctMS0xLTEtMA_71085c89-2b48-4973-8d21-01fecced1351">355</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNDctMy0xLTEtMA_f7418b6b-5fdd-4e40-8623-b936be6656b6">416</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities, net of current portion</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNDgtMS0xLTEtMA_27934e3b-0ac6-4cc2-ac17-b35a80065384">17,418</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNDgtMy0xLTEtMA_af37b674-6cc0-47f2-9929-34eb2c7c7d7d">11,373</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term debt, net of current portion and deferred financing costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNDktMS0xLTEtMA_0d11b7d8-aaab-4709-b905-a301359adad0">230,455</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNDktMy0xLTEtMA_f9715e78-099a-42c1-837d-5f4d0f66b65a">232,172</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total noncurrent liabilities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNTEtMS0xLTEtMA_12287908-1efe-4e2c-86fc-9332cfd1abf9">261,882</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNTEtMy0xLTEtMA_a5db1b61-8fbc-45f0-a615-f9d7ebe17a28">262,230</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Total liabilities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNTMtMS0xLTEtMA_25e8bbc6-563d-4d97-873e-bc97931db998">414,389</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNTMtMy0xLTEtMA_424b3360-eb5e-400c-8578-4777911f95a1">367,653</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Commitments and contingencies (Note 11)</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span><br/></span></div><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNTUtMS0xLTEtMA_de59835b-9119-43eb-b328-4c04ed0eb277"></ix:nonFraction></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNTUtMy0xLTEtMA_0c65a926-cbe6-4f67-a0d0-b5771e50c49b"></ix:nonFraction>Mezzanine equity</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Noncontrolling interest in Allied Physicians of California, a Professional Medical Corporation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNTgtMS0xLTEtMA_8854dda4-dc76-4d8a-9d1d-8b66fd576d2f">210,980</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNTgtMy0xLTEtMA_2c6a23bf-c839-4277-ac87-95ffc8d4be44">168,725</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Stockholders&#8217; equity</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Series A Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i17d58afdf6094c3f9289f4089d3a6678_I20200630" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjEtMC0xLTEtMC90ZXh0cmVnaW9uOjk5ZGJiNjkyZmM4YzRjYjBhODhlMTZmM2Q0YjQ0NGEyXzQ5NDc4MDIzMjUxOTM_2f35f76e-38e9-4d12-af1a-4671fb87c1a6"><ix:nonFraction unitRef="usdPerShare" contextRef="ia6e2f1d8c41a4e708493e14e80f2e50d_I20191231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjEtMC0xLTEtMC90ZXh0cmVnaW9uOjk5ZGJiNjkyZmM4YzRjYjBhODhlMTZmM2Q0YjQ0NGEyXzQ5NDc4MDIzMjUxOTM_ce4f8501-6143-4bed-8b22-6a9bd75137e6">0.001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="shares" contextRef="i17d58afdf6094c3f9289f4089d3a6678_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjEtMC0xLTEtMC90ZXh0cmVnaW9uOjk5ZGJiNjkyZmM4YzRjYjBhODhlMTZmM2Q0YjQ0NGEyXzQ5NDc4MDIzMjUyMDQ_7e6bbdac-b2a9-43f3-b67e-4673e305b8d0"><ix:nonFraction unitRef="shares" contextRef="ia6e2f1d8c41a4e708493e14e80f2e50d_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjEtMC0xLTEtMC90ZXh0cmVnaW9uOjk5ZGJiNjkyZmM4YzRjYjBhODhlMTZmM2Q0YjQ0NGEyXzQ5NDc4MDIzMjUyMDQ_889ebddb-ebf7-4d74-8a9b-ec0f983ce4ef">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized (inclusive of all preferred stock, including Series B Preferred stock); <ix:nonFraction unitRef="shares" contextRef="ia6e2f1d8c41a4e708493e14e80f2e50d_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjEtMC0xLTEtMC90ZXh0cmVnaW9uOjk5ZGJiNjkyZmM4YzRjYjBhODhlMTZmM2Q0YjQ0NGEyXzQ5NDc4MDIzMjUyMTU_1873fe2b-4373-43c6-80b1-453b3041cd29"><ix:nonFraction unitRef="shares" contextRef="i17d58afdf6094c3f9289f4089d3a6678_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjEtMC0xLTEtMC90ZXh0cmVnaW9uOjk5ZGJiNjkyZmM4YzRjYjBhODhlMTZmM2Q0YjQ0NGEyXzQ5NDc4MDIzMjUyMTU_ff089cdb-b18f-4c4a-b5c6-379fed919527">1,111,111</ix:nonFraction></ix:nonFraction> issued and <ix:nonFraction unitRef="shares" contextRef="ia6e2f1d8c41a4e708493e14e80f2e50d_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjEtMC0xLTEtMC90ZXh0cmVnaW9uOjk5ZGJiNjkyZmM4YzRjYjBhODhlMTZmM2Q0YjQ0NGEyXzU0OTc1NTgxMzkxMDk_425db5b1-e87e-44f4-906b-c518ffe6b269"><ix:nonFraction unitRef="shares" contextRef="i17d58afdf6094c3f9289f4089d3a6678_I20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjEtMC0xLTEtMC90ZXh0cmVnaW9uOjk5ZGJiNjkyZmM4YzRjYjBhODhlMTZmM2Q0YjQ0NGEyXzU0OTc1NTgxMzkxMDk_7efede2f-b976-4b57-8fb7-e35bedfa6275">zero</ix:nonFraction></ix:nonFraction> outstanding</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i17d58afdf6094c3f9289f4089d3a6678_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjEtMS0xLTEtMA_7f317f74-4eba-45b8-9fa5-0b6d4fad49d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6e2f1d8c41a4e708493e14e80f2e50d_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjEtMy0xLTEtMA_9509b1e7-1f3f-4a8e-88f5-63aa179354fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Series B Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ie3ded1fe24c44729a7d30f51269fad23_I20191231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjItMC0xLTEtMC90ZXh0cmVnaW9uOjdkYWIwNzVlMWQ3NDQ2ZDM4NGU4NjA3M2ZiNzcyMDU4XzQ5NDc4MDIzMjUxOTE_224c8eb8-f38a-4b6f-86a4-ed7b2f0d01f0"><ix:nonFraction unitRef="usdPerShare" contextRef="i83686cfeea3643b2ab0ba5131ab70154_I20200630" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjItMC0xLTEtMC90ZXh0cmVnaW9uOjdkYWIwNzVlMWQ3NDQ2ZDM4NGU4NjA3M2ZiNzcyMDU4XzQ5NDc4MDIzMjUxOTE_5ede97e5-c9e9-48b7-bda3-7a62340b7d66">0.001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="shares" contextRef="ie3ded1fe24c44729a7d30f51269fad23_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjItMC0xLTEtMC90ZXh0cmVnaW9uOjdkYWIwNzVlMWQ3NDQ2ZDM4NGU4NjA3M2ZiNzcyMDU4XzQ5NDc4MDIzMjUyMDI_f6ed8215-1d99-4d22-8b22-444e88aac3cc"><ix:nonFraction unitRef="shares" contextRef="i83686cfeea3643b2ab0ba5131ab70154_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjItMC0xLTEtMC90ZXh0cmVnaW9uOjdkYWIwNzVlMWQ3NDQ2ZDM4NGU4NjA3M2ZiNzcyMDU4XzQ5NDc4MDIzMjUyMDI_fd2b1cc2-954b-43f5-ac6c-ded45891e2bf">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized (inclusive of all preferred stock, including Series A Preferred stock); <ix:nonFraction unitRef="shares" contextRef="ie3ded1fe24c44729a7d30f51269fad23_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjItMC0xLTEtMC90ZXh0cmVnaW9uOjdkYWIwNzVlMWQ3NDQ2ZDM4NGU4NjA3M2ZiNzcyMDU4XzQ5NDc4MDIzMjUyMTE_413928ae-1334-46e3-aa2a-34157990e5ef"><ix:nonFraction unitRef="shares" contextRef="i83686cfeea3643b2ab0ba5131ab70154_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjItMC0xLTEtMC90ZXh0cmVnaW9uOjdkYWIwNzVlMWQ3NDQ2ZDM4NGU4NjA3M2ZiNzcyMDU4XzQ5NDc4MDIzMjUyMTE_e2a73fde-fd30-4148-996a-b4f2f00f6f1a">555,555</ix:nonFraction></ix:nonFraction> issued and <ix:nonFraction unitRef="shares" contextRef="i83686cfeea3643b2ab0ba5131ab70154_I20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjItMC0xLTEtMC90ZXh0cmVnaW9uOjdkYWIwNzVlMWQ3NDQ2ZDM4NGU4NjA3M2ZiNzcyMDU4XzU0OTc1NTgxMzkxMDU_4770ca18-092c-4d21-a29a-487f3749d7af"><ix:nonFraction unitRef="shares" contextRef="ie3ded1fe24c44729a7d30f51269fad23_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjItMC0xLTEtMC90ZXh0cmVnaW9uOjdkYWIwNzVlMWQ3NDQ2ZDM4NGU4NjA3M2ZiNzcyMDU4XzU0OTc1NTgxMzkxMDU_d958523d-3f68-482b-b947-e725a7988e51">zero</ix:nonFraction></ix:nonFraction> outstanding</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i83686cfeea3643b2ab0ba5131ab70154_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjItMS0xLTEtMA_2807f1bd-2ee2-4679-8beb-2e4f71b92df5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie3ded1fe24c44729a7d30f51269fad23_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjItMy0xLTEtMA_d5a497ce-6e82-4e62-b866-9f45f0552eb7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOjBiOWI0NzFiOWJmNjQ1MTI5Y2RjNzI4ZDczOWJiYTgzXzQ5NDc4MDIzMjUyMjg_7bc90250-a8b3-438b-b25a-516fa47bd8b9"><ix:nonFraction unitRef="usdPerShare" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOjBiOWI0NzFiOWJmNjQ1MTI5Y2RjNzI4ZDczOWJiYTgzXzQ5NDc4MDIzMjUyMjg_f72c9da6-eab2-488b-a7d9-e59ef6f82502">0.001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="shares" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOjBiOWI0NzFiOWJmNjQ1MTI5Y2RjNzI4ZDczOWJiYTgzXzQ5NDc4MDIzMjUyNDE_618b7c34-cc1e-4c5d-b861-c6f7aa7c7107"><ix:nonFraction unitRef="shares" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOjBiOWI0NzFiOWJmNjQ1MTI5Y2RjNzI4ZDczOWJiYTgzXzQ5NDc4MDIzMjUyNDE_701f08b0-0b22-4aaa-a2f8-aa408776ca18">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOjBiOWI0NzFiOWJmNjQ1MTI5Y2RjNzI4ZDczOWJiYTgzXzQ5NDc4MDIzMjUyNTM_02a75fd9-43b9-422e-b278-3499c13dcc05">36,309,513</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOjBiOWI0NzFiOWJmNjQ1MTI5Y2RjNzI4ZDczOWJiYTgzXzQ5NDc4MDIzMjUyNzc_3897cb08-92aa-46aa-a0ce-c9da59049540">35,908,057</ix:nonFraction> shares outstanding, excluding <ix:nonFraction unitRef="shares" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockCommonShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOjBiOWI0NzFiOWJmNjQ1MTI5Y2RjNzI4ZDczOWJiYTgzXzQ5NDc4MDIzMjUyNjU_e445687c-0246-44cc-a7d3-e3bc99a871bf">17,475,707</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockCommonShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOjBiOWI0NzFiOWJmNjQ1MTI5Y2RjNzI4ZDczOWJiYTgzXzQ5NDc4MDIzMjUyODk_bdcf3d19-9980-4b9a-9ffa-5eb2251e8bc6">17,458,810</ix:nonFraction> treasury shares, at June&#160;30, 2020, and December&#160;31, 2019, respectively</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjMtMS0xLTEtMA_09d9837f-727b-403f-a3f4-058865e15627">36</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjMtMy0xLTEtMA_27810675-ab1e-4423-baf3-cf5178b7fd7a">36</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additional paid-in capital</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjQtMS0xLTEtMA_eeec4fa0-0ea5-46a7-a77c-18a6b2f2090f">163,986</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjQtMy0xLTEtMA_476114e0-721f-4de5-899b-2cec91c6dbf1">159,608</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Retained earnings</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjUtMS0xLTEtMA_fe8fccfa-12f7-43f9-a54f-784f3f334b71">43,001</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjUtMy0xLTEtMA_5a6b8202-5294-400e-b4be-5a7884ca0dc0">31,905</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjYtMS0xLTEtMA_8806087c-e3ba-4ec7-a3ed-e74c170f17a6">207,023</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjYtMy0xLTEtMA_df481ba0-4803-4af3-b814-1cd1d9f78b28">191,549</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Noncontrolling interest</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjgtMS0xLTEtMA_5135b126-667b-456d-b5fc-cfd565a89157">825</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjgtMy0xLTEtMA_b6008e89-bf65-4246-a71c-26e15726fce0">786</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total stockholders&#8217; equity</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNzAtMS0xLTEtMA_1a97eb45-9c61-45a2-80cb-f3dd2275a665">207,848</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNzAtMy0xLTEtMA_98b4ecff-c3c2-4fa6-8c11-458790c7bffd">192,335</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Total liabilities, mezzanine equity and stockholders&#8217; equity</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNzItMS0xLTEtMA_424d3a14-a024-4485-94b1-f3a365ff065e">833,217</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNzItMy0xLTEtMA_b30e474e-888c-4cd0-8d54-cdd1be8bd20f">728,713</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying notes are an integral part of these unaudited consolidated financial statements.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">6</span></div></div></div><div id="icc5d6783c1494a1f886c03c93e398cee_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">APOLLO MEDICAL HOLDINGS, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(UNAUDITED)</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:54.871%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.672%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.672%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.356%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.677%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Capitation, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie034b8ac717f4e0f821b2e6846cc21da_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMy0xLTEtMS0w_5da20b73-8158-43fd-9a1b-bd6cbe37df90">140,949</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3c020c0256064c2e9f9890db9de73a18_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMy0zLTEtMS0w_cf7b599f-6e03-4139-8a44-3542eb1f2dd5">103,224</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifb543017186b41428d7d61876f751a53_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMy01LTEtMS0w_22715171-f108-4be3-a13b-6cc557b452f4">281,370</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibca1f4a0742946218cb28c01d1e69d3a_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMy03LTEtMS0w_43d8bc96-ada9-4adf-8da1-774061992d5d">174,740</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk pool settlements and incentives</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie935f35786ac43c595cc0e1bdd2bfa7a_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfNC0xLTEtMS0w_82f8b0fc-1f8f-49b2-927b-6921e37dc1e1">12,003</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4e76ce3a79df48a5b2aef434c3026411_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfNC0zLTEtMS0w_a46a1f25-8ded-49bb-ba42-404aa3efdf0d">11,191</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic9a5e5a435384ed9b47445e91f2e5dbe_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfNC01LTEtMS0w_4ffc2d1a-ccd7-45e2-b6f4-7f8b1ba28331">23,239</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfc4299f8823436fac5fd23586298d02_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfNC03LTEtMS0w_b02b0047-2912-4228-b2be-18d1afb9ea87">21,285</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Management fee income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i86ffd806ab8441679dbed516276b4734_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfNS0xLTEtMS0w_1385fafd-de9f-4505-80e2-84fc14bd8ff8">8,690</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id2c681dbab0b446cafe1a39de28bedb6_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfNS0zLTEtMS0w_99a8e15a-3a96-41e2-85ba-3bab043b83f3">10,353</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic862c6560a614f5abea31e3ad439d0fe_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfNS01LTEtMS0w_995f2bbb-19f6-4229-8114-d3e8a2a38831">17,505</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7276b0b6cad94ed6955187e2affe1b27_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfNS03LTEtMS0w_de114b5c-5dc3-46a2-b956-a4116210baac">19,349</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fee-for-service, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia03e0ac0e02248b881a5720c0b7bcc62_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfNi0xLTEtMS0w_8b5dd0fc-f889-4d97-979c-b49d42c7220a">2,270</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i352052d598714a3aa1bc0f6be299be80_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfNi0zLTEtMS0w_01e717a7-81d1-423a-898d-44e20a540a9c">3,878</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0a83b91f96d642cb888e655253482c99_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfNi01LTEtMS0w_d83cef79-ba82-44a9-ba4c-dcd4a6156a28">5,697</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i18eff8c461884069b655593a6463d4b2_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfNi03LTEtMS0w_a034639c-816a-401f-ad6b-f22cca4cb925">7,959</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i17c717d9ab9c4c13925e6d4f409d3e67_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfNy0xLTEtMS0w_6c04fdcd-c5db-4e26-8b67-301afe308d0b">1,257</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic79fc17a0341400e9e62338ca77a93da_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfNy0zLTEtMS0w_6a60e569-c7d8-4aab-94e5-54a75b980ff0">1,404</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie229ade0fac144a8a4262469a1176554_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfNy01LTEtMS0w_5bea77d3-0c23-42a5-aa0d-8282e465ea1e">2,463</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i455aac9cb9b24b88861613f2d5737086_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfNy03LTEtMS0w_967b6c3a-848c-41b2-bc95-ee34cbd29217">2,473</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total revenue</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfOS0xLTEtMS0w_5d3535ba-d6b4-4168-adf1-d54a6eac714d">165,169</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfOS0zLTEtMS0w_aa2860f1-bc83-4f33-bb17-f092c8d29e0f">130,050</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfOS01LTEtMS0w_d2596615-d805-480a-bdea-ccefaab9a10f">330,274</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfOS03LTEtMS0w_09dc5492-f168-4883-96f9-33829bed8dca">225,806</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of services</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMTItMS0xLTEtMA_5989a382-b948-4db5-8a76-ff2f84c65baf">136,079</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMTItMy0xLTEtMA_e6385b30-13bb-45a2-b868-b5fe2bff2a8d">101,363</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMTItNS0xLTEtMA_57b21d26-1efd-4ac8-bf20-faa9a5a69da9">280,283</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMTItNy0xLTEtMA_7aecc9fc-7600-4f12-a6a4-21b26f09532c">184,795</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMTMtMS0xLTEtMA_f728ca89-9dbd-4cd8-8e10-f5a2c0f8daab">11,556</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMTMtMy0xLTEtMA_4c779172-ec1d-4f41-84bf-27ae7c532e20">11,818</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMTMtNS0xLTEtMA_0970f1fa-de7e-48c9-a4fc-9b95a2839b28">23,390</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMTMtNy0xLTEtMA_25071ea2-cc24-4986-8e88-8c4d43ced9e6">22,081</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation and amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="ameh:DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMTQtMS0xLTEtMA_6089377a-1ca1-46dc-8274-b78c4380294e">4,628</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="ameh:DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMTQtMy0xLTEtMA_6646c139-f579-4a92-9237-77fbd93287c9">4,455</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="ameh:DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMTQtNS0xLTEtMA_8f2003c0-a98f-4d23-9446-7b853e47faa2">9,330</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="ameh:DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMTQtNy0xLTEtMA_3bef738b-e9d3-45ed-a07c-f6b1ae1b3de8">8,872</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Provision for doubtful accounts</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMTUtMS0xLTEtMA_5b22a78a-f1de-48ff-83a0-ab2e19c7c181">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMTUtMy0xLTEtMA_83e67198-1059-4984-be97-fd51a31bca3f">2,314</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMTUtNS0xLTEtMA_a5d5b29a-99bb-4502-b0dd-b2359f903eb3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMTUtNy0xLTEtMA_c0e92b84-984e-4693-ad9b-4ae1494cfb7c">1,363</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total expenses</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMTctMS0xLTEtMA_7251e682-4991-4f66-b227-43dcf50ab787">152,263</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMTctMy0xLTEtMA_148c2ccd-d182-4518-a1e6-2b0163e60e2a">115,322</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMTctNS0xLTEtMA_992a0454-6168-4d9e-bd10-bb718e476e24">313,003</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMTctNy0xLTEtMA_e14bfbaa-2dc6-44ef-9833-1b5c004be596">214,385</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income from operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMTktMS0xLTEtMA_fbbfc034-c9fc-4671-9271-4b29c8fcf8c1">12,906</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMTktMy0xLTEtMA_30db1792-0549-4d85-a21c-7c3bf03921ca">14,728</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMTktNS0xLTEtMA_dd6f0232-3e87-472a-907f-023c21990e1e">17,271</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMTktNy0xLTEtMA_5a4d37ee-8845-410e-a513-821498049655">11,421</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income (expense)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income (loss) from equity method investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMjItMS0xLTEtMA_efbd1a10-12d3-4988-af1f-26adcf493d62">834</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMjItMy0xLTEtMA_d01745ce-c26a-499b-ab88-3d99a5f46950">42</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMjItNS0xLTEtMA_3ced0138-a8cd-489c-a647-6052e89f3771">2,888</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMjItNy0xLTEtMA_d50be0a6-2261-4c81-b02e-0321a28a35a4">892</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gain on sale of equity method investment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMjMtMS0xLTEtNDY2NQ_43919e66-e477-433c-bf80-14cad4f285ab">99,647</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMjMtMy0xLTEtNDY2NQ_ccfd3c82-dafb-46a0-bf9e-1177b40c465b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMjMtNS0xLTEtNDY1Ng_cf72bea9-56c0-4a97-87ab-bd88c02c02b7">99,647</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMjMtNy0xLTEtNDY1Ng_6ebb2f4e-859a-4049-9a9e-3d200c1e48aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMjMtMS0xLTEtMA_b0f1f2c0-d5ad-470b-bf6b-bc7a55f4b14c">2,673</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMjMtMy0xLTEtMA_d887ed17-0ca4-4038-962f-22da7605f57e">311</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMjMtNS0xLTEtMA_0e2d19d9-594c-4b33-810a-43296988c2a5">5,541</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMjMtNy0xLTEtMA_aa25b86e-95e0-4d2a-90ac-b3450236f71e">522</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMjQtMS0xLTEtMA_2a51ee15-2f60-4099-a3fe-d17a3da93774">863</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMjQtMy0xLTEtMA_311700c1-09fc-4728-a421-e642d39d5b8f">474</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMjQtNS0xLTEtMA_10467c00-f6cd-4067-ac5f-71586a6cf4b0">1,792</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMjQtNy0xLTEtMA_b580cbb7-8db0-4d03-a73b-6f1ed48973f2">797</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMjUtMS0xLTEtMA_b7c4406b-5d46-4073-8d20-a5f03bcee5fb">1,282</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMjUtMy0xLTEtMA_69ae0bd6-0f94-4ade-b732-96739b932ad1">24</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMjUtNS0xLTEtMA_e4804f13-e926-4611-81a9-122ff3456a85">1,384</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMjUtNy0xLTEtMA_51f2c305-bef7-4abe-9cac-e7a558027e2c">211</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total other income (expense), net</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMjctMS0xLTEtMA_831dafaf-ed9b-4186-97e7-bdec8ba20ea1">99,953</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMjctMy0xLTEtMA_57cf0609-636e-4488-9079-7e87170555c1">145</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMjctNS0xLTEtMA_4d35274a-f319-4043-b08f-397304b9f19e">100,170</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMjctNy0xLTEtMA_341a9f79-1c9b-4326-a69d-eaf86bb87e7b">406</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income before provision for income taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMjktMS0xLTEtMA_49472043-6af7-4bdc-9717-fa9a642be35c">112,859</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMjktMy0xLTEtMA_0fa05167-e78c-4c06-8198-81d67451cf70">14,873</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMjktNS0xLTEtMA_1f78f550-39e1-46ee-aa73-0650ceb5625e">117,441</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMjktNy0xLTEtMA_a083a1c8-360c-4b4d-9a5b-8cc1b0d78e37">11,015</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Provision for income taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMzEtMS0xLTEtMA_ece16360-802d-4179-8f93-2a0b0a94ebe4">31,858</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMzEtMy0xLTEtMA_debc947b-b6e8-4b79-b00c-0a7a9eb5d7af">4,209</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMzEtNS0xLTEtMA_637af34b-2cac-447c-9148-4020f57a9191">33,453</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMzEtNy0xLTEtMA_769e3301-4783-4780-824c-549ed89c988c">2,801</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Net income</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMzMtMS0xLTEtMA_5b1dca2d-1204-41a2-94c8-cc017856b230">81,001</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMzMtMy0xLTEtMA_8f836eb1-7c56-416c-94b3-58bdf265f1e8">10,664</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMzMtNS0xLTEtMA_b288b949-86f1-4dce-8fc0-88c06427704d">83,988</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMzMtNy0xLTEtMA_2ca7c156-a661-4130-b7fc-bbd53264c908">8,214</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMzUtMS0xLTEtMA_d8e51332-62ff-4fcf-8f08-aabfdb4fb3cb">73,957</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMzUtMy0xLTEtMA_87764573-783e-4e8a-aee6-98dbcece5beb">7,119</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMzUtNS0xLTEtMA_4f3d1f19-3b9f-44c6-a610-155906e92b67">72,892</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMzUtNy0xLTEtMA_823bba58-509a-447e-96da-a2e1013f76b9">4,529</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Net income attributable to Apollo Medical Holdings, Inc.</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMzctMS0xLTEtMA_5831b659-bf12-4b2e-b4fd-5c8f2980496d">7,044</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMzctMy0xLTEtMA_df803b84-dd90-4789-8359-d7354d1fc671">3,545</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMzctNS0xLTEtMA_07716871-df75-41f4-b38d-4365ae339408">11,096</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMzctNy0xLTEtMA_2ef2f23f-3398-4440-a33f-059bbdcd8581">3,685</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Earnings per share &#8211; basic</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMzktMS0xLTEtMA_4fb6f628-b2a4-44fd-a7e2-590f4981f882">0.20</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMzktMy0xLTEtMA_dbd8a9ae-140c-442c-91ba-2725d7c793be">0.10</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMzktNS0xLTEtMA_cbbd260a-3d0d-44eb-81ad-b754fcd24444">0.31</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMzktNy0xLTEtMA_95e22dfa-f9e1-462d-bff1-86aff196ec78">0.11</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Earnings per share &#8211; diluted</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfNDEtMS0xLTEtMA_a17485a0-7ae8-49d2-9321-d790a6918a36">0.19</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfNDEtMy0xLTEtMA_5bcb12ba-9526-4824-9690-e91eb8aaeeef">0.09</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfNDEtNS0xLTEtMA_7ca6d738-8e56-4b1a-b68b-ffa8d54d1cfe">0.30</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfNDEtNy0xLTEtMA_f0b5ac02-dd61-4965-b97f-6dca282bbf00">0.10</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying notes are an integral part of these unaudited consolidated financial statements.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">7</span></div></div></div><div id="icc5d6783c1494a1f886c03c93e398cee_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">APOLLO MEDICAL HOLDINGS, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(IN THOUSANDS, EXCEPT SHARE DATA)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(UNAUDITED)</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:19.083%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.980%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.809%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.809%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.980%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.980%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.980%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.987%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="3" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%;">Mezzanine</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%;">Equity&#160;&#8211;</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%;">Noncontrolling</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%;">Interest&#160;in&#160;APC</span></div></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="3" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%;">Retained</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%;">Earnings</span></div></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%;">Common&#160;Stock&#160;Outstanding</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%;">Additional</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%;">Paid-in&#160;Capital</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%;">Noncontrolling</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%;">Interest</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%;">Shareholders&#8217;</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%;">Equity</span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%;">Shares</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%;">Amount</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at January 1, 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5a40c5284da24efa84bc4df89f4f2705_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMy0xLTEtMS0w_f3c9e6a2-bf1e-4bbc-a75c-993174fcef2f">168,725</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ie4e637eec6484f0786a6ed5c1f6430cb_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMy0zLTEtMS0w_3a34964b-8084-408d-a262-6b72744f045c">35,908,057</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie4e637eec6484f0786a6ed5c1f6430cb_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMy01LTEtMS0w_4a52da8b-bf23-4f4c-8a16-083aceb38bdb">36</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icdd5d78f45b9441eba8b9eacaa9bf76e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMy03LTEtMS0w_ecd77eab-5716-4765-99df-5834c02dea0a">159,608</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i11c1b7b9b865434fa9576e7784c2dc13_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMy05LTEtMS0w_80921506-d627-4934-b351-681f6cb65357">31,905</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia43dbbf6ada5449bacec1ab39ed62847_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMy0xMS0xLTEtMA_9bd7eecf-15e9-4bd0-a24a-12136ca85177">786</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMy0xMy0xLTEtMA_a1c057e5-482f-4f01-906d-e1f30d751a3a">192,335</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net (loss) income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1f94bdfba2434414a07e834a64442b28_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfNC0xLTEtMS0w_5f66d351-de75-4d8f-bd5b-2c6fefce9671">1,161</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie1f8b99761ef4aa3ad4c66bc1cdef075_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfNC05LTEtMS0w_48d26366-c300-44c3-b54a-643ebde6626e">4,052</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i67cb29fa35d447558cebf0c44017ecd8_D20200101-20200331" decimals="-3" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfNC0xMS0xLTEtMA_ee1ddf9f-5f90-4687-83ca-fb4d0d9a3094">95</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib557e6848b8949778b46babd52ad1570_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfNC0xMy0xLTEtMA_48f727a1-e088-4863-922a-2c350259e56a">4,147</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;">Purchase of treasury shares</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i691e279196924ed386447cfa2fdb3c0a_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfNS0zLTEtMS0w_7125d8c3-6552-48d1-aee1-eb540a6403b1">16,897</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia8c91ec953b9448fb223cb4a034a52d3_D20200101-20200331" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredParValueMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfNS03LTEtMS0w_df7a7e61-971d-430e-9481-26656c004cdb">301</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib557e6848b8949778b46babd52ad1570_D20200101-20200331" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredParValueMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfNS0xMy0xLTEtMA_630c56b4-bf51-4349-977a-91484f730537">301</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchase of noncontrolling interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1f94bdfba2434414a07e834a64442b28_D20200101-20200331" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfNi0xLTEtMS0w_232e7578-1971-49ef-bf0a-5c7793b189aa">125</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib557e6848b8949778b46babd52ad1570_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfNi0xMy0xLTEtMA_8972df85-252a-4e67-8780-89519fa80d5e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares issued for exercise of options and warrants</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i691e279196924ed386447cfa2fdb3c0a_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfNy0zLTEtMS0w_d413d8e3-89d4-4942-8a8e-87ac4ecae54a">151,601</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia8c91ec953b9448fb223cb4a034a52d3_D20200101-20200331" decimals="-3" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfNy03LTEtMS0w_2ed91917-19c6-49d2-97fb-2f951389bed5">722</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib557e6848b8949778b46babd52ad1570_D20200101-20200331" decimals="-3" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfNy0xMy0xLTEtMA_022a2f9d-084f-4a9b-ad76-cc36f5eb880a">722</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia8c91ec953b9448fb223cb4a034a52d3_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfOC03LTEtMS0w_f9400ec5-1d16-48eb-89e2-e0013228ed4c">1,058</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib557e6848b8949778b46babd52ad1570_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfOC0xMy0xLTEtMA_282ebb0f-bb7f-4aaf-bf5d-05cb33c7569e">1,058</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dividends</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1f94bdfba2434414a07e834a64442b28_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfOS0xLTEtMS0w_57fde2fd-9c7c-49c7-8f39-2adb739a617d">10,000</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib557e6848b8949778b46babd52ad1570_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfOS0xMy0xLTEtMA_7bad001d-7bfe-44a7-a818-a644afe2eb06">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at March 31, 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic62aa01d15f74e74b86bfdec19d0c108_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTAtMS0xLTEtMA_2344661f-97a2-4413-b90c-7690765a4275">157,439</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ie5f49e82ee9c46f680d56792f282a687_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTAtMy0xLTEtMA_374d4d6e-f049-4384-be1e-e4408095c9e1">36,042,761</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5f49e82ee9c46f680d56792f282a687_I20200331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTAtNS0xLTEtMA_6b6acb6f-4fb8-40de-bfca-f1eb9427c108">36</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i083b9bc8a05048a5840ae066d8501457_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTAtNy0xLTEtMA_baaac71e-4aa0-4a8d-9dd5-9ecf46521ec0">161,087</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4b2a896675d04c7d9830d427157f52b0_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTAtOS0xLTEtMA_933ec953-2c34-4a7f-91f6-92260016b38b">35,957</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8d951dc1190e45e2ac445202aec7daa9_I20200331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTAtMTEtMS0xLTA_ab0c2b1a-d685-4b3d-9482-589813e90803">881</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iee021f30ec494988b04ffd293da80842_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTAtMTMtMS0xLTA_7f3cad1b-b4ff-400e-bc39-17073a50f000">197,961</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iab3938dc2790442bbae7aab01097fc8b_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTEtMS0xLTEtMzI5_4b3c4492-6315-4295-89d2-80d889e734b0">73,667</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id415104b7a1f4a52af19c2f74be0a88d_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTEtOS0xLTEtMzMy_4e80b50b-a90b-43e5-af07-f654e192ffc8">7,044</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieff7bbd8785d4105a279ebbb1b6569a6_D20200401-20200630" decimals="-3" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTEtMTEtMS0xLTMzNQ_475ea1c7-6308-4010-9fe0-572df4ead85f">291</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTEtMTMtMS0xLTMzNQ_7479533f-c7a3-4a09-8c06-d178ffd804e6">7,335</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchase of noncontrolling interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iab3938dc2790442bbae7aab01097fc8b_D20200401-20200630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTItMS0xLTEtMzI5_a92bbc49-bd29-4751-a0f1-979e39b4e22f">126</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTItMTMtMS0xLTMzNQ_e1b74a2f-1ae5-40f9-bffa-146fa3f7030e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares issued for vesting of restricted stock awards</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ic6205a2691794f12816d94e2384216d4_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTMtMy0xLTEtNjE4Mg_9f14d54b-af84-43b8-ae69-f5271f6c52d3">24,453</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTMtMTMtMS0xLTYxODI_7794de50-1950-4f96-82f7-8523528eee62">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares issued for exercise of options and warrants</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ic6205a2691794f12816d94e2384216d4_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTQtMy0xLTEtMzMy_0431ad45-260b-4349-a2ef-517a7d6ba555">242,299</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f79c810c09544658e32ad8904dcddfb_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTQtNy0xLTEtMzMy_233ccb38-42f8-4272-bbf4-c3bdb1dbeb94">2,283</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTQtMTMtMS0xLTMzNQ_15ba9d5d-ff93-4dac-a744-3758503a61ea">2,283</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f79c810c09544658e32ad8904dcddfb_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTUtNy0xLTEtMzMy_c0a9a1eb-f945-4a21-888f-2f3d1951702b">852</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTUtMTMtMS0xLTMzNQ_7660e9e1-980b-402a-a529-18193328e7e9">852</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cancellation of restricted stock awards</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8f79c810c09544658e32ad8904dcddfb_D20200401-20200630" decimals="-3" name="ameh:StockIssuedDuringPeriodValueRestrictedStockAwardCancelled" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTYtNy0xLTEtMjUyMQ_b29674f8-33d6-400c-b400-9dcab0d34c9a">236</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630" decimals="-3" name="ameh:StockIssuedDuringPeriodValueRestrictedStockAwardCancelled" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTYtMTMtMS0xLTI1MjE_96cafed5-f08c-4de7-8708-8eac6e9ed418">236</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dividends</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iab3938dc2790442bbae7aab01097fc8b_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTYtMS0xLTEtMzI5_fbef340d-f832-43a1-991e-b56777061a38">20,000</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ieff7bbd8785d4105a279ebbb1b6569a6_D20200401-20200630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTYtMTEtMS0xLTMzNQ_7ffef991-8a8d-46cf-9616-6320095a3014">347</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTYtMTMtMS0xLTMzNQ_dbfa385d-334b-4c60-887f-4fccc8175ee7">347</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at June 30, 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i601b184c6fdf4eada4f627de564a12d2_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTctMS0xLTEtMzM4_0101bb62-f03b-412a-b740-7ee1cf3271f0">210,980</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i56db13635c644c7eb66668022d8f8878_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTctMy0xLTEtMzM4_12b1dd22-fa00-4dc5-8b95-5cadfd559fff">36,309,513</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i56db13635c644c7eb66668022d8f8878_I20200630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTctNS0xLTEtMzM4_61d0e5c3-d13e-477b-9509-0e83122f3f0c">36</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5ccf0e9ee2e64a3182ccb11330048327_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTctNy0xLTEtMzM4_6104da0a-1819-458a-a6be-62acd254623d">163,986</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icb7195fbea754ef3b0e02c161fbcbf6c_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTctOS0xLTEtMzM4_9da9da57-b10e-48d8-9d2a-ea16d5b681ca">43,001</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1e6a563a26fa49f79fe7e401bb5fec30_I20200630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTctMTEtMS0xLTMzOA_a7631b1e-dc3d-4b12-8983-d4ab960f411a">825</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTctMTMtMS0xLTMzOA_541bb140-5a04-4131-a227-298747bdfae5">207,848</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:19.083%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.980%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.809%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.809%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.980%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.980%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.980%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.987%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="3" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%;">Mezzanine</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%;">Equity&#160;&#8211;</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%;">Noncontrolling</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%;">Interest&#160;in&#160;APC</span></div></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="3" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%;">Retained</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%;">Earnings</span></div></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%;">Common&#160;Stock&#160;Outstanding</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%;">Additional</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%;">Paid-in&#160;Capital</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%;">Noncontrolling</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%;">Interest</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shareholders&#8217;<br/>Equity</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%;">Shares</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%;">Amount</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at January 1, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i88dd112506904c6cb0c741b6ed17ccaf_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfMy0xLTEtMS0w_9974f4e7-38ff-452c-9d69-7843a3363f33">225,117</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i8af5fb33859043a8b3f81453abfe1293_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfMy0zLTEtMS0w_f84ac32d-1182-4923-8420-8ff9342ce9cc">34,578,040</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8af5fb33859043a8b3f81453abfe1293_I20181231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfMy01LTEtMS0w_a6f9ad07-4074-4a7b-83b5-a7fe67af3095">35</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i86cd437dd5a04045874dddd70078b5dd_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfMy03LTEtMS0w_b16fe0fc-21f7-4649-979e-4e92b53a68b5">162,723</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i10e399c42ec54ff9a466cf51bb20fe33_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfMy05LTEtMS0w_193f3dc8-d359-41a6-8bfb-f30c0a03c3f4">17,788</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic0d5534ac5c5479487b6ae9068ef457e_I20181231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfMy0xMS0xLTEtMA_ca33b389-29fb-4aea-bc97-50a86da31c08">998</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i009fc823ec144ee3b772b4396d458c88_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfMy0xMy0xLTEtMA_35d1fe1a-3335-4f19-9dc1-9177a36de0e2">181,544</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;">Net (loss) income</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iadd4f63ba5ae42d4ac92cc9136de9da2_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfNC0xLTEtMS0w_bb7168d9-b066-4e65-9e2c-abc87e66024a">3,000</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i22c58b4fa0a543509216aa49494d6aba_D20190101-20190331" decimals="-3" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfNC05LTEtMS0w_299e248e-156a-4a61-9aa3-a765a73bcc4a">140</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if3adcf989a11491086e545b6aee38fc5_D20190101-20190331" decimals="-3" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfNC0xMS0xLTEtMA_2da3d164-fc67-455f-8b93-bd60d0d6dc58">410</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5a6c0314826740a281244477bbba6dfa_D20190101-20190331" decimals="-3" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfNC0xMy0xLTEtMA_08a70558-7bc6-40d3-9345-e56a965da456">550</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchase of treasury shares</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iadd4f63ba5ae42d4ac92cc9136de9da2_D20190101-20190331" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredParValueMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfNS0xLTEtMS0w_c6b29ff1-c46e-4608-8f1d-1923825213e4">40</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i5ee6d5d8a1594010bfbaaec890b48045_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfNS0zLTEtMS0w_53bd66ef-418d-43e4-a77b-0a083a5add62">93,451</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5a6c0314826740a281244477bbba6dfa_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:TreasuryStockValueAcquiredParValueMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfNS0xMy0xLTEtMA_b89d4715-1ea3-4619-af51-5c27c05bd496">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares issued for exercise of options and warrants</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iadd4f63ba5ae42d4ac92cc9136de9da2_D20190101-20190331" decimals="-3" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfNi0xLTEtMS0w_8a626e55-2b45-4133-9632-a31bd8720749">155</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i5ee6d5d8a1594010bfbaaec890b48045_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfNi0zLTEtMS0w_252515f6-c4d7-467f-96bb-5ff87a440c66">17,516</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5148fbc9970c485988d70ba64178db69_D20190101-20190331" decimals="-3" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfNi03LTEtMS0w_2a06c02d-bd70-4efe-969e-28697b3f1f80">140</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5a6c0314826740a281244477bbba6dfa_D20190101-20190331" decimals="-3" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfNi0xMy0xLTEtMA_0926e5bf-6542-4f3a-9983-c4457a9b7908">140</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iadd4f63ba5ae42d4ac92cc9136de9da2_D20190101-20190331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfNy0xLTEtMS0w_7fb59235-3856-4420-98b0-0bc93178e742">202</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i5ee6d5d8a1594010bfbaaec890b48045_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfNy0zLTEtMS0w_dd7dff1e-1c5f-4987-ba14-f8191542306d">1,599</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5148fbc9970c485988d70ba64178db69_D20190101-20190331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfNy03LTEtMS0w_208ffeb6-e836-4934-b71e-f48668d51dfc">143</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5a6c0314826740a281244477bbba6dfa_D20190101-20190331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfNy0xMy0xLTEtMA_ee68fa7d-4078-4d78-b9cd-368ab5b392b5">143</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dividends</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iadd4f63ba5ae42d4ac92cc9136de9da2_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfOC0xLTEtMS0w_2dc7d4e1-7af7-4fea-88a5-18814a7665bc">10,000</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5a6c0314826740a281244477bbba6dfa_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfOC0xMy0xLTEtMA_777b293c-aebe-4a9d-8b37-30cc401c75dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at March 31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4974f1b145d14972a8e0b668e4693f24_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfOS0xLTEtMS0w_012c15d8-0958-4f01-8fe0-ddb76a16752a">212,434</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i78399cf970d54e8fa6805bb19581eedc_I20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfOS0zLTEtMS0w_d9bf2451-1ca4-4870-a65e-665d3266fe3d">34,503,704</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i78399cf970d54e8fa6805bb19581eedc_I20190331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfOS01LTEtMS0w_66577327-fe13-443c-a8de-645c6124986b">35</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i24b621b2e16049f5821822f6c6b515c8_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfOS03LTEtMS0w_2c851046-2ce5-43a8-9749-7ff1cdd738dc">163,006</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i726581c835934409b022b695e21f02c5_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfOS05LTEtMS0w_3894680e-b6de-4e25-81ca-d74c173bcd59">17,928</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i949449b3a63b462bb5ac492454d52236_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfOS0xMS0xLTEtMA_5a25fc58-3c44-43ae-ae94-5b170bfcbc4d">1,408</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcb813ea894446d389589a68e78f85f8_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfOS0xMy0xLTEtMA_81aefb7c-24d6-4821-bb33-6b9cf01092ba">182,377</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i95b98be4bbee40bb905948aa3d1b28ea_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfMTAtMS0xLTEtMA_6d77beaf-1a6f-461a-9114-0179a3df08c6">6,896</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i71a1516b4672496586bb6ad8954b6d32_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfMTAtOS0xLTEtMA_9302f270-588f-46e4-8890-c0be16e3010d">3,545</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6c10cea2d1d546b486e52aae1b79c77a_D20190401-20190630" decimals="-3" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfMTAtMTEtMS0xLTA_c9208382-76d9-41f3-a533-ed96cdb1bfa1">223</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfMTAtMTMtMS0xLTA_4b4e1288-918d-4d2a-9a3f-f74fb1af3595">3,768</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares issued for exercise of options and warrants</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i95b98be4bbee40bb905948aa3d1b28ea_D20190401-20190630" decimals="-3" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfMTItMS0xLTEtMA_4cfe9ce2-78b4-4d64-ac46-7cbf9e1c39ad">50</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="id43602e4d3ec401c85cc9e362fcdbb4b_D20190401-20190630" decimals="INF" format="ixt:numdotdecimal" name="ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfMTItMy0xLTEtMA_cd221cfc-c563-4e2f-8d2d-be640dc4ae01">135,108</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i87ba6bb181b44445a257ca2168e67b6f_D20190401-20190630" decimals="-3" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfMTItNy0xLTEtMA_ec2340c9-cdae-46c9-8464-70e3e67d4426">758</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630" decimals="-3" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfMTItMTMtMS0xLTA_07f9dae3-2aa2-43a9-8438-0d4a5eb96708">758</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i95b98be4bbee40bb905948aa3d1b28ea_D20190401-20190630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfMTMtMS0xLTEtMA_13fec2d4-f18b-4532-a503-e53c57e55be9">203</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i87ba6bb181b44445a257ca2168e67b6f_D20190401-20190630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfMTMtNy0xLTEtMA_e680ee91-f874-47e0-bee4-eba88d21e15c">128</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfMTMtMTMtMS0xLTA_ab971074-6bd5-4dc9-b80e-c0b14a51d4ba">128</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dividends</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6c10cea2d1d546b486e52aae1b79c77a_D20190401-20190630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfMTQtMTEtMS0xLTA_3b97b59a-f627-45cb-aee6-4c9c4db24ef0">942</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfMTQtMTMtMS0xLTA_44f632f0-c42c-47a7-8ec4-8b6411b691ea">942</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at June 30, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3af73b22faf94113b2f3aeaf70427a31_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfMTUtMS0xLTEtMA_21a40ce7-4cec-47ca-9cf0-03c2b2f526f7">219,583</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i4bcbf8bc939c4eb8b67d8f9031b07763_I20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfMTUtMy0xLTEtMA_d875cdd4-f295-4fcd-adc6-1b2e61ac54df">34,638,812</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4bcbf8bc939c4eb8b67d8f9031b07763_I20190630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfMTUtNS0xLTEtMA_7fd105c3-5d56-49fb-a6f5-f029eab2e905">35</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i27980f94484946c1a35649f7381b97d6_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfMTUtNy0xLTEtMA_76c034d7-6074-442f-aa05-bb276bfd990f">163,892</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic610016f8d084d548913bcfa0f781a33_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfMTUtOS0xLTEtMA_3f6ba190-ddde-4e87-9dac-7c3508e85fb0">21,473</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf1828c07785428dbc2e0059af0c356e_I20190630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfMTUtMTEtMS0xLTA_c895aea0-52a7-4d77-84d9-c2e214b0db34">689</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2db2c0d074c34657a5d523b0ae1e5784_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfMTUtMTMtMS0xLTA_27e74325-b64a-4f61-b6c3-fa04d14b6315">186,089</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying notes are an integral part of these unaudited consolidated financial statements.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">8</span></div></div></div><div id="icc5d6783c1494a1f886c03c93e398cee_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">APOLLO MEDICAL HOLDINGS, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(IN THOUSANDS)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(UNAUDITED)</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:71.792%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.739%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Cash flows from operating activities</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMy0xLTEtMS0w_0faf176b-4372-4656-86cc-180d0d862bc0">83,988</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMy0zLTEtMS0w_513b24b5-6988-429d-a7bc-ae5dfcedad31">8,214</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments to reconcile net income to net cash provided by (used in) operating activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Depreciation and amortization</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNS0xLTEtMS0w_d4c3e027-8641-4a65-a218-7c769d86152b">9,330</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNS0zLTEtMS0w_b1d6de7f-75fc-490b-b2cd-f8e70007b9e8">8,872</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of debt issuance costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNi0xLTEtMS02MjQx_e3cda71e-d4e1-45cb-bcfd-8ee4afe50133">658</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNi0zLTEtMS02MjQx_36feeccb-acf9-4932-a67b-9f8e0170d46d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Provision for doubtful accounts</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNi0xLTEtMS0w_086382ba-69b5-42dc-952e-9fb2f2b731a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNi0zLTEtMS0w_bbc84301-ad97-488d-bc88-233cb0a2132c">1,363</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Share-based compensation</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNy0xLTEtMS0w_c9addc21-763d-4f3d-a150-7b3333eb5d80">1,910</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNy0zLTEtMS0w_0c50ec21-01a7-4312-b266-73fd18b9bdd4">676</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized loss (gain) from investment in equity securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfOC0xLTEtMS0w_a817ffc0-2bbd-4687-8b1f-f87953b4bd02">25</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfOC0zLTEtMS0w_78b9b440-5614-44f3-9c87-4943605db9e8">15</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(Income) loss from equity method investments</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfOS0xLTEtMS0w_0416d9a7-ed56-40b4-a10c-dba943ba4a3b">2,888</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfOS0zLTEtMS0w_419b164d-6ff0-49d0-b03c-a0c81b18e9e1">892</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gain on sale of equity method investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMTAtMS0xLTEtNTE2Ng_4c6cb799-4a6c-4402-aeaf-dac73885f27a">99,647</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMTAtMy0xLTEtNTE2Ng_884b953e-25ef-4831-aa0a-7b442ce91f90">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Deferred tax</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMTAtMS0xLTEtMA_6e0bc33b-824d-4031-8a20-0cd2d0fe1a09">4,473</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMTAtMy0xLTEtMA_ddbc9e91-a5d3-43ff-83c5-3cce82dd5242">549</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Changes in operating assets and liabilities, net of business combinations:</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Receivables, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMTItMS0xLTEtMA_7521bdb4-f497-4f7f-b1c4-1156811a6bbd">6,284</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMTItMy0xLTEtMA_e4a682c3-75ee-46bd-90b2-de1e7475193d">588</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Receivables, net &#8211; related parties</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMTMtMS0xLTEtMA_432361dc-5ccc-4502-aed0-b86c803b0ee5">11,191</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMTMtMy0xLTEtMA_6ff37162-1082-48b3-ba32-bf7bcb040358">12,665</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other receivables</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMTQtMS0xLTEtMA_4bc08974-f374-41e2-b229-a11a2fa88d26">966</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMTQtMy0xLTEtMA_726bd3d8-a14f-4779-971e-dac29b47685f">11,897</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" name="ameh:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMTUtMS0xLTEtMA_d91c10f0-8e77-4edb-895c-098d2347a362">873</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="ameh:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMTUtMy0xLTEtMA_d6d3e0b2-5a94-435e-a5ef-ee39b31f04be">2,740</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Right-of-use assets</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="ameh:IncreaseDecreaseInOperatingLeaseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMTYtMS0xLTEtMA_8e69f5a0-533a-4411-94c3-5e65d3e90eef">1,680</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="ameh:IncreaseDecreaseInOperatingLeaseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMTYtMy0xLTEtMA_251b9c7a-c22a-46bd-84a7-c041663b34cb">1,098</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other assets</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMTctMS0xLTEtMA_47d880d4-b165-43cd-95c1-887f4130bb0d">5,095</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMTctMy0xLTEtMA_99a8cbf7-a946-401c-9109-b62a24d29ba6">243</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accounts payable and accrued expenses</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMTgtMS0xLTEtMA_65f60531-135d-41fb-9065-cd0a82275a68">3,043</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMTgtMy0xLTEtMA_50beef5c-e3d3-4b44-ad7f-81db0a3c86a7">3,340</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Fiduciary accounts payable</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMTktMS0xLTEtMA_e2ff4cf2-555d-47f0-859e-522eda1e2d02">174</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMTktMy0xLTEtMA_dd4485f9-b510-4d17-bd88-b1a12af5a8ad">260</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Medical liabilities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="ameh:IncreaseDecreaseInMedicalLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMjAtMS0xLTEtMA_9fd8907f-de5f-4704-9f01-9de1fba2aaf5">11,252</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="ameh:IncreaseDecreaseInMedicalLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMjAtMy0xLTEtMA_5249e5b6-bd18-41ad-b18f-53b73cbcb49a">3,819</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Income taxes payable</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMjEtMS0xLTEtMA_a77710d5-8b61-4886-a77e-ad6e2bd721d1">37,681</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMjEtMy0xLTEtMA_c5ec535e-18db-492c-830c-44ebc2ee97b8">11,622</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating lease liabilities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="ameh:IncreaseDecreaseInOtherOperatingLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMjItMS0xLTEtMA_93812867-0f75-4fb8-9707-641bb308723a">1,247</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="ameh:IncreaseDecreaseInOtherOperatingLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMjItMy0xLTEtMA_573d89b4-53e5-40cd-9bd6-118489d95f34">1,044</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by (used in) operating activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMjMtMS0xLTEtMA_f475d976-866f-4711-80de-b979d8d438eb">12,575</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMjMtMy0xLTEtMA_5f80029c-cdaa-4279-a299-db8d92ba6916">22,017</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Cash flows from investing activities</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments for business acquisition, net of cash acquired</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMjYtMS0xLTEtMA_302b1c2d-fb17-4a49-9f16-59694c95ac3e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMjYtMy0xLTEtMA_391f116d-87af-40a8-803b-6e35651a480e">41,518</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from repayment of loans receivable &#8211; related parties</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromCollectionOfLoansReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMjctMS0xLTEtMzY5Mg_08733376-4874-43d9-ad28-91f6ab2a4716">16,500</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromCollectionOfLoansReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMjctMy0xLTEtMzY5Mg_c1d7d5a7-90b0-47ce-a025-878078e0d87e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Advances on loans receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToFundLongtermLoansToRelatedParties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMjctMS0xLTEtMA_408a5f75-9e1e-4b81-a823-e852037fa154">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToFundLongtermLoansToRelatedParties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMjctMy0xLTEtMA_64932490-2a06-4a0c-b176-f64189dedb53">6,425</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Purchases of marketable securities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMjgtMS0xLTEtMA_9153f74a-4539-436e-a51d-6588a85b454f">1,142</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMjgtMy0xLTEtMA_3f27b198-2edb-4973-8b64-99af212098a9">8</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchases of investment &#8211; equity method</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMjktMS0xLTEtMA_79f37ad1-8f19-4619-893a-68ef41c695d5">500</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMjktMy0xLTEtMA_b75afe45-8a68-4f8c-ad86-44e7fc5c6c7c">2,158</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from sale of equity method investment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMzAtMS0xLTEtMjg5OA_df64875b-01a8-4a9a-be6b-82cd710c03fa">52,743</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMzAtMy0xLTEtMjg5OA_a1913515-8846-4d0e-bc7b-736d516a1348">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Purchases of property and equipment</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMzAtMS0xLTEtMA_28f60ca0-7d33-4a53-9f33-e736963d832c">451</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMzAtMy0xLTEtMA_04472926-13b0-4db8-bdb3-a6fadb5f64ca">378</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dividend received</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMzEtMS0xLTEtMA_7a7ef576-40fe-433d-849d-a6d2a6c7bba0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMzEtMy0xLTEtMA_677b59b8-9def-4812-9ebf-111209ba11bc">240</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMzItMS0xLTEtMA_0cbb7989-d009-4077-a8b7-e6c811dd5678">67,150</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMzItMy0xLTEtMA_cfbf7577-63d6-4c55-a616-cb46f58528d6">50,247</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Cash flows from financing activities</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Repayment of bank loan and lines of credit</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="ameh:RepaymentsOfBankLoanAndLinesOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMzUtMS0xLTEtMA_fb2082a5-40e1-4057-a377-cbe90a2f89f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="ameh:RepaymentsOfBankLoanAndLinesOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMzUtMy0xLTEtMA_bda122ff-f23d-4d07-8b1e-e59ee410cb70">8,040</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Dividends paid</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDividends" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMzYtMS0xLTEtMA_4d5d9647-b22e-4f9c-aa57-630bc424d9c7">30,187</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDividends" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMzYtMy0xLTEtMA_960a0477-ceb9-4e66-9c03-c5a1a445013a">10,942</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Repayment of term loan</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMzctMS0xLTEtMA_732c2b2f-aad6-49c0-b6d7-966f4e1ee472">2,375</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMzctMy0xLTEtMA_03851c64-33da-41a8-bf92-f3b1d41d1be3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:71.792%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.739%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Payment of finance lease obligations</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMzgtMS0xLTEtMA_0df2336f-08f9-4d6a-884d-e9dc9ca167c3">61</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMzgtMy0xLTEtMA_bdbdf4a1-9260-4753-8a6c-4d4da83f9904">50</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Proceeds from the exercise of stock options and warrants</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMzktMS0xLTEtMA_30ca354c-02a0-4b2d-9d39-84f7270fdb8b">2,863</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMzktMy0xLTEtMA_3c1d6da1-da3c-4039-a159-08c89e679d4d">898</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Repurchase of shares</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNDAtMS0xLTEtMA_70165d20-4d4e-4be0-8693-ccd9d868d87a">788</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNDAtMy0xLTEtMA_9beac94f-5d15-4b75-926f-fca857cadf13">40</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Borrowings on line of credit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromLongTermLinesOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNDEtMS0xLTEtMA_cc871881-ef41-45f8-8b60-fd723f15a195">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLongTermLinesOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNDEtMy0xLTEtMA_57a1940c-c55d-437f-a3c6-db0a7faf7452">39,600</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Proceeds from common stock offering</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNDItMS0xLTEtMA_0df53bff-4900-42c3-999b-3ca5f2323d67">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNDItMy0xLTEtMA_ea2ff132-b8c5-4d05-ab15-fffb78939b92">205</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash (used in) provided by financing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNDMtMS0xLTEtMA_ca2e015e-b9d9-4357-ace2-ef0f7006f6bb">30,548</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNDMtMy0xLTEtMA_fffba940-84a3-480a-893c-f28717595303">21,631</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net increase (decrease) in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNDUtMS0xLTEtMA_7a708173-c0d4-4ea7-8331-f5e65aabe654">49,177</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNDUtMy0xLTEtMA_92d45720-dd16-4e3e-bb30-efcbbdfe5f46">50,633</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Cash, cash equivalents and restricted cash, beginning of period</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNDctMS0xLTEtMA_b288ac55-b568-41d0-9002-d5de63658f5a">104,010</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i009fc823ec144ee3b772b4396d458c88_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNDctMy0xLTEtMA_c7bacdac-9adb-4273-8988-b070fd28f05e">107,637</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Cash, cash equivalents and restricted cash, end of period</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNDktMS0xLTEtMA_b8d1a9b7-4ae6-46a5-b140-84a3bfaadbed">153,187</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2db2c0d074c34657a5d523b0ae1e5784_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNDktMy0xLTEtMA_bf53373d-faa7-400b-b040-24c3ccb044e9">57,004</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Supplementary disclosures of cash flow information:</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid for income taxes</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxesPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNTItMS0xLTEtMA_d7986e27-266d-4526-9ccf-d5b0a3ed7c7e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNTItMy0xLTEtMA_6d243534-52dc-421f-bd00-889220784990">16,700</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash paid for interest</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNTMtMS0xLTEtMA_be70c43e-9779-490c-b9bb-39ccaac57553">2,623</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNTMtMy0xLTEtMA_824990a4-b742-49e4-ab81-fdadd428a8d6">439</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Supplemental disclosures of non-cash investing and financing activities</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Dividend declared included in dividend payable</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" name="us-gaap:DividendsPayableCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNTYtMS0xLTEtMA_704549d5-1521-4cca-a0c8-387f96dea5fd">160</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2db2c0d074c34657a5d523b0ae1e5784_I20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:DividendsPayableCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNTYtMy0xLTEtMA_82486f9d-6650-4841-9748-a36c1bab2061">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax liability adjustment to goodwill</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="ameh:DeferredTaxLiabilityAdjustedToGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNTctMS0xLTEtODQx_8f3db34e-3cf4-45d1-8910-8fccd848c10f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="ameh:DeferredTaxLiabilityAdjustedToGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNTctMy0xLTEtMTMzMQ_8a7e3372-2281-44d1-952c-b6c1a6e84fd1">8,355</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Preferred shares received from sale of equity method investment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNjAtMS0xLTEtMzY4Mg_75a6b307-8791-4a16-ba30-6f5717d73132">36,179</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNjAtMy0xLTEtMzY4Mg_a13ce764-6e94-484b-8614-61b72212f1dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total amounts of cash, cash equivalents, and restricted cash shown in the consolidated statements of cash flows (in thousands):</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:71.792%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.739%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjdhYTNmMDFlNGIyZTRiYjJiNjlkZTBlNGFkY2I1NTdkL3RhYmxlcmFuZ2U6N2FhM2YwMWU0YjJlNGJiMmI2OWRlMGU0YWRjYjU1N2RfMi0xLTEtMS0w_946e0bff-00f6-4388-ab15-cb9c9071ea77">152,441</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2db2c0d074c34657a5d523b0ae1e5784_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjdhYTNmMDFlNGIyZTRiYjJiNjlkZTBlNGFkY2I1NTdkL3RhYmxlcmFuZ2U6N2FhM2YwMWU0YjJlNGJiMmI2OWRlMGU0YWRjYjU1N2RfMi0zLTEtMS0w_8ca55293-e343-4d7e-b94f-585c624d1f55">52,726</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted cash &#8211; non-current</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" name="us-gaap:RestrictedCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjdhYTNmMDFlNGIyZTRiYjJiNjlkZTBlNGFkY2I1NTdkL3RhYmxlcmFuZ2U6N2FhM2YwMWU0YjJlNGJiMmI2OWRlMGU0YWRjYjU1N2RfNC0xLTEtMS0w_0419b237-aa7b-4b9d-aba5-b0c7440ac06e">746</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2db2c0d074c34657a5d523b0ae1e5784_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjdhYTNmMDFlNGIyZTRiYjJiNjlkZTBlNGFkY2I1NTdkL3RhYmxlcmFuZ2U6N2FhM2YwMWU0YjJlNGJiMmI2OWRlMGU0YWRjYjU1N2RfNC0zLTEtMS0w_fd71779e-14fe-4e08-884a-f533dfd51d83">4,278</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash, cash equivalents, and restricted cash shown in the statement of cash flows</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjdhYTNmMDFlNGIyZTRiYjJiNjlkZTBlNGFkY2I1NTdkL3RhYmxlcmFuZ2U6N2FhM2YwMWU0YjJlNGJiMmI2OWRlMGU0YWRjYjU1N2RfNS0xLTEtMS0w_8d505800-7500-4c20-8135-5af5f7baf94c">153,187</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2db2c0d074c34657a5d523b0ae1e5784_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjdhYTNmMDFlNGIyZTRiYjJiNjlkZTBlNGFkY2I1NTdkL3RhYmxlcmFuZ2U6N2FhM2YwMWU0YjJlNGJiMmI2OWRlMGU0YWRjYjU1N2RfNS0zLTEtMS0w_4f3024d7-6633-466f-8c8c-d9d3fc39f451">57,004</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying notes are an integral part of these unaudited consolidated financial statements.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">10</span></div></div></div><div id="icc5d6783c1494a1f886c03c93e398cee_37"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">APOLLO MEDICAL HOLDINGS, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(UNAUDITED)</span></div><div id="icc5d6783c1494a1f886c03c93e398cee_40"></div><div style="text-indent:-18pt;padding-left:18pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">1.&#160;<ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfMTMzMTY_68cf7095-41ff-411a-881f-d3a84253e54b" continuedAt="ibccf62eef7be473cb481ee06660acbc2" escape="true">Description of Business</ix:nonNumeric></span></div><ix:continuation id="ibccf62eef7be473cb481ee06660acbc2" continuedAt="i8ebfc923633c4e84bc9f3feeec95e983"><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Overview</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Apollo Medical Holdings, Inc. (&#8220;ApolloMed&#8221;), together with its affiliated physician groups and consolidated entities (collectively, the &#8220;Company&#8221;) is a physician-centric integrated population health management company working to provide coordinated, outcome-based medical care in a cost-effective manner to patients in California, the majority of whom are covered by private or public insurance such as Medicare, Medicaid and health maintenance organization (&#8220;HMO&#8221;) plans, with a portion of the Company&#8217;s revenue coming from non-insured patients. The Company provides care coordination services to each major constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups and health plans. The Company&#8217;s physician network consists of primary care physicians, specialist physicians, and hospitalists. The Company operates primarily through the following subsidiaries of ApolloMed: Network Medical Management, Inc. (&#8220;NMM&#8221;), Apollo Medical Management, Inc. (&#8220;AMM&#8221;), APA ACO, Inc. ("APAACO"), Apollo Care Connect, Inc. (&#8220;Apollo Care Connect&#8221;), and their consolidated entities.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">NMM was formed in 1994 as a management service organization (&#8220;MSO&#8221;) for the purposes of providing management services to medical companies and independent practice associations (&#8220;IPAs&#8221;). The management services primarily include billing, collection, accounting, administration, quality assurance, marketing, compliance, and education. Following a business combination, NMM became a wholly-owned subsidiary of ApolloMed in December 2017. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Allied Physicians of California IPA, a Professional Medical Corporation d.b.a. Allied Pacific of California IPA (&#8220;APC&#8221;) was incorporated in 1992, for the purpose of arranging healthcare services as an IPA. APC has contracts with various HMOs and other licensed healthcare service plans as defined in the California Knox-Keene Health Care Service Plan Act of 1975. Each HMO negotiates a fixed amount per member per month (&#8220;PMPM&#8221;) that is to be paid to APC. In return, APC arranges for the delivery of healthcare services by contracting with physicians or professional medical corporations for primary care and specialty care services. APC assumes the financial risk of the cost of delivering healthcare services in excess of the fixed amounts received. Some of the risk is transferred to the contracted physicians or professional corporations. The risk is also minimized by stop-loss provisions in contracts with HMOs.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In July 1999, APC entered into an amended and restated management and administrative services agreement with NMM (the initial management services agreement was entered into in 1997) for an initial fixed term of <ix:nonNumeric contextRef="i4d3c15f58ae34e5680acaea7c6ae5cd1_D19990701-19990701" format="ixt-sec:duryear" name="ameh:InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfMjc5Mg_01364458-1894-44e2-9d23-a7b0d54f5c5b">30</ix:nonNumeric> years. In accordance with relevant accounting guidance, APC is determined to be a variable interest entity ("VIE") of the Company as NMM is the primary beneficiary with the ability to direct the activities (excluding clinical decisions) that most significantly affect APC&#8217;s economic performance through its majority representation on the APC Joint Planning Board; therefore APC is consolidated by NMM.  </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">AP-AMH Medical Corporation (&#8220;AP-AMH&#8221;) was formed in May 2019, as a designated shareholder professional corporation. Dr. Thomas Lam, a shareholder, and the Chief Executive Officer and Chief Financial Officer of APC and Co-Chief Executive Officer of ApolloMed, is the sole shareholder of AP-AMH. ApolloMed makes all the decisions on behalf of AP-AMH and funds and receives all the distributions from its operations. ApolloMed has the rights to receive benefits from the operations of AP-AMH and has the option, but not the obligation, to cover losses. Therefore, AP-AMH is controlled and consolidated by ApolloMed as the primary beneficiary of this VIE.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In September 2019, ApolloMed completed the following series of transactions with its affiliates, AP-AMH and APC;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">1.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">ApolloMed loaned AP-AMH $<ix:nonFraction unitRef="usd" contextRef="ie580169aa3e849ceb22d709b7d624f59_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesReceivableNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfMzk0Mg_f560a751-e343-4452-8b8f-2e36a3494931">545.0</ix:nonFraction> million pursuant to a <ix:nonNumeric contextRef="i1456ec083d5c410eb2ebf5f48f52fd2d_D20190901-20190930" format="ixt-sec:duryear" name="ameh:FinanceReceivableTermOfReceivable" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfMzk1OQ_5edec8c0-6f12-4205-87d3-a9b821ed403a">10</ix:nonNumeric>-year secured loan agreement (the &#8220;AP-AMH Loan&#8221;). The loan bears interest at a rate of <ix:nonFraction unitRef="number" contextRef="ie580169aa3e849ceb22d709b7d624f59_I20190930" decimals="2" name="ameh:FinanceReceivableStatedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfNDA0OA_645d48e5-80ed-404f-80ee-18d8326194f4">10</ix:nonFraction>% per annum simple interest, is not prepayable (except in certain limited circumstances), requires quarterly payments of interest only in arrears, and is secured by a first priority security interest in all of AP-AMH</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">&#8217;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">s assets, including the shares of APC Series A Preferred Stock purchased by AP-AMH, as described below. To the extent that AP-AMH is unable to make any interest payment when due because it has received dividends on the APC Series A Preferred Stock insufficient to pay in full such interest payment, then the outstanding principal amount of the loan will be increased by the amount of any such accrued but unpaid interest, and any such increased principal amounts will bear interest at the rate of <ix:nonFraction unitRef="number" contextRef="ie580169aa3e849ceb22d709b7d624f59_I20190930" decimals="4" name="ameh:FinanceReceivableModificationsSubsequentDefaultInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfNDc0OQ_b7bc8f94-b0e9-43a7-946c-b18600cae312">10.75</ix:nonFraction>% per annum simple interest.</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">2.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">AP-AMH purchased <ix:nonFraction unitRef="shares" contextRef="ia151a285a5884ae0892fe7f6a0836f46_D20190901-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfNDc5Ng_f9a1fca9-1511-47a9-bd31-3995ce22333d">1,000,000</ix:nonFraction> shares of APC Series A Preferred Stock for aggregate consideration of $<ix:nonFraction unitRef="usd" contextRef="ie580169aa3e849ceb22d709b7d624f59_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesReceivableNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfNDg2OQ_a05e5a92-f1ce-491f-b014-3fe08c9529f9">545.0</ix:nonFraction> million in a private placement. Under the terms of the APC Certificate of Determination of Preferences of Series A Preferred </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><ix:continuation id="i8ebfc923633c4e84bc9f3feeec95e983" continuedAt="i782f8d95f48f49efa17876765caab77b"><div style="padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Stock (the &#8220;Certificate of Determination&#8221;), AP-AMH is entitled to receive preferential, cumulative dividends that accrue on a daily basis and that are equal to the sum of (i) APC&#8217;s net income from healthcare services (as defined in the Certificate of Determination), plus (ii) any dividends received by APC from certain of APC&#8217;s affiliated entities, less (iii) any Retained Amounts (as defined in the Certificate of Determination).</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">3.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">APC purchased <ix:nonFraction unitRef="shares" contextRef="i15770f5ee2dc453aafa11b7b82d77e5d_D20190901-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfNTQzNQ_424fc16f-dfe0-416f-bd58-f5bd42a6d59b">15,015,015</ix:nonFraction> shares of ApolloMed&#8217;s common stock for total consideration of $<ix:nonFraction unitRef="usd" contextRef="i15770f5ee2dc453aafa11b7b82d77e5d_D20190901-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfNTUwMA_05c88208-354c-4999-9d61-357975ed4e11">300.0</ix:nonFraction> million in private placement. In connection therewith, ApolloMed granted APC certain registration rights with respect to ApolloMed&#8217;s common stock that APC purchased, and APC agreed that APC votes in excess of <ix:nonFraction unitRef="number" contextRef="i15770f5ee2dc453aafa11b7b82d77e5d_D20190901-20190930" decimals="4" name="ameh:StockIssuedDuringPeriodProxyVotesPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfNTcwNA_cf67d3ea-fdee-489f-a12e-05bef55d922f">9.99</ix:nonFraction>% of ApolloMed&#8217;s then outstanding shares will be voted by proxy given to ApolloMed&#8217;s management, and that those proxy holders will cast the excess votes in the same proportion as all other votes cast on any specific proposal coming before ApolloMed&#8217;s stockholders.</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">4.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">ApolloMed licensed to AP-AMH the right to use certain trade names for certain specified purposes for a fee equal to a percentage of the aggregate gross revenues of AP-AMH. The license fee is payable out of any Series A Preferred Stock dividends received by AP-AMH from APC.</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">5.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Through its subsidiary, NMM, the Company agreed to provide certain administrative services to AP-AMH for a fee equal to a percentage of the aggregate gross revenues of AP-AMH. The administrative fee also is payable out of any APC Series A Preferred Stock dividends received by AP-AMH from APC.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">APC's ownership in ApolloMed was <ix:nonFraction unitRef="number" contextRef="i5a7880e80374477ab2037c274813c2fd_I20200630" decimals="4" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfNjU3OA_7da44c33-8af2-479f-a2a7-78247f8249af">32.28</ix:nonFraction>% at June&#160;30, 2020 and <ix:nonFraction unitRef="number" contextRef="i8449be3fd6d243ea8e51a64ca55d07be_I20191231" decimals="4" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfNjU5MQ_2345d1a0-d9ba-428b-a6d2-cb89924493ba">32.50</ix:nonFraction>% at December&#160;31, 2019. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Concourse Diagnostic Surgery Center, LLC (&#8220;CDSC&#8221;) was formed in March&#160;2010 in the state of California. CDSC is an ambulatory surgery center in City of Industry, California organized by a group of highly qualified physicians, which utilizes some of the most advanced equipment in the eastern part of Los Angeles County and the San Gabriel Valley. The facility is Medicare certified and accredited by the Accreditation Association for Ambulatory Healthcare, Inc. As of June&#160;30, 2020, APC owned <ix:nonFraction unitRef="number" contextRef="i02112e8965954796a8e1a049bed45005_I20200630" decimals="4" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfNzEwOA_9cf95944-6f13-489e-be63-69147cdbd0a4">45.01</ix:nonFraction>% of CDSC</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">&#8217;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">s capital stock. CDSC is determined to be a VIE and APC is determined to be the primary beneficiary. APC has the ability to direct the activities that most significantly affect CDSC&#8217;s economic performance and receives the most economic benefits; therefore CDSC is consolidated by APC.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">APC-LSMA Designated Shareholder Medical Corporation (&#8220;APC-LSMA&#8221;) was formed in October&#160;2012 as a designated shareholder professional corporation. Dr. Thomas Lam, a stockholder and the Chief Executive Officer and Chief Financial Officer of APC and Co-Chief Executive Officer of ApolloMed, is a nominee shareholder of APC. APC makes all investment decisions on behalf of APC-LSMA, funds all investments and receives all distributions from the investments. APC has the obligation to absorb losses and right to receive benefits from all investments made by APC-LSMA. APC-LSMA&#8217;s sole function is to act as the nominee shareholder for APC in other California medical professional corporations. Therefore, APC-LSMA is controlled and consolidated by APC as the primary beneficiary of this VIE. The only activity of APC-LSMA is to hold the investments in medical corporations, including the IPA lines of business of LaSalle Medical Associates (&#8220;LMA&#8221;), Pacific Medical Imaging and Oncology Center, Inc. (&#8220;PMIOC&#8221;), Diagnostic Medical Group (&#8220;DMG&#8221;) and AHMC International Cancer Center, a Medical Corporation (&#8220;ICC&#8221;). APC-LSMA also holds a <ix:nonFraction unitRef="number" contextRef="i09e180bcec104dbe8bbc280162a1b502_I20200630" decimals="INF" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfODUzMw_07a54916-f608-4c61-87b2-e311ac5165ad">100</ix:nonFraction>% ownership interest in Maverick Medical Group, Inc. (&#8220;MMG&#8221;), Alpha Care Medical Group, Inc. (&#8220;Alpha Care&#8221;), Accountable Health Care IPA, a Professional Medical Corporation (&#8220;Accountable Health Care&#8221;), and AMG, a Professional Medical Corporation (&#8220;AMG&#8221;).</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Alpha Care, an IPA acquired by the Company in May 2019, has been operating in California since 1993 as a risk bearing organization engaged in providing professional services under capitation arrangements with its contracted health plans through a provider network consisting of primary care and specialty care physicians. Alpha Care specializes in delivering high-quality healthcare to approximately <ix:nonFraction unitRef="enrollee" contextRef="i1291ccf07b4747d5a674402448bcc8b7_I20200630" decimals="-3" format="ixt:numdotdecimal" name="ameh:NumberOfEnrollees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfOTE4MA_edcd2b4e-880b-4079-b211-55884b453e2e">170,000</ix:nonFraction> enrollees, as of June&#160;30, 2020, and focuses on Medi-Cal/Medicaid, Commercial, and Medicare and Dual Eligible members in the Riverside and San Bernardino counties of Southern California.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accountable Health Care is a California-based IPA that has served the local community in the greater Los Angeles County area through a network of physicians and health care providers for more than 20 years. Accountable Health Care currently has a network of over <ix:nonFraction unitRef="primary_care_physician" contextRef="if0f1246eac284240868626e2943e4052_I20200630" decimals="INF" name="ameh:NumberOfEmployees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfOTYyMA_471bbc90-4af5-4265-bb2b-894803beeb02">400</ix:nonFraction> primary care physicians and <ix:nonFraction unitRef="specialty_care_physician" contextRef="if0f1246eac284240868626e2943e4052_I20200630" decimals="INF" name="ameh:NumberOfEmployees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfOTY1MQ_73c03f5f-3e9a-48c3-8cfd-610b135a9db7">700</ix:nonFraction> specialty care physicians, and <ix:nonFraction unitRef="medical_center" contextRef="if0f1246eac284240868626e2943e4052_I20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfStores" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfOTY4NQ_5c7f75da-93b0-46df-8476-ae4cc0cad1db">four</ix:nonFraction> community and regional hospital medical centers that provide quality health care services to approximately <ix:nonFraction unitRef="member" contextRef="if0f1246eac284240868626e2943e4052_I20200630" decimals="-3" format="ixt:numdotdecimal" name="ameh:NumberOfMembersOfFederallyQualifiedHealthPlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfOTc5MQ_eda093cc-32bd-4c09-b879-1e9a1e21fccf">80,000</ix:nonFraction> members of <ix:nonFraction unitRef="plan" contextRef="if0f1246eac284240868626e2943e4052_I20200630" decimals="INF" format="ixt-sec:numwordsen" name="ameh:NumberOfFederallyQualifiedHealthPlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfOTgwNQ_d7e16a6d-1f1b-4b3c-8b96-022afeb2b22e">three</ix:nonFraction> federally qualified health plans and multiple product lines, including Medi-Cal, Commercial, Medicare and the California Healthy Families program. In August 2019, APC and APC-LSMA acquired the remaining outstanding shares of Accountable Health Care&#8217;s capital stock that they did not already own (comprising <ix:nonFraction unitRef="number" contextRef="ib00db7be80b34cfaa597d79cb3128aff_I20190830" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfMTAxMTY_7778e2f8-5bb6-43dc-bccf-c28f609caf45">75</ix:nonFraction>%) for&#160;$<ix:nonFraction unitRef="usd" contextRef="i26cbf8fca0d84265be9879b3b17db702_D20190830-20190830" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfMTAxMjQ_5fce0098-5058-4e58-9db4-cee3d9b5e35b">7.3</ix:nonFraction> million&#160;in cash (see Note 3).</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">AMG is a network of family practice clinics operating out of <ix:nonFraction unitRef="clinic" contextRef="if5945e9c877b4ccea72cbc601bc3a9b6_I20200630" decimals="INF" format="ixt-sec:numwordsen" name="ameh:NumberOfFamilyPracticeClinics" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfMTAyMTA_acbfc486-f958-4d0d-bc5a-59a074f446f9">three</ix:nonFraction> main locations in Southern California. AMG provides professional and post-acute care services to Medicare, Medi-Cal/Medicaid, and Commercial patients through its network of </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><ix:continuation id="i782f8d95f48f49efa17876765caab77b"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">doctors and nurse practitioners. In September 2019, APC-LSMA purchased <ix:nonFraction unitRef="number" contextRef="ia9f8aa30820f40aaa284eb4906fe92a2_I20190930" decimals="INF" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfMTA0NTc_4ddf2a15-ba22-49d8-b8de-dc1268302e2a">100</ix:nonFraction>% of the shares of capital stock of AMG for $<ix:nonFraction unitRef="usd" contextRef="i11b99b377a6a43aa865ba7d01fecd1e5_D20190901-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfMTA1MDI_6725d1c5-acd9-4212-9c56-53a30b142125">1.2</ix:nonFraction> million in cash and $<ix:nonFraction unitRef="usd" contextRef="if3e410ddfdb74a3daeb61a44c92264d8_D20190901-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfMTA1MTc_bc539e34-d49a-401f-bf2d-e29a9d6d2732">0.4</ix:nonFraction> million of APC common stock (see Note 3).</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Universal Care Acquisition Partners, LLC (&#8220;UCAP&#8221;), a <ix:nonFraction unitRef="number" contextRef="i5d896ebc98ae47969367089670863233_I20140630" decimals="INF" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfMTA2MDc_156852b2-2504-484f-bad2-78d3b8f54a72">100</ix:nonFraction>% owned subsidiary of APC, was formed in June&#160;2014, for the purpose of holding an investment in Universal Care, Inc. (&#8220;UCI&#8221;). On April 30, 2020, UCAP completed the sale of its <ix:nonFraction unitRef="number" contextRef="ic4fe11ff13bc463aa7c7d46c9968606e_I20200430" decimals="3" name="ameh:EquityMethodInvestmentOwnershipPercentageDisposed" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfMTA3OTE_87cf25c4-edc9-48de-ada1-ce761de1a085">48.9</ix:nonFraction>% ownership interest in UCI to Bright Health Company of California, Inc. ("Bright") for approximately $<ix:nonFraction unitRef="usd" contextRef="i4a23351d6549453987064b1ed4ccd7a5_D20200430-20200430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfMTA4OTQ_048b7b12-6af2-46a6-9cf4-2256e523f3c0">69.2</ix:nonFraction> million in cash proceeds (including $<ix:nonFraction unitRef="usd" contextRef="i4a23351d6549453987064b1ed4ccd7a5_D20200430-20200430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRepaymentsOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfMTA5MjU_ec9be68b-d815-463a-b35c-090a13d742a6">16.5</ix:nonFraction> million as repayment of indebtedness owed to APC), plus non-cash consideration consisting of shares of Bright Health, Inc.'s preferred stock having an estimated fair value of approximately $<ix:nonFraction unitRef="usd" contextRef="icbe089761e214533973bb396d097bec6_D20200430-20200430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfMTExOTk_7c75d161-1bf5-4c34-8d68-1671e05e18aa">36.2</ix:nonFraction> million on the date of sale. In addition, pursuant to the terms of the stock purchase agreement, APC has a beneficial interest in the equity method investment sold. The estimated fair value of such interest on April 30, 2020 was&#160;$<ix:nonFraction unitRef="usd" contextRef="i9c07037f02c24f758bbadde10f2a6d6b_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="ameh:AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfMTE0ODA_9dba054a-58c2-469e-a92e-4de5641d3f05">15.7</ix:nonFraction> million (see Note 5). As set forth in the Company&#8217;s definitive proxy statement filed with the SEC on July 31, 2019 (the &#8220;Proxy Statement&#8221;), the <ix:nonFraction unitRef="number" contextRef="ic4fe11ff13bc463aa7c7d46c9968606e_I20200430" decimals="3" name="ameh:EquityMethodInvestmentOwnershipPercentageDisposed" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfMTE3NjI_611f4642-2294-4a7a-a17a-c167e059c485">48.9</ix:nonFraction>% interest in UCI is an &#8220;Excluded Asset&#8221; that remains solely for the benefit of APC and its shareholders. As such, any proceeds or gain on the sale of APC&#8217;s indirect ownership interest in UCI has no impact on the Series A Dividend payable by APC to AP-AMH Medical Corporation as described in the Proxy Statement and consequently the sale did not affect net income attributable to ApolloMed.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">APAACO, jointly owned by NMM and AMM, began participating in the Next Generation Accountable Care Organization (&#8220;NGACO") Model of the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) in January 2017. The NGACO Model is a CMS program that allows provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participating in this new attribution-based risk sharing model. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">AMM, a wholly-owned subsidiary of ApolloMed, manages affiliated medical groups, ApolloMed Hospitalists, a Medical Corporation (&#8220;AMH&#8221;) and Southern California Heart Centers, a Medical Corporation (&#8220;SCHC&#8221;). AMH provides hospitalist, intensivist, and physician advisory services. SCHC is a specialty clinic that focuses on cardiac care and diagnostic testing. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Apollo Care Connect, Inc. ("Apollo Care Connect"), a wholly-owned subsidiary of ApolloMed, provides a cloud and mobile-based population health management platform that includes digital care plans, a case management module, connectivity with multiple healthcare tracking devices and the ability to integrate with multiple electronic health records to capture clinical data.</span></div></ix:continuation><div id="icc5d6783c1494a1f886c03c93e398cee_43"></div><div style="text-indent:-18pt;padding-left:18pt;margin-top:10pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:18pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">2.&#160;<ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMTI2NDQzODM3Njg0MzM_0d699ecb-380e-4006-bc28-657a0b9b8f45" continuedAt="if69b7eacddb442e9a9179750add613ca" escape="true">Basis of Presentation and Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="if69b7eacddb442e9a9179750add613ca" continuedAt="i803106b4a6144f4e838ef406fe67bb85"><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDg5MDA_c34e3db4-f6e4-4472-b6fe-523d53b2fb94" continuedAt="i7013a86768034726b29e76661780a60d" escape="true">Basis of Presentation</ix:nonNumeric></span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i7013a86768034726b29e76661780a60d">The accompanying consolidated balance sheets at December&#160;31, 2019, has been derived from the Company&#8217;s audited consolidated financial statements, but does not include all disclosures required by generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;). The accompanying unaudited consolidated financial statements as of June&#160;30, 2020, and for the three and six months ended June&#160;30, 2020 and 2019, have been prepared in accordance with U.S. GAAP for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements, and should be read in conjunction with the audited consolidated financial statements and related notes to the financial statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2019 as filed with the SEC on March 16, 2020. In the opinion of management, all material adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been made to make the consolidated financial statements not misleading as required by Regulation S-X, Rule 10-01.</ix:continuation> Operating results for the three and six months ended June&#160;30, 2020, are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2020, or any future periods.</span></div><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDg4ODQ_2d6c2f51-b9cf-40ea-adf1-3951d7943542" escape="true"><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Principles of Consolidation</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The consolidated balance sheets as of June&#160;30, 2020 and December&#160;31, 2019, and the consolidated statements of income for the three and six months ended June&#160;30, 2020 and 2019, &#160;include the accounts of ApolloMed, its consolidated subsidiaries, NMM, AMM, APAACO, and Apollo Care Connect, its consolidated VIE, AP-AMH, NMM's consolidated subsidiaries, and consolidated VIE, APC, APC&#8217;s subsidiary, UCAP, and APC&#8217;s consolidated VIEs, CDSC, APC-LSMA, ICC, and APC-LSMA&#8217;s consolidated subsidiaries Alpha Care and Accountable Health Care.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">All material intercompany balances and transactions have been eliminated in consolidation.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify;margin-top:10pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><ix:continuation id="i803106b4a6144f4e838ef406fe67bb85" continuedAt="ie434bb7912ed4e6abe4783950b3ea646"><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDg4NzE_61729d7c-7832-4fff-90c5-8ce4bfe0b4d4" escape="true"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of the consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.&#160;Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combination and goodwill valuation and impairment, accrual of medical liabilities (incurred, but not reported (&#8220;IBNR&#8221;) claims), determination of full-risk and shared-risk revenue and receivables (including constraints and completion factors, including historical medical loss ratios (&#8220;MLR&#8221;)), income taxes, valuation of share-based compensation and right-of-use ("ROU") assets and lease liabilities. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDg4OTI_27a6c3a5-3bc9-43e0-943e-f598dd26e0d6" escape="true"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Reportable Segments</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company operates as <ix:nonFraction unitRef="segment" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMzQzMA_671aedb3-5086-4b8a-ae64-682c13581997">one</ix:nonFraction> reportable segment, the healthcare delivery segment, and implements and operates innovative health care models to create a patient-centered, physician-centric experience. The Company reports its consolidated financial statements in the aggregate, including all activities in <ix:nonFraction unitRef="segment" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMzcwOA_b59621d3-65bd-4c20-899e-b28025193a76">one</ix:nonFraction> reportable segment.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDg4NDE_86df3749-0f31-4318-9d84-0dbcaeaebc7b" continuedAt="i9818d0bdf4904684a3b63c4ac6b80799" escape="true"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash and Cash Equivalents</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s cash and cash equivalents primarily consist of money market funds and certificates of deposit. The Company considers all highly liquid investments that are both readily convertible into known amounts of cash and mature within 90 days from their date of purchase to be cash equivalents.</span></div></ix:nonNumeric><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i9818d0bdf4904684a3b63c4ac6b80799">The Company maintains its cash in deposit accounts with several banks, which at times may&#160;exceed the insured limits of the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;). The Company believes it is not exposed to any significant credit risk with respect to its cash, cash equivalents and restricted cash.</ix:continuation> As of June&#160;30, 2020, the Company&#8217;s deposit accounts with banks exceeded the FDIC&#8217;s insured limit by approximately $<ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashUninsuredAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDc0Mg_30bcac89-fe83-429f-bff3-46a7f1c05546">290.9</ix:nonFraction> million, including approximately $<ix:nonFraction unitRef="usd" contextRef="ib671a237f06845ccacc1a406f5790edd_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDc3MA_b531b04b-bacf-40b7-850f-712429eec60a">117.6</ix:nonFraction> million in certificates of deposit that were recognized as investments in marketable securities. The Company has not experienced any losses to date and performs ongoing evaluations of these financial institutions to limit the Company&#8217;s concentration of risk exposure.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDg4Nzg_c3aa5b80-5dea-4e04-9716-0edeb1b41fb5" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Restricted Cash</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Restricted cash consists of cash held as collateral to secure standby letters of credits as required by certain contracts.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="us-gaap:MarketableSecuritiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDg4NjU_587a7520-a802-458f-bab5-84dda6b4b134" escape="true"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Investments in Marketable Securities</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The appropriate classification of investments is determined at the time of purchase and such designation is reevaluated at each balance sheet date. As of June&#160;30, 2020 and December&#160;31, 2019, investments in marketable securities amounted to approximately $<ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNTQ0MA_c541c4cc-91b4-4403-b34f-31a10589a35f">117.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNTQ0Nw_8fb01d40-bb97-4fbf-aa27-f404e237424e">116.5</ix:nonFraction> million, respectively, and consisted of equity securities and certificates of deposit with various financial institutions, reported at par value, plus accrued interest, with maturity dates from <ix:nonNumeric contextRef="i6dab3a2b4fba451e82b3256455eeec2b_D20200101-20200630" format="ixt-sec:durwordsen" name="ameh:MarketableSecuritiesCurrentMaturityPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMTA5OTUxMTY4NDgxMA_b473a9c4-9b15-4b68-b3de-a5ab5efebe63">four months</ix:nonNumeric> to <ix:nonNumeric contextRef="ibcd3d205d526423cbea49810dc2340a8_D20200101-20200630" format="ixt-sec:durmonth" name="ameh:MarketableSecuritiesCurrentMaturityPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMTA5OTUxMTY4NDgxMQ_6b9814d2-8bb5-404f-ad89-d810006d98a4">24</ix:nonNumeric> months (see fair value measurements of financial instruments below). Investments in certificates of deposits are classified as Level 1 investments in the fair value hierarchy.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="ameh:ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDg5MTk_996c8d9d-039a-4a00-88a8-a48eefdbcee2" continuedAt="i5b696dd6243343729ad8f4a3e54d2cf7" escape="true"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Receivables and Receivables &#8211; Related Parties</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s receivables are comprised of accounts receivable, capitation and claims receivable, risk pool settlements and incentive receivables, management fee income and other receivables. Accounts receivable are recorded and stated at the amount expected to be collected.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s receivables &#8211; related parties are comprised of risk pool settlements, management fee income and incentive receivables, and other receivables. Receivables &#8211; related parties are recorded and stated at the amount expected to be collected.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Capitation and claims receivable relate to each health plan&#8217;s capitation and is received by the Company in the month following the month of service. Risk pool settlements and incentive receivables mainly consist of the Company&#8217;s full risk pool receivable that is recorded quarterly based on reports received from the Company&#8217;s hospital partners and management&#8217;s estimate of the Company&#8217;s portion of the estimated risk pool surplus for open performance years. Settlement of risk pool surplus or deficits occurs approximately <ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" format="ixt-sec:durmonth" name="ameh:RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNjkxNQ_09d7a3dc-514d-4bb2-a8e8-ecdb9f15503c">18</ix:nonNumeric> months after the risk pool performance year is completed. Other receivables consists of recoverable claims paid related to the 2019 APAACO performance year to be administered following instructions from CMS, fee-for-</span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><ix:continuation id="ie434bb7912ed4e6abe4783950b3ea646" continuedAt="i2b1cfcf53bee44daa962748faa6408ac"><ix:continuation id="i5b696dd6243343729ad8f4a3e54d2cf7" continuedAt="i1d91577c5cd5456ca9ba0e71df2a20ee"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">services (&#8220;FFS&#8221;) reimbursement for patient care, certain expense reimbursements, transportation reimbursements from the hospitals, and stop loss insurance premium reimbursements.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company maintains reserves for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends and changes in customer payment patterns to evaluate the adequacy of these reserves. The Company also regularly analyzes the ultimate collectability of accounts receivable after certain stages of the collection cycle using a look-back analysis to determine the amount of receivables subsequently collected and adjustments are recorded when necessary. Reserves are recorded primarily on a specific identification basis.</span></div></ix:continuation><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i1d91577c5cd5456ca9ba0e71df2a20ee">Receivables are recorded when the Company is able to determine amounts receivable under applicable contracts and agreements based on information provided and collection is reasonably likely to occur. In regards to the credit loss standard, the Company continuously monitors its collections of receivables and our expectation is that the historical credit loss experienced across our receivable portfolio is materially similar to any current expected credit losses that would be estimated under the current expected credit losses (CECL) model. As of June 30, 2020 and December 31, 2019 the Company had</ix:continuation> $<ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMTY0OTI2NzQ5ODkwNA_87c5f388-283f-492a-94f8-17fed5ce1363">1.3</ix:nonFraction>&#160;million and  $<ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMTA5OTUxMTYzMzQ3OTc_9a788a73-9c49-4938-a85a-96b6e83c6070">2.9</ix:nonFraction>&#160;million of allowance for doubtful accounts, respectively. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDg4ODk_ab80f52c-fb2e-4014-9794-3840ce8b05ce" continuedAt="i0f9e939f0cbf4ba0bda4e5ea352ffb0f" escape="true">Concentrations of Risks</ix:nonNumeric></span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i0f9e939f0cbf4ba0bda4e5ea352ffb0f">The Company disaggregates revenue from contracts by service type and payor type. This level of detail provides useful information pertaining to how the Company generates revenue by significant revenue stream and by type of direct contracts. The consolidated statements of income present disaggregated revenue by service type.</ix:continuation> <ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDg4NTI_e3bd7759-8f94-47c5-80cf-2c5755466d55" continuedAt="ic19c4755cb0d4c22bdaefbd1af0668c3" escape="true">The following table presents disaggregated revenue generated by payor type for the three and six months ended June&#160;30, 2020 and 2019 (in thousands):</ix:nonNumeric></span></div><ix:continuation id="ic19c4755cb0d4c22bdaefbd1af0668c3"><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:71.792%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.739%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Commercial</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0dd8dccc65a74133a54656bd7c8b4677_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjllNmE4YWQ0NjRlMDRlYzRhYTc1MTkyNTc4YWEzNjQwL3RhYmxlcmFuZ2U6OWU2YThhZDQ2NGUwNGVjNGFhNzUxOTI1NzhhYTM2NDBfMy0xLTEtMS0w_4996f3fb-f909-48cc-a168-7716827e019d">25,479</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2a042bfad69542c1b01c261138a48a66_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjllNmE4YWQ0NjRlMDRlYzRhYTc1MTkyNTc4YWEzNjQwL3RhYmxlcmFuZ2U6OWU2YThhZDQ2NGUwNGVjNGFhNzUxOTI1NzhhYTM2NDBfMy0zLTEtMS0w_ac2b3830-56c5-4ed2-a235-bc7b605d4204">25,365</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Medicare</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i29b931e0f69a45658584dcdb33cccae8_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjllNmE4YWQ0NjRlMDRlYzRhYTc1MTkyNTc4YWEzNjQwL3RhYmxlcmFuZ2U6OWU2YThhZDQ2NGUwNGVjNGFhNzUxOTI1NzhhYTM2NDBfNC0xLTEtMS0w_3c4cd76f-f729-4b9c-8a4b-47d57019abb5">62,038</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5e9ac126c4447a892ae9c1c466ce045_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjllNmE4YWQ0NjRlMDRlYzRhYTc1MTkyNTc4YWEzNjQwL3RhYmxlcmFuZ2U6OWU2YThhZDQ2NGUwNGVjNGFhNzUxOTI1NzhhYTM2NDBfNC0zLTEtMS0w_b8c439bf-0fad-4aa8-8943-818968d0f5e5">57,965</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Medicaid</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf70769b3ae24d8bbf5cea51b1569ce3_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjllNmE4YWQ0NjRlMDRlYzRhYTc1MTkyNTc4YWEzNjQwL3RhYmxlcmFuZ2U6OWU2YThhZDQ2NGUwNGVjNGFhNzUxOTI1NzhhYTM2NDBfNS0xLTEtMS0w_3de50eab-2702-46e6-b92f-4bce52f8555c">68,450</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a6065f0bcd44f40b22cc3dee9debebc_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjllNmE4YWQ0NjRlMDRlYzRhYTc1MTkyNTc4YWEzNjQwL3RhYmxlcmFuZ2U6OWU2YThhZDQ2NGUwNGVjNGFhNzUxOTI1NzhhYTM2NDBfNS0zLTEtMS0w_1c4e35c9-e248-455a-882a-cb68de9e8acf">36,277</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other third parties</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9d46920109e94a34afa570bab6edc321_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjllNmE4YWQ0NjRlMDRlYzRhYTc1MTkyNTc4YWEzNjQwL3RhYmxlcmFuZ2U6OWU2YThhZDQ2NGUwNGVjNGFhNzUxOTI1NzhhYTM2NDBfNi0xLTEtMS0w_a4f0a64b-e543-4d3b-8d38-3cf739cc376b">9,202</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifd7a28bbb9224f319f70f1a38371eb43_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjllNmE4YWQ0NjRlMDRlYzRhYTc1MTkyNTc4YWEzNjQwL3RhYmxlcmFuZ2U6OWU2YThhZDQ2NGUwNGVjNGFhNzUxOTI1NzhhYTM2NDBfNi0zLTEtMS0w_af653245-ce05-4b9c-9290-4dd00cb49440">10,443</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenue</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjllNmE4YWQ0NjRlMDRlYzRhYTc1MTkyNTc4YWEzNjQwL3RhYmxlcmFuZ2U6OWU2YThhZDQ2NGUwNGVjNGFhNzUxOTI1NzhhYTM2NDBfNy0xLTEtMS0w_3f3f4321-e66c-473d-a4e9-7520fa01d50d">165,169</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjllNmE4YWQ0NjRlMDRlYzRhYTc1MTkyNTc4YWEzNjQwL3RhYmxlcmFuZ2U6OWU2YThhZDQ2NGUwNGVjNGFhNzUxOTI1NzhhYTM2NDBfNy0zLTEtMS0w_ea75a4aa-bc13-45d5-beb7-2b759ff973f6">130,050</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:71.792%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.739%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Commercial</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i512f416ef63d4ba3abe4a36d380da0b0_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOmNmZDExMmJmZDc2MzQ3NGY4MmY0N2JiMTEzNDJhM2M2L3RhYmxlcmFuZ2U6Y2ZkMTEyYmZkNzYzNDc0ZjgyZjQ3YmIxMTM0MmEzYzZfMy0xLTEtMS0w_6875cbcc-1cc3-4d5f-b557-ffc0c88e583a">50,192</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iddb4dfed860740f3a71ee2c530ce3733_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOmNmZDExMmJmZDc2MzQ3NGY4MmY0N2JiMTEzNDJhM2M2L3RhYmxlcmFuZ2U6Y2ZkMTEyYmZkNzYzNDc0ZjgyZjQ3YmIxMTM0MmEzYzZfMy0zLTEtMS0w_d5745076-fa54-4a1b-b46e-c0cf9764b963">50,383</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Medicare</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4ecfacaa79e54b258148a979b14f66f4_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOmNmZDExMmJmZDc2MzQ3NGY4MmY0N2JiMTEzNDJhM2M2L3RhYmxlcmFuZ2U6Y2ZkMTEyYmZkNzYzNDc0ZjgyZjQ3YmIxMTM0MmEzYzZfNC0xLTEtMS0w_08cc88ed-f9e8-41ee-b410-6517baf84496">126,918</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i947f9298713445cea034b7b41f37b6b7_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOmNmZDExMmJmZDc2MzQ3NGY4MmY0N2JiMTEzNDJhM2M2L3RhYmxlcmFuZ2U6Y2ZkMTEyYmZkNzYzNDc0ZjgyZjQ3YmIxMTM0MmEzYzZfNC0zLTEtMS0w_5e5f025c-8df6-40b1-a89b-6dacca0be508">95,063</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Medicaid</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7ff9e8dbf4b24be7b22e1054c2cdb0fa_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOmNmZDExMmJmZDc2MzQ3NGY4MmY0N2JiMTEzNDJhM2M2L3RhYmxlcmFuZ2U6Y2ZkMTEyYmZkNzYzNDc0ZjgyZjQ3YmIxMTM0MmEzYzZfNS0xLTEtMS0w_809e0c8f-39df-4770-8b1d-e2597be45093">134,897</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i04580df691394c6fb1c265641dc8e4fa_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOmNmZDExMmJmZDc2MzQ3NGY4MmY0N2JiMTEzNDJhM2M2L3RhYmxlcmFuZ2U6Y2ZkMTEyYmZkNzYzNDc0ZjgyZjQ3YmIxMTM0MmEzYzZfNS0zLTEtMS0w_d78a3128-1b13-4972-ad12-d23bb938ecd1">61,647</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other third parties</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib2fca4eb23c541db83ecd5805b54ba56_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOmNmZDExMmJmZDc2MzQ3NGY4MmY0N2JiMTEzNDJhM2M2L3RhYmxlcmFuZ2U6Y2ZkMTEyYmZkNzYzNDc0ZjgyZjQ3YmIxMTM0MmEzYzZfNi0xLTEtMS0w_b7498d55-883d-459a-ad6e-10b34965daeb">18,267</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9b8d4a587e3e4ac684b3f6a5d7d7ffed_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOmNmZDExMmJmZDc2MzQ3NGY4MmY0N2JiMTEzNDJhM2M2L3RhYmxlcmFuZ2U6Y2ZkMTEyYmZkNzYzNDc0ZjgyZjQ3YmIxMTM0MmEzYzZfNi0zLTEtMS0w_0801c54a-489d-44ea-8b52-3403171b0a6c">18,713</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenue</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOmNmZDExMmJmZDc2MzQ3NGY4MmY0N2JiMTEzNDJhM2M2L3RhYmxlcmFuZ2U6Y2ZkMTEyYmZkNzYzNDc0ZjgyZjQ3YmIxMTM0MmEzYzZfNy0xLTEtMS0w_e862c3e9-9171-48b3-a42f-12962403536f">330,274</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOmNmZDExMmJmZDc2MzQ3NGY4MmY0N2JiMTEzNDJhM2M2L3RhYmxlcmFuZ2U6Y2ZkMTEyYmZkNzYzNDc0ZjgyZjQ3YmIxMTM0MmEzYzZfNy0zLTEtMS0w_f093188b-e25a-43dc-807e-997cdd13d111">225,806</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:continuation><div><span><br/></span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDg4OTQ_024647b2-849a-45f1-8701-5a23688cabe8" continuedAt="i6fd16c95d70544a691290ade0d65d756" escape="true">The Company had major payors that contributed the following percentages of net revenue:</ix:nonNumeric></span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><ix:continuation id="i2b1cfcf53bee44daa962748faa6408ac" continuedAt="ib2486e6bfac643b99a16b5b47be4922b"><ix:continuation id="i6fd16c95d70544a691290ade0d65d756"><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:71.792%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.739%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Payor A</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i66d29491233d435a9781fc3960674175_D20200401-20200630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjg3NTFlMDhkNmQ3NTQzZDNhZTExNWNjZmZmNjRhZDQ0L3RhYmxlcmFuZ2U6ODc1MWUwOGQ2ZDc1NDNkM2FlMTE1Y2NmZmY2NGFkNDRfMy0xLTEtMS0w_3da85f2e-a7f8-4c91-9f55-c062b2d9810e">11.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i8fea9adc9dbd4dfcb6c28fcec10b58ca_D20190401-20190630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjg3NTFlMDhkNmQ3NTQzZDNhZTExNWNjZmZmNjRhZDQ0L3RhYmxlcmFuZ2U6ODc1MWUwOGQ2ZDc1NDNkM2FlMTE1Y2NmZmY2NGFkNDRfMy0zLTEtMS0w_fe95cf88-d482-4694-9d48-9fec1917b0d1">13.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Payor B</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="iba2f1722e182406485b06e7780640a59_D20200401-20200630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjg3NTFlMDhkNmQ3NTQzZDNhZTExNWNjZmZmNjRhZDQ0L3RhYmxlcmFuZ2U6ODc1MWUwOGQ2ZDc1NDNkM2FlMTE1Y2NmZmY2NGFkNDRfNC0xLTEtMS0w_81b436e8-e6d6-46a8-9488-24f8ae185dae">10.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i92d5ad54dc7b46a692cb712060a47f6f_D20190401-20190630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjg3NTFlMDhkNmQ3NTQzZDNhZTExNWNjZmZmNjRhZDQ0L3RhYmxlcmFuZ2U6ODc1MWUwOGQ2ZDc1NDNkM2FlMTE1Y2NmZmY2NGFkNDRfNC0zLTEtMS0w_eb5c1c28-80f3-4f14-a33f-5c38a11ab6ad">12.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Payor C</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i100279b65cca403299b145ef5c501434_D20190401-20190630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjg3NTFlMDhkNmQ3NTQzZDNhZTExNWNjZmZmNjRhZDQ0L3RhYmxlcmFuZ2U6ODc1MWUwOGQ2ZDc1NDNkM2FlMTE1Y2NmZmY2NGFkNDRfNS0zLTEtMS0w_7034c7d1-93a0-4f69-9fe3-74de5a2fe884">10.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Payor D</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i46aa5cd04c64411ca7afff2e510cebe6_D20200401-20200630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjg3NTFlMDhkNmQ3NTQzZDNhZTExNWNjZmZmNjRhZDQ0L3RhYmxlcmFuZ2U6ODc1MWUwOGQ2ZDc1NDNkM2FlMTE1Y2NmZmY2NGFkNDRfNi0xLTEtMS0w_409656d7-0e7c-45c9-9852-7b41ddc9dbc1">17.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i36fac0be4bce47a8a6f1debf5fb86518_D20190401-20190630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjg3NTFlMDhkNmQ3NTQzZDNhZTExNWNjZmZmNjRhZDQ0L3RhYmxlcmFuZ2U6ODc1MWUwOGQ2ZDc1NDNkM2FlMTE1Y2NmZmY2NGFkNDRfNi0zLTEtMS0w_14e17950-d3dd-418c-b6d7-89020a43919d">13.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Payor E</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i8c897dd4206d414da215cddbc7679657_D20200401-20200630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjg3NTFlMDhkNmQ3NTQzZDNhZTExNWNjZmZmNjRhZDQ0L3RhYmxlcmFuZ2U6ODc1MWUwOGQ2ZDc1NDNkM2FlMTE1Y2NmZmY2NGFkNDRfNy0xLTEtMS0w_c034b211-f649-4ef7-9b3b-2d5925a69b3f">12.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payor F</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="icf6775dc61fe4ce084d261017e9ef958_D20200401-20200630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjg3NTFlMDhkNmQ3NTQzZDNhZTExNWNjZmZmNjRhZDQ0L3RhYmxlcmFuZ2U6ODc1MWUwOGQ2ZDc1NDNkM2FlMTE1Y2NmZmY2NGFkNDRfOC0xLTEtMS0zNjUw_32afc7d2-3dbb-437b-8421-0a9303d68916">10.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td></tr></table></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:71.792%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.739%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Payor A</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ibbe89b583f4b4cac886b6bd1886fc66b_D20200101-20200630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjI3YmEyZThiMWQ5YzRkNDBiYmExMGQxNDVhZDU2NmI3L3RhYmxlcmFuZ2U6MjdiYTJlOGIxZDljNGQ0MGJiYTEwZDE0NWFkNTY2YjdfMy0xLTEtMS0xNjYy_9b7ede9e-f672-439b-bb71-a47ba9e674c5">11.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="icc08a7c3b8514351988c046d7326f98b_D20190101-20190630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjI3YmEyZThiMWQ5YzRkNDBiYmExMGQxNDVhZDU2NmI3L3RhYmxlcmFuZ2U6MjdiYTJlOGIxZDljNGQ0MGJiYTEwZDE0NWFkNTY2YjdfMy0zLTEtMS0w_123209c5-eb68-4517-ac8b-399ec440f578">15.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Payor B</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="iea3de6234363414c85c4cadd8273d9a4_D20200101-20200630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjI3YmEyZThiMWQ5YzRkNDBiYmExMGQxNDVhZDU2NmI3L3RhYmxlcmFuZ2U6MjdiYTJlOGIxZDljNGQ0MGJiYTEwZDE0NWFkNTY2YjdfNC0xLTEtMS0xNjYy_a488ba3a-bb69-4436-a090-55a285bfcdcb">10.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i5fc422ddf26946f9b6595157d37a7e4d_D20190101-20190630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjI3YmEyZThiMWQ5YzRkNDBiYmExMGQxNDVhZDU2NmI3L3RhYmxlcmFuZ2U6MjdiYTJlOGIxZDljNGQ0MGJiYTEwZDE0NWFkNTY2YjdfNC0zLTEtMS0w_7e902dda-027b-4256-a602-c93e15b573a2">14.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Payor C</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ia98e92f83fb948a4a5b27c9b21933f87_D20190101-20190630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjI3YmEyZThiMWQ5YzRkNDBiYmExMGQxNDVhZDU2NmI3L3RhYmxlcmFuZ2U6MjdiYTJlOGIxZDljNGQ0MGJiYTEwZDE0NWFkNTY2YjdfNS0zLTEtMS0w_c7cf1fea-926e-4663-8e40-70e7696af7bb">11.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Payor D</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i7ad5e28b46a94718807f8ff7283fa384_D20200101-20200630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjI3YmEyZThiMWQ5YzRkNDBiYmExMGQxNDVhZDU2NmI3L3RhYmxlcmFuZ2U6MjdiYTJlOGIxZDljNGQ0MGJiYTEwZDE0NWFkNTY2YjdfNi0xLTEtMS0xNjYy_30e7c5de-9a7f-4d91-a7fc-507d89abbbc9">17.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Payor E</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="id916e080e86746bb89c3cd06f5f75ae6_D20200101-20200630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjI3YmEyZThiMWQ5YzRkNDBiYmExMGQxNDVhZDU2NmI3L3RhYmxlcmFuZ2U6MjdiYTJlOGIxZDljNGQ0MGJiYTEwZDE0NWFkNTY2YjdfNy0xLTEtMS0xNjYy_347a4a62-c847-4a21-84c1-12cc6f52b5ac">12.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payor F</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i71e3a0e877e1403587f03dd1d16e1041_D20200101-20200630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjI3YmEyZThiMWQ5YzRkNDBiYmExMGQxNDVhZDU2NmI3L3RhYmxlcmFuZ2U6MjdiYTJlOGIxZDljNGQ0MGJiYTEwZDE0NWFkNTY2YjdfOC0xLTEtMS0zNjYx_588a119d-6edf-4a72-a7d0-55e99478a0cc">10.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">*&#160;Less than 10% of total net revenues</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company had major payors that contributed to the following percentages of receivables and receivables &#8211; related parties:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:62.181%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:15.543%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:15.546%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Payor D</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i11b3d315843d44af8440a243a1ec9346_D20200101-20200630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjg0ODc5NDlkYTg1MDRjM2ZiZDM1OTlmNDVhODVmMjg0L3RhYmxlcmFuZ2U6ODQ4Nzk0OWRhODUwNGMzZmJkMzU5OWY0NWE4NWYyODRfMi0xLTEtMS0w_a2120ed6-17fe-4456-b3d8-f2e7f59279dc">12.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payor G</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i84779c02d5604bc6bfe042cc4a70617c_D20200101-20200630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjg0ODc5NDlkYTg1MDRjM2ZiZDM1OTlmNDVhODVmMjg0L3RhYmxlcmFuZ2U6ODQ4Nzk0OWRhODUwNGMzZmJkMzU5OWY0NWE4NWYyODRfMy0xLTEtMS0w_5b7a9c17-7691-45d6-a9ad-f11d68ae2a64">33.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="id6e01a159a3e4416b534f097f6b023a9_D20190101-20191231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjg0ODc5NDlkYTg1MDRjM2ZiZDM1OTlmNDVhODVmMjg0L3RhYmxlcmFuZ2U6ODQ4Nzk0OWRhODUwNGMzZmJkMzU5OWY0NWE4NWYyODRfMy0zLTEtMS0w_44108c81-eef0-4feb-b115-ca0f2efda33a">30.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payor H</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i1dc8d99226664ef48c410daff8c273d8_D20200101-20200630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjg0ODc5NDlkYTg1MDRjM2ZiZDM1OTlmNDVhODVmMjg0L3RhYmxlcmFuZ2U6ODQ4Nzk0OWRhODUwNGMzZmJkMzU5OWY0NWE4NWYyODRfNC0xLTEtMS0w_34f58804-e92e-4ff5-82a9-0060df1429ce">35.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ieb7ca1d55e834afd9682b7e0f9cd250b_D20190101-20191231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjg0ODc5NDlkYTg1MDRjM2ZiZDM1OTlmNDVhODVmMjg0L3RhYmxlcmFuZ2U6ODQ4Nzk0OWRhODUwNGMzZmJkMzU5OWY0NWE4NWYyODRfNC0zLTEtMS0w_d982b59c-43c5-40d4-965c-68a9c7b0797e">36.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-indent:-18pt;padding-left:18pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">*&#160;Less than 10% of total receivables and receivables &#8212; related parties, net</span></div></ix:continuation><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDg4NzY_ec2ddf0d-50a3-425e-8362-c570e1f21648" continuedAt="if4e12528cc25468a8588319c1c681297" escape="true"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Fair Value Measurements of Financial Instruments</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s financial instruments consist of cash and cash equivalents, fiduciary cash, restricted cash, investment in marketable securities, receivables, loans receivable, accounts payable, certain accrued expenses, finance lease obligations, and long-term debt. The carrying values of the financial instruments classified as current in the accompanying consolidated balance sheets are considered to be at their fair values, due to the short maturity of these instruments. The carrying amounts of finance lease obligations and long-term debt approximate fair value as they bear interest at rates that approximate current market rates for debt with similar maturities and credit quality.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 820, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Fair Value Measurement</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASC 820&#8221;), applies to all financial assets and financial liabilities that are measured and reported on a fair value basis and requires disclosure that establishes a framework for measuring fair value and expands disclosure about fair value measurements. ASC&#160;820 establishes a fair value hierarchy for disclosure of the inputs to valuations used to measure fair value.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This hierarchy prioritizes the inputs into three broad levels as follows:</span></div><div style="padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Level&#160;1</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> &#8212; Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that can be accessed at the measurement date.</span></div><div style="padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Level&#160;2</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> &#8212; Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the </span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><ix:continuation id="ib2486e6bfac643b99a16b5b47be4922b" continuedAt="i8ff44b1a22504358a2846e6ef16578c1"><ix:continuation id="if4e12528cc25468a8588319c1c681297"><div style="padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">asset or liability (i.e., interest rates and yield curves), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).</span></div><div style="padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Level&#160;3</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> &#8212; Unobservable inputs that reflect assumptions about what market participants would use in pricing the asset or liability. These inputs would be based on the best information available, including the Company&#8217;s own data.</span></div></ix:continuation><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDg4OTA_70c4e1b3-5355-405a-a5b8-8eebd3f2715d" escape="true"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The carrying amounts and fair values of the Company&#8217;s financial instruments as of June&#160;30, 2020, are presented below (in thousands):</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:44.852%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.741%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Fair Value Measurements</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Level 1</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Level 2</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Level 3</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Total</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Money market funds*</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaacb62a7ead1402e943c4985b979a303_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjhiZDlhYjhjMTljNTQ4MTc4YjRiYmZkMWYxYjMyNDI5L3RhYmxlcmFuZ2U6OGJkOWFiOGMxOWM1NDgxNzhiNGJiZmQxZjFiMzI0MjlfMy0xLTEtMS0w_72c9166c-82ca-4c5c-8c58-2ed6cb66d9d5">108,195</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i65e1f17227cc4de2a22981878af26dee_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjhiZDlhYjhjMTljNTQ4MTc4YjRiYmZkMWYxYjMyNDI5L3RhYmxlcmFuZ2U6OGJkOWFiOGMxOWM1NDgxNzhiNGJiZmQxZjFiMzI0MjlfMy0zLTEtMS0w_603cd667-17b2-44b3-adf2-18b2c6ec4b64">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i34d83ddf3e164119a0619b2f774d028a_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjhiZDlhYjhjMTljNTQ4MTc4YjRiYmZkMWYxYjMyNDI5L3RhYmxlcmFuZ2U6OGJkOWFiOGMxOWM1NDgxNzhiNGJiZmQxZjFiMzI0MjlfMy01LTEtMS0w_7e54fba9-4ae5-4993-976a-e30925f1f921">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjhiZDlhYjhjMTljNTQ4MTc4YjRiYmZkMWYxYjMyNDI5L3RhYmxlcmFuZ2U6OGJkOWFiOGMxOWM1NDgxNzhiNGJiZmQxZjFiMzI0MjlfMy03LTEtMS0w_46d4a248-0b9f-47e3-b1f9-250ce4dd7221">108,195</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Marketable securities &#8211; certificates of deposit</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaacb62a7ead1402e943c4985b979a303_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjhiZDlhYjhjMTljNTQ4MTc4YjRiYmZkMWYxYjMyNDI5L3RhYmxlcmFuZ2U6OGJkOWFiOGMxOWM1NDgxNzhiNGJiZmQxZjFiMzI0MjlfNC0xLTEtMS0w_da6361ca-a4db-40b6-9564-0dbffd74c9ba">117,611</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i65e1f17227cc4de2a22981878af26dee_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjhiZDlhYjhjMTljNTQ4MTc4YjRiYmZkMWYxYjMyNDI5L3RhYmxlcmFuZ2U6OGJkOWFiOGMxOWM1NDgxNzhiNGJiZmQxZjFiMzI0MjlfNC0zLTEtMS0w_409b0170-1f45-438f-9928-0f8bdb077d98">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i34d83ddf3e164119a0619b2f774d028a_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjhiZDlhYjhjMTljNTQ4MTc4YjRiYmZkMWYxYjMyNDI5L3RhYmxlcmFuZ2U6OGJkOWFiOGMxOWM1NDgxNzhiNGJiZmQxZjFiMzI0MjlfNC01LTEtMS0w_5c2175c3-6191-4953-9735-c9b23dd61d95">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjhiZDlhYjhjMTljNTQ4MTc4YjRiYmZkMWYxYjMyNDI5L3RhYmxlcmFuZ2U6OGJkOWFiOGMxOWM1NDgxNzhiNGJiZmQxZjFiMzI0MjlfNC03LTEtMS0w_b8fdadab-a1b9-463f-a8da-06305722a026">117,611</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Marketable securities &#8211; equity securities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaacb62a7ead1402e943c4985b979a303_I20200630" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjhiZDlhYjhjMTljNTQ4MTc4YjRiYmZkMWYxYjMyNDI5L3RhYmxlcmFuZ2U6OGJkOWFiOGMxOWM1NDgxNzhiNGJiZmQxZjFiMzI0MjlfNS0xLTEtMS0w_2daacbd3-6bcb-430c-b751-cf5d618f0e49">45</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i65e1f17227cc4de2a22981878af26dee_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjhiZDlhYjhjMTljNTQ4MTc4YjRiYmZkMWYxYjMyNDI5L3RhYmxlcmFuZ2U6OGJkOWFiOGMxOWM1NDgxNzhiNGJiZmQxZjFiMzI0MjlfNS0zLTEtMS0w_81b21ec5-d6d2-4bbb-8f65-f82664da60ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span><ix:nonFraction unitRef="usd" contextRef="i34d83ddf3e164119a0619b2f774d028a_I20200630" xsi:nil="true" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjhiZDlhYjhjMTljNTQ4MTc4YjRiYmZkMWYxYjMyNDI5L3RhYmxlcmFuZ2U6OGJkOWFiOGMxOWM1NDgxNzhiNGJiZmQxZjFiMzI0MjlfNS01LTEtMS0w_066ff469-00bd-4db4-9ee1-a982de5f5789"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjhiZDlhYjhjMTljNTQ4MTc4YjRiYmZkMWYxYjMyNDI5L3RhYmxlcmFuZ2U6OGJkOWFiOGMxOWM1NDgxNzhiNGJiZmQxZjFiMzI0MjlfNS03LTEtMS0w_f51cf8e1-a75b-4a78-9cbe-bcce1d7a719b">45</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaacb62a7ead1402e943c4985b979a303_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjhiZDlhYjhjMTljNTQ4MTc4YjRiYmZkMWYxYjMyNDI5L3RhYmxlcmFuZ2U6OGJkOWFiOGMxOWM1NDgxNzhiNGJiZmQxZjFiMzI0MjlfNy0xLTEtMS0w_bf776450-6393-4c20-93ab-52aaa872a332">225,851</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i65e1f17227cc4de2a22981878af26dee_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjhiZDlhYjhjMTljNTQ4MTc4YjRiYmZkMWYxYjMyNDI5L3RhYmxlcmFuZ2U6OGJkOWFiOGMxOWM1NDgxNzhiNGJiZmQxZjFiMzI0MjlfNy0zLTEtMS0w_b98a82fd-3b9a-4e0c-8867-d21bedfce5e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i34d83ddf3e164119a0619b2f774d028a_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjhiZDlhYjhjMTljNTQ4MTc4YjRiYmZkMWYxYjMyNDI5L3RhYmxlcmFuZ2U6OGJkOWFiOGMxOWM1NDgxNzhiNGJiZmQxZjFiMzI0MjlfNy01LTEtMS0w_90a88adc-530d-4fbe-a868-9c86dae53dc1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjhiZDlhYjhjMTljNTQ4MTc4YjRiYmZkMWYxYjMyNDI5L3RhYmxlcmFuZ2U6OGJkOWFiOGMxOWM1NDgxNzhiNGJiZmQxZjFiMzI0MjlfNy03LTEtMS0w_7f4ca79b-3c63-462d-8b0b-e256145712ac">225,851</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The carrying amounts and fair values of the Company&#8217;s financial instruments as of December&#160;31, 2019, are presented below (in thousands):</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:44.852%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.741%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Measurements</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds*</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iee4970fdbd0c4e57965c08b65849a300_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOmEyOWFmNjE2MjMxZTRlOThhMjUyNWNmZDdlN2FmNWE1L3RhYmxlcmFuZ2U6YTI5YWY2MTYyMzFlNGU5OGEyNTI1Y2ZkN2U3YWY1YTVfMy0xLTEtMS0w_1732e754-8f16-4a77-9a4a-34d31b848789">50,731</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3be99826872a4e079e77a494a475c430_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOmEyOWFmNjE2MjMxZTRlOThhMjUyNWNmZDdlN2FmNWE1L3RhYmxlcmFuZ2U6YTI5YWY2MTYyMzFlNGU5OGEyNTI1Y2ZkN2U3YWY1YTVfMy0zLTEtMS0w_6acfe4ee-d142-42fa-ab0d-1c9e9a4de80d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia5c34ba4f1f24e1e87163828fbf170f9_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOmEyOWFmNjE2MjMxZTRlOThhMjUyNWNmZDdlN2FmNWE1L3RhYmxlcmFuZ2U6YTI5YWY2MTYyMzFlNGU5OGEyNTI1Y2ZkN2U3YWY1YTVfMy01LTEtMS0w_078feaa0-9696-4808-bc2e-702360276705">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOmEyOWFmNjE2MjMxZTRlOThhMjUyNWNmZDdlN2FmNWE1L3RhYmxlcmFuZ2U6YTI5YWY2MTYyMzFlNGU5OGEyNTI1Y2ZkN2U3YWY1YTVfMy03LTEtMS0w_d5858050-0e72-4175-a7d6-dc35dcab9564">50,731</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities &#8211; certificates of deposit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iee4970fdbd0c4e57965c08b65849a300_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOmEyOWFmNjE2MjMxZTRlOThhMjUyNWNmZDdlN2FmNWE1L3RhYmxlcmFuZ2U6YTI5YWY2MTYyMzFlNGU5OGEyNTI1Y2ZkN2U3YWY1YTVfNC0xLTEtMS0w_6f8a3a94-bc07-4fc6-82d6-cad0496d7982">116,469</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3be99826872a4e079e77a494a475c430_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOmEyOWFmNjE2MjMxZTRlOThhMjUyNWNmZDdlN2FmNWE1L3RhYmxlcmFuZ2U6YTI5YWY2MTYyMzFlNGU5OGEyNTI1Y2ZkN2U3YWY1YTVfNC0zLTEtMS0w_0c5fc19f-1145-412b-8a94-685cd3779401">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia5c34ba4f1f24e1e87163828fbf170f9_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOmEyOWFmNjE2MjMxZTRlOThhMjUyNWNmZDdlN2FmNWE1L3RhYmxlcmFuZ2U6YTI5YWY2MTYyMzFlNGU5OGEyNTI1Y2ZkN2U3YWY1YTVfNC01LTEtMS0w_a64d750b-32fa-420e-94bd-2e242ad3c9d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOmEyOWFmNjE2MjMxZTRlOThhMjUyNWNmZDdlN2FmNWE1L3RhYmxlcmFuZ2U6YTI5YWY2MTYyMzFlNGU5OGEyNTI1Y2ZkN2U3YWY1YTVfNC03LTEtMS0w_1a3979a6-983c-4d1d-a301-46af5b909812">116,469</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities &#8211; equity securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iee4970fdbd0c4e57965c08b65849a300_I20191231" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOmEyOWFmNjE2MjMxZTRlOThhMjUyNWNmZDdlN2FmNWE1L3RhYmxlcmFuZ2U6YTI5YWY2MTYyMzFlNGU5OGEyNTI1Y2ZkN2U3YWY1YTVfNS0xLTEtMS0w_0c68b18d-f284-40d1-94b9-d0f96f01335f">70</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3be99826872a4e079e77a494a475c430_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOmEyOWFmNjE2MjMxZTRlOThhMjUyNWNmZDdlN2FmNWE1L3RhYmxlcmFuZ2U6YTI5YWY2MTYyMzFlNGU5OGEyNTI1Y2ZkN2U3YWY1YTVfNS0zLTEtMS0w_6d5cb8a8-662f-45e3-b6e5-84730daaff2d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia5c34ba4f1f24e1e87163828fbf170f9_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOmEyOWFmNjE2MjMxZTRlOThhMjUyNWNmZDdlN2FmNWE1L3RhYmxlcmFuZ2U6YTI5YWY2MTYyMzFlNGU5OGEyNTI1Y2ZkN2U3YWY1YTVfNS01LTEtMS0w_8d83359a-f121-4468-82d2-546df3275751">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOmEyOWFmNjE2MjMxZTRlOThhMjUyNWNmZDdlN2FmNWE1L3RhYmxlcmFuZ2U6YTI5YWY2MTYyMzFlNGU5OGEyNTI1Y2ZkN2U3YWY1YTVfNS03LTEtMS0w_6c59c0ae-95cc-494c-b956-d502da31cbbc">70</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iee4970fdbd0c4e57965c08b65849a300_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOmEyOWFmNjE2MjMxZTRlOThhMjUyNWNmZDdlN2FmNWE1L3RhYmxlcmFuZ2U6YTI5YWY2MTYyMzFlNGU5OGEyNTI1Y2ZkN2U3YWY1YTVfNy0xLTEtMS0w_c4eebd13-7d40-46a2-a8fd-c96b8c982e55">167,270</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3be99826872a4e079e77a494a475c430_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOmEyOWFmNjE2MjMxZTRlOThhMjUyNWNmZDdlN2FmNWE1L3RhYmxlcmFuZ2U6YTI5YWY2MTYyMzFlNGU5OGEyNTI1Y2ZkN2U3YWY1YTVfNy0zLTEtMS0w_37c9a63e-7a97-48e8-8eb4-b50460c1a6bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia5c34ba4f1f24e1e87163828fbf170f9_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOmEyOWFmNjE2MjMxZTRlOThhMjUyNWNmZDdlN2FmNWE1L3RhYmxlcmFuZ2U6YTI5YWY2MTYyMzFlNGU5OGEyNTI1Y2ZkN2U3YWY1YTVfNy01LTEtMS0w_20d7a409-e1f8-4e72-9c13-e28b809261f9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOmEyOWFmNjE2MjMxZTRlOThhMjUyNWNmZDdlN2FmNWE1L3RhYmxlcmFuZ2U6YTI5YWY2MTYyMzFlNGU5OGEyNTI1Y2ZkN2U3YWY1YTVfNy03LTEtMS0w_e24cfc2d-d44a-41b3-92d4-04ef5b57782c">167,270</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="padding-left:18pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">*&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Included in cash and cash equivalents</span></div></ix:nonNumeric><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There have been no changes in Level 1, Level 2, or Level 3 classification and no changes in valuation techniques for these assets for the six months ended June&#160;30, 2020.</span></div><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDg4OTY_2e042819-64fd-42fa-977b-bc40180b39e7" continuedAt="i592da10ca1744da29ea5966106474dae" escape="true"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Intangible Assets and Long-Lived Assets</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Intangible assets with finite lives include network-payor relationships, management contracts and member relationships and are stated at cost, less accumulated amortization and impairment losses. These intangible assets are amortized on the accelerated method using the discounted cash flow rate.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Intangible assets with finite lives also include a patient management platform, as well as trade names and trademarks, whose valuations were determined using the cost to recreate method and the relief from royalty method, respectively. These assets are stated at cost, less accumulated amortization and impairment losses, and are amortized using the straight-line method.</span></div></ix:nonNumeric><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i592da10ca1744da29ea5966106474dae">Finite-lived intangibles and long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may&#160;not be recoverable. If the expected future cash flows from the use of such assets (undiscounted and without interest charges) are less than the carrying value, a write-down would be recorded to reduce the carrying value of the asset to its estimated fair value. Fair value is determined based on appropriate valuation techniques.</ix:continuation> The Company determined that there was <ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMTM0ODc_37af8660-072f-4710-b14a-ded2d39c03d0"><ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMTM0ODc_ad64d65b-5aa9-4e08-9cee-69db8cc5453d"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMTM0ODc_c9720230-a084-4f06-b080-6225da4deccf"><ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMTM0ODc_e1562270-19c0-4ed0-bc29-7a5251b33119">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> impairment of its finite-lived intangible or long-lived assets during the six months ended June&#160;30, 2020 and 2019.</span></div><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDg4OTE_352cfb8c-1c1a-482c-8d26-1196f90225eb" continuedAt="id22e35d8fb584025bb977f76e5901c38" escape="true"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Goodwill and Indefinite-Lived Intangible Assets</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under ASC 350, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Intangibles &#8211; Goodwill and Other</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, goodwill and indefinite-lived intangible assets are reviewed at least annually for impairment.</span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><ix:continuation id="i8ff44b1a22504358a2846e6ef16578c1" continuedAt="ic6fc16f35d794676802eb6dd285d9f0d"><ix:continuation id="id22e35d8fb584025bb977f76e5901c38"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At least annually, at the Company&#8217;s fiscal year-end, or sooner if events or changes in circumstances indicate that an impairment has occurred, the Company performs a qualitative assessment to determine whether it is more likely than not that the fair value of each reporting unit is less than its carrying amount as a basis for determining whether it is necessary to complete quantitative impairment assessments for each of the Company&#8217;s <ix:nonFraction unitRef="unit" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportingUnits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMTQyMjE_4ba2571d-cd3e-40c0-9a4a-2a88a42c8fe8">three</ix:nonFraction> main reporting units (1) management services, (2) IPAs, and (3) ACOs. The Company is required to perform a quantitative goodwill impairment test only if the conclusion from the qualitative assessment is that it is more likely than not that a reporting unit&#8217;s fair value is less than the carrying value of its assets. Should this be the case, a quantitative analysis is performed to identify whether a potential impairment exists by comparing the estimated fair values of the reporting units with their respective carrying values, including goodwill.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">An impairment loss is recognized if the implied fair value of the asset being tested is less than its carrying value. In this event, the asset is written down accordingly. The fair values of goodwill are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At least annually, indefinite-lived intangible assets are tested for impairment. Impairment for intangible assets with indefinite lives exists if the carrying value of the intangible asset exceeds its fair value. The fair values of indefinite-lived intangible assets are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances.</span></div></ix:continuation><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company had <ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMTU1NDk_7e35bbeb-6678-40df-bb8a-8baf30955897"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMTU1NDk_9ba01974-ff13-4d74-81db-2477f79d2ad5"><ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMTU1NDk_9c53e393-d987-4e09-8429-1d8b04fe753d"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMTU1NDk_a279a16d-e208-4350-95b1-b598bdeec617">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> impairment of its goodwill or indefinite-lived intangible assets during the six months ended June&#160;30, 2020 and 2019. </span></div><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMTA5OTUxMTY4NDgyNg_0d9ecbf8-30ec-43d6-bb7b-62d1a9f6c685" escape="true"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Investments in Other Entities &#8212; Equity Method</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accounts for certain investments using the equity method of accounting when it is determined that the investment provides the Company with the ability to exercise significant influence, but not control, over the investee. Significant influence is generally deemed to exist if the Company has an ownership interest in the voting stock of the investee of between 20% and 50%, although other factors, such as representation on the investee&#8217;s board of directors, are considered in determining whether the equity method of accounting is appropriate. Under the equity method of accounting, the investment, originally recorded at cost, is adjusted to recognize the Company&#8217;s share of net earnings or losses of the investee and is recognized in the accompanying consolidated statements of income under &#8220;Income (loss) from equity method investments&#8221; and also is adjusted by contributions to and distributions from the investee. Equity method investments are subject to impairment evaluation. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Investments in Privately Held Entities</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accounts for certain investments using the cost method of accounting when it is determined that the investment provides the Company with little or no influence over the investee. Under the cost method of accounting, the investment is measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income. The investments in privately held entities that do not report NAV are subject to qualitative assessment for indicators of impairments.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="us-gaap:HealthCareCostsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDg4NTM_205e2ea6-2bb6-463f-a875-b477bbc1dcc7" escape="true"><div style="text-align:justify;margin-top:10pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Medical Liabilities</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">APC, Alpha Care, Accountable Health Care, APAACO and MMG are responsible for integrated care that the associated physicians and contracted hospitals provide to their enrollees. APC, Alpha Care, Accountable Health Care, APAACO and MMG provide integrated care to HMOs, Medicare and Medi-Cal enrollees through a network of contracted providers under sub-capitation and direct patient service arrangements. Medical costs for professional and institutional services rendered by contracted providers are recorded as cost of services expenses in the accompanying consolidated statements of income.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">An estimate of amounts due to contracted physicians, hospitals, and other professional providers is included in medical liabilities in the accompanying consolidated balance sheets. Medical liabilities include claims reported as of the balance sheet date and estimates IBNR claims. Such estimates are developed using actuarial methods and are based on numerous variables, including the utilization of health care services, historical payment patterns, cost trends, product mix, seasonality, changes in membership, and other factors. The estimation methods and the resulting reserves are periodically reviewed and updated. Many of the medical contracts are complex in nature and may&#160;be subject to differing interpretations regarding amounts due for the provision of various services. Such differing interpretations may&#160;not come to light until a substantial period of time has passed following the contract implementation.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDg4NjQ_7c3e15a3-5331-459b-ad6f-ffd71026b8b9" continuedAt="id34b063e41904c4ba9390029785157c5" escape="true"><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue Recognition</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company receives payments from the following sources for services rendered: (i) commercial insurers; (ii) the federal government under the Medicare program administered by CMS; (iii) state governments under the Medicaid and other programs; (iv) other third-party payors (e.g., hospitals and IPAs); and (v) individual patients and clients.</span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><ix:continuation id="ic6fc16f35d794676802eb6dd285d9f0d" continuedAt="i5d2f94bb0fbe4267814f0d45952339e7"><ix:continuation id="id34b063e41904c4ba9390029785157c5" continuedAt="if1dd016b33bf449fbb753cf6e2a34a37"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Nature of Services and Revenue Streams</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenue primarily consists of capitation revenue, risk pool settlements and incentives, NGACO All-Inclusive Population-Based Payments (&#8220;AIPBP&#8221;), management fee income, and FFS revenue. Revenue is recorded in the period in which services are rendered or the period in which the Company is obligated to provide services. The form of billing and related risk of collection for such services may&#160;vary by type of revenue and the customer. The following is a summary of the principal forms of the Company&#8217;s billing arrangements and how revenue is recognized for each.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Capitation, Net</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Managed care revenues of the Company consist primarily of capitated fees for medical services provided by the Company under a capitated arrangement directly made with various managed care providers including HMOs. Capitation revenue is typically prepaid monthly to the Company based on the number of enrollees selecting the Company as their healthcare provider. Capitation revenue is recognized in the month in which the Company is obligated to provide services to plan enrollees under contracts with various health plans. Minor ongoing adjustments to prior months&#8217; capitation, primarily arising from contracted HMOs finalizing their monthly patient eligibility data for additions or subtractions of enrollees, are recognized in the month they are communicated to the Company. Additionally, Medicare pays capitation using a &#8220;Risk Adjustment&#8221; model, which compensates managed care organizations and providers based on the health status (acuity) of each individual enrollee. Health plans and providers with higher acuity enrollees will receive more and those with lower acuity enrollees will receive less. Under Risk Adjustment, capitation is determined based on health severity, measured using patient encounter data. Capitation is paid on a monthly basis based on data submitted for the enrollee for the preceding year and is adjusted in subsequent periods after the final data is compiled. Positive or negative capitation adjustments are made for Medicare enrollees with conditions requiring more or less healthcare services than assumed in the interim payments. Since the Company cannot reliably predict these adjustments, periodic changes in capitation amounts earned as a result of Risk Adjustment are recognized when those changes are communicated by the health plans to the Company.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">PMPM managed care contracts generally have a term of <ix:nonNumeric contextRef="i86d36b0423244dd6a1ef5fb8fed9dc60_D20200101-20200630" name="us-gaap:RevenuePerformanceObligationDescriptionOfTiming" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMjEwNTA_8389bca6-0e1f-4dac-b73d-0b2b47d9142b">one year</ix:nonNumeric> or longer. All managed care contracts have a single performance obligation that constitutes a series for the provision of managed healthcare services for a population of enrolled members for the duration of the contract. The transaction price for PMPM contracts is variable as it primarily includes PMPM fees associated with unspecified membership that fluctuates throughout the contract. In certain contracts, PMPM fees also include adjustments for items such as performance incentives, performance guarantees and risk shares. The Company generally estimates the transaction price using the most likely amount methodology and amounts are only included in the net transaction price to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The majority of the Company&#8217;s net PMPM transaction price relates specifically to the Company&#8217;s efforts to transfer the service for a distinct increment of the series (e.g., day or month) and is recognized as revenue in the month in which members are entitled to service.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Risk Pool Settlements and Incentives</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">APC enters into full risk capitation arrangements with certain health plans and local hospitals, which are administered by a third party, where the hospital is responsible for providing, arranging and paying for institutional risk and APC is responsible for providing, arranging and paying for professional risk. Under a full risk pool sharing agreement, APC generally receives a percentage of the net surplus from the affiliated hospital&#8217;s risk pools with HMOs after deductions for the affiliated hospitals costs. Advance settlement payments are typically made quarterly in arrears if there is a surplus. The Company&#8217;s risk pool settlements under arrangements with health plans and hospitals are recognized using the most likely amount methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The assumptions for historical MLR, IBNR completion factors and constraint percentages were used by management in applying the most likely amount methodology.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under capitated arrangements with certain HMOs, APC participates in one or more shared risk arrangements relating to the provision of institutional services to enrollees (shared risk arrangements) and thus can earn additional revenue or incur losses based upon the enrollee utilization of institutional services. Shared risk capitation arrangements are entered into with certain health plans, which are administered by the health plan, where APC is responsible for rendering professional services, but the health plan does not enter into a capitation arrangement with a hospital and therefore the health plan retains the institutional risk. Shared risk deficits, if any, are not payable until and unless (and only to the extent of any) risk-sharing surpluses are generated. At the termination of the HMO contract, any accumulated deficit will be extinguished.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s risk pool settlements under arrangements with HMOs are recognized, using the most likely methodology, and only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur. Given </span></div></ix:continuation></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><ix:continuation id="i5d2f94bb0fbe4267814f0d45952339e7" continuedAt="i487045c71f63488f83f8bc1e5484d684"><ix:continuation id="if1dd016b33bf449fbb753cf6e2a34a37" continuedAt="ic08f14fc694a48f198c643ce10da01b5"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">the lack of access to the health plans&#8217; data and control over the members assigned to APC, the adjustments and/or the withheld amounts are unpredictable and as such APC&#8217;s risk share revenue is deemed to be fully constrained until APC is notified of the amount by the health plan. Risk pools for the prior contract years are generally final settled in the third or fourth quarter of the following year.</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to risk-sharing revenues, the Company also receives incentives under &#8220;pay-for-performance&#8221; programs for quality medical care, based on various criteria. As an incentive to control enrollee utilization and to promote quality care, certain HMOs have designed quality incentive programs and commercial generic pharmacy incentive programs to compensate the Company for its efforts to improve the quality of services and efficient and effective use of pharmacy supplemental benefits provided to HMO members. The incentive programs track specific performance measures and calculate payments to the Company based on the performance measures. The Company&#8217;s incentives under &#8220;pay-for-performance&#8221; programs are recognized using the most likely methodology. However, as the Company does not have sufficient insight from the health plans on the amount and timing of the shared risk pool and incentive payments these amounts are considered to be fully constrained and only recorded when such payments are known and/or received.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Generally, for the foregoing arrangements, the final settlement is dependent on each distinct day&#8217;s performance within the annual measurement period but cannot be allocated to specific days until the full measurement period has occurred and performance can be assessed. As such, this is a form of variable consideration estimated at contract inception and updated through the measurement period (i.e., the contract year), to the extent the risk of reversal does not exist and the consideration is not constrained.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">NGACO AIPBP Revenue</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">APAACO and CMS entered into a NGACO Model Participation Agreement (the &#8220;Participation Agreement&#8221;) with an initial term of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMjY0NTk_5c465777-41e6-4d7a-b713-4cd6abec3b70">two</span> performance years through December&#160;31, 2018, which term was extended for <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMjY1MzU_16e36149-7c47-4c0c-bc55-d85a3cf36fbe">two</span> additional renewal years.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For each performance year, the Company must submit to CMS its selections for risk arrangement; the amount of the profit/loss cap; alternative payment mechanism; benefits enhancements, if any; and its decision regarding voluntary alignment under the NGACO Model. The Company must obtain CMS consent before voluntarily discontinuing any benefit enhancement during a performance year.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the NGACO Model, CMS aligns beneficiaries to the Company to manage (direct care and pay providers) based on a budgetary benchmark established with CMS. The Company is responsible for managing medical costs for these beneficiaries. The beneficiaries will receive services from physicians and other medical service providers that are both in-network and out-of-network. The Company receives capitation from CMS on a monthly basis to pay claims from in-network providers. The Company records such capitation received from CMS as revenue as the Company is primarily responsible and liable for managing the patient care and for satisfying provider obligations, is assuming the credit risk for the services provided by in-network providers through its arrangement with CMS, and has control of the funds, the services provided and the process by which the providers are ultimately paid. Claims from out-of-network providers are processed and paid by CMS and the Company&#8217;s shared savings or losses in managing the services provided by out-of-network providers are generally determined on an annual basis after reconciliation with CMS. Pursuant to the Company&#8217;s risk share agreement with CMS, the Company will be eligible to receive the savings or be liable for the deficit according to the budget established by CMS based on the Company&#8217;s efficiency in managing how the beneficiaries aligned to the Company by CMS are served by in-network and out-of-network providers. The Company&#8217;s savings or losses on providing such services are both capped by CMS, and are subject to significant estimation risk, whereby payments can vary significantly depending upon certain patient characteristics and other variable factors. Accordingly, the Company recognizes such surplus or deficit upon substantial completion of reconciliation and determination of the amounts. The Company records NGACO capitation revenues monthly. Excess over claims paid, plus an estimate for the related IBNR claims (see Note 8), and monthly capitation received are deferred and recorded as a liability until actual claims are paid or incurred. CMS will determine if there were any excess capitation paid for the performance year and the excess is refunded to CMS.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For each performance year, CMS pays the Company in accordance with the alternative payment mechanism, if any, for which CMS has approved the Company; the risk arrangement for which the Company has been approved by CMS; and as otherwise provided in the Participation Agreement. Following the end of each performance year and at such other times as may be required under the Participation Agreement, CMS will issue a settlement report to the Company setting forth the amount of any shared savings or shared losses and the amount of other monies. If CMS owes the Company shared savings or other monies, CMS will pay the Company in full within <ix:nonNumeric contextRef="id5fbfd0a0b9b4ab3876be59e23e3f101_D20200101-20200630" format="ixt-sec:durday" name="ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMjk4MDM_fd2673ad-4165-4ac9-b2d0-fda96b9bba54">30</ix:nonNumeric> days after the date on which the relevant settlement report is deemed final, except as provided in the Participation Agreement. If the Company owes CMS shared losses or other monies owed as a result of a final settlement, the Company will pay CMS in full within <ix:nonNumeric contextRef="id5fbfd0a0b9b4ab3876be59e23e3f101_D20200101-20200630" format="ixt-sec:durday" name="ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMzAwNjQ_dddebf36-3e02-449e-9d95-0db761f21827">30</ix:nonNumeric> days after the relevant settlement report is deemed final. If the </span></div></ix:continuation></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><ix:continuation id="i487045c71f63488f83f8bc1e5484d684" continuedAt="i62cba6abd6b34032a89d046205454ebd"><ix:continuation id="ic08f14fc694a48f198c643ce10da01b5" continuedAt="iacca39cad624491ab7e45487b012dfe5"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Company fails to pay the amounts due to CMS in full within <ix:nonNumeric contextRef="id5fbfd0a0b9b4ab3876be59e23e3f101_D20200101-20200630" format="ixt-sec:durday" name="ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMzAxODc_dddebf36-3e02-449e-9d95-0db761f21827">30</ix:nonNumeric> days after the date of a demand letter or settlement report, CMS will assess simple interest on the unpaid balance at the rate applicable to other Medicare debts under current provisions of law and applicable regulations. In addition, CMS and the U.S. Department of the Treasury may use any applicable debt collection tools available to collect any amounts owed by the Company.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company participates in the AIPBP track of the NGACO Model. Under the AIPBP track, CMS estimates the total annual expenditures for APAACO&#8217;s assigned patients and pays that projected amount to the Company in monthly installments, and the Company is responsible for all Part A and Part B costs for in-network participating providers and preferred providers contracted by the Company to provide services to the assigned patients.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As APAACO does not have sufficient insight into the financial performance of the shared risk pool with CMS because of unknown factors related to IBNR claims, risk adjustment factors, and stop loss provisions, among other factors, an estimate cannot be developed. Due to these limitations, APAACO cannot determine the amount of surplus or deficit that will likely be recognized in the future and therefore this shared risk pool revenue is considered fully constrained.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For performance year 2020, the Company continues to receive monthly AIPBP payments at a rate of approximately $<ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentOfRevenueMonthlyAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMzE1NjI_397fab6e-73a3-4055-82fc-ecb297ad278d">7.6</ix:nonFraction> million per month from CMS, and will need to continue to comply with all terms and conditions in the Participation Agreement and various regulatory requirements to be eligible to participate in the AIPBP mechanism and/or NGACO Model. The Company has received approximately $<ix:nonFraction unitRef="usd" contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentOfRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMTA5OTUxMTY5MDg4OQ_8b15ea4f-1d2e-44d9-a435-40a4652c6856">22.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentOfRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMzE4MzA_ee5fdb5e-ed8f-4cd3-8a8b-59045b18e569">45.5</ix:nonFraction> million in total AIPBP payments for the three and six months ended June&#160;30, 2020, respectively, of which $<ix:nonFraction unitRef="usd" contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNjA0NzMxNDAwNzg0NQ_68398c18-80f3-4b85-bc2e-678ffde5072a">20.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMzE4OTM_0f9a88bc-2ca7-403a-b5cc-0ac17a4779fa">42.4</ix:nonFraction> million has been recognized as revenue for the three and six months ended June 30, 2020, respectively. The Company also recorded assets of approximately $<ix:nonFraction unitRef="usd" contextRef="ie8986202564b4172b0aab2302c7971a4_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ReinsuranceRecoverables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMzE5Nzg_061f15c6-3398-4412-998e-2350afcfe193">8.5</ix:nonFraction> million related to IBNR claims as of June&#160;30, 2020, and $<ix:nonFraction unitRef="usd" contextRef="ie1e6d8b85f4246bf94ae0b52733c146d_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ReinsuranceRecoverables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMzIwMzE_8353eb79-b28a-4343-8fec-3578663dcf76">3.2</ix:nonFraction> million related to final settlement of the 2018 performance year. These balances are included in &#8220;Other receivables&#8221; in the accompanying consolidated balance sheets.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Management Fee Income</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Management fee income encompasses fees paid for management, physician advisory, healthcare staffing, administrative and other non-medical services provided by the Company to IPAs, hospitals and other healthcare providers. Such fees may be in the form of billings at agreed-upon hourly rates, percentages of revenue or fee collections, or amounts fixed on a monthly, quarterly or annual basis. The revenue may include variable arrangements measuring factors such as hours staffed, patient visits or collections per visit against benchmarks, and, in certain cases, may be subject to achieving quality metrics or fee collections. The Company recognizes such variable supplemental revenues in the period when such amounts are determined to be fixed and therefore contractually obligated as payable by the customer under the terms of the applicable agreement.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company provides a significant service of integrating the services selected by the Company&#8217;s clients into one overall output for which the client has contracted. Therefore, such management contracts generally contain a single performance obligation. The nature of the Company&#8217;s performance obligation is to stand ready to provide services over the contractual period. Also, the Company&#8217;s performance obligation forms a series of distinct periods of time over which the Company stands ready to perform. The Company&#8217;s performance obligation is satisfied as the Company completes each period&#8217;s obligations.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Consideration from management contracts is variable in nature because the majority of the fees are generally based on revenue or collections, which can vary from period to period. The Company has control over pricing. Contractual fees are invoiced to the Company&#8217;s clients generally monthly and payment terms are typically due within 30 days. The variable consideration in the Company&#8217;s management contracts meets the criteria to be allocated to the distinct period of time to which it relates because (i) it is due to the activities performed to satisfy the performance obligation during that period and (ii) it represents the consideration to which the Company expects to be entitled.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s management contracts generally have long terms (e.g., <ix:nonNumeric contextRef="ic862c6560a614f5abea31e3ad439d0fe_D20200101-20200630" name="us-gaap:RevenuePerformanceObligationDescriptionOfTiming" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMzQ0Mjc_e6e3e166-dd9a-4fe4-ad62-79f81e20fb04">10 years</ix:nonNumeric>), although they may be terminated earlier under the terms of the applicable contracts. Since the remaining variable consideration will be allocated to a wholly unsatisfied promise that forms part of a single performance obligation recognized under the series guidance, the Company has applied the optional exemption to exclude disclosure of the allocation of the transaction price to remaining performance obligations.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Fee-for-Service Revenue</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">FFS revenue represents revenue earned under contracts in which the Company bills and collects the professional component of charges for medical services rendered by the Company&#8217;s contracted physicians and employed physicians. Under the FFS arrangements, the Company bills the hospitals and third-party payors for the physician staffing and further bills patients or their third-party payors for patient care services provided and receives payment. FFS revenue related to the patient care services is reported net of contractual allowances and policy discounts and are recognized in the period in which the services are rendered to specific patients. All services provided are expected to result in cash flows and are therefore reflected as net revenue in the </span></div></ix:continuation></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><ix:continuation id="i62cba6abd6b34032a89d046205454ebd" continuedAt="i28953a8760d54a63a19bc5bb7e1ca113"><ix:continuation id="iacca39cad624491ab7e45487b012dfe5" continuedAt="ia0b3da0b59d64a38a017a23793996355"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">consolidated financial statements. The recognition of net revenue (gross charges less contractual allowances) from such services is dependent on such factors as proper completion of medical charts following a patient visit, the forwarding of such charts to the Company&#8217;s billing center for medical coding and entering into the Company&#8217;s billing system and the verification of each patient&#8217;s submission or representation at the time services are rendered as to the payor(s) responsible for payment of such services. Revenue is recorded based on the information known at the time of entering of such information into the Company&#8217;s billing systems, as well as an estimate of the revenue associated with medical services.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is responsible for confirming member eligibility, performing program utilization review, potentially directing payment to the provider and accepting the financial risk of loss associated with services rendered, as specified within the Company&#8217;s client contracts. The Company has the ability to adjust contractual fees with clients and possess the financial risk of loss in certain contractual obligations. These factors indicate the Company is the principal and, as such, the Company records gross fees contracted with clients in revenues.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Consideration from FFS arrangements is variable in nature because fees are based on patient encounters, credits due to clients and reimbursement of provider costs, all of which can vary from period to period.&#160;Patient encounters and related episodes of care and procedures qualify as distinct goods and services, provided simultaneously together with other readily available resources, in a single instance of service, and thereby constitute a single performance obligation for each patient encounter and, in most instances, occur at readily determinable transaction prices. As a practical expedient, the Company adopted a portfolio approach for the FFS revenue stream to group together contracts with similar characteristics and analyze historical cash collections trends. The contracts within the portfolio share the characteristics conducive to ensuring that the results do not materially differ under the new standard if it were to be applied to individual patient contracts related to each patient encounter. Accordingly, there was no change in the Company&#8217;s method to recognize revenue under ASC 606 </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue from Contracts with Customers</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> from the previous accounting guidance.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Estimating net FFS revenue is a complex process, largely due to the volume of transactions, the number and complexity of contracts with payors, the limited availability at times of certain patient and payor information at the time services are provided, and the length of time it takes for collections to fully mature. These expected collections are based on fees and negotiated payment rates in the case of third-party payors, the specific benefits provided for under each patient&#8217;s healthcare plans, mandated payment rates in the case of Medicare and Medicaid programs, and historical cash collections (net of recoveries) in combination with expected collections from third-party payors.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The relationship between gross charges and the transaction price recognized is significantly influenced by payor mix, as collections on gross charges may vary significantly, depending on whether and with whom the patients the Company provides services to in the period are insured and the Company&#8217;s contractual relationships with those payors. Payor mix is subject to change as additional patient and payor information is obtained after the period services are provided. The Company periodically assesses the estimates of unbilled revenue, contractual adjustments and discounts, and payor mix by analyzing actual results, including cash collections, against estimates. Changes in these estimates are charged or credited to the consolidated statements of income in the period that the assessment is made. Significant changes in payor mix, contractual arrangements with payors, specialty mix, acuity, general economic conditions and health care coverage provided by federal or state governments or private insurers may have a significant impact on estimates and significantly affect the results of operations and cash flows.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Contract Assets</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Typically, revenues and receivables are recognized once the Company has satisfied its performance obligation. Accordingly, the Company&#8217;s contract assets are comprised of receivables and receivables &#8211; related parties.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8217;</span><span style="background-color:rgb(255,255,255, 0.0);color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">s billing and accounting systems provide historical trends of cash collections and contractual write-offs, accounts receivable agings and established fee adjustments from third-party payors. These estimates are recorded and monitored monthly as revenues are recognized.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The principal exposure for uncollectible fee for service visits is from self-pay patients and, to a lesser extent, for co-payments and deductibles from patients with insurance.</span></div></ix:continuation></ix:continuation><div style="text-align:justify;margin-top:10pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><ix:continuation id="i28953a8760d54a63a19bc5bb7e1ca113" continuedAt="i14b76c1d1c134e4fae92dcc394faa973"><div style="text-align:justify;margin-top:10pt;"><ix:continuation id="ia0b3da0b59d64a38a017a23793996355" continuedAt="ie9b300332b9e451a9fa229773eb1ff7c"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Contract Liabilities (Deferred Revenue</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">)</span></ix:continuation></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="ie9b300332b9e451a9fa229773eb1ff7c">Contract liabilities are recorded when cash payments are received in advance of the Company&#8217;s performance, or in the case of the Company&#8217;s NGACO, the excess of AIPBP capitation received and the actual claims paid or incurred.</ix:continuation> The Company&#8217;s contract liability balance was $<ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDA5MTM_08178166-5653-4ac3-b703-a05b43766b45">3.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDA5MjA_107dd19b-c59c-4815-99d4-d2c58696506e">8.9</ix:nonFraction> million as of June&#160;30, 2020, and December&#160;31, 2019, respectively, and is presented within &#8220;Accounts payable and accrued expenses&#8221; in the accompanying consolidated balance sheets. During the six months ended June&#160;30, 2020, $<ix:nonFraction unitRef="usd" contextRef="i9f4243e46d3647e093788a742f11debf_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDEwOTg_ee4f2a2e-87a2-4538-8076-2b1bf6ea5fb4">0.4</ix:nonFraction> million of the Company&#8217;s contract liability accrued in 2019 has been recognized as revenue and $<ix:nonFraction unitRef="usd" contextRef="i9f4243e46d3647e093788a742f11debf_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="ameh:ContractWithCustomerLiabilityRepaidCapitationReceivedAndNotEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDExODY_a81f7997-e460-40e8-b894-2396c0904fa9">8.5</ix:nonFraction> million was repaid back to CMS for AIPBP capitation received and not earned.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other Financial Information</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2020, the Company made a deposit of $<ix:nonFraction unitRef="usd" contextRef="iee021f30ec494988b04ffd293da80842_I20200331" decimals="-5" format="ixt:numdotdecimal" name="ameh:InvestmentDeposit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDEzMzE_126b316e-8f93-4363-9d63-afb1761f820b">4.0</ix:nonFraction> million for future investment opportunities. The investment was made with cash strictly related to the APC excluded assets that was generated from the series of transactions with AP-AMH. The deposit is included in &#8220;Other assets&#8221; in the accompanying consolidated balance sheets.</span></div><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDg4OTk_58c76831-0a13-4ffe-a0aa-889ee77aa40c" escape="true"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Income Taxes</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Federal and state income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the consolidated financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the consolidated financial statements.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDg5MTg_ebdca82c-0e7d-4918-ab48-e91dac7f3343" escape="true"><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Share-Based Compensation</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company maintains a stock-based compensation program for employees, non-employees, directors and consultants. The value of share-based awards such as options is recognized as compensation expense on a cumulative straight-line basis over the vesting period of the awards, adjusted for expected forfeitures. From time to time, the Company issues shares of its common stock to its employees, directors and consultants, which shares may be subject to the Company&#8217;s repurchase right (but not obligation) that lapses based on time-based and performance-based vesting schedules.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDg4NDM_71f71d48-4eae-4f2c-887d-920b478613c0" escape="true"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basic and Diluted Earnings Per Share</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Basic earnings per share is computed by dividing net income attributable to holders of the Company&#8217;s common stock by the weighted average number of shares of common stock outstanding during the periods presented. Diluted earnings per share is computed using the weighted average number of shares of common stock outstanding, plus the effect of dilutive securities outstanding during the periods presented, using the treasury stock method. Refer to Note 14 for a discussion of shares treated as treasury shares for accounting purposes.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="ameh:MinorityInterestPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDg4NjE_d8d27765-cf20-4080-908a-f80a584536c3" escape="true"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Noncontrolling Interests</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company consolidates entities in which the Company has a controlling financial interest. The Company consolidates subsidiaries in which the Company holds, directly or indirectly, more than <ix:nonFraction unitRef="number" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="INF" name="us-gaap:VariableInterestEntityOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDQ2Mzk_26e19047-cf31-4802-9d92-16e87243cc4b">50</ix:nonFraction>% of the voting rights, and VIEs in which the Company is the primary beneficiary. Noncontrolling interests represent third-party equity ownership interests (including equity ownership interests held by certain VIEs) in the Company&#8217;s consolidated entities. Net income attributable to noncontrolling interests is disclosed in the consolidated statements of income.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="ameh:TemporaryEquityPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDg5MDU_af42b10d-e478-4064-946a-6cabe8ce1fda" continuedAt="i3802afab530c4c11a4e1519c785efdb8" escape="true"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Mezzanine Equity</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to APC&#8217;s shareholder agreements, in the event of a disqualifying event, as defined in the agreements, APC could be required to repurchase the shares from the respective shareholders based on certain triggers outlined in the shareholder agreements. As the redemption feature of the shares is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as mezzanine or temporary equity. Accordingly, the Company recognizes </span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><ix:continuation id="i14b76c1d1c134e4fae92dcc394faa973"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i3802afab530c4c11a4e1519c785efdb8">noncontrolling interests in APC as mezzanine equity in the consolidated financial statements.</ix:continuation> As of June&#160;30, 2020 and December&#160;31, 2019, APC's shares were not redeemable, nor was it probable the shares would become redeemable.</span></div><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDg4NTQ_da34dd7e-9bae-4efb-a238-e7a78af60990" escape="true"><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Accounting Pronouncements</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financial Instruments-Credit Losses (Topic 326)-Measurement of Credit Losses on Financial Instruments</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASU 2016-13&#8221;). The new standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. ASU 2016-13 became effective for fiscal years beginning after December 15, 2019, with early adoption permitted. The Company adopted ASU 2016-13 on January 1, 2020. The adoption of ASU 2016-13 did not have a material impact on the consolidated financial statements.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In October 2018, the FASB issued ASU No. 2018-17, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Consolidation (Topic 810): Targeted Improvements to Related Party Guidance for Variable Interest Entities</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASU 2018-17&#8221;). This ASU reduces the cost and complexity of financial reporting associated with consolidation of VIEs. A VIE is an organization in which consolidation is not based on a majority of voting rights. The new guidance supersedes the private company alternative for common control leasing arrangements issued in 2014 and expands it to all qualifying common control arrangements. The amendments in this ASU became effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The Company adopted ASU 2018-17 on January 1, 2020. The adoption of ASU 2018-17 did not have a material impact on the consolidated financial statements.</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASU 2019-12&#8221;). This ASU simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740 </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Income Taxes </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The amendments in this ASU are effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company is currently assessing the impact that the adoption of ASU 2019-12 will have on the Company's consolidated financial statements.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2020, the FASB issued ASU No. 2020-01, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Investments - Equity Securities (Topic 321), Investments - Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(&#8220;ASU 2020-01&#8221;). This ASU clarifies the interaction between accounting for equity securities, equity method investments and certain derivative instruments. The amendments in this ASU are effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company is currently assessing the impact that the adoption of ASU 2020-01 will have on the Company's consolidation financial statements.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other than the standards discussed above, there have been no other new accounting pronouncements that have significance, or potential significance, to the Company&#8217;s financial position, results of operations and cash flows.</span></div></ix:nonNumeric></ix:continuation><div id="icc5d6783c1494a1f886c03c93e398cee_49"></div><div style="text-indent:-18pt;padding-left:18pt;margin-top:10pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:18pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">3.&#160;<ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RleHRyZWdpb246MjJkNDk5OGM1YmExNDc0OGIxODUyMjQ3ZGMzYThmYzNfMzA5Mw_e558478a-2842-4cf8-b520-9cf70917e1bc" continuedAt="i2971c748f51f44409e66380148c7532e" escape="true">Business Combinations and Goodwill</ix:nonNumeric></span></div><ix:continuation id="i2971c748f51f44409e66380148c7532e" continuedAt="i52a3f69fbf8e4212a5daca9c95d0412b"><div style="text-indent:-18pt;padding-left:18pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Alpha Care Medical Group, Inc.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On May 31, 2019, APC and APC-LSMA completed their acquisition of <ix:nonFraction unitRef="number" contextRef="iab3766c2a60b42849e233d9acb377205_I20190531" decimals="INF" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RleHRyZWdpb246MjJkNDk5OGM1YmExNDc0OGIxODUyMjQ3ZGMzYThmYzNfMTMy_3d5d0ceb-d803-4ee5-bcf5-54919a55da78">100</ix:nonFraction>% of the capital stock of Alpha Care from Dr. Kevin Tyson for an aggregate purchase price of approximately $<ix:nonFraction unitRef="usd" contextRef="i8e2f250049ae44589256e0929aad4803_D20190531-20190531" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RleHRyZWdpb246MjJkNDk5OGM1YmExNDc0OGIxODUyMjQ3ZGMzYThmYzNfMjQw_ca5fe5b1-cc6a-4867-b3d7-d10512a68c41">45.1</ix:nonFraction> million in cash, subject to post-closing adjustments. As part of the transaction the Company deposited $<ix:nonFraction unitRef="usd" contextRef="iab3766c2a60b42849e233d9acb377205_I20190531" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EscrowDeposit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RleHRyZWdpb246MjJkNDk5OGM1YmExNDc0OGIxODUyMjQ3ZGMzYThmYzNfMzM4_0a4aa14b-bad4-4d20-9a8a-3ed3939c0fc3">2.0</ix:nonFraction> million into an escrow account for potential post-closing adjustments. As of June&#160;30, 2020, no post-closing adjustment is expected to be paid to Dr. Tyson and the full amount of the escrow account is expected to be returned to the Company. As such, the escrow amount is presented within prepaid expenses and other current assets in the accompanying consolidated balance sheets. </span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RleHRyZWdpb246MjJkNDk5OGM1YmExNDc0OGIxODUyMjQ3ZGMzYThmYzNfMzA5NA_c75fb1a2-835b-4c58-85e1-948b8f33b8d1" continuedAt="i481f35d5f7eb4d4dbc2a40ee92324ac7" escape="true">The following table summarizes the estimated fair values of the assets acquired and liabilities assumed, as of the acquisition date (in thousands):</ix:nonNumeric></span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><ix:continuation id="i52a3f69fbf8e4212a5daca9c95d0412b" continuedAt="i514d908ff75e40c9bedba10533773033"><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><ix:continuation id="i481f35d5f7eb4d4dbc2a40ee92324ac7" continuedAt="ib865a881316f41909ab1de90620ebeef"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:78.498%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.502%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance Sheet</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Assets acquired</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iab3766c2a60b42849e233d9acb377205_I20190531" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RhYmxlOjFkZjA4MzcwZGRiOTQzOTVhNjQ4NzI0NGI1YTc1ZTU4L3RhYmxlcmFuZ2U6MWRmMDgzNzBkZGI5NDM5NWE2NDg3MjQ0YjVhNzVlNThfMi0xLTEtMS0w_d1914f96-4915-4af1-aafb-986b194f93b7">3,569</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iab3766c2a60b42849e233d9acb377205_I20190531" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RhYmxlOjFkZjA4MzcwZGRiOTQzOTVhNjQ4NzI0NGI1YTc1ZTU4L3RhYmxlcmFuZ2U6MWRmMDgzNzBkZGI5NDM5NWE2NDg3MjQ0YjVhNzVlNThfMy0xLTEtMS0w_4d45e629-b8fc-4717-b606-5c7ee9708f5e">10,336</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iab3766c2a60b42849e233d9acb377205_I20190531" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RhYmxlOjFkZjA4MzcwZGRiOTQzOTVhNjQ4NzI0NGI1YTc1ZTU4L3RhYmxlcmFuZ2U6MWRmMDgzNzBkZGI5NDM5NWE2NDg3MjQ0YjVhNzVlNThfNC0xLTEtMS0w_b6068264-ee7d-432f-b8c9-6c0371cae0d2">4,675</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Network relationship intangible assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iab3766c2a60b42849e233d9acb377205_I20190531" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RhYmxlOjFkZjA4MzcwZGRiOTQzOTVhNjQ4NzI0NGI1YTc1ZTU4L3RhYmxlcmFuZ2U6MWRmMDgzNzBkZGI5NDM5NWE2NDg3MjQ0YjVhNzVlNThfNS0xLTEtMS0w_d89891ec-ebb7-4328-a661-056c83d89793">22,636</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iab3766c2a60b42849e233d9acb377205_I20190531" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RhYmxlOjFkZjA4MzcwZGRiOTQzOTVhNjQ4NzI0NGI1YTc1ZTU4L3RhYmxlcmFuZ2U6MWRmMDgzNzBkZGI5NDM5NWE2NDg3MjQ0YjVhNzVlNThfNi0xLTEtMS0w_0f9a3b8d-92cf-4455-b50c-d7e8974a95a1">28,585</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iab3766c2a60b42849e233d9acb377205_I20190531" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RhYmxlOjFkZjA4MzcwZGRiOTQzOTVhNjQ4NzI0NGI1YTc1ZTU4L3RhYmxlcmFuZ2U6MWRmMDgzNzBkZGI5NDM5NWE2NDg3MjQ0YjVhNzVlNThfNy0xLTEtMS0w_c9b7a623-92f0-4e37-a07e-4b888513014f">2,795</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iab3766c2a60b42849e233d9acb377205_I20190531" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RhYmxlOjFkZjA4MzcwZGRiOTQzOTVhNjQ4NzI0NGI1YTc1ZTU4L3RhYmxlcmFuZ2U6MWRmMDgzNzBkZGI5NDM5NWE2NDg3MjQ0YjVhNzVlNThfOC0xLTEtMS0w_1e7aedff-0bde-45f5-8771-6a5bc0912fc2">6,334</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Medical liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iab3766c2a60b42849e233d9acb377205_I20190531" decimals="-3" format="ixt:numdotdecimal" name="ameh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RhYmxlOjFkZjA4MzcwZGRiOTQzOTVhNjQ4NzI0NGI1YTc1ZTU4L3RhYmxlcmFuZ2U6MWRmMDgzNzBkZGI5NDM5NWE2NDg3MjQ0YjVhNzVlNThfOS0xLTEtMS0w_a16d79e2-cdb8-419a-a698-f6c7165b4c14">15,616</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;Net assets acquired</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iab3766c2a60b42849e233d9acb377205_I20190531" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RhYmxlOjFkZjA4MzcwZGRiOTQzOTVhNjQ4NzI0NGI1YTc1ZTU4L3RhYmxlcmFuZ2U6MWRmMDgzNzBkZGI5NDM5NWE2NDg3MjQ0YjVhNzVlNThfMTAtMS0xLTEtMA_6789f35d-73ee-4c39-b8c8-2e0c8886f32d">45,056</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8e2f250049ae44589256e0929aad4803_D20190531-20190531" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RhYmxlOjFkZjA4MzcwZGRiOTQzOTVhNjQ4NzI0NGI1YTc1ZTU4L3RhYmxlcmFuZ2U6MWRmMDgzNzBkZGI5NDM5NWE2NDg3MjQ0YjVhNzVlNThfMTItMS0xLTEtMA_dc10f8db-074b-4466-a3c2-f995693b92cd">45,056</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:continuation></div><div style="text-align:center;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accountable Health Care, IPA, a Professional Medical Corporation</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On August 30, 2019, APC and APC-LSMA acquired the remaining outstanding shares of capital stock (comprising <ix:nonFraction unitRef="number" contextRef="i9004566cce7c4ef7b4abb21095da7358_I20190830" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RleHRyZWdpb246MjJkNDk5OGM1YmExNDc0OGIxODUyMjQ3ZGMzYThmYzNfMTAwMg_2d1e9341-0e8c-4adb-bd68-807e6d27ebf9">75</ix:nonFraction>%) in Accountable Health Care in exchange for $<ix:nonFraction unitRef="usd" contextRef="i26cbf8fca0d84265be9879b3b17db702_D20190830-20190830" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RleHRyZWdpb246MjJkNDk5OGM1YmExNDc0OGIxODUyMjQ3ZGMzYThmYzNfMTA0OQ_5fce0098-5058-4e58-9db4-cee3d9b5e35b">7.3</ix:nonFraction> million. In addition to the payment of $<ix:nonFraction unitRef="usd" contextRef="i26cbf8fca0d84265be9879b3b17db702_D20190830-20190830" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RleHRyZWdpb246MjJkNDk5OGM1YmExNDc0OGIxODUyMjQ3ZGMzYThmYzNfMTA4Mw_5fce0098-5058-4e58-9db4-cee3d9b5e35b">7.3</ix:nonFraction> million, APC assumed all assets and liabilities of Accountable Health Care, including loans payable to NMM and APC of $<ix:nonFraction unitRef="usd" contextRef="i9efe901318bb4ed08cc6432008f3343c_I20190830" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RleHRyZWdpb246MjJkNDk5OGM1YmExNDc0OGIxODUyMjQ3ZGMzYThmYzNfMTE5NQ_319bf01c-4cac-49bb-bb5a-8c5012520c5d">15.4</ix:nonFraction> million, which have been eliminated upon consolidation and contributed the <ix:nonFraction unitRef="number" contextRef="i460f9923ee7347d6aa697c85d63b74e1_I20190830" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RleHRyZWdpb246MjJkNDk5OGM1YmExNDc0OGIxODUyMjQ3ZGMzYThmYzNfMTI2NQ_2350ca72-05f9-42f5-9844-fd4f558ff805">25</ix:nonFraction>% investment totaling $<ix:nonFraction unitRef="usd" contextRef="i9519fc3d763e44bba24ad68ede94a1c0_D20190830-20190830" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RleHRyZWdpb246MjJkNDk5OGM1YmExNDc0OGIxODUyMjQ3ZGMzYThmYzNfMTI4OA_90fd2050-a2ec-4cec-9fa7-ca5d2072fc16">2.4</ix:nonFraction> million, total purchase price was $<ix:nonFraction unitRef="usd" contextRef="i40df6f98654940f690d8f5bfc4d573bc_D20190830-20190830" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RleHRyZWdpb246MjJkNDk5OGM1YmExNDc0OGIxODUyMjQ3ZGMzYThmYzNfMTMxNw_6e56cb74-706c-4df5-b6e6-1d241e615ecf">25.1</ix:nonFraction> million (see Note 5). </span></div><ix:continuation id="ib865a881316f41909ab1de90620ebeef"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the estimated fair values of the assets acquired and liabilities assumed, as of the acquisition date (in thousands):</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:78.498%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.502%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance Sheet</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Assets acquired</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic772c23a08d84f8da481202e5fe65be4_I20190830" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RhYmxlOjY2NTc3ODA5NmMwYzRiNjA5ZTVlOTQ0NzEyYjg1MzFhL3RhYmxlcmFuZ2U6NjY1Nzc4MDk2YzBjNGI2MDllNWU5NDQ3MTJiODUzMWFfMi0xLTEtMS0w_05bde798-191d-4b01-903e-06b0bb65c8f7">582</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic772c23a08d84f8da481202e5fe65be4_I20190830" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RhYmxlOjY2NTc3ODA5NmMwYzRiNjA5ZTVlOTQ0NzEyYjg1MzFhL3RhYmxlcmFuZ2U6NjY1Nzc4MDk2YzBjNGI2MDllNWU5NDQ3MTJiODUzMWFfMy0xLTEtMS0w_56a05fda-9a84-4aa8-99e6-f3a29415c160">5,150</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic772c23a08d84f8da481202e5fe65be4_I20190830" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RhYmxlOjY2NTc3ODA5NmMwYzRiNjA5ZTVlOTQ0NzEyYjg1MzFhL3RhYmxlcmFuZ2U6NjY1Nzc4MDk2YzBjNGI2MDllNWU5NDQ3MTJiODUzMWFfNC0xLTEtMS0w_7c4a65c3-3fa3-4178-a572-1fbcd22b6fa8">198</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Network relationship intangible assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic772c23a08d84f8da481202e5fe65be4_I20190830" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RhYmxlOjY2NTc3ODA5NmMwYzRiNjA5ZTVlOTQ0NzEyYjg1MzFhL3RhYmxlcmFuZ2U6NjY1Nzc4MDk2YzBjNGI2MDllNWU5NDQ3MTJiODUzMWFfNS0xLTEtMS0w_b380570d-6d1b-47ae-a7c4-e7a3b728b415">11,411</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic772c23a08d84f8da481202e5fe65be4_I20190830" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RhYmxlOjY2NTc3ODA5NmMwYzRiNjA5ZTVlOTQ0NzEyYjg1MzFhL3RhYmxlcmFuZ2U6NjY1Nzc4MDk2YzBjNGI2MDllNWU5NDQ3MTJiODUzMWFfNi0xLTEtMS0w_59a1e4ea-2e98-4990-beb2-ce776aefb0a1">23,566</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic772c23a08d84f8da481202e5fe65be4_I20190830" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RhYmxlOjY2NTc3ODA5NmMwYzRiNjA5ZTVlOTQ0NzEyYjg1MzFhL3RhYmxlcmFuZ2U6NjY1Nzc4MDk2YzBjNGI2MDllNWU5NDQ3MTJiODUzMWFfNy0xLTEtMS0w_a9e6f6d5-c3a5-4ca8-b361-f4872d55f147">3,759</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Medical liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic772c23a08d84f8da481202e5fe65be4_I20190830" decimals="-3" format="ixt:numdotdecimal" name="ameh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RhYmxlOjY2NTc3ODA5NmMwYzRiNjA5ZTVlOTQ0NzEyYjg1MzFhL3RhYmxlcmFuZ2U6NjY1Nzc4MDk2YzBjNGI2MDllNWU5NDQ3MTJiODUzMWFfOC0xLTEtMS0w_06849f3d-c943-41a5-a96c-7d825b9e71f4">12,154</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Subordinated loan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic772c23a08d84f8da481202e5fe65be4_I20190830" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RhYmxlOjY2NTc3ODA5NmMwYzRiNjA5ZTVlOTQ0NzEyYjg1MzFhL3RhYmxlcmFuZ2U6NjY1Nzc4MDk2YzBjNGI2MDllNWU5NDQ3MTJiODUzMWFfOS0xLTEtMS0w_5f9ceb62-32ce-44b1-b583-0bbd88ef31eb">15,327</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net asset acquired</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic772c23a08d84f8da481202e5fe65be4_I20190830" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RhYmxlOjY2NTc3ODA5NmMwYzRiNjA5ZTVlOTQ0NzEyYjg1MzFhL3RhYmxlcmFuZ2U6NjY1Nzc4MDk2YzBjNGI2MDllNWU5NDQ3MTJiODUzMWFfMTAtMS0xLTEtMA_a2367db8-3593-4432-afce-faf438274cff">9,667</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity investment contributed</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic772c23a08d84f8da481202e5fe65be4_I20190830" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RhYmxlOjY2NTc3ODA5NmMwYzRiNjA5ZTVlOTQ0NzEyYjg1MzFhL3RhYmxlcmFuZ2U6NjY1Nzc4MDk2YzBjNGI2MDllNWU5NDQ3MTJiODUzMWFfMTItMS0xLTEtMA_72f77e28-39c6-4598-aaf3-735984977aa3">2,417</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i38b436d30e5240e3965b3cb5408fc04b_D20190830-20190830" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RhYmxlOjY2NTc3ODA5NmMwYzRiNjA5ZTVlOTQ0NzEyYjg1MzFhL3RhYmxlcmFuZ2U6NjY1Nzc4MDk2YzBjNGI2MDllNWU5NDQ3MTJiODUzMWFfMTMtMS0xLTEtMA_5dec2212-9d5d-441d-8fef-58da97f9f487">7,250</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:continuation><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">AMG, a Professional Medical Corporation</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company acquired AMG in September 2019, for total consideration of $<ix:nonFraction unitRef="usd" contextRef="i226c14d75f674f3aace656903b7c99e1_D20190901-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RleHRyZWdpb246MjJkNDk5OGM1YmExNDc0OGIxODUyMjQ3ZGMzYThmYzNfMTU1NQ_e9779405-7c98-49f5-a758-4e79351592d9">1.6</ix:nonFraction> million, of which $<ix:nonFraction unitRef="usd" contextRef="if3e410ddfdb74a3daeb61a44c92264d8_D20190901-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RleHRyZWdpb246MjJkNDk5OGM1YmExNDc0OGIxODUyMjQ3ZGMzYThmYzNfMTU2OA_d57c651c-a319-441b-bf09-230b79c75ad7">0.4</ix:nonFraction> million was in the form of APC common stock. The business combination did not meet the quantitative thresholds to require separate disclosures based on the Company&#8217;s consolidated net assets, investments and net income.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The acquisitions were accounted for under the acquisition method of accounting. The fair value of the consideration for the acquired company was allocated to acquired tangible and intangible assets and liabilities based upon their fair values. The excess of the purchase consideration over the fair value of the net tangible and identifiable intangible assets acquired was recorded as goodwill. The determination of the fair value of assets and liabilities acquired requires the Company to make estimates and use valuation techniques when market value is not readily available. The results of operations of the company </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><ix:continuation id="i514d908ff75e40c9bedba10533773033"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">acquired have been included in the Company&#8217;s financial statements from the date of acquisition. Transaction costs associated with business acquisitions are expensed as they are incurred.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At the time of acquisition, the Company estimates the amount of the identifiable intangible assets based on a valuation and the facts and circumstances available at the time. The Company determines the final value of the identifiable intangible assets as soon as information is available, but not more than one year from the date of acquisition.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Goodwill is not deductible for tax purposes.</span></div><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RleHRyZWdpb246MjJkNDk5OGM1YmExNDc0OGIxODUyMjQ3ZGMzYThmYzNfMzA4OA_d417fd97-db18-4f21-8b09-6c6af202007d" escape="true"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The change in the carrying value of goodwill for the six months ended June&#160;30, 2020, was as follows (in thousands);</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:78.498%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.502%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, January 1, 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RhYmxlOjU2ZWZjYzVlMTM3ZTQ1ZWY4NGU5N2Y5MjIwOWZhNWVkL3RhYmxlcmFuZ2U6NTZlZmNjNWUxMzdlNDVlZjg0ZTk3ZjkyMjA5ZmE1ZWRfMC0xLTEtMS0w_ff8f85a7-2298-4864-8b54-1969c1a5db3b">238,505</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RhYmxlOjU2ZWZjYzVlMTM3ZTQ1ZWY4NGU5N2Y5MjIwOWZhNWVkL3RhYmxlcmFuZ2U6NTZlZmNjNWUxMzdlNDVlZjg0ZTk3ZjkyMjA5ZmE1ZWRfMS0xLTEtMS0w_83b52057-97e6-4531-933a-a0d5bc1ade4a">548</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, June 30, 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RhYmxlOjU2ZWZjYzVlMTM3ZTQ1ZWY4NGU5N2Y5MjIwOWZhNWVkL3RhYmxlcmFuZ2U6NTZlZmNjNWUxMzdlNDVlZjg0ZTk3ZjkyMjA5ZmE1ZWRfMy0xLTEtMS0w_3c4385ac-f704-4948-bc70-4f7cc15bdf63">239,053</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="icc5d6783c1494a1f886c03c93e398cee_52"></div><div style="text-indent:-18pt;padding-left:18pt;margin-top:10pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:18pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">4.&#160;<ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RleHRyZWdpb246YzU4NjQ0ZjNjZDg3NDQ1Nzk1ZWZhYmJhZGNiN2Q2ZGVfNDg2_9c98e441-4b21-409c-889d-d4ccd29cfdc9" continuedAt="ibae26b08f11e4d658e006b13bf36d109" escape="true">Intangible Assets, Net</ix:nonNumeric></span></div><ix:continuation id="ibae26b08f11e4d658e006b13bf36d109" continuedAt="i466bc7f6873543fcbe3ce56fc5e2b781"><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RleHRyZWdpb246YzU4NjQ0ZjNjZDg3NDQ1Nzk1ZWZhYmJhZGNiN2Q2ZGVfNDgy_22c08c94-ea59-480c-ad41-97c4ce883deb" escape="true"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At June&#160;30, 2020, the Company&#8217;s intangible assets, net, consisted of the following (in thousands):</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:42.199%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:7.544%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.684%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.684%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.687%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Useful</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Life</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Years)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Amortization</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net June 30,<br/>2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Amortized intangible assets:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Network relationships</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="i73be6919be5e46b1a06e1ea222b2fdbe_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmMzNTFhMmEyMWJhOTQ0Yzc5OTliZjRlM2I3YWUxZDUwL3RhYmxlcmFuZ2U6YzM1MWEyYTIxYmE5NDRjNzk5OWJmNGUzYjdhZTFkNTBfMi0xLTEtMS0wL3RleHRyZWdpb246NmRhNjVmNjA0Njk4NGQ0NDkyMGUxOGZkMTZmYzRjYThfNjU5NzA2OTc2NjY2Nw_9a1940d4-9773-4d3a-a31f-dbd236d64418">11</ix:nonNumeric>-<ix:nonNumeric contextRef="ia02225d6109046c78a438c6a8b4976e7_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmMzNTFhMmEyMWJhOTQ0Yzc5OTliZjRlM2I3YWUxZDUwL3RhYmxlcmFuZ2U6YzM1MWEyYTIxYmE5NDRjNzk5OWJmNGUzYjdhZTFkNTBfMi0xLTEtMS0wL3RleHRyZWdpb246NmRhNjVmNjA0Njk4NGQ0NDkyMGUxOGZkMTZmYzRjYThfNjU5NzA2OTc2NjY3OQ_095467a6-f25d-4281-8a1f-0e72e1e0f400">15</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9a061ecd0e88428da9167e4c5ef52ac3_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmMzNTFhMmEyMWJhOTQ0Yzc5OTliZjRlM2I3YWUxZDUwL3RhYmxlcmFuZ2U6YzM1MWEyYTIxYmE5NDRjNzk5OWJmNGUzYjdhZTFkNTBfMi0zLTEtMS0w_8f67b307-44a3-46cf-8183-17e3f14031e6">143,930</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9a061ecd0e88428da9167e4c5ef52ac3_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmMzNTFhMmEyMWJhOTQ0Yzc5OTliZjRlM2I3YWUxZDUwL3RhYmxlcmFuZ2U6YzM1MWEyYTIxYmE5NDRjNzk5OWJmNGUzYjdhZTFkNTBfMi01LTEtMS0w_371a16f3-0375-48a5-8577-86256aac52bd">67,015</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9a061ecd0e88428da9167e4c5ef52ac3_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmMzNTFhMmEyMWJhOTQ0Yzc5OTliZjRlM2I3YWUxZDUwL3RhYmxlcmFuZ2U6YzM1MWEyYTIxYmE5NDRjNzk5OWJmNGUzYjdhZTFkNTBfMi03LTEtMS0w_e119aa6a-6056-443b-88f6-a01c2be66c49">76,915</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Management contracts</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i57bb690a343d4f7d8bad8f8f0b00a299_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmMzNTFhMmEyMWJhOTQ0Yzc5OTliZjRlM2I3YWUxZDUwL3RhYmxlcmFuZ2U6YzM1MWEyYTIxYmE5NDRjNzk5OWJmNGUzYjdhZTFkNTBfMy0xLTEtMS0w_14ec078a-5d2e-4fc8-b795-09f6fb4fdce6">15</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5588309d1fff48048fb83af0ddcb456b_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmMzNTFhMmEyMWJhOTQ0Yzc5OTliZjRlM2I3YWUxZDUwL3RhYmxlcmFuZ2U6YzM1MWEyYTIxYmE5NDRjNzk5OWJmNGUzYjdhZTFkNTBfMy0zLTEtMS0w_c527ac6c-8920-420f-a725-6b343953b3da">22,832</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5588309d1fff48048fb83af0ddcb456b_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmMzNTFhMmEyMWJhOTQ0Yzc5OTliZjRlM2I3YWUxZDUwL3RhYmxlcmFuZ2U6YzM1MWEyYTIxYmE5NDRjNzk5OWJmNGUzYjdhZTFkNTBfMy01LTEtMS0w_1ffed547-3bc3-4241-a511-0300442573a0">10,736</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5588309d1fff48048fb83af0ddcb456b_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmMzNTFhMmEyMWJhOTQ0Yzc5OTliZjRlM2I3YWUxZDUwL3RhYmxlcmFuZ2U6YzM1MWEyYTIxYmE5NDRjNzk5OWJmNGUzYjdhZTFkNTBfMy03LTEtMS0w_9a1ed65d-b205-4598-903b-07ba721e927b">12,096</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Member relationships</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i7cb7d40948da4beb88d80ee62fb3d330_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmMzNTFhMmEyMWJhOTQ0Yzc5OTliZjRlM2I3YWUxZDUwL3RhYmxlcmFuZ2U6YzM1MWEyYTIxYmE5NDRjNzk5OWJmNGUzYjdhZTFkNTBfNC0xLTEtMS0w_c4155a5c-14aa-40ad-8caf-c743c3b1ce49">12</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic456fd261edf4e6b9386c6e78baefd90_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmMzNTFhMmEyMWJhOTQ0Yzc5OTliZjRlM2I3YWUxZDUwL3RhYmxlcmFuZ2U6YzM1MWEyYTIxYmE5NDRjNzk5OWJmNGUzYjdhZTFkNTBfNC0zLTEtMS0w_c874e5c7-c86e-4109-b551-57acbbe6cdc1">6,696</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic456fd261edf4e6b9386c6e78baefd90_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmMzNTFhMmEyMWJhOTQ0Yzc5OTliZjRlM2I3YWUxZDUwL3RhYmxlcmFuZ2U6YzM1MWEyYTIxYmE5NDRjNzk5OWJmNGUzYjdhZTFkNTBfNC01LTEtMS0w_8c5d1a55-7fb1-49a9-9407-18f1123cfaf6">2,793</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic456fd261edf4e6b9386c6e78baefd90_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmMzNTFhMmEyMWJhOTQ0Yzc5OTliZjRlM2I3YWUxZDUwL3RhYmxlcmFuZ2U6YzM1MWEyYTIxYmE5NDRjNzk5OWJmNGUzYjdhZTFkNTBfNC03LTEtMS0w_03123459-a163-4f32-9caf-5ec53a2aca14">3,903</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Patient management platform</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i0e1880f00d4d4d1e9e8b42e76237839e_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmMzNTFhMmEyMWJhOTQ0Yzc5OTliZjRlM2I3YWUxZDUwL3RhYmxlcmFuZ2U6YzM1MWEyYTIxYmE5NDRjNzk5OWJmNGUzYjdhZTFkNTBfNS0xLTEtMS0w_09a4f188-75c1-4c20-96c1-167a4d452ac9">5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i200a2160c6bc4775ad07f433b5e95e1a_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmMzNTFhMmEyMWJhOTQ0Yzc5OTliZjRlM2I3YWUxZDUwL3RhYmxlcmFuZ2U6YzM1MWEyYTIxYmE5NDRjNzk5OWJmNGUzYjdhZTFkNTBfNS0zLTEtMS0w_2cb719d1-d051-4833-81e7-bfa7d2b8bd54">2,060</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i200a2160c6bc4775ad07f433b5e95e1a_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmMzNTFhMmEyMWJhOTQ0Yzc5OTliZjRlM2I3YWUxZDUwL3RhYmxlcmFuZ2U6YzM1MWEyYTIxYmE5NDRjNzk5OWJmNGUzYjdhZTFkNTBfNS01LTEtMS0w_677d3093-d690-45a3-9274-6a88dc04fe2f">1,064</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i200a2160c6bc4775ad07f433b5e95e1a_I20200630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmMzNTFhMmEyMWJhOTQ0Yzc5OTliZjRlM2I3YWUxZDUwL3RhYmxlcmFuZ2U6YzM1MWEyYTIxYmE5NDRjNzk5OWJmNGUzYjdhZTFkNTBfNS03LTEtMS0w_d6ab8319-79a0-4efd-bbb6-5019cef577a0">996</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Trade names/trademarks</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ic7bfc72f47df49e08bf78786c1c3f3a8_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmMzNTFhMmEyMWJhOTQ0Yzc5OTliZjRlM2I3YWUxZDUwL3RhYmxlcmFuZ2U6YzM1MWEyYTIxYmE5NDRjNzk5OWJmNGUzYjdhZTFkNTBfNi0xLTEtMS0w_12cf94f9-d3de-4646-b251-cacd9b6a1043">20</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5f688ddde99b4f1e907fddc9a3a91b08_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmMzNTFhMmEyMWJhOTQ0Yzc5OTliZjRlM2I3YWUxZDUwL3RhYmxlcmFuZ2U6YzM1MWEyYTIxYmE5NDRjNzk5OWJmNGUzYjdhZTFkNTBfNi0zLTEtMS0w_d34a51f8-931f-4ece-819f-a5ec494d9c3c">1,011</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5f688ddde99b4f1e907fddc9a3a91b08_I20200630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmMzNTFhMmEyMWJhOTQ0Yzc5OTliZjRlM2I3YWUxZDUwL3RhYmxlcmFuZ2U6YzM1MWEyYTIxYmE5NDRjNzk5OWJmNGUzYjdhZTFkNTBfNi01LTEtMS0w_ea4bd6c4-af9e-491c-a713-6b56b6016ac1">131</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5f688ddde99b4f1e907fddc9a3a91b08_I20200630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmMzNTFhMmEyMWJhOTQ0Yzc5OTliZjRlM2I3YWUxZDUwL3RhYmxlcmFuZ2U6YzM1MWEyYTIxYmE5NDRjNzk5OWJmNGUzYjdhZTFkNTBfNi03LTEtMS0w_250542e1-f2f5-484d-888a-cf4c25db1dae">880</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmMzNTFhMmEyMWJhOTQ0Yzc5OTliZjRlM2I3YWUxZDUwL3RhYmxlcmFuZ2U6YzM1MWEyYTIxYmE5NDRjNzk5OWJmNGUzYjdhZTFkNTBfNy0zLTEtMS0w_b77d448c-a2b6-42bc-be0b-3f12ff26d6f0">176,529</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmMzNTFhMmEyMWJhOTQ0Yzc5OTliZjRlM2I3YWUxZDUwL3RhYmxlcmFuZ2U6YzM1MWEyYTIxYmE5NDRjNzk5OWJmNGUzYjdhZTFkNTBfNy01LTEtMS0w_90215bd4-3c29-4d3a-bc45-2a6b8d094744">81,739</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmMzNTFhMmEyMWJhOTQ0Yzc5OTliZjRlM2I3YWUxZDUwL3RhYmxlcmFuZ2U6YzM1MWEyYTIxYmE5NDRjNzk5OWJmNGUzYjdhZTFkNTBfNy03LTEtMS0w_3ccea650-870e-4992-9858-e98dcbf1d264">94,790</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At December&#160;31, 2019, the Company&#8217;s intangible assets, net, consisted of the following (in thousands):</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:38.789%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.426%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.619%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.888%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.234%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Useful</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Life</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Years)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross December 31,<br/>2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Amortization</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Amortized intangible assets:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Network relationships</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="id11fed723b204eccb39c30a6f9bcb4ec_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmVhN2FjM2FmNzhjNDQzZmM4MDExMDdlMzc0ZTA1NjFhL3RhYmxlcmFuZ2U6ZWE3YWMzYWY3OGM0NDNmYzgwMTEwN2UzNzRlMDU2MWFfMi0xLTEtMS0wL3RleHRyZWdpb246YWNiZGFmMzUxZmRlNGViODkwMTg2MjI1MTFjMWNhNDRfNjU5NzA2OTc2NjY2Nw_afa00b1c-4607-4408-9130-60e7139576a8">11</ix:nonNumeric>-<ix:nonNumeric contextRef="i0041ee30d491407b91c0d34ee0fd8035_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmVhN2FjM2FmNzhjNDQzZmM4MDExMDdlMzc0ZTA1NjFhL3RhYmxlcmFuZ2U6ZWE3YWMzYWY3OGM0NDNmYzgwMTEwN2UzNzRlMDU2MWFfMi0xLTEtMS0wL3RleHRyZWdpb246YWNiZGFmMzUxZmRlNGViODkwMTg2MjI1MTFjMWNhNDRfNjU5NzA2OTc2NjY3MQ_306475a5-1e1f-4f8e-8d54-23ec14cabf2c">15</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i80ad21fe7a3a4d959fdd8ebdbe3e6e65_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmVhN2FjM2FmNzhjNDQzZmM4MDExMDdlMzc0ZTA1NjFhL3RhYmxlcmFuZ2U6ZWE3YWMzYWY3OGM0NDNmYzgwMTEwN2UzNzRlMDU2MWFfMi0zLTEtMS0w_95ebba82-05a3-4444-bf22-7335ea7e47b4">143,930</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i80ad21fe7a3a4d959fdd8ebdbe3e6e65_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmVhN2FjM2FmNzhjNDQzZmM4MDExMDdlMzc0ZTA1NjFhL3RhYmxlcmFuZ2U6ZWE3YWMzYWY3OGM0NDNmYzgwMTEwN2UzNzRlMDU2MWFfMi01LTEtMS0w_575e910d-eba8-46a3-a38a-5a557ddf4526">60,526</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i80ad21fe7a3a4d959fdd8ebdbe3e6e65_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmVhN2FjM2FmNzhjNDQzZmM4MDExMDdlMzc0ZTA1NjFhL3RhYmxlcmFuZ2U6ZWE3YWMzYWY3OGM0NDNmYzgwMTEwN2UzNzRlMDU2MWFfMi03LTEtMS0w_3ff66919-e430-4d2d-980b-c6a94c6c2366">83,404</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Management contracts</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ibf9258f9195d44eebf1af16facb1fb4a_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmVhN2FjM2FmNzhjNDQzZmM4MDExMDdlMzc0ZTA1NjFhL3RhYmxlcmFuZ2U6ZWE3YWMzYWY3OGM0NDNmYzgwMTEwN2UzNzRlMDU2MWFfMy0xLTEtMS0w_d74bbf97-783f-4651-8554-2f5a1e999aaf">15</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ife724f4c09364f2587ef6b1db0ffb506_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmVhN2FjM2FmNzhjNDQzZmM4MDExMDdlMzc0ZTA1NjFhL3RhYmxlcmFuZ2U6ZWE3YWMzYWY3OGM0NDNmYzgwMTEwN2UzNzRlMDU2MWFfMy0zLTEtMS0w_e3998fba-0627-481d-b8e8-dad055aa92c8">22,832</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ife724f4c09364f2587ef6b1db0ffb506_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmVhN2FjM2FmNzhjNDQzZmM4MDExMDdlMzc0ZTA1NjFhL3RhYmxlcmFuZ2U6ZWE3YWMzYWY3OGM0NDNmYzgwMTEwN2UzNzRlMDU2MWFfMy01LTEtMS0w_ea4fa135-c81e-40ef-b8d8-9f6842ee7e00">9,676</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ife724f4c09364f2587ef6b1db0ffb506_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmVhN2FjM2FmNzhjNDQzZmM4MDExMDdlMzc0ZTA1NjFhL3RhYmxlcmFuZ2U6ZWE3YWMzYWY3OGM0NDNmYzgwMTEwN2UzNzRlMDU2MWFfMy03LTEtMS0w_6b3489f2-6b1c-4ea6-bc6a-740ffeaad649">13,156</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Member relationships</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="id69c143aef794cd8af6e5723d91edb2c_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmVhN2FjM2FmNzhjNDQzZmM4MDExMDdlMzc0ZTA1NjFhL3RhYmxlcmFuZ2U6ZWE3YWMzYWY3OGM0NDNmYzgwMTEwN2UzNzRlMDU2MWFfNC0xLTEtMS0w_e4c0fdcf-c1b5-4e09-934a-f06294151aee">12</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if0aef9156d514b559b4f1bc502166379_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmVhN2FjM2FmNzhjNDQzZmM4MDExMDdlMzc0ZTA1NjFhL3RhYmxlcmFuZ2U6ZWE3YWMzYWY3OGM0NDNmYzgwMTEwN2UzNzRlMDU2MWFfNC0zLTEtMS0w_b0e37c3d-5e9e-4db9-af13-0a00300da2ef">6,696</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if0aef9156d514b559b4f1bc502166379_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmVhN2FjM2FmNzhjNDQzZmM4MDExMDdlMzc0ZTA1NjFhL3RhYmxlcmFuZ2U6ZWE3YWMzYWY3OGM0NDNmYzgwMTEwN2UzNzRlMDU2MWFfNC01LTEtMS0w_867c2086-f575-4926-a2fb-e3dba36d9471">2,352</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if0aef9156d514b559b4f1bc502166379_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmVhN2FjM2FmNzhjNDQzZmM4MDExMDdlMzc0ZTA1NjFhL3RhYmxlcmFuZ2U6ZWE3YWMzYWY3OGM0NDNmYzgwMTEwN2UzNzRlMDU2MWFfNC03LTEtMS0w_7942f76a-bfd8-4126-ac72-233bc9499377">4,344</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Patient management platform</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i3fcb4ca5c3c4484fa5efae17077926cd_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmVhN2FjM2FmNzhjNDQzZmM4MDExMDdlMzc0ZTA1NjFhL3RhYmxlcmFuZ2U6ZWE3YWMzYWY3OGM0NDNmYzgwMTEwN2UzNzRlMDU2MWFfNS0xLTEtMS0w_51fb747e-b457-4f9c-b552-2a0dfafc6f8f">5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i04ee375bba5d426fae0a9eb750e81925_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmVhN2FjM2FmNzhjNDQzZmM4MDExMDdlMzc0ZTA1NjFhL3RhYmxlcmFuZ2U6ZWE3YWMzYWY3OGM0NDNmYzgwMTEwN2UzNzRlMDU2MWFfNS0zLTEtMS0w_ecc53a49-f05c-4c5f-8cfd-4b56c4c55e90">2,060</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i04ee375bba5d426fae0a9eb750e81925_I20191231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmVhN2FjM2FmNzhjNDQzZmM4MDExMDdlMzc0ZTA1NjFhL3RhYmxlcmFuZ2U6ZWE3YWMzYWY3OGM0NDNmYzgwMTEwN2UzNzRlMDU2MWFfNS01LTEtMS0w_dc6fa25b-adde-44f0-bb7b-011fd7553207">858</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i04ee375bba5d426fae0a9eb750e81925_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmVhN2FjM2FmNzhjNDQzZmM4MDExMDdlMzc0ZTA1NjFhL3RhYmxlcmFuZ2U6ZWE3YWMzYWY3OGM0NDNmYzgwMTEwN2UzNzRlMDU2MWFfNS03LTEtMS0w_a9f07c8c-ed5b-4f93-8fa0-ddcda9e876e7">1,202</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Trade names/trademarks</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i3ccf5d499e3e4698884b846f6d3df73d_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmVhN2FjM2FmNzhjNDQzZmM4MDExMDdlMzc0ZTA1NjFhL3RhYmxlcmFuZ2U6ZWE3YWMzYWY3OGM0NDNmYzgwMTEwN2UzNzRlMDU2MWFfNi0xLTEtMS0w_a68f15e5-34e3-4cb3-b532-75768efa89ba">20</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia58b0f57301940558ebd969a25e55261_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmVhN2FjM2FmNzhjNDQzZmM4MDExMDdlMzc0ZTA1NjFhL3RhYmxlcmFuZ2U6ZWE3YWMzYWY3OGM0NDNmYzgwMTEwN2UzNzRlMDU2MWFfNi0zLTEtMS0w_65384037-38cd-42d8-8599-48540a8b35ca">1,011</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia58b0f57301940558ebd969a25e55261_I20191231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmVhN2FjM2FmNzhjNDQzZmM4MDExMDdlMzc0ZTA1NjFhL3RhYmxlcmFuZ2U6ZWE3YWMzYWY3OGM0NDNmYzgwMTEwN2UzNzRlMDU2MWFfNi01LTEtMS0w_1ad07427-0b6d-4893-bac2-7a8383048bb8">105</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia58b0f57301940558ebd969a25e55261_I20191231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmVhN2FjM2FmNzhjNDQzZmM4MDExMDdlMzc0ZTA1NjFhL3RhYmxlcmFuZ2U6ZWE3YWMzYWY3OGM0NDNmYzgwMTEwN2UzNzRlMDU2MWFfNi03LTEtMS0w_101fceb3-d353-4801-81b7-c130f2d7e985">906</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmVhN2FjM2FmNzhjNDQzZmM4MDExMDdlMzc0ZTA1NjFhL3RhYmxlcmFuZ2U6ZWE3YWMzYWY3OGM0NDNmYzgwMTEwN2UzNzRlMDU2MWFfNy0zLTEtMS0w_c5f3a9e6-ce98-4a3e-aef4-0fc2dd493753">176,529</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmVhN2FjM2FmNzhjNDQzZmM4MDExMDdlMzc0ZTA1NjFhL3RhYmxlcmFuZ2U6ZWE3YWMzYWY3OGM0NDNmYzgwMTEwN2UzNzRlMDU2MWFfNy01LTEtMS0w_4d1b444d-0fbc-46c6-a43e-7fd21fd4e818">73,517</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmVhN2FjM2FmNzhjNDQzZmM4MDExMDdlMzc0ZTA1NjFhL3RhYmxlcmFuZ2U6ZWE3YWMzYWY3OGM0NDNmYzgwMTEwN2UzNzRlMDU2MWFfNy03LTEtMS0w_424ad924-b447-4b42-8bc1-617b9f7c6065">103,012</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Included in depreciation and amortization on the accompanying consolidated statements of income is amortization expense of $<ix:nonFraction unitRef="usd" contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RleHRyZWdpb246YzU4NjQ0ZjNjZDg3NDQ1Nzk1ZWZhYmJhZGNiN2Q2ZGVfMjM2_dbd09770-1a3f-4776-be15-c407524786a2">4.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RleHRyZWdpb246YzU4NjQ0ZjNjZDg3NDQ1Nzk1ZWZhYmJhZGNiN2Q2ZGVfMjQz_484b69b2-1073-4c5c-b179-338c364cca28">3.9</ix:nonFraction> million for the three months ended June&#160;30, 2020 and 2019, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RleHRyZWdpb246YzU4NjQ0ZjNjZDg3NDQ1Nzk1ZWZhYmJhZGNiN2Q2ZGVfMzIw_80725e4a-e127-42ae-88e0-3499d1a678eb">8.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RleHRyZWdpb246YzU4NjQ0ZjNjZDg3NDQ1Nzk1ZWZhYmJhZGNiN2Q2ZGVfMzI3_a6ad3e11-920e-49fa-970a-bd4b59f4946b">7.7</ix:nonFraction> million for the six months ended June&#160;30, 2020 and 2019, respectively.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RleHRyZWdpb246YzU4NjQ0ZjNjZDg3NDQ1Nzk1ZWZhYmJhZGNiN2Q2ZGVfNDgw_fd5e1304-4831-462a-8784-ea8591f4d489" continuedAt="i96a74a33d62d47c9819c24a48086a76d" escape="true">Future amortization expense is estimated to be as follows for the following years ending December&#160;31 (in thousands):</ix:nonNumeric></span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><div style="margin-top:5pt;margin-bottom:5pt;"><ix:continuation id="i466bc7f6873543fcbe3ce56fc5e2b781"><ix:continuation id="i96a74a33d62d47c9819c24a48086a76d"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:85.262%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.738%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020 (excluding the six months ended June 30, 2020)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOjZmOGRlNDdiYmVmODQyNzVhMWFkNjA1Mjk5Zjc0NmI4L3RhYmxlcmFuZ2U6NmY4ZGU0N2JiZWY4NDI3NWExYWQ2MDUyOTlmNzQ2YjhfMi0xLTEtMS0w_2ac6aae8-fab7-49f3-aac7-55ba2d6e820b">7,807</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOjZmOGRlNDdiYmVmODQyNzVhMWFkNjA1Mjk5Zjc0NmI4L3RhYmxlcmFuZ2U6NmY4ZGU0N2JiZWY4NDI3NWExYWQ2MDUyOTlmNzQ2YjhfMy0xLTEtMS0w_5c2912ec-a338-4367-8943-b454e66710be">14,524</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOjZmOGRlNDdiYmVmODQyNzVhMWFkNjA1Mjk5Zjc0NmI4L3RhYmxlcmFuZ2U6NmY4ZGU0N2JiZWY4NDI3NWExYWQ2MDUyOTlmNzQ2YjhfNC0xLTEtMS0w_1c57244b-b80d-4d69-a86e-57b2037ed797">12,673</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOjZmOGRlNDdiYmVmODQyNzVhMWFkNjA1Mjk5Zjc0NmI4L3RhYmxlcmFuZ2U6NmY4ZGU0N2JiZWY4NDI3NWExYWQ2MDUyOTlmNzQ2YjhfNS0xLTEtMS0w_4fb5d1bc-8b65-4cfa-8472-d83df83e9831">10,842</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOjZmOGRlNDdiYmVmODQyNzVhMWFkNjA1Mjk5Zjc0NmI4L3RhYmxlcmFuZ2U6NmY4ZGU0N2JiZWY4NDI3NWExYWQ2MDUyOTlmNzQ2YjhfNi0xLTEtMS0w_22e26c1d-67ec-41ff-a7d9-d51cd50295bc">9,830</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="ameh:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOjZmOGRlNDdiYmVmODQyNzVhMWFkNjA1Mjk5Zjc0NmI4L3RhYmxlcmFuZ2U6NmY4ZGU0N2JiZWY4NDI3NWExYWQ2MDUyOTlmNzQ2YjhfNy0xLTEtMS0w_cadaa91c-0392-4ed4-920a-3c93dcb106c2">39,114</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOjZmOGRlNDdiYmVmODQyNzVhMWFkNjA1Mjk5Zjc0NmI4L3RhYmxlcmFuZ2U6NmY4ZGU0N2JiZWY4NDI3NWExYWQ2MDUyOTlmNzQ2YjhfOS0xLTEtMS0w_65a2ae31-4728-459c-912f-0aee7668dcd2">94,790</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:continuation></ix:continuation></div><div id="icc5d6783c1494a1f886c03c93e398cee_58"></div><div style="text-indent:-18pt;padding-left:18pt;margin-top:10pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:18pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">5.&#160;<ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="ameh:EquityMethodAndOtherEquityInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMTE1NDQ4NzIxMDUyMjQ_dfd5d988-5fed-4072-b4fa-79277d20b0ba" continuedAt="i3bc2c1e53a4d4540a914504408c53f7f" escape="true">Investments in Other Entities &#8212; Equity Method</ix:nonNumeric></span></div><ix:continuation id="i3bc2c1e53a4d4540a914504408c53f7f" continuedAt="ib0d43c98423f47ec9d9801f9603777a8"><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="us-gaap:EquityMethodInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfOTcyMA_fb1e7085-1ffc-416a-b238-5d99fe81c32e" continuedAt="ib948aa1dd1384280b4cc401c7ad173df" escape="true"><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Rollforward of Equity Method Investment (in thousands)</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:39.374%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.964%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.011%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.134%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.549%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.632%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Allocation of Income (Loss)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Contribution</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sale</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">LaSalle Medical Associates &#8211; IPA Line of Business</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic3925100079946168d1204aa44f455d9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU4NDZlOWI2OTNmMzQyNjM5NzdhZmE2NGQ0YjA0NThhL3RhYmxlcmFuZ2U6ZTg0NmU5YjY5M2YzNDI2Mzk3N2FmYTY0ZDRiMDQ1OGFfMS0xLTEtMS0w_3ecf0756-e5ae-4922-9c9c-34a92fe628b5">6,397</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4fdfa470671c47fdbbc39c5426a4e251_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU4NDZlOWI2OTNmMzQyNjM5NzdhZmE2NGQ0YjA0NThhL3RhYmxlcmFuZ2U6ZTg0NmU5YjY5M2YzNDI2Mzk3N2FmYTY0ZDRiMDQ1OGFfMS0yLTEtMS0w_57ef8131-c352-45b2-965c-ddb3e775aa07">428</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4fdfa470671c47fdbbc39c5426a4e251_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="ameh:EquityMethodInvestmentsContribution" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU4NDZlOWI2OTNmMzQyNjM5NzdhZmE2NGQ0YjA0NThhL3RhYmxlcmFuZ2U6ZTg0NmU5YjY5M2YzNDI2Mzk3N2FmYTY0ZDRiMDQ1OGFfMS0zLTEtMS0w_6aa46588-b5f4-49e4-996a-709b606069eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie050574270bf4bdba21a2294fe288e97_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU4NDZlOWI2OTNmMzQyNjM5NzdhZmE2NGQ0YjA0NThhL3RhYmxlcmFuZ2U6ZTg0NmU5YjY5M2YzNDI2Mzk3N2FmYTY0ZDRiMDQ1OGFfMS00LTEtMS0w_00784414-a073-4a7d-85d2-d77c24978482">5,969</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pacific Medical Imaging &amp; Oncology Center, Inc.</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i723d471168484995a1f33bc20e25ae83_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU4NDZlOWI2OTNmMzQyNjM5NzdhZmE2NGQ0YjA0NThhL3RhYmxlcmFuZ2U6ZTg0NmU5YjY5M2YzNDI2Mzk3N2FmYTY0ZDRiMDQ1OGFfMi0xLTEtMS0w_70183375-14db-48c1-aa3c-40f8c27ea6fc">1,396</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie984a2ae967749fbb28bc018191f1448_D20200101-20200630" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU4NDZlOWI2OTNmMzQyNjM5NzdhZmE2NGQ0YjA0NThhL3RhYmxlcmFuZ2U6ZTg0NmU5YjY5M2YzNDI2Mzk3N2FmYTY0ZDRiMDQ1OGFfMi0yLTEtMS0w_411ec138-8a0b-4bb9-90de-c1e76076428f">77</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie984a2ae967749fbb28bc018191f1448_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="ameh:EquityMethodInvestmentsContribution" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU4NDZlOWI2OTNmMzQyNjM5NzdhZmE2NGQ0YjA0NThhL3RhYmxlcmFuZ2U6ZTg0NmU5YjY5M2YzNDI2Mzk3N2FmYTY0ZDRiMDQ1OGFfMi0zLTEtMS0w_3bd790a2-35be-4edd-ad15-b351da92a695">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i509c376a3e0f41cdbfb08128ed5aff20_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU4NDZlOWI2OTNmMzQyNjM5NzdhZmE2NGQ0YjA0NThhL3RhYmxlcmFuZ2U6ZTg0NmU5YjY5M2YzNDI2Mzk3N2FmYTY0ZDRiMDQ1OGFfMi00LTEtMS0w_877c9966-388c-4af3-899d-fcbc7c4af2e5">1,473</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Universal Care, Inc.</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d9b625d40984cada77fed26b2662304_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU4NDZlOWI2OTNmMzQyNjM5NzdhZmE2NGQ0YjA0NThhL3RhYmxlcmFuZ2U6ZTg0NmU5YjY5M2YzNDI2Mzk3N2FmYTY0ZDRiMDQ1OGFfMy0xLTEtMS0w_8b75ff87-f2a8-4d98-a69c-66896034ddb4">1,438</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0a335fe94da74cc1b74cfe701830c693_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU4NDZlOWI2OTNmMzQyNjM5NzdhZmE2NGQ0YjA0NThhL3RhYmxlcmFuZ2U6ZTg0NmU5YjY5M2YzNDI2Mzk3N2FmYTY0ZDRiMDQ1OGFfMy0yLTEtMS0w_e56c4853-8dbe-42b6-92e0-a477c08b2924">3,560</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0a335fe94da74cc1b74cfe701830c693_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="ameh:EquityMethodInvestmentsContribution" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU4NDZlOWI2OTNmMzQyNjM5NzdhZmE2NGQ0YjA0NThhL3RhYmxlcmFuZ2U6ZTg0NmU5YjY5M2YzNDI2Mzk3N2FmYTY0ZDRiMDQ1OGFfMy0zLTEtMS0w_8ced4641-3c59-4180-9021-d2919383d095">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0a335fe94da74cc1b74cfe701830c693_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU4NDZlOWI2OTNmMzQyNjM5NzdhZmE2NGQ0YjA0NThhL3RhYmxlcmFuZ2U6ZTg0NmU5YjY5M2YzNDI2Mzk3N2FmYTY0ZDRiMDQ1OGFfMy00LTEtMS0xOTI1_5ef6e9c9-b1d9-4090-a715-5a7d65e60c7c">4,998</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iadefc20aa4134071bd9a5346e792b746_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU4NDZlOWI2OTNmMzQyNjM5NzdhZmE2NGQ0YjA0NThhL3RhYmxlcmFuZ2U6ZTg0NmU5YjY5M2YzNDI2Mzk3N2FmYTY0ZDRiMDQ1OGFfMy00LTEtMS0w_030a07b1-9f5b-4f8f-a587-d6ae8cc91070">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Diagnostic Medical Group</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5fd06ba095124e0abdcc0d7f91fc1472_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU4NDZlOWI2OTNmMzQyNjM5NzdhZmE2NGQ0YjA0NThhL3RhYmxlcmFuZ2U6ZTg0NmU5YjY5M2YzNDI2Mzk3N2FmYTY0ZDRiMDQ1OGFfNC0xLTEtMS0w_4c41870a-b973-47cd-a0f6-7bef34f9172c">2,334</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9c66cc2214574c8e905c03e9a5ac08d7_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU4NDZlOWI2OTNmMzQyNjM5NzdhZmE2NGQ0YjA0NThhL3RhYmxlcmFuZ2U6ZTg0NmU5YjY5M2YzNDI2Mzk3N2FmYTY0ZDRiMDQ1OGFfNC0yLTEtMS0w_d8034608-0f27-4f66-a4e1-95fe2c15948e">102</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9c66cc2214574c8e905c03e9a5ac08d7_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="ameh:EquityMethodInvestmentsContribution" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU4NDZlOWI2OTNmMzQyNjM5NzdhZmE2NGQ0YjA0NThhL3RhYmxlcmFuZ2U6ZTg0NmU5YjY5M2YzNDI2Mzk3N2FmYTY0ZDRiMDQ1OGFfNC0zLTEtMS0w_485330ea-b7ca-439f-9a00-29bdeba475f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i314c4ccc348b436ba49cb07ab3848d81_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU4NDZlOWI2OTNmMzQyNjM5NzdhZmE2NGQ0YjA0NThhL3RhYmxlcmFuZ2U6ZTg0NmU5YjY5M2YzNDI2Mzk3N2FmYTY0ZDRiMDQ1OGFfNC00LTEtMS0w_a222d992-7555-4429-ba57-30f256448321">2,232</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">531 W. College, LLC &#8211; related party</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3451c081a11c49aea7b55e24c90e4721_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU4NDZlOWI2OTNmMzQyNjM5NzdhZmE2NGQ0YjA0NThhL3RhYmxlcmFuZ2U6ZTg0NmU5YjY5M2YzNDI2Mzk3N2FmYTY0ZDRiMDQ1OGFfNS0xLTEtMS0w_c7005ad7-d94b-44ef-8c5f-74476f1b85fa">16,698</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i357af7bf55294d7b86954b0bf136c8c6_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU4NDZlOWI2OTNmMzQyNjM5NzdhZmE2NGQ0YjA0NThhL3RhYmxlcmFuZ2U6ZTg0NmU5YjY5M2YzNDI2Mzk3N2FmYTY0ZDRiMDQ1OGFfNS0yLTEtMS0w_afe0583d-538d-4ed4-b91c-158714ec4b44">231</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i357af7bf55294d7b86954b0bf136c8c6_D20200101-20200630" decimals="-3" name="ameh:EquityMethodInvestmentsContribution" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU4NDZlOWI2OTNmMzQyNjM5NzdhZmE2NGQ0YjA0NThhL3RhYmxlcmFuZ2U6ZTg0NmU5YjY5M2YzNDI2Mzk3N2FmYTY0ZDRiMDQ1OGFfNS0zLTEtMS0w_a0c60975-3e99-402b-9306-63fca8606b6e">500</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic39201e9036d43759acb734c62b0b8d4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU4NDZlOWI2OTNmMzQyNjM5NzdhZmE2NGQ0YjA0NThhL3RhYmxlcmFuZ2U6ZTg0NmU5YjY5M2YzNDI2Mzk3N2FmYTY0ZDRiMDQ1OGFfNS00LTEtMS0w_f8bc12df-36b6-406e-a2e1-41063a089f74">16,967</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">MWN, LLC &#8211; related party</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4cd0390dd82a461ebe94ea5eebf97a2a_I20191231" decimals="-3" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU4NDZlOWI2OTNmMzQyNjM5NzdhZmE2NGQ0YjA0NThhL3RhYmxlcmFuZ2U6ZTg0NmU5YjY5M2YzNDI2Mzk3N2FmYTY0ZDRiMDQ1OGFfNi0xLTEtMS0w_409a902d-cb99-4a32-9ad1-9b41ddc828fa">164</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ied6eb8f6738c4de2bcbeba58131b807b_D20200101-20200630" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU4NDZlOWI2OTNmMzQyNjM5NzdhZmE2NGQ0YjA0NThhL3RhYmxlcmFuZ2U6ZTg0NmU5YjY5M2YzNDI2Mzk3N2FmYTY0ZDRiMDQ1OGFfNi0yLTEtMS0w_ea5173db-5503-4186-aea0-a3d695caedf1">12</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ied6eb8f6738c4de2bcbeba58131b807b_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="ameh:EquityMethodInvestmentsContribution" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU4NDZlOWI2OTNmMzQyNjM5NzdhZmE2NGQ0YjA0NThhL3RhYmxlcmFuZ2U6ZTg0NmU5YjY5M2YzNDI2Mzk3N2FmYTY0ZDRiMDQ1OGFfNi0zLTEtMS0w_d4ebdd07-50a3-4a47-9a76-43510bf4ee03">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibdc4f73cb093421a92e71951326cfe64_I20200630" decimals="-3" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU4NDZlOWI2OTNmMzQyNjM5NzdhZmE2NGQ0YjA0NThhL3RhYmxlcmFuZ2U6ZTg0NmU5YjY5M2YzNDI2Mzk3N2FmYTY0ZDRiMDQ1OGFfNi00LTEtMS0w_2ac44869-e530-4b0d-a5bb-f193a0c074a1">176</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU4NDZlOWI2OTNmMzQyNjM5NzdhZmE2NGQ0YjA0NThhL3RhYmxlcmFuZ2U6ZTg0NmU5YjY5M2YzNDI2Mzk3N2FmYTY0ZDRiMDQ1OGFfNy0xLTEtMS0w_2748d750-c468-40b7-97ea-35f70bc18f58">28,427</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU4NDZlOWI2OTNmMzQyNjM5NzdhZmE2NGQ0YjA0NThhL3RhYmxlcmFuZ2U6ZTg0NmU5YjY5M2YzNDI2Mzk3N2FmYTY0ZDRiMDQ1OGFfNy0yLTEtMS0w_59b667a3-e29b-4743-a6d2-4a6cdb8baf1f">2,888</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" name="ameh:EquityMethodInvestmentsContribution" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU4NDZlOWI2OTNmMzQyNjM5NzdhZmE2NGQ0YjA0NThhL3RhYmxlcmFuZ2U6ZTg0NmU5YjY5M2YzNDI2Mzk3N2FmYTY0ZDRiMDQ1OGFfNy0zLTEtMS0w_2c10d732-ca0c-46e1-a5dd-8521be57049d">500</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU4NDZlOWI2OTNmMzQyNjM5NzdhZmE2NGQ0YjA0NThhL3RhYmxlcmFuZ2U6ZTg0NmU5YjY5M2YzNDI2Mzk3N2FmYTY0ZDRiMDQ1OGFfNy00LTEtMS0xOTQx_1b0d7b3d-43af-4d06-afe2-47fde756aaa8">4,998</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU4NDZlOWI2OTNmMzQyNjM5NzdhZmE2NGQ0YjA0NThhL3RhYmxlcmFuZ2U6ZTg0NmU5YjY5M2YzNDI2Mzk3N2FmYTY0ZDRiMDQ1OGFfNy00LTEtMS0w_7d91137f-ad10-489b-bfad-c17d4176198e">26,817</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">LaSalle Medical Associates &#8212; </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">IPA Line of Business</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">LMA was founded by Dr. Albert Arteaga in 1996 and currently operates <ix:nonFraction unitRef="medical_center" contextRef="ie050574270bf4bdba21a2294fe288e97_I20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfStores" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMjMw_4f6c530b-c84e-4496-8624-d91429fe5005">six</ix:nonFraction> neighborhood medical centers through its network of approximately <ix:nonFraction unitRef="provider" contextRef="ie050574270bf4bdba21a2294fe288e97_I20200630" decimals="INF" format="ixt:numdotdecimal" name="ameh:NumberOfEmployees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMjk1_3d6ddb8d-f7f8-4b3d-905c-dc134c9916d2">2,300</ix:nonFraction> PCP and Specialists providers, treating children, adults and seniors in San Bernardino County, California. LMA&#8217;s patients are primarily served by Medi-Cal. LMA also accepts Blue Cross, Blue Shield, Molina, Care 1st, Health Net and Inland Empire Health Plan. LMA is also an IPA of independently contracted doctors, hospitals and clinics, delivering high-quality care to approximately <ix:nonFraction unitRef="patient" contextRef="ie050574270bf4bdba21a2294fe288e97_I20200630" decimals="-3" format="ixt:numdotdecimal" name="ameh:NumberOfPatients" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNjgw_dddb1ee0-ae07-40ae-91e0-a91c3fb40689">290,000</ix:nonFraction> patients in Fresno, Kings, Los Angeles, Madera, Riverside, San Bernardino and Tulare Counties. During 2012, APC-LSMA and LMA entered into a share purchase agreement whereby APC-LSMA invested $<ix:nonFraction unitRef="usd" contextRef="i82b0e8a55cc14efc8f01a2a693617301_I20121231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentAggregateCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfODc0_57b5780f-a5b5-47d9-9ce6-d718e583db35">5.0</ix:nonFraction> million for a <ix:nonFraction unitRef="number" contextRef="i82b0e8a55cc14efc8f01a2a693617301_I20121231" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfODgz_d398be11-6c57-4f5d-bcdf-71183d545b11">25</ix:nonFraction>% interest in LMA&#8217;s IPA line of business. NMM has a management services agreement with LMA. APC accounts for its investment in LMA under the equity method as APC has the ability to exercise significant influence, but not control over LMA&#8217;s operations. For the three months ended June&#160;30, 2020, APC recognized income from this investment of $<ix:nonFraction unitRef="usd" contextRef="i50b118c2801142889220d4c0dfe9842d_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMTIxNQ_e81cf6f7-87bb-4ea4-9323-7fa603e65838">0.2</ix:nonFraction> million. For the three months ended June&#160;30, 2019, APC recognized a loss from this investment of $<ix:nonFraction unitRef="usd" contextRef="i50bd805f807f463da5c172dec611a78f_D20190401-20190630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMTIyMg_352ea7d8-7fad-4cf0-aed0-50147fab1fdd">1.3</ix:nonFraction> million. For the six months ended June&#160;30, 2020 and 2019, APC recognized losses of $<ix:nonFraction unitRef="usd" contextRef="i16e5d9ad68cf4cacbf2ae6fc6a2646a1_D20200101-20200630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMTM3NA_5d09ed83-6131-4f01-ace9-63113719d907">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if450a74f42464ca8ac08b054152aac34_D20190101-20190630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMTM4MQ_a080b934-b056-43ff-a6a2-6400f5c2f90d">2.4</ix:nonFraction> million, respectively, in the accompanying consolidated statements of income. The accompanying consolidated balance sheets include the related investment balance of $<ix:nonFraction unitRef="usd" contextRef="ie050574270bf4bdba21a2294fe288e97_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMTU0MA_c041b801-d086-4a6b-a85c-3e403ea9770d">6.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic3925100079946168d1204aa44f455d9_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMTU0Nw_07cc7a4e-b50e-4600-9e1b-c0de426dbda5">6.4</ix:nonFraction> million at June&#160;30, 2020 and December&#160;31, 2019, respectively.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="ib948aa1dd1384280b4cc401c7ad173df" continuedAt="i464a45fd2cc84e8b86a2621c3036f25d">LMA&#8217;s summarized balance sheets at June&#160;30, 2020 and December&#160;31, 2019, and summarized statements of operations for the six months ended June&#160;30, 2020 and 2019, with respect to its IPA line of business are as follows (in thousands):</ix:continuation></span></div></ix:continuation><div style="text-align:justify;margin-top:10pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:10pt;"><span><br/></span></div><ix:continuation id="ib0d43c98423f47ec9d9801f9603777a8" continuedAt="i9a85768e7eef4437a0f9194bcab76f57"><ix:continuation id="i464a45fd2cc84e8b86a2621c3036f25d" continuedAt="i6b64cc3d6e8e4a15808c37f2176bf5c3"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Balance Sheets</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:70.620%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.909%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.739%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash and cash equivalents</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie1f5324dabcd473b8949ece8d5f9bcbc_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU3ZWYyNmFkMmM1OTQwZmU4ZDhkNGViOWVmNDRiZGQ3L3RhYmxlcmFuZ2U6ZTdlZjI2YWQyYzU5NDBmZThkOGQ0ZWI5ZWY0NGJkZDdfMy0xLTEtMS0w_eb36d7da-cd96-49b8-9adb-250323eb2dd7">2,852</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i953f113f807a4b629361138a8c340c45_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU3ZWYyNmFkMmM1OTQwZmU4ZDhkNGViOWVmNDRiZGQ3L3RhYmxlcmFuZ2U6ZTdlZjI2YWQyYzU5NDBmZThkOGQ0ZWI5ZWY0NGJkZDdfMy0zLTEtMS0w_70040bd0-d725-401b-be33-9fd7a8384f71">6,345</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Receivables, net</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie1f5324dabcd473b8949ece8d5f9bcbc_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU3ZWYyNmFkMmM1OTQwZmU4ZDhkNGViOWVmNDRiZGQ3L3RhYmxlcmFuZ2U6ZTdlZjI2YWQyYzU5NDBmZThkOGQ0ZWI5ZWY0NGJkZDdfNC0xLTEtMS0w_a3887c70-e309-4140-9cca-5b340410c83a">6,751</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i953f113f807a4b629361138a8c340c45_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU3ZWYyNmFkMmM1OTQwZmU4ZDhkNGViOWVmNDRiZGQ3L3RhYmxlcmFuZ2U6ZTdlZjI2YWQyYzU5NDBmZThkOGQ0ZWI5ZWY0NGJkZDdfNC0zLTEtMS0w_8c1ace17-16ff-49f4-8186-d71419cb7562">5,124</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other current assets</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie1f5324dabcd473b8949ece8d5f9bcbc_I20200630" decimals="-3" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU3ZWYyNmFkMmM1OTQwZmU4ZDhkNGViOWVmNDRiZGQ3L3RhYmxlcmFuZ2U6ZTdlZjI2YWQyYzU5NDBmZThkOGQ0ZWI5ZWY0NGJkZDdfNS0xLTEtMS0w_382c4cd5-a5cf-4ef8-89ce-a2e1877e552c">880</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i953f113f807a4b629361138a8c340c45_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU3ZWYyNmFkMmM1OTQwZmU4ZDhkNGViOWVmNDRiZGQ3L3RhYmxlcmFuZ2U6ZTdlZjI2YWQyYzU5NDBmZThkOGQ0ZWI5ZWY0NGJkZDdfNS0zLTEtMS0w_95cd63e5-ff81-4148-99e0-882891531ed2">3,526</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Loan receivable</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie1f5324dabcd473b8949ece8d5f9bcbc_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NotesAndLoansReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU3ZWYyNmFkMmM1OTQwZmU4ZDhkNGViOWVmNDRiZGQ3L3RhYmxlcmFuZ2U6ZTdlZjI2YWQyYzU5NDBmZThkOGQ0ZWI5ZWY0NGJkZDdfNi0xLTEtMS0w_59b7f13c-3d62-412e-937e-c4be967accdd">2,250</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i953f113f807a4b629361138a8c340c45_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NotesAndLoansReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU3ZWYyNmFkMmM1OTQwZmU4ZDhkNGViOWVmNDRiZGQ3L3RhYmxlcmFuZ2U6ZTdlZjI2YWQyYzU5NDBmZThkOGQ0ZWI5ZWY0NGJkZDdfNi0zLTEtMS0w_45855ee1-c578-4d23-98fa-f677887328d0">2,250</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Restricted cash</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie1f5324dabcd473b8949ece8d5f9bcbc_I20200630" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU3ZWYyNmFkMmM1OTQwZmU4ZDhkNGViOWVmNDRiZGQ3L3RhYmxlcmFuZ2U6ZTdlZjI2YWQyYzU5NDBmZThkOGQ0ZWI5ZWY0NGJkZDdfNy0xLTEtMS0w_4f031162-3bc8-418b-b9b6-90e177b62e7b">688</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i953f113f807a4b629361138a8c340c45_I20191231" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU3ZWYyNmFkMmM1OTQwZmU4ZDhkNGViOWVmNDRiZGQ3L3RhYmxlcmFuZ2U6ZTdlZjI2YWQyYzU5NDBmZThkOGQ0ZWI5ZWY0NGJkZDdfNy0zLTEtMS0w_202f9059-f785-4a41-adb1-07501eb3f22b">683</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total assets</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie1f5324dabcd473b8949ece8d5f9bcbc_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU3ZWYyNmFkMmM1OTQwZmU4ZDhkNGViOWVmNDRiZGQ3L3RhYmxlcmFuZ2U6ZTdlZjI2YWQyYzU5NDBmZThkOGQ0ZWI5ZWY0NGJkZDdfOS0xLTEtMS0w_4dc16231-1092-4dac-8b5c-1e7f160968a3">13,421</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i953f113f807a4b629361138a8c340c45_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU3ZWYyNmFkMmM1OTQwZmU4ZDhkNGViOWVmNDRiZGQ3L3RhYmxlcmFuZ2U6ZTdlZjI2YWQyYzU5NDBmZThkOGQ0ZWI5ZWY0NGJkZDdfOS0zLTEtMS0w_2b9a6ad8-f09e-42e2-a31e-60da32032d79">17,928</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Liabilities and Stockholders&#8217; (Deficit) Equity</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Current liabilities</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie1f5324dabcd473b8949ece8d5f9bcbc_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU3ZWYyNmFkMmM1OTQwZmU4ZDhkNGViOWVmNDRiZGQ3L3RhYmxlcmFuZ2U6ZTdlZjI2YWQyYzU5NDBmZThkOGQ0ZWI5ZWY0NGJkZDdfMTItMS0xLTEtMA_36f89004-f3cc-4f51-89fe-5a8bc925dc11">20,735</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i953f113f807a4b629361138a8c340c45_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU3ZWYyNmFkMmM1OTQwZmU4ZDhkNGViOWVmNDRiZGQ3L3RhYmxlcmFuZ2U6ZTdlZjI2YWQyYzU5NDBmZThkOGQ0ZWI5ZWY0NGJkZDdfMTItMy0xLTEtMA_88ab8750-0538-4f5f-b11d-349ee855ee5b">23,530</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Stockholders&#8217; deficit</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie1f5324dabcd473b8949ece8d5f9bcbc_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU3ZWYyNmFkMmM1OTQwZmU4ZDhkNGViOWVmNDRiZGQ3L3RhYmxlcmFuZ2U6ZTdlZjI2YWQyYzU5NDBmZThkOGQ0ZWI5ZWY0NGJkZDdfMTMtMS0xLTEtMA_2d4b87af-3394-4c46-b22c-1326e525303c">7,314</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i953f113f807a4b629361138a8c340c45_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU3ZWYyNmFkMmM1OTQwZmU4ZDhkNGViOWVmNDRiZGQ3L3RhYmxlcmFuZ2U6ZTdlZjI2YWQyYzU5NDBmZThkOGQ0ZWI5ZWY0NGJkZDdfMTMtMy0xLTEtMA_549be60c-c7c6-440f-83e7-3b50a6a3da05">5,602</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total liabilities and stockholders&#8217; deficit</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie1f5324dabcd473b8949ece8d5f9bcbc_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU3ZWYyNmFkMmM1OTQwZmU4ZDhkNGViOWVmNDRiZGQ3L3RhYmxlcmFuZ2U6ZTdlZjI2YWQyYzU5NDBmZThkOGQ0ZWI5ZWY0NGJkZDdfMTUtMS0xLTEtMA_59cbfc9b-95ff-4fed-8882-8cef9f77a2e6">13,421</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i953f113f807a4b629361138a8c340c45_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU3ZWYyNmFkMmM1OTQwZmU4ZDhkNGViOWVmNDRiZGQ3L3RhYmxlcmFuZ2U6ZTdlZjI2YWQyYzU5NDBmZThkOGQ0ZWI5ZWY0NGJkZDdfMTUtMy0xLTEtMA_f8e6f5e3-16e6-4fe7-b200-f8d1d411f0c2">17,928</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:10pt;"><span><br/></span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Statements of Operations</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:69.114%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.809%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.344%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i475942101d5b4fb6bf5d97d6d803565f_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmE4ODM5YmVmZTVjYjQ4Njg4YTQ0ZjE3NDliYWY2ODZkL3RhYmxlcmFuZ2U6YTg4MzliZWZlNWNiNDg2ODhhNDRmMTc0OWJhZjY4NmRfMy0xLTEtMS0w_21ba569d-e176-446e-a2ad-f039df518178">92,113</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8e6db84cfdcf4e68a45f60ccbfcef795_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmE4ODM5YmVmZTVjYjQ4Njg4YTQ0ZjE3NDliYWY2ODZkL3RhYmxlcmFuZ2U6YTg4MzliZWZlNWNiNDg2ODhhNDRmMTc0OWJhZjY4NmRfMy0zLTEtMS0w_c9d5f448-aa93-4c74-b16f-ad755189ba5a">93,434</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Expenses</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i475942101d5b4fb6bf5d97d6d803565f_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmE4ODM5YmVmZTVjYjQ4Njg4YTQ0ZjE3NDliYWY2ODZkL3RhYmxlcmFuZ2U6YTg4MzliZWZlNWNiNDg2ODhhNDRmMTc0OWJhZjY4NmRfNC0xLTEtMS0w_1459f77d-0ac4-484b-ba27-b3bd4dafc9c5">93,680</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8e6db84cfdcf4e68a45f60ccbfcef795_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmE4ODM5YmVmZTVjYjQ4Njg4YTQ0ZjE3NDliYWY2ODZkL3RhYmxlcmFuZ2U6YTg4MzliZWZlNWNiNDg2ODhhNDRmMTc0OWJhZjY4NmRfNC0zLTEtMS0w_5514fd06-401b-4773-ade9-81de1e530ed4">102,845</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net loss</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i475942101d5b4fb6bf5d97d6d803565f_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmE4ODM5YmVmZTVjYjQ4Njg4YTQ0ZjE3NDliYWY2ODZkL3RhYmxlcmFuZ2U6YTg4MzliZWZlNWNiNDg2ODhhNDRmMTc0OWJhZjY4NmRfNi0xLTEtMS0w_a4c86c90-f067-4850-9693-7c6cc94f5535">1,567</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8e6db84cfdcf4e68a45f60ccbfcef795_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmE4ODM5YmVmZTVjYjQ4Njg4YTQ0ZjE3NDliYWY2ODZkL3RhYmxlcmFuZ2U6YTg4MzliZWZlNWNiNDg2ODhhNDRmMTc0OWJhZjY4NmRfNi0zLTEtMS0w_dcdfdda9-5518-414e-919f-b967376328c2">9,411</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:continuation><div style="text-align:justify;margin-top:10pt;"><span><br/></span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Pacific Medical Imaging and Oncology Center, Inc.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Incorporated in California in 2004, PMIOC provides comprehensive diagnostic imaging services using state-of-the-art technology. PMIOC offers high-quality diagnostic services, such as MRI/MRA, PET/CT, CT, nuclear medicine, ultrasound, digital x-rays, bone densitometry and digital mammography, at its facilities.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In July&#160;2015, APC-LSMA and PMIOC entered into a share purchase agreement whereby APC-LSMA invested $<ix:nonFraction unitRef="usd" contextRef="ia7524fa990e04653b73c016dce167669_I20150731" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentAggregateCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMjI3Nw_3d545968-0c8f-4a4e-96e3-951386daba71">1.2</ix:nonFraction> million for a <ix:nonFraction unitRef="number" contextRef="ia7524fa990e04653b73c016dce167669_I20150731" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMjI4Ng_b968784e-1405-4109-a265-a80eed3f122a">40</ix:nonFraction>% ownership interest in PMIOC.</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">APC and PMIOC have an Ancillary Service Contract together whereby PMIOC provides covered services on behalf of APC to enrollees of the plans of APC. Under the Ancillary Service Contract, APC paid PMIOC fees of approximately $<ix:nonFraction unitRef="usd" contextRef="id6aa1fa085114394a6e85030a974182f_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsForFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMjU0Mw_4c62628b-9364-42f1-9488-a4c0f644af8a">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6c258e6f71044221a1fb158a0d855efb_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsForFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMjU1MA_ebe6b8cb-23d3-4324-aa93-10449dcd4d18">0.6</ix:nonFraction> million, for the three months ended June&#160;30, 2020 and 2019, respectively, and fees of approximately $<ix:nonFraction unitRef="usd" contextRef="i6610cb295b3947a5b0b3747521ffcc00_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsForFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMjYyOQ_50080cf3-ac12-4822-a537-94a739ef15d0">1.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i5aa2f3de1fe244a09059fe1a984dab17_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsForFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMjYzNg_ecc195bc-b845-4a1a-9b8d-ded222251d42">1.4</ix:nonFraction> million for the six months ended June&#160;30, 2020 and 2019. APC accounts for its investment in PMIOC under the equity method of accounting as APC has the ability to exercise significant influence, but not control over PMIOC&#8217;s operations. For the three months ended June&#160;30, 2020, APC recognized a loss from this investment of $<ix:nonFraction unitRef="usd" contextRef="i9b5e25abcace4fa0adbbc4c02841298d_D20200401-20200630" decimals="-2" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMjk1Nw_9865f8c5-3c22-4ca6-b34a-d403461aa7c5">10,200</ix:nonFraction>. For the three months ended June&#160;30, 2019, APC recognized income from this investment of $<ix:nonFraction unitRef="usd" contextRef="i36438be782f84c0ab30c9128983e63ae_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMjk2NA_409bc36d-af9a-4cd8-9e20-67e76635059e">0.1</ix:nonFraction> million. For the six months ended June&#160;30, 2020 and 2019, APC recognized income of $<ix:nonFraction unitRef="usd" contextRef="i8bec381b83b140e5a9bfeac12bc0b911_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMjk4Ng_0240e2e5-21e5-4435-8450-0769f16e77cc">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ib53dd899d00f4b69a3502812c5cc65dc_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMjk5Mw_c301daf0-72a9-49b0-b837-a35b189bd4ed">0.2</ix:nonFraction> million, respectively, in the accompanying consolidated statements of income. The accompanying consolidated balance sheets include the related investment balance of $<ix:nonFraction unitRef="usd" contextRef="i157f8e47c0564056805baaf2a463ba46_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMzA5Ng_bd8183e2-c092-4d80-9165-6aac929b41e4">1.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia85acbdd13224660a5969a4561ebdc1c_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMzEwMw_fea899fb-6d5b-49f9-9bc5-f4b07f5cf870">1.4</ix:nonFraction> million at June&#160;30, 2020 and December&#160;31, 2019, respectively.</span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><ix:continuation id="i9a85768e7eef4437a0f9194bcab76f57" continuedAt="ib716959d7f0e40df9b4fa7f138d9d38b"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Universal Care, Inc.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">UCI is a privately held health plan that has been in operation since 1985. UCI holds a license under the California Knox-Keene Health Care Services Plan Act to operate as a full-service health plan. UCI contracts with CMS under the Medicare Advantage Prescription Drug Program.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2015, UCAP purchased <ix:nonFraction unitRef="shares" contextRef="i5150473a0c7e46868c76e2b4a7a9fc96_I20150831" decimals="INF" format="ixt:numdotdecimal" name="ameh:EquityMethodInvestmentsPurchaseOfShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMzQ2OA_39a48ee8-0cf8-4f2e-8098-498b7cc68fdd">100,000</ix:nonFraction> shares of UCI class A-2 voting common stock from UCI for $<ix:nonFraction unitRef="usd" contextRef="i6176328037a345afb5006679c54758ba_D20150801-20150831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMzUyOA_f4b7796e-5392-42e7-bbaa-ed67d1f6e633">10.0</ix:nonFraction> million, which shares comprise <ix:nonFraction unitRef="number" contextRef="i9e93302086af4602804bb434c398a652_I20150831" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMzU1NA_9dff0d51-6557-42d2-9404-c655abbd19a2">48.9</ix:nonFraction>% of UCI&#8217;s total outstanding shares and <ix:nonFraction unitRef="number" contextRef="i5150473a0c7e46868c76e2b4a7a9fc96_I20150831" decimals="2" name="ameh:EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMzU5NQ_31123b42-63f9-41a8-9fe3-e55ca5b88f17">50</ix:nonFraction>% of UCI&#8217;s voting common stock. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On April 30, 2020, UCAP completed the sale of its <ix:nonFraction unitRef="number" contextRef="i170e72202cdd4b73a7b7a48e85b5dd54_I20200430" decimals="3" name="ameh:EquityMethodInvestmentOwnershipPercentageDisposed" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNDE0Nw_39e04407-d5c5-47a6-aee8-da0d1338461e">48.9</ix:nonFraction>% ownership interest in UCI to Bright for approximately $<ix:nonFraction unitRef="usd" contextRef="i19617cb0db6c48aea309f2c2b2bbd2ca_D20200430-20200430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNDIwNA_1aa9125f-972d-4547-b7a4-4d8b1b93b0a2">69.2</ix:nonFraction> million in cash proceeds (including $<ix:nonFraction unitRef="usd" contextRef="i2e1d4837a47949caa2ce6ff7a21167cc_D20200430-20200430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRepaymentsOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNDIzNQ_490179b7-d72e-416b-b587-1adec34d4052">16.5</ix:nonFraction> million as repayment of indebtedness owed to APC), plus non-cash consideration consisting of shares of Bright Health, Inc.&#8217;s preferred stock having an estimated fair value of approximately $<ix:nonFraction unitRef="usd" contextRef="i4d3be425c4e74837aa2e7e572caa5cdc_I20200630" decimals="-5" format="ixt:numdotdecimal" name="ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNDQxNA_ca8c7077-106b-424d-bd42-42576007b30a">36.2</ix:nonFraction> million on the date of sale, included in investments in privately held entities. The fair value of the preferred shares was determined utilizing a market approach which includes significant unobservable inputs (Level 3) including forecasted revenue along with estimates of revenue multiples, volatility and time-to-liquidity. In addition, pursuant to the terms of the stock purchase agreement, APC has a beneficial interest in the equity method investment sold. The estimated fair value of such interest on April 30, 2020 was&#160;$<ix:nonFraction unitRef="usd" contextRef="i4a23351d6549453987064b1ed4ccd7a5_D20200430-20200430" decimals="-5" format="ixt:numdotdecimal" name="ameh:AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNDY2Mg_c54e1764-b51d-44b7-b69d-3727973f83df">15.7</ix:nonFraction> million and is included in "Other assets" in the accompanying consolidated balance sheets. The beneficial interest is the result of a gross margin provision in the stock purchase agreement which entitles UCAP to potentially receive additional cash and preferred shares (currently held in an escrow account with cash of $<ix:nonFraction unitRef="usd" contextRef="i7ca6abb962c644ebad2d7e2afff211f2_I20200430" decimals="-5" format="ixt:numdotdecimal" name="ameh:EquityMethodInvestmentSaleContingentConsiderationCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMTA5OTUxMTY0NjU5Mg_79b848e1-8b86-4b13-b2b7-e8d139a7a030">15.6</ix:nonFraction>&#160;million and preferred shares with an estimated fair value of $<ix:nonFraction unitRef="usd" contextRef="i7ca6abb962c644ebad2d7e2afff211f2_I20200430" decimals="-5" format="ixt:numdotdecimal" name="ameh:EquityMethodInvestmentSaleContingentConsiderationPreferredShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMTA5OTUxMTY0NjYwNw_ac207a06-b774-4d2c-aadf-9b692fbe782f">6.4</ix:nonFraction>&#160;million, total estimated fair value of $<ix:nonFraction unitRef="usd" contextRef="i7ca6abb962c644ebad2d7e2afff211f2_I20200430" decimals="-5" format="ixt:numdotdecimal" name="ameh:EquityMethodInvestmentSaleContingentConsiderationFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMTA5OTUxMTY0NjYyMQ_c5986bfa-5b8c-4aa2-b810-3d701a30c7a8">22.0</ix:nonFraction>&#160;million on the date of sale) based on the gross margin of UCI for calendar year 2020 as measured against a target. The amount to be received varies dependent upon the gross margin as compared to the target but cannot exceed the amounts that are in the escrow account. Additionally, the stock purchase agreement includes a tangible net equity provision that may result in the receipt or payment of additional amounts based on a comparison of final tangible net equity of UCI on the date of sale (determined with the benefit of one year of hindsight) as compared to the estimated tangible net equity at the time of sale. It is expected that settlement of the beneficial interest will begin in the second half of 2021. The Company determined the fair value of the beneficial interest using an income approach which includes significant unobservable inputs (Level 3). Specifically, the Company utilized a probability weighted discounted cash flow model using a risk-free treasury rate to estimate fair value which considered various scenarios of gross margin adjustment and the impact of each adjustment to the expected proceeds from the escrow account and assigned probabilities to each such scenario in determining fair value. The gross margin adjustment is defined as three times any deficit in actual gross margin of UCI for the year ended December 31, 2020 below a target gross margin unless such deficit is within a specific collar amount.</span></div><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="ameh:EquityMethodInvestmentGainOnSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMTA5OTUxMTY0NjYzNQ_94a2a8aa-938d-408a-aafb-87558a6b0e49" escape="true"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The gain on sale of equity method investment recognized in connection with this transaction was determined as follows:</span></div><div style="text-align:justify;margin-top:10pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:78.116%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.884%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount (in '000s)</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash proceeds (excludes proceeds to settle indebtedness owed to APC from UCI)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if482ba97bdb84bda9cf6288b01d207b9_D20200430-20200430" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjQ1ZTZmY2ZjZmI0MzRlNjlhOTJjMGMwMDgzMDUzMTJiL3RhYmxlcmFuZ2U6NDVlNmZjZmNmYjQzNGU2OWE5MmMwYzAwODMwNTMxMmJfMi0xLTEtMS02NzI0_3cbb46b3-32c9-4804-b299-7d941a00adfc">52,743</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Preferred shares in Bright Health, Inc.</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcfb848097a34b5a83ecc1ab0b752557_I20200430" decimals="-3" format="ixt:numdotdecimal" name="ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjQ1ZTZmY2ZjZmI0MzRlNjlhOTJjMGMwMDgzMDUzMTJiL3RhYmxlcmFuZ2U6NDVlNmZjZmNmYjQzNGU2OWE5MmMwYzAwODMwNTMxMmJfMy0xLTEtMS02NzI0_873ab673-ad44-474b-888d-01fed296b150">36,179</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Beneficial interest in UCI</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if482ba97bdb84bda9cf6288b01d207b9_D20200430-20200430" decimals="-3" format="ixt:numdotdecimal" name="ameh:AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjQ1ZTZmY2ZjZmI0MzRlNjlhOTJjMGMwMDgzMDUzMTJiL3RhYmxlcmFuZ2U6NDVlNmZjZmNmYjQzNGU2OWE5MmMwYzAwODMwNTMxMmJfNC0xLTEtMS02NzI0_63f4831f-4179-4d44-9ef7-a669817e2d15">15,723</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Carrying value of equity method investment on date of sale</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9beb3a18cbe642a8aa4c713b758e5b41_I20200430" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjQ1ZTZmY2ZjZmI0MzRlNjlhOTJjMGMwMDgzMDUzMTJiL3RhYmxlcmFuZ2U6NDVlNmZjZmNmYjQzNGU2OWE5MmMwYzAwODMwNTMxMmJfNS0xLTEtMS02NzI0_dcd30e6b-fd13-4541-86a7-948259a916dd">4,998</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gain on sale of equity method investment</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if482ba97bdb84bda9cf6288b01d207b9_D20200430-20200430" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjQ1ZTZmY2ZjZmI0MzRlNjlhOTJjMGMwMDgzMDUzMTJiL3RhYmxlcmFuZ2U6NDVlNmZjZmNmYjQzNGU2OWE5MmMwYzAwODMwNTMxMmJfNy0xLTEtMS02NzI2_e52f0457-1e12-42d7-b66c-f0e441906dc4">99,647</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three months ended June 30, 2020 and June&#160;30, 2019 APC recorded income from this investment of approximately $<ix:nonFraction unitRef="usd" contextRef="ia1f85d23728f488aa706b6728075d6a6_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMTA5OTUxMTY0NjYzOA_649dad1e-f343-4cf7-b558-5355fbef63d1">0.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i371098e379a64f1ab0452b0340ffdcd8_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNDk0NzgwMjMzNTQyMA_031c1551-b580-4aa3-a1d2-c0474f1ca919">4.5</ix:nonFraction> million. For the six months ended June 30, 2020 and June 30, 2019 APC recorded income from this investment of approximately $<ix:nonFraction unitRef="usd" contextRef="i0a335fe94da74cc1b74cfe701830c693_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMTA5OTUxMTY0NjY1Mg_7adb48c5-34a4-4b37-8eab-52d64de25641">3.6</ix:nonFraction>&#160;million  and $<ix:nonFraction unitRef="usd" contextRef="icceb687a46d94c0d8314ae9896a926f0_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNDk0NzgwMjMzNTQ0OQ_d7ad20e4-9b4c-4fd7-8775-fcbea77f0101">5.5</ix:nonFraction> million in the accompanying consolidated statements of income, respectively. As a result of the sale, there was <ix:nonFraction unitRef="usd" contextRef="iadefc20aa4134071bd9a5346e792b746_I20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMTA5OTUxMTY0MjU2MQ_0d4099db-d941-40ec-be2a-52d51c96a9c2">no</ix:nonFraction> investment balance as of June&#160;30, 2020 as compared to an investment balance of $<ix:nonFraction unitRef="usd" contextRef="i1d9b625d40984cada77fed26b2662304_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNDk0NzgwMjMzNTY1NA_39915b5d-2fdb-44f9-a1bd-af0ee766ab98">1.4</ix:nonFraction> million as of December&#160;31, 2019.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i6b64cc3d6e8e4a15808c37f2176bf5c3" continuedAt="ie38b9793ce5d40a1968f446d4a26ea95">UCI's balance sheet at December 31, 2019 and statements of income for the four months ended April 30, 2020 and six months ended June 30, 2019 are as follows (in thousands):</ix:continuation></span></div></ix:continuation><div style="text-align:justify;margin-top:10pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><ix:continuation id="ib716959d7f0e40df9b4fa7f138d9d38b" continuedAt="id225051e357f4607abd24790d60efed1"><ix:continuation id="ie38b9793ce5d40a1968f446d4a26ea95" continuedAt="i6606f623a075417bb3742db633ff23b6"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Balance Sheets</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:83.526%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.474%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash and cash equivalents</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibd24a1722d5b442bba297bcc460eb0c0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmMzZGQ1MmM1OWRhNDRiZmM4YjAzMzkyZDk1M2Q5MDk1L3RhYmxlcmFuZ2U6YzNkZDUyYzU5ZGE0NGJmYzhiMDMzOTJkOTUzZDkwOTVfMy0zLTEtMS02Mzc1_a6ba49b4-9527-4001-a8d6-2d9ec467533e">33,890</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Receivables, net</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibd24a1722d5b442bba297bcc460eb0c0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmMzZGQ1MmM1OWRhNDRiZmM4YjAzMzkyZDk1M2Q5MDk1L3RhYmxlcmFuZ2U6YzNkZDUyYzU5ZGE0NGJmYzhiMDMzOTJkOTUzZDkwOTVfNC0zLTEtMS02Mzc1_4f252e2e-8159-4dc3-b3e6-843c2b1d2eba">63,843</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other current assets</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibd24a1722d5b442bba297bcc460eb0c0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmMzZGQ1MmM1OWRhNDRiZmM4YjAzMzkyZDk1M2Q5MDk1L3RhYmxlcmFuZ2U6YzNkZDUyYzU5ZGE0NGJmYzhiMDMzOTJkOTUzZDkwOTVfNS0zLTEtMS02Mzc1_446a6ca7-dae7-4b2e-b5f5-99d347997bfb">38,280</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Loan receivable</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibd24a1722d5b442bba297bcc460eb0c0_I20191231" decimals="-3" name="us-gaap:NotesAndLoansReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmMzZGQ1MmM1OWRhNDRiZmM4YjAzMzkyZDk1M2Q5MDk1L3RhYmxlcmFuZ2U6YzNkZDUyYzU5ZGE0NGJmYzhiMDMzOTJkOTUzZDkwOTVfNi0zLTEtMS02Mzc1_1355d7d5-a6a3-4a87-bb3c-68d8de4268c1">882</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Restricted cash</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibd24a1722d5b442bba297bcc460eb0c0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmMzZGQ1MmM1OWRhNDRiZmM4YjAzMzkyZDk1M2Q5MDk1L3RhYmxlcmFuZ2U6YzNkZDUyYzU5ZGE0NGJmYzhiMDMzOTJkOTUzZDkwOTVfNy0zLTEtMS02Mzc1_6bc78e0a-4756-45d4-9a15-ba5cfe282471">4,021</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total assets</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibd24a1722d5b442bba297bcc460eb0c0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmMzZGQ1MmM1OWRhNDRiZmM4YjAzMzkyZDk1M2Q5MDk1L3RhYmxlcmFuZ2U6YzNkZDUyYzU5ZGE0NGJmYzhiMDMzOTJkOTUzZDkwOTVfOS0zLTEtMS02Mzc1_045a4916-3c9b-4c7d-b8a6-382417f692f5">140,916</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Liabilities and Stockholders&#8217; (Deficit) Equity</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Current liabilities</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibd24a1722d5b442bba297bcc460eb0c0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmMzZGQ1MmM1OWRhNDRiZmM4YjAzMzkyZDk1M2Q5MDk1L3RhYmxlcmFuZ2U6YzNkZDUyYzU5ZGE0NGJmYzhiMDMzOTJkOTUzZDkwOTVfMTItMy0xLTEtNjM3NQ_5d8df3ef-e5f8-4e87-83cc-66dbd83cb30e">128,330</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibd24a1722d5b442bba297bcc460eb0c0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmMzZGQ1MmM1OWRhNDRiZmM4YjAzMzkyZDk1M2Q5MDk1L3RhYmxlcmFuZ2U6YzNkZDUyYzU5ZGE0NGJmYzhiMDMzOTJkOTUzZDkwOTVfMTMtMS0xLTEtNjQyNA_a59f5fbe-c8e5-48db-b779-4da88e523706">33,133</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Stockholders&#8217; deficit</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibd24a1722d5b442bba297bcc460eb0c0_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmMzZGQ1MmM1OWRhNDRiZmM4YjAzMzkyZDk1M2Q5MDk1L3RhYmxlcmFuZ2U6YzNkZDUyYzU5ZGE0NGJmYzhiMDMzOTJkOTUzZDkwOTVfMTMtMy0xLTEtNjM3NQ_44fcf966-0ca8-4727-8757-684b2152561e">20,547</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total liabilities and stockholders&#8217; deficit</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibd24a1722d5b442bba297bcc460eb0c0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmMzZGQ1MmM1OWRhNDRiZmM4YjAzMzkyZDk1M2Q5MDk1L3RhYmxlcmFuZ2U6YzNkZDUyYzU5ZGE0NGJmYzhiMDMzOTJkOTUzZDkwOTVfMTUtMy0xLTEtNjM3NQ_f89cae62-617d-4ca3-a05b-e7a2db8fac63">140,916</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Statements of Operations</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:59.549%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:16.859%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:16.862%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Four Months Ended</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">April 30,<br/>2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2019</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e9c10a96719436f9bc86a015712be60_D20200101-20200430" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjc2NjgwOTg3M2QzODQ1ZGJiYzEwODA0NDI3MTJlMTA2L3RhYmxlcmFuZ2U6NzY2ODA5ODczZDM4NDVkYmJjMTA4MDQ0MjcxMmUxMDZfMy0xLTEtMS02Mzc1_0aa4c80d-b750-4bf0-b9c1-6e184654e357">195,308</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie24c440e5f474a2884cc40d10efab865_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjc2NjgwOTg3M2QzODQ1ZGJiYzEwODA0NDI3MTJlMTA2L3RhYmxlcmFuZ2U6NzY2ODA5ODczZDM4NDVkYmJjMTA4MDQ0MjcxMmUxMDZfMy0zLTEtMS02Mzc1_bbf18ccb-2570-4be3-a660-586b6f533866">247,517</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Expenses</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e9c10a96719436f9bc86a015712be60_D20200101-20200430" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjc2NjgwOTg3M2QzODQ1ZGJiYzEwODA0NDI3MTJlMTA2L3RhYmxlcmFuZ2U6NzY2ODA5ODczZDM4NDVkYmJjMTA4MDQ0MjcxMmUxMDZfNC0xLTEtMS02Mzc1_28475de5-0b83-4d52-9e26-81a2eca127cc">189,028</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie24c440e5f474a2884cc40d10efab865_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjc2NjgwOTg3M2QzODQ1ZGJiYzEwODA0NDI3MTJlMTA2L3RhYmxlcmFuZ2U6NzY2ODA5ODczZDM4NDVkYmJjMTA4MDQ0MjcxMmUxMDZfNC0zLTEtMS02Mzc1_c2dc681c-d0a6-4bd0-b8db-217584922819">239,389</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income before benefit from income taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e9c10a96719436f9bc86a015712be60_D20200101-20200430" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjc2NjgwOTg3M2QzODQ1ZGJiYzEwODA0NDI3MTJlMTA2L3RhYmxlcmFuZ2U6NzY2ODA5ODczZDM4NDVkYmJjMTA4MDQ0MjcxMmUxMDZfNi0xLTEtMS02NDc1_994b798e-80c3-49f4-87f0-bd62371bb7d9">6,280</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie24c440e5f474a2884cc40d10efab865_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjc2NjgwOTg3M2QzODQ1ZGJiYzEwODA0NDI3MTJlMTA2L3RhYmxlcmFuZ2U6NzY2ODA5ODczZDM4NDVkYmJjMTA4MDQ0MjcxMmUxMDZfNi0zLTEtMS02NDY5_d7890d36-a2b3-44dd-9f55-0643b83a020c">8,128</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Benefit from income taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e9c10a96719436f9bc86a015712be60_D20200101-20200430" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjc2NjgwOTg3M2QzODQ1ZGJiYzEwODA0NDI3MTJlMTA2L3RhYmxlcmFuZ2U6NzY2ODA5ODczZDM4NDVkYmJjMTA4MDQ0MjcxMmUxMDZfNy0xLTEtMS02NDc1_87046e36-736e-4363-8728-64f9b1914c5d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie24c440e5f474a2884cc40d10efab865_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjc2NjgwOTg3M2QzODQ1ZGJiYzEwODA0NDI3MTJlMTA2L3RhYmxlcmFuZ2U6NzY2ODA5ODczZDM4NDVkYmJjMTA4MDQ0MjcxMmUxMDZfNy0zLTEtMS02NDY5_25b75adb-1e87-44c1-b399-e4447145fd3e">3,167</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e9c10a96719436f9bc86a015712be60_D20200101-20200430" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjc2NjgwOTg3M2QzODQ1ZGJiYzEwODA0NDI3MTJlMTA2L3RhYmxlcmFuZ2U6NzY2ODA5ODczZDM4NDVkYmJjMTA4MDQ0MjcxMmUxMDZfNi0xLTEtMS02Mzc1_be5c82b1-a5be-4f7f-87a0-68940ff6caa6">6,280</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie24c440e5f474a2884cc40d10efab865_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjc2NjgwOTg3M2QzODQ1ZGJiYzEwODA0NDI3MTJlMTA2L3RhYmxlcmFuZ2U6NzY2ODA5ODczZDM4NDVkYmJjMTA4MDQ0MjcxMmUxMDZfNi0zLTEtMS02Mzc1_35e292c0-7901-432f-aced-0c7460908373">11,295</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:continuation><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Diagnostic Medical Group</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May 2016, David C.P. Chen M.D., individually, and APC-LSMA, entered into a share purchase agreement whereby APC-LSMA acquired a <ix:nonFraction unitRef="number" contextRef="ifaefb6ce9ff24e308243a14d1cc7814f_I20160514" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNTE0Ng_f6a360ca-b8ae-410a-9b58-6284c121c92b">40</ix:nonFraction>% ownership interest in DMG.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">APC accounts for its investment in DMG under the equity method of accounting as APC has the ability to exercise significant influence, but not control over DMG&#8217;s operations. For the three months ended June&#160;30, 2020 and 2019, APC recognized loss and income from this investment of $<ix:nonFraction unitRef="usd" contextRef="i74f5fd5d4b8a44e882631f206e038bd7_D20200401-20200630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNTQ0Nw_cd4e87dd-532a-4388-ab1e-eb8f7a2842e6">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i61394655c4ad4039984a2f0503f8cb4d_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNTQ1NA_917feed2-2b5f-4eb6-9fb9-fbd228b78af1">0.2</ix:nonFraction> million, respectively, in the consolidated statements of income. For the six months ended  June&#160;30, 2020 and 2019, APC recognized loss and income from investment of $<ix:nonFraction unitRef="usd" contextRef="i0cc11225aa314266a6ef2696d7d4dfad_D20200101-20200630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNTQ3Ng_9febc6df-35b3-49fb-9124-3a925df57a31">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="id158f4ef37084b119e97ae1e8a41d0c9_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNTQ4Mw_7efd087a-8599-47c7-9fef-9b8625e3e069">0.4</ix:nonFraction> million, respectively, in the consolidated statements of income. The accompanying consolidated balance sheets include the related investment balances of $<ix:nonFraction unitRef="usd" contextRef="i314c4ccc348b436ba49cb07ab3848d81_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNTYzMQ_9d78110e-fb79-4fae-9392-0b0f2f13be6f">2.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5fd06ba095124e0abdcc0d7f91fc1472_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNjA0NzMxMzk2NzQ5OA_8010972d-e5e0-4efc-b4cb-8041b7685593">2.3</ix:nonFraction> million as of June&#160;30, 2020 and December&#160;31, 2019, respectively.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">531 W. College LLC &#8211; Related Party</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2018, College Street Investment LP, a California limited partnership (&#8220;CSI&#8221;), APC and NMM entered into an operating agreement to govern the limited liability company, 531 W. College, LLC and the conduct of its business, and to specify their relative rights and obligations. CSI, APC and NMM, each owns <ix:nonFraction unitRef="number" contextRef="ic80c408963dd4f07a4718bf817b59f78_I20180630" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNjAxMA_96a8e288-46b6-4da6-bf81-32983abcbbda">50</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="ib33ce2cceba04d82b64d3b892ada4ad8_I20180630" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNjAxNA_d3c6e4c5-9f69-4497-968f-3b68646edf18">25</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="id2d9c71932034be7bd4932da0626f712_I20180630" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNjAyMQ_9f158626-d6d4-4e50-b385-57324f398ae0">25</ix:nonFraction>%, respectively, of member units based on initial capital contributions of $<ix:nonFraction unitRef="usd" contextRef="ic80c408963dd4f07a4718bf817b59f78_I20180630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:MembersCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNjA5Nw_dc228c4f-7e60-4b7b-862c-6a78a43015bd">16.7</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ib33ce2cceba04d82b64d3b892ada4ad8_I20180630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:MembersCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNjEwMQ_43f9585b-57c5-4a46-aad4-ecc01c8c51f3">8.3</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="id2d9c71932034be7bd4932da0626f712_I20180630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:MembersCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNjEwOQ_fcfc97d3-05f5-4633-a59d-5d65c9fbf5d7">8.3</ix:nonFraction> million, respectively.</span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><ix:continuation id="id225051e357f4607abd24790d60efed1" continuedAt="i634896cd37ff47c3a97e3ec9f32fa211"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2018, 531 W. College, LLC closed its purchase of a non-operational hospital located in Los Angeles from Societe Francaise De Bienfaisance Mutuelle De Los Angeles, a California nonprofit corporation, for a total purchase price of $<ix:nonFraction unitRef="usd" contextRef="id61177debadf4225a858af823bca90d6_D20180601-20180630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireRealEstate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNjM2OA_8b3175c5-2594-48e3-8752-61dedf39190d">33.3</ix:nonFraction> million. On April 23, 2019, NMM and APC entered into an agreement whereby NMM assigned and APC assumed NMM&#8217;s <ix:nonFraction unitRef="number" contextRef="idda53a861d504beea7993e7de2f52ee0_I20190423" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNjQ3Mg_5781b0ed-049b-4f38-98cb-fd42ee6bd021">25</ix:nonFraction>% membership interest in 531 W. College, LLC for approximately $<ix:nonFraction unitRef="usd" contextRef="idda53a861d504beea7993e7de2f52ee0_I20190423" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentAggregateCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNjUzNg_e489a574-7402-48f2-be8b-2bd3cd24ead3">8.3</ix:nonFraction> million. Subsequently, APC has a <ix:nonFraction unitRef="number" contextRef="i74302930c31d45b8a80be7e006522de5_I20200630" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNjU2NA_0038b376-cf7e-428d-9313-192425b1f984">50</ix:nonFraction>% ownership in 531 W. College LLC with a total investment balance of approximately $<ix:nonFraction unitRef="usd" contextRef="ic39201e9036d43759acb734c62b0b8d4_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNjY0OA_8037cf08-60ae-4760-baf8-8abc1ee5e94d">17.0</ix:nonFraction> million. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">APC accounts for its investment in 531 W. College, LLC under the equity method of accounting as APC has the ability to exercise significant influence, but not control over the operations of this joint venture. For the three months ended June&#160;30, 2020 and 2019, APC recognized loss and income of $<ix:nonFraction unitRef="usd" contextRef="i051b582accf543bc87134371ea6f7726_D20200401-20200630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNjkyOA_0e2f4b87-33e6-4737-b2e1-74f265d8ed47">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib8b7f2e4ee2a4d2c9a3e1fe33363b2d3_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNjkzNg_c16adb51-47c4-4ce2-85e0-74b8b0d091bf">12,649</ix:nonFraction>, respectively. For the six months ended June&#160;30, 2020 and 2019, APC recorded losses of $<ix:nonFraction unitRef="usd" contextRef="ia3ac42f4999448a69359a25a83b0f908_D20200101-20200630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNjk1OA_62bf6f55-abbd-481a-91a6-cc657368a689">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if55f174a731f484e9a8b88ed6a99666e_D20190101-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNjk2NQ_ef99054e-6bc7-4632-91dc-212ab364299d">34,319</ix:nonFraction> in the accompanying consolidated statements of income, respectively. During the period ended June&#160;30, 2020, the Company contributed $<ix:nonFraction unitRef="usd" contextRef="i357af7bf55294d7b86954b0bf136c8c6_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="ameh:EquityMethodInvestmentsContribution" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNzA3NQ_6277d5d3-8d65-4ad2-be33-e7751edc73b6">0.5</ix:nonFraction> million to 531 W. College LLC as part of its <ix:nonFraction unitRef="number" contextRef="i74302930c31d45b8a80be7e006522de5_I20200630" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNzExNQ_20ae1a4d-f05e-45fb-a43f-5f2effc2fdc0">50</ix:nonFraction>% interest and had investment balances of $<ix:nonFraction unitRef="usd" contextRef="ic39201e9036d43759acb734c62b0b8d4_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNzE1OA_8037cf08-60ae-4760-baf8-8abc1ee5e94d">17.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3451c081a11c49aea7b55e24c90e4721_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNzE2NQ_dbccce6f-a3a5-426c-be72-68cca3ad2990">16.7</ix:nonFraction> million, respectively, at June&#160;30, 2020 and December&#160;31, 2019. </span></div><ix:continuation id="i6606f623a075417bb3742db633ff23b6"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">531 W. College LLC&#8217;s balance sheets at June&#160;30, 2020 and December&#160;31, 2019, and statements of operations for the six months ended June&#160;30, 2020 and 2019, are as follows (in thousands):</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Balance sheets</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:71.206%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.323%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.739%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idbb6a15f7620432bb5505e89f3004b9c_I20200630" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjU1OTk2ZDRjYTk4ZjQ1ZWFiOWY4ZGEzMmIwZDBlNjU0L3RhYmxlcmFuZ2U6NTU5OTZkNGNhOThmNDVlYWI5ZjhkYTMyYjBkMGU2NTRfMy0xLTEtMS0w_94e0ea12-3055-4177-9bbd-bf1736abdc61">126</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i703c2ff9263240b296697549156a727f_I20191231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjU1OTk2ZDRjYTk4ZjQ1ZWFiOWY4ZGEzMmIwZDBlNjU0L3RhYmxlcmFuZ2U6NTU5OTZkNGNhOThmNDVlYWI5ZjhkYTMyYjBkMGU2NTRfMy0zLTEtMS0w_fc709e81-0cd9-4799-baf9-39d6c40dca80">139</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other current assets</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idbb6a15f7620432bb5505e89f3004b9c_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjU1OTk2ZDRjYTk4ZjQ1ZWFiOWY4ZGEzMmIwZDBlNjU0L3RhYmxlcmFuZ2U6NTU5OTZkNGNhOThmNDVlYWI5ZjhkYTMyYjBkMGU2NTRfNC0xLTEtMS0w_576edcf0-a11e-4806-8354-a8a1388aca75">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i703c2ff9263240b296697549156a727f_I20191231" decimals="-3" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjU1OTk2ZDRjYTk4ZjQ1ZWFiOWY4ZGEzMmIwZDBlNjU0L3RhYmxlcmFuZ2U6NTU5OTZkNGNhOThmNDVlYWI5ZjhkYTMyYjBkMGU2NTRfNC0zLTEtMS0w_23aa6b45-4def-4d52-9042-b26a83555766">17</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other assets</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idbb6a15f7620432bb5505e89f3004b9c_I20200630" decimals="-3" name="us-gaap:OtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjU1OTk2ZDRjYTk4ZjQ1ZWFiOWY4ZGEzMmIwZDBlNjU0L3RhYmxlcmFuZ2U6NTU5OTZkNGNhOThmNDVlYWI5ZjhkYTMyYjBkMGU2NTRfNS0xLTEtMS0w_1dceeeed-e993-4949-ad25-5dac321be9f3">70</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i703c2ff9263240b296697549156a727f_I20191231" decimals="-3" name="us-gaap:OtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjU1OTk2ZDRjYTk4ZjQ1ZWFiOWY4ZGEzMmIwZDBlNjU0L3RhYmxlcmFuZ2U6NTU5OTZkNGNhOThmNDVlYWI5ZjhkYTMyYjBkMGU2NTRfNS0zLTEtMS0w_8e6e74ab-7bcf-45c0-a045-85176f5127b8">70</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Property and equipment, net</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idbb6a15f7620432bb5505e89f3004b9c_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjU1OTk2ZDRjYTk4ZjQ1ZWFiOWY4ZGEzMmIwZDBlNjU0L3RhYmxlcmFuZ2U6NTU5OTZkNGNhOThmNDVlYWI5ZjhkYTMyYjBkMGU2NTRfNi0xLTEtMS0w_ecd2c046-35b1-4d18-bea5-284cd5470c56">33,697</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i703c2ff9263240b296697549156a727f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjU1OTk2ZDRjYTk4ZjQ1ZWFiOWY4ZGEzMmIwZDBlNjU0L3RhYmxlcmFuZ2U6NTU5OTZkNGNhOThmNDVlYWI5ZjhkYTMyYjBkMGU2NTRfNi0zLTEtMS0w_2059e63e-c808-485f-930b-7d9516434ee5">33,581</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total assets</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idbb6a15f7620432bb5505e89f3004b9c_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjU1OTk2ZDRjYTk4ZjQ1ZWFiOWY4ZGEzMmIwZDBlNjU0L3RhYmxlcmFuZ2U6NTU5OTZkNGNhOThmNDVlYWI5ZjhkYTMyYjBkMGU2NTRfOC0xLTEtMS0w_f3b8ad1f-c84e-4190-82ff-ee6d2356bf38">33,893</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i703c2ff9263240b296697549156a727f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjU1OTk2ZDRjYTk4ZjQ1ZWFiOWY4ZGEzMmIwZDBlNjU0L3RhYmxlcmFuZ2U6NTU5OTZkNGNhOThmNDVlYWI5ZjhkYTMyYjBkMGU2NTRfOC0zLTEtMS0w_eb86d1c3-1500-42ed-bfe9-782ae7f87a4f">33,807</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Liabilities and Members&#8217; Equity</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Current liabilities</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idbb6a15f7620432bb5505e89f3004b9c_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjU1OTk2ZDRjYTk4ZjQ1ZWFiOWY4ZGEzMmIwZDBlNjU0L3RhYmxlcmFuZ2U6NTU5OTZkNGNhOThmNDVlYWI5ZjhkYTMyYjBkMGU2NTRfMTItMS0xLTEtMA_73357363-790e-4b7f-9228-17de7f5c897d">1,109</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i703c2ff9263240b296697549156a727f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjU1OTk2ZDRjYTk4ZjQ1ZWFiOWY4ZGEzMmIwZDBlNjU0L3RhYmxlcmFuZ2U6NTU5OTZkNGNhOThmNDVlYWI5ZjhkYTMyYjBkMGU2NTRfMTItMy0xLTEtMA_6110eb05-1c10-496c-928f-043653a539b9">1,062</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Stockholders&#8217; equity</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idbb6a15f7620432bb5505e89f3004b9c_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjU1OTk2ZDRjYTk4ZjQ1ZWFiOWY4ZGEzMmIwZDBlNjU0L3RhYmxlcmFuZ2U6NTU5OTZkNGNhOThmNDVlYWI5ZjhkYTMyYjBkMGU2NTRfMTMtMS0xLTEtMA_e5614c4a-cf77-4d7e-813d-d8ecc1da2802">32,784</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i703c2ff9263240b296697549156a727f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjU1OTk2ZDRjYTk4ZjQ1ZWFiOWY4ZGEzMmIwZDBlNjU0L3RhYmxlcmFuZ2U6NTU5OTZkNGNhOThmNDVlYWI5ZjhkYTMyYjBkMGU2NTRfMTMtMy0xLTEtMA_b24eaeef-add1-48f8-aa2d-c58182064491">32,745</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total liabilities and members&#8217; equity</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idbb6a15f7620432bb5505e89f3004b9c_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjU1OTk2ZDRjYTk4ZjQ1ZWFiOWY4ZGEzMmIwZDBlNjU0L3RhYmxlcmFuZ2U6NTU5OTZkNGNhOThmNDVlYWI5ZjhkYTMyYjBkMGU2NTRfMTUtMS0xLTEtMA_6f8851fc-8759-4bdd-a7ba-4e888a71ab0b">33,893</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i703c2ff9263240b296697549156a727f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjU1OTk2ZDRjYTk4ZjQ1ZWFiOWY4ZGEzMmIwZDBlNjU0L3RhYmxlcmFuZ2U6NTU5OTZkNGNhOThmNDVlYWI5ZjhkYTMyYjBkMGU2NTRfMTUtMy0xLTEtMA_4584def1-c6cc-4000-adcc-afb673e25f9f">33,807</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Statements of Operation</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:69.114%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.929%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.224%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0af7733faffb48348018de02ffdfff6a_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmIyMTdmOWRiMTFlOTQxMGI5NWU2MjlmMDA1MDYyOWM5L3RhYmxlcmFuZ2U6YjIxN2Y5ZGIxMWU5NDEwYjk1ZTYyOWYwMDUwNjI5YzlfMi0xLTEtMS0w_1aa01449-1a96-4b9a-a0e8-0aba66d2d45d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iea1fae3b79a34d86b70cbdfb21ad3dbb_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmIyMTdmOWRiMTFlOTQxMGI5NWU2MjlmMDA1MDYyOWM5L3RhYmxlcmFuZ2U6YjIxN2Y5ZGIxMWU5NDEwYjk1ZTYyOWYwMDUwNjI5YzlfMi0zLTEtMS0w_d0afceaf-1e10-4abc-8e6f-23620ffc6da4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Expenses</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0af7733faffb48348018de02ffdfff6a_D20200101-20200630" decimals="-3" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmIyMTdmOWRiMTFlOTQxMGI5NWU2MjlmMDA1MDYyOWM5L3RhYmxlcmFuZ2U6YjIxN2Y5ZGIxMWU5NDEwYjk1ZTYyOWYwMDUwNjI5YzlfMy0xLTEtMS0w_726322a4-27ec-4a98-a3a5-05f070df9cea">579</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iea1fae3b79a34d86b70cbdfb21ad3dbb_D20190101-20190630" decimals="-3" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmIyMTdmOWRiMTFlOTQxMGI5NWU2MjlmMDA1MDYyOWM5L3RhYmxlcmFuZ2U6YjIxN2Y5ZGIxMWU5NDEwYjk1ZTYyOWYwMDUwNjI5YzlfMy0zLTEtMS0w_2a58741e-c5cb-4e61-960f-fed736f164ee">538</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Loss from operations</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0af7733faffb48348018de02ffdfff6a_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmIyMTdmOWRiMTFlOTQxMGI5NWU2MjlmMDA1MDYyOWM5L3RhYmxlcmFuZ2U6YjIxN2Y5ZGIxMWU5NDEwYjk1ZTYyOWYwMDUwNjI5YzlfNC0xLTEtMS0w_5b4224b4-d865-49ae-b2f2-7b14579f1824">579</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iea1fae3b79a34d86b70cbdfb21ad3dbb_D20190101-20190630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmIyMTdmOWRiMTFlOTQxMGI5NWU2MjlmMDA1MDYyOWM5L3RhYmxlcmFuZ2U6YjIxN2Y5ZGIxMWU5NDEwYjk1ZTYyOWYwMDUwNjI5YzlfNC0zLTEtMS0w_ed29c86c-5d7c-461c-859c-cc9cf58ed1bb">538</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other income</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0af7733faffb48348018de02ffdfff6a_D20200101-20200630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmIyMTdmOWRiMTFlOTQxMGI5NWU2MjlmMDA1MDYyOWM5L3RhYmxlcmFuZ2U6YjIxN2Y5ZGIxMWU5NDEwYjk1ZTYyOWYwMDUwNjI5YzlfNi0xLTEtMS0w_f068ca9e-096e-4637-bfb3-07b318180197">21</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iea1fae3b79a34d86b70cbdfb21ad3dbb_D20190101-20190630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmIyMTdmOWRiMTFlOTQxMGI5NWU2MjlmMDA1MDYyOWM5L3RhYmxlcmFuZ2U6YjIxN2Y5ZGIxMWU5NDEwYjk1ZTYyOWYwMDUwNjI5YzlfNi0zLTEtMS0w_7ffc3212-f640-4a69-aaee-c8b459fd04d5">385</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net loss</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0af7733faffb48348018de02ffdfff6a_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmIyMTdmOWRiMTFlOTQxMGI5NWU2MjlmMDA1MDYyOWM5L3RhYmxlcmFuZ2U6YjIxN2Y5ZGIxMWU5NDEwYjk1ZTYyOWYwMDUwNjI5YzlfOC0xLTEtMS0w_69caeb49-e554-4080-b2f6-42591cec6834">558</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iea1fae3b79a34d86b70cbdfb21ad3dbb_D20190101-20190630" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmIyMTdmOWRiMTFlOTQxMGI5NWU2MjlmMDA1MDYyOWM5L3RhYmxlcmFuZ2U6YjIxN2Y5ZGIxMWU5NDEwYjk1ZTYyOWYwMDUwNjI5YzlfOC0zLTEtMS0w_4ad34d77-4667-48eb-a716-9ba0e0c99d68">153</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:continuation><div style="margin-top:10pt;"><span><br/></span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">MWN LLC &#8211; Related Party</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2018, NMM, 6 Founders LLC, a California limited liability company doing business as Pacific6 Enterprises (&#8220;Pacific6&#8221;), and Health Source MSO Inc., a California corporation (&#8220;HSMSO&#8221;) entered into an operating agreement to govern </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><ix:continuation id="i634896cd37ff47c3a97e3ec9f32fa211"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">MWN Community Hospital, LLC and the conduct of its business and to specify their relative rights and obligations. NMM, Pacific6, and HSMSO each own <ix:nonFraction unitRef="number" contextRef="ifd12b893ddc54a6ead35cdb2bc89c8bc_I20181231" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNzgwMA_6cb19339-f6dc-4970-8a28-1cc036b1e5f8"><ix:nonFraction unitRef="number" contextRef="i00815df6bd294d36b80661bd7ee807a7_I20181231" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNzgwMA_876beef1-2df1-49f4-b32a-dbae1cbe9656"><ix:nonFraction unitRef="number" contextRef="i4c9caf98dc0642adba42edbbc942a39e_I20181231" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNzgwMA_a30ce0c9-38c6-45c1-b8f7-fb218fd291b1">33.3</ix:nonFraction></ix:nonFraction></ix:nonFraction>% of the membership shares based on each member&#8217;s initial capital contributions of $<ix:nonFraction unitRef="usd" contextRef="id084b778b0c0437ca9710b2d345a5e1c_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:MembersCapital" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNzg4NA_2d6b5afb-f778-4962-a1f2-014e5cae1b37"><ix:nonFraction unitRef="usd" contextRef="i802f55fac88e49498a6b008731c49198_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:MembersCapital" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNzg4NA_2f71a6f8-b040-4045-be4e-54b2a6091967"><ix:nonFraction unitRef="usd" contextRef="i4c9caf98dc0642adba42edbbc942a39e_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:MembersCapital" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNzg4NA_4b686c55-e882-4c34-930c-69d44db68e13">3,000</ix:nonFraction></ix:nonFraction></ix:nonFraction> and working capital contributions of $<ix:nonFraction unitRef="usd" contextRef="i802f55fac88e49498a6b008731c49198_I20181231" decimals="INF" format="ixt:numdotdecimal" name="ameh:WorkingCapitalContribution" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNzkyNA_021c1a3f-d951-4131-a786-ed08c5d06126"><ix:nonFraction unitRef="usd" contextRef="id084b778b0c0437ca9710b2d345a5e1c_I20181231" decimals="INF" format="ixt:numdotdecimal" name="ameh:WorkingCapitalContribution" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNzkyNA_1b986eb2-1d54-4465-9c3d-b3397ba438e0"><ix:nonFraction unitRef="usd" contextRef="i4c9caf98dc0642adba42edbbc942a39e_I20181231" decimals="INF" format="ixt:numdotdecimal" name="ameh:WorkingCapitalContribution" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNzkyNA_4f40d14c-f741-4309-b771-d27939926eac">30,000</ix:nonFraction></ix:nonFraction></ix:nonFraction>. NMM invested an additional $<ix:nonFraction unitRef="usd" contextRef="ieb3fd4253957445eb4629822911925ed_I20190831" decimals="-5" format="ixt:numdotdecimal" name="ameh:WorkingCapitalContribution" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNzk1NQ_ca899772-59f5-487b-a755-f5550b21bd36">0.3</ix:nonFraction> million for working capital purposes in August 2019. For the three and six months ended June&#160;30, 2020, NMM recorded loss and income from its investment in MWN LLC of $<ix:nonFraction unitRef="usd" contextRef="i1757e23b7dae4837b5c342d3a54fdb9f_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfODA5Mw_964770e4-b8a5-4243-9e7f-5670e5564633">43,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i9729bda7911148aea82f02fafc542f1e_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfODEwMA_7396cf1a-00f4-4108-a001-e46ec75e3796">12,000</ix:nonFraction>, respectively, in the accompanying consolidated statements of income and had an investment balance of $<ix:nonFraction unitRef="usd" contextRef="i21ee88acf5e24e5aa9702c3e569cdb0d_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfODIwNQ_907b262a-10a5-4bb5-a36e-d1c2be49ad5e"><ix:nonFraction unitRef="usd" contextRef="ifc2b7046e5434c1188649346120d70f7_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfODIwNQ_e9cb671d-f6d7-499b-80a6-172719a1b62d">0.2</ix:nonFraction></ix:nonFraction> million as of June&#160;30, 2020 and December&#160;31, 2019.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Investments in privately held entities that do not report net asset value</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">MediPortal, LLC</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May 2018, APC purchased <ix:nonFraction unitRef="shares" contextRef="i3635f2277d854166953f31769a15549d_I20180531" decimals="INF" format="ixt:numdotdecimal" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfODM1OA_745334b5-fa91-4012-b6b1-65addca4a36e">270,000</ix:nonFraction> membership interests of MediPortal LLC, a New York limited liability company, for $<ix:nonFraction unitRef="usd" contextRef="ia0bdfa92f0584697bf3e23e968030cd7_D20180501-20180531" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfODQ0Mw_a4897824-4bdb-466c-ac05-6339fb8fd350">0.4</ix:nonFraction> million or $<ix:nonFraction unitRef="shares" contextRef="i3635f2277d854166953f31769a15549d_I20180531" decimals="INF" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfODQ0OQ_dcf3c5c2-d026-4c31-9775-c5e1354373f1">1.50</ix:nonFraction> per membership interest, which represented an approximately <ix:nonFraction unitRef="number" contextRef="i3635f2277d854166953f31769a15549d_I20180531" decimals="3" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfODUxMg_d3b84e0e-f0d2-4be1-af50-13f24c2a661b">2.8</ix:nonFraction>% ownership interest. In connection with the initial purchase, APC received a <ix:nonNumeric contextRef="i3635f2277d854166953f31769a15549d_I20180531" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMTA5OTUxMTY0MjU2OQ_62844435-4ffe-469b-ab2d-76e2726b9e8d">five-year</ix:nonNumeric> warrant to purchase an additional <ix:nonFraction unitRef="shares" contextRef="i3635f2277d854166953f31769a15549d_I20180531" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfODYzMw_3f67ab55-40da-4ea0-8db5-18c0e1840872">270,000</ix:nonFraction> membership interests. Additionally, APC received a <ix:nonNumeric contextRef="ia0bdfa92f0584697bf3e23e968030cd7_D20180501-20180531" format="ixt-sec:durwordsen" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMTA5OTUxMTY0MjU3MA_71835439-1478-4dde-b5ab-805eb3ccc6a0">five-year</ix:nonNumeric> option to purchase an additional <ix:nonFraction unitRef="shares" contextRef="ia0bdfa92f0584697bf3e23e968030cd7_D20180501-20180531" decimals="INF" format="ixt:numdotdecimal" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfODcyOA_15bbf5f1-ea3a-4f09-b656-f5c7ef311b5e">380,000</ix:nonFraction> membership interests and a <ix:nonNumeric contextRef="i3635f2277d854166953f31769a15549d_I20180531" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMTA5OTUxMTY0MjU3MQ_625b6317-c0ac-4d03-aa78-2a5e1a48f2f5">five-year</ix:nonNumeric> warrant to purchase <ix:nonFraction unitRef="shares" contextRef="i3635f2277d854166953f31769a15549d_I20180531" decimals="INF" format="ixt:numdotdecimal" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfODc4Ng_06c2b11d-7497-4637-91a5-a7ae536cf993">480,000</ix:nonFraction> membership interests, which MediPortal LLC will grant APC upon completion of its health portal. As of June&#160;30, 2020, the health portal has not been completed. As APC does not have the ability to exercise significant influence, and lacks control, over the investee, this investment is accounted for using a measurement alternative which allows the investment to be measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">AchievaMed</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On July 1, 2019, NMM and AchievaMed, Inc., a California corporation (&#8220;AchievaMed&#8221;), entered into an agreement in which NMM would purchase <ix:nonFraction unitRef="number" contextRef="id2fefe9326624bf8a6e101283a7f761f_I20190701" decimals="2" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfOTQwMw_e1e80f95-f0b8-4ed5-82a7-f911cb8bd1e1">50</ix:nonFraction>% of the aggregate shares of capital stock of AchievaMed over a period of time not to exceed <ix:nonNumeric contextRef="ie1f0176357034096b162de4acd821801_D20190701-20190701" format="ixt-sec:durwordsen" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfOTQ5Nw_f9c2edbe-2544-4260-aa1b-2ceffe049e34">five years</ix:nonNumeric>. As a result of this transaction NMM invested $<ix:nonFraction unitRef="usd" contextRef="id2fefe9326624bf8a6e101283a7f761f_I20190701" decimals="-5" format="ixt:numdotdecimal" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfOTU0Ng_6a8f6c5f-c3c2-49a1-8d29-36ea4bd8e8f7">0.5</ix:nonFraction> million for a <ix:nonFraction unitRef="number" contextRef="id2fefe9326624bf8a6e101283a7f761f_I20190701" decimals="2" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfOTU1NQ_d8598246-9820-4b07-a10b-1b735afac8b9">10</ix:nonFraction>% interest. The related investment balance of $<ix:nonFraction unitRef="usd" contextRef="i4b00da16353446959bec407e221c7666_I20200630" decimals="-5" format="ixt:numdotdecimal" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfOTYwMg_7e07e491-e9fe-42ec-a242-6f892b82a149">0.5</ix:nonFraction> million is included in &#8220;Investment in privately held entities&#8221; in the accompanying consolidated balance sheets as of June&#160;30, 2020.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Bright Health, Inc.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2020, UCAP completed the sale of its <ix:nonFraction unitRef="number" contextRef="i170e72202cdd4b73a7b7a48e85b5dd54_I20200430" decimals="3" name="ameh:EquityMethodInvestmentOwnershipPercentageDisposed" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNzY5NjU4MTQwNjU1NA_39e04407-d5c5-47a6-aee8-da0d1338461e">48.9</ix:nonFraction>% ownership interest in UCI to Bright for approximately $<ix:nonFraction unitRef="usd" contextRef="i19617cb0db6c48aea309f2c2b2bbd2ca_D20200430-20200430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNzY5NjU4MTQwNjYxMQ_1aa9125f-972d-4547-b7a4-4d8b1b93b0a2">69.2</ix:nonFraction> million in cash proceeds (including $<ix:nonFraction unitRef="usd" contextRef="i2e1d4837a47949caa2ce6ff7a21167cc_D20200430-20200430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRepaymentsOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNzY5NjU4MTQwNjY0Mg_490179b7-d72e-416b-b587-1adec34d4052">16.5</ix:nonFraction> million as repayment of indebtedness owed to APC), plus non-cash consideration consisting of shares of Bright Health, Inc.&#8217;s preferred stock having an estimated fair value of approximately $<ix:nonFraction unitRef="usd" contextRef="i4d3be425c4e74837aa2e7e572caa5cdc_I20200630" decimals="-5" format="ixt:numdotdecimal" name="ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNzY5NjU4MTQwNjgyMQ_ca8c7077-106b-424d-bd42-42576007b30a">36.2</ix:nonFraction> million on the date of sale. The related investment balance of $<ix:nonFraction unitRef="usd" contextRef="i4d3be425c4e74837aa2e7e572caa5cdc_I20200630" decimals="-5" format="ixt:numdotdecimal" name="ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNzY5NjU4MTQwNzczOA_ca8c7077-106b-424d-bd42-42576007b30a">36.2</ix:nonFraction> million is included in &#8220;Investment in privately held entities&#8221; in the accompanying consolidated balance sheets as of June&#160;30, 2020.</span></div></ix:continuation><div id="icc5d6783c1494a1f886c03c93e398cee_64"></div><div style="text-indent:-18pt;padding-left:18pt;margin-top:10pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:18pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">6.&#160;<ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="ameh:LoanReceivableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV82NC9mcmFnOmQ4NDJlMDllZDY2NTQzNGZiZTJmZDc5Y2Q1YjYzNGRiL3RleHRyZWdpb246ZDg0MmUwOWVkNjY1NDM0ZmJlMmZkNzljZDViNjM0ZGJfMzQyMA_9ea5c5e6-775e-4c7e-8a4a-2ac27c2a80c8" continuedAt="i72fe212e67af466888143a4be041a916" escape="true">Loan Receivable and Loan Receivable &#8211; Related Parties</ix:nonNumeric></span></div><ix:continuation id="i72fe212e67af466888143a4be041a916" continuedAt="i50de8ef768cf49bc99cf9bc47d67ec18"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Loan receivable</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Dr. Albert Arteaga</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On June 28, 2019, APC entered into a convertible secured promissory note with Dr. Albert H. Arteaga, M.D. (&#8220;Dr. Arteaga&#8221;), Chief Executive Officer of LMA, to loan $<ix:nonFraction unitRef="usd" contextRef="i68d3a067d0bf4b79866706938706fb56_I20190628" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesReceivableNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV82NC9mcmFnOmQ4NDJlMDllZDY2NTQzNGZiZTJmZDc5Y2Q1YjYzNGRiL3RleHRyZWdpb246ZDg0MmUwOWVkNjY1NDM0ZmJlMmZkNzljZDViNjM0ZGJfMjYw_3aeb4506-5c1c-42b2-a22d-95335acef8de">6.4</ix:nonFraction> million to Dr. Arteaga.  Interest on the loan accrues at a rate that is equal to the prime rate, plus <ix:nonFraction unitRef="number" contextRef="ie7a2683890994e1893345aed93623d96_D20200101-20200630" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV82NC9mcmFnOmQ4NDJlMDllZDY2NTQzNGZiZTJmZDc5Y2Q1YjYzNGRiL3RleHRyZWdpb246ZDg0MmUwOWVkNjY1NDM0ZmJlMmZkNzljZDViNjM0ZGJfMzU3_6b64e03d-2a3c-45f3-a9e9-d24ea3430750">1</ix:nonFraction>% (<ix:nonFraction unitRef="number" contextRef="ia0ac55575d2248d28bbb2cd6f69b2d1b_I20200630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV82NC9mcmFnOmQ4NDJlMDllZDY2NTQzNGZiZTJmZDc5Y2Q1YjYzNGRiL3RleHRyZWdpb246ZDg0MmUwOWVkNjY1NDM0ZmJlMmZkNzljZDViNjM0ZGJfMzYx_b772b48e-7abe-4500-8c56-68ec9af80543">4.25</ix:nonFraction>% as of June&#160;30, 2020) and payable in monthly installments of interest only on the first day of each month until the maturity date of December 31, 2020, at which time, all outstanding principal and accrued interest thereon shall be due and payable in full. The note is secured by certain shares of LMA common stock held by Dr. Arteaga. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At any time on or before December&#160;31, 2020, and upon written notice by APC to Dr. Arteaga, APC has the right, but not the obligation, to convert the entire outstanding principal amount of this note into shares of LMA common stock, which equal <ix:nonFraction unitRef="number" contextRef="i68d3a067d0bf4b79866706938706fb56_I20190628" decimals="4" name="ameh:FinancingReceivableConvertibleToCommonStockPercentageOfOutstandingSharesConvertible" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV82NC9mcmFnOmQ4NDJlMDllZDY2NTQzNGZiZTJmZDc5Y2Q1YjYzNGRiL3RleHRyZWdpb246ZDg0MmUwOWVkNjY1NDM0ZmJlMmZkNzljZDViNjM0ZGJfOTIy_aff93fc0-c6bb-4f9a-aae8-2bdb215296b5">21.25</ix:nonFraction>% of the aggregate then-issued and outstanding shares of LMA common stock to be held by APC&#8217;s designee, which may include APC-LSMA. If converted, APC-LSMA and APC&#8217;s designee will collectively own <ix:nonFraction unitRef="number" contextRef="ie109929786d34e3893f52ead1a5eb485_I20190628" decimals="4" name="ameh:EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV82NC9mcmFnOmQ4NDJlMDllZDY2NTQzNGZiZTJmZDc5Y2Q1YjYzNGRiL3RleHRyZWdpb246ZDg0MmUwOWVkNjY1NDM0ZmJlMmZkNzljZDViNjM0ZGJfMTExOQ_1c82001b-953a-44ed-b269-f499ceac50c3">46.25</ix:nonFraction>% of the equity of LMA with the remaining <ix:nonFraction unitRef="number" contextRef="i901365bdd3be4af6a404cf5c6e1a6075_I20190628" decimals="4" name="ameh:EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV82NC9mcmFnOmQ4NDJlMDllZDY2NTQzNGZiZTJmZDc5Y2Q1YjYzNGRiL3RleHRyZWdpb246ZDg0MmUwOWVkNjY1NDM0ZmJlMmZkNzljZDViNjM0ZGJfMTE2Mg_ea4d4fe3-4f95-4276-85a8-87966538c518">53.75</ix:nonFraction>% to be owned by Dr. Arteaga. The entire note receivable has been classified under loans receivable on the consolidated balance sheets in the amount of $<ix:nonFraction unitRef="usd" contextRef="i1cce33515e484386a173dc2819744d21_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesReceivableNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV82NC9mcmFnOmQ4NDJlMDllZDY2NTQzNGZiZTJmZDc5Y2Q1YjYzNGRiL3RleHRyZWdpb246ZDg0MmUwOWVkNjY1NDM0ZmJlMmZkNzljZDViNjM0ZGJfMTMzMw_96b8b9b6-5b5c-4ccf-91c3-d0f15ed81a09">6.4</ix:nonFraction> million as of June&#160;30, 2020. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On February 28, 2020, the Company entered into an agreement to advance Dr. Arteaga $<ix:nonFraction unitRef="usd" contextRef="i2719e7d006164071b43867d77f417602_I20200228" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesReceivableNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV82NC9mcmFnOmQ4NDJlMDllZDY2NTQzNGZiZTJmZDc5Y2Q1YjYzNGRiL3RleHRyZWdpb246ZDg0MmUwOWVkNjY1NDM0ZmJlMmZkNzljZDViNjM0ZGJfMTQ0Nw_422bc936-09e9-4d7a-b0b3-8c9fb8719279">2.2</ix:nonFraction> million related to claims that were overpaid in the ordinary course of business. The advanced amount is repaid as the overpaid claims are recovered. As of June&#160;30, 2020, the outstanding amount due was $<ix:nonFraction unitRef="usd" contextRef="ib85a0e470e8b45179bd029ecf6828423_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV82NC9mcmFnOmQ4NDJlMDllZDY2NTQzNGZiZTJmZDc5Y2Q1YjYzNGRiL3RleHRyZWdpb246ZDg0MmUwOWVkNjY1NDM0ZmJlMmZkNzljZDViNjM0ZGJfMTY0Mw_49f9f412-d4eb-48ec-bc90-5b83d6b2118f">0.9</ix:nonFraction> million and included in the &#8220;Prepaid expenses and other current assets&#8221; in the accompanying consolidated balance sheets.</span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><ix:continuation id="i50de8ef768cf49bc99cf9bc47d67ec18"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company assessed the loan receivables under the CECL model by assessing the party's ability to pay by reviewing their interest payment history quarterly, financial history annually and reassessing any insolvency risk that is identified. If a failure to pay occurs, the Company assesses the terms of the notes and estimates an expected credit loss based on the remittance schedule of the note.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Loan receivable </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#8211;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"> related parties</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Universal Care, Inc.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In 2015, APC advanced $<ix:nonFraction unitRef="usd" contextRef="i718197c336244bfaae074a41bf6ba00c_I20151231" decimals="-5" format="ixt:numdotdecimal" name="ameh:AdvancedForWorkingCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV82NC9mcmFnOmQ4NDJlMDllZDY2NTQzNGZiZTJmZDc5Y2Q1YjYzNGRiL3RleHRyZWdpb246ZDg0MmUwOWVkNjY1NDM0ZmJlMmZkNzljZDViNjM0ZGJfMTgzNg_44bebf88-6d82-4a8b-b012-ce1db9abf390">5.0</ix:nonFraction> million on behalf of UCAP to UCI for working capital purposes. On June 29, 2018, November 28, 2018, and December 13, 2019, APC advanced an additional $<ix:nonFraction unitRef="usd" contextRef="i620d8d9b4ce144e39fd90208e9f296c6_I20180629" decimals="-5" format="ixt:numdotdecimal" name="ameh:LineOfCreditFacilityAdditionalAdvances" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV82NC9mcmFnOmQ4NDJlMDllZDY2NTQzNGZiZTJmZDc5Y2Q1YjYzNGRiL3RleHRyZWdpb246ZDg0MmUwOWVkNjY1NDM0ZmJlMmZkNzljZDViNjM0ZGJfMTk3OQ_5375b1c1-be4c-49a9-b344-89145850355f">2.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ica83580f8f45424a8053d06ddb0d6b69_I20181128" decimals="-5" format="ixt:numdotdecimal" name="ameh:LineOfCreditFacilityAdditionalAdvances" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV82NC9mcmFnOmQ4NDJlMDllZDY2NTQzNGZiZTJmZDc5Y2Q1YjYzNGRiL3RleHRyZWdpb246ZDg0MmUwOWVkNjY1NDM0ZmJlMmZkNzljZDViNjM0ZGJfMTk4Mw_d575fc29-7d79-4cbd-8bac-2be8543fcaf4">5.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i99b8494c9ac5475fb455098946c75db9_I20191213" decimals="-5" format="ixt:numdotdecimal" name="ameh:LineOfCreditFacilityAdditionalAdvances" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV82NC9mcmFnOmQ4NDJlMDllZDY2NTQzNGZiZTJmZDc5Y2Q1YjYzNGRiL3RleHRyZWdpb246ZDg0MmUwOWVkNjY1NDM0ZmJlMmZkNzljZDViNjM0ZGJfMTk5MA_a9fb025d-d225-460d-a89c-2d04277945ed">4.0</ix:nonFraction> million, respectively. The loans accrue interest at the prime rate, plus <ix:nonFraction unitRef="number" contextRef="i67a0fe9f9fdd46d7b8bf35810922c6aa_D20200101-20200331" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV82NC9mcmFnOmQ4NDJlMDllZDY2NTQzNGZiZTJmZDc5Y2Q1YjYzNGRiL3RleHRyZWdpb246ZDg0MmUwOWVkNjY1NDM0ZmJlMmZkNzljZDViNjM0ZGJfMjA1OA_36b0c219-c17e-4b2f-a9df-134553ef375d">1.00</ix:nonFraction>%, or <ix:nonFraction unitRef="number" contextRef="ifaa289066f18409dae39bd6fe0b1bf0a_I20200331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV82NC9mcmFnOmQ4NDJlMDllZDY2NTQzNGZiZTJmZDc5Y2Q1YjYzNGRiL3RleHRyZWdpb246ZDg0MmUwOWVkNjY1NDM0ZmJlMmZkNzljZDViNjM0ZGJfNjU5NzA2OTc3MDEzMw_6c6b533e-2579-40cb-b1b1-3c3725d466b8">4.25</ix:nonFraction>%, as of March 31, 2020, and <ix:nonFraction unitRef="number" contextRef="i2219841d151045028ba5da60cd719d17_I20191231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV82NC9mcmFnOmQ4NDJlMDllZDY2NTQzNGZiZTJmZDc5Y2Q1YjYzNGRiL3RleHRyZWdpb246ZDg0MmUwOWVkNjY1NDM0ZmJlMmZkNzljZDViNjM0ZGJfMjA4Mg_6bfee4bf-bd0a-495b-bdcd-6f5efcb377a8">5.75</ix:nonFraction>% as of December&#160;31, 2019, with interest to be paid monthly. On April 30, 2020, the outstanding balance was fully repaid as part of UCAP's disposition of its <ix:nonFraction unitRef="number" contextRef="i59aea64b29bd441fbc9a872ccf8d6901_I20200430" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV82NC9mcmFnOmQ4NDJlMDllZDY2NTQzNGZiZTJmZDc5Y2Q1YjYzNGRiL3RleHRyZWdpb246ZDg0MmUwOWVkNjY1NDM0ZmJlMmZkNzljZDViNjM0ZGJfMjM1MA_8fa61189-1e93-4051-b62c-3f4f2b274523">48.9</ix:nonFraction>% ownership interest in UCI to Bright.</span></div></ix:continuation><div id="icc5d6783c1494a1f886c03c93e398cee_70"></div><div style="text-indent:-18pt;padding-left:18pt;margin-top:10pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:18pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">7.&#160;<ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83MC9mcmFnOmZjNDFkMWE3NzgzMzRlYWRhOTgxNGQ1YzViNzNlMWUzL3RleHRyZWdpb246ZmM0MWQxYTc3ODMzNGVhZGE5ODE0ZDVjNWI3M2UxZTNfMTQ0_b4c9c568-485c-47a3-8f20-cb5ffd31a9f3" continuedAt="i18510ecaaf4f480e90f7364e02dcd249" escape="true">Accounts Payable and Accrued Expenses</ix:nonNumeric></span></div><ix:continuation id="i18510ecaaf4f480e90f7364e02dcd249"><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83MC9mcmFnOmZjNDFkMWE3NzgzMzRlYWRhOTgxNGQ1YzViNzNlMWUzL3RleHRyZWdpb246ZmM0MWQxYTc3ODMzNGVhZGE5ODE0ZDVjNWI3M2UxZTNfMTQ3_49cca6b8-df2a-49c3-a486-b5fbda9d2131" escape="true"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s accounts payable and accrued expenses consisted of the following (in thousands):</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:71.206%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.323%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.739%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accounts payable</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83MC9mcmFnOmZjNDFkMWE3NzgzMzRlYWRhOTgxNGQ1YzViNzNlMWUzL3RhYmxlOmI4Zjk2ZGMwNzViNTRjNjBiNmY1ZDQxODVhZTgyODU1L3RhYmxlcmFuZ2U6YjhmOTZkYzA3NWI1NGM2MGI2ZjVkNDE4NWFlODI4NTVfMS0xLTEtMS0w_e9b7414f-4e60-425a-a060-b48ad9579dfc">10,425</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83MC9mcmFnOmZjNDFkMWE3NzgzMzRlYWRhOTgxNGQ1YzViNzNlMWUzL3RhYmxlOmI4Zjk2ZGMwNzViNTRjNjBiNmY1ZDQxODVhZTgyODU1L3RhYmxlcmFuZ2U6YjhmOTZkYzA3NWI1NGM2MGI2ZjVkNDE4NWFlODI4NTVfMS0zLTEtMS0w_c8981c3a-6d56-4210-aedb-eb4977d40d40">6,914</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Capitation payable</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="ameh:SpecialtyCapitationPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83MC9mcmFnOmZjNDFkMWE3NzgzMzRlYWRhOTgxNGQ1YzViNzNlMWUzL3RhYmxlOmI4Zjk2ZGMwNzViNTRjNjBiNmY1ZDQxODVhZTgyODU1L3RhYmxlcmFuZ2U6YjhmOTZkYzA3NWI1NGM2MGI2ZjVkNDE4NWFlODI4NTVfMi0xLTEtMS0w_eebf5457-e785-48ca-ac83-2c36932e13f3">2,754</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="ameh:SpecialtyCapitationPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83MC9mcmFnOmZjNDFkMWE3NzgzMzRlYWRhOTgxNGQ1YzViNzNlMWUzL3RhYmxlOmI4Zjk2ZGMwNzViNTRjNjBiNmY1ZDQxODVhZTgyODU1L3RhYmxlcmFuZ2U6YjhmOTZkYzA3NWI1NGM2MGI2ZjVkNDE4NWFlODI4NTVfMi0zLTEtMS0w_4d947fa0-2cd3-4b97-b74d-aac2c2cf91ea">2,813</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Subcontractor IPA payable</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="ameh:SubcontractorIPAPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83MC9mcmFnOmZjNDFkMWE3NzgzMzRlYWRhOTgxNGQ1YzViNzNlMWUzL3RhYmxlOmI4Zjk2ZGMwNzViNTRjNjBiNmY1ZDQxODVhZTgyODU1L3RhYmxlcmFuZ2U6YjhmOTZkYzA3NWI1NGM2MGI2ZjVkNDE4NWFlODI4NTVfMy0xLTEtMS0w_af57f3a7-3309-4104-a904-d9da331df0cd">3,083</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="ameh:SubcontractorIPAPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83MC9mcmFnOmZjNDFkMWE3NzgzMzRlYWRhOTgxNGQ1YzViNzNlMWUzL3RhYmxlOmI4Zjk2ZGMwNzViNTRjNjBiNmY1ZDQxODVhZTgyODU1L3RhYmxlcmFuZ2U6YjhmOTZkYzA3NWI1NGM2MGI2ZjVkNDE4NWFlODI4NTVfMy0zLTEtMS0w_08640de4-814c-4a18-8289-bd52f63ba8ae">3,360</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Professional fees</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83MC9mcmFnOmZjNDFkMWE3NzgzMzRlYWRhOTgxNGQ1YzViNzNlMWUzL3RhYmxlOmI4Zjk2ZGMwNzViNTRjNjBiNmY1ZDQxODVhZTgyODU1L3RhYmxlcmFuZ2U6YjhmOTZkYzA3NWI1NGM2MGI2ZjVkNDE4NWFlODI4NTVfNC0xLTEtMS0w_bcda705c-188c-4d29-b329-9d70f5cfdceb">2,325</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83MC9mcmFnOmZjNDFkMWE3NzgzMzRlYWRhOTgxNGQ1YzViNzNlMWUzL3RhYmxlOmI4Zjk2ZGMwNzViNTRjNjBiNmY1ZDQxODVhZTgyODU1L3RhYmxlcmFuZ2U6YjhmOTZkYzA3NWI1NGM2MGI2ZjVkNDE4NWFlODI4NTVfNC0zLTEtMS0w_d3758d53-75af-458d-ab24-81699f15bbc8">1,837</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Due to related parties</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" name="us-gaap:DueToRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83MC9mcmFnOmZjNDFkMWE3NzgzMzRlYWRhOTgxNGQ1YzViNzNlMWUzL3RhYmxlOmI4Zjk2ZGMwNzViNTRjNjBiNmY1ZDQxODVhZTgyODU1L3RhYmxlcmFuZ2U6YjhmOTZkYzA3NWI1NGM2MGI2ZjVkNDE4NWFlODI4NTVfNS0xLTEtMS0w_38c76362-ded3-4e83-be7b-491ffcfb74eb">80</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" name="us-gaap:DueToRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83MC9mcmFnOmZjNDFkMWE3NzgzMzRlYWRhOTgxNGQ1YzViNzNlMWUzL3RhYmxlOmI4Zjk2ZGMwNzViNTRjNjBiNmY1ZDQxODVhZTgyODU1L3RhYmxlcmFuZ2U6YjhmOTZkYzA3NWI1NGM2MGI2ZjVkNDE4NWFlODI4NTVfNS0zLTEtMS0w_f355ee1c-f464-423c-8ab2-33dfe96ac409">225</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accrued compensation</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83MC9mcmFnOmZjNDFkMWE3NzgzMzRlYWRhOTgxNGQ1YzViNzNlMWUzL3RhYmxlOmI4Zjk2ZGMwNzViNTRjNjBiNmY1ZDQxODVhZTgyODU1L3RhYmxlcmFuZ2U6YjhmOTZkYzA3NWI1NGM2MGI2ZjVkNDE4NWFlODI4NTVfNi0xLTEtMS0w_18146a14-8cd3-4f4e-9c0d-60bdc6922270">3,060</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83MC9mcmFnOmZjNDFkMWE3NzgzMzRlYWRhOTgxNGQ1YzViNzNlMWUzL3RhYmxlOmI4Zjk2ZGMwNzViNTRjNjBiNmY1ZDQxODVhZTgyODU1L3RhYmxlcmFuZ2U6YjhmOTZkYzA3NWI1NGM2MGI2ZjVkNDE4NWFlODI4NTVfNi0zLTEtMS0w_d3a43bc3-e4cf-4c41-a0a3-873d0e077d14">3,238</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Contract liabilities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83MC9mcmFnOmZjNDFkMWE3NzgzMzRlYWRhOTgxNGQ1YzViNzNlMWUzL3RhYmxlOmI4Zjk2ZGMwNzViNTRjNjBiNmY1ZDQxODVhZTgyODU1L3RhYmxlcmFuZ2U6YjhmOTZkYzA3NWI1NGM2MGI2ZjVkNDE4NWFlODI4NTVfNy0xLTEtMS0w_5df695ae-221e-4961-a129-fa2cd7347b70">3,061</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83MC9mcmFnOmZjNDFkMWE3NzgzMzRlYWRhOTgxNGQ1YzViNzNlMWUzL3RhYmxlOmI4Zjk2ZGMwNzViNTRjNjBiNmY1ZDQxODVhZTgyODU1L3RhYmxlcmFuZ2U6YjhmOTZkYzA3NWI1NGM2MGI2ZjVkNDE4NWFlODI4NTVfNy0zLTEtMS0w_a91a7257-7a30-4c9b-beb8-0b013758ce21">8,892</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total accounts payable and accrued expenses</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83MC9mcmFnOmZjNDFkMWE3NzgzMzRlYWRhOTgxNGQ1YzViNzNlMWUzL3RhYmxlOmI4Zjk2ZGMwNzViNTRjNjBiNmY1ZDQxODVhZTgyODU1L3RhYmxlcmFuZ2U6YjhmOTZkYzA3NWI1NGM2MGI2ZjVkNDE4NWFlODI4NTVfOS0xLTEtMS0w_c437b2bd-2304-49eb-ba44-f7a3f029bea5">24,788</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83MC9mcmFnOmZjNDFkMWE3NzgzMzRlYWRhOTgxNGQ1YzViNzNlMWUzL3RhYmxlOmI4Zjk2ZGMwNzViNTRjNjBiNmY1ZDQxODVhZTgyODU1L3RhYmxlcmFuZ2U6YjhmOTZkYzA3NWI1NGM2MGI2ZjVkNDE4NWFlODI4NTVfOS0zLTEtMS0w_50eb7ca3-0493-463d-aef9-c0822b7df2ae">27,279</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="icc5d6783c1494a1f886c03c93e398cee_73"></div><div style="text-indent:-18pt;padding-left:18pt;margin-top:10pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:18pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">8.&#160;<ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83My9mcmFnOjEzZDQzMjA0MTY1MDRjMjdhMmMzOGZlZjgwOGE1MTEwL3RleHRyZWdpb246MTNkNDMyMDQxNjUwNGMyN2EyYzM4ZmVmODA4YTUxMTBfMTA3_ce3ee496-9070-4624-8c58-1f0fc38ca6e7" continuedAt="i8b879681efcb43f3bce48da4131ea996" escape="true">Medical Liabilities</ix:nonNumeric></span></div><ix:continuation id="i8b879681efcb43f3bce48da4131ea996"><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83My9mcmFnOjEzZDQzMjA0MTY1MDRjMjdhMmMzOGZlZjgwOGE1MTEwL3RleHRyZWdpb246MTNkNDMyMDQxNjUwNGMyN2EyYzM4ZmVmODA4YTUxMTBfMTEw_5191ba6a-4b49-4602-afe8-16c13ff570c7" escape="true"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s medical liabilities consisted of the following (in thousands):</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:71.206%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.323%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.739%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Medical liabilities, beginning of period</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83My9mcmFnOjEzZDQzMjA0MTY1MDRjMjdhMmMzOGZlZjgwOGE1MTEwL3RhYmxlOjQyOWQyMzM0NGYzZDQzNzc5OTgxNzg3MjU3YmMxZjk3L3RhYmxlcmFuZ2U6NDI5ZDIzMzQ0ZjNkNDM3Nzk5ODE3ODcyNTdiYzFmOTdfMS0xLTEtMS0w_7c4a6be6-7f29-4483-a49a-1906a5a58aee">58,725</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i009fc823ec144ee3b772b4396d458c88_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83My9mcmFnOjEzZDQzMjA0MTY1MDRjMjdhMmMzOGZlZjgwOGE1MTEwL3RhYmxlOjQyOWQyMzM0NGYzZDQzNzc5OTgxNzg3MjU3YmMxZjk3L3RhYmxlcmFuZ2U6NDI5ZDIzMzQ0ZjNkNDM3Nzk5ODE3ODcyNTdiYzFmOTdfMS0zLTEtMS0w_5ee7c0bf-3c99-4b8c-8a70-13adc36d75d2">33,642</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Components of medical care costs related to claims incurred:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current period</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83My9mcmFnOjEzZDQzMjA0MTY1MDRjMjdhMmMzOGZlZjgwOGE1MTEwL3RhYmxlOjQyOWQyMzM0NGYzZDQzNzc5OTgxNzg3MjU3YmMxZjk3L3RhYmxlcmFuZ2U6NDI5ZDIzMzQ0ZjNkNDM3Nzk5ODE3ODcyNTdiYzFmOTdfMy0xLTEtMS0w_5a46b8e7-5633-4ca9-b75b-850a979c8490">165,571</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83My9mcmFnOjEzZDQzMjA0MTY1MDRjMjdhMmMzOGZlZjgwOGE1MTEwL3RhYmxlOjQyOWQyMzM0NGYzZDQzNzc5OTgxNzg3MjU3YmMxZjk3L3RhYmxlcmFuZ2U6NDI5ZDIzMzQ0ZjNkNDM3Nzk5ODE3ODcyNTdiYzFmOTdfMy0zLTEtMS0w_4d8af9bf-6bcb-431c-ae60-b5417684d1a2">93,833</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prior periods</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83My9mcmFnOjEzZDQzMjA0MTY1MDRjMjdhMmMzOGZlZjgwOGE1MTEwL3RhYmxlOjQyOWQyMzM0NGYzZDQzNzc5OTgxNzg3MjU3YmMxZjk3L3RhYmxlcmFuZ2U6NDI5ZDIzMzQ0ZjNkNDM3Nzk5ODE3ODcyNTdiYzFmOTdfNC0xLTEtMS0w_f926b86f-b4fa-48d8-a520-68b97fbfa679">233</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83My9mcmFnOjEzZDQzMjA0MTY1MDRjMjdhMmMzOGZlZjgwOGE1MTEwL3RhYmxlOjQyOWQyMzM0NGYzZDQzNzc5OTgxNzg3MjU3YmMxZjk3L3RhYmxlcmFuZ2U6NDI5ZDIzMzQ0ZjNkNDM3Nzk5ODE3ODcyNTdiYzFmOTdfNC0zLTEtMS0w_5b6d86b0-be98-4083-8ac0-6ad9cd0b279d">2,688</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total medical care costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83My9mcmFnOjEzZDQzMjA0MTY1MDRjMjdhMmMzOGZlZjgwOGE1MTEwL3RhYmxlOjQyOWQyMzM0NGYzZDQzNzc5OTgxNzg3MjU3YmMxZjk3L3RhYmxlcmFuZ2U6NDI5ZDIzMzQ0ZjNkNDM3Nzk5ODE3ODcyNTdiYzFmOTdfNS0xLTEtMS0w_fef131f7-5ad9-4c7f-8e41-13d1774c8c07">165,804</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83My9mcmFnOjEzZDQzMjA0MTY1MDRjMjdhMmMzOGZlZjgwOGE1MTEwL3RhYmxlOjQyOWQyMzM0NGYzZDQzNzc5OTgxNzg3MjU3YmMxZjk3L3RhYmxlcmFuZ2U6NDI5ZDIzMzQ0ZjNkNDM3Nzk5ODE3ODcyNTdiYzFmOTdfNS0zLTEtMS0w_9d576534-6308-4859-872d-dbd677bafb09">96,521</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments for medical care costs related to claims incurred:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current period</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83My9mcmFnOjEzZDQzMjA0MTY1MDRjMjdhMmMzOGZlZjgwOGE1MTEwL3RhYmxlOjQyOWQyMzM0NGYzZDQzNzc5OTgxNzg3MjU3YmMxZjk3L3RhYmxlcmFuZ2U6NDI5ZDIzMzQ0ZjNkNDM3Nzk5ODE3ODcyNTdiYzFmOTdfNy0xLTEtMS0w_ca49e32f-43b5-41fa-96a5-c87294141bb5">97,112</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83My9mcmFnOjEzZDQzMjA0MTY1MDRjMjdhMmMzOGZlZjgwOGE1MTEwL3RhYmxlOjQyOWQyMzM0NGYzZDQzNzc5OTgxNzg3MjU3YmMxZjk3L3RhYmxlcmFuZ2U6NDI5ZDIzMzQ0ZjNkNDM3Nzk5ODE3ODcyNTdiYzFmOTdfNy0zLTEtMS0w_05f08340-cad0-4f9e-94d4-800ae5c4d7f1">60,440</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prior periods</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83My9mcmFnOjEzZDQzMjA0MTY1MDRjMjdhMmMzOGZlZjgwOGE1MTEwL3RhYmxlOjQyOWQyMzM0NGYzZDQzNzc5OTgxNzg3MjU3YmMxZjk3L3RhYmxlcmFuZ2U6NDI5ZDIzMzQ0ZjNkNDM3Nzk5ODE3ODcyNTdiYzFmOTdfOC0xLTEtMS0w_c6771e63-7584-464c-b031-6726c897194a">57,470</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83My9mcmFnOjEzZDQzMjA0MTY1MDRjMjdhMmMzOGZlZjgwOGE1MTEwL3RhYmxlOjQyOWQyMzM0NGYzZDQzNzc5OTgxNzg3MjU3YmMxZjk3L3RhYmxlcmFuZ2U6NDI5ZDIzMzQ0ZjNkNDM3Nzk5ODE3ODcyNTdiYzFmOTdfOC0zLTEtMS0w_1fd759f4-cf22-4690-bcd6-578f7a1fc511">39,744</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total paid</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83My9mcmFnOjEzZDQzMjA0MTY1MDRjMjdhMmMzOGZlZjgwOGE1MTEwL3RhYmxlOjQyOWQyMzM0NGYzZDQzNzc5OTgxNzg3MjU3YmMxZjk3L3RhYmxlcmFuZ2U6NDI5ZDIzMzQ0ZjNkNDM3Nzk5ODE3ODcyNTdiYzFmOTdfOS0xLTEtMS0w_b027518d-6862-45d1-b414-8d321c559ea5">154,582</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83My9mcmFnOjEzZDQzMjA0MTY1MDRjMjdhMmMzOGZlZjgwOGE1MTEwL3RhYmxlOjQyOWQyMzM0NGYzZDQzNzc5OTgxNzg3MjU3YmMxZjk3L3RhYmxlcmFuZ2U6NDI5ZDIzMzQ0ZjNkNDM3Nzk5ODE3ODcyNTdiYzFmOTdfOS0zLTEtMS0w_41a02e54-b9e3-46f9-ba5f-7ed39e57399b">100,184</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acquired from Alpha Care</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83My9mcmFnOjEzZDQzMjA0MTY1MDRjMjdhMmMzOGZlZjgwOGE1MTEwL3RhYmxlOjQyOWQyMzM0NGYzZDQzNzc5OTgxNzg3MjU3YmMxZjk3L3RhYmxlcmFuZ2U6NDI5ZDIzMzQ0ZjNkNDM3Nzk5ODE3ODcyNTdiYzFmOTdfMTAtMS0xLTEtMTY4OA_591309af-9733-41f7-92a7-0cdbbcaa34d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83My9mcmFnOjEzZDQzMjA0MTY1MDRjMjdhMmMzOGZlZjgwOGE1MTEwL3RhYmxlOjQyOWQyMzM0NGYzZDQzNzc5OTgxNzg3MjU3YmMxZjk3L3RhYmxlcmFuZ2U6NDI5ZDIzMzQ0ZjNkNDM3Nzk5ODE3ODcyNTdiYzFmOTdfMTAtMy0xLTEtODA0_48e490b2-4390-4f18-a122-f83b6ffcb2ba">13,120</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83My9mcmFnOjEzZDQzMjA0MTY1MDRjMjdhMmMzOGZlZjgwOGE1MTEwL3RhYmxlOjQyOWQyMzM0NGYzZDQzNzc5OTgxNzg3MjU3YmMxZjk3L3RhYmxlcmFuZ2U6NDI5ZDIzMzQ0ZjNkNDM3Nzk5ODE3ODcyNTdiYzFmOTdfMTAtMS0xLTEtMA_5ed746ee-dd41-4c19-9e0e-f8be9db08197">326</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" sign="-" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83My9mcmFnOjEzZDQzMjA0MTY1MDRjMjdhMmMzOGZlZjgwOGE1MTEwL3RhYmxlOjQyOWQyMzM0NGYzZDQzNzc5OTgxNzg3MjU3YmMxZjk3L3RhYmxlcmFuZ2U6NDI5ZDIzMzQ0ZjNkNDM3Nzk5ODE3ODcyNTdiYzFmOTdfMTAtMy0xLTEtMA_01481170-958b-4bdf-ae93-bbde7249806b">156</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Medical liabilities, end of period</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83My9mcmFnOjEzZDQzMjA0MTY1MDRjMjdhMmMzOGZlZjgwOGE1MTEwL3RhYmxlOjQyOWQyMzM0NGYzZDQzNzc5OTgxNzg3MjU3YmMxZjk3L3RhYmxlcmFuZ2U6NDI5ZDIzMzQ0ZjNkNDM3Nzk5ODE3ODcyNTdiYzFmOTdfMTItMS0xLTEtMA_6c9e9830-d42e-48b8-a2fb-f02ba83df8c8">70,273</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2db2c0d074c34657a5d523b0ae1e5784_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83My9mcmFnOjEzZDQzMjA0MTY1MDRjMjdhMmMzOGZlZjgwOGE1MTEwL3RhYmxlOjQyOWQyMzM0NGYzZDQzNzc5OTgxNzg3MjU3YmMxZjk3L3RhYmxlcmFuZ2U6NDI5ZDIzMzQ0ZjNkNDM3Nzk5ODE3ODcyNTdiYzFmOTdfMTItMy0xLTEtMA_31d3b140-d7cb-4007-9021-2f74e52703f2">42,943</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="icc5d6783c1494a1f886c03c93e398cee_76"></div><div style="text-indent:-18pt;padding-left:18pt;text-align:right;margin-top:10pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><div style="text-indent:-18pt;padding-left:18pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">9.&#160;<ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTA5OTUxMTY0Njg1NA_d8278731-14f2-49b6-9a34-3b538cf59631" continuedAt="i90689ec4c8b447ddad506aaf1fd9289c" escape="true">Credit Facility, Bank Loan and Lines of Credit</ix:nonNumeric></span></div><ix:continuation id="i90689ec4c8b447ddad506aaf1fd9289c" continuedAt="i67c7a974a85c43c697e9458c7846c885"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Credit Facility</span></div><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTYxNzY_2853c32a-e870-4e87-90ac-3f8458b0aa33" escape="true"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s credit facility consisted of the following (in thousands):</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:82.017%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.983%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Term loan A</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iff4cb76a3da64b79b6a83acbf4ac62d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LineOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RhYmxlOmY3MmIyN2Q1ZjVjYzRiOWI5YTFkNjdlM2ZiODFkNjI3L3RhYmxlcmFuZ2U6ZjcyYjI3ZDVmNWNjNGI5YjlhMWQ2N2UzZmI4MWQ2MjdfMi0xLTEtMS0w_c161c39b-41b0-45f4-93bb-9a8f865d5a95">185,250</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revolver loan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie8692d3a0d3f43509f73c146da09a16f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LineOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RhYmxlOmY3MmIyN2Q1ZjVjYzRiOWI5YTFkNjdlM2ZiODFkNjI3L3RhYmxlcmFuZ2U6ZjcyYjI3ZDVmNWNjNGI5YjlhMWQ2N2UzZmI4MWQ2MjdfMy0xLTEtMS0w_3ec35e04-7f96-4b65-9c11-a89267722f50">60,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total debt</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LineOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RhYmxlOmY3MmIyN2Q1ZjVjYzRiOWI5YTFkNjdlM2ZiODFkNjI3L3RhYmxlcmFuZ2U6ZjcyYjI3ZDVmNWNjNGI5YjlhMWQ2N2UzZmI4MWQ2MjdfNC0xLTEtMS0w_d4f88a58-76e7-4500-9ac4-faa07cb1eb75">245,250</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Current portion of debt</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LinesOfCreditCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RhYmxlOmY3MmIyN2Q1ZjVjYzRiOWI5YTFkNjdlM2ZiODFkNjI3L3RhYmxlcmFuZ2U6ZjcyYjI3ZDVmNWNjNGI5YjlhMWQ2N2UzZmI4MWQ2MjdfNi0xLTEtMS0w_189e7e6b-7baa-4329-931f-5af3430c9b17">9,500</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Unamortized financing costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RhYmxlOmY3MmIyN2Q1ZjVjYzRiOWI5YTFkNjdlM2ZiODFkNjI3L3RhYmxlcmFuZ2U6ZjcyYjI3ZDVmNWNjNGI5YjlhMWQ2N2UzZmI4MWQ2MjdfNy0xLTEtMS0w_bc309f99-0763-469b-aa91-081d0999d773">5,295</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term debt</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RhYmxlOmY3MmIyN2Q1ZjVjYzRiOWI5YTFkNjdlM2ZiODFkNjI3L3RhYmxlcmFuZ2U6ZjcyYjI3ZDVmNWNjNGI5YjlhMWQ2N2UzZmI4MWQ2MjdfOS0xLTEtMS0w_78d32e1d-2594-411d-b85d-aad4155a6a7e">230,455</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTYxNzc_477304ae-37bc-4286-b073-55447ef524ad" escape="true"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Future commitments of the Company&#8217;s credit facility is to be as follows for the years ending December&#160;31 (in thousands):</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:82.017%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.983%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020 (excluding the six months ended June 30, 2020)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RhYmxlOjA0OTY4NTE3NDI1ZTQ4ZDdiOGY2M2M1NDU5YzlhZGEzL3RhYmxlcmFuZ2U6MDQ5Njg1MTc0MjVlNDhkN2I4ZjYzYzU0NTljOWFkYTNfMS0xLTEtMS0w_5eef840a-6c9d-424c-9c4b-8d27930c149c">7,125</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RhYmxlOjA0OTY4NTE3NDI1ZTQ4ZDdiOGY2M2M1NDU5YzlhZGEzL3RhYmxlcmFuZ2U6MDQ5Njg1MTc0MjVlNDhkN2I4ZjYzYzU0NTljOWFkYTNfMi0xLTEtMS0w_7064f553-dd62-4af9-8652-0a409690e49f">10,688</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RhYmxlOjA0OTY4NTE3NDI1ZTQ4ZDdiOGY2M2M1NDU5YzlhZGEzL3RhYmxlcmFuZ2U6MDQ5Njg1MTc0MjVlNDhkN2I4ZjYzYzU0NTljOWFkYTNfMy0xLTEtMS0w_be0b4b6a-b0b9-455c-9d5b-3ac75a835e63">14,250</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RhYmxlOjA0OTY4NTE3NDI1ZTQ4ZDdiOGY2M2M1NDU5YzlhZGEzL3RhYmxlcmFuZ2U6MDQ5Njg1MTc0MjVlNDhkN2I4ZjYzYzU0NTljOWFkYTNfNC0xLTEtMS0w_3ad2dc20-14b0-41e5-b1d9-d4d32668fcf2">15,437</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RhYmxlOjA0OTY4NTE3NDI1ZTQ4ZDdiOGY2M2M1NDU5YzlhZGEzL3RhYmxlcmFuZ2U6MDQ5Njg1MTc0MjVlNDhkN2I4ZjYzYzU0NTljOWFkYTNfNS0xLTEtMS0w_d1a7dae5-5217-4396-a54a-48bb64b3951d">197,750</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LineOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RhYmxlOjA0OTY4NTE3NDI1ZTQ4ZDdiOGY2M2M1NDU5YzlhZGEzL3RhYmxlcmFuZ2U6MDQ5Njg1MTc0MjVlNDhkN2I4ZjYzYzU0NTljOWFkYTNfNy0xLTEtMS0w_22e720fe-38c8-403f-89fa-24357bf84d16">245,250</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Credit Agreement</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In September 2019, the Company entered into a secured credit agreement (the &#8220;Credit Agreement,&#8221; and the credit facility thereunder, the "Credit Facility") with Truist Bank (formerly known as SunTrust Bank), in its capacity as administrative agent for the lenders (in such capacity, the &#8220;Agent&#8221;), as a lender, an issuer of letters of credit and as swingline lender, and Preferred Bank, JPMorgan Chase Bank, N.A., MUFG Union Bank, N.A., Royal Bank of Canada, Fifth Third Bank and City National Bank, as lenders (the &#8220;Lenders&#8221;). In connection with the closing of the Credit Agreement, the Company, its subsidiary, NMM, and the Agent entered into a Guaranty and Security Agreement (the &#8220;Guaranty and Security Agreement&#8221;), pursuant to which, among other things, NMM guaranteed the obligations of the Company under the Credit Agreement. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Credit Agreement provides for a <ix:nonNumeric contextRef="i91da1a2343864108babfdb0d2e98962a_D20190901-20190930" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTA5OTUxMTY0Njg1Nw_5c1894b0-aae3-4090-849d-6e1a87366009">five-year</ix:nonNumeric> revolving credit facility to the Company of $<ix:nonFraction unitRef="usd" contextRef="i8f0dc8ddd67e4b4c8a1d5a71831e1067_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTIwMg_e9173348-6543-4743-9987-e3cc4d58d74e">100.0</ix:nonFraction> million (&#8220;Revolver Loan&#8221;), which includes a letter of credit subfacility of up to $<ix:nonFraction unitRef="usd" contextRef="i8ac3810d42dd495ca842271bd91690b0_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTI3OQ_92294399-b03a-4c1b-85d3-2aa3e2c22ada">25.0</ix:nonFraction> million. The Credit Agreement also provides for a term loan of $<ix:nonFraction unitRef="usd" contextRef="i89df1d2e4cc246138d52d9f6d8cd6e7f_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTMzNw_7983fb9b-86a3-4c06-8e12-da5322720510">190.0</ix:nonFraction> million, (&#8220;Term Loan A&#8221;). The unpaid principal amount of the term loan is payable in quarterly installments on the last day of each fiscal quarter commencing on December 31, 2019. The principal payment for each of the first eight fiscal quarters is $<ix:nonFraction unitRef="usd" contextRef="if7490feb65964fa796425290739b321d_D20190901-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityPeriodicPaymentPrincipal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTU4MQ_076a4a3b-a5dd-40da-a4dc-20e7d75c3264">2.4</ix:nonFraction> million, for the following eight fiscal quarters thereafter is $<ix:nonFraction unitRef="usd" contextRef="i65f643704c1c43d88db131c9dcf5f1c4_D20190901-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityPeriodicPaymentPrincipal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTYzOQ_a902ddaf-89cb-46a4-bae2-de11c807aa10">3.6</ix:nonFraction> million and for the following three fiscal quarters thereafter is $<ix:nonFraction unitRef="usd" contextRef="i7d42642f16854ea2855614113b660e84_D20190901-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityPeriodicPaymentPrincipal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTcwMA_7377d865-55d2-4740-8b8a-0c30803a5664">4.8</ix:nonFraction> million. The remaining principal payment on the term loan is due on September&#160;11, 2024.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The proceeds of the term loan and up to $<ix:nonFraction unitRef="usd" contextRef="i15f80bd5e8b04174974b1f69d1519f06_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTgyMw_b226f5e5-474d-49e6-8053-b45f082bdbf0">60.0</ix:nonFraction> million of the revolving credit facility were used to (i) finance a portion of the AP-AMH Loan, (ii) refinance certain indebtedness of the Company and its subsidiaries and, indirectly, APC, (iii) pay transaction costs and expenses arising in connection with the Credit Agreement, the AP-AMH Loan and certain other related transactions and (iv) provide for working capital, capital expenditures and other general corporate purposes. The remainder of the revolving credit facility will be used to finance future acquisitions and investments and to provide for working capital needs, capital expenditures and other general corporate purposes.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is required to pay an annual facility fee of <ix:nonFraction unitRef="number" contextRef="ic96d1c4217de472a84ac6f11bbb720c3_D20190901-20190930" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMjUxNQ_ed03a3fa-1a52-4238-aa27-e28d5c2545a4">0.20</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i663b5171da0843d99423875dfcef6e74_D20190901-20190930" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMjUyMQ_5a8caf00-7e1f-49fc-901d-d04379a38ec8">0.35</ix:nonFraction>% on the available commitments under the Credit Agreement, regardless of usage, with the applicable fee determined on a quarterly basis based on the Company&#8217;s leverage ratio. The Company is also required to pay customary fees as specified in a separate fee agreement between the Company and SunTrust Robinson Humphrey, Inc., the lead arranger of the Credit Agreement.</span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><ix:continuation id="i67c7a974a85c43c697e9458c7846c885" continuedAt="ied8270b705f74bfeb00c09ae69c34090"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Amounts borrowed under the Credit Agreement will bear interest at an annual rate equal to either, at the Company&#8217;s option, (a) the rate for Eurocurrency deposits for the corresponding deposits of U.S. dollars appearing on Reuters Screen LIBOR01 Page (&#8220;LIBOR&#8221;), adjusted for any reserve requirement in effect, plus a spread of between <ix:nonFraction unitRef="number" contextRef="id0e05edf24764d42964dacb1936f8e5f_D20200101-20200630" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMzIyNA_f439a0d6-10f2-4e78-8ec6-e612c226e231">2.00</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i1fdcc51ad0fd4793ad2145ddf9d3333f_D20200101-20200630" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMzIzMQ_606a6898-c2d7-44de-a108-267ae13ebde6">3.00</ix:nonFraction>%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio, or (b) a base rate, plus a spread between <ix:nonFraction unitRef="number" contextRef="i9c4c1dc5b0424494b3aa09efc8137c81_D20200101-20200630" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMzM1MQ_493cc899-529c-42e7-adc5-cb9a86f3bcdd">1.00</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i3b7ff140c5b34302b6867e8581216396_D20200101-20200630" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMzM1OA_d17b2c22-d86e-4a7f-8413-a48509c0f2b7">2.00</ix:nonFraction>%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio. As of June&#160;30, 2020, the interest rate on Term Loan A and Revolver Loan was <ix:nonFraction unitRef="number" contextRef="iff4cb76a3da64b79b6a83acbf4ac62d5_I20200630" decimals="4" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMzUwMQ_3ee91e49-6d17-480f-83b0-2d33dc5f7c41">3.57</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ie8692d3a0d3f43509f73c146da09a16f_I20200630" decimals="4" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMzUwOA_3beab100-359b-4b94-b5ff-fae9cddc94b0">3.24</ix:nonFraction>%, respectively. The base rate is defined in a manner such that it will not be less than LIBOR. The Company will pay fees for standby letters of credit at an annual rate of between <ix:nonFraction unitRef="number" contextRef="ic1d8ce42602448a88e6e94a295508d62_D20200101-20200630" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMzY5MA_e1febb26-c227-4a5f-b6df-097a1da972a2">2.00</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i45e40a83e59c4f21b6a684d812a61ca2_D20200101-20200630" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMzY5Nw_eac7e0fd-a2e3-4db9-a3e9-1789f626d7b0">3.00</ix:nonFraction>%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio, plus facing fees and standard fees payable to the issuing bank on the respective letter of credit. Loans outstanding under the Credit Agreement may be prepaid at any time without penalty, except for LIBOR breakage costs and expenses. If LIBOR ceases to be reported, the Credit Agreement requires the Company and the Agent to endeavor to establish a commercially reasonable alternative rate of interest and until they are able to do so, all borrowings must be at the base rate.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Credit Agreement requires the Company and its subsidiaries to comply with various affirmative covenants, including, without limitation, furnishing updated financial and other information, preserving existence and entitlements, maintaining properties and insurance, complying with laws, maintaining books and records, requiring any new domestic subsidiary meeting a materiality threshold specified in the Credit Agreement to become a guarantor thereunder and paying obligations. The Credit Agreement requires the Company and its subsidiaries to comply with, and to use commercially reasonable efforts to the extent permitted by law to cause certain material associated practices of the Company, including APC, to comply with, restrictions on liens, indebtedness and investments (including restrictions on acquisitions by the Company), subject to specified exceptions. The Credit Agreement also contains various other negative covenants binding the Company and its subsidiaries, including, without limitation, restrictions on fundamental changes, dividends and distributions, sales and leasebacks, transactions with affiliates, burdensome agreements, use of proceeds, maintenance of business, amendments of organizational documents, accounting changes and prepayments and modifications of subordinated debt.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Credit Agreement requires the Company to comply with <ix:nonFraction unitRef="financial_ratio" contextRef="i1a435515824f4e14934a70bbffa79e42_I20200630" decimals="INF" format="ixt-sec:numwordsen" name="ameh:DebtInstrumentNumberOfKeyFinancialRatios" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfNTYxOQ_035c4c0e-ad44-4225-95b9-354272dbde52">two</ix:nonFraction> key financial ratios, each calculated on a consolidated basis. The Company must maintain a maximum consolidated leverage ratio of not greater than <ix:nonFraction unitRef="number" contextRef="i1a435515824f4e14934a70bbffa79e42_I20200630" decimals="INF" name="ameh:DebtInstrumentCovenantLeverageRatioMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfNTc2OQ_9a775326-5610-47cd-b61d-3557f0ea0bc5">3.75</ix:nonFraction> to 1.00 as of the last day of each fiscal quarter. The maximum consolidated leverage ratio decreases by <ix:nonFraction unitRef="number" contextRef="i1a435515824f4e14934a70bbffa79e42_I20200630" decimals="INF" name="ameh:DebtInstrumentCovenantLeverageRatioIncrementalChange" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfNTg3Ng_ff2527b6-c3fb-4d7a-94ff-2fc7985abca5">0.25</ix:nonFraction> each year, until it is reduced to <ix:nonFraction unitRef="number" contextRef="i1a435515824f4e14934a70bbffa79e42_I20200630" decimals="INF" name="ameh:DebtInstrumentCovenantLeverageRatioMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfNTkxMw_2b54f7f1-9f36-47d5-9d00-88f0f6160174">3.00</ix:nonFraction> to 1.00 for each fiscal quarter ending after September 30, 2022. The Company must maintain a minimum consolidated interest coverage ratio of not less than <ix:nonFraction unitRef="number" contextRef="i44c831b5e48a42e88b05d16f1fdb9240_D20200101-20200630" decimals="INF" name="ameh:DebtInstrumentCovenantInterestCoverageRatioMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfNjA1NQ_721e5bee-e047-42f5-87a2-f9c3f455d39c">3.25</ix:nonFraction> to 1.00 as of the last day of each fiscal quarter. As of June&#160;30, 2020, the Company was in compliance with the covenants relating to its credit facility.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the Guaranty and Security Agreement, the Company and NMM have granted the Lenders a security interest in all of their assets, including, without limitation, all stock and other equity issued by their subsidiaries (including NMM) and all rights with respect to the AP-AMH Loan. The Guaranty and Security Agreement requires the Company and NMM to comply with various affirmative and negative covenants, including, without limitation, covenants relating to maintaining perfected security interests, providing information and documentation to the Agent, complying with contractual obligations relating to the collateral, restricting the sale and issuance of securities by their respective subsidiaries and providing the Agent access to the collateral.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Credit Agreement contains events of default, including, without limitation, failure to make a payment when due, default on various covenants in the Credit Agreement, breach of representations or warranties, cross-default on other material indebtedness, bankruptcy or insolvency, occurrence of certain judgments and certain events under the Employee Retirement Income Security Act of 1974 aggregating more than $<ix:nonFraction unitRef="usd" contextRef="i6cbb20b8a5374294838553f9c534c7e6_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtDefaultLongtermDebtAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfNzM3NQ_54fcc5f2-47af-4ad1-a0be-7f8bb7a8b0c6">10.0</ix:nonFraction> million, invalidity of the loan documents, any lien under the Guaranty and Security Agreement ceasing to be valid and perfected, any change in control, as defined in the Credit Agreement, an event of default under the AP-AMH Loan, failure by APC to pay dividends in cash for any period of two consecutive fiscal quarters, failure by AP-AMH to pay cash interest to the Company, or if any modification is made to the Certificate of Determination or the Special Purpose Shareholder Agreement that directly or indirectly restricts, conditions, impairs, reduces or otherwise limits the payment of the Series A Preferred dividend by APC to AP-AMH. In addition, it will constitute an event of default under the Credit Agreement if APC uses all or any portion of the consideration received by APC from AP-AMH on account of AP-AMH&#8217;s purchase of Series A Preferred Stock for any purpose other than certain specific approved uses described in the following sentence, unless not less than <ix:nonFraction unitRef="number" contextRef="i7a1baad6dc7444dc9016d658275316ce_D20200101-20200630" decimals="INF" name="ameh:DebtInstrumentApprovalThresholdOfShareholdersForUseOfFundsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfODM0Ng_62187253-d7db-4e8c-8053-5a6f3b215b6e">50.01</ix:nonFraction>% of all holders of common stock of APC at such time approve such use; provided that APC may use up to $<ix:nonFraction unitRef="usd" contextRef="i9a8fc30c8bb8493fa605fcaa4207f068_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtDefaultLongtermDebtAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfODQ1MA_91008923-7a1d-494f-8d4d-b05a19e403f4">50.0</ix:nonFraction> million in the aggregate of such consideration for any purpose without any requirement to obtain such approval of the holders of common stock of APC. The approved uses include (i) any permitted investment, (ii) any dividend or distribution to the holders of the common stock of APC, (iii) any repurchase of common stock of APC, (iv) paying taxes relating to or arising from certain assets and transactions, or (v) funding losses, deficits or working capital support on account of certain non-healthcare assets in an amount not to exceed $<ix:nonFraction unitRef="usd" contextRef="i9a8fc30c8bb8493fa605fcaa4207f068_I20200630" decimals="INF" format="ixt:numdotdecimal" name="ameh:DebtInstrumentApprovedThresholdUseOfFunds" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfODk4Mg_dc7f5786-0ced-42c3-82b1-27dbc95c2566">125.0</ix:nonFraction> million. If any event of default occurs and is continuing under the Credit Agreement, the Lenders may terminate their commitments, and may require the Company and its guarantors to repay outstanding debt and/or to provide a cash deposit as additional security for outstanding letters of credit. In </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><ix:continuation id="ied8270b705f74bfeb00c09ae69c34090" continuedAt="i2da3edf5fee842e484ec18e65411e1be"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">addition, the Agent, on behalf of the Lenders, may pursue remedies under the Guaranty and Security Agreement, including, without limitation, transferring pledged securities of the Company&#8217;s subsidiaries in the name of the Agent and exercising all rights with respect thereto (including the right to vote and to receive dividends), collect on pledged accounts, instruments and other receivables (including the AP-AMH Loan), and all other rights provided by law or under the loan documents and the AP-AMH Loan.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the ordinary course of business, certain of the Lenders under the Credit Agreement and their affiliates have provided to the Company and its subsidiaries and the associated practices, and may in the future provide, (i) investment banking, commercial banking (including pursuant to certain existing business loan and credit agreements being terminated in connection with entering into the Credit Agreement), cash management, foreign exchange or other financial services, and (ii) services as a bond trustee and other trust and fiduciary services, for which they have received compensation and may receive compensation in the future.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Deferred Financing Costs</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In September 2019, the Company recorded deferred financing costs of $<ix:nonFraction unitRef="usd" contextRef="i15f80bd5e8b04174974b1f69d1519f06_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTA0OTU_08f51240-f659-4788-9f41-5497de4c6ce6">6.5</ix:nonFraction> million related to the issuance of the Credit Facility. This amount was recorded as a direct reduction of the carrying amount of the related debt liability. The deferred financing costs will be amortized over the life of the Credit Facility using the effective interest rate method. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Effective Interest Rate</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s average effective interest rate on its total debt during the six months ended June&#160;30, 2020 and 2019, was <ix:nonFraction unitRef="number" contextRef="i44c831b5e48a42e88b05d16f1fdb9240_D20200101-20200630" decimals="4" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTA5MDU_9c9e8185-c679-44d3-b295-729c87f65295">3.93</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ia8ce6e89d9dc47b7a39dd3dd0614631b_D20190101-20190630" decimals="4" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTA5MTI_ab327d82-9195-4409-accc-ed7f32251e01">4.71</ix:nonFraction>%, respectively. Interest expense in the consolidated statements of income included amortization of deferred debt issuance costs for the three and six months ended June&#160;30, 2020 and 2019, of $<ix:nonFraction unitRef="usd" contextRef="i8c34126de2c140689211bd3a59b45b51_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTEwODI_1099b081-9bfe-4d49-99a9-30d579be904d">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i44c831b5e48a42e88b05d16f1fdb9240_D20200101-20200630" decimals="-6" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTEwODk_cca36c67-01f5-4133-a316-7fb4044ff331">0</ix:nonFraction>, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i4bfbe9abbba34f0183c6540bd57fce10_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTY0OTI2NzQ2MDIyOQ_e98ccf0a-e614-4807-a9e8-652f2eb4e270">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia8ce6e89d9dc47b7a39dd3dd0614631b_D20190101-20190630" decimals="-5" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTI2NDQzODM3MzYxMTc_83a07477-b914-443c-9271-9ab1f1103596">0</ix:nonFraction>, respectively.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Lines of Credit &#8211; Related Party</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">NMM Business Loan</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On June&#160;14, 2018, NMM amended its promissory note agreement with Preferred Bank (&#8220;NMM Business Loan Agreement&#8221;), which provides for loan availability of up to $<ix:nonFraction unitRef="usd" contextRef="ib2719f73504548bbae721f92df01a971_I20180614" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTEzMDU_ce1eb367-233b-414d-adc6-5eb9a98cead9">20.0</ix:nonFraction> million with a maturity date of June&#160;22, 2020. One of the Company&#8217;s board members is the chairman and CEO of Preferred Bank. The NMM Business Loan Agreement was subsequently amended on September&#160;1, 2018, to temporarily increase the loan availability from $<ix:nonFraction unitRef="usd" contextRef="ib2719f73504548bbae721f92df01a971_I20180614" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTE1Mjg_ce1eb367-233b-414d-adc6-5eb9a98cead9">20.0</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="ibff1604bc099467eb93746f757585546_I20180901" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTE1MzQ_f484c018-7ff5-4db1-a040-9f762aa1d9da">27.0</ix:nonFraction> million for the period from September 1, 2018 through January 31, 2019, further extended to October&#160;31, 2019, to facilitate the issuance of an additional standby letter of credit for the benefit of CMS. The interest rate is based on the Wall Street Journal &#8220;prime rate,&#8221; plus <ix:nonFraction unitRef="number" contextRef="i16eef96539a54340912379d5350ec95c_D20181231-20181231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTE3NTA_d8f9daac-ff42-4bdd-970d-c7e6b767e549">0.125</ix:nonFraction>%, or <ix:nonFraction unitRef="number" contextRef="ie40c6e5bceac47058b37a4f4c0981530_I20181231" decimals="INF" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTE3NTc_27c36f12-998d-4673-b615-f7512672ab98">5.625</ix:nonFraction>% as of December&#160;31, 2018. The loan was guaranteed by Apollo Medical Holdings, Inc. and is collateralized by substantially all of the assets of NMM. The amounts outstanding as of June&#160;30, 2019, of $<ix:nonFraction unitRef="usd" contextRef="i13403ca944e64582bbcaa0105295fb08_I20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTE5NDM_07aca5a1-12c2-47a3-99fb-8ce93f2aa8b2">5.0</ix:nonFraction> million was fully repaid on September&#160;11, 2019.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On September&#160;5, 2018, NMM entered into a non-revolving line of credit agreement with Preferred Bank, which provides for loan availability of up to $<ix:nonFraction unitRef="usd" contextRef="i5266cd1d689d4ec2b6a1329887bfa026_I20180905" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTIxMDI_b50a8f86-2800-42d0-9de2-6229a41599ed">20.0</ix:nonFraction> million with a maturity date of September&#160;5, 2019. This credit facility was subsequently amended on April&#160;17, 2019, and July&#160;29, 2019, to reduce the loan availability from $<ix:nonFraction unitRef="usd" contextRef="i5266cd1d689d4ec2b6a1329887bfa026_I20180905" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTIyMjk_b50a8f86-2800-42d0-9de2-6229a41599ed">20.0</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="ia2cd4816f5eb443c93bc954045c6a0d2_I20190417" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTIyMzU_69441358-c317-4e3b-a702-763be09b477f">16.0</ix:nonFraction> million and from $<ix:nonFraction unitRef="usd" contextRef="ia2cd4816f5eb443c93bc954045c6a0d2_I20190417" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTIyNDc_69441358-c317-4e3b-a702-763be09b477f">16.0</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="i83420fb7674741a7adf09dd0edce6cb9_I20190729" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTIyNTM_02d0c1a3-4679-4909-a487-4b85c41e208d">2.2</ix:nonFraction> million, respectively. The interest rate is based on the Wall Street Journal &#8220;prime rate,&#8221; plus <ix:nonFraction unitRef="number" contextRef="ifd9d64e834b04bf7b54467b2c29f3db8_D20200101-20200630" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTIzNDQ_a70a19ea-0e67-481e-824c-9f5ddddf9126">0.125</ix:nonFraction>%, or <ix:nonFraction unitRef="number" contextRef="ie9253d136d6c409ea392551405cd59a3_I20200630" decimals="INF" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTIzNTE_e24d29b8-c646-4eff-bdd1-d357e3ffb76f">3.375</ix:nonFraction>% as of June&#160;30, 2020, and <ix:nonFraction unitRef="number" contextRef="i4ceb41120b5c427da8f7a165eb95d2a4_I20191231" decimals="INF" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTIzNjc_a021843c-bec8-42fe-ac00-0d3b98148ead">4.875</ix:nonFraction>% as of December&#160;31, 2019. The line of credit is guaranteed by Apollo Medical Holdings, Inc. and is collateralized by substantially all assets of NMM. NMM obtained this line of credit to finance potential acquisitions. Each drawdown from the line of credit is converted into a <ix:nonNumeric contextRef="i889eb6bfb2e4488e843c332fa29a6f88_D20180905-20180905" format="ixt-sec:durwordsen" name="ameh:LineOfCreditFacilityGuaranteeGivenByRelatedParties" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTA5OTUxMTY0Njg1Ng_8d524dd3-b2b2-4068-b94a-1ce9e061c294">five-year</ix:nonNumeric> term loan with monthly principal payments, plus interest based on a <ix:nonNumeric contextRef="i889eb6bfb2e4488e843c332fa29a6f88_D20180905-20180905" format="ixt-sec:durwordsen" name="us-gaap:LineOfCreditFacilityExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTA5OTUxMTY0Njg1NQ_35c4bf1a-0173-4937-93dd-c70224fc38af">five-year</ix:nonNumeric> amortization schedule.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On September 11, 2019, the NMM Business Loan Agreement, dated as of June&#160;14, 2018, between NMM and Preferred Bank, as amended, and the Line of Credit Agreement, dated as of September&#160;5, 2018, between NMM and Preferred Bank, as amended, were terminated in connection with the closing of the credit facility.&#160;Certain letters of credit issued by Preferred Bank under the Line of Credit Agreement were terminated and reissued under the Credit Agreement. As of June&#160;30, 2020,  outstanding letters of credit totaled $<ix:nonFraction unitRef="usd" contextRef="i6929d7ef6c724b578ebd614e9aac9b40_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LettersOfCreditOutstandingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTMyMDM_e5847cee-b952-4972-9b42-2f68212e530e">14.8</ix:nonFraction> million and the Company has $<ix:nonFraction unitRef="usd" contextRef="i489c8baa67d6408a868e6bdf3c0b60ea_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTMyMzU_267af3ec-cccd-4502-82f5-b68d538409e7">10.2</ix:nonFraction> million available under the revolving credit facility for letters of credit.</span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><ix:continuation id="i2da3edf5fee842e484ec18e65411e1be"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">APC Business Loan</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On June&#160;14, 2018, APC amended its promissory note agreement with Preferred Bank, which provides for loan availability of up to $<ix:nonFraction unitRef="usd" contextRef="i7d75edd516124fbb828f66a694cd578d_I20180614" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTM0NDA_1f7adc99-9d4f-4503-a6b2-90cfe1f87797">10.0</ix:nonFraction> million with a maturity date of June&#160;22, 2020. This credit facility was subsequently amended on April&#160;17, 2019, and June&#160;11, 2019, to increase the loan availability from $<ix:nonFraction unitRef="usd" contextRef="i7d75edd516124fbb828f66a694cd578d_I20180614" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTM1Njk_1f7adc99-9d4f-4503-a6b2-90cfe1f87797">10.0</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="i5c7162ddeee34091b6e14c1103b27d19_I20190611" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTM1NzU_33fb39cb-979f-4ef7-a5af-724210aa5dd5">40.0</ix:nonFraction> million and extend the maturity date through December&#160;31, 2020. On August&#160;1, 2019, and September&#160;10, 2019, this credit facility was further amended to increase loan availability from $<ix:nonFraction unitRef="usd" contextRef="i5c7162ddeee34091b6e14c1103b27d19_I20190611" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTM3MDk_33fb39cb-979f-4ef7-a5af-724210aa5dd5">40.0</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="i4b837318f7d8458cb42d750eb8bbe6ef_I20190801" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTM3MTU_fdc7cfb2-bbee-4cab-bc6a-d856f97ae262">43.8</ix:nonFraction> million, and decrease loan availability from $<ix:nonFraction unitRef="usd" contextRef="i4b837318f7d8458cb42d750eb8bbe6ef_I20190801" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTM3NTU_fdc7cfb2-bbee-4cab-bc6a-d856f97ae262">43.8</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="if65f3f073a4e4926bd996e2b6f3709ca_I20190910" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTM3NjE_acb0714c-a0bd-48fe-85a8-8212a416e7d4">4.1</ix:nonFraction> million, respectively. This decrease further limited the purpose of the indebtedness under APC Business Loan Agreement to the issuance of standby letters of credit, and added as a permitted lien the security interest in all of its assets granted by APC in favor of NMM under a Security Agreement dated on or about September 11, 2019, securing APC&#8217;s obligations to NMM under, and as required pursuant to, the APC management services agreement dated as of July 1, 1999, as amended. The interest rate is based on the Wall Street Journal &#8220;prime rate,&#8221; plus <ix:nonFraction unitRef="number" contextRef="i39925af9c158412d82ae7eac78d51ab3_D20200101-20200630" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTQzMDg_2231597a-eab4-4af2-873f-2272236f551d">0.125</ix:nonFraction>%, or <ix:nonFraction unitRef="number" contextRef="iadd3b4557abb442c93c1de563072e1bb_I20200630" decimals="INF" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTQzMTU_baf2beeb-d3b5-4d83-af6c-5b08b63664d2">3.375</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i349ef1b628184659aacbb0718a7d4338_I20191231" decimals="INF" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTQzMjI_6ab2cd13-33e1-4032-9b69-8204f1edb2ba">4.875</ix:nonFraction>% as of June&#160;30, 2020, and December&#160;31, 2019, respectively. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020 and December&#160;31, 2019, there was <ix:nonFraction unitRef="usd" contextRef="iadd3b4557abb442c93c1de563072e1bb_I20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTQzODQ_27edeb5f-4dc8-4010-a280-dabc69d91c3e"><ix:nonFraction unitRef="usd" contextRef="i349ef1b628184659aacbb0718a7d4338_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTQzODQ_c6cdcd0f-64a0-42ca-9a92-a1d50a472c1d">no</ix:nonFraction></ix:nonFraction> availability under this line of credit.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Standby Letters of Credit</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On October&#160;2, 2018, APAACO established a second irrevocable standby letter of credit with Preferred Bank (through the NMM Business Loan Agreement) for $<ix:nonFraction unitRef="usd" contextRef="i256fed6446054355bc000991eae06751_I20181002" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTQ1OTE_6863a786-3e46-4203-a978-6bdb898fdc1e">6.6</ix:nonFraction> million for the benefit of CMS. The letter of credit expires on December&#160;31, 2020, and is automatically extended without amendment for additional <ix:nonNumeric contextRef="i180bcd7578544f3fa0a9e820344d67de_D20181002-20181002" format="ixt-sec:durwordsen" name="us-gaap:LineOfCreditFacilityExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTA5OTUxMTY0Njg1MQ_e99db0b1-efd0-404c-ab26-6c01b3cccb2a">one-year</ix:nonNumeric> periods from the present or any future expiration date, unless notified by the institution to terminate prior to <ix:nonNumeric contextRef="i180bcd7578544f3fa0a9e820344d67de_D20181002-20181002" format="ixt-sec:durday" name="ameh:LineOfCreditFacilityExpirationPeriodPeriodOfNotification" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTQ4Mzc_4f6c5935-6631-4d72-b626-90f35226f12a">90</ix:nonNumeric> days from any expiration date. APAACO may continue to draw from the letter of credit for one year following the bank&#8217;s notification of non-renewal. This standby letter of credit was subsequently amended on August&#160;14, 2019, to increase amount from $<ix:nonFraction unitRef="usd" contextRef="i256fed6446054355bc000991eae06751_I20181002" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTUwNzM_6863a786-3e46-4203-a978-6bdb898fdc1e">6.6</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="i65b7438288394c098e39150948dddc7d_I20190814" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTUwNzk_66de7e36-39c9-4b1f-a013-39a993ab0ccf">14.8</ix:nonFraction> million and extended expiration date on December&#160;31, 2020, with all other terms and conditions remain unchanged. In connection with the closing of the Credit Facility,&#160;this letter of credit was terminated and reissued under the Credit Agreement.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">APC established irrevocable standby letters of credit with Preferred Bank under the APC Business Loan Agreement for a total of $<ix:nonFraction unitRef="usd" contextRef="i28f48691115042d086bf50c14043181c_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTU0MzE_9e972a18-e146-4d5f-9240-e1f15138f947">0.3</ix:nonFraction> million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional <ix:nonNumeric contextRef="i1cdc831367ff4a8584c4a6fb205fddcd_D20200101-20200630" format="ixt-sec:durwordsen" name="us-gaap:LineOfCreditFacilityExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTA5OTUxMTY0Njg1Mw_389b5c9b-950a-49f9-bcfd-b03c9c789628">one-year</ix:nonNumeric> periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Alpha Care established irrevocable standby letters of credit with Preferred Bank under the APC Business Loan Agreement for a total of $<ix:nonFraction unitRef="usd" contextRef="i3fc12c8dd5b743488bb6c1675f17858f_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTU4Njg_3b321c93-6459-491f-a79c-f475ad12681f">3.8</ix:nonFraction> million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional <ix:nonNumeric contextRef="i5fcdc1d2217741c292117f4a0d9fff3e_D20200101-20200630" format="ixt-sec:durwordsen" name="us-gaap:LineOfCreditFacilityExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTA5OTUxMTY0Njg1Mg_adb09bb3-a249-4d81-b889-d4a8ecc90142">one-year</ix:nonNumeric> periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated.</span></div></ix:continuation><div id="icc5d6783c1494a1f886c03c93e398cee_82"></div><div style="text-indent:-18pt;padding-left:18pt;margin-top:10pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:18pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">10.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfMTI2NDQzODM3MzM4MTg_ffe89571-8152-44a7-8012-1bfd14794c18" continuedAt="i1689e9e5a98347df8273ae01c94980a3" escape="true">Mezzanine and Stockholders&#8217; Equity</ix:nonNumeric></span></div><ix:continuation id="i1689e9e5a98347df8273ae01c94980a3" continuedAt="id492483dfdc04315b0687c3726c352cc"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Mezzanine</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As the redemption feature (see Note 2) of the shares is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as noncontrolling interest in APC as mezzanine or temporary equity. APC&#8217;s shares are not redeemable and it is not probable that the shares will become redeemable as of June&#160;30, 2020 and December&#160;31, 2019.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stockholders&#8217; Equity</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, <ix:nonFraction unitRef="shares" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="ameh:StockIssuedDuringPeriodSharesMerger" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfNDM4_809c83cd-6696-4b45-9946-5e72be872680">302,732</ix:nonFraction> holdback shares have not been issued to certain former NMM shareholders who were NMM shareholders at the time of closing of the merger between NMM and ApolloMed in December 2017 (the "Merger"), as they have yet to submit properly completed letters of transmittal to ApolloMed in order to receive their pro rata portion of ApolloMed common stock and warrants as contemplated under the merger agreement. Pending such receipt, such former NMM shareholders have the right to receive, without interest, their pro rata share of dividends or distributions with a record date after the effectiveness of the Merger. The consolidated financial statements have treated such shares of common stock as outstanding, given the receipt of the letter of transmittal is considered perfunctory and the Company is legally obligated to issue these shares in connection with the Merger.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See options and warrants section below for common stock issued upon exercise of stock options and stock purchase warrants.</span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><ix:continuation id="id492483dfdc04315b0687c3726c352cc" continuedAt="i125da4ea00a54dcbbfdf976d8d35bca9"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Options</span></div><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfNDY2Nw_886e6fd4-c52d-4aae-8dbf-bf465f3b1a64" escape="true"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s outstanding stock options consisted of the following:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:44.920%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.756%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.756%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.730%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.639%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Shares</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Weighted</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exercise Price</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Weighted</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Remaining</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Contractual</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Term</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Years)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Aggregate</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Intrinsic</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Value</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(in thousands)</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Options outstanding at January&#160;1, 2020</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmE1M2M2OGE3MjEwZDRkZjQ4NWQyNTRmNDIyNTQ0MjU4L3RhYmxlcmFuZ2U6YTUzYzY4YTcyMTBkNGRmNDg1ZDI1NGY0MjI1NDQyNThfMS0xLTEtMS0w_b3436d6e-ee89-4f9e-9672-ad9d39f7bed0">607,346</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmE1M2M2OGE3MjEwZDRkZjQ4NWQyNTRmNDIyNTQ0MjU4L3RhYmxlcmFuZ2U6YTUzYzY4YTcyMTBkNGRmNDg1ZDI1NGY0MjI1NDQyNThfMS0zLTEtMS0w_f4ffc20b-a562-4253-95e0-a2f787ac79da">9.22</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i165dffaa08f24a1888f81cae72742649_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmE1M2M2OGE3MjEwZDRkZjQ4NWQyNTRmNDIyNTQ0MjU4L3RhYmxlcmFuZ2U6YTUzYzY4YTcyMTBkNGRmNDg1ZDI1NGY0MjI1NDQyNThfMS01LTEtMS0w_265b4f34-2ec7-458a-947d-40d2e9159bff">3.42</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmE1M2M2OGE3MjEwZDRkZjQ4NWQyNTRmNDIyNTQ0MjU4L3RhYmxlcmFuZ2U6YTUzYzY4YTcyMTBkNGRmNDg1ZDI1NGY0MjI1NDQyNThfMS03LTEtMS0w_dfd8a11e-42c3-4c15-9007-26a311e2d6f7">5,600</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Options granted</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmE1M2M2OGE3MjEwZDRkZjQ4NWQyNTRmNDIyNTQ0MjU4L3RhYmxlcmFuZ2U6YTUzYzY4YTcyMTBkNGRmNDg1ZDI1NGY0MjI1NDQyNThfMi0xLTEtMS0w_8eb67be5-453c-448c-800f-7c65b771307f">11,742</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmE1M2M2OGE3MjEwZDRkZjQ4NWQyNTRmNDIyNTQ0MjU4L3RhYmxlcmFuZ2U6YTUzYzY4YTcyMTBkNGRmNDg1ZDI1NGY0MjI1NDQyNThfMi0zLTEtMS0w_8b81c057-71d0-44b1-b506-099df21b812d">18.41</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Options exercised</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmE1M2M2OGE3MjEwZDRkZjQ4NWQyNTRmNDIyNTQ0MjU4L3RhYmxlcmFuZ2U6YTUzYzY4YTcyMTBkNGRmNDg1ZDI1NGY0MjI1NDQyNThfMy0xLTEtMS0w_d5ae6563-7e65-4ff1-9274-7dc690a1e616">120,000</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmE1M2M2OGE3MjEwZDRkZjQ4NWQyNTRmNDIyNTQ0MjU4L3RhYmxlcmFuZ2U6YTUzYzY4YTcyMTBkNGRmNDg1ZDI1NGY0MjI1NDQyNThfMy0zLTEtMS0w_61d6699b-3931-482d-b42d-49c04a37657c">2.58</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmE1M2M2OGE3MjEwZDRkZjQ4NWQyNTRmNDIyNTQ0MjU4L3RhYmxlcmFuZ2U6YTUzYzY4YTcyMTBkNGRmNDg1ZDI1NGY0MjI1NDQyNThfMy03LTEtMS0w_c6cd3339-3cf9-44be-93ab-65589414f59d">1,800</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Options forfeited</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmE1M2M2OGE3MjEwZDRkZjQ4NWQyNTRmNDIyNTQ0MjU4L3RhYmxlcmFuZ2U6YTUzYzY4YTcyMTBkNGRmNDg1ZDI1NGY0MjI1NDQyNThfNC0xLTEtMS0w_6bf88d05-b4f2-4308-91d2-8064b4f01aec">12,228</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmE1M2M2OGE3MjEwZDRkZjQ4NWQyNTRmNDIyNTQ0MjU4L3RhYmxlcmFuZ2U6YTUzYzY4YTcyMTBkNGRmNDg1ZDI1NGY0MjI1NDQyNThfNC0zLTEtMS0w_8889b858-a64f-44f3-a9ba-0731a2af700c">17.57</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options outstanding at June 30, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmE1M2M2OGE3MjEwZDRkZjQ4NWQyNTRmNDIyNTQ0MjU4L3RhYmxlcmFuZ2U6YTUzYzY4YTcyMTBkNGRmNDg1ZDI1NGY0MjI1NDQyNThfNi0xLTEtMS0w_02b764f5-ec5a-4aef-9265-2b8341a3d18f">486,860</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmE1M2M2OGE3MjEwZDRkZjQ4NWQyNTRmNDIyNTQ0MjU4L3RhYmxlcmFuZ2U6YTUzYzY4YTcyMTBkNGRmNDg1ZDI1NGY0MjI1NDQyNThfNi0zLTEtMS0w_866e81d5-879d-40d9-b39a-6875b7e4b835">10.86</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmE1M2M2OGE3MjEwZDRkZjQ4NWQyNTRmNDIyNTQ0MjU4L3RhYmxlcmFuZ2U6YTUzYzY4YTcyMTBkNGRmNDg1ZDI1NGY0MjI1NDQyNThfNi01LTEtMS0w_dfd39206-1a8e-418d-be8b-8e79fbdffcc7">3.70</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmE1M2M2OGE3MjEwZDRkZjQ4NWQyNTRmNDIyNTQ0MjU4L3RhYmxlcmFuZ2U6YTUzYzY4YTcyMTBkNGRmNDg1ZDI1NGY0MjI1NDQyNThfNi03LTEtMS0w_fc3f321f-7ea3-403b-8364-e8bccdc6ec36">2,900</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options exercisable at June 30, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmE1M2M2OGE3MjEwZDRkZjQ4NWQyNTRmNDIyNTQ0MjU4L3RhYmxlcmFuZ2U6YTUzYzY4YTcyMTBkNGRmNDg1ZDI1NGY0MjI1NDQyNThfOC0xLTEtMS0w_1d4e8e00-6010-47fa-aae1-947664d1b464">380,894</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmE1M2M2OGE3MjEwZDRkZjQ4NWQyNTRmNDIyNTQ0MjU4L3RhYmxlcmFuZ2U6YTUzYzY4YTcyMTBkNGRmNDg1ZDI1NGY0MjI1NDQyNThfOC0zLTEtMS0w_0669ddae-3d1c-4a96-9272-3298be21725d">7.11</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmE1M2M2OGE3MjEwZDRkZjQ4NWQyNTRmNDIyNTQ0MjU4L3RhYmxlcmFuZ2U6YTUzYzY4YTcyMTBkNGRmNDg1ZDI1NGY0MjI1NDQyNThfOC01LTEtMS0w_0517f912-d875-4f3c-be26-2ccdf5cd21de">2.74</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmE1M2M2OGE3MjEwZDRkZjQ4NWQyNTRmNDIyNTQ0MjU4L3RhYmxlcmFuZ2U6YTUzYzY4YTcyMTBkNGRmNDg1ZDI1NGY0MjI1NDQyNThfOC03LTEtMS0w_27c4e9b8-c056-42d1-aa4e-1048cc9faed6">3,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the six months ended June&#160;30, 2020 and 2019, stock options were exercised for <ix:nonFraction unitRef="shares" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfMTU3OA_b8e13237-5729-43b0-9d0f-08586426c2fe">120,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfMTU4NQ_aa69d218-891e-4845-9336-51378218dbcc">111,000</ix:nonFraction> shares, respectively, of the Company&#8217;s common stock, which resulted in proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="ic7bf1ad2136147739b9d3573b799cfb2_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfMTY4NQ_51d16f18-26bb-4b98-a7d6-be02919651ae">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9147cda570b34114b9da7922c7249550_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfMTY5Mg_48c60c61-e690-4c80-bb15-78c014c9ebe1">0.5</ix:nonFraction> million, respectively. The exercise price ranged from $<ix:nonFraction unitRef="usdPerShare" contextRef="if0190ef7dee34fbda65c048ee6b393c7_I20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfMTczMw_66e38a4f-8334-40df-9f44-710c09348cd2">2.10</ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="i4688143439664825ac968a174665ba3d_I20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfNjA0NzMxMzk1NzU0NA_504c48bb-24cf-4024-9d0a-b81e8aa32cba">5.00</ix:nonFraction> per share for the exercises during the six months ended June&#160;30, 2020, and ranged from $<ix:nonFraction unitRef="usdPerShare" contextRef="i394a53913abc46b7840e4b3b601af231_I20190630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfMTgxNA_222f54de-c363-4f59-81fe-a1ac70773557">1.50</ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="ia7f3c7099ea7466e8c0372573a9eb42b_I20190630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfMTgyMA_c61c5a5e-9385-4024-bc0e-8cc8c7f1ac28">5.79</ix:nonFraction> per share for the exercises during the six months ended June&#160;30, 2019.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the six months ended June&#160;30, 2020 and 2019, <ix:nonFraction unitRef="shares" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="INF" format="ixt-sec:numwordsen" name="ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfMTkyMA_a4bc79cc-5078-463e-a17f-d0e479a7d366"><ix:nonFraction unitRef="shares" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfMTkyMA_d0d23550-8452-48d5-80bc-47bb0627ccd5">no</ix:nonFraction></ix:nonFraction> stock options were exercised pursuant to the cashless exercise provision.</span></div><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfNDY3MA_44698fb0-f5be-4936-8a35-11246e0e97c3" escape="true"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the six months ended June&#160;30, 2020, the Company granted <ix:nonFraction unitRef="shares" contextRef="i9ec7494ea7af48fda7c1d23e2672ba9d_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfMjA0OA_cf05f023-dcf9-402e-8311-a474cdd5e6a8">11,742</ix:nonFraction> stock options with a vesting period of <ix:nonNumeric contextRef="i9c63f7d7fa16447cb33f1cc3ad14ba3f_D20200101-20200630" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfMTE1NDQ4NzIxMDYxMzI_fcff4f97-de4e-48db-a2a7-ac86c3dca671">five-years</ix:nonNumeric> to certain ApolloMed board members with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i5c5087d6c84a4583badaea62a58fdd8a_I20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfMjEzNA_ff170517-fc55-4b30-ab41-e5a43a85093e">18.41</ix:nonFraction>, which were recognized at fair value, as determined using the Black-Scholes option pricing model and the following assumptions:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:80.258%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:15.742%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">June 30, 2020</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Board Members</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Expected term</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i9ec7494ea7af48fda7c1d23e2672ba9d_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOjBmMGU1ZDA2NWJiMTRjMDRiNDcxZjExNjMyZDkxYjUxL3RhYmxlcmFuZ2U6MGYwZTVkMDY1YmIxNGMwNGI0NzFmMTE2MzJkOTFiNTFfMS0xLTEtMS0w_a05273e8-cb28-4bf8-ad89-5e2144562e0a">3.0</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Expected volatility</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i9ec7494ea7af48fda7c1d23e2672ba9d_D20200101-20200630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOjBmMGU1ZDA2NWJiMTRjMDRiNDcxZjExNjMyZDkxYjUxL3RhYmxlcmFuZ2U6MGYwZTVkMDY1YmIxNGMwNGI0NzFmMTE2MzJkOTFiNTFfMi0xLTEtMS0w_16e3f3a3-8de8-4acf-8f50-6dc285197c58">90.01</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Risk-free interest rate</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i9ec7494ea7af48fda7c1d23e2672ba9d_D20200101-20200630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOjBmMGU1ZDA2NWJiMTRjMDRiNDcxZjExNjMyZDkxYjUxL3RhYmxlcmFuZ2U6MGYwZTVkMDY1YmIxNGMwNGI0NzFmMTE2MzJkOTFiNTFfMy0xLTEtMS0w_cc928c49-17db-4287-a623-b6da135bb882">1.43</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Market value of common stock</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i5c5087d6c84a4583badaea62a58fdd8a_I20200630" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOjBmMGU1ZDA2NWJiMTRjMDRiNDcxZjExNjMyZDkxYjUxL3RhYmxlcmFuZ2U6MGYwZTVkMDY1YmIxNGMwNGI0NzFmMTE2MzJkOTFiNTFfNC0xLTEtMS0w_0d9d2c42-7735-41c0-9897-2142daae47f9">10.56</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Annual dividend yield</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i9ec7494ea7af48fda7c1d23e2672ba9d_D20200101-20200630" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOjBmMGU1ZDA2NWJiMTRjMDRiNDcxZjExNjMyZDkxYjUxL3RhYmxlcmFuZ2U6MGYwZTVkMDY1YmIxNGMwNGI0NzFmMTE2MzJkOTFiNTFfNS0xLTEtMS0w_663f82b5-4e42-40ef-aa3c-1fd653bbdf11">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Forfeiture rate</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i9ec7494ea7af48fda7c1d23e2672ba9d_D20200101-20200630" decimals="INF" format="ixt:zerodash" name="ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOjBmMGU1ZDA2NWJiMTRjMDRiNDcxZjExNjMyZDkxYjUxL3RhYmxlcmFuZ2U6MGYwZTVkMDY1YmIxNGMwNGI0NzFmMTE2MzJkOTFiNTFfNi0xLTEtMS0w_e11c0777-a047-4457-a45e-27979169c9f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Restricted Stock Awards</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company grants restricted stock awards to employees which are earned based on service conditions. The grant date fair value of the restricted stock awards is that day&#8217;s closing market price of the Company&#8217;s common stock. During the six months ended June&#160;30, 2020, the Company granted restricted stock awards totaling <ix:nonFraction unitRef="shares" contextRef="id3ba07d0aaff4c4cbfb30aa71876350e_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfMjYwMA_548ea2be-d890-49aa-aabe-6f35ba9aa600">97,447</ix:nonFraction> shares with a weighted average grant date fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="id3ba07d0aaff4c4cbfb30aa71876350e_D20200101-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfMjY1OQ_21d12861-ec59-4dbe-8302-bf18368c5086">17.58</ix:nonFraction>. The grant date fair value of the restricted stock was $<ix:nonFraction unitRef="usd" contextRef="id5b38446c9f64ce5babcd929b0922482_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfMjcxNw_0556f658-cba2-4ef1-b191-1d20d37514ce">1.6</ix:nonFraction> million to be recognized on a straight-line basis over the awards&#8217; vesting period of <ix:nonNumeric contextRef="id3ba07d0aaff4c4cbfb30aa71876350e_D20200101-20200630" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfMjc5Nw_2fc37294-390c-490c-9712-4ae0963496be">three years</ix:nonNumeric>. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three and six months ended June&#160;30, 2020, the Company recorded approximately $<ix:nonFraction unitRef="usd" contextRef="id57bfd29aaf44d4d95e8e561bbe67cf2_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfMjg2OA_4151a5ce-5083-4541-a915-ea9feb9af840">0.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i414264e0cb1e499287a23f8ddf6b9498_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfNjA0NzMxMzk1NzU1OA_313a8fb0-6a14-46ee-8124-a29659131f83">1.6</ix:nonFraction> million of share-based compensation expense associated with the issuance of restricted shares of common stock and vesting of stock options which is included in general and administrative expenses in the accompanying consolidated statements of income, respectively. Unrecognized compensation expense related to total share-based payments outstanding as of June&#160;30, 2020, was $<ix:nonFraction unitRef="usd" contextRef="id265c5c2e7f34a2bbb064c838d92d806_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfNjU5NzA2OTc3OTUyNA_9880e5bc-a51c-4212-b9ac-906ae93706d7">3.8</ix:nonFraction> million. </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><ix:continuation id="i125da4ea00a54dcbbfdf976d8d35bca9"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Warrants</span></div><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfNDY3Nw_a7cffe42-efd0-41bd-8903-b11a5f0f5131" escape="true"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s outstanding warrants consisted of the following:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:43.680%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.913%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Shares</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Weighted</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exercise Price</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Weighted</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Remaining</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Contractual</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Term</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Years)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Aggregate</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Intrinsic</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Value</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(in thousands)</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Warrants outstanding at January&#160;1, 2020</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmFhYWI2YTAzYWFjMTRlOGRiNzA4Y2VlNzU3MTBkNzYzL3RhYmxlcmFuZ2U6YWFhYjZhMDNhYWMxNGU4ZGI3MDhjZWU3NTcxMGQ3NjNfMS0xLTEtMS0w_86f3b48e-d2ba-43fc-b7b3-da29ce7a3a3a">3,154,590</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="2" name="ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmFhYWI2YTAzYWFjMTRlOGRiNzA4Y2VlNzU3MTBkNzYzL3RhYmxlcmFuZ2U6YWFhYjZhMDNhYWMxNGU4ZGI3MDhjZWU3NTcxMGQ3NjNfMS0zLTEtMS0w_cf5978d8-250c-4570-9aea-d9eff0ca63f1">9.96</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i165dffaa08f24a1888f81cae72742649_D20190101-20191231" format="ixt-sec:duryear" name="ameh:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmFhYWI2YTAzYWFjMTRlOGRiNzA4Y2VlNzU3MTBkNzYzL3RhYmxlcmFuZ2U6YWFhYjZhMDNhYWMxNGU4ZGI3MDhjZWU3NTcxMGQ3NjNfMS01LTEtMS0w_131ecd7f-aaa9-4d9a-bfab-43d28adf28c2">2.01</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="ameh:ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmFhYWI2YTAzYWFjMTRlOGRiNzA4Y2VlNzU3MTBkNzYzL3RhYmxlcmFuZ2U6YWFhYjZhMDNhYWMxNGU4ZGI3MDhjZWU3NTcxMGQ3NjNfMS03LTEtMS0w_b9b33f9e-9b32-452c-bae5-e61d9080c548">26,700</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Warrants granted</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="INF" format="ixt:zerodash" name="ameh:NumberOfWarrantsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmFhYWI2YTAzYWFjMTRlOGRiNzA4Y2VlNzU3MTBkNzYzL3RhYmxlcmFuZ2U6YWFhYjZhMDNhYWMxNGU4ZGI3MDhjZWU3NTcxMGQ3NjNfMi0xLTEtMS0w_4aa4dec6-f8df-4578-9f6a-029e315def1c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="2" format="ixt:zerodash" name="ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmFhYWI2YTAzYWFjMTRlOGRiNzA4Y2VlNzU3MTBkNzYzL3RhYmxlcmFuZ2U6YWFhYjZhMDNhYWMxNGU4ZGI3MDhjZWU3NTcxMGQ3NjNfMi0zLTEtMS0w_ecf3330f-a62b-4b16-b501-3e56a79682e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:zerodash" name="ameh:ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmFhYWI2YTAzYWFjMTRlOGRiNzA4Y2VlNzU3MTBkNzYzL3RhYmxlcmFuZ2U6YWFhYjZhMDNhYWMxNGU4ZGI3MDhjZWU3NTcxMGQ3NjNfMi03LTEtMS0w_1e279de5-84d9-4e8f-9217-9517616505cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Warrants exercised</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="ameh:NumberOfWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmFhYWI2YTAzYWFjMTRlOGRiNzA4Y2VlNzU3MTBkNzYzL3RhYmxlcmFuZ2U6YWFhYjZhMDNhYWMxNGU4ZGI3MDhjZWU3NTcxMGQ3NjNfMy0xLTEtMS0w_7ff0e31d-f531-44c8-a63f-42d13753b4e3">273,900</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="2" name="ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmFhYWI2YTAzYWFjMTRlOGRiNzA4Y2VlNzU3MTBkNzYzL3RhYmxlcmFuZ2U6YWFhYjZhMDNhYWMxNGU4ZGI3MDhjZWU3NTcxMGQ3NjNfMy0zLTEtMS0w_cbfedb90-9773-42be-8cbd-a9fab8c3bd86">9.32</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="ameh:ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmFhYWI2YTAzYWFjMTRlOGRiNzA4Y2VlNzU3MTBkNzYzL3RhYmxlcmFuZ2U6YWFhYjZhMDNhYWMxNGU4ZGI3MDhjZWU3NTcxMGQ3NjNfMy03LTEtMS0w_d091eb1e-1e58-4064-8f82-3c2fc3de477b">2,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Warrants expired/forfeited</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="INF" format="ixt:zerodash" name="ameh:ClassOfWarrantOrRightCancelledInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmFhYWI2YTAzYWFjMTRlOGRiNzA4Y2VlNzU3MTBkNzYzL3RhYmxlcmFuZ2U6YWFhYjZhMDNhYWMxNGU4ZGI3MDhjZWU3NTcxMGQ3NjNfNC0xLTEtMS0w_15fde319-351f-4be1-ab6f-d3a7260cb406">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="2" format="ixt:zerodash" name="ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmFhYWI2YTAzYWFjMTRlOGRiNzA4Y2VlNzU3MTBkNzYzL3RhYmxlcmFuZ2U6YWFhYjZhMDNhYWMxNGU4ZGI3MDhjZWU3NTcxMGQ3NjNfNC0zLTEtMS0w_6e1445fb-281b-432d-83b4-d62badd0cf09">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:zerodash" name="ameh:ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmFhYWI2YTAzYWFjMTRlOGRiNzA4Y2VlNzU3MTBkNzYzL3RhYmxlcmFuZ2U6YWFhYjZhMDNhYWMxNGU4ZGI3MDhjZWU3NTcxMGQ3NjNfNC03LTEtMS0w_5976f2e8-20c0-45f4-8dda-42ea00b95525">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Warrants outstanding at June 30, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmFhYWI2YTAzYWFjMTRlOGRiNzA4Y2VlNzU3MTBkNzYzL3RhYmxlcmFuZ2U6YWFhYjZhMDNhYWMxNGU4ZGI3MDhjZWU3NTcxMGQ3NjNfNi0xLTEtMS0w_fabd2713-41f0-4326-9b03-43de647277b3">2,880,690</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="2" name="ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmFhYWI2YTAzYWFjMTRlOGRiNzA4Y2VlNzU3MTBkNzYzL3RhYmxlcmFuZ2U6YWFhYjZhMDNhYWMxNGU4ZGI3MDhjZWU3NTcxMGQ3NjNfNi0zLTEtMS0w_3f9348a9-c94f-4fd4-acc3-273ff21fa5f4">10.02</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" format="ixt-sec:duryear" name="ameh:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmFhYWI2YTAzYWFjMTRlOGRiNzA4Y2VlNzU3MTBkNzYzL3RhYmxlcmFuZ2U6YWFhYjZhMDNhYWMxNGU4ZGI3MDhjZWU3NTcxMGQ3NjNfNi01LTEtMS0w_c49ee2a7-7047-459a-9ab1-d378f7a4275e">1.61</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="ameh:ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmFhYWI2YTAzYWFjMTRlOGRiNzA4Y2VlNzU3MTBkNzYzL3RhYmxlcmFuZ2U6YWFhYjZhMDNhYWMxNGU4ZGI3MDhjZWU3NTcxMGQ3NjNfNi03LTEtMS0w_520ce50c-2baf-4e10-8d29-48d9af89bdb3">18,700</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:19.637%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.152%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:16.567%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:15.982%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.742%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exercise&#160;Price&#160;Per Share</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Warrants&#8232;Outstanding</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Weighted</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Remaining</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Contractual&#160;Life</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Warrants</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exercisable</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Weighted</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exercise&#160;Price</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Per Share</span></div></td></tr><tr><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i0652754b1e534a8089d0c0347af659b7_I20200630" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOjRjYWJiYWJiNGZiZTQ2NWJiMGIwM2ZjMzE1YzdhNjA2L3RhYmxlcmFuZ2U6NGNhYmJhYmI0ZmJlNDY1YmIwYjAzZmMzMTVjN2E2MDZfMS0wLTEtMS0w_19cf193d-00e9-4f6e-a9a8-dc5334280da2">9.00</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ia1f01a331d6248978588759d09efd270_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="ameh:ClassOfWarrantOrRightIssuedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOjRjYWJiYWJiNGZiZTQ2NWJiMGIwM2ZjMzE1YzdhNjA2L3RhYmxlcmFuZ2U6NGNhYmJhYmI0ZmJlNDY1YmIwYjAzZmMzMTVjN2E2MDZfMS0yLTEtMS0w_42db0101-d0bb-4a7d-936f-1036f30ccb57">754,870</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ia1f01a331d6248978588759d09efd270_D20200101-20200630" format="ixt-sec:duryear" name="ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOjRjYWJiYWJiNGZiZTQ2NWJiMGIwM2ZjMzE1YzdhNjA2L3RhYmxlcmFuZ2U6NGNhYmJhYmI0ZmJlNDY1YmIwYjAzZmMzMTVjN2E2MDZfMS00LTEtMS0w_d05a9c12-0384-4cb3-884f-57c79ba95436">0.29</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i0652754b1e534a8089d0c0347af659b7_I20200630" decimals="INF" format="ixt:numdotdecimal" name="ameh:ClassOfWarrantOrRightExercisable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOjRjYWJiYWJiNGZiZTQ2NWJiMGIwM2ZjMzE1YzdhNjA2L3RhYmxlcmFuZ2U6NGNhYmJhYmI0ZmJlNDY1YmIwYjAzZmMzMTVjN2E2MDZfMS02LTEtMS0w_2791d46d-f54e-45e8-9cba-7073e42afd5d">754,870</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i0652754b1e534a8089d0c0347af659b7_I20200630" decimals="2" name="ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOjRjYWJiYWJiNGZiZTQ2NWJiMGIwM2ZjMzE1YzdhNjA2L3RhYmxlcmFuZ2U6NGNhYmJhYmI0ZmJlNDY1YmIwYjAzZmMzMTVjN2E2MDZfMS04LTEtMS0w_f1c663ad-9c25-436e-8673-5321ab96ff7a">9.00</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i717848bf538848ab855a3a3e35ae4238_I20200630" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOjRjYWJiYWJiNGZiZTQ2NWJiMGIwM2ZjMzE1YzdhNjA2L3RhYmxlcmFuZ2U6NGNhYmJhYmI0ZmJlNDY1YmIwYjAzZmMzMTVjN2E2MDZfMi0wLTEtMS0w_42a14ac5-8e51-474d-ba8f-bdf23b0ae972">10.00</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ia4f9f7ea8c4f4b079f5fc8ba6a915106_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="ameh:ClassOfWarrantOrRightIssuedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOjRjYWJiYWJiNGZiZTQ2NWJiMGIwM2ZjMzE1YzdhNjA2L3RhYmxlcmFuZ2U6NGNhYmJhYmI0ZmJlNDY1YmIwYjAzZmMzMTVjN2E2MDZfMi0yLTEtMS0w_2df13e91-f9a4-43f6-8c95-ebeb20f825ac">1,313,345</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ia4f9f7ea8c4f4b079f5fc8ba6a915106_D20200101-20200630" format="ixt-sec:duryear" name="ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOjRjYWJiYWJiNGZiZTQ2NWJiMGIwM2ZjMzE1YzdhNjA2L3RhYmxlcmFuZ2U6NGNhYmJhYmI0ZmJlNDY1YmIwYjAzZmMzMTVjN2E2MDZfMi00LTEtMS0w_3e131efa-4f80-4b42-84fe-45d682fc1f92">1.85</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i717848bf538848ab855a3a3e35ae4238_I20200630" decimals="INF" format="ixt:numdotdecimal" name="ameh:ClassOfWarrantOrRightExercisable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOjRjYWJiYWJiNGZiZTQ2NWJiMGIwM2ZjMzE1YzdhNjA2L3RhYmxlcmFuZ2U6NGNhYmJhYmI0ZmJlNDY1YmIwYjAzZmMzMTVjN2E2MDZfMi02LTEtMS0w_15490aab-ebbc-4ebe-bd6b-a2efe15a6f60">1,313,345</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i717848bf538848ab855a3a3e35ae4238_I20200630" decimals="2" name="ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOjRjYWJiYWJiNGZiZTQ2NWJiMGIwM2ZjMzE1YzdhNjA2L3RhYmxlcmFuZ2U6NGNhYmJhYmI0ZmJlNDY1YmIwYjAzZmMzMTVjN2E2MDZfMi04LTEtMS0w_3efb2152-7544-48fd-9314-9c7a9120039c">10.00</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ie1b7b6fb52d049f38e00e0bc30605358_I20200630" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOjRjYWJiYWJiNGZiZTQ2NWJiMGIwM2ZjMzE1YzdhNjA2L3RhYmxlcmFuZ2U6NGNhYmJhYmI0ZmJlNDY1YmIwYjAzZmMzMTVjN2E2MDZfMy0wLTEtMS0w_e6039dcc-b3c0-49ee-a611-cd43d03149b4">11.00</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i8b530cfd9afc42f2a4a14a51d941740c_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="ameh:ClassOfWarrantOrRightIssuedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOjRjYWJiYWJiNGZiZTQ2NWJiMGIwM2ZjMzE1YzdhNjA2L3RhYmxlcmFuZ2U6NGNhYmJhYmI0ZmJlNDY1YmIwYjAzZmMzMTVjN2E2MDZfMy0yLTEtMS0w_1255cb25-f1de-4c0a-9cbe-527045e4f9d7">812,475</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i8b530cfd9afc42f2a4a14a51d941740c_D20200101-20200630" format="ixt-sec:duryear" name="ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOjRjYWJiYWJiNGZiZTQ2NWJiMGIwM2ZjMzE1YzdhNjA2L3RhYmxlcmFuZ2U6NGNhYmJhYmI0ZmJlNDY1YmIwYjAzZmMzMTVjN2E2MDZfMy00LTEtMS0w_54210ce7-ff7e-4375-8b85-159df73dfb0e">2.44</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ie1b7b6fb52d049f38e00e0bc30605358_I20200630" decimals="INF" format="ixt:numdotdecimal" name="ameh:ClassOfWarrantOrRightExercisable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOjRjYWJiYWJiNGZiZTQ2NWJiMGIwM2ZjMzE1YzdhNjA2L3RhYmxlcmFuZ2U6NGNhYmJhYmI0ZmJlNDY1YmIwYjAzZmMzMTVjN2E2MDZfMy02LTEtMS0w_159b3a97-1a22-4f78-9061-93c0e9c523d9">812,475</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ie1b7b6fb52d049f38e00e0bc30605358_I20200630" decimals="2" name="ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOjRjYWJiYWJiNGZiZTQ2NWJiMGIwM2ZjMzE1YzdhNjA2L3RhYmxlcmFuZ2U6NGNhYmJhYmI0ZmJlNDY1YmIwYjAzZmMzMTVjN2E2MDZfMy04LTEtMS0w_fccb7180-1300-49fa-9d3a-5b5d3ea22729">11.00</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">$                                              $                     <ix:nonFraction unitRef="usdPerShare" contextRef="i228644db04a54aeea81ac55c214613cf_I20200630" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOjRjYWJiYWJiNGZiZTQ2NWJiMGIwM2ZjMzE1YzdhNjA2L3RhYmxlcmFuZ2U6NGNhYmJhYmI0ZmJlNDY1YmIwYjAzZmMzMTVjN2E2MDZfNS0wLTEtMS0wL3RleHRyZWdpb246ODVhMGRhZTMyYWVlNGQyOThkZTllZmRjYjEzZjYyMGVfNjA0NzMxMzk1Mjk3Ng_da7d116c-5f06-4182-8295-67e5ba4ba9d0">9.00</ix:nonFraction> &#8211;<ix:nonFraction unitRef="usdPerShare" contextRef="i070e64c85f6a46f3abd4745871816551_I20200630" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOjRjYWJiYWJiNGZiZTQ2NWJiMGIwM2ZjMzE1YzdhNjA2L3RhYmxlcmFuZ2U6NGNhYmJhYmI0ZmJlNDY1YmIwYjAzZmMzMTVjN2E2MDZfNS0wLTEtMS0wL3RleHRyZWdpb246ODVhMGRhZTMyYWVlNGQyOThkZTllZmRjYjEzZjYyMGVfNjA0NzMxMzk1Mjk3OQ_734d3030-6c1c-4013-8f05-7bb9e30664a6">11.00</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i7a07edf9a6d9427cbb8e495a1c38dba1_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="ameh:ClassOfWarrantOrRightIssuedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOjRjYWJiYWJiNGZiZTQ2NWJiMGIwM2ZjMzE1YzdhNjA2L3RhYmxlcmFuZ2U6NGNhYmJhYmI0ZmJlNDY1YmIwYjAzZmMzMTVjN2E2MDZfNS0yLTEtMS0w_68e45002-f374-4a6a-ab51-9f576c44800c">2,880,690</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i7a07edf9a6d9427cbb8e495a1c38dba1_D20200101-20200630" format="ixt-sec:duryear" name="ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOjRjYWJiYWJiNGZiZTQ2NWJiMGIwM2ZjMzE1YzdhNjA2L3RhYmxlcmFuZ2U6NGNhYmJhYmI0ZmJlNDY1YmIwYjAzZmMzMTVjN2E2MDZfNS00LTEtMS0w_72bcca86-9f85-4f07-aeb5-33dd55aaf324">1.61</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i58c8b96e915044a5a2285690f262e2f1_I20200630" decimals="INF" format="ixt:numdotdecimal" name="ameh:ClassOfWarrantOrRightExercisable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOjRjYWJiYWJiNGZiZTQ2NWJiMGIwM2ZjMzE1YzdhNjA2L3RhYmxlcmFuZ2U6NGNhYmJhYmI0ZmJlNDY1YmIwYjAzZmMzMTVjN2E2MDZfNS02LTEtMS0w_158d5b2c-a94f-4999-9df1-e654a38c4834">2,880,690</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i58c8b96e915044a5a2285690f262e2f1_I20200630" decimals="2" name="ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOjRjYWJiYWJiNGZiZTQ2NWJiMGIwM2ZjMzE1YzdhNjA2L3RhYmxlcmFuZ2U6NGNhYmJhYmI0ZmJlNDY1YmIwYjAzZmMzMTVjN2E2MDZfNS04LTEtMS0w_367529e8-287c-45e9-b3ca-3cb34b881fe4">10.02</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the six months ended June&#160;30, 2020 and 2019, common stock warrants were exercised for <ix:nonFraction unitRef="shares" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfMzUyOQ_fe88c3f6-9a6c-49b2-a2c4-1136dba7e45f">273,900</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="INF" format="ixt:numdotdecimal" name="ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfMzUzNg_4730dad2-a8d0-4002-a5c0-624fc11e063d">41,624</ix:nonFraction> shares, respectively, of the Company&#8217;s common stock, which resulted in proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="ameh:WarrantIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfMzYzNg_e3ab2bb9-1e9d-4ce7-bcc7-8e51a62e1fb8">2.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="ameh:WarrantIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfMzY0Mw_1c3ac901-cf8c-49b7-9ed8-74e4b55198b0">0.4</ix:nonFraction> million, respectively. The exercise price ranged from $<ix:nonFraction unitRef="usdPerShare" contextRef="i5348fddd2d3647eab57aabde18624e3e_D20190101-20190630" decimals="2" name="ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfMzY5Mg_67660db8-14a8-438b-bb76-43ff4bb0aee1"><ix:nonFraction unitRef="usdPerShare" contextRef="i6dab3a2b4fba451e82b3256455eeec2b_D20200101-20200630" decimals="2" name="ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfMzY5Mg_f3f953fe-dc28-494a-8e25-225dc8bd38ad">9.00</ix:nonFraction></ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="i59b3484b35404c20b3bede5ccbf47667_D20190101-20190630" decimals="2" name="ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfMzY5OA_0c3fafb6-4255-4288-9136-02c30e9c850c"><ix:nonFraction unitRef="usdPerShare" contextRef="ibcd3d205d526423cbea49810dc2340a8_D20200101-20200630" decimals="2" name="ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfMzY5OA_c8193134-a7b7-4ee1-9300-b44f853a77fe">11.00</ix:nonFraction></ix:nonFraction> per share for the exercises during the six months ended June&#160;30, 2020 and 2019, respectively.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Treasury Stock</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">APC owned <ix:nonFraction unitRef="shares" contextRef="i4081b94ec67249e5a1d21eae73e8d25e_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockCommonShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfMzgwNg_f5f7fd67-e20f-4273-a8bc-5252c5c2fd43">17,307,214</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="if21a86c3eed7480aad7e5a1485553c3f_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockCommonShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfMzgxMw_ed90941c-3a81-4ec4-85b1-4398454caea3">17,290,317</ix:nonFraction> shares of ApolloMed&#8217;s common stock as of June&#160;30, 2020 and December&#160;31, 2019, which are legally issued and outstanding but excluded from shares of common stock outstanding in the consolidated financial statements, as such shares are treated as treasury shares for accounting purposes (see Note 1).</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the year ended December 31, 2019, APC established a brokerage account to invest excess capital in the equity market. The brokerage account is managed directly by an independent investment committee of the APC board of directors, from which Dr. Kenneth Sim and Dr. Thomas Lam have been excluded. As of June&#160;30, 2020, the brokerage account only held shares of ApolloMed totaling&#160;$<ix:nonFraction unitRef="usd" contextRef="i2b03d1915fa54978a6378c9edaa22474_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfNDQ3OA_d84c1ea9-ddae-4cad-b199-c0e23c18db88">7.6</ix:nonFraction> million, and as such the ApolloMed shares in the brokerage account&#160;have been recorded as treasury shares.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Dividends</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the six months ended June&#160;30, 2020 and 2019, APC paid dividends of $<ix:nonFraction unitRef="usd" contextRef="i255d39881fdb459ba312544c3eb6589e_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfNjU5NzA2OTc3MTM1NQ_b12357ce-b152-44f5-a0d1-f56385847248">29.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i82a52038c4164e77a3f6e20b01157134_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfNjU5NzA2OTc3MTM2Mw_6dcccbff-6fe8-403c-b3aa-fe9485f6324f">10.0</ix:nonFraction> million, respectively.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the six months ended  June&#160;30, 2020 and 2019, CDSC paid dividends of $<ix:nonFraction unitRef="usd" contextRef="idf76f2b7860f4f6a97ee09255e45287d_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfNjU5NzA2OTc4MDk5Mw_89100edf-ea22-402c-a569-3f45c02bba1b">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5fa3d2acebea43c3a0c0f3e590d02ad4_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfNjU5NzA2OTc4MDk4Mw_f276a30d-3b7c-4976-a98c-1149ce6fb610">1.2</ix:nonFraction> million, respectively.</span></div></ix:continuation><div id="icc5d6783c1494a1f886c03c93e398cee_88"></div><div style="text-indent:-18pt;padding-left:18pt;margin-top:10pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:18pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">11.&#160;<ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84OC9mcmFnOmY1NTNmMDg5OWEzYjRlMzBiZDNlNDNjZGZjNjhiOGU3L3RleHRyZWdpb246ZjU1M2YwODk5YTNiNGUzMGJkM2U0M2NkZmM2OGI4ZTdfMTA5OTUxMTYzMzgyMg_af3cadb5-92a3-49c7-863b-264793ed127a" continuedAt="i2080e4d1b78d40cba9c72e6809f3b15a" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i2080e4d1b78d40cba9c72e6809f3b15a" continuedAt="i9965f61c1aa143bb820ff4d25dd5b981"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Regulatory Matters</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Laws and regulations governing the Medicare program and healthcare generally are complex and subject to interpretation. The Company believes that it is in compliance with all applicable laws and regulations and is not aware of any pending or </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><ix:continuation id="i9965f61c1aa143bb820ff4d25dd5b981" continuedAt="i956eff1a470d4b5fb37583f38aa22f23"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">threatened investigations involving allegations of potential wrongdoing. While no regulatory inquiries have been made, compliance with such laws and regulations can be subject to future government review and interpretation, as well as significant regulatory action, including fines, penalties, and exclusion from the Medicare and Medi-Cal programs.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As risk-bearing organizations, APC, Alpha Care and Accountable Health Care are required to comply with California DMHC regulations, including maintenance of minimum working capital, tangible net equity (&#8220;TNE&#8221;), cash-to-claims ratio and claims payment requirements prescribed by the California DMHC. TNE is defined as net equity less intangibles, less non-allowable assets (which include unsecured amounts due from affiliates), plus subordinated obligations. At&#160;June&#160;30, 2020 and December&#160;31, 2019, APC, Alpha Care and Accountable Health Care were in compliance with these regulations.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Many of the Company&#8217;s payor and provider contracts are complex in nature and may be subject to differing interpretations regarding amounts due for the provision of medical services. Such differing interpretations may not come to light until a substantial period of time has passed following contract implementation. Liabilities for claims disputes are recorded when the loss is probable and can be estimated. Any adjustments to reserves are reflected in current operations.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Standby Letters of Credit</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As part of the APAACO participation with CMS, the Company must provide a financial guarantee to CMS, the guarantee generally must be in an amount equal to <ix:nonFraction unitRef="number" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="2" name="ameh:PercentageOfFinancialGuaranteeBenchmarkAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84OC9mcmFnOmY1NTNmMDg5OWEzYjRlMzBiZDNlNDNjZGZjNjhiOGU3L3RleHRyZWdpb246ZjU1M2YwODk5YTNiNGUzMGJkM2U0M2NkZmM2OGI4ZTdfMTg3OA_ebef6d8d-46f6-41da-8462-7b3e11b796bb">2</ix:nonFraction>% of the Company&#8217;s benchmark Medicare Part A and Part B expenditures. The Company has established an irrevocable standby letter of credit with Preferred Bank of $<ix:nonFraction unitRef="usd" contextRef="i2abd2d27dacd4cf191ac018ca9039a4a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84OC9mcmFnOmY1NTNmMDg5OWEzYjRlMzBiZDNlNDNjZGZjNjhiOGU3L3RleHRyZWdpb246ZjU1M2YwODk5YTNiNGUzMGJkM2U0M2NkZmM2OGI4ZTdfMjA0MA_390009f1-c4ea-4e79-8ee1-7603855725b4">8.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib5bc5df3e2c84bd598e901cd27c8df93_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84OC9mcmFnOmY1NTNmMDg5OWEzYjRlMzBiZDNlNDNjZGZjNjhiOGU3L3RleHRyZWdpb246ZjU1M2YwODk5YTNiNGUzMGJkM2U0M2NkZmM2OGI4ZTdfMjA0Nw_3c172ae6-2d1e-4b78-ad17-363eb42d9228">6.6</ix:nonFraction> million for the 2019 and 2018 performance years (see Note 9).</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">APC established irrevocable standby letters of credit with a financial institution for a total of $<ix:nonFraction unitRef="usd" contextRef="i43ace250a7394cfe9446cf2a610e1531_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84OC9mcmFnOmY1NTNmMDg5OWEzYjRlMzBiZDNlNDNjZGZjNjhiOGU3L3RleHRyZWdpb246ZjU1M2YwODk5YTNiNGUzMGJkM2U0M2NkZmM2OGI4ZTdfMjIwMg_f7820e4b-2003-4c94-b9ac-dd2f315c0089">0.3</ix:nonFraction> million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional <ix:nonNumeric contextRef="iaebe0c39b9204bfbbf9445aa9abc70d5_D20200101-20200630" format="ixt-sec:durwordsen" name="us-gaap:LineOfCreditFacilityExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84OC9mcmFnOmY1NTNmMDg5OWEzYjRlMzBiZDNlNDNjZGZjNjhiOGU3L3RleHRyZWdpb246ZjU1M2YwODk5YTNiNGUzMGJkM2U0M2NkZmM2OGI4ZTdfMTA5OTUxMTYyODM4MjA_d023bb69-cd4e-4422-aba4-59d6ea4f535b">one-year</ix:nonNumeric> periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated (see Note 9).</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Alpha Care established irrevocable standby letters of credit with a financial institution for a total of $<ix:nonFraction unitRef="usd" contextRef="id6e276121e9b45228da8ba0bab8f06ba_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84OC9mcmFnOmY1NTNmMDg5OWEzYjRlMzBiZDNlNDNjZGZjNjhiOGU3L3RleHRyZWdpb246ZjU1M2YwODk5YTNiNGUzMGJkM2U0M2NkZmM2OGI4ZTdfMjYyMw_4074acc3-ffba-4e65-8b7e-e5a813b30dad">3.8</ix:nonFraction> million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional <ix:nonNumeric contextRef="ic5904f2bef064b47980c2947e43ad5d1_D20200101-20200630" format="ixt-sec:durwordsen" name="us-gaap:LineOfCreditFacilityExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84OC9mcmFnOmY1NTNmMDg5OWEzYjRlMzBiZDNlNDNjZGZjNjhiOGU3L3RleHRyZWdpb246ZjU1M2YwODk5YTNiNGUzMGJkM2U0M2NkZmM2OGI4ZTdfMTA5OTUxMTYzMzgxOA_c634ffba-5773-4dfd-af40-8d5d2d682fa4">one-year</ix:nonNumeric> periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated (see Note 9). </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Litigation</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">From time to time, the Company is involved in various legal proceedings and other matters arising in the normal course of its business. The resolution of any claim or litigation is subject to inherent uncertainty and could have a material adverse effect on the Company&#8217;s financial condition, cash flows or results of operations.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Prospect Medical Systems</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On or about March 23, 2018, and April 3, 2018, a Demand for Arbitration and an Amended Demand for Arbitration were filed by Prospect Medical Group, Inc. and Prospect Medical Systems, Inc. (collectively, &#8220;Prospect&#8221;) against MMG, ApolloMed and AMM with Judicial Arbitration Mediation Services in California, arising out of MMG&#8217;s purported business plans, seeking damages in excess of $<ix:nonFraction unitRef="usd" contextRef="ia04e3870deaf4cb7ae407dafc0ffd53d_D20180323-20180403" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LossContingencyDamagesSoughtValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84OC9mcmFnOmY1NTNmMDg5OWEzYjRlMzBiZDNlNDNjZGZjNjhiOGU3L3RleHRyZWdpb246ZjU1M2YwODk5YTNiNGUzMGJkM2U0M2NkZmM2OGI4ZTdfMzY3Mw_60682176-303a-42b6-9014-53ceff1fd6bc">5.0</ix:nonFraction> million, and alleging breach of contract, violation of unfair competition laws, and tortious interference with Prospect&#8217;s current and future economic relationships with its health plans and their members. By stipulation and order dated April 28, 2020, ApolloMed and AMM were dismissed without prejudice from the arbitration for lack of jurisdiction on the basis that neither of them were a party to any arbitration agreement with Prospect, subject, however, to Prospect reserving its rights against ApolloMed and AMM and tolling of applicable statute of limitation. MMG disputes the allegations and intends to vigorously defend against this matter. The resolution of this matter and any potential range of loss in excess of any current accrual cannot be reasonably determined or estimated at this time primarily because the matter has not been fully arbitrated and presents unique regulatory and contractual interpretation issues. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Liability Insurance</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company believes that its insurance coverage is appropriate based upon the Company&#8217;s claims experience and the nature and risks of the Company&#8217;s business. In addition to the known incidents that have resulted in the assertion of claims, the Company cannot be certain that its insurance coverage will be adequate to cover liabilities arising out of claims asserted against the Company, the Company&#8217;s affiliated professional organizations or the Company&#8217;s affiliated hospitalists in the future where the outcomes of such claims are unfavorable. The Company believes that the ultimate resolution of all pending claims, including liabilities in excess of the Company&#8217;s insurance coverage, will not have a material adverse effect on the Company&#8217;s financial position, results of operations or cash flows; however, there can be no assurance that future claims will not have such </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><ix:continuation id="i956eff1a470d4b5fb37583f38aa22f23"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a material adverse effect on the Company&#8217;s business. Contracted physicians are required to obtain their own insurance coverage.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Although the Company currently maintains liability insurance policies on a claims-made basis, which are intended to cover malpractice liability and certain other claims, the coverage must be renewed annually, and may&#160;not continue to be available to the Company in future years at acceptable costs, and on favorable terms.</span></div></ix:continuation><div id="icc5d6783c1494a1f886c03c93e398cee_91"></div><div style="text-indent:-18pt;padding-left:18pt;margin-top:10pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:18pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">12.&#160;<ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMTA5OTUxMTYzMjY4OA_b9810fd9-375e-4379-92a5-aa1a5190cbe8" continuedAt="i8d377ee2d64945a68a2eb3c511749b6a" escape="true">Related-Party Transactions</ix:nonNumeric></span></div><ix:continuation id="i8d377ee2d64945a68a2eb3c511749b6a" continuedAt="i7fa441bfdc7f4c638cac83d838a53fe4"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On November 16, 2015, UCAP entered into a subordinated note receivable agreement with UCI, a <ix:nonFraction unitRef="number" contextRef="i41ded2bb0c6348508704a83b2f25e6bc_I20151116" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMTI5_b0ab0af8-c269-4c56-a6ec-e868d8e4dd30">48.9</ix:nonFraction>% owned equity method investee (see Note 5), in the amount of $<ix:nonFraction unitRef="usd" contextRef="i47e9a1771bc24da387426527e858cf9b_I20151116" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMTky_5a5480ff-a765-4b14-9763-e4f2040a4bf4">5.0</ix:nonFraction> million. On June 28, 2018 and November 28, 2018, UCAP entered into <ix:nonFraction unitRef="agreement" contextRef="iac4018695bd347a1a544a3f52b293cce_I20181128" decimals="INF" format="ixt-sec:numwordsen" name="ameh:AccountsAndOtherReceivablesNumberOfAdditionalAgreements" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMjU0_63d6f967-61ee-462f-9055-7663f7f19852">two</ix:nonFraction> additional subordinated note receivable agreements with UCI in the amount of $<ix:nonFraction unitRef="usd" contextRef="i122ebc0907a746cd87fa56f04f446654_I20180628" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMzM0_89a7661c-b050-4896-b5e9-ae50fb2d5923">2.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iac4018695bd347a1a544a3f52b293cce_I20181128" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMzQx_ef2eb74e-9812-457b-af43-c1efda167f48">5.0</ix:nonFraction> million, respectively. On April 30, 2020, the outstanding balance was fully repaid as part of UCAP's disposition of its <ix:nonFraction unitRef="number" contextRef="i59aea64b29bd441fbc9a872ccf8d6901_I20200430" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfNDk0NzgwMjMyOTQ3Mw_8fa61189-1e93-4051-b62c-3f4f2b274523">48.9</ix:nonFraction>% ownership interest in UCI to Bright (see Note 6).</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three and six months ended June&#160;30, 2020 and 2019, NMM earned approximately $<ix:nonFraction unitRef="usd" contextRef="ia70ec1e9fb224dbcab815eb4726d1011_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfNDQy_66bc4a2a-76ae-4dc3-a87d-3c38269451a6">4.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i55654d78599d405eb7c57be43551a331_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfNDQ5_60312b30-f230-4426-9ed2-7dc1e90f1d69">5.2</ix:nonFraction> million, respectively, and $<ix:nonFraction unitRef="usd" contextRef="ic5c167aa7b744e4890c04342962e5ae7_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfNDcx_f76fb01f-333b-40f4-8390-54657642b02a">8.4</ix:nonFraction>&#160;million, respectively, in management fees from LMA, which is accounted for under the equity method based on <ix:nonFraction unitRef="number" contextRef="i72f269c8a584404ba65db62cbf5e0711_I20190630" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfNTgx_0d47f285-1645-4746-8184-8329fd2147a9"><ix:nonFraction unitRef="number" contextRef="i2586f7c4e99c40dabdf57469f68203ca_I20200630" decimals="INF" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfNTgx_8a9e39b4-625f-44f1-b5f9-3deb8a4161b5">25</ix:nonFraction></ix:nonFraction>% equity ownership interest held by APC in LMA&#8217;s IPA line of business (see Note 5).</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three and six months ended June&#160;30, 2020 and 2019, APC paid approximately $<ix:nonFraction unitRef="usd" contextRef="i08b5e965334b4ac8b0d2c0c36dd50b77_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfNzM0_221c52a5-6d9b-48d0-9df5-fa5a83fdfc85">0.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i6d443f60c53b4d9dbf390091cef3b913_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfNzQx_4a44aaf3-dbcf-4cb7-942b-b63544f62029">0.6</ix:nonFraction> million, respectively, and $<ix:nonFraction unitRef="usd" contextRef="id80519ef0ba24fdcafbe65246db80663_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfNzYz_7e8f0ff6-5b15-4b02-bf1e-310aead51f34">1.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6e8fcf6df1fc4d238058ca06726c6b36_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfNzcw_0379b340-8aa8-492b-9f50-fcf1f429527a">1.4</ix:nonFraction> million, respectively, to PMIOC for provider services, which is accounted for under the equity method based on <ix:nonFraction unitRef="number" contextRef="i6ac733b67d504bb484f4fb9e53a73cde_I20190630" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfODc2_7302b3e9-95e4-4446-acbf-e33ca542d8ea"><ix:nonFraction unitRef="number" contextRef="i8163cedd4bfb49cba3c59247fab38128_I20200630" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfODc2_a9c243a5-6c1e-43c9-b638-d5968fed196b">40</ix:nonFraction></ix:nonFraction>% equity ownership interest held by APC (see Note 5).</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three and six months ended June&#160;30, 2020 and 2019, APC paid approximately $<ix:nonFraction unitRef="usd" contextRef="i3b7917e163c9464c858059b5c869b1da_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfOTk5_7f7dcf23-b83b-49a1-b3ac-078691c71ae7">0.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i7267113c36ba4c0ca445f3971b88da9e_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMTAwNg_541463a2-78d0-40cb-a432-9083a9ba0d62">1.8</ix:nonFraction> million, respectively, and $<ix:nonFraction unitRef="usd" contextRef="ide7ed8079ad649bd9de797dff9e87471_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMTAyOA_0ed5f6f1-9492-4f36-bdfe-ce86575358e9">2.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4bafd7f9c77a44129ecb7839f0bf7f38_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMTAzNQ_73a355ba-b1fa-4b06-8658-72f1de08177b">3.8</ix:nonFraction> million, respectively, to DMG for provider services, which is accounted for under the equity method based on <ix:nonFraction unitRef="number" contextRef="i0138e45151034c838711c008d2c84fde_I20200630" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMTEzOQ_b80cc574-ce96-41f4-af75-bcd994612933"><ix:nonFraction unitRef="number" contextRef="ibd86a14da8ce4c19b459bfe1b8ee8770_I20190630" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMTEzOQ_be078422-2ea3-48ab-8cf7-bbc3b0caa558">40</ix:nonFraction></ix:nonFraction>% equity ownership interest held by APC (see Note 5).</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three and six months ended June&#160;30, 2020 and 2019, APC paid approximately $<ix:nonFraction unitRef="usd" contextRef="i3921017da3f648c8bc7eb46abb24b98e_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMTI2Mg_3368e79a-2a9a-428c-8fce-0254e209477f">0.1</ix:nonFraction>&#160;million, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i0ce5207c08154b16a3abfc694d36072c_D20190401-20190630" decimals="-2" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMTI5Mg_005b682a-64f1-4a17-a628-e953e4e0f3a3">0.1</ix:nonFraction>&#160;million, respectively, to Advanced Diagnostic Surgery Center for services as a provider. Advanced Diagnostic Surgery Center shares common ownership with certain board members of APC.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three months ended June&#160;30, 2020 and 2019, APC paid an aggregate of approximately $<ix:nonFraction unitRef="usd" contextRef="i74b45c805f954374b47abc23fa83e224_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfNjA0NzMxMzk1ODM1OA_215b2d41-66a7-46e6-8d26-64ec2520fa21">9.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i26a7e7336a074ec58f3aadf344b86686_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfNjA0NzMxMzk1ODM2NQ_66799aef-cb07-467a-a91f-0ba108eac6b7">7.1</ix:nonFraction> million, respectively,  which include approximately $<ix:nonFraction unitRef="usd" contextRef="i23919fb2bb874604b0836a44a501d87e_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfNjA0NzMxMzk1ODQxMg_3308eefb-015b-4a85-ba76-8bcbc5179c53">3.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i6966114f283543be9a6c6ecfb91dcb1a_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfNjA0NzMxMzk1ODQxOQ_06df191e-7493-4ad0-9156-46c072a64573">1.9</ix:nonFraction> million, respectively, to shareholders who are also officers of APC. During the six months ended June&#160;30, 2020 and 2019, APC paid an aggregate of approximately of $<ix:nonFraction unitRef="usd" contextRef="i558c42e47d0740c28d1824777489c673_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMTU5MA_0c6e3a59-f702-408f-a130-0aec8a5f1b38">16.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0238892dfcac44a1ab11666f4229eff6_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMTU5Nw_ea916c72-f48c-4eeb-b490-70ed46db7d16">16.4</ix:nonFraction> million, respectively, to shareholders of APC for provider services, which include approximately $<ix:nonFraction unitRef="usd" contextRef="i73ff4025db084040a797fa1c7d3e1949_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMTcxOA_64434bda-7972-48dd-ae97-968f3a82d03d">4.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib304e370b0554caf951b8a9f9f09d259_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMTcyNQ_9895c0cb-1930-4e58-91bb-89bd9c781854">5.1</ix:nonFraction> million, respectively, to shareholders who are also officers of APC.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three and six months ended June&#160;30, 2020 and 2019, NMM paid approximately $<ix:nonFraction unitRef="usd" contextRef="i11e982a75af145058c37f804c38acd6b_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfNTQ5NzU1ODE0NDA1Nw_41c15b3b-04ab-4ca9-8ea9-2b26d9bef8b8"><ix:nonFraction unitRef="usd" contextRef="i974cbc9f20e14ae6bf9611c0590bba01_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfNTQ5NzU1ODE0NDA1Nw_f028d819-3b6c-451c-b47f-a8c0e9042888">0.3</ix:nonFraction></ix:nonFraction> million, respectively and $<ix:nonFraction unitRef="usd" contextRef="i232d93f7f5aa4f659c5d32bb1ce43cb7_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfNTQ5NzU1ODE0NDA4Mw_351e9034-14c5-495c-a685-948f3827bb15"><ix:nonFraction unitRef="usd" contextRef="i4d7d20d05cc44774b777b10316295823_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfNTQ5NzU1ODE0NDA4Mw_e8f47d9d-1659-43cb-bdc0-9e4bbe4a7492">0.5</ix:nonFraction></ix:nonFraction> million, respectively, to Medical Property Partners (&#8220;MPP&#8221;) for an office lease. MPP shares common ownership with certain board members of NMM.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three and six months ended June&#160;30, 2020, NMM paid approximately $<ix:nonFraction unitRef="usd" contextRef="i0a9d069f26ee4fcab93f166f59b290ee_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMjA2NA_67d04cdb-67c1-44a7-b6fd-5f24ab666dd8">0.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i6349dc89b0824f79a96623fb0a3f9237_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMjA3MQ_3b772a45-54fa-47bb-80a0-174e8ba15e1e">0.7</ix:nonFraction> million, respectively, to One MSO, Inc. ("One MSO") for an office lease. One MSO is indirectly <ix:nonFraction unitRef="number" contextRef="i725b298255bc442d989d2da38e506475_I20200630" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMTA5OTUxMTYzMjY4NA_e0d56e04-8ab8-4148-b1e5-1220d624485c">50</ix:nonFraction>% owned by Drs. Sim and Lam.  As of June 30, 2020, the Company had $<ix:nonFraction unitRef="usd" contextRef="ifa7e8193abcb43cabefbe6e0890b995d_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfNTQ5NzU1ODE0NDE2Mg_59ab0d77-357d-4880-8713-4b3a1977a8f4"><ix:nonFraction unitRef="usd" contextRef="ifa7e8193abcb43cabefbe6e0890b995d_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfNTQ5NzU1ODE0NDE2Mg_7b0a1c36-878c-4fac-8b12-004f0736a811">10.6</ix:nonFraction></ix:nonFraction>&#160;million of ROU assets and lease liabilities, respectively, related to its office lease with One MSO to be amortized over the remaining life of the lease.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three and six months ended June&#160;30, 2020 and 2019, the Company paid approximately $<ix:nonFraction unitRef="usd" contextRef="ia52b05b7d3c744de85af06e314bf01e0_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMjQ2OA_2bb5c4af-2e38-4c64-9fb1-ace03062dc64">0.1</ix:nonFraction>&#160;million, respectively, and $<ix:nonFraction unitRef="usd" contextRef="ie772acedf7f24e9c9b7eba3a1c2c4b74_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMjQ5OQ_c2bda6fd-8fed-4609-b2d9-026e406aff0d">0.2</ix:nonFraction> million, respectively, to Critical Quality Management Corporation (&#8220;CQMC&#8221;) for an office lease. CQMC shares common ownership with certain board members of APC.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three and six months ended June&#160;30, 2020 and 2019, SCHC paid approximately $<ix:nonFraction unitRef="usd" contextRef="ia8b1a37d00a1473aa256f482831880c0_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMjczMA_1b9ca716-f05e-4566-af97-027a2c5d63d1"><ix:nonFraction unitRef="usd" contextRef="i40cef4f9cb574f67ae5763a10bf872ae_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMjczMA_af77be0f-6eb0-4088-8a3c-b72efbf6fbb6">0.1</ix:nonFraction></ix:nonFraction>&#160;million, respectively, and $<ix:nonFraction unitRef="usd" contextRef="icd17dbf950ae420ba6642ac1f2e76be4_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMjc1OQ_6c76d965-a2e8-49e7-877f-304666965118"><ix:nonFraction unitRef="usd" contextRef="i3889cb5090e84ede9aeaa5cb4970cb04_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMjc1OQ_c14cc9c1-86f6-4c2f-870f-f9b462408679">0.2</ix:nonFraction></ix:nonFraction> million, respectively, to Numen, LLC (&#8220;Numen&#8221;) for an office lease. Numen is owned by a shareholder of APC. As of June 30, 2020, the Company had $<ix:nonFraction unitRef="usd" contextRef="i7badae2658444d349982f8266469914b_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfNTQ5NzU1ODE0NDE1OQ_689f803d-1f30-4d36-96c6-b76ff046db18"><ix:nonFraction unitRef="usd" contextRef="i7badae2658444d349982f8266469914b_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfNTQ5NzU1ODE0NDE1OQ_eec35e87-5bb9-4fa3-9c4f-d8ed177d4ff4">1.4</ix:nonFraction></ix:nonFraction>&#160;million of ROU assets and lease liabilities, respectively, related to its office lease with One MSO to be amortized over the remaining life of the lease.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has agreements with HSMSO, Aurion Corporation (&#8220;Aurion&#8221;), and AHMC Healthcare (&#8220;AHMC&#8221;) for services provided to the Company. One of the Company&#8217;s board members is an officer of AHMC, HSMSO and Aurion. Aurion is also partially owned by one of the Company&#8217;s board members. <ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfNDMwOQ_787b2f99-1f7a-4eaf-9991-0957af01f77c" continuedAt="i640cfad644ab4e0db3a512d0fcc1b427" escape="true">The following table sets forth fees incurred and income earned related to AHMC, HSMSO and Aurion (in thousands):</ix:nonNumeric></span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><ix:continuation id="i7fa441bfdc7f4c638cac83d838a53fe4"><div style="margin-top:5pt;margin-bottom:5pt;"><ix:continuation id="i640cfad644ab4e0db3a512d0fcc1b427"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:40.606%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.323%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.323%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.909%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.643%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Six Months Ended June 30,</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">AHMC &#8211; Risk pool, capitation, claims payment, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9b1e96ab04c2463f8f4b975abf5cd0e1_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RhYmxlOjQyYWI5ZmM5ZTI1NjQ4MjBiM2I2Zjg1YjM0MDA5MTk5L3RhYmxlcmFuZ2U6NDJhYjlmYzllMjU2NDgyMGIzYjZmODViMzQwMDkxOTlfMi0xLTEtMS0w_15d567fb-46e9-40ec-9e68-4d746075df2a">6,057</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8624e665c0b14f12bb96c8f05d6efefc_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RhYmxlOjQyYWI5ZmM5ZTI1NjQ4MjBiM2I2Zjg1YjM0MDA5MTk5L3RhYmxlcmFuZ2U6NDJhYjlmYzllMjU2NDgyMGIzYjZmODViMzQwMDkxOTlfMi0zLTEtMS0w_bfc10901-5aa5-4c6d-9f6f-4546e2a400f1">16,350</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i345a15f206fb4db5b7f79fbbfcd4823d_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RhYmxlOjQyYWI5ZmM5ZTI1NjQ4MjBiM2I2Zjg1YjM0MDA5MTk5L3RhYmxlcmFuZ2U6NDJhYjlmYzllMjU2NDgyMGIzYjZmODViMzQwMDkxOTlfMi01LTEtMS0w_a073c263-4702-4061-b834-05d72dc5a02e">18,056</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i297705914c5f4af994b21ae2e9e0dda8_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RhYmxlOjQyYWI5ZmM5ZTI1NjQ4MjBiM2I2Zjg1YjM0MDA5MTk5L3RhYmxlcmFuZ2U6NDJhYjlmYzllMjU2NDgyMGIzYjZmODViMzQwMDkxOTlfMi03LTEtMS0w_07250312-5b2c-49d9-90eb-2d484ae69d73">27,950</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">HSMSO &#8211; Management fees, net</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia5bc423a58e44f17b75caa9dcd78c5d9_D20200401-20200630" decimals="-3" name="us-gaap:ManagementFeeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RhYmxlOjQyYWI5ZmM5ZTI1NjQ4MjBiM2I2Zjg1YjM0MDA5MTk5L3RhYmxlcmFuZ2U6NDJhYjlmYzllMjU2NDgyMGIzYjZmODViMzQwMDkxOTlfMy0xLTEtMS0w_0bcdb4a6-110f-434e-a052-62a5895390ad">189</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib978cd0ae3f8463592332de24798e91f_D20190401-20190630" decimals="-3" name="us-gaap:ManagementFeeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RhYmxlOjQyYWI5ZmM5ZTI1NjQ4MjBiM2I2Zjg1YjM0MDA5MTk5L3RhYmxlcmFuZ2U6NDJhYjlmYzllMjU2NDgyMGIzYjZmODViMzQwMDkxOTlfMy0zLTEtMS0w_97e2c9f2-bb5c-4408-9715-d92a2ae57ce9">265</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3e3dd126351d40269ef3b0cff2e2cc12_D20200101-20200630" decimals="-3" name="us-gaap:ManagementFeeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RhYmxlOjQyYWI5ZmM5ZTI1NjQ4MjBiM2I2Zjg1YjM0MDA5MTk5L3RhYmxlcmFuZ2U6NDJhYjlmYzllMjU2NDgyMGIzYjZmODViMzQwMDkxOTlfMy01LTEtMS0w_2e1bdba0-b8a5-49cd-a9f3-ab8e9ffa3874">321</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i187e0af77f734ccebbbd27aabf183e43_D20190101-20190630" decimals="-3" name="us-gaap:ManagementFeeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RhYmxlOjQyYWI5ZmM5ZTI1NjQ4MjBiM2I2Zjg1YjM0MDA5MTk5L3RhYmxlcmFuZ2U6NDJhYjlmYzllMjU2NDgyMGIzYjZmODViMzQwMDkxOTlfMy03LTEtMS0w_cb7b07e3-6a06-4eeb-a2b6-71528f600b6b">915</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Aurion &#8211; Management fees</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2c2ea55436e04e569ef824cc8bf38f62_D20200401-20200630" decimals="-3" name="us-gaap:ManagementFeeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RhYmxlOjQyYWI5ZmM5ZTI1NjQ4MjBiM2I2Zjg1YjM0MDA5MTk5L3RhYmxlcmFuZ2U6NDJhYjlmYzllMjU2NDgyMGIzYjZmODViMzQwMDkxOTlfNC0xLTEtMS0w_11d7a59b-0254-4e44-86a5-d629d1ce37ce">53</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3c92e2a8835d47c094fdb6ae01f4010e_D20190401-20190630" decimals="-3" name="us-gaap:ManagementFeeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RhYmxlOjQyYWI5ZmM5ZTI1NjQ4MjBiM2I2Zjg1YjM0MDA5MTk5L3RhYmxlcmFuZ2U6NDJhYjlmYzllMjU2NDgyMGIzYjZmODViMzQwMDkxOTlfNC0zLTEtMS0w_9aa4a101-3f83-45b1-8c6a-b6ea0f2c33d4">100</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ied3ee0af55294b1c90c71dc22ea57f02_D20200101-20200630" decimals="-3" name="us-gaap:ManagementFeeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RhYmxlOjQyYWI5ZmM5ZTI1NjQ4MjBiM2I2Zjg1YjM0MDA5MTk5L3RhYmxlcmFuZ2U6NDJhYjlmYzllMjU2NDgyMGIzYjZmODViMzQwMDkxOTlfNC01LTEtMS0w_b195c6ec-cf32-4221-97a8-3a325e102d89">128</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i07ec194477214462b08c359051ff95f4_D20190101-20190630" decimals="-3" name="us-gaap:ManagementFeeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RhYmxlOjQyYWI5ZmM5ZTI1NjQ4MjBiM2I2Zjg1YjM0MDA5MTk5L3RhYmxlcmFuZ2U6NDJhYjlmYzllMjU2NDgyMGIzYjZmODViMzQwMDkxOTlfNC03LTEtMS0w_9815cdcc-1566-4810-a6a4-859419c1d57f">200</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net total</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RhYmxlOjQyYWI5ZmM5ZTI1NjQ4MjBiM2I2Zjg1YjM0MDA5MTk5L3RhYmxlcmFuZ2U6NDJhYjlmYzllMjU2NDgyMGIzYjZmODViMzQwMDkxOTlfNi0xLTEtMS0w_6a8a1ae4-c5f5-4f4c-b6cb-96fa2ddff5e4">5,815</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RhYmxlOjQyYWI5ZmM5ZTI1NjQ4MjBiM2I2Zjg1YjM0MDA5MTk5L3RhYmxlcmFuZ2U6NDJhYjlmYzllMjU2NDgyMGIzYjZmODViMzQwMDkxOTlfNi0zLTEtMS0w_c0689eec-2d5d-419c-a875-8e54da3743e7">15,985</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RhYmxlOjQyYWI5ZmM5ZTI1NjQ4MjBiM2I2Zjg1YjM0MDA5MTk5L3RhYmxlcmFuZ2U6NDJhYjlmYzllMjU2NDgyMGIzYjZmODViMzQwMDkxOTlfNi01LTEtMS0w_6adb7b6b-54a6-41c3-93af-13491c45add3">17,607</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RhYmxlOjQyYWI5ZmM5ZTI1NjQ4MjBiM2I2Zjg1YjM0MDA5MTk5L3RhYmxlcmFuZ2U6NDJhYjlmYzllMjU2NDgyMGIzYjZmODViMzQwMDkxOTlfNi03LTEtMS0w_b3533367-1b80-4206-94c4-2dcb3574f39a">26,835</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:continuation></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company and AHMC have a risk sharing agreement with certain AHMC hospitals to share the surplus and deficits of each of the hospital pools. During the three and six months ended June&#160;30, 2020 and 2019, the Company has recognized risk pool revenue under this agreement of $<ix:nonFraction unitRef="usd" contextRef="i9b1e96ab04c2463f8f4b975abf5cd0e1_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMzUyNg_e48e9d91-c66c-4dd4-8916-a9abc2419a86">10.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i345a15f206fb4db5b7f79fbbfcd4823d_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMzUzMw_0d7b5ec7-c583-47da-b408-c607870b0e29">10.2</ix:nonFraction> million, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i8624e665c0b14f12bb96c8f05d6efefc_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMzU1NQ_5652df1c-d63f-45f0-b3c6-6fc0a3e7f1e4">21.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i297705914c5f4af994b21ae2e9e0dda8_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMzU2Mg_89d47592-e9ad-46a2-9a98-09fb3c401b8b">25.0</ix:nonFraction> million, respectively, for which $<ix:nonFraction unitRef="usd" contextRef="i11c2bb41ca6348fb8713e36fda662dfe_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredCreditsAndOtherLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMzU5MA_516b8209-bcd4-4855-95d9-aed8d0b60d1a">53.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if379bd0a6704484a92b75bcaee392d54_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredCreditsAndOtherLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMzU5Nw_1c227ad6-fe3b-4e2d-903e-a5919ff2fe7b">40.4</ix:nonFraction> million remain outstanding as of June&#160;30, 2020 and December&#160;31, 2019, respectively.</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three and six months ended June&#160;30, 2020 and 2019, NMM paid approximately&#160;$<ix:nonFraction unitRef="usd" contextRef="i83ceffd8ac474d21a39c47ca896605c6_D20200401-20200630" decimals="-6" name="ameh:PaymentConsultingFees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMjE5OTAyMzI2MDg4Mw_8b0e8e72-373c-4dcb-a9ab-c41e162d4efb">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i94a7e25c8cae461cae1b75c5fa5c6e2b_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentConsultingFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMjE5OTAyMzI2MDg5MA_ee7b1779-6cdf-422d-a0eb-e81a4e5a09c5">0.1</ix:nonFraction> million, respectively, and $<ix:nonFraction unitRef="usd" contextRef="ica6dee6dfddc4d1daed02284b5602d0e_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="ameh:PaymentConsultingFees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMzcyMA_0eb60ad7-420d-4ad2-970d-6ba07cd1052a">27,000</ix:nonFraction>&#160;and $<ix:nonFraction unitRef="usd" contextRef="i08491d90fbdd471d983861bcd2288ac8_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentConsultingFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMjE5OTAyMzI2MDkxNg_bf6f4e54-0dbc-4c05-9e81-f21140ad90b8">0.1</ix:nonFraction> million, respectively, to ApolloMed board member, Matthew Mazdyasni, for consulting services. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, affiliates wholly owned by the Company&#8217;s officers, including the Company's Co-CEOs, Dr. Sim and Dr. Lam, are reported in the accompanying consolidated statements of income on a consolidated basis, together with the Company&#8217;s subsidiaries, and therefore, the Company does not separately disclose transactions between such affiliates and the Company&#8217;s subsidiaries as related-party transactions.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For equity method investments, loans receivable and line of credits from related parties, see Notes 5, 6 and 9, respectively.</span></div></ix:continuation><div id="icc5d6783c1494a1f886c03c93e398cee_97"></div><div style="text-indent:-18pt;padding-left:18pt;margin-top:10pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:18pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">13.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85Ny9mcmFnOmEwMjA5ZTcxYTJmZjQyMzA5MGU2ZGJkNjdkMmJkOGJjL3RleHRyZWdpb246YTAyMDllNzFhMmZmNDIzMDkwZTZkYmQ2N2QyYmQ4YmNfMjc2MA_b8385088-7520-47a3-9ecb-b613b496c06c" continuedAt="i8b3ebdaa11534f17b21a34e2711ef45c" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="i8b3ebdaa11534f17b21a34e2711ef45c" continuedAt="ie8bf3095c8bf45debc7bb81ee5c83b39"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company uses the liability method of accounting for income taxes as set forth in ASC 740. Under the liability method, deferred taxes are determined based on differences between the financial statement and tax bases of assets and liabilities using enacted tax rates.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On an interim basis, the Company estimates what its anticipated annual effective tax rate will be and records a quarterly income tax provision (benefit) in accordance with the estimated annual rate, plus the tax effect of certain discrete items that arise during the quarter. As the fiscal year progresses, the Company refines its estimates based on actual events and financial results during the quarter. This process can result in significant changes to the Company&#8217;s estimated effective tax rate. When this occurs, the income tax provision (benefit) is adjusted during the quarter in which the estimates are refined so that the year-to-date provision reflects the estimated annual effective tax rate. These changes, along with adjustments to the Company&#8217;s deferred taxes and related valuation allowance, may create fluctuations in the overall effective tax rate from quarter to quarter.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, due to the overall cumulative losses incurred in recent years, the Company maintained a full valuation allowance against its deferred tax assets related to loss entities the Company cannot consolidate under the federal consolidation rules, as realization of these assets is uncertain.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s effective tax rate for the six months ended June&#160;30, 2020, differed from the U.S. federal statutory rate primarily due to state income taxes, income from flow through entities, nondeductible permanent items, and change in valuation allowance.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, the Company does not have any unrecognized tax benefits related to various federal and state income tax matters. The Company will recognize accrued interest and penalties related to unrecognized tax benefits in income tax expense.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is subject to U.S. federal income tax as well as income tax in California. The Company and its subsidiaries&#8217; state and Federal income tax returns are open to audit under the statute of limitations for the years ended December 31, 2015 through December&#160;31, 2018, and for the years ended December 31, 2016 through December&#160;31, 2018, respectively. The Company does not anticipate material unrecognized tax benefits within the next 12 months.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On March 27, 2020, the Coronavirus Aid, Relief and Economic Security Act ("CARES Act") was signed into law. The CARES Act includes various income and payroll tax provisions that we are in the process of analyzing to determine the tax impacts. </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="ie8bf3095c8bf45debc7bb81ee5c83b39">However, we do not expect the benefits of the CARES Act to impact the Company&#8217;s annual estimated tax rate for the period June 30, 2020.</ix:continuation></span></div><div id="icc5d6783c1494a1f886c03c93e398cee_100"></div><div style="text-indent:-18pt;padding-left:18pt;margin-top:10pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:18pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">14.&#160;<ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90ZXh0cmVnaW9uOmYwMTk0MGEzYTc5ZDQyZjA4OWM1MDA3YjRlNmE1ZDdlXzExMzQ_e13ff807-2dca-48ea-824c-f55e9fd07008" continuedAt="i820dca6f973c40018805cc52f9ea2c8c" escape="true">Earnings Per Share</ix:nonNumeric></span></div><ix:continuation id="i820dca6f973c40018805cc52f9ea2c8c"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Basic earnings per share is calculated using the weighted average number of shares of the Company&#8217;s common stock issued and outstanding during a certain period, and is calculated by dividing net income attributable to ApolloMed by the weighted average number of shares of the Company&#8217;s common stock issued and outstanding during such period. Diluted earnings per share is calculated using the weighted average number of shares of common stock and potentially dilutive shares of common stock outstanding during the period, using the as-if converted method for secured convertible notes, preferred stock, and the treasury stock method for options and common stock warrants.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020 and December&#160;31, 2019, APC held <ix:nonFraction unitRef="shares" contextRef="i255d39881fdb459ba312544c3eb6589e_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="ameh:AntidilutiveSecuritiesExcludedFromEarningsComputationShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90ZXh0cmVnaW9uOmYwMTk0MGEzYTc5ZDQyZjA4OWM1MDA3YjRlNmE1ZDdlXzc0NQ_79d5667c-a0d1-4f3c-a223-75bf139e2e8b">17,307,214</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i7e330acfd08c4813a18296547a2a33b7_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="ameh:AntidilutiveSecuritiesExcludedFromEarningsComputationShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90ZXh0cmVnaW9uOmYwMTk0MGEzYTc5ZDQyZjA4OWM1MDA3YjRlNmE1ZDdlXzc1Mg_fb814010-6199-47e2-9f3e-ee463b8c0dbb">17,290,317</ix:nonFraction> shares of ApolloMed&#8217;s common stock, respectively, which are treated as treasury shares for accounting purposes and not included in the number of shares of common stock outstanding used to calculate earnings per share.</span></div><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90ZXh0cmVnaW9uOmYwMTk0MGEzYTc5ZDQyZjA4OWM1MDA3YjRlNmE1ZDdlXzExNDM_44f57ca1-8665-4e45-8a96-1f9cc08b37c0" escape="true"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Below is a summary of the earnings per share computations:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:71.060%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.739%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Earnings per share &#8211; basic</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTo0MDgyNzkwZjQ5MjY0M2YzYTY3NjI0YWM4ODc4OTVhOS90YWJsZXJhbmdlOjQwODI3OTBmNDkyNjQzZjNhNjc2MjRhYzg4Nzg5NWE5XzEtMi0xLTEtMA_e7f01d97-07fa-4110-9178-70cc273505fd">0.20</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTo0MDgyNzkwZjQ5MjY0M2YzYTY3NjI0YWM4ODc4OTVhOS90YWJsZXJhbmdlOjQwODI3OTBmNDkyNjQzZjNhNjc2MjRhYzg4Nzg5NWE5XzEtNC0xLTEtMA_91f3706a-f9be-4c8a-b85b-ee8e32699ae4">0.10</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Earnings per share &#8211; diluted</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTo0MDgyNzkwZjQ5MjY0M2YzYTY3NjI0YWM4ODc4OTVhOS90YWJsZXJhbmdlOjQwODI3OTBmNDkyNjQzZjNhNjc2MjRhYzg4Nzg5NWE5XzItMi0xLTEtMA_2b829f91-357f-4faf-97a7-c273cbe84760">0.19</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTo0MDgyNzkwZjQ5MjY0M2YzYTY3NjI0YWM4ODc4OTVhOS90YWJsZXJhbmdlOjQwODI3OTBmNDkyNjQzZjNhNjc2MjRhYzg4Nzg5NWE5XzItNC0xLTEtMA_264f2e7d-bd0d-4ce3-9678-678ea77cad7a">0.09</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Weighted average shares of common stock outstanding &#8211; basic</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTo0MDgyNzkwZjQ5MjY0M2YzYTY3NjI0YWM4ODc4OTVhOS90YWJsZXJhbmdlOjQwODI3OTBmNDkyNjQzZjNhNjc2MjRhYzg4Nzg5NWE5XzMtMi0xLTEtMA_025495ef-c3e4-4301-a46f-5f7af3b46390">36,071,604</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTo0MDgyNzkwZjQ5MjY0M2YzYTY3NjI0YWM4ODc4OTVhOS90YWJsZXJhbmdlOjQwODI3OTBmNDkyNjQzZjNhNjc2MjRhYzg4Nzg5NWE5XzMtNC0xLTEtMA_b5b26335-1ff8-4512-82d2-28a96441d30d">34,540,059</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Weighted average shares of common stock outstanding &#8211; diluted</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTo0MDgyNzkwZjQ5MjY0M2YzYTY3NjI0YWM4ODc4OTVhOS90YWJsZXJhbmdlOjQwODI3OTBmNDkyNjQzZjNhNjc2MjRhYzg4Nzg5NWE5XzQtMi0xLTEtMA_7db6ee84-8362-41cc-81f5-bf19f953cb16">37,285,585</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTo0MDgyNzkwZjQ5MjY0M2YzYTY3NjI0YWM4ODc4OTVhOS90YWJsZXJhbmdlOjQwODI3OTBmNDkyNjQzZjNhNjc2MjRhYzg4Nzg5NWE5XzQtNC0xLTEtMA_eec87c7b-8a23-475a-8355-698b1fd6d0b8">37,962,555</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"><tr><td style="width:1.0%;"></td><td style="width:70.941%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.794%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.795%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Earnings per share &#8211; basic</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTplNWYzNWE3YWNiNDY0Y2JkYWJiYjgyNzJlOTdiNzYyNi90YWJsZXJhbmdlOmU1ZjM1YTdhY2I0NjRjYmRhYmJiODI3MmU5N2I3NjI2XzEtMi0xLTEtMA_40ac7536-ff39-4a49-a39e-ffab8e05c019">0.31</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTplNWYzNWE3YWNiNDY0Y2JkYWJiYjgyNzJlOTdiNzYyNi90YWJsZXJhbmdlOmU1ZjM1YTdhY2I0NjRjYmRhYmJiODI3MmU5N2I3NjI2XzEtNC0xLTEtMA_a0a030f0-27d2-402a-848f-ccb4ad3b51de">0.11</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Earnings per share &#8211; diluted</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTplNWYzNWE3YWNiNDY0Y2JkYWJiYjgyNzJlOTdiNzYyNi90YWJsZXJhbmdlOmU1ZjM1YTdhY2I0NjRjYmRhYmJiODI3MmU5N2I3NjI2XzItMi0xLTEtMA_3d4e5615-e194-4c0c-9a82-6b9e74984d05">0.30</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTplNWYzNWE3YWNiNDY0Y2JkYWJiYjgyNzJlOTdiNzYyNi90YWJsZXJhbmdlOmU1ZjM1YTdhY2I0NjRjYmRhYmJiODI3MmU5N2I3NjI2XzItNC0xLTEtMA_e7cec0aa-a6c5-49e8-b519-4ee457f07d79">0.10</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Weighted average shares of common stock outstanding &#8211; basic</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTplNWYzNWE3YWNiNDY0Y2JkYWJiYjgyNzJlOTdiNzYyNi90YWJsZXJhbmdlOmU1ZjM1YTdhY2I0NjRjYmRhYmJiODI3MmU5N2I3NjI2XzMtMi0xLTEtMA_476fcac9-9303-48e5-86c4-c7628290a34a">36,040,936</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTplNWYzNWE3YWNiNDY0Y2JkYWJiYjgyNzJlOTdiNzYyNi90YWJsZXJhbmdlOmU1ZjM1YTdhY2I0NjRjYmRhYmJiODI3MmU5N2I3NjI2XzMtNC0xLTEtMA_4dfc4378-da45-4d11-8259-f388eeb4ef01">34,518,461</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Weighted average shares of common stock outstanding &#8211; diluted</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTplNWYzNWE3YWNiNDY0Y2JkYWJiYjgyNzJlOTdiNzYyNi90YWJsZXJhbmdlOmU1ZjM1YTdhY2I0NjRjYmRhYmJiODI3MmU5N2I3NjI2XzQtMi0xLTEtMA_28fc127d-32f9-436c-8015-15de76ac6f15">37,296,913</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTplNWYzNWE3YWNiNDY0Y2JkYWJiYjgyNzJlOTdiNzYyNi90YWJsZXJhbmdlOmU1ZjM1YTdhY2I0NjRjYmRhYmJiODI3MmU5N2I3NjI2XzQtNC0xLTEtMA_823b259f-e36c-4a91-a650-09862e7c00c6">37,896,837</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90ZXh0cmVnaW9uOmYwMTk0MGEzYTc5ZDQyZjA4OWM1MDA3YjRlNmE1ZDdlXzEyNjQ0MzgzNzIwNTcx_ab0e329e-05be-466d-9ff0-413c269214e2" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Below is a summary of the shares included in the diluted earnings per share computations:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:71.060%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.739%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Weighted average shares of common stock outstanding &#8211; basic</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTpmMWFmMDI2MzljNzM0OTIyYTYxZGRiZTQ3ZTM2ZDQ4Ni90YWJsZXJhbmdlOmYxYWYwMjYzOWM3MzQ5MjJhNjFkZGJlNDdlMzZkNDg2XzEtMi0xLTEtMA_146ef7b9-3cbc-49b4-bcff-b6b62e1f9ad1">36,071,604</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTpmMWFmMDI2MzljNzM0OTIyYTYxZGRiZTQ3ZTM2ZDQ4Ni90YWJsZXJhbmdlOmYxYWYwMjYzOWM3MzQ5MjJhNjFkZGJlNDdlMzZkNDg2XzEtNC0xLTEtMA_6d5df357-4416-41cc-8064-2a75028adec1">34,540,059</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonFraction unitRef="number" contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630" decimals="INF" name="ameh:BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTpmMWFmMDI2MzljNzM0OTIyYTYxZGRiZTQ3ZTM2ZDQ4Ni90YWJsZXJhbmdlOmYxYWYwMjYzOWM3MzQ5MjJhNjFkZGJlNDdlMzZkNDg2XzItMC0xLTEtMC90ZXh0cmVnaW9uOmY2NDQwNzZhZDA0NDQyMjc5MTg0ZDc2MzczYjBkMDA0XzY1OTcwNjk3NjY3MTk_0251292d-5e21-453f-b8a2-12857fdc5285"><ix:nonFraction unitRef="number" contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630" decimals="INF" name="ameh:BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTpmMWFmMDI2MzljNzM0OTIyYTYxZGRiZTQ3ZTM2ZDQ4Ni90YWJsZXJhbmdlOmYxYWYwMjYzOWM3MzQ5MjJhNjFkZGJlNDdlMzZkNDg2XzItMC0xLTEtMC90ZXh0cmVnaW9uOmY2NDQwNzZhZDA0NDQyMjc5MTg0ZDc2MzczYjBkMDA0XzY1OTcwNjk3NjY3MTk_11093073-f1f9-4f83-be56-ec936b8a714c">10</ix:nonFraction></ix:nonFraction>% shares held back pursuant to indemnification clause</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ic6205a2691794f12816d94e2384216d4_D20200401-20200630" decimals="0" format="ixt:zerodash" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTpmMWFmMDI2MzljNzM0OTIyYTYxZGRiZTQ3ZTM2ZDQ4Ni90YWJsZXJhbmdlOmYxYWYwMjYzOWM3MzQ5MjJhNjFkZGJlNDdlMzZkNDg2XzItMi0xLTEtMA_2a6e206e-eed1-42c1-89f8-bf2d70af9c9c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="id43602e4d3ec401c85cc9e362fcdbb4b_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTpmMWFmMDI2MzljNzM0OTIyYTYxZGRiZTQ3ZTM2ZDQ4Ni90YWJsZXJhbmdlOmYxYWYwMjYzOWM3MzQ5MjJhNjFkZGJlNDdlMzZkNDg2XzItNC0xLTEtMA_1ce7bc13-a107-44c6-9387-ab0f312f0c8a">1,519,805</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Stock options</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ie7d554f31b964866b8df4f6b60c0a919_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTpmMWFmMDI2MzljNzM0OTIyYTYxZGRiZTQ3ZTM2ZDQ4Ni90YWJsZXJhbmdlOmYxYWYwMjYzOWM3MzQ5MjJhNjFkZGJlNDdlMzZkNDg2XzMtMi0xLTEtMA_548517f0-2ccc-4344-9677-f00ffcd607d4">169,402</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i450dc203ab3a40b6a28283cf284bd195_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTpmMWFmMDI2MzljNzM0OTIyYTYxZGRiZTQ3ZTM2ZDQ4Ni90YWJsZXJhbmdlOmYxYWYwMjYzOWM3MzQ5MjJhNjFkZGJlNDdlMzZkNDg2XzMtNC0xLTEtMA_ea0ba48f-1e6f-4680-b73d-463440b469af">363,593</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Warrants</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i8f7252c42eff45858f156999763bf992_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTpmMWFmMDI2MzljNzM0OTIyYTYxZGRiZTQ3ZTM2ZDQ4Ni90YWJsZXJhbmdlOmYxYWYwMjYzOWM3MzQ5MjJhNjFkZGJlNDdlMzZkNDg2XzQtMi0xLTEtMA_dea9faea-2968-4651-b4e6-cba05d6edd9d">1,041,784</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ifced76c7228e456281eecd440fc4200c_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTpmMWFmMDI2MzljNzM0OTIyYTYxZGRiZTQ3ZTM2ZDQ4Ni90YWJsZXJhbmdlOmYxYWYwMjYzOWM3MzQ5MjJhNjFkZGJlNDdlMzZkNDg2XzQtNC0xLTEtMA_32b75090-2ba9-4ddf-ad56-303a86242add">1,539,098</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock awards</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i02765d0185984e60929a5d510dd803fe_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTpmMWFmMDI2MzljNzM0OTIyYTYxZGRiZTQ3ZTM2ZDQ4Ni90YWJsZXJhbmdlOmYxYWYwMjYzOWM3MzQ5MjJhNjFkZGJlNDdlMzZkNDg2XzUtMi0xLTEtMA_d4234444-e358-4531-8082-9410f6266a5e">2,795</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i1d2d3cf0b58a46d1835e2032498d600a_D20190401-20190630" decimals="0" format="ixt:zerodash" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTpmMWFmMDI2MzljNzM0OTIyYTYxZGRiZTQ3ZTM2ZDQ4Ni90YWJsZXJhbmdlOmYxYWYwMjYzOWM3MzQ5MjJhNjFkZGJlNDdlMzZkNDg2XzUtNC0xLTEtMA_d22dc237-c810-4b48-9ff8-052317276243">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Weighted average shares of common stock outstanding &#8211; diluted</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTpmMWFmMDI2MzljNzM0OTIyYTYxZGRiZTQ3ZTM2ZDQ4Ni90YWJsZXJhbmdlOmYxYWYwMjYzOWM3MzQ5MjJhNjFkZGJlNDdlMzZkNDg2XzYtMi0xLTEtMA_cf6c176d-ceb8-4bce-9c55-b299a557d4d9">37,285,585</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTpmMWFmMDI2MzljNzM0OTIyYTYxZGRiZTQ3ZTM2ZDQ4Ni90YWJsZXJhbmdlOmYxYWYwMjYzOWM3MzQ5MjJhNjFkZGJlNDdlMzZkNDg2XzYtNC0xLTEtMA_89b821c3-f58d-4e26-b4ae-0209d80257a4">37,962,555</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:71.060%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.739%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Weighted average shares of common stock outstanding &#8211; basic</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTplMjNiNDkwYTAxNWU0MmRiOTViMDYyOTJlNTU5NGFiMi90YWJsZXJhbmdlOmUyM2I0OTBhMDE1ZTQyZGI5NWIwNjI5MmU1NTk0YWIyXzEtMi0xLTEtMA_a7c6031a-c573-4147-b141-3f9a65236890">36,040,936</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTplMjNiNDkwYTAxNWU0MmRiOTViMDYyOTJlNTU5NGFiMi90YWJsZXJhbmdlOmUyM2I0OTBhMDE1ZTQyZGI5NWIwNjI5MmU1NTk0YWIyXzEtNC0xLTEtMA_9c23d042-593d-4cf6-975d-b6fa164ecd1f">34,518,461</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonFraction unitRef="number" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="INF" name="ameh:BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTplMjNiNDkwYTAxNWU0MmRiOTViMDYyOTJlNTU5NGFiMi90YWJsZXJhbmdlOmUyM2I0OTBhMDE1ZTQyZGI5NWIwNjI5MmU1NTk0YWIyXzItMC0xLTEtMjM0NS90ZXh0cmVnaW9uOjIxN2ZmZTdmMzY2YzQ5Njc5NDFhY2E4ZGM5NTY4ZjY2XzY1OTcwNjk3NjY3Mjc_378abe6f-27de-4d79-97d9-0e1e024a61d7"><ix:nonFraction unitRef="number" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="INF" name="ameh:BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTplMjNiNDkwYTAxNWU0MmRiOTViMDYyOTJlNTU5NGFiMi90YWJsZXJhbmdlOmUyM2I0OTBhMDE1ZTQyZGI5NWIwNjI5MmU1NTk0YWIyXzItMC0xLTEtMjM0NS90ZXh0cmVnaW9uOjIxN2ZmZTdmMzY2YzQ5Njc5NDFhY2E4ZGM5NTY4ZjY2XzY1OTcwNjk3NjY3Mjc_551d3715-2d08-464c-b0ff-f77ab39c12fe">10</ix:nonFraction></ix:nonFraction>% shares held back pursuant to indemnification clause</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i5ba5a4313e034d9c9d26fa5c9c002ef7_D20200101-20200630" decimals="0" format="ixt:zerodash" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTplMjNiNDkwYTAxNWU0MmRiOTViMDYyOTJlNTU5NGFiMi90YWJsZXJhbmdlOmUyM2I0OTBhMDE1ZTQyZGI5NWIwNjI5MmU1NTk0YWIyXzItMi0xLTEtMA_b92e1092-cc96-41b3-bea1-effea91b1294">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i1acd759fc07341a7815dd2541d1fa444_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTplMjNiNDkwYTAxNWU0MmRiOTViMDYyOTJlNTU5NGFiMi90YWJsZXJhbmdlOmUyM2I0OTBhMDE1ZTQyZGI5NWIwNjI5MmU1NTk0YWIyXzItNC0xLTEtMA_31b32752-c2df-4c97-a4ca-dc3ee584e713">1,519,805</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Stock options</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="if9d48ee182734c28b3a941a4ea33ad0a_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTplMjNiNDkwYTAxNWU0MmRiOTViMDYyOTJlNTU5NGFiMi90YWJsZXJhbmdlOmUyM2I0OTBhMDE1ZTQyZGI5NWIwNjI5MmU1NTk0YWIyXzMtMi0xLTEtMA_a3123ae6-74ef-4189-873e-28a871e479b0">173,299</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ib7bd39987453433c8655b734992caa99_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTplMjNiNDkwYTAxNWU0MmRiOTViMDYyOTJlNTU5NGFiMi90YWJsZXJhbmdlOmUyM2I0OTBhMDE1ZTQyZGI5NWIwNjI5MmU1NTk0YWIyXzMtNC0xLTEtMA_b87135ec-aa7a-48df-aff7-362eb91fa1d8">368,273</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Warrants</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i27599a16780e40908fb6bbc9191294f0_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTplMjNiNDkwYTAxNWU0MmRiOTViMDYyOTJlNTU5NGFiMi90YWJsZXJhbmdlOmUyM2I0OTBhMDE1ZTQyZGI5NWIwNjI5MmU1NTk0YWIyXzQtMi0xLTEtMA_8df6b833-22a3-40ec-866d-2007e80882e4">1,076,802</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i954924a949ec4f81b4ccce5827b40713_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTplMjNiNDkwYTAxNWU0MmRiOTViMDYyOTJlNTU5NGFiMi90YWJsZXJhbmdlOmUyM2I0OTBhMDE1ZTQyZGI5NWIwNjI5MmU1NTk0YWIyXzQtNC0xLTEtMA_9b9e3460-4815-4b11-b9ed-79479ea621d6">1,490,298</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock awards</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ife480d762a994b8685aef3f1fd37b377_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTplMjNiNDkwYTAxNWU0MmRiOTViMDYyOTJlNTU5NGFiMi90YWJsZXJhbmdlOmUyM2I0OTBhMDE1ZTQyZGI5NWIwNjI5MmU1NTk0YWIyXzUtMi0xLTEtMA_0e2e540d-79a1-4249-a6fd-587216ee6568">5,876</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i7a92fa7d1d5341c18bcd43745c8b8460_D20190101-20190630" decimals="0" format="ixt:zerodash" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTplMjNiNDkwYTAxNWU0MmRiOTViMDYyOTJlNTU5NGFiMi90YWJsZXJhbmdlOmUyM2I0OTBhMDE1ZTQyZGI5NWIwNjI5MmU1NTk0YWIyXzUtNC0xLTEtMA_845cd327-d13e-401c-96cb-0546100d50be">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Weighted average shares of common stock outstanding &#8211; diluted</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTplMjNiNDkwYTAxNWU0MmRiOTViMDYyOTJlNTU5NGFiMi90YWJsZXJhbmdlOmUyM2I0OTBhMDE1ZTQyZGI5NWIwNjI5MmU1NTk0YWIyXzYtMi0xLTEtMA_80f3a933-2c7c-4bb5-b7b3-d3fccab9ac8e">37,296,913</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTplMjNiNDkwYTAxNWU0MmRiOTViMDYyOTJlNTU5NGFiMi90YWJsZXJhbmdlOmUyM2I0OTBhMDE1ZTQyZGI5NWIwNjI5MmU1NTk0YWIyXzYtNC0xLTEtMA_142011d9-ee4e-4c1c-a5ce-2885e3aedfda">37,896,837</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="icc5d6783c1494a1f886c03c93e398cee_103"></div><div style="margin-top:10pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">15.&#160;<ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="us-gaap:VariableInterestEntityDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90ZXh0cmVnaW9uOjFjMzZhNDJhYTJjNTQwYzM5Y2MzOTM2YTdmODFjMjQ4XzE4NTY_4a6d3aee-0e91-4ff0-91ae-68996e75c02f" continuedAt="i9d676ba73ec64083947b6740507ceb14" escape="true">Variable Interest Entities (VIEs)</ix:nonNumeric></span></div><ix:continuation id="i9d676ba73ec64083947b6740507ceb14" continuedAt="i95e537db21c04720a047830dcba1631e"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A VIE is defined as a legal entity whose equity owners do not have sufficient equity at risk, or, as a group, the holders of the equity investment at risk lack any of the following three characteristics: decision-making rights, the obligation to absorb losses, or the right to receive the expected residual returns of the entity. The primary beneficiary is identified as the variable interest holder that has both the power to direct the activities of the VIE that most significantly affect the entity&#8217;s economic performance and the obligation to absorb expected losses or the right to receive benefits from the entity that could potentially be significant to the VIE.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company follows guidance on the consolidation of VIEs that requires companies to utilize a qualitative approach to determine whether it is the primary beneficiary of a VIE. See Note 2 &#8211; &#8220;Basis of Presentation and Summary of Significant Accounting Policies&#8221; to the accompanying consolidated financial statements for information on how the Company determines VIEs and its treatment.</span></div><div style="text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="us-gaap:ScheduleOfVariableInterestEntitiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90ZXh0cmVnaW9uOjFjMzZhNDJhYTJjNTQwYzM5Y2MzOTM2YTdmODFjMjQ4XzE4NTk_5d2f1c2d-f790-4a0f-87e1-8eca0a1068db" continuedAt="ic1c219fa3a794fb4b4fb653e233a7a1b" escape="true">The following table includes assets that can only be used to settle the liabilities of APC and its VIEs, including Alpha Care and Accountable Health Care, and to which the creditors of APC, including Alpha Care and Accountable Health Care, have no recourse to the Company, nor do creditors of the Company have recourse against the assets of APC, including Alpha Care and Accountable Health Care. These assets and liabilities, with the exception of the investment in a privately held entity that does not report net asset value per share and amounts due to affiliates, which are eliminated upon consolidation with NMM, are included in the accompanying consolidated balance sheets (in thousands).</ix:nonNumeric></span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><div style="margin-top:14pt;margin-bottom:5pt;"><ix:continuation id="i95e537db21c04720a047830dcba1631e" continuedAt="i66c30fa640e04d5daecabad360d2364b"><ix:continuation id="ic1c219fa3a794fb4b4fb653e233a7a1b" continuedAt="ie13ee7c9d88f404bae5ae5a9dff6ae1a"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:70.873%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.636%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.758%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Assets</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current assets</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzQtMS0xLTEtMA_5c440102-c1eb-446e-a638-9c3535230a46">113,790</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzQtMy0xLTEtMA_e2da8ef0-7c1c-4752-962b-95ff286dd00e">87,110</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzUtMS0xLTEtMA_a54f4c51-c9e2-4405-89fa-3474987832eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzUtMy0xLTEtMA_3e76e1df-378f-4068-9f67-fa72ba92bf74">75</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investment in marketable securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzYtMS0xLTEtMA_a01bdd06-92be-4413-a07a-b8bf7b38fcde">117,611</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzYtMy0xLTEtMA_f7b0036c-6c80-4a20-9f36-6761c102a8e0">123,948</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Receivables, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzctMS0xLTEtMA_1473e046-c030-4ea3-98d6-ac145a7dce52">15,687</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzctMy0xLTEtMA_4aa02dd5-d75a-43ef-b833-5b9118095d81">9,300</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Receivables, net &#8211; related party</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzgtMS0xLTEtMA_1c83201e-dc2a-4688-ae93-c457ea63fcc7">55,889</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzgtMy0xLTEtMA_0808ce69-da50-4e8e-bab7-4eb0fe23667e">42,976</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other receivables</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzktMS0xLTEtMA_97bbf984-a102-4d41-ae3d-71045a7e3678">734</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzktMy0xLTEtMA_a48bd1ee-5811-4b26-8565-c967b2648fe9">744</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses and other current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzEwLTEtMS0xLTA_98272b1d-dcca-43f7-b6c1-be5467049157">7,752</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzEwLTMtMS0xLTA_5df7fbf1-87e5-468d-9d11-5ad451239b36">7,403</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loan receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NotesAndLoansReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzExLTEtMS0xLTA_70a63daf-1a6c-434d-801c-7ae7d37f3f42">6,425</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NotesAndLoansReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzExLTMtMS0xLTA_7e8fb237-15cd-4cb0-a18d-22c81a0a8f2e">6,425</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loan receivable &#8211; related parties</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:NotesReceivableRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzEyLTEtMS0xLTA_4e818b42-9a69-427d-b547-83f7e8247384">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NotesReceivableRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzEyLTMtMS0xLTA_03786dc7-eb70-4191-a48f-8984bff155fb">16,500</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total current assets</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzEzLTEtMS0xLTA_2ae687ed-f1e0-4f80-947d-7f2812338896">317,888</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzEzLTMtMS0xLTA_bc619732-6262-429c-bd51-63678b0b4d56">294,481</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Land, property and equipment, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzE2LTEtMS0xLTA_79570d7b-0dea-4336-aa51-306ed80fffd2">9,085</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzE2LTMtMS0xLTA_c1ae854f-5475-4ae5-958c-acc4c59ea540">9,547</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intangible assets, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzE3LTEtMS0xLTA_bf5a86be-1c65-4140-8585-b7d2aefbbd06">75,177</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzE3LTMtMS0xLTA_b3c3956f-e120-48de-ab09-5c39ce6c3978">81,439</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzE4LTEtMS0xLTA_59d143b0-089f-4ff6-b576-621d02d6cfbb">109,460</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzE4LTMtMS0xLTA_448ba43a-2234-4035-b1c1-ceacc40a1ad8">108,913</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investment in affiliates</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLongTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzE5LTEtMS0xLTA_ec85057d-a50f-4e2d-8c15-b8cb2f2aee04">285,569</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLongTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzE5LTMtMS0xLTA_99ac6b8d-c493-4124-aacf-45ecd1540481">318,315</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investment in privately held entities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzIwLTEtMS0xLTY4NTQ_f38dcc31-b48e-4bb0-b339-26eb329178cf">36,584</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzIwLTMtMS0xLTY4NTQ_8aafda03-0a22-4430-ae77-87f52a9a0fc9">1,615</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investments in other entities &#8211; equity method</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzIwLTEtMS0xLTA_debc4d33-ed88-4032-94f3-8522fa3f816c">26,864</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzIwLTMtMS0xLTA_089d6aea-9cfc-4d02-a6fb-db5cf8fb87ba">28,427</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzIxLTEtMS0xLTA_b31df2ac-24a4-41ca-b0d5-4937fce3b0a2">746</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzIxLTMtMS0xLTA_fc10ff25-e9ea-4a06-bfc5-3bea69c29459">746</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease right-of-use assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzIyLTEtMS0xLTA_76340143-46b5-4cf4-b419-6e4c79f5a369">7,017</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzIyLTMtMS0xLTA_2045e4b6-6b5a-4f8a-84ab-5853baa57f97">4,751</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzIzLTEtMS0xLTA_29fb1189-c86d-4de3-a9f9-48d871a6ef0a">20,750</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzIzLTMtMS0xLTA_ca2dfa1b-d373-4ee4-9c7b-49b2b8546baa">1,057</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total noncurrent assets</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzI1LTEtMS0xLTA_2254a941-6a2f-4d2f-8195-14a3bae96698">571,252</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzI1LTMtMS0xLTA_caba7537-4be4-4349-8bde-0b3496860644">554,810</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Total assets</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzI3LTEtMS0xLTA_4762f591-1b9c-4f32-9b31-bf8bed6ca3f3">889,140</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzI3LTMtMS0xLTA_d3a034a8-53ee-4790-a8a7-91870d546590">849,291</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable and accrued expenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzMwLTEtMS0xLTA_22ff8567-921a-4169-937a-4a413fe83503">11,822</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzMwLTMtMS0xLTA_1f60d2d6-11e7-4dad-a96d-3c27e2d55e61">11,187</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fiduciary accounts payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630" decimals="-3" format="ixt:numdotdecimal" name="ameh:FiduciaryAccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzMxLTEtMS0xLTA_fcc5ffe7-94f0-4aec-b3bc-3e80360dbd8c">1,853</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231" decimals="-3" format="ixt:numdotdecimal" name="ameh:FiduciaryAccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzMxLTMtMS0xLTA_1a5ae52c-3778-4deb-bfe9-aa20fad2b302">2,027</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Medical liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzMyLTEtMS0xLTA_b9bc6b74-618b-4b22-8c14-aa25936ee23b">47,304</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzMyLTMtMS0xLTA_7e355f00-1ab5-483d-822c-643cf4f47234">49,019</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income taxes payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TaxesPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzMzLTEtMS0xLTA_bf000c36-a0c9-46f0-b55f-774a8b667b04">42,211</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TaxesPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzMzLTMtMS0xLTA_3fc42c92-1f48-4eb0-bfa1-0f04fd1a289e">4,530</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount due to affiliate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DueToAffiliateCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzM0LTEtMS0xLTA_8a8d1528-ef1f-4f45-9fe2-94bb3da663d3">21,533</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DueToAffiliateCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzM0LTMtMS0xLTA_18403430-fc63-4c9a-b0af-094083050194">28,058</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dividends payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630" decimals="-3" name="us-gaap:DividendsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzM1LTEtMS0xLTA_5d7f5ed4-c185-4e5b-bb5f-395e85f4feea">431</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231" decimals="-3" name="us-gaap:DividendsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzM1LTMtMS0xLTA_f4f5dc79-8cb3-4e27-b8f6-d0ef1054ca0b">271</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance lease liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzM2LTEtMS0xLTA_f4f8a03f-35ef-4bb7-884a-b310470c6836">102</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzM2LTMtMS0xLTA_eb3b8564-82a2-4e2a-a51d-e79f60069a52">102</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzM3LTEtMS0xLTA_481c5649-5be9-4e76-b2fe-ad3e5afd0128">1,319</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzM3LTMtMS0xLTA_798e5d92-4581-41a9-86a5-76a8cd85e063">1,088</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total current liabilities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzM5LTEtMS0xLTA_805cbeed-4bde-48d6-b8ef-49dd77a2b644">126,575</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzM5LTMtMS0xLTA_6b90eee9-c8b9-490c-8fb3-f3f8547f4ac6">96,282</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Noncurrent liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzQyLTEtMS0xLTA_9c2f884a-6d4c-4812-9eee-479e53f91131">9,490</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzQyLTMtMS0xLTA_2601c9f2-c86b-4347-8b2a-85051c7e49c0">14,059</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance lease liabilities, net of current portion</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzQzLTEtMS0xLTA_447ec8e5-d0aa-4f77-abe5-d6ce225642e8">355</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzQzLTMtMS0xLTA_4cb9594f-74d3-409e-a02f-3d11b8bcd1a2">416</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities, net of current portion</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzQ0LTEtMS0xLTA_8ba8c26a-5891-40e5-9195-fc861879508a">5,833</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzQ0LTMtMS0xLTA_5cd2a252-177b-4748-b3cc-461a1bb95942">3,742</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total noncurrent liabilities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzQ2LTEtMS0xLTA_1a395672-1072-497a-adbf-0c8637568d44">15,678</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzQ2LTMtMS0xLTA_7a5b375d-fe8d-41f6-a073-55c2f61531c3">18,217</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></ix:continuation></ix:continuation></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><ix:continuation id="i66c30fa640e04d5daecabad360d2364b"><div style="margin-top:14pt;margin-bottom:5pt;"><ix:continuation id="ie13ee7c9d88f404bae5ae5a9dff6ae1a"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:70.873%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.636%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.758%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Total liabilities</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzQ4LTEtMS0xLTA_fe893408-fdd5-489f-a158-bf6f20bd3519">142,253</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzQ4LTMtMS0xLTA_549aa2c9-de56-46e2-bb6b-8d27a3779d2d">114,499</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:continuation></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The assets of the Company&#8217;s other consolidated VIEs were not considered significant.</span></div></ix:continuation><div id="icc5d6783c1494a1f886c03c93e398cee_106"></div><div style="margin-top:10pt;"><span><br/></span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">16.&#160;<ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="us-gaap:LesseeFinanceLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90ZXh0cmVnaW9uOjBiNjNjZGMyNTJlYzQ3Y2E4YjQ3MWY3YzIyOTIzYmJjXzEwMzk_b0053f62-6184-4137-b8e9-5c6f5ea0168f" continuedAt="i38d62306cc2244ae8ed9a85b9e910b18" escape="true"><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90ZXh0cmVnaW9uOjBiNjNjZGMyNTJlYzQ3Y2E4YjQ3MWY3YzIyOTIzYmJjXzEwNTE_24fb3dd3-04c2-4abc-898c-de16abfc9f12" continuedAt="ifa4d4f12111c45cbb8ba2f3006bab5dd" escape="true">Leases</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="i38d62306cc2244ae8ed9a85b9e910b18" continuedAt="i0e395b04d72c4c5da946e793746df00a"><ix:continuation id="ifa4d4f12111c45cbb8ba2f3006bab5dd" continuedAt="i95f7665bd0a2414695c453cefef84485"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has operating and finance leases for corporate offices, doctors&#8217; offices, and certain equipment. These leases have remaining lease terms of <ix:nonNumeric contextRef="if0190ef7dee34fbda65c048ee6b393c7_I20200630" format="ixt-sec:durmonth" name="us-gaap:LesseeFinanceLeaseRemainingLeaseTerm" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90ZXh0cmVnaW9uOjBiNjNjZGMyNTJlYzQ3Y2E4YjQ3MWY3YzIyOTIzYmJjXzE2OA_04912863-ca76-4c45-a7ac-ce874c1ac538"><ix:nonNumeric contextRef="if0190ef7dee34fbda65c048ee6b393c7_I20200630" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90ZXh0cmVnaW9uOjBiNjNjZGMyNTJlYzQ3Y2E4YjQ3MWY3YzIyOTIzYmJjXzE2OA_33d1608a-4757-441c-9d81-95e80ae62683">1</ix:nonNumeric></ix:nonNumeric> month to <ix:nonNumeric contextRef="i4688143439664825ac968a174665ba3d_I20200630" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90ZXh0cmVnaW9uOjBiNjNjZGMyNTJlYzQ3Y2E4YjQ3MWY3YzIyOTIzYmJjXzE3NA_3711b51c-b000-4a07-833f-6731a5a6c793"><ix:nonNumeric contextRef="i4688143439664825ac968a174665ba3d_I20200630" format="ixt-sec:duryear" name="us-gaap:LesseeFinanceLeaseRemainingLeaseTerm" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90ZXh0cmVnaW9uOjBiNjNjZGMyNTJlYzQ3Y2E4YjQ3MWY3YzIyOTIzYmJjXzE3NA_8fcbd946-4eb1-4ae4-9368-6725d0c5577d">5</ix:nonNumeric></ix:nonNumeric> years, some of which may include options to extend the leases for up to <ix:nonNumeric contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" format="ixt-sec:duryear" name="us-gaap:LesseeFinanceLeaseRenewalTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90ZXh0cmVnaW9uOjBiNjNjZGMyNTJlYzQ3Y2E4YjQ3MWY3YzIyOTIzYmJjXzI0Mw_4588fa0f-017f-42c6-bd12-6d082b3bbb79"><ix:nonNumeric contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90ZXh0cmVnaW9uOjBiNjNjZGMyNTJlYzQ3Y2E4YjQ3MWY3YzIyOTIzYmJjXzI0Mw_8b73e392-1280-49ed-8831-6aaa67ba863f">10</ix:nonNumeric></ix:nonNumeric> years, and some of which may include options to terminate the leases within <ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" format="ixt-sec:durwordsen" name="ameh:LesseeOperatingLeaseTerminationPeriodIfApplicable" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90ZXh0cmVnaW9uOjBiNjNjZGMyNTJlYzQ3Y2E4YjQ3MWY3YzIyOTIzYmJjXzMyMg_43c94f91-457c-4768-bc1d-82eccc038087"><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" format="ixt-sec:durwordsen" name="ameh:LesseeFinanceLeaseTerminationPeriodIfApplicable" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90ZXh0cmVnaW9uOjBiNjNjZGMyNTJlYzQ3Y2E4YjQ3MWY3YzIyOTIzYmJjXzMyMg_ebac538c-ca16-4bd3-b851-40ab07a5325e">one year</ix:nonNumeric></ix:nonNumeric>. As of June&#160;30, 2020 and December&#160;31, 2019, assets recorded under finance leases were $<ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90ZXh0cmVnaW9uOjBiNjNjZGMyNTJlYzQ3Y2E4YjQ3MWY3YzIyOTIzYmJjXzYwNDczMTM5NTM4NzU_fd64d504-2a24-4086-b1f6-1f33a454c5c6">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90ZXh0cmVnaW9uOjBiNjNjZGMyNTJlYzQ3Y2E4YjQ3MWY3YzIyOTIzYmJjXzE2NDkyNjc0NDI3MzI_6c373589-cff8-4e08-aaef-74d0dfffaaf0">0.5</ix:nonFraction> million, respectively, and accumulated depreciation associated with finance leases was $<ix:nonFraction unitRef="usd" contextRef="i1fe8e8ce30b4463d841ecdce075f4f3d_D20200630-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90ZXh0cmVnaW9uOjBiNjNjZGMyNTJlYzQ3Y2E4YjQ3MWY3YzIyOTIzYmJjXzQ2Nw_47b9a24c-72b8-4e4c-9226-f57296997208"><ix:nonFraction unitRef="usd" contextRef="if1ac92c6e4a04bde94c7027334556000_D20191231-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90ZXh0cmVnaW9uOjBiNjNjZGMyNTJlYzQ3Y2E4YjQ3MWY3YzIyOTIzYmJjXzQ2Nw_6dfbd64a-5700-489f-8e1c-f5fa87a33a3b">0.3</ix:nonFraction></ix:nonFraction> million, respectively. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Also, the Company rents or subleases certain real estate to third parties, which are accounted for as operating leases.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Leases with an initial term of 12 months or less are not recorded on the balance sheet.</span></div><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90ZXh0cmVnaW9uOjBiNjNjZGMyNTJlYzQ3Y2E4YjQ3MWY3YzIyOTIzYmJjXzEwNDA_b916327d-37f8-4245-9813-b8bc157cfb0c" continuedAt="i0887ecb58d6f4b59bfd02c4eeed14943" escape="true"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The components of lease expense were as follows (in thousands):</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:77.824%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:7.941%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.505%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating lease cost</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo4ODRkY2U0ZWJlZjY0YzQ5YThkOGQzYjE5NWYxNDdmZi90YWJsZXJhbmdlOjg4NGRjZTRlYmVmNjRjNDlhOGQ4ZDNiMTk1ZjE0N2ZmXzMtMS0xLTEtMA_8850d94c-0758-448f-85f1-c190148658d7">1,446</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo4ODRkY2U0ZWJlZjY0YzQ5YThkOGQzYjE5NWYxNDdmZi90YWJsZXJhbmdlOjg4NGRjZTRlYmVmNjRjNDlhOGQ4ZDNiMTk1ZjE0N2ZmXzMtMy0xLTEtMA_7967a334-3b84-4136-83d2-2a02682edfc2">1,240</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Finance lease cost</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Amortization of lease expense</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo4ODRkY2U0ZWJlZjY0YzQ5YThkOGQzYjE5NWYxNDdmZi90YWJsZXJhbmdlOjg4NGRjZTRlYmVmNjRjNDlhOGQ4ZDNiMTk1ZjE0N2ZmXzYtMS0xLTEtMA_4834bb62-e820-4db5-8ad0-c5f0e74f20a1">35</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo4ODRkY2U0ZWJlZjY0YzQ5YThkOGQzYjE5NWYxNDdmZi90YWJsZXJhbmdlOjg4NGRjZTRlYmVmNjRjNDlhOGQ4ZDNiMTk1ZjE0N2ZmXzYtMy0xLTEtMA_fa5d84af-f116-4fe2-b7d4-ee8ea4d3673e">25</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Interest on lease liabilities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo4ODRkY2U0ZWJlZjY0YzQ5YThkOGQzYjE5NWYxNDdmZi90YWJsZXJhbmdlOjg4NGRjZTRlYmVmNjRjNDlhOGQ4ZDNiMTk1ZjE0N2ZmXzctMS0xLTEtMA_665a2716-6408-4e24-8495-cc1c50a1d8f1">4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo4ODRkY2U0ZWJlZjY0YzQ5YThkOGQzYjE5NWYxNDdmZi90YWJsZXJhbmdlOjg4NGRjZTRlYmVmNjRjNDlhOGQ4ZDNiMTk1ZjE0N2ZmXzctMy0xLTEtMA_a6cbbc4d-7eb3-4cd1-8214-8b83af853b26">4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Sublease income</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo4ODRkY2U0ZWJlZjY0YzQ5YThkOGQzYjE5NWYxNDdmZi90YWJsZXJhbmdlOjg4NGRjZTRlYmVmNjRjNDlhOGQ4ZDNiMTk1ZjE0N2ZmXzktMS0xLTEtMA_b570bb95-8ec5-47e3-8144-51010167f07c">226</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo4ODRkY2U0ZWJlZjY0YzQ5YThkOGQzYjE5NWYxNDdmZi90YWJsZXJhbmdlOjg4NGRjZTRlYmVmNjRjNDlhOGQ4ZDNiMTk1ZjE0N2ZmXzktMy0xLTEtMA_0a381ae5-ede2-4863-825f-765825ab522f">106</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total finance lease cost, net</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo4ODRkY2U0ZWJlZjY0YzQ5YThkOGQzYjE5NWYxNDdmZi90YWJsZXJhbmdlOjg4NGRjZTRlYmVmNjRjNDlhOGQ4ZDNiMTk1ZjE0N2ZmXzExLTEtMS0xLTA_9f7ef088-5f88-42ac-b640-d87b0b0a1f61">1,259</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo4ODRkY2U0ZWJlZjY0YzQ5YThkOGQzYjE5NWYxNDdmZi90YWJsZXJhbmdlOjg4NGRjZTRlYmVmNjRjNDlhOGQ4ZDNiMTk1ZjE0N2ZmXzExLTMtMS0xLTA_436345f7-a1d9-4cbb-811e-325496ef72a6">1,163</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:77.678%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.380%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.212%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating lease cost</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTpmODZjMjI3MjVjN2Y0MTE1OGFkNmYzYTU3NjdkMzQ5MS90YWJsZXJhbmdlOmY4NmMyMjcyNWM3ZjQxMTU4YWQ2ZjNhNTc2N2QzNDkxXzMtMS0xLTEtMA_8f278a3e-9605-43aa-8b5c-a05813e60f2f">3,388</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTpmODZjMjI3MjVjN2Y0MTE1OGFkNmYzYTU3NjdkMzQ5MS90YWJsZXJhbmdlOmY4NmMyMjcyNWM3ZjQxMTU4YWQ2ZjNhNTc2N2QzNDkxXzMtMy0xLTEtMA_861a260d-b26d-4a24-8e14-b988fb427bae">2,343</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Finance lease cost</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Amortization of lease expense</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTpmODZjMjI3MjVjN2Y0MTE1OGFkNmYzYTU3NjdkMzQ5MS90YWJsZXJhbmdlOmY4NmMyMjcyNWM3ZjQxMTU4YWQ2ZjNhNTc2N2QzNDkxXzYtMS0xLTEtMA_2411e97b-0a82-473f-816a-b179706925f0">61</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTpmODZjMjI3MjVjN2Y0MTE1OGFkNmYzYTU3NjdkMzQ5MS90YWJsZXJhbmdlOmY4NmMyMjcyNWM3ZjQxMTU4YWQ2ZjNhNTc2N2QzNDkxXzYtMy0xLTEtMA_eb8fabef-d085-42c8-86c9-80f7af0d0837">50</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Interest on lease liabilities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTpmODZjMjI3MjVjN2Y0MTE1OGFkNmYzYTU3NjdkMzQ5MS90YWJsZXJhbmdlOmY4NmMyMjcyNWM3ZjQxMTU4YWQ2ZjNhNTc2N2QzNDkxXzctMS0xLTEtMA_6c5901c0-61a2-4c37-8448-37e68ce3268a">7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTpmODZjMjI3MjVjN2Y0MTE1OGFkNmYzYTU3NjdkMzQ5MS90YWJsZXJhbmdlOmY4NmMyMjcyNWM3ZjQxMTU4YWQ2ZjNhNTc2N2QzNDkxXzctMy0xLTEtMA_0e45df20-e11d-40c2-ace5-073d2f82f2ef">9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Sublease income</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTpmODZjMjI3MjVjN2Y0MTE1OGFkNmYzYTU3NjdkMzQ5MS90YWJsZXJhbmdlOmY4NmMyMjcyNWM3ZjQxMTU4YWQ2ZjNhNTc2N2QzNDkxXzktMS0xLTEtMA_1259e6dc-9763-42d2-a748-8fab26692725">360</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTpmODZjMjI3MjVjN2Y0MTE1OGFkNmYzYTU3NjdkMzQ5MS90YWJsZXJhbmdlOmY4NmMyMjcyNWM3ZjQxMTU4YWQ2ZjNhNTc2N2QzNDkxXzktMy0xLTEtMA_4e89d8ae-551b-4a0f-81ce-385e3c9411c1">206</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total finance lease cost, net</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTpmODZjMjI3MjVjN2Y0MTE1OGFkNmYzYTU3NjdkMzQ5MS90YWJsZXJhbmdlOmY4NmMyMjcyNWM3ZjQxMTU4YWQ2ZjNhNTc2N2QzNDkxXzExLTEtMS0xLTA_72a20949-89ed-4f9a-8276-3cf2710c7800">3,096</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTpmODZjMjI3MjVjN2Y0MTE1OGFkNmYzYTU3NjdkMzQ5MS90YWJsZXJhbmdlOmY4NmMyMjcyNWM3ZjQxMTU4YWQ2ZjNhNTc2N2QzNDkxXzExLTMtMS0xLTA_87b7f0c3-9601-4842-a59f-026fd507f9e8">2,196</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation></ix:continuation><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><ix:continuation id="i0e395b04d72c4c5da946e793746df00a" continuedAt="if62938737b3b4bbca08abc5014634cac"><ix:continuation id="i95f7665bd0a2414695c453cefef84485" continuedAt="i147d42f3376b4c98a7e0669ec79c1d76"><ix:continuation id="i0887ecb58d6f4b59bfd02c4eeed14943"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other information related to leases was as follows (in thousands):</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:77.295%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.425%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.546%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Supplemental Cash Flows Information</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash paid for amounts included in the measurement of lease liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating cash flows from operating leases</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo3NTkwMjUxOGI4OGI0OTZmOWEzY2FlNTBjODIyM2JjNC90YWJsZXJhbmdlOjc1OTAyNTE4Yjg4YjQ5NmY5YTNjYWU1MGM4MjIzYmM0XzYtMS0xLTEtMA_4439e785-86c0-4d9f-8cc3-d9d52ab2b8fb">1,333</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo3NTkwMjUxOGI4OGI0OTZmOWEzY2FlNTBjODIyM2JjNC90YWJsZXJhbmdlOjc1OTAyNTE4Yjg4YjQ5NmY5YTNjYWU1MGM4MjIzYmM0XzYtMy0xLTEtMA_4572027f-b509-4159-9318-d3bfa8ea15c2">1,239</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating cash flows from finance leases</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo3NTkwMjUxOGI4OGI0OTZmOWEzY2FlNTBjODIyM2JjNC90YWJsZXJhbmdlOjc1OTAyNTE4Yjg4YjQ5NmY5YTNjYWU1MGM4MjIzYmM0XzctMS0xLTEtMA_e43d33fd-d953-4837-8147-3d59064ceba5">4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo3NTkwMjUxOGI4OGI0OTZmOWEzY2FlNTBjODIyM2JjNC90YWJsZXJhbmdlOjc1OTAyNTE4Yjg4YjQ5NmY5YTNjYWU1MGM4MjIzYmM0XzctMy0xLTEtMA_6c4e47b4-eb54-4254-b625-38e43e0ebe2f">4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Financing cash flows from finance leases</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo3NTkwMjUxOGI4OGI0OTZmOWEzY2FlNTBjODIyM2JjNC90YWJsZXJhbmdlOjc1OTAyNTE4Yjg4YjQ5NmY5YTNjYWU1MGM4MjIzYmM0XzgtMS0xLTEtMA_5f22802f-d78b-4990-b0dd-1c3c1804cd95">35</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo3NTkwMjUxOGI4OGI0OTZmOWEzY2FlNTBjODIyM2JjNC90YWJsZXJhbmdlOjc1OTAyNTE4Yjg4YjQ5NmY5YTNjYWU1MGM4MjIzYmM0XzgtMy0xLTEtMA_fee018c8-d36b-4891-bcb7-5a75da997a7f">25</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Right-of-use assets obtained in exchange for lease liabilities:</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating leases</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo3NTkwMjUxOGI4OGI0OTZmOWEzY2FlNTBjODIyM2JjNC90YWJsZXJhbmdlOjc1OTAyNTE4Yjg4YjQ5NmY5YTNjYWU1MGM4MjIzYmM0XzExLTEtMS0xLTA_9526b316-02a5-4e4f-93f2-ddb71781a00d">2,907</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo3NTkwMjUxOGI4OGI0OTZmOWEzY2FlNTBjODIyM2JjNC90YWJsZXJhbmdlOjc1OTAyNTE4Yjg4YjQ5NmY5YTNjYWU1MGM4MjIzYmM0XzExLTMtMS0xLTA_bee49540-5525-424b-a5e5-b63919456d80">6,441</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Supplemental Cash Flows Information</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash paid for amounts included in the measurement of lease liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating cash flows from operating leases</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo3NTkwMjUxOGI4OGI0OTZmOWEzY2FlNTBjODIyM2JjNC90YWJsZXJhbmdlOjc1OTAyNTE4Yjg4YjQ5NmY5YTNjYWU1MGM4MjIzYmM0XzE5LTEtMS0xLTA_10f1f1bc-2e90-452a-819f-40e2ece91f4d">2,880</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo3NTkwMjUxOGI4OGI0OTZmOWEzY2FlNTBjODIyM2JjNC90YWJsZXJhbmdlOjc1OTAyNTE4Yjg4YjQ5NmY5YTNjYWU1MGM4MjIzYmM0XzE5LTMtMS0xLTA_fe843cbf-cfd2-4ec5-a09c-be1279ebb3a6">2,273</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating cash flows from finance leases</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo3NTkwMjUxOGI4OGI0OTZmOWEzY2FlNTBjODIyM2JjNC90YWJsZXJhbmdlOjc1OTAyNTE4Yjg4YjQ5NmY5YTNjYWU1MGM4MjIzYmM0XzIwLTEtMS0xLTA_db30a1ff-4d1d-4983-b6c3-281fee74f8f0">7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo3NTkwMjUxOGI4OGI0OTZmOWEzY2FlNTBjODIyM2JjNC90YWJsZXJhbmdlOjc1OTAyNTE4Yjg4YjQ5NmY5YTNjYWU1MGM4MjIzYmM0XzIwLTMtMS0xLTA_0def8882-804b-441a-9793-0b2f47569dc1">9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Financing cash flows from finance leases</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo3NTkwMjUxOGI4OGI0OTZmOWEzY2FlNTBjODIyM2JjNC90YWJsZXJhbmdlOjc1OTAyNTE4Yjg4YjQ5NmY5YTNjYWU1MGM4MjIzYmM0XzIxLTEtMS0xLTA_25a09864-526e-4c5a-994f-ce19ee625460">61</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo3NTkwMjUxOGI4OGI0OTZmOWEzY2FlNTBjODIyM2JjNC90YWJsZXJhbmdlOjc1OTAyNTE4Yjg4YjQ5NmY5YTNjYWU1MGM4MjIzYmM0XzIxLTMtMS0xLTA_ce59f52d-be12-4d48-9558-598c02a4d6f3">50</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Right-of-use assets obtained in exchange for lease liabilities:</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating leases</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo3NTkwMjUxOGI4OGI0OTZmOWEzY2FlNTBjODIyM2JjNC90YWJsZXJhbmdlOjc1OTAyNTE4Yjg4YjQ5NmY5YTNjYWU1MGM4MjIzYmM0XzI0LTEtMS0xLTA_04c8cdec-ada9-49c3-be31-4669e87ee4d4">7,652</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo3NTkwMjUxOGI4OGI0OTZmOWEzY2FlNTBjODIyM2JjNC90YWJsZXJhbmdlOjc1OTAyNTE4Yjg4YjQ5NmY5YTNjYWU1MGM4MjIzYmM0XzI0LTMtMS0xLTA_772ab570-7826-4184-b99c-e1aa3264a678">15,417</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Weighted Average Remaining Lease Term</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating leases</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo3NTkwMjUxOGI4OGI0OTZmOWEzY2FlNTBjODIyM2JjNC90YWJsZXJhbmdlOjc1OTAyNTE4Yjg4YjQ5NmY5YTNjYWU1MGM4MjIzYmM0XzMxLTEtMS0xLTA_4222f497-0d48-4507-a9ff-10534c879d2b">7.06</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i2db2c0d074c34657a5d523b0ae1e5784_I20190630" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo3NTkwMjUxOGI4OGI0OTZmOWEzY2FlNTBjODIyM2JjNC90YWJsZXJhbmdlOjc1OTAyNTE4Yjg4YjQ5NmY5YTNjYWU1MGM4MjIzYmM0XzMxLTMtMS0xLTA_a4a5e2e9-df75-4e84-9e6c-bf8a9c3108e5">6.87</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Finance leases</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo3NTkwMjUxOGI4OGI0OTZmOWEzY2FlNTBjODIyM2JjNC90YWJsZXJhbmdlOjc1OTAyNTE4Yjg4YjQ5NmY5YTNjYWU1MGM4MjIzYmM0XzMyLTEtMS0xLTA_66175ec0-0598-40ab-b0d8-7493fcae60c0">4.17</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i2db2c0d074c34657a5d523b0ae1e5784_I20190630" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo3NTkwMjUxOGI4OGI0OTZmOWEzY2FlNTBjODIyM2JjNC90YWJsZXJhbmdlOjc1OTAyNTE4Yjg4YjQ5NmY5YTNjYWU1MGM4MjIzYmM0XzMyLTMtMS0xLTA_77b8ea9a-ce20-4edf-998b-3976aac40450">5.00</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Weighted Average Discount Rate</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating leases</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo3NTkwMjUxOGI4OGI0OTZmOWEzY2FlNTBjODIyM2JjNC90YWJsZXJhbmdlOjc1OTAyNTE4Yjg4YjQ5NmY5YTNjYWU1MGM4MjIzYmM0XzM2LTEtMS0xLTA_fe0ef567-0a3c-48b2-9e47-5349492f5bdd">6.10</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i2db2c0d074c34657a5d523b0ae1e5784_I20190630" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo3NTkwMjUxOGI4OGI0OTZmOWEzY2FlNTBjODIyM2JjNC90YWJsZXJhbmdlOjc1OTAyNTE4Yjg4YjQ5NmY5YTNjYWU1MGM4MjIzYmM0XzM2LTMtMS0xLTA_75dffe4f-6e74-414f-aaa8-e9a4970516e8">6.18</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Finance leases</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="4" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo3NTkwMjUxOGI4OGI0OTZmOWEzY2FlNTBjODIyM2JjNC90YWJsZXJhbmdlOjc1OTAyNTE4Yjg4YjQ5NmY5YTNjYWU1MGM4MjIzYmM0XzM3LTEtMS0xLTA_ca6cedfa-197d-42da-8965-87b44c58352c">3.00</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i2db2c0d074c34657a5d523b0ae1e5784_I20190630" decimals="4" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo3NTkwMjUxOGI4OGI0OTZmOWEzY2FlNTBjODIyM2JjNC90YWJsZXJhbmdlOjc1OTAyNTE4Yjg4YjQ5NmY5YTNjYWU1MGM4MjIzYmM0XzM3LTMtMS0xLTA_064ca8f8-e88d-489c-9872-a34e1b494584">3.00</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div></ix:continuation></ix:continuation></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><ix:continuation id="if62938737b3b4bbca08abc5014634cac"><ix:continuation id="i147d42f3376b4c98a7e0669ec79c1d76"><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90ZXh0cmVnaW9uOjBiNjNjZGMyNTJlYzQ3Y2E4YjQ3MWY3YzIyOTIzYmJjXzEwMzc_98db1a1e-d15b-4c21-b289-18edb9e9f0b3" escape="true"><ix:nonNumeric contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90ZXh0cmVnaW9uOjBiNjNjZGMyNTJlYzQ3Y2E4YjQ3MWY3YzIyOTIzYmJjXzEwNDM_68ff79b1-4b18-4379-8733-803f4b6f99a5" escape="true"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Future minimum lease payments under non-cancellable leases as of June&#160;30, 2020 is as follows (in thousands):</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:70.620%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.323%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.325%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Operating Leases</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Finance Leases</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020 (excluding the six months ended June 30, 2020)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZToxYjc0YmUxZWExMWI0OTU0YTBjNzQ5OGQxY2M3YjQ2Yi90YWJsZXJhbmdlOjFiNzRiZTFlYTExYjQ5NTRhMGM3NDk4ZDFjYzdiNDZiXzEtMS0xLTEtMA_6fb64b63-18b2-457d-8f87-d5e79c5823a0">2,337</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZToxYjc0YmUxZWExMWI0OTU0YTBjNzQ5OGQxY2M3YjQ2Yi90YWJsZXJhbmdlOjFiNzRiZTFlYTExYjQ5NTRhMGM3NDk4ZDFjYzdiNDZiXzEtMy0xLTEtMA_54cad65b-53e2-4cb4-9d2a-1d9cd47ed83f">59</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZToxYjc0YmUxZWExMWI0OTU0YTBjNzQ5OGQxY2M3YjQ2Yi90YWJsZXJhbmdlOjFiNzRiZTFlYTExYjQ5NTRhMGM3NDk4ZDFjYzdiNDZiXzItMS0xLTEtMA_2763262d-d623-47fe-a87d-63f050d0bf12">4,297</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZToxYjc0YmUxZWExMWI0OTU0YTBjNzQ5OGQxY2M3YjQ2Yi90YWJsZXJhbmdlOjFiNzRiZTFlYTExYjQ5NTRhMGM3NDk4ZDFjYzdiNDZiXzItMy0xLTEtMA_7da4f434-978d-4939-86c8-ba65a6e5702b">119</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZToxYjc0YmUxZWExMWI0OTU0YTBjNzQ5OGQxY2M3YjQ2Yi90YWJsZXJhbmdlOjFiNzRiZTFlYTExYjQ5NTRhMGM3NDk4ZDFjYzdiNDZiXzMtMS0xLTEtMA_59d4f026-93b0-4e7c-a7d3-3cd2498add14">3,529</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZToxYjc0YmUxZWExMWI0OTU0YTBjNzQ5OGQxY2M3YjQ2Yi90YWJsZXJhbmdlOjFiNzRiZTFlYTExYjQ5NTRhMGM3NDk4ZDFjYzdiNDZiXzMtMy0xLTEtMA_5ef13070-4428-4071-a054-794425d808e3">119</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZToxYjc0YmUxZWExMWI0OTU0YTBjNzQ5OGQxY2M3YjQ2Yi90YWJsZXJhbmdlOjFiNzRiZTFlYTExYjQ5NTRhMGM3NDk4ZDFjYzdiNDZiXzQtMS0xLTEtMA_e8f72467-8375-49dc-bf22-028f0f43c74f">3,303</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZToxYjc0YmUxZWExMWI0OTU0YTBjNzQ5OGQxY2M3YjQ2Yi90YWJsZXJhbmdlOjFiNzRiZTFlYTExYjQ5NTRhMGM3NDk4ZDFjYzdiNDZiXzQtMy0xLTEtMA_e584c192-4838-4d71-babf-5d224b33c198">119</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZToxYjc0YmUxZWExMWI0OTU0YTBjNzQ5OGQxY2M3YjQ2Yi90YWJsZXJhbmdlOjFiNzRiZTFlYTExYjQ5NTRhMGM3NDk4ZDFjYzdiNDZiXzUtMS0xLTEtMA_4842817c-749a-4056-a806-95e9bd20a890">2,940</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZToxYjc0YmUxZWExMWI0OTU0YTBjNzQ5OGQxY2M3YjQ2Yi90YWJsZXJhbmdlOjFiNzRiZTFlYTExYjQ5NTRhMGM3NDk4ZDFjYzdiNDZiXzUtMy0xLTEtMA_22f161aa-6034-467e-8c90-6c060bd70bd3">79</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Thereafter</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="ameh:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZToxYjc0YmUxZWExMWI0OTU0YTBjNzQ5OGQxY2M3YjQ2Yi90YWJsZXJhbmdlOjFiNzRiZTFlYTExYjQ5NTRhMGM3NDk4ZDFjYzdiNDZiXzYtMS0xLTEtMA_84e38a34-c18a-450e-baf6-801f91c67b04">9,459</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:zerodash" name="ameh:FinanceLeaseLiabilityToBePaidAfterYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZToxYjc0YmUxZWExMWI0OTU0YTBjNzQ5OGQxY2M3YjQ2Yi90YWJsZXJhbmdlOjFiNzRiZTFlYTExYjQ5NTRhMGM3NDk4ZDFjYzdiNDZiXzYtMy0xLTEtMA_dfd99f5c-64ad-4598-b5eb-6c12d66c8899">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total future minimum lease payments</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZToxYjc0YmUxZWExMWI0OTU0YTBjNzQ5OGQxY2M3YjQ2Yi90YWJsZXJhbmdlOjFiNzRiZTFlYTExYjQ5NTRhMGM3NDk4ZDFjYzdiNDZiXzgtMS0xLTEtMA_e75ebab3-f137-498e-a748-99082057113a">25,865</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZToxYjc0YmUxZWExMWI0OTU0YTBjNzQ5OGQxY2M3YjQ2Yi90YWJsZXJhbmdlOjFiNzRiZTFlYTExYjQ5NTRhMGM3NDk4ZDFjYzdiNDZiXzgtMy0xLTEtMA_f8a56121-c0cc-4686-b707-a4c44ac38242">495</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Less: imputed interest</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZToxYjc0YmUxZWExMWI0OTU0YTBjNzQ5OGQxY2M3YjQ2Yi90YWJsZXJhbmdlOjFiNzRiZTFlYTExYjQ5NTRhMGM3NDk4ZDFjYzdiNDZiXzktMS0xLTEtMA_10435b48-5360-451b-bbae-8d89cacfaffa">5,097</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZToxYjc0YmUxZWExMWI0OTU0YTBjNzQ5OGQxY2M3YjQ2Yi90YWJsZXJhbmdlOjFiNzRiZTFlYTExYjQ5NTRhMGM3NDk4ZDFjYzdiNDZiXzktMy0xLTEtMA_f20025f9-cd39-439c-8785-5a361ef68939">38</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total lease liabilities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZToxYjc0YmUxZWExMWI0OTU0YTBjNzQ5OGQxY2M3YjQ2Yi90YWJsZXJhbmdlOjFiNzRiZTFlYTExYjQ5NTRhMGM3NDk4ZDFjYzdiNDZiXzEwLTEtMS0xLTA_5fe9a787-dbc0-4096-bb79-492b6cb204ff">20,768</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" name="us-gaap:FinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZToxYjc0YmUxZWExMWI0OTU0YTBjNzQ5OGQxY2M3YjQ2Yi90YWJsZXJhbmdlOjFiNzRiZTFlYTExYjQ5NTRhMGM3NDk4ZDFjYzdiNDZiXzEwLTMtMS0xLTA_4265d6df-86bd-4f62-a1ef-6e2418fb732d">457</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Less: current portion</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZToxYjc0YmUxZWExMWI0OTU0YTBjNzQ5OGQxY2M3YjQ2Yi90YWJsZXJhbmdlOjFiNzRiZTFlYTExYjQ5NTRhMGM3NDk4ZDFjYzdiNDZiXzExLTEtMS0xLTA_fba17a9b-ec62-49cc-baa1-bd92494c7bed">3,350</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZToxYjc0YmUxZWExMWI0OTU0YTBjNzQ5OGQxY2M3YjQ2Yi90YWJsZXJhbmdlOjFiNzRiZTFlYTExYjQ5NTRhMGM3NDk4ZDFjYzdiNDZiXzExLTMtMS0xLTA_cb52c3d3-df40-4052-ba28-281fab8a552f">102</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Long-term lease liabilities</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZToxYjc0YmUxZWExMWI0OTU0YTBjNzQ5OGQxY2M3YjQ2Yi90YWJsZXJhbmdlOjFiNzRiZTFlYTExYjQ5NTRhMGM3NDk4ZDFjYzdiNDZiXzEyLTEtMS0xLTA_5c96e86c-40a6-4a38-ad95-e8a5c33502cf">17,418</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bce3c5038344323935db8cc2710a157_I20200630" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZToxYjc0YmUxZWExMWI0OTU0YTBjNzQ5OGQxY2M3YjQ2Yi90YWJsZXJhbmdlOjFiNzRiZTFlYTExYjQ5NTRhMGM3NDk4ZDFjYzdiNDZiXzEyLTMtMS0xLTA_b9d838d4-fbaa-451f-9428-abd2a5a4cdf0">355</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, the Company does not have additional operating and finance leases that have not yet commenced.</span></div></ix:continuation></ix:continuation><div id="icc5d6783c1494a1f886c03c93e398cee_115"></div><div style="text-align:justify;margin-top:10pt;"><span><br/></span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM 2.&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">The following management&#8217;s discussion and analysis should be read in conjunction with the unaudited consolidated financial statements and the notes thereto included in Part I, Item 1, &#8220;Financial Statements&#8221; of this Quarterly Report on Form 10-Q. In addition, reference is made to our audited consolidated financial statements and notes thereto and related Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December&#160;31, 2019, filed with the SEC on March 16, 2020.</span></div><div id="icc5d6783c1494a1f886c03c93e398cee_118"></div><div style="text-align:justify;margin-top:10pt;"><span><br/></span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Overview</span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We, together with our affiliated physician groups and consolidated entities, are a physician-centric integrated population health management company providing coordinated, outcomes-based medical care in a cost-effective manner and serving patients in California, the majority of whom are covered by private or public insurance provided through Medicare, Medicaid and HMOs, with a small portion of our revenues coming from non-insured patients. We provide care coordination services to each major constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups and health plans. Our physician network consists of primary care physicians, specialist physicians and hospitalists. We operate primarily through ApolloMed and the following subsidiaries: NMM, AMM, APAACO and Apollo Care Connect, and their consolidated entities.</span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Through our NGACO model and a network of IPAs with more than 7,000 contracted physicians, which physician groups have agreements with various health plans, hospitals and other HMOs, we are, as of June 30, 2020, currently responsible for coordinating the care for approximately 1.1 million patients in California as of June&#160;30, 2020. These covered patients are comprised of managed care members whose health coverage is provided through their employers or who have acquired health coverage directly from a health plan or as a result of their eligibility for Medicaid or Medicare benefits. Our managed patients benefit from an integrated approach that places physicians at the center of patient care and utilizes sophisticated risk management techniques and clinical protocols to provide high-quality, cost effective care. To implement a patient-centered, physician-centric experience, we also have other integrated and synergistic operations, including (i) MSOs that provide management and other services to our affiliated IPAs, (ii) outpatient clinics and (iii) hospitalists that coordinate the care of patients in hospitals.</span></div><div id="icc5d6783c1494a1f886c03c93e398cee_121"></div><div style="text-align:justify;margin-top:10pt;"><span><br/></span></div><div id="icc5d6783c1494a1f886c03c93e398cee_124"></div><div style="text-align:justify;margin-top:10pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Key Financial Measures and Indicators</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Operating Revenues</span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our revenue primarily consists of capitation revenue, risk pool settlements and incentives, NGACO AIPBP revenue, management fee income and FFS revenue. The form of billing and related risk of collection for such services may&#160;vary by type of revenue and the customer.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Operating Expenses</span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our largest expense is the patient care cost paid to contracted physicians, and the cost of providing management and administrative support services to our affiliated physician groups. These services include providing utilization and case management, physician practice billing, revenue cycle services, physician practice management, administrative oversight, coding services, and other consulting services.</span></div><div id="icc5d6783c1494a1f886c03c93e398cee_127"></div><div style="margin-top:10pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Results of Operations</span></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Apollo Medical Holdings, Inc.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Consolidated Statements of Income</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(In thousands)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(Unaudited)</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:43.534%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.469%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.323%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.741%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">For the Three Months Ended</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">$ Change</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">% Change</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Revenue</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Capitation, net</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">140,949&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">103,224&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,725&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Risk pool settlements and incentives</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,003&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,191&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">812&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Management fee income</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,690&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,353&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,663)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(16)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Fee-for-services, net</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,270&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,878&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,608)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(41)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other income</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,257&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,404&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(147)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total revenue</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">165,169&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">130,050&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35,119&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Operating expenses</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cost of services</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">136,079&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101,363&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34,716&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">General and administrative expenses</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,556&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,818&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(262)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Depreciation and amortization</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,628&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,455&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">173&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Provision for doubtful accounts</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,314)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,314&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(100)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total expenses</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">152,263&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">115,322&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,941&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income from operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,906&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,728&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,822)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(12)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Income (loss) from equity method investments</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">834&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(42)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">876&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gain on sale of equity method investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">99,647&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">99,647&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Interest expense</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,673)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(311)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,362)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Interest income</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">863&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">474&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">389&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">82&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other income</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,282&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,258&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total other income, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">99,953&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">145&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">99,808&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Income before provision for income taxes</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">112,859&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,873&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">97,986&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Provision for income taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31,858&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,209&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27,649&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">81,001&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,664&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">70,337&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:20.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net income attributable to noncontrolling interests</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73,957&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,119&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">66,838&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Net income attributable to ApolloMed</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,044&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,545&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,499&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">99&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">*&#160;Percentage change of over 500%</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"><tr><td style="width:1.0%;"></td><td style="width:43.441%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.382%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.382%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.794%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.796%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">For the Six Months Ended</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">$ Change</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">% Change</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Revenue</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Capitation, net</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">281,370&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">174,740&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">106,630&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">61&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Risk pool settlements and incentives</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,239&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,285&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,954&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Management fee income</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,505&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,349&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,844)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Fee-for-services, net</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,697&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,959&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,262)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(28)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other income</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,463&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,473&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total revenue</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">330,274&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">225,806&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">104,468&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Operating expenses</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cost of services</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">280,283&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">184,795&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">95,488&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">52&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">General and administrative expenses</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,390&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,081&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,309&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Depreciation and amortization</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,330&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,872&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">458&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Provision for doubtful accounts</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,363)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,363&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(100)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total expenses</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">313,003&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">214,385&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">98,618&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income from operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,271&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,421&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,850&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Other income (expense)</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Income (loss) from equity method investments</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,888&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(892)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,780&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gain on sale of equity method investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">99,647&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">99,647&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Interest expense</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5,541)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(522)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5,019)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Interest income</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,792&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">797&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">995&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">125&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other income</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,384&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">211&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,173&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total other income (expense), net</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100,170&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(406)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100,576&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Income before provision for income taxes</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">117,441&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,015&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">106,426&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Provision for income taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33,453&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,801&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30,652&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">83,988&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,214&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75,774&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:20.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net income attributable to noncontrolling interests</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">72,892&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,529&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">68,363&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Net income attributable to ApolloMed</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,096&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,685&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,411&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">201&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">*&#160;Percentage change of over 500%</span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Net Income Attributable to ApolloMed</span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our net income attributable to ApolloMed for the three months ended June&#160;30, 2020 was $7.0 million, as compared to net income attributable to ApolloMed of $3.5 million for the same period in 2019, an increase of $3.5 million. </span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our net income attributable to ApolloMed for the six months ended June&#160;30, 2020 was $11.1 million, as compared to net income attributable to ApolloMed of $3.7 million for the same period in 2019, an increase of $7.4 million. </span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The increase in net income attributable to ApolloMed for the three and six months ended June 30, 2020 was primarily driven by the completion of a series of transactions with APC as further described in Note 1 to our financial statements above, which resulted in preferred, cumulative dividends from APC being allocated to AP-AMH.</span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Physician Groups and Patients</span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020 and 2019, we managed a total of 13 and 11 groups of affiliated physicians, respectively, and the total number of patients for whom we managed the delivery of healthcare services was approximately 1.1 million and 1.0 million, respectively. The increase was attributable to a management services agreement we entered with an independent practice association, Community Family Care Medical Group IPA, Inc. ("CFC"), which contributed 0.1 million new members and increased membership at the other physician groups we manage.</span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our revenue for the three months ended June&#160;30, 2020, was $165.2 million, as compared to $130.1 million for the three months ended June&#160;30, 2019, an increase of $35.1 million, or 27%. The increase in revenue was primarily attributable to the following:</span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(i) Capitation revenue increased by approximately $37.7 million primarily due to our acquisitions of Alpha Care on May 31, 2019 and Accountable Health Care on August 30, 2019, which contributed additional revenue of approximately $20.7 million and $11.8 million, respectively, in addition to organic capitation revenue growth at APC of $2.5 million, for the three months ended June&#160;30, 2020. Further, APA ACO generated additional capitation revenue of approximately $2.7 million for the three months ended June&#160;30, 2020 as compared to June 30, 2019 due to the delayed start of 2019 APA ACO performance year.</span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(ii) Risk pool revenue increased by $0.8 million due to the refinement of the assumptions used to estimate the amount of net surplus expected to be received from the affiliated hospitals&#8217; risk pools. Our estimated risk pool receivable is calculated based on reports received from our hospital partners and on management&#8217;s estimate of the Company&#8217;s portion of any estimated risk pool surpluses for which payments have not been received. The actual risk pool surpluses are settled approximately 18 months later.</span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(iii) Management fee income decreased by $1.7 million mainly due to acquisition of Accountable Health Care, which reduced management fee income by $2.2 million and a decrease in LMA's management fee of $1.0 million. This decrease was offset by management fee income of $1.7 million for the three months ended June 30, 2020 generated from the management services agreement we entered into with CFC, which became effective on January 1, 2020.</span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(iv) Fee-for-service revenue decreased by $1.6 million due to reduced demand at our surgery centers and heart center as a result of the COVID-19 outbreak.</span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(v) Other income decreased by $0.1 million as a result of decreased revenue related to maternity supplemental payments.</span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our revenue for the six months ended June&#160;30, 2020 was $330.3 million, as compared to $225.8 million for the six months ended June&#160;30, 2019, an increase of $104.5 million, or 46%. The increase in revenue was primarily attributable to the following:</span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(i) Capitation revenue increased by approximately $106.6 million primarily due to our acquisitions of Alpha Care on May 31, 2019 and Accountable Health Care on August 30, 2019, which contributed additional revenue of approximately $53.2 million and $24.3 million, respectively, in addition to organic capitation revenue growth at APC of $4.5 million, for the six months ended June&#160;30, 2020. Further, APA ACO generated additional capitation revenue of approximately $24.6 million for the six months ended June 30, 2020 as compared June 30, 2019 due to the delayed start of the 2019 APA ACO performance year.</span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(ii) Risk pool revenue increased by $2.0 million due to the refinement of the assumptions used to estimate the amount of net surplus expected to be received from the affiliated hospitals&#8217; risk pools. Our estimated risk pool receivable is calculated based on reports received from our hospital partners and on management&#8217;s estimate of the Company&#8217;s portion of any estimated risk pool surpluses for which payments have not been received. The actual risk pool surpluses are settled approximately 18 months later.</span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(iii) Management fee income decreased by $1.8 million mainly due to the acquisition of Accountable Health Care, which reduced management fee income by $4.2 million and a reduction in hospitalist stipend of $1.0 million. This decrease was offset by management fee income of $3.4 million for the six months ended June 30, 2020 generated from the management services agreement we entered into with CFC, which became effective on January 1, 2020.</span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(iv) Fee-for-service revenue decreased by $2.3 million due to reduced procedures performed at our surgery centers and heart center as a result of the COVID-19 outbreak.</span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cost of Services</span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Expenses related to cost of services for the three months ended June&#160;30, 2020, were $136.1 million, as compared to $101.4 million for the same period in 2019, an increase of $34.7 million, or 34%. The overall increase was due to a $32.8 million increase in medical claims, capitation and other health services expenses, primarily driven by the acquisitions of Alpha Care, Accountable Health Care and AMG and a $1.9 million increase in payroll costs to support the continued growth of the business.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Expenses related to cost of services for the six months ended June&#160;30, 2020, were $280.3 million, as compared to $184.8 million for the same period in 2019, an increase of $95.5 million, or 52%. The overall increase was due to a $99.3 million increase in medical claims, capitation and other health services expenses, primarily driven by the acquisition of Alpha Care, Accountable Health Care and AMG, in addition to increased costs at APA ACO for the six month period ended June 30, 2020 as compared to the same period in 2019 due to the delayed start of the 2019 APA ACO performance year and a $4.2 million increase in payroll costs to support the continued growth of the business. The increased costs were offset by a net decrease of $8.0 million in bonus payments made to providers for the six months ended June 30, 2020 as compared to the bonus payments made to providers during the same period in 2019.</span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">General and Administrative Expenses</span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">General and administrative expenses for the three months ended June&#160;30, 2020, were $11.6 million, as compared to $11.8 million for the same period in 2019, a decrease of $0.2 million, or 2%. The decrease is primarily due to fewer supplies required as COVID-19 outbreak caused a reduction of procedures performed on site at the surgery centers and heart centers. </span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">General and administrative expenses for the six months ended June&#160;30, 2020 were $23.4 million, as compared to $22.1 million for the same period in 2019, an increase of $1.3 million, or 6%. The increase is primarily due to increased rent expense to support the continued growth in depth and breadth of our operations.</span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Depreciation and Amortization</span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Depreciation and amortization expenses for the three months ended June&#160;30, 2020 were $4.6 million as compared to $4.5 million for the same period in 2019. This amount includes depreciation of property and equipment and the amortization of intangible assets.</span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Depreciation and amortization expenses for the six months ended June&#160;30, 2020 were $9.3 million as compared to $8.9 million for the same period in 2019. This amount includes depreciation of property and equipment and the amortization of intangible assets.</span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Provision for Doubtful Accounts</span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three and six months ended June&#160;30, 2019, we released reserves related to certain management fees in the amount of approximately $2.3 million and $1.4 million, respectively, as collectability of the outstanding amount was no longer in doubt. These reserves were related to various preacquisition obligations of Accountable Health Care and were no longer necessary as a result of our acquisition of Accountable Health Care. </span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Income (Loss) from Equity Method Investments</span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Income from equity method investments for the three months ended June&#160;30, 2020, was $0.8 million, as compared to loss from equity method investments of $42,000 for the same period in 2019, an increase of $0.9 million. The increase was primarily due to equity earnings from UCI of $0.9 million.</span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Income from equity method investments for the six months ended June&#160;30, 2020, was $2.9 million, as compared to loss from equity method investments of $0.9 million for the same period in 2019, an increase of $3.8 million. The increase was primarily due to equity earnings from our investments in UCI and PMIOC of $3.5 million and $0.1 million, respectively, offset by equity losses from our investments in LMA's IPA line of business, 531 W. College, and DMG of $0.4 million, $0.2 million, and $0.1 million, respectively, for the six months ended June 30, 2020, as compared with losses from our investments in LMA's IPA line of business and Accountable Health Care of $2.4 million and $4.3 million, respectively, in the six months ended June 30, 2019. In addition to the recognition of an impairment loss of $0.3 million related to our investment in PASC. These losses were offset with earnings from our investments in UCI, DMG, and PMIOC of $5.5 million, $0.4 million, and $0.2 million, respectively. </span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Gain on Sale of Equity Method Investments</span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Gain from equity method investments for the three and six months ended June&#160;30, 2020, was $99.6 million primarily due to the sale of UCI which closed on April 30, 2020.</span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Interest Expense</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Interest expense for the three months ended June&#160;30, 2020, was $2.7 million, as compared to $0.3 million for the same period in 2019, an increase of $2.4 million. The increase was primarily due to the new credit facility we secured in September 2019 to fund growth, primarily through acquisitions.</span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Interest expense for the six months ended June&#160;30, 2020, was $5.5 million, as compared to $0.5 million for the same period in 2019, an increase of $5.0 million. The increase was primarily due to the new credit facility we secured in September 2019 to fund growth, primarily through acquisitions.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Interest Income</span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Interest income for the three and six months ended June&#160;30, 2020, was $0.9 million and $1.8 million, respectively, as compared to $0.5 million and $0.8 million, respectively, for the three and six months ended June&#160;30, 2019. Interest income reflects interest earned on cash held in money market and certificate of deposit accounts and the interest from notes receivable.</span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other Income</span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other income for the three and six months ended June&#160;30, 2020, was $1.3 million and $1.4 million as compared to other income of $24,000 and $0.2 million, respectively, for the same periods in 2019. The increase in other income was primarily due to government grants received during the three and six months ended June 30, 2020 of $0.9 million. </span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Provision for Income Tax</span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Income tax expense was $31.9 million for the three months ended June&#160;30, 2020, as compared to a tax provision of $4.2 million for the same period in 2019. The increase in tax expense was due to increased income in the three months ended June&#160;30, 2020, period as compared to the same period in 2019, as described above.</span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Income tax expense was $33.5 million for the six months ended June&#160;30, 2020, as compared to a tax provision of $2.8 million for the same period in 2019. The increase in tax expense was due to increased income in the six months ended June&#160;30, 2020 period as compared to the same period in 2019, as described above.</span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Net Income Attributable to Noncontrolling Interests</span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net income attributable to noncontrolling interests was $74.0 million for the three months ended June&#160;30, 2020, compared to $7.1 million for the same period in 2019, an increase of $66.9 million. The increase was primarily due to our sale of equity interests in UCI in April 2020, the gain from which constitutes an excluded asset of APC.</span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net income attributable to noncontrolling interests was $72.9 million for the six months ended June&#160;30, 2020, compared to $4.5 million for the same period in 2019, an increase of $68.4 million. The increase was primarily due to of sale of an excluded asset, UCI in April 2020 where the gain remains strictly with APC.</span></div><div id="icc5d6783c1494a1f886c03c93e398cee_130"></div><div style="margin-top:5pt;margin-bottom:5pt;"><span><br/></span></div><div style="margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">2020 Guidance</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Our stable, subscription-based revenue model allows us to maintain our previously disclosed 2020 guidance for total revenue and adjusted Earnings Before Interest, Taxes, Depreciation and Amortization (&#8220;EBITDA&#8221;). </span></div><div style="margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Our guidance for the year ending December 31, 2020, is as follows:</span></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Maintain total revenue of between $665.0 million and $675.0 million,</span></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Maintain net income of between $100.0 million and $110.0 million,</span></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Maintain EBITDA of between $155.0 million and $167.0 million, and</span></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Maintain adjusted EBITDA of between $75.0 million and $90.0 million.</span></div><div style="text-align:justify;margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Refer to the "Guidance Reconciliation of Net Income to EBITDA and adjusted EBITDA</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">"</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> and "Use of Non-GAAP Financial Measures</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">"</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> for additional information. There can be no assurance that actual amounts will not be materially higher or lower than these expectations. Refer to our discussion of "Forward-Looking Statements" within this Quarterly Report on Form 10-Q.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><div style="text-align:center;margin-top:5pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:66.035%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.249%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.250%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA (in thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Year Ending</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">December 31, 2020</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Low</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">High</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Net income</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">110,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Provision for income taxes</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Interest expense</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Interest income</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,000)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,000)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">EBITDA</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">155,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">167,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#160;&#160;&#160;&#160;&#160;Income from equity method investments </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(2)</sup></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(95,000)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(94,000)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;EBITDA adjustment for recently acquired IPAs</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjusted EBITDA</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">90,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(1) </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net income and EBITDA includes the gain on sale of UCAP's 48.9% investment in UCI to Bright, which closed on April 30, 2020. UCAP is a 100% owned subsidiary of APC and its 48.9% investment in UCI is an excluded asset and as such remained solely for the benefit of APC and its shareholders. As such, any proceeds or gain on sale has not affected the net income and adjusted EBITDA attributable to ApolloMed.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(2)&#160;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Income from equity method investments is mainly attributed to the sale of UCAP's 48.9% investment in UCI to Bright, which closed on April 30, 2020. UCAP is a 100% owned subsidiary of APC and its 48.9% investment in UCI is an excluded asset and as such remained solely for the benefit of APC and its shareholders. As such, any proceeds or gain on sale has not affected the net income and adjusted EBITDA attributable to ApolloMed.</span></div><div style="text-align:center;"><span><br/></span></div><div style="margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%;">Use of Non-GAAP Financial Measures</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;">This Quarterly Report on Form 10-Q contains the non-GAAP financial measures EBITDA and adjusted EBITDA, of which the most directly comparable financial measure presented in accordance with GAAP is net (loss) income. These measures are not in accordance with, or an alternative to, U.S. generally accepted accounting principles, (&#8220;GAAP&#8221;), and may be different from other non-GAAP financial measures used by other companies. The Company uses adjusted EBITDA as a supplemental performance measure of our operations,&#160;for financial and operational decision-making, and as a supplemental means of evaluating period-to-period comparisons on a consistent basis. Adjusted EBITDA is calculated as earnings before interest, taxes, depreciation, and amortization, excluding income from equity method investments and other income earned that is not related to the Company's normal operations. Adjusted EBITDA also excludes the effect on EBITDA of certain IPAs we recently acquired. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;">The Company believes the presentation of these non-GAAP financial measures provides investors with relevant and useful information as it allows investors to evaluate the operating performance of the business activities without having to account for differences recognized because of non-core and non-recurring financial information. When GAAP financial measures are viewed in conjunction with non-GAAP financial measures, investors are provided with a more meaningful understanding of ApolloMed's ongoing operating performance. In addition, these non-GAAP financial measures are among those indicators the Company uses as a basis for evaluating operational performance, allocating resources and planning and forecasting future periods. Non-GAAP financial measures are not intended to be considered in isolation, or as a substitute for, GAAP financial measures. To the extent this release contains historical or future non-GAAP financial measures, the Company has provided corresponding GAAP financial measures for comparative purposes. The reconciliation between certain GAAP and non-GAAP measures is provided above.</span></div><div id="icc5d6783c1494a1f886c03c93e398cee_133"></div><div style="text-align:justify;margin-top:10pt;"><span><br/></span></div><div style="text-align:justify;margin-top:10pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Liquidity and Capital Resources</span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash, cash equivalents and investment in marketable securities at June&#160;30, 2020, totaled $270.1 million. Working capital totaled $228.0 million at June&#160;30, 2020, as compared to $223.7 million at December&#160;31, 2019, an increase of $4.3 million, or 1.9%.</span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have historically financed our operations primarily through internally generated funds. We generate cash primarily from capitation contracts, risk pool settlements and incentives, fees for medical management services provided to our affiliated physician groups, as well as fee-for-service reimbursements. We generally invest cash in money market accounts, which are classified as cash and cash equivalents. We believe we have sufficient liquidity to fund our operations at least through the next 12 months.</span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our cash, cash equivalents and restricted cash increased by $49.2 million from $104.0 million at December&#160;31, 2019, to $153.2 million at June&#160;30, 2020. Cash generated by operating activities during the six months ended June&#160;30, 2020, was $12.6 million, as compared cash used of $22.0 million for the six months ended June 30, 2019. The cash provided by operations during the six months ended June&#160;30, 2020, is a function of net income of $84.0 million, adjusted for the following non-cash operating items: depreciation and amortization of $9.3 million, share-based compensation of $1.9 million, which were offset by a change in deferred tax liability of $4.5 million, gain on sale of equity method investment of $99.3 million and earnings from equity method investments of approximately $2.9 million. Our cash provided by operating activities included a net decrease in operating assets and liabilities of $23.7 million.</span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash generated from investing activities during the six months ended June&#160;30, 2020, was $67.2 million due primarily to the proceeds received related to the sale of UCI totaling $52.7 million and loan receivables of $16.5 million offset with cash outflow related to the purchase of marketable securities of $1.1 million, funding for an equity method investment of $0.5 million, and capital expenditures (mainly purchases of property and equipment) of $0.4 million. This is compared to cash used of $50.2 million for the six months ended June 30, 2019 due to payments for business acquisition of $41.5 million, advances on loans receivable of $6.4 million, funding for an equity method investment of $2.2 million, and capital expenditures of $0.4 million offset with dividends received of $0.3 million.</span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash used in financing activities during the six months ended June&#160;30, 2020, was $30.5 million as compared to cash provided by financing activities of $21.6 million for the six months ended June 30, 2019. Cash used for the six months ended June 30, 2020 was due to the payments of dividends totaling $30.2 million, repayment on our term loan totaling $2.4 million and repurchase of shares of $0.8 million, offset with proceeds from exercise of stock options and warrants of $2.9 million. This is compared to cash generated for the six months period ended June 30, 2019 due to proceeds from borrowings on our line of credit of $39.6 million, proceeds from the exercise of stock options and warrants of $0.9 million and proceeds from common stock offering of $0.2 million offset with payments of dividends and repayments on our bank loan and lines of credit totaling $10.9 million and $8.0 million, respectively.</span></div><div id="icc5d6783c1494a1f886c03c93e398cee_136"></div><div style="text-align:justify;margin-top:10pt;"><span><br/></span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Credit Facilities</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s credit facility consisted of the following (in thousands):</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:82.017%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.983%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Term loan A</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">185,250&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revolver loan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">60,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total debt</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">245,250&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Current portion of debt</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9,500)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Unamortized financing costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5,295)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term debt</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">230,455&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents scheduled commitments of the Company&#8217;s credit facility is to be as follows for the years ending </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">December 31</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  (in thousands):</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:82.017%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.983%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020 (excluding the six months ended June 30, 2020)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,125&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,688&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,250&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,437&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">197,750&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">245,250&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Credit Agreement</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In September 2019, the Company entered into a secured credit agreement (the &#8220;Credit Agreement,&#8221; and the credit facility thereunder, the "Credit Facility") with Truist Bank (formerly known as SunTrust Bank), in its capacity as administrative agent for the lenders (in such capacity, the &#8220;Agent&#8221;), as a lender, an issuer of letters of credit and as swingline lender, and Preferred Bank, JPMorgan Chase Bank, N.A., MUFG Union Bank, N.A., Royal Bank of Canada, Fifth Third Bank and City National Bank, as lenders (the &#8220;Lenders&#8221;). In connection with the closing of the Credit Agreement, the Company, its subsidiary, NMM, and the Agent entered into a Guaranty and Security Agreement (the &#8220;Guaranty and Security Agreement&#8221;), pursuant to which, among other things, NMM guaranteed the obligations of the Company under the Credit Agreement. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Credit Agreement provides for a five-year revolving credit facility to the Company of $100.0 million (&#8220;Revolver Loan&#8221;), which includes a letter of credit subfacility of up to $25.0 million. The Credit Agreement also provides for a term loan of $190.0 million, (&#8220;Term Loan A&#8221;). The unpaid principal amount of the term loan is payable in quarterly installments on the last day of each fiscal quarter commencing on December 31, 2019. The principal payment for each of the first eight fiscal quarters is $2.4 million, for the following eight fiscal quarters thereafter is $3.6 million and for the following three fiscal quarters thereafter is $4.8 million. The remaining principal payment on the term loan is due on September&#160;11, 2024.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The proceeds of the term loan and up to $60.0 million of the revolving credit facility were used to (i) finance a portion of the AP-AMH Loan, (ii) refinance certain indebtedness of the Company and its subsidiaries and, indirectly, APC, (iii) pay transaction costs and expenses arising in connection with the Credit Agreement, the AP-AMH Loan and certain other related transactions and (iv) provide for working capital, capital expenditures and other general corporate purposes. The remainder of the revolving credit facility will be used to finance future acquisitions and investments and to provide for working capital needs, capital expenditures and other general corporate purposes.</span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is required to pay an annual facility fee of 0.20% to 0.35% on the available commitments under the Credit Agreement, regardless of usage, with the applicable fee determined on a quarterly basis based on the Company&#8217;s leverage ratio. The Company is also required to pay customary fees as specified in a separate fee agreement between the Company and SunTrust Robinson Humphrey, Inc., the lead arranger of the Credit Agreement.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Amounts borrowed under the Credit Agreement will bear interest at an annual rate equal to either, at the Company&#8217;s option, (a) the rate for Eurocurrency deposits for the corresponding deposits of U.S. dollars appearing on Reuters Screen LIBOR01 Page (&#8220;LIBOR&#8221;), adjusted for any reserve requirement in effect, plus a spread of between 2.00% and 3.00%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio, or (b) a base rate, plus a spread between 1.00% and 2.00%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio. As of June&#160;30, 2020, the interest rate on Term Loan A and Revolver Loan was 3.57% and 3.24%, respectively. The base rate is defined in a manner such that it will not be less than LIBOR. The Company will pay fees for standby letters of credit at an annual rate of between 2.00% and 3.00%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio, plus facing fees and standard fees payable to the issuing bank on the respective letter of credit. Loans outstanding under the Credit Agreement may be prepaid at any time without penalty, except for LIBOR breakage costs and expenses. If LIBOR ceases to be reported, the Credit Agreement requires the Company and the Agent to endeavor to establish a commercially reasonable alternative rate of interest and until they are able to do so, all borrowings must be at the base rate.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Credit Agreement requires the Company and its subsidiaries to comply with various affirmative covenants, including, without limitation, furnishing updated financial and other information, preserving existence and entitlements, maintaining properties and insurance, complying with laws, maintaining books and records, requiring any new domestic subsidiary meeting a materiality threshold specified in the Credit Agreement to become a guarantor thereunder and paying obligations. The Credit Agreement requires the Company and its subsidiaries to comply with, and to use commercially reasonable efforts to the extent permitted by law to cause certain material associated practices of the Company, including APC, to comply with, restrictions on liens, indebtedness and investments (including restrictions on acquisitions by the Company), subject to specified exceptions. </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Credit Agreement also contains various other negative covenants binding the Company and its subsidiaries, including, without limitation, restrictions on fundamental changes, dividends and distributions, sales and leasebacks, transactions with affiliates, burdensome agreements, use of proceeds, maintenance of business, amendments of organizational documents, accounting changes and prepayments and modifications of subordinated debt.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Credit Agreement requires the Company to comply with two key financial ratios, each calculated on a consolidated basis. The Company must maintain a maximum consolidated leverage ratio of not greater than 3.75 to 1.00 as of the last day of each fiscal quarter. The maximum consolidated leverage ratio decreases by 0.25 each year, until it is reduced to 3.00 to 1.00 for each fiscal quarter ending after September&#160;30, 2022. The Company must maintain a minimum consolidated interest coverage ratio of not less than 3.25 to 1.00 as of the last day of each fiscal quarter. As of June&#160;30, 2020, the Company was in compliance with the covenants relating to its credit facility.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the Guaranty and Security Agreement, the Company and NMM have granted the Lenders a security interest in all of their assets, including, without limitation, all stock and other equity issued by their subsidiaries (including NMM) and all rights with respect to the AP-AMH Loan. The Guaranty and Security Agreement requires the Company and NMM to comply with various affirmative and negative covenants, including, without limitation, covenants relating to maintaining perfected security interests, providing information and documentation to the Agent, complying with contractual obligations relating to the collateral, restricting the sale and issuance of securities by their respective subsidiaries and providing the Agent access to the collateral.</span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Credit Agreement contains events of default, including, without limitation, failure to make a payment when due, default on various covenants in the Credit Agreement, breach of representations or warranties, cross-default on other material indebtedness, bankruptcy or insolvency, occurrence of certain judgments and certain events under the Employee Retirement Income Security Act of 1974 aggregating more than $10.0 million, invalidity of the loan documents, any lien under the Guaranty and Security Agreement ceasing to be valid and perfected, any change in control, as defined in the Credit Agreement, an event of default under the AP-AMH Loan, failure by APC to pay dividends in cash for any period of two consecutive fiscal quarters, failure by AP-AMH to pay cash interest to the Company, or if any modification is made to the Certificate of Determination or the Special Purpose Shareholder Agreement that directly or indirectly restricts, conditions, impairs, reduces or otherwise limits the payment of the Series A Preferred dividend by APC to AP-AMH. In addition, it will constitute an event of default under the Credit Agreement if APC uses all or any portion of the consideration received by APC from AP-AMH on account of AP-AMH&#8217;s purchase of Series A Preferred Stock for any purpose other than certain specific approved uses described in the following sentence, unless not less than 50.01% of all holders of common stock of APC at such time approve such use; provided that APC may use up to $50.0 million in the aggregate of such consideration for any purpose without any requirement to obtain such approval of the holders of common stock of APC. The approved uses include (i) any permitted investment, (ii) any dividend or distribution to the holders of the common stock of APC, (iii) any repurchase of common stock of APC, (iv) paying taxes relating to or arising from certain assets and transactions, or (v) funding losses, deficits or working capital support on account of certain non-healthcare assets in an amount not to exceed $125.0 million. If any event of default occurs and is continuing under the Credit Agreement, the Lenders may terminate their commitments, and may require the Company and its guarantors to repay outstanding debt and/or to provide a cash deposit as additional security for outstanding letters of credit. In addition, the Agent, on behalf of the Lenders, may pursue remedies under the Guaranty and Security Agreement, including, without limitation, transferring pledged securities of the Company&#8217;s subsidiaries in the name of the Agent and exercising all rights with respect thereto (including the right to vote and to receive dividends), collect on pledged accounts, instruments and other receivables (including the AP-AMH Loan), and all other rights provided by law or under the loan documents and the AP-AMH Loan.</span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the ordinary course of business, certain of the Lenders under the Credit Agreement and their affiliates have provided to the Company and its subsidiaries and the associated practices, and may in the future provide, (i) investment banking, commercial banking (including pursuant to certain existing business loan and credit agreements being terminated in connection with entering into the Credit Agreement), cash management, foreign exchange or other financial services, and (ii) services as a bond trustee and other trust and fiduciary services, for which they have received compensation and may receive compensation in the future.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Deferred Financing Costs</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In September 2019, the Company recorded deferred financing costs of $6.5 million related to the issuance of the Credit Facility. This amount was recorded as a direct reduction of the carrying amount of the related debt liability. The deferred financing costs will be amortized over the life of the Credit Facility using the effective interest rate method. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Effective Interest Rate</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s average effective interest rate on its total debt during the six months ended June&#160;30, 2020 and 2019, was 3.93% and 4.71%, respectively. Interest expense in the consolidated statements of income included amortization of deferred debt issuance costs for the three and six months ended June&#160;30, 2020 and 2019, of $0.3 million and $0, respectively, and $0.7 million and $0, respectively.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Lines of Credit &#8211; Related Party</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">NMM Business Loan</span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On June&#160;14, 2018, NMM amended its promissory note agreement with Preferred Bank (&#8220;NMM Business Loan Agreement&#8221;), which provides for loan availability of up to $20.0 million with a maturity date of June&#160;22, 2020. One of the Company&#8217;s board members is the chairman and CEO of Preferred Bank. The NMM Business Loan Agreement was subsequently amended on September&#160;1, 2018, to temporarily increase the loan availability from $20.0 million to $27.0 million for the period from September 1, 2018 through January 31, 2019, further extended to October&#160;31, 2019, to facilitate the issuance of an additional standby letter of credit for the benefit of CMS. The interest rate is based on the Wall Street Journal &#8220;prime rate,&#8221; plus 0.125%, or 5.625% as of December&#160;31, 2018. The loan was guaranteed by Apollo Medical Holdings, Inc. and is collateralized by substantially all of the assets of NMM. The amounts outstanding as of June&#160;30, 2019, of $5.0 million was fully repaid on September&#160;11, 2019.</span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On September&#160;5, 2018, NMM entered into a non-revolving line of credit agreement with Preferred Bank, which provides for loan availability of up to $20.0 million with a maturity date of September&#160;5, 2019. This credit facility was subsequently amended on April&#160;17, 2019, and July&#160;29, 2019, to reduce the loan availability from $20.0 million to $16.0 million and from $16.0 million to $2.2 million, respectively. The interest rate is based on the Wall Street Journal &#8220;prime rate,&#8221; plus 0.125%, or 3.375% as of June&#160;30, 2020, and 4.875% as of December&#160;31, 2019. The line of credit is guaranteed by Apollo Medical Holdings, Inc. and is collateralized by substantially all assets of NMM. NMM obtained this line of credit to finance potential acquisitions. Each drawdown from the line of credit is converted into a five-year term loan with monthly principal payments, plus interest based on a five-year amortization schedule.</span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On September 11, 2019, the NMM Business Loan Agreement, dated as of June&#160;14, 2018, between NMM and Preferred Bank, as amended, and the Line of Credit Agreement, dated as of September&#160;5, 2018, between NMM and Preferred Bank, as amended, were terminated in connection with the closing of the credit facility.&#160;Certain letters of credit issued by Preferred Bank under the Line of Credit Agreement were terminated and reissued under the Credit Agreement. As of June&#160;30, 2020,  outstanding letters of credit totaled $14.8 million and the Company has $10.2 million available under the revolving credit facility for letters of credit.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">APC Business Loan</span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On June&#160;14, 2018, APC amended its promissory note agreement with Preferred Bank, which provides for loan availability of up to $10.0 million with a maturity date of June&#160;22, 2020. This credit facility was subsequently amended on April&#160;17, 2019, and June&#160;11, 2019, to increase the loan availability from $10.0 million to $40.0 million and extend the maturity date through December&#160;31, 2020. On August&#160;1, 2019, and September&#160;10, 2019, this credit facility was further amended to increase loan availability from $40.0 million to $43.8 million, and decrease loan availability from $43.8 million to $4.1 million, respectively. This decrease further limited the purpose of the indebtedness under APC Business Loan Agreement to the issuance of standby letters of credit, and added as a permitted lien the security interest in all of its assets granted by APC in favor of NMM under a Security Agreement dated on or about September 11, 2019, securing APC&#8217;s obligations to NMM under, and as required pursuant to, the APC management services agreement dated as of July 1, 1999, as amended. The interest rate is based on the Wall Street Journal &#8220;prime rate,&#8221; plus 0.125%, or 3.375% and 4.875% as of June&#160;30, 2020, and December&#160;31, 2019, respectively. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020 and December&#160;31, 2019, there was no availability under this line of credit.</span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Intercompany Loans</span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Each of AMH, MMG, BAHA, Apollo Care Connect, AKM Medical Group, Inc. ("AKM") and SCHC has entered into an Intercompany Loan Agreement with AMM under which AMM has agreed to provide a revolving loan commitment to each such affiliated entities in an amount set forth in each Intercompany Loan Agreement. Each Intercompany Loan Agreement provides that AMM&#8217;s obligation to make any advances automatically terminates concurrently with the termination of the management agreement with the applicable affiliated entity. In addition, each Intercompany Loan Agreement provides that (i) any material breach by the shareholder of record of the applicable Physician Shareholder Agreement or (ii) the termination of </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">the management agreement with the applicable affiliated entity constitutes an event of default under the Intercompany Loan Agreement. All the intercompany loans have been eliminated in consolidation (in thousands).</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:19.732%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.334%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.306%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.362%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.187%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.362%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.313%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30, 2020</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Entity</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Facility</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest<br/>Rate<br/>per Annum</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Maximum</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Balance</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">During</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Period</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Ending</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Balance</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Principal Paid</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">During&#160;Period</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Interest</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Paid</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">During</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Period</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">AMH</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,193&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,193&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Apollo Care Connect</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,283&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,283&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">MMG</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,571&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,571&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">AKM</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">SCHC</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,940&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,940&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">BAHA</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">250&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,066&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,066&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,250&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,053&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,053&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div id="icc5d6783c1494a1f886c03c93e398cee_139"></div><div style="text-align:justify;margin-top:10pt;"><span><br/></span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Critical Accounting Policies and Estimates</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of financial statements and related disclosures in conformity with U.S. GAAP requires our management to make judgments, assumptions and estimates that affect the amounts of revenue, expenses, income, assets and liabilities, reported in our consolidated financial statements and accompanying notes. Actual results and the timing of recognition of such amounts could differ from those judgments, assumptions and estimates. In addition, judgments, assumptions and estimates routinely require adjustment based on changing circumstances and the receipt of new or better information. Understanding our accounting policies and the extent to which our management uses judgment, assumptions and estimates in applying these policies, therefore, is integral to understanding our financial statements. Critical accounting policies and estimates are defined as those that are reflective of significant judgments and uncertainties, and potentially result in materially different results under different assumptions and conditions.&#160;We summarize our most significant accounting policies in relation to the accompanying consolidated financial statements in Note 2 thereto. Please also refer to the Critical Accounting Policies section of Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2019.</span></div><div id="icc5d6783c1494a1f886c03c93e398cee_142"></div><div style="text-align:justify;margin-top:10pt;"><span><br/></span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">New Accounting Pronouncements</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See Note 2 to the accompanying consolidated financial statements for recently issued accounting pronouncements, including information on new accounting standards and the future adoption of such standards.</span></div><div style="text-align:justify;margin-top:10pt;"><span><br/></span></div><div id="icc5d6783c1494a1f886c03c93e398cee_145"></div><div style="text-align:justify;margin-top:10pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Off-Balance Sheet Arrangements</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, we had no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.</span></div><div style="text-align:justify;margin-top:10pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">61</span></div></div></div><div id="icc5d6783c1494a1f886c03c93e398cee_148"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Inflation</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Inflation and changing prices have had de minimis effect on our continuing operations over our two most recent fiscal years.</span></div><div id="icc5d6783c1494a1f886c03c93e398cee_151"></div><div style="margin-top:10pt;"><span><br/></span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM 3.&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Interest Rate Risk</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Borrowings under our Credit Agreement exposed us to interest rate risk. As of June&#160;30, 2020, we had&#160;$245.3 million&#160;in outstanding borrowings under our Credit Agreement. The amount borrowed under the Credit Agreement bears interest at an annual rate equal to either, at the Company&#8217;s option, (a) the rate for Eurocurrency deposits for the corresponding deposits of U.S. dollars appearing on LIBOR, adjusted for any reserve requirement in effect, plus a spread of 2.00% to 3.00%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio, or (b) a base rate, plus a spread of 1.00% to 2.00%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio. The base rate is defined in a manner such that it will not be less than LIBOR.&#160;The Company will pay fees for standby letters of credit at an annual rate equal to 2.00% to 3.00%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio, plus facing fees and standard fees payable to the issuing bank on the respective letter of credit.&#160;A hypothetical 1% change in our interest rates would have increased or decreased our interest expense for the three months ended June&#160;30, 2020, by&#160;$2.5 million.</span></div><div id="icc5d6783c1494a1f886c03c93e398cee_154"></div><div style="margin-top:10pt;"><span><br/></span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM 4.&#160;&#160;CONTROLS AND PROCEDURES</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Evaluation of Disclosure Controls and Procedures</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, we carried out an evaluation, under the supervision and with the participation of our management, including our Co-Chief Executive Officers and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based on that evaluation, our management, including Co-Chief Executive Officers and Chief Financial Officer, concluded that our disclosure controls and procedures as defined in Rules 13a-15(e) and 15(d)-15(e) under the Exchange Act, were effective as of June&#160;30, 2020, to ensure that information required to be disclosed by us in this Quarterly Report on Form 10-Q or submitted under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission rules and forms and (ii) accumulated and communicated to our management, including our principal executive officers and principal financial officer, as appropriate, to allow timely decisions regarding required disclosures.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Changes in Internal Control Over Financial Reporting</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There were no other changes in our internal control over financial reporting (as defined in Rule&#160;13a-15(f)&#160;under Exchange Act during our second fiscal quarter of 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="text-align:justify;margin-top:10pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">62</span></div></div></div><div id="icc5d6783c1494a1f886c03c93e398cee_157"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PART II &#8211; OTHER INFORMATION</span></div><div id="icc5d6783c1494a1f886c03c93e398cee_160"></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM 1.&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the ordinary course of our business, we from time to time become involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services that are provided by our affiliated hospitalists. Many of the Company&#8217;s payor and provider contracts are complex in nature and may be subject to differing interpretations regarding amounts due for the provision of medical services, which may not come to light until a substantial period of time has passed following contract implementation. We may also become subject to other lawsuits which could involve significant claims and/or significant defense costs, but as of the date of this Quarterly Report on Form 10-Q, except as disclosed, we are not a party to any lawsuit or proceeding, which in the opinion of management is expected to individually or in the aggregate have a material adverse effect on us or our business. The resolution of any claim or litigation is subject to inherent uncertainty and could have a material adverse effect on the Company&#8217;s financial condition, cash flows or results of operations.</span></div><div id="icc5d6783c1494a1f886c03c93e398cee_163"></div><div style="text-align:justify;margin-top:10pt;"><span><br/></span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM 1A. RISK FACTORS</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our business, financial condition and operating results are affected by a number of factors, whether currently known or unknown, including risks specific to us or the healthcare industry, as well as&#160;risks that affect businesses in general. In addition to the information and risk factors set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in Part I, Item 1A, &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended December&#160;31, 2019, filed with the SEC on March&#160;16, 2020. The risks disclosed in such Annual Report and in this Quarterly Report could materially adversely affect our business, financial condition, cash flows or results of operations and thus our stock price. We believe there have been no material changes in our risk factors from those disclosed in the Annual Report except as described below. However, additional risks and uncertainties not currently known or we currently deem to be immaterial may also materially adversely affect our business, financial condition or results of operations.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These risk factors may be important to understanding other statements in this Quarterly Report and should be read in conjunction with the consolidated financial statements and related notes in Part I, Item 1, &#8220;Financial Statements&#8221; and Part I, Item 2, &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; of this Quarterly Report on Form 10-Q. Because of such risk factors, as well as other factors affecting the Company&#8217;s financial condition and operating results, past financial performance should not be considered to be a reliable indicator of future performance, and investors should not use historical trends to anticipate results or trends in future periods.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The current outbreak of the novel coronavirus disease, or COVID-19, or the future outbreak of any other highly infectious or contagious diseases, could adversely impact or cause disruption to our business, financial condition and results of operations.</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;">An epidemic outbreak or other public health crisis nationally or in the markets where we operate could adversely affect our operations and financial results.&#160; For example, the recent outbreak of COVID-19, the World Health Organization declared a pandemic on March 11, 2020, and which the U.S. declared a national emergency on March 13, 2020, has caused governments and the private sector globally to take a number of drastic precautionary measures to contain the spread of the coronavirus, including the restriction and suspension of in-person classes at schools, colleges and universities, the cancellation of public events and other nonessential mass gatherings and the implementation of work from home, stay at home and other quarantine directives.&#160; The potential impact and duration of the COVID-19 pandemic has had, and continues to have, a significant adverse impact across regional and global economies and financial markets. The global impact of the outbreak has been rapidly evolving and as new cases of the virus have continued, particularly in the U.S., countries around the world and states around the U.S., have reacted by instituting quarantines and restrictions on travel.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;">Almost every state implemented shelter-in-place or stay-at-home directives between March and May 2020, including, among others, Los Angeles and San Bernardino counties, and the state of California, where we operate. The lockdown restrictions implemented included quarantines, restrictions on travel, shelter-in-place orders, school closures, restrictions on types of business that may continue to operate, and/or restrictions on types of construction projects that could continue. These quarantines generally came with exceptions for essential healthcare and public health operations, among other essential businesses.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;">Beginning in early May 2020, the U.S. began to lift the lockdown restrictions and allow for the reopening of businesses. The gradual reopening of retail, manufacturing, and office facilities came with required or recommended safety protocols. There is no assurance that the reopening of businesses, even if those businesses adhere to recommended safety protocols, will enable us or our subsidiaries, VIEs, affiliated IPAs, contracted physician groups, service providers and suppliers to avoid adverse effects on our or their operations and businesses. Due to the increase in the number of COVID-19 cases after the reopening of many states beginning in early June 2020, there is no assurance that local and state governments will not reinstitute new lockdown directives.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In order to protect our employees, we have implemented a number of precautionary measures, including a work from home policy, under which the vast majority of our employees currently operate. Such measures may have a substantial impact on employee attendance or productivity, or adversely affect our ability to recruit, attract or retain skilled personnel, which in turn may adversely affect our operations, including our ability to effectively provide management services to our affiliated IPAs and contracted physician groups in compliance with regulatory requirements.&#160; An extended outbreak may also result in disruptions to critical infrastructures and our supply chains and the supply chains of our affiliated IPAs and contracted physician groups, including the supply of pharmaceuticals and medical supplies.&#160; The duration and extent of the impact from the coronavirus outbreak depends on future developments that cannot be accurately predicted at this time, such as the severity and transmission rate of the virus, the extent and effectiveness of containment actions. If we are not able to respond to and manage the impact of such events effectively, our business could be harmed.</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Although the Company&#8217;s operations have not been directly affected as of the date of this Quarterly Report on Form 10-Q, the Company is also monitoring potential impacts from weeks of widespread protests and civil unrest that began at the end of May 2020 related to efforts to institute law enforcement and other social and political reforms.</span></div><div style="text-align:justify;margin-top:10pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">64</span></div></div></div><div id="icc5d6783c1494a1f886c03c93e398cee_166"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM 2.&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three months ended June&#160;30, 2020, the Company issued an aggregate of 214,033 shares of common stock and received approximately $1,976,152 from the exercise of certain warrants at exercise prices ranging between $9.00 and $10.00 per share. The foregoing issuances were exempt from the registration provisions of the Securities Act of 1933, as amended, pursuant to Section 4(a)(2) thereof, and/or Regulation D promulgated thereunder.</span></div><div id="icc5d6783c1494a1f886c03c93e398cee_169"></div><div style="margin-top:10pt;"><span><br/></span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM 3.&#160;&#160;DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None </span></div><div id="icc5d6783c1494a1f886c03c93e398cee_172"></div><div style="margin-top:10pt;"><span><br/></span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM 4. MINE SAFETY DISCLOSURES</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Not applicable.</span></div><div id="icc5d6783c1494a1f886c03c93e398cee_175"></div><div style="margin-top:10pt;"><span><br/></span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM 5.&#160;&#160;OTHER INFORMATION</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">65</span></div></div></div><div id="icc5d6783c1494a1f886c03c93e398cee_178"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM 6.&#160;&#160;EXHIBITS</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following exhibits are either incorporated by reference into or filed or furnished with this Quarterly Report on Form 10-Q, as indicated below.</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:7.809%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.703%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:86.288%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">No.</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Description</span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420417059199/tv479301_424b3.htm">2.1&#8224;</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420417059199/tv479301_424b3.htm">Agreement and Plan of Merger, dated December 21, 2016, among Apollo Medical Holdings, Inc., Network Medical Management, Inc., Apollo Acquisition Corp. and Kenneth Sim, M.D. (the &#8220;Merger Agreement&#8221;) (incorporated herein by reference to Annex A to the joint proxy statement/prospectus filed pursuant to Rule 424(b)(3) on November 15, 2017 that is a part of a Registration Statement on Form S-4)</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420417059199/tv479301_424b3.htm">2.2</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420417059199/tv479301_424b3.htm">Amendment to the Merger Agreement, dated March 30, 2017, among Apollo Medical Holdings, Inc., Network Medical Management, Inc., Apollo Acquisition Corp. and Kenneth Sim, M.D. (incorporated herein by reference to Annex A to the joint proxy statement/prospectus filed pursuant to Rule 424(b)(3) on November 15, 2017 that is a part of a Registration Statement on Form S-4)</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420417059199/tv479301_424b3.htm">2.3</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420417059199/tv479301_424b3.htm">Amendment No. 2 to the Merger Agreement, dated October 17, 2017, among Apollo Medical Holdings, Inc., Network Medical Management, Inc., Apollo Acquisition Corp. and Kenneth Sim, M.D. (incorporated herein by reference to Annex A to the joint proxy statement/prospectus filed pursuant to Rule 424(b)(3) on November 15, 2017 that is a part of a Registration Statement on Form S-4)</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420419025049/tv520199_ex2-4.htm">2.4</a>&#8224;</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420419025049/tv520199_ex2-4.htm">Stock purchase agreement dated March 15, 2019</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">(incorporated herein by reference to Exhibit 2.4 to the Company&#8217;s Quarterly Report on Form 10-Q filed on May 10, 2019)</span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420415002897/v398912_ex3-1.htm">3.1</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420415002897/v398912_ex3-1.htm">Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on January 21, 2015)</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420415025170/v408340_ex3-1.htm">3.2</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420415025170/v408340_ex3-1.htm">Certificate of Amendment of Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on April 27, 2015)</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420417063540/tv481301_ex3-1.htm">3.3</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420417063540/tv481301_ex3-1.htm">Certificate of Amendment of Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on December 13, 2017)</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420418035195/tv496923_ex3-1.htm">3.4</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420418035195/tv496923_ex3-1.htm">Certificate of Amendment of Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed June 21, 2018)</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420415066090/v423843_ex3-2.htm">3.5</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420415066090/v423843_ex3-2.htm">Restated Bylaws (incorporated herein by reference to Exhibit 3.2 to the Company&#8217;s Quarterly Report on Form 10-Q filed on November 16, 2015)</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420417063540/tv481301_ex3-2.htm">3.6</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420417063540/tv481301_ex3-2.htm">Amendment to Sections 3.1 and 3.2 of Article III of Bylaws (incorporated herein by reference to Exhibit 3.2 to the Company&#8217;s Current Report on Form 8-K filed on December 13, 2017)</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420418035195/tv496923_ex3-2.htm">3.7</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420418035195/tv496923_ex3-2.htm">Amendment to Sections 3.1 and 3.2 of Article III of Bylaws (incorporated herein by reference to Exhibit 3.2 to the Company&#8217;s Current Report on Form 8-K filed on June 21, 2018)</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="ex1012020063010-qngksim.htm">Employment Agreement, dated June 8, 2020, between Network Medical Management, Inc. and Kenneth Sim, M.D.</a></span></div></td></tr><tr><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="ex1022020063010qngtlam.htm">Employment Agreement, dated June 8, 2020, between Network Medical Management, Inc. and Thomas Lam, M.D.</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="ex1032020063010qngechin.htm">Employment Agreement, dated June 8, 2020, between Network Medical Management, Inc. and Eric Chin</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.4</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="ex1042020063010qngavaz.htm">Employment Agreement, dated June 8, 2020, between Network Medical Management, Inc. and Adrian Vazquez, M.D.</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.5</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="ex1052020063010qngayou.htm">Employment Agreement, dated June 8, 2020, between Network Medical Management, Inc. and Albert Young, M.D.</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.6</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="ex1062020063010qngbsim.htm">Employment Agreement, dated June 8, 2020, between Network Medical Management, Inc. and Brandon Sim</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.1*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="ex3112020063010-qng.htm">Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.2*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;-sec-extract:exhibit;" href="ex3122020063010-qng.htm">Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.3*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="ex3132020063010-qng.htm">Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:7.809%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.703%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:86.288%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32**</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="ex322020063010-qng.htm">Certification of Principal Executive Officers and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">101.INS*</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">XBRL Instance Document</span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">101.SCH*</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">XBRL Taxonomy Extension Schema Document</span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">101.CAL*</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">XBRL Taxonomy Extension Calculation Linkbase Document</span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">101.DEF*</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">XBRL Taxonomy Extension Definition Linkbase</span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">101.LAB*</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:justify;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">101.PRE*</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">XBRL Taxonomy Extension Presentation Linkbase Document</span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">*</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Filed herewith.</span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">**</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Furnished herewith</span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8224;</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">The schedules and exhibits thereof have been omitted pursuant to Item&#160;601(b)(2) of Regulation&#160;S-K. A copy of any omitted schedule or exhibit will be furnished to the SEC upon request.</span></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">67</span></div></div></div><div id="icc5d6783c1494a1f886c03c93e398cee_181"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#icc5d6783c1494a1f886c03c93e398cee_7">Table of Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">SIGNATURE</span></div><div style="text-indent:18pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:38.995%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:2.538%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:52.467%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">APOLLO MEDICAL HOLDINGS, INC.</span></div></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dated: August 7, 2020</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">By:</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">/s/ Kenneth Sim</span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Kenneth Sim, M.D.<br/>Executive Chairman &amp; Co-Chief Executive Officer<br/>(Principal Executive Officer)</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dated: August 7, 2020</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">By:</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">/s/ Thomas Lam</span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Thomas Lam, M.D., M.P.H.<br/>Co-Chief Executive Officer &amp; President<br/>(Principal Executive Officer)</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dated: August 7, 2020</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">By:</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">/s/ Eric Chin</span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Eric Chin<br/>Chief Financial Officer and Interim Co-Chief Operating Officer<br/>(Principal Financial Officer)</span></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">68</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ex1012020063010-qngksim.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i8095ce7046524458815a04479b03c773_1"></div><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="padding-left:167.2pt;padding-right:166.4pt;text-align:center;margin-top:4pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EMPLOYMENT AGREEMENT</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:6pt;padding-right:3.05pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">THIS EMPLOYMENT AGREEMENT </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(this &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) is made and entered into as of June 8, 2020, by and between Network Medical Management, Inc., a California corporation (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Employer</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;), and Kenneth Sim, M.D. (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Employee</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; and together with the Employer referred to as the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Parties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) to become effective as of the date hereof (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Effective</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;).</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.2pt;text-align:justify;margin-top:1.9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;">WHEREAS, the Employer desires to employ the Employee from and after the Effective Date on the terms and conditions set forth below, and the Employee is willing to serve the Employer on such terms and conditions.</font></div><div style="margin-top:0.45pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">NOW, THEREFORE, in consideration of the mutual covenants and agreements contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows&#58;</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="padding-left:6pt;padding-right:3.1pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.           </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Term</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The term of this Agreement shall initially be for a one (1) year period commencing on the Effective Date. The term of this Agreement shall automatically renew for an additional year on each anniversary of the Effective Date unless either Party gives the other written notice of intent not to renew at least sixty (60) days prior to such date. Notwithstanding the foregoing, the initial term and any renewal year shall be subject to earlier termination as provided in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> below. The initial term and any renewal years are referred to herein as the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Term</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;.</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="padding-left:6pt;padding-right:3.15pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.           </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Positions and Duties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. During the Term, the Employee shall serve as a senior executive officer of the Employer. The Employee shall perform for the Employer the duties customarily associated with being a senior executive officer that are consistent with your experience and skills and such other duties as may be assigned to the Employee from time to time by the Employer&#8217;s Board of Directors (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Board</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) that are consistent with the duties normally performed by those performing the role of the most senior executives of similar entities. The Employee shall devote such working time, attention, knowledge, skills and efforts as may be required to fulfill the Employee&#8217;s duties hereunder, as reasonably determined by the Board. The Employee shall be permitted to perform services as required under the Hospitalist Participation Service Agreement, and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">further</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> that the Employee may participate as a member of the board of directors or advisory board of other entities and in professional organizations and civic and charitable organizations so long as any such positions are disclosed to the Board and do not materially interfere with the Employee&#8217;s duties and responsibilities to the Employer. The Employee shall be based in Alhambra, California.</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="padding-left:6pt;padding-right:3.2pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3.           </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Compensation and Related Matters</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employer shall provide the Employee with the compensation and benefits set forth in this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> during the Term. Authority to take action under this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> with respect to the Employee&#8217;s compensation and benefits may be delegated by the Board to its compensation committee.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.25pt;text-align:justify;margin-top:1.7pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(a)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Base Salary</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">. The Employer shall pay the Employee for all services rendered a base salary of Nine Hundred Fifty Thousand Dollars ($950,000) per year (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Base Salary</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">&#8221;), payable in accordance with the Employer&#8217;s payroll procedures, subject to customary withholdings and employment taxes. The Base Salary shall be evaluated annually by the Board for increase only.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.2pt;text-align:justify;margin-top:1.7pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(b)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Annual Bonus</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">. The Employee will be eligible to receive an annual cash bonus (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Annual Bonus</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">&#8221;) for each fiscal year during the Term on such terms and conditions as the Board shall determine in its discretion consistent with the terms of the Employer&#8217;s business plan.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.05pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Long Term Incentive Awards</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employee shall be eligible to participate in any long term incentive plan that may be available to similarly positioned executives. The Board may determine to grant long-term incentive awards in cash or in equity awards settled in shares of the Employer&#8217;s stock, including but not limited to stock options, restricted stock and performance shares. In the event the Employee terminates service due to being a Good Leaver, any requirements under a long-term incentive award held by the Employee shall be deemed to have been satisfied by the Employer immediately prior to such termination. A &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Good Leaver</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; means that, during the </font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="padding-left:6pt;padding-right:3.05pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Term, either the Employee has resigned for Good Reason (as defined in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> below), the Employer has terminated the Employee&#8217;s employment without Cause (as defined in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> below or the Employee terminates employment on account of death or Disability (as defined in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> below). For avoidance of doubt, being a Good Leaver entitles the Employee to be fully vested with respect to any stock options with vesting conditions based solely on continued employment, and to be entitled to payment with respect to any long-term incentive award subject to corporate or business goals to the extent that such goals are met during the performance period on the same basis as if he had remained continuously employed with the Employer.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(d)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Paid Time Off</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. During the term, the Employee shall be entitled to twenty (20) business days of paid time off (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">PTO</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) per calendar year which shall be accrued ratably during the calendar year, to be taken at such times and intervals as shall be agreed to by Employer and the Employee in their reasonable discretion. The Employee shall be entitled to accrue a maximum of twenty (20) business days of paid time off. When the maximum accrual is reached, no additional PTO time will accrue until Employee uses one or more accrued PTO days. Accrued and unused PTO shall be paid in cash at the end of a calendar year.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(e)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Expenses</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employee shall be entitled to prompt reimbursement of reasonable and usual business expenses incurred on behalf of Employer in accordance with the Employer&#8217;s expense reimbursement policy.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.1pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(f)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Other Benefits</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employee shall be entitled to continue to participate in or receive benefits under any employee benefit plan or arrangement which is or may, in the future, be made available by the Employer to its employees, subject to and on a basis consistent with the terms, conditions and overall administration of such plan or arrangement. Irrespective of other benefits provided to employees, the Employee&#8217;s benefits package shall include&#58; (i) the Employer&#8217;s payment of premiums for medical, dental and vision care coverage&#59; (ii) the Employer&#8217;s payment of insurance premiums for short-term and long-term disability insurance providing for no less than sixty percent (60%) of Employee&#8217;s Base Salary to be payable to the Employee as long as the covered disability persists in a manner that substantially prevents employment in the same occupation as the position Employee last held with Employer but not beyond age sixty-five (65)&#59; and (iii) the Employer&#8217;s payment of insurance premiums for term life insurance providing for no less than two million dollars of coverage (subject to meeting applicable underwriting requirements).</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(g)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Tax Withholding</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employer shall undertake to make deductions, withholdings and tax reports with respect to payments and benefits under this Agreement, to the extent it reasonably and in good faith believes it is required to make such deductions, withholdings and tax reports. Payments with respect to compensation and benefits referred to under this Agreement shall be in amounts net of any such deductions or withholdings. Nothing in this Agreement shall be construed to require the Employer to make any payments to compensate the Employee for any adverse tax effect associated with any payments or benefits, or for any deduction or withholding from any payment or benefit.</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="padding-left:6pt;padding-right:3.2pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employee&#8217;s employment hereunder may be terminated during the Term without any breach of this Agreement under the following circumstances&#58;</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="padding-left:42pt;padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">(a)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;">Death</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">. The Employee&#8217;s employment hereunder shall terminate upon the Employee&#8217;s death.</font></div><div style="margin-top:0.45pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.2pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Disability</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employer may terminate the Employee&#8217;s employment if the Employee is disabled and, because of the disability, is unable to perform the essential functions of the Employee&#8217;s then existing position or positions under this Agreement with or without reasonable accommodation. This provision is not intended to reduce any rights the Employee may have pursuant to any law, including without limitation the California Family Rights Act, the Family and Medical Leave Act, the California Fair Employment and Housing Act, and the Americans with Disabilities Act.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Termination by the Employer for Cause</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. At any time during the Term, the Employer may terminate the Employee&#8217;s employment hereunder for Cause. For purposes of this Agreement, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Cause</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; shall mean&#58; (i) conduct by the Employee constituting a material act of willful misconduct in connection with the performance of the Employee&#8217;s duties that results in loss, damage or injury that is material to the Employer&#59; (ii) the commission by the </font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="padding-left:6pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Employee of any felony&#59; (iii) continued, willful and deliberate non-performance by the Employee of the Employee&#8217;s duties hereunder (other than by reason of the Employee&#8217;s physical or mental illness, incapacity or disability)&#59; (iv) a material breach, according to the standard of the Employer, by the Employee of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement that results in loss, damage or injury that is material to the Employer&#59; (v) willful failure to cooperate with a bona fide internal investigation or an investigation by regulatory or law enforcement authorities, after being instructed by the Employer to cooperate, or the willful destruction or failure to preserve documents or other materials known to be relevant to such investigation or the willful inducement of others to fail to cooperate or to produce documents or other materials in connection with such investigations&#59; or (vi) fraud, embezzlement or theft against the Employer or any of its Affiliates (as defined in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> below). With respect to the events in (i), (iii) and (iv) herein, the Employer shall have delivered written notice to the Employee of its intention to terminate the Employee&#8217;s employment for Cause, which notice specifies in reasonable detail the circumstances claimed to give rise to the Employer&#8217;s right to terminate the Employee&#8217;s employment for Cause and the Employee shall not have cured such circumstances to the extent such circumstances are reasonably susceptible to cure as determined by the Board in good faith within thirty (30) days following the Employer&#8217;s delivery of such notice. For avoidance of doubt, &#8220;Cause&#8221; shall not include (x) expense reimbursement disputes in which the Employee acts in reasonable good faith&#59; (y) occasional, customary and de minimis use of the Employer&#8217;s property for personal purposes&#59; and (z) acting in good faith upon advice of Employer&#8217;s legal counsel.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.15pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(d)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Termination without Cause</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. At any time during the Term, the Employer may terminate the Employee&#8217;s employment hereunder without Cause by providing the Employee with thirty (30) days advance written notice. Any termination by the Employer of the Employee&#8217;s employment under this Agreement that does not constitute a termination for Cause under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> and does not result from the death or Disability of the Employee under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Sections 4(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> or </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">4(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> shall be deemed a termination without Cause under this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Any suspension of the Employee&#8217;s employment with pay or benefits by the Board in good faith pending an investigation of alleged improper activities by the Employee that, if determined to be accurate, would be grounds for a Cause termination, shall not be considered a termination of the Employee&#8217;s employment without Cause or provide with Good Reason to terminate employment.</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(e)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Termination by the Employee</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. At any time during the Term, the Employee may terminate his employment hereunder for any reason, including, but not limited to, Good Reason. For purposes of this Agreement, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Good Reason</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; shall mean that the Employee has complied with the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Good Reason Process</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; (hereinafter defined) following the occurrence of any of the following events&#58; (i) a material diminution in the Employee&#8217;s responsibilities, authority or duties&#59; (ii) the material breach of this Agreement by the Employer, including but not limited to a failure to pay Base Salary or Annual Bonus as provided for under this Agreement&#59; or (iii) any relocation of the Employee&#8217;s principal place of business to a location more than 30 miles from the Employer&#8217;s current executive offices in Alhambra, California&#59; provided, however, that this clause (iii) will not apply to the extent that any new office location is less than 30 miles from the Employee&#8217;s residence. &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Good Reason Process</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; shall mean (i) the Employee reasonably determines in good faith that a &#8220;Good Reason&#8221; condition has occurred&#59; (ii) the Employee notifies the Employer in writing of the occurrence of the Good Reason condition within (60) days of the occurrence of such condition&#59; (iii) the Employee cooperates in good faith with the Employer&#8217;s efforts, for a period of sixty (60) days following such notice (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Cure Period</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;), to remedy the condition&#59; (iv) notwithstanding such efforts, the Good Reason condition continues to exist&#59; and (v) the Employee terminates his employment within thirty (30) days after the end of the Cure Period. If the Employer cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not to have occurred.</font></div><div style="margin-top:0.25pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.2pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(f)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Notice of Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Except for termination as specified in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, any termination of the Employee&#8217;s employment shall be communicated by written Notice of Termination by the terminating Party to the other Party hereto. For purposes of this Agreement, a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Notice of Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; shall mean a notice which shall indicate the specific termination provision in this Agreement relied upon.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(g)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Date of Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Date of Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; shall mean the earliest of the following&#58; (i) if the Employee&#8217;s employment is terminated by the Employee&#8217;s death, the date of the Employee&#8217;s death&#59; (ii) if the Employee&#8217;s employment is terminated on account of Disability under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> or by the Employer for Cause under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, the date on which Notice of Termination is given that follows any applicable required cure </font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="padding-left:6pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">period&#59; (iii) if the Employee&#8217;s employment is terminated by the Employer under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, thirty (30) days after the date on which a Notice of Termination is given&#59; (iv) if the Employee&#8217;s employment is terminated by the Employee under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> without Good Reason, thirty (30) days after the date of which a Notice of Termination is given or such shorter period agreed to by the Employer&#59; or (v) if the Employee&#8217;s employment is terminated by the Employee under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> with Good Reason, the date on which Notice of Termination is given after the end of the Cure Period. Notwithstanding the foregoing, in the event that the Employee gives a Notice of Termination to the Employer, the Employer may unilaterally accelerate the Date of Termination but such acceleration shall nevertheless be deemed a termination by the Employee on the accelerated date for purposes of this Agreement. For purposes of determining the time when the lump sum portion of the Severance Amount, if any, is to be paid under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 5(b)(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Date of Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; means the Employee&#8217;s separation from service as defined under Section 409A.</font></div><div style="padding-right:3.1pt;text-align:justify;margin-bottom:0.1pt;"><font><br></font></div><div style="padding-left:8.5pt;padding-right:-1pt;margin-top:4pt;margin-bottom:0.1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">5.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;">Compensation upon Termination.</font></div><div style="margin-top:0.45pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.05pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Accrued Benefits.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> If the Employee&#8217;s employment with the Employer is terminated for any reason during the Term, or if the Term is not renewed, the Employer shall pay or provide the Employee (or the Employee&#8217;s authorized representative or estate) any earned but unpaid Base Salary or Annual Bonus for services rendered through the Date of Termination, unpaid expense reimbursements, and accrued but unused paid time off (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Accrued</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Benefits</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) within the time prescribed by California law. With respect to vested compensation or benefits the Employee may have under any employee benefit or compensation plan, program or arrangement of the Employer, payment will be made to the Employee under the terms of the applicable plan, program or arrangement.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Termination by  the Employer without Cause or by the Employee with Good</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Reason</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. If the Employee&#8217;s employment is terminated by the Employer without Cause as provided in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, or the Employee terminates his employment for Good Reason as provided in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, or the Employee terminates employment at the end of the Term after the Employer provides notice of intent not to renew pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> for reasons other than would provide grounds for a Cause termination, then, (i) the Employer shall, through the Date of Termination, pay the Employee his or her Accrued Benefits, and (ii) if the Employee signs a general release of claims substantially in the form which is attached as </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Exhibit A</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to this Agreement) (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Release</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) within twenty-one (21) days of the receipt of the form of the Release (extended to forty-five (45) days in the event of a group termination or exit incentive program) and does not revoke such Release during the seven-day revocation period&#58;</font></div><div style="margin-top:0.25pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:42pt;padding-right:3.05pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(i)         the Employer shall pay the Employee an amount equal to one-twelfth (1&#47;12) of the Employee&#8217;s most recent Base Salary times the number of full years of service completed, not to exceed twelve (12) years of service (but determined prior to any action involving Base Salary that would constitute Good Reason) (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Severance Amount</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;). Employer acknowledges that Employee has completed not less than twelve (12) full years of service (including Employee&#8217;s service for the Employer&#8217;s parent entity, subsidiaries and affiliates), such that the Severance Amount payable to Employee pursuant to the terms of this Agreement shall equal the maximum Severance Amount of one (1) year of the Employee&#8217;s most recent Base Salary. To the extent that such Severance Amount exceeds the 409A Separation Pay Limit (as defined below), such amount shall be paid in a single lump sum on the regular payroll date of the Employer, pertaining to then current salaried employees of the Employer, (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">payroll date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) next following the first anniversary date of the Employee&#8217;s Date of Termination. The portion of the Severance Amount that does not exceed the 409A Separation Pay Limit shall be paid in substantially equal amounts on each payroll date over a one year period&#59; and</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:42pt;padding-right:3.15pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(ii)        the Employer shall pay the Employee an amount in cash equal to the Employer&#8217;s premium amounts paid for coverage of Employee at the time of the Employee&#8217;s termination of coverage under the Employer&#8217;s group medical, dental and vision programs for a period of twelve (12) months, to be paid directly to the Employee at the same times such payments would be paid on behalf of a current employee for such coverage&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#58;</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="text-indent:36pt;padding-left:78pt;padding-right:3.15pt;text-align:justify;margin-top:1.7pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(A)        No  payments shall  be  made  under  this  paragraph (ii)  unless  and  until  the Employee timely elects continued coverage under such plan(s) pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1985 as amended (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">COBRA</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">&#8221;)&#59;</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:78pt;padding-right:3.25pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(B)&#160;This paragraph (ii) shall not be read or construed as placing any restrictions upon amounts paid under this paragraph (ii) as to their use&#59;</font></div><div style="margin-top:0.75pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:78pt;padding-right:3.2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;">(C)&#160;Payments under this paragraph (ii) shall cease as of the earliest to occur of the following&#58;</font></div><div style="margin-top:0.45pt;"><font><br></font></div><div style="padding-left:150pt;padding-right:-1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(1)&#160;the Employee is no longer eligible for and continuing to receive the</font></div><div style="padding-left:114pt;padding-right:-1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">COBRA coverage elected in subparagraph (A)&#59;</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="padding-left:150pt;padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(2)&#160;the time period set forth in the first sentence of this paragraph (ii),</font></div><div style="padding-right:-1pt;margin-bottom:0.1pt;"><font><br></font></div><div style="padding-left:149pt;padding-right:3.2pt;text-align:justify;margin-top:4pt;margin-bottom:0.1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(3)        the date on which the Employee first becomes eligible to enroll in a group health plan in which eligibility is based on employment with an employer, and</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:149pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(4)        if the Employer in good faith determines that payments under this paragraph (ii) would result in a discriminatory health plan pursuant to the Patient Protection and Affordable Care Act of 2010, as amended.</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="padding-left:185pt;padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(iii)&#160;Each individual payment of Severance Amount under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section</font></div><div style="padding-left:149pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;">5(b)(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">, and each payment under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;">Section 5(b)(ii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> of this Agreement, shall be deemed to be a separate &#8220;payment&#8221; for purposes and within the meaning of Treasury Regulation Section 1.409A-2(b)(2)(iii).</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:149pt;padding-right:3.15pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(iv)       Each    individual    payment    of    the    Severance    Amount under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Section   5(b)(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">,   and   each   payment   under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Section   5(b)(ii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">,   of   this Agreement, which are considered &#8220;non-qualified deferred compensation&#8221; (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">NQDC</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">&#8221;) under Section 409A shall be made on the date(s) provided herein and no request to accelerate or defer any such payment under this Agreement shall be considered or approved for any reason whatsoever, except as permitted under Section 409A and as the Employer allows in its sole discretion. The Employer may in its sole discretion accelerate or defer (but not beyond the time limit set forth below) any severance payments which do not constitute NQDC in order to allow for the payment of taxes due, but not beyond the time limit specified for such payment such that the payment would be treated as NQDC. Subject to the requirements of  Section 409A, if  any severance payment or  reimbursement under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Section 5(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;"> of this Agreement is determined in good faith by the Employer to constitute NQDC payable to a &#8220;specified employee&#8221; as defined under Section</font></div><div style="padding-left:149pt;padding-right:3.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">409A, then the Employer shall make any such payment not earlier than the earlier of&#58; (x) the first payroll date which is six (6) months following the Employee&#8217;s separation from service (as defined under Section 409A) with the Employer, or (y) the date of Employee&#8217;s death.</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="padding-left:185pt;padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(v)&#160;for purposes of this Section 5, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 409A</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; means Section</font></div><div style="padding-left:149pt;padding-right:18.3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">409A of the Internal Revenue Code of 1986, as amended, and the regulations thereunder.</font></div><div style="margin-top:0.45pt;"><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="text-indent:36pt;padding-left:149pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(vi)       for purposes of this Section 5, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">409A Separation Pay Limit</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; means two times the lesser of (</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">x</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">) the Employee&#8217;s annual compensation during the calendar year preceding the year of the termination of employment&#59; and (</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">y</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">) the adjusted compensation limit under Code Section 401(a)(17) in effect for the year of the termination.</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="padding-left:5pt;padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">6.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;">Confidential Information, Nonsolicitation, and Cooperation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">.</font></div><div style="margin-top:0.1pt;"><font><br></font></div><div style="padding-left:41pt;padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">(a)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;">Definitions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">.</font></div><div style="margin-top:0.1pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:41pt;padding-right:3.05pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(i)          As used in this Agreement, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Affiliate</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">&#8221; means, as to any Person, (i) any other Person which directly, or indirectly through one or more intermediaries, controls such Person or is consolidated with such Person in accordance with GAAP, (ii) any other Person which directly, or indirectly through one or more intermediaries, is controlled by or is under common control with such Person, or (iii) any other Person of which such Person owns, directly or indirectly, fifty percent (50%) or more of the common stock or equivalent equity interests. As used herein, the term &#8220;control&#8221; means possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of a Person, whether through the ownership of voting securities or otherwise.</font></div><div style="text-indent:36pt;padding-left:42pt;padding-right:3.2pt;margin-top:4pt;margin-bottom:0.1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(ii)&#160;As used in this Agreement, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Person</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; means an individual, a corporation, a partnership, a limited liability company, an association, a trust or any other entity or organization.</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.1pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Confidential  Information</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  As   used   in   this   Agreement,  &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Confidential</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Information</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;  means information belonging to the Employer or its Affiliates which is of value to the Employer or any of its Affiliates in the course of conducting its business (whether having existed, now existing, or to be developed or created during Employee&#8217;s employment by Employer) and the disclosure of which could result in a competitive or other disadvantage to the Employer or its Affiliates. Confidential Information includes, without limitation, contract terms and rates&#59; negotiating and contracting strategies&#59; financial information, reports, and forecasts&#59; inventions, improvements and other intellectual property&#59; product plans or proposed product plans&#59; trade secrets&#59; designs, processes or formulae&#59; software&#59; employee, customer, patient, provider and supplier information&#59; information from patient medical records&#59; financial data&#59; insurance reimbursement methodologies, strategies and practices&#59; product and service pricing methodologies, strategies and practices&#59; contracts with physicians, providers, provider networks, payors, physician databases and contracts with hospitals&#59; regulatory and clinical manuals&#59; and business plans, prospects and opportunities (such as possible acquisitions or dispositions of businesses or facilities) that have been discussed or considered by the Employer or its Affiliates, including, without limitation, the management of the Employer or its Affiliates. Confidential Information includes information developed by the Employee in the course of the Employee&#8217;s employment by the Employer, as well as other information to which the Employee may have access in connection with the Employee&#8217;s employment. Confidential Information also includes the confidential information of others with which the Employer or its Affiliates has a business relationship. Notwithstanding the foregoing, Confidential Information does not include information in the public domain, unless due to breach of the Employee&#8217;s duties under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, unless otherwise due to Employee&#8217;s breach of the obligations in this Agreement, or unless due to violation of another Person&#8217;s obligations to the Employer or its Affiliates that Employee should have taken reasonable measures to prevent but that Employee did not take.</font></div><div style="margin-top:0.45pt;"><font><br></font></div><div style="text-indent:38.5pt;padding-left:6pt;padding-right:4.85pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Confidentiality</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employee understands and agrees that the Employee&#8217;s employment creates a relationship of confidence and trust between the Employer and the Employee with respect to all Confidential Information. At all times, both during the Employee&#8217;s employment with the Employer and after the Employee&#8217;s termination from employment for any reason, the Employee shall keep in confidence and trust all such Confidential Information, and shall not use, disclose, or transfer any such Confidential Information without the written consent of the Employer, except as may be necessary within the scope of Employee&#8217;s duties with Employer and in the ordinary course of performing the Employee&#8217;s duties to the Employer or as otherwise provided in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Employee understands and agrees not to sell, license or otherwise exploit any products or services which embody or otherwise exploit in whole or in part any Confidential Information or materials. Employee acknowledges and agrees that the sale, misappropriation, or unauthorized use or disclosure in writing, orally or by electronic means, at any time of </font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="padding-left:6pt;padding-right:4.85pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Confidential Information obtained by Employee during or in connection with the course of Employee&#8217;s employment constitutes unfair competition. Employee agrees and promises not to engage in unfair competition with Employer or its Affiliates, either during employment, or at any time thereafter.</font></div><div style="margin-top:0.45pt;"><font><br></font></div><div><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(d)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Protected Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Notwithstanding anything to the contrary in this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, this Agreement is not intended to, and shall not, in any way prohibit, limit or otherwise interfere with the Employee&#8217;s protected rights under federal, state or local law to, without notice to the Employer, (i) communicate or file a charge with a government regulator&#59; (ii) participate in an investigation or proceeding conducted by a government regulator&#59; or (iii) receive an award paid by a government regulator for providing information.</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.15pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(e)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Documents, Records, etc</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. All documents, records, data, apparatus, equipment and other physical property, whether or not pertaining to Confidential Information, that are furnished to the Employee by the Employer or its Affiliates or are produced by the Employee in connection with the Employee&#8217;s employment will be and remain the sole property of the Employer and its Affiliates. The Employee shall return to the Employer all such materials and property as and when requested by the Employer. In any event, the Employee shall return all such materials and property immediately upon termination of the Employee&#8217;s employment for any reason. The Employee shall not retain any such material or property or any copies thereof after such termination. It is specifically agreed that any documents, card files, notebooks, programs, or similar items containing customer or patient information are the property of the Employer and its Affiliates regardless of by whom they were compiled.</font></div><div style="padding-right:3.15pt;text-align:justify;margin-bottom:0.1pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:5pt;padding-right:3.05pt;text-align:justify;margin-top:1.9pt;margin-bottom:0.1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;">(f)          </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration: underline;">Disclosure Prevention</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;">. The Employee will take all reasonable precautions to prevent the inadvertent or accidental exposure of Confidential Information.</font></div><div style="padding-right:3.05pt;text-align:justify;margin-bottom:0.1pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:5pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">(g)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;">Removal of Material</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. The Employee will not remove any Confidential Information from the Employer&#8217;s or its Affiliate&#8217;s premises except for use in the Employer&#8217;s business, and only consistent with the Employee&#8217;s duties with the Employer.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:5pt;padding-right:3.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(h)          </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Copying</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">. The Employee agrees that copying or transferring Confidential Information (by any means) shall be done only as needed in furtherance of and for use in the Employer&#8217;s and its Affiliate&#8217;s business, and consistent with the Employee&#8217;s duties with the Employer. The Employee further agrees that copies of Confidential Information shall be treated with the same degree of confidentiality as the original information and shall be subject to all restrictions herein.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:5pt;padding-right:3.15pt;text-align:justify;margin-top:1.9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;">(i)           </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration: underline;">Computer Security</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;">. The Employee agrees to comply with the Employer&#8217;s policies and procedures concerning computer security.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:5pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(j)           </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">E-Mail</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employee acknowledges that the Employer retains the right to review any and all electronic mail communications made with employer provided email accounts, hardware, software, or networks, with or without notice, at any time.</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:5pt;padding-right:3.15pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(k)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Assignment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employee acknowledges that any and all inventions, discoveries, designs, developments, methods, modifications, trade secrets, processes, software, formulae, data, &#8220;know-how,&#8221; databases, algorithms, techniques and works of authorship whether or not patentable or protectable by copyright or trade secret, made or conceived, first reduced to practice, or learned by the Employee, either alone or jointly with others, during the Term that (i) relate to or are useful in the business of the Employer or its Affiliates, or (ii) are conceived, made or worked on at the expense of or during the Employee&#8217;s work time for the Employer, or using any resources or materials of the Employer or its Affiliates, or (iii) arise out of tasks assigned to the Employee by the Employer (together &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Proprietary Inventions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) will be the sole property of the Employer or its Affiliates. The Employee acknowledges that all work performed by the Employee is on a &#8220;work for hire&#8221; basis and the Employee hereby assigns or agrees to assign to the Employer the Employee&#8217;s entire right, title and interest in and to any and all Proprietary Inventions and related intellectual property rights. The Employee agrees to assist the Employer to obtain, </font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">7</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="padding-left:5pt;padding-right:3.15pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">maintain and enforce intellectual property rights for Proprietary Inventions in any and all countries during the Term, and thereafter for as long as such intellectual property rights exist.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="padding-left:144.7pt;padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:113%;text-decoration: underline;">NOTICE TO CALIFORNIA EMPLOYEES</font></div><div style="margin-top:0.1pt;"><font><br></font></div><div style="padding-left:41pt;padding-right:39.1pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">Pursuant to California Labor Code &#167;2870, an agreement requiring the employee to assign or offer to assign any of his or her rights in any invention to his or her employer does not apply to an invention which qualifies fully under the provisions of California Labor Code &#167; 2870, which provides as follows&#58;</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:41pt;padding-right:39.05pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)         Any provision in an employment agreement which provides that an employee shall assign, or offer to assign, any of his or her rights in an invention to his or her employer shall not apply to an invention that the employee developed entirely on his or her own time without using the employer&#8217;s equipment, supplies, facilities, or trade secret information except for those inventions that either&#58;</font></div><div style="margin-top:0.6pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:77pt;padding-right:39.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(1)        Relate at the time of conception or reduction to practice of the invention to the employer&#8217;s business, or actual or demonstrably anticipated research or development of the employer&#59; or</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="padding-left:113pt;padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(2)&#160;Result from any work performed by the employee for the employer.</font></div><div style="margin-top:0.75pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:41pt;padding-right:39.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;">(b)         To the extent a provision in an employment agreement purports to require an employee to assign an invention otherwise excluded from being required to be assigned under subdivision (a),  the  provision is  against the  public policy  of  the  State  of  California and  is unenforceable.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(l)           </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Nonsolicitation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Employee agrees and covenants that, at any time during Employee&#8217;s employment with the Employer and for a period of twelve (12) months immediately following the termination of Employee&#8217;s relationship with the Employer for any reason, whether with or without cause, Employee shall not, either on Employee&#8217;s own behalf or on behalf of any other Person&#58; (i) solicit the services of the Employer&#8217;s employees or entice away, directly or indirectly, any Person employed or engaged by or otherwise providing services to the Employer or its Affiliates, whether in an employment capacity or otherwise (this provision does not prohibit the Employee&#8217;s post- termination acceptance of unsolicited applications for employment)&#59; or (ii) take any illegal action or engage in any unfair business practice, including, without limitation, any misappropriation of confidential, proprietary or trade secret information of the Employer or its Affiliates, as a result of which relations between the Employer or its Affiliates, and any of their customers, clients, suppliers, distributors or others, may be impaired or which might otherwise be detrimental to the business interests or reputation of the Employer or its Affiliates.</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(m)        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Third-Party Agreements and Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employee hereby confirms that the Employee is not bound by the terms of any agreement with any previous employer or other party which restricts in any way the Employee&#8217;s use or disclosure of information or the Employee&#8217;s engagement in any business except as Employee has previously provided written notice to Employer and has attached to this Agreement. The Employee represents to the Employer that the Employee&#8217;s execution of this Agreement, the Employee&#8217;s employment with the Employer and the performance of the Employee&#8217;s proposed duties for the Employer will not violate any obligations the Employee may have to any previous employer or other party. In the Employee&#8217;s work for the Employer, the Employee will not disclose or use any information in violation of any agreements with or rights of any such previous employer or other party, and the Employee will not bring to (by any means) the premises of the Employer any copies or other tangible embodiments of non- public information belonging to or obtained from any such previous employment or other party.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(n)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Litigation  and  Regulatory  Cooperation.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  During  and  after  the  Employee&#8217;s  employment,  the Employee shall cooperate fully with the Employer in the defense or prosecution of any claims or actions now in </font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">8</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="padding-left:6pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">existence or that may be brought in the future against or on behalf of the Employer that relate to events or occurrences that transpired while the Employee was employed by the Employer. The Employee&#8217;s full cooperation in connection with such claims or actions shall include, but not be limited to, being available to meet with counsel to prepare for discovery or trial and to act as a witness on behalf of the Employer at mutually convenient times. During and after the Employee&#8217;s employment, the Employee also shall cooperate fully with the Employer in connection with any investigation or review of any federal, state, or local regulatory authority as any such investigation or review relates to events or occurrences that transpired while the Employee was employed by the Employer. The Employer shall reimburse the Employee for any reasonable out of pocket expenses incurred in connection with the Employee&#8217;s performance of obligations pursuant to this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. &#8220;Full cooperation&#8221; shall not be construed to in any way require any violation of law or any testimony that is false or misleading.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(o)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Enforcement&#59; Injunction.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The Employee acknowledges and agrees that the restrictions contained in this Agreement are reasonable and necessary to protect the business and interests of the Employer and its Affiliates, do not create any undue hardship for the Employee, and that any violation of the restrictions in this Agreement would cause the Employer and its Affiliates substantial irreparable injury. Accordingly, the Employee agrees that a remedy at law for any breach or threatened breach of the covenants or other obligations in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement would be inadequate and that the Employer, in addition to any other remedies available, shall be entitled to obtain preliminary and permanent injunctive relief to secure specific performance of such covenants and to prevent a breach or contemplated or threatened breach of this Agreement without the necessity of proving actual damage and without the necessity of posting bond or security, which the Employee expressly waives. Moreover, the Employee will provide the Employer a full accounting of all proceeds and profits received by the Employee as a result of or in connection with a breach of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement. Unless prohibited by law, the Employer shall have the right to retain any amounts otherwise payable by the Employer to the Employee to satisfy any of the Employee&#8217;s obligations as a result of any breach of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement. The Employee hereby agrees to indemnify and hold harmless the Employer and its Affiliates from and against any damages incurred by the Employer or its Affiliates as assessed by a court of competent jurisdiction as a result of any breach of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement by the Employee. The prevailing party shall be entitled to recover its reasonable attorneys&#8217; fees and costs if it prevails in any action to enforce </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement. It is the express intention of the parties that the obligations of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement shall survive the termination of the Employee&#8217;s employment. The Employee agrees that each obligation specified in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement is a separate and independent covenant that shall survive any termination of this Agreement and that the unenforceability of any of them shall not preclude the enforcement of any other covenants in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement. No change in the Employee&#8217;s duties or compensation shall be construed to affect, alter or otherwise release the Employee from the covenants herein.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="padding-left:5pt;padding-right:3.05pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">7.          </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Successors</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">. This Agreement shall be binding upon and inure to the benefit of both parties and their respective successors and permitted assigns, including any corporation or entity with which or into which the Employer may be merged or which may succeed to its assets or business, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">, that Employee&#8217;s obligations are personal and shall not be assigned by Employee. The Employee consents to be bound by the provisions of this Agreement for the benefit of the Employer or its Affiliates to whose employ the Employee may be transferred without the necessity that this Agreement be resigned at the time of such transfer. In the event of the Employee&#8217;s death after the Date of Termination but prior to the completion by the Employer of all payments due to the Employee under this Agreement, the Employer shall continue such payments to the Employee&#8217;s beneficiary designated in writing to the Employer prior to the Employee&#8217;s death (or to the Employee&#8217;s estate, if the Employee fails to make such designation).</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="padding-left:5pt;padding-right:3.1pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">8.         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Enforceability</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">. If any portion or provision of this Agreement shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="padding-left:5pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">9.          </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Waiver</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">. No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party. The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach.</font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">9</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="padding-left:5pt;padding-right:3.15pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">10.        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Notices</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Any notices, requests, demands and other communications provided for by this Agreement shall be sufficient if in writing and delivered in person or sent by registered or certified mail, postage prepaid, to the Employee at the last address for which the Employee has provided written notice to the Employer, or to the Employer at its main office, to the attention of Human Resources</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:5pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">11.        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Publicity</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employee hereby grants to the Employer the right to use the Employee&#8217;s name and likeness, without additional consideration, on, in and in connection with technical, marketing and&#47;or disclosure materials published by or for the Employer for the duration of Employee&#8217;s employment with Employer.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="padding-left:5pt;padding-right:3.05pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">12.        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Conflicting Obligations and Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">. The Employee agrees to inform the Employer of any apparent conflicts between the Employee&#8217;s work for the Employer and (a) any obligations the Employee may have to preserve the confidentiality of another&#8217;s proprietary information or materials or (b) any rights the Employee claims to any inventions or ideas before using the same on the Employer&#8217;s behalf. Otherwise, the Employer may conclude that no such conflict exists and the Employee agrees thereafter to make no such claim against the Employer. The Employer shall receive such disclosures in confidence and consistent with the objectives of avoiding any conflict of obligations and rights or the appearance of any conflict of interest.</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="padding-left:5pt;padding-right:3.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">13.        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Notification of New Employer</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. In the event that the Employee leaves the employ of the Employer, voluntarily or involuntarily, the Employee agrees to inform any subsequent employer of the Employee&#8217;s obligations under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section</font></div><div style="padding-left:5pt;padding-right:3.25pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement. The Employee further hereby authorizes the Employer to notify the Employee&#8217;s new employer about the Employee&#8217;s obligations under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement.</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="padding-left:5pt;padding-right:3.15pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">14.        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Entire Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. This Agreement constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes any previous oral or written communications, negotiations, representations,  understandings, or agreements between them. Any modification of this Agreement shall be effective only if set forth in a written document signed by the Employee and a duly authorized officer of the Employer.</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="padding-left:5pt;padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">15.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Amendment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. This Agreement may be amended or modified only by a written instrument signed by the</font></div><div style="padding-left:5pt;padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Employee and by a duly authorized representative of the Employer.  </font></div><div style="padding-right:-1pt;margin-bottom:0.1pt;"><font><br></font></div><div style="padding-left:6pt;padding-right:3.15pt;margin-top:1.9pt;margin-bottom:0.1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;">16.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration: underline;">Governing Law</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;">. This is a California contract and shall be construed under and be governed in all respects by the laws of the State of California, without giving effect to the conflict of laws principles of such State.</font></div><div style="margin-top:0.25pt;"><font><br></font></div><div style="padding-left:6pt;padding-right:3.15pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">17.        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Obligations of Successors</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employer shall require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Employer to expressly assume and agree to perform this Agreement in the same manner and to the same extent that the Employer would be required to perform if no such succession had taken place.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:6pt;padding-right:266pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">18.        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;">Limitation on Payments in Certain Events.</font></div><div style="margin-top:0.1pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.15pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Limitation on Payments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Notwithstanding anything to the contrary in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement, if any payment or distribution that the Employee would receive pursuant to this Agreement or otherwise (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Payment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) would (a) constitute a &#8220;parachute payment&#8221; within the meaning of Section 280G of the Code), and (b) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Excise Tax</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;), then the Employer shall cause to be determined, before any amounts of the Payment are paid to the Employee, which of the following alternative forms of payment would maximize the Employee&#8217;s after-tax proceeds&#58; (i) payment in full of the entire amount of the Payment (a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Full Payment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;), or (ii) payment of only a part of the Payment so that the Employee receives that largest Payment possible without being subject to the Excise Tax (a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Reduced Payment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;), whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the Excise Tax (all computed at the highest marginal rate, net of the maximum reduction in federal income taxes which could be </font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">10</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="padding-left:6pt;padding-right:3.15pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">obtained from a deduction of such state and local taxes), results in the Employee&#8217;s receipt, on an after-tax basis, of the greater amount of the Payment, notwithstanding that all or some portion the Payment may be subject to the Excise Tax.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.1pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)         The independent registered public accounting firm engaged by the Employer for general audit purposes as of the day prior to the date the first Payment is due shall make all determinations required to be made under this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 18.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> If the independent registered public accounting firm so engaged by the Employer is serving as accountant or auditor for the individual, group or entity effecting the transaction, the Employer shall appoint a nationally recognized independent registered public accounting firm to make the determinations required hereunder. The Employer shall bear all expenses with respect to the determinations by such independent registered public accounting firm required to be made hereunder.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c)&#160;The independent registered public accounting firm engaged to make the determinations hereunder shall provide its calculations, together with detailed supporting documentation, to the Employer and the Employee at such time as requested by the Employer or the Employee. If the independent registered public accounting firm determines that no Excise Tax is payable with respect to a Payment, either before or after the application of the Reduced Payment, it shall furnish the Employer and the Employee with an opinion reasonably acceptable to the Employee that no Excise Tax will be imposed with respect to such Payment. Any good faith determinations of the accounting firm made hereunder shall be final, binding and conclusive upon the Parties.</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="padding-left:6pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">19.        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Consent to Jurisdiction&#59; Forum Selection</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. At all times the Employee and Employer&#58; (a) irrevocably submit to the exclusive jurisdiction of the Los Angeles Superior Court and United States District Court for the Central District of California, whichever may have competent subject matter jurisdiction, in any action or proceeding arising out of or relating to this Agreement, and irrevocably agree that all claims in respect of any such action or proceeding may be heard and determined in such court&#59; (b) to the extent permitted by law, irrevocably consent to the service of any and all process in any such action or proceeding by the mailing of copies of such process to such party at the address set forth in this Agreement (or otherwise on record with the Employer)&#59; (c) to the extent permitted by law, irrevocably confirm that service of process out of such courts in such manner shall be deemed due service upon such party for the purposes of such action or proceeding&#59; (d) to the extent permitted by law, irrevocably waives (i) any objection the Employee or Employer may have to the laying of venue of any such action or proceeding in any of such courts, or (ii) any claim that the Employee or Employer may have that any such action or proceeding has been brought in an inconvenient forum&#59; and (e) to the extent permitted by law, irrevocably agrees that a final nonappealable judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law. Nothing in this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> shall affect the right of any party hereto to serve legal process in any manner permitted by law.</font></div><div style="padding-right:3.1pt;text-align:justify;margin-bottom:0.1pt;"><font><br></font></div><div style="padding-left:5pt;padding-right:3.1pt;text-align:justify;margin-top:4.05pt;margin-bottom:0.1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">20.        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Counterparts</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">. This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be taken to be an original&#59; but such counterparts shall together constitute one and the same document.</font></div><div><font><br></font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:183.25pt;padding-right:188pt;text-align:center;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#91;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Signature Page Follows</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#93;</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><div id="i8095ce7046524458815a04479b03c773_34"></div><hr style="page-break-after:always"><div style="min-height:6pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="padding-left:5pt;padding-right:-1pt;margin-top:3.9pt;"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:60pt;padding-right:28.15pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">IN WITNESS WHEREOF, this Agreement has been executed as a sealed instrument by the Employer by its duly authorized officer, and by the Employee, as of the date first above written.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:60pt;padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EMPLOYER&#58;</font></div><div style="padding-left:60pt;padding-right:285.55pt;margin-top:0.05pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:230%;">NETWORK MEDICAL MANAGEMENT, INC.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:230%;">&#58; By&#58;                                         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:230%;text-decoration: underline;">&#47;s&#47;Thomas Lam, M.D. &#160;                                                                                                              </font></div><div style="margin-top:0.8pt;"><font><br></font></div><div style="padding-left:60pt;padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">Printed Name&#58;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;">Thomas Lam, M.D. &#160;</font></div><div style="margin-top:0.05pt;"><font><br></font></div><div style="padding-left:60pt;padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">Its&#58;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;">Co-Chief Executive Officer &#160;</font></div><div><font><br></font></div><div style="margin-top:0.45pt;"><font><br></font></div><div style="padding-left:60pt;padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EMPLOYEE&#58;</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="padding-left:60pt;padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">Signed&#58;                                   </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;">&#47;s&#47;Kenneth Sim, M.D. &#160;                                                                                                              </font></div><div style="margin-top:0.05pt;"><font><br></font></div><div style="padding-left:60pt;padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">Printed Name&#58;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;">Kenneth Sim, M.D. &#160;</font></div><div style="margin-top:0.05pt;"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:203.15pt;padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">&#91;Signature page to Employment Agreement&#93;</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:14pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><div id="i8095ce7046524458815a04479b03c773_37"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="padding-left:210.95pt;padding-right:211.1pt;text-align:center;margin-top:4pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EXHIBIT A</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:199.45pt;padding-right:199.4pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:113%;text-decoration: underline;">Release of Claims</font></div><div style="margin-top:0.1pt;"><font><br></font></div><div style="padding-left:41pt;padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">I,&#160;, in consideration of and subject to the performance by Network Medical Management,</font></div><div style="padding-left:5pt;padding-right:3.4pt;text-align:justify;margin-top:0.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Inc., a California corporation (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Company</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) of its obligations under the Employment Agreement, dated as of _ _,</font></div><div style="padding-left:5pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">20 (as amended from time to time, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">&#8221;), do hereby release and forever discharge as of the date of my execution of this release (this &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Release</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">&#8221;) the Company, its affiliated and related entities, its and their respective predecessors, successors and assigns, its and their respective employee benefit plans and fiduciaries of such plans, and the current and former officers, directors, shareholders, employees, attorneys, accountants and agents of each of the foregoing in their official and personal capacities (collectively, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Released Parties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">&#8221;) to the extent provided below.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:41.35pt;padding-right:3.1pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">1.&#160;I understand that any payments or benefits paid or granted to me under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Section 5(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;"> of the Agreement represent, in part, consideration for signing this Release and are not salary, wages or benefits to which I was already entitled. Such payments and benefits will not be considered compensation for purposes of any employee benefit plan, program, policy or arrangement maintained or hereafter established by the Company or its affiliates.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="padding-left:5.35pt;padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.&#160;Releases.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:41pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)         I knowingly and voluntarily (on behalf of myself, my spouse, my heirs, executors, administrators, agents and assigns, past and present) fully and forever release and discharge the Company and the other Released Parties from any and all claims, suits, controversies, actions, causes of action, cross claims, counterclaims, demands, debts, liens, contracts, covenants, suits, rights, obligations, expenses, judgments, compensatory damages, liquid damages, punitive or exemplary damages, other damages, claims for costs and attorneys&#8217; fees, orders and liabilities of whatever kind of nature, in law and in equity, in contract of in tort, both past and present (through the date this General Release becomes effective and enforceable) and whether known or unknown, vested or contingent, suspected, or claimed, against the Company or any of the Released Parties which I, my spouse, or any of my heirs, executors, administrators or assigns, may have, which arise out of or relate to my employment with, or my separation or termination from, the Company up to the date of my execution of this Release (including, but not limited to, any allegation, claim of violation arising under&#58; Title VII of the Civil Rights Act of 1964, as amended&#59; the Civil Rights Act of 1991&#59; the Age Discrimination in Employment Act of 1967, as amended (including the Older Workers Benefit Protection Act), the Equal Pay Act of 1963, as amended&#59; the Americans with Disabilities Act of 1990&#59; the Family and Medical Leave Act of 1993&#59; the Worker Adjustment Retraining and Notification Act&#59; the Employee Retirement Income Security Act of 1974&#59; the Fair Labor Standards Act&#59; or their state or local counterparts&#59; or under any other federal, state or local civil or human rights law, or under any other local state or federal law, regulation or ordinance&#59; or under any public policy, contract of tort, or under common law&#59; or arising under any policies, practices or procedures of the Company&#59; or any claim for wrongful discharge, breach of the Agreement, infliction of emotional distress or defamation&#59; or any claim for costs, fees, or other expenses, including attorneys&#8217; fees incurred in these matters) (collectively, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Claims</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;).</font></div><div style="margin-top:0.15pt;"><font><br></font></div><div style="padding-left:41pt;padding-right:3.15pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)          </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">SECTION 1542 WAIVER</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Employee agrees that all rights he may have under Section 1542 of the California Civil Code are hereby waived. Section 1542 provides&#58;</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="padding-left:77pt;padding-right:3.3pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:116%;">&#8220;A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM OR HER MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.&#8221;</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">13</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="padding-left:41pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Notwithstanding the provisions of Section 1542, and for the purpose of implementing a full and complete release, Employee agrees that this Agreement is intended to include all claims, if any, that Employee may have against the Company, and that this Agreement extinguishes those claims.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:41.35pt;padding-right:3.2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3.&#160;I represent that I have made no assignment of transfer of any right, claim, demand, cause of action, or other matter covered by </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> above.</font></div><div style="padding-right:3.2pt;margin-bottom:0.1pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:41.35pt;padding-right:3.1pt;text-align:justify;margin-top:1.65pt;margin-bottom:0.1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4.&#160;In signing this Release, I acknowledge and intend that it shall be effective as a bar to each and every one of the claims, demands and causes of action herein above mentioned or implied. I expressly consent that this Release shall be given full force and effect according to each and all of its express terms and provisions, including those relating to unknown and unsuspected claims up to the date of my execution of this Release, if any, as well as those relating to any other claims hereinabove mentioned. I acknowledge and agree that this waiver is an essential and material term of this Release and that without such waiver the Company would not have agreed to the terms of the Agreement. I further agree that in the event I should bring a claim seeking damages against the Company, this Release shall serve as a complete defense to such claims as to my rights and entitlements. I further agree that I am not aware of any pending charge or complaint of the type described in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> above as of the date of my execution of this Release.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:41.35pt;padding-right:3.2pt;text-align:justify;margin-top:1.7pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">5.&#160;I agree that neither this Release, nor the furnishing of the consideration for this Release, shall be deemed or constructed at any time to be an admission or acknowledgement by the Company, any Released Party or myself of any improper or unlawful conduct.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:41.35pt;padding-right:3.05pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">6.&#160;I agree and acknowledge that the provisions, conditions, and negotiations of this Release are confidential and agree not to disclose any information regarding the terms, conditions and negotiations of this Release, nor transfer any copy of this Release to any person or entity, other than my immediate family and any tax, legal or other counsel or advisor I have consulted regarding the meaning or effect hereof or as required by applicable law, and I will instruct each of the foregoing not to disclose the same to anyone.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:41.35pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">7.&#160;Notwithstanding anything in the Release to the contrary, nothing in this Release shall be deemed to affect, impair, relinquish, diminish, or in any way affect any rights or claims in any respect to (i) any vested rights or other entitlements that I may have as of the date of my execution of this Release under the Company&#8217;s</font></div><div style="padding-left:41.35pt;padding-right:3.05pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">401(k) plan&#59; (ii) any other vested rights or other entitlements that I may have as of the date of my execution of this Release under any employee benefit plan or program, in which I participated in my capacity as an employee of the Company&#59; (iii) my rights under the Agreement&#59; or (iv) my rights under the Release.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:5.35pt;padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">8.&#160;I understand that I continue to be bound by Section 6 of the Agreement.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:41.35pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">9.&#160;Whenever possible, each provision of this Release shall be interpreted in such a manner as to be effective and valid under applicable law, but if any provisions of this Release are held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other provision or any other jurisdiction, but this Release shall be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provisions had never been contained herein.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:41.35pt;padding-right:3.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">10.&#160;This Release shall be governed by and construed in accordance with the laws of the State of California, without giving effect to the conflict of laws principles of the State of California.</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="padding-left:41pt;padding-right:147.8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:231%;">BY SIGNING THIS RELEASE, I REPRESENT AND AGREE THAT&#58; (i)&#160;I HAVE READ IT CAREFULLY&#59;</font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">14</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="text-indent:-36pt;padding-left:77pt;padding-right:3.35pt;text-align:justify;margin-top:0.55pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(ii)         I UNDERSTAND ALL OF ITS TERMS AND KNOW THAT I AM GIVING UP IMPORTANT RIGHTS, INCLUDING BUT NOT LIMITED TO, RIGHTS UNDER THE AGE DISCRIMINATION IN EMPLOYMENT ACT OF 1967, AS AMENDED&#59;</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:41pt;padding-right:162.9pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(iii)        I VOLUNTARILY CONSENT TO EVERYTHING IN IT&#59;</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:77pt;padding-right:3.4pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(iv)        THE COMPANY IS HEREBY ADVISING ME TO CONSULT WITH AN ATTORNEY BEFORE EXECUTING IT, I HAVE HAD THE OPPORTUNITY TO SO CONSULT, AND HAVE AVAILED MYSELF OF SUCH ADVICE TO THE EXTENT I HAVE DEEMED NECESSARY TO MAKE A VOLUNTARY AND INFORMED CHOICE TO EXECUTE THIS RELEASE&#59;</font></div><div style="padding-right:3.4pt;text-align:justify;margin-bottom:0.1pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:77pt;padding-right:3.35pt;text-align:justify;margin-top:4.05pt;margin-bottom:0.1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(v)         I HAVE HAD AT LEAST TWENTY ONE (21) DAYS &#91;45 DAYS IN CONNECTION WITH A GROUP TERMINATION OR EXIT INCENTIVE PLAN&#93; FOLLOWING THE DATE OF TERMINATION OF MY EMPLOYMENT TO CONSIDER THIS RELEASE&#59;</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:77pt;padding-right:3.3pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(vi)       CHANGES TO THIS RELEASE, WHETHER MATERIAL OR IMMATERIAL, DO NOT RESTART THE RUNNING OF THE 21-DAY &#91;OR 45 DAY&#93; CONSIDERATION PERIOD&#59;</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:77pt;padding-right:3.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(vii)      I UNDERSTAND THAT I HAVE SEVEN (7) DAYS AFTER THE EXECUTION OF THIS RELEASE TO REVOKE IT, SUCH REVOCATION TO BE RECEIVED IN WRITING BY THE COMPANY BY THE END OF THE SEVENTH DAY AFTER THE DATE HEREOF, AND THAT THIS RELEASE SHALL NOT BECOME EFFECTIVE OR ENFORCEABLE UNTIL THE REVOCATION PERIOD HAS EXPIRED&#59;</font></div><div style="margin-top:0.75pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:77pt;padding-right:3.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;">(viii)      I HAVE SIGNED THIS RELEASE KNOWINGLY AND VOLUNTARILY AND WITH THE ADVICE OF ANY COUNSEL RETAINED TO ADVISE ME WITH RESPECT TO IT&#59; AND</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:77pt;padding-right:3.35pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(ix)        I AGREE THAT THE PROVISIONS OF THIS RELEASE MAY NOT BE AMENDED, WAIVED OR MODIFIED EXCEPT BY AN INSTRUMENT IN WRITING SIGNED BY AN AUTHORIZED REPRESENTATIVE OF THE COMPANY AND BY ME.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:5pt;padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">DATED AS OF </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;"> &#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">, 20</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;"> &#160;</font></div><div><font><br></font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="padding-left:5pt;padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#91;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Name</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#93;</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">15</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>ex1022020063010qngtlam.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ic67489550e3e41c1b112d75c8032d954_1"></div><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="padding-left:167.2pt;padding-right:166.4pt;text-align:center;margin-top:4pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EMPLOYMENT AGREEMENT</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:6pt;padding-right:3.05pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">THIS EMPLOYMENT AGREEMENT </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(this &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) is made and entered into as of June 8, 2020, by and between Network Medical Management, Inc., a California corporation (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Employer</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;), and Thomas Lam, M.D. (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Employee</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; and together with the Employer referred to as the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Parties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) to become effective as of the date hereof (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Effective</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;).</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.2pt;text-align:justify;margin-top:1.9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;">WHEREAS, the Employer desires to employ the Employee from and after the Effective Date on the terms and conditions set forth below, and the Employee is willing to serve the Employer on such terms and conditions.</font></div><div style="margin-top:0.45pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">NOW, THEREFORE, in consideration of the mutual covenants and agreements contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows&#58;</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="padding-left:6pt;padding-right:3.15pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.           </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Term</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The term of this Agreement shall initially be for a one (1) year period commencing on the Effective Date. The term of this Agreement shall automatically renew for an additional year on each anniversary of the Effective Date unless either Party gives the other written notice of intent not to renew at least sixty (60) days prior to such date. Notwithstanding the foregoing, the initial term and any renewal year shall be subject to earlier termination as provided in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> below. The initial term and any renewal years are referred to herein as the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Term</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;.</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="padding-left:6pt;padding-right:3.15pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.           </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Positions and Duties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. During the Term, the Employee shall serve as a senior executive officer of the Employer. The Employee shall perform for the Employer the duties customarily associated with being a senior executive officer that are consistent with your experience and skills and such other duties as may be assigned to the Employee from time to time by the Employer&#8217;s Board of Directors (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Board</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) that are consistent with the duties normally performed by those performing the role of the most senior executives of similar entities. The Employee shall devote such working time, attention, knowledge, skills and efforts as may be required to fulfill the Employee&#8217;s duties hereunder, as reasonably determined by the Board. The Employee shall be permitted to perform services as required under the Hospitalist Participation Service Agreement, and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">further</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> that the Employee may participate as a member of the board of directors or advisory board of other entities and in professional organizations and civic and charitable organizations so long as any such positions are disclosed to the Board and do not materially interfere with the Employee&#8217;s duties and responsibilities to the Employer. The Employee shall be based in Alhambra, California.</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="padding-left:6pt;padding-right:3.2pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3.           </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Compensation and Related Matters</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employer shall provide the Employee with the compensation and benefits set forth in this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> during the Term. Authority to take action under this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> with respect to the Employee&#8217;s compensation and benefits may be delegated by the Board to its compensation committee.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.2pt;text-align:justify;margin-top:1.7pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(a)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Base Salary</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">. The Employer shall pay the Employee for all services rendered a base salary of Nine Hundred Fifty Thousand Dollars ($950,000) per year (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Base Salary</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">&#8221;), payable in accordance with the Employer&#8217;s payroll procedures, subject to customary withholdings and employment taxes. The Base Salary shall be evaluated annually by the Board for increase only.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.2pt;text-align:justify;margin-top:1.7pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(b)        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Annual Bonus</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">. The Employee will be eligible to receive an annual cash bonus (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Annual Bonus</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">&#8221;) for each fiscal year during the Term on such terms and conditions as the Board shall determine in its discretion consistent with the terms of the Employer&#8217;s business plan.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.05pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c)      </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Long Term Incentive Awards</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employee shall be eligible to participate in any long term incentive plan that may be available to similarly positioned executives. The Board may determine to grant long-term incentive awards in cash or in equity awards settled in shares of the Employer&#8217;s stock, including but not limited to stock options, restricted stock and performance shares. In the event the Employee terminates service due to being a Good Leaver, any requirements under a long-term incentive award held by the Employee shall be deemed to have been satisfied by the Employer immediately prior to such termination. A &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Good Leaver</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; means that, during the </font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="padding-left:6pt;padding-right:3.05pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Term, either the Employee has resigned for Good Reason (as defined in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> below), the Employer has terminated the Employee&#8217;s employment without Cause (as defined in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> below or the Employee terminates employment on account of death or Disability (as defined in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> below). For avoidance of doubt, being a Good Leaver entitles the Employee to be fully vested with respect to any stock options with vesting conditions based solely on continued employment, and to be entitled to payment with respect to any long-term incentive award subject to corporate or business goals to the extent that such goals are met during the performance period on the same basis as if he had remained continuously employed with the Employer.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(d)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Paid Time Off</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. During the term, the Employee shall be entitled to twenty (20) business days of paid time off (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">PTO</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) per calendar year which shall be accrued ratably during the calendar year, to be taken at such times and intervals as shall be agreed to by Employer and the Employee in their reasonable discretion. The Employee shall be entitled to accrue a maximum of twenty (20) business days of paid time off. When the maximum accrual is reached, no additional PTO time will accrue until Employee uses one or more accrued PTO days. Accrued and unused PTO shall be paid in cash at the end of a calendar year.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(e)       </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Expenses</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employee shall be entitled to prompt reimbursement of reasonable and usual business expenses incurred on behalf of Employer in accordance with the Employer&#8217;s expense reimbursement policy.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.1pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(f)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Other Benefits</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employee shall be entitled to continue to participate in or receive benefits under any employee benefit plan or arrangement which is or may, in the future, be made available by the Employer to its employees, subject to and on a basis consistent with the terms, conditions and overall administration of such plan or arrangement. Irrespective of other benefits provided to employees, the Employee&#8217;s benefits package shall include&#58; (i) the Employer&#8217;s payment of premiums for medical, dental and vision care coverage&#59; (ii) the Employer&#8217;s payment of insurance premiums for short-term and long-term disability insurance providing for no less than sixty percent (60%) of Employee&#8217;s Base Salary to be payable to the Employee as long as the covered disability persists in a manner that substantially prevents employment in the same occupation as the position Employee last held with Employer but not beyond age sixty-five (65)&#59; and (iii) the Employer&#8217;s payment of insurance premiums for term life insurance providing for no less than two million dollars of coverage (subject to meeting applicable underwriting requirements).</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(g)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Tax Withholding</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employer shall undertake to make deductions, withholdings and tax reports with respect to payments and benefits under this Agreement, to the extent it reasonably and in good faith believes it is required to make such deductions, withholdings and tax reports. Payments with respect to compensation and benefits referred to under this Agreement shall be in amounts net of any such deductions or withholdings. Nothing in this Agreement shall be construed to require the Employer to make any payments to compensate the Employee for any adverse tax effect associated with any payments or benefits, or for any deduction or withholding from any payment or benefit.</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="padding-left:6pt;padding-right:3.2pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employee&#8217;s employment hereunder may be terminated during the Term without any breach of this Agreement under the following circumstances&#58;</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="padding-left:42pt;padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">(a)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;">Death</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">. The Employee&#8217;s employment hereunder shall terminate upon the Employee&#8217;s death.</font></div><div style="padding-right:-1pt;margin-bottom:0.1pt;"><font><br></font></div><div style="padding-left:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">             (b)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;">Disability</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. The Employer may terminate the Employee&#8217;s employment if the Employee is disabled and, because of the disability, is unable to perform the essential functions of the Employee&#8217;s then existing position or positions under this Agreement with or without reasonable accommodation. This provision is not intended to reduce any rights the Employee may have pursuant to any law, including without limitation the California Family Rights Act, the Family and Medical Leave Act, the California Fair Employment and Housing Act, and the Americans with Disabilities Act.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Termination by the Employer for Cause</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. At any time during the Term, the Employer may terminate the Employee&#8217;s employment hereunder for Cause. For purposes of this Agreement, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Cause</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; shall mean&#58; (i) conduct by the Employee constituting a material act of willful misconduct in connection with the performance of the Employee&#8217;s duties that results in loss, damage or injury that is material to the Employer&#59; (ii) the commission by the </font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="padding-left:6pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Employee of any felony&#59; (iii) continued, willful and deliberate non-performance by the Employee of the Employee&#8217;s duties hereunder (other than by reason of the Employee&#8217;s physical or mental illness, incapacity or disability)&#59; (iv) a material breach, according to the standard of the Employer, by the Employee of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement that results in loss, damage or injury that is material to the Employer&#59; (v) willful failure to cooperate with a bona fide internal investigation or an investigation by regulatory or law enforcement authorities, after being instructed by the Employer to cooperate, or the willful destruction or failure to preserve documents or other materials known to be relevant to such investigation or the willful inducement of others to fail to cooperate or to produce documents or other materials in connection with such investigations&#59; or (vi) fraud, embezzlement or theft against the Employer or any of its Affiliates (as defined in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> below). With respect to the events in (i), (iii) and (iv) herein, the Employer shall have delivered written notice to the Employee of its intention to terminate the Employee&#8217;s employment for Cause, which notice specifies in reasonable detail the circumstances claimed to give rise to the Employer&#8217;s right to terminate the Employee&#8217;s employment for Cause and the Employee shall not have cured such circumstances to the extent such circumstances are reasonably susceptible to cure as determined by the Board in good faith within thirty (30) days following the Employer&#8217;s delivery of such notice. For avoidance of doubt, &#8220;Cause&#8221; shall not include (x) expense reimbursement disputes in which the Employee acts in reasonable good faith&#59; (y) occasional, customary and de minimis use of the Employer&#8217;s property for personal purposes&#59; and (z) acting in good faith upon advice of Employer&#8217;s legal counsel.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.15pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(d)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Termination without Cause</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. At any time during the Term, the Employer may terminate the Employee&#8217;s employment hereunder without Cause by providing the Employee with thirty (30) days advance written notice. Any termination by the Employer of the Employee&#8217;s employment under this Agreement that does not constitute a termination for Cause under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> and does not result from the death or Disability of the Employee under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Sections 4(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> or </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">4(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> shall be deemed a termination without Cause under this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Any suspension of the Employee&#8217;s employment with pay or benefits by the Board in good faith pending an investigation of alleged improper activities by the Employee that, if determined to be accurate, would be grounds for a Cause termination, shall not be considered a termination of the Employee&#8217;s employment without Cause or provide with Good Reason to terminate employment.</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(e)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Termination by the Employee</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. At any time during the Term, the Employee may terminate his employment hereunder for any reason, including, but not limited to, Good Reason. For purposes of this Agreement, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Good Reason</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; shall mean that the Employee has complied with the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Good Reason Process</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; (hereinafter defined) following the occurrence of any of the following events&#58; (i) a material diminution in the Employee&#8217;s responsibilities, authority or duties&#59; (ii) the material breach of this Agreement by the Employer, including but not limited to a failure to pay Base Salary or Annual Bonus as provided for under this Agreement&#59; or (iii) any relocation of the Employee&#8217;s principal place of business to a location more than 30 miles from the Employer&#8217;s current executive offices in Alhambra, California&#59; provided, however, that this clause (iii) will not apply to the extent that any new office location is less than 30 miles from the Employee&#8217;s residence. &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Good Reason Process</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; shall mean (i) the Employee reasonably determines in good faith that a &#8220;Good Reason&#8221; condition has occurred&#59; (ii) the Employee notifies the Employer in writing of the occurrence of the Good Reason condition within (60) days of the occurrence of such condition&#59; (iii) the Employee cooperates in good faith with the Employer&#8217;s efforts, for a period of sixty (60) days following such notice (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Cure Period</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;), to remedy the condition&#59; (iv) notwithstanding such efforts, the Good Reason condition continues to exist&#59; and (v) the Employee terminates his employment within thirty (30) days after the end of the Cure Period. If the Employer cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not to have occurred.</font></div><div style="margin-top:0.25pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.2pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(f)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Notice of Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Except for termination as specified in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, any termination of the Employee&#8217;s employment shall be communicated by written Notice of Termination by the terminating Party to the other Party hereto. For purposes of this Agreement, a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Notice of Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; shall mean a notice which shall indicate the specific termination provision in this Agreement relied upon.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(g)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Date of Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Date of Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; shall mean the earliest of the following&#58; (i) if the Employee&#8217;s employment is terminated by the Employee&#8217;s death, the date of the Employee&#8217;s death&#59; (ii) if the Employee&#8217;s employment is terminated on account of Disability under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> or by the Employer for Cause under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, the date on which Notice of Termination is given that follows any applicable required cure </font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="padding-left:6pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">period&#59; (iii) if the Employee&#8217;s employment is terminated by the Employer under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, thirty (30) days after the date on which a Notice of Termination is given&#59; (iv) if the Employee&#8217;s employment is terminated by the Employee under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> without Good Reason, thirty (30) days after the date of which a Notice of Termination is given or such shorter period agreed to by the Employer&#59; or (v) if the Employee&#8217;s employment is terminated by the Employee under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> with Good Reason, the date on which Notice of Termination is given after the end of the Cure Period. Notwithstanding the foregoing, in the event that the Employee gives a Notice of Termination to the Employer, the Employer may unilaterally accelerate the Date of Termination but such acceleration shall nevertheless be deemed a termination by the Employee on the accelerated date for purposes of this Agreement. For purposes of determining the time when the lump sum portion of the Severance Amount, if any, is to be paid under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 5(b)(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Date of Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; means the Employee&#8217;s separation from service as defined under Section 409A.</font></div><div style="text-align:justify;"><font><br></font></div><div style="padding-left:8.5pt;padding-right:-1pt;margin-top:4pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">5.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;">Compensation upon Termination.</font></div><div style="margin-top:0.45pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.05pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Accrued Benefits.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> If the Employee&#8217;s employment with the Employer is terminated for any reason during the Term, or if the Term is not renewed, the Employer shall pay or provide the Employee (or the Employee&#8217;s authorized representative or estate) any earned but unpaid Base Salary or Annual Bonus for services rendered through the Date of Termination, unpaid expense reimbursements, and accrued but unused paid time off (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Accrued</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Benefits</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) within the time prescribed by California law. With respect to vested compensation or benefits the Employee may have under any employee benefit or compensation plan, program or arrangement of the Employer, payment will be made to the Employee under the terms of the applicable plan, program or arrangement.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Termination by  the Employer without Cause or by the Employee with Good</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Reason</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. If the Employee&#8217;s employment is terminated by the Employer without Cause as provided in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, or the Employee terminates his employment for Good Reason as provided in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, or the Employee terminates employment at the end of the Term after the Employer provides notice of intent not to renew pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> for reasons other than would provide grounds for a Cause termination, then, (i) the Employer shall, through the Date of Termination, pay the Employee his or her Accrued Benefits, and (ii) if the Employee signs a general release of claims substantially in the form which is attached as </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Exhibit A</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to this Agreement) (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Release</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) within twenty-one (21) days of the receipt of the form of the Release (extended to forty-five (45) days in the event of a group termination or exit incentive program) and does not revoke such Release during the seven-day revocation period&#58;</font></div><div style="margin-top:0.25pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:42pt;padding-right:3.05pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(i)         the Employer shall pay the Employee an amount equal to one-twelfth (1&#47;12) of the Employee&#8217;s most recent Base Salary times the number of full years of service completed, not to exceed twelve (12) years of service (but determined prior to any action involving Base Salary that would constitute Good Reason) (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Severance Amount</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;). Employer acknowledges that Employee has completed not less than twelve (12) full years of service (including Employee&#8217;s service for the Employer&#8217;s parent entity, subsidiaries and affiliates), such that the Severance Amount payable to Employee pursuant to the terms of this Agreement shall equal the maximum Severance Amount of one (1) year of the Employee&#8217;s most recent Base Salary. To the extent that such Severance Amount exceeds the 409A Separation Pay Limit (as defined below), such amount shall be paid in a single lump sum on the regular payroll date of the Employer, pertaining to then current salaried employees of the Employer, (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">payroll date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) next following the first anniversary date of the Employee&#8217;s Date of Termination. The portion of the Severance Amount that does not exceed the 409A Separation Pay Limit shall be paid in substantially equal amounts on each payroll date over a one year period&#59; and</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:42pt;padding-right:3.15pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(ii)        the Employer shall pay the Employee an amount in cash equal to the Employer&#8217;s premium amounts paid for coverage of Employee at the time of the Employee&#8217;s termination of coverage under the Employer&#8217;s group medical, dental and vision programs for a period of twelve (12) months, to be paid directly to the Employee at the same times such payments would be paid on behalf of a current employee for such coverage&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#58;</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="text-indent:36pt;padding-left:78pt;padding-right:3.15pt;text-align:justify;margin-top:1.7pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(A)        No  payments shall  be  made  under  this  paragraph (ii)  unless  and  until  the Employee timely elects continued coverage under such plan(s) pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1985 as amended (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">COBRA</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">&#8221;)&#59;</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:78pt;padding-right:3.25pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(B)&#160;This paragraph (ii) shall not be read or construed as placing any restrictions upon amounts paid under this paragraph (ii) as to their use&#59;</font></div><div style="margin-top:0.75pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:78pt;padding-right:3.2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;">(C)&#160;Payments under this paragraph (ii) shall cease as of the earliest to occur of the following&#58;</font></div><div style="margin-top:0.45pt;"><font><br></font></div><div style="padding-left:150pt;padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(1)&#160;the Employee is no longer eligible for and continuing to receive the</font></div><div style="padding-left:114pt;padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">COBRA coverage elected in subparagraph (A)&#59;</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="padding-left:150pt;padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(2)&#160;the time period set forth in the first sentence of this paragraph (ii),</font></div><div><font><br></font></div><div style="padding-left:149pt;padding-right:3.2pt;text-align:justify;margin-top:4pt;margin-bottom:0.1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(3)        the date on which the Employee first becomes eligible to enroll in a group health plan in which eligibility is based on employment with an employer, and</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:149pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(4)        if the Employer in good faith determines that payments under this paragraph (ii) would result in a discriminatory health plan pursuant to the Patient Protection and Affordable Care Act of 2010, as amended.</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="padding-left:185pt;padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(iii)&#160;Each individual payment of Severance Amount under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section</font></div><div style="padding-left:149pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;">5(b)(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">, and each payment under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;">Section 5(b)(ii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> of this Agreement, shall be deemed to be a separate &#8220;payment&#8221; for purposes and within the meaning of Treasury Regulation Section 1.409A-2(b)(2)(iii).</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:149pt;padding-right:3.15pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(iv)       Each    individual    payment    of    the    Severance    Amount under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Section   5(b)(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">,   and   each   payment   under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Section   5(b)(ii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">,   of   this Agreement, which are considered &#8220;non-qualified deferred compensation&#8221; (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">NQDC</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">&#8221;) under Section 409A shall be made on the date(s) provided herein and no request to accelerate or defer any such payment under this Agreement shall be considered or approved for any reason whatsoever, except as permitted under Section 409A and as the Employer allows in its sole discretion. The Employer may in its sole discretion accelerate or defer (but not beyond the time limit set forth below) any severance payments which do not constitute NQDC in order to allow for the payment of taxes due, but not beyond the time limit specified for such payment such that the payment would be treated as NQDC. Subject to the requirements of  Section 409A, if  any severance payment or  reimbursement under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Section 5(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;"> of this Agreement is determined in good faith by the Employer to constitute NQDC payable to a &#8220;specified employee&#8221; as defined under Section</font></div><div style="padding-left:149pt;padding-right:3.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">409A, then the Employer shall make any such payment not earlier than the earlier of&#58; (x) the first payroll date which is six (6) months following the Employee&#8217;s separation from service (as defined under Section 409A) with the Employer, or (y) the date of Employee&#8217;s death.</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="padding-left:185pt;padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(v)&#160;for purposes of this Section 5, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 409A</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; means Section</font></div><div style="padding-left:149pt;padding-right:18.3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">409A of the Internal Revenue Code of 1986, as amended, and the regulations thereunder.</font></div><div style="margin-top:0.45pt;"><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="text-indent:36pt;padding-left:149pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(vi)       for purposes of this Section 5, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">409A Separation Pay Limit</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; means two times the lesser of (</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">x</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">) the Employee&#8217;s annual compensation during the calendar year preceding the year of the termination of employment&#59; and (</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">y</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">) the adjusted compensation limit under Code Section 401(a)(17) in effect for the year of the termination.</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="padding-left:5pt;padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">6.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;">Confidential Information, Nonsolicitation, and Cooperation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">.</font></div><div style="margin-top:0.1pt;"><font><br></font></div><div style="padding-left:41pt;padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">(a)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;">Definitions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">.</font></div><div style="margin-top:0.1pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:41pt;padding-right:3.05pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(i)          As used in this Agreement, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Affiliate</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">&#8221; means, as to any Person, (i) any other Person which directly, or indirectly through one or more intermediaries, controls such Person or is consolidated with such Person in accordance with GAAP, (ii) any other Person which directly, or indirectly through one or more intermediaries, is controlled by or is under common control with such Person, or (iii) any other Person of which such Person owns, directly or indirectly, fifty percent (50%) or more of the common stock or equivalent equity interests. As used herein, the term &#8220;control&#8221; means possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of a Person, whether through the ownership of voting securities or otherwise.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:36pt;padding-left:42pt;padding-right:3.2pt;margin-top:4pt;margin-bottom:0.1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(ii)&#160;As used in this Agreement, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Person</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; means an individual, a corporation, a partnership, a limited liability company, an association, a trust or any other entity or organization.</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.1pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Confidential  Information</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  As   used   in   this   Agreement,  &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Confidential</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Information</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;  means information belonging to the Employer or its Affiliates which is of value to the Employer or any of its Affiliates in the course of conducting its business (whether having existed, now existing, or to be developed or created during Employee&#8217;s employment by Employer) and the disclosure of which could result in a competitive or other disadvantage to the Employer or its Affiliates. Confidential Information includes, without limitation, contract terms and rates&#59; negotiating and contracting strategies&#59; financial information, reports, and forecasts&#59; inventions, improvements and other intellectual property&#59; product plans or proposed product plans&#59; trade secrets&#59; designs, processes or formulae&#59; software&#59; employee, customer, patient, provider and supplier information&#59; information from patient medical records&#59; financial data&#59; insurance reimbursement methodologies, strategies and practices&#59; product and service pricing methodologies, strategies and practices&#59; contracts with physicians, providers, provider networks, payors, physician databases and contracts with hospitals&#59; regulatory and clinical manuals&#59; and business plans, prospects and opportunities (such as possible acquisitions or dispositions of businesses or facilities) that have been discussed or considered by the Employer or its Affiliates, including, without limitation, the management of the Employer or its Affiliates. Confidential Information includes information developed by the Employee in the course of the Employee&#8217;s employment by the Employer, as well as other information to which the Employee may have access in connection with the Employee&#8217;s employment. Confidential Information also includes the confidential information of others with which the Employer or its Affiliates has a business relationship. Notwithstanding the foregoing, Confidential Information does not include information in the public domain, unless due to breach of the Employee&#8217;s duties under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, unless otherwise due to Employee&#8217;s breach of the obligations in this Agreement, or unless due to violation of another Person&#8217;s obligations to the Employer or its Affiliates that Employee should have taken reasonable measures to prevent but that Employee did not take.</font></div><div style="margin-top:0.45pt;"><font><br></font></div><div><font><br></font></div><div style="text-indent:38.5pt;padding-left:6pt;padding-right:4.9pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Confidentiality</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employee understands and agrees that the Employee&#8217;s employment creates a relationship of confidence and trust between the Employer and the Employee with respect to all Confidential Information. At all times, both during the Employee&#8217;s employment with the Employer and after the Employee&#8217;s termination from employment for any reason, the Employee shall keep in confidence and trust all such Confidential Information, and shall not use, disclose, or transfer any such Confidential Information without the written consent of the Employer, except as may be necessary within the scope of Employee&#8217;s duties with Employer and in the ordinary course of performing the Employee&#8217;s duties to the Employer or as otherwise provided in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Employee understands and agrees not to sell, license or otherwise exploit any products or services which embody or otherwise </font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="padding-left:6pt;padding-right:4.9pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">exploit in whole or in part any Confidential Information or materials. Employee acknowledges and agrees that the sale, misappropriation, or unauthorized use or disclosure in writing, orally or by electronic means, at any time of Confidential Information obtained by Employee during or in connection with the course of Employee&#8217;s employment constitutes unfair competition. Employee agrees and promises not to engage in unfair competition with Employer or its Affiliates, either during employment, or at any time thereafter.</font></div><div style="margin-top:0.45pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(d)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Protected Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Notwithstanding anything to the contrary in this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, this Agreement is not intended to, and shall not, in any way prohibit, limit or otherwise interfere with the Employee&#8217;s protected rights under federal, state or local law to, without notice to the Employer, (i) communicate or file a charge with a government regulator&#59; (ii) participate in an investigation or proceeding conducted by a government regulator&#59; or (iii) receive an award paid by a government regulator for providing information.</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.2pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(e)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Documents, Records, etc</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. All documents, records, data, apparatus, equipment and other physical property, whether or not pertaining to Confidential Information, that are furnished to the Employee by the Employer or its Affiliates or are produced by the Employee in connection with the Employee&#8217;s employment will be and remain the sole property of the Employer and its Affiliates. The Employee shall return to the Employer all such materials and property as and when requested by the Employer. In any event, the Employee shall return all such materials and property immediately upon termination of the Employee&#8217;s employment for any reason. The Employee shall not retain any such material or property or any copies thereof after such termination. It is specifically agreed that any documents, card files, notebooks, programs, or similar items containing customer or patient information are the property of the Employer and its Affiliates regardless of by whom they were compiled.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:36pt;padding-left:5pt;padding-right:3.15pt;text-align:justify;margin-top:1.9pt;margin-bottom:0.1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;">(f)          </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration: underline;">Disclosure Prevention</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;">. The Employee will take all reasonable precautions to prevent the inadvertent or accidental exposure of Confidential Information.</font></div><div style="padding-right:3.15pt;text-align:justify;margin-bottom:0.1pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:5pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">(g)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;">Removal of Material</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. The Employee will not remove any Confidential Information from the Employer&#8217;s or its Affiliate&#8217;s premises except for use in the Employer&#8217;s business, and only consistent with the Employee&#8217;s duties with the Employer.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:5pt;padding-right:3.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(h)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Copying</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">. The Employee agrees that copying or transferring Confidential Information (by any means) shall be done only as needed in furtherance of and for use in the Employer&#8217;s and its Affiliate&#8217;s business, and consistent with the Employee&#8217;s duties with the Employer. The Employee further agrees that copies of Confidential Information shall be treated with the same degree of confidentiality as the original information and shall be subject to all restrictions herein.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:5pt;padding-right:3.15pt;text-align:justify;margin-top:1.9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;">(i)           </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration: underline;">Computer Security</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;">. The Employee agrees to comply with the Employer&#8217;s policies and procedures concerning computer security.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:5pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(j)           </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">E-Mail</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employee acknowledges that the Employer retains the right to review any and all electronic mail communications made with employer provided email accounts, hardware, software, or networks, with or without notice, at any time.</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:5pt;padding-right:3.15pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(k)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Assignment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employee acknowledges that any and all inventions, discoveries, designs, developments, methods, modifications, trade secrets, processes, software, formulae, data, &#8220;know-how,&#8221; databases, algorithms, techniques and works of authorship whether or not patentable or protectable by copyright or trade secret, made or conceived, first reduced to practice, or learned by the Employee, either alone or jointly with others, during the Term that (i) relate to or are useful in the business of the Employer or its Affiliates, or (ii) are conceived, made or worked on at the expense of or during the Employee&#8217;s work time for the Employer, or using any resources or materials of the Employer or its Affiliates, or (iii) arise out of tasks assigned to the Employee by the Employer (together &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Proprietary Inventions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) will be the sole property of the Employer or its Affiliates. The Employee acknowledges that all work performed by the Employee is on a &#8220;work for hire&#8221; basis and the Employee hereby assigns or agrees to assign to the Employer the Employee&#8217;s entire right, title and interest in and to any and all Proprietary Inventions and related intellectual property rights. The Employee agrees to assist the Employer to obtain, </font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">7</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="padding-left:5pt;padding-right:3.15pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">maintain and enforce intellectual property rights for Proprietary Inventions in any and all countries during the Term, and thereafter for as long as such intellectual property rights exist.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="padding-left:144.7pt;padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:113%;text-decoration: underline;">NOTICE TO CALIFORNIA EMPLOYEES</font></div><div style="margin-top:0.1pt;"><font><br></font></div><div style="padding-left:41pt;padding-right:39.1pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">Pursuant to California Labor Code &#167;2870, an agreement requiring the employee to assign or offer to assign any of his or her rights in any invention to his or her employer does not apply to an invention which qualifies fully under the provisions of California Labor Code &#167; 2870, which provides as follows&#58;</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:41pt;padding-right:39.05pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)         Any provision in an employment agreement which provides that an employee shall assign, or offer to assign, any of his or her rights in an invention to his or her employer shall not apply to an invention that the employee developed entirely on his or her own time without using the employer&#8217;s equipment, supplies, facilities, or trade secret information except for those inventions that either&#58;</font></div><div style="margin-top:0.6pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:77pt;padding-right:39.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(1)        Relate at the time of conception or reduction to practice of the invention to the employer&#8217;s business, or actual or demonstrably anticipated research or development of the employer&#59; or</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="padding-left:113pt;padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(2)&#160;Result from any work performed by the employee for the employer.</font></div><div style="margin-top:0.75pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:41pt;padding-right:39.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;">(b)         To the extent a provision in an employment agreement purports to require an employee to assign an invention otherwise excluded from being required to be assigned under</font></div><div style="text-align:justify;"><font><br></font></div><div style="padding-left:42pt;padding-right:39.15pt;margin-top:4pt;margin-bottom:0.1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">subdivision (a),  the  provision is  against the  public policy  of  the  State  of  California and  is unenforceable.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(l)           </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Nonsolicitation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Employee agrees and covenants that, at any time during Employee&#8217;s employment with the Employer and for a period of twelve (12) months immediately following the termination of Employee&#8217;s relationship with the Employer for any reason, whether with or without cause, Employee shall not, either on Employee&#8217;s own behalf or on behalf of any other Person&#58; (i) solicit the services of the Employer&#8217;s employees or entice away, directly or indirectly, any Person employed or engaged by or otherwise providing services to the Employer or its Affiliates, whether in an employment capacity or otherwise (this provision does not prohibit the Employee&#8217;s post- termination acceptance of unsolicited applications for employment)&#59; or (ii) take any illegal action or engage in any unfair business practice, including, without limitation, any misappropriation of confidential, proprietary or trade secret information of the Employer or its Affiliates, as a result of which relations between the Employer or its Affiliates, and any of their customers, clients, suppliers, distributors or others, may be impaired or which might otherwise be detrimental to the business interests or reputation of the Employer or its Affiliates.</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.05pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(m)        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Third-Party Agreements and Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employee hereby confirms that the Employee is not bound by the terms of any agreement with any previous employer or other party which restricts in any way the Employee&#8217;s use or disclosure of information or the Employee&#8217;s engagement in any business except as Employee has previously provided written notice to Employer and has attached to this Agreement. The Employee represents to the Employer that the Employee&#8217;s execution of this Agreement, the Employee&#8217;s employment with the Employer and the performance of the Employee&#8217;s proposed duties for the Employer will not violate any obligations the Employee may have to any previous employer or other party. In the Employee&#8217;s work for the Employer, the Employee will not disclose or use any information in violation of any agreements with or rights of any such previous employer or other party, and the Employee will not bring to (by any means) the premises of the Employer any copies or other tangible embodiments of non- public information belonging to or obtained from any such previous employment or other party.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">8</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(n)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Litigation  and  Regulatory  Cooperation.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  During  and  after  the  Employee&#8217;s  employment,  the Employee shall cooperate fully with the Employer in the defense or prosecution of any claims or actions now in existence or that may be brought in the future against or on behalf of the Employer that relate to events or occurrences that transpired while the Employee was employed by the Employer. The Employee&#8217;s full cooperation in connection with such claims or actions shall include, but not be limited to, being available to meet with counsel to prepare for discovery or trial and to act as a witness on behalf of the Employer at mutually convenient times. During and after the Employee&#8217;s employment, the Employee also shall cooperate fully with the Employer in connection with any investigation or review of any federal, state, or local regulatory authority as any such investigation or review relates to events or occurrences that transpired while the Employee was employed by the Employer. The Employer shall reimburse the Employee for any reasonable out of pocket expenses incurred in connection with the Employee&#8217;s performance of obligations pursuant to this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. &#8220;Full cooperation&#8221; shall not be construed to in any way require any violation of law or any testimony that is false or misleading.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(o)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Enforcement&#59; Injunction.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The Employee acknowledges and agrees that the restrictions contained in this Agreement are reasonable and necessary to protect the business and interests of the Employer and its Affiliates, do not create any undue hardship for the Employee, and that any violation of the restrictions in this Agreement would cause the Employer and its Affiliates substantial irreparable injury. Accordingly, the Employee agrees that a remedy at law for any breach or threatened breach of the covenants or other obligations in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement would be inadequate and that the Employer, in addition to any other remedies available, shall be entitled to obtain preliminary and permanent injunctive relief to secure specific performance of such covenants and to prevent a breach or contemplated or threatened breach of this Agreement without the necessity of proving actual damage and without the necessity of posting bond or security, which the Employee expressly waives. Moreover, the Employee will provide the Employer a full accounting of all proceeds and profits received by the Employee as a result of or in connection with a breach of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement. Unless prohibited by law, the Employer shall have the right to retain any amounts otherwise payable by the Employer to the Employee to satisfy any of the Employee&#8217;s obligations as a result of any breach of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement. The Employee hereby agrees to indemnify and hold harmless the Employer and its Affiliates from and against any damages incurred by the Employer or its Affiliates as assessed by a court of competent jurisdiction as a result of any breach of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement by the Employee. The prevailing party shall be entitled to recover its reasonable attorneys&#8217; fees and costs if it prevails in any action to enforce </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement. It is the express intention of the parties that the obligations of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement shall survive the termination of the Employee&#8217;s employment. The Employee agrees that each obligation specified in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement is a separate and independent covenant that shall survive any termination of this Agreement and that the unenforceability of any of them shall not preclude the enforcement of any other covenants in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement. No change in the Employee&#8217;s duties or compensation shall be construed to affect, alter or otherwise release the Employee from the covenants herein.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="padding-left:6pt;padding-right:3.05pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">7.          </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Successors</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">. This Agreement shall be binding upon and inure to the benefit of both parties and their respective successors and permitted assigns, including any corporation or entity with which or into which the Employer may be merged or which may succeed to its assets or business, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">, that Employee&#8217;s obligations are personal and shall not be assigned by Employee. The Employee consents to be bound by the provisions of this Agreement for the benefit of the Employer or its Affiliates to whose employ the Employee may be transferred without the necessity that this Agreement be resigned at the time of such transfer. In the event of the Employee&#8217;s death after the Date of Termination but prior to the completion by the Employer of all payments due to the Employee under this Agreement, the Employer shall continue such payments to the Employee&#8217;s beneficiary designated in writing to the Employer prior to the Employee&#8217;s death (or to the Employee&#8217;s estate, if the Employee fails to make such designation).</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="padding-left:6pt;padding-right:3.1pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">8.         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Enforceability</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">. If any portion or provision of this Agreement shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="padding-left:6pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">9.          </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Waiver</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">. No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party. The failure of any party to require the performance of any term or obligation of this Agreement, or the </font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">9</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="padding-left:6pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">waiver by any party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="padding-left:6pt;padding-right:3.15pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">10.        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Notices</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Any notices, requests, demands and other communications provided for by this Agreement shall be sufficient if in writing and delivered in person or sent by registered or certified mail, postage prepaid, to the Employee at the last address for which the Employee has provided written notice to the Employer, or to the Employer at its main office, to the attention of Human Resources</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:6pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">11.        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Publicity</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employee hereby grants to the Employer the right to use the Employee&#8217;s name and likeness, without additional consideration, on, in and in connection with technical, marketing and&#47;or disclosure materials published by or for the Employer for the duration of Employee&#8217;s employment with Employer.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="padding-left:6pt;padding-right:3.1pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">12.        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Conflicting Obligations and Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">. The Employee agrees to inform the Employer of any apparent conflicts between the Employee&#8217;s work for the Employer and (a) any obligations the Employee may have to preserve the confidentiality of another&#8217;s proprietary information or materials or (b) any rights the Employee claims to any inventions or ideas before using the same on the Employer&#8217;s behalf. Otherwise, the Employer may conclude that no such conflict exists and the Employee agrees thereafter to make no such claim against the Employer. The Employer shall receive such disclosures in confidence and consistent with the objectives of avoiding any conflict of obligations and rights or the appearance of any conflict of interest.</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="padding-left:6pt;padding-right:3.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">13.        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Notification of New Employer</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. In the event that the Employee leaves the employ of the Employer, voluntarily or involuntarily, the Employee agrees to inform any subsequent employer of the Employee&#8217;s obligations under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section</font></div><div style="padding-left:6pt;padding-right:3.25pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement. The Employee further hereby authorizes the Employer to notify the Employee&#8217;s new employer about the Employee&#8217;s obligations under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement.</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="padding-left:6pt;padding-right:3.1pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">14.        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Entire Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. This Agreement constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes any previous oral or written communications, negotiations, representations, understandings, or agreements between them. Any modification of this Agreement shall be effective only if set forth in a written document signed by the Employee and a duly authorized officer of the Employer.</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="padding-left:6pt;padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">15.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Amendment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. This Agreement may be amended or modified only by a written instrument signed by the</font></div><div style="padding-left:6pt;padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Employee and by a duly authorized representative of the Employer.</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:3.15pt;margin-top:1.9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;">16.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration: underline;">Governing Law</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;">. This is a California contract and shall be construed under and be governed in all respects by the laws of the State of California, without giving effect to the conflict of laws principles of such State.</font></div><div style="margin-top:0.25pt;"><font><br></font></div><div style="padding-left:6pt;padding-right:3.15pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">17.        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Obligations of Successors</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employer shall require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Employer to expressly assume and agree to perform this Agreement in the same manner and to the same extent that the Employer would be required to perform if no such succession had taken place.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:6pt;padding-right:265.95pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">18.        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;">Limitation on Payments in Certain Events.</font></div><div style="margin-top:0.1pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.15pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Limitation on Payments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Notwithstanding anything to the contrary in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement, if any payment or distribution that the Employee would receive pursuant to this Agreement or otherwise (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Payment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) would (a) constitute a &#8220;parachute payment&#8221; within the meaning of Section 280G of the Code), and (b) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Excise Tax</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;), then the Employer shall cause to be determined, before any amounts of the Payment are paid to the Employee, which of the following alternative forms of payment would maximize the Employee&#8217;s after-tax proceeds&#58; (i) payment in full of the entire amount of the Payment (a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Full Payment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;), or (ii) payment of only a part of the Payment so that the Employee receives that largest Payment possible without being subject to the Excise Tax (a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Reduced Payment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;), whichever of </font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">10</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="padding-left:6pt;padding-right:3.15pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">the foregoing amounts, taking into account the applicable federal, state and local income taxes and the Excise Tax (all computed at the highest marginal rate, net of the maximum reduction in federal income taxes which could be obtained from a deduction of such state and local taxes), results in the Employee&#8217;s receipt, on an after-tax basis, of the greater amount of the Payment, notwithstanding that all or some portion the Payment may be subject to the Excise Tax.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.1pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)         The independent registered public accounting firm engaged by the Employer for general audit purposes as of the day prior to the date the first Payment is due shall make all determinations required to be made under this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 18.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> If the independent registered public accounting firm so engaged by the Employer is serving as accountant or auditor for the individual, group or entity effecting the transaction, the Employer shall appoint a nationally recognized independent registered public accounting firm to make the determinations required hereunder. The Employer shall bear all expenses with respect to the determinations by such independent registered public accounting firm required to be made hereunder.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.65pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c)&#160;The independent registered public accounting firm engaged to make the determinations hereunder shall provide its calculations, together with detailed supporting documentation, to the Employer and the Employee at such time as requested by the Employer or the Employee. If the independent registered public accounting firm determines that no Excise Tax is payable with respect to a Payment, either before or after the application of the Reduced Payment, it shall furnish the Employer and the Employee with an opinion reasonably acceptable to the Employee that no Excise Tax will be imposed with respect to such Payment. Any good faith determinations of the accounting firm made hereunder shall be final, binding and conclusive upon the Parties.</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="padding-left:6pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">19.        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Consent to Jurisdiction&#59; Forum Selection</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. At all times the Employee and Employer&#58; (a) irrevocably submit to the exclusive jurisdiction of the Los Angeles Superior Court and United States District Court for the Central District of California, whichever may have competent subject matter jurisdiction, in any action or proceeding arising out of or relating to this Agreement, and irrevocably agree that all claims in respect of any such action or proceeding may be heard and determined in such court&#59; (b) to the extent permitted by law, irrevocably consent to the service of any and all process in any such action or proceeding by the mailing of copies of such process to such party at the address set forth in this Agreement (or otherwise on record with the Employer)&#59; (c) to the extent permitted by law, irrevocably confirm that service of process out of such courts in such manner shall be deemed due service upon such party for the purposes of such action or proceeding&#59; (d) to the extent permitted by law, irrevocably waives (i) any objection the Employee or Employer may have to the laying of venue of any such action or proceeding in any of such courts, or (ii) any claim that the Employee or Employer may have that any such action or proceeding has been brought in an inconvenient forum&#59; and (e) to the extent permitted by law, irrevocably agrees that a final nonappealable judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law. Nothing in this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> shall affect the right of any party hereto to serve legal process in any manner permitted by law.</font></div><div style="text-align:justify;"><font><br></font></div><div style="padding-left:5pt;padding-right:3.1pt;text-align:justify;margin-top:4.05pt;margin-bottom:0.1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">20.        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Counterparts</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">. This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be taken to be an original&#59; but such counterparts shall together constitute one and the same document.</font></div><div><font><br></font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:183.25pt;padding-right:188pt;text-align:center;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#91;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Signature Page Follows</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#93;</font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;"><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;"><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;"><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;"><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;"><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;"><font><br></font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="text-indent:36pt;padding-right:28.1pt;margin-top:1.65pt;margin-bottom:0.1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">IN WITNESS WHEREOF, this Agreement has been executed as a sealed instrument by the Employer by its duly authorized officer, and by the Employee, as of the date first above written.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EMPLOYER&#58;</font></div><div style="padding-right:-1pt;margin-bottom:0.1pt;"><font><br></font></div><div style="padding-right:285.55pt;margin-top:0.05pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:230%;">NETWORK MEDICAL MANAGEMENT, INC.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:230%;">&#58; </font></div><div style="padding-right:285.55pt;margin-bottom:0.1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;">By&#58;&#160;&#160;            </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration: underline;">&#47;s&#47; Kenneth Sim                                                                                                                                               </font></div><div style="margin-top:0.8pt;"><font><br></font></div><div style="padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">Printed Name&#58;                  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;">Kenneth Sim, M.D.                                                                                                                                        </font></div><div style="margin-top:0.05pt;"><font><br></font></div><div style="padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">Its&#58;                                    </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;">Co-Chief Executive Officer                                                                                                                            </font></div><div><font><br></font></div><div style="margin-top:0.45pt;"><font><br></font></div><div style="padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EMPLOYEE&#58;</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">Signed&#58;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;">&#47;s&#47; Thomas Lam                                                                                                                                             </font></div><div style="margin-top:0.05pt;"><font><br></font></div><div style="padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">Printed Name&#58;                   </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;">Thomas Lam, M.D.&#160;</font></div><div style="margin-top:0.05pt;"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:36pt;padding-left:108pt;padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">&#91;Signature page to Employment Agreement&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">12</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="padding-left:210.95pt;padding-right:211.1pt;text-align:center;margin-top:4pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EXHIBIT A</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:199.45pt;padding-right:199.4pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:113%;text-decoration: underline;">Release of Claims</font></div><div style="margin-top:0.1pt;"><font><br></font></div><div style="padding-left:41pt;padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">I,&#160;, in consideration of and subject to the performance by Network Medical Management,</font></div><div style="padding-left:5pt;padding-right:3.4pt;text-align:justify;margin-top:0.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Inc., a California corporation (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Company</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) of its obligations under the Employment Agreement, dated as of _ _,</font></div><div style="padding-left:5pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">20 (as amended from time to time, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">&#8221;), do hereby release and forever discharge as of the date of my execution of this release (this &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Release</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">&#8221;) the Company, its affiliated and related entities, its and their respective predecessors, successors and assigns, its and their respective employee benefit plans and fiduciaries of such plans, and the current and former officers, directors, shareholders, employees, attorneys, accountants and agents of each of the foregoing in their official and personal capacities (collectively, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Released Parties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">&#8221;) to the extent provided below.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:41.35pt;padding-right:3.1pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">1.&#160;I understand that any payments or benefits paid or granted to me under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Section 5(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;"> of the Agreement represent, in part, consideration for signing this Release and are not salary, wages or benefits to which I was already entitled. Such payments and benefits will not be considered compensation for purposes of any employee benefit plan, program, policy or arrangement maintained or hereafter established by the Company or its affiliates.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="padding-left:5.35pt;padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.&#160;Releases.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:41pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)         I knowingly and voluntarily (on behalf of myself, my spouse, my heirs, executors, administrators, agents and assigns, past and present) fully and forever release and discharge the Company and the other Released Parties from any and all claims, suits, controversies, actions, causes of action, cross claims, counterclaims, demands, debts, liens, contracts, covenants, suits, rights, obligations, expenses, judgments, compensatory damages, liquid damages, punitive or exemplary damages, other damages, claims for costs and attorneys&#8217; fees, orders and liabilities of whatever kind of nature, in law and in equity, in contract of in tort, both past and present (through the date this General Release becomes effective and enforceable) and whether known or unknown, vested or contingent, suspected, or claimed, against the Company or any of the Released Parties which I, my spouse, or any of my heirs, executors, administrators or assigns, may have, which arise out of or relate to my employment with, or my separation or termination from, the Company up to the date of my execution of this Release (including, but not limited to, any allegation, claim of violation arising under&#58; Title VII of the Civil Rights Act of 1964, as amended&#59; the Civil Rights Act of 1991&#59; the Age Discrimination in Employment Act of 1967, as amended (including the Older Workers Benefit Protection Act), the Equal Pay Act of 1963, as amended&#59; the Americans with Disabilities Act of 1990&#59; the Family and Medical Leave Act of 1993&#59; the Worker Adjustment Retraining and Notification Act&#59; the Employee Retirement Income Security Act of 1974&#59; the Fair Labor Standards Act&#59; or their state or local counterparts&#59; or under any other federal, state or local civil or human rights law, or under any other local state or federal law, regulation or ordinance&#59; or under any public policy, contract of tort, or under common law&#59; or arising under any policies, practices or procedures of the Company&#59; or any claim for wrongful discharge, breach of the Agreement, infliction of emotional distress or defamation&#59; or any claim for costs, fees, or other expenses, including attorneys&#8217; fees incurred in these matters) (collectively, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Claims</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;).</font></div><div style="margin-top:0.15pt;"><font><br></font></div><div style="padding-left:41pt;padding-right:3.15pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">SECTION 1542 WAIVER</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Employee agrees that all rights he may have under Section 1542 of the California Civil Code are hereby waived. Section 1542 provides&#58;</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="padding-left:77pt;padding-right:3.3pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:116%;">&#8220;A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM OR HER MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.&#8221;</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">13</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="padding-left:41pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Notwithstanding the provisions of Section 1542, and for the purpose of implementing a full and complete release, Employee agrees that this Agreement is intended to include all claims, if any, that Employee may have against the Company, and that this Agreement extinguishes those claims.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:41.35pt;padding-right:3.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3.&#160;I represent that I have made no assignment of transfer of any right, claim, demand, cause of action, or other matter covered by </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> above.</font></div><div><font><br></font></div><div style="text-indent:-36pt;padding-left:41.35pt;padding-right:3.1pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4.&#160;In signing this Release, I acknowledge and intend that it shall be effective as a bar to each and every one of the claims, demands and causes of action herein above mentioned or implied. I expressly consent that this Release shall be given full force and effect according to each and all of its express terms and provisions, including those relating to unknown and unsuspected claims up to the date of my execution of this Release, if any, as well as those relating to any other claims hereinabove mentioned. I acknowledge and agree that this waiver is an essential and material term of this Release and that without such waiver the Company would not have agreed to the terms of the Agreement. I further agree that in the event I should bring a claim seeking damages against the Company, this Release shall serve as a complete defense to such claims as to my rights and entitlements. I further agree that I am not aware of any pending charge or complaint of the type described in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> above as of the date of my execution of this Release.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:41.35pt;padding-right:3.2pt;text-align:justify;margin-top:1.7pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">5.&#160;I agree that neither this Release, nor the furnishing of the consideration for this Release, shall be deemed or constructed at any time to be an admission or acknowledgement by the Company, any Released Party or myself of any improper or unlawful conduct.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:41.35pt;padding-right:3pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">6.&#160;I agree and acknowledge that the provisions, conditions, and negotiations of this Release are confidential and agree not to disclose any information regarding the terms, conditions and negotiations of this Release, nor transfer any copy of this Release to any person or entity, other than my immediate family and any tax, legal or other counsel or advisor I have consulted regarding the meaning or effect hereof or as required by applicable law, and I will instruct each of the foregoing not to disclose the same to anyone.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:41.35pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">7.&#160;Notwithstanding anything in the Release to the contrary, nothing in this Release shall be deemed to affect, impair, relinquish, diminish, or in any way affect any rights or claims in any respect to (i) any vested rights or other entitlements that I may have as of the date of my execution of this Release under the Company&#8217;s</font></div><div style="padding-left:41.35pt;padding-right:3.05pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">401(k) plan&#59; (ii) any other vested rights or other entitlements that I may have as of the date of my execution of this Release under any employee benefit plan or program, in which I participated in my capacity as an employee of the Company&#59; (iii) my rights under the Agreement&#59; or (iv) my rights under the Release.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:5.35pt;padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">8.&#160;I understand that I continue to be bound by Section 6 of the Agreement.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:41.35pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">9.&#160;Whenever possible, each provision of this Release shall be interpreted in such a manner as to be effective and valid under applicable law, but if any provisions of this Release are held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other provision or any other jurisdiction, but this Release shall be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provisions had never been contained herein.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:41.35pt;padding-right:3.25pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">10.&#160;This Release shall be governed by and construed in accordance with the laws of the State of California, without giving effect to the conflict of laws principles of the State of California.</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="padding-left:41pt;padding-right:147.8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:231%;">BY SIGNING THIS RELEASE, I REPRESENT AND AGREE THAT&#58; (i)&#160;I HAVE READ IT CAREFULLY&#59;</font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">14</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="text-indent:-36pt;padding-left:77pt;padding-right:3.35pt;text-align:justify;margin-top:0.55pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(ii)         I UNDERSTAND ALL OF ITS TERMS AND KNOW THAT I AM GIVING UP IMPORTANT RIGHTS, INCLUDING BUT NOT LIMITED TO, RIGHTS UNDER THE AGE DISCRIMINATION IN EMPLOYMENT ACT OF 1967, AS AMENDED&#59;</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:41pt;padding-right:162.9pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(iii)        I VOLUNTARILY CONSENT TO EVERYTHING IN IT&#59;</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:77pt;padding-right:3.4pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(iv)        THE COMPANY IS HEREBY ADVISING ME TO CONSULT WITH AN ATTORNEY BEFORE EXECUTING IT, I HAVE HAD THE OPPORTUNITY TO SO CONSULT, AND HAVE AVAILED MYSELF OF SUCH ADVICE TO THE EXTENT I HAVE DEEMED NECESSARY TO MAKE A VOLUNTARY AND INFORMED CHOICE TO EXECUTE THIS RELEASE&#59;</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:-36pt;padding-left:77pt;padding-right:3.35pt;text-align:justify;margin-top:4.05pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(v)         I HAVE HAD AT LEAST TWENTY ONE (21) DAYS &#91;45 DAYS IN CONNECTION WITH A GROUP TERMINATION OR EXIT INCENTIVE PLAN&#93; FOLLOWING THE DATE OF TERMINATION OF MY EMPLOYMENT TO CONSIDER THIS RELEASE&#59;</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:77pt;padding-right:3.35pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(vi)       CHANGES TO THIS RELEASE, WHETHER MATERIAL OR IMMATERIAL, DO NOT RESTART THE RUNNING OF THE 21-DAY &#91;OR 45 DAY&#93; CONSIDERATION PERIOD&#59;</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:77pt;padding-right:3.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(vii)      I UNDERSTAND THAT I HAVE SEVEN (7) DAYS AFTER THE EXECUTION OF THIS RELEASE TO REVOKE IT, SUCH REVOCATION TO BE RECEIVED IN WRITING BY THE COMPANY BY THE END OF THE SEVENTH DAY AFTER THE DATE HEREOF, AND THAT THIS RELEASE SHALL NOT BECOME EFFECTIVE OR ENFORCEABLE UNTIL THE REVOCATION PERIOD HAS EXPIRED&#59;</font></div><div style="margin-top:0.75pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:77pt;padding-right:3.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;">(viii)      I HAVE SIGNED THIS RELEASE KNOWINGLY AND VOLUNTARILY AND WITH THE ADVICE OF ANY COUNSEL RETAINED TO ADVISE ME WITH RESPECT TO IT&#59; AND</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:77pt;padding-right:3.35pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(ix)        I AGREE THAT THE PROVISIONS OF THIS RELEASE MAY NOT BE AMENDED, WAIVED OR MODIFIED EXCEPT BY AN INSTRUMENT IN WRITING SIGNED BY AN AUTHORIZED REPRESENTATIVE OF THE COMPANY AND BY ME.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:5pt;padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">DATED AS OF </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;"> &#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">, 20</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;"> &#160;</font></div><div><font><br></font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="padding-left:5pt;padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#91;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Name</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">15</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>ex1032020063010qngechin.htm
<DESCRIPTION>EX-10.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i93576799b1734362b9fb4b08401df7d4_1"></div><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="padding-left:167.2pt;padding-right:166.4pt;text-align:center;margin-top:4pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EMPLOYMENT AGREEMENT</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:6pt;padding-right:3.05pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">THIS EMPLOYMENT AGREEMENT </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(this &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) is made and entered into as of June 8, 2020, by and between  Network Medical Management, Inc.,  a  California corporation (the  &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Employer</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;), and  Eric  Chin  (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Employee</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; and together with the Employer referred to as the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Parties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) to become effective as of the date hereof (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Effective</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;).</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.2pt;text-align:justify;margin-top:1.9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;">WHEREAS, the Employer desires to employ the Employee from and after the Effective Date on the terms and conditions set forth below, and the Employee is willing to serve the Employer on such terms and conditions.</font></div><div style="margin-top:0.45pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">NOW, THEREFORE, in consideration of the mutual covenants and agreements contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows&#58;</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="padding-left:6pt;padding-right:3.15pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.           </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Term</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The term of this Agreement shall initially be for a one (1) year period commencing on the Effective Date. The term of this Agreement shall automatically renew for an additional year on each anniversary of the Effective Date unless either Party gives the other written notice of intent not to renew at least sixty (60) days prior to such date. Notwithstanding the foregoing, the initial term and any renewal year shall be subject to earlier termination as provided in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> below. The initial term and any renewal years are referred to herein as the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Term</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;.</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="padding-left:6pt;padding-right:3.15pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.           </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Positions and Duties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. During the Term, the Employee shall serve as a senior executive officer of the Employer. The Employee shall perform for the Employer the duties customarily associated with being a senior executive officer that are consistent with your experience and skills and such other duties as may be assigned to the Employee from time to time by the Employer&#8217;s Board of Directors (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Board</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) that are consistent with the duties normally performed by those performing the role of the most senior executives of similar entities. The Employee shall devote such working time, attention, knowledge, skills and efforts as may be required to fulfill the Employee&#8217;s duties hereunder, as reasonably determined by the Board, and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">further</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> that the Employee may participate as a member of the board of directors or advisory board of other entities and in professional organizations and civic and charitable organizations so long as any such positions are disclosed to the Board and do not materially interfere with the Employee&#8217;s duties and responsibilities to the Employer. The Employee shall be based in Alhambra, California.</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="padding-left:6pt;padding-right:3.2pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3.           </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Compensation and Related Matters</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employer shall provide the Employee with the compensation and benefits set forth in this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> during the Term. Authority to take action under this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> with respect to the Employee&#8217;s compensation and benefits may be delegated by the Board to its compensation committee.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.1pt;text-align:justify;margin-top:1.7pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(a)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Base Salary</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">. The Employer shall pay the Employee for all services rendered a base salary of Three Hundred Thousand Dollars ($300,000) per year (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Base Salary</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">&#8221;), payable in accordance with the Employer&#8217;s payroll procedures, subject to customary withholdings and employment taxes. The Base Salary shall be evaluated annually by the Board for increase only.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.2pt;text-align:justify;margin-top:1.7pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(b)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Annual Bonus</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">. The Employee will be eligible to receive an annual cash bonus (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Annual Bonus</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">&#8221;) for each fiscal year during the Term on such terms and conditions as the Board shall determine in its discretion consistent with the terms of the Employer&#8217;s business plan.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.05pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Long Term Incentive Awards</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employee shall be eligible to participate in any long term incentive plan that may be available to similarly positioned executives. The Board may determine to grant long-term incentive awards in cash or in equity awards settled in shares of the Employer&#8217;s stock, including but not limited to stock options, restricted stock and performance shares. In the event the Employee terminates service due to being a Good Leaver, any requirements under a long-term incentive award held by the Employee shall be deemed to have been satisfied by the Employer immediately prior to such termination. A &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Good Leaver</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; means that, during the Term, either the Employee has resigned for Good Reason (as defined in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> below), the Employer has terminated the Employee&#8217;s employment without Cause (as defined in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> below or the Employee terminates </font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="padding-left:6pt;padding-right:3.05pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">employment on account of death or Disability (as defined in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> below). For avoidance of doubt, being a Good Leaver entitles the Employee to be fully vested with respect to any stock options with vesting conditions based solely on continued employment, and to be entitled to payment with respect to any long-term incentive award subject to corporate or business goals to the extent that such goals are met during the performance period on the same basis as if he had remained continuously employed with the Employer.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(d)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Paid Time Off</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. During the term, the Employee shall be entitled to twenty (20) business days of paid time off (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">PTO</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) per calendar year which shall be accrued ratably during the calendar year, to be taken at such times and intervals as shall be agreed to by Employer and the Employee in their reasonable discretion. The Employee shall be entitled to accrue a maximum of twenty (20) business days of paid time off. When the maximum accrual is reached, no additional PTO time will accrue until Employee uses one or more accrued PTO days. Accrued and unused PTO shall be paid in cash at the end of a calendar year.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(e)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Expenses</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employee shall be entitled to prompt reimbursement of reasonable and usual business expenses incurred on behalf of Employer in accordance with the Employer&#8217;s expense reimbursement policy.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.1pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(f)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Other Benefits</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employee shall be entitled to continue to participate in or receive benefits under any employee benefit plan or arrangement which is or may, in the future, be made available by the Employer to its employees, subject to and on a basis consistent with the terms, conditions and overall administration of such plan or arrangement. Irrespective of other benefits provided to employees, the Employee&#8217;s benefits package shall include&#58; (i) the Employer&#8217;s payment of premiums for medical, dental and vision care coverage&#59; (ii) the Employer&#8217;s payment of insurance premiums for short-term and long-term disability insurance providing for no less than sixty percent (60%) of Employee&#8217;s Base Salary to be payable to the Employee as long as the covered disability persists in a manner that substantially prevents employment in the same occupation as the position Employee last held with Employer but not beyond age sixty-five (65)&#59; and (iii) the Employer&#8217;s payment of insurance premiums for term life insurance providing for no less than two million dollars of coverage (subject to meeting applicable underwriting requirements).</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(g)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Tax Withholding.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The Employer shall undertake to make deductions, withholdings and tax reports with respect to payments and benefits under this Agreement, to the extent it reasonably and in good faith believes it is required to make such deductions, withholdings and tax reports. Payments with respect to compensation and benefits referred to under this Agreement shall be in amounts net of any such deductions or withholdings. Nothing in this Agreement shall be construed to require the Employer to make any payments to compensate the Employee for any adverse tax effect associated with any payments or benefits, or for any deduction or withholding from any payment or benefit.</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="padding-left:6pt;padding-right:3.2pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employee&#8217;s employment hereunder may be terminated during the Term without any breach of this Agreement under the following circumstances&#58;</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="padding-left:42pt;padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">(a)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;">Death</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">. The Employee&#8217;s employment hereunder shall terminate upon the Employee&#8217;s death.</font></div><div style="margin-top:0.45pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.2pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Disability</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employer may terminate the Employee&#8217;s employment if the Employee is disabled and, because of the disability, is unable to perform the essential functions of the Employee&#8217;s then existing position or positions under this Agreement with or without reasonable accommodation. This provision is not intended to reduce any rights the Employee may have pursuant to any law, including without limitation the California Family Rights Act, the Family and Medical Leave Act, the California Fair Employment and Housing Act, and the Americans with Disabilities Act.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Termination by the Employer for Cause</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. At any time during the Term, the Employer may terminate the Employee&#8217;s employment hereunder for Cause. For purposes of this Agreement, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Cause</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; shall mean&#58; (i) conduct by the Employee constituting a material act of willful misconduct in connection with the performance of the Employee&#8217;s duties that results in loss, damage or injury that is material to the Employer&#59; (ii) the commission by the Employee of any felony&#59; (iii) continued, willful and deliberate non-performance by the Employee of the Employee&#8217;s duties hereunder (other than by reason of the Employee&#8217;s physical or mental illness, incapacity or disability)&#59; (iv) a </font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="padding-left:6pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">material breach, according to the standard of the Employer, by the Employee of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement that results in loss, damage or injury that is material to the Employer&#59; (v) willful failure to cooperate with a bona fide internal investigation or an investigation by regulatory or law enforcement authorities, after being instructed by the Employer to cooperate, or the willful destruction or failure to preserve documents or other materials known to be relevant to such investigation or the willful inducement of others to fail to cooperate or to produce documents or other materials in connection with such investigations&#59; or (vi) fraud, embezzlement or theft against the Employer or any of its Affiliates (as defined in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> below). With respect to the events in (i), (iii) and (iv) herein, the Employer shall have delivered written notice to the Employee of its intention to terminate the Employee&#8217;s employment for Cause, which notice specifies in reasonable detail the circumstances claimed to give rise to the Employer&#8217;s right to terminate the Employee&#8217;s employment for Cause and the Employee shall not have cured such circumstances to the extent such circumstances are reasonably susceptible to cure as determined by the Board in good faith within thirty (30) days following the Employer&#8217;s delivery of such notice. For avoidance of doubt, &#8220;Cause&#8221; shall not include (x) expense reimbursement disputes in which the Employee acts in reasonable good faith&#59; (y) occasional, customary and de minimis use of the Employer&#8217;s property for personal purposes&#59; and (z) acting in good faith upon advice of Employer&#8217;s legal counsel.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:5pt;padding-right:3.15pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(d)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Termination without Cause</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. At any time during the Term, the Employer may terminate the Employee&#8217;s employment hereunder without Cause by providing the Employee with thirty (30) days advance written notice. Any termination by the Employer of the Employee&#8217;s employment under this Agreement that does not constitute a termination for Cause under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> and does not result from the death or Disability of the Employee under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Sections 4(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> or </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">4(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> shall be deemed a termination without Cause under this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Any suspension of the Employee&#8217;s employment with pay or benefits by the Board in good faith pending an investigation of alleged improper activities by the Employee that, if determined to be accurate, would be grounds for a Cause termination, shall not be considered a termination of the Employee&#8217;s employment without Cause or provide with Good Reason to terminate employment.</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:5pt;padding-right:3pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(e)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Termination by the Employee</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. At any time during the Term, the Employee may terminate his employment hereunder for any reason, including, but not limited to, Good Reason. For purposes of this Agreement, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Good Reason</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; shall mean that the Employee has complied with the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Good Reason Process</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; (hereinafter defined) following the occurrence of any of the following events&#58; (i) a material diminution in the Employee&#8217;s responsibilities, authority or duties&#59; (ii) the material breach of this Agreement by the Employer, including but not limited to a failure to pay Base Salary or Annual Bonus as provided for under this Agreement&#59; or (iii) any relocation of the Employee&#8217;s principal place of business to a location more than 30 miles from the Employer&#8217;s current executive offices in Alhambra, California&#59; provided, however, that this clause (iii) will not apply to the extent that any new office location is less than 30 miles from the Employee&#8217;s residence. &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Good Reason Process</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; shall mean (i) the Employee reasonably determines in good faith that a &#8220;Good Reason&#8221; condition has occurred&#59; (ii) the Employee notifies the Employer in writing of the occurrence of the Good Reason condition within (60) days of the occurrence of such condition&#59; (iii) the Employee cooperates in good faith with the Employer&#8217;s efforts, for a period of sixty (60) days following such notice (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Cure Period</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;), to remedy the condition&#59; (iv) notwithstanding such efforts, the Good Reason condition continues to exist&#59; and (v) the Employee terminates his employment within thirty (30) days after the end of the Cure Period. If the Employer cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not to have occurred.</font></div><div style="margin-top:0.25pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:5pt;padding-right:3.2pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(f)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Notice of Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Except for termination as specified in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, any termination of the Employee&#8217;s employment shall be communicated by written Notice of Termination by the terminating Party to the other Party hereto. For purposes of this Agreement, a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Notice of Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; shall mean a notice which shall indicate the specific termination provision in this Agreement relied upon.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:5pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(g)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Date of Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Date of Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; shall mean the earliest of the following&#58; (i) if the Employee&#8217;s employment is terminated by the Employee&#8217;s death, the date of the Employee&#8217;s death&#59; (ii) if the Employee&#8217;s employment is terminated on account of Disability under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> or by the Employer for Cause under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, the date on which Notice of Termination is given that follows any applicable required cure period&#59; (iii) if the Employee&#8217;s employment is terminated by the Employer under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, thirty (30) days after the date on which a Notice of Termination is given&#59; (iv) if the Employee&#8217;s employment is terminated by the </font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="padding-left:5pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Employee under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> without Good Reason, thirty (30) days after the date of which a Notice of Termination is given or such shorter period agreed to by the Employer&#59; or (v) if the Employee&#8217;s employment is terminated by the Employee under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> with Good Reason, the date on which Notice of Termination is given after the end of the Cure Period. Notwithstanding the foregoing, in the event that the Employee gives a Notice of Termination to the Employer, the Employer may unilaterally accelerate the Date of Termination but such acceleration shall nevertheless be deemed a termination by the Employee on the accelerated date for purposes of this Agreement. For purposes of determining the time when the lump sum portion of the Severance Amount, if any, is to be paid under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 5(b)(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Date of Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; means the Employee&#8217;s separation from service as defined under Section 409A.</font></div><div style="text-align:justify;"><font><br></font></div><div style="padding-left:8.5pt;padding-right:-1pt;margin-top:4pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">5.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;">Compensation upon Termination.</font></div><div style="margin-top:0.45pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.05pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Accrued Benefits.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> If the Employee&#8217;s employment with the Employer is terminated for any reason during the Term, or if the Term is not renewed, the Employer shall pay or provide the Employee (or the Employee&#8217;s authorized representative or estate) any earned but unpaid Base Salary or Annual Bonus for services rendered through the Date of Termination, unpaid expense reimbursements, and accrued but unused paid time off (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Accrued</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Benefits</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) within the time prescribed by California law. With respect to vested compensation or benefits the Employee may have under any employee benefit or compensation plan, program or arrangement of the Employer, payment will be made to the Employee under the terms of the applicable plan, program or arrangement.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Termination by  the Employer without Cause or by the Employee with Good</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Reason</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. If the Employee&#8217;s employment is terminated by the Employer without Cause as provided in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, or the Employee terminates his employment for Good Reason as provided in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, or the Employee terminates employment at the end of the Term after the Employer provides notice of intent not to renew pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> for reasons other than would provide grounds for a Cause termination, then, (i) the Employer shall, through the Date of Termination, pay the Employee his or her Accrued Benefits, and (ii) if the Employee signs a general release of claims substantially in the form which is attached as </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Exhibit A</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to this Agreement) (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Release</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) within twenty-one (21) days of the receipt of the form of the Release (extended to forty-five (45) days in the event of a group termination or exit incentive program) and does not revoke such Release during the seven-day revocation period&#58;</font></div><div style="margin-top:0.25pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:42pt;padding-right:2.95pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(i)         the Employer shall pay the Employee an amount equal to one-twelfth (1&#47;12) of the Employee&#8217;s most recent Base Salary times the number of full years of service completed, not to exceed twelve (12) years of service (but determined prior to any action involving Base Salary that would constitute Good Reason) (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Severance Amount</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;). For the avoidance of doubt, the maximum Severance Amount payable to Employee pursuant to the terms of this Agreement shall equal one (1) year of the Employee&#8217;s most recent Base Salary. To the extent that such Severance Amount exceeds the 409A Separation Pay Limit (as defined below), such amount shall be paid in a single lump sum on the regular payroll date of the Employer, pertaining to then current salaried employees of the Employer, (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">payroll date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) next following the first anniversary date of the Employee&#8217;s Date of Termination. The portion of the Severance Amount that does not exceed the 409A Separation Pay Limit shall be paid in substantially equal amounts on each payroll date over a one year period&#59; and</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:42pt;padding-right:3.15pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(ii)        the Employer shall pay the Employee an amount in cash equal to the Employer&#8217;s premium amounts paid for coverage of Employee at the time of the Employee&#8217;s termination of coverage under the Employer&#8217;s group medical, dental and vision programs for a period of twelve (12) months, to be paid directly to the Employee at the same times such payments would be paid on behalf of a current employee for such coverage&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#58;</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:78pt;padding-right:3.15pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(A)        No  payments shall  be  made  under  this  paragraph (ii)  unless  and  until  the Employee timely elects continued coverage under such plan(s) pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1985 as amended (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">COBRA</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;)&#59;</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="text-indent:36pt;padding-left:78pt;padding-right:3.25pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(B)&#160;This paragraph (ii) shall not be read or construed as placing any restrictions upon amounts paid under this paragraph (ii) as to their use&#59;</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:78pt;padding-right:3.2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(C)&#160;Payments under this paragraph (ii) shall cease as of the earliest to occur of the following&#58;</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:150pt;padding-right:-1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(1)&#160;the Employee is no longer eligible for and continuing to receive the</font></div><div style="padding-left:114pt;padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">COBRA coverage elected in subparagraph (A)&#59;</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="padding-left:150pt;padding-right:-1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(2)&#160;the time period set forth in the first sentence of this paragraph (ii),</font></div><div style="padding-right:-1pt;margin-bottom:0.1pt;"><font><br></font></div><div style="padding-left:150pt;padding-right:3.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;">(3)&#160;the date on which the Employee first becomes eligible to enroll in a group health plan in which eligibility is based on employment with an employer, and</font></div><div style="padding-right:3.2pt;margin-bottom:0.1pt;"><font><br></font></div><div style="padding-left:149pt;padding-right:3.1pt;text-align:justify;margin-top:4.05pt;margin-bottom:0.1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(4)        if the Employer in good faith determines that payments under this paragraph (ii) would result in a discriminatory health plan pursuant to the Patient Protection and Affordable Care Act of 2010, as amended.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="padding-left:185pt;padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(iii)&#160;Each individual payment of Severance Amount under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section</font></div><div style="padding-left:149pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">5(b)(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, and each payment under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 5(b)(ii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement, shall be deemed to be a separate &#8220;payment&#8221; for purposes and within the meaning of Treasury Regulation Section 1.409A-2(b)(2)(iii).</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:149pt;padding-right:3.15pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(iv)       Each    individual    payment    of    the    Severance    Amount under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section   5(b)(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">,   and   each   payment   under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section   5(b)(ii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">,   of   this Agreement, which are considered &#8220;non-qualified deferred compensation&#8221; (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">NQDC</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) under Section 409A shall be made on the date(s) provided herein and no request to accelerate or defer any such payment under this Agreement shall be considered or approved for any reason whatsoever, except as permitted under Section 409A and as the Employer allows in its sole discretion. The Employer may in its sole discretion accelerate or defer (but not beyond the time limit set forth below) any severance payments which do not constitute NQDC in order to allow for the payment of taxes due, but not beyond the time limit specified for such payment such that the payment would be treated as NQDC. Subject to the requirements of  Section 409A, if  any severance payment or  reimbursement under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 5(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement is determined in good faith by the Employer to constitute NQDC payable to a &#8220;specified employee&#8221; as defined under Section</font></div><div style="padding-left:149pt;padding-right:3.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">409A, then the Employer shall make any such payment not earlier than the earlier of&#58; (x) the first payroll date which is six (6) months following the Employee&#8217;s separation from service (as defined under Section 409A) with the Employer, or (y) the date of Employee&#8217;s death.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="padding-left:185pt;padding-right:-1pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(v)&#160;for purposes of this Section 5, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 409A</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; means Section</font></div><div style="padding-left:149pt;padding-right:18.3pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">409A of the Internal Revenue Code of 1986, as amended, and the regulations thereunder.</font></div><div style="margin-top:0.45pt;"><font><br></font></div><div><font><br></font></div><div style="text-indent:36pt;padding-left:149pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(vi)       for purposes of this Section 5, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">409A Separation Pay Limit</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">&#8221; means two times the lesser of (</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:116%;">x</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">) the Employee&#8217;s annual compensation during the calendar year preceding the year of the termination of employment&#59; and (</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:116%;">y</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">) the </font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="padding-left:149pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">adjusted compensation limit under Code Section 401(a)(17) in effect for the year of the termination.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="padding-left:5pt;padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">6.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;">Confidential Information, Nonsolicitation, and Cooperation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">.</font></div><div style="margin-top:0.45pt;"><font><br></font></div><div style="padding-left:41pt;padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">(a)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;">Definitions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">.</font></div><div style="margin-top:0.1pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:41pt;padding-right:3.05pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(i)          As used in this Agreement, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Affiliate</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; means, as to any Person, (i) any other Person which directly, or indirectly through one or more intermediaries, controls such Person or is consolidated with such Person in accordance with GAAP, (ii) any other Person which directly, or indirectly through one or more intermediaries, is controlled by or is under common control with such Person, or (iii) any other Person of which such Person owns, directly or indirectly, fifty percent (50%) or more of the common stock or equivalent equity interests. As used herein, the term &#8220;control&#8221; means possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of a Person, whether through the ownership of voting securities or otherwise.</font></div><div style="margin-top:0.7pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:41pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;">(ii)        As used in this Agreement, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration: underline;">Person</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;">&#8221; means an individual, a corporation, a partnership, a limited liability company, an association, a trust or any other entity or organization.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.1pt;text-align:justify;margin-top:4pt;margin-bottom:0.1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Confidential  Information</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  As   used   in   this   Agreement,  &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Confidential</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Information</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;  means information belonging to the Employer or its Affiliates which is of value to the Employer or any of its Affiliates in the course of conducting its business (whether having existed, now existing, or to be developed or created during Employee&#8217;s employment by Employer) and the disclosure of which could result in a competitive or other disadvantage to the Employer or its Affiliates. Confidential Information includes, without limitation, contract terms and rates&#59; negotiating and contracting strategies&#59; financial information, reports, and forecasts&#59; inventions, improvements and other intellectual property&#59; product plans or proposed product plans&#59; trade secrets&#59; designs, processes or formulae&#59; software&#59; employee, customer, patient, provider and supplier information&#59; information from patient medical records&#59; financial data&#59; insurance reimbursement methodologies, strategies and practices&#59; product and service pricing methodologies, strategies and practices&#59; contracts with physicians, providers, provider networks, payors, physician databases and contracts with hospitals&#59; regulatory and clinical manuals&#59; and business plans, prospects and opportunities (such as possible acquisitions or dispositions of businesses or facilities) that have been discussed or considered by the Employer or its Affiliates, including, without limitation, the management of the Employer or its Affiliates. Confidential Information includes information developed by the Employee in the course of the Employee&#8217;s employment by the Employer, as well as other information to which the Employee may have access in connection with the Employee&#8217;s employment. Confidential Information also includes the confidential information of others with which the Employer or its Affiliates has a business relationship. Notwithstanding the foregoing, Confidential Information does not include information in the public domain, unless due to breach of the Employee&#8217;s duties under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, unless otherwise due to Employee&#8217;s breach of the obligations in this Agreement, or unless due to violation of another Person&#8217;s obligations to the Employer or its Affiliates that Employee should have taken reasonable measures to prevent but that Employee did not take.</font></div><div style="margin-top:0.1pt;"><font><br></font></div><div><font><br></font></div><div style="text-indent:38.5pt;padding-left:6pt;padding-right:4.85pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Confidentiality</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employee understands and agrees that the Employee&#8217;s employment creates a relationship of confidence and trust between the Employer and the Employee with respect to all Confidential Information. At all times, both during the Employee&#8217;s employment with the Employer and after the Employee&#8217;s termination from employment for any reason, the Employee shall keep in confidence and trust all such Confidential Information, and shall not use, disclose, or transfer any such Confidential Information without the written consent of the Employer, except as may be necessary within the scope of Employee&#8217;s duties with Employer and in the ordinary course of performing the Employee&#8217;s duties to the Employer or as otherwise provided in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Employee understands and agrees not to sell, license or otherwise exploit any products or services which embody or otherwise exploit in whole or in part any Confidential Information or materials. Employee acknowledges and agrees that the sale, misappropriation, or unauthorized use or disclosure in writing, orally or by electronic means, at any time of Confidential Information obtained by Employee during or in connection with the course of Employee&#8217;s employment </font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="padding-left:6pt;padding-right:4.85pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">constitutes unfair competition. Employee agrees and promises not to engage in unfair competition with Employer or its Affiliates, either during employment, or at any time thereafter.</font></div><div style="margin-top:0.45pt;"><font><br></font></div><div><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(d)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Protected Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">. Notwithstanding anything to the contrary in this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">, this Agreement is not intended to, and shall not, in any way prohibit, limit or otherwise interfere with the Employee&#8217;s protected rights under federal, state or local law to, without notice to the Employer, (i) communicate or file a charge with a government regulator&#59; (ii) participate in an investigation or proceeding conducted by a government regulator&#59; or (iii) receive an award paid by a government regulator for providing information.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.15pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(e)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Documents, Records, etc</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. All documents, records, data, apparatus, equipment and other physical property, whether or not pertaining to Confidential Information, that are furnished to the Employee by the Employer or its Affiliates or are produced by the Employee in connection with the Employee&#8217;s employment will be and remain the sole property of the Employer and its Affiliates. The Employee shall return to the Employer all such materials and property as and when requested by the Employer. In any event, the Employee shall return all such materials and property immediately upon termination of the Employee&#8217;s employment for any reason. The Employee shall not retain any such material or property or any copies thereof after such termination. It is specifically agreed that any documents, card files, notebooks, programs, or similar items containing customer or patient information are the property of the Employer and its Affiliates regardless of by whom they were compiled.</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.05pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(f)          </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Disclosure Prevention</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employee will take all reasonable precautions to prevent the inadvertent or accidental exposure of Confidential Information.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:36pt;padding-left:5pt;padding-right:3.15pt;text-align:justify;margin-top:4.05pt;margin-bottom:0.1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(g)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Removal of Material</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">. The Employee will not remove any Confidential Information from the Employer&#8217;s or its Affiliate&#8217;s premises except for use in the Employer&#8217;s business, and only consistent with the Employee&#8217;s duties with the Employer.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:5pt;padding-right:3.2pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(h)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Copying</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">. The Employee agrees that copying or transferring Confidential Information (by any means) shall be done only as needed in furtherance of and for use in the Employer&#8217;s and its Affiliate&#8217;s business, and consistent with the Employee&#8217;s duties with the Employer. The Employee further agrees that copies of Confidential Information shall be treated with the same degree of confidentiality as the original information and shall be subject to all restrictions herein.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:5pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(i)           </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Computer Security</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employee agrees to comply with the Employer&#8217;s policies and procedures concerning computer security.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:5pt;padding-right:3.15pt;text-align:justify;margin-top:1.7pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(j)           </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">E-Mail</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">. The Employee acknowledges that the Employer retains the right to review any and all electronic mail communications made with employer provided email accounts, hardware, software, or networks, with or without notice, at any time.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:5pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(k)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Assignment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employee acknowledges that any and all inventions, discoveries, designs, developments, methods, modifications, trade secrets, processes, software, formulae, data, &#8220;know-how,&#8221; databases, algorithms, techniques and works of authorship whether or not patentable or protectable by copyright or trade secret, made or conceived, first reduced to practice, or learned by the Employee, either alone or jointly with others, during the Term that (i) relate to or are useful in the business of the Employer or its Affiliates, or (ii) are conceived, made or worked on at the expense of or during the Employee&#8217;s work time for the Employer, or using any resources or materials of the Employer or its Affiliates, or (iii) arise out of tasks assigned to the Employee by the Employer (together &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Proprietary Inventions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) will be the sole property of the Employer or its Affiliates. The Employee acknowledges that all work performed by the Employee is on a &#8220;work for hire&#8221; basis and the Employee hereby assigns or agrees to assign to the Employer the Employee&#8217;s entire right, title and interest in and to any and all Proprietary Inventions and related intellectual property rights. The Employee agrees to assist the Employer to obtain, </font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">7</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="padding-left:5pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">maintain and enforce intellectual property rights for Proprietary Inventions in any and all countries during the Term, and thereafter for as long as such intellectual property rights exist.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:144.7pt;padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">NOTICE TO CALIFORNIA EMPLOYEES</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="padding-left:41pt;padding-right:39.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to California Labor Code &#167;2870, an agreement requiring the employee to assign or offer to assign any of his or her rights in any invention to his or her employer does not apply to an invention which qualifies fully under the provisions of California Labor Code &#167; 2870, which provides as follows&#58;</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:41pt;padding-right:39.05pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)         Any provision in an employment agreement which provides that an employee shall assign, or offer to assign, any of his or her rights in an invention to his or her employer shall not apply to an invention that the employee developed entirely on his or her own time without using the employer&#8217;s equipment, supplies, facilities, or trade secret information except for those inventions that either&#58;</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:77pt;padding-right:39.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(1)        Relate at the time of conception or reduction to practice of the invention to the employer&#8217;s business, or actual or demonstrably anticipated research or development of the employer&#59; or</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:112.95pt;padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(2)&#160;Result from any work performed by the employee for the employer.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:41pt;padding-right:39.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)         To the extent a provision in an employment agreement purports to require an employee to assign an invention otherwise excluded from being required to be assigned under subdivision (a), the provision is against the public policy of the State of California and is unenforceable.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:0.1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;">(l) &#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration: underline;">Nonsolicitation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;">. Employee agrees and covenants that, at any time during Employee&#8217;s employment</font></div><div style="padding-left:6pt;padding-right:3.15pt;text-align:justify;margin-top:0.2pt;margin-bottom:0.1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">with the Employer and for a period of twelve (12) months immediately following the termination of Employee&#8217;s relationship with the Employer for any reason, whether with or without cause, Employee shall not, either on Employee&#8217;s own behalf or on behalf of any other Person&#58; (i) solicit the services of the Employer&#8217;s employees or entice away, directly or indirectly, any Person employed or engaged by or otherwise providing services to the Employer or its Affiliates, whether in an employment capacity or otherwise (this provision does not prohibit the Employee&#8217;s post- termination acceptance of unsolicited applications for employment)&#59; or (ii) take any illegal action or engage in any unfair business practice, including, without limitation, any misappropriation of confidential, proprietary or trade secret information of the Employer or its Affiliates, as a result of which relations between the Employer or its Affiliates, and any of their customers, clients, suppliers, distributors or others, may be impaired or which might otherwise be detrimental to the business interests or reputation of the Employer or its Affiliates.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.05pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(m)        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Third-Party Agreements and Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employee hereby confirms that the Employee is not bound by the terms of any agreement with any previous employer or other party which restricts in any way the Employee&#8217;s use or disclosure of information or the Employee&#8217;s engagement in any business except as Employee has previously provided written notice to Employer and has attached to this Agreement. The Employee represents to the Employer that the Employee&#8217;s execution of this Agreement, the Employee&#8217;s employment with the Employer and the performance of the Employee&#8217;s proposed duties for the Employer will not violate any obligations the Employee may have to any previous employer or other party. In the Employee&#8217;s work for the Employer, the Employee will not disclose or use any information in violation of any agreements with or rights of any such previous employer or other party, and the Employee will not bring to (by any means) the premises of the Employer any copies or other tangible embodiments of non- public information belonging to or obtained from any such previous employment or other party.</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">8</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(n)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Litigation  and  Regulatory  Cooperation.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  During  and  after  the  Employee&#8217;s  employment,  the Employee shall cooperate fully with the Employer in the defense or prosecution of any claims or actions now in existence or that may be brought in the future against or on behalf of the Employer that relate to events or occurrences that transpired while the Employee was employed by the Employer. The Employee&#8217;s full cooperation in connection with such claims or actions shall include, but not be limited to, being available to meet with counsel to prepare for discovery or trial and to act as a witness on behalf of the Employer at mutually convenient times. During and after the Employee&#8217;s employment, the Employee also shall cooperate fully with the Employer in connection with any investigation or review of any federal, state, or local regulatory authority as any such investigation or review relates to events or occurrences that transpired while the Employee was employed by the Employer. The Employer shall reimburse the Employee for any reasonable out of pocket expenses incurred in connection with the Employee&#8217;s performance of obligations pursuant to this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. &#8220;Full cooperation&#8221; shall not be construed to in any way require any violation of law or any testimony that is false or misleading.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.05pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(o)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Enforcement&#59; Injunction.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The Employee acknowledges and agrees that the restrictions contained in this Agreement are reasonable and necessary to protect the business and interests of the Employer and its Affiliates, do not create any undue hardship for the Employee, and that any violation of the restrictions in this Agreement would cause the Employer and its Affiliates substantial irreparable injury. Accordingly, the Employee agrees that a remedy at law for any breach or threatened breach of the covenants or other obligations in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement would be inadequate and that the Employer, in addition to any other remedies available, shall be entitled to obtain preliminary and permanent injunctive relief to secure specific performance of such covenants and to prevent a breach or contemplated or threatened breach of this Agreement without the necessity of proving actual damage and without the necessity of posting bond or security, which the Employee expressly waives. Moreover, the Employee will provide the Employer a full accounting of all proceeds and profits received by the Employee as a result of or in connection with a breach of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement. Unless prohibited by law, the Employer shall have the right to retain any amounts otherwise payable by the Employer to the Employee to satisfy any of the Employee&#8217;s obligations as a result of any breach of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement. The Employee hereby agrees to indemnify and hold harmless the Employer and its Affiliates from and against any damages incurred by the Employer or its Affiliates as assessed by a court of competent jurisdiction as a result of any breach of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement by the Employee. The prevailing party shall be entitled to recover its reasonable attorneys&#8217; fees and costs if it prevails in any action to enforce </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement. It is the express intention of the parties that the obligations of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement shall survive the termination of the Employee&#8217;s employment. The Employee agrees that each obligation specified in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement is a separate and independent covenant that shall survive any termination of this Agreement and that the unenforceability of any of them shall not preclude the enforcement of any other covenants in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement. No change in the Employee&#8217;s duties or compensation shall be construed to affect, alter or otherwise release the Employee from the covenants herein.</font></div><div style="margin-top:0.45pt;"><font><br></font></div><div style="padding-left:5pt;padding-right:3.05pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">7.          </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Successors</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. This Agreement shall be binding upon and inure to the benefit of both parties and their respective successors and permitted assigns, including any corporation or entity with which or into which the Employer may be merged or which may succeed to its assets or business, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, that Employee&#8217;s obligations are personal and shall not be assigned by Employee. The Employee consents to be bound by the provisions of this Agreement for the benefit of the Employer or its Affiliates to whose employ the Employee may be transferred without the necessity that this Agreement be resigned at the time of such transfer. In the event of the Employee&#8217;s death after the Date of Termination but prior to the completion by the Employer of all payments due to the Employee under this Agreement, the Employer shall continue such payments to the Employee&#8217;s beneficiary designated in writing to the Employer prior to the Employee&#8217;s death (or to the Employee&#8217;s estate, if the Employee fails to make such designation).</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="padding-left:5pt;padding-right:3.1pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">8.         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Enforceability</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">. If any portion or provision of this Agreement shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="padding-left:5pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">9.          </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Waiver</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">. No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party. The failure of any party to require the performance of any term or obligation of this Agreement, or the </font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">9</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="padding-left:5pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">waiver by any party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="padding-left:5pt;padding-right:3.2pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">10.        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Notices</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">. Any notices, requests, demands and other communications provided for by this Agreement shall be sufficient if in writing and delivered in person or sent by registered or certified mail, postage prepaid, to the Employee at the last address for which the Employee has provided written notice to the Employer, or to the Employer at its main office, to the attention of Human Resources</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:116%;">.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="padding-left:5pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">11.        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Publicity</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">. The Employee hereby grants to the Employer the right to use the Employee&#8217;s name and likeness, without additional consideration, on, in and in connection with technical, marketing and&#47;or disclosure materials published by or for the Employer for the duration of Employee&#8217;s employment with Employer.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="padding-left:5pt;padding-right:3.05pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">12.        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Conflicting Obligations and Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employee agrees to inform the Employer of any apparent conflicts between the Employee&#8217;s work for the Employer and (a) any obligations the Employee may have to preserve the confidentiality of another&#8217;s proprietary information or materials or (b) any rights the Employee claims to any inventions or ideas before using the same on the Employer&#8217;s behalf. Otherwise, the Employer may conclude that no such conflict exists and the Employee agrees thereafter to make no such claim against the Employer. The Employer shall receive such disclosures in confidence and consistent with the objectives of avoiding any conflict of obligations and rights or the appearance of any conflict of interest.</font></div><div style="margin-top:0.75pt;"><font><br></font></div><div style="padding-left:5pt;padding-right:3.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;">13.        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration: underline;">Notification of New Employer</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;">. In the event that the Employee leaves the employ of the Employer, voluntarily or involuntarily, the Employee agrees to inform any subsequent employer of the Employee&#8217;s obligations under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration: underline;">Section</font></div><div style="padding-left:5pt;padding-right:3.25pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;">6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> of this Agreement. The Employee further hereby authorizes the Employer to notify the Employee&#8217;s new employer about the Employee&#8217;s obligations under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> of this Agreement.</font></div><div style="margin-top:0.25pt;"><font><br></font></div><div style="padding-left:5pt;padding-right:3.15pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">14.        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Entire Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">. This Agreement constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes any previous oral or written communications, negotiations, representations, understandings, or agreements between them. Any modification of this Agreement shall be effective only if set forth in a written document signed by the Employee and a duly authorized officer of the Employer.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="padding-left:5pt;padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">15.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Amendment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. This Agreement may be amended or modified only by a written instrument signed by the</font></div><div style="padding-left:5pt;padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Employee and by a duly authorized representative of the Employer.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:5pt;padding-right:3.15pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">16.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Governing Law</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. This is a California contract and shall be construed under and be governed in all respects by the laws of the State of California, without giving effect to the conflict of laws principles of such State.</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:3.15pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">17.        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Obligations of Successors</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">. The Employer shall require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Employer to expressly assume and agree to perform this Agreement in the same manner and to the same extent that the Employer would be required to perform if no such succession had taken place.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="padding-left:6pt;padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">18.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;">Limitation on Payments in Certain Events.</font></div><div style="margin-top:0.45pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.15pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Limitation on Payments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Notwithstanding anything to the contrary in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement, if any payment or distribution that the Employee would receive pursuant to this Agreement or otherwise (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Payment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) would (a) constitute a &#8220;parachute payment&#8221; within the meaning of Section 280G of the Code), and (b) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Excise Tax</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;), then the Employer shall cause to be determined, before any amounts of the Payment are paid to the Employee, which of the following alternative forms of payment would maximize the Employee&#8217;s after-tax proceeds&#58; (i) payment in full of the entire amount of the Payment (a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Full Payment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;), or (ii) payment of only a part of the Payment so that the Employee receives that largest Payment possible without being subject to the Excise Tax (a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Reduced Payment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;), whichever of </font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">10</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="padding-left:6pt;padding-right:3.15pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">the foregoing amounts, taking into account the applicable federal, state and local income taxes and the Excise Tax (all computed at the highest marginal rate, net of the maximum reduction in federal income taxes which could be obtained from a deduction of such state and local taxes), results in the Employee&#8217;s receipt, on an after-tax basis, of the greater amount of the Payment, notwithstanding that all or some portion the Payment may be subject to the Excise Tax.</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.1pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)         The independent registered public accounting firm engaged by the Employer for general audit purposes as of the day prior to the date the first Payment is due shall make all determinations required to be made under this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 18.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> If the independent registered public accounting firm so engaged by the Employer is serving as accountant or auditor for the individual, group or entity effecting the transaction, the Employer shall appoint a nationally recognized independent registered public accounting firm to make the determinations required hereunder. The Employer shall bear all expenses with respect to the determinations by such independent registered public accounting firm required to be made hereunder.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.65pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c)&#160;The independent registered public accounting firm engaged to make the determinations hereunder shall provide its calculations, together with detailed supporting documentation, to the Employer and the Employee at such time as requested by the Employer or the Employee. If the independent registered public accounting firm determines that no Excise Tax is payable with respect to a Payment, either before or after the application of the Reduced Payment, it shall furnish the Employer and the Employee with an opinion reasonably acceptable to the Employee that no Excise Tax will be imposed with respect to such Payment. Any good faith determinations of the accounting firm made hereunder shall be final, binding and conclusive upon the Parties.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:6pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">19.        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Consent to Jurisdiction&#59; Forum Selection</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. At all times the Employee and Employer&#58; (a) irrevocably submit to the exclusive jurisdiction of the Los Angeles Superior Court and United States District Court for the Central District of California, whichever may have competent subject matter jurisdiction, in any action or proceeding arising out of or relating to this Agreement, and irrevocably agree that all claims in respect of any such action or proceeding may be heard and determined in such court&#59; (b) to the extent permitted by law, irrevocably consent to the service of any and all process in any such action or proceeding by the mailing of copies of such process to such party at the address set forth in this Agreement (or otherwise on record with the Employer)&#59; (c) to the extent permitted by law, irrevocably confirm that service of process out of such courts in such manner shall be deemed due service upon such party for the purposes of such action or proceeding&#59; (d) to the extent permitted by law, irrevocably waives (i) any objection the Employee or Employer may have to the laying of venue of any such action or proceeding in any of such courts, or (ii) any claim that the Employee or Employer may have that any such action or proceeding has been brought in an inconvenient forum&#59; and (e) to the extent permitted by law, irrevocably agrees that a final nonappealable judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law. Nothing in this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> shall affect the right of any party hereto to serve legal process in any manner permitted by law.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="padding-left:6pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">20.        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Counterparts</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">. This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be taken to be an original&#59; but such counterparts shall together constitute one and the same document.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;margin-bottom:0.1pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:0.1pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:0.1pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:0.1pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:0.1pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:144pt;text-align:justify;margin-bottom:0.1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;">&#91;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%;">Signature Page Follows</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;">&#93;</font></div><div style="padding-right:168pt;text-align:center;margin-bottom:0.1pt;"><font><br></font></div><div style="padding-right:168pt;text-align:center;margin-bottom:0.1pt;"><font><br></font></div><div style="padding-right:168pt;text-align:center;margin-bottom:0.1pt;"><font><br></font></div><div style="padding-right:168pt;text-align:center;margin-bottom:0.1pt;"><font><br></font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="padding-right:168pt;text-align:center;margin-bottom:0.1pt;"><font><br></font></div><div style="padding-right:168pt;text-align:center;margin-bottom:0.1pt;"><font><br></font></div><div style="text-indent:36pt;padding-right:28.15pt;margin-top:1.65pt;margin-bottom:0.1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">IN WITNESS WHEREOF, this Agreement has been executed as a sealed instrument by the Employer by its duly authorized officer, and by the Employee, as of the date first above written.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EMPLOYER&#58;</font></div><div style="padding-right:-1pt;margin-bottom:0.1pt;"><font><br></font></div><div style="padding-right:285.55pt;margin-top:0.05pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:230%;">NETWORK MEDICAL MANAGEMENT, INC.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:230%;">&#58; </font></div><div style="padding-right:285.55pt;margin-bottom:0.1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;">By&#58;                                  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration: underline;"> &#47;s&#47; Thomas Lam                                                                                                                               </font></div><div style="margin-top:0.8pt;"><font><br></font></div><div style="padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">Printed Name&#58;                 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;">Thomas Lam, M.D.                                                                                                                          </font></div><div style="margin-top:0.05pt;"><font><br></font></div><div style="padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">Its&#58;                                   </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;">Co-Chief Executive Officer                                                                                                              </font></div><div><font><br></font></div><div style="margin-top:0.45pt;"><font><br></font></div><div style="padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EMPLOYEE&#58;</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">Signed&#58;                           </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;"> &#47;s&#47; Eric Chin                                                                                                                                     </font></div><div style="margin-top:0.05pt;"><font><br></font></div><div style="padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">Printed Name&#58;                 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;">Eric Chin &#160;                                                                                                                           </font></div><div style="margin-top:0.05pt;"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div><div><font><br></font></div><div style="text-indent:36pt;padding-left:108pt;padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">&#91;Signature page to Employment Agreement&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">12</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="margin-bottom:0.1pt;"><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div><div style="padding-left:210.95pt;padding-right:211.1pt;text-align:center;margin-top:4pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EXHIBIT A</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:199.45pt;padding-right:199.4pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:113%;text-decoration: underline;">Release of Claims</font></div><div style="margin-top:0.1pt;"><font><br></font></div><div style="padding-left:41pt;padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">I,&#160;, in consideration of and subject to the performance by Network Medical Management,</font></div><div style="padding-left:5pt;padding-right:3.4pt;text-align:justify;margin-top:0.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Inc., a California corporation (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Company</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) of its obligations under the Employment Agreement, dated as of _ _,</font></div><div style="padding-left:5pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">20 (as amended from time to time, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">&#8221;), do hereby release and forever discharge as of the date of my execution of this release (this &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Release</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">&#8221;) the Company, its affiliated and related entities, its and their respective predecessors, successors and assigns, its and their respective employee benefit plans and fiduciaries of such plans, and the current and former officers, directors, shareholders, employees, attorneys, accountants and agents of each of the foregoing in their official and personal capacities (collectively, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Released Parties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">&#8221;) to the extent provided below.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:41.35pt;padding-right:3.1pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">1.&#160;I understand that any payments or benefits paid or granted to me under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Section 5(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;"> of the Agreement represent, in part, consideration for signing this Release and are not salary, wages or benefits to which I was already entitled. Such payments and benefits will not be considered compensation for purposes of any employee benefit plan, program, policy or arrangement maintained or hereafter established by the Company or its affiliates.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="padding-left:5.35pt;padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.&#160;Releases.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:41pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)         I knowingly and voluntarily (on behalf of myself, my spouse, my heirs, executors, administrators, agents and assigns, past and present) fully and forever release and discharge the Company and the other Released Parties from any and all claims, suits, controversies, actions, causes of action, cross claims, counterclaims, demands, debts, liens, contracts, covenants, suits, rights, obligations, expenses, judgments, compensatory damages, liquid damages, punitive or exemplary damages, other damages, claims for costs and attorneys&#8217; fees, orders and liabilities of whatever kind of nature, in law and in equity, in contract of in tort, both past and present (through the date this General Release becomes effective and enforceable) and whether known or unknown, vested or contingent, suspected, or claimed, against the Company or any of the Released Parties which I, my spouse, or any of my heirs, executors, administrators or assigns, may have, which arise out of or relate to my employment with, or my separation or termination from, the Company up to the date of my execution of this Release (including, but not limited to, any allegation, claim of violation arising under&#58; Title VII of the Civil Rights Act of 1964, as amended&#59; the Civil Rights Act of 1991&#59; the Age Discrimination in Employment Act of 1967, as amended (including the Older Workers Benefit Protection Act), the Equal Pay Act of 1963, as amended&#59; the Americans with Disabilities Act of 1990&#59; the Family and Medical Leave Act of 1993&#59; the Worker Adjustment Retraining and Notification Act&#59; the Employee Retirement Income Security Act of 1974&#59; the Fair Labor Standards Act&#59; or their state or local counterparts&#59; or under any other federal, state or local civil or human rights law, or under any other local state or federal law, regulation or ordinance&#59; or under any public policy, contract of tort, or under common law&#59; or arising under any policies, practices or procedures of the Company&#59; or any claim for wrongful discharge, breach of the Agreement, infliction of emotional distress or defamation&#59; or any claim for costs, fees, or other expenses, including attorneys&#8217; fees incurred in these matters) (collectively, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Claims</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;).</font></div><div style="margin-top:0.15pt;"><font><br></font></div><div style="padding-left:41pt;padding-right:3.15pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">SECTION 1542 WAIVER</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Employee agrees that all rights he may have under Section 1542 of the California Civil Code are hereby waived. Section 1542 provides&#58;</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="padding-left:77pt;padding-right:3.3pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:116%;">&#8220;A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM OR HER MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.&#8221;</font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">13</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="padding-left:41pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Notwithstanding the provisions of Section 1542, and for the purpose of implementing a full and complete release, Employee agrees that this Agreement is intended to include all claims, if any, that Employee may have against the Company, and that this Agreement extinguishes those claims.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:41.35pt;padding-right:3.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3.&#160;I represent that I have made no assignment of transfer of any right, claim, demand, cause of action, or other matter covered by </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> above.</font></div><div><font><br></font></div><div style="text-indent:-36pt;padding-left:41.35pt;padding-right:3.1pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4.&#160;In signing this Release, I acknowledge and intend that it shall be effective as a bar to each and every one of the claims, demands and causes of action herein above mentioned or implied. I expressly consent that this Release shall be given full force and effect according to each and all of its express terms and provisions, including those relating to unknown and unsuspected claims up to the date of my execution of this Release, if any, as well as those relating to any other claims hereinabove mentioned. I acknowledge and agree that this waiver is an essential and material term of this Release and that without such waiver the Company would not have agreed to the terms of the Agreement. I further agree that in the event I should bring a claim seeking damages against the Company, this Release shall serve as a complete defense to such claims as to my rights and entitlements. I further agree that I am not aware of any pending charge or complaint of the type described in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> above as of the date of my execution of this Release.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:41.35pt;padding-right:3.25pt;text-align:justify;margin-top:1.7pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">5.&#160;I agree that neither this Release, nor the furnishing of the consideration for this Release, shall be deemed or constructed at any time to be an admission or acknowledgement by the Company, any Released Party or myself of any improper or unlawful conduct.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:41.35pt;padding-right:3pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">6.&#160;I agree and acknowledge that the provisions, conditions, and negotiations of this Release are confidential and agree not to disclose any information regarding the terms, conditions and negotiations of this Release, nor transfer any copy of this Release to any person or entity, other than my immediate family and any tax, legal or other counsel or advisor I have consulted regarding the meaning or effect hereof or as required by applicable law, and I will instruct each of the foregoing not to disclose the same to anyone.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:41.35pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">7.&#160;Notwithstanding anything in the Release to the contrary, nothing in this Release shall be deemed to affect, impair, relinquish, diminish, or in any way affect any rights or claims in any respect to (i) any vested rights or other entitlements that I may have as of the date of my execution of this Release under the Company&#8217;s</font></div><div style="padding-left:41.35pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">401(k) plan&#59; (ii) any other vested rights or other entitlements that I may have as of the date of my execution of this Release under any employee benefit plan or program, in which I participated in my capacity as an employee of the Company&#59; (iii) my rights under the Agreement&#59; or (iv) my rights under the Release.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:5.35pt;padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">8.&#160;I understand that I continue to be bound by Section 6 of the Agreement.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:41.35pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">9.&#160;Whenever possible, each provision of this Release shall be interpreted in such a manner as to be effective and valid under applicable law, but if any provisions of this Release are held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other provision or any other jurisdiction, but this Release shall be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provisions had never been contained herein.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:41.35pt;padding-right:3.25pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">10.&#160;This Release shall be governed by and construed in accordance with the laws of the State of California, without giving effect to the conflict of laws principles of the State of California.</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="padding-left:41pt;padding-right:147.8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:231%;">BY SIGNING THIS RELEASE, I REPRESENT AND AGREE THAT&#58; (i)&#160;I HAVE READ IT CAREFULLY&#59;</font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">14</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="text-indent:-36pt;padding-left:77pt;padding-right:3.35pt;text-align:justify;margin-top:0.55pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(ii)         I UNDERSTAND ALL OF ITS TERMS AND KNOW THAT I AM GIVING UP IMPORTANT RIGHTS, INCLUDING BUT NOT LIMITED TO, RIGHTS UNDER THE AGE DISCRIMINATION IN EMPLOYMENT ACT OF 1967, AS AMENDED&#59;</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:41pt;padding-right:162.9pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(iii)        I VOLUNTARILY CONSENT TO EVERYTHING IN IT&#59;</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:77pt;padding-right:3.4pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(iv)        THE COMPANY IS HEREBY ADVISING ME TO CONSULT WITH AN ATTORNEY BEFORE EXECUTING IT, I HAVE HAD THE OPPORTUNITY TO SO CONSULT, AND HAVE AVAILED MYSELF OF SUCH ADVICE TO THE EXTENT I HAVE DEEMED NECESSARY TO MAKE A VOLUNTARY AND INFORMED CHOICE TO EXECUTE THIS RELEASE&#59;</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:-36pt;padding-left:77pt;padding-right:3.35pt;text-align:justify;margin-top:4.05pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(v)         I HAVE HAD AT LEAST TWENTY ONE (21) DAYS &#91;45 DAYS IN CONNECTION WITH A GROUP TERMINATION OR EXIT INCENTIVE PLAN&#93; FOLLOWING THE DATE OF TERMINATION OF MY EMPLOYMENT TO CONSIDER THIS RELEASE&#59;</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:77pt;padding-right:3.35pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(vi)       CHANGES TO THIS RELEASE, WHETHER MATERIAL OR IMMATERIAL, DO NOT RESTART THE RUNNING OF THE 21-DAY &#91;OR 45 DAY&#93; CONSIDERATION PERIOD&#59;</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:77pt;padding-right:3.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(vii)      I UNDERSTAND THAT I HAVE SEVEN (7) DAYS AFTER THE EXECUTION OF THIS RELEASE TO REVOKE IT, SUCH REVOCATION TO BE RECEIVED IN WRITING BY THE COMPANY BY THE END OF THE SEVENTH DAY AFTER THE DATE HEREOF, AND THAT THIS RELEASE SHALL NOT BECOME EFFECTIVE OR ENFORCEABLE UNTIL THE REVOCATION PERIOD HAS EXPIRED&#59;</font></div><div style="margin-top:0.75pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:77pt;padding-right:3.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;">(viii)      I HAVE SIGNED THIS RELEASE KNOWINGLY AND VOLUNTARILY AND WITH THE ADVICE OF ANY COUNSEL RETAINED TO ADVISE ME WITH RESPECT TO IT&#59; AND</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:77pt;padding-right:3.35pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(ix)        I AGREE THAT THE PROVISIONS OF THIS RELEASE MAY NOT BE AMENDED, WAIVED OR MODIFIED EXCEPT BY AN INSTRUMENT IN WRITING SIGNED BY AN AUTHORIZED REPRESENTATIVE OF THE COMPANY AND BY ME.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:5pt;padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">DATED AS OF </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;"> &#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">, 20</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;"> &#160;</font></div><div><font><br></font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="padding-left:5pt;padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#91;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Name</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">15</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>5
<FILENAME>ex1042020063010qngavaz.htm
<DESCRIPTION>EX-10.4
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i34816b94819f40389759f681ff5d22cb_1"></div><div style="min-height:18pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:36pt;padding-left:180pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%;">EMPLOYMENT AGREEMENT</font></div><div style="margin-top:0.75pt;"><font><br></font></div><div style="padding-left:60pt;padding-right:3pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%;">THIS EMPLOYMENT AGREEMENT </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;">(this &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration: underline;">Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;">&#8221;) is made and entered into as of June </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration: underline;"> 8</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;">, 2020, by and between Network Medical Management, Inc., a California corporation (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration: underline;">Employer</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;">&#8221;), and Adrian Vazquez, M.D. (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration: underline;">Employee</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;">&#8221; and together with the Employer referred to as the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration: underline;">Parties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;">&#8221;) to become effective as of the date hereof (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration: underline;">Effective</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration: underline;">Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;">&#8221;).</font></div><div style="margin-top:0.45pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:60pt;padding-right:3.15pt;text-align:justify;margin-top:1.9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;">WHEREAS, the Employer desires to employ the Employee from and after the Effective Date on the terms and conditions set forth below, and the Employee is willing to serve the Employer on such terms and conditions.</font></div><div style="margin-top:0.45pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:60pt;padding-right:3.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">NOW, THEREFORE, in consideration of the mutual covenants and agreements contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows&#58;</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="padding-left:60pt;padding-right:3.1pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.           </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Term</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The term of this Agreement shall initially be for a one (1) year period commencing on the Effective Date. The term of this Agreement shall automatically renew for an additional year on each anniversary of the Effective Date unless either Party gives the other written notice of intent not to renew at least sixty (60) days prior to such date. Notwithstanding the foregoing, the initial term and any renewal year shall be subject to earlier termination as provided in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> below. The initial term and any renewal years are referred to herein as the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Term</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;.</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="padding-left:60pt;padding-right:3.1pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.           </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Positions and Duties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. During the Term, the Employee shall serve as a senior executive officer of the Employer. The Employee shall perform for the Employer the duties customarily associated with being a senior executive officer that are consistent with your experience and skills and such other duties as may be assigned to the Employee from time to time by the Employer&#8217;s Board of Directors (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Board</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) that are consistent with the duties normally performed by those performing the role of the most senior executives of similar entities. The Employee shall devote such working time, attention, knowledge, skills and efforts as may be required to fulfill the Employee&#8217;s duties hereunder, as reasonably determined by the Board. The Employee shall be permitted to perform services as required under the Hospitalist Participation Service Agreement, and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">further</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> that the Employee may participate as a member of the board of directors or advisory board of other entities and in professional organizations and civic and charitable organizations so long as any such positions are disclosed to the Board and do not materially interfere with the Employee&#8217;s duties and responsibilities to the Employer. The Employee shall be based in Alhambra, California.</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="padding-left:60pt;padding-right:3.2pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3.           </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Compensation and Related Matters</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employer shall provide the Employee with the compensation and benefits set forth in this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> during the Term. Authority to take action under this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> with respect to the Employee&#8217;s compensation and benefits may be delegated by the Board to its compensation committee.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:60pt;padding-right:3.2pt;text-align:justify;margin-top:1.7pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(a)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Base Salary</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">. The Employer shall pay the Employee for all services rendered a base salary of Four Hundred Fifty Thousand Dollars ($450,000) per year (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Base Salary</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">&#8221;), payable in accordance with the Employer&#8217;s payroll procedures, subject to customary withholdings and employment taxes. The Base Salary shall be evaluated annually by the Board for increase only.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:60pt;padding-right:3.2pt;text-align:justify;margin-top:1.7pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(b)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Annual Bonus</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">. The Employee will be eligible to receive an annual cash bonus (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Annual Bonus</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">&#8221;) for each fiscal year during the Term on such terms and conditions as the Board shall determine in its discretion consistent with the terms of the Employer&#8217;s business plan.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:60pt;padding-right:3.05pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Long Term Incentive Awards</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employee shall be eligible to participate in any long term incentive plan that may be available to similarly positioned executives. The Board may determine to grant long-term incentive awards in cash or in equity awards settled in shares of the Employer&#8217;s stock, including but not limited to stock options, restricted stock and performance shares. In the event the Employee terminates service due to being a Good Leaver, any requirements under a long-term incentive award held by the Employee shall be deemed to have been satisfied by the Employer immediately prior to such termination. A &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Good Leaver</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; means that, during the Term, either the Employee has resigned for Good Reason (as defined in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> below), the Employer has terminated the Employee&#8217;s employment without Cause (as defined in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> below or the Employee terminates </font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:18pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="padding-left:60pt;padding-right:3.05pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">employment on account of death or Disability (as defined in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> below). For avoidance of doubt, being a Good Leaver entitles the Employee to be fully vested with respect to any stock options with vesting conditions based solely on continued employment, and to be entitled to payment with respect to any long-term incentive award subject to corporate or business goals to the extent that such goals are met during the performance period on the same basis as if he had remained continuously employed with the Employer.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:60pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(d)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Paid Time Off</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. During the term, the Employee shall be entitled to twenty (20) business days of paid time off (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">PTO</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) per calendar year which shall be accrued ratably during the calendar year, to be taken at such times and intervals as shall be agreed to by Employer and the Employee in their reasonable discretion. The Employee shall be entitled to accrue a maximum of twenty (20) business days of paid time off. When the maximum accrual is reached, no additional PTO time will accrue until Employee uses one or more accrued PTO days. Accrued and unused PTO shall be paid in cash at the end of a calendar year.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:60pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(e)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Expenses</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employee shall be entitled to prompt reimbursement of reasonable and usual business expenses incurred on behalf of Employer in accordance with the Employer&#8217;s expense reimbursement policy.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:60pt;padding-right:3.1pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(f)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Other Benefits</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employee shall be entitled to continue to participate in or receive benefits under any employee benefit plan or arrangement which is or may, in the future, be made available by the Employer to its employees, subject to and on a basis consistent with the terms, conditions and overall administration of such plan or arrangement. Irrespective of other benefits provided to employees, the Employee&#8217;s benefits package shall include&#58; (i) the Employer&#8217;s payment of premiums for medical, dental and vision care coverage&#59; (ii) the Employer&#8217;s payment of insurance premiums for short-term and long-term disability insurance providing for no less than sixty percent (60%) of Employee&#8217;s Base Salary to be payable to the Employee as long as the covered disability persists in a manner that substantially prevents employment in the same occupation as the position Employee last held with Employer but not beyond age sixty-five (65)&#59; and (iii) the Employer&#8217;s payment of insurance premiums for term life insurance providing for no less than two million dollars of coverage (subject to meeting applicable underwriting requirements).</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:60pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(g)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Tax Withholding</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employer shall undertake to make deductions, withholdings and tax reports with respect to payments and benefits under this Agreement, to the extent it reasonably and in good faith believes it is required to make such deductions, withholdings and tax reports. Payments with respect to compensation and benefits referred to under this Agreement shall be in amounts net of any such deductions or withholdings. Nothing in this Agreement shall be construed to require the Employer to make any payments to compensate the Employee for any adverse tax effect associated with any payments or benefits, or for any deduction or withholding from any payment or benefit.</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="padding-left:60pt;padding-right:3.15pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employee&#8217;s employment hereunder may be terminated during the Term without any breach of this Agreement under the following circumstances&#58;</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="padding-left:96pt;padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">(a)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;">Death</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">. The Employee&#8217;s employment hereunder shall terminate upon the Employee&#8217;s death.</font></div><div style="margin-top:0.45pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:60pt;padding-right:3.15pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Disability</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employer may terminate the Employee&#8217;s employment if the Employee is disabled and, because of the disability, is unable to perform the essential functions of the Employee&#8217;s then existing position or positions under this Agreement with or without reasonable accommodation. This provision is not intended to reduce any rights the Employee may have pursuant to any law, including without limitation the California Family Rights Act, the Family and Medical Leave Act, the California Fair Employment and Housing Act, and the Americans with Disabilities Act.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:60pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Termination by the Employer for Cause</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. At any time during the Term, the Employer may terminate the Employee&#8217;s employment hereunder for Cause. For purposes of this Agreement, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Cause</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; shall mean&#58; (i) conduct by the Employee constituting a material act of willful misconduct in connection with the performance of the Employee&#8217;s duties that results in loss, damage or injury that is material to the Employer&#59; (ii) the commission by the Employee of any felony&#59; (iii) continued, willful and deliberate non-performance by the Employee of the Employee&#8217;s duties hereunder (other than by reason of the Employee&#8217;s physical or mental illness, incapacity or disability)&#59; (iv) a material breach, according to the standard of the Employer, by the Employee of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement that results in loss, damage or injury that is material to the Employer&#59; (v) willful failure to cooperate with a bona fide internal investigation or an investigation by regulatory or law enforcement authorities, after being instructed by the Employer to cooperate, or the willful destruction or failure to preserve documents or other materials known to be </font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:18pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="padding-left:60pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">relevant to such investigation or the willful inducement of others to fail to cooperate or to produce documents or other materials in connection with such investigations&#59; or (vi) fraud, embezzlement or theft against the Employer or any of its Affiliates (as defined in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> below). With respect to the events in (i), (iii) and (iv) herein, the Employer shall have delivered written notice to the Employee of its intention to terminate the Employee&#8217;s employment for Cause, which notice specifies in reasonable detail the circumstances claimed to give rise to the Employer&#8217;s right to terminate the Employee&#8217;s employment for Cause and the Employee shall not have cured such circumstances to the extent such circumstances are reasonably susceptible to cure as determined by the Board in good faith within thirty (30) days following the Employer&#8217;s delivery of such notice. For avoidance of doubt, &#8220;Cause&#8221; shall not include (x) expense reimbursement disputes in which the Employee acts in reasonable good faith&#59; (y) occasional, customary and de minimis use of the Employer&#8217;s property for personal purposes&#59; and (z) acting in good faith upon advice of Employer&#8217;s legal counsel.</font></div><div style="padding-right:3.1pt;text-align:justify;margin-bottom:0.1pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:60pt;padding-right:3.1pt;text-align:justify;margin-top:1.65pt;margin-bottom:0.1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(d)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Termination without Cause</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. At any time during the Term, the Employer may terminate the Employee&#8217;s employment hereunder without Cause by providing the Employee with thirty (30) days advance written notice. Any termination by the Employer of the Employee&#8217;s employment under this Agreement that does not constitute a termination for Cause under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> and does not result from the death or Disability of the Employee under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Sections 4(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> or </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">4(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> shall be deemed a termination without Cause under this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Any suspension of the Employee&#8217;s employment with pay or benefits by the Board in good faith pending an investigation of alleged improper activities by the Employee that, if determined to be accurate, would be grounds for a Cause termination, shall not be considered a termination of the Employee&#8217;s employment without Cause or provide with Good Reason to terminate employment.</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:60pt;padding-right:3pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(e)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Termination by the Employee</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. At any time during the Term, the Employee may terminate his employment hereunder for any reason, including, but not limited to, Good Reason. For purposes of this Agreement, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Good Reason</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; shall mean that the Employee has complied with the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Good Reason Process</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; (hereinafter defined) following the occurrence of any of the following events&#58; (i) a material diminution in the Employee&#8217;s responsibilities, authority or duties&#59; (ii) the material breach of this Agreement by the Employer, including but not limited to a failure to pay Base Salary or Annual Bonus as provided for under this Agreement&#59; or (iii) any relocation of the Employee&#8217;s principal place of business to a location more than 30 miles from the Employer&#8217;s current executive offices in Alhambra, California&#59; provided, however, that this clause (iii) will not apply to the extent that any new office location is less than 30 miles from the Employee&#8217;s residence. &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Good Reason Process</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; shall mean (i) the Employee reasonably determines in good faith that a &#8220;Good Reason&#8221; condition has occurred&#59; (ii) the Employee notifies the Employer in writing of the occurrence of the Good Reason condition within (60) days of the occurrence of such condition&#59; (iii) the Employee cooperates in good faith with the Employer&#8217;s efforts, for a period of sixty (60) days following such notice (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Cure Period</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;), to remedy the condition&#59; (iv) notwithstanding such efforts, the Good Reason condition continues to exist&#59; and (v) the Employee terminates his employment within thirty (30) days after the end of the Cure Period. If the Employer cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not to have occurred.</font></div><div style="margin-top:0.25pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:60pt;padding-right:3.2pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(f)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Notice of Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Except for termination as specified in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, any termination of the Employee&#8217;s employment shall be communicated by written Notice of Termination by the terminating Party to the other Party hereto. For purposes of this Agreement, a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Notice of Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; shall mean a notice which shall indicate the specific termination provision in this Agreement relied upon.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:60pt;padding-right:3.05pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(g)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Date of Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Date of Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; shall mean the earliest of the following&#58; (i) if the Employee&#8217;s employment is terminated by the Employee&#8217;s death, the date of the Employee&#8217;s death&#59; (ii) if the Employee&#8217;s employment is terminated on account of Disability under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> or by the Employer for Cause under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, the date on which Notice of Termination is given that follows any applicable required cure period&#59; (iii) if the Employee&#8217;s employment is terminated by the Employer under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, thirty (30) days after the date on which a Notice of Termination is given&#59; (iv) if the Employee&#8217;s employment is terminated by the Employee under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> without Good Reason, thirty (30) days after the date of which a Notice of Termination is given or such shorter period agreed to by the Employer&#59; or (v) if the Employee&#8217;s employment is terminated by the Employee under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> with Good Reason, the date on which Notice of Termination is given after the end of the Cure Period. Notwithstanding the foregoing, in the event that the Employee gives a Notice of Termination to the Employer, the Employer may unilaterally accelerate the Date of Termination but such acceleration shall nevertheless be deemed a termination by the Employee on the accelerated date for purposes of this Agreement. For purposes of determining the time when the lump sum portion of the Severance Amount, if any, is to be paid under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 5(b)(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:18pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="padding-left:60pt;padding-right:3.05pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">of this Agreement, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Date of Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; means the Employee&#8217;s separation from service as defined under Section 409A.</font></div><div style="padding-right:3.05pt;text-align:justify;margin-bottom:0.1pt;"><font><br></font></div><div style="padding-left:62.5pt;padding-right:-1pt;margin-top:1.65pt;margin-bottom:0.1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">5.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;">Compensation upon Termination.</font></div><div style="margin-top:0.45pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:60pt;padding-right:3.05pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Accrued Benefits. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> If the Employee&#8217;s employment with the Employer is terminated for any reason during the Term, or if the Term is not renewed, the Employer shall pay or provide the Employee (or the Employee&#8217;s authorized representative or estate) any earned but unpaid Base Salary or Annual Bonus for services rendered through the Date of Termination, unpaid expense reimbursements, and accrued but unused paid time off (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Accrued</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Benefits</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) within the time prescribed by California law. With respect to vested compensation or benefits the Employee may have under any employee benefit or compensation plan, program or arrangement of the Employer, payment will be made to the Employee under the terms of the applicable plan, program or arrangement.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:60pt;padding-right:3pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Termination by the Employer without Cause or by the Employee with Good</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Reason</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. If the Employee&#8217;s employment is terminated by the Employer without Cause as provided in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, or the Employee terminates his employment for Good Reason as provided in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, or the Employee terminates employment at the end of the Term after the Employer provides notice of intent not to renew pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> for reasons other than would provide grounds for a Cause termination, then, (i) the Employer shall, through the Date of Termination, pay the Employee his or her Accrued Benefits, and (ii) if the Employee signs a general release of claims substantially in the form which is attached as </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Exhibit A</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to this Agreement) (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Release</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) within twenty-one (21) days of the receipt of the form of the Release (extended to forty-five (45) days in the event of a group termination or exit incentive program) and does not revoke such Release during the seven-day revocation period&#58;</font></div><div style="margin-top:0.25pt;"><font><br></font></div><div style="text-indent:36.05pt;padding-left:95.95pt;padding-right:3.05pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(i)         the Employer shall pay the Employee an amount equal to one-twelfth (1&#47;12) of the Employee&#8217;s most recent Base Salary times the number of full years of service completed, not to exceed twelve (12) years of service (but determined prior to any action involving Base Salary that would constitute Good Reason) (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Severance Amount</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;). Employer acknowledges that Employee has completed not less than twelve (12) full years of service (including Employee&#8217;s service for the Employer&#8217;s parent entity, subsidiaries and affiliates), such that the Severance Amount payable to Employee pursuant to the terms of this Agreement shall equal the maximum Severance Amount of one (1) year of the Employee&#8217;s most recent Base Salary. To the extent that such Severance Amount exceeds the 409A Separation Pay Limit (as defined below), such amount shall be paid in a single lump sum on the regular payroll date of the Employer, pertaining to then current salaried employees of the Employer, (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">payroll date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) next following the first anniversary date of the Employee&#8217;s Date of Termination. The portion of the Severance Amount that does not exceed the 409A Separation Pay Limit shall be paid in substantially equal amounts on each payroll date over a one year period&#59; and</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:96pt;padding-right:3.1pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(ii)        the Employer shall pay the Employee an amount in cash equal to the Employer&#8217;s premium amounts paid for coverage of Employee at the time of the Employee&#8217;s termination of coverage under the Employer&#8217;s group medical, dental and vision programs for a period of twelve (12) months, to be paid directly to the Employee at the same times such payments would be paid on behalf of a current employee for such coverage&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#58;</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:132pt;padding-right:3.15pt;text-align:justify;margin-top:1.7pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(A)        No  payments shall  be  made  under  this  paragraph (ii)  unless  and  until  the Employee timely elects continued coverage under such plan(s) pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1985 as amended (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">COBRA</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">&#8221;)&#59;</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:132pt;padding-right:3.2pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(B)&#160;This paragraph (ii) shall not be read or construed as placing any restrictions upon amounts paid under this paragraph (ii) as to their use&#59;</font></div><div style="margin-top:0.75pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:132pt;padding-right:3.15pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;">(C)&#160;Payments under this paragraph (ii) shall cease as of the earliest to occur of the following&#58;</font></div><div style="padding-left:62.5pt;padding-right:-1pt;margin-top:1.65pt;"><font><br></font></div><div style="padding-left:204pt;padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(1)&#160;the Employee is no longer eligible for and continuing to receive the</font></div><div style="padding-left:168pt;padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">COBRA coverage elected in subparagraph (A)&#59;</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:18pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="padding-left:204pt;padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(2)&#160;the time period set forth in the first sentence of this paragraph (ii),</font></div><div><font><br></font></div><div style="padding-left:204pt;padding-right:3.2pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(3)        the date on which the Employee first becomes eligible to enroll in a group health plan in which eligibility is based on employment with an employer, and</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:204pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(4)        if the Employer in good faith determines that payments under this paragraph (ii) would result in a discriminatory health plan pursuant to the Patient Protection and Affordable Care Act of 2010, as amended.</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="padding-left:240pt;padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(iii)&#160;Each individual payment of Severance Amount under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section</font></div><div style="padding-left:204pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;">5(b)(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">, and each payment under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;">Section 5(b)(ii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> of this Agreement, shall be deemed to be a separate &#8220;payment&#8221; for purposes and within the meaning of Treasury Regulation Section 1.409A-2(b)(2)(iii).</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:204pt;padding-right:3.1pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(iv)       Each    individual    payment    of    the    Severance    Amount under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Section  5(b)(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">,   and   each   payment   under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Section   5(b)(ii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">,   of   this Agreement, which are considered &#8220;non-qualified deferred compensation&#8221; (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">NQDC</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">&#8221;) under Section 409A shall be made on the date(s) provided herein and no request to accelerate or defer any such payment under this Agreement shall be considered or approved for any reason whatsoever, except as permitted under Section 409A and as the Employer allows in its sole discretion. The Employer may in its sole discretion accelerate or defer (but not beyond the time limit set forth below) any severance payments which do not constitute NQDC in order to allow for the payment of taxes due, but not beyond the time limit specified for such payment such that the payment would be treated as NQDC. Subject to the requirements of  Section 409A, if  any severance payment or  reimbursement under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Section 5(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;"> of this Agreement is determined in good faith by the Employer to constitute NQDC payable to a &#8220;specified employee&#8221; as defined under Section</font></div><div style="padding-left:204pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">409A, then the Employer shall make any such payment not earlier than the earlier of&#58; (x) the first payroll date which is six (6) months following the Employee&#8217;s separation from service (as defined under Section 409A) with the Employer, or (y) the date of Employee&#8217;s death.</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="padding-left:240pt;padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(v)&#160;for purposes of this Section 5, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 409A</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; means Section</font></div><div style="padding-left:204pt;padding-right:18.3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">409A of the Internal Revenue Code of 1986, as amended, and the regulations thereunder.</font></div><div style="margin-top:0.45pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:204pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(vi)       for purposes of this Section 5, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">409A Separation Pay Limit</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; means two times the lesser of (</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">x</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">) the Employee&#8217;s annual compensation during the calendar year preceding the year of the termination of employment&#59; and (</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">y</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">) the adjusted compensation limit under Code Section 401(a)(17) in effect for the year of the termination.</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="padding-left:60pt;padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">6.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;">Confidential Information, Nonsolicitation, and Cooperation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">.</font></div><div style="margin-top:0.1pt;"><font><br></font></div><div style="padding-left:96pt;padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">(a)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;">Definitions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">.</font></div><div style="margin-top:0.1pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:96pt;padding-right:3.05pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(i)          As used in this Agreement, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Affiliate</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">&#8221; means, as to any Person, (i) any other Person which directly, or indirectly through one or more intermediaries, controls such Person or is consolidated with such Person in accordance with GAAP, (ii) any other Person which directly, or indirectly through one or more intermediaries, is controlled by or is under common control with such Person, or (iii) any other Person of which such Person owns, directly or indirectly, fifty percent (50%) or more of the common stock or equivalent equity interests. As used herein, the term &#8220;control&#8221; means possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of a Person, whether through the ownership of voting securities or otherwise.</font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:18pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:36pt;padding-left:96pt;padding-right:3.2pt;margin-top:1.65pt;margin-bottom:0.1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(ii)&#160;As used in this Agreement, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Person</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; means an individual, a corporation, a partnership, a limited liability company, an association, a trust or any other entity or organization.</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:60pt;padding-right:3.1pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Confidential  Information</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  As   used   in   this   Agreement,  &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Confidential</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Information</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;  means information belonging to the Employer or its Affiliates which is of value to the Employer or any of its Affiliates in the course of conducting its business (whether having existed, now existing, or to be developed or created during Employee&#8217;s employment by Employer) and the disclosure of which could result in a competitive or other disadvantage to the Employer or its Affiliates. Confidential Information includes, without limitation, contract terms and rates&#59; negotiating and contracting strategies&#59; financial information, reports, and forecasts&#59; inventions, improvements and other intellectual property&#59; product plans or proposed product plans&#59; trade secrets&#59; designs, processes or formulae&#59; software&#59; employee, customer, patient, provider and supplier information&#59; information from patient medical records&#59; financial data&#59; insurance reimbursement methodologies, strategies and practices&#59; product and service pricing methodologies, strategies and practices&#59; contracts with physicians, providers, provider networks, payors, physician databases and contracts with hospitals&#59; regulatory and clinical manuals&#59; and business plans, prospects and opportunities (such as possible acquisitions or dispositions of businesses or facilities) that have been discussed or considered by the Employer or its Affiliates, including, without limitation, the management of the Employer or its Affiliates. Confidential Information includes information developed by the Employee in the course of the Employee&#8217;s employment by the Employer, as well as other information to which the Employee may have access in connection with the Employee&#8217;s employment. Confidential Information also includes the confidential information of others with which the Employer or its Affiliates has a business relationship. Notwithstanding the foregoing, Confidential Information does not include information in the public domain, unless due to breach of the Employee&#8217;s duties under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, unless otherwise due to Employee&#8217;s breach of the obligations in this Agreement, or unless due to violation of another Person&#8217;s obligations to the Employer or its Affiliates that Employee should have taken reasonable measures to prevent but that Employee did not take.</font></div><div><font><br></font></div><div style="text-indent:38.5pt;padding-left:60pt;padding-right:4.85pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Confidentiality</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employee understands and agrees that the Employee&#8217;s employment creates a relationship of confidence and trust between the Employer and the Employee with respect to all Confidential Information. At all times, both during the Employee&#8217;s employment with the Employer and after the Employee&#8217;s termination from employment for any reason, the Employee shall keep in confidence and trust all such Confidential Information, and shall not use, disclose, or transfer any such Confidential Information without the written consent of the Employer, except as may be necessary within the scope of Employee&#8217;s duties with Employer and in the ordinary course of performing the Employee&#8217;s duties to the Employer or as otherwise provided in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Employee understands and agrees not to sell, license or otherwise exploit any products or services which embody or otherwise exploit in whole or in part any Confidential Information or materials. Employee acknowledges and agrees that the sale, misappropriation, or unauthorized use or disclosure in writing, orally or by electronic means, at any time of Confidential Information obtained by Employee during or in connection with the course of Employee&#8217;s employment constitutes unfair competition. Employee agrees and promises not to engage in unfair competition with Employer or its Affiliates, either during employment, or at any time thereafter.</font></div><div style="margin-top:0.45pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:60pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(d)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Protected Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Notwithstanding anything to the contrary in this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, this Agreement is not intended to, and shall not, in any way prohibit, limit or otherwise interfere with the Employee&#8217;s protected rights under federal, state or local law to, without notice to the Employer, (i) communicate or file a charge with a government regulator&#59; (ii) participate in an investigation or proceeding conducted by a government regulator&#59; or (iii) receive an award paid by a government regulator for providing information.</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:60pt;padding-right:3.15pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(e)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Documents, Records, etc</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. All documents, records, data, apparatus, equipment and other physical property, whether or not pertaining to Confidential Information, that are furnished to the Employee by the Employer or its Affiliates or are produced by the Employee in connection with the Employee&#8217;s employment will be and remain the sole property of the Employer and its Affiliates. The Employee shall return to the Employer all such materials and property as and when requested by the Employer. In any event, the Employee shall return all such materials and property immediately upon termination of the Employee&#8217;s employment for any reason. The Employee shall not retain any such material or property or any copies thereof after such termination. It is specifically agreed that any documents, card files, notebooks, programs, or similar items containing customer or patient information are the property of the Employer and its Affiliates regardless of by whom they were compiled.</font></div><div style="text-align:justify;"><font><br></font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:18pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="text-indent:36pt;padding-left:60pt;padding-right:3.05pt;text-align:justify;margin-top:1.9pt;margin-bottom:0.1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;">(f)          </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration: underline;">Disclosure Prevention</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;">. The Employee will take all reasonable precautions to prevent the inadvertent or accidental exposure of Confidential Information.</font></div><div style="padding-right:3.05pt;text-align:justify;margin-bottom:0.1pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:60pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">(g)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;">Removal of Material</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. The Employee will not remove any Confidential Information from the Employer&#8217;s or its Affiliate&#8217;s premises except for use in the Employer&#8217;s business, and only consistent with the Employee&#8217;s duties with the Employer.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:60pt;padding-right:3.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(h)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Copying</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">. The Employee agrees that copying or transferring Confidential Information (by any means) shall be done only as needed in furtherance of and for use in the Employer&#8217;s and its Affiliate&#8217;s business, and consistent with the Employee&#8217;s duties with the Employer. The Employee further agrees that copies of Confidential Information shall be treated with the same degree of confidentiality as the original information and shall be subject to all restrictions herein.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:60pt;padding-right:3.15pt;text-align:justify;margin-top:1.9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;">(i)           </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration: underline;">Computer Security</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;">. The Employee agrees to comply with the Employer&#8217;s policies and procedures concerning computer security.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:60pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(j)           </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">E-Mail</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employee acknowledges that the Employer retains the right to review any and all electronic mail communications made with employer provided email accounts, hardware, software, or networks, with or without notice, at any time.</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:60pt;padding-right:3.1pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(k)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Assignment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employee acknowledges that any and all inventions, discoveries, designs, developments, methods, modifications, trade secrets, processes, software, formulae, data, &#8220;know-how,&#8221; databases, algorithms, techniques and works of authorship whether or not patentable or protectable by copyright or trade secret, made or conceived, first reduced to practice, or learned by the Employee, either alone or jointly with others, during the Term that (i) relate to or are useful in the business of the Employer or its Affiliates, or (ii) are conceived, made or worked on at the expense of or during the Employee&#8217;s work time for the Employer, or using any resources or materials of the Employer or its Affiliates, or (iii) arise out of tasks assigned to the Employee by the Employer (together &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Proprietary Inventions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) will be the sole property of the Employer or its Affiliates. The Employee acknowledges that all work performed by the Employee is on a &#8220;work for hire&#8221; basis and the Employee hereby assigns or agrees to assign to the Employer the Employee&#8217;s entire right, title and interest in and to any and all Proprietary Inventions and related intellectual property rights. The Employee agrees to assist the Employer to obtain, maintain and enforce intellectual property rights for Proprietary Inventions in any and all countries during the Term, and thereafter for as long as such intellectual property rights exist.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="padding-left:199.7pt;padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:113%;text-decoration: underline;">NOTICE TO CALIFORNIA EMPLOYEES</font></div><div style="margin-top:0.1pt;"><font><br></font></div><div style="padding-left:96pt;padding-right:39.1pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">Pursuant to California Labor Code &#167;2870, an agreement requiring the employee to assign or offer to assign any of his or her rights in any invention to his or her employer does not apply to an invention which qualifies fully under the provisions of California Labor Code &#167; 2870, which provides as follows&#58;</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:96pt;padding-right:39.05pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)         Any provision in an employment agreement which provides that an employee shall assign, or offer to assign, any of his or her rights in an invention to his or her employer shall not apply to an invention that the employee developed entirely on his or her own time without using the employer&#8217;s equipment, supplies, facilities, or trade secret information except for those inventions that either&#58;</font></div><div style="margin-top:0.6pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:132pt;padding-right:39.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(1)        Relate at the time of conception or reduction to practice of the invention to the employer&#8217;s business, or actual or demonstrably anticipated research or development of the employer&#59; or</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="padding-left:168pt;padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(2)&#160;Result from any work performed by the employee for the employer.</font></div><div style="margin-top:0.75pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:96pt;padding-right:39.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;">(b)         To the extent a provision in an employment agreement purports to require an employee to assign an invention otherwise excluded from being required to be assigned under subdivision (a),  the  provision is  against the  public policy  of  the  State  of  California and  is unenforceable.</font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">7</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:18pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:60pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(l)           </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Nonsolicitation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Employee agrees and covenants that, at any time during Employee&#8217;s employment with the Employer and for a period of twelve (12) months immediately following the termination of Employee&#8217;s relationship with the Employer for any reason, whether with or without cause, Employee shall not, either on Employee&#8217;s own behalf or on behalf of any other Person&#58; (i) solicit the services of the Employer&#8217;s employees or entice away, directly or indirectly, any Person employed or engaged by or otherwise providing services to the Employer or its Affiliates, whether in an employment capacity or otherwise (this provision does not prohibit the Employee&#8217;s post- termination acceptance of unsolicited applications for employment)&#59; or (ii) take any illegal action or engage in any unfair business practice, including, without limitation, any misappropriation of confidential, proprietary or trade secret information of the Employer or its Affiliates, as a result of which relations between the Employer or its Affiliates, and any of their customers, clients, suppliers, distributors or others, may be impaired or which might otherwise be detrimental to the business interests or reputation of the Employer or its Affiliates.</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:60pt;padding-right:3pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(m)        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Third-Party Agreements and Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employee hereby confirms that the Employee is not bound by the terms of any agreement with any previous employer or other party which restricts in any way the Employee&#8217;s use or disclosure of information or the Employee&#8217;s engagement in any business except as Employee has previously provided written notice to Employer and has attached to this Agreement. The Employee represents to the Employer that the Employee&#8217;s execution of this Agreement, the Employee&#8217;s employment with the Employer and the performance of the Employee&#8217;s proposed duties for the Employer will not violate any obligations the Employee may have to any previous employer or other party. In the Employee&#8217;s work for the Employer, the Employee will not disclose or use any information in violation of any agreements with or rights of any such previous employer or other party, and the Employee will not bring to (by any means) the premises of the Employer any copies or other tangible embodiments of non- public information belonging to or obtained from any such previous employment or other party.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:60pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(n)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Litigation  and  Regulatory  Cooperation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  During  and  after  the  Employee&#8217;s  employment,  the Employee shall cooperate fully with the Employer in the defense or prosecution of any claims or actions now in existence or that may be brought in the future against or on behalf of the Employer that relate to events or occurrences that transpired while the Employee was employed by the Employer. The Employee&#8217;s full cooperation in connection with such claims or actions shall include, but not be limited to, being available to meet with counsel to prepare for discovery or trial and to act as a witness on behalf of the Employer at mutually convenient times. During and after the Employee&#8217;s employment, the Employee also shall cooperate fully with the Employer in connection with any investigation or review of any federal, state, or local regulatory authority as any such investigation or review relates to events or occurrences that transpired while the Employee was employed by the Employer. The Employer shall reimburse the Employee for any reasonable out of pocket expenses incurred in connection with the Employee&#8217;s performance of obligations pursuant to this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. &#8220;Full cooperation&#8221; shall not be construed to in any way require any violation of law or any testimony that is false or misleading.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:60pt;padding-right:3pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(o)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Enforcement&#59; Injunction</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employee acknowledges and agrees that the restrictions contained in this Agreement are reasonable and necessary to protect the business and interests of the Employer and its Affiliates, do not create any undue hardship for the Employee, and that any violation of the restrictions in this Agreement would cause the Employer and its Affiliates substantial irreparable injury. Accordingly, the Employee agrees that a remedy at law for any breach or threatened breach of the covenants or other obligations in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement would be inadequate and that the Employer, in addition to any other remedies available, shall be entitled to obtain preliminary and permanent injunctive relief to secure specific performance of such covenants and to prevent a breach or contemplated or threatened breach of this Agreement without the necessity of proving actual damage and without the necessity of posting bond or security, which the Employee expressly waives. Moreover, the Employee will provide the Employer a full accounting of all proceeds and profits received by the Employee as a result of or in connection with a breach of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement. Unless prohibited by law, the Employer shall have the right to retain any amounts otherwise payable by the Employer to the Employee to satisfy any of the Employee&#8217;s obligations as a result of any breach of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement. The Employee hereby agrees to indemnify and hold harmless the Employer and its Affiliates from and against any damages incurred by the Employer or its Affiliates as assessed by a court of competent jurisdiction as a result of any breach of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement by the Employee. The prevailing party shall be entitled to recover its reasonable attorneys&#8217; fees and costs if it prevails in any action to enforce </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement. It is the express intention of the parties that the obligations of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement shall survive the termination of the Employee&#8217;s employment. The Employee agrees that each obligation specified in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement is a separate and independent covenant that shall survive any termination of this Agreement and that the unenforceability of any of them shall not preclude the enforcement of any </font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">8</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:18pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="padding-left:60pt;padding-right:3pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">other covenants in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement. No change in the Employee&#8217;s duties or compensation shall be construed to affect, alter or otherwise release the Employee from the covenants herein.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="padding-left:60pt;padding-right:3pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">7.          </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Successors</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">. This Agreement shall be binding upon and inure to the benefit of both parties and their respective successors and permitted assigns, including any corporation or entity with which or into which the Employer may be merged or which may succeed to its assets or business, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">, that Employee&#8217;s obligations are personal and shall not be assigned by Employee. The Employee consents to be bound by the provisions of this Agreement for the benefit of the Employer or its Affiliates to whose employ the Employee may be transferred without the necessity that this Agreement be resigned at the time of such transfer. In the event of the Employee&#8217;s death after the Date of Termination but prior to the completion by the Employer of all payments due to the Employee under this Agreement, the Employer shall continue such payments to the Employee&#8217;s beneficiary designated in writing to the Employer prior to the Employee&#8217;s death (or to the Employee&#8217;s estate, if the Employee fails to make such designation).</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="padding-left:60pt;padding-right:3.1pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">8.         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Enforceability</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">. If any portion or provision of this Agreement shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="padding-left:60pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">9.          </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Waiver</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">. No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party. The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="padding-left:60pt;padding-right:3.1pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">10.        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Notices</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Any notices, requests, demands and other communications provided for by this Agreement shall be sufficient if in writing and delivered in person or sent by registered or certified mail, postage prepaid, to the Employee at the last address for which the Employee has provided written notice to the Employer, or to the Employer at its main office, to the attention of Human Resources</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:60pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">11.        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Publicity</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employee hereby grants to the Employer the right to use the Employee&#8217;s name and likeness, without additional consideration, on, in and in connection with technical, marketing and&#47;or disclosure materials published by or for the Employer for the duration of Employee&#8217;s employment with Employer.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="padding-left:60pt;padding-right:3.05pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">12.        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Conflicting Obligations and Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">. The Employee agrees to inform the Employer of any apparent conflicts between the Employee&#8217;s work for the Employer and (a) any obligations the Employee may have to preserve the confidentiality of another&#8217;s proprietary information or materials or (b) any rights the Employee claims to any inventions or ideas before using the same on the Employer&#8217;s behalf. Otherwise, the Employer may conclude that no such conflict exists and the Employee agrees thereafter to make no such claim against the Employer. The Employer shall receive such disclosures in confidence and consistent with the objectives of avoiding any conflict of obligations and rights or the appearance of any conflict of interest.</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="padding-left:60pt;padding-right:3.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">13.        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Notification of New Employer</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. In the event that the Employee leaves the employ of the Employer, voluntarily or involuntarily, the Employee agrees to inform any subsequent employer of the Employee&#8217;s obligations under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section</font></div><div style="padding-left:60pt;padding-right:3.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement. The Employee further hereby authorizes the Employer to notify the Employee&#8217;s new employer about the Employee&#8217;s obligations under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement.</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="padding-left:60pt;padding-right:3.15pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">14.        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Entire Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. This Agreement constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes any previous oral or written communications, negotiations, representations, understandings, or agreements between them, including, without limitation, the Employment Agreement dated December 20, 2016, between Employer&#8217;s affiliate, Apollo Medical Management, Inc., a California corporation, and Employee, which shall be cancelled in its entirety and of no further force or effect. Any modification of this Agreement shall be effective only if set forth in a written document signed by the Employee and a duly authorized officer of the Employer.</font></div><div style="text-align:justify;"><font><br></font></div><div style="padding-left:60pt;padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">15.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Amendment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. This Agreement may be amended or modified only by a written instrument signed by the</font></div><div style="padding-left:60pt;padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;">Employee and by a duly authorized representative of the Employer.</font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">9</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:18pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="margin-top:0.1pt;"><font><br></font></div><div style="padding-left:60pt;padding-right:3.15pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">16.        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Governing Law</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. This is a California contract and shall be construed under and be governed in all respects by the laws of the State of California, without giving effect to the conflict of laws principles of such State.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="padding-left:60pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">17.        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Obligations of Successors</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">. The Employer shall require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Employer to expressly assume and agree to perform this Agreement in the same manner and to the same extent that the Employer would be required to perform if no such succession had taken place.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="padding-left:60pt;padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">18.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;">Limitation on Payments in Certain Events.</font></div><div style="margin-top:0.45pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:60pt;padding-right:3.1pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Limitation on Payments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Notwithstanding anything to the contrary in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement, if any payment or distribution that the Employee would receive pursuant to this Agreement or otherwise (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Payment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) would (a) constitute a &#8220;parachute payment&#8221; within the meaning of Section 280G of the Code), and (b) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Excise Tax</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;), then the Employer shall cause to be determined, before any amounts of the Payment are paid to the Employee, which of the following alternative forms of payment would maximize the Employee&#8217;s after-tax proceeds&#58; (i) payment in full of the entire amount of the Payment (a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Full Payment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;), or (ii) payment of only a part of the Payment so that the Employee receives that largest Payment possible without being subject to the Excise Tax (a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Reduced Payment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;), whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the Excise Tax (all computed at the highest marginal rate, net of the maximum reduction in federal income taxes which could be obtained from a deduction of such state and local taxes), results in the Employee&#8217;s receipt, on an after-tax basis, of the greater amount of the Payment, notwithstanding that all or some portion the Payment may be subject to the Excise Tax.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:60pt;padding-right:3.1pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)         The independent registered public accounting firm engaged by the Employer for general audit purposes as of the day prior to the date the first Payment is due shall make all determinations required to be made under this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 18</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. If the independent registered public accounting firm so engaged by the Employer is serving as accountant or auditor for the individual, group or entity effecting the transaction, the Employer shall appoint a nationally recognized independent registered public accounting firm to make the determinations required hereunder. The Employer shall bear all expenses with respect to the determinations by such independent registered public accounting firm required to be made hereunder.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:60pt;padding-right:3.65pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c)&#160;The independent registered public accounting firm engaged to make the determinations hereunder shall provide its calculations, together with detailed supporting documentation, to the Employer and the Employee at such time as requested by the Employer or the Employee. If the independent registered public accounting firm determines that no Excise Tax is payable with respect to a Payment, either before or after the application of the Reduced Payment, it shall furnish the Employer and the Employee with an opinion reasonably acceptable to the Employee that no Excise Tax will be imposed with respect to such Payment. Any good faith determinations of the accounting firm made hereunder shall be final, binding and conclusive upon the Parties.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:60pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">19.        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Consent to Jurisdiction&#59; Forum Selection</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. At all times the Employee and Employer&#58; (a) irrevocably submit to the exclusive jurisdiction of the Los Angeles Superior Court and United States District Court for the Central District of California, whichever may have competent subject matter jurisdiction, in any action or proceeding arising out of or relating to this Agreement, and irrevocably agree that all claims in respect of any such action or proceeding may be heard and determined in such court&#59; (b) to the extent permitted by law, irrevocably consent to the service of any and all process in any such action or proceeding by the mailing of copies of such process to such party at the address set forth in this Agreement (or otherwise on record with the Employer)&#59; (c) to the extent permitted by law, irrevocably confirm that service of process out of such courts in such manner shall be deemed due service upon such party for the purposes of such action or proceeding&#59; (d) to the extent permitted by law, irrevocably waives (i) any objection the Employee or Employer may have to the laying of venue of any such action or proceeding in any of such courts, or (ii) any claim that the Employee or Employer may have that any such action or proceeding has been brought in an inconvenient forum&#59; and (e) to the extent permitted by law, irrevocably agrees that a final nonappealable judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment </font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:60pt;padding-right:3.1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">or in any other manner provided by law. Nothing in this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> shall affect the right of any party hereto to serve legal process in any manner permitted by law.</font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">10</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:18pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="padding-left:60pt;padding-right:3.1pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">20.        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Counterparts</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be taken to be an original&#59; but such counterparts shall together constitute one and the same document.</font></div><div><font><br></font></div><div style="margin-top:0.9pt;"><font><br></font></div><div style="padding-left:238.25pt;padding-right:188pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#91;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Signature Page Follows</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#93;</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;margin-bottom:0.1pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:0.1pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:0.1pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:0.1pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:0.1pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:0.1pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:0.1pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:0.1pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:0.1pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:0.1pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:0.1pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:0.1pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:0.1pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:0.1pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:0.1pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:0.1pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:0.1pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:0.1pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:0.1pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:0.1pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:0.1pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:0.1pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:0.1pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:0.1pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:0.1pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:0.1pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:0.1pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:0.1pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:0.1pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:0.1pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:0.1pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:0.1pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:0.1pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:0.1pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:0.1pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:0.1pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:0.1pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:0.1pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:0.1pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:0.1pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:0.1pt;"><font><br></font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:18pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:0.1pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:60pt;padding-right:28.1pt;margin-top:1.65pt;margin-bottom:0.1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">IN WITNESS WHEREOF, this Agreement has been executed as a sealed instrument by the Employer by its duly authorized officer, and by the Employee, as of the date first above written.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:60pt;padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EMPLOYER&#58;</font></div><div style="padding-right:-1pt;margin-bottom:0.1pt;"><font><br></font></div><div style="padding-left:60pt;padding-right:285.55pt;margin-top:0.05pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:230%;">NETWORK MEDICAL MANAGEMENT, INC.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:230%;">&#58; </font></div><div style="padding-left:36pt;padding-right:285.55pt;margin-bottom:0.1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;">         By&#58;                                          </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration: underline;">&#47;s&#47;Thomas Lam                                                                                                                           </font></div><div style="margin-top:0.8pt;"><font><br></font></div><div style="padding-left:60pt;padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">Printed Name&#58;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;">Thomas Lam, M.D. &#160;</font></div><div style="margin-top:0.05pt;"><font><br></font></div><div style="padding-left:60pt;padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">Its&#58;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;">Co-Chief Executive Officer &#160;</font></div><div><font><br></font></div><div style="margin-top:0.45pt;"><font><br></font></div><div style="padding-left:60pt;padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EMPLOYEE&#58;</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="padding-left:60pt;padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">Signed&#58;&#160;&#160;&#160;    </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;">&#47;s&#47;Adrian Vazquez          &#160;                                                                                                  </font></div><div style="margin-top:0.05pt;"><font><br></font></div><div style="padding-left:60pt;padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">Printed Name&#58;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;">Adrian Vazquez, M.D. &#160;</font></div><div style="margin-top:0.05pt;"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:203.15pt;padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">&#91;Signature page to Employment Agreement&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">12</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:18pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="margin-bottom:0.1pt;"><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div><div><font><br></font></div><div style="padding-right:211.1pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%;">EXHIBIT A</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:254.45pt;padding-right:199.4pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:113%;text-decoration: underline;">Release of Claims</font></div><div style="margin-top:0.1pt;"><font><br></font></div><div style="padding-left:96pt;padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">I,&#160;, in consideration of and subject to the performance by Network Medical Management,</font></div><div style="padding-left:60pt;padding-right:3.35pt;text-align:justify;margin-top:0.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Inc., a California corporation (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Company</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) of its obligations under the Employment Agreement, dated as of _ _,</font></div><div style="padding-left:60pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">20 (as amended from time to time, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">&#8221;), do hereby release and forever discharge as of the date of my execution of this release (this &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Release</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">&#8221;) the Company, its affiliated and related entities, its and their respective predecessors, successors and assigns, its and their respective employee benefit plans and fiduciaries of such plans, and the current and former officers, directors, shareholders, employees, attorneys, accountants and agents of each of the foregoing in their official and personal capacities (collectively, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Released Parties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">&#8221;) to the extent provided below.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:96.35pt;padding-right:3.1pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">1.&#160;I understand that any payments or benefits paid or granted to me under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Section 5(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;"> of the Agreement represent, in part, consideration for signing this Release and are not salary, wages or benefits to which I was already entitled. Such payments and benefits will not be considered compensation for purposes of any employee benefit plan, program, policy or arrangement maintained or hereafter established by the Company or its affiliates.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="padding-left:60.35pt;padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.&#160;Releases.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:96pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)         I knowingly and voluntarily (on behalf of myself, my spouse, my heirs, executors, administrators, agents and assigns, past and present) fully and forever release and discharge the Company and the other Released Parties from any and all claims, suits, controversies, actions, causes of action, cross claims, counterclaims, demands, debts, liens, contracts, covenants, suits, rights, obligations, expenses, judgments, compensatory damages, liquid damages, punitive or exemplary damages, other damages, claims for costs and attorneys&#8217; fees, orders and liabilities of whatever kind of nature, in law and in equity, in contract of in tort, both past and present (through the date this General Release becomes effective and enforceable) and whether known or unknown, vested or contingent, suspected, or claimed, against the Company or any of the Released Parties which I, my spouse, or any of my heirs, executors, administrators or assigns, may have, which arise out of or relate to my employment with, or my separation or termination from, the Company up to the date of my execution of this Release (including, but not limited to, any allegation, claim of violation arising under&#58; Title VII of the Civil Rights Act of 1964, as amended&#59; the Civil Rights Act of 1991&#59; the Age Discrimination in Employment Act of 1967, as amended (including the Older Workers Benefit Protection Act), the Equal Pay Act of 1963, as amended&#59; the Americans with Disabilities Act of 1990&#59; the Family and Medical Leave Act of 1993&#59; the Worker Adjustment Retraining and Notification Act&#59; the Employee Retirement Income Security Act of 1974&#59; the Fair Labor Standards Act&#59; or their state or local counterparts&#59; or under any other federal, state or local civil or human rights law, or under any other local state or federal law, regulation or ordinance&#59; or under any public policy, contract of tort, or under common law&#59; or arising under any policies, practices or procedures of the Company&#59; or any claim for wrongful discharge, breach of the Agreement, infliction of emotional distress or defamation&#59; or any claim for costs, fees, or other expenses, including attorneys&#8217; fees incurred in these matters) (collectively, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Claims</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;).</font></div><div style="margin-top:0.15pt;"><font><br></font></div><div style="padding-left:96pt;padding-right:3.15pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)          </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">SECTION 1542 WAIVER</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Employee agrees that all rights he may have under Section 1542 of the California Civil Code are hereby waived. Section 1542 provides&#58;</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="padding-left:132pt;padding-right:3.3pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:116%;">&#8220;A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM OR HER MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.&#8221;</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">13</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:18pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="padding-left:96pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Notwithstanding the provisions of Section 1542, and for the purpose of implementing a full and complete release, Employee agrees that this Agreement is intended to include all claims, if any, that Employee may have against the Company, and that this Agreement extinguishes those claims.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:96.35pt;padding-right:3.2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3.&#160;I represent that I have made no assignment of transfer of any right, claim, demand, cause of action, or other matter covered by </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> above.</font></div><div style="margin-top:0.95pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:96.35pt;padding-right:3.05pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4.&#160;In signing this Release, I acknowledge and intend that it shall be effective as a bar to each and every one of the claims, demands and causes of action herein above mentioned or implied. I expressly consent that this Release shall be given full force and effect according to each and all of its express terms and provisions, including those relating to unknown and unsuspected claims up to the date of my execution of this Release, if any, as well as those relating to any other claims hereinabove mentioned. I acknowledge and agree that this waiver is an essential and material term of this Release and that without such waiver the Company would not have agreed to the terms of the Agreement. I further agree that in the event I should bring a claim seeking damages against the Company, this Release shall serve as a complete defense to such claims as to my rights and entitlements. I further agree that I am not aware of any pending charge or complaint of the type described in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> above as of the date of my execution of this Release.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:96.35pt;padding-right:3.2pt;text-align:justify;margin-top:1.7pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">5.&#160;I agree that neither this Release, nor the furnishing of the consideration for this Release, shall be deemed or constructed at any time to be an admission or acknowledgement by the Company, any Released Party or myself of any improper or unlawful conduct.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:96.35pt;padding-right:3pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">6.&#160;I agree and acknowledge that the provisions, conditions, and negotiations of this Release are confidential and agree not to disclose any information regarding the terms, conditions and negotiations of this Release, nor transfer any copy of this Release to any person or entity, other than my immediate family and any tax, legal or other counsel or advisor I have consulted regarding the meaning or effect hereof or as required by applicable law, and I will instruct each of the foregoing not to disclose the same to anyone.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:96.35pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">7.&#160;Notwithstanding anything in the Release to the contrary, nothing in this Release shall be deemed to affect, impair, relinquish, diminish, or in any way affect any rights or claims in any respect to (i) any vested rights or other entitlements that I may have as of the date of my execution of this Release under the Company&#8217;s</font></div><div style="padding-left:96.35pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">401(k) plan&#59; (ii) any other vested rights or other entitlements that I may have as of the date of my execution of this Release under any employee benefit plan or program, in which I participated in my capacity as an employee of the Company&#59; (iii) my rights under the Agreement&#59; or (iv) my rights under the Release.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:60.35pt;padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">8.&#160;I understand that I continue to be bound by Section 6 of the Agreement.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:96.35pt;padding-right:3.05pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">9.&#160;Whenever possible, each provision of this Release shall be interpreted in such a manner as to be effective and valid under applicable law, but if any provisions of this Release are held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other provision or any other jurisdiction, but this Release shall be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provisions had never been contained herein.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:96.35pt;padding-right:3.25pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">10.&#160;This Release shall be governed by and construed in accordance with the laws of the State of California, without giving effect to the conflict of laws principles of the State of California.</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="padding-left:96pt;padding-right:147.75pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:231%;">BY SIGNING THIS RELEASE, I REPRESENT AND AGREE THAT&#58; (i)&#160;I HAVE READ IT CAREFULLY&#59;</font></div><div style="text-indent:-36pt;padding-left:132pt;padding-right:3.3pt;text-align:justify;margin-top:0.55pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(ii)         I UNDERSTAND ALL OF ITS TERMS AND KNOW THAT I AM GIVING UP IMPORTANT RIGHTS, INCLUDING BUT NOT LIMITED TO, RIGHTS UNDER THE AGE DISCRIMINATION IN EMPLOYMENT ACT OF 1967, AS AMENDED&#59;</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:96pt;padding-right:162.85pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(iii)        I VOLUNTARILY CONSENT TO EVERYTHING IN IT&#59;</font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">14</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:18pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:132pt;padding-right:3.3pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(iv)        THE COMPANY IS HEREBY ADVISING ME TO CONSULT WITH AN ATTORNEY BEFORE EXECUTING IT, I HAVE HAD THE OPPORTUNITY TO SO CONSULT, AND HAVE AVAILED MYSELF OF SUCH ADVICE TO THE EXTENT I HAVE DEEMED NECESSARY TO MAKE A VOLUNTARY AND INFORMED CHOICE TO EXECUTE THIS RELEASE&#59;</font></div><div style="text-indent:-36pt;padding-left:132pt;padding-right:3.3pt;text-align:justify;margin-top:1.7pt;margin-bottom:0.1pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:132pt;padding-right:3.3pt;text-align:justify;margin-top:1.7pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(v)         I HAVE HAD AT LEAST TWENTY ONE (21) DAYS &#91;45 DAYS IN CONNECTION WITH A GROUP TERMINATION OR EXIT INCENTIVE PLAN&#93; FOLLOWING THE DATE OF TERMINATION OF MY EMPLOYMENT TO CONSIDER THIS RELEASE&#59;</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:132pt;padding-right:3.3pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(vi)       CHANGES TO THIS RELEASE, WHETHER MATERIAL OR IMMATERIAL, DO NOT RESTART THE RUNNING OF THE 21-DAY &#91;OR 45 DAY&#93; CONSIDERATION PERIOD&#59;</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:132pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(vii)      I UNDERSTAND THAT I HAVE SEVEN (7) DAYS AFTER THE EXECUTION OF THIS RELEASE TO REVOKE IT, SUCH REVOCATION TO BE RECEIVED IN WRITING BY THE COMPANY BY THE END OF THE SEVENTH DAY AFTER THE DATE HEREOF, AND THAT THIS RELEASE SHALL NOT BECOME EFFECTIVE OR ENFORCEABLE UNTIL THE REVOCATION PERIOD HAS EXPIRED&#59;</font></div><div style="margin-top:0.75pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:132pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;">(viii)      I HAVE SIGNED THIS RELEASE KNOWINGLY AND VOLUNTARILY AND WITH THE ADVICE OF ANY COUNSEL RETAINED TO ADVISE ME WITH RESPECT TO IT&#59; AND</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:132pt;padding-right:3.3pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(ix)        I AGREE THAT THE PROVISIONS OF THIS RELEASE MAY NOT BE AMENDED, WAIVED OR MODIFIED EXCEPT BY AN INSTRUMENT IN WRITING SIGNED BY AN AUTHORIZED REPRESENTATIVE OF THE COMPANY AND BY ME.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:60pt;padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">DATED AS OF </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;"> &#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">, 20</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;"> &#160;</font></div><div><font><br></font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="padding-left:60pt;padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#91;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Name</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#93;</font></div><div style="text-align:justify;"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:265.95pt;padding-right:211.1pt;text-align:center;margin-top:1.65pt;"><font><br></font></div><div style="padding-right:211.1pt;text-align:center;margin-bottom:0.1pt;"><font><br></font></div><div style="padding-right:211.1pt;text-align:center;margin-bottom:0.1pt;"><font><br></font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">15</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>6
<FILENAME>ex1052020063010qngayou.htm
<DESCRIPTION>EX-10.5
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i35325ffa380148d5b5342cffa00b7e11_1"></div><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="padding-left:167.2pt;padding-right:166.4pt;text-align:center;margin-top:4pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EMPLOYMENT AGREEMENT</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:6pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">THIS EMPLOYMENT AGREEMENT </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(this &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) is made and entered into as of June 8, 2020, by and between Network Medical Management, Inc., a California corporation (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Employer</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;), and Albert Young, M.D. (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Employee</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; and together with the Employer referred to as the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Parties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) to become effective as of the date hereof (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Effective</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;).</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.2pt;text-align:justify;margin-top:1.9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;">WHEREAS, the Employer desires to employ the Employee from and after the Effective Date on the terms and conditions set forth below, and the Employee is willing to serve the Employer on such terms and conditions.</font></div><div style="margin-top:0.45pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">NOW, THEREFORE, in consideration of the mutual covenants and agreements contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows&#58;</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="padding-left:6pt;padding-right:3.15pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.           </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Term</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The term of this Agreement shall initially be for a one (1) year period commencing on the Effective Date. The term of this Agreement shall automatically renew for an additional year on each anniversary of the Effective Date unless either Party gives the other written notice of intent not to renew at least sixty (60) days prior to such date. Notwithstanding the foregoing, the initial term and any renewal year shall be subject to earlier termination as provided in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> below. The initial term and any renewal years are referred to herein as the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Term</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;.</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="padding-left:6pt;padding-right:3.15pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.           </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Positions and Duties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. During the Term, the Employee shall serve as a senior executive officer of the Employer. The Employee shall perform for the Employer the duties customarily associated with being a senior executive officer that are consistent with your experience and skills and such other duties as may be assigned to the Employee from time to time by the Employer&#8217;s Board of Directors (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Board</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) that are consistent with the duties normally performed by those performing the role of the most senior executives of similar entities. The Employee shall devote such working time, attention, knowledge, skills and efforts as may be required to fulfill the Employee&#8217;s duties hereunder, as reasonably determined by the Board. The Employee shall be permitted to perform services as required under the Hospitalist Participation Service Agreement, and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">further</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> that the Employee may participate as a member of the board of directors or advisory board of other entities and in professional organizations and civic and charitable organizations so long as any such positions are disclosed to the Board and do not materially interfere with the Employee&#8217;s duties and responsibilities to the Employer. The Employee shall be based in Alhambra, California.</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="padding-left:6pt;padding-right:3.2pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3.           </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Compensation and Related Matters</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employer shall provide the Employee with the compensation and benefits set forth in this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> during the Term. Authority to take action under this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> with respect to the Employee&#8217;s compensation and benefits may be delegated by the Board to its compensation committee.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.2pt;text-align:justify;margin-top:1.7pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(a)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Base Salary</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">. The Employer shall pay the Employee for all services rendered a base salary of Three Hundred Forty-Six Thousand Two Hundred Eighty-Six Dollars ($346,286) per year (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Base Salary</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">&#8221;), payable in accordance with the Employer&#8217;s payroll procedures, subject to customary withholdings and employment taxes. The Base Salary shall be evaluated annually by the Board for increase only.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.2pt;text-align:justify;margin-top:1.7pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(b)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Annual Bonus</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">. The Employee will be eligible to receive an annual cash bonus (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Annual Bonus</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">&#8221;) for each fiscal year during the Term on such terms and conditions as the Board shall determine in its discretion consistent with the terms of the Employer&#8217;s business plan.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.05pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Long Term Incentive Awards</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employee shall be eligible to participate in any long term incentive plan that may be available to similarly positioned executives. The Board may determine to grant long-term incentive awards in cash or in equity awards settled in shares of the Employer&#8217;s stock, including but not limited to stock options, restricted stock and performance shares. In the event the Employee terminates service due to being a Good Leaver, any requirements under a long-term incentive award held by the Employee shall be deemed to have been satisfied by the Employer immediately prior to such termination. A &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Good Leaver</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; means that, during the </font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="padding-left:6pt;padding-right:3.05pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Term, either the Employee has resigned for Good Reason (as defined in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> below), the Employer has terminated the Employee&#8217;s employment without Cause (as defined in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> below or the Employee terminates employment on account of death or Disability (as defined in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> below). For avoidance of doubt, being a Good Leaver entitles the Employee to be fully vested with respect to any stock options with vesting conditions based solely on continued employment, and to be entitled to payment with respect to any long-term incentive award subject to corporate or business goals to the extent that such goals are met during the performance period on the same basis as if he had remained continuously employed with the Employer.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(d)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Paid Time Off</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. During the term, the Employee shall be entitled to twenty (20) business days of paid time off (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">PTO</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) per calendar year which shall be accrued ratably during the calendar year, to be taken at such times and intervals as shall be agreed to by Employer and the Employee in their reasonable discretion. The Employee shall be entitled to accrue a maximum of twenty (20) business days of paid time off. When the maximum accrual is reached, no additional PTO time will accrue until Employee uses one or more accrued PTO days. Accrued and unused PTO shall be paid in cash at the end of a calendar year.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(e)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Expenses</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employee shall be entitled to prompt reimbursement of reasonable and usual business expenses incurred on behalf of Employer in accordance with the Employer&#8217;s expense reimbursement policy.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.1pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(f)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Other Benefits</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employee shall be entitled to continue to participate in or receive benefits under any employee benefit plan or arrangement which is or may, in the future, be made available by the Employer to its employees, subject to and on a basis consistent with the terms, conditions and overall administration of such plan or arrangement. Irrespective of other benefits provided to employees, the Employee&#8217;s benefits package shall include&#58; (i) the Employer&#8217;s payment of premiums for medical, dental and vision care coverage&#59; (ii) the Employer&#8217;s payment of insurance premiums for short-term and long-term disability insurance providing for no less than sixty percent (60%) of Employee&#8217;s Base Salary to be payable to the Employee as long as the covered disability persists in a manner that substantially prevents employment in the same occupation as the position Employee last held with Employer but not beyond age sixty-five (65)&#59; and (iii) the Employer&#8217;s payment of insurance premiums for term life insurance providing for no less than two million dollars of coverage (subject to meeting applicable underwriting requirements).</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(g)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Tax Withholding</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employer shall undertake to make deductions, withholdings and tax reports with respect to payments and benefits under this Agreement, to the extent it reasonably and in good faith believes it is required to make such deductions, withholdings and tax reports. Payments with respect to compensation and benefits referred to under this Agreement shall be in amounts net of any such deductions or withholdings. Nothing in this Agreement shall be construed to require the Employer to make any payments to compensate the Employee for any adverse tax effect associated with any payments or benefits, or for any deduction or withholding from any payment or benefit.</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="padding-left:6pt;padding-right:3.2pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employee&#8217;s employment hereunder may be terminated during the Term without any breach of this Agreement under the following circumstances&#58;</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="padding-left:42pt;padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">(a)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;">Death</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">. The Employee&#8217;s employment hereunder shall terminate upon the Employee&#8217;s death.</font></div><div style="margin-top:0.45pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.2pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Disability</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employer may terminate the Employee&#8217;s employment if the Employee is disabled and, because of the disability, is unable to perform the essential functions of the Employee&#8217;s then existing position or positions under this Agreement with or without reasonable accommodation. This provision is not intended to reduce any rights the Employee may have pursuant to any law, including without limitation the California Family Rights Act, the Family and Medical Leave Act, the California Fair Employment and Housing Act, and the Americans with Disabilities Act.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Termination by the Employer for Cause</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. At any time during the Term, the Employer may terminate the Employee&#8217;s employment hereunder for Cause. For purposes of this Agreement, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Cause</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; shall mean&#58; (i) conduct by the Employee constituting a material act of willful misconduct in connection with the performance of the Employee&#8217;s duties that results in loss, damage or injury that is material to the Employer&#59; (ii) the commission by the </font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="padding-left:6pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Employee of any felony&#59; (iii) continued, willful and deliberate non-performance by the Employee of the Employee&#8217;s duties hereunder (other than by reason of the Employee&#8217;s physical or mental illness, incapacity or disability)&#59; (iv) a material breach, according to the standard of the Employer, by the Employee of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement that results in loss, damage or injury that is material to the Employer&#59; (v) willful failure to cooperate with a bona fide internal investigation or an investigation by regulatory or law enforcement authorities, after being instructed by the Employer to cooperate, or the willful destruction or failure to preserve documents or other materials known to be relevant to such investigation or the willful inducement of others to fail to cooperate or to produce documents or other materials in connection with such investigations&#59; or (vi) fraud, embezzlement or theft against the Employer or any of its Affiliates (as defined in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> below). With respect to the events in (i), (iii) and (iv) herein, the Employer shall have delivered written notice to the Employee of its intention to terminate the Employee&#8217;s employment for Cause, which notice specifies in reasonable detail the circumstances claimed to give rise to the Employer&#8217;s right to terminate the Employee&#8217;s employment for Cause and the Employee shall not have cured such circumstances to the extent such circumstances are reasonably susceptible to cure as determined by the Board in good faith within thirty (30) days following the Employer&#8217;s delivery of such notice. For avoidance of doubt, &#8220;Cause&#8221; shall not include (x) expense reimbursement disputes in which the Employee acts in reasonable good faith&#59; (y) occasional, customary and de minimis use of the Employer&#8217;s property for personal purposes&#59; and (z) acting in good faith upon advice of Employer&#8217;s legal counsel.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.15pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(d)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Termination without Cause</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. At any time during the Term, the Employer may terminate the Employee&#8217;s employment hereunder without Cause by providing the Employee with thirty (30) days advance written notice. Any termination by the Employer of the Employee&#8217;s employment under this Agreement that does not constitute a termination for Cause under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> and does not result from the death or Disability of the Employee under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Sections 4(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> or </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">4(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> shall be deemed a termination without Cause under this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Any suspension of the Employee&#8217;s employment with pay or benefits by the Board in good faith pending an investigation of alleged improper activities by the Employee that, if determined to be accurate, would be grounds for a Cause termination, shall not be considered a termination of the Employee&#8217;s employment without Cause or provide with Good Reason to terminate employment.</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(e)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Termination by the Employee</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. At any time during the Term, the Employee may terminate his employment hereunder for any reason, including, but not limited to, Good Reason. For purposes of this Agreement, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Good Reason</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; shall mean that the Employee has complied with the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Good Reason Process</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; (hereinafter defined) following the occurrence of any of the following events&#58; (i) a material diminution in the Employee&#8217;s responsibilities, authority or duties&#59; (ii) the material breach of this Agreement by the Employer, including but not limited to a failure to pay Base Salary or Annual Bonus as provided for under this Agreement&#59; or (iii) any relocation of the Employee&#8217;s principal place of business to a location more than 30 miles from the Employer&#8217;s current executive offices in Alhambra, California&#59; provided, however, that this clause (iii) will not apply to the extent that any new office location is less than 30 miles from the Employee&#8217;s residence. &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Good Reason Process</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; shall mean (i) the Employee reasonably determines in good faith that a &#8220;Good Reason&#8221; condition has occurred&#59; (ii) the Employee notifies the Employer in writing of the occurrence of the Good Reason condition within (60) days of the occurrence of such condition&#59; (iii) the Employee cooperates in good faith with the Employer&#8217;s efforts, for a period of sixty (60) days following such notice (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Cure Period</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;), to remedy the condition&#59; (iv) notwithstanding such efforts, the Good Reason condition continues to exist&#59; and (v) the Employee terminates his employment within thirty (30) days after the end of the Cure Period. If the Employer cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not to have occurred.</font></div><div style="margin-top:0.25pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.2pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(f)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Notice of Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Except for termination as specified in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, any termination of the Employee&#8217;s employment shall be communicated by written Notice of Termination by the terminating Party to the other Party hereto. For purposes of this Agreement, a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Notice of Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; shall mean a notice which shall indicate the specific termination provision in this Agreement relied upon.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(g)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Date of Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Date of Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; shall mean the earliest of the following&#58; (i) if the Employee&#8217;s employment is terminated by the Employee&#8217;s death, the date of the Employee&#8217;s death&#59; (ii) if the Employee&#8217;s employment is terminated on account of Disability under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> or by the Employer for Cause under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, the date on which Notice of Termination is given that follows any applicable required cure </font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="padding-left:6pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">period&#59; (iii) if the Employee&#8217;s employment is terminated by the Employer under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, thirty (30) days after the date on which a Notice of Termination is given&#59; (iv) if the Employee&#8217;s employment is terminated by the Employee under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> without Good Reason, thirty (30) days after the date of which a Notice of Termination is given or such shorter period agreed to by the Employer&#59; or (v) if the Employee&#8217;s employment is terminated by the Employee under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> with Good Reason, the date on which Notice of Termination is given after the end of the Cure Period. Notwithstanding the foregoing, in the event that the Employee gives a Notice of Termination to the Employer, the Employer may unilaterally accelerate the Date of Termination but such acceleration shall nevertheless be deemed a termination by the Employee on the accelerated date for purposes of this Agreement. For purposes of determining the time when the lump sum portion of the Severance Amount, if any, is to be paid under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 5(b)(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Date of Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; means the Employee&#8217;s separation from service as defined under Section 409A.</font></div><div style="text-align:justify;"><font><br></font></div><div style="padding-left:8.5pt;padding-right:-1pt;margin-top:4pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">5.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;">Compensation upon Termination.</font></div><div style="margin-top:0.45pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.05pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Accrued Benefits.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> If the Employee&#8217;s employment with the Employer is terminated for any reason during the Term, or if the Term is not renewed, the Employer shall pay or provide the Employee (or the Employee&#8217;s authorized representative or estate) any earned but unpaid Base Salary or Annual Bonus for services rendered through the Date of Termination, unpaid expense reimbursements, and accrued but unused paid time off (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Accrued</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Benefits</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) within the time prescribed by California law. With respect to vested compensation or benefits the Employee may have under any employee benefit or compensation plan, program or arrangement of the Employer, payment will be made to the Employee under the terms of the applicable plan, program or arrangement.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Termination by  the Employer without Cause or by the Employee with Good</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Reason</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. If the Employee&#8217;s employment is terminated by the Employer without Cause as provided in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, or the Employee terminates his employment for Good Reason as provided in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, or the Employee terminates employment at the end of the Term after the Employer provides notice of intent not to renew pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> for reasons other than would provide grounds for a Cause termination, then, (i) the Employer shall, through the Date of Termination, pay the Employee his or her Accrued Benefits, and (ii) if the Employee signs a general release of claims substantially in the form which is attached as </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Exhibit A</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to this Agreement) (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Release</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) within twenty-one (21) days of the receipt of the form of the Release (extended to forty-five (45) days in the event of a group termination or exit incentive program) and does not revoke such Release during the seven-day revocation period&#58;</font></div><div style="margin-top:0.25pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:42pt;padding-right:3.05pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(i)         the Employer shall pay the Employee an amount equal to one-twelfth (1&#47;12) of the Employee&#8217;s most recent Base Salary times the number of full years of service completed, not to exceed twelve (12) years of service (but determined prior to any action involving Base Salary that would constitute Good Reason) (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Severance Amount</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;). Employer acknowledges that Employee has completed not less than twelve (12) full years of service (including Employee&#8217;s service for the Employer&#8217;s parent entity, subsidiaries and affiliates), such that the Severance Amount payable to Employee pursuant to the terms of this Agreement shall equal the maximum Severance Amount of one (1) year of the Employee&#8217;s most recent Base Salary. To the extent that such Severance Amount exceeds the 409A Separation Pay Limit (as defined below), such amount shall be paid in a single lump sum on the regular payroll date of the Employer, pertaining to then current salaried employees of the Employer, (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">payroll date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) next following the first anniversary date of the Employee&#8217;s Date of Termination. The portion of the Severance Amount that does not exceed the 409A Separation Pay Limit shall be paid in substantially equal amounts on each payroll date over a one year period&#59; and</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:42pt;padding-right:3.15pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(ii)        the Employer shall pay the Employee an amount in cash equal to the Employer&#8217;s premium amounts paid for coverage of Employee at the time of the Employee&#8217;s termination of coverage under the Employer&#8217;s group medical, dental and vision programs for a period of twelve (12) months, to be paid directly to the Employee at the same times such payments would be paid on behalf of a current employee for such coverage&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#58;</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="text-indent:36pt;padding-left:78pt;padding-right:3.15pt;text-align:justify;margin-top:1.7pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(A)        No  payments shall  be  made  under  this  paragraph (ii)  unless  and  until  the Employee timely elects continued coverage under such plan(s) pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1985 as amended (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">COBRA</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">&#8221;)&#59;</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:78pt;padding-right:3.25pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(B)&#160;This paragraph (ii) shall not be read or construed as placing any restrictions upon amounts paid under this paragraph (ii) as to their use&#59;</font></div><div style="margin-top:0.75pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:78pt;padding-right:3.2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;">(C)&#160;Payments under this paragraph (ii) shall cease as of the earliest to occur of the following&#58;</font></div><div style="margin-top:0.45pt;"><font><br></font></div><div style="padding-left:150pt;padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(1)&#160;the Employee is no longer eligible for and continuing to receive the</font></div><div style="padding-left:114pt;padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">COBRA coverage elected in subparagraph (A)&#59;</font></div><div style="padding-right:-1pt;margin-bottom:0.1pt;"><font><br></font></div><div style="padding-left:150pt;padding-right:-1pt;margin-bottom:0.1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(2)&#160;the time period set forth in the first sentence of this paragraph (ii),</font></div><div><font><br></font></div><div style="padding-left:149pt;padding-right:3.2pt;text-align:justify;margin-top:4pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(3)        the date on which the Employee first becomes eligible to enroll in a group health plan in which eligibility is based on employment with an employer, and</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:149pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(4)        if the Employer in good faith determines that payments under this paragraph (ii) would result in a discriminatory health plan pursuant to the Patient Protection and Affordable Care Act of 2010, as amended.</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="padding-left:185pt;padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(iii)&#160;Each individual payment of Severance Amount under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section</font></div><div style="padding-left:149pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;">5(b)(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">, and each payment under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;">Section 5(b)(ii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> of this Agreement, shall be deemed to be a separate &#8220;payment&#8221; for purposes and within the meaning of Treasury Regulation Section 1.409A-2(b)(2)(iii).</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:149pt;padding-right:3.15pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(iv)       Each    individual    payment    of    the    Severance    Amount under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Section   5(b)(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">,   and   each   payment   under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Section   5(b)(ii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">,   of   this Agreement, which are considered &#8220;non-qualified deferred compensation&#8221; (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">NQDC</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">&#8221;) under Section 409A shall be made on the date(s) provided herein and no request to accelerate or defer any such payment under this Agreement shall be considered or approved for any reason whatsoever, except as permitted under Section 409A and as the Employer allows in its sole discretion. The Employer may in its sole discretion accelerate or defer (but not beyond the time limit set forth below) any severance payments which do not constitute NQDC in order to allow for the payment of taxes due, but not beyond the time limit specified for such payment such that the payment would be treated as NQDC. Subject to the requirements of  Section 409A, if  any severance payment or  reimbursement under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Section 5(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;"> of this Agreement is determined in good faith by the Employer to constitute NQDC payable to a &#8220;specified employee&#8221; as defined under Section</font></div><div style="padding-left:149pt;padding-right:3.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">409A, then the Employer shall make any such payment not earlier than the earlier of&#58; (x) the first payroll date which is six (6) months following the Employee&#8217;s separation from service (as defined under Section 409A) with the Employer, or (y) the date of Employee&#8217;s death.</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="padding-left:185pt;padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(v)&#160;for purposes of this Section 5, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 409A</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; means Section</font></div><div style="padding-left:149pt;padding-right:18.3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">409A of the Internal Revenue Code of 1986, as amended, and the regulations thereunder.</font></div><div style="margin-top:0.45pt;"><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="text-indent:36pt;padding-left:149pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(vi)       for purposes of this Section 5, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">409A Separation Pay Limit</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; means two times the lesser of (</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">x</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">) the Employee&#8217;s annual compensation during the calendar year preceding the year of the termination of employment&#59; and (</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">y</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">) the adjusted compensation limit under Code Section 401(a)(17) in effect for the year of the termination.</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="padding-left:5pt;padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">6.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;">Confidential Information, Nonsolicitation, and Cooperation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">.</font></div><div style="margin-top:0.1pt;"><font><br></font></div><div style="padding-left:41pt;padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">(a)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;">Definitions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">.</font></div><div style="margin-top:0.1pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:41pt;padding-right:3.05pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(i)          As used in this Agreement, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Affiliate</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">&#8221; means, as to any Person, (i) any other Person which directly, or indirectly through one or more intermediaries, controls such Person or is consolidated with such Person in accordance with GAAP, (ii) any other Person which directly, or indirectly through one or more intermediaries, is controlled by or is under common control with such Person, or (iii) any other Person of which such Person owns, directly or indirectly, fifty percent (50%) or more of the common stock or equivalent equity interests. As used herein, the term &#8220;control&#8221; means possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of a Person, whether through the ownership of voting securities or otherwise.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:36pt;padding-left:42pt;padding-right:3.2pt;margin-top:4pt;margin-bottom:0.1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(ii)&#160;As used in this Agreement, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Person</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; means an individual, a corporation, a partnership, a limited liability company, an association, a trust or any other entity or organization.</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.1pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Confidential  Information</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  As   used   in   this   Agreement,  &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Confidential</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Information</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;  means information belonging to the Employer or its Affiliates which is of value to the Employer or any of its Affiliates in the course of conducting its business (whether having existed, now existing, or to be developed or created during Employee&#8217;s employment by Employer) and the disclosure of which could result in a competitive or other disadvantage to the Employer or its Affiliates. Confidential Information includes, without limitation, contract terms and rates&#59; negotiating and contracting strategies&#59; financial information, reports, and forecasts&#59; inventions, improvements and other intellectual property&#59; product plans or proposed product plans&#59; trade secrets&#59; designs, processes or formulae&#59; software&#59; employee, customer, patient, provider and supplier information&#59; information from patient medical records&#59; financial data&#59; insurance reimbursement methodologies, strategies and practices&#59; product and service pricing methodologies, strategies and practices&#59; contracts with physicians, providers, provider networks, payors, physician databases and contracts with hospitals&#59; regulatory and clinical manuals&#59; and business plans, prospects and opportunities (such as possible acquisitions or dispositions of businesses or facilities) that have been discussed or considered by the Employer or its Affiliates, including, without limitation, the management of the Employer or its Affiliates. Confidential Information includes information developed by the Employee in the course of the Employee&#8217;s employment by the Employer, as well as other information to which the Employee may have access in connection with the Employee&#8217;s employment. Confidential Information also includes the confidential information of others with which the Employer or its Affiliates has a business relationship. Notwithstanding the foregoing, Confidential Information does not include information in the public domain, unless due to breach of the Employee&#8217;s duties under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, unless otherwise due to Employee&#8217;s breach of the obligations in this Agreement, or unless due to violation of another Person&#8217;s obligations to the Employer or its Affiliates that Employee should have taken reasonable measures to prevent but that Employee did not take.</font></div><div style="margin-top:0.45pt;"><font><br></font></div><div><font><br></font></div><div style="text-indent:38.5pt;padding-left:6pt;padding-right:4.9pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Confidentiality</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employee understands and agrees that the Employee&#8217;s employment creates a relationship of confidence and trust between the Employer and the Employee with respect to all Confidential Information. At all times, both during the Employee&#8217;s employment with the Employer and after the Employee&#8217;s termination from employment for any reason, the Employee shall keep in confidence and trust all such Confidential Information, and shall not use, disclose, or transfer any such Confidential Information without the written consent of the Employer, except as may be necessary within the scope of Employee&#8217;s duties with Employer and in the ordinary course of performing the Employee&#8217;s duties to the Employer or as otherwise provided in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Employee understands and agrees not to sell, license or otherwise exploit any products or services which embody or otherwise </font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="padding-left:6pt;padding-right:4.9pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">exploit in whole or in part any Confidential Information or materials. Employee acknowledges and agrees that the sale, misappropriation, or unauthorized use or disclosure in writing, orally or by electronic means, at any time of Confidential Information obtained by Employee during or in connection with the course of Employee&#8217;s employment constitutes unfair competition. Employee agrees and promises not to engage in unfair competition with Employer or its Affiliates, either during employment, or at any time thereafter.</font></div><div style="margin-top:0.45pt;"><font><br></font></div><div><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(d)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Protected Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Notwithstanding anything to the contrary in this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, this Agreement is not intended to, and shall not, in any way prohibit, limit or otherwise interfere with the Employee&#8217;s protected rights under federal, state or local law to, without notice to the Employer, (i) communicate or file a charge with a government regulator&#59; (ii) participate in an investigation or proceeding conducted by a government regulator&#59; or (iii) receive an award paid by a government regulator for providing information.</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.2pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(e)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Documents, Records, etc</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. All documents, records, data, apparatus, equipment and other physical property, whether or not pertaining to Confidential Information, that are furnished to the Employee by the Employer or its Affiliates or are produced by the Employee in connection with the Employee&#8217;s employment will be and remain the sole property of the Employer and its Affiliates. The Employee shall return to the Employer all such materials and property as and when requested by the Employer. In any event, the Employee shall return all such materials and property immediately upon termination of the Employee&#8217;s employment for any reason. The Employee shall not retain any such material or property or any copies thereof after such termination. It is specifically agreed that any documents, card files, notebooks, programs, or similar items containing customer or patient information are the property of the Employer and its Affiliates regardless of by whom they were compiled.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:36pt;padding-left:5pt;padding-right:3.05pt;text-align:justify;margin-top:1.9pt;margin-bottom:0.1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;">(f)          </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration: underline;">Disclosure Prevention</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;">. The Employee will take all reasonable precautions to prevent the inadvertent or accidental exposure of Confidential Information.</font></div><div style="padding-right:3.05pt;text-align:justify;margin-bottom:0.1pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:5pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">(g)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;">Removal of Material</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. The Employee will not remove any Confidential Information from the Employer&#8217;s or its Affiliate&#8217;s premises except for use in the Employer&#8217;s business, and only consistent with the Employee&#8217;s duties with the Employer.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:5pt;padding-right:3.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(h)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Copying</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">. The Employee agrees that copying or transferring Confidential Information (by any means) shall be done only as needed in furtherance of and for use in the Employer&#8217;s and its Affiliate&#8217;s business, and consistent with the Employee&#8217;s duties with the Employer. The Employee further agrees that copies of Confidential Information shall be treated with the same degree of confidentiality as the original information and shall be subject to all restrictions herein.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:5pt;padding-right:3.15pt;text-align:justify;margin-top:1.9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;">(i)           </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration: underline;">Computer Security</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;">. The Employee agrees to comply with the Employer&#8217;s policies and procedures concerning computer security.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:5pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(j)           </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">E-Mail</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employee acknowledges that the Employer retains the right to review any and all electronic mail communications made with employer provided email accounts, hardware, software, or networks, with or without notice, at any time.</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:5pt;padding-right:3.1pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(k)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Assignment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employee acknowledges that any and all inventions, discoveries, designs, developments, methods, modifications, trade secrets, processes, software, formulae, data, &#8220;know-how,&#8221; databases, algorithms, techniques and works of authorship whether or not patentable or protectable by copyright or trade secret, made or conceived, first reduced to practice, or learned by the Employee, either alone or jointly with others, during the Term that (i) relate to or are useful in the business of the Employer or its Affiliates, or (ii) are conceived, made or worked on at the expense of or during the Employee&#8217;s work time for the Employer, or using any resources or materials of the Employer or its Affiliates, or (iii) arise out of tasks assigned to the Employee by the Employer (together &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Proprietary Inventions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) will be the sole property of the Employer or its Affiliates. The Employee acknowledges that all work performed by the Employee is on a &#8220;work for hire&#8221; basis and the Employee hereby assigns or agrees to assign to the Employer the Employee&#8217;s entire right, title and interest in and to any and all </font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">7</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="padding-left:5pt;padding-right:3.1pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Proprietary Inventions and related intellectual property rights. The Employee agrees to assist the Employer to obtain, maintain and enforce intellectual property rights for Proprietary Inventions in any and all countries during the Term, and thereafter for as long as such intellectual property rights exist.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="padding-left:144.7pt;padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:113%;text-decoration: underline;">NOTICE TO CALIFORNIA EMPLOYEES</font></div><div style="margin-top:0.1pt;"><font><br></font></div><div style="padding-left:41pt;padding-right:39.1pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">Pursuant to California Labor Code &#167;2870, an agreement requiring the employee to assign or offer to assign any of his or her rights in any invention to his or her employer does not apply to an invention which qualifies fully under the provisions of California Labor Code &#167; 2870, which provides as follows&#58;</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:41pt;padding-right:39.05pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)         Any provision in an employment agreement which provides that an employee shall assign, or offer to assign, any of his or her rights in an invention to his or her employer shall not apply to an invention that the employee developed entirely on his or her own time without using the employer&#8217;s equipment, supplies, facilities, or trade secret information except for those inventions that either&#58;</font></div><div style="margin-top:0.6pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:77pt;padding-right:39.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(1)        Relate at the time of conception or reduction to practice of the invention to the employer&#8217;s business, or actual or demonstrably anticipated research or development of the employer&#59; or</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="padding-left:113pt;padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(2)&#160;Result from any work performed by the employee for the employer.</font></div><div style="margin-top:0.75pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:41pt;padding-right:39.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;">(b)         To the extent a provision in an employment agreement purports to require an employee to assign an invention otherwise excluded from being required to be assigned under subdivision (a),  the  provision is  against the  public policy  of  the  State  of  California and  is unenforceable.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(l)           </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Nonsolicitation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Employee agrees and covenants that, at any time during Employee&#8217;s employment with the Employer and for a period of twelve (12) months immediately following the termination of Employee&#8217;s relationship with the Employer for any reason, whether with or without cause, Employee shall not, either on Employee&#8217;s own behalf or on behalf of any other Person&#58; (i) solicit the services of the Employer&#8217;s employees or entice away, directly or indirectly, any Person employed or engaged by or otherwise providing services to the Employer or its Affiliates, whether in an employment capacity or otherwise (this provision does not prohibit the Employee&#8217;s post- termination acceptance of unsolicited applications for employment)&#59; or (ii) take any illegal action or engage in any unfair business practice, including, without limitation, any misappropriation of confidential, proprietary or trade secret information of the Employer or its Affiliates, as a result of which relations between the Employer or its Affiliates, and any of their customers, clients, suppliers, distributors or others, may be impaired or which might otherwise be detrimental to the business interests or reputation of the Employer or its Affiliates.</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.05pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(m)        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Third-Party Agreements and Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employee hereby confirms that the Employee is not bound by the terms of any agreement with any previous employer or other party which restricts in any way the Employee&#8217;s use or disclosure of information or the Employee&#8217;s engagement in any business except as Employee has previously provided written notice to Employer and has attached to this Agreement. The Employee represents to the Employer that the Employee&#8217;s execution of this Agreement, the Employee&#8217;s employment with the Employer and the performance of the Employee&#8217;s proposed duties for the Employer will not violate any obligations the Employee may have to any previous employer or other party. In the Employee&#8217;s work for the Employer, the Employee will not disclose or use any information in violation of any agreements with or rights of any such previous employer or other party, and the Employee will not bring to (by any means) the premises of the Employer any copies or other tangible embodiments of non- public information belonging to or obtained from any such previous employment or other party.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">8</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(n)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Litigation  and  Regulatory  Cooperation.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  During  and  after  the  Employee&#8217;s  employment,  the Employee shall cooperate fully with the Employer in the defense or prosecution of any claims or actions now in existence or that may be brought in the future against or on behalf of the Employer that relate to events or occurrences that transpired while the Employee was employed by the Employer. The Employee&#8217;s full cooperation in connection with such claims or actions shall include, but not be limited to, being available to meet with counsel to prepare for discovery or trial and to act as a witness on behalf of the Employer at mutually convenient times. During and after the Employee&#8217;s employment, the Employee also shall cooperate fully with the Employer in connection with any investigation or review of any federal, state, or local regulatory authority as any such investigation or review relates to events or occurrences that transpired while the Employee was employed by the Employer. The Employer shall reimburse the Employee for any reasonable out of pocket expenses incurred in connection with the Employee&#8217;s performance of obligations pursuant to this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. &#8220;Full cooperation&#8221; shall not be construed to in any way require any violation of law or any testimony that is false or misleading.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(o)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Enforcement&#59; Injunction.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The Employee acknowledges and agrees that the restrictions contained in this Agreement are reasonable and necessary to protect the business and interests of the Employer and its Affiliates, do not create any undue hardship for the Employee, and that any violation of the restrictions in this Agreement would cause the Employer and its Affiliates substantial irreparable injury. Accordingly, the Employee agrees that a remedy at law for any breach or threatened breach of the covenants or other obligations in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement would be inadequate and that the Employer, in addition to any other remedies available, shall be entitled to obtain preliminary and permanent injunctive relief to secure specific performance of such covenants and to prevent a breach or contemplated or threatened breach of this Agreement without the necessity of proving actual damage and without the necessity of posting bond or security, which the Employee expressly waives. Moreover, the Employee will provide the Employer a full accounting of all proceeds and profits received by the Employee as a result of or in connection with a breach of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement. Unless prohibited by law, the Employer shall have the right to retain any amounts otherwise payable by the Employer to the Employee to satisfy any of the Employee&#8217;s obligations as a result of any breach of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement. The Employee hereby agrees to indemnify and hold harmless the Employer and its Affiliates from and against any damages incurred by the Employer or its Affiliates as assessed by a court of competent jurisdiction as a result of any breach of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement by the Employee. The prevailing party shall be entitled to recover its reasonable attorneys&#8217; fees and costs if it prevails in any action to enforce </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement. It is the express intention of the parties that the obligations of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Agreement shall survive the termination of the Employee&#8217;s employment. The Employee agrees that each obligation specified in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement is a separate and independent covenant that shall survive any termination of this Agreement and that the unenforceability of any of them shall not preclude the enforcement of any other covenants in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement. No change in the Employee&#8217;s duties or compensation shall be construed to affect, alter or otherwise release the Employee from the covenants herein.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="padding-left:6pt;padding-right:3.05pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">7.          </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Successors</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">. This Agreement shall be binding upon and inure to the benefit of both parties and their respective successors and permitted assigns, including any corporation or entity with which or into which the Employer may be merged or which may succeed to its assets or business, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">, that Employee&#8217;s obligations are personal and shall not be assigned by Employee. The Employee consents to be bound by the provisions of this Agreement for the benefit of the Employer or its Affiliates to whose employ the Employee may be transferred without the necessity that this Agreement be resigned at the time of such transfer. In the event of the Employee&#8217;s death after the Date of Termination but prior to the completion by the Employer of all payments due to the Employee under this Agreement, the Employer shall continue such payments to the Employee&#8217;s beneficiary designated in writing to the Employer prior to the Employee&#8217;s death (or to the Employee&#8217;s estate, if the Employee fails to make such designation).</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="padding-left:6pt;padding-right:3.1pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">8.         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Enforceability</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">. If any portion or provision of this Agreement shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="padding-left:6pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">9.          </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Waiver</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">. No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party. The failure of any party to require the performance of any term or obligation of this Agreement, or the </font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">9</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="padding-left:6pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">waiver by any party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="padding-left:6pt;padding-right:3.15pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">10.        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Notices</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Any notices, requests, demands and other communications provided for by this Agreement shall be sufficient if in writing and delivered in person or sent by registered or certified mail, postage prepaid, to the Employee at the last address for which the Employee has provided written notice to the Employer, or to the Employer at its main office, to the attention of Human Resources</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:6pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">11.        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Publicity</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employee hereby grants to the Employer the right to use the Employee&#8217;s name and likeness, without additional consideration, on, in and in connection with technical, marketing and&#47;or disclosure materials published by or for the Employer for the duration of Employee&#8217;s employment with Employer.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="padding-left:6pt;padding-right:3.1pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">12.        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Conflicting Obligations and Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">. The Employee agrees to inform the Employer of any apparent conflicts between the Employee&#8217;s work for the Employer and (a) any obligations the Employee may have to preserve the confidentiality of another&#8217;s proprietary information or materials or (b) any rights the Employee claims to any inventions or ideas before using the same on the Employer&#8217;s behalf. Otherwise, the Employer may conclude that no such conflict exists and the Employee agrees thereafter to make no such claim against the Employer. The Employer shall receive such disclosures in confidence and consistent with the objectives of avoiding any conflict of obligations and rights or the appearance of any conflict of interest.</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="padding-left:6pt;padding-right:3.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">13.        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Notification of New Employer</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. In the event that the Employee leaves the employ of the Employer, voluntarily or involuntarily, the Employee agrees to inform any subsequent employer of the Employee&#8217;s obligations under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section</font></div><div style="padding-left:6pt;padding-right:3.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement. The Employee further hereby authorizes the Employer to notify the Employee&#8217;s new employer about the Employee&#8217;s obligations under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement.</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="padding-left:6pt;padding-right:3.15pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">14.        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Entire Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. This Agreement constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes any previous oral or written communications, negotiations, representations, understandings, or agreements between them. Any modification of this Agreement shall be effective only if set forth in a written document signed by the Employee and a duly authorized officer of the Employer.</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="padding-left:6pt;padding-right:-1pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">15.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Amendment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. This Agreement may be amended or modified only by a written instrument signed by the</font></div><div style="padding-left:6pt;padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Employee and by a duly authorized representative of the Employer.</font></div><div style="padding-right:-1pt;margin-bottom:0.1pt;"><font><br></font></div><div style="padding-left:6pt;padding-right:3.15pt;margin-top:1.9pt;margin-bottom:0.1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;">16.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration: underline;">Governing Law</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;">. This is a California contract and shall be construed under and be governed in all respects by the laws of the State of California, without giving effect to the conflict of laws principles of such State.</font></div><div style="margin-top:0.25pt;"><font><br></font></div><div style="padding-left:6pt;padding-right:3.15pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">17.        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Obligations of Successors</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employer shall require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Employer to expressly assume and agree to perform this Agreement in the same manner and to the same extent that the Employer would be required to perform if no such succession had taken place.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:6pt;padding-right:266pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">18.        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;">Limitation on Payments in Certain Events.</font></div><div style="margin-top:0.1pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.15pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Limitation on Payments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Notwithstanding anything to the contrary in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement, if any payment or distribution that the Employee would receive pursuant to this Agreement or otherwise (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Payment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) would (a) constitute a &#8220;parachute payment&#8221; within the meaning of Section 280G of the Code), and (b) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Excise Tax</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;), then the Employer shall cause to be determined, before any amounts of the Payment are paid to the Employee, which of the following alternative forms of payment would maximize the Employee&#8217;s after-tax proceeds&#58; (i) payment in full of the entire amount of the Payment (a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Full Payment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;), or (ii) payment of only a part of the Payment so that the Employee receives that largest Payment possible without being subject to the Excise Tax (a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Reduced Payment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;), whichever of </font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">10</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="padding-left:6pt;padding-right:3.15pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">the foregoing amounts, taking into account the applicable federal, state and local income taxes and the Excise Tax (all computed at the highest marginal rate, net of the maximum reduction in federal income taxes which could be obtained from a deduction of such state and local taxes), results in the Employee&#8217;s receipt, on an after-tax basis, of the greater amount of the Payment, notwithstanding that all or some portion the Payment may be subject to the Excise Tax.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.1pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)         The independent registered public accounting firm engaged by the Employer for general audit purposes as of the day prior to the date the first Payment is due shall make all determinations required to be made under this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 18.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> If the independent registered public accounting firm so engaged by the Employer is serving as accountant or auditor for the individual, group or entity effecting the transaction, the Employer shall appoint a nationally recognized independent registered public accounting firm to make the determinations required hereunder. The Employer shall bear all expenses with respect to the determinations by such independent registered public accounting firm required to be made hereunder.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.65pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c)&#160;The independent registered public accounting firm engaged to make the determinations hereunder shall provide its calculations, together with detailed supporting documentation, to the Employer and the Employee at such time as requested by the Employer or the Employee. If the independent registered public accounting firm determines that no Excise Tax is payable with respect to a Payment, either before or after the application of the Reduced Payment, it shall furnish the Employer and the Employee with an opinion reasonably acceptable to the Employee that no Excise Tax will be imposed with respect to such Payment. Any good faith determinations of the accounting firm made hereunder shall be final, binding and conclusive upon the Parties.</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="padding-left:6pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">19.        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Consent to Jurisdiction&#59; Forum Selection</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. At all times the Employee and Employer&#58; (a) irrevocably submit to the exclusive jurisdiction of the Los Angeles Superior Court and United States District Court for the Central District of California, whichever may have competent subject matter jurisdiction, in any action or proceeding arising out of or relating to this Agreement, and irrevocably agree that all claims in respect of any such action or proceeding may be heard and determined in such court&#59; (b) to the extent permitted by law, irrevocably consent to the service of any and all process in any such action or proceeding by the mailing of copies of such process to such party at the address set forth in this Agreement (or otherwise on record with the Employer)&#59; (c) to the extent permitted by law, irrevocably confirm that service of process out of such courts in such manner shall be deemed due service upon such party for the purposes of such action or proceeding&#59; (d) to the extent permitted by law, irrevocably waives (i) any objection the Employee or Employer may have to the laying of venue of any such action or proceeding in any of such courts, or (ii) any claim that the Employee or Employer may have that any such action or proceeding has been brought in an inconvenient forum&#59; and (e) to the extent permitted by law, irrevocably agrees that a final nonappealable judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law. Nothing in this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> shall affect the right of any party hereto to serve legal process in any manner permitted by law.</font></div><div style="padding-right:3.1pt;text-align:justify;margin-bottom:0.1pt;"><font><br></font></div><div style="padding-left:5pt;padding-right:3.1pt;text-align:justify;margin-top:4.05pt;margin-bottom:0.1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">20.        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Counterparts</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">. This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be taken to be an original&#59; but such counterparts shall together constitute one and the same document.</font></div><div><font><br></font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:183.25pt;padding-right:188pt;text-align:center;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#91;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Signature Page Follows</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#93;</font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="margin-bottom:0.1pt;"><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div><div style="text-indent:36pt;padding-right:28.1pt;margin-top:1.65pt;margin-bottom:0.1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">IN WITNESS WHEREOF, this Agreement has been executed as a sealed instrument by the Employer by its duly authorized officer, and by the Employee, as of the date first above written.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EMPLOYER&#58;</font></div><div style="padding-right:-1pt;margin-bottom:0.1pt;"><font><br></font></div><div style="padding-right:285.55pt;margin-top:0.05pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:230%;">NETWORK MEDICAL MANAGEMENT, INC.</font></div><div style="padding-right:285.55pt;margin-bottom:0.1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;">By&#58;                                    </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration: underline;">&#47;s&#47; Thomas Lam                                                                                                                           </font></div><div style="margin-top:0.8pt;"><font><br></font></div><div style="padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">Printed Name&#58;                   </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;">Thomas Lam, M.D.                                                                                                                      </font></div><div style="margin-top:0.05pt;"><font><br></font></div><div style="padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">Its&#58;                                     </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;">Co-Chief Executive Officer                                                                                                         </font></div><div><font><br></font></div><div style="margin-top:0.45pt;"><font><br></font></div><div style="padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EMPLOYEE&#58;</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">Signed&#58;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;">&#47;s&#47; Albert Young                                                                                                                           </font></div><div style="margin-top:0.05pt;"><font><br></font></div><div style="padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">Printed Name&#58;                   </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;">Albert Young, M.D.                                                                                                                       </font></div><div style="margin-top:0.05pt;"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">                                                        </font></div><div style="padding-right:-1pt;margin-bottom:0.1pt;"><font><br></font></div><div style="padding-right:-1pt;margin-bottom:0.1pt;"><font><br></font></div><div style="padding-right:-1pt;margin-bottom:0.1pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:108pt;padding-right:-1pt;margin-bottom:0.1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:133%;">&#91;Signature page to Employment Agreement&#93;</font></div><div style="padding-right:-1pt;margin-bottom:0.1pt;"><font><br></font></div><div style="padding-right:-1pt;margin-bottom:0.1pt;"><font><br></font></div><div style="padding-right:-1pt;margin-bottom:0.1pt;"><font><br></font></div><div style="padding-right:-1pt;margin-bottom:0.1pt;"><font><br></font></div><div style="padding-right:-1pt;margin-bottom:0.1pt;"><font><br></font></div><div style="padding-right:-1pt;margin-bottom:0.1pt;"><font><br></font></div><div style="padding-right:-1pt;margin-bottom:0.1pt;"><font><br></font></div><div style="padding-right:-1pt;margin-bottom:0.1pt;"><font><br></font></div><div style="padding-right:-1pt;margin-bottom:0.1pt;"><font><br></font></div><div style="padding-right:-1pt;margin-bottom:0.1pt;"><font><br></font></div><div style="padding-right:-1pt;margin-bottom:0.1pt;"><font><br></font></div><div style="padding-right:-1pt;margin-bottom:0.1pt;"><font><br></font></div><div style="padding-right:-1pt;margin-bottom:0.1pt;"><font><br></font></div><div style="padding-right:-1pt;margin-bottom:0.1pt;"><font><br></font></div><div style="padding-right:-1pt;margin-bottom:0.1pt;"><font><br></font></div><div style="padding-right:-1pt;margin-bottom:0.1pt;"><font><br></font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">12</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="padding-right:-1pt;margin-bottom:0.1pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:180pt;padding-right:-1pt;margin-bottom:0.1pt;"><font><br></font></div><div style="padding-right:-1pt;text-align:center;margin-bottom:0.1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%;">EXHIBIT A</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:199.45pt;padding-right:199.4pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:113%;text-decoration: underline;">Release of Claims</font></div><div style="margin-top:0.1pt;"><font><br></font></div><div style="padding-left:41pt;padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">I,&#160;, in consideration of and subject to the performance by Network Medical Management,</font></div><div style="padding-left:5pt;padding-right:3.4pt;text-align:justify;margin-top:0.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Inc., a California corporation (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Company</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) of its obligations under the Employment Agreement, dated as of _ _,</font></div><div style="padding-left:5pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">20 (as amended from time to time, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">&#8221;), do hereby release and forever discharge as of the date of my execution of this release (this &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Release</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">&#8221;) the Company, its affiliated and related entities, its and their respective predecessors, successors and assigns, its and their respective employee benefit plans and fiduciaries of such plans, and the current and former officers, directors, shareholders, employees, attorneys, accountants and agents of each of the foregoing in their official and personal capacities (collectively, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Released Parties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">&#8221;) to the extent provided below.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:41.35pt;padding-right:3.1pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">1.&#160;I understand that any payments or benefits paid or granted to me under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Section 5(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;"> of the Agreement represent, in part, consideration for signing this Release and are not salary, wages or benefits to which I was already entitled. Such payments and benefits will not be considered compensation for purposes of any employee benefit plan, program, policy or arrangement maintained or hereafter established by the Company or its affiliates.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="padding-left:5.35pt;padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.&#160;Releases.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:41pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)         I knowingly and voluntarily (on behalf of myself, my spouse, my heirs, executors, administrators, agents and assigns, past and present) fully and forever release and discharge the Company and the other Released Parties from any and all claims, suits, controversies, actions, causes of action, cross claims, counterclaims, demands, debts, liens, contracts, covenants, suits, rights, obligations, expenses, judgments, compensatory damages, liquid damages, punitive or exemplary damages, other damages, claims for costs and attorneys&#8217; fees, orders and liabilities of whatever kind of nature, in law and in equity, in contract of in tort, both past and present (through the date this General Release becomes effective and enforceable) and whether known or unknown, vested or contingent, suspected, or claimed, against the Company or any of the Released Parties which I, my spouse, or any of my heirs, executors, administrators or assigns, may have, which arise out of or relate to my employment with, or my separation or termination from, the Company up to the date of my execution of this Release (including, but not limited to, any allegation, claim of violation arising under&#58; Title VII of the Civil Rights Act of 1964, as amended&#59; the Civil Rights Act of 1991&#59; the Age Discrimination in Employment Act of 1967, as amended (including the Older Workers Benefit Protection Act), the Equal Pay Act of 1963, as amended&#59; the Americans with Disabilities Act of 1990&#59; the Family and Medical Leave Act of 1993&#59; the Worker Adjustment Retraining and Notification Act&#59; the Employee Retirement Income Security Act of 1974&#59; the Fair Labor Standards Act&#59; or their state or local counterparts&#59; or under any other federal, state or local civil or human rights law, or under any other local state or federal law, regulation or ordinance&#59; or under any public policy, contract of tort, or under common law&#59; or arising under any policies, practices or procedures of the Company&#59; or any claim for wrongful discharge, breach of the Agreement, infliction of emotional distress or defamation&#59; or any claim for costs, fees, or other expenses, including attorneys&#8217; fees incurred in these matters) (collectively, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Claims</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;).</font></div><div style="margin-top:0.15pt;"><font><br></font></div><div style="padding-left:41pt;padding-right:3.15pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">SECTION 1542 WAIVER</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Employee agrees that all rights he may have under Section 1542 of the California Civil Code are hereby waived. Section 1542 provides&#58;</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="padding-left:77pt;padding-right:3.3pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:116%;">&#8220;A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM OR HER MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.&#8221;</font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">13</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="padding-left:41pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Notwithstanding the provisions of Section 1542, and for the purpose of implementing a full and complete release, Employee agrees that this Agreement is intended to include all claims, if any, that Employee may have against the Company, and that this Agreement extinguishes those claims.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:41.35pt;padding-right:3.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3.&#160;I represent that I have made no assignment of transfer of any right, claim, demand, cause of action, or other matter covered by </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> above.</font></div><div><font><br></font></div><div style="text-indent:-36pt;padding-left:41.35pt;padding-right:3.1pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4.&#160;In signing this Release, I acknowledge and intend that it shall be effective as a bar to each and every one of the claims, demands and causes of action herein above mentioned or implied. I expressly consent that this Release shall be given full force and effect according to each and all of its express terms and provisions, including those relating to unknown and unsuspected claims up to the date of my execution of this Release, if any, as well as those relating to any other claims hereinabove mentioned. I acknowledge and agree that this waiver is an essential and material term of this Release and that without such waiver the Company would not have agreed to the terms of the Agreement. I further agree that in the event I should bring a claim seeking damages against the Company, this Release shall serve as a complete defense to such claims as to my rights and entitlements. I further agree that I am not aware of any pending charge or complaint of the type described in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> above as of the date of my execution of this Release.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:41.35pt;padding-right:3.25pt;text-align:justify;margin-top:1.7pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">5.&#160;I agree that neither this Release, nor the furnishing of the consideration for this Release, shall be deemed or constructed at any time to be an admission or acknowledgement by the Company, any Released Party or myself of any improper or unlawful conduct.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:41.35pt;padding-right:3pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">6.&#160;I agree and acknowledge that the provisions, conditions, and negotiations of this Release are confidential and agree not to disclose any information regarding the terms, conditions and negotiations of this Release, nor transfer any copy of this Release to any person or entity, other than my immediate family and any tax, legal or other counsel or advisor I have consulted regarding the meaning or effect hereof or as required by applicable law, and I will instruct each of the foregoing not to disclose the same to anyone.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:41.35pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">7.&#160;Notwithstanding anything in the Release to the contrary, nothing in this Release shall be deemed to affect, impair, relinquish, diminish, or in any way affect any rights or claims in any respect to (i) any vested rights or other entitlements that I may have as of the date of my execution of this Release under the Company&#8217;s</font></div><div style="padding-left:41.35pt;padding-right:3.05pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">401(k) plan&#59; (ii) any other vested rights or other entitlements that I may have as of the date of my execution of this Release under any employee benefit plan or program, in which I participated in my capacity as an employee of the Company&#59; (iii) my rights under the Agreement&#59; or (iv) my rights under the Release.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:5.35pt;padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">8.&#160;I understand that I continue to be bound by Section 6 of the Agreement.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:41.35pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">9.&#160;Whenever possible, each provision of this Release shall be interpreted in such a manner as to be effective and valid under applicable law, but if any provisions of this Release are held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other provision or any other jurisdiction, but this Release shall be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provisions had never been contained herein.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:41.35pt;padding-right:3.25pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">10.&#160;This Release shall be governed by and construed in accordance with the laws of the State of California, without giving effect to the conflict of laws principles of the State of California.</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="padding-left:41pt;padding-right:147.8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:231%;">BY SIGNING THIS RELEASE, I REPRESENT AND AGREE THAT&#58; (i)&#160;I HAVE READ IT CAREFULLY&#59;</font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">14</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="text-indent:-36pt;padding-left:77pt;padding-right:3.35pt;text-align:justify;margin-top:0.55pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(ii)         I UNDERSTAND ALL OF ITS TERMS AND KNOW THAT I AM GIVING UP IMPORTANT RIGHTS, INCLUDING BUT NOT LIMITED TO, RIGHTS UNDER THE AGE DISCRIMINATION IN EMPLOYMENT ACT OF 1967, AS AMENDED&#59;</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:41pt;padding-right:162.9pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(iii)        I VOLUNTARILY CONSENT TO EVERYTHING IN IT&#59;</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:77pt;padding-right:3.4pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(iv)        THE COMPANY IS HEREBY ADVISING ME TO CONSULT WITH AN ATTORNEY BEFORE EXECUTING IT, I HAVE HAD THE OPPORTUNITY TO SO CONSULT, AND HAVE AVAILED MYSELF OF SUCH ADVICE TO THE EXTENT I HAVE DEEMED NECESSARY TO MAKE A VOLUNTARY AND INFORMED CHOICE TO EXECUTE THIS RELEASE&#59;</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:-36pt;padding-left:77pt;padding-right:3.3pt;text-align:justify;margin-top:4.05pt;margin-bottom:0.1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(v)         I HAVE HAD AT LEAST TWENTY ONE (21) DAYS &#91;45 DAYS IN CONNECTION WITH A GROUP TERMINATION OR EXIT INCENTIVE PLAN&#93; FOLLOWING THE DATE OF TERMINATION OF MY EMPLOYMENT TO CONSIDER THIS RELEASE&#59;</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:77pt;padding-right:3.35pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(vi)       CHANGES TO THIS RELEASE, WHETHER MATERIAL OR IMMATERIAL, DO NOT RESTART THE RUNNING OF THE 21-DAY &#91;OR 45 DAY&#93; CONSIDERATION PERIOD&#59;</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:77pt;padding-right:3.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(vii)      I UNDERSTAND THAT I HAVE SEVEN (7) DAYS AFTER THE EXECUTION OF THIS RELEASE TO REVOKE IT, SUCH REVOCATION TO BE RECEIVED IN WRITING BY THE COMPANY BY THE END OF THE SEVENTH DAY AFTER THE DATE HEREOF, AND THAT THIS RELEASE SHALL NOT BECOME EFFECTIVE OR ENFORCEABLE UNTIL THE REVOCATION PERIOD HAS EXPIRED&#59;</font></div><div style="margin-top:0.75pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:77pt;padding-right:3.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;">(viii)      I HAVE SIGNED THIS RELEASE KNOWINGLY AND VOLUNTARILY AND WITH THE ADVICE OF ANY COUNSEL RETAINED TO ADVISE ME WITH RESPECT TO IT&#59; AND</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:77pt;padding-right:3.35pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(ix)        I AGREE THAT THE PROVISIONS OF THIS RELEASE MAY NOT BE AMENDED, WAIVED OR MODIFIED EXCEPT BY AN INSTRUMENT IN WRITING SIGNED BY AN AUTHORIZED REPRESENTATIVE OF THE COMPANY AND BY ME.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:5pt;padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">DATED AS OF </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;"> &#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">, 20</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;"> &#160;</font></div><div><font><br></font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="padding-left:5pt;padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#91;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Name</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#93;</font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">15</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>7
<FILENAME>ex1062020063010qngbsim.htm
<DESCRIPTION>EX-10.6
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="iab9c34623958412ab0571dece2b1be2f_1"></div><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="padding-left:167.2pt;padding-right:166.4pt;text-align:center;margin-top:4pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EMPLOYMENT AGREEMENT</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:6pt;padding-right:3.05pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">THIS EMPLOYMENT AGREEMENT </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(this &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) is made and entered into as of June 8, 2020, by and between Network Medical Management, Inc., a California corporation (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Employer</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;), and Brandon Sim (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Employee</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; and together with the Employer referred to as the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Parties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) to become effective as of the date hereof (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Effective</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;).</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.2pt;text-align:justify;margin-top:1.9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;">WHEREAS, the Employer desires to employ the Employee from and after the Effective Date on the terms and conditions set forth below, and the Employee is willing to serve the Employer on such terms and conditions.</font></div><div style="margin-top:0.45pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">NOW, THEREFORE, in consideration of the mutual covenants and agreements contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows&#58;</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="padding-left:6pt;padding-right:3.15pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.           </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Term</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The term of this Agreement shall initially be for a one (1) year period commencing on the Effective Date. The term of this Agreement shall automatically renew for an additional year on each anniversary of the Effective Date unless either Party gives the other written notice of intent not to renew at least sixty (60) days prior to such date. Notwithstanding the foregoing, the initial term and any renewal year shall be subject to earlier termination as provided in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> below. The initial term and any renewal years are referred to herein as the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Term</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;.</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="padding-left:6pt;padding-right:3.15pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Positions and Duties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. During the Term, the Employee shall serve as a senior executive officer of the Employer. The Employee shall perform for the Employer the duties customarily associated with being a senior executive officer that are consistent with your experience and skills and such other duties as may be assigned to the Employee from time to time by the Employer&#8217;s Board of Directors (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Board</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) that are consistent with the duties normally performed by those performing the role of the most senior executives of similar entities. The Employee shall devote such working time, attention, knowledge, skills and efforts as may be required to fulfill the Employee&#8217;s duties hereunder, as reasonably determined by the Board, and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">further</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> that the Employee may participate as a member of the board of directors or advisory board of other entities and in professional organizations and civic and charitable organizations so long as any such positions are disclosed to the Board and do not materially interfere with the Employee&#8217;s duties and responsibilities to the Employer. The Employee shall be based in Alhambra, California.</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="padding-left:6pt;padding-right:3.2pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3.           </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Compensation and Related Matters</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employer shall provide the Employee with the compensation and benefits set forth in this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> during the Term. Authority to take action under this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> with respect to the Employee&#8217;s compensation and benefits may be delegated by the Board to its compensation committee.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.1pt;text-align:justify;margin-top:1.7pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(a)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Base Salary</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">. The Employer shall pay the Employee for all services rendered a base salary of One Hundred Thousand Dollars ($100,000) per year (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Base Salary</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">&#8221;), payable in accordance with the Employer&#8217;s payroll procedures, subject to customary withholdings and employment taxes. The Base Salary shall be evaluated annually by the Board for increase only.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.2pt;text-align:justify;margin-top:1.7pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(b)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Annual Bonus</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">. The Employee will be eligible to receive an annual cash bonus (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Annual Bonus</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">&#8221;) for each fiscal year during the Term on such terms and conditions as the Board shall determine in its discretion consistent with the terms of the Employer&#8217;s business plan.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.05pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Long Term Incentive Awards</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employee shall be eligible to participate in any long term incentive plan that may be available to similarly positioned executives. The Board may determine to grant long-term incentive awards in cash or in equity awards settled in shares of the Employer&#8217;s stock, including but not limited to stock options, restricted stock and performance shares. In the event the Employee terminates service due to being a Good Leaver, any requirements under a long-term incentive award held by the Employee shall be deemed to have been satisfied by the Employer immediately prior to such termination. A &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Good Leaver</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; means that, during the Term, either the Employee has resigned for Good Reason (as defined in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> below), the Employer has terminated the Employee&#8217;s employment without Cause (as defined in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> below or the Employee terminates </font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="padding-left:6pt;padding-right:3.05pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">employment on account of death or Disability (as defined in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> below). For avoidance of doubt, being a Good Leaver entitles the Employee to be fully vested with respect to any stock options with vesting conditions based solely on continued employment, and to be entitled to payment with respect to any long-term incentive award subject to corporate or business goals to the extent that such goals are met during the performance period on the same basis as if he had remained continuously employed with the Employer.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(d)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Paid Time Off</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. During the term, the Employee shall be entitled to twenty (20) business days of paid time off (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">PTO</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) per calendar year which shall be accrued ratably during the calendar year, to be taken at such times and intervals as shall be agreed to by Employer and the Employee in their reasonable discretion. The Employee shall be entitled to accrue a maximum of twenty (20) business days of paid time off. When the maximum accrual is reached, no additional PTO time will accrue until Employee uses one or more accrued PTO days. Accrued and unused PTO shall be paid in cash at the end of a calendar year.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(e)       </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Expenses</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employee shall be entitled to prompt reimbursement of reasonable and usual business expenses incurred on behalf of Employer in accordance with the Employer&#8217;s expense reimbursement policy.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.1pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(f)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Other Benefits</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employee shall be entitled to continue to participate in or receive benefits under any employee benefit plan or arrangement which is or may, in the future, be made available by the Employer to its employees, subject to and on a basis consistent with the terms, conditions and overall administration of such plan or arrangement. Irrespective of other benefits provided to employees, the Employee&#8217;s benefits package shall include&#58; (i) the Employer&#8217;s payment of premiums for medical, dental and vision care coverage&#59; (ii) the Employer&#8217;s payment of insurance premiums for short-term and long-term disability insurance providing for no less than sixty percent (60%) of Employee&#8217;s Base Salary to be payable to the Employee as long as the covered disability persists in a manner that substantially prevents employment in the same occupation as the position Employee last held with Employer but not beyond age sixty-five (65)&#59; and (iii) the Employer&#8217;s payment of insurance premiums for term life insurance providing for no less than two million dollars of coverage (subject to meeting applicable underwriting requirements).</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(g)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Tax Withholding.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The Employer shall undertake to make deductions, withholdings and tax reports with respect to payments and benefits under this Agreement, to the extent it reasonably and in good faith believes it is required to make such deductions, withholdings and tax reports. Payments with respect to compensation and benefits referred to under this Agreement shall be in amounts net of any such deductions or withholdings. Nothing in this Agreement shall be construed to require the Employer to make any payments to compensate the Employee for any adverse tax effect associated with any payments or benefits, or for any deduction or withholding from any payment or benefit.</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="padding-left:6pt;padding-right:3.2pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employee&#8217;s employment hereunder may be terminated during the Term without any breach of this Agreement under the following circumstances&#58;</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="padding-left:42pt;padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">(a)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;">Death</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">. The Employee&#8217;s employment hereunder shall terminate upon the Employee&#8217;s death.</font></div><div style="margin-top:0.45pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.2pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Disability</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employer may terminate the Employee&#8217;s employment if the Employee is disabled and, because of the disability, is unable to perform the essential functions of the Employee&#8217;s then existing position or positions under this Agreement with or without reasonable accommodation. This provision is not intended to reduce any rights the Employee may have pursuant to any law, including without limitation the California Family Rights Act, the Family and Medical Leave Act, the California Fair Employment and Housing Act, and the Americans with Disabilities Act.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Termination by the Employer for Cause</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. At any time during the Term, the Employer may terminate the Employee&#8217;s employment hereunder for Cause. For purposes of this Agreement, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Cause</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; shall mean&#58; (i) conduct by the Employee constituting a material act of willful misconduct in connection with the performance of the Employee&#8217;s duties that results in loss, damage or injury that is material to the Employer&#59; (ii) the commission by the Employee of any felony&#59; (iii) continued, willful and deliberate non-performance by the Employee of the Employee&#8217;s duties hereunder (other than by reason of the Employee&#8217;s physical or mental illness, incapacity or disability)&#59; (iv) a </font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="padding-left:6pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">material breach, according to the standard of the Employer, by the Employee of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement that results in loss, damage or injury that is material to the Employer&#59; (v) willful failure to cooperate with a bona fide internal investigation or an investigation by regulatory or law enforcement authorities, after being instructed by the Employer to cooperate, or the willful destruction or failure to preserve documents or other materials known to be relevant to such investigation or the willful inducement of others to fail to cooperate or to produce documents or other materials in connection with such investigations&#59; or (vi) fraud, embezzlement or theft against the Employer or any of its Affiliates (as defined in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> below). With respect to the events in (i), (iii) and (iv) herein, the Employer shall have delivered written notice to the Employee of its intention to terminate the Employee&#8217;s employment for Cause, which notice specifies in reasonable detail the circumstances claimed to give rise to the Employer&#8217;s right to terminate the Employee&#8217;s employment for Cause and the Employee shall not have cured such circumstances to the extent such circumstances are reasonably susceptible to cure as determined by the Board in good faith within thirty (30) days following the Employer&#8217;s delivery of such notice. For avoidance of doubt, &#8220;Cause&#8221; shall not include (x) expense reimbursement disputes in which the Employee acts in reasonable good faith&#59; (y) occasional, customary and de minimis use of the Employer&#8217;s property for personal purposes&#59; and (z) acting in good faith upon advice of Employer&#8217;s legal counsel.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:5pt;padding-right:3.15pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(d)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Termination without Cause</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. At any time during the Term, the Employer may terminate the Employee&#8217;s employment hereunder without Cause by providing the Employee with thirty (30) days advance written notice. Any termination by the Employer of the Employee&#8217;s employment under this Agreement that does not constitute a termination for Cause under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> and does not result from the death or Disability of the Employee under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Sections 4(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> or </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">4(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> shall be deemed a termination without Cause under this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Any suspension of the Employee&#8217;s employment with pay or benefits by the Board in good faith pending an investigation of alleged improper activities by the Employee that, if determined to be accurate, would be grounds for a Cause termination, shall not be considered a termination of the Employee&#8217;s employment without Cause or provide with Good Reason to terminate employment.</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:5pt;padding-right:3pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(e)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Termination by the Employee</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. At any time during the Term, the Employee may terminate his employment hereunder for any reason, including, but not limited to, Good Reason. For purposes of this Agreement, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Good Reason</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; shall mean that the Employee has complied with the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Good Reason Process</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; (hereinafter defined) following the occurrence of any of the following events&#58; (i) a material diminution in the Employee&#8217;s responsibilities, authority or duties&#59; (ii) the material breach of this Agreement by the Employer, including but not limited to a failure to pay Base Salary or Annual Bonus as provided for under this Agreement&#59; or (iii) any relocation of the Employee&#8217;s principal place of business to a location more than 30 miles from the Employer&#8217;s current executive offices in Alhambra, California&#59; provided, however, that this clause (iii) will not apply to the extent that any new office location is less than 30 miles from the Employee&#8217;s residence. &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Good Reason Process</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; shall mean (i) the Employee reasonably determines in good faith that a &#8220;Good Reason&#8221; condition has occurred&#59; (ii) the Employee notifies the Employer in writing of the occurrence of the Good Reason condition within (60) days of the occurrence of such condition&#59; (iii) the Employee cooperates in good faith with the Employer&#8217;s efforts, for a period of sixty (60) days following such notice (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Cure Period</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;), to remedy the condition&#59; (iv) notwithstanding such efforts, the Good Reason condition continues to exist&#59; and (v) the Employee terminates his employment within thirty (30) days after the end of the Cure Period. If the Employer cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not to have occurred.</font></div><div style="margin-top:0.25pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:5pt;padding-right:3.2pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(f)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Notice of Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Except for termination as specified in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, any termination of the Employee&#8217;s employment shall be communicated by written Notice of Termination by the terminating Party to the other Party hereto. For purposes of this Agreement, a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Notice of Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; shall mean a notice which shall indicate the specific termination provision in this Agreement relied upon.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:5pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(g)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Date of Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Date of Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; shall mean the earliest of the following&#58; (i) if the Employee&#8217;s employment is terminated by the Employee&#8217;s death, the date of the Employee&#8217;s death&#59; (ii) if the Employee&#8217;s employment is terminated on account of Disability under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> or by the Employer for Cause under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, the date on which Notice of Termination is given that follows any applicable required cure period&#59; (iii) if the Employee&#8217;s employment is terminated by the Employer under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, thirty (30) days after the date on which a Notice of Termination is given&#59; (iv) if the Employee&#8217;s employment is terminated by the </font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="padding-left:5pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Employee under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> without Good Reason, thirty (30) days after the date of which a Notice of Termination is given or such shorter period agreed to by the Employer&#59; or (v) if the Employee&#8217;s employment is terminated by the Employee under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> with Good Reason, the date on which Notice of Termination is given after the end of the Cure Period. Notwithstanding the foregoing, in the event that the Employee gives a Notice of Termination to the Employer, the Employer may unilaterally accelerate the Date of Termination but such acceleration shall nevertheless be deemed a termination by the Employee on the accelerated date for purposes of this Agreement. For purposes of determining the time when the lump sum portion of the Severance Amount, if any, is to be paid under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 5(b)(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Date of Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; means the Employee&#8217;s separation from service as defined under Section 409A.</font></div><div style="text-align:justify;"><font><br></font></div><div style="padding-left:8.5pt;padding-right:-1pt;margin-top:4pt;margin-bottom:0.1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">5.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;">Compensation upon Termination.</font></div><div style="margin-top:0.45pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.05pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Accrued Benefits.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> If the Employee&#8217;s employment with the Employer is terminated for any reason during the Term, or if the Term is not renewed, the Employer shall pay or provide the Employee (or the Employee&#8217;s authorized representative or estate) any earned but unpaid Base Salary or Annual Bonus for services rendered through the Date of Termination, unpaid expense reimbursements, and accrued but unused paid time off (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Accrued</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Benefits</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) within the time prescribed by California law. With respect to vested compensation or benefits the Employee may have under any employee benefit or compensation plan, program or arrangement of the Employer, payment will be made to the Employee under the terms of the applicable plan, program or arrangement.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Termination by  the Employer without Cause or by the Employee with Good</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Reason</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. If the Employee&#8217;s employment is terminated by the Employer without Cause as provided in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, or the Employee terminates his employment for Good Reason as provided in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, or the Employee terminates employment at the end of the Term after the Employer provides notice of intent not to renew pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> for reasons other than would provide grounds for a Cause termination, then, (i) the Employer shall, through the Date of Termination, pay the Employee his or her Accrued Benefits, and (ii) if the Employee signs a general release of claims substantially in the form which is attached as </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Exhibit A</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to this Agreement) (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Release</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) within twenty-one (21) days of the receipt of the form of the Release (extended to forty-five (45) days in the event of a group termination or exit incentive program) and does not revoke such Release during the seven-day revocation period&#58;</font></div><div style="margin-top:0.25pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:42pt;padding-right:2.95pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(i)         the Employer shall pay the Employee an amount equal to one-twelfth (1&#47;12) of the Employee&#8217;s most recent Base Salary times the number of full years of service completed, not to exceed twelve (12) years of service (but determined prior to any action involving Base Salary that would constitute Good Reason) (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Severance Amount</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;). For the avoidance of doubt, the maximum Severance Amount payable to Employee pursuant to the terms of this Agreement shall equal one (1) year of the Employee&#8217;s most recent Base Salary. To the extent that such Severance Amount exceeds the 409A Separation Pay Limit (as defined below), such amount shall be paid in a single lump sum on the regular payroll date of the Employer, pertaining to then current salaried employees of the Employer, (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">payroll date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) next following the first anniversary date of the Employee&#8217;s Date of Termination. The portion of the Severance Amount that does not exceed the 409A Separation Pay Limit shall be paid in substantially equal amounts on each payroll date over a one year period&#59; and</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:42pt;padding-right:3.15pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(ii)        the Employer shall pay the Employee an amount in cash equal to the Employer&#8217;s premium amounts paid for coverage of Employee at the time of the Employee&#8217;s termination of coverage under the Employer&#8217;s group medical, dental and vision programs for a period of twelve (12) months, to be paid directly to the Employee at the same times such payments would be paid on behalf of a current employee for such coverage&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#58;</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:78pt;padding-right:3.15pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(A)        No  payments shall  be  made  under  this  paragraph (ii)  unless  and  until  the Employee timely elects continued coverage under such plan(s) pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1985 as amended (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">COBRA</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;)&#59;</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="text-indent:36pt;padding-left:78pt;padding-right:3.25pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(B)&#160;This paragraph (ii) shall not be read or construed as placing any restrictions upon amounts paid under this paragraph (ii) as to their use&#59;</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:78pt;padding-right:3.2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(C)&#160;Payments under this paragraph (ii) shall cease as of the earliest to occur of the following&#58;</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:150pt;padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(1)&#160;the Employee is no longer eligible for and continuing to receive the</font></div><div style="padding-left:114pt;padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">COBRA coverage elected in subparagraph (A)&#59;</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="padding-left:150pt;padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(2)&#160;the time period set forth in the first sentence of this paragraph (ii),</font></div><div style="margin-top:0.75pt;"><font><br></font></div><div style="padding-left:150pt;padding-right:3.2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;">(3)&#160;the date on which the Employee first becomes eligible to enroll in a group health plan in which eligibility is based on employment with an employer, and</font></div><div><font><br></font></div><div style="padding-left:149pt;padding-right:3.1pt;text-align:justify;margin-top:4.05pt;margin-bottom:0.1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(4)        if the Employer in good faith determines that payments under this paragraph (ii) would result in a discriminatory health plan pursuant to the Patient Protection and Affordable Care Act of 2010, as amended.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="padding-left:185pt;padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(iii)&#160;Each individual payment of Severance Amount under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section</font></div><div style="padding-left:149pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">5(b)(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, and each payment under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 5(b)(ii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement, shall be deemed to be a separate &#8220;payment&#8221; for purposes and within the meaning of Treasury Regulation Section 1.409A-2(b)(2)(iii).</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:149pt;padding-right:3.15pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(iv)       Each    individual    payment    of    the    Severance    Amount under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section   5(b)(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">,   and   each   payment   under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section   5(b)(ii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">,   of   this Agreement, which are considered &#8220;non-qualified deferred compensation&#8221; (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">NQDC</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) under Section 409A shall be made on the date(s) provided herein and no request to accelerate or defer any such payment under this Agreement shall be considered or approved for any reason whatsoever, except as permitted under Section 409A and as the Employer allows in its sole discretion. The Employer may in its sole discretion accelerate or defer (but not beyond the time limit set forth below) any severance payments which do not constitute NQDC in order to allow for the payment of taxes due, but not beyond the time limit specified for such payment such that the payment would be treated as NQDC. Subject to the requirements of  Section 409A, if  any severance payment or  reimbursement under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 5(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement is determined in good faith by the Employer to constitute NQDC payable to a &#8220;specified employee&#8221; as defined under Section</font></div><div style="padding-left:149pt;padding-right:3.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">409A, then the Employer shall make any such payment not earlier than the earlier of&#58; (x) the first payroll date which is six (6) months following the Employee&#8217;s separation from service (as defined under Section 409A) with the Employer, or (y) the date of Employee&#8217;s death.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="padding-left:185pt;padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(v)&#160;for purposes of this Section 5, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 409A</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; means Section</font></div><div style="padding-left:149pt;padding-right:18.3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">409A of the Internal Revenue Code of 1986, as amended, and the regulations thereunder.</font></div><div><font><br></font></div><div style="text-indent:36pt;padding-left:149pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(vi)       for purposes of this Section 5, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">409A Separation Pay Limit</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">&#8221; means two times the lesser of (</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:116%;">x</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">) the Employee&#8217;s annual compensation during the calendar year preceding the year of the termination of employment&#59; and (</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:116%;">y</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">) the adjusted compensation limit under Code Section 401(a)(17) in effect for the year of the termination.</font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="padding-left:5pt;padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">6.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;">Confidential Information, Nonsolicitation, and Cooperation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">.</font></div><div style="margin-top:0.45pt;"><font><br></font></div><div style="padding-left:41pt;padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">(a)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;">Definitions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">.</font></div><div style="margin-top:0.1pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:41pt;padding-right:3.05pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(i)          As used in this Agreement, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Affiliate</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; means, as to any Person, (i) any other Person which directly, or indirectly through one or more intermediaries, controls such Person or is consolidated with such Person in accordance with GAAP, (ii) any other Person which directly, or indirectly through one or more intermediaries, is controlled by or is under common control with such Person, or (iii) any other Person of which such Person owns, directly or indirectly, fifty percent (50%) or more of the common stock or equivalent equity interests. As used herein, the term &#8220;control&#8221; means possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of a Person, whether through the ownership of voting securities or otherwise.</font></div><div style="margin-top:0.7pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:41pt;padding-right:3.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;">(ii)        As used in this Agreement, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration: underline;">Person</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;">&#8221; means an individual, a corporation, a partnership, a limited liability company, an association, a trust or any other entity or organization.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:36pt;padding-left:5pt;padding-right:3.05pt;text-align:justify;margin-top:4pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Confidential  Information</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  As   used   in   this   Agreement,  &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Confidential</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Information</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;  means information belonging to the Employer or its Affiliates which is of value to the Employer or any of its Affiliates in the course of conducting its business (whether having existed, now existing, or to be developed or created during Employee&#8217;s employment by Employer) and the disclosure of which could result in a competitive or other disadvantage to the Employer or its Affiliates. Confidential Information includes, without limitation, contract terms and rates&#59; negotiating and contracting strategies&#59; financial information, reports, and forecasts&#59; inventions, improvements and other intellectual property&#59; product plans or proposed product plans&#59; trade secrets&#59; designs, processes or formulae&#59; software&#59; employee, customer, patient, provider and supplier information&#59; information from patient medical records&#59; financial data&#59; insurance reimbursement methodologies, strategies and practices&#59; product and service pricing methodologies, strategies and practices&#59; contracts with physicians, providers, provider networks, payors, physician databases and contracts with hospitals&#59; regulatory and clinical manuals&#59; and business plans, prospects and opportunities (such as possible acquisitions or dispositions of businesses or facilities) that have been discussed or considered by the Employer or its Affiliates, including, without limitation, the management of the Employer or its Affiliates. Confidential Information includes information developed by the Employee in the course of the Employee&#8217;s employment by the Employer, as well as other information to which the Employee may have access in connection with the Employee&#8217;s employment. Confidential Information also includes the confidential information of others with which the Employer or its Affiliates has a business relationship. Notwithstanding the foregoing, Confidential Information does not include information in the public domain, unless due to breach of the Employee&#8217;s duties under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, unless otherwise due to Employee&#8217;s breach of the obligations in this Agreement, or unless due to violation of another Person&#8217;s obligations to the Employer or its Affiliates that Employee should have taken reasonable measures to prevent but that Employee did not take.</font></div><div style="margin-top:0.1pt;"><font><br></font></div><div style="text-indent:38.5pt;padding-left:5pt;padding-right:4.85pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Confidentiality</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employee understands and agrees that the Employee&#8217;s employment creates a relationship of confidence and trust between the Employer and the Employee with respect to all Confidential Information. At all times, both during the Employee&#8217;s employment with the Employer and after the Employee&#8217;s termination from employment for any reason, the Employee shall keep in confidence and trust all such Confidential Information, and shall not use, disclose, or transfer any such Confidential Information without the written consent of the Employer, except as may be necessary within the scope of Employee&#8217;s duties with Employer and in the ordinary course of performing the Employee&#8217;s duties to the Employer or as otherwise provided in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Employee understands and agrees not to sell, license or otherwise exploit any products or services which embody or otherwise exploit in whole or in part any Confidential Information or materials. Employee acknowledges and agrees that the sale, misappropriation, or unauthorized use or disclosure in writing, orally or by electronic means, at any time of Confidential Information obtained by Employee during or in connection with the course of Employee&#8217;s employment constitutes unfair competition. Employee agrees and promises not to engage in unfair competition with Employer or its Affiliates, either during employment, or at any time thereafter.</font></div><div style="margin-top:0.45pt;"><font><br></font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="text-indent:36pt;padding-left:5pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(d)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Protected Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">. Notwithstanding anything to the contrary in this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">, this Agreement is not intended to, and shall not, in any way prohibit, limit or otherwise interfere with the Employee&#8217;s protected rights under federal, state or local law to, without notice to the Employer, (i) communicate or file a charge with a government regulator&#59; (ii) participate in an investigation or proceeding conducted by a government regulator&#59; or (iii) receive an award paid by a government regulator for providing information.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:5pt;padding-right:3.15pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(e)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Documents, Records, etc</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. All documents, records, data, apparatus, equipment and other physical property, whether or not pertaining to Confidential Information, that are furnished to the Employee by the Employer or its Affiliates or are produced by the Employee in connection with the Employee&#8217;s employment will be and remain the sole property of the Employer and its Affiliates. The Employee shall return to the Employer all such materials and property as and when requested by the Employer. In any event, the Employee shall return all such materials and property immediately upon termination of the Employee&#8217;s employment for any reason. The Employee shall not retain any such material or property or any copies thereof after such termination. It is specifically agreed that any documents, card files, notebooks, programs, or similar items containing customer or patient information are the property of the Employer and its Affiliates regardless of by whom they were compiled.</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:5pt;padding-right:3.05pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(f)          </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Disclosure Prevention</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employee will take all reasonable precautions to prevent the inadvertent or accidental exposure of Confidential Information.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:36pt;padding-left:5pt;padding-right:3.15pt;text-align:justify;margin-top:4.05pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(g)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Removal of Material</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">. The Employee will not remove any Confidential Information from the Employer&#8217;s or its Affiliate&#8217;s premises except for use in the Employer&#8217;s business, and only consistent with the Employee&#8217;s duties with the Employer.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:5pt;padding-right:3.2pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(h)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Copying</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">. The Employee agrees that copying or transferring Confidential Information (by any means) shall be done only as needed in furtherance of and for use in the Employer&#8217;s and its Affiliate&#8217;s business, and consistent with the Employee&#8217;s duties with the Employer. The Employee further agrees that copies of Confidential Information shall be treated with the same degree of confidentiality as the original information and shall be subject to all restrictions herein.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:5pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(i)           </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Computer Security</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employee agrees to comply with the Employer&#8217;s policies and procedures concerning computer security.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:5pt;padding-right:3.15pt;text-align:justify;margin-top:1.7pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(j)           </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">E-Mail</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">. The Employee acknowledges that the Employer retains the right to review any and all electronic mail communications made with employer provided email accounts, hardware, software, or networks, with or without notice, at any time.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:5pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(k)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Assignment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employee acknowledges that any and all inventions, discoveries, designs, developments, methods, modifications, trade secrets, processes, software, formulae, data, &#8220;know-how,&#8221; databases, algorithms, techniques and works of authorship whether or not patentable or protectable by copyright or trade secret, made or conceived, first reduced to practice, or learned by the Employee, either alone or jointly with others, during the Term that (i) relate to or are useful in the business of the Employer or its Affiliates, or (ii) are conceived, made or worked on at the expense of or during the Employee&#8217;s work time for the Employer, or using any resources or materials of the Employer or its Affiliates, or (iii) arise out of tasks assigned to the Employee by the Employer (together &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Proprietary Inventions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) will be the sole property of the Employer or its Affiliates. The Employee acknowledges that all work performed by the Employee is on a &#8220;work for hire&#8221; basis and the Employee hereby assigns or agrees to assign to the Employer the Employee&#8217;s entire right, title and interest in and to any and all Proprietary Inventions and related intellectual property rights. The Employee agrees to assist the Employer to obtain, maintain and enforce intellectual property rights for Proprietary Inventions in any and all countries during the Term, and thereafter for as long as such intellectual property rights exist.</font></div><div style="padding-right:3.15pt;text-align:justify;margin-bottom:0.1pt;"><font><br></font></div><div style="padding-left:144.7pt;padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">NOTICE TO CALIFORNIA EMPLOYEES</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">7</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="padding-left:41pt;padding-right:39.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to California Labor Code &#167;2870, an agreement requiring the employee to assign or offer to assign any of his or her rights in any invention to his or her employer does not apply to an invention which qualifies fully under the provisions of California Labor Code &#167; 2870, which provides as follows&#58;</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:41pt;padding-right:39.05pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)         Any provision in an employment agreement which provides that an employee shall assign, or offer to assign, any of his or her rights in an invention to his or her employer shall not apply to an invention that the employee developed entirely on his or her own time without using the employer&#8217;s equipment, supplies, facilities, or trade secret information except for those inventions that either&#58;</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:77pt;padding-right:39.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(1)        Relate at the time of conception or reduction to practice of the invention to the employer&#8217;s business, or actual or demonstrably anticipated research or development of the employer&#59; or</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:112.95pt;padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(2)&#160;Result from any work performed by the employee for the employer.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:41pt;padding-right:39.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)         To the extent a provision in an employment agreement purports to require an employee to assign an invention otherwise excluded from being required to be assigned under subdivision (a), the provision is against the public policy of the State of California and is unenforceable.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:0.1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;">(l)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration: underline;">Nonsolicitation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;">. Employee agrees and covenants that, at any time during Employee&#8217;s employment with the Employer and for a period of twelve (12) months immediately following the termination of Employee&#8217;s relationship with the Employer for any reason, whether with or without cause, Employee shall not, either on Employee&#8217;s own behalf or on behalf of any other Person&#58; (i) solicit the services of the Employer&#8217;s employees or entice away, directly or indirectly, any Person employed or engaged by or otherwise providing services to the Employer or its Affiliates, whether in an employment capacity or otherwise (this provision does not prohibit the Employee&#8217;s post- termination acceptance of unsolicited applications for employment)&#59; or (ii) take any illegal action or engage in any unfair business practice, including, without limitation, any misappropriation of confidential, proprietary or trade secret information of the Employer or its Affiliates, as a result of which relations between the Employer or its Affiliates, and any of their customers, clients, suppliers, distributors or others, may be impaired or which might otherwise be detrimental to the business interests or reputation of the Employer or its Affiliates.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:5pt;padding-right:3.05pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(m)        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Third-Party Agreements and Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employee hereby confirms that the Employee is not bound by the terms of any agreement with any previous employer or other party which restricts in any way the Employee&#8217;s use or disclosure of information or the Employee&#8217;s engagement in any business except as Employee has previously provided written notice to Employer and has attached to this Agreement. The Employee represents to the Employer that the Employee&#8217;s execution of this Agreement, the Employee&#8217;s employment with the Employer and the performance of the Employee&#8217;s proposed duties for the Employer will not violate any obligations the Employee may have to any previous employer or other party. In the Employee&#8217;s work for the Employer, the Employee will not disclose or use any information in violation of any agreements with or rights of any such previous employer or other party, and the Employee will not bring to (by any means) the premises of the Employer any copies or other tangible embodiments of non- public information belonging to or obtained from any such previous employment or other party.</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:5pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(n)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Litigation  and  Regulatory  Cooperation.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  During  and  after  the  Employee&#8217;s  employment,  the Employee shall cooperate fully with the Employer in the defense or prosecution of any claims or actions now in existence or that may be brought in the future against or on behalf of the Employer that relate to events or occurrences that transpired while the Employee was employed by the Employer. The Employee&#8217;s full cooperation in connection with such claims or actions shall include, but not be limited to, being available to meet with counsel to prepare for discovery or trial and to act as a witness on behalf of the Employer at mutually convenient times. During and after the Employee&#8217;s employment, the Employee also shall cooperate fully with the Employer in connection with </font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">8</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="padding-left:5pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">any investigation or review of any federal, state, or local regulatory authority as any such investigation or review relates to events or occurrences that transpired while the Employee was employed by the Employer. The Employer shall reimburse the Employee for any reasonable out of pocket expenses incurred in connection with the Employee&#8217;s performance of obligations pursuant to this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. &#8220;Full cooperation&#8221; shall not be construed to in any way require any violation of law or any testimony that is false or misleading.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:5pt;padding-right:3.05pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(o)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Enforcement&#59; Injunction.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The Employee acknowledges and agrees that the restrictions contained in this Agreement are reasonable and necessary to protect the business and interests of the Employer and its Affiliates, do not create any undue hardship for the Employee, and that any violation of the restrictions in this Agreement would cause the Employer and its Affiliates substantial irreparable injury. Accordingly, the Employee agrees that a remedy at law for any breach or threatened breach of the covenants or other obligations in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement would be inadequate and that the Employer, in addition to any other remedies available, shall be entitled to obtain preliminary and permanent injunctive relief to secure specific performance of such covenants and to prevent a breach or contemplated or threatened breach of this Agreement without the necessity of proving actual damage and without the necessity of posting bond or security, which the Employee expressly waives. Moreover, the Employee will provide the Employer a full accounting of all proceeds and profits received by the Employee as a result of or in connection with a breach of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement. Unless prohibited by law, the Employer shall have the right to retain any amounts otherwise payable by the Employer to the Employee to satisfy any of the Employee&#8217;s obligations as a result of any breach of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement. The Employee hereby agrees to indemnify and hold harmless the Employer and its Affiliates from and against any damages incurred by the Employer or its Affiliates as assessed by a court of competent jurisdiction as a result of any breach of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement by the Employee. The prevailing party shall be entitled to recover its reasonable attorneys&#8217; fees and costs if it prevails in any action to enforce </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement. It is the express intention of the parties that the obligations of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement shall survive the termination of the Employee&#8217;s employment. The Employee agrees that each obligation specified in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement is a separate and independent covenant that shall survive any termination of this Agreement and that the unenforceability of any of them shall not preclude the enforcement of any other covenants in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement. No change in the Employee&#8217;s duties or compensation shall be construed to affect, alter or otherwise release the Employee from the covenants herein.</font></div><div style="margin-top:0.45pt;"><font><br></font></div><div style="padding-left:5pt;padding-right:3.05pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">7.          </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Successors</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. This Agreement shall be binding upon and inure to the benefit of both parties and their respective successors and permitted assigns, including any corporation or entity with which or into which the Employer may be merged or which may succeed to its assets or business, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, that Employee&#8217;s obligations are personal and shall not be assigned by Employee. The Employee consents to be bound by the provisions of this Agreement for the benefit of the Employer or its Affiliates to whose employ the Employee may be transferred without the necessity that this Agreement be resigned at the time of such transfer. In the event of the Employee&#8217;s death after the Date of Termination but prior to the completion by the Employer of all payments due to the Employee under this Agreement, the Employer shall continue such payments to the Employee&#8217;s beneficiary designated in writing to the Employer prior to the Employee&#8217;s death (or to the Employee&#8217;s estate, if the Employee fails to make such designation).</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="padding-left:5pt;padding-right:3.1pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">8.         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Enforceability</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">. If any portion or provision of this Agreement shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="padding-left:5pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">9.          </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Waiver</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">. No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party. The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="padding-left:5pt;padding-right:3.2pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">10.        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Notices</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">. Any notices, requests, demands and other communications provided for by this Agreement shall be sufficient if in writing and delivered in person or sent by registered or certified mail, postage prepaid, to the Employee at the last address for which the Employee has provided written notice to the Employer, or to the Employer at its main office, to the attention of Human Resources</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:116%;">.</font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">9</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="padding-left:5pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">11.        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Publicity</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">. The Employee hereby grants to the Employer the right to use the Employee&#8217;s name and likeness, without additional consideration, on, in and in connection with technical, marketing and&#47;or disclosure materials published by or for the Employer for the duration of Employee&#8217;s employment with Employer.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="padding-left:5pt;padding-right:3.1pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">12.        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Conflicting Obligations and Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Employee agrees to inform the Employer of any apparent conflicts between the Employee&#8217;s work for the Employer and (a) any obligations the Employee may have to preserve the confidentiality of another&#8217;s proprietary information or materials or (b) any rights the Employee claims to any inventions or ideas before using the same on the Employer&#8217;s behalf. Otherwise, the Employer may conclude that no such conflict exists and the Employee agrees thereafter to make no such claim against the Employer. The Employer shall receive such disclosures in confidence and consistent with the objectives of avoiding any conflict of obligations and rights or the appearance of any conflict of interest.</font></div><div style="margin-top:0.75pt;"><font><br></font></div><div style="padding-left:5pt;padding-right:3.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;">13.        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration: underline;">Notification of New Employer</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;">. In the event that the Employee leaves the employ of the Employer, voluntarily or involuntarily, the Employee agrees to inform any subsequent employer of the Employee&#8217;s obligations under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration: underline;">Section</font></div><div style="padding-left:5pt;padding-right:3.25pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;">6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> of this Agreement. The Employee further hereby authorizes the Employer to notify the Employee&#8217;s new employer about the Employee&#8217;s obligations under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;">Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> of this Agreement.</font></div><div style="margin-top:0.25pt;"><font><br></font></div><div style="padding-left:5pt;padding-right:3.15pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">14.        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Entire Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">. This Agreement constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes any previous oral or written communications, negotiations, representations, understandings, or agreements between them. Any modification of this Agreement shall be effective only if set forth in a written document signed by the Employee and a duly authorized officer of the Employer.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="padding-left:5pt;padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">15.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Amendment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. This Agreement may be amended or modified only by a written instrument signed by the</font></div><div style="padding-left:5pt;padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Employee and by a duly authorized representative of the Employer.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:5pt;padding-right:3.15pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">16.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Governing Law</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. This is a California contract and shall be construed under and be governed in all respects by the laws of the State of California, without giving effect to the conflict of laws principles of such State.</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:3.1pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">17.        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Obligations of Successors</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">. The Employer shall require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Employer to expressly assume and agree to perform this Agreement in the same manner and to the same extent that the Employer would be required to perform if no such succession had taken place.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="padding-left:6pt;padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">18.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;">Limitation on Payments in Certain Events.</font></div><div style="margin-top:0.45pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.15pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)         </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Limitation on Payments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Notwithstanding anything to the contrary in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of this Agreement, if any payment or distribution that the Employee would receive pursuant to this Agreement or otherwise (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Payment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) would (a) constitute a &#8220;parachute payment&#8221; within the meaning of Section 280G of the Code), and (b) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Excise Tax</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;), then the Employer shall cause to be determined, before any amounts of the Payment are paid to the Employee, which of the following alternative forms of payment would maximize the Employee&#8217;s after-tax proceeds&#58; (i) payment in full of the entire amount of the Payment (a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Full Payment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;), or (ii) payment of only a part of the Payment so that the Employee receives that largest Payment possible without being subject to the Excise Tax (a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Reduced Payment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;), whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the Excise Tax (all computed at the highest marginal rate, net of the maximum reduction in federal income taxes which could be obtained from a deduction of such state and local taxes), results in the Employee&#8217;s receipt, on an after-tax basis, of the greater amount of the Payment, notwithstanding that all or some portion the Payment may be subject to the Excise Tax.</font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">10</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.1pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)         The independent registered public accounting firm engaged by the Employer for general audit purposes as of the day prior to the date the first Payment is due shall make all determinations required to be made under this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 18.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> If the independent registered public accounting firm so engaged by the Employer is serving as accountant or auditor for the individual, group or entity effecting the transaction, the Employer shall appoint a nationally recognized independent registered public accounting firm to make the determinations required hereunder. The Employer shall bear all expenses with respect to the determinations by such independent registered public accounting firm required to be made hereunder.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:6pt;padding-right:3.65pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c)&#160;The independent registered public accounting firm engaged to make the determinations hereunder shall provide its calculations, together with detailed supporting documentation, to the Employer and the Employee at such time as requested by the Employer or the Employee. If the independent registered public accounting firm determines that no Excise Tax is payable with respect to a Payment, either before or after the application of the Reduced Payment, it shall furnish the Employer and the Employee with an opinion reasonably acceptable to the Employee that no Excise Tax will be imposed with respect to such Payment. Any good faith determinations of the accounting firm made hereunder shall be final, binding and conclusive upon the Parties.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:6pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">19.        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Consent to Jurisdiction&#59; Forum Selection</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. At all times the Employee and Employer&#58; (a) irrevocably submit to the exclusive jurisdiction of the Los Angeles Superior Court and United States District Court for the Central District of California, whichever may have competent subject matter jurisdiction, in any action or proceeding arising out of or relating to this Agreement, and irrevocably agree that all claims in respect of any such action or proceeding may be heard and determined in such court&#59; (b) to the extent permitted by law, irrevocably consent to the service of any and all process in any such action or proceeding by the mailing of copies of such process to such party at the address set forth in this Agreement (or otherwise on record with the Employer)&#59; (c) to the extent permitted by law, irrevocably confirm that service of process out of such courts in such manner shall be deemed due service upon such party for the purposes of such action or proceeding&#59; (d) to the extent permitted by law, irrevocably waives (i) any objection the Employee or Employer may have to the laying of venue of any such action or proceeding in any of such courts, or (ii) any claim that the Employee or Employer may have that any such action or proceeding has been brought in an inconvenient forum&#59; and (e) to the extent permitted by law, irrevocably agrees that a final nonappealable judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law. Nothing in this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> shall affect the right of any party hereto to serve legal process in any manner permitted by law.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="padding-left:6pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">20.        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Counterparts</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">. This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be taken to be an original&#59; but such counterparts shall together constitute one and the same document.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;margin-bottom:0.1pt;"><font><br></font></div><div style="padding-left:178.25pt;padding-right:168pt;text-align:center;margin-top:1.65pt;margin-bottom:0.1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#91;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Signature Page Follows</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#93;</font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;"><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;"><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;"><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;"><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;"><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;"><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;"><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;"><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;"><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;"><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;"><font><br></font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="text-indent:36pt;padding-right:28.1pt;margin-top:1.65pt;margin-bottom:0.1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">IN WITNESS WHEREOF, this Agreement has been executed as a sealed instrument by the Employer by its duly authorized officer, and by the Employee, as of the date first above written.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EMPLOYER&#58;</font></div><div style="padding-right:-1pt;margin-bottom:0.1pt;"><font><br></font></div><div style="padding-right:285.55pt;margin-top:0.05pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:230%;">NETWORK MEDICAL MANAGEMENT, INC.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:230%;">&#58; </font></div><div style="padding-right:285.55pt;margin-bottom:0.1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;">By&#58;&#160;&#160;&#160;      </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration: underline;">&#47;s&#47; Thomas Lam                                                                                                                            </font></div><div style="margin-top:0.8pt;"><font><br></font></div><div style="padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">Printed Name&#58;                          </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;">Thomas Lam, M.D.                                                                                                                        </font></div><div style="margin-top:0.05pt;"><font><br></font></div><div style="padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">Its&#58;                                            </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;">Co-Chief Executive Officer                                                                                                           </font></div><div><font><br></font></div><div style="margin-top:0.45pt;"><font><br></font></div><div style="padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EMPLOYEE&#58;</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">Signed&#58;&#160;&#160;&#160;     </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;"> &#47;s&#47; Brandon Sim                                                                                                                                 </font></div><div style="margin-top:0.05pt;"><font><br></font></div><div style="padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">Printed Name&#58;                          </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;">Brandon Sim                                                                                                                                      </font></div><div style="margin-top:0.05pt;"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:36pt;padding-left:108pt;padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">&#91;Signature page to Employment Agreement&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div><div style="margin-bottom:0.1pt;"><font><br></font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">12</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="padding-left:210.95pt;padding-right:211.1pt;text-align:center;margin-top:4pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EXHIBIT A</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:199.45pt;padding-right:199.4pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:113%;text-decoration: underline;">Release of Claims</font></div><div style="margin-top:0.1pt;"><font><br></font></div><div style="padding-left:41pt;padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">I,&#160;, in consideration of and subject to the performance by Network Medical Management,</font></div><div style="padding-left:5pt;padding-right:3.35pt;text-align:justify;margin-top:0.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Inc., a California corporation (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Company</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) of its obligations under the Employment Agreement, dated as of _ _,</font></div><div style="padding-left:5pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">20 (as amended from time to time, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">&#8221;), do hereby release and forever discharge as of the date of my execution of this release (this &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Release</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">&#8221;) the Company, its affiliated and related entities, its and their respective predecessors, successors and assigns, its and their respective employee benefit plans and fiduciaries of such plans, and the current and former officers, directors, shareholders, employees, attorneys, accountants and agents of each of the foregoing in their official and personal capacities (collectively, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Released Parties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">&#8221;) to the extent provided below.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:41.35pt;padding-right:3.1pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">1.&#160;I understand that any payments or benefits paid or granted to me under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration: underline;">Section 5(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;"> of the Agreement represent, in part, consideration for signing this Release and are not salary, wages or benefits to which I was already entitled. Such payments and benefits will not be considered compensation for purposes of any employee benefit plan, program, policy or arrangement maintained or hereafter established by the Company or its affiliates.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="padding-left:5.35pt;padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.&#160;Releases.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:41pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)         I knowingly and voluntarily (on behalf of myself, my spouse, my heirs, executors, administrators, agents and assigns, past and present) fully and forever release and discharge the Company and the other Released Parties from any and all claims, suits, controversies, actions, causes of action, cross claims, counterclaims, demands, debts, liens, contracts, covenants, suits, rights, obligations, expenses, judgments, compensatory damages, liquid damages, punitive or exemplary damages, other damages, claims for costs and attorneys&#8217; fees, orders and liabilities of whatever kind of nature, in law and in equity, in contract of in tort, both past and present (through the date this General Release becomes effective and enforceable) and whether known or unknown, vested or contingent, suspected, or claimed, against the Company or any of the Released Parties which I, my spouse, or any of my heirs, executors, administrators or assigns, may have, which arise out of or relate to my employment with, or my separation or termination from, the Company up to the date of my execution of this Release (including, but not limited to, any allegation, claim of violation arising under&#58; Title VII of the Civil Rights Act of 1964, as amended&#59; the Civil Rights Act of 1991&#59; the Age Discrimination in Employment Act of 1967, as amended (including the Older Workers Benefit Protection Act), the Equal Pay Act of 1963, as amended&#59; the Americans with Disabilities Act of 1990&#59; the Family and Medical Leave Act of 1993&#59; the Worker Adjustment Retraining and Notification Act&#59; the Employee Retirement Income Security Act of 1974&#59; the Fair Labor Standards Act&#59; or their state or local counterparts&#59; or under any other federal, state or local civil or human rights law, or under any other local state or federal law, regulation or ordinance&#59; or under any public policy, contract of tort, or under common law&#59; or arising under any policies, practices or procedures of the Company&#59; or any claim for wrongful discharge, breach of the Agreement, infliction of emotional distress or defamation&#59; or any claim for costs, fees, or other expenses, including attorneys&#8217; fees incurred in these matters) (collectively, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Claims</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;).</font></div><div style="margin-top:0.15pt;"><font><br></font></div><div style="padding-left:41pt;padding-right:3.2pt;text-align:justify;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)          </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">SECTION 1542 WAIVER</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Employee agrees that all rights he may have under Section 1542 of the California Civil Code are hereby waived. Section 1542 provides&#58;</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="padding-left:77pt;padding-right:3.3pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:116%;">&#8220;A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM OR HER MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.&#8221;</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">13</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="padding-left:41pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Notwithstanding the provisions of Section 1542, and for the purpose of implementing a full and complete release, Employee agrees that this Agreement is intended to include all claims, if any, that Employee may have against the Company, and that this Agreement extinguishes those claims.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:41.35pt;padding-right:3.2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3.&#160;I represent that I have made no assignment of transfer of any right, claim, demand, cause of action, or other matter covered by </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> above.</font></div><div><font><br></font></div><div style="text-indent:-36pt;padding-left:41.35pt;padding-right:3.1pt;text-align:justify;margin-top:1.65pt;margin-bottom:0.1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4.&#160;In signing this Release, I acknowledge and intend that it shall be effective as a bar to each and every one of the claims, demands and causes of action herein above mentioned or implied. I expressly consent that this Release shall be given full force and effect according to each and all of its express terms and provisions, including those relating to unknown and unsuspected claims up to the date of my execution of this Release, if any, as well as those relating to any other claims hereinabove mentioned. I acknowledge and agree that this waiver is an essential and material term of this Release and that without such waiver the Company would not have agreed to the terms of the Agreement. I further agree that in the event I should bring a claim seeking damages against the Company, this Release shall serve as a complete defense to such claims as to my rights and entitlements. I further agree that I am not aware of any pending charge or complaint of the type described in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> above as of the date of my execution of this Release.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:41.35pt;padding-right:3.25pt;text-align:justify;margin-top:1.7pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">5.&#160;I agree that neither this Release, nor the furnishing of the consideration for this Release, shall be deemed or constructed at any time to be an admission or acknowledgement by the Company, any Released Party or myself of any improper or unlawful conduct.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:41.35pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">6.&#160;I agree and acknowledge that the provisions, conditions, and negotiations of this Release are confidential and agree not to disclose any information regarding the terms, conditions and negotiations of this Release, nor transfer any copy of this Release to any person or entity, other than my immediate family and any tax, legal or other counsel or advisor I have consulted regarding the meaning or effect hereof or as required by applicable law, and I will instruct each of the foregoing not to disclose the same to anyone.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:41.35pt;padding-right:3.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">7.&#160;Notwithstanding anything in the Release to the contrary, nothing in this Release shall be deemed to affect, impair, relinquish, diminish, or in any way affect any rights or claims in any respect to (i) any vested rights or other entitlements that I may have as of the date of my execution of this Release under the Company&#8217;s</font></div><div style="padding-left:41.35pt;padding-right:3.05pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">401(k) plan&#59; (ii) any other vested rights or other entitlements that I may have as of the date of my execution of this Release under any employee benefit plan or program, in which I participated in my capacity as an employee of the Company&#59; (iii) my rights under the Agreement&#59; or (iv) my rights under the Release.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:5.35pt;padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">8.&#160;I understand that I continue to be bound by Section 6 of the Agreement.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:41.35pt;padding-right:3.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">9.&#160;Whenever possible, each provision of this Release shall be interpreted in such a manner as to be effective and valid under applicable law, but if any provisions of this Release are held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other provision or any other jurisdiction, but this Release shall be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provisions had never been contained herein.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:41.35pt;padding-right:3.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">10.&#160;This Release shall be governed by and construed in accordance with the laws of the State of California, without giving effect to the conflict of laws principles of the State of California.</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="padding-left:41pt;padding-right:147.8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:231%;">BY SIGNING THIS RELEASE, I REPRESENT AND AGREE THAT&#58; (i)&#160;I HAVE READ IT CAREFULLY&#59;</font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">14</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%;"><div style="margin-bottom:0.1pt;"><font><br></font></div></div><div style="text-indent:-36pt;padding-left:77pt;padding-right:3.35pt;text-align:justify;margin-top:0.55pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(ii)         I UNDERSTAND ALL OF ITS TERMS AND KNOW THAT I AM GIVING UP IMPORTANT RIGHTS, INCLUDING BUT NOT LIMITED TO, RIGHTS UNDER THE AGE DISCRIMINATION IN EMPLOYMENT ACT OF 1967, AS AMENDED&#59;</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:41pt;padding-right:162.9pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(iii)        I VOLUNTARILY CONSENT TO EVERYTHING IN IT&#59;</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:77pt;padding-right:3.4pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(iv)        THE COMPANY IS HEREBY ADVISING ME TO CONSULT WITH AN ATTORNEY BEFORE EXECUTING IT, I HAVE HAD THE OPPORTUNITY TO SO CONSULT, AND HAVE AVAILED MYSELF OF SUCH ADVICE TO THE EXTENT I HAVE DEEMED NECESSARY TO MAKE A VOLUNTARY AND INFORMED CHOICE TO EXECUTE THIS RELEASE&#59;</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:-36pt;padding-left:77pt;padding-right:3.35pt;text-align:justify;margin-top:4.05pt;margin-bottom:0.1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(v)         I HAVE HAD AT LEAST TWENTY ONE (21) DAYS &#91;45 DAYS IN CONNECTION WITH A GROUP TERMINATION OR EXIT INCENTIVE PLAN&#93; FOLLOWING THE DATE OF TERMINATION OF MY EMPLOYMENT TO CONSIDER THIS RELEASE&#59;</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:77pt;padding-right:3.35pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(vi)       CHANGES TO THIS RELEASE, WHETHER MATERIAL OR IMMATERIAL, DO NOT RESTART THE RUNNING OF THE 21-DAY &#91;OR 45 DAY&#93; CONSIDERATION PERIOD&#59;</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:77pt;padding-right:3.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;">(vii)      I UNDERSTAND THAT I HAVE SEVEN (7) DAYS AFTER THE EXECUTION OF THIS RELEASE TO REVOKE IT, SUCH REVOCATION TO BE RECEIVED IN WRITING BY THE COMPANY BY THE END OF THE SEVENTH DAY AFTER THE DATE HEREOF, AND THAT THIS RELEASE SHALL NOT BECOME EFFECTIVE OR ENFORCEABLE UNTIL THE REVOCATION PERIOD HAS EXPIRED&#59;</font></div><div style="margin-top:0.75pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:77pt;padding-right:3.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;">(viii)      I HAVE SIGNED THIS RELEASE KNOWINGLY AND VOLUNTARILY AND WITH THE ADVICE OF ANY COUNSEL RETAINED TO ADVISE ME WITH RESPECT TO IT&#59; AND</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:77pt;padding-right:3.35pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(ix)        I AGREE THAT THE PROVISIONS OF THIS RELEASE MAY NOT BE AMENDED, WAIVED OR MODIFIED EXCEPT BY AN INSTRUMENT IN WRITING SIGNED BY AN AUTHORIZED REPRESENTATIVE OF THE COMPANY AND BY ME.</font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="padding-left:5pt;padding-right:-1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">DATED AS OF </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;"> &#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;">, 20</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration: underline;"> &#160;</font></div><div><font><br></font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="padding-left:5pt;padding-right:-1pt;margin-top:1.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#91;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Name</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#93;</font></div><div style="position:relative;width:100%;height:62pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;margin-bottom:0.1pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">15</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%;"> -</font></div><div style="margin-bottom:0.1pt;"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>8
<FILENAME>ex3112020063010-qng.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="if16689144947483aabab1d1695d520b1_1"></div><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EXHIBIT 31.1</font></div><div style="text-indent:36pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%;">PURSUANT TO</font></div><div style="text-align:center;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:justify;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I, Kenneth Sim, M.D., certify that&#58;</font></div><div style="text-indent:-27pt;padding-left:36pt;text-align:justify;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt;">I have reviewed this annual report on Form 10-Q of Apollo Medical Holdings, Inc.&#59;</font></div><div style="text-indent:-27pt;padding-left:36pt;text-align:justify;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-indent:-27pt;padding-left:36pt;text-align:justify;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-indent:-27pt;padding-left:36pt;text-align:justify;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-indent:-27pt;padding-left:45pt;text-align:justify;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:-27pt;padding-left:45pt;text-align:justify;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:-27pt;padding-left:45pt;text-align:justify;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:-27pt;padding-left:45pt;text-align:justify;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-indent:-27pt;padding-left:36pt;text-align:justify;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-indent:-27pt;padding-left:45pt;text-align:justify;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:-27pt;padding-left:45pt;text-align:justify;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:6.052%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:36.799%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:51.149%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">August 7, 2020</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Kenneth Sim</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Kenneth Sim</font></div><div style="text-align:center;margin-top:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Executive Chairman and Co-Chief Executive Officer</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">(Principal Executive Officer)</font></div></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>9
<FILENAME>ex3122020063010-qng.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i2688b10669a64f90bf3bf8b4693a3ccd_1"></div><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EXHIBIT 31.2</font></div><div style="text-indent:36pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%;">PURSUANT TO</font></div><div style="text-align:center;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:justify;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I, Thomas Lam, M.D., certify that&#58;</font></div><div style="text-indent:-27pt;padding-left:36pt;text-align:justify;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt;">I have reviewed this annual report on Form 10-Q of Apollo Medical Holdings, Inc.&#59;</font></div><div style="text-indent:-27pt;padding-left:36pt;text-align:justify;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-indent:-27pt;padding-left:36pt;text-align:justify;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-indent:-27pt;padding-left:36pt;text-align:justify;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-indent:-27pt;padding-left:45pt;text-align:justify;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:-27pt;padding-left:45pt;text-align:justify;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:-27pt;padding-left:45pt;text-align:justify;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:-27pt;padding-left:45pt;text-align:justify;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-indent:-27pt;padding-left:36pt;text-align:justify;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-indent:-27pt;padding-left:45pt;text-align:justify;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:-27pt;padding-left:45pt;text-align:justify;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:6.052%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:36.799%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:51.149%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">August 7, 2020</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Thomas Lam</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Thomas Lam</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Co-Chief Executive Officer and President</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">(Principal Executive Officer)</font></div></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.3
<SEQUENCE>10
<FILENAME>ex3132020063010-qng.htm
<DESCRIPTION>EX-31.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i4a0aaf602ac74509870d2348335365d6_1"></div><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EXHIBIT 31.3</font></div><div style="text-align:center;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%;">PURSUANT TO</font></div><div style="text-align:center;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I, Eric Chin, certify that&#58;</font></div><div style="text-indent:-27pt;padding-left:36pt;text-align:justify;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt;">I have reviewed this annual report on Form 10-Q of Apollo Medical Holdings, Inc.&#59;</font></div><div style="text-indent:-27pt;padding-left:36pt;text-align:justify;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-indent:-27pt;padding-left:36pt;text-align:justify;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-indent:-27pt;padding-left:36pt;text-align:justify;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-indent:-27pt;padding-left:45pt;text-align:justify;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:-27pt;padding-left:45pt;text-align:justify;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:-27pt;padding-left:45pt;text-align:justify;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:-27pt;padding-left:45pt;text-align:justify;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-indent:-27pt;padding-left:36pt;text-align:justify;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-indent:-27pt;padding-left:45pt;text-align:justify;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:-27pt;padding-left:45pt;text-align:justify;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:6.052%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:36.799%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:51.149%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">August 7, 2020</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Eric Chin</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Eric Chin</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Chief Financial Officer and Interim Co-Chief Operating Officer</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">(Principal Financial Officer)</font></div></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>11
<FILENAME>ex322020063010-qng.htm
<DESCRIPTION>EX-32
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i5a7096d99c2a4f7e9f1c7294cfaf1061_1"></div><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EXHIBIT 32</font></div><div style="text-indent:36pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICERS AND PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PURSUANT TO</font></div><div><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">18 U.S.C. SECTION 1350.</font></div><div><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">AS ADOPTED PURSUANT TO</font></div><div><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-indent:36pt;text-align:justify;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I, Kenneth Sim, M.D., certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report on Form 10-Q of Apollo Medical Holdings, Inc. for the quarter ended June&#160;30, 2020, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of Apollo Medical Holdings, Inc.</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:3.417%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:37.092%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:53.491%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58; </font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:justify;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">August 7, 2020</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Kenneth Sim</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Kenneth Sim</font></div><div style="text-align:center;margin-top:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Executive Chairman and Co-Chief Executive Officer</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">(Principal Executive Officer)</font></div></td></tr></table></div><div style="text-indent:36pt;text-align:justify;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I, Thomas Lam, M.D., certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report on Form 10-Q of Apollo Medical Holdings, Inc. for the quarter ended June&#160;30, 2020, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of Apollo Medical Holdings, Inc.</font></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:3.417%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:37.092%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:53.491%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58; </font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:justify;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">August 7, 2020</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Thomas Lam</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Thomas Lam</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Co-Chief Executive Officer and President</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">(Principal Executive Officer)</font></div></td></tr></table></div><div style="text-indent:36pt;text-align:justify;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I, Eric Chin, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report on Form 10-Q of Apollo Medical Holdings, Inc. for the quarter ended June&#160;30, 2020, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of Apollo Medical Holdings, Inc.</font></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:3.417%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:37.092%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:53.491%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58; </font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:justify;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">August 7, 2020</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Eric Chin</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Eric Chin</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Chief Financial Officer and Interim Co-Chief Operating Officer</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">(Principal Financial Officer)</font></div></td></tr></table></div><div style="text-align:justify;"><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>12
<FILENAME>ameh-20200630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:b88c77a1-c027-414b-9d80-e41583dc701a,g:39bb5244-cfb0-4a0f-b0d7-a52c48426910-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ameh="http://www.apollomed.net/20200630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.apollomed.net/20200630">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ameh-20200630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ameh-20200630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ameh-20200630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ameh-20200630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformation" roleURI="http://www.apollomed.net/role/DocumentandEntityInformation">
        <link:definition>0001001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSUNAUDITED" roleURI="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED">
        <link:definition>1001002 - Statement - CONSOLIDATED BALANCE SHEETS (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" roleURI="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical">
        <link:definition>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED">
        <link:definition>1003004 - Statement - CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED" roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED">
        <link:definition>1004005 - Statement - CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS' EQUITY (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED">
        <link:definition>1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusiness" roleURI="http://www.apollomed.net/role/DescriptionofBusiness">
        <link:definition>2101101 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails">
        <link:definition>2402401 - Disclosure - Description of Business - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPolicies" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables">
        <link:definition>2305301 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>2406402 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails">
        <link:definition>2407403 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information, Performance Obligation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails_1" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails_1">
        <link:definition>2407403 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information, Performance Obligation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails">
        <link:definition>2408404 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Disaggregation of Revenue by Each Payor Type (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails">
        <link:definition>2409405 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Contributions to Revenue and Receivables by Payor (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails">
        <link:definition>2410406 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Carrying Amounts and Fair Values of Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsandGoodwill" roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwill">
        <link:definition>2111103 - Disclosure - Business Combinations and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsandGoodwillTables" roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwillTables">
        <link:definition>2312302 - Disclosure - Business Combinations and Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsandGoodwillAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails">
        <link:definition>2413407 - Disclosure - Business Combinations and Goodwill - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails" roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails">
        <link:definition>2414408 - Disclosure - Business Combinations and Goodwill - Identifiable Assets Acquired and Liabilities Assumed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsandGoodwillSummaryofGoodwillDetails" roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwillSummaryofGoodwillDetails">
        <link:definition>2415409 - Disclosure - Business Combinations and Goodwill - Summary of Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNet" roleURI="http://www.apollomed.net/role/IntangibleAssetsNet">
        <link:definition>2116104 - Disclosure - Intangible Assets, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetTables" roleURI="http://www.apollomed.net/role/IntangibleAssetsNetTables">
        <link:definition>2317303 - Disclosure - Intangible Assets, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetScheduleofIntangibleAssetsDetails" roleURI="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails">
        <link:definition>2418410 - Disclosure - Intangible Assets, Net - Schedule of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1" roleURI="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1">
        <link:definition>2418410 - Disclosure - Intangible Assets, Net - Schedule of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails">
        <link:definition>2419411 - Disclosure - Intangible Assets, Net - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetFutureAmortizationExpenseDetails" roleURI="http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails">
        <link:definition>2420412 - Disclosure - Intangible Assets, Net - Future Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinOtherEntitiesEquityMethod" roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethod">
        <link:definition>2121105 - Disclosure - Investments in Other Entities &#8212; Equity Method</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinOtherEntitiesEquityMethodTables" roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodTables">
        <link:definition>2322304 - Disclosure - Investments in Other Entities &#8212; Equity Method (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails" roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails">
        <link:definition>2423413 - Disclosure - Investments in Other Entities &#8212; Equity Method - Equity Method Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails">
        <link:definition>2424414 - Disclosure - Investments in Other Entities &#8212; Equity Method - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinOtherEntitiesEquityMethodGainonSaleDetails" roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodGainonSaleDetails">
        <link:definition>2425415 - Disclosure - Investments in Other Entities &#8212; Equity Method - Gain on Sale (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails" roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails">
        <link:definition>2426416 - Disclosure - Investments in Other Entities &#8212; Equity Method - Summarized Balance Sheets and Statements of Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LoanReceivableandLoanReceivableRelatedParties" roleURI="http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedParties">
        <link:definition>2127106 - Disclosure - Loan Receivable and Loan Receivable &#8211; Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails">
        <link:definition>2428417 - Disclosure - Loan Receivable and Loan Receivable &#8211; Related Parties - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedExpenses" roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpenses">
        <link:definition>2129107 - Disclosure - Accounts Payable and Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedExpensesTables" roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesTables">
        <link:definition>2330305 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails" roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails">
        <link:definition>2431418 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalLiabilities" roleURI="http://www.apollomed.net/role/MedicalLiabilities">
        <link:definition>2132108 - Disclosure - Medical Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalLiabilitiesTables" roleURI="http://www.apollomed.net/role/MedicalLiabilitiesTables">
        <link:definition>2333306 - Disclosure - Medical Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails" roleURI="http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails">
        <link:definition>2434419 - Disclosure - Medical Liabilities - Schedule of Medical Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditFacilityBankLoanandLinesofCredit" roleURI="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCredit">
        <link:definition>2135109 - Disclosure - Credit Facility, Bank Loan and Lines of Credit</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditFacilityBankLoanandLinesofCreditTables" roleURI="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditTables">
        <link:definition>2336307 - Disclosure - Credit Facility, Bank Loan and Lines of Credit (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails" roleURI="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails">
        <link:definition>2437420 - Disclosure - Credit Facility, Bank Loan and Lines of Credit - Credit Facility (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails" roleURI="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails">
        <link:definition>2438421 - Disclosure - Credit Facility, Bank Loan and Lines of Credit - Schedule of Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails">
        <link:definition>2439422 - Disclosure - Credit Facility, Bank Loan and Lines of Credit - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MezzanineandStockholdersEquity" roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquity">
        <link:definition>2140110 - Disclosure - Mezzanine and Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MezzanineandStockholdersEquityTables" roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquityTables">
        <link:definition>2341308 - Disclosure - Mezzanine and Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MezzanineandStockholdersEquityAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails">
        <link:definition>2442423 - Disclosure - Mezzanine and Stockholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails" roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails">
        <link:definition>2443424 - Disclosure - Mezzanine and Stockholders' Equity - Schedule of Stock Options Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MezzanineandStockholdersEquityStockOptionActivityUnderBlackScholesOptionPricingModelDetails" roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquityStockOptionActivityUnderBlackScholesOptionPricingModelDetails">
        <link:definition>2444425 - Disclosure - Mezzanine and Stockholders' Equity - Stock Option Activity Under Black-Scholes Option Pricing Model (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MezzanineandStockholdersEquitySummaryofWarrantDetails" roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquitySummaryofWarrantDetails">
        <link:definition>2445426 - Disclosure - Mezzanine and Stockholders' Equity - Summary of Warrant (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MezzanineandStockholdersEquityWarrantsDetails" roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquityWarrantsDetails">
        <link:definition>2446427 - Disclosure - Mezzanine and Stockholders' Equity - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.apollomed.net/role/CommitmentsandContingencies">
        <link:definition>2147111 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails">
        <link:definition>2448428 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.apollomed.net/role/RelatedPartyTransactions">
        <link:definition>2149112 - Disclosure - Related-Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsTables" roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsTables">
        <link:definition>2350309 - Disclosure - Related-Party Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>2451429 - Disclosure - Related-Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails" roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails">
        <link:definition>2452430 - Disclosure - Related-Party Transactions - Fees Incurred and Income Received (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.apollomed.net/role/IncomeTaxes">
        <link:definition>2153113 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://www.apollomed.net/role/EarningsPerShare">
        <link:definition>2154114 - Disclosure - Earnings Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.apollomed.net/role/EarningsPerShareTables">
        <link:definition>2355310 - Disclosure - Earnings Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails">
        <link:definition>2456431 - Disclosure - Earnings Per Share - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareEarningsPerShareComputationsDetails" roleURI="http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails">
        <link:definition>2457432 - Disclosure - Earnings Per Share - Earnings Per Share Computations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails" roleURI="http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails">
        <link:definition>2458433 - Disclosure - Earnings Per Share - Shares Included in Diluted Earnings Per Share Computations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="VariableInterestEntitiesVIEs" roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEs">
        <link:definition>2159115 - Disclosure - Variable Interest Entities (VIEs)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="VariableInterestEntitiesVIEsTables" roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables">
        <link:definition>2360311 - Disclosure - Variable Interest Entities (VIEs) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="VariableInterestEntitiesVIEsDetails" roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails">
        <link:definition>2461434 - Disclosure - Variable Interest Entities (VIEs) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.apollomed.net/role/Leases">
        <link:definition>2162116 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.apollomed.net/role/LeasesTables">
        <link:definition>2363312 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesAdditionalinformationDetails" roleURI="http://www.apollomed.net/role/LeasesAdditionalinformationDetails">
        <link:definition>2464435 - Disclosure - Leases - Additional information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesComponentsofLeaseExpenseDetails" roleURI="http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails">
        <link:definition>2465436 - Disclosure - Leases - Components of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesOtherInformationRelatedtoLeasesDetails" roleURI="http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails">
        <link:definition>2466437 - Disclosure - Leases - Other Information Related to Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails" roleURI="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails">
        <link:definition>2467438 - Disclosure - Leases - Future Minimum Payments Under Non-cancelable Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1" roleURI="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1">
        <link:definition>2467438 - Disclosure - Leases - Future Minimum Payments Under Non-cancelable Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" abstract="false" name="IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentsContribution" abstract="false" name="EquityMethodInvestmentsContribution" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_CreditAgreementMember" abstract="true" name="CreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_OneMSOInc.Member" abstract="true" name="OneMSOInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_StockIssuedDuringPeriodProxyVotesPercentage" abstract="false" name="StockIssuedDuringPeriodProxyVotesPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ameh_UniversalCareIncMember" abstract="true" name="UniversalCareIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" abstract="false" name="ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" abstract="false" name="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_LineOfCreditFacilityGuaranteeGivenByRelatedParties" abstract="false" name="LineOfCreditFacilityGuaranteeGivenByRelatedParties" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_ConcourseDiagnosticSurgeryCenterLlcMember" abstract="true" name="ConcourseDiagnosticSurgeryCenterLlcMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_CommitmentsAndContingenciesLineItems" abstract="true" name="CommitmentsAndContingenciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" abstract="false" name="ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="ameh_ApcBusinessLoanAgreementMember" abstract="true" name="ApcBusinessLoanAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_DiagnosticMedicalGroupMember" abstract="true" name="DiagnosticMedicalGroupMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_MedicalCareCostsAbstract" abstract="true" name="MedicalCareCostsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_WarrantExercisePriceRangeThreeMember" abstract="true" name="WarrantExercisePriceRangeThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_AccountsReceivableAndNetRevenueTable" abstract="true" name="AccountsReceivableAndNetRevenueTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" abstract="false" name="InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_DebtInstrumentApprovedThresholdUseOfFunds" abstract="false" name="DebtInstrumentApprovedThresholdUseOfFunds" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_CommitmentsAndContingenciesTable" abstract="true" name="CommitmentsAndContingenciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ameh_PaymentPeriodOneMember" abstract="true" name="PaymentPeriodOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_SCHCMember" abstract="true" name="SCHCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_Dr.JayMember" abstract="true" name="Dr.JayMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_FinancingReceivableConvertibleToCommonStockPercentageOfOutstandingSharesConvertible" abstract="false" name="FinancingReceivableConvertibleToCommonStockPercentageOfOutstandingSharesConvertible" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ameh_NumberOfEnrollees" abstract="false" name="NumberOfEnrollees" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ameh_PayorAMember" abstract="true" name="PayorAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_PaymentOfRevenueMonthlyAmount" abstract="false" name="PaymentOfRevenueMonthlyAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_SummaryOfSignificantAccountingPoliciesTable" abstract="true" name="SummaryOfSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" abstract="false" name="ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" abstract="false" name="ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="ameh_AHMCMember" abstract="true" name="AHMCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_IncreaseDecreaseInOperatingLeaseAssets" abstract="false" name="IncreaseDecreaseInOperatingLeaseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_AncillaryServiceContractMember" abstract="true" name="AncillaryServiceContractMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_ContractTypeAxis" abstract="true" name="ContractTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="ameh_WarrantExercisePriceRangeOneMember" abstract="true" name="WarrantExercisePriceRangeOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_LoanReceivableTextBlock" abstract="false" name="LoanReceivableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="ameh_PayorHMember" abstract="true" name="PayorHMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" abstract="false" name="ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ameh_ClassOfWarrantOrRightExercisable" abstract="false" name="ClassOfWarrantOrRightExercisable" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_LineOfCreditFacilityAdditionalAdvances" abstract="false" name="LineOfCreditFacilityAdditionalAdvances" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_NextGenerationACOModelParticipationAgreementMember" abstract="true" name="NextGenerationACOModelParticipationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_ContractTypeDomain" abstract="true" name="ContractTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_NetworkMedicalManagementIncMember" abstract="true" name="NetworkMedicalManagementIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet" abstract="false" name="InsuranceServicesRevenueCapitationAndClaimsPaymentNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_MedicalPropertyPartnersMember" abstract="true" name="MedicalPropertyPartnersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_PayorFMember" abstract="true" name="PayorFMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_DebtInstrumentApprovalThresholdOfShareholdersForUseOfFundsPercentage" abstract="false" name="DebtInstrumentApprovalThresholdOfShareholdersForUseOfFundsPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_IncreaseDecreaseInMedicalLiabilities" abstract="false" name="IncreaseDecreaseInMedicalLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_PaymentPeriodTwoMember" abstract="true" name="PaymentPeriodTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_PayorCMember" abstract="true" name="PayorCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_MezzanineMember" abstract="true" name="MezzanineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_NMMLineOfCreditAgreementMember" abstract="true" name="NMMLineOfCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_InvestmentDeposit" abstract="false" name="InvestmentDeposit" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_MedicareMember" abstract="true" name="MedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_Dr.ArteagaMember" abstract="true" name="Dr.ArteagaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_LineOfCreditFacilityExpirationPeriodPeriodOfNotification" abstract="false" name="LineOfCreditFacilityExpirationPeriodPeriodOfNotification" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_EarningsPerShareLineItems" abstract="true" name="EarningsPerShareLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_AccountableHealthCareIPAMember" abstract="true" name="AccountableHealthCareIPAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_ClassOfWarrantOrRightIssuedInPeriod" abstract="false" name="ClassOfWarrantOrRightIssuedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_AchievaMedInc.Member" abstract="true" name="AchievaMedInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_TemporaryEquityPolicyTextBlock" abstract="false" name="TemporaryEquityPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="ameh_CriticalQualityManagementCorpMember" abstract="true" name="CriticalQualityManagementCorpMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_MarketableSecuritiesCurrentMaturityPeriod" abstract="false" name="MarketableSecuritiesCurrentMaturityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_DebtInstrumentCovenantLeverageRatioMinimum" abstract="false" name="DebtInstrumentCovenantLeverageRatioMinimum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate" abstract="false" name="FinanceReceivableModificationsSubsequentDefaultInterestRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ameh_LeaseWeightedAverageDiscountRateAbstract" abstract="true" name="LeaseWeightedAverageDiscountRateAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_OtherReceivablesFinalSettlement2018PerformanceYearMember" abstract="true" name="OtherReceivablesFinalSettlement2018PerformanceYearMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" abstract="false" name="ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_AccountsReceivableAndNetRevenueLineItems" abstract="true" name="AccountsReceivableAndNetRevenueLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_MemberRelationshipsMember" abstract="true" name="MemberRelationshipsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_CommercialMember" abstract="true" name="CommercialMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_AccountsPayableAndAccruedExpensesMember" abstract="true" name="AccountsPayableAndAccruedExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentSaleContingentConsiderationCash" abstract="false" name="EquityMethodInvestmentSaleContingentConsiderationCash" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_VotingCommonStockTwoMember" abstract="true" name="VotingCommonStockTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" abstract="true" name="LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable" abstract="false" name="LesseeFinanceLeaseTerminationPeriodIfApplicable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_PayorDMember" abstract="true" name="PayorDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_NumenLLCMember" abstract="true" name="NumenLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_CMSMember" abstract="true" name="CMSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_DeferredTaxLiabilityAdjustedToGoodwill" abstract="false" name="DeferredTaxLiabilityAdjustedToGoodwill" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_PmiocMember" abstract="true" name="PmiocMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_DescriptionOfBusinessLineItems" abstract="true" name="DescriptionOfBusinessLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" abstract="false" name="ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_BrightHealthCompanyOfCaliforniaInc.Member" abstract="true" name="BrightHealthCompanyOfCaliforniaInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_Pacific6EnterprisesMember" abstract="true" name="Pacific6EnterprisesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_PaymentMadeToRelatedParty" abstract="false" name="PaymentMadeToRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_WarrantExercisePriceRangeFourMember" abstract="true" name="WarrantExercisePriceRangeFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_MedicaidMember" abstract="true" name="MedicaidMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_CollegeStreetInvestmentLpMember" abstract="true" name="CollegeStreetInvestmentLpMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_ApaacoMember" abstract="true" name="ApaacoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" abstract="false" name="PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_DrSimAndDrLamMember" abstract="true" name="DrSimAndDrLamMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_WorkingCapitalContribution" abstract="false" name="WorkingCapitalContribution" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet" abstract="false" name="AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" abstract="false" name="ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_MWNCommunityHospitalLLCMember" abstract="true" name="MWNCommunityHospitalLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentsRollForward" abstract="true" name="EquityMethodInvestmentsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised" abstract="false" name="WarrantIssuedDuringPeriodValueStockOptionsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ameh_PercentageOfFinancialGuaranteeBenchmarkAmount" abstract="false" name="PercentageOfFinancialGuaranteeBenchmarkAmount" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ameh_EquityMethodAndOtherEquityInvestmentsTextBlock" abstract="false" name="EquityMethodAndOtherEquityInvestmentsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="ameh_WeightedAverageExercisePriceWarrantsRollForward" abstract="true" name="WeightedAverageExercisePriceWarrantsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_PaymentsForMedicalCareCostsAbstract" abstract="true" name="PaymentsForMedicalCareCostsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_EarningsPerShareTable" abstract="true" name="EarningsPerShareTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ameh_NumberOfMembersOfFederallyQualifiedHealthPlans" abstract="false" name="NumberOfMembersOfFederallyQualifiedHealthPlans" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ameh_NumberOfWarrantsExercised" abstract="false" name="NumberOfWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum" abstract="false" name="DebtInstrumentCovenantInterestCoverageRatioMinimum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_AurionMember" abstract="true" name="AurionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_MinorityInterestPolicyPolicyTextBlock" abstract="false" name="MinorityInterestPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="ameh_MediPortalLLCMember" abstract="true" name="MediPortalLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_AlphaCareMedicalGroupInc.Member" abstract="true" name="AlphaCareMedicalGroupInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" abstract="false" name="ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_AmgIncMember" abstract="true" name="AmgIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_DebtInstrumentNumberOfKeyFinancialRatios" abstract="false" name="DebtInstrumentNumberOfKeyFinancialRatios" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts" abstract="false" name="DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_LeaseWeightedAverageRemainingLeaseTermAbstract" abstract="true" name="LeaseWeightedAverageRemainingLeaseTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_FinanceReceivableStatedInterestRate" abstract="false" name="FinanceReceivableStatedInterestRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ameh_FinanceLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="FinanceLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities" abstract="false" name="IncreaseDecreaseInOtherOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_SpecialtyCapitationPayableCurrent" abstract="false" name="SpecialtyCapitationPayableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_LasalleMedicalAssociatesIpaMember" abstract="true" name="LasalleMedicalAssociatesIpaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_SummaryOfSignificantAccountingPoliciesLineItems" abstract="true" name="SummaryOfSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" abstract="false" name="ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="ameh_PaymentConsultingFees" abstract="false" name="PaymentConsultingFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_PaymentPeriodThreeMember" abstract="true" name="PaymentPeriodThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_ApcLsmaMember" abstract="true" name="ApcLsmaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_MezzanineEquityAbstract" abstract="true" name="MezzanineEquityAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage" abstract="false" name="BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ameh_OtherThirdPartiesMember" abstract="true" name="OtherThirdPartiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_ApcStockOptionMember" abstract="true" name="ApcStockOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_PreferredBankMember" abstract="true" name="PreferredBankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" abstract="false" name="ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="ameh_ShareholdersAndOfficersMember" abstract="true" name="ShareholdersAndOfficersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_LmaMember" abstract="true" name="LmaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_NmmBusinessLoanAgreementMember" abstract="true" name="NmmBusinessLoanAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_RepaymentsOfBankLoanAndLinesOfCredit" abstract="false" name="RepaymentsOfBankLoanAndLinesOfCredit" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange" abstract="false" name="DebtInstrumentCovenantLeverageRatioIncrementalChange" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue" abstract="false" name="EquityMethodInvestmentSaleContingentConsiderationFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" abstract="false" name="FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_NumberOfEmployees" abstract="false" name="NumberOfEmployees" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ameh_PatientManagementPlatformMember" abstract="true" name="PatientManagementPlatformMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_SharesWarrantsRollForward" abstract="true" name="SharesWarrantsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_DescriptionOfBusinessTable" abstract="true" name="DescriptionOfBusinessTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" abstract="false" name="InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentsPurchaseOfShares" abstract="false" name="EquityMethodInvestmentsPurchaseOfShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" abstract="false" name="NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_NumberOfPatients" abstract="false" name="NumberOfPatients" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ameh_HSMSOMember" abstract="true" name="HSMSOMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_AdvancedForWorkingCapital" abstract="false" name="AdvancedForWorkingCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_AntidilutiveSecuritiesExcludedFromEarningsComputationShares" abstract="false" name="AntidilutiveSecuritiesExcludedFromEarningsComputationShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_PaymentOfRevenue" abstract="false" name="PaymentOfRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_MaverickMedicalGroupIncMember" abstract="true" name="MaverickMedicalGroupIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_PayorGMember" abstract="true" name="PayorGMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_StockIssuedDuringPeriodSharesMerger" abstract="false" name="StockIssuedDuringPeriodSharesMerger" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" abstract="true" name="ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_AggregateintrinsicvalueAbstract" abstract="true" name="AggregateintrinsicvalueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_AdvanceDiagnosticSurgeryCenterMember" abstract="true" name="AdvanceDiagnosticSurgeryCenterMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_OtherReceivablesMember" abstract="true" name="OtherReceivablesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_FinanceReceivableTermOfReceivable" abstract="false" name="FinanceReceivableTermOfReceivable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_NumberOfFamilyPracticeClinics" abstract="false" name="NumberOfFamilyPracticeClinics" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ameh_ClassOfWarrantOrRightCancelledInPeriod" abstract="false" name="ClassOfWarrantOrRightCancelledInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock" abstract="false" name="EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ameh_TermLoanAMember" abstract="true" name="TermLoanAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares" abstract="false" name="EquityMethodInvestmentSaleContingentConsiderationPreferredShares" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_AlliedPacificofCaliforniaBrokerageAccountMember" abstract="true" name="AlliedPacificofCaliforniaBrokerageAccountMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_ContractWithCustomerLiabilityRepaidCapitationReceivedAndNotEarned" abstract="false" name="ContractWithCustomerLiabilityRepaidCapitationReceivedAndNotEarned" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" abstract="false" name="ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="ameh_PayorBMember" abstract="true" name="PayorBMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_ApcShareholdersMember" abstract="true" name="ApcShareholdersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentGainOnSaleTableTextBlock" abstract="false" name="EquityMethodInvestmentGainOnSaleTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" abstract="false" name="RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_DmgMember" abstract="true" name="DmgMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_StockIssuedDuringPeriodValueRestrictedStockAwardCancelled" abstract="false" name="StockIssuedDuringPeriodValueRestrictedStockAwardCancelled" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_FiveThreeOneW.CollegeLLCMember" abstract="true" name="FiveThreeOneW.CollegeLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_APCAndAPCLSMAMember" abstract="true" name="APCAndAPCLSMAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_CDSCMember" abstract="true" name="CDSCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_FiduciaryAccountsPayableCurrent" abstract="false" name="FiduciaryAccountsPayableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_ManagementContractsMember" abstract="true" name="ManagementContractsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentOwnershipPercentageDisposed" abstract="false" name="EquityMethodInvestmentOwnershipPercentageDisposed" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable" abstract="false" name="LesseeOperatingLeaseTerminationPeriodIfApplicable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_HealthCareCapitationRevenueMember" abstract="true" name="HealthCareCapitationRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_DrJayLoanMember" abstract="true" name="DrJayLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_NumberOfWarrantsGranted" abstract="false" name="NumberOfWarrantsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_CashPaidForLeaseLiabilitiesAbstractAbstract" abstract="true" name="CashPaidForLeaseLiabilitiesAbstractAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_PayorEMember" abstract="true" name="PayorEMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_NumberOfFederallyQualifiedHealthPlans" abstract="false" name="NumberOfFederallyQualifiedHealthPlans" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" abstract="false" name="StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_SubcontractorIPAPayable" abstract="false" name="SubcontractorIPAPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_PerMemberPerMonthManagedCareContractMember" abstract="true" name="PerMemberPerMonthManagedCareContractMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_AccountsAndOtherReceivablesNumberOfAdditionalAgreements" abstract="false" name="AccountsAndOtherReceivablesNumberOfAdditionalAgreements" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ameh_NetworkMedicalManagementMember" abstract="true" name="NetworkMedicalManagementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_WeightedaverageremainingcontractualtermyearsAbstract" abstract="true" name="WeightedaverageremainingcontractualtermyearsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_AlliedPacificOfCaliforniaIPAMember" abstract="true" name="AlliedPacificOfCaliforniaIPAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_UniversalCareAcquisitionPartnersLlcMember" abstract="true" name="UniversalCareAcquisitionPartnersLlcMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" abstract="false" name="StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_HealthSourceMSOInc.Member" abstract="true" name="HealthSourceMSOInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_WarrantExercisePriceRangeTwoMember" abstract="true" name="WarrantExercisePriceRangeTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion" abstract="false" name="EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ameh_APAMHMedicalCorporationMember" abstract="true" name="APAMHMedicalCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_ApolloMedicalHoldingsIncMember" abstract="true" name="ApolloMedicalHoldingsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_PacificMedicalImagingAndOncologyCenterIncMember" abstract="true" name="PacificMedicalImagingAndOncologyCenterIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_DebtInstrumentCovenantLeverageRatioMaximum" abstract="false" name="DebtInstrumentCovenantLeverageRatioMaximum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ameh_NetworkRelationshipsMember" abstract="true" name="NetworkRelationshipsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>13
<FILENAME>ameh-20200630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:b88c77a1-c027-414b-9d80-e41583dc701a,g:39bb5244-cfb0-4a0f-b0d7-a52c48426910-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.apollomed.net/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="ameh-20200630.xsd#DocumentandEntityInformation"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/DocumentandEntityInformation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED" xlink:type="simple" xlink:href="ameh-20200630.xsd#CONSOLIDATEDBALANCESHEETSUNAUDITED"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_b124839b-aee9-49b8-9b75-386bf8c19e06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ffc5a9c9-1c4f-4b3a-94fb-b335446540ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b124839b-aee9-49b8-9b75-386bf8c19e06" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ffc5a9c9-1c4f-4b3a-94fb-b335446540ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_379bd0c0-9bf7-4e67-9e74-2c15b31b0d79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b124839b-aee9-49b8-9b75-386bf8c19e06" xlink:to="loc_us-gaap_RestrictedCashCurrent_379bd0c0-9bf7-4e67-9e74-2c15b31b0d79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_2ee51440-acd9-409c-8cea-2820f9035c80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b124839b-aee9-49b8-9b75-386bf8c19e06" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_2ee51440-acd9-409c-8cea-2820f9035c80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4b22c268-6eb4-4311-9bf7-42ed8e8907de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b124839b-aee9-49b8-9b75-386bf8c19e06" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4b22c268-6eb4-4311-9bf7-42ed8e8907de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_bce029a0-1b36-4851-8d64-81069a73ae4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b124839b-aee9-49b8-9b75-386bf8c19e06" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_bce029a0-1b36-4851-8d64-81069a73ae4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_fa8f396f-b81e-429f-8620-d837950c59b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b124839b-aee9-49b8-9b75-386bf8c19e06" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_fa8f396f-b81e-429f-8620-d837950c59b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_40c7a915-8981-4ca3-b68a-86afd055916e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b124839b-aee9-49b8-9b75-386bf8c19e06" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_40c7a915-8981-4ca3-b68a-86afd055916e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent_c5439a6c-d44e-4545-a307-c27ac493a38f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b124839b-aee9-49b8-9b75-386bf8c19e06" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetCurrent_c5439a6c-d44e-4545-a307-c27ac493a38f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesCurrent_d3122dbd-65df-490e-bfce-c1f692219be1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesReceivableRelatedPartiesCurrent"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b124839b-aee9-49b8-9b75-386bf8c19e06" xlink:to="loc_us-gaap_NotesReceivableRelatedPartiesCurrent_d3122dbd-65df-490e-bfce-c1f692219be1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a1a1bc04-67e3-4829-80da-6f490a048abd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_c4690879-323f-4cd3-adc3-7aeac2040968" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a1a1bc04-67e3-4829-80da-6f490a048abd" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_c4690879-323f-4cd3-adc3-7aeac2040968" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent_cd77a589-3516-41f2-a249-961ec6fbefff" xlink:href="ameh-20200630.xsd#ameh_FiduciaryAccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a1a1bc04-67e3-4829-80da-6f490a048abd" xlink:to="loc_ameh_FiduciaryAccountsPayableCurrent_cd77a589-3516-41f2-a249-961ec6fbefff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_731bfc7e-926f-40a2-81fc-f9cbdd28ec0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a1a1bc04-67e3-4829-80da-6f490a048abd" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_731bfc7e-926f-40a2-81fc-f9cbdd28ec0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_8c40013d-5fca-445c-bf8d-5b46634bec04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a1a1bc04-67e3-4829-80da-6f490a048abd" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_8c40013d-5fca-445c-bf8d-5b46634bec04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_59439514-d00a-4246-9fd6-fdb4e91cc937" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a1a1bc04-67e3-4829-80da-6f490a048abd" xlink:to="loc_us-gaap_DividendsPayableCurrent_59439514-d00a-4246-9fd6-fdb4e91cc937" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_914b0a54-00c5-40a8-b505-d99b0abd108c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a1a1bc04-67e3-4829-80da-6f490a048abd" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_914b0a54-00c5-40a8-b505-d99b0abd108c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_04a84de4-da5d-4555-94d2-014215eb2cbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a1a1bc04-67e3-4829-80da-6f490a048abd" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_04a84de4-da5d-4555-94d2-014215eb2cbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_7ff2a36d-0e3b-4f98-a5ad-985e652160ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a1a1bc04-67e3-4829-80da-6f490a048abd" xlink:to="loc_us-gaap_LongTermDebtCurrent_7ff2a36d-0e3b-4f98-a5ad-985e652160ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e4354c0d-ca8a-45ba-a4d0-adef76984459" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_8fcb4329-c515-4ab4-82b1-5707ffe5d0f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e4354c0d-ca8a-45ba-a4d0-adef76984459" xlink:to="loc_us-gaap_LiabilitiesCurrent_8fcb4329-c515-4ab4-82b1-5707ffe5d0f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_182bac81-be1f-4a0b-a185-e9823695d753" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e4354c0d-ca8a-45ba-a4d0-adef76984459" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_182bac81-be1f-4a0b-a185-e9823695d753" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_003eb0d5-e1cb-4610-9da9-f84cb882c9cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_312ded0d-09a3-4ad5-a091-5feea736455f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_003eb0d5-e1cb-4610-9da9-f84cb882c9cf" xlink:to="loc_us-gaap_AssetsCurrent_312ded0d-09a3-4ad5-a091-5feea736455f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_5f446821-8064-4520-a0e4-7f468c5ecee7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_003eb0d5-e1cb-4610-9da9-f84cb882c9cf" xlink:to="loc_us-gaap_AssetsNoncurrent_5f446821-8064-4520-a0e4-7f468c5ecee7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_af89c561-5456-4cdd-bba0-13c288cac040" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_6b204f94-4b53-40d7-9d01-f37795a3eae3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_af89c561-5456-4cdd-bba0-13c288cac040" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_6b204f94-4b53-40d7-9d01-f37795a3eae3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_de6b3c18-58b2-41c4-abe2-33fa80d616dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_af89c561-5456-4cdd-bba0-13c288cac040" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_de6b3c18-58b2-41c4-abe2-33fa80d616dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a777ccda-e4d7-4e15-96ed-49c0a1ee7e02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_af89c561-5456-4cdd-bba0-13c288cac040" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a777ccda-e4d7-4e15-96ed-49c0a1ee7e02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_70bf0e69-ac2f-463c-8d50-49cb2f41552d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_af89c561-5456-4cdd-bba0-13c288cac040" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_70bf0e69-ac2f-463c-8d50-49cb2f41552d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_705ff7b9-0554-4225-81e2-ffcfd36844a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_5bf12290-a336-451b-95ba-b5779e6d6c82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_705ff7b9-0554-4225-81e2-ffcfd36844a1" xlink:to="loc_us-gaap_CommonStockValue_5bf12290-a336-451b-95ba-b5779e6d6c82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_bdea8fb3-948a-4a9a-9098-17c33ef9c731" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_705ff7b9-0554-4225-81e2-ffcfd36844a1" xlink:to="loc_us-gaap_AdditionalPaidInCapital_bdea8fb3-948a-4a9a-9098-17c33ef9c731" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_58c5e2c6-2366-49a0-8994-db28557ebcc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_705ff7b9-0554-4225-81e2-ffcfd36844a1" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_58c5e2c6-2366-49a0-8994-db28557ebcc8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_bc90f481-729c-4f54-a683-4db586d30ad0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_705ff7b9-0554-4225-81e2-ffcfd36844a1" xlink:to="loc_us-gaap_PreferredStockValue_bc90f481-729c-4f54-a683-4db586d30ad0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_1684bd86-9af6-42d8-a610-45d71e22e5ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_80199ed4-2fc6-4b6d-8055-15059a2f3738" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_1684bd86-9af6-42d8-a610-45d71e22e5ca" xlink:to="loc_us-gaap_Liabilities_80199ed4-2fc6-4b6d-8055-15059a2f3738" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_7b763abe-ad30-4d1c-878d-1f0c5d1852b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_1684bd86-9af6-42d8-a610-45d71e22e5ca" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_7b763abe-ad30-4d1c-878d-1f0c5d1852b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_100f67d7-d5f0-41ea-831a-a02a4c7cff4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_1684bd86-9af6-42d8-a610-45d71e22e5ca" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_100f67d7-d5f0-41ea-831a-a02a4c7cff4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_9751ba0b-a296-48c3-92ac-801f974699ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_1684bd86-9af6-42d8-a610-45d71e22e5ca" xlink:to="loc_us-gaap_CommitmentsAndContingencies_9751ba0b-a296-48c3-92ac-801f974699ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_8f80c17d-fc35-4bc0-a159-aea86dc99716" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_2ce93c34-6d68-4999-a993-921f0df75951" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_8f80c17d-fc35-4bc0-a159-aea86dc99716" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_2ce93c34-6d68-4999-a993-921f0df75951" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_33cf9d17-3f51-4a38-9e18-acd83c13c6b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_8f80c17d-fc35-4bc0-a159-aea86dc99716" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_33cf9d17-3f51-4a38-9e18-acd83c13c6b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_07e621f9-de0b-40f7-a0ee-518e33788aff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_8f80c17d-fc35-4bc0-a159-aea86dc99716" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_07e621f9-de0b-40f7-a0ee-518e33788aff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_93dee6e3-4d7c-4030-840b-6abcf354abe0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_8f80c17d-fc35-4bc0-a159-aea86dc99716" xlink:to="loc_us-gaap_Goodwill_93dee6e3-4d7c-4030-840b-6abcf354abe0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_677f86a5-44ab-4836-a31b-36ff454a46be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_8f80c17d-fc35-4bc0-a159-aea86dc99716" xlink:to="loc_us-gaap_EquityMethodInvestments_677f86a5-44ab-4836-a31b-36ff454a46be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_954ed227-eca9-4743-a58f-ed43e4dd2784" xlink:href="ameh-20200630.xsd#ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_8f80c17d-fc35-4bc0-a159-aea86dc99716" xlink:to="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_954ed227-eca9-4743-a58f-ed43e4dd2784" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_f7af6d4f-d15f-485e-b2ed-5486d815f7d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_8f80c17d-fc35-4bc0-a159-aea86dc99716" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_f7af6d4f-d15f-485e-b2ed-5486d815f7d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_33d6cd38-c914-4846-8952-1fb142f1d70d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_8f80c17d-fc35-4bc0-a159-aea86dc99716" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_33d6cd38-c914-4846-8952-1fb142f1d70d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4c96c951-6d0d-4d38-ba4d-5fd5f1393e13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5757c837-82cd-4628-aa7f-e5d6f9e53353" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4c96c951-6d0d-4d38-ba4d-5fd5f1393e13" xlink:to="loc_us-gaap_StockholdersEquity_5757c837-82cd-4628-aa7f-e5d6f9e53353" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_684a3fbd-eb7f-464f-8690-49ae292fd73c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4c96c951-6d0d-4d38-ba4d-5fd5f1393e13" xlink:to="loc_us-gaap_MinorityInterest_684a3fbd-eb7f-464f-8690-49ae292fd73c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" xlink:type="simple" xlink:href="ameh-20200630.xsd#CONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" xlink:type="simple" xlink:href="ameh-20200630.xsd#CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_7f1c0a57-84a7-44d9-99a7-51bb3e8db554" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_da7ec5c9-afd8-455b-8dae-10930a05a85e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_7f1c0a57-84a7-44d9-99a7-51bb3e8db554" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_da7ec5c9-afd8-455b-8dae-10930a05a85e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b2fbc903-f91c-45cc-bdc7-55eef3c0c601" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_7f1c0a57-84a7-44d9-99a7-51bb3e8db554" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b2fbc903-f91c-45cc-bdc7-55eef3c0c601" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_c10072ba-6739-4500-bae9-5e7b0b3bb7b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_6accaa69-dba2-4d4f-b401-640b12cb894a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_c10072ba-6739-4500-bae9-5e7b0b3bb7b2" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_6accaa69-dba2-4d4f-b401-640b12cb894a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_b1aec3ac-f6b4-4355-9648-36e32c34b70a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_c10072ba-6739-4500-bae9-5e7b0b3bb7b2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_b1aec3ac-f6b4-4355-9648-36e32c34b70a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts_7ca9416d-5e76-45da-81ef-d78c77f1e1f4" xlink:href="ameh-20200630.xsd#ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_c10072ba-6739-4500-bae9-5e7b0b3bb7b2" xlink:to="loc_ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts_7ca9416d-5e76-45da-81ef-d78c77f1e1f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_3f5e5dfb-50af-4463-bf88-6445609cb27f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_c10072ba-6739-4500-bae9-5e7b0b3bb7b2" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_3f5e5dfb-50af-4463-bf88-6445609cb27f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_98cd0857-0c9d-4b20-b8e6-dfc4228de696" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_8ae0ab39-c6bb-456b-b6ad-1c2e58a40d06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_98cd0857-0c9d-4b20-b8e6-dfc4228de696" xlink:to="loc_us-gaap_ProfitLoss_8ae0ab39-c6bb-456b-b6ad-1c2e58a40d06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_974addf1-7157-48e8-93e4-e8cbaae19ed9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_98cd0857-0c9d-4b20-b8e6-dfc4228de696" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_974addf1-7157-48e8-93e4-e8cbaae19ed9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_64f1a52d-c0c1-4771-ac12-b8f089839b21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_850f2634-8925-44e3-848d-543c1e536431" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_64f1a52d-c0c1-4771-ac12-b8f089839b21" xlink:to="loc_us-gaap_OperatingIncomeLoss_850f2634-8925-44e3-848d-543c1e536431" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_7c5a8da8-ba3b-4929-a156-d156e4010a33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_64f1a52d-c0c1-4771-ac12-b8f089839b21" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_7c5a8da8-ba3b-4929-a156-d156e4010a33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_f5f6adb1-68ce-4743-968d-738b71e60ab4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_066c6d5f-e69f-4eea-8647-3f0909718cd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_f5f6adb1-68ce-4743-968d-738b71e60ab4" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_066c6d5f-e69f-4eea-8647-3f0909718cd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_75069558-7013-4f12-95ad-0a3c6969a6d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_f5f6adb1-68ce-4743-968d-738b71e60ab4" xlink:to="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_75069558-7013-4f12-95ad-0a3c6969a6d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_94f77f6c-566b-4709-b83a-c2dedd5a5942" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_f5f6adb1-68ce-4743-968d-738b71e60ab4" xlink:to="loc_us-gaap_InterestExpense_94f77f6c-566b-4709-b83a-c2dedd5a5942" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_cd28af18-b5bf-4c63-a981-92f956a702f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_f5f6adb1-68ce-4743-968d-738b71e60ab4" xlink:to="loc_us-gaap_InvestmentIncomeInterest_cd28af18-b5bf-4c63-a981-92f956a702f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7d1998e4-3e62-4a08-ac24-993a0254144e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_f5f6adb1-68ce-4743-968d-738b71e60ab4" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_7d1998e4-3e62-4a08-ac24-993a0254144e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b30c9506-0a25-4347-b848-29cc1c8b35c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_73db46ef-0379-48c1-879f-19a375927120" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_b30c9506-0a25-4347-b848-29cc1c8b35c1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_73db46ef-0379-48c1-879f-19a375927120" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_50330d12-4a8d-4dd7-ae95-5fbd40ec1a97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_b30c9506-0a25-4347-b848-29cc1c8b35c1" xlink:to="loc_us-gaap_CostsAndExpenses_50330d12-4a8d-4dd7-ae95-5fbd40ec1a97" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED" xlink:type="simple" xlink:href="ameh-20200630.xsd#CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" xlink:type="simple" xlink:href="ameh-20200630.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_cae5df95-3e10-40f8-989f-c839f7f0059b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1551aeb5-97b3-4f11-9361-3635ef9ed65e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_cae5df95-3e10-40f8-989f-c839f7f0059b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1551aeb5-97b3-4f11-9361-3635ef9ed65e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_63628268-4827-47d9-bd56-6e6570ba398a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_cae5df95-3e10-40f8-989f-c839f7f0059b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_63628268-4827-47d9-bd56-6e6570ba398a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_16c26b21-1181-4f0c-9162-ca7f6d5494dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_cae5df95-3e10-40f8-989f-c839f7f0059b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_16c26b21-1181-4f0c-9162-ca7f6d5494dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_de143563-a556-47a5-8f18-64ab8c619c82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_78b76e2c-5068-4d45-b5f6-1b048f897268" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_de143563-a556-47a5-8f18-64ab8c619c82" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_78b76e2c-5068-4d45-b5f6-1b048f897268" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsNoncurrent_321f3045-3404-4de3-bb29-61c7b60852fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashEquivalentsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_de143563-a556-47a5-8f18-64ab8c619c82" xlink:to="loc_us-gaap_RestrictedCashEquivalentsNoncurrent_321f3045-3404-4de3-bb29-61c7b60852fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4145b43d-5b57-4029-aba5-8391b33325c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_33d1f55e-eee8-47ea-ab93-9e73a27909ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4145b43d-5b57-4029-aba5-8391b33325c4" xlink:to="loc_us-gaap_ProfitLoss_33d1f55e-eee8-47ea-ab93-9e73a27909ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_4e96b33f-d2a7-4add-be7d-eecd6bd8e50e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4145b43d-5b57-4029-aba5-8391b33325c4" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_4e96b33f-d2a7-4add-be7d-eecd6bd8e50e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_c5487191-8856-447f-8f81-7274c1879b24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4145b43d-5b57-4029-aba5-8391b33325c4" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_c5487191-8856-447f-8f81-7274c1879b24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_b0c0ee13-f15c-4d94-8e2a-d85566b19bc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4145b43d-5b57-4029-aba5-8391b33325c4" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_b0c0ee13-f15c-4d94-8e2a-d85566b19bc5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_9aba0724-9ccf-4fd2-a249-96e96d06347b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4145b43d-5b57-4029-aba5-8391b33325c4" xlink:to="loc_us-gaap_ShareBasedCompensation_9aba0724-9ccf-4fd2-a249-96e96d06347b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_a794faea-1cf4-4f11-b6ad-e0022750e300" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4145b43d-5b57-4029-aba5-8391b33325c4" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_a794faea-1cf4-4f11-b6ad-e0022750e300" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_b172f3c7-3acc-435e-b50f-dd81f2480641" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4145b43d-5b57-4029-aba5-8391b33325c4" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_b172f3c7-3acc-435e-b50f-dd81f2480641" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_2c50214a-4bca-40f1-b14c-05e65712444d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4145b43d-5b57-4029-aba5-8391b33325c4" xlink:to="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_2c50214a-4bca-40f1-b14c-05e65712444d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_53e0a5d0-fc9b-424e-9f7d-6b1d337cf487" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4145b43d-5b57-4029-aba5-8391b33325c4" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_53e0a5d0-fc9b-424e-9f7d-6b1d337cf487" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_d484ecfb-aceb-41d0-aff6-2b3dd2ce1d34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4145b43d-5b57-4029-aba5-8391b33325c4" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_d484ecfb-aceb-41d0-aff6-2b3dd2ce1d34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_7d41ff53-1aa7-4b77-ab3c-0e53c5035a5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4145b43d-5b57-4029-aba5-8391b33325c4" xlink:to="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_7d41ff53-1aa7-4b77-ab3c-0e53c5035a5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_dc2a887b-0c8e-465a-af27-2ab71d13973a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4145b43d-5b57-4029-aba5-8391b33325c4" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_dc2a887b-0c8e-465a-af27-2ab71d13973a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_99d53655-09db-4528-9cda-f4a95be6bb9a" xlink:href="ameh-20200630.xsd#ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4145b43d-5b57-4029-aba5-8391b33325c4" xlink:to="loc_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_99d53655-09db-4528-9cda-f4a95be6bb9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInOperatingLeaseAssets_9eec08c8-2e11-40ca-bf1c-9391731b815b" xlink:href="ameh-20200630.xsd#ameh_IncreaseDecreaseInOperatingLeaseAssets"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4145b43d-5b57-4029-aba5-8391b33325c4" xlink:to="loc_ameh_IncreaseDecreaseInOperatingLeaseAssets_9eec08c8-2e11-40ca-bf1c-9391731b815b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_2805815d-446e-466e-b0e1-3cabeec36c84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4145b43d-5b57-4029-aba5-8391b33325c4" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_2805815d-446e-466e-b0e1-3cabeec36c84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_17ebccf3-a53e-4589-af8c-676872602066" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4145b43d-5b57-4029-aba5-8391b33325c4" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_17ebccf3-a53e-4589-af8c-676872602066" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable_bdbbab9f-3805-418a-a687-427cac0110e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4145b43d-5b57-4029-aba5-8391b33325c4" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable_bdbbab9f-3805-418a-a687-427cac0110e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInMedicalLiabilities_2488aa63-230c-466d-9d8e-c3a668bd4c62" xlink:href="ameh-20200630.xsd#ameh_IncreaseDecreaseInMedicalLiabilities"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4145b43d-5b57-4029-aba5-8391b33325c4" xlink:to="loc_ameh_IncreaseDecreaseInMedicalLiabilities_2488aa63-230c-466d-9d8e-c3a668bd4c62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_52cead1a-f1fb-4277-9347-153dcc89f273" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:calculationArc order="19" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4145b43d-5b57-4029-aba5-8391b33325c4" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_52cead1a-f1fb-4277-9347-153dcc89f273" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities_b2ee15b3-bc83-4fa3-b6ab-afbb75253a2d" xlink:href="ameh-20200630.xsd#ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities"/>
    <link:calculationArc order="20" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4145b43d-5b57-4029-aba5-8391b33325c4" xlink:to="loc_ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities_b2ee15b3-bc83-4fa3-b6ab-afbb75253a2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9e5b0378-8cc0-4359-a9c2-919c63564788" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_6ac9de41-a5c2-4392-bbdd-3463964042bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9e5b0378-8cc0-4359-a9c2-919c63564788" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_6ac9de41-a5c2-4392-bbdd-3463964042bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfLoansReceivable_ca69957c-e05d-4459-b40b-f6d7b17edb7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollectionOfLoansReceivable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9e5b0378-8cc0-4359-a9c2-919c63564788" xlink:to="loc_us-gaap_ProceedsFromCollectionOfLoansReceivable_ca69957c-e05d-4459-b40b-f6d7b17edb7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToFundLongtermLoansToRelatedParties_0702d806-a8b1-4560-bb62-e315795dc2b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToFundLongtermLoansToRelatedParties"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9e5b0378-8cc0-4359-a9c2-919c63564788" xlink:to="loc_us-gaap_PaymentsToFundLongtermLoansToRelatedParties_0702d806-a8b1-4560-bb62-e315795dc2b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_e1e4d056-b207-4e1d-8c26-a5767995b014" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9e5b0378-8cc0-4359-a9c2-919c63564788" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_e1e4d056-b207-4e1d-8c26-a5767995b014" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_71e4dae4-5b3b-446b-a5d3-7a5825c4bb1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9e5b0378-8cc0-4359-a9c2-919c63564788" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_71e4dae4-5b3b-446b-a5d3-7a5825c4bb1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_f74bd264-ff44-4b2d-9590-90fe4b160283" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9e5b0378-8cc0-4359-a9c2-919c63564788" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_f74bd264-ff44-4b2d-9590-90fe4b160283" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_85cdbd6f-0b1e-4ba9-b298-c26cec8de4f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9e5b0378-8cc0-4359-a9c2-919c63564788" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_85cdbd6f-0b1e-4ba9-b298-c26cec8de4f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_eaadd971-82b4-4094-8f9e-aba8d15f9f61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9e5b0378-8cc0-4359-a9c2-919c63564788" xlink:to="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_eaadd971-82b4-4094-8f9e-aba8d15f9f61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_df28c42b-1406-4de5-9043-6d981e868b08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_RepaymentsOfBankLoanAndLinesOfCredit_a0da9f81-4f43-4e27-9cc8-01d0f7455f54" xlink:href="ameh-20200630.xsd#ameh_RepaymentsOfBankLoanAndLinesOfCredit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_df28c42b-1406-4de5-9043-6d981e868b08" xlink:to="loc_ameh_RepaymentsOfBankLoanAndLinesOfCredit_a0da9f81-4f43-4e27-9cc8-01d0f7455f54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_8107bfc7-20c4-41dd-b996-d37d4397357a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_df28c42b-1406-4de5-9043-6d981e868b08" xlink:to="loc_us-gaap_PaymentsOfDividends_8107bfc7-20c4-41dd-b996-d37d4397357a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_55b157c5-dd4d-4711-a60c-ac07ca051b80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_df28c42b-1406-4de5-9043-6d981e868b08" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_55b157c5-dd4d-4711-a60c-ac07ca051b80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_ccf9d8bb-767c-496d-8952-429fb50d2a5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_df28c42b-1406-4de5-9043-6d981e868b08" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_ccf9d8bb-767c-496d-8952-429fb50d2a5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_668db7c5-382a-4966-93d5-153985830d61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_df28c42b-1406-4de5-9043-6d981e868b08" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_668db7c5-382a-4966-93d5-153985830d61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_b5762d8e-1706-49c3-880f-04b62b85dee0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_df28c42b-1406-4de5-9043-6d981e868b08" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_b5762d8e-1706-49c3-880f-04b62b85dee0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_25b13173-fd57-474f-9cc5-685d3392ed9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_df28c42b-1406-4de5-9043-6d981e868b08" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_25b13173-fd57-474f-9cc5-685d3392ed9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_a1aaf737-f7fc-4066-bbdf-c5a81ad0a570" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_df28c42b-1406-4de5-9043-6d981e868b08" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_a1aaf737-f7fc-4066-bbdf-c5a81ad0a570" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/DescriptionofBusiness" xlink:type="simple" xlink:href="ameh-20200630.xsd#DescriptionofBusiness"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/DescriptionofBusiness" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#DescriptionofBusinessAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="ameh-20200630.xsd#BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="ameh-20200630.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="ameh-20200630.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails_1" xlink:type="simple" xlink:href="ameh-20200630.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails_1"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_06ee5318-e88e-4e4a-82d5-acdb3a09ed00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_02dbe01b-b7db-4274-a944-fa8f79fd6783" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_06ee5318-e88e-4e4a-82d5-acdb3a09ed00" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_02dbe01b-b7db-4274-a944-fa8f79fd6783" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2109eacd-dad6-4c3f-933b-a38020018e70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_06ee5318-e88e-4e4a-82d5-acdb3a09ed00" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2109eacd-dad6-4c3f-933b-a38020018e70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_d26faf5c-3a5a-47ad-be63-33d459ff9c28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_06ee5318-e88e-4e4a-82d5-acdb3a09ed00" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_d26faf5c-3a5a-47ad-be63-33d459ff9c28" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwill" xlink:type="simple" xlink:href="ameh-20200630.xsd#BusinessCombinationsandGoodwill"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/BusinessCombinationsandGoodwill" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwillTables" xlink:type="simple" xlink:href="ameh-20200630.xsd#BusinessCombinationsandGoodwillTables"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/BusinessCombinationsandGoodwillTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#BusinessCombinationsandGoodwillAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_3ea113e6-f53b-4836-a138-2c8327900e30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_185d2e06-a269-462d-8953-f530efd48910" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_3ea113e6-f53b-4836-a138-2c8327900e30" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_185d2e06-a269-462d-8953-f530efd48910" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_c5e3bfc2-ede9-4893-993b-416af876c0e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_3ea113e6-f53b-4836-a138-2c8327900e30" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_c5e3bfc2-ede9-4893-993b-416af876c0e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_c81b06a5-23cf-455a-afa0-4ed93c6cdffc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_3ea113e6-f53b-4836-a138-2c8327900e30" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_c81b06a5-23cf-455a-afa0-4ed93c6cdffc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_ab645c52-7da2-46d4-8c2a-794852b7a5db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_3ea113e6-f53b-4836-a138-2c8327900e30" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_ab645c52-7da2-46d4-8c2a-794852b7a5db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f66f5a5d-0772-43c7-9649-94bcc1e55183" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_3ea113e6-f53b-4836-a138-2c8327900e30" xlink:to="loc_us-gaap_Goodwill_f66f5a5d-0772-43c7-9649-94bcc1e55183" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_d1dfb296-81e9-4877-b590-8c7856117bca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_3ea113e6-f53b-4836-a138-2c8327900e30" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_d1dfb296-81e9-4877-b590-8c7856117bca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_550eda0b-e368-4b28-a569-30768d3945ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_3ea113e6-f53b-4836-a138-2c8327900e30" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_550eda0b-e368-4b28-a569-30768d3945ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities_2b5ea0aa-9892-45e7-955f-afe05652f5bb" xlink:href="ameh-20200630.xsd#ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_3ea113e6-f53b-4836-a138-2c8327900e30" xlink:to="loc_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities_2b5ea0aa-9892-45e7-955f-afe05652f5bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities_3d793c48-0b64-48c4-bae1-fb5740607ae7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_3ea113e6-f53b-4836-a138-2c8327900e30" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities_3d793c48-0b64-48c4-bae1-fb5740607ae7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwillSummaryofGoodwillDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#BusinessCombinationsandGoodwillSummaryofGoodwillDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/BusinessCombinationsandGoodwillSummaryofGoodwillDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNet" xlink:type="simple" xlink:href="ameh-20200630.xsd#IntangibleAssetsNet"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNet" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetTables" xlink:type="simple" xlink:href="ameh-20200630.xsd#IntangibleAssetsNetTables"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#IntangibleAssetsNetScheduleofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f5eb58ba-1dd0-4acd-b15c-6b2b988b6ef6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ac562369-8a2b-44d9-a6d4-1288ac50270f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f5eb58ba-1dd0-4acd-b15c-6b2b988b6ef6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ac562369-8a2b-44d9-a6d4-1288ac50270f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_eb4adf3d-23ee-40e4-bd5a-50a0174f594b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f5eb58ba-1dd0-4acd-b15c-6b2b988b6ef6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_eb4adf3d-23ee-40e4-bd5a-50a0174f594b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_20903dc7-baec-4a67-8426-46ddd3572614" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_658447a6-4d76-4c0e-b72a-99f0b5e9bbc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_20903dc7-baec-4a67-8426-46ddd3572614" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_658447a6-4d76-4c0e-b72a-99f0b5e9bbc0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d83f3645-f770-4c01-b3e9-3fc96d7fa617" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_da75f721-e766-4c06-94be-12fa61ab4224" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d83f3645-f770-4c01-b3e9-3fc96d7fa617" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_da75f721-e766-4c06-94be-12fa61ab4224" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="ameh-20200630.xsd#IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_46e9377e-fbeb-4a95-9c70-1e0ebe8a214f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_5ab7c8a7-0f9b-43e9-8c19-b1e5a99543f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_46e9377e-fbeb-4a95-9c70-1e0ebe8a214f" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_5ab7c8a7-0f9b-43e9-8c19-b1e5a99543f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_bb4334b6-cbc1-4875-9690-d65e24256d4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_46e9377e-fbeb-4a95-9c70-1e0ebe8a214f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_bb4334b6-cbc1-4875-9690-d65e24256d4e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#IntangibleAssetsNetAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#IntangibleAssetsNetFutureAmortizationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_dfcfad44-e70c-4616-9535-2d81b7f770c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_c04b9eb5-ae99-463a-9504-6946964bb2d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_dfcfad44-e70c-4616-9535-2d81b7f770c1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_c04b9eb5-ae99-463a-9504-6946964bb2d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_201e85a5-2e1b-4278-9f05-9021791a60d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_dfcfad44-e70c-4616-9535-2d81b7f770c1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_201e85a5-2e1b-4278-9f05-9021791a60d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_6bab69b6-84e1-415a-b678-ecf5b440e9ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_dfcfad44-e70c-4616-9535-2d81b7f770c1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_6bab69b6-84e1-415a-b678-ecf5b440e9ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_2410ffa4-80d5-41c5-9bc7-281482fb17a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_dfcfad44-e70c-4616-9535-2d81b7f770c1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_2410ffa4-80d5-41c5-9bc7-281482fb17a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_fbf7f3ea-f816-4719-ae28-b983c0ced5e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_dfcfad44-e70c-4616-9535-2d81b7f770c1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_fbf7f3ea-f816-4719-ae28-b983c0ced5e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_ed477c59-207b-44aa-bb94-0b9ce7bc2bd4" xlink:href="ameh-20200630.xsd#ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_dfcfad44-e70c-4616-9535-2d81b7f770c1" xlink:to="loc_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_ed477c59-207b-44aa-bb94-0b9ce7bc2bd4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethod" xlink:type="simple" xlink:href="ameh-20200630.xsd#InvestmentsinOtherEntitiesEquityMethod"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethod" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodTables" xlink:type="simple" xlink:href="ameh-20200630.xsd#InvestmentsinOtherEntitiesEquityMethodTables"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodGainonSaleDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#InvestmentsinOtherEntitiesEquityMethodGainonSaleDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodGainonSaleDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_07ce4d79-7e38-45fd-9b3e-fce7ebd24a01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3643878c-786c-4e28-adf5-d1cbf76372d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_07ce4d79-7e38-45fd-9b3e-fce7ebd24a01" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3643878c-786c-4e28-adf5-d1cbf76372d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_9cb69fc5-58de-4402-9bba-5c427c585b12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_07ce4d79-7e38-45fd-9b3e-fce7ebd24a01" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_9cb69fc5-58de-4402-9bba-5c427c585b12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_9c074808-9186-4df5-96d0-6e53bcdbfaff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_07ce4d79-7e38-45fd-9b3e-fce7ebd24a01" xlink:to="loc_us-gaap_OtherAssetsCurrent_9c074808-9186-4df5-96d0-6e53bcdbfaff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent_b51f0f72-7444-4cbf-b73a-ba1163c38ec6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_07ce4d79-7e38-45fd-9b3e-fce7ebd24a01" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetCurrent_b51f0f72-7444-4cbf-b73a-ba1163c38ec6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_5a9555cc-99da-4d57-aa04-c24d817027cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_07ce4d79-7e38-45fd-9b3e-fce7ebd24a01" xlink:to="loc_us-gaap_RestrictedCashCurrent_5a9555cc-99da-4d57-aa04-c24d817027cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets_f2940c29-d0b7-46d6-84ba-3685057e344a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssets"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_07ce4d79-7e38-45fd-9b3e-fce7ebd24a01" xlink:to="loc_us-gaap_OtherAssets_f2940c29-d0b7-46d6-84ba-3685057e344a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_b26818db-b25e-4154-840b-76659d4bb425" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_07ce4d79-7e38-45fd-9b3e-fce7ebd24a01" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_b26818db-b25e-4154-840b-76659d4bb425" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedParties" xlink:type="simple" xlink:href="ameh-20200630.xsd#LoanReceivableandLoanReceivableRelatedParties"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedParties" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpenses" xlink:type="simple" xlink:href="ameh-20200630.xsd#AccountsPayableandAccruedExpenses"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/AccountsPayableandAccruedExpenses" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesTables" xlink:type="simple" xlink:href="ameh-20200630.xsd#AccountsPayableandAccruedExpensesTables"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_2482d7ec-a187-4bc0-aeba-43db7f61f6fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_3c040086-afc4-4dfb-99d9-03ea50a64d01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_2482d7ec-a187-4bc0-aeba-43db7f61f6fe" xlink:to="loc_us-gaap_AccountsPayableCurrent_3c040086-afc4-4dfb-99d9-03ea50a64d01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SpecialtyCapitationPayableCurrent_a6851452-0f69-4da3-80da-211e94cfe03b" xlink:href="ameh-20200630.xsd#ameh_SpecialtyCapitationPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_2482d7ec-a187-4bc0-aeba-43db7f61f6fe" xlink:to="loc_ameh_SpecialtyCapitationPayableCurrent_a6851452-0f69-4da3-80da-211e94cfe03b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SubcontractorIPAPayable_648a490f-3e68-44a4-8d02-e489e1586402" xlink:href="ameh-20200630.xsd#ameh_SubcontractorIPAPayable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_2482d7ec-a187-4bc0-aeba-43db7f61f6fe" xlink:to="loc_ameh_SubcontractorIPAPayable_648a490f-3e68-44a4-8d02-e489e1586402" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_f89419d6-25e2-461a-bcf4-885da3f3815a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_2482d7ec-a187-4bc0-aeba-43db7f61f6fe" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_f89419d6-25e2-461a-bcf4-885da3f3815a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_5e0cdb39-83cc-466b-a18b-b14d695949cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_2482d7ec-a187-4bc0-aeba-43db7f61f6fe" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_5e0cdb39-83cc-466b-a18b-b14d695949cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_5ececf5a-4f98-4086-86f9-9c5852444fe1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_2482d7ec-a187-4bc0-aeba-43db7f61f6fe" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_5ececf5a-4f98-4086-86f9-9c5852444fe1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9f3db762-36ea-4d51-8b34-60d4dd56756c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_2482d7ec-a187-4bc0-aeba-43db7f61f6fe" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9f3db762-36ea-4d51-8b34-60d4dd56756c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MedicalLiabilities" xlink:type="simple" xlink:href="ameh-20200630.xsd#MedicalLiabilities"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/MedicalLiabilities" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/MedicalLiabilitiesTables" xlink:type="simple" xlink:href="ameh-20200630.xsd#MedicalLiabilitiesTables"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/MedicalLiabilitiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_8997200e-e60c-4b58-9913-6d87d30c16d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_84cac8de-b81c-4fb4-bc49-3a4b947cf8a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_8997200e-e60c-4b58-9913-6d87d30c16d0" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_84cac8de-b81c-4fb4-bc49-3a4b947cf8a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_565a8648-cec3-400e-b38c-505dd47b2ec9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_8997200e-e60c-4b58-9913-6d87d30c16d0" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_565a8648-cec3-400e-b38c-505dd47b2ec9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_8b25dc8c-640a-4393-894e-f7e4d8377e55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_f04eb59d-7656-4fed-8862-51a3a8f754f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_8b25dc8c-640a-4393-894e-f7e4d8377e55" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_f04eb59d-7656-4fed-8862-51a3a8f754f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_e183bf89-60aa-4415-a8ef-783c223f057e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_8b25dc8c-640a-4393-894e-f7e4d8377e55" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_e183bf89-60aa-4415-a8ef-783c223f057e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCredit" xlink:type="simple" xlink:href="ameh-20200630.xsd#CreditFacilityBankLoanandLinesofCredit"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCredit" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditTables" xlink:type="simple" xlink:href="ameh-20200630.xsd#CreditFacilityBankLoanandLinesofCreditTables"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_2da45b9c-ae31-4b80-9c25-471cfc881634" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_ebdfdb16-2133-403d-8669-d112305a7f75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LineOfCredit_2da45b9c-ae31-4b80-9c25-471cfc881634" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_ebdfdb16-2133-403d-8669-d112305a7f75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_eb51e36c-29c0-4456-8915-94412d3a6d1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LineOfCredit_2da45b9c-ae31-4b80-9c25-471cfc881634" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_eb51e36c-29c0-4456-8915-94412d3a6d1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_71632d3f-d460-4c32-a24f-d719568e4796" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LineOfCredit_2da45b9c-ae31-4b80-9c25-471cfc881634" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_71632d3f-d460-4c32-a24f-d719568e4796" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_9b1334bd-0adc-43ae-b682-feec7ab8a829" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LineOfCredit_2da45b9c-ae31-4b80-9c25-471cfc881634" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_9b1334bd-0adc-43ae-b682-feec7ab8a829" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_cea900ef-a2e5-44a6-8eca-d9130c4956c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LineOfCredit_2da45b9c-ae31-4b80-9c25-471cfc881634" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_cea900ef-a2e5-44a6-8eca-d9130c4956c4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquity" xlink:type="simple" xlink:href="ameh-20200630.xsd#MezzanineandStockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/MezzanineandStockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquityTables" xlink:type="simple" xlink:href="ameh-20200630.xsd#MezzanineandStockholdersEquityTables"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/MezzanineandStockholdersEquityTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#MezzanineandStockholdersEquityAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquityStockOptionActivityUnderBlackScholesOptionPricingModelDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#MezzanineandStockholdersEquityStockOptionActivityUnderBlackScholesOptionPricingModelDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/MezzanineandStockholdersEquityStockOptionActivityUnderBlackScholesOptionPricingModelDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquitySummaryofWarrantDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#MezzanineandStockholdersEquitySummaryofWarrantDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/MezzanineandStockholdersEquitySummaryofWarrantDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquityWarrantsDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#MezzanineandStockholdersEquityWarrantsDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/MezzanineandStockholdersEquityWarrantsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="ameh-20200630.xsd#CommitmentsandContingencies"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/CommitmentsandContingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="ameh-20200630.xsd#RelatedPartyTransactions"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactions" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsTables" xlink:type="simple" xlink:href="ameh-20200630.xsd#RelatedPartyTransactionsTables"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactionsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#RelatedPartyTransactionsAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_a75bccba-ee1e-464b-a878-9b3120fa59a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_fdf4701d-be3a-436e-9f94-8e38c181534f" xlink:href="ameh-20200630.xsd#ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_a75bccba-ee1e-464b-a878-9b3120fa59a7" xlink:to="loc_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_fdf4701d-be3a-436e-9f94-8e38c181534f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementFeeExpense_1bcb36be-7a0a-4ff0-be97-8dd0e397ee93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ManagementFeeExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_a75bccba-ee1e-464b-a878-9b3120fa59a7" xlink:to="loc_us-gaap_ManagementFeeExpense_1bcb36be-7a0a-4ff0-be97-8dd0e397ee93" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IncomeTaxes" xlink:type="simple" xlink:href="ameh-20200630.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShare" xlink:type="simple" xlink:href="ameh-20200630.xsd#EarningsPerShare"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/EarningsPerShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareTables" xlink:type="simple" xlink:href="ameh-20200630.xsd#EarningsPerShareTables"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/EarningsPerShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#EarningsPerShareAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#EarningsPerShareEarningsPerShareComputationsDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_763679be-5d0a-45f8-a623-20b24245dec4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e47e0582-b694-48e5-afb1-897308686784" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_763679be-5d0a-45f8-a623-20b24245dec4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e47e0582-b694-48e5-afb1-897308686784" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_6fa6d087-2510-4d5a-a9c3-1b66bbcd521c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_763679be-5d0a-45f8-a623-20b24245dec4" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_6fa6d087-2510-4d5a-a9c3-1b66bbcd521c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEs" xlink:type="simple" xlink:href="ameh-20200630.xsd#VariableInterestEntitiesVIEs"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/VariableInterestEntitiesVIEs" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables" xlink:type="simple" xlink:href="ameh-20200630.xsd#VariableInterestEntitiesVIEsTables"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#VariableInterestEntitiesVIEsDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_35321cb0-a5ee-4249-9af7-3d02a3b83d29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_0f69af8c-8c51-48c2-9950-15c2b9c86c54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_35321cb0-a5ee-4249-9af7-3d02a3b83d29" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_0f69af8c-8c51-48c2-9950-15c2b9c86c54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent_90274a08-80cf-4ae6-9aba-1dc15aec10f5" xlink:href="ameh-20200630.xsd#ameh_FiduciaryAccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_35321cb0-a5ee-4249-9af7-3d02a3b83d29" xlink:to="loc_ameh_FiduciaryAccountsPayableCurrent_90274a08-80cf-4ae6-9aba-1dc15aec10f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_b76a52b7-88c1-49e4-b62d-529f304ef751" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_35321cb0-a5ee-4249-9af7-3d02a3b83d29" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_b76a52b7-88c1-49e4-b62d-529f304ef751" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_eb601cfb-3b2f-45c9-8718-ee2e2d0ef86e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_35321cb0-a5ee-4249-9af7-3d02a3b83d29" xlink:to="loc_us-gaap_TaxesPayableCurrent_eb601cfb-3b2f-45c9-8718-ee2e2d0ef86e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToAffiliateCurrent_ffe20363-c38f-4169-aae1-5d4eac516a36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToAffiliateCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_35321cb0-a5ee-4249-9af7-3d02a3b83d29" xlink:to="loc_us-gaap_DueToAffiliateCurrent_ffe20363-c38f-4169-aae1-5d4eac516a36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_c5b2ed08-8f4c-433a-857c-4e87d66e28a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_35321cb0-a5ee-4249-9af7-3d02a3b83d29" xlink:to="loc_us-gaap_DividendsPayableCurrent_c5b2ed08-8f4c-433a-857c-4e87d66e28a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_61aad586-fd67-4ad3-ab9e-5b7d5e77d3df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_35321cb0-a5ee-4249-9af7-3d02a3b83d29" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_61aad586-fd67-4ad3-ab9e-5b7d5e77d3df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_c861bb1a-fe41-463b-a1ae-e7a58b25bb74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_35321cb0-a5ee-4249-9af7-3d02a3b83d29" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_c861bb1a-fe41-463b-a1ae-e7a58b25bb74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_04ca8675-1be3-4812-8930-64e1c0d79c1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_55c77ace-1f96-496c-b005-d61809973249" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_04ca8675-1be3-4812-8930-64e1c0d79c1f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_55c77ace-1f96-496c-b005-d61809973249" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_022e2ae4-1a26-4f7d-bd20-5a75985f8bf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_04ca8675-1be3-4812-8930-64e1c0d79c1f" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_022e2ae4-1a26-4f7d-bd20-5a75985f8bf6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_037d6061-4a24-4b07-8e81-618285520d39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_04ca8675-1be3-4812-8930-64e1c0d79c1f" xlink:to="loc_us-gaap_Goodwill_037d6061-4a24-4b07-8e81-618285520d39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_273c1d6e-d86a-413c-ac1a-9a3ea92c5eb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_04ca8675-1be3-4812-8930-64e1c0d79c1f" xlink:to="loc_us-gaap_OtherLongTermInvestments_273c1d6e-d86a-413c-ac1a-9a3ea92c5eb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_1b95a24d-e792-4bd3-94b5-aabc48f679cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_04ca8675-1be3-4812-8930-64e1c0d79c1f" xlink:to="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_1b95a24d-e792-4bd3-94b5-aabc48f679cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_8cf63bd0-8b6a-49d9-8ac7-3a4fa868b231" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_04ca8675-1be3-4812-8930-64e1c0d79c1f" xlink:to="loc_us-gaap_EquityMethodInvestments_8cf63bd0-8b6a-49d9-8ac7-3a4fa868b231" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_b8113b9e-bef6-42a0-afc0-4ffd1f8f419b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_04ca8675-1be3-4812-8930-64e1c0d79c1f" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_b8113b9e-bef6-42a0-afc0-4ffd1f8f419b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_a74d360b-ff3f-4494-983e-7f28f3b7b120" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_04ca8675-1be3-4812-8930-64e1c0d79c1f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_a74d360b-ff3f-4494-983e-7f28f3b7b120" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b3c63254-f4e2-44d4-80d3-983b572adacf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_04ca8675-1be3-4812-8930-64e1c0d79c1f" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b3c63254-f4e2-44d4-80d3-983b572adacf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/Leases" xlink:type="simple" xlink:href="ameh-20200630.xsd#Leases"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/Leases" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesTables" xlink:type="simple" xlink:href="ameh-20200630.xsd#LeasesTables"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/LeasesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesAdditionalinformationDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#LeasesAdditionalinformationDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/LeasesAdditionalinformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#LeasesComponentsofLeaseExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_437873b1-53c1-4741-90fa-32d429d47108" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_0adfb808-1fea-4ec2-bf83-cbb57ad902eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_437873b1-53c1-4741-90fa-32d429d47108" xlink:to="loc_us-gaap_OperatingLeaseCost_0adfb808-1fea-4ec2-bf83-cbb57ad902eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_01eb5864-d5bd-410c-9c34-5fe3a47ea728" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_437873b1-53c1-4741-90fa-32d429d47108" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_01eb5864-d5bd-410c-9c34-5fe3a47ea728" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_b36bbd64-039d-4026-8815-3b8bdc5d8df2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_437873b1-53c1-4741-90fa-32d429d47108" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_b36bbd64-039d-4026-8815-3b8bdc5d8df2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_5364e1ed-70a9-4c08-ba79-5056124d2d13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_437873b1-53c1-4741-90fa-32d429d47108" xlink:to="loc_us-gaap_SubleaseIncome_5364e1ed-70a9-4c08-ba79-5056124d2d13" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#LeasesOtherInformationRelatedtoLeasesDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_baa13480-b4a0-4f44-8dea-12273b151091" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_da6171fa-9b5d-4c99-be64-0b6e8c3166c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_baa13480-b4a0-4f44-8dea-12273b151091" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_da6171fa-9b5d-4c99-be64-0b6e8c3166c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_e88d3793-5ab4-4688-a520-a5aa6612a003" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_baa13480-b4a0-4f44-8dea-12273b151091" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_e88d3793-5ab4-4688-a520-a5aa6612a003" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_f9199c67-b3a2-4f60-a4c2-181832a600e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_baa13480-b4a0-4f44-8dea-12273b151091" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_f9199c67-b3a2-4f60-a4c2-181832a600e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_10e9b863-169c-4626-a997-9838a2ebba5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_baa13480-b4a0-4f44-8dea-12273b151091" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_10e9b863-169c-4626-a997-9838a2ebba5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_6f357db0-e7c2-49c4-9170-ab86c1a929b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_baa13480-b4a0-4f44-8dea-12273b151091" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_6f357db0-e7c2-49c4-9170-ab86c1a929b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour_ff169030-d300-474c-91d2-8bddc8a5704e" xlink:href="ameh-20200630.xsd#ameh_FinanceLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_baa13480-b4a0-4f44-8dea-12273b151091" xlink:to="loc_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour_ff169030-d300-474c-91d2-8bddc8a5704e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_976a5592-1561-475c-9321-996d42add966" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f59f3271-8f29-4ba2-9a12-6bedb7a0bd5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_976a5592-1561-475c-9321-996d42add966" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f59f3271-8f29-4ba2-9a12-6bedb7a0bd5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_072a886b-c2d8-4e58-8c43-a26b916b846e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_976a5592-1561-475c-9321-996d42add966" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_072a886b-c2d8-4e58-8c43-a26b916b846e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a917bf9c-affa-44b7-9373-dfe14487f88b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_db2a6f69-7e0f-4984-929e-dc4374b4c3d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a917bf9c-affa-44b7-9373-dfe14487f88b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_db2a6f69-7e0f-4984-929e-dc4374b4c3d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_ae9a44f8-ee16-44bc-a02f-ce35a61a4fa9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a917bf9c-affa-44b7-9373-dfe14487f88b" xlink:to="loc_us-gaap_OperatingLeaseLiability_ae9a44f8-ee16-44bc-a02f-ce35a61a4fa9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_cae383f7-998f-4863-b6e5-df3088f58d06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_907879a3-80be-4533-bdaa-e8f28acbbfff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_cae383f7-998f-4863-b6e5-df3088f58d06" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_907879a3-80be-4533-bdaa-e8f28acbbfff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_73cd648d-a52f-44be-9e42-d2f99f728369" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_cae383f7-998f-4863-b6e5-df3088f58d06" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_73cd648d-a52f-44be-9e42-d2f99f728369" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1" xlink:type="simple" xlink:href="ameh-20200630.xsd#LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_eaad3be5-ac2c-4166-8fd9-31936b58d74d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_64077f79-1be9-4eb9-8e6f-a9e81a3911f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_eaad3be5-ac2c-4166-8fd9-31936b58d74d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_64077f79-1be9-4eb9-8e6f-a9e81a3911f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_e19fb3b9-2a2a-4ca1-9f7d-fd6833e41f75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_eaad3be5-ac2c-4166-8fd9-31936b58d74d" xlink:to="loc_us-gaap_FinanceLeaseLiability_e19fb3b9-2a2a-4ca1-9f7d-fd6833e41f75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b6992686-9a2f-4359-b146-cbb3599e3305" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_3adf4b4b-d48d-4202-be9a-ac6d16b0b8d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b6992686-9a2f-4359-b146-cbb3599e3305" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_3adf4b4b-d48d-4202-be9a-ac6d16b0b8d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_22f08310-e2ae-4ef4-aac4-84b87c27fe4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b6992686-9a2f-4359-b146-cbb3599e3305" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_22f08310-e2ae-4ef4-aac4-84b87c27fe4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_86989adf-2ba1-492a-9f19-1640181a3c29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b6992686-9a2f-4359-b146-cbb3599e3305" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_86989adf-2ba1-492a-9f19-1640181a3c29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_dc4e1a36-4744-49fa-aa00-948336c034c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b6992686-9a2f-4359-b146-cbb3599e3305" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_dc4e1a36-4744-49fa-aa00-948336c034c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_9d17a932-1ec3-4c79-a726-92770d3e41d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b6992686-9a2f-4359-b146-cbb3599e3305" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_9d17a932-1ec3-4c79-a726-92770d3e41d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_4093f996-b0dc-4924-b3df-7cd4eae661f5" xlink:href="ameh-20200630.xsd#ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b6992686-9a2f-4359-b146-cbb3599e3305" xlink:to="loc_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_4093f996-b0dc-4924-b3df-7cd4eae661f5" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>14
<FILENAME>ameh-20200630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:b88c77a1-c027-414b-9d80-e41583dc701a,g:39bb5244-cfb0-4a0f-b0d7-a52c48426910-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="ameh-20200630.xsd#DocumentandEntityInformation"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/DocumentandEntityInformation" xlink:type="extended" id="i0569f063c27c4c15a86ccda9bf813765_DocumentandEntityInformation"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED" xlink:type="simple" xlink:href="ameh-20200630.xsd#CONSOLIDATEDBALANCESHEETSUNAUDITED"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED" xlink:type="extended" id="id8a4eae32e8f45e5b78755532ef181d3_CONSOLIDATEDBALANCESHEETSUNAUDITED">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4087035e-ac0f-491e-8a0f-89bd5883f7ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_2149a2be-57f9-4a10-8b49-777efd1251e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4087035e-ac0f-491e-8a0f-89bd5883f7ac" xlink:to="loc_us-gaap_AssetsAbstract_2149a2be-57f9-4a10-8b49-777efd1251e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_2f77d0d1-79fa-45b4-aad0-f90412e2caa8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2149a2be-57f9-4a10-8b49-777efd1251e6" xlink:to="loc_us-gaap_AssetsCurrentAbstract_2f77d0d1-79fa-45b4-aad0-f90412e2caa8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e030d32d-6bac-475a-aa93-bf4750fa6ef6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2f77d0d1-79fa-45b4-aad0-f90412e2caa8" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e030d32d-6bac-475a-aa93-bf4750fa6ef6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_c9cb2c22-896c-4287-9378-300308143e7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2f77d0d1-79fa-45b4-aad0-f90412e2caa8" xlink:to="loc_us-gaap_RestrictedCashCurrent_c9cb2c22-896c-4287-9378-300308143e7b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_2861480b-a4eb-4bcf-9831-c0d31b303338" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2f77d0d1-79fa-45b4-aad0-f90412e2caa8" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_2861480b-a4eb-4bcf-9831-c0d31b303338" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_a2553d19-15ee-49a8-80b6-1048da549c79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2f77d0d1-79fa-45b4-aad0-f90412e2caa8" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_a2553d19-15ee-49a8-80b6-1048da549c79" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_e10822cb-b08a-4d17-96c6-c3be62e6d0db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2f77d0d1-79fa-45b4-aad0-f90412e2caa8" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_e10822cb-b08a-4d17-96c6-c3be62e6d0db" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_ea942f0b-e028-496f-acb1-a1fb83624f71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2f77d0d1-79fa-45b4-aad0-f90412e2caa8" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_ea942f0b-e028-496f-acb1-a1fb83624f71" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f56890f8-d8ee-4e92-a0a1-e1ea700e0468" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2f77d0d1-79fa-45b4-aad0-f90412e2caa8" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f56890f8-d8ee-4e92-a0a1-e1ea700e0468" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent_25419234-419d-4483-9865-55089962af49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2f77d0d1-79fa-45b4-aad0-f90412e2caa8" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetCurrent_25419234-419d-4483-9865-55089962af49" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesCurrent_4c654832-08fa-4bc7-9e0f-a203b71c57ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesReceivableRelatedPartiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2f77d0d1-79fa-45b4-aad0-f90412e2caa8" xlink:to="loc_us-gaap_NotesReceivableRelatedPartiesCurrent_4c654832-08fa-4bc7-9e0f-a203b71c57ba" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c58325ac-d8a1-4f68-a172-44f16dc522c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2f77d0d1-79fa-45b4-aad0-f90412e2caa8" xlink:to="loc_us-gaap_AssetsCurrent_c58325ac-d8a1-4f68-a172-44f16dc522c2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_27fd2b08-4c75-4f02-8794-f4681b0aed37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2149a2be-57f9-4a10-8b49-777efd1251e6" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_27fd2b08-4c75-4f02-8794-f4681b0aed37" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_6b24c6fd-9c67-496c-a490-60e93ceb84be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_27fd2b08-4c75-4f02-8794-f4681b0aed37" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_6b24c6fd-9c67-496c-a490-60e93ceb84be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_77a8db26-4e3c-4e51-abc4-9880a6bb2e55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_27fd2b08-4c75-4f02-8794-f4681b0aed37" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_77a8db26-4e3c-4e51-abc4-9880a6bb2e55" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_4b6f3337-2cf4-43c5-87eb-9a9430f3279b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_27fd2b08-4c75-4f02-8794-f4681b0aed37" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_4b6f3337-2cf4-43c5-87eb-9a9430f3279b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_09e54724-37a3-4c6f-a298-1bef6aef36fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_27fd2b08-4c75-4f02-8794-f4681b0aed37" xlink:to="loc_us-gaap_Goodwill_09e54724-37a3-4c6f-a298-1bef6aef36fa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_ce29eaa6-c064-4016-9338-3202bf906a3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_27fd2b08-4c75-4f02-8794-f4681b0aed37" xlink:to="loc_us-gaap_EquityMethodInvestments_ce29eaa6-c064-4016-9338-3202bf906a3f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_8786b4cc-1867-4284-96e3-07b19033d298" xlink:href="ameh-20200630.xsd#ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_27fd2b08-4c75-4f02-8794-f4681b0aed37" xlink:to="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_8786b4cc-1867-4284-96e3-07b19033d298" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_d36f0eab-b17c-4609-8af9-d58c715d0768" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_27fd2b08-4c75-4f02-8794-f4681b0aed37" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_d36f0eab-b17c-4609-8af9-d58c715d0768" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_1131ef14-68da-4de8-9233-dcb824adb1d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_27fd2b08-4c75-4f02-8794-f4681b0aed37" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_1131ef14-68da-4de8-9233-dcb824adb1d9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_1aaa00dd-8dd2-44d6-a6d9-ea27a5b34336" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_27fd2b08-4c75-4f02-8794-f4681b0aed37" xlink:to="loc_us-gaap_AssetsNoncurrent_1aaa00dd-8dd2-44d6-a6d9-ea27a5b34336" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_53f9af42-b9fa-403a-81b0-285e5ff74ea0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2149a2be-57f9-4a10-8b49-777efd1251e6" xlink:to="loc_us-gaap_Assets_53f9af42-b9fa-403a-81b0-285e5ff74ea0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_563ccede-83ba-4996-9182-c8e4dbfcb55d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4087035e-ac0f-491e-8a0f-89bd5883f7ac" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_563ccede-83ba-4996-9182-c8e4dbfcb55d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_95f81445-d05c-43e0-8969-951120e0a49c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_563ccede-83ba-4996-9182-c8e4dbfcb55d" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_95f81445-d05c-43e0-8969-951120e0a49c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_b8b1078a-78d8-420f-82f8-b5615da1bcef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_95f81445-d05c-43e0-8969-951120e0a49c" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_b8b1078a-78d8-420f-82f8-b5615da1bcef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent_bc07f8fc-2ee4-49eb-9f54-749154ebb7ec" xlink:href="ameh-20200630.xsd#ameh_FiduciaryAccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_95f81445-d05c-43e0-8969-951120e0a49c" xlink:to="loc_ameh_FiduciaryAccountsPayableCurrent_bc07f8fc-2ee4-49eb-9f54-749154ebb7ec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_d2078514-1294-4c6f-9af8-ed99a71efae0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_95f81445-d05c-43e0-8969-951120e0a49c" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_d2078514-1294-4c6f-9af8-ed99a71efae0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_69909967-71fb-4b08-a1ab-8195beb95a54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_95f81445-d05c-43e0-8969-951120e0a49c" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_69909967-71fb-4b08-a1ab-8195beb95a54" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_9e984967-fce2-40a0-b646-2aad807b76e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_95f81445-d05c-43e0-8969-951120e0a49c" xlink:to="loc_us-gaap_DividendsPayableCurrent_9e984967-fce2-40a0-b646-2aad807b76e2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_36e3f616-4d1b-41e4-b6ec-189cdc8d1f03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_95f81445-d05c-43e0-8969-951120e0a49c" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_36e3f616-4d1b-41e4-b6ec-189cdc8d1f03" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_798990b4-7f9b-4861-8733-7a3c67872a6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_95f81445-d05c-43e0-8969-951120e0a49c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_798990b4-7f9b-4861-8733-7a3c67872a6c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_59c6ef8e-3167-492d-93a0-f4336404d7ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_95f81445-d05c-43e0-8969-951120e0a49c" xlink:to="loc_us-gaap_LongTermDebtCurrent_59c6ef8e-3167-492d-93a0-f4336404d7ea" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f988fa74-e130-4c71-bdc7-060d9d67e84a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_95f81445-d05c-43e0-8969-951120e0a49c" xlink:to="loc_us-gaap_LiabilitiesCurrent_f988fa74-e130-4c71-bdc7-060d9d67e84a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_516b88d3-13d9-4f55-abc3-81552b1a23d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_563ccede-83ba-4996-9182-c8e4dbfcb55d" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_516b88d3-13d9-4f55-abc3-81552b1a23d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_ba27a477-58c4-42a3-9744-b780f66c29a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_516b88d3-13d9-4f55-abc3-81552b1a23d6" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_ba27a477-58c4-42a3-9744-b780f66c29a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_1c048d63-b2ee-4299-b24e-79c0dff9089c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_516b88d3-13d9-4f55-abc3-81552b1a23d6" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_1c048d63-b2ee-4299-b24e-79c0dff9089c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1f40eac3-6c38-4395-aeb2-9dcd622f8ed4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_516b88d3-13d9-4f55-abc3-81552b1a23d6" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1f40eac3-6c38-4395-aeb2-9dcd622f8ed4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_76002bf6-90d0-4a23-a40f-faa878e6b157" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_516b88d3-13d9-4f55-abc3-81552b1a23d6" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_76002bf6-90d0-4a23-a40f-faa878e6b157" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_398db4ee-2eaf-41c4-a34a-ec626fde957c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_516b88d3-13d9-4f55-abc3-81552b1a23d6" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_398db4ee-2eaf-41c4-a34a-ec626fde957c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_0e3934fb-a9fc-48a4-906a-249447bbed63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_563ccede-83ba-4996-9182-c8e4dbfcb55d" xlink:to="loc_us-gaap_Liabilities_0e3934fb-a9fc-48a4-906a-249447bbed63" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_c9c8d99d-7234-40bb-a9a7-b2d531ee01b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_563ccede-83ba-4996-9182-c8e4dbfcb55d" xlink:to="loc_us-gaap_CommitmentsAndContingencies_c9c8d99d-7234-40bb-a9a7-b2d531ee01b5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MezzanineEquityAbstract_69d703a7-47c1-405a-808c-4fb92b465164" xlink:href="ameh-20200630.xsd#ameh_MezzanineEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_563ccede-83ba-4996-9182-c8e4dbfcb55d" xlink:to="loc_ameh_MezzanineEquityAbstract_69d703a7-47c1-405a-808c-4fb92b465164" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_fa1f259c-9a68-44cd-819c-f03dbc1487dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_MezzanineEquityAbstract_69d703a7-47c1-405a-808c-4fb92b465164" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_fa1f259c-9a68-44cd-819c-f03dbc1487dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_5c696bd1-1b22-4678-8a19-6617a7523bc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_563ccede-83ba-4996-9182-c8e4dbfcb55d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_5c696bd1-1b22-4678-8a19-6617a7523bc6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_3cdf6030-cec2-4dcf-bc1d-12dbaf804226" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_5c696bd1-1b22-4678-8a19-6617a7523bc6" xlink:to="loc_us-gaap_PreferredStockValue_3cdf6030-cec2-4dcf-bc1d-12dbaf804226" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_3ba9acf7-a7ca-4384-8402-da512b8ab85a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_5c696bd1-1b22-4678-8a19-6617a7523bc6" xlink:to="loc_us-gaap_CommonStockValue_3ba9acf7-a7ca-4384-8402-da512b8ab85a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_c13a10f7-dbe3-4e5d-9b42-096575094530" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_5c696bd1-1b22-4678-8a19-6617a7523bc6" xlink:to="loc_us-gaap_AdditionalPaidInCapital_c13a10f7-dbe3-4e5d-9b42-096575094530" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e01fe6a0-387c-408e-9c3b-2e4cb1b6c42c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_5c696bd1-1b22-4678-8a19-6617a7523bc6" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e01fe6a0-387c-408e-9c3b-2e4cb1b6c42c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c2a81856-b468-4634-b8c1-bf835ee547e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_5c696bd1-1b22-4678-8a19-6617a7523bc6" xlink:to="loc_us-gaap_StockholdersEquity_c2a81856-b468-4634-b8c1-bf835ee547e2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_9259bdc1-11e8-40ff-a4f2-85e896d7461f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_5c696bd1-1b22-4678-8a19-6617a7523bc6" xlink:to="loc_us-gaap_MinorityInterest_9259bdc1-11e8-40ff-a4f2-85e896d7461f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9138f225-402f-4282-8d6d-c306a04cad21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_5c696bd1-1b22-4678-8a19-6617a7523bc6" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9138f225-402f-4282-8d6d-c306a04cad21" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_4bd9d199-f1d7-43bd-9bdb-b7b83bf52525" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_563ccede-83ba-4996-9182-c8e4dbfcb55d" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_4bd9d199-f1d7-43bd-9bdb-b7b83bf52525" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_67f82501-f2a6-4f20-a959-f89c49a9c419" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4087035e-ac0f-491e-8a0f-89bd5883f7ac" xlink:to="loc_us-gaap_StatementTable_67f82501-f2a6-4f20-a959-f89c49a9c419" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_11cefe57-d780-4eb5-bf84-966a43babcde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_67f82501-f2a6-4f20-a959-f89c49a9c419" xlink:to="loc_us-gaap_StatementClassOfStockAxis_11cefe57-d780-4eb5-bf84-966a43babcde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_11cefe57-d780-4eb5-bf84-966a43babcde_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_11cefe57-d780-4eb5-bf84-966a43babcde" xlink:to="loc_us-gaap_ClassOfStockDomain_11cefe57-d780-4eb5-bf84-966a43babcde_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_29885690-50d7-4b34-85ca-011774a08a7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_11cefe57-d780-4eb5-bf84-966a43babcde" xlink:to="loc_us-gaap_ClassOfStockDomain_29885690-50d7-4b34-85ca-011774a08a7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_7bf9f904-f9df-4b61-8353-8fb5efb63929" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_29885690-50d7-4b34-85ca-011774a08a7d" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_7bf9f904-f9df-4b61-8353-8fb5efb63929" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_5abff7bf-11da-4592-b9e4-780cc13e3f96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_29885690-50d7-4b34-85ca-011774a08a7d" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_5abff7bf-11da-4592-b9e4-780cc13e3f96" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" xlink:type="simple" xlink:href="ameh-20200630.xsd#CONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" xlink:type="extended" id="ic7b79a1a6db64720bc64bab244441848_CONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_06845bf4-c959-42f3-a96c-4af25e854795" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_abd532d3-2168-4896-b6c9-7acd623be8f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_06845bf4-c959-42f3-a96c-4af25e854795" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_abd532d3-2168-4896-b6c9-7acd623be8f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_fd9110ba-5a62-4ea1-9707-99387ca04bac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_06845bf4-c959-42f3-a96c-4af25e854795" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_fd9110ba-5a62-4ea1-9707-99387ca04bac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_8a5d4edf-c540-42e3-ae5d-b86900ee56c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_06845bf4-c959-42f3-a96c-4af25e854795" xlink:to="loc_us-gaap_PreferredStockSharesIssued_8a5d4edf-c540-42e3-ae5d-b86900ee56c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_01d56683-4cd1-4ec3-84b5-cf1a96cf3b61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_06845bf4-c959-42f3-a96c-4af25e854795" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_01d56683-4cd1-4ec3-84b5-cf1a96cf3b61" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_b4de3018-3a94-46b3-85c8-c35ce4dfcc09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_06845bf4-c959-42f3-a96c-4af25e854795" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_b4de3018-3a94-46b3-85c8-c35ce4dfcc09" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_661c7c28-2d9c-48d8-9e2d-b8fae871452e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_06845bf4-c959-42f3-a96c-4af25e854795" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_661c7c28-2d9c-48d8-9e2d-b8fae871452e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_bc5be01d-4f00-4d36-a689-090bb4631314" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_06845bf4-c959-42f3-a96c-4af25e854795" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_bc5be01d-4f00-4d36-a689-090bb4631314" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_f57061dc-e18a-491e-9a48-0f2610198514" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_06845bf4-c959-42f3-a96c-4af25e854795" xlink:to="loc_us-gaap_TreasuryStockCommonShares_f57061dc-e18a-491e-9a48-0f2610198514" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ff8f5ee8-fd52-4860-a68a-a1cff2992840" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_06845bf4-c959-42f3-a96c-4af25e854795" xlink:to="loc_us-gaap_StatementTable_ff8f5ee8-fd52-4860-a68a-a1cff2992840" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3ebb8462-49b7-4e8e-ab47-1ab811b7e9d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ff8f5ee8-fd52-4860-a68a-a1cff2992840" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3ebb8462-49b7-4e8e-ab47-1ab811b7e9d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3ebb8462-49b7-4e8e-ab47-1ab811b7e9d0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3ebb8462-49b7-4e8e-ab47-1ab811b7e9d0" xlink:to="loc_us-gaap_ClassOfStockDomain_3ebb8462-49b7-4e8e-ab47-1ab811b7e9d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2e263eac-f3d4-444f-b4cf-52445102e36f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3ebb8462-49b7-4e8e-ab47-1ab811b7e9d0" xlink:to="loc_us-gaap_ClassOfStockDomain_2e263eac-f3d4-444f-b4cf-52445102e36f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_8522d724-2889-4634-ba86-48bbcacbc0e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2e263eac-f3d4-444f-b4cf-52445102e36f" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_8522d724-2889-4634-ba86-48bbcacbc0e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_c8068189-76ef-4ed9-98cf-7e79cab873af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2e263eac-f3d4-444f-b4cf-52445102e36f" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_c8068189-76ef-4ed9-98cf-7e79cab873af" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" xlink:type="simple" xlink:href="ameh-20200630.xsd#CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" xlink:type="extended" id="i35a40271aee6478ebc440e8b5350030a_CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_13f7d2d9-94fb-42d9-a13b-27989c21aa34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_1cc21a0f-bf19-4989-becd-155a05aae55a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_13f7d2d9-94fb-42d9-a13b-27989c21aa34" xlink:to="loc_us-gaap_RevenuesAbstract_1cc21a0f-bf19-4989-becd-155a05aae55a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_939e50e8-f8cd-4302-94ee-d0eb687899ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_1cc21a0f-bf19-4989-becd-155a05aae55a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_939e50e8-f8cd-4302-94ee-d0eb687899ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_f3e78016-0ab0-4bfe-ab68-b858079846fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_13f7d2d9-94fb-42d9-a13b-27989c21aa34" xlink:to="loc_us-gaap_OperatingExpensesAbstract_f3e78016-0ab0-4bfe-ab68-b858079846fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_3a6e2996-875f-4955-9bc1-b20a43d5a681" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f3e78016-0ab0-4bfe-ab68-b858079846fb" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_3a6e2996-875f-4955-9bc1-b20a43d5a681" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_abeabaec-9553-4492-8386-27cfec84ae6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f3e78016-0ab0-4bfe-ab68-b858079846fb" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_abeabaec-9553-4492-8386-27cfec84ae6f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts_bb084039-0936-497e-9a41-2d10572fcbed" xlink:href="ameh-20200630.xsd#ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f3e78016-0ab0-4bfe-ab68-b858079846fb" xlink:to="loc_ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts_bb084039-0936-497e-9a41-2d10572fcbed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_d22287c9-aabd-4f0b-b663-45d3f501fd65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f3e78016-0ab0-4bfe-ab68-b858079846fb" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_d22287c9-aabd-4f0b-b663-45d3f501fd65" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_7dffdaf3-d38b-427f-8545-e0fad7b0193e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f3e78016-0ab0-4bfe-ab68-b858079846fb" xlink:to="loc_us-gaap_CostsAndExpenses_7dffdaf3-d38b-427f-8545-e0fad7b0193e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c94f1868-f70c-4041-80c2-9e825546478e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_13f7d2d9-94fb-42d9-a13b-27989c21aa34" xlink:to="loc_us-gaap_OperatingIncomeLoss_c94f1868-f70c-4041-80c2-9e825546478e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_dc6f2aba-397f-4e56-afde-bc09d322bcbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_13f7d2d9-94fb-42d9-a13b-27989c21aa34" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_dc6f2aba-397f-4e56-afde-bc09d322bcbf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_0ae109ce-bedb-4ede-8f81-6c6c70be5ff1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_dc6f2aba-397f-4e56-afde-bc09d322bcbf" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_0ae109ce-bedb-4ede-8f81-6c6c70be5ff1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_87b0f755-241c-49fe-a1da-4aa91e90f326" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_dc6f2aba-397f-4e56-afde-bc09d322bcbf" xlink:to="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_87b0f755-241c-49fe-a1da-4aa91e90f326" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_e4a02435-cf9e-41d9-be73-94b984a75303" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_dc6f2aba-397f-4e56-afde-bc09d322bcbf" xlink:to="loc_us-gaap_InterestExpense_e4a02435-cf9e-41d9-be73-94b984a75303" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_86859e2c-f13f-4ffb-bf08-1b6456092d79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_dc6f2aba-397f-4e56-afde-bc09d322bcbf" xlink:to="loc_us-gaap_InvestmentIncomeInterest_86859e2c-f13f-4ffb-bf08-1b6456092d79" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_35ed27cc-d39a-4e46-a235-7516838bd0f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_dc6f2aba-397f-4e56-afde-bc09d322bcbf" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_35ed27cc-d39a-4e46-a235-7516838bd0f8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_756f1034-76b1-49a4-8189-44473925ceee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_dc6f2aba-397f-4e56-afde-bc09d322bcbf" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_756f1034-76b1-49a4-8189-44473925ceee" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_9603c55b-4116-4dd3-9b30-e26ca66f845c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_13f7d2d9-94fb-42d9-a13b-27989c21aa34" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_9603c55b-4116-4dd3-9b30-e26ca66f845c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b1979723-a70e-4fb2-a764-8ca428470d88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_13f7d2d9-94fb-42d9-a13b-27989c21aa34" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b1979723-a70e-4fb2-a764-8ca428470d88" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_fd19805e-28bf-4eac-b42b-5f9142701c38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_13f7d2d9-94fb-42d9-a13b-27989c21aa34" xlink:to="loc_us-gaap_ProfitLoss_fd19805e-28bf-4eac-b42b-5f9142701c38" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_3530f6ce-ce73-43bf-aac1-dffcc8e28ad4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_13f7d2d9-94fb-42d9-a13b-27989c21aa34" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_3530f6ce-ce73-43bf-aac1-dffcc8e28ad4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_868ae344-b512-4223-bc64-d3a9bb674643" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_13f7d2d9-94fb-42d9-a13b-27989c21aa34" xlink:to="loc_us-gaap_NetIncomeLoss_868ae344-b512-4223-bc64-d3a9bb674643" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_3a4d5164-d210-4939-8004-6de0345cfe23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_13f7d2d9-94fb-42d9-a13b-27989c21aa34" xlink:to="loc_us-gaap_EarningsPerShareBasic_3a4d5164-d210-4939-8004-6de0345cfe23" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_de446bda-b0fc-4b91-8e31-32250a8b8207" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_13f7d2d9-94fb-42d9-a13b-27989c21aa34" xlink:to="loc_us-gaap_EarningsPerShareDiluted_de446bda-b0fc-4b91-8e31-32250a8b8207" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5e1d9878-288b-46a3-a414-5e543cea84c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_13f7d2d9-94fb-42d9-a13b-27989c21aa34" xlink:to="loc_us-gaap_StatementTable_5e1d9878-288b-46a3-a414-5e543cea84c2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ee4d422f-b479-4359-bace-8be6e2eda604" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_5e1d9878-288b-46a3-a414-5e543cea84c2" xlink:to="loc_srt_ProductOrServiceAxis_ee4d422f-b479-4359-bace-8be6e2eda604" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ee4d422f-b479-4359-bace-8be6e2eda604_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ee4d422f-b479-4359-bace-8be6e2eda604" xlink:to="loc_srt_ProductsAndServicesDomain_ee4d422f-b479-4359-bace-8be6e2eda604_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7a8f0124-3823-4e1c-a638-ed2102174d10" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ee4d422f-b479-4359-bace-8be6e2eda604" xlink:to="loc_srt_ProductsAndServicesDomain_7a8f0124-3823-4e1c-a638-ed2102174d10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_HealthCareCapitationRevenueMember_09f7d947-5cc2-45ef-b840-68c127d89792" xlink:href="ameh-20200630.xsd#ameh_HealthCareCapitationRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7a8f0124-3823-4e1c-a638-ed2102174d10" xlink:to="loc_ameh_HealthCareCapitationRevenueMember_09f7d947-5cc2-45ef-b840-68c127d89792" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOtherMember_a082bbbe-9ead-489c-bcac-92f98d328569" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7a8f0124-3823-4e1c-a638-ed2102174d10" xlink:to="loc_us-gaap_HealthCareOtherMember_a082bbbe-9ead-489c-bcac-92f98d328569" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementServiceMember_c659ab3f-01a8-4b43-80eb-31b425b34f4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ManagementServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7a8f0124-3823-4e1c-a638-ed2102174d10" xlink:to="loc_us-gaap_ManagementServiceMember_c659ab3f-01a8-4b43-80eb-31b425b34f4a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCarePatientServiceMember_a322962a-da0b-41e0-b3d2-b6682283e859" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCarePatientServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7a8f0124-3823-4e1c-a638-ed2102174d10" xlink:to="loc_us-gaap_HealthCarePatientServiceMember_a322962a-da0b-41e0-b3d2-b6682283e859" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_6dc7d0e9-375c-4114-8775-5053235166da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7a8f0124-3823-4e1c-a638-ed2102174d10" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_6dc7d0e9-375c-4114-8775-5053235166da" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED" xlink:type="simple" xlink:href="ameh-20200630.xsd#CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED" xlink:type="extended" id="ifdb596e8dd7e45089fec5c55626510df_CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_18415265-84fc-47a3-8a87-c113e5bf709e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e4e80326-d9a9-4b53-948a-886a06737560" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_18415265-84fc-47a3-8a87-c113e5bf709e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e4e80326-d9a9-4b53-948a-886a06737560" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_5e0cb546-8834-483c-a9c5-b7952191c859" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_18415265-84fc-47a3-8a87-c113e5bf709e" xlink:to="loc_us-gaap_SharesOutstanding_5e0cb546-8834-483c-a9c5-b7952191c859" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity_1d4f6d21-a64f-4b3a-8dda-159828b3c09c" xlink:href="ameh-20200630.xsd#ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_18415265-84fc-47a3-8a87-c113e5bf709e" xlink:to="loc_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity_1d4f6d21-a64f-4b3a-8dda-159828b3c09c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredParValueMethod_a2809336-7f27-47ee-ae40-9fd93bac17ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredParValueMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_18415265-84fc-47a3-8a87-c113e5bf709e" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredParValueMethod_a2809336-7f27-47ee-ae40-9fd93bac17ba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_d734f21e-1057-47bd-b057-02523d0dd0de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_18415265-84fc-47a3-8a87-c113e5bf709e" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_d734f21e-1057-47bd-b057-02523d0dd0de" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_59f1fcaf-a3b8-4fd6-b91c-5ce57731df30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_18415265-84fc-47a3-8a87-c113e5bf709e" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_59f1fcaf-a3b8-4fd6-b91c-5ce57731df30" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_7be7d6c6-930c-4af0-b1e1-d0b65da6b464" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_18415265-84fc-47a3-8a87-c113e5bf709e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_7be7d6c6-930c-4af0-b1e1-d0b65da6b464" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_13320dac-92c0-490b-afcc-86c405a18cac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_18415265-84fc-47a3-8a87-c113e5bf709e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_13320dac-92c0-490b-afcc-86c405a18cac" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants_a0051437-221b-4960-a578-ea3f6c4038b5" xlink:href="ameh-20200630.xsd#ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_18415265-84fc-47a3-8a87-c113e5bf709e" xlink:to="loc_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants_a0051437-221b-4960-a578-ea3f6c4038b5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants_c84e2025-deae-4420-8219-5a027fc2898c" xlink:href="ameh-20200630.xsd#ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_18415265-84fc-47a3-8a87-c113e5bf709e" xlink:to="loc_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants_c84e2025-deae-4420-8219-5a027fc2898c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_84a84445-1db1-45a4-990b-111b302997f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_18415265-84fc-47a3-8a87-c113e5bf709e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_84a84445-1db1-45a4-990b-111b302997f1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_d505046f-b3bf-44f7-869e-9a177026940e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_18415265-84fc-47a3-8a87-c113e5bf709e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_d505046f-b3bf-44f7-869e-9a177026940e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodValueRestrictedStockAwardCancelled_95bb19b6-f205-4c12-8501-21dbc44cede1" xlink:href="ameh-20200630.xsd#ameh_StockIssuedDuringPeriodValueRestrictedStockAwardCancelled"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_18415265-84fc-47a3-8a87-c113e5bf709e" xlink:to="loc_ameh_StockIssuedDuringPeriodValueRestrictedStockAwardCancelled_95bb19b6-f205-4c12-8501-21dbc44cede1" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_95096b40-89e2-4f52-83dc-edd2b55a14df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_18415265-84fc-47a3-8a87-c113e5bf709e" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_95096b40-89e2-4f52-83dc-edd2b55a14df" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_05c6aebb-a393-4530-8b9b-aa30154ff3c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_b2904474-b692-450d-80b4-0f13ba416e3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_194e6b2d-2646-4ea2-978c-31c6773fb661" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_18415265-84fc-47a3-8a87-c113e5bf709e" xlink:to="loc_us-gaap_StatementTable_194e6b2d-2646-4ea2-978c-31c6773fb661" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_35c154b7-400b-408e-b4c5-045f4d90dc49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_194e6b2d-2646-4ea2-978c-31c6773fb661" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_35c154b7-400b-408e-b4c5-045f4d90dc49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_35c154b7-400b-408e-b4c5-045f4d90dc49_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_35c154b7-400b-408e-b4c5-045f4d90dc49" xlink:to="loc_us-gaap_EquityComponentDomain_35c154b7-400b-408e-b4c5-045f4d90dc49_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ed5281d5-554f-40ce-b5f1-d1777a919f64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_35c154b7-400b-408e-b4c5-045f4d90dc49" xlink:to="loc_us-gaap_EquityComponentDomain_ed5281d5-554f-40ce-b5f1-d1777a919f64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_87a3a393-48a0-4d6f-82cc-b6e6e3bb2ef4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ed5281d5-554f-40ce-b5f1-d1777a919f64" xlink:to="loc_us-gaap_CommonStockMember_87a3a393-48a0-4d6f-82cc-b6e6e3bb2ef4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_b048999b-e3e6-417b-ac80-54d0e391de70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ed5281d5-554f-40ce-b5f1-d1777a919f64" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_b048999b-e3e6-417b-ac80-54d0e391de70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_28048779-5191-422b-b837-5d73b4faf33b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ed5281d5-554f-40ce-b5f1-d1777a919f64" xlink:to="loc_us-gaap_RetainedEarningsMember_28048779-5191-422b-b837-5d73b4faf33b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_7bdb2bb9-25af-49a2-9906-f65ded1ab708" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ed5281d5-554f-40ce-b5f1-d1777a919f64" xlink:to="loc_us-gaap_NoncontrollingInterestMember_7bdb2bb9-25af-49a2-9906-f65ded1ab708" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_9da3acc7-789e-4407-bb8d-f6cbe6e259f3" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_194e6b2d-2646-4ea2-978c-31c6773fb661" xlink:to="loc_dei_LegalEntityAxis_9da3acc7-789e-4407-bb8d-f6cbe6e259f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_9da3acc7-789e-4407-bb8d-f6cbe6e259f3_default" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_9da3acc7-789e-4407-bb8d-f6cbe6e259f3" xlink:to="loc_dei_EntityDomain_9da3acc7-789e-4407-bb8d-f6cbe6e259f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_751c458c-7dde-4320-bdd7-486638dccb3f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_9da3acc7-789e-4407-bb8d-f6cbe6e259f3" xlink:to="loc_dei_EntityDomain_751c458c-7dde-4320-bdd7-486638dccb3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MezzanineMember_db55625c-2815-4d09-b0fe-b1ca1b593734" xlink:href="ameh-20200630.xsd#ameh_MezzanineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_751c458c-7dde-4320-bdd7-486638dccb3f" xlink:to="loc_ameh_MezzanineMember_db55625c-2815-4d09-b0fe-b1ca1b593734" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" xlink:type="simple" xlink:href="ameh-20200630.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" xlink:type="extended" id="ia68bed9db76340a5a828c7904562234a_CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/DescriptionofBusiness" xlink:type="simple" xlink:href="ameh-20200630.xsd#DescriptionofBusiness"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/DescriptionofBusiness" xlink:type="extended" id="i194bcf3e337d4f6781f280d7db21c3d6_DescriptionofBusiness"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#DescriptionofBusinessAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails" xlink:type="extended" id="ie697a6ae14b24cc0a16f6f8df9cf7645_DescriptionofBusinessAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DescriptionOfBusinessLineItems_3d67e0b3-3bdd-4b7a-8252-70932d161062" xlink:href="ameh-20200630.xsd#ameh_DescriptionOfBusinessLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement_737ee347-86d6-4139-945d-07af9cd5eb8f" xlink:href="ameh-20200630.xsd#ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_3d67e0b3-3bdd-4b7a-8252-70932d161062" xlink:to="loc_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement_737ee347-86d6-4139-945d-07af9cd5eb8f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet_d8c8db4c-5e49-4ad6-b808-1b79fb350d14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_3d67e0b3-3bdd-4b7a-8252-70932d161062" xlink:to="loc_us-gaap_NotesReceivableNet_d8c8db4c-5e49-4ad6-b808-1b79fb350d14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableTermOfReceivable_cfcf20c8-2a22-43bf-9137-f442a3a3c43e" xlink:href="ameh-20200630.xsd#ameh_FinanceReceivableTermOfReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_3d67e0b3-3bdd-4b7a-8252-70932d161062" xlink:to="loc_ameh_FinanceReceivableTermOfReceivable_cfcf20c8-2a22-43bf-9137-f442a3a3c43e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableStatedInterestRate_6939457f-b2b1-4766-aa23-4e0e0a22b202" xlink:href="ameh-20200630.xsd#ameh_FinanceReceivableStatedInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_3d67e0b3-3bdd-4b7a-8252-70932d161062" xlink:to="loc_ameh_FinanceReceivableStatedInterestRate_6939457f-b2b1-4766-aa23-4e0e0a22b202" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate_501d127f-2926-4e42-a211-0bfcdedb0944" xlink:href="ameh-20200630.xsd#ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_3d67e0b3-3bdd-4b7a-8252-70932d161062" xlink:to="loc_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate_501d127f-2926-4e42-a211-0bfcdedb0944" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f37ee850-1cd7-4264-8af9-da2bf580ca0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_3d67e0b3-3bdd-4b7a-8252-70932d161062" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f37ee850-1cd7-4264-8af9-da2bf580ca0a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_31276859-5c88-41df-bbd1-dc2e82a7a2a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_3d67e0b3-3bdd-4b7a-8252-70932d161062" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_31276859-5c88-41df-bbd1-dc2e82a7a2a0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodProxyVotesPercentage_fb483f80-eb69-4b26-8bff-285c549081ec" xlink:href="ameh-20200630.xsd#ameh_StockIssuedDuringPeriodProxyVotesPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_3d67e0b3-3bdd-4b7a-8252-70932d161062" xlink:to="loc_ameh_StockIssuedDuringPeriodProxyVotesPercentage_fb483f80-eb69-4b26-8bff-285c549081ec" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_4cd35cba-3ce5-465a-a3ff-0cddd1429f79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_3d67e0b3-3bdd-4b7a-8252-70932d161062" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_4cd35cba-3ce5-465a-a3ff-0cddd1429f79" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentOwnershipPercentageDisposed_6d70d02d-72c3-478a-986c-38a245b5cb96" xlink:href="ameh-20200630.xsd#ameh_EquityMethodInvestmentOwnershipPercentageDisposed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_3d67e0b3-3bdd-4b7a-8252-70932d161062" xlink:to="loc_ameh_EquityMethodInvestmentOwnershipPercentageDisposed_6d70d02d-72c3-478a-986c-38a245b5cb96" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_3e9b3833-3785-43f6-8759-e64da14c82aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_3d67e0b3-3bdd-4b7a-8252-70932d161062" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_3e9b3833-3785-43f6-8759-e64da14c82aa" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfEnrollees_f3571b0a-c26c-448d-95ba-24a7c76bd1f4" xlink:href="ameh-20200630.xsd#ameh_NumberOfEnrollees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_3d67e0b3-3bdd-4b7a-8252-70932d161062" xlink:to="loc_ameh_NumberOfEnrollees_f3571b0a-c26c-448d-95ba-24a7c76bd1f4" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfEmployees_a8127dbc-8f7c-44dd-b3bb-3a13b2842adb" xlink:href="ameh-20200630.xsd#ameh_NumberOfEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_3d67e0b3-3bdd-4b7a-8252-70932d161062" xlink:to="loc_ameh_NumberOfEmployees_a8127dbc-8f7c-44dd-b3bb-3a13b2842adb" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStores_b62a82bc-68f6-4765-8dcb-86847737b6fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfStores"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_3d67e0b3-3bdd-4b7a-8252-70932d161062" xlink:to="loc_us-gaap_NumberOfStores_b62a82bc-68f6-4765-8dcb-86847737b6fd" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfMembersOfFederallyQualifiedHealthPlans_4e8dad7e-2673-4db0-82eb-b3842c2f0725" xlink:href="ameh-20200630.xsd#ameh_NumberOfMembersOfFederallyQualifiedHealthPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_3d67e0b3-3bdd-4b7a-8252-70932d161062" xlink:to="loc_ameh_NumberOfMembersOfFederallyQualifiedHealthPlans_4e8dad7e-2673-4db0-82eb-b3842c2f0725" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfFederallyQualifiedHealthPlans_53668b24-c688-4049-b9b1-08f54acb1daf" xlink:href="ameh-20200630.xsd#ameh_NumberOfFederallyQualifiedHealthPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_3d67e0b3-3bdd-4b7a-8252-70932d161062" xlink:to="loc_ameh_NumberOfFederallyQualifiedHealthPlans_53668b24-c688-4049-b9b1-08f54acb1daf" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_0a79eca8-8e16-4d51-845c-446cf9fbf0be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_3d67e0b3-3bdd-4b7a-8252-70932d161062" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_0a79eca8-8e16-4d51-845c-446cf9fbf0be" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_dc0bbc34-0109-4ed7-94f0-e0b2c994e9fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_3d67e0b3-3bdd-4b7a-8252-70932d161062" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_dc0bbc34-0109-4ed7-94f0-e0b2c994e9fe" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfFamilyPracticeClinics_5d477b90-e296-4925-9202-d18672d57966" xlink:href="ameh-20200630.xsd#ameh_NumberOfFamilyPracticeClinics"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_3d67e0b3-3bdd-4b7a-8252-70932d161062" xlink:to="loc_ameh_NumberOfFamilyPracticeClinics_5d477b90-e296-4925-9202-d18672d57966" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_9e29a61d-b8c7-4a63-ab48-058feadaeb51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_3d67e0b3-3bdd-4b7a-8252-70932d161062" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_9e29a61d-b8c7-4a63-ab48-058feadaeb51" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_f107a2a7-94e2-4b89-a89e-bef8f55a868d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_3d67e0b3-3bdd-4b7a-8252-70932d161062" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_f107a2a7-94e2-4b89-a89e-bef8f55a868d" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_11af16cf-6619-404e-90f4-9863eaf29062" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_3d67e0b3-3bdd-4b7a-8252-70932d161062" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_11af16cf-6619-404e-90f4-9863eaf29062" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfDebt_13547f89-f8f0-4da9-a96a-67dbdc34c4c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_3d67e0b3-3bdd-4b7a-8252-70932d161062" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfDebt_13547f89-f8f0-4da9-a96a-67dbdc34c4c9" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1_f0b19838-4102-49b2-8b43-d85948fbf656" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_3d67e0b3-3bdd-4b7a-8252-70932d161062" xlink:to="loc_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1_f0b19838-4102-49b2-8b43-d85948fbf656" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet_b439b8bd-8ef0-4776-947d-8c76fb371b17" xlink:href="ameh-20200630.xsd#ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_3d67e0b3-3bdd-4b7a-8252-70932d161062" xlink:to="loc_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet_b439b8bd-8ef0-4776-947d-8c76fb371b17" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DescriptionOfBusinessTable_a8e4cb68-04c2-4cf4-a2a7-a79f081e1f31" xlink:href="ameh-20200630.xsd#ameh_DescriptionOfBusinessTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_3d67e0b3-3bdd-4b7a-8252-70932d161062" xlink:to="loc_ameh_DescriptionOfBusinessTable_a8e4cb68-04c2-4cf4-a2a7-a79f081e1f31" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_4d6a6ac1-7d67-4ea1-82a1-305b14dcd3c3" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_a8e4cb68-04c2-4cf4-a2a7-a79f081e1f31" xlink:to="loc_dei_LegalEntityAxis_4d6a6ac1-7d67-4ea1-82a1-305b14dcd3c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_4d6a6ac1-7d67-4ea1-82a1-305b14dcd3c3_default" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_4d6a6ac1-7d67-4ea1-82a1-305b14dcd3c3" xlink:to="loc_dei_EntityDomain_4d6a6ac1-7d67-4ea1-82a1-305b14dcd3c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_bfb82b4f-a5df-4d77-bd59-812f0f287f2e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_4d6a6ac1-7d67-4ea1-82a1-305b14dcd3c3" xlink:to="loc_dei_EntityDomain_bfb82b4f-a5df-4d77-bd59-812f0f287f2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_ae343df2-643c-4cee-b9b3-791fa5a5fb41" xlink:href="ameh-20200630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_bfb82b4f-a5df-4d77-bd59-812f0f287f2e" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_ae343df2-643c-4cee-b9b3-791fa5a5fb41" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcLsmaMember_2984b013-ce73-46dc-b92a-92e3c17ebe02" xlink:href="ameh-20200630.xsd#ameh_ApcLsmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_bfb82b4f-a5df-4d77-bd59-812f0f287f2e" xlink:to="loc_ameh_ApcLsmaMember_2984b013-ce73-46dc-b92a-92e3c17ebe02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlphaCareMedicalGroupInc.Member_10a91f0f-8551-48cc-b82b-352085849389" xlink:href="ameh-20200630.xsd#ameh_AlphaCareMedicalGroupInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_bfb82b4f-a5df-4d77-bd59-812f0f287f2e" xlink:to="loc_ameh_AlphaCareMedicalGroupInc.Member_10a91f0f-8551-48cc-b82b-352085849389" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountableHealthCareIPAMember_17a0f2ae-0cba-4232-a349-27596a7f6b1e" xlink:href="ameh-20200630.xsd#ameh_AccountableHealthCareIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_bfb82b4f-a5df-4d77-bd59-812f0f287f2e" xlink:to="loc_ameh_AccountableHealthCareIPAMember_17a0f2ae-0cba-4232-a349-27596a7f6b1e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AmgIncMember_7a9671a9-ec9c-42af-92cf-b08a0a51bd36" xlink:href="ameh-20200630.xsd#ameh_AmgIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_bfb82b4f-a5df-4d77-bd59-812f0f287f2e" xlink:to="loc_ameh_AmgIncMember_7a9671a9-ec9c-42af-92cf-b08a0a51bd36" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_45a45bb6-8411-4fde-8f57-152f6fbd2185" xlink:href="ameh-20200630.xsd#ameh_UniversalCareAcquisitionPartnersLlcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_bfb82b4f-a5df-4d77-bd59-812f0f287f2e" xlink:to="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_45a45bb6-8411-4fde-8f57-152f6fbd2185" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2a451f27-a58f-4e97-b1e6-67ace330a8dd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_a8e4cb68-04c2-4cf4-a2a7-a79f081e1f31" xlink:to="loc_srt_CounterpartyNameAxis_2a451f27-a58f-4e97-b1e6-67ace330a8dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2a451f27-a58f-4e97-b1e6-67ace330a8dd_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_2a451f27-a58f-4e97-b1e6-67ace330a8dd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2a451f27-a58f-4e97-b1e6-67ace330a8dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5e2e6698-c27b-4803-b9b1-3ea4a152fd45" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_2a451f27-a58f-4e97-b1e6-67ace330a8dd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5e2e6698-c27b-4803-b9b1-3ea4a152fd45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_APAMHMedicalCorporationMember_6191ae44-d080-441f-b21e-2dfd88d934ae" xlink:href="ameh-20200630.xsd#ameh_APAMHMedicalCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5e2e6698-c27b-4803-b9b1-3ea4a152fd45" xlink:to="loc_ameh_APAMHMedicalCorporationMember_6191ae44-d080-441f-b21e-2dfd88d934ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_742e3259-3f54-499f-8440-c6c5f6fa9d37" xlink:href="ameh-20200630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5e2e6698-c27b-4803-b9b1-3ea4a152fd45" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_742e3259-3f54-499f-8440-c6c5f6fa9d37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Dr.JayMember_35b0af47-572a-4391-b154-4472dcbd85fe" xlink:href="ameh-20200630.xsd#ameh_Dr.JayMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5e2e6698-c27b-4803-b9b1-3ea4a152fd45" xlink:to="loc_ameh_Dr.JayMember_35b0af47-572a-4391-b154-4472dcbd85fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BrightHealthCompanyOfCaliforniaInc.Member_ce7a170d-8f3a-47e3-b6bd-3a9957ba02ae" xlink:href="ameh-20200630.xsd#ameh_BrightHealthCompanyOfCaliforniaInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5e2e6698-c27b-4803-b9b1-3ea4a152fd45" xlink:to="loc_ameh_BrightHealthCompanyOfCaliforniaInc.Member_ce7a170d-8f3a-47e3-b6bd-3a9957ba02ae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_536a226a-5f05-478a-8b72-a13c6d7dd87b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_a8e4cb68-04c2-4cf4-a2a7-a79f081e1f31" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_536a226a-5f05-478a-8b72-a13c6d7dd87b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_536a226a-5f05-478a-8b72-a13c6d7dd87b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_536a226a-5f05-478a-8b72-a13c6d7dd87b" xlink:to="loc_us-gaap_RelatedPartyDomain_536a226a-5f05-478a-8b72-a13c6d7dd87b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_56c166c7-e477-4af4-a31c-a6a1a543a3a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_536a226a-5f05-478a-8b72-a13c6d7dd87b" xlink:to="loc_us-gaap_RelatedPartyDomain_56c166c7-e477-4af4-a31c-a6a1a543a3a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_b27ce3aa-6af9-4cc7-863c-7d18742ddc42" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_56c166c7-e477-4af4-a31c-a6a1a543a3a2" xlink:to="loc_srt_AffiliatedEntityMember_b27ce3aa-6af9-4cc7-863c-7d18742ddc42" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5870e9a9-a9c1-4643-be35-8b9f47237f8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_a8e4cb68-04c2-4cf4-a2a7-a79f081e1f31" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5870e9a9-a9c1-4643-be35-8b9f47237f8a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5870e9a9-a9c1-4643-be35-8b9f47237f8a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5870e9a9-a9c1-4643-be35-8b9f47237f8a" xlink:to="loc_us-gaap_ClassOfStockDomain_5870e9a9-a9c1-4643-be35-8b9f47237f8a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4ac9544c-8d72-4144-9456-25c8c00821ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5870e9a9-a9c1-4643-be35-8b9f47237f8a" xlink:to="loc_us-gaap_ClassOfStockDomain_4ac9544c-8d72-4144-9456-25c8c00821ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_3dea908f-82b9-4a17-bf51-ec52ac7fd286" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4ac9544c-8d72-4144-9456-25c8c00821ff" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_3dea908f-82b9-4a17-bf51-ec52ac7fd286" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_ef84a7c9-3eb2-4c49-a45b-142a35e8b17f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4ac9544c-8d72-4144-9456-25c8c00821ff" xlink:to="loc_us-gaap_PreferredStockMember_ef84a7c9-3eb2-4c49-a45b-142a35e8b17f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a531371f-975d-4d5a-baa7-4006bb8d5576" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_a8e4cb68-04c2-4cf4-a2a7-a79f081e1f31" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a531371f-975d-4d5a-baa7-4006bb8d5576" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_a531371f-975d-4d5a-baa7-4006bb8d5576_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a531371f-975d-4d5a-baa7-4006bb8d5576" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_a531371f-975d-4d5a-baa7-4006bb8d5576_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_8c5bf709-3f0d-489d-8934-193324b0729e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a531371f-975d-4d5a-baa7-4006bb8d5576" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_8c5bf709-3f0d-489d-8934-193324b0729e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApolloMedicalHoldingsIncMember_3f9a1ba5-c733-493f-921f-dd7bfda89a41" xlink:href="ameh-20200630.xsd#ameh_ApolloMedicalHoldingsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_8c5bf709-3f0d-489d-8934-193324b0729e" xlink:to="loc_ameh_ApolloMedicalHoldingsIncMember_3f9a1ba5-c733-493f-921f-dd7bfda89a41" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ConcourseDiagnosticSurgeryCenterLlcMember_1e1ae5c8-5e64-4354-8f63-d222e564cbfb" xlink:href="ameh-20200630.xsd#ameh_ConcourseDiagnosticSurgeryCenterLlcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_8c5bf709-3f0d-489d-8934-193324b0729e" xlink:to="loc_ameh_ConcourseDiagnosticSurgeryCenterLlcMember_1e1ae5c8-5e64-4354-8f63-d222e564cbfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareIncMember_98d537f7-4529-4758-9809-0d2efc878920" xlink:href="ameh-20200630.xsd#ameh_UniversalCareIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_8c5bf709-3f0d-489d-8934-193324b0729e" xlink:to="loc_ameh_UniversalCareIncMember_98d537f7-4529-4758-9809-0d2efc878920" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_afab50fb-8385-4fef-aa08-795a759fabad" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_a8e4cb68-04c2-4cf4-a2a7-a79f081e1f31" xlink:to="loc_srt_OwnershipAxis_afab50fb-8385-4fef-aa08-795a759fabad" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_afab50fb-8385-4fef-aa08-795a759fabad_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_afab50fb-8385-4fef-aa08-795a759fabad" xlink:to="loc_srt_OwnershipDomain_afab50fb-8385-4fef-aa08-795a759fabad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_8b66fe62-54c0-438c-b435-bd2b15751469" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_afab50fb-8385-4fef-aa08-795a759fabad" xlink:to="loc_srt_OwnershipDomain_8b66fe62-54c0-438c-b435-bd2b15751469" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MaverickMedicalGroupIncMember_51f53426-5ba4-4daf-8c9d-1ee7d61ca540" xlink:href="ameh-20200630.xsd#ameh_MaverickMedicalGroupIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_8b66fe62-54c0-438c-b435-bd2b15751469" xlink:to="loc_ameh_MaverickMedicalGroupIncMember_51f53426-5ba4-4daf-8c9d-1ee7d61ca540" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_042614e5-4ac8-4aeb-a40f-add020970d9f" xlink:href="ameh-20200630.xsd#ameh_UniversalCareAcquisitionPartnersLlcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_8b66fe62-54c0-438c-b435-bd2b15751469" xlink:to="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_042614e5-4ac8-4aeb-a40f-add020970d9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d840a5f5-7cf4-4908-94d2-e03c69d7c4d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_a8e4cb68-04c2-4cf4-a2a7-a79f081e1f31" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d840a5f5-7cf4-4908-94d2-e03c69d7c4d1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d840a5f5-7cf4-4908-94d2-e03c69d7c4d1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d840a5f5-7cf4-4908-94d2-e03c69d7c4d1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d840a5f5-7cf4-4908-94d2-e03c69d7c4d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_90abe2c3-ff09-4ef8-aaee-4ac848461b84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d840a5f5-7cf4-4908-94d2-e03c69d7c4d1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_90abe2c3-ff09-4ef8-aaee-4ac848461b84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountableHealthCareIPAMember_92b9c87a-981d-429d-8e42-b97022de4d7e" xlink:href="ameh-20200630.xsd#ameh_AccountableHealthCareIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_90abe2c3-ff09-4ef8-aaee-4ac848461b84" xlink:to="loc_ameh_AccountableHealthCareIPAMember_92b9c87a-981d-429d-8e42-b97022de4d7e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AmgIncMember_1ac6b74e-3364-4227-8a0e-a2bcb3af3110" xlink:href="ameh-20200630.xsd#ameh_AmgIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_90abe2c3-ff09-4ef8-aaee-4ac848461b84" xlink:to="loc_ameh_AmgIncMember_1ac6b74e-3364-4227-8a0e-a2bcb3af3110" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="ameh-20200630.xsd#BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="extended" id="iecda4cc35ce546d5bf2f7cafdaf5fa3b_BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="ameh-20200630.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="i0a1aa3b5e83e4d6784b1bca7f98fb0aa_BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="ameh-20200630.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended" id="i1b63831b97d74cd79ba218aeab64cfd0_BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" id="ic006d3e70dac4d3c8d82a2cfbf34664f_BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_50592e17-4de4-46ff-865f-e1b9acc3880a" xlink:href="ameh-20200630.xsd#ameh_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_ee39f2d0-f055-4e3b-95c0-c2cb489b5044" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_50592e17-4de4-46ff-865f-e1b9acc3880a" xlink:to="loc_us-gaap_NumberOfOperatingSegments_ee39f2d0-f055-4e3b-95c0-c2cb489b5044" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_57ddb472-5364-4de0-85a0-94c8a7ad3f7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_50592e17-4de4-46ff-865f-e1b9acc3880a" xlink:to="loc_us-gaap_NumberOfReportableSegments_57ddb472-5364-4de0-85a0-94c8a7ad3f7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashUninsuredAmount_cfaee711-d0a5-49e4-a419-02ef9056252a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashUninsuredAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_50592e17-4de4-46ff-865f-e1b9acc3880a" xlink:to="loc_us-gaap_CashUninsuredAmount_cfaee711-d0a5-49e4-a419-02ef9056252a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_e702fe7f-e353-42e5-9460-cd62ad9d446b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_50592e17-4de4-46ff-865f-e1b9acc3880a" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_e702fe7f-e353-42e5-9460-cd62ad9d446b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MarketableSecuritiesCurrentMaturityPeriod_ebb2cf45-67a2-4832-80f0-67a75cee90b9" xlink:href="ameh-20200630.xsd#ameh_MarketableSecuritiesCurrentMaturityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_50592e17-4de4-46ff-865f-e1b9acc3880a" xlink:to="loc_ameh_MarketableSecuritiesCurrentMaturityPeriod_ebb2cf45-67a2-4832-80f0-67a75cee90b9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear_ce639a83-6213-4873-9cdb-eca4a74ae059" xlink:href="ameh-20200630.xsd#ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_50592e17-4de4-46ff-865f-e1b9acc3880a" xlink:to="loc_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear_ce639a83-6213-4873-9cdb-eca4a74ae059" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_63967148-20cf-4f26-8129-c5412b1884e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_50592e17-4de4-46ff-865f-e1b9acc3880a" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_63967148-20cf-4f26-8129-c5412b1884e6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_1827721c-b434-405b-baf3-576e7d212863" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_50592e17-4de4-46ff-865f-e1b9acc3880a" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_1827721c-b434-405b-baf3-576e7d212863" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_54157788-0ff5-455c-9892-a3b385624dad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_50592e17-4de4-46ff-865f-e1b9acc3880a" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_54157788-0ff5-455c-9892-a3b385624dad" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_95f8843f-778d-4c16-a292-5aef62caeb26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_50592e17-4de4-46ff-865f-e1b9acc3880a" xlink:to="loc_us-gaap_NumberOfReportingUnits_95f8843f-778d-4c16-a292-5aef62caeb26" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_943ed1c2-eec6-48d5-8458-0a5e2a57e370" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_50592e17-4de4-46ff-865f-e1b9acc3880a" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_943ed1c2-eec6-48d5-8458-0a5e2a57e370" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_7a018f4d-a9d3-408f-a821-c0d17a38fc47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_50592e17-4de4-46ff-865f-e1b9acc3880a" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_7a018f4d-a9d3-408f-a821-c0d17a38fc47" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_872ab395-34c2-4361-9f17-406c6a216106" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfTiming"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_50592e17-4de4-46ff-865f-e1b9acc3880a" xlink:to="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_872ab395-34c2-4361-9f17-406c6a216106" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport_d48a508d-74d2-4afc-9205-ae1cbeb04486" xlink:href="ameh-20200630.xsd#ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_50592e17-4de4-46ff-865f-e1b9acc3880a" xlink:to="loc_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport_d48a508d-74d2-4afc-9205-ae1cbeb04486" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentOfRevenueMonthlyAmount_b58918e5-3a7b-43a3-89fb-4b522f43164d" xlink:href="ameh-20200630.xsd#ameh_PaymentOfRevenueMonthlyAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_50592e17-4de4-46ff-865f-e1b9acc3880a" xlink:to="loc_ameh_PaymentOfRevenueMonthlyAmount_b58918e5-3a7b-43a3-89fb-4b522f43164d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentOfRevenue_9f92a093-8a25-449d-8061-cdfd58cfe54d" xlink:href="ameh-20200630.xsd#ameh_PaymentOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_50592e17-4de4-46ff-865f-e1b9acc3880a" xlink:to="loc_ameh_PaymentOfRevenue_9f92a093-8a25-449d-8061-cdfd58cfe54d" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_fc31e847-0739-414b-af66-17b8736e2720" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_50592e17-4de4-46ff-865f-e1b9acc3880a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_fc31e847-0739-414b-af66-17b8736e2720" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverables_b80a8b22-0e6b-44a2-98fc-db99d238ceb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReinsuranceRecoverables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_50592e17-4de4-46ff-865f-e1b9acc3880a" xlink:to="loc_us-gaap_ReinsuranceRecoverables_b80a8b22-0e6b-44a2-98fc-db99d238ceb5" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_cb756656-8d9f-41e4-8db3-f31ac5c5e4bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_50592e17-4de4-46ff-865f-e1b9acc3880a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_cb756656-8d9f-41e4-8db3-f31ac5c5e4bf" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContractWithCustomerLiabilityRepaidCapitationReceivedAndNotEarned_17eaf5e8-74a4-41ef-b91e-377782e17d2b" xlink:href="ameh-20200630.xsd#ameh_ContractWithCustomerLiabilityRepaidCapitationReceivedAndNotEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_50592e17-4de4-46ff-865f-e1b9acc3880a" xlink:to="loc_ameh_ContractWithCustomerLiabilityRepaidCapitationReceivedAndNotEarned_17eaf5e8-74a4-41ef-b91e-377782e17d2b" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InvestmentDeposit_8c030df2-d11c-4602-80df-92779225b02f" xlink:href="ameh-20200630.xsd#ameh_InvestmentDeposit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_50592e17-4de4-46ff-865f-e1b9acc3880a" xlink:to="loc_ameh_InvestmentDeposit_8c030df2-d11c-4602-80df-92779225b02f" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityOwnershipPercentage_18e11451-abae-4324-9eb6-a7ad71efdfe3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_50592e17-4de4-46ff-865f-e1b9acc3880a" xlink:to="loc_us-gaap_VariableInterestEntityOwnershipPercentage_18e11451-abae-4324-9eb6-a7ad71efdfe3" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_58c893b5-ebe7-498b-b1e6-f5cb5ae8a11b" xlink:href="ameh-20200630.xsd#ameh_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_50592e17-4de4-46ff-865f-e1b9acc3880a" xlink:to="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_58c893b5-ebe7-498b-b1e6-f5cb5ae8a11b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_4803a6b8-33e5-4952-a360-279279e4c75c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_58c893b5-ebe7-498b-b1e6-f5cb5ae8a11b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_4803a6b8-33e5-4952-a360-279279e4c75c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_4803a6b8-33e5-4952-a360-279279e4c75c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_4803a6b8-33e5-4952-a360-279279e4c75c" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_4803a6b8-33e5-4952-a360-279279e4c75c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_7d4a09c9-0232-4796-b9e4-e6ea67d2f013" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_4803a6b8-33e5-4952-a360-279279e4c75c" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_7d4a09c9-0232-4796-b9e4-e6ea67d2f013" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_7709dfa3-c5a1-419e-a278-1229098c6e24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_7d4a09c9-0232-4796-b9e4-e6ea67d2f013" xlink:to="loc_us-gaap_CertificatesOfDepositMember_7709dfa3-c5a1-419e-a278-1229098c6e24" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8899ed92-29f4-46a5-9ea3-f78d2894281f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_58c893b5-ebe7-498b-b1e6-f5cb5ae8a11b" xlink:to="loc_srt_RangeAxis_8899ed92-29f4-46a5-9ea3-f78d2894281f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8899ed92-29f4-46a5-9ea3-f78d2894281f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_8899ed92-29f4-46a5-9ea3-f78d2894281f" xlink:to="loc_srt_RangeMember_8899ed92-29f4-46a5-9ea3-f78d2894281f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8b4155a6-3e58-490e-9fa2-fd9b0c010bd5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_8899ed92-29f4-46a5-9ea3-f78d2894281f" xlink:to="loc_srt_RangeMember_8b4155a6-3e58-490e-9fa2-fd9b0c010bd5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0cb7f315-d072-4cdd-9e44-fedb7caf9d7a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8b4155a6-3e58-490e-9fa2-fd9b0c010bd5" xlink:to="loc_srt_MinimumMember_0cb7f315-d072-4cdd-9e44-fedb7caf9d7a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_33f10b49-8608-4498-af55-496a485f5ed9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8b4155a6-3e58-490e-9fa2-fd9b0c010bd5" xlink:to="loc_srt_MaximumMember_33f10b49-8608-4498-af55-496a485f5ed9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8eeb3bdf-435a-46a2-b2a4-f8e72d5b42c8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_58c893b5-ebe7-498b-b1e6-f5cb5ae8a11b" xlink:to="loc_srt_CounterpartyNameAxis_8eeb3bdf-435a-46a2-b2a4-f8e72d5b42c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8eeb3bdf-435a-46a2-b2a4-f8e72d5b42c8_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_8eeb3bdf-435a-46a2-b2a4-f8e72d5b42c8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8eeb3bdf-435a-46a2-b2a4-f8e72d5b42c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b2fa49cf-eef8-425c-86ab-4dc351e5952f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_8eeb3bdf-435a-46a2-b2a4-f8e72d5b42c8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b2fa49cf-eef8-425c-86ab-4dc351e5952f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CMSMember_cb58067e-8798-4cd6-a282-581544d407a7" xlink:href="ameh-20200630.xsd#ameh_CMSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b2fa49cf-eef8-425c-86ab-4dc351e5952f" xlink:to="loc_ameh_CMSMember_cb58067e-8798-4cd6-a282-581544d407a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_4401f483-fa72-43e7-b1bd-281c32c5a76c" xlink:href="ameh-20200630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b2fa49cf-eef8-425c-86ab-4dc351e5952f" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_4401f483-fa72-43e7-b1bd-281c32c5a76c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b651a6a8-2157-463e-a19d-c1c9b7f1b14d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_58c893b5-ebe7-498b-b1e6-f5cb5ae8a11b" xlink:to="loc_srt_ProductOrServiceAxis_b651a6a8-2157-463e-a19d-c1c9b7f1b14d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b651a6a8-2157-463e-a19d-c1c9b7f1b14d_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_b651a6a8-2157-463e-a19d-c1c9b7f1b14d" xlink:to="loc_srt_ProductsAndServicesDomain_b651a6a8-2157-463e-a19d-c1c9b7f1b14d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d7670ccc-80c0-49ff-8233-facfbb23eb4e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_b651a6a8-2157-463e-a19d-c1c9b7f1b14d" xlink:to="loc_srt_ProductsAndServicesDomain_d7670ccc-80c0-49ff-8233-facfbb23eb4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PerMemberPerMonthManagedCareContractMember_2e125aa3-6dfc-4690-986a-8b38b378f0fa" xlink:href="ameh-20200630.xsd#ameh_PerMemberPerMonthManagedCareContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d7670ccc-80c0-49ff-8233-facfbb23eb4e" xlink:to="loc_ameh_PerMemberPerMonthManagedCareContractMember_2e125aa3-6dfc-4690-986a-8b38b378f0fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NextGenerationACOModelParticipationAgreementMember_ed14a2d5-4d6f-49cb-9c62-196d0e22d83d" xlink:href="ameh-20200630.xsd#ameh_NextGenerationACOModelParticipationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d7670ccc-80c0-49ff-8233-facfbb23eb4e" xlink:to="loc_ameh_NextGenerationACOModelParticipationAgreementMember_ed14a2d5-4d6f-49cb-9c62-196d0e22d83d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementServiceMember_402142be-969d-4e9e-a0f0-668597327449" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ManagementServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d7670ccc-80c0-49ff-8233-facfbb23eb4e" xlink:to="loc_us-gaap_ManagementServiceMember_402142be-969d-4e9e-a0f0-668597327449" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_ba19b6e8-9dc6-45c6-9eba-8295135bd17d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_58c893b5-ebe7-498b-b1e6-f5cb5ae8a11b" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_ba19b6e8-9dc6-45c6-9eba-8295135bd17d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_ba19b6e8-9dc6-45c6-9eba-8295135bd17d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_ba19b6e8-9dc6-45c6-9eba-8295135bd17d" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_ba19b6e8-9dc6-45c6-9eba-8295135bd17d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_e056d302-8445-4e0b-b0bb-2fc3de9638c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_ba19b6e8-9dc6-45c6-9eba-8295135bd17d" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_e056d302-8445-4e0b-b0bb-2fc3de9638c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OtherReceivablesMember_817b83a5-f7f6-4fb7-a3f9-df7c26429d20" xlink:href="ameh-20200630.xsd#ameh_OtherReceivablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e056d302-8445-4e0b-b0bb-2fc3de9638c6" xlink:to="loc_ameh_OtherReceivablesMember_817b83a5-f7f6-4fb7-a3f9-df7c26429d20" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsPayableAndAccruedExpensesMember_98d27b1e-58b9-418c-9c61-9ddb6bd5721b" xlink:href="ameh-20200630.xsd#ameh_AccountsPayableAndAccruedExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e056d302-8445-4e0b-b0bb-2fc3de9638c6" xlink:to="loc_ameh_AccountsPayableAndAccruedExpensesMember_98d27b1e-58b9-418c-9c61-9ddb6bd5721b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_8150e164-a3db-4bad-a071-4467c91abdd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_58c893b5-ebe7-498b-b1e6-f5cb5ae8a11b" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_8150e164-a3db-4bad-a071-4467c91abdd5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_8150e164-a3db-4bad-a071-4467c91abdd5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_8150e164-a3db-4bad-a071-4467c91abdd5" xlink:to="loc_us-gaap_ReceivableTypeDomain_8150e164-a3db-4bad-a071-4467c91abdd5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_dc37adfb-7fb4-4447-9e83-0eb54af191b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_8150e164-a3db-4bad-a071-4467c91abdd5" xlink:to="loc_us-gaap_ReceivableTypeDomain_dc37adfb-7fb4-4447-9e83-0eb54af191b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OtherReceivablesFinalSettlement2018PerformanceYearMember_bd9e236d-dca0-4f4c-9f6d-56c3976e8f53" xlink:href="ameh-20200630.xsd#ameh_OtherReceivablesFinalSettlement2018PerformanceYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_dc37adfb-7fb4-4447-9e83-0eb54af191b1" xlink:to="loc_ameh_OtherReceivablesFinalSettlement2018PerformanceYearMember_bd9e236d-dca0-4f4c-9f6d-56c3976e8f53" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails" xlink:type="extended" id="i72f211dba11b4ca99510c7a083849454_BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_9712c8d6-9b76-4568-af5f-fa0c052c9f83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_9e7cf63e-e401-4642-b859-6e09093ea5da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_9712c8d6-9b76-4568-af5f-fa0c052c9f83" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_9e7cf63e-e401-4642-b859-6e09093ea5da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_b8fca488-4b4d-4f03-8b57-b05ca49d8d60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_9712c8d6-9b76-4568-af5f-fa0c052c9f83" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_b8fca488-4b4d-4f03-8b57-b05ca49d8d60" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_76573e04-7a6b-4553-a337-7ed243e7ccf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_b8fca488-4b4d-4f03-8b57-b05ca49d8d60" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_76573e04-7a6b-4553-a337-7ed243e7ccf9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f322d3e7-5254-445b-86b3-5e7b6ac60e44" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_b8fca488-4b4d-4f03-8b57-b05ca49d8d60" xlink:to="loc_srt_ProductOrServiceAxis_f322d3e7-5254-445b-86b3-5e7b6ac60e44" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f322d3e7-5254-445b-86b3-5e7b6ac60e44_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_f322d3e7-5254-445b-86b3-5e7b6ac60e44" xlink:to="loc_srt_ProductsAndServicesDomain_f322d3e7-5254-445b-86b3-5e7b6ac60e44_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0396e240-9b15-4917-89cd-d0da53020d6e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_f322d3e7-5254-445b-86b3-5e7b6ac60e44" xlink:to="loc_srt_ProductsAndServicesDomain_0396e240-9b15-4917-89cd-d0da53020d6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NextGenerationACOModelParticipationAgreementMember_777d8f86-e8de-4f5f-b0eb-389a0dce18b6" xlink:href="ameh-20200630.xsd#ameh_NextGenerationACOModelParticipationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0396e240-9b15-4917-89cd-d0da53020d6e" xlink:to="loc_ameh_NextGenerationACOModelParticipationAgreementMember_777d8f86-e8de-4f5f-b0eb-389a0dce18b6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails_1" xlink:type="simple" xlink:href="ameh-20200630.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails_1"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails_1" xlink:type="extended" id="i573e39cb646f45ccbea0ca5a0198424c_BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails_1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_9712c8d6-9b76-4568-af5f-fa0c052c9f83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_9e7cf63e-e401-4642-b859-6e09093ea5da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_9712c8d6-9b76-4568-af5f-fa0c052c9f83" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_9e7cf63e-e401-4642-b859-6e09093ea5da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_b8fca488-4b4d-4f03-8b57-b05ca49d8d60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_9712c8d6-9b76-4568-af5f-fa0c052c9f83" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_b8fca488-4b4d-4f03-8b57-b05ca49d8d60" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f322d3e7-5254-445b-86b3-5e7b6ac60e44" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_b8fca488-4b4d-4f03-8b57-b05ca49d8d60" xlink:to="loc_srt_ProductOrServiceAxis_f322d3e7-5254-445b-86b3-5e7b6ac60e44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f322d3e7-5254-445b-86b3-5e7b6ac60e44_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_f322d3e7-5254-445b-86b3-5e7b6ac60e44" xlink:to="loc_srt_ProductsAndServicesDomain_f322d3e7-5254-445b-86b3-5e7b6ac60e44_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0396e240-9b15-4917-89cd-d0da53020d6e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_f322d3e7-5254-445b-86b3-5e7b6ac60e44" xlink:to="loc_srt_ProductsAndServicesDomain_0396e240-9b15-4917-89cd-d0da53020d6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NextGenerationACOModelParticipationAgreementMember_777d8f86-e8de-4f5f-b0eb-389a0dce18b6" xlink:href="ameh-20200630.xsd#ameh_NextGenerationACOModelParticipationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0396e240-9b15-4917-89cd-d0da53020d6e" xlink:to="loc_ameh_NextGenerationACOModelParticipationAgreementMember_777d8f86-e8de-4f5f-b0eb-389a0dce18b6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails" xlink:type="extended" id="ia72b31f0db8d47c2a1074e8af0303593_BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_f5643c46-bef0-403b-b7f0-2445f0420c11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8477a912-d2fc-4bba-b4ad-85b1176d3a58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f5643c46-bef0-403b-b7f0-2445f0420c11" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8477a912-d2fc-4bba-b4ad-85b1176d3a58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_b0ceea25-ec2c-4db7-93ee-023a750ce2fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f5643c46-bef0-403b-b7f0-2445f0420c11" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_b0ceea25-ec2c-4db7-93ee-023a750ce2fa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_57967c9d-adeb-4ceb-ba23-8c0e83c31b26" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b0ceea25-ec2c-4db7-93ee-023a750ce2fa" xlink:to="loc_srt_MajorCustomersAxis_57967c9d-adeb-4ceb-ba23-8c0e83c31b26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_57967c9d-adeb-4ceb-ba23-8c0e83c31b26_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_57967c9d-adeb-4ceb-ba23-8c0e83c31b26" xlink:to="loc_srt_NameOfMajorCustomerDomain_57967c9d-adeb-4ceb-ba23-8c0e83c31b26_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_404b6b6b-f323-44ee-bf8e-c48eb5230df3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_57967c9d-adeb-4ceb-ba23-8c0e83c31b26" xlink:to="loc_srt_NameOfMajorCustomerDomain_404b6b6b-f323-44ee-bf8e-c48eb5230df3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommercialMember_abfa0f00-8643-41cd-888f-174485c44f54" xlink:href="ameh-20200630.xsd#ameh_CommercialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_404b6b6b-f323-44ee-bf8e-c48eb5230df3" xlink:to="loc_ameh_CommercialMember_abfa0f00-8643-41cd-888f-174485c44f54" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicareMember_8b9c542e-bbb3-4a83-94ea-308c0d1f1433" xlink:href="ameh-20200630.xsd#ameh_MedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_404b6b6b-f323-44ee-bf8e-c48eb5230df3" xlink:to="loc_ameh_MedicareMember_8b9c542e-bbb3-4a83-94ea-308c0d1f1433" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicaidMember_76500d3b-30fc-47b9-be02-10431fafe4a8" xlink:href="ameh-20200630.xsd#ameh_MedicaidMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_404b6b6b-f323-44ee-bf8e-c48eb5230df3" xlink:to="loc_ameh_MedicaidMember_76500d3b-30fc-47b9-be02-10431fafe4a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OtherThirdPartiesMember_714d3586-a096-4aa7-946f-f79a2f7816ba" xlink:href="ameh-20200630.xsd#ameh_OtherThirdPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_404b6b6b-f323-44ee-bf8e-c48eb5230df3" xlink:to="loc_ameh_OtherThirdPartiesMember_714d3586-a096-4aa7-946f-f79a2f7816ba" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails" xlink:type="extended" id="i6901b254bb434342b763e3f122cfe666_BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsReceivableAndNetRevenueLineItems_63f16f50-7a3a-4b40-b703-4964d280f05a" xlink:href="ameh-20200630.xsd#ameh_AccountsReceivableAndNetRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_ddef5e69-c3d6-425a-b303-2d5ff47395e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueLineItems_63f16f50-7a3a-4b40-b703-4964d280f05a" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_ddef5e69-c3d6-425a-b303-2d5ff47395e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsReceivableAndNetRevenueTable_625ee747-e73f-406b-85a5-a6baab4fcd2e" xlink:href="ameh-20200630.xsd#ameh_AccountsReceivableAndNetRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueLineItems_63f16f50-7a3a-4b40-b703-4964d280f05a" xlink:to="loc_ameh_AccountsReceivableAndNetRevenueTable_625ee747-e73f-406b-85a5-a6baab4fcd2e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7d685d2a-1aa0-44a6-b2b8-eb09d3ba0922" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueTable_625ee747-e73f-406b-85a5-a6baab4fcd2e" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7d685d2a-1aa0-44a6-b2b8-eb09d3ba0922" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7d685d2a-1aa0-44a6-b2b8-eb09d3ba0922_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7d685d2a-1aa0-44a6-b2b8-eb09d3ba0922" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7d685d2a-1aa0-44a6-b2b8-eb09d3ba0922_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_16d699a7-fe2c-496a-896e-d7b54f8ef0e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7d685d2a-1aa0-44a6-b2b8-eb09d3ba0922" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_16d699a7-fe2c-496a-896e-d7b54f8ef0e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_976c1417-c3f6-4500-bdf7-3d66c36e73d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_16d699a7-fe2c-496a-896e-d7b54f8ef0e6" xlink:to="loc_us-gaap_SalesRevenueNetMember_976c1417-c3f6-4500-bdf7-3d66c36e73d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_dbe14a0d-f3ea-470e-9cd3-9e172499aa02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_16d699a7-fe2c-496a-896e-d7b54f8ef0e6" xlink:to="loc_us-gaap_AccountsReceivableMember_dbe14a0d-f3ea-470e-9cd3-9e172499aa02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_91be38b8-8d8a-46e0-a5a1-4b887996aed9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueTable_625ee747-e73f-406b-85a5-a6baab4fcd2e" xlink:to="loc_srt_MajorCustomersAxis_91be38b8-8d8a-46e0-a5a1-4b887996aed9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_91be38b8-8d8a-46e0-a5a1-4b887996aed9_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_91be38b8-8d8a-46e0-a5a1-4b887996aed9" xlink:to="loc_srt_NameOfMajorCustomerDomain_91be38b8-8d8a-46e0-a5a1-4b887996aed9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_5dbe8e3b-147a-4369-95d8-a6259f88c773" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_91be38b8-8d8a-46e0-a5a1-4b887996aed9" xlink:to="loc_srt_NameOfMajorCustomerDomain_5dbe8e3b-147a-4369-95d8-a6259f88c773" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorAMember_f3a49a40-00c0-4216-bae3-1c9b46fc804f" xlink:href="ameh-20200630.xsd#ameh_PayorAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_5dbe8e3b-147a-4369-95d8-a6259f88c773" xlink:to="loc_ameh_PayorAMember_f3a49a40-00c0-4216-bae3-1c9b46fc804f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorBMember_3df6e3e9-15f8-4713-a49b-50ccfdb639d4" xlink:href="ameh-20200630.xsd#ameh_PayorBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_5dbe8e3b-147a-4369-95d8-a6259f88c773" xlink:to="loc_ameh_PayorBMember_3df6e3e9-15f8-4713-a49b-50ccfdb639d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorCMember_59d5374d-7510-4eae-b936-64d8049af3b5" xlink:href="ameh-20200630.xsd#ameh_PayorCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_5dbe8e3b-147a-4369-95d8-a6259f88c773" xlink:to="loc_ameh_PayorCMember_59d5374d-7510-4eae-b936-64d8049af3b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorDMember_2fde087b-f7d2-4788-8d0b-ea3b4ff2c6eb" xlink:href="ameh-20200630.xsd#ameh_PayorDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_5dbe8e3b-147a-4369-95d8-a6259f88c773" xlink:to="loc_ameh_PayorDMember_2fde087b-f7d2-4788-8d0b-ea3b4ff2c6eb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorEMember_d6c70901-3f23-4be3-856d-68b60deac770" xlink:href="ameh-20200630.xsd#ameh_PayorEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_5dbe8e3b-147a-4369-95d8-a6259f88c773" xlink:to="loc_ameh_PayorEMember_d6c70901-3f23-4be3-856d-68b60deac770" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorFMember_65e98dd2-0cb7-411d-a3aa-9027cca440e1" xlink:href="ameh-20200630.xsd#ameh_PayorFMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_5dbe8e3b-147a-4369-95d8-a6259f88c773" xlink:to="loc_ameh_PayorFMember_65e98dd2-0cb7-411d-a3aa-9027cca440e1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorGMember_c6b9bb26-1709-4ea0-b6f5-0f4d89ce0a9c" xlink:href="ameh-20200630.xsd#ameh_PayorGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_5dbe8e3b-147a-4369-95d8-a6259f88c773" xlink:to="loc_ameh_PayorGMember_c6b9bb26-1709-4ea0-b6f5-0f4d89ce0a9c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorHMember_60577758-03b2-41b7-a7c3-a1549582e97c" xlink:href="ameh-20200630.xsd#ameh_PayorHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_5dbe8e3b-147a-4369-95d8-a6259f88c773" xlink:to="loc_ameh_PayorHMember_60577758-03b2-41b7-a7c3-a1549582e97c" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails" xlink:type="extended" id="i35d5729c3ed74cf2920df0ac5b333ad7_BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_95a40ac1-5e5f-4377-b5c6-3782c43d3b31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_5054d8f7-99a1-4322-8241-918c7565eb32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_95a40ac1-5e5f-4377-b5c6-3782c43d3b31" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_5054d8f7-99a1-4322-8241-918c7565eb32" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ab3746d5-aa58-4059-ba10-6e49fb4628f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_5054d8f7-99a1-4322-8241-918c7565eb32" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ab3746d5-aa58-4059-ba10-6e49fb4628f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_65705ea0-020a-43f3-a547-8316d3860da3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_5054d8f7-99a1-4322-8241-918c7565eb32" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_65705ea0-020a-43f3-a547-8316d3860da3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_2f164316-8de2-4bbb-ac6e-1115ea635897" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_5054d8f7-99a1-4322-8241-918c7565eb32" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_2f164316-8de2-4bbb-ac6e-1115ea635897" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_04460a35-198c-437e-ba6b-ee219cc2424e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_5054d8f7-99a1-4322-8241-918c7565eb32" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_04460a35-198c-437e-ba6b-ee219cc2424e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_142b226e-adcd-468e-8b14-000abad65dc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_95a40ac1-5e5f-4377-b5c6-3782c43d3b31" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_142b226e-adcd-468e-8b14-000abad65dc6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6583259f-c761-4280-a429-5bb49428cd1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_142b226e-adcd-468e-8b14-000abad65dc6" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6583259f-c761-4280-a429-5bb49428cd1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6583259f-c761-4280-a429-5bb49428cd1c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6583259f-c761-4280-a429-5bb49428cd1c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6583259f-c761-4280-a429-5bb49428cd1c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54abd81a-38c8-45b3-bb5b-eabf3b60c036" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6583259f-c761-4280-a429-5bb49428cd1c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54abd81a-38c8-45b3-bb5b-eabf3b60c036" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_b17b70e2-c306-4465-912a-38a737f643c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54abd81a-38c8-45b3-bb5b-eabf3b60c036" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_b17b70e2-c306-4465-912a-38a737f643c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_7751ea06-aa67-45f9-9712-5cac9740d02b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54abd81a-38c8-45b3-bb5b-eabf3b60c036" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_7751ea06-aa67-45f9-9712-5cac9740d02b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_46082b5a-9701-45a2-97d1-84828e94d687" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54abd81a-38c8-45b3-bb5b-eabf3b60c036" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_46082b5a-9701-45a2-97d1-84828e94d687" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwill" xlink:type="simple" xlink:href="ameh-20200630.xsd#BusinessCombinationsandGoodwill"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/BusinessCombinationsandGoodwill" xlink:type="extended" id="i2c10f575aa644cc2bc4a7f4fb9f30d3b_BusinessCombinationsandGoodwill"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwillTables" xlink:type="simple" xlink:href="ameh-20200630.xsd#BusinessCombinationsandGoodwillTables"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/BusinessCombinationsandGoodwillTables" xlink:type="extended" id="i39a333d335e04261b586ce49a2f79507_BusinessCombinationsandGoodwillTables"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#BusinessCombinationsandGoodwillAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails" xlink:type="extended" id="i6ccc7ac94aa4404fa4aa29e9777bd378_BusinessCombinationsandGoodwillAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_a07c94dd-1831-49f2-a374-b2500c09ebfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_6a5bf811-9cae-4240-bba5-26506ace9558" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a07c94dd-1831-49f2-a374-b2500c09ebfe" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_6a5bf811-9cae-4240-bba5-26506ace9558" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_01067a0b-68c1-4492-be2e-667d7c749ef8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a07c94dd-1831-49f2-a374-b2500c09ebfe" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_01067a0b-68c1-4492-be2e-667d7c749ef8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EscrowDeposit_ba4c6223-6e1a-442a-a281-b3895efeaaf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EscrowDeposit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a07c94dd-1831-49f2-a374-b2500c09ebfe" xlink:to="loc_us-gaap_EscrowDeposit_ba4c6223-6e1a-442a-a281-b3895efeaaf6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_0a18b75b-c5b9-4c42-9918-1706216f61ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a07c94dd-1831-49f2-a374-b2500c09ebfe" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_0a18b75b-c5b9-4c42-9918-1706216f61ec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_36b4d540-0d81-49e9-a9c6-bc0cf0e18743" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a07c94dd-1831-49f2-a374-b2500c09ebfe" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_36b4d540-0d81-49e9-a9c6-bc0cf0e18743" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_5700aefb-3095-4370-817f-83a7ebc35a62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a07c94dd-1831-49f2-a374-b2500c09ebfe" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_5700aefb-3095-4370-817f-83a7ebc35a62" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_4af8061b-7efb-47a6-8630-994da85319a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a07c94dd-1831-49f2-a374-b2500c09ebfe" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_4af8061b-7efb-47a6-8630-994da85319a3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ee17345d-32a0-4960-9ea2-45f0a195a1d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a07c94dd-1831-49f2-a374-b2500c09ebfe" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ee17345d-32a0-4960-9ea2-45f0a195a1d6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_29535d8d-cb1d-4336-aad9-5def29e9c9f9" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ee17345d-32a0-4960-9ea2-45f0a195a1d6" xlink:to="loc_dei_LegalEntityAxis_29535d8d-cb1d-4336-aad9-5def29e9c9f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_29535d8d-cb1d-4336-aad9-5def29e9c9f9_default" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_29535d8d-cb1d-4336-aad9-5def29e9c9f9" xlink:to="loc_dei_EntityDomain_29535d8d-cb1d-4336-aad9-5def29e9c9f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_d3645b33-82ef-4307-a0b7-4526fdd85f3f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_29535d8d-cb1d-4336-aad9-5def29e9c9f9" xlink:to="loc_dei_EntityDomain_d3645b33-82ef-4307-a0b7-4526fdd85f3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_APCAndAPCLSMAMember_95b1122e-1736-4dbc-9bb1-29d8395e3e18" xlink:href="ameh-20200630.xsd#ameh_APCAndAPCLSMAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_d3645b33-82ef-4307-a0b7-4526fdd85f3f" xlink:to="loc_ameh_APCAndAPCLSMAMember_95b1122e-1736-4dbc-9bb1-29d8395e3e18" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_47b2ec1b-99b0-4c7b-b4df-e5585cd44148" xlink:href="ameh-20200630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_d3645b33-82ef-4307-a0b7-4526fdd85f3f" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_47b2ec1b-99b0-4c7b-b4df-e5585cd44148" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_75ee3c92-734f-4f75-bd43-8c74c5088205" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ee17345d-32a0-4960-9ea2-45f0a195a1d6" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_75ee3c92-734f-4f75-bd43-8c74c5088205" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_75ee3c92-734f-4f75-bd43-8c74c5088205_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_75ee3c92-734f-4f75-bd43-8c74c5088205" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_75ee3c92-734f-4f75-bd43-8c74c5088205_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6c500cdc-425c-428a-b044-e89be67d2cec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_75ee3c92-734f-4f75-bd43-8c74c5088205" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6c500cdc-425c-428a-b044-e89be67d2cec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlphaCareMedicalGroupInc.Member_78a8671f-4e2a-4899-b75c-d994c7ba7b7b" xlink:href="ameh-20200630.xsd#ameh_AlphaCareMedicalGroupInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6c500cdc-425c-428a-b044-e89be67d2cec" xlink:to="loc_ameh_AlphaCareMedicalGroupInc.Member_78a8671f-4e2a-4899-b75c-d994c7ba7b7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountableHealthCareIPAMember_9de42d08-c1e8-415e-bfbc-02bedfc18307" xlink:href="ameh-20200630.xsd#ameh_AccountableHealthCareIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6c500cdc-425c-428a-b044-e89be67d2cec" xlink:to="loc_ameh_AccountableHealthCareIPAMember_9de42d08-c1e8-415e-bfbc-02bedfc18307" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AmgIncMember_97154529-50fe-4933-a11c-4e6878395714" xlink:href="ameh-20200630.xsd#ameh_AmgIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6c500cdc-425c-428a-b044-e89be67d2cec" xlink:to="loc_ameh_AmgIncMember_97154529-50fe-4933-a11c-4e6878395714" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0f1e3e10-2b3d-4664-93eb-5e2f26c56d7b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ee17345d-32a0-4960-9ea2-45f0a195a1d6" xlink:to="loc_srt_CounterpartyNameAxis_0f1e3e10-2b3d-4664-93eb-5e2f26c56d7b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0f1e3e10-2b3d-4664-93eb-5e2f26c56d7b_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_0f1e3e10-2b3d-4664-93eb-5e2f26c56d7b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0f1e3e10-2b3d-4664-93eb-5e2f26c56d7b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f1a0b40f-00c3-4ca7-b668-6d7e7ed8dddc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_0f1e3e10-2b3d-4664-93eb-5e2f26c56d7b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f1a0b40f-00c3-4ca7-b668-6d7e7ed8dddc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Dr.JayMember_cc1770e2-c775-4228-a64e-ca688f949c80" xlink:href="ameh-20200630.xsd#ameh_Dr.JayMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f1a0b40f-00c3-4ca7-b668-6d7e7ed8dddc" xlink:to="loc_ameh_Dr.JayMember_cc1770e2-c775-4228-a64e-ca688f949c80" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended" id="i5eb7b60347b44238b81c3222e4212e11_BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_01b697df-0ccd-46cc-9eba-cd4f9d36fe31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_e73cc2d0-91fb-4da6-87ad-1d412b015ee7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_01b697df-0ccd-46cc-9eba-cd4f9d36fe31" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_e73cc2d0-91fb-4da6-87ad-1d412b015ee7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_501b5237-0abe-4e0a-a69a-a0f29d194452" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_e73cc2d0-91fb-4da6-87ad-1d412b015ee7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_501b5237-0abe-4e0a-a69a-a0f29d194452" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_27aff902-b2aa-4f04-9f14-7de1cb49e902" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_e73cc2d0-91fb-4da6-87ad-1d412b015ee7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_27aff902-b2aa-4f04-9f14-7de1cb49e902" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_8b3be2a3-f888-4271-a7d7-e350ec796346" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_e73cc2d0-91fb-4da6-87ad-1d412b015ee7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_8b3be2a3-f888-4271-a7d7-e350ec796346" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_218398b2-2515-47a1-8c39-0cf578d19c23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_e73cc2d0-91fb-4da6-87ad-1d412b015ee7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_218398b2-2515-47a1-8c39-0cf578d19c23" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f41aa0f2-bc98-4823-893b-1e491345c72a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_e73cc2d0-91fb-4da6-87ad-1d412b015ee7" xlink:to="loc_us-gaap_Goodwill_f41aa0f2-bc98-4823-893b-1e491345c72a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_04f2a2b0-578e-4db7-b0c7-03462653b48f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_01b697df-0ccd-46cc-9eba-cd4f9d36fe31" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_04f2a2b0-578e-4db7-b0c7-03462653b48f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_92790138-40ac-4e6f-94c5-e425d14e1b09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_01b697df-0ccd-46cc-9eba-cd4f9d36fe31" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_92790138-40ac-4e6f-94c5-e425d14e1b09" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities_29b72c14-65cc-4366-80b3-8b2c1a4aa3c2" xlink:href="ameh-20200630.xsd#ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_01b697df-0ccd-46cc-9eba-cd4f9d36fe31" xlink:to="loc_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities_29b72c14-65cc-4366-80b3-8b2c1a4aa3c2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities_bcfbc688-1641-4374-899b-3ef4a99eaf32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_01b697df-0ccd-46cc-9eba-cd4f9d36fe31" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities_bcfbc688-1641-4374-899b-3ef4a99eaf32" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_006aa483-844f-48a9-95bf-6c1d3585140d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_01b697df-0ccd-46cc-9eba-cd4f9d36fe31" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_006aa483-844f-48a9-95bf-6c1d3585140d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_384b101f-8e94-4101-ad07-b17021b9cc79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_01b697df-0ccd-46cc-9eba-cd4f9d36fe31" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_384b101f-8e94-4101-ad07-b17021b9cc79" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_8549bd7d-687e-4f4d-beea-052e114851f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_01b697df-0ccd-46cc-9eba-cd4f9d36fe31" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_8549bd7d-687e-4f4d-beea-052e114851f5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2365312a-53c5-47f6-b12b-d12c85f6a6f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_01b697df-0ccd-46cc-9eba-cd4f9d36fe31" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2365312a-53c5-47f6-b12b-d12c85f6a6f5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_3d02009b-0972-478f-941e-f2291c5b3bde" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2365312a-53c5-47f6-b12b-d12c85f6a6f5" xlink:to="loc_dei_LegalEntityAxis_3d02009b-0972-478f-941e-f2291c5b3bde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_3d02009b-0972-478f-941e-f2291c5b3bde_default" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_3d02009b-0972-478f-941e-f2291c5b3bde" xlink:to="loc_dei_EntityDomain_3d02009b-0972-478f-941e-f2291c5b3bde_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_ac31c3a5-51da-4ddf-af5d-0f1fdc04e966" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_3d02009b-0972-478f-941e-f2291c5b3bde" xlink:to="loc_dei_EntityDomain_ac31c3a5-51da-4ddf-af5d-0f1fdc04e966" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_APCAndAPCLSMAMember_50b4c823-91ce-422b-9a64-b55d44bfcabc" xlink:href="ameh-20200630.xsd#ameh_APCAndAPCLSMAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_ac31c3a5-51da-4ddf-af5d-0f1fdc04e966" xlink:to="loc_ameh_APCAndAPCLSMAMember_50b4c823-91ce-422b-9a64-b55d44bfcabc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6f2ce3fd-9d96-411d-acab-ccc1fe1eb714" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2365312a-53c5-47f6-b12b-d12c85f6a6f5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6f2ce3fd-9d96-411d-acab-ccc1fe1eb714" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6f2ce3fd-9d96-411d-acab-ccc1fe1eb714_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6f2ce3fd-9d96-411d-acab-ccc1fe1eb714" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6f2ce3fd-9d96-411d-acab-ccc1fe1eb714_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_17c4742d-e739-4f51-b025-7f8552fef6ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6f2ce3fd-9d96-411d-acab-ccc1fe1eb714" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_17c4742d-e739-4f51-b025-7f8552fef6ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlphaCareMedicalGroupInc.Member_1fe24088-5419-4b95-8369-0a48c5b5918f" xlink:href="ameh-20200630.xsd#ameh_AlphaCareMedicalGroupInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_17c4742d-e739-4f51-b025-7f8552fef6ff" xlink:to="loc_ameh_AlphaCareMedicalGroupInc.Member_1fe24088-5419-4b95-8369-0a48c5b5918f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountableHealthCareIPAMember_38846186-06eb-428e-ba88-1bc6008dd015" xlink:href="ameh-20200630.xsd#ameh_AccountableHealthCareIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_17c4742d-e739-4f51-b025-7f8552fef6ff" xlink:to="loc_ameh_AccountableHealthCareIPAMember_38846186-06eb-428e-ba88-1bc6008dd015" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e2f90e15-320d-4807-92b0-225db9a7c662" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2365312a-53c5-47f6-b12b-d12c85f6a6f5" xlink:to="loc_srt_CounterpartyNameAxis_e2f90e15-320d-4807-92b0-225db9a7c662" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e2f90e15-320d-4807-92b0-225db9a7c662_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_e2f90e15-320d-4807-92b0-225db9a7c662" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e2f90e15-320d-4807-92b0-225db9a7c662_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_029d603a-18c0-4272-be6d-59726f60cea8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_e2f90e15-320d-4807-92b0-225db9a7c662" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_029d603a-18c0-4272-be6d-59726f60cea8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Dr.JayMember_da038d2f-a215-4d0c-921e-4f2022a4f0aa" xlink:href="ameh-20200630.xsd#ameh_Dr.JayMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_029d603a-18c0-4272-be6d-59726f60cea8" xlink:to="loc_ameh_Dr.JayMember_da038d2f-a215-4d0c-921e-4f2022a4f0aa" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwillSummaryofGoodwillDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#BusinessCombinationsandGoodwillSummaryofGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/BusinessCombinationsandGoodwillSummaryofGoodwillDetails" xlink:type="extended" id="i655becdf710548b9bff3ef57af5e27b1_BusinessCombinationsandGoodwillSummaryofGoodwillDetails"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNet" xlink:type="simple" xlink:href="ameh-20200630.xsd#IntangibleAssetsNet"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNet" xlink:type="extended" id="iaf9e850181454673a877ff68611b6b0c_IntangibleAssetsNet"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetTables" xlink:type="simple" xlink:href="ameh-20200630.xsd#IntangibleAssetsNetTables"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetTables" xlink:type="extended" id="ic3efa11e4607491d827a7f4b905514db_IntangibleAssetsNetTables"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#IntangibleAssetsNetScheduleofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails" xlink:type="extended" id="i1bdc015b442444548fd06f560c2e97da_IntangibleAssetsNetScheduleofIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_19bf0725-7ef9-4ae6-b8ef-da4fcadcbc6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_95a44f45-7f2a-498a-b501-9cddc86e07c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_19bf0725-7ef9-4ae6-b8ef-da4fcadcbc6f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_95a44f45-7f2a-498a-b501-9cddc86e07c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_b3f8cb00-8672-49da-9bfb-5de997f6b395" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_19bf0725-7ef9-4ae6-b8ef-da4fcadcbc6f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_b3f8cb00-8672-49da-9bfb-5de997f6b395" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ad7ba57c-220d-4347-8e4b-ae26d14c1d9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_19bf0725-7ef9-4ae6-b8ef-da4fcadcbc6f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ad7ba57c-220d-4347-8e4b-ae26d14c1d9f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d63cbc8b-c846-4a4f-b616-e068f0dd879d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_19bf0725-7ef9-4ae6-b8ef-da4fcadcbc6f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d63cbc8b-c846-4a4f-b616-e068f0dd879d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_9cfe0771-3d82-4687-9644-100668947a2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_19bf0725-7ef9-4ae6-b8ef-da4fcadcbc6f" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_9cfe0771-3d82-4687-9644-100668947a2d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_09207a12-d55b-4828-b2ae-f6d1b217fabe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_19bf0725-7ef9-4ae6-b8ef-da4fcadcbc6f" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_09207a12-d55b-4828-b2ae-f6d1b217fabe" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_be6e7aeb-b09e-429d-8975-516ec3159ced" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_19bf0725-7ef9-4ae6-b8ef-da4fcadcbc6f" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_be6e7aeb-b09e-429d-8975-516ec3159ced" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c14acb00-658b-4c23-90c3-5508590099ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_be6e7aeb-b09e-429d-8975-516ec3159ced" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c14acb00-658b-4c23-90c3-5508590099ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c14acb00-658b-4c23-90c3-5508590099ba_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c14acb00-658b-4c23-90c3-5508590099ba" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c14acb00-658b-4c23-90c3-5508590099ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_438b9b69-c341-432f-9680-a6de6af602d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c14acb00-658b-4c23-90c3-5508590099ba" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_438b9b69-c341-432f-9680-a6de6af602d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkRelationshipsMember_c1220441-d169-4eb4-8ee4-fb41a488cf53" xlink:href="ameh-20200630.xsd#ameh_NetworkRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_438b9b69-c341-432f-9680-a6de6af602d7" xlink:to="loc_ameh_NetworkRelationshipsMember_c1220441-d169-4eb4-8ee4-fb41a488cf53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ManagementContractsMember_7b57ddcf-b65b-4412-a9ac-5ec16e53a229" xlink:href="ameh-20200630.xsd#ameh_ManagementContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_438b9b69-c341-432f-9680-a6de6af602d7" xlink:to="loc_ameh_ManagementContractsMember_7b57ddcf-b65b-4412-a9ac-5ec16e53a229" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MemberRelationshipsMember_89bbc6c0-3322-4b8e-b295-1898aaa1887b" xlink:href="ameh-20200630.xsd#ameh_MemberRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_438b9b69-c341-432f-9680-a6de6af602d7" xlink:to="loc_ameh_MemberRelationshipsMember_89bbc6c0-3322-4b8e-b295-1898aaa1887b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PatientManagementPlatformMember_004e5d9c-0001-4a91-8943-50d63419c054" xlink:href="ameh-20200630.xsd#ameh_PatientManagementPlatformMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_438b9b69-c341-432f-9680-a6de6af602d7" xlink:to="loc_ameh_PatientManagementPlatformMember_004e5d9c-0001-4a91-8943-50d63419c054" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_728ed596-76d7-46f9-ab05-f14a5467b9b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_438b9b69-c341-432f-9680-a6de6af602d7" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_728ed596-76d7-46f9-ab05-f14a5467b9b1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4bb7ce29-8fb4-4925-9d07-b8525f70849c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_be6e7aeb-b09e-429d-8975-516ec3159ced" xlink:to="loc_srt_RangeAxis_4bb7ce29-8fb4-4925-9d07-b8525f70849c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4bb7ce29-8fb4-4925-9d07-b8525f70849c_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_4bb7ce29-8fb4-4925-9d07-b8525f70849c" xlink:to="loc_srt_RangeMember_4bb7ce29-8fb4-4925-9d07-b8525f70849c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d852824b-18da-406a-b4eb-27595bcc90f8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_4bb7ce29-8fb4-4925-9d07-b8525f70849c" xlink:to="loc_srt_RangeMember_d852824b-18da-406a-b4eb-27595bcc90f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_05cd26ca-0376-4187-9a6e-2558e90f3fd8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d852824b-18da-406a-b4eb-27595bcc90f8" xlink:to="loc_srt_MinimumMember_05cd26ca-0376-4187-9a6e-2558e90f3fd8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b305ccc4-0c14-4207-99c9-3ae2383ccc08" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d852824b-18da-406a-b4eb-27595bcc90f8" xlink:to="loc_srt_MaximumMember_b305ccc4-0c14-4207-99c9-3ae2383ccc08" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#IntangibleAssetsNetAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails" xlink:type="extended" id="i3ee0a4668523458f9d51e75f607c9d33_IntangibleAssetsNetAdditionalInformationDetails"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#IntangibleAssetsNetFutureAmortizationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails" xlink:type="extended" id="i9709b6f79f2c48e8a263d3733a269ac7_IntangibleAssetsNetFutureAmortizationExpenseDetails"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethod" xlink:type="simple" xlink:href="ameh-20200630.xsd#InvestmentsinOtherEntitiesEquityMethod"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethod" xlink:type="extended" id="ie5383176599a4424955a9f4ee343061d_InvestmentsinOtherEntitiesEquityMethod"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodTables" xlink:type="simple" xlink:href="ameh-20200630.xsd#InvestmentsinOtherEntitiesEquityMethodTables"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodTables" xlink:type="extended" id="i6ae97332a1944717b5e9a049f9776b7f_InvestmentsinOtherEntitiesEquityMethodTables"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails" xlink:type="extended" id="i6521b515b0ec44a3b5cd47ae48409b0f_InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a9b0bc9a-538e-4625-abe4-2ead7b177cba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsRollForward_df9eee11-dd00-4a31-81ac-145f67c7a4d0" xlink:href="ameh-20200630.xsd#ameh_EquityMethodInvestmentsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a9b0bc9a-538e-4625-abe4-2ead7b177cba" xlink:to="loc_ameh_EquityMethodInvestmentsRollForward_df9eee11-dd00-4a31-81ac-145f67c7a4d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_65e1df79-e3f9-4d50-a7dc-8b1bc02b33ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_df9eee11-dd00-4a31-81ac-145f67c7a4d0" xlink:to="loc_us-gaap_EquityMethodInvestments_65e1df79-e3f9-4d50-a7dc-8b1bc02b33ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_ba26f51e-8c34-469e-9050-aa03b2d586d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_df9eee11-dd00-4a31-81ac-145f67c7a4d0" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_ba26f51e-8c34-469e-9050-aa03b2d586d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsContribution_1def9712-8e83-46f2-b1f1-77fd6cc799e8" xlink:href="ameh-20200630.xsd#ameh_EquityMethodInvestmentsContribution"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_df9eee11-dd00-4a31-81ac-145f67c7a4d0" xlink:to="loc_ameh_EquityMethodInvestmentsContribution_1def9712-8e83-46f2-b1f1-77fd6cc799e8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_038c31a9-08bf-4eaf-9ea0-435f6d9dfe4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_df9eee11-dd00-4a31-81ac-145f67c7a4d0" xlink:to="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_038c31a9-08bf-4eaf-9ea0-435f6d9dfe4d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_4d4a3481-1c3d-4240-83ea-691f41e10788" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1e7bb2fe-b239-419d-aaf4-c6249156f22c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a9b0bc9a-538e-4625-abe4-2ead7b177cba" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1e7bb2fe-b239-419d-aaf4-c6249156f22c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_946015ce-34f3-45e8-8455-2f9d5d4c1cd6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1e7bb2fe-b239-419d-aaf4-c6249156f22c" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_946015ce-34f3-45e8-8455-2f9d5d4c1cd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_946015ce-34f3-45e8-8455-2f9d5d4c1cd6_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_946015ce-34f3-45e8-8455-2f9d5d4c1cd6" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_946015ce-34f3-45e8-8455-2f9d5d4c1cd6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_bfd95bd5-b8ff-42f6-bfe1-663e6b44b88c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_946015ce-34f3-45e8-8455-2f9d5d4c1cd6" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_bfd95bd5-b8ff-42f6-bfe1-663e6b44b88c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember_8fa83180-6fe4-4141-9fad-5ddc28b002cf" xlink:href="ameh-20200630.xsd#ameh_LasalleMedicalAssociatesIpaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_bfd95bd5-b8ff-42f6-bfe1-663e6b44b88c" xlink:to="loc_ameh_LasalleMedicalAssociatesIpaMember_8fa83180-6fe4-4141-9fad-5ddc28b002cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_128fbbf7-299d-4ef9-9c9b-a3609cb4c204" xlink:href="ameh-20200630.xsd#ameh_PacificMedicalImagingAndOncologyCenterIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_bfd95bd5-b8ff-42f6-bfe1-663e6b44b88c" xlink:to="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_128fbbf7-299d-4ef9-9c9b-a3609cb4c204" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareIncMember_be0a1394-6a40-4f5e-a83c-6665d23fc9a6" xlink:href="ameh-20200630.xsd#ameh_UniversalCareIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_bfd95bd5-b8ff-42f6-bfe1-663e6b44b88c" xlink:to="loc_ameh_UniversalCareIncMember_be0a1394-6a40-4f5e-a83c-6665d23fc9a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DiagnosticMedicalGroupMember_a7abd179-4b89-495a-9a86-8d74cfa40703" xlink:href="ameh-20200630.xsd#ameh_DiagnosticMedicalGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_bfd95bd5-b8ff-42f6-bfe1-663e6b44b88c" xlink:to="loc_ameh_DiagnosticMedicalGroupMember_a7abd179-4b89-495a-9a86-8d74cfa40703" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiveThreeOneW.CollegeLLCMember_71a7d322-c0b0-48b7-b97c-a870a45ba9d3" xlink:href="ameh-20200630.xsd#ameh_FiveThreeOneW.CollegeLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_bfd95bd5-b8ff-42f6-bfe1-663e6b44b88c" xlink:to="loc_ameh_FiveThreeOneW.CollegeLLCMember_71a7d322-c0b0-48b7-b97c-a870a45ba9d3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MWNCommunityHospitalLLCMember_fa587210-6856-4de2-81ef-02d44598e081" xlink:href="ameh-20200630.xsd#ameh_MWNCommunityHospitalLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_bfd95bd5-b8ff-42f6-bfe1-663e6b44b88c" xlink:to="loc_ameh_MWNCommunityHospitalLLCMember_fa587210-6856-4de2-81ef-02d44598e081" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails" xlink:type="extended" id="ie444f99f23c644af82d191fb3860ce66_InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStores_2642b7cd-1390-4080-a0ef-09aedd664350" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfStores"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_us-gaap_NumberOfStores_2642b7cd-1390-4080-a0ef-09aedd664350" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfEmployees_731bcccf-f714-478a-9c01-2e84a6640a14" xlink:href="ameh-20200630.xsd#ameh_NumberOfEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_ameh_NumberOfEmployees_731bcccf-f714-478a-9c01-2e84a6640a14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfPatients_2ac9a245-8a74-47ec-8caf-9bb682a823a7" xlink:href="ameh-20200630.xsd#ameh_NumberOfPatients"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_ameh_NumberOfPatients_2ac9a245-8a74-47ec-8caf-9bb682a823a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_df7ddcdf-ffca-4e09-b1ad-5cc536233762" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_df7ddcdf-ffca-4e09-b1ad-5cc536233762" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_d8cca888-645c-4ad5-8e64-2635fc918803" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_d8cca888-645c-4ad5-8e64-2635fc918803" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_ebe10902-4ab0-4739-a2c5-415a1736c714" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_ebe10902-4ab0-4739-a2c5-415a1736c714" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_9ee0acce-7171-403b-9f22-975937b146c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_us-gaap_EquityMethodInvestments_9ee0acce-7171-403b-9f22-975937b146c5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForFees_614f4ed7-bd73-4f4c-ab02-34689183f716" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_us-gaap_PaymentsForFees_614f4ed7-bd73-4f4c-ab02-34689183f716" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsPurchaseOfShares_ee77e19e-88c7-4676-b7a5-4bb1a2aafbe0" xlink:href="ameh-20200630.xsd#ameh_EquityMethodInvestmentsPurchaseOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_ameh_EquityMethodInvestmentsPurchaseOfShares_ee77e19e-88c7-4676-b7a5-4bb1a2aafbe0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_f2eb8482-1028-4b9b-b1a9-de2bd40a0360" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_f2eb8482-1028-4b9b-b1a9-de2bd40a0360" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock_9c4c407f-b3aa-4bd7-9fe8-c93ddcd69548" xlink:href="ameh-20200630.xsd#ameh_EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_ameh_EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock_9c4c407f-b3aa-4bd7-9fe8-c93ddcd69548" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentOwnershipPercentageDisposed_64d6e476-2aeb-46f4-8f35-cf4105fadd56" xlink:href="ameh-20200630.xsd#ameh_EquityMethodInvestmentOwnershipPercentageDisposed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_ameh_EquityMethodInvestmentOwnershipPercentageDisposed_64d6e476-2aeb-46f4-8f35-cf4105fadd56" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_3854372a-1330-4cc6-bdad-b235c476812e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_3854372a-1330-4cc6-bdad-b235c476812e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfDebt_36aba422-a343-4f74-83b7-9460c4c632d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfDebt_36aba422-a343-4f74-83b7-9460c4c632d9" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_437e4c02-e548-46c0-9b76-72f1a4da90ad" xlink:href="ameh-20200630.xsd#ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_437e4c02-e548-46c0-9b76-72f1a4da90ad" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet_578fa8bc-1c81-4281-bfce-5be7a9c53e13" xlink:href="ameh-20200630.xsd#ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet_578fa8bc-1c81-4281-bfce-5be7a9c53e13" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationCash_b51637bc-1fd3-4c36-86e1-e1e689a635a0" xlink:href="ameh-20200630.xsd#ameh_EquityMethodInvestmentSaleContingentConsiderationCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationCash_b51637bc-1fd3-4c36-86e1-e1e689a635a0" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares_2f735a77-87e0-4ab7-a4aa-e400d988b8f1" xlink:href="ameh-20200630.xsd#ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares_2f735a77-87e0-4ab7-a4aa-e400d988b8f1" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue_9ea74678-bd73-468f-b88a-f9fee7a51ad5" xlink:href="ameh-20200630.xsd#ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue_9ea74678-bd73-468f-b88a-f9fee7a51ad5" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MembersCapital_990db7bf-7238-43a9-a860-151e59463779" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MembersCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_us-gaap_MembersCapital_990db7bf-7238-43a9-a860-151e59463779" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireRealEstate_28a4d4ed-e2f0-40e4-9a00-7001254377cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireRealEstate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_us-gaap_PaymentsToAcquireRealEstate_28a4d4ed-e2f0-40e4-9a00-7001254377cc" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsContribution_ed6c4f67-3dcf-44c1-a03e-f1b63f32165a" xlink:href="ameh-20200630.xsd#ameh_EquityMethodInvestmentsContribution"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_ameh_EquityMethodInvestmentsContribution_ed6c4f67-3dcf-44c1-a03e-f1b63f32165a" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WorkingCapitalContribution_27c32305-6a44-445a-922d-4842f62cc634" xlink:href="ameh-20200630.xsd#ameh_WorkingCapitalContribution"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_ameh_WorkingCapitalContribution_27c32305-6a44-445a-922d-4842f62cc634" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares_eb61d87d-501a-4f75-abc6-975157d4c706" xlink:href="ameh-20200630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares_eb61d87d-501a-4f75-abc6-975157d4c706" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_a0adc618-7eda-4ee2-a7b0-599bd91a8773" xlink:href="ameh-20200630.xsd#ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_a0adc618-7eda-4ee2-a7b0-599bd91a8773" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest_1f3b2570-d08d-4c72-afe9-a48870c70f70" xlink:href="ameh-20200630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest_1f3b2570-d08d-4c72-afe9-a48870c70f70" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage_6e38bb5d-9b46-49a7-af13-7e851125ed46" xlink:href="ameh-20200630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage_6e38bb5d-9b46-49a7-af13-7e851125ed46" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_44fc1f29-a7bb-4aa4-867e-1a37bd985bf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_44fc1f29-a7bb-4aa4-867e-1a37bd985bf4" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_fd6edebc-35ee-4710-90e7-d1cdd924eeab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_fd6edebc-35ee-4710-90e7-d1cdd924eeab" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption_8d0b037d-412e-42e5-a093-8ab1e6e71d6a" xlink:href="ameh-20200630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption_8d0b037d-412e-42e5-a093-8ab1e6e71d6a" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests_acae4a6d-e291-4a3f-92b1-c4b499fed8d3" xlink:href="ameh-20200630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests_acae4a6d-e291-4a3f-92b1-c4b499fed8d3" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet_7d301c0c-b6af-40bf-ad14-a2792598894b" xlink:href="ameh-20200630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet_7d301c0c-b6af-40bf-ad14-a2792598894b" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears_d65ed1c0-b2e4-464e-8c80-b40105838834" xlink:href="ameh-20200630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears_d65ed1c0-b2e4-464e-8c80-b40105838834" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment_05bd95ed-0180-4553-a0b8-faeb7797a302" xlink:href="ameh-20200630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment_05bd95ed-0180-4553-a0b8-faeb7797a302" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost_f36dd05c-09c7-494b-9fa4-16bedcd17e54" xlink:href="ameh-20200630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost_f36dd05c-09c7-494b-9fa4-16bedcd17e54" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_54d93dee-6965-41a2-bccf-f9cccf9f97f1" xlink:href="ameh-20200630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_54d93dee-6965-41a2-bccf-f9cccf9f97f1" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_b69374cc-543f-4173-876e-0d36457c3915" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_b69374cc-543f-4173-876e-0d36457c3915" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_fb3c2411-50a1-491f-836e-af72191756f1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_b69374cc-543f-4173-876e-0d36457c3915" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_fb3c2411-50a1-491f-836e-af72191756f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_fb3c2411-50a1-491f-836e-af72191756f1_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_fb3c2411-50a1-491f-836e-af72191756f1" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_fb3c2411-50a1-491f-836e-af72191756f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_1169c703-ca93-42f9-ae1a-d29eb7735f36" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_fb3c2411-50a1-491f-836e-af72191756f1" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_1169c703-ca93-42f9-ae1a-d29eb7735f36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember_39978da4-5293-448e-9506-36b71995322a" xlink:href="ameh-20200630.xsd#ameh_LasalleMedicalAssociatesIpaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1169c703-ca93-42f9-ae1a-d29eb7735f36" xlink:to="loc_ameh_LasalleMedicalAssociatesIpaMember_39978da4-5293-448e-9506-36b71995322a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_531ad277-ddf1-48e9-9b0c-387b9172b9c3" xlink:href="ameh-20200630.xsd#ameh_PacificMedicalImagingAndOncologyCenterIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1169c703-ca93-42f9-ae1a-d29eb7735f36" xlink:to="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_531ad277-ddf1-48e9-9b0c-387b9172b9c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareIncMember_5f4a75ee-4fed-4261-8d7a-115c636e9d69" xlink:href="ameh-20200630.xsd#ameh_UniversalCareIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1169c703-ca93-42f9-ae1a-d29eb7735f36" xlink:to="loc_ameh_UniversalCareIncMember_5f4a75ee-4fed-4261-8d7a-115c636e9d69" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DiagnosticMedicalGroupMember_5a247bea-59ec-4293-a535-194b97577c43" xlink:href="ameh-20200630.xsd#ameh_DiagnosticMedicalGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1169c703-ca93-42f9-ae1a-d29eb7735f36" xlink:to="loc_ameh_DiagnosticMedicalGroupMember_5a247bea-59ec-4293-a535-194b97577c43" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiveThreeOneW.CollegeLLCMember_41c49788-a21f-410f-8d9e-6da98e3bcdb2" xlink:href="ameh-20200630.xsd#ameh_FiveThreeOneW.CollegeLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1169c703-ca93-42f9-ae1a-d29eb7735f36" xlink:to="loc_ameh_FiveThreeOneW.CollegeLLCMember_41c49788-a21f-410f-8d9e-6da98e3bcdb2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MWNCommunityHospitalLLCMember_27f7ff4f-09e8-429b-8cb3-8e90557ff37a" xlink:href="ameh-20200630.xsd#ameh_MWNCommunityHospitalLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1169c703-ca93-42f9-ae1a-d29eb7735f36" xlink:to="loc_ameh_MWNCommunityHospitalLLCMember_27f7ff4f-09e8-429b-8cb3-8e90557ff37a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_35dccf57-3f84-4528-b00e-c28b30184662" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_b69374cc-543f-4173-876e-0d36457c3915" xlink:to="loc_dei_LegalEntityAxis_35dccf57-3f84-4528-b00e-c28b30184662" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_35dccf57-3f84-4528-b00e-c28b30184662_default" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_35dccf57-3f84-4528-b00e-c28b30184662" xlink:to="loc_dei_EntityDomain_35dccf57-3f84-4528-b00e-c28b30184662_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_33b87d7a-2ffb-4408-bde6-52fd27c8dd64" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_35dccf57-3f84-4528-b00e-c28b30184662" xlink:to="loc_dei_EntityDomain_33b87d7a-2ffb-4408-bde6-52fd27c8dd64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcLsmaMember_c660a94c-595b-48a6-8ca9-728b553fba3c" xlink:href="ameh-20200630.xsd#ameh_ApcLsmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_33b87d7a-2ffb-4408-bde6-52fd27c8dd64" xlink:to="loc_ameh_ApcLsmaMember_c660a94c-595b-48a6-8ca9-728b553fba3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_c3dc959b-958e-486f-8fa8-0393ec70d269" xlink:href="ameh-20200630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_33b87d7a-2ffb-4408-bde6-52fd27c8dd64" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_c3dc959b-958e-486f-8fa8-0393ec70d269" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_dbb98ead-ecd4-42ad-915e-ca64af50d2f9" xlink:href="ameh-20200630.xsd#ameh_UniversalCareAcquisitionPartnersLlcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_33b87d7a-2ffb-4408-bde6-52fd27c8dd64" xlink:to="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_dbb98ead-ecd4-42ad-915e-ca64af50d2f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountableHealthCareIPAMember_b42b5211-3b7f-4691-afd4-d082670489f6" xlink:href="ameh-20200630.xsd#ameh_AccountableHealthCareIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_33b87d7a-2ffb-4408-bde6-52fd27c8dd64" xlink:to="loc_ameh_AccountableHealthCareIPAMember_b42b5211-3b7f-4691-afd4-d082670489f6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CollegeStreetInvestmentLpMember_4d317d11-1d3d-4124-ae7f-8b15c0a6beec" xlink:href="ameh-20200630.xsd#ameh_CollegeStreetInvestmentLpMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_33b87d7a-2ffb-4408-bde6-52fd27c8dd64" xlink:to="loc_ameh_CollegeStreetInvestmentLpMember_4d317d11-1d3d-4124-ae7f-8b15c0a6beec" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementIncMember_f16ea598-ef9f-4b4a-b95a-ab4d337ac918" xlink:href="ameh-20200630.xsd#ameh_NetworkMedicalManagementIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_33b87d7a-2ffb-4408-bde6-52fd27c8dd64" xlink:to="loc_ameh_NetworkMedicalManagementIncMember_f16ea598-ef9f-4b4a-b95a-ab4d337ac918" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Pacific6EnterprisesMember_68150018-96a9-4ae1-b8c0-4ad118a07647" xlink:href="ameh-20200630.xsd#ameh_Pacific6EnterprisesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_33b87d7a-2ffb-4408-bde6-52fd27c8dd64" xlink:to="loc_ameh_Pacific6EnterprisesMember_68150018-96a9-4ae1-b8c0-4ad118a07647" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_HealthSourceMSOInc.Member_5723388b-b02c-4bb6-9366-8b1f78bcc1dc" xlink:href="ameh-20200630.xsd#ameh_HealthSourceMSOInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_33b87d7a-2ffb-4408-bde6-52fd27c8dd64" xlink:to="loc_ameh_HealthSourceMSOInc.Member_5723388b-b02c-4bb6-9366-8b1f78bcc1dc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContractTypeAxis_f683a8da-ca48-40ac-b7ae-36205b4d0cd5" xlink:href="ameh-20200630.xsd#ameh_ContractTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_b69374cc-543f-4173-876e-0d36457c3915" xlink:to="loc_ameh_ContractTypeAxis_f683a8da-ca48-40ac-b7ae-36205b4d0cd5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContractTypeDomain_f683a8da-ca48-40ac-b7ae-36205b4d0cd5_default" xlink:href="ameh-20200630.xsd#ameh_ContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ameh_ContractTypeAxis_f683a8da-ca48-40ac-b7ae-36205b4d0cd5" xlink:to="loc_ameh_ContractTypeDomain_f683a8da-ca48-40ac-b7ae-36205b4d0cd5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContractTypeDomain_b3c8b1f6-4f6f-487e-aab6-f8f3e7bb0a9e" xlink:href="ameh-20200630.xsd#ameh_ContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ameh_ContractTypeAxis_f683a8da-ca48-40ac-b7ae-36205b4d0cd5" xlink:to="loc_ameh_ContractTypeDomain_b3c8b1f6-4f6f-487e-aab6-f8f3e7bb0a9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AncillaryServiceContractMember_b6c049b6-13a3-4800-bf46-c2fbb41b762a" xlink:href="ameh-20200630.xsd#ameh_AncillaryServiceContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_ContractTypeDomain_b3c8b1f6-4f6f-487e-aab6-f8f3e7bb0a9e" xlink:to="loc_ameh_AncillaryServiceContractMember_b6c049b6-13a3-4800-bf46-c2fbb41b762a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_fb65ab19-9dc8-4bca-8e4a-c6e2c5a15ae4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_b69374cc-543f-4173-876e-0d36457c3915" xlink:to="loc_us-gaap_StatementClassOfStockAxis_fb65ab19-9dc8-4bca-8e4a-c6e2c5a15ae4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_fb65ab19-9dc8-4bca-8e4a-c6e2c5a15ae4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_fb65ab19-9dc8-4bca-8e4a-c6e2c5a15ae4" xlink:to="loc_us-gaap_ClassOfStockDomain_fb65ab19-9dc8-4bca-8e4a-c6e2c5a15ae4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_fae4e07d-eed7-4d4d-b676-627418061811" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_fb65ab19-9dc8-4bca-8e4a-c6e2c5a15ae4" xlink:to="loc_us-gaap_ClassOfStockDomain_fae4e07d-eed7-4d4d-b676-627418061811" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_VotingCommonStockTwoMember_60439da5-46a5-42eb-9142-32d63a6f2384" xlink:href="ameh-20200630.xsd#ameh_VotingCommonStockTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_fae4e07d-eed7-4d4d-b676-627418061811" xlink:to="loc_ameh_VotingCommonStockTwoMember_60439da5-46a5-42eb-9142-32d63a6f2384" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_fa87aa7a-eaee-4904-8f76-6bb888eb6ba9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_fae4e07d-eed7-4d4d-b676-627418061811" xlink:to="loc_us-gaap_PreferredStockMember_fa87aa7a-eaee-4904-8f76-6bb888eb6ba9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_bb717b7a-375e-4300-a47d-0c7f4f4e02b5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_b69374cc-543f-4173-876e-0d36457c3915" xlink:to="loc_srt_CounterpartyNameAxis_bb717b7a-375e-4300-a47d-0c7f4f4e02b5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bb717b7a-375e-4300-a47d-0c7f4f4e02b5_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_bb717b7a-375e-4300-a47d-0c7f4f4e02b5" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bb717b7a-375e-4300-a47d-0c7f4f4e02b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_829ce20b-53d4-45b1-8ac6-b19b6fea75e1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_bb717b7a-375e-4300-a47d-0c7f4f4e02b5" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_829ce20b-53d4-45b1-8ac6-b19b6fea75e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_e6d37319-4351-4a14-9217-5abd9505b751" xlink:href="ameh-20200630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_829ce20b-53d4-45b1-8ac6-b19b6fea75e1" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_e6d37319-4351-4a14-9217-5abd9505b751" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BrightHealthCompanyOfCaliforniaInc.Member_32843415-42db-4039-bc78-0abe5258b305" xlink:href="ameh-20200630.xsd#ameh_BrightHealthCompanyOfCaliforniaInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_829ce20b-53d4-45b1-8ac6-b19b6fea75e1" xlink:to="loc_ameh_BrightHealthCompanyOfCaliforniaInc.Member_32843415-42db-4039-bc78-0abe5258b305" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_a93800f3-1d31-49d2-8ba2-87970094c4a4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_b69374cc-543f-4173-876e-0d36457c3915" xlink:to="loc_srt_OwnershipAxis_a93800f3-1d31-49d2-8ba2-87970094c4a4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_a93800f3-1d31-49d2-8ba2-87970094c4a4_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_a93800f3-1d31-49d2-8ba2-87970094c4a4" xlink:to="loc_srt_OwnershipDomain_a93800f3-1d31-49d2-8ba2-87970094c4a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_49b4bb48-0d3b-4ca0-801f-45f7677967e5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_a93800f3-1d31-49d2-8ba2-87970094c4a4" xlink:to="loc_srt_OwnershipDomain_49b4bb48-0d3b-4ca0-801f-45f7677967e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MediPortalLLCMember_fbe3e7d2-ec11-4cc8-9531-87601cab2b47" xlink:href="ameh-20200630.xsd#ameh_MediPortalLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_49b4bb48-0d3b-4ca0-801f-45f7677967e5" xlink:to="loc_ameh_MediPortalLLCMember_fbe3e7d2-ec11-4cc8-9531-87601cab2b47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AchievaMedInc.Member_851bf0b7-a7fb-43c1-9277-bef2875ed88b" xlink:href="ameh-20200630.xsd#ameh_AchievaMedInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_49b4bb48-0d3b-4ca0-801f-45f7677967e5" xlink:to="loc_ameh_AchievaMedInc.Member_851bf0b7-a7fb-43c1-9277-bef2875ed88b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodGainonSaleDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#InvestmentsinOtherEntitiesEquityMethodGainonSaleDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodGainonSaleDetails" xlink:type="extended" id="id65f5002c5434ea78cf865ede25b6f0a_InvestmentsinOtherEntitiesEquityMethodGainonSaleDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_12110f3b-011f-4e3e-a65a-ec52c365f863" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_46b840c3-8ebb-4027-adb1-e089626228d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_12110f3b-011f-4e3e-a65a-ec52c365f863" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_46b840c3-8ebb-4027-adb1-e089626228d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_4bc7da30-3940-4766-b8b7-0a886efd3bbf" xlink:href="ameh-20200630.xsd#ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_12110f3b-011f-4e3e-a65a-ec52c365f863" xlink:to="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_4bc7da30-3940-4766-b8b7-0a886efd3bbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet_3b416000-8f6e-49b6-8928-01c0610a6f13" xlink:href="ameh-20200630.xsd#ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_12110f3b-011f-4e3e-a65a-ec52c365f863" xlink:to="loc_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet_3b416000-8f6e-49b6-8928-01c0610a6f13" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_2a51dd6a-c1a4-4eef-ba6d-93f2bca8d95b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_12110f3b-011f-4e3e-a65a-ec52c365f863" xlink:to="loc_us-gaap_EquityMethodInvestments_2a51dd6a-c1a4-4eef-ba6d-93f2bca8d95b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_95cf11a7-c847-4f77-afee-c558a4fbfd8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_12110f3b-011f-4e3e-a65a-ec52c365f863" xlink:to="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_95cf11a7-c847-4f77-afee-c558a4fbfd8b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_7b7c3998-7f65-48d8-a985-3d4248b70393" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_12110f3b-011f-4e3e-a65a-ec52c365f863" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_7b7c3998-7f65-48d8-a985-3d4248b70393" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_99b040e7-a741-4f58-b33b-45f33e9988a5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_7b7c3998-7f65-48d8-a985-3d4248b70393" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_99b040e7-a741-4f58-b33b-45f33e9988a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_99b040e7-a741-4f58-b33b-45f33e9988a5_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_99b040e7-a741-4f58-b33b-45f33e9988a5" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_99b040e7-a741-4f58-b33b-45f33e9988a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_01a59534-309a-476d-89c0-7d60c3c3147e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_99b040e7-a741-4f58-b33b-45f33e9988a5" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_01a59534-309a-476d-89c0-7d60c3c3147e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareIncMember_475490dc-4f5a-4aaf-bc25-6aff75505510" xlink:href="ameh-20200630.xsd#ameh_UniversalCareIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_01a59534-309a-476d-89c0-7d60c3c3147e" xlink:to="loc_ameh_UniversalCareIncMember_475490dc-4f5a-4aaf-bc25-6aff75505510" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_38a0fe9f-22d0-4b31-b9da-2df5023b788c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_7b7c3998-7f65-48d8-a985-3d4248b70393" xlink:to="loc_srt_CounterpartyNameAxis_38a0fe9f-22d0-4b31-b9da-2df5023b788c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_38a0fe9f-22d0-4b31-b9da-2df5023b788c_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_38a0fe9f-22d0-4b31-b9da-2df5023b788c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_38a0fe9f-22d0-4b31-b9da-2df5023b788c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e8fe04c1-2108-4c4b-b9be-135182322608" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_38a0fe9f-22d0-4b31-b9da-2df5023b788c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e8fe04c1-2108-4c4b-b9be-135182322608" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BrightHealthCompanyOfCaliforniaInc.Member_087490bd-14f8-4210-9c50-74270d87afc2" xlink:href="ameh-20200630.xsd#ameh_BrightHealthCompanyOfCaliforniaInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e8fe04c1-2108-4c4b-b9be-135182322608" xlink:to="loc_ameh_BrightHealthCompanyOfCaliforniaInc.Member_087490bd-14f8-4210-9c50-74270d87afc2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f1e9b5a7-f55b-4254-b9a1-260920e4d2a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_7b7c3998-7f65-48d8-a985-3d4248b70393" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f1e9b5a7-f55b-4254-b9a1-260920e4d2a2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f1e9b5a7-f55b-4254-b9a1-260920e4d2a2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f1e9b5a7-f55b-4254-b9a1-260920e4d2a2" xlink:to="loc_us-gaap_ClassOfStockDomain_f1e9b5a7-f55b-4254-b9a1-260920e4d2a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ba7ee61b-d90e-427f-ac9e-38f7028e2c07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f1e9b5a7-f55b-4254-b9a1-260920e4d2a2" xlink:to="loc_us-gaap_ClassOfStockDomain_ba7ee61b-d90e-427f-ac9e-38f7028e2c07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_f564a6ab-8e50-4b78-9a0a-031358792840" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_ba7ee61b-d90e-427f-ac9e-38f7028e2c07" xlink:to="loc_us-gaap_PreferredStockMember_f564a6ab-8e50-4b78-9a0a-031358792840" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails" xlink:type="extended" id="i6b1f836fa2744a0abe015e88b8607878_InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_e9385d11-df13-4c1a-8835-d9451621b1c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_95d3bbab-2426-4ea7-85f7-3c5c81d4ddf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_e9385d11-df13-4c1a-8835-d9451621b1c7" xlink:to="loc_us-gaap_AssetsAbstract_95d3bbab-2426-4ea7-85f7-3c5c81d4ddf5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f2b2d8aa-ffd3-4811-9777-22b37bc2cf77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_95d3bbab-2426-4ea7-85f7-3c5c81d4ddf5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f2b2d8aa-ffd3-4811-9777-22b37bc2cf77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_915f944d-fe62-406d-9482-c20807504967" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_95d3bbab-2426-4ea7-85f7-3c5c81d4ddf5" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_915f944d-fe62-406d-9482-c20807504967" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_71165036-3052-437b-84ce-45c558807082" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_95d3bbab-2426-4ea7-85f7-3c5c81d4ddf5" xlink:to="loc_us-gaap_OtherAssetsCurrent_71165036-3052-437b-84ce-45c558807082" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent_0148cf4f-de38-43f3-93a4-230fc30be717" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_95d3bbab-2426-4ea7-85f7-3c5c81d4ddf5" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetCurrent_0148cf4f-de38-43f3-93a4-230fc30be717" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_3e2ec748-a00d-4eb2-b185-aba85db09117" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_95d3bbab-2426-4ea7-85f7-3c5c81d4ddf5" xlink:to="loc_us-gaap_RestrictedCashCurrent_3e2ec748-a00d-4eb2-b185-aba85db09117" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets_07e3f249-023c-40d4-ba40-7c7c79576e14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_95d3bbab-2426-4ea7-85f7-3c5c81d4ddf5" xlink:to="loc_us-gaap_OtherAssets_07e3f249-023c-40d4-ba40-7c7c79576e14" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_02c1eabd-65c3-4eda-ac82-183d4a00336b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_95d3bbab-2426-4ea7-85f7-3c5c81d4ddf5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_02c1eabd-65c3-4eda-ac82-183d4a00336b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_6151ede4-5655-443d-ad7a-4c03dee2e9c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_95d3bbab-2426-4ea7-85f7-3c5c81d4ddf5" xlink:to="loc_us-gaap_Assets_6151ede4-5655-443d-ad7a-4c03dee2e9c1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2eea7f7f-f826-4ae7-9b7e-5388bcf23457" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_e9385d11-df13-4c1a-8835-d9451621b1c7" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2eea7f7f-f826-4ae7-9b7e-5388bcf23457" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_04d57844-97e4-4c7b-a95a-b1a6bc1fea2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2eea7f7f-f826-4ae7-9b7e-5388bcf23457" xlink:to="loc_us-gaap_LiabilitiesCurrent_04d57844-97e4-4c7b-a95a-b1a6bc1fea2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilities_7780d4b9-6eda-40ba-976e-a4a1c7901f72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2eea7f7f-f826-4ae7-9b7e-5388bcf23457" xlink:to="loc_us-gaap_OtherLiabilities_7780d4b9-6eda-40ba-976e-a4a1c7901f72" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8697ce39-e65f-48c6-bae9-f7a2b36cf7a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2eea7f7f-f826-4ae7-9b7e-5388bcf23457" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8697ce39-e65f-48c6-bae9-f7a2b36cf7a1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_894c5227-3427-4201-8c69-26220c6c735f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2eea7f7f-f826-4ae7-9b7e-5388bcf23457" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_894c5227-3427-4201-8c69-26220c6c735f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_fb42f509-ff71-4ebc-8c26-32394d4314dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_e9385d11-df13-4c1a-8835-d9451621b1c7" xlink:to="loc_us-gaap_IncomeStatementAbstract_fb42f509-ff71-4ebc-8c26-32394d4314dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_eceaedc9-6cbd-4229-8bdd-ec755cf19f8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_fb42f509-ff71-4ebc-8c26-32394d4314dc" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_eceaedc9-6cbd-4229-8bdd-ec755cf19f8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_048dcb97-df54-4afc-8908-9fdba33c930e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_fb42f509-ff71-4ebc-8c26-32394d4314dc" xlink:to="loc_us-gaap_CostsAndExpenses_048dcb97-df54-4afc-8908-9fdba33c930e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_231bf4d3-a15e-4d08-91fe-bc8f3d1bf159" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_fb42f509-ff71-4ebc-8c26-32394d4314dc" xlink:to="loc_us-gaap_OperatingIncomeLoss_231bf4d3-a15e-4d08-91fe-bc8f3d1bf159" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_f17a962b-2540-40fd-bb5d-be6355f1a528" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_fb42f509-ff71-4ebc-8c26-32394d4314dc" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_f17a962b-2540-40fd-bb5d-be6355f1a528" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_dad3bc9d-210f-44ad-9d55-d5010c51d90e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_fb42f509-ff71-4ebc-8c26-32394d4314dc" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_dad3bc9d-210f-44ad-9d55-d5010c51d90e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c6a826c8-a614-471a-bd10-b4b9c05123b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_fb42f509-ff71-4ebc-8c26-32394d4314dc" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_c6a826c8-a614-471a-bd10-b4b9c05123b8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_0e8d6dc8-3b6e-4b93-8ceb-946459e029f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_fb42f509-ff71-4ebc-8c26-32394d4314dc" xlink:to="loc_us-gaap_ProfitLoss_0e8d6dc8-3b6e-4b93-8ceb-946459e029f1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_6d140ac8-d7af-4a0e-a701-6aae16e3b136" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_e9385d11-df13-4c1a-8835-d9451621b1c7" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_6d140ac8-d7af-4a0e-a701-6aae16e3b136" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_4754e914-505a-4f06-b81f-f4a312374e6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_6d140ac8-d7af-4a0e-a701-6aae16e3b136" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_4754e914-505a-4f06-b81f-f4a312374e6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_4754e914-505a-4f06-b81f-f4a312374e6f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_4754e914-505a-4f06-b81f-f4a312374e6f" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_4754e914-505a-4f06-b81f-f4a312374e6f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_1ad333c1-53fc-42e4-aded-817f19af00ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_4754e914-505a-4f06-b81f-f4a312374e6f" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_1ad333c1-53fc-42e4-aded-817f19af00ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember_da83b4e4-e2bd-4799-b8f9-79a6068995f0" xlink:href="ameh-20200630.xsd#ameh_LasalleMedicalAssociatesIpaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_1ad333c1-53fc-42e4-aded-817f19af00ee" xlink:to="loc_ameh_LasalleMedicalAssociatesIpaMember_da83b4e4-e2bd-4799-b8f9-79a6068995f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiveThreeOneW.CollegeLLCMember_a0544ac5-5285-4f7a-8306-752d51e2dce4" xlink:href="ameh-20200630.xsd#ameh_FiveThreeOneW.CollegeLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_1ad333c1-53fc-42e4-aded-817f19af00ee" xlink:to="loc_ameh_FiveThreeOneW.CollegeLLCMember_a0544ac5-5285-4f7a-8306-752d51e2dce4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareIncMember_8c1035d1-ea20-449c-8a55-51f44531a3e3" xlink:href="ameh-20200630.xsd#ameh_UniversalCareIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_1ad333c1-53fc-42e4-aded-817f19af00ee" xlink:to="loc_ameh_UniversalCareIncMember_8c1035d1-ea20-449c-8a55-51f44531a3e3" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedParties" xlink:type="simple" xlink:href="ameh-20200630.xsd#LoanReceivableandLoanReceivableRelatedParties"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedParties" xlink:type="extended" id="i52e49b033da84f868529ff7c74d72926_LoanReceivableandLoanReceivableRelatedParties"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails" xlink:type="extended" id="idceab7c174f9431392ecaaa764458a20_LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_ab3c4536-516f-40d5-a445-2333ec69911f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet_017d43f5-fdaf-46e9-8da5-a68c2c995136" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_ab3c4536-516f-40d5-a445-2333ec69911f" xlink:to="loc_us-gaap_NotesReceivableNet_017d43f5-fdaf-46e9-8da5-a68c2c995136" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_55cdd4df-c66e-4bda-9049-41ef968eed09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_ab3c4536-516f-40d5-a445-2333ec69911f" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_55cdd4df-c66e-4bda-9049-41ef968eed09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_933de066-9974-48a2-944c-d4b71d46ed0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_ab3c4536-516f-40d5-a445-2333ec69911f" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_933de066-9974-48a2-944c-d4b71d46ed0f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinancingReceivableConvertibleToCommonStockPercentageOfOutstandingSharesConvertible_0c04c5cc-47a3-4b6b-b8f0-ccf15d9333a2" xlink:href="ameh-20200630.xsd#ameh_FinancingReceivableConvertibleToCommonStockPercentageOfOutstandingSharesConvertible"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_ab3c4536-516f-40d5-a445-2333ec69911f" xlink:to="loc_ameh_FinancingReceivableConvertibleToCommonStockPercentageOfOutstandingSharesConvertible_0c04c5cc-47a3-4b6b-b8f0-ccf15d9333a2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion_fa205885-9cb5-4182-a608-6ead0d562088" xlink:href="ameh-20200630.xsd#ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_ab3c4536-516f-40d5-a445-2333ec69911f" xlink:to="loc_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion_fa205885-9cb5-4182-a608-6ead0d562088" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4a08820e-c2e5-4c50-bfa0-0259dcd4f11c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_ab3c4536-516f-40d5-a445-2333ec69911f" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4a08820e-c2e5-4c50-bfa0-0259dcd4f11c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AdvancedForWorkingCapital_af295618-f3bb-49c9-9415-ec8400dca400" xlink:href="ameh-20200630.xsd#ameh_AdvancedForWorkingCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_ab3c4536-516f-40d5-a445-2333ec69911f" xlink:to="loc_ameh_AdvancedForWorkingCapital_af295618-f3bb-49c9-9415-ec8400dca400" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LineOfCreditFacilityAdditionalAdvances_b303c79e-3578-4f11-ab0b-ea9fc8fafe76" xlink:href="ameh-20200630.xsd#ameh_LineOfCreditFacilityAdditionalAdvances"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_ab3c4536-516f-40d5-a445-2333ec69911f" xlink:to="loc_ameh_LineOfCreditFacilityAdditionalAdvances_b303c79e-3578-4f11-ab0b-ea9fc8fafe76" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_61cfde64-c0bc-4ee4-b994-8278944afb5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_ab3c4536-516f-40d5-a445-2333ec69911f" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_61cfde64-c0bc-4ee4-b994-8278944afb5d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_be698141-a10c-4b00-95fe-7f58cb7543b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_ab3c4536-516f-40d5-a445-2333ec69911f" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_be698141-a10c-4b00-95fe-7f58cb7543b1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_bf66c944-6866-4a7a-954d-afbcbf7dcf33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_be698141-a10c-4b00-95fe-7f58cb7543b1" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_bf66c944-6866-4a7a-954d-afbcbf7dcf33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_bf66c944-6866-4a7a-954d-afbcbf7dcf33_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_bf66c944-6866-4a7a-954d-afbcbf7dcf33" xlink:to="loc_us-gaap_ReceivableTypeDomain_bf66c944-6866-4a7a-954d-afbcbf7dcf33_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_56cff6cf-487a-4f55-9cdc-a334bb79fdc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_bf66c944-6866-4a7a-954d-afbcbf7dcf33" xlink:to="loc_us-gaap_ReceivableTypeDomain_56cff6cf-487a-4f55-9cdc-a334bb79fdc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableMember_b5f2f519-2cf8-4440-818a-8cbd53875348" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_56cff6cf-487a-4f55-9cdc-a334bb79fdc8" xlink:to="loc_us-gaap_NotesReceivableMember_b5f2f519-2cf8-4440-818a-8cbd53875348" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceReceivablesMember_2410d652-fe83-4d0d-b9f4-e61ad9058176" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceReceivablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_56cff6cf-487a-4f55-9cdc-a334bb79fdc8" xlink:to="loc_us-gaap_FinanceReceivablesMember_2410d652-fe83-4d0d-b9f4-e61ad9058176" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_56deb266-6cd0-4150-97b9-bf193892a0fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_be698141-a10c-4b00-95fe-7f58cb7543b1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_56deb266-6cd0-4150-97b9-bf193892a0fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_56deb266-6cd0-4150-97b9-bf193892a0fb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_56deb266-6cd0-4150-97b9-bf193892a0fb" xlink:to="loc_us-gaap_RelatedPartyDomain_56deb266-6cd0-4150-97b9-bf193892a0fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_bd9665fa-b14a-461a-b814-7240ba430ded" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_56deb266-6cd0-4150-97b9-bf193892a0fb" xlink:to="loc_us-gaap_RelatedPartyDomain_bd9665fa-b14a-461a-b814-7240ba430ded" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Dr.ArteagaMember_68cf7ab6-2775-4ae4-a3f6-c8fbc52968d1" xlink:href="ameh-20200630.xsd#ameh_Dr.ArteagaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_bd9665fa-b14a-461a-b814-7240ba430ded" xlink:to="loc_ameh_Dr.ArteagaMember_68cf7ab6-2775-4ae4-a3f6-c8fbc52968d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DrJayLoanMember_5b3a136b-ee1d-4d10-8e12-90dcabef549a" xlink:href="ameh-20200630.xsd#ameh_DrJayLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_bd9665fa-b14a-461a-b814-7240ba430ded" xlink:to="loc_ameh_DrJayLoanMember_5b3a136b-ee1d-4d10-8e12-90dcabef549a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_e82a7e0e-d8b1-46ba-8514-8852f90cd9eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_be698141-a10c-4b00-95fe-7f58cb7543b1" xlink:to="loc_us-gaap_VariableRateAxis_e82a7e0e-d8b1-46ba-8514-8852f90cd9eb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_e82a7e0e-d8b1-46ba-8514-8852f90cd9eb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_e82a7e0e-d8b1-46ba-8514-8852f90cd9eb" xlink:to="loc_us-gaap_VariableRateDomain_e82a7e0e-d8b1-46ba-8514-8852f90cd9eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_bcd40099-ec2d-4ada-b727-34a654cd53d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_e82a7e0e-d8b1-46ba-8514-8852f90cd9eb" xlink:to="loc_us-gaap_VariableRateDomain_bcd40099-ec2d-4ada-b727-34a654cd53d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_c93ea068-9d44-414b-b745-8c4b31673d33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrimeRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_bcd40099-ec2d-4ada-b727-34a654cd53d9" xlink:to="loc_us-gaap_PrimeRateMember_c93ea068-9d44-414b-b745-8c4b31673d33" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_1ddd80fc-9a97-4ae3-972a-f6a889ba7267" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_be698141-a10c-4b00-95fe-7f58cb7543b1" xlink:to="loc_dei_LegalEntityAxis_1ddd80fc-9a97-4ae3-972a-f6a889ba7267" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_1ddd80fc-9a97-4ae3-972a-f6a889ba7267_default" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1ddd80fc-9a97-4ae3-972a-f6a889ba7267" xlink:to="loc_dei_EntityDomain_1ddd80fc-9a97-4ae3-972a-f6a889ba7267_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_5b347c55-8a05-4d6b-8c3e-a1d29d8ed9af" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1ddd80fc-9a97-4ae3-972a-f6a889ba7267" xlink:to="loc_dei_EntityDomain_5b347c55-8a05-4d6b-8c3e-a1d29d8ed9af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_869ae1da-327f-4b8e-aabc-48dfbab6998f" xlink:href="ameh-20200630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_5b347c55-8a05-4d6b-8c3e-a1d29d8ed9af" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_869ae1da-327f-4b8e-aabc-48dfbab6998f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_APCAndAPCLSMAMember_5440634c-8dda-437e-94fa-43431fed6e1c" xlink:href="ameh-20200630.xsd#ameh_APCAndAPCLSMAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_5b347c55-8a05-4d6b-8c3e-a1d29d8ed9af" xlink:to="loc_ameh_APCAndAPCLSMAMember_5440634c-8dda-437e-94fa-43431fed6e1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Dr.ArteagaMember_0e8f191b-8e29-4c35-b888-b972b977d3bd" xlink:href="ameh-20200630.xsd#ameh_Dr.ArteagaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_5b347c55-8a05-4d6b-8c3e-a1d29d8ed9af" xlink:to="loc_ameh_Dr.ArteagaMember_0e8f191b-8e29-4c35-b888-b972b977d3bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_bb7152de-148a-46b6-bd06-19d899f19229" xlink:href="ameh-20200630.xsd#ameh_UniversalCareAcquisitionPartnersLlcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_5b347c55-8a05-4d6b-8c3e-a1d29d8ed9af" xlink:to="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_bb7152de-148a-46b6-bd06-19d899f19229" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_09564fe7-0f3a-49f8-b5f5-21c5ecaf9e71" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_be698141-a10c-4b00-95fe-7f58cb7543b1" xlink:to="loc_srt_CounterpartyNameAxis_09564fe7-0f3a-49f8-b5f5-21c5ecaf9e71" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_09564fe7-0f3a-49f8-b5f5-21c5ecaf9e71_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_09564fe7-0f3a-49f8-b5f5-21c5ecaf9e71" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_09564fe7-0f3a-49f8-b5f5-21c5ecaf9e71_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_db574b7f-4763-4bec-b86f-6aa0b07d2435" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_09564fe7-0f3a-49f8-b5f5-21c5ecaf9e71" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_db574b7f-4763-4bec-b86f-6aa0b07d2435" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_16d63104-d097-4e79-9a10-1dc20f8b2594" xlink:href="ameh-20200630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_db574b7f-4763-4bec-b86f-6aa0b07d2435" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_16d63104-d097-4e79-9a10-1dc20f8b2594" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_c1cec427-0fd6-4e01-9849-d43a83e3996f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_be698141-a10c-4b00-95fe-7f58cb7543b1" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_c1cec427-0fd6-4e01-9849-d43a83e3996f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_c1cec427-0fd6-4e01-9849-d43a83e3996f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_c1cec427-0fd6-4e01-9849-d43a83e3996f" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_c1cec427-0fd6-4e01-9849-d43a83e3996f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_9ecbdb99-fb6a-4f0e-8abd-9e941a1cd0ac" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_c1cec427-0fd6-4e01-9849-d43a83e3996f" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_9ecbdb99-fb6a-4f0e-8abd-9e941a1cd0ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LmaMember_1386c76e-bdfc-4cbc-9e40-4cebbf0ff038" xlink:href="ameh-20200630.xsd#ameh_LmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_9ecbdb99-fb6a-4f0e-8abd-9e941a1cd0ac" xlink:to="loc_ameh_LmaMember_1386c76e-bdfc-4cbc-9e40-4cebbf0ff038" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareIncMember_9be8e69d-c11a-42d9-9ba0-dea01faa3db8" xlink:href="ameh-20200630.xsd#ameh_UniversalCareIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_9ecbdb99-fb6a-4f0e-8abd-9e941a1cd0ac" xlink:to="loc_ameh_UniversalCareIncMember_9be8e69d-c11a-42d9-9ba0-dea01faa3db8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpenses" xlink:type="simple" xlink:href="ameh-20200630.xsd#AccountsPayableandAccruedExpenses"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/AccountsPayableandAccruedExpenses" xlink:type="extended" id="i1109199b22aa457480ba4195ad6d3f9d_AccountsPayableandAccruedExpenses"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesTables" xlink:type="simple" xlink:href="ameh-20200630.xsd#AccountsPayableandAccruedExpensesTables"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesTables" xlink:type="extended" id="i4c8dd8ac1f1f4b9ca36afdf5088a896d_AccountsPayableandAccruedExpensesTables"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails" xlink:type="extended" id="i073592a884c24e5da19dd6479a34163b_AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/MedicalLiabilities" xlink:type="simple" xlink:href="ameh-20200630.xsd#MedicalLiabilities"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/MedicalLiabilities" xlink:type="extended" id="ic749a40a92be470bb0e45457f67cdb45_MedicalLiabilities"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/MedicalLiabilitiesTables" xlink:type="simple" xlink:href="ameh-20200630.xsd#MedicalLiabilitiesTables"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/MedicalLiabilitiesTables" xlink:type="extended" id="i0bbd759f63b24de488f97e6a690579bf_MedicalLiabilitiesTables"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails" xlink:type="extended" id="i99eb833899a2413db5a16efb9b2fefa3_MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCredit" xlink:type="simple" xlink:href="ameh-20200630.xsd#CreditFacilityBankLoanandLinesofCredit"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCredit" xlink:type="extended" id="i9c5b903cd3da4005a456cf44bddad817_CreditFacilityBankLoanandLinesofCredit"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditTables" xlink:type="simple" xlink:href="ameh-20200630.xsd#CreditFacilityBankLoanandLinesofCreditTables"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditTables" xlink:type="extended" id="ifb26476805af427db04d406f5762bcb3_CreditFacilityBankLoanandLinesofCreditTables"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails" xlink:type="extended" id="i559cfbd7c9b749e5adfc2b9170468d9c_CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_fabd27e2-cb69-4481-b628-8b1e55d9583c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_b0f9889a-fa71-4732-90ef-ee36e406bf55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_fabd27e2-cb69-4481-b628-8b1e55d9583c" xlink:to="loc_us-gaap_LineOfCredit_b0f9889a-fa71-4732-90ef-ee36e406bf55" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LinesOfCreditCurrent_82b4f7fe-cd24-46ad-b114-74cd4bd97091" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LinesOfCreditCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_fabd27e2-cb69-4481-b628-8b1e55d9583c" xlink:to="loc_us-gaap_LinesOfCreditCurrent_82b4f7fe-cd24-46ad-b114-74cd4bd97091" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_f3d26b41-4d51-41e3-8da5-259d3ae0f3c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_fabd27e2-cb69-4481-b628-8b1e55d9583c" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_f3d26b41-4d51-41e3-8da5-259d3ae0f3c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_97cbc10f-4fec-4d61-baa6-0d5d5b0b91f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_fabd27e2-cb69-4481-b628-8b1e55d9583c" xlink:to="loc_us-gaap_LongTermDebt_97cbc10f-4fec-4d61-baa6-0d5d5b0b91f8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_1fde9e61-1fd5-499e-937c-0c814c9907b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_fabd27e2-cb69-4481-b628-8b1e55d9583c" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_1fde9e61-1fd5-499e-937c-0c814c9907b4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_e4fa655a-b250-4b42-8c3c-81a04bfbc3f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_1fde9e61-1fd5-499e-937c-0c814c9907b4" xlink:to="loc_us-gaap_CreditFacilityAxis_e4fa655a-b250-4b42-8c3c-81a04bfbc3f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_e4fa655a-b250-4b42-8c3c-81a04bfbc3f6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_e4fa655a-b250-4b42-8c3c-81a04bfbc3f6" xlink:to="loc_us-gaap_CreditFacilityDomain_e4fa655a-b250-4b42-8c3c-81a04bfbc3f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_0ada0dd8-7432-4ee3-9448-204bfa5bc34e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_e4fa655a-b250-4b42-8c3c-81a04bfbc3f6" xlink:to="loc_us-gaap_CreditFacilityDomain_0ada0dd8-7432-4ee3-9448-204bfa5bc34e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_TermLoanAMember_6f9b8e65-0a4b-4dcf-a0b2-4de7ae88a75b" xlink:href="ameh-20200630.xsd#ameh_TermLoanAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_0ada0dd8-7432-4ee3-9448-204bfa5bc34e" xlink:to="loc_ameh_TermLoanAMember_6f9b8e65-0a4b-4dcf-a0b2-4de7ae88a75b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_e7670224-623e-4383-94e2-748d6f8320af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_0ada0dd8-7432-4ee3-9448-204bfa5bc34e" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_e7670224-623e-4383-94e2-748d6f8320af" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails" xlink:type="extended" id="i782b6637cc6b4f7388936b859450b2f8_CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails" xlink:type="extended" id="i03bfffaee5c448f0b1231db05cf05b66_CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_aaa7c65b-5229-4310-8d2a-c5e847931035" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_5d8e4fb1-617e-4535-b995-e8ce98ff5d1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aaa7c65b-5229-4310-8d2a-c5e847931035" xlink:to="loc_us-gaap_DebtInstrumentTerm_5d8e4fb1-617e-4535-b995-e8ce98ff5d1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_0902c519-0ad2-438f-b538-5c5a60870196" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aaa7c65b-5229-4310-8d2a-c5e847931035" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_0902c519-0ad2-438f-b538-5c5a60870196" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal_038ff918-2671-49b8-b505-d2ff4f7b08e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aaa7c65b-5229-4310-8d2a-c5e847931035" xlink:to="loc_us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal_038ff918-2671-49b8-b505-d2ff4f7b08e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_97d5cd89-03c9-4333-a2b5-6fbe0a2281fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aaa7c65b-5229-4310-8d2a-c5e847931035" xlink:to="loc_us-gaap_LineOfCredit_97d5cd89-03c9-4333-a2b5-6fbe0a2281fd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_50212e93-ef34-4424-9435-f5b2f5e0221a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aaa7c65b-5229-4310-8d2a-c5e847931035" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_50212e93-ef34-4424-9435-f5b2f5e0221a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_7bc8cf27-2e8f-458d-b638-cca1312dff60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aaa7c65b-5229-4310-8d2a-c5e847931035" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_7bc8cf27-2e8f-458d-b638-cca1312dff60" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_cde3644c-53fb-44e3-85c6-cd494d03d31a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aaa7c65b-5229-4310-8d2a-c5e847931035" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_cde3644c-53fb-44e3-85c6-cd494d03d31a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentNumberOfKeyFinancialRatios_61783f5e-de29-4957-a52a-05e38f618741" xlink:href="ameh-20200630.xsd#ameh_DebtInstrumentNumberOfKeyFinancialRatios"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aaa7c65b-5229-4310-8d2a-c5e847931035" xlink:to="loc_ameh_DebtInstrumentNumberOfKeyFinancialRatios_61783f5e-de29-4957-a52a-05e38f618741" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantLeverageRatioMaximum_1c86c206-af4b-44c5-96e2-d42767ec5033" xlink:href="ameh-20200630.xsd#ameh_DebtInstrumentCovenantLeverageRatioMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aaa7c65b-5229-4310-8d2a-c5e847931035" xlink:to="loc_ameh_DebtInstrumentCovenantLeverageRatioMaximum_1c86c206-af4b-44c5-96e2-d42767ec5033" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange_f56bb59d-5785-42cc-b626-e47a7c090346" xlink:href="ameh-20200630.xsd#ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aaa7c65b-5229-4310-8d2a-c5e847931035" xlink:to="loc_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange_f56bb59d-5785-42cc-b626-e47a7c090346" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantLeverageRatioMinimum_49109c00-d5d8-4143-8bfb-cdd58d671b56" xlink:href="ameh-20200630.xsd#ameh_DebtInstrumentCovenantLeverageRatioMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aaa7c65b-5229-4310-8d2a-c5e847931035" xlink:to="loc_ameh_DebtInstrumentCovenantLeverageRatioMinimum_49109c00-d5d8-4143-8bfb-cdd58d671b56" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum_1fec12bc-e30a-431c-b1df-7bbc18d99892" xlink:href="ameh-20200630.xsd#ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aaa7c65b-5229-4310-8d2a-c5e847931035" xlink:to="loc_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum_1fec12bc-e30a-431c-b1df-7bbc18d99892" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDefaultLongtermDebtAmount_40d58c0c-39ae-4e40-a632-f6b882b91306" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDefaultLongtermDebtAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aaa7c65b-5229-4310-8d2a-c5e847931035" xlink:to="loc_us-gaap_DebtDefaultLongtermDebtAmount_40d58c0c-39ae-4e40-a632-f6b882b91306" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentApprovalThresholdOfShareholdersForUseOfFundsPercentage_740d2197-69a0-41e2-ba8b-744e0b2ad6c7" xlink:href="ameh-20200630.xsd#ameh_DebtInstrumentApprovalThresholdOfShareholdersForUseOfFundsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aaa7c65b-5229-4310-8d2a-c5e847931035" xlink:to="loc_ameh_DebtInstrumentApprovalThresholdOfShareholdersForUseOfFundsPercentage_740d2197-69a0-41e2-ba8b-744e0b2ad6c7" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentApprovedThresholdUseOfFunds_420d70ef-de5e-4407-b92b-712e695544a3" xlink:href="ameh-20200630.xsd#ameh_DebtInstrumentApprovedThresholdUseOfFunds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aaa7c65b-5229-4310-8d2a-c5e847931035" xlink:to="loc_ameh_DebtInstrumentApprovedThresholdUseOfFunds_420d70ef-de5e-4407-b92b-712e695544a3" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_bdf4e218-ddc0-43cd-99e8-9720913e0350" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aaa7c65b-5229-4310-8d2a-c5e847931035" xlink:to="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_bdf4e218-ddc0-43cd-99e8-9720913e0350" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_e56ddf99-5c17-4e7c-9000-486e52816017" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aaa7c65b-5229-4310-8d2a-c5e847931035" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_e56ddf99-5c17-4e7c-9000-486e52816017" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_b0a49fd7-b62c-4404-b26d-ab44a710ff33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aaa7c65b-5229-4310-8d2a-c5e847931035" xlink:to="loc_us-gaap_InterestExpense_b0a49fd7-b62c-4404-b26d-ab44a710ff33" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LineOfCreditFacilityGuaranteeGivenByRelatedParties_1450b1b9-d552-4a54-8409-69ff50cc1775" xlink:href="ameh-20200630.xsd#ameh_LineOfCreditFacilityGuaranteeGivenByRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aaa7c65b-5229-4310-8d2a-c5e847931035" xlink:to="loc_ameh_LineOfCreditFacilityGuaranteeGivenByRelatedParties_1450b1b9-d552-4a54-8409-69ff50cc1775" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_a794741d-bb3d-4acb-8b7d-044e8525e71e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aaa7c65b-5229-4310-8d2a-c5e847931035" xlink:to="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_a794741d-bb3d-4acb-8b7d-044e8525e71e" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_e12d79c5-bff0-49b6-bb2e-0a72a53dbe93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aaa7c65b-5229-4310-8d2a-c5e847931035" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_e12d79c5-bff0-49b6-bb2e-0a72a53dbe93" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_027c186e-7d5d-40b7-89e7-253e1108083f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aaa7c65b-5229-4310-8d2a-c5e847931035" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_027c186e-7d5d-40b7-89e7-253e1108083f" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LineOfCreditFacilityExpirationPeriodPeriodOfNotification_4e79895f-7f4e-480c-8c41-a1c71b54e1ff" xlink:href="ameh-20200630.xsd#ameh_LineOfCreditFacilityExpirationPeriodPeriodOfNotification"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aaa7c65b-5229-4310-8d2a-c5e847931035" xlink:to="loc_ameh_LineOfCreditFacilityExpirationPeriodPeriodOfNotification_4e79895f-7f4e-480c-8c41-a1c71b54e1ff" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_13ff7009-9299-4581-ab54-999485858b2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aaa7c65b-5229-4310-8d2a-c5e847931035" xlink:to="loc_us-gaap_LongTermDebt_13ff7009-9299-4581-ab54-999485858b2d" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_0b8be17d-6a87-4cd8-b62a-db0a970ce2f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aaa7c65b-5229-4310-8d2a-c5e847931035" xlink:to="loc_us-gaap_DebtInstrumentTable_0b8be17d-6a87-4cd8-b62a-db0a970ce2f6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_48c4ee81-7a9f-4951-ba0f-d124aa8ee849" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0b8be17d-6a87-4cd8-b62a-db0a970ce2f6" xlink:to="loc_us-gaap_CreditFacilityAxis_48c4ee81-7a9f-4951-ba0f-d124aa8ee849" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_48c4ee81-7a9f-4951-ba0f-d124aa8ee849_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_48c4ee81-7a9f-4951-ba0f-d124aa8ee849" xlink:to="loc_us-gaap_CreditFacilityDomain_48c4ee81-7a9f-4951-ba0f-d124aa8ee849_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_7a31b5f6-5003-4cf9-8c7d-7a1f22ebecfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_48c4ee81-7a9f-4951-ba0f-d124aa8ee849" xlink:to="loc_us-gaap_CreditFacilityDomain_7a31b5f6-5003-4cf9-8c7d-7a1f22ebecfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_5304cd97-b6b8-4b48-a2bb-b5d35da496c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_7a31b5f6-5003-4cf9-8c7d-7a1f22ebecfb" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_5304cd97-b6b8-4b48-a2bb-b5d35da496c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_9c8948cb-481a-49e6-a71b-b0b354c02512" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_7a31b5f6-5003-4cf9-8c7d-7a1f22ebecfb" xlink:to="loc_us-gaap_LetterOfCreditMember_9c8948cb-481a-49e6-a71b-b0b354c02512" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_TermLoanAMember_92c22673-14a6-4070-8fa8-db68687271f7" xlink:href="ameh-20200630.xsd#ameh_TermLoanAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_7a31b5f6-5003-4cf9-8c7d-7a1f22ebecfb" xlink:to="loc_ameh_TermLoanAMember_92c22673-14a6-4070-8fa8-db68687271f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_f122f7c7-8e56-4fb1-9ed4-4d4cc514c7ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_7a31b5f6-5003-4cf9-8c7d-7a1f22ebecfb" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_f122f7c7-8e56-4fb1-9ed4-4d4cc514c7ed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_8c27d64c-eda6-4078-a7d4-5379df782d05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_7a31b5f6-5003-4cf9-8c7d-7a1f22ebecfb" xlink:to="loc_us-gaap_LineOfCreditMember_8c27d64c-eda6-4078-a7d4-5379df782d05" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e9400177-5f26-499b-b051-f9e3c7364745" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0b8be17d-6a87-4cd8-b62a-db0a970ce2f6" xlink:to="loc_us-gaap_DebtInstrumentAxis_e9400177-5f26-499b-b051-f9e3c7364745" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e9400177-5f26-499b-b051-f9e3c7364745_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_e9400177-5f26-499b-b051-f9e3c7364745" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e9400177-5f26-499b-b051-f9e3c7364745_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0796d94c-9035-47ce-99e7-dbc058f4223e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_e9400177-5f26-499b-b051-f9e3c7364745" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0796d94c-9035-47ce-99e7-dbc058f4223e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CreditAgreementMember_0834b8e6-5590-462f-ba98-bc12f2ffbfee" xlink:href="ameh-20200630.xsd#ameh_CreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0796d94c-9035-47ce-99e7-dbc058f4223e" xlink:to="loc_ameh_CreditAgreementMember_0834b8e6-5590-462f-ba98-bc12f2ffbfee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NMMLineOfCreditAgreementMember_5b4e13e5-5890-47c4-b6e6-6d4a0a23f3c2" xlink:href="ameh-20200630.xsd#ameh_NMMLineOfCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0796d94c-9035-47ce-99e7-dbc058f4223e" xlink:to="loc_ameh_NMMLineOfCreditAgreementMember_5b4e13e5-5890-47c4-b6e6-6d4a0a23f3c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NmmBusinessLoanAgreementMember_57a2125d-60b5-42b6-887b-a210e92dd9d6" xlink:href="ameh-20200630.xsd#ameh_NmmBusinessLoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0796d94c-9035-47ce-99e7-dbc058f4223e" xlink:to="loc_ameh_NmmBusinessLoanAgreementMember_57a2125d-60b5-42b6-887b-a210e92dd9d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcBusinessLoanAgreementMember_8af8b26e-7737-4c5a-800d-ee1df3da10d9" xlink:href="ameh-20200630.xsd#ameh_ApcBusinessLoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0796d94c-9035-47ce-99e7-dbc058f4223e" xlink:to="loc_ameh_ApcBusinessLoanAgreementMember_8af8b26e-7737-4c5a-800d-ee1df3da10d9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_0db45547-1c14-4d13-961a-5a9598a47213" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0b8be17d-6a87-4cd8-b62a-db0a970ce2f6" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_0db45547-1c14-4d13-961a-5a9598a47213" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0db45547-1c14-4d13-961a-5a9598a47213_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_0db45547-1c14-4d13-961a-5a9598a47213" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0db45547-1c14-4d13-961a-5a9598a47213_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6d6427d0-adcf-47ea-bcd2-623908c2ab21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_0db45547-1c14-4d13-961a-5a9598a47213" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6d6427d0-adcf-47ea-bcd2-623908c2ab21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_5888c30d-2472-4226-8179-770e3a8a9135" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6d6427d0-adcf-47ea-bcd2-623908c2ab21" xlink:to="loc_us-gaap_LineOfCreditMember_5888c30d-2472-4226-8179-770e3a8a9135" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_7222d3f3-6393-44a9-a00f-384c0a652a6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0b8be17d-6a87-4cd8-b62a-db0a970ce2f6" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_7222d3f3-6393-44a9-a00f-384c0a652a6b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_7222d3f3-6393-44a9-a00f-384c0a652a6b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_7222d3f3-6393-44a9-a00f-384c0a652a6b" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_7222d3f3-6393-44a9-a00f-384c0a652a6b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_17d4e7c9-b6a6-4c99-b337-a18842abc45f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_7222d3f3-6393-44a9-a00f-384c0a652a6b" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_17d4e7c9-b6a6-4c99-b337-a18842abc45f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentPeriodOneMember_822b72d5-9b58-4f01-a553-d1c24415a04e" xlink:href="ameh-20200630.xsd#ameh_PaymentPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_17d4e7c9-b6a6-4c99-b337-a18842abc45f" xlink:to="loc_ameh_PaymentPeriodOneMember_822b72d5-9b58-4f01-a553-d1c24415a04e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentPeriodTwoMember_59c14da3-8734-4577-86c5-daec0e58ccd1" xlink:href="ameh-20200630.xsd#ameh_PaymentPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_17d4e7c9-b6a6-4c99-b337-a18842abc45f" xlink:to="loc_ameh_PaymentPeriodTwoMember_59c14da3-8734-4577-86c5-daec0e58ccd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentPeriodThreeMember_0569d8b9-d151-410f-a23d-bd83a0dd8a84" xlink:href="ameh-20200630.xsd#ameh_PaymentPeriodThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_17d4e7c9-b6a6-4c99-b337-a18842abc45f" xlink:to="loc_ameh_PaymentPeriodThreeMember_0569d8b9-d151-410f-a23d-bd83a0dd8a84" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1d70007f-c03b-4760-9ff6-c2b3a11e47fb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0b8be17d-6a87-4cd8-b62a-db0a970ce2f6" xlink:to="loc_srt_RangeAxis_1d70007f-c03b-4760-9ff6-c2b3a11e47fb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1d70007f-c03b-4760-9ff6-c2b3a11e47fb_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1d70007f-c03b-4760-9ff6-c2b3a11e47fb" xlink:to="loc_srt_RangeMember_1d70007f-c03b-4760-9ff6-c2b3a11e47fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_edde8a6d-c3bb-45bb-8511-b30ddc4bb7cb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1d70007f-c03b-4760-9ff6-c2b3a11e47fb" xlink:to="loc_srt_RangeMember_edde8a6d-c3bb-45bb-8511-b30ddc4bb7cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0e2524fd-25bc-46fd-b748-0b4ac9a974d2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_edde8a6d-c3bb-45bb-8511-b30ddc4bb7cb" xlink:to="loc_srt_MinimumMember_0e2524fd-25bc-46fd-b748-0b4ac9a974d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_34e10d20-3375-4190-afad-1d7280090432" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_edde8a6d-c3bb-45bb-8511-b30ddc4bb7cb" xlink:to="loc_srt_MaximumMember_34e10d20-3375-4190-afad-1d7280090432" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_0abd1cb8-821e-4a8c-aea3-ed6d42546bb6" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0b8be17d-6a87-4cd8-b62a-db0a970ce2f6" xlink:to="loc_dei_LegalEntityAxis_0abd1cb8-821e-4a8c-aea3-ed6d42546bb6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_0abd1cb8-821e-4a8c-aea3-ed6d42546bb6_default" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_0abd1cb8-821e-4a8c-aea3-ed6d42546bb6" xlink:to="loc_dei_EntityDomain_0abd1cb8-821e-4a8c-aea3-ed6d42546bb6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_bfbf5e59-c5a0-46ed-8eef-1479c48c77dd" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_0abd1cb8-821e-4a8c-aea3-ed6d42546bb6" xlink:to="loc_dei_EntityDomain_bfbf5e59-c5a0-46ed-8eef-1479c48c77dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementMember_63923ca4-7005-4998-9c97-586745db7efd" xlink:href="ameh-20200630.xsd#ameh_NetworkMedicalManagementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_bfbf5e59-c5a0-46ed-8eef-1479c48c77dd" xlink:to="loc_ameh_NetworkMedicalManagementMember_63923ca4-7005-4998-9c97-586745db7efd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_f9feff85-802b-4620-9b5c-1817b03ebfde" xlink:href="ameh-20200630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_bfbf5e59-c5a0-46ed-8eef-1479c48c77dd" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_f9feff85-802b-4620-9b5c-1817b03ebfde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApaacoMember_244b3a44-8812-4ece-bc76-cd9e74772516" xlink:href="ameh-20200630.xsd#ameh_ApaacoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_bfbf5e59-c5a0-46ed-8eef-1479c48c77dd" xlink:to="loc_ameh_ApaacoMember_244b3a44-8812-4ece-bc76-cd9e74772516" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlphaCareMedicalGroupInc.Member_93958bab-6ae3-42f9-a08e-ad1d4e06e553" xlink:href="ameh-20200630.xsd#ameh_AlphaCareMedicalGroupInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_bfbf5e59-c5a0-46ed-8eef-1479c48c77dd" xlink:to="loc_ameh_AlphaCareMedicalGroupInc.Member_93958bab-6ae3-42f9-a08e-ad1d4e06e553" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CDSCMember_c4b1861c-493e-4a9e-b5f4-bc875c8beafc" xlink:href="ameh-20200630.xsd#ameh_CDSCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_bfbf5e59-c5a0-46ed-8eef-1479c48c77dd" xlink:to="loc_ameh_CDSCMember_c4b1861c-493e-4a9e-b5f4-bc875c8beafc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AmgIncMember_122d91dc-3f4b-4310-8ad6-052abf9e1d10" xlink:href="ameh-20200630.xsd#ameh_AmgIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_bfbf5e59-c5a0-46ed-8eef-1479c48c77dd" xlink:to="loc_ameh_AmgIncMember_122d91dc-3f4b-4310-8ad6-052abf9e1d10" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_adf287af-da3c-4941-a66e-9b9791de4cbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0b8be17d-6a87-4cd8-b62a-db0a970ce2f6" xlink:to="loc_us-gaap_VariableRateAxis_adf287af-da3c-4941-a66e-9b9791de4cbb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_adf287af-da3c-4941-a66e-9b9791de4cbb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_adf287af-da3c-4941-a66e-9b9791de4cbb" xlink:to="loc_us-gaap_VariableRateDomain_adf287af-da3c-4941-a66e-9b9791de4cbb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_6592507c-35f3-41b6-8044-b8b56987088d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_adf287af-da3c-4941-a66e-9b9791de4cbb" xlink:to="loc_us-gaap_VariableRateDomain_6592507c-35f3-41b6-8044-b8b56987088d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_5badc0e3-9c82-438a-9529-aff94612e341" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_6592507c-35f3-41b6-8044-b8b56987088d" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_5badc0e3-9c82-438a-9529-aff94612e341" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_77bf5788-85a4-4bf2-ba18-6d7e1d58d9c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrimeRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_6592507c-35f3-41b6-8044-b8b56987088d" xlink:to="loc_us-gaap_PrimeRateMember_77bf5788-85a4-4bf2-ba18-6d7e1d58d9c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_4f6d1faf-812f-4b11-a76e-5174d7451d10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0b8be17d-6a87-4cd8-b62a-db0a970ce2f6" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_4f6d1faf-812f-4b11-a76e-5174d7451d10" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_4f6d1faf-812f-4b11-a76e-5174d7451d10_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_4f6d1faf-812f-4b11-a76e-5174d7451d10" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_4f6d1faf-812f-4b11-a76e-5174d7451d10_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_b6324546-cb93-452f-9e9d-8574c322187e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_4f6d1faf-812f-4b11-a76e-5174d7451d10" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_b6324546-cb93-452f-9e9d-8574c322187e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PreferredBankMember_8cae379b-920b-47ea-980f-64ef43d94569" xlink:href="ameh-20200630.xsd#ameh_PreferredBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_b6324546-cb93-452f-9e9d-8574c322187e" xlink:to="loc_ameh_PreferredBankMember_8cae379b-920b-47ea-980f-64ef43d94569" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquity" xlink:type="simple" xlink:href="ameh-20200630.xsd#MezzanineandStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/MezzanineandStockholdersEquity" xlink:type="extended" id="i1c9993419abc49db98f38c46997b2d88_MezzanineandStockholdersEquity"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquityTables" xlink:type="simple" xlink:href="ameh-20200630.xsd#MezzanineandStockholdersEquityTables"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/MezzanineandStockholdersEquityTables" xlink:type="extended" id="ib9c3c4694a9e40b68a106baca974a5ad_MezzanineandStockholdersEquityTables"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#MezzanineandStockholdersEquityAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails" xlink:type="extended" id="ia6b8b53ceba54a04b383e3999dc74c9f_MezzanineandStockholdersEquityAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_33a04ff0-0d30-41f8-b089-7fe127549978" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodSharesMerger_edacbdfb-c613-4179-a847-bc7fff2d404a" xlink:href="ameh-20200630.xsd#ameh_StockIssuedDuringPeriodSharesMerger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_33a04ff0-0d30-41f8-b089-7fe127549978" xlink:to="loc_ameh_StockIssuedDuringPeriodSharesMerger_edacbdfb-c613-4179-a847-bc7fff2d404a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e84a53db-b048-46c3-a753-52977e4a6fdf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_33a04ff0-0d30-41f8-b089-7fe127549978" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e84a53db-b048-46c3-a753-52977e4a6fdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_4b4af310-c238-4411-9b3d-543a333c9698" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_33a04ff0-0d30-41f8-b089-7fe127549978" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_4b4af310-c238-4411-9b3d-543a333c9698" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_f2c5ce06-72ce-4420-a97c-29ecd8ee53c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_33a04ff0-0d30-41f8-b089-7fe127549978" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_f2c5ce06-72ce-4420-a97c-29ecd8ee53c9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod_d15a06fa-0113-4ef1-b78f-1353e36e877a" xlink:href="ameh-20200630.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_33a04ff0-0d30-41f8-b089-7fe127549978" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod_d15a06fa-0113-4ef1-b78f-1353e36e877a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d8233381-0e4d-478a-95bb-23afd7919b65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_33a04ff0-0d30-41f8-b089-7fe127549978" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d8233381-0e4d-478a-95bb-23afd7919b65" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_51d82311-79e9-4f0f-970d-ae5c7f7353dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_33a04ff0-0d30-41f8-b089-7fe127549978" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_51d82311-79e9-4f0f-970d-ae5c7f7353dd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_554fb3de-7cc0-4811-8348-0eb7084916a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_33a04ff0-0d30-41f8-b089-7fe127549978" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_554fb3de-7cc0-4811-8348-0eb7084916a4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ae557618-99d1-4ce7-bc19-d5be26adbfde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_33a04ff0-0d30-41f8-b089-7fe127549978" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ae557618-99d1-4ce7-bc19-d5be26adbfde" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_34a7fa1f-54d4-4c32-8ad1-57ad4bb015e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_33a04ff0-0d30-41f8-b089-7fe127549978" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_34a7fa1f-54d4-4c32-8ad1-57ad4bb015e1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_d8b6cc38-d17d-40cc-bc47-63edcf4b5b3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_33a04ff0-0d30-41f8-b089-7fe127549978" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_d8b6cc38-d17d-40cc-bc47-63edcf4b5b3f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_0099ed89-e9c8-4497-b139-4a7288291379" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_33a04ff0-0d30-41f8-b089-7fe127549978" xlink:to="loc_us-gaap_ShareBasedCompensation_0099ed89-e9c8-4497-b139-4a7288291379" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_fb36a4e1-edb6-43b7-8b6a-d8e8933615c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_33a04ff0-0d30-41f8-b089-7fe127549978" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_fb36a4e1-edb6-43b7-8b6a-d8e8933615c1" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod_8ef19753-d7f7-41ba-9732-715fddb82e60" xlink:href="ameh-20200630.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_33a04ff0-0d30-41f8-b089-7fe127549978" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod_8ef19753-d7f7-41ba-9732-715fddb82e60" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised_c0116c03-3d2e-4e36-9a12-80712a47dc39" xlink:href="ameh-20200630.xsd#ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_33a04ff0-0d30-41f8-b089-7fe127549978" xlink:to="loc_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised_c0116c03-3d2e-4e36-9a12-80712a47dc39" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice_dbd7a435-50d9-4c48-93eb-b4503bd79287" xlink:href="ameh-20200630.xsd#ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_33a04ff0-0d30-41f8-b089-7fe127549978" xlink:to="loc_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice_dbd7a435-50d9-4c48-93eb-b4503bd79287" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_cdc719a2-222b-444c-897f-1409decf13ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_33a04ff0-0d30-41f8-b089-7fe127549978" xlink:to="loc_us-gaap_TreasuryStockCommonShares_cdc719a2-222b-444c-897f-1409decf13ae" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_3464ca20-023b-4f58-a694-6aa3b5422a72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_33a04ff0-0d30-41f8-b089-7fe127549978" xlink:to="loc_us-gaap_TreasuryStockValue_3464ca20-023b-4f58-a694-6aa3b5422a72" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_a09174d0-57c2-4a0e-9b20-ea2ed147aaa7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Dividends"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_33a04ff0-0d30-41f8-b089-7fe127549978" xlink:to="loc_us-gaap_Dividends_a09174d0-57c2-4a0e-9b20-ea2ed147aaa7" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_991baf71-6e85-4ee8-99e4-a29a16d6395d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_33a04ff0-0d30-41f8-b089-7fe127549978" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_991baf71-6e85-4ee8-99e4-a29a16d6395d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_3acf957a-8161-49c8-9e9e-0630e1b900c2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_991baf71-6e85-4ee8-99e4-a29a16d6395d" xlink:to="loc_srt_TitleOfIndividualAxis_3acf957a-8161-49c8-9e9e-0630e1b900c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_3acf957a-8161-49c8-9e9e-0630e1b900c2_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_3acf957a-8161-49c8-9e9e-0630e1b900c2" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_3acf957a-8161-49c8-9e9e-0630e1b900c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_cb7b8ace-09ac-4de9-9068-6fe4f62b8c4b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_3acf957a-8161-49c8-9e9e-0630e1b900c2" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_cb7b8ace-09ac-4de9-9068-6fe4f62b8c4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcStockOptionMember_9e6dddc9-34fb-4dac-9eb4-aea7e26e75b5" xlink:href="ameh-20200630.xsd#ameh_ApcStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_cb7b8ace-09ac-4de9-9068-6fe4f62b8c4b" xlink:to="loc_ameh_ApcStockOptionMember_9e6dddc9-34fb-4dac-9eb4-aea7e26e75b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_847d160d-cdf4-4218-9d83-8f8ed2301d20" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_cb7b8ace-09ac-4de9-9068-6fe4f62b8c4b" xlink:to="loc_srt_DirectorMember_847d160d-cdf4-4218-9d83-8f8ed2301d20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e6ff421f-83f9-48d3-8af3-743c8f97a052" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_991baf71-6e85-4ee8-99e4-a29a16d6395d" xlink:to="loc_srt_RangeAxis_e6ff421f-83f9-48d3-8af3-743c8f97a052" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e6ff421f-83f9-48d3-8af3-743c8f97a052_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e6ff421f-83f9-48d3-8af3-743c8f97a052" xlink:to="loc_srt_RangeMember_e6ff421f-83f9-48d3-8af3-743c8f97a052_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fa89e49c-180d-4726-965c-f82e21735004" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e6ff421f-83f9-48d3-8af3-743c8f97a052" xlink:to="loc_srt_RangeMember_fa89e49c-180d-4726-965c-f82e21735004" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_33bb0146-df75-4987-a882-0a63bb3e5984" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fa89e49c-180d-4726-965c-f82e21735004" xlink:to="loc_srt_MinimumMember_33bb0146-df75-4987-a882-0a63bb3e5984" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_71f48824-026d-491c-9bf2-8629e2e2b252" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fa89e49c-180d-4726-965c-f82e21735004" xlink:to="loc_srt_MaximumMember_71f48824-026d-491c-9bf2-8629e2e2b252" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b8c7cbe6-6e6e-4c70-9090-40360d9da3c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_991baf71-6e85-4ee8-99e4-a29a16d6395d" xlink:to="loc_us-gaap_AwardTypeAxis_b8c7cbe6-6e6e-4c70-9090-40360d9da3c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b8c7cbe6-6e6e-4c70-9090-40360d9da3c8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_b8c7cbe6-6e6e-4c70-9090-40360d9da3c8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b8c7cbe6-6e6e-4c70-9090-40360d9da3c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f6dbe61a-e5c8-459f-959c-2587ee4d6a44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_b8c7cbe6-6e6e-4c70-9090-40360d9da3c8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f6dbe61a-e5c8-459f-959c-2587ee4d6a44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ceaa651e-b314-4b31-a8eb-d48a912d89f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f6dbe61a-e5c8-459f-959c-2587ee4d6a44" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ceaa651e-b314-4b31-a8eb-d48a912d89f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_331fa828-438e-48cd-ad17-d847da8c5d10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f6dbe61a-e5c8-459f-959c-2587ee4d6a44" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_331fa828-438e-48cd-ad17-d847da8c5d10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_528ad604-feb6-458d-a26e-74dc47ec41cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f6dbe61a-e5c8-459f-959c-2587ee4d6a44" xlink:to="loc_us-gaap_RestrictedStockMember_528ad604-feb6-458d-a26e-74dc47ec41cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_71f9e856-2f75-4cf0-8aa7-42dab0e6017a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_991baf71-6e85-4ee8-99e4-a29a16d6395d" xlink:to="loc_dei_LegalEntityAxis_71f9e856-2f75-4cf0-8aa7-42dab0e6017a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_71f9e856-2f75-4cf0-8aa7-42dab0e6017a_default" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_71f9e856-2f75-4cf0-8aa7-42dab0e6017a" xlink:to="loc_dei_EntityDomain_71f9e856-2f75-4cf0-8aa7-42dab0e6017a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a3aed4cc-0df7-4f0f-9a8a-6b4f0dd12612" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_71f9e856-2f75-4cf0-8aa7-42dab0e6017a" xlink:to="loc_dei_EntityDomain_a3aed4cc-0df7-4f0f-9a8a-6b4f0dd12612" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_d621ce5e-3bd7-4c92-ab88-9dc8a66cd398" xlink:href="ameh-20200630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_a3aed4cc-0df7-4f0f-9a8a-6b4f0dd12612" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_d621ce5e-3bd7-4c92-ab88-9dc8a66cd398" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CDSCMember_87b4fd3b-9927-4d78-93f9-3e8702954553" xlink:href="ameh-20200630.xsd#ameh_CDSCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_a3aed4cc-0df7-4f0f-9a8a-6b4f0dd12612" xlink:to="loc_ameh_CDSCMember_87b4fd3b-9927-4d78-93f9-3e8702954553" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d54c3e7a-3533-4843-be95-671dc6b5d4df" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_991baf71-6e85-4ee8-99e4-a29a16d6395d" xlink:to="loc_srt_CounterpartyNameAxis_d54c3e7a-3533-4843-be95-671dc6b5d4df" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d54c3e7a-3533-4843-be95-671dc6b5d4df_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_d54c3e7a-3533-4843-be95-671dc6b5d4df" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d54c3e7a-3533-4843-be95-671dc6b5d4df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ac58df24-c8a2-424a-b0e2-7a126330a587" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_d54c3e7a-3533-4843-be95-671dc6b5d4df" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ac58df24-c8a2-424a-b0e2-7a126330a587" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificofCaliforniaBrokerageAccountMember_ec0e3668-aac9-48a8-91f1-35fa9934a932" xlink:href="ameh-20200630.xsd#ameh_AlliedPacificofCaliforniaBrokerageAccountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ac58df24-c8a2-424a-b0e2-7a126330a587" xlink:to="loc_ameh_AlliedPacificofCaliforniaBrokerageAccountMember_ec0e3668-aac9-48a8-91f1-35fa9934a932" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails" xlink:type="extended" id="i5a77948e042d48bbbda07b16ea99b4dc_MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquityStockOptionActivityUnderBlackScholesOptionPricingModelDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#MezzanineandStockholdersEquityStockOptionActivityUnderBlackScholesOptionPricingModelDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/MezzanineandStockholdersEquityStockOptionActivityUnderBlackScholesOptionPricingModelDetails" xlink:type="extended" id="i57f64a398ee045f28e9e86852a8e8df3_MezzanineandStockholdersEquityStockOptionActivityUnderBlackScholesOptionPricingModelDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7b551161-df46-4b1a-9c3e-817e98dbece5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_11e3a3a3-6c84-42d1-bf58-f0a7d417cca9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7b551161-df46-4b1a-9c3e-817e98dbece5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_11e3a3a3-6c84-42d1-bf58-f0a7d417cca9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ef0690db-e001-4689-8f67-27a82928adf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7b551161-df46-4b1a-9c3e-817e98dbece5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ef0690db-e001-4689-8f67-27a82928adf2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_07a01ec7-9b71-4ee6-89eb-a62bb10bd48e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7b551161-df46-4b1a-9c3e-817e98dbece5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_07a01ec7-9b71-4ee6-89eb-a62bb10bd48e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_9394e96f-e201-493c-8fdc-50ced18db2be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7b551161-df46-4b1a-9c3e-817e98dbece5" xlink:to="loc_us-gaap_SharePrice_9394e96f-e201-493c-8fdc-50ced18db2be" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dbac0dd4-6bba-4e91-8dcb-e0b136f10b9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7b551161-df46-4b1a-9c3e-817e98dbece5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dbac0dd4-6bba-4e91-8dcb-e0b136f10b9f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_e82a98f6-71dc-4186-818a-da9ce44910b7" xlink:href="ameh-20200630.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7b551161-df46-4b1a-9c3e-817e98dbece5" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_e82a98f6-71dc-4186-818a-da9ce44910b7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f8dedcf5-cfb7-4c8c-8f30-2f7eaab66720" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7b551161-df46-4b1a-9c3e-817e98dbece5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f8dedcf5-cfb7-4c8c-8f30-2f7eaab66720" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_ae5b8e2f-6419-45cd-b5ae-d3c334da2678" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f8dedcf5-cfb7-4c8c-8f30-2f7eaab66720" xlink:to="loc_srt_TitleOfIndividualAxis_ae5b8e2f-6419-45cd-b5ae-d3c334da2678" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ae5b8e2f-6419-45cd-b5ae-d3c334da2678_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_ae5b8e2f-6419-45cd-b5ae-d3c334da2678" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ae5b8e2f-6419-45cd-b5ae-d3c334da2678_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6a0440b4-55f5-41ca-b2d8-126a277e49b3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_ae5b8e2f-6419-45cd-b5ae-d3c334da2678" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6a0440b4-55f5-41ca-b2d8-126a277e49b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_1af9daf4-864d-473d-beb6-b70a4fad1970" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6a0440b4-55f5-41ca-b2d8-126a277e49b3" xlink:to="loc_srt_DirectorMember_1af9daf4-864d-473d-beb6-b70a4fad1970" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquitySummaryofWarrantDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#MezzanineandStockholdersEquitySummaryofWarrantDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/MezzanineandStockholdersEquitySummaryofWarrantDetails" xlink:type="extended" id="i4aabd083ecb04d6ea3d98621f330645e_MezzanineandStockholdersEquitySummaryofWarrantDetails"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquityWarrantsDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#MezzanineandStockholdersEquityWarrantsDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/MezzanineandStockholdersEquityWarrantsDetails" xlink:type="extended" id="i83a18fd74cde4869874f769d99794144_MezzanineandStockholdersEquityWarrantsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_24fc618f-eb5b-4e57-8b8b-e035ceaefb56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_b78fdf0b-c77f-49a7-b310-9f6f3d781ad4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_24fc618f-eb5b-4e57-8b8b-e035ceaefb56" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_b78fdf0b-c77f-49a7-b310-9f6f3d781ad4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightIssuedInPeriod_2ee51212-e4da-49be-912a-ba3ef0eabeb8" xlink:href="ameh-20200630.xsd#ameh_ClassOfWarrantOrRightIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_24fc618f-eb5b-4e57-8b8b-e035ceaefb56" xlink:to="loc_ameh_ClassOfWarrantOrRightIssuedInPeriod_2ee51212-e4da-49be-912a-ba3ef0eabeb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm_4870fc01-67ec-4e52-8fae-f1855b5a53b8" xlink:href="ameh-20200630.xsd#ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_24fc618f-eb5b-4e57-8b8b-e035ceaefb56" xlink:to="loc_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm_4870fc01-67ec-4e52-8fae-f1855b5a53b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightExercisable_a75242e4-06ec-4ee2-9e43-716908a1e314" xlink:href="ameh-20200630.xsd#ameh_ClassOfWarrantOrRightExercisable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_24fc618f-eb5b-4e57-8b8b-e035ceaefb56" xlink:to="loc_ameh_ClassOfWarrantOrRightExercisable_a75242e4-06ec-4ee2-9e43-716908a1e314" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_80ac58b6-df06-48fe-8d69-5c4ce53afd85" xlink:href="ameh-20200630.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_24fc618f-eb5b-4e57-8b8b-e035ceaefb56" xlink:to="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_80ac58b6-df06-48fe-8d69-5c4ce53afd85" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_afade0ce-20a0-40bd-8255-0c624b914b7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_24fc618f-eb5b-4e57-8b8b-e035ceaefb56" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_afade0ce-20a0-40bd-8255-0c624b914b7c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_14946b36-ed21-4ecb-b1be-1058aa4fadc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_afade0ce-20a0-40bd-8255-0c624b914b7c" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_14946b36-ed21-4ecb-b1be-1058aa4fadc9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_14946b36-ed21-4ecb-b1be-1058aa4fadc9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_14946b36-ed21-4ecb-b1be-1058aa4fadc9" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_14946b36-ed21-4ecb-b1be-1058aa4fadc9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_9e9ae659-15cb-42a5-8be6-5c719a0cc017" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_14946b36-ed21-4ecb-b1be-1058aa4fadc9" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_9e9ae659-15cb-42a5-8be6-5c719a0cc017" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeOneMember_450dcd17-e7c1-43e0-bd2d-28e46c5fd4cf" xlink:href="ameh-20200630.xsd#ameh_WarrantExercisePriceRangeOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_9e9ae659-15cb-42a5-8be6-5c719a0cc017" xlink:to="loc_ameh_WarrantExercisePriceRangeOneMember_450dcd17-e7c1-43e0-bd2d-28e46c5fd4cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeTwoMember_52586d3f-d1ed-4949-ad1d-29389a407c3b" xlink:href="ameh-20200630.xsd#ameh_WarrantExercisePriceRangeTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_9e9ae659-15cb-42a5-8be6-5c719a0cc017" xlink:to="loc_ameh_WarrantExercisePriceRangeTwoMember_52586d3f-d1ed-4949-ad1d-29389a407c3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeThreeMember_afffad95-c3bb-4514-bf57-c378573106dc" xlink:href="ameh-20200630.xsd#ameh_WarrantExercisePriceRangeThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_9e9ae659-15cb-42a5-8be6-5c719a0cc017" xlink:to="loc_ameh_WarrantExercisePriceRangeThreeMember_afffad95-c3bb-4514-bf57-c378573106dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeFourMember_c05d512e-c3f6-4159-8ae7-a56ee8977a9a" xlink:href="ameh-20200630.xsd#ameh_WarrantExercisePriceRangeFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_9e9ae659-15cb-42a5-8be6-5c719a0cc017" xlink:to="loc_ameh_WarrantExercisePriceRangeFourMember_c05d512e-c3f6-4159-8ae7-a56ee8977a9a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_51b50ee5-3e66-4a2d-b5da-ec65ba9a999d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_afade0ce-20a0-40bd-8255-0c624b914b7c" xlink:to="loc_srt_RangeAxis_51b50ee5-3e66-4a2d-b5da-ec65ba9a999d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_51b50ee5-3e66-4a2d-b5da-ec65ba9a999d_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_51b50ee5-3e66-4a2d-b5da-ec65ba9a999d" xlink:to="loc_srt_RangeMember_51b50ee5-3e66-4a2d-b5da-ec65ba9a999d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3ea4ff99-815c-4caa-9740-cc5c435e77ac" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_51b50ee5-3e66-4a2d-b5da-ec65ba9a999d" xlink:to="loc_srt_RangeMember_3ea4ff99-815c-4caa-9740-cc5c435e77ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_153e57b1-cf01-4a8c-a4aa-dd6410fabce4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3ea4ff99-815c-4caa-9740-cc5c435e77ac" xlink:to="loc_srt_MinimumMember_153e57b1-cf01-4a8c-a4aa-dd6410fabce4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d5e3e5ac-4496-4308-ada2-d9ac323047fa" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3ea4ff99-815c-4caa-9740-cc5c435e77ac" xlink:to="loc_srt_MaximumMember_d5e3e5ac-4496-4308-ada2-d9ac323047fa" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="ameh-20200630.xsd#CommitmentsandContingencies"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CommitmentsandContingencies" xlink:type="extended" id="i6122ad9d99c34054b112e9cc7c3a3cbf_CommitmentsandContingencies"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended" id="i7922132f038942498b06f9a348e0715a_CommitmentsandContingenciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommitmentsAndContingenciesLineItems_1bca2b8e-0f36-400d-a965-68d264fe1272" xlink:href="ameh-20200630.xsd#ameh_CommitmentsAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount_69f124a4-3106-43a7-9bae-5783a00c1bc4" xlink:href="ameh-20200630.xsd#ameh_PercentageOfFinancialGuaranteeBenchmarkAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems_1bca2b8e-0f36-400d-a965-68d264fe1272" xlink:to="loc_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount_69f124a4-3106-43a7-9bae-5783a00c1bc4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_288b195d-837a-4ab0-8a05-a9c66c244f16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems_1bca2b8e-0f36-400d-a965-68d264fe1272" xlink:to="loc_us-gaap_LineOfCredit_288b195d-837a-4ab0-8a05-a9c66c244f16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_075a0027-1484-4c03-812b-0ae8e38b9ec3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems_1bca2b8e-0f36-400d-a965-68d264fe1272" xlink:to="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_075a0027-1484-4c03-812b-0ae8e38b9ec3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities_d03e70aa-e7c9-45bb-9adb-6ffed7e5369f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems_1bca2b8e-0f36-400d-a965-68d264fe1272" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities_d03e70aa-e7c9-45bb-9adb-6ffed7e5369f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_2ff171ad-29c4-47fc-9893-cb68e2c80661" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems_1bca2b8e-0f36-400d-a965-68d264fe1272" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_2ff171ad-29c4-47fc-9893-cb68e2c80661" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommitmentsAndContingenciesTable_10f89879-23d0-4e3e-a08a-3bbd56282994" xlink:href="ameh-20200630.xsd#ameh_CommitmentsAndContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems_1bca2b8e-0f36-400d-a965-68d264fe1272" xlink:to="loc_ameh_CommitmentsAndContingenciesTable_10f89879-23d0-4e3e-a08a-3bbd56282994" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4bdc94dd-49da-496a-9017-841761cb2a6d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_10f89879-23d0-4e3e-a08a-3bbd56282994" xlink:to="loc_srt_ProductOrServiceAxis_4bdc94dd-49da-496a-9017-841761cb2a6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4bdc94dd-49da-496a-9017-841761cb2a6d_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_4bdc94dd-49da-496a-9017-841761cb2a6d" xlink:to="loc_srt_ProductsAndServicesDomain_4bdc94dd-49da-496a-9017-841761cb2a6d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3f81c4a3-dae7-409a-a96b-2dff7c7ad95c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_4bdc94dd-49da-496a-9017-841761cb2a6d" xlink:to="loc_srt_ProductsAndServicesDomain_3f81c4a3-dae7-409a-a96b-2dff7c7ad95c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PreferredBankMember_0e221fb0-1e75-4c74-95d8-faf78bfbebea" xlink:href="ameh-20200630.xsd#ameh_PreferredBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3f81c4a3-dae7-409a-a96b-2dff7c7ad95c" xlink:to="loc_ameh_PreferredBankMember_0e221fb0-1e75-4c74-95d8-faf78bfbebea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_55add9d3-4129-4a86-91c0-93c4ffde0f3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_10f89879-23d0-4e3e-a08a-3bbd56282994" xlink:to="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_55add9d3-4129-4a86-91c0-93c4ffde0f3a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_55add9d3-4129-4a86-91c0-93c4ffde0f3a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_55add9d3-4129-4a86-91c0-93c4ffde0f3a" xlink:to="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_55add9d3-4129-4a86-91c0-93c4ffde0f3a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_808e48ef-c566-4120-97b7-8e2e40ce18a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_55add9d3-4129-4a86-91c0-93c4ffde0f3a" xlink:to="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_808e48ef-c566-4120-97b7-8e2e40ce18a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_0f7396c8-ec10-431f-922e-ff810f507151" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_808e48ef-c566-4120-97b7-8e2e40ce18a6" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_0f7396c8-ec10-431f-922e-ff810f507151" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_adea8329-7847-44f1-a2ea-110048a7d227" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_10f89879-23d0-4e3e-a08a-3bbd56282994" xlink:to="loc_dei_LegalEntityAxis_adea8329-7847-44f1-a2ea-110048a7d227" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_adea8329-7847-44f1-a2ea-110048a7d227_default" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_adea8329-7847-44f1-a2ea-110048a7d227" xlink:to="loc_dei_EntityDomain_adea8329-7847-44f1-a2ea-110048a7d227_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_66c222f5-9321-4459-b9eb-d2a190e62b8a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_adea8329-7847-44f1-a2ea-110048a7d227" xlink:to="loc_dei_EntityDomain_66c222f5-9321-4459-b9eb-d2a190e62b8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_ab2fc4c7-34b2-45b6-8843-958607481b4d" xlink:href="ameh-20200630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_66c222f5-9321-4459-b9eb-d2a190e62b8a" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_ab2fc4c7-34b2-45b6-8843-958607481b4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlphaCareMedicalGroupInc.Member_90ce1dd3-4afc-484a-bcc4-da55f620caf2" xlink:href="ameh-20200630.xsd#ameh_AlphaCareMedicalGroupInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_66c222f5-9321-4459-b9eb-d2a190e62b8a" xlink:to="loc_ameh_AlphaCareMedicalGroupInc.Member_90ce1dd3-4afc-484a-bcc4-da55f620caf2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_c567029e-9b8e-4821-bfdc-7dc086fafdac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_10f89879-23d0-4e3e-a08a-3bbd56282994" xlink:to="loc_us-gaap_CreditFacilityAxis_c567029e-9b8e-4821-bfdc-7dc086fafdac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_c567029e-9b8e-4821-bfdc-7dc086fafdac_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_c567029e-9b8e-4821-bfdc-7dc086fafdac" xlink:to="loc_us-gaap_CreditFacilityDomain_c567029e-9b8e-4821-bfdc-7dc086fafdac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_4ac11285-4b79-4da4-b83f-76d0b4cc2fed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_c567029e-9b8e-4821-bfdc-7dc086fafdac" xlink:to="loc_us-gaap_CreditFacilityDomain_4ac11285-4b79-4da4-b83f-76d0b4cc2fed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_225e59a9-66c0-4fdd-807a-9d627c64c2d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_4ac11285-4b79-4da4-b83f-76d0b4cc2fed" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_225e59a9-66c0-4fdd-807a-9d627c64c2d9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="ameh-20200630.xsd#RelatedPartyTransactions"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactions" xlink:type="extended" id="i99435a5ebe714b9a9822309f1651cdd7_RelatedPartyTransactions"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsTables" xlink:type="simple" xlink:href="ameh-20200630.xsd#RelatedPartyTransactionsTables"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactionsTables" xlink:type="extended" id="i363a5227f4184c57b393524b27ed1ce4_RelatedPartyTransactionsTables"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#RelatedPartyTransactionsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="extended" id="ic79bb6ba8878428dbe5af06c42d14bb3_RelatedPartyTransactionsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_2fd74bc0-fcec-4d6a-b57f-bde2b66e8817" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_3515e65c-4a2f-412a-8da8-dd52fc443c22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2fd74bc0-fcec-4d6a-b57f-bde2b66e8817" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_3515e65c-4a2f-412a-8da8-dd52fc443c22" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_a99afead-f3bc-4133-ae2e-ce9f8f382221" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2fd74bc0-fcec-4d6a-b57f-bde2b66e8817" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_a99afead-f3bc-4133-ae2e-ce9f8f382221" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsAndOtherReceivablesNumberOfAdditionalAgreements_1f6b9434-bc13-4241-a79c-345e18b1803b" xlink:href="ameh-20200630.xsd#ameh_AccountsAndOtherReceivablesNumberOfAdditionalAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2fd74bc0-fcec-4d6a-b57f-bde2b66e8817" xlink:to="loc_ameh_AccountsAndOtherReceivablesNumberOfAdditionalAgreements_1f6b9434-bc13-4241-a79c-345e18b1803b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties_7cdf3391-589b-4dcb-8ca9-03e58632c2fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2fd74bc0-fcec-4d6a-b57f-bde2b66e8817" xlink:to="loc_us-gaap_RevenueFromRelatedParties_7cdf3391-589b-4dcb-8ca9-03e58632c2fb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentMadeToRelatedParty_13b2f099-2a5e-4f18-9613-bd34d212a270" xlink:href="ameh-20200630.xsd#ameh_PaymentMadeToRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2fd74bc0-fcec-4d6a-b57f-bde2b66e8817" xlink:to="loc_ameh_PaymentMadeToRelatedParty_13b2f099-2a5e-4f18-9613-bd34d212a270" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_6a3e97fd-4e58-4ae1-b288-92164dd0680d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2fd74bc0-fcec-4d6a-b57f-bde2b66e8817" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_6a3e97fd-4e58-4ae1-b288-92164dd0680d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_9a8c7e03-4730-42c9-9d27-cba9e78cde3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2fd74bc0-fcec-4d6a-b57f-bde2b66e8817" xlink:to="loc_us-gaap_OperatingLeaseLiability_9a8c7e03-4730-42c9-9d27-cba9e78cde3e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_f5b19149-080a-47f1-a602-606fd1b021c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2fd74bc0-fcec-4d6a-b57f-bde2b66e8817" xlink:to="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_f5b19149-080a-47f1-a602-606fd1b021c7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilities_804ca932-f67a-4403-85bf-be46d0ca9e52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2fd74bc0-fcec-4d6a-b57f-bde2b66e8817" xlink:to="loc_us-gaap_DeferredCreditsAndOtherLiabilities_804ca932-f67a-4403-85bf-be46d0ca9e52" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentConsultingFees_50af5293-2f00-4324-861b-5be0d0d37a74" xlink:href="ameh-20200630.xsd#ameh_PaymentConsultingFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2fd74bc0-fcec-4d6a-b57f-bde2b66e8817" xlink:to="loc_ameh_PaymentConsultingFees_50af5293-2f00-4324-861b-5be0d0d37a74" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_938a636c-f7b5-44f2-8e4a-884961b83984" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2fd74bc0-fcec-4d6a-b57f-bde2b66e8817" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_938a636c-f7b5-44f2-8e4a-884961b83984" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d922d685-d87c-4402-a987-aa794a646e44" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_938a636c-f7b5-44f2-8e4a-884961b83984" xlink:to="loc_srt_CounterpartyNameAxis_d922d685-d87c-4402-a987-aa794a646e44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d922d685-d87c-4402-a987-aa794a646e44_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_d922d685-d87c-4402-a987-aa794a646e44" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d922d685-d87c-4402-a987-aa794a646e44_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_278a50d4-3b0c-43d5-8a2d-36ec21adfb79" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_d922d685-d87c-4402-a987-aa794a646e44" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_278a50d4-3b0c-43d5-8a2d-36ec21adfb79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_261817ca-474e-4762-a648-6d3e74fc53fa" xlink:href="ameh-20200630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_278a50d4-3b0c-43d5-8a2d-36ec21adfb79" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_261817ca-474e-4762-a648-6d3e74fc53fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0b8cf2dc-d880-4d4c-a89b-e431ca132b6f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_938a636c-f7b5-44f2-8e4a-884961b83984" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0b8cf2dc-d880-4d4c-a89b-e431ca132b6f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_0b8cf2dc-d880-4d4c-a89b-e431ca132b6f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0b8cf2dc-d880-4d4c-a89b-e431ca132b6f" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_0b8cf2dc-d880-4d4c-a89b-e431ca132b6f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_f4ed4197-9592-49d7-83a8-aa7835078dd8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0b8cf2dc-d880-4d4c-a89b-e431ca132b6f" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_f4ed4197-9592-49d7-83a8-aa7835078dd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareIncMember_cb7d4bbc-3971-407a-8c47-ba1c49ec4faf" xlink:href="ameh-20200630.xsd#ameh_UniversalCareIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f4ed4197-9592-49d7-83a8-aa7835078dd8" xlink:to="loc_ameh_UniversalCareIncMember_cb7d4bbc-3971-407a-8c47-ba1c49ec4faf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LmaMember_cefc5eec-e14f-445e-8928-d388ab6bd457" xlink:href="ameh-20200630.xsd#ameh_LmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f4ed4197-9592-49d7-83a8-aa7835078dd8" xlink:to="loc_ameh_LmaMember_cefc5eec-e14f-445e-8928-d388ab6bd457" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PmiocMember_e2ca8a59-ad9e-4d9c-9062-53269a0d2591" xlink:href="ameh-20200630.xsd#ameh_PmiocMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f4ed4197-9592-49d7-83a8-aa7835078dd8" xlink:to="loc_ameh_PmiocMember_e2ca8a59-ad9e-4d9c-9062-53269a0d2591" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DmgMember_9afd658a-7382-4f91-8609-f92707f38cfc" xlink:href="ameh-20200630.xsd#ameh_DmgMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f4ed4197-9592-49d7-83a8-aa7835078dd8" xlink:to="loc_ameh_DmgMember_9afd658a-7382-4f91-8609-f92707f38cfc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOInc.Member_701977a3-aad7-489f-8956-3d97f1cbbf9a" xlink:href="ameh-20200630.xsd#ameh_OneMSOInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f4ed4197-9592-49d7-83a8-aa7835078dd8" xlink:to="loc_ameh_OneMSOInc.Member_701977a3-aad7-489f-8956-3d97f1cbbf9a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_95b7f1d8-2e2f-4ab3-aff5-223ffddaa571" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_938a636c-f7b5-44f2-8e4a-884961b83984" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_95b7f1d8-2e2f-4ab3-aff5-223ffddaa571" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_95b7f1d8-2e2f-4ab3-aff5-223ffddaa571_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_95b7f1d8-2e2f-4ab3-aff5-223ffddaa571" xlink:to="loc_us-gaap_RelatedPartyDomain_95b7f1d8-2e2f-4ab3-aff5-223ffddaa571_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_f24e2d04-0cd7-425d-98e0-efb63425ce40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_95b7f1d8-2e2f-4ab3-aff5-223ffddaa571" xlink:to="loc_us-gaap_RelatedPartyDomain_f24e2d04-0cd7-425d-98e0-efb63425ce40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareIncMember_5995395e-a898-487e-afeb-dbadb45c1234" xlink:href="ameh-20200630.xsd#ameh_UniversalCareIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_f24e2d04-0cd7-425d-98e0-efb63425ce40" xlink:to="loc_ameh_UniversalCareIncMember_5995395e-a898-487e-afeb-dbadb45c1234" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_1e84e195-8328-4fdb-a2a7-f298a1012767" xlink:href="ameh-20200630.xsd#ameh_UniversalCareAcquisitionPartnersLlcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_f24e2d04-0cd7-425d-98e0-efb63425ce40" xlink:to="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_1e84e195-8328-4fdb-a2a7-f298a1012767" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcShareholdersMember_2c9ffb6d-782a-4bc9-81c1-302b867cc147" xlink:href="ameh-20200630.xsd#ameh_ApcShareholdersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_f24e2d04-0cd7-425d-98e0-efb63425ce40" xlink:to="loc_ameh_ApcShareholdersMember_2c9ffb6d-782a-4bc9-81c1-302b867cc147" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AdvanceDiagnosticSurgeryCenterMember_0cd217bd-34f8-4dee-8f97-02ac4aee2cf3" xlink:href="ameh-20200630.xsd#ameh_AdvanceDiagnosticSurgeryCenterMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_f24e2d04-0cd7-425d-98e0-efb63425ce40" xlink:to="loc_ameh_AdvanceDiagnosticSurgeryCenterMember_0cd217bd-34f8-4dee-8f97-02ac4aee2cf3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareholdersAndOfficersMember_07517a80-cf64-4b37-b0d2-5c42e8e3180f" xlink:href="ameh-20200630.xsd#ameh_ShareholdersAndOfficersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_f24e2d04-0cd7-425d-98e0-efb63425ce40" xlink:to="loc_ameh_ShareholdersAndOfficersMember_07517a80-cf64-4b37-b0d2-5c42e8e3180f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicalPropertyPartnersMember_540c02c3-cd1e-4ff1-a00f-a0a4a14f43db" xlink:href="ameh-20200630.xsd#ameh_MedicalPropertyPartnersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_f24e2d04-0cd7-425d-98e0-efb63425ce40" xlink:to="loc_ameh_MedicalPropertyPartnersMember_540c02c3-cd1e-4ff1-a00f-a0a4a14f43db" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOInc.Member_44d40e46-abc9-409b-987b-ffae47c75a6e" xlink:href="ameh-20200630.xsd#ameh_OneMSOInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_f24e2d04-0cd7-425d-98e0-efb63425ce40" xlink:to="loc_ameh_OneMSOInc.Member_44d40e46-abc9-409b-987b-ffae47c75a6e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CriticalQualityManagementCorpMember_c16526aa-fd11-4b98-b909-f2c52e91ac7b" xlink:href="ameh-20200630.xsd#ameh_CriticalQualityManagementCorpMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_f24e2d04-0cd7-425d-98e0-efb63425ce40" xlink:to="loc_ameh_CriticalQualityManagementCorpMember_c16526aa-fd11-4b98-b909-f2c52e91ac7b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumenLLCMember_c353a65d-5eb9-4caa-a25f-8bd588b296cf" xlink:href="ameh-20200630.xsd#ameh_NumenLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_f24e2d04-0cd7-425d-98e0-efb63425ce40" xlink:to="loc_ameh_NumenLLCMember_c353a65d-5eb9-4caa-a25f-8bd588b296cf" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AHMCMember_cb1bd554-21ab-4069-a455-4971b77343d1" xlink:href="ameh-20200630.xsd#ameh_AHMCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_f24e2d04-0cd7-425d-98e0-efb63425ce40" xlink:to="loc_ameh_AHMCMember_cb1bd554-21ab-4069-a455-4971b77343d1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_451ae134-0235-4cad-94af-903bb1753749" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_938a636c-f7b5-44f2-8e4a-884961b83984" xlink:to="loc_dei_LegalEntityAxis_451ae134-0235-4cad-94af-903bb1753749" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_451ae134-0235-4cad-94af-903bb1753749_default" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_451ae134-0235-4cad-94af-903bb1753749" xlink:to="loc_dei_EntityDomain_451ae134-0235-4cad-94af-903bb1753749_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e279b219-7acf-45a4-a1e9-c1dbb54a8ec4" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_451ae134-0235-4cad-94af-903bb1753749" xlink:to="loc_dei_EntityDomain_e279b219-7acf-45a4-a1e9-c1dbb54a8ec4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementMember_824ac479-0636-46bb-847e-1479147b2744" xlink:href="ameh-20200630.xsd#ameh_NetworkMedicalManagementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_e279b219-7acf-45a4-a1e9-c1dbb54a8ec4" xlink:to="loc_ameh_NetworkMedicalManagementMember_824ac479-0636-46bb-847e-1479147b2744" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_250f09f2-9f7d-475a-ae8b-c9bad5485bd4" xlink:href="ameh-20200630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_e279b219-7acf-45a4-a1e9-c1dbb54a8ec4" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_250f09f2-9f7d-475a-ae8b-c9bad5485bd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SCHCMember_f9c6567a-6211-469c-891f-549d22923e92" xlink:href="ameh-20200630.xsd#ameh_SCHCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_e279b219-7acf-45a4-a1e9-c1dbb54a8ec4" xlink:to="loc_ameh_SCHCMember_f9c6567a-6211-469c-891f-549d22923e92" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_e14d4045-7ef7-4141-8415-64d19838c6c3" xlink:href="ameh-20200630.xsd#ameh_UniversalCareAcquisitionPartnersLlcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_e279b219-7acf-45a4-a1e9-c1dbb54a8ec4" xlink:to="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_e14d4045-7ef7-4141-8415-64d19838c6c3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DrSimAndDrLamMember_e43d0c85-13e9-412f-9145-aab9519ea86e" xlink:href="ameh-20200630.xsd#ameh_DrSimAndDrLamMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_e279b219-7acf-45a4-a1e9-c1dbb54a8ec4" xlink:to="loc_ameh_DrSimAndDrLamMember_e43d0c85-13e9-412f-9145-aab9519ea86e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_b3ca457b-f471-45ed-ab04-37eebd9ddfd8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_938a636c-f7b5-44f2-8e4a-884961b83984" xlink:to="loc_srt_ConsolidatedEntitiesAxis_b3ca457b-f471-45ed-ab04-37eebd9ddfd8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_b3ca457b-f471-45ed-ab04-37eebd9ddfd8_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_b3ca457b-f471-45ed-ab04-37eebd9ddfd8" xlink:to="loc_srt_ConsolidatedEntitiesDomain_b3ca457b-f471-45ed-ab04-37eebd9ddfd8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_0f65fba9-2d1e-41c1-9561-e66ad320ad81" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_b3ca457b-f471-45ed-ab04-37eebd9ddfd8" xlink:to="loc_srt_ConsolidatedEntitiesDomain_0f65fba9-2d1e-41c1-9561-e66ad320ad81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LmaMember_88d7675d-3fba-41c9-a4ad-ba9e0ca8f53d" xlink:href="ameh-20200630.xsd#ameh_LmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_0f65fba9-2d1e-41c1-9561-e66ad320ad81" xlink:to="loc_ameh_LmaMember_88d7675d-3fba-41c9-a4ad-ba9e0ca8f53d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PmiocMember_7c42862a-cd68-46b9-ba69-a55390b7824c" xlink:href="ameh-20200630.xsd#ameh_PmiocMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_0f65fba9-2d1e-41c1-9561-e66ad320ad81" xlink:to="loc_ameh_PmiocMember_7c42862a-cd68-46b9-ba69-a55390b7824c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DmgMember_b3385f51-ab4e-4eb9-b64e-0b1f7035e179" xlink:href="ameh-20200630.xsd#ameh_DmgMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_0f65fba9-2d1e-41c1-9561-e66ad320ad81" xlink:to="loc_ameh_DmgMember_b3385f51-ab4e-4eb9-b64e-0b1f7035e179" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_6769af41-332d-4787-a9cb-20a4f8c73dc9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_938a636c-f7b5-44f2-8e4a-884961b83984" xlink:to="loc_srt_TitleOfIndividualAxis_6769af41-332d-4787-a9cb-20a4f8c73dc9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6769af41-332d-4787-a9cb-20a4f8c73dc9_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_6769af41-332d-4787-a9cb-20a4f8c73dc9" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6769af41-332d-4787-a9cb-20a4f8c73dc9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_68900bfd-a5c8-4f3e-bb10-da5427fc710e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_6769af41-332d-4787-a9cb-20a4f8c73dc9" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_68900bfd-a5c8-4f3e-bb10-da5427fc710e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_2c1a637b-6787-4f6b-a27c-7f16a516fdea" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_68900bfd-a5c8-4f3e-bb10-da5427fc710e" xlink:to="loc_srt_DirectorMember_2c1a637b-6787-4f6b-a27c-7f16a516fdea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_6e15827f-f409-4f85-86cb-a1b4a4aadc52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_938a636c-f7b5-44f2-8e4a-884961b83984" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_6e15827f-f409-4f85-86cb-a1b4a4aadc52" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_6e15827f-f409-4f85-86cb-a1b4a4aadc52_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_6e15827f-f409-4f85-86cb-a1b4a4aadc52" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_6e15827f-f409-4f85-86cb-a1b4a4aadc52_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1c90053e-8522-4cba-ab41-a64af76bb7f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_6e15827f-f409-4f85-86cb-a1b4a4aadc52" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1c90053e-8522-4cba-ab41-a64af76bb7f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_9b450ce7-eb40-4ec5-b4c5-543196d88542" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1c90053e-8522-4cba-ab41-a64af76bb7f9" xlink:to="loc_us-gaap_ServiceMember_9b450ce7-eb40-4ec5-b4c5-543196d88542" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails" xlink:type="extended" id="i8819d8856734431e93cdbdfcaf0ada16_RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_707a155b-edd8-4440-8f2b-0f2bb6a9a07b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_98bc4b99-2028-49b9-8f46-e388dc8dc2a7" xlink:href="ameh-20200630.xsd#ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_707a155b-edd8-4440-8f2b-0f2bb6a9a07b" xlink:to="loc_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_98bc4b99-2028-49b9-8f46-e388dc8dc2a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementFeeExpense_b79d63d9-544e-46da-a917-353f75cd6e20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ManagementFeeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_707a155b-edd8-4440-8f2b-0f2bb6a9a07b" xlink:to="loc_us-gaap_ManagementFeeExpense_b79d63d9-544e-46da-a917-353f75cd6e20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_64d495a9-3db8-47ea-aaec-f2feef8f6f7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_707a155b-edd8-4440-8f2b-0f2bb6a9a07b" xlink:to="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_64d495a9-3db8-47ea-aaec-f2feef8f6f7b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_41ec71ce-bc3f-4524-80e2-046c9d032f13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_707a155b-edd8-4440-8f2b-0f2bb6a9a07b" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_41ec71ce-bc3f-4524-80e2-046c9d032f13" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_404066da-6753-4859-893a-0d262e3f046e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_41ec71ce-bc3f-4524-80e2-046c9d032f13" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_404066da-6753-4859-893a-0d262e3f046e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_404066da-6753-4859-893a-0d262e3f046e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_404066da-6753-4859-893a-0d262e3f046e" xlink:to="loc_us-gaap_RelatedPartyDomain_404066da-6753-4859-893a-0d262e3f046e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_08df495c-4855-41e8-9537-53a2d2b4a23f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_404066da-6753-4859-893a-0d262e3f046e" xlink:to="loc_us-gaap_RelatedPartyDomain_08df495c-4855-41e8-9537-53a2d2b4a23f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AHMCMember_022045d0-4e9a-4506-b223-1811b23226f9" xlink:href="ameh-20200630.xsd#ameh_AHMCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_08df495c-4855-41e8-9537-53a2d2b4a23f" xlink:to="loc_ameh_AHMCMember_022045d0-4e9a-4506-b223-1811b23226f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_HSMSOMember_aeea9679-6f91-40eb-a847-edff4ef9dc54" xlink:href="ameh-20200630.xsd#ameh_HSMSOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_08df495c-4855-41e8-9537-53a2d2b4a23f" xlink:to="loc_ameh_HSMSOMember_aeea9679-6f91-40eb-a847-edff4ef9dc54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AurionMember_9ed94950-1dbd-4b52-bc8b-6339bb898ab0" xlink:href="ameh-20200630.xsd#ameh_AurionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_08df495c-4855-41e8-9537-53a2d2b4a23f" xlink:to="loc_ameh_AurionMember_9ed94950-1dbd-4b52-bc8b-6339bb898ab0" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IncomeTaxes" xlink:type="simple" xlink:href="ameh-20200630.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/IncomeTaxes" xlink:type="extended" id="i5269a94a1f714049b56786855bf501ec_IncomeTaxes"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShare" xlink:type="simple" xlink:href="ameh-20200630.xsd#EarningsPerShare"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/EarningsPerShare" xlink:type="extended" id="ida835f5b14a44a5abffbf613df355097_EarningsPerShare"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareTables" xlink:type="simple" xlink:href="ameh-20200630.xsd#EarningsPerShareTables"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/EarningsPerShareTables" xlink:type="extended" id="iea510278172a4fdab1c603c808e4c317_EarningsPerShareTables"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#EarningsPerShareAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails" xlink:type="extended" id="i1c031dbab538418db9e6f577ff5d0a73_EarningsPerShareAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EarningsPerShareLineItems_1d8ff331-64ed-4891-8533-1ed3ae28bdd2" xlink:href="ameh-20200630.xsd#ameh_EarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AntidilutiveSecuritiesExcludedFromEarningsComputationShares_ff39ba98-e22c-41f0-aa22-f15c614b2dda" xlink:href="ameh-20200630.xsd#ameh_AntidilutiveSecuritiesExcludedFromEarningsComputationShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_EarningsPerShareLineItems_1d8ff331-64ed-4891-8533-1ed3ae28bdd2" xlink:to="loc_ameh_AntidilutiveSecuritiesExcludedFromEarningsComputationShares_ff39ba98-e22c-41f0-aa22-f15c614b2dda" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EarningsPerShareTable_796bcc76-2da1-4a28-ac65-377854d7cedc" xlink:href="ameh-20200630.xsd#ameh_EarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ameh_EarningsPerShareLineItems_1d8ff331-64ed-4891-8533-1ed3ae28bdd2" xlink:to="loc_ameh_EarningsPerShareTable_796bcc76-2da1-4a28-ac65-377854d7cedc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_41167a92-3dd3-4949-a0b1-6d2e183afa20" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_EarningsPerShareTable_796bcc76-2da1-4a28-ac65-377854d7cedc" xlink:to="loc_dei_LegalEntityAxis_41167a92-3dd3-4949-a0b1-6d2e183afa20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_41167a92-3dd3-4949-a0b1-6d2e183afa20_default" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_41167a92-3dd3-4949-a0b1-6d2e183afa20" xlink:to="loc_dei_EntityDomain_41167a92-3dd3-4949-a0b1-6d2e183afa20_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a341af11-265b-43e5-ba7b-f9e0de9bac6f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_41167a92-3dd3-4949-a0b1-6d2e183afa20" xlink:to="loc_dei_EntityDomain_a341af11-265b-43e5-ba7b-f9e0de9bac6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_0dfc8c41-8f91-4957-9230-f10174e19b4a" xlink:href="ameh-20200630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_a341af11-265b-43e5-ba7b-f9e0de9bac6f" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_0dfc8c41-8f91-4957-9230-f10174e19b4a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#EarningsPerShareEarningsPerShareComputationsDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails" xlink:type="extended" id="i6274caa4bb514f03876dc67ee30205ee_EarningsPerShareEarningsPerShareComputationsDetails"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails" xlink:type="extended" id="i44c491fd77704629b0b39b5dc82c4d20_EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EarningsPerShareLineItems_51e4de2e-c2af-4ef3-b062-0fb47bfc9193" xlink:href="ameh-20200630.xsd#ameh_EarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_430c0820-db61-4c66-bd8f-6ffead99a09a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_EarningsPerShareLineItems_51e4de2e-c2af-4ef3-b062-0fb47bfc9193" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_430c0820-db61-4c66-bd8f-6ffead99a09a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_180c3140-8f87-41e9-b2a4-ad5661a5ef8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_EarningsPerShareLineItems_51e4de2e-c2af-4ef3-b062-0fb47bfc9193" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_180c3140-8f87-41e9-b2a4-ad5661a5ef8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_62aa9f56-5a5e-4f84-85dc-3f2f00749dff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_EarningsPerShareLineItems_51e4de2e-c2af-4ef3-b062-0fb47bfc9193" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_62aa9f56-5a5e-4f84-85dc-3f2f00749dff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage_3a9c2979-4045-4bf3-af48-d2f8b21666db" xlink:href="ameh-20200630.xsd#ameh_BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_EarningsPerShareLineItems_51e4de2e-c2af-4ef3-b062-0fb47bfc9193" xlink:to="loc_ameh_BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage_3a9c2979-4045-4bf3-af48-d2f8b21666db" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EarningsPerShareTable_bd84d6bd-c247-4436-8997-c4320b08d34f" xlink:href="ameh-20200630.xsd#ameh_EarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ameh_EarningsPerShareLineItems_51e4de2e-c2af-4ef3-b062-0fb47bfc9193" xlink:to="loc_ameh_EarningsPerShareTable_bd84d6bd-c247-4436-8997-c4320b08d34f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_78a262b9-33aa-4735-8b1c-fe2441d5f335" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_EarningsPerShareTable_bd84d6bd-c247-4436-8997-c4320b08d34f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_78a262b9-33aa-4735-8b1c-fe2441d5f335" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_78a262b9-33aa-4735-8b1c-fe2441d5f335_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_78a262b9-33aa-4735-8b1c-fe2441d5f335" xlink:to="loc_us-gaap_EquityComponentDomain_78a262b9-33aa-4735-8b1c-fe2441d5f335_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e63e7bc5-bc72-452c-b308-32fafb02c98f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_78a262b9-33aa-4735-8b1c-fe2441d5f335" xlink:to="loc_us-gaap_EquityComponentDomain_e63e7bc5-bc72-452c-b308-32fafb02c98f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c0917608-4b92-4280-92ca-ffa76fb312e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e63e7bc5-bc72-452c-b308-32fafb02c98f" xlink:to="loc_us-gaap_CommonStockMember_c0917608-4b92-4280-92ca-ffa76fb312e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_458ab023-4563-4f6e-926b-e0330d332492" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e63e7bc5-bc72-452c-b308-32fafb02c98f" xlink:to="loc_us-gaap_WarrantMember_458ab023-4563-4f6e-926b-e0330d332492" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8999ec09-6649-4050-8d0f-cba6d2e3c76e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_EarningsPerShareTable_bd84d6bd-c247-4436-8997-c4320b08d34f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8999ec09-6649-4050-8d0f-cba6d2e3c76e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8999ec09-6649-4050-8d0f-cba6d2e3c76e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8999ec09-6649-4050-8d0f-cba6d2e3c76e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8999ec09-6649-4050-8d0f-cba6d2e3c76e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3b580ada-5019-481f-80cb-3854d0cca8b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8999ec09-6649-4050-8d0f-cba6d2e3c76e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3b580ada-5019-481f-80cb-3854d0cca8b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_901cd3e3-cc87-4d50-8e2f-132e5e9a5286" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3b580ada-5019-481f-80cb-3854d0cca8b0" xlink:to="loc_us-gaap_EmployeeStockOptionMember_901cd3e3-cc87-4d50-8e2f-132e5e9a5286" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_c1db7bdb-ac99-44e0-a562-a2f803bca1a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3b580ada-5019-481f-80cb-3854d0cca8b0" xlink:to="loc_us-gaap_RestrictedStockMember_c1db7bdb-ac99-44e0-a562-a2f803bca1a1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEs" xlink:type="simple" xlink:href="ameh-20200630.xsd#VariableInterestEntitiesVIEs"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/VariableInterestEntitiesVIEs" xlink:type="extended" id="iaa84d3d7a8da471b95fb9ab7556152d3_VariableInterestEntitiesVIEs"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables" xlink:type="simple" xlink:href="ameh-20200630.xsd#VariableInterestEntitiesVIEsTables"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables" xlink:type="extended" id="i81a01c40b5224c97b994153d4df23d11_VariableInterestEntitiesVIEsTables"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#VariableInterestEntitiesVIEsDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails" xlink:type="extended" id="i24ab42dda0fd48388a5df52ac1ecf7a5_VariableInterestEntitiesVIEsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_d23e5726-5dfa-4fb9-b203-3e5c94e3bfe1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_86b36f17-0474-4075-8f3c-16dda4b63996" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_d23e5726-5dfa-4fb9-b203-3e5c94e3bfe1" xlink:to="loc_us-gaap_AssetsAbstract_86b36f17-0474-4075-8f3c-16dda4b63996" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_0142a6b7-6189-4712-a44c-8a7c1451df35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_86b36f17-0474-4075-8f3c-16dda4b63996" xlink:to="loc_us-gaap_AssetsCurrentAbstract_0142a6b7-6189-4712-a44c-8a7c1451df35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4a9f686e-c6d0-48cf-abb2-0992018381b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0142a6b7-6189-4712-a44c-8a7c1451df35" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4a9f686e-c6d0-48cf-abb2-0992018381b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_06801b4c-af63-4194-803a-465fb9d47212" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0142a6b7-6189-4712-a44c-8a7c1451df35" xlink:to="loc_us-gaap_RestrictedCashCurrent_06801b4c-af63-4194-803a-465fb9d47212" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_763dac75-2524-4ffa-a1bf-d5f29a8c562c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0142a6b7-6189-4712-a44c-8a7c1451df35" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_763dac75-2524-4ffa-a1bf-d5f29a8c562c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_2e23bf66-dcc6-4d21-b0d5-2b7667b55aae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0142a6b7-6189-4712-a44c-8a7c1451df35" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_2e23bf66-dcc6-4d21-b0d5-2b7667b55aae" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_1a181eb9-8a26-43f6-9eb4-3aa412eefa50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0142a6b7-6189-4712-a44c-8a7c1451df35" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_1a181eb9-8a26-43f6-9eb4-3aa412eefa50" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_22531f3f-9c99-4bb4-9334-13f933aca2f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0142a6b7-6189-4712-a44c-8a7c1451df35" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_22531f3f-9c99-4bb4-9334-13f933aca2f8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_eb72f4c4-f5ff-4b84-af9a-9f3f57c0882a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0142a6b7-6189-4712-a44c-8a7c1451df35" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_eb72f4c4-f5ff-4b84-af9a-9f3f57c0882a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent_0034ca05-da42-4ef5-a4a9-baa3bbf34e05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0142a6b7-6189-4712-a44c-8a7c1451df35" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetCurrent_0034ca05-da42-4ef5-a4a9-baa3bbf34e05" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesCurrent_fcc756a7-589e-41cd-ba35-1363136e4ca8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesReceivableRelatedPartiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0142a6b7-6189-4712-a44c-8a7c1451df35" xlink:to="loc_us-gaap_NotesReceivableRelatedPartiesCurrent_fcc756a7-589e-41cd-ba35-1363136e4ca8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_dc29cdde-6b2f-4502-a1e9-cabdcd482a53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0142a6b7-6189-4712-a44c-8a7c1451df35" xlink:to="loc_us-gaap_AssetsCurrent_dc29cdde-6b2f-4502-a1e9-cabdcd482a53" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_8da2914b-f179-4d76-98f1-c59b026a2274" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_86b36f17-0474-4075-8f3c-16dda4b63996" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_8da2914b-f179-4d76-98f1-c59b026a2274" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ba9df389-5c45-41c6-bc28-3d61f763568a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8da2914b-f179-4d76-98f1-c59b026a2274" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ba9df389-5c45-41c6-bc28-3d61f763568a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8add0573-c88f-4149-835c-ace86b89808b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8da2914b-f179-4d76-98f1-c59b026a2274" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8add0573-c88f-4149-835c-ace86b89808b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_9e582393-9a07-47d7-855f-d1a9c4add8f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8da2914b-f179-4d76-98f1-c59b026a2274" xlink:to="loc_us-gaap_Goodwill_9e582393-9a07-47d7-855f-d1a9c4add8f0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_f984db4a-3aae-4b4d-87b9-63f3039825d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8da2914b-f179-4d76-98f1-c59b026a2274" xlink:to="loc_us-gaap_OtherLongTermInvestments_f984db4a-3aae-4b4d-87b9-63f3039825d3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_cb283f0d-41af-45b4-86d5-b3e9fcf52fd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8da2914b-f179-4d76-98f1-c59b026a2274" xlink:to="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_cb283f0d-41af-45b4-86d5-b3e9fcf52fd3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_45024011-38f5-4ba7-a0be-b9d2ec264776" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8da2914b-f179-4d76-98f1-c59b026a2274" xlink:to="loc_us-gaap_EquityMethodInvestments_45024011-38f5-4ba7-a0be-b9d2ec264776" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_207be538-edc3-446f-9c84-5dae01c732ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8da2914b-f179-4d76-98f1-c59b026a2274" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_207be538-edc3-446f-9c84-5dae01c732ef" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_10e7e7b8-8c46-4a4b-9612-26f96d0aa0ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8da2914b-f179-4d76-98f1-c59b026a2274" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_10e7e7b8-8c46-4a4b-9612-26f96d0aa0ca" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_3bec4708-5160-4729-a771-e00f02fd3702" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8da2914b-f179-4d76-98f1-c59b026a2274" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_3bec4708-5160-4729-a771-e00f02fd3702" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_13d64d5c-516f-433d-a161-a72c4eabd260" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8da2914b-f179-4d76-98f1-c59b026a2274" xlink:to="loc_us-gaap_AssetsNoncurrent_13d64d5c-516f-433d-a161-a72c4eabd260" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_0b258a61-3255-4c76-b2dc-f1b38078679d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_86b36f17-0474-4075-8f3c-16dda4b63996" xlink:to="loc_us-gaap_Assets_0b258a61-3255-4c76-b2dc-f1b38078679d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_70e59b62-a6f4-40cf-a22c-809f994d9c44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_d23e5726-5dfa-4fb9-b203-3e5c94e3bfe1" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_70e59b62-a6f4-40cf-a22c-809f994d9c44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4c6d3933-6340-4dcb-9e02-ed3bd8191cb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_70e59b62-a6f4-40cf-a22c-809f994d9c44" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4c6d3933-6340-4dcb-9e02-ed3bd8191cb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent_cd1f45bf-e53b-4ff7-8e8e-1cf917a1e46a" xlink:href="ameh-20200630.xsd#ameh_FiduciaryAccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_70e59b62-a6f4-40cf-a22c-809f994d9c44" xlink:to="loc_ameh_FiduciaryAccountsPayableCurrent_cd1f45bf-e53b-4ff7-8e8e-1cf917a1e46a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_8a7ecd05-7dd4-4e4c-9528-622ea8c675c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_70e59b62-a6f4-40cf-a22c-809f994d9c44" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_8a7ecd05-7dd4-4e4c-9528-622ea8c675c9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_a9a200eb-2800-471d-a4cf-fd2de5a7a91e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_70e59b62-a6f4-40cf-a22c-809f994d9c44" xlink:to="loc_us-gaap_TaxesPayableCurrent_a9a200eb-2800-471d-a4cf-fd2de5a7a91e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToAffiliateCurrent_0a8b7232-e4c3-4dd3-a1e5-ac01cbd0acd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToAffiliateCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_70e59b62-a6f4-40cf-a22c-809f994d9c44" xlink:to="loc_us-gaap_DueToAffiliateCurrent_0a8b7232-e4c3-4dd3-a1e5-ac01cbd0acd4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_e28221a3-3d2f-479f-9bfb-032f637959be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_70e59b62-a6f4-40cf-a22c-809f994d9c44" xlink:to="loc_us-gaap_DividendsPayableCurrent_e28221a3-3d2f-479f-9bfb-032f637959be" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_e6fce027-fc27-4501-857a-2f38724fcbdf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_70e59b62-a6f4-40cf-a22c-809f994d9c44" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_e6fce027-fc27-4501-857a-2f38724fcbdf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_98bb068d-ab4c-4c55-b20a-0ba26b6d208b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_70e59b62-a6f4-40cf-a22c-809f994d9c44" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_98bb068d-ab4c-4c55-b20a-0ba26b6d208b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e56b045a-38fd-43a1-a564-2191aa917c85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_70e59b62-a6f4-40cf-a22c-809f994d9c44" xlink:to="loc_us-gaap_LiabilitiesCurrent_e56b045a-38fd-43a1-a564-2191aa917c85" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_24cb660e-3e17-4713-b0b1-c17ae395da91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_d23e5726-5dfa-4fb9-b203-3e5c94e3bfe1" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_24cb660e-3e17-4713-b0b1-c17ae395da91" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_e46151dd-10b7-4392-b1a0-821cc3014853" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_24cb660e-3e17-4713-b0b1-c17ae395da91" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_e46151dd-10b7-4392-b1a0-821cc3014853" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_0bff7e27-111d-4ce6-9f03-cc68f36c6c45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_24cb660e-3e17-4713-b0b1-c17ae395da91" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_0bff7e27-111d-4ce6-9f03-cc68f36c6c45" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7e92c2ad-90b3-410b-9ba6-0e9c33189ed0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_24cb660e-3e17-4713-b0b1-c17ae395da91" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7e92c2ad-90b3-410b-9ba6-0e9c33189ed0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_3276bd1e-73bd-45b1-83cd-ce3799f04e39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_24cb660e-3e17-4713-b0b1-c17ae395da91" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_3276bd1e-73bd-45b1-83cd-ce3799f04e39" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_3a8e8dce-acd5-4417-a24d-becb12228ae9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_d23e5726-5dfa-4fb9-b203-3e5c94e3bfe1" xlink:to="loc_us-gaap_Liabilities_3a8e8dce-acd5-4417-a24d-becb12228ae9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_669e1b9e-bb4e-4ff0-841d-38c787e9c85e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_d23e5726-5dfa-4fb9-b203-3e5c94e3bfe1" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_669e1b9e-bb4e-4ff0-841d-38c787e9c85e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_a96b5a7b-9df3-4340-8f13-8a8fdc565659" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_669e1b9e-bb4e-4ff0-841d-38c787e9c85e" xlink:to="loc_srt_ConsolidatedEntitiesAxis_a96b5a7b-9df3-4340-8f13-8a8fdc565659" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_a96b5a7b-9df3-4340-8f13-8a8fdc565659_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_a96b5a7b-9df3-4340-8f13-8a8fdc565659" xlink:to="loc_srt_ConsolidatedEntitiesDomain_a96b5a7b-9df3-4340-8f13-8a8fdc565659_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_a1dbc51e-ebf3-46ed-836b-ecee4a687a42" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_a96b5a7b-9df3-4340-8f13-8a8fdc565659" xlink:to="loc_srt_ConsolidatedEntitiesDomain_a1dbc51e-ebf3-46ed-836b-ecee4a687a42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_da9b3767-4ce8-48b6-8ce9-5f03d63db2cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_a1dbc51e-ebf3-46ed-836b-ecee4a687a42" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_da9b3767-4ce8-48b6-8ce9-5f03d63db2cd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/Leases" xlink:type="simple" xlink:href="ameh-20200630.xsd#Leases"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/Leases" xlink:type="extended" id="i7fcea1ef296a4e6aa4119db8fbe97081_Leases"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesTables" xlink:type="simple" xlink:href="ameh-20200630.xsd#LeasesTables"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/LeasesTables" xlink:type="extended" id="i01e1664fb9594be3aff96d423177d16a_LeasesTables"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesAdditionalinformationDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#LeasesAdditionalinformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/LeasesAdditionalinformationDetails" xlink:type="extended" id="i156a4b0aca284f399a99f8859d58119f_LeasesAdditionalinformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_716a3d40-e25e-4318-b951-99ac111e607e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_c5f4afb1-7316-469a-830b-8b38bb72c11a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_716a3d40-e25e-4318-b951-99ac111e607e" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_c5f4afb1-7316-469a-830b-8b38bb72c11a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_9dcd517c-5a8e-4a41-8899-e5309c9c533f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_716a3d40-e25e-4318-b951-99ac111e607e" xlink:to="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_9dcd517c-5a8e-4a41-8899-e5309c9c533f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_acdcf51a-2760-44bc-ac9b-12d652c619bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_716a3d40-e25e-4318-b951-99ac111e607e" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_acdcf51a-2760-44bc-ac9b-12d652c619bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1_33d10598-7aa5-48ba-9539-20a306cda751" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_716a3d40-e25e-4318-b951-99ac111e607e" xlink:to="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1_33d10598-7aa5-48ba-9539-20a306cda751" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable_74811453-4922-4cdb-896a-5644dcfef5ad" xlink:href="ameh-20200630.xsd#ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_716a3d40-e25e-4318-b951-99ac111e607e" xlink:to="loc_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable_74811453-4922-4cdb-896a-5644dcfef5ad" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable_f7fa2cdd-f2b0-4ab8-a443-e8e86bd467d1" xlink:href="ameh-20200630.xsd#ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_716a3d40-e25e-4318-b951-99ac111e607e" xlink:to="loc_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable_f7fa2cdd-f2b0-4ab8-a443-e8e86bd467d1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_0392f9a7-8ef6-4194-a319-6a72523bc64b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_716a3d40-e25e-4318-b951-99ac111e607e" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_0392f9a7-8ef6-4194-a319-6a72523bc64b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_a52025a2-6001-43b9-a615-14cc51ce1f13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_716a3d40-e25e-4318-b951-99ac111e607e" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_a52025a2-6001-43b9-a615-14cc51ce1f13" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_739c1120-13f1-44bb-a117-4d894f85ba18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_716a3d40-e25e-4318-b951-99ac111e607e" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_739c1120-13f1-44bb-a117-4d894f85ba18" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8edc7c3e-adeb-41e7-bf02-6e95d1d8e600" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_739c1120-13f1-44bb-a117-4d894f85ba18" xlink:to="loc_srt_RangeAxis_8edc7c3e-adeb-41e7-bf02-6e95d1d8e600" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8edc7c3e-adeb-41e7-bf02-6e95d1d8e600_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_8edc7c3e-adeb-41e7-bf02-6e95d1d8e600" xlink:to="loc_srt_RangeMember_8edc7c3e-adeb-41e7-bf02-6e95d1d8e600_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6d1ad470-eb58-49b5-9c24-2e9d4902298e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_8edc7c3e-adeb-41e7-bf02-6e95d1d8e600" xlink:to="loc_srt_RangeMember_6d1ad470-eb58-49b5-9c24-2e9d4902298e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2ddb8b81-bb8d-4139-841e-7198c017a5fa" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6d1ad470-eb58-49b5-9c24-2e9d4902298e" xlink:to="loc_srt_MinimumMember_2ddb8b81-bb8d-4139-841e-7198c017a5fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7c1e4a29-fa67-403a-a73f-48b5dcb4ecba" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6d1ad470-eb58-49b5-9c24-2e9d4902298e" xlink:to="loc_srt_MaximumMember_7c1e4a29-fa67-403a-a73f-48b5dcb4ecba" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#LeasesComponentsofLeaseExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="extended" id="i21c76cfd1cd84fa393f66fb517af176d_LeasesComponentsofLeaseExpenseDetails"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#LeasesOtherInformationRelatedtoLeasesDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails" xlink:type="extended" id="i1cdd5765fe94422c914a83bbbf68c587_LeasesOtherInformationRelatedtoLeasesDetails"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails" xlink:type="extended" id="i728dc4d314f144939a8c1e245dbf4378_LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>15
<FILENAME>ameh-20200630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:b88c77a1-c027-414b-9d80-e41583dc701a,g:39bb5244-cfb0-4a0f-b0d7-a52c48426910-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4588cc8d-44ed-4a52-bdfc-4bb380e75ab4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock awards granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LinesOfCreditCurrent_cbf9b4e6-c8a9-432a-a74e-1a8b9524aa78_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LinesOfCreditCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Current portion of debt</link:label>
    <link:label id="lab_us-gaap_LinesOfCreditCurrent_label_en-US" xlink:label="lab_us-gaap_LinesOfCreditCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LinesOfCreditCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LinesOfCreditCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LinesOfCreditCurrent" xlink:to="lab_us-gaap_LinesOfCreditCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_3c323e19-f025-4d06-852f-ce53e31ead42_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_label_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_168352a5-1c93-418f-a089-11e958c70d5a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_66aac5f2-1f82-4980-855e-30240d72b49b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_aae53569-20fc-440f-a17f-e2188ee23ac8_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d5f74f22-748f-47dd-999f-aa2f310be8ef_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_3ba828df-7a64-44f8-b05e-61417cae50a8_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities_95276f78-0ed4-45a0-b437-9226a0cc1afe_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subordinated loan</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities_5d827091-ccee-4462-8ba9-64fd48086a0a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standby letters of credit assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Financial Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_8c1d0275-20ba-4b1a-9219-9637330c529a_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MedicaidMember_b6525624-293e-4f52-a572-15c6df9b384c_terseLabel_en-US" xlink:label="lab_ameh_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid</link:label>
    <link:label id="lab_ameh_MedicaidMember_label_en-US" xlink:label="lab_ameh_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid [Member]</link:label>
    <link:label id="lab_ameh_MedicaidMember_documentation_en-US" xlink:label="lab_ameh_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ameh:MedicaidMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicaidMember" xlink:href="ameh-20200630.xsd#ameh_MedicaidMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MedicaidMember" xlink:to="lab_ameh_MedicaidMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_f8b610b9-bd35-40ba-b4ad-a351360519f2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Outstanding Warrants</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_66710fb3-6ec1-4248-9fe5-8649e1a3644f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the exercise of stock options and warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_89625198-96db-4337-b465-a020356afc94_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d875d18a-fb84-4a39-993d-604cc0852193_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, mezzanine equity and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3a6b48da-344a-4f06-8c39-7e946a9a3839_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; (Deficit) Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d3b68630-5348-45a4-9b75-ca877c4ee3d8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_17a18d9f-4a74-468e-909f-fa20d7563513_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_53c1a11e-3e2c-4048-9b14-86c9a1d87328_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation associated with finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_e8070297-9835-4675-8b82-77371ae662dd_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of lease expense</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm_608d2f0e-01ac-4b32-85d4-9edb5876aec8_verboseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm_label_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Rights Outstanding Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Rights outstanding Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" xlink:href="ameh-20200630.xsd#ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="lab_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_030fead7-6962-4cc0-900d-9789d3288940_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_dd15d4a8-04db-4650-968c-75ad611f7649_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NetworkMedicalManagementIncMember_bd5abcd6-78f2-4fa8-a2ba-04640454cc68_terseLabel_en-US" xlink:label="lab_ameh_NetworkMedicalManagementIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Network Medical Management, Inc.</link:label>
    <link:label id="lab_ameh_NetworkMedicalManagementIncMember_label_en-US" xlink:label="lab_ameh_NetworkMedicalManagementIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Network Medical Management, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementIncMember" xlink:href="ameh-20200630.xsd#ameh_NetworkMedicalManagementIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NetworkMedicalManagementIncMember" xlink:to="lab_ameh_NetworkMedicalManagementIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AdvancedForWorkingCapital_6adb2914-2ec8-4eb6-8177-f1f0f114c553_terseLabel_en-US" xlink:label="lab_ameh_AdvancedForWorkingCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advance for working capital</link:label>
    <link:label id="lab_ameh_AdvancedForWorkingCapital_label_en-US" xlink:label="lab_ameh_AdvancedForWorkingCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advanced For Working Capital</link:label>
    <link:label id="lab_ameh_AdvancedForWorkingCapital_documentation_en-US" xlink:label="lab_ameh_AdvancedForWorkingCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount advanced for working capital purposes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AdvancedForWorkingCapital" xlink:href="ameh-20200630.xsd#ameh_AdvancedForWorkingCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AdvancedForWorkingCapital" xlink:to="lab_ameh_AdvancedForWorkingCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_34073f8e-6e96-4521-80f9-1c5ab0f7a0b4_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_4a2976f2-0720-408a-a6a1-655cded7e745_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CommercialMember_7a75bdb4-1f4a-4123-bc82-8f76dbf16a53_terseLabel_en-US" xlink:label="lab_ameh_CommercialMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial</link:label>
    <link:label id="lab_ameh_CommercialMember_label_en-US" xlink:label="lab_ameh_CommercialMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial [Member]</link:label>
    <link:label id="lab_ameh_CommercialMember_documentation_en-US" xlink:label="lab_ameh_CommercialMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ameh:CommercialMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommercialMember" xlink:href="ameh-20200630.xsd#ameh_CommercialMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CommercialMember" xlink:to="lab_ameh_CommercialMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_be822cd3-1aae-4722-86e1-a7d9c1c1ca6f_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_00a1ad6a-b9c3-4d53-8e47-52ba2d45a09d_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_da36d801-12b7-48a9-aecf-1bfcde13c3c4_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_0effb0ba-6339-4d13-b72c-820757705260_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AggregateintrinsicvalueAbstract_32978de1-72d0-4341-ac10-b3f2aeb7ea6f_terseLabel_en-US" xlink:label="lab_ameh_AggregateintrinsicvalueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value (in thousands)</link:label>
    <link:label id="lab_ameh_AggregateintrinsicvalueAbstract_label_en-US" xlink:label="lab_ameh_AggregateintrinsicvalueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AggregateintrinsicvalueAbstract" xlink:href="ameh-20200630.xsd#ameh_AggregateintrinsicvalueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AggregateintrinsicvalueAbstract" xlink:to="lab_ameh_AggregateintrinsicvalueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_b8ad3709-5fa2-4670-9f73-fe9323ff828c_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payment, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_61a16369-dea8-4a3b-95b2-91cc59829943_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_e81348fb-da81-41f8-8818-8e784e41a2b7_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d3382e99-c03b-4717-abbc-9420f77d50c4_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CDSCMember_a22dc44a-085f-4293-a7cf-479fd54c388e_terseLabel_en-US" xlink:label="lab_ameh_CDSCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CDSC</link:label>
    <link:label id="lab_ameh_CDSCMember_label_en-US" xlink:label="lab_ameh_CDSCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CDSC [Member]</link:label>
    <link:label id="lab_ameh_CDSCMember_documentation_en-US" xlink:label="lab_ameh_CDSCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CDSC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CDSCMember" xlink:href="ameh-20200630.xsd#ameh_CDSCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CDSCMember" xlink:to="lab_ameh_CDSCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_aed85866-36e2-46ff-9652-784d56c4f54d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_e1cba2a4-0edd-46a2-8eb3-a075155f0eb1_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_fba8b0a7-036d-442f-8cde-cac6f7314af6_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_IncreaseDecreaseInMedicalLiabilities_805b6144-c85e-40aa-84b1-3c3b02305ce6_verboseLabel_en-US" xlink:label="lab_ameh_IncreaseDecreaseInMedicalLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical liabilities</link:label>
    <link:label id="lab_ameh_IncreaseDecreaseInMedicalLiabilities_label_en-US" xlink:label="lab_ameh_IncreaseDecreaseInMedicalLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Medical Liabilities</link:label>
    <link:label id="lab_ameh_IncreaseDecreaseInMedicalLiabilities_documentation_en-US" xlink:label="lab_ameh_IncreaseDecreaseInMedicalLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The increase (decrease) during the reporting period in the aggregate amount of medical liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInMedicalLiabilities" xlink:href="ameh-20200630.xsd#ameh_IncreaseDecreaseInMedicalLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_IncreaseDecreaseInMedicalLiabilities" xlink:to="lab_ameh_IncreaseDecreaseInMedicalLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_5d65f422-4f40-43a6-b64f-c3ad294c768a_verboseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to related parties</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MinorityInterestPolicyPolicyTextBlock_210f49be-b7c8-498e-811a-f16dda09c82d_terseLabel_en-US" xlink:label="lab_ameh_MinorityInterestPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interests</link:label>
    <link:label id="lab_ameh_MinorityInterestPolicyPolicyTextBlock_label_en-US" xlink:label="lab_ameh_MinorityInterestPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minority Interest Policy [Policy Text Block]</link:label>
    <link:label id="lab_ameh_MinorityInterestPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_ameh_MinorityInterestPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minority Interest Policy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MinorityInterestPolicyPolicyTextBlock" xlink:href="ameh-20200630.xsd#ameh_MinorityInterestPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MinorityInterestPolicyPolicyTextBlock" xlink:to="lab_ameh_MinorityInterestPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_51f20478-acb8-4628-9b03-a095eb1f22b4_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_fd0f0c9c-48cd-4373-8d82-66309da36862_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_5231ef2e-2147-43be-94a9-86d56b05730a_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_dccd300e-cb46-46c8-bac7-677a60fc771e_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_c21e3a47-4693-4061-ba45-7d234e875f32_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AncillaryServiceContractMember_a102ee1a-f981-412e-b487-d141371817a7_terseLabel_en-US" xlink:label="lab_ameh_AncillaryServiceContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ancillary Service Contract</link:label>
    <link:label id="lab_ameh_AncillaryServiceContractMember_label_en-US" xlink:label="lab_ameh_AncillaryServiceContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ancillary Service Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AncillaryServiceContractMember" xlink:href="ameh-20200630.xsd#ameh_AncillaryServiceContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AncillaryServiceContractMember" xlink:to="lab_ameh_AncillaryServiceContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock_0e38e406-d3b4-4ed9-97d1-0703713c17e1_terseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of voting common stock</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Proportion of Ownership Interest in Voting Common Stock</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The proportion of investment in Voting common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock" xlink:href="ameh-20200630.xsd#ameh_EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock" xlink:to="lab_ameh_EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate_1dc0e37c-01dd-4acb-adf9-e15784c8da06_terseLabel_en-US" xlink:label="lab_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate in the event of default</link:label>
    <link:label id="lab_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate_label_en-US" xlink:label="lab_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Receivable, Modifications, Subsequent Default, Interest Rate</link:label>
    <link:label id="lab_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate_documentation_en-US" xlink:label="lab_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Receivable, Modifications, Subsequent Default, Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate" xlink:href="ameh-20200630.xsd#ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate" xlink:to="lab_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_007de8ab-efe2-4978-b1f3-c30dadddd92a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_d76346f7-3a35-474d-bba7-b1c291b16cc8_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of treasury shares (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_62963808-1631-438b-8263-9f0e63a0dfb7_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_90abbaa3-87b2-4f62-8ae6-42cba62185fc_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_6be70e4a-012c-4528-841e-bcb3fea9ef23_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_4a05ab15-911f-4ea1-a790-d51274e6b9aa_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_f64d105e-0730-4703-8abc-38192a7f5c82_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PaymentMadeToRelatedParty_2043bbab-ffa3-4a1d-91cc-2b4bb3d76731_terseLabel_en-US" xlink:label="lab_ameh_PaymentMadeToRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to related parties</link:label>
    <link:label id="lab_ameh_PaymentMadeToRelatedParty_label_en-US" xlink:label="lab_ameh_PaymentMadeToRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Made To Related Party</link:label>
    <link:label id="lab_ameh_PaymentMadeToRelatedParty_documentation_en-US" xlink:label="lab_ameh_PaymentMadeToRelatedParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit/Duration (Amount paid to related party in relation to providing services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentMadeToRelatedParty" xlink:href="ameh-20200630.xsd#ameh_PaymentMadeToRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PaymentMadeToRelatedParty" xlink:to="lab_ameh_PaymentMadeToRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_500f8b2c-eebc-4fd0-ba0b-70851fe3b1db_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_ffc77097-a1f6-407d-96f5-50e2b6f0d69f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_618afff2-d9a4-4590-8b16-105b62d137f9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of finance lease obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_cce19d0f-75b0-4301-ac3c-1a88ee92d640_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing cash flows from finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_fe9b7b39-5546-4d7b-a15d-af23bdc48070_verboseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_04af5623-3971-4980-b237-8760fc5ad707_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of short-term marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_f6dde9ac-9fe8-48d1-abf0-179a5a24462f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_SubcontractorIPAPayable_09a88ed2-6c01-4333-b9ae-ecb18d8b102d_verboseLabel_en-US" xlink:label="lab_ameh_SubcontractorIPAPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subcontractor IPA payable</link:label>
    <link:label id="lab_ameh_SubcontractorIPAPayable_label_en-US" xlink:label="lab_ameh_SubcontractorIPAPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subcontractor IPA Payable</link:label>
    <link:label id="lab_ameh_SubcontractorIPAPayable_documentation_en-US" xlink:label="lab_ameh_SubcontractorIPAPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subcontractor IPA Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SubcontractorIPAPayable" xlink:href="ameh-20200630.xsd#ameh_SubcontractorIPAPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_SubcontractorIPAPayable" xlink:to="lab_ameh_SubcontractorIPAPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_8e78d2ae-9c78-4fc6-a396-0e7143895552_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_be6cfd71-7ef5-45e9-9ace-1dff590ad808_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForFees_53e4e94e-c37a-411c-baaf-76247b93e7b4_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fees paid</link:label>
    <link:label id="lab_us-gaap_PaymentsForFees_label_en-US" xlink:label="lab_us-gaap_PaymentsForFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Other Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForFees" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForFees" xlink:to="lab_us-gaap_PaymentsForFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_2a318662-cff8-4b49-bb96-f94d1e88ddd9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving credit facility term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_66b349b8-e5ee-4e9a-b0a1-dff94c2d1715_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PayorEMember_a22a8f99-1637-4d26-b074-1dd1b475a8be_terseLabel_en-US" xlink:label="lab_ameh_PayorEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor E</link:label>
    <link:label id="lab_ameh_PayorEMember_label_en-US" xlink:label="lab_ameh_PayorEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor E [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorEMember" xlink:href="ameh-20200630.xsd#ameh_PayorEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PayorEMember" xlink:to="lab_ameh_PayorEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_cc85d40e-bc35-4e32-9c8f-8b4e9b984dbc_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_dd3aab05-f28e-4f01-95f0-f250f216e346_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes and Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet_7e4d1dde-2f7d-4c52-8b31-5d59b5ff6b19_terseLabel_en-US" xlink:label="lab_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional cash consideration entitled to be received</link:label>
    <link:label id="lab_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet_6e8b5e0d-ff94-4fa5-8610-9bff5642a5e6_verboseLabel_en-US" xlink:label="lab_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional cash and non-cash consideration entitled to be received</link:label>
    <link:label id="lab_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet_7670da7e-ad05-4e8f-bf27-73a7c30b2180_netLabel_en-US" xlink:label="lab_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beneficial interest in UCI</link:label>
    <link:label id="lab_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet_label_en-US" xlink:label="lab_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Proceeds To Be Received From Sale Of Equity Method Investments, If Circumstances Met</link:label>
    <link:label id="lab_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet_documentation_en-US" xlink:label="lab_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Proceeds To Be Received From Sale Of Equity Method Investments, If Circumstances Met</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet" xlink:href="ameh-20200630.xsd#ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet" xlink:to="lab_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_85b0a5a9-5d69-490c-9295-5d710edb58e2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_1e7ea836-e0b0-4bcc-91d7-18b9ef1e19d7_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Shares Included in the Diluted Earnings Per Share Computations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted Average Number of Shares [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_aa6fe519-863f-49ea-97c0-7f06ac4f502c_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise&#160;Price&#160;Per Share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashUninsuredAmount_3d1b99bb-5605-4eb1-becc-c49280e9043a_terseLabel_en-US" xlink:label="lab_us-gaap_CashUninsuredAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount deposit accounts exceeded FDIC insured limit</link:label>
    <link:label id="lab_us-gaap_CashUninsuredAmount_label_en-US" xlink:label="lab_us-gaap_CashUninsuredAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Uninsured Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashUninsuredAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashUninsuredAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashUninsuredAmount" xlink:to="lab_us-gaap_CashUninsuredAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_09145aeb-0582-4e9f-ad75-fe6468515c4a_verboseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MembersCapital_fab58676-e8d5-40c3-8ee7-c9a85ecd7613_terseLabel_en-US" xlink:label="lab_us-gaap_MembersCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial capital contributions</link:label>
    <link:label id="lab_us-gaap_MembersCapital_label_en-US" xlink:label="lab_us-gaap_MembersCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Members' Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MembersCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MembersCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MembersCapital" xlink:to="lab_us-gaap_MembersCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MarketableSecuritiesCurrentMaturityPeriod_2a793b71-0138-41c7-8350-4a2409fc472c_terseLabel_en-US" xlink:label="lab_ameh_MarketableSecuritiesCurrentMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term marketable securities, maturity period</link:label>
    <link:label id="lab_ameh_MarketableSecuritiesCurrentMaturityPeriod_label_en-US" xlink:label="lab_ameh_MarketableSecuritiesCurrentMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current, Maturity Period</link:label>
    <link:label id="lab_ameh_MarketableSecuritiesCurrentMaturityPeriod_documentation_en-US" xlink:label="lab_ameh_MarketableSecuritiesCurrentMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current, Maturity Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MarketableSecuritiesCurrentMaturityPeriod" xlink:href="ameh-20200630.xsd#ameh_MarketableSecuritiesCurrentMaturityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MarketableSecuritiesCurrentMaturityPeriod" xlink:to="lab_ameh_MarketableSecuritiesCurrentMaturityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_5b479ce2-dc5c-4ef5-8355-c6682742dd00_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PmiocMember_db668287-a870-4cb9-b62e-3a7e6ab212b9_terseLabel_en-US" xlink:label="lab_ameh_PmiocMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PMIOC</link:label>
    <link:label id="lab_ameh_PmiocMember_label_en-US" xlink:label="lab_ameh_PmiocMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PMIOC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PmiocMember" xlink:href="ameh-20200630.xsd#ameh_PmiocMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PmiocMember" xlink:to="lab_ameh_PmiocMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_00b8b317-6b3b-487e-8991-b2733fc305c2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility, Bank Loan and Lines of Credit</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7437fbee-9db6-45a1-afc7-20fbb27446f1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_436c7c36-36e6-40a1-b0e4-dfdf645d14a8_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_eed8b435-3d91-4f0a-97fb-a7538b67a3df_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investment contributed</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Value Assigned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear_9ed6ee7b-9617-4c0f-8679-427bd3f76c36_terseLabel_en-US" xlink:label="lab_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk pool surplus or deficits, settlement period after risk pool performance year</link:label>
    <link:label id="lab_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear_label_en-US" xlink:label="lab_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk Pool Surplus Or Deficits, Settlement Period After Performance Year</link:label>
    <link:label id="lab_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear_documentation_en-US" xlink:label="lab_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk Pool Surplus Or Deficits, Settlement Period After Performance Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" xlink:href="ameh-20200630.xsd#ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" xlink:to="lab_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceReceivablesMember_fbd938ad-dc78-44f1-b734-febaa5235ed4_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable</link:label>
    <link:label id="lab_us-gaap_FinanceReceivablesMember_label_en-US" xlink:label="lab_us-gaap_FinanceReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceReceivablesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceReceivablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceReceivablesMember" xlink:to="lab_us-gaap_FinanceReceivablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashEquivalentsNoncurrent_35788990-e776-4550-8bda-a2526b10730d_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash &#8211; non-current</link:label>
    <link:label id="lab_us-gaap_RestrictedCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesBPreferredStockMember_fbd18c60-be29-4a9c-934a-28d508f3aa2a_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesBPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesBPreferredStockMember" xlink:to="lab_us-gaap_SeriesBPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AlliedPacificOfCaliforniaIPAMember_4fee3a7f-86a7-42e6-b46a-c5cc971aac47_verboseLabel_en-US" xlink:label="lab_ameh_AlliedPacificOfCaliforniaIPAMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC</link:label>
    <link:label id="lab_ameh_AlliedPacificOfCaliforniaIPAMember_label_en-US" xlink:label="lab_ameh_AlliedPacificOfCaliforniaIPAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allied Pacific Of California IPA [Member]</link:label>
    <link:label id="lab_ameh_AlliedPacificOfCaliforniaIPAMember_documentation_en-US" xlink:label="lab_ameh_AlliedPacificOfCaliforniaIPAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allied Pacific Of California IPA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember" xlink:href="ameh-20200630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AlliedPacificOfCaliforniaIPAMember" xlink:to="lab_ameh_AlliedPacificOfCaliforniaIPAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StandbyLettersOfCreditMember_08cb9bc6-0bc8-4216-8338-2108a3ecdc3c_terseLabel_en-US" xlink:label="lab_us-gaap_StandbyLettersOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standby Letters of Credit</link:label>
    <link:label id="lab_us-gaap_StandbyLettersOfCreditMember_label_en-US" xlink:label="lab_us-gaap_StandbyLettersOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standby Letters of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StandbyLettersOfCreditMember" xlink:to="lab_us-gaap_StandbyLettersOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HealthCareCostsPolicyPolicyTextBlock_41c68577-edb2-4fc8-9471-43e2fa9be1f1_verboseLabel_en-US" xlink:label="lab_us-gaap_HealthCareCostsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Liabilities</link:label>
    <link:label id="lab_us-gaap_HealthCareCostsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_HealthCareCostsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareCostsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareCostsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareCostsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_HealthCareCostsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_ed139b38-822f-4ba5-acbe-ea16fb9cf0cb_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_6e40e699-412e-4970-b8a4-3ec0e4f7a1e3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease option to extend (up to)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ApcShareholdersMember_e0691cf8-0475-4bb3-ad90-4a62dd17aa9b_terseLabel_en-US" xlink:label="lab_ameh_ApcShareholdersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC Shareholders</link:label>
    <link:label id="lab_ameh_ApcShareholdersMember_label_en-US" xlink:label="lab_ameh_ApcShareholdersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC Shareholders [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcShareholdersMember" xlink:href="ameh-20200630.xsd#ameh_ApcShareholdersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ApcShareholdersMember" xlink:to="lab_ameh_ApcShareholdersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_52f991c8-5265-4a14-9d97-f1aefab75c47_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to weighted average shares of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DrSimAndDrLamMember_0ae925e3-a3ba-40db-8d29-c55629905fe8_terseLabel_en-US" xlink:label="lab_ameh_DrSimAndDrLamMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Sim And Dr. Lam</link:label>
    <link:label id="lab_ameh_DrSimAndDrLamMember_label_en-US" xlink:label="lab_ameh_DrSimAndDrLamMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Sim And Dr. Lam [Member]</link:label>
    <link:label id="lab_ameh_DrSimAndDrLamMember_documentation_en-US" xlink:label="lab_ameh_DrSimAndDrLamMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Sim And Dr. Lam</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DrSimAndDrLamMember" xlink:href="ameh-20200630.xsd#ameh_DrSimAndDrLamMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DrSimAndDrLamMember" xlink:to="lab_ameh_DrSimAndDrLamMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_b92f81a0-355a-44de-bcf9-66384a7dc975_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_62f1954f-7557-4a6e-8bb1-ce79a8fe81f6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_e755fe7a-2fd5-44fc-8c33-68ea6ef3b352_terseLabel_en-US" xlink:label="lab_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract]</link:label>
    <link:label id="lab_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract" xlink:to="lab_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MedicalPropertyPartnersMember_d3fba9f9-6b8e-4587-9267-e478f32969f7_terseLabel_en-US" xlink:label="lab_ameh_MedicalPropertyPartnersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Property Partners</link:label>
    <link:label id="lab_ameh_MedicalPropertyPartnersMember_label_en-US" xlink:label="lab_ameh_MedicalPropertyPartnersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Property Partners [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicalPropertyPartnersMember" xlink:href="ameh-20200630.xsd#ameh_MedicalPropertyPartnersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MedicalPropertyPartnersMember" xlink:to="lab_ameh_MedicalPropertyPartnersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d92aa79c-eb4d-4b16-84be-fd6e32db9246_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions_8c0d79f7-81cc-42e6-8f23-25d42e58e08c_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired from Alpha Care</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Business Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_dda97fbc-35bc-4483-8c44-088c2e3b14eb_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information Related to Lease Costs</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount_8481676b-fdc1-4fa8-8e30-1e4c82468331_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Amount Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:to="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PayorAMember_62a836a5-ff4b-4aa9-a8a2-ec9b0612b43b_terseLabel_en-US" xlink:label="lab_ameh_PayorAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor A</link:label>
    <link:label id="lab_ameh_PayorAMember_label_en-US" xlink:label="lab_ameh_PayorAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor A [Member]</link:label>
    <link:label id="lab_ameh_PayorAMember_documentation_en-US" xlink:label="lab_ameh_PayorAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorAMember" xlink:href="ameh-20200630.xsd#ameh_PayorAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PayorAMember" xlink:to="lab_ameh_PayorAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_669053b7-81eb-4c26-a6c3-7e1a8d05aee4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_eefb1afa-6118-4ab3-9af6-eb1287e2c9c2_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_2b4c500a-48a4-4ea7-a94a-9d8d71e5843d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7579ac2d-625e-4678-8350-13d65d1b316d_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PaymentOfRevenue_a071cea6-75fe-45c0-8519-bca11946fad7_terseLabel_en-US" xlink:label="lab_ameh_PaymentOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments received</link:label>
    <link:label id="lab_ameh_PaymentOfRevenue_label_en-US" xlink:label="lab_ameh_PaymentOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Of Revenue</link:label>
    <link:label id="lab_ameh_PaymentOfRevenue_documentation_en-US" xlink:label="lab_ameh_PaymentOfRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentOfRevenue" xlink:href="ameh-20200630.xsd#ameh_PaymentOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PaymentOfRevenue" xlink:to="lab_ameh_PaymentOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_938b5a67-ec70-4255-9aaf-24cd8dc40876_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CriticalQualityManagementCorpMember_bccf430f-d8bb-4f40-ba9a-d24e01b3e589_terseLabel_en-US" xlink:label="lab_ameh_CriticalQualityManagementCorpMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Critical Quality Management Corp</link:label>
    <link:label id="lab_ameh_CriticalQualityManagementCorpMember_label_en-US" xlink:label="lab_ameh_CriticalQualityManagementCorpMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Critical Quality Management Corp [Member]</link:label>
    <link:label id="lab_ameh_CriticalQualityManagementCorpMember_documentation_en-US" xlink:label="lab_ameh_CriticalQualityManagementCorpMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">xxx_Critical Quality Management Corp Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CriticalQualityManagementCorpMember" xlink:href="ameh-20200630.xsd#ameh_CriticalQualityManagementCorpMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CriticalQualityManagementCorpMember" xlink:to="lab_ameh_CriticalQualityManagementCorpMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_5e280bbf-37fe-4859-bbf8-fa4ec7b03d20_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related-Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_b9e968d5-29ce-4c1e-b229-1e392916812e_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DebtInstrumentNumberOfKeyFinancialRatios_ef729ac2-e04b-42da-9cae-26b5fa1bd3e2_terseLabel_en-US" xlink:label="lab_ameh_DebtInstrumentNumberOfKeyFinancialRatios" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of key financial ratios</link:label>
    <link:label id="lab_ameh_DebtInstrumentNumberOfKeyFinancialRatios_label_en-US" xlink:label="lab_ameh_DebtInstrumentNumberOfKeyFinancialRatios" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Number Of Key Financial Ratios</link:label>
    <link:label id="lab_ameh_DebtInstrumentNumberOfKeyFinancialRatios_documentation_en-US" xlink:label="lab_ameh_DebtInstrumentNumberOfKeyFinancialRatios" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Number Of Key Financial Ratios</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentNumberOfKeyFinancialRatios" xlink:href="ameh-20200630.xsd#ameh_DebtInstrumentNumberOfKeyFinancialRatios"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DebtInstrumentNumberOfKeyFinancialRatios" xlink:to="lab_ameh_DebtInstrumentNumberOfKeyFinancialRatios" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_b82808d9-85dc-42a7-9626-1f5eacbb950e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NumberOfEmployees_c2591294-d0fe-437a-bd3a-7724590598da_verboseLabel_en-US" xlink:label="lab_ameh_NumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of employees (over)</link:label>
    <link:label id="lab_ameh_NumberOfEmployees_886ebb0b-e2d8-4162-a01a-adc2a2b8afab_terseLabel_en-US" xlink:label="lab_ameh_NumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of employees (more than)</link:label>
    <link:label id="lab_ameh_NumberOfEmployees_label_en-US" xlink:label="lab_ameh_NumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Employees</link:label>
    <link:label id="lab_ameh_NumberOfEmployees_documentation_en-US" xlink:label="lab_ameh_NumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfEmployees" xlink:href="ameh-20200630.xsd#ameh_NumberOfEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NumberOfEmployees" xlink:to="lab_ameh_NumberOfEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DebtInstrumentApprovalThresholdOfShareholdersForUseOfFundsPercentage_f5b9083a-ce67-4f9d-91ab-be1f03aafbdd_terseLabel_en-US" xlink:label="lab_ameh_DebtInstrumentApprovalThresholdOfShareholdersForUseOfFundsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholder approval percentage (not less than)</link:label>
    <link:label id="lab_ameh_DebtInstrumentApprovalThresholdOfShareholdersForUseOfFundsPercentage_label_en-US" xlink:label="lab_ameh_DebtInstrumentApprovalThresholdOfShareholdersForUseOfFundsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Approval Threshold Of Shareholders For Use Of Funds, Percentage</link:label>
    <link:label id="lab_ameh_DebtInstrumentApprovalThresholdOfShareholdersForUseOfFundsPercentage_documentation_en-US" xlink:label="lab_ameh_DebtInstrumentApprovalThresholdOfShareholdersForUseOfFundsPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Approval Threshold Of Shareholders For Use Of Funds, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentApprovalThresholdOfShareholdersForUseOfFundsPercentage" xlink:href="ameh-20200630.xsd#ameh_DebtInstrumentApprovalThresholdOfShareholdersForUseOfFundsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DebtInstrumentApprovalThresholdOfShareholdersForUseOfFundsPercentage" xlink:to="lab_ameh_DebtInstrumentApprovalThresholdOfShareholdersForUseOfFundsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock_0538a173-80f4-4696-a2f1-816ae2bd72ca_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Future Policy Benefits and Unpaid Claims Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:to="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_906e7732-62e4-44bb-8642-825b01f5cd0c_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_819878c1-1105-401f-96e6-4f60127c656a_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LineOfCreditFacilityAdditionalAdvances_6c18efb0-cf14-43fd-ba3b-126ea79f5b45_terseLabel_en-US" xlink:label="lab_ameh_LineOfCreditFacilityAdditionalAdvances" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional advances</link:label>
    <link:label id="lab_ameh_LineOfCreditFacilityAdditionalAdvances_label_en-US" xlink:label="lab_ameh_LineOfCreditFacilityAdditionalAdvances" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility Additional Advances</link:label>
    <link:label id="lab_ameh_LineOfCreditFacilityAdditionalAdvances_documentation_en-US" xlink:label="lab_ameh_LineOfCreditFacilityAdditionalAdvances" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of line of credit facility additional amount advances as a loan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LineOfCreditFacilityAdditionalAdvances" xlink:href="ameh-20200630.xsd#ameh_LineOfCreditFacilityAdditionalAdvances"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LineOfCreditFacilityAdditionalAdvances" xlink:to="lab_ameh_LineOfCreditFacilityAdditionalAdvances" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_b2ad0038-d21c-4de8-96f2-9d5ee2f76012_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Risks</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_ddf0d2aa-fe7c-4a4b-b3a4-272043f1dd02_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_7be90ee1-ed4f-44e4-9642-ed416e012220_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_StockIssuedDuringPeriodSharesMerger_03c1e8c6-7ca7-4a4d-8979-156aea25339c_terseLabel_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodSharesMerger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Holdback shares not issued to former shareholders (in shares)</link:label>
    <link:label id="lab_ameh_StockIssuedDuringPeriodSharesMerger_label_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodSharesMerger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Merger</link:label>
    <link:label id="lab_ameh_StockIssuedDuringPeriodSharesMerger_documentation_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodSharesMerger" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares of stock issued during the period pursuant to merger.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodSharesMerger" xlink:href="ameh-20200630.xsd#ameh_StockIssuedDuringPeriodSharesMerger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_StockIssuedDuringPeriodSharesMerger" xlink:to="lab_ameh_StockIssuedDuringPeriodSharesMerger" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_379cf7ee-3b5b-4698-bf0a-a72d421dfa64_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_SharesWarrantsRollForward_bdde09a5-41d5-444c-892f-e3084acee716_terseLabel_en-US" xlink:label="lab_ameh_SharesWarrantsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_ameh_SharesWarrantsRollForward_label_en-US" xlink:label="lab_ameh_SharesWarrantsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Warrants [Roll Forward]</link:label>
    <link:label id="lab_ameh_SharesWarrantsRollForward_documentation_en-US" xlink:label="lab_ameh_SharesWarrantsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Warrants [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SharesWarrantsRollForward" xlink:href="ameh-20200630.xsd#ameh_SharesWarrantsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_SharesWarrantsRollForward" xlink:to="lab_ameh_SharesWarrantsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_82193d8d-6def-4ab8-acaa-0e5dff6184a6_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Damages sought</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Sought, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8f05f119-614a-4963-b311-e49a4f52b67b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ff2a0b3e-90c6-4853-b5c1-9ed622812ef5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AccountsPayableAndAccruedExpensesMember_8063f82f-7d32-46fd-a805-37376b68c818_terseLabel_en-US" xlink:label="lab_ameh_AccountsPayableAndAccruedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Expenses</link:label>
    <link:label id="lab_ameh_AccountsPayableAndAccruedExpensesMember_label_en-US" xlink:label="lab_ameh_AccountsPayableAndAccruedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable And Accrued Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsPayableAndAccruedExpensesMember" xlink:href="ameh-20200630.xsd#ameh_AccountsPayableAndAccruedExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AccountsPayableAndAccruedExpensesMember" xlink:to="lab_ameh_AccountsPayableAndAccruedExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ContractTypeDomain_6a948363-2aee-4b9a-bdfe-4b3f780f673d_terseLabel_en-US" xlink:label="lab_ameh_ContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Type [Domain]</link:label>
    <link:label id="lab_ameh_ContractTypeDomain_label_en-US" xlink:label="lab_ameh_ContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContractTypeDomain" xlink:href="ameh-20200630.xsd#ameh_ContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ContractTypeDomain" xlink:to="lab_ameh_ContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4a82f21b-d45e-4ec1-82c7-9523eb44d77a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bf64e5ff-144e-4b32-9e0b-c7c97ea7e449_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ApaacoMember_7a508af8-072d-4616-923c-ab65038dfc7d_terseLabel_en-US" xlink:label="lab_ameh_ApaacoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APAACO</link:label>
    <link:label id="lab_ameh_ApaacoMember_label_en-US" xlink:label="lab_ameh_ApaacoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APAACO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApaacoMember" xlink:href="ameh-20200630.xsd#ameh_ApaacoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ApaacoMember" xlink:to="lab_ameh_ApaacoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_e4901a6e-1ab2-415d-87a0-80c5716ec427_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_8a269fd7-82a3-47d4-ad44-8fea6e317ef6_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_625b9d0f-d24e-47e5-803b-f188258f2cb8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DiagnosticMedicalGroupMember_22162a16-a12d-4c86-b4e3-b131a95ae0f8_terseLabel_en-US" xlink:label="lab_ameh_DiagnosticMedicalGroupMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diagnostic Medical Group</link:label>
    <link:label id="lab_ameh_DiagnosticMedicalGroupMember_label_en-US" xlink:label="lab_ameh_DiagnosticMedicalGroupMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diagnostic Medical Group [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DiagnosticMedicalGroupMember" xlink:href="ameh-20200630.xsd#ameh_DiagnosticMedicalGroupMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DiagnosticMedicalGroupMember" xlink:to="lab_ameh_DiagnosticMedicalGroupMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_256dabb1-e30b-44ec-a09f-f2c2695015ab_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in&#160;Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised_4994195b-4f4b-4adc-affd-8227465bc974_terseLabel_en-US" xlink:label="lab_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from warrants exercised</link:label>
    <link:label id="lab_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Issued During Period Value Stock Options Exercised</link:label>
    <link:label id="lab_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised_documentation_en-US" xlink:label="lab_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Issued During Period Value Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised" xlink:href="ameh-20200630.xsd#ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssets_9fd5fa24-cd83-44e3-a99b-505158cda7c6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssets_label_en-US" xlink:label="lab_us-gaap_OtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssets" xlink:to="lab_us-gaap_OtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DeferredTaxLiabilityAdjustedToGoodwill_76ea95bb-79ce-4c88-9ab0-1d6fc4f23a85_terseLabel_en-US" xlink:label="lab_ameh_DeferredTaxLiabilityAdjustedToGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability adjustment to goodwill</link:label>
    <link:label id="lab_ameh_DeferredTaxLiabilityAdjustedToGoodwill_label_en-US" xlink:label="lab_ameh_DeferredTaxLiabilityAdjustedToGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liability Adjusted To Goodwill</link:label>
    <link:label id="lab_ameh_DeferredTaxLiabilityAdjustedToGoodwill_documentation_en-US" xlink:label="lab_ameh_DeferredTaxLiabilityAdjustedToGoodwill" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liability Adjusted To Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DeferredTaxLiabilityAdjustedToGoodwill" xlink:href="ameh-20200630.xsd#ameh_DeferredTaxLiabilityAdjustedToGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DeferredTaxLiabilityAdjustedToGoodwill" xlink:to="lab_ameh_DeferredTaxLiabilityAdjustedToGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_0aa2ac43-e579-423d-9523-34f12aff7bc7_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest on lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment_2b97a709-1d32-4b31-a29b-0ea02706597a_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Duration of investment</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Duration Of Investment</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Duration Of Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" xlink:href="ameh-20200630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_8624ce46-79de-4af4-b6da-aba05ecdaa00_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_9a73bf91-235e-415a-ae8f-6f6bd58fe109_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_689b6a15-481e-4dbc-bd0d-0fad911b8c2e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_OtherThirdPartiesMember_e05a54e3-b942-41c1-9d61-ba8419a45135_terseLabel_en-US" xlink:label="lab_ameh_OtherThirdPartiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other third parties</link:label>
    <link:label id="lab_ameh_OtherThirdPartiesMember_label_en-US" xlink:label="lab_ameh_OtherThirdPartiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Third Parties [Member]</link:label>
    <link:label id="lab_ameh_OtherThirdPartiesMember_documentation_en-US" xlink:label="lab_ameh_OtherThirdPartiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ameh:OtherThirdPartiesMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OtherThirdPartiesMember" xlink:href="ameh-20200630.xsd#ameh_OtherThirdPartiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_OtherThirdPartiesMember" xlink:to="lab_ameh_OtherThirdPartiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_a3e1f62d-6967-42f5-9dba-6f3dc87cd61b_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_22f82083-2ba8-42c5-b1cc-6b2ca2874840_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in other entities &#8211; equity method</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_53021ff6-8df0-421b-9b37-ad99a1e9f369_periodStartLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_ae1f1e3d-eb1c-44ae-9684-29f38a564a9c_periodEndLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_729b84ae-324c-496d-be4c-4faabd6b0a84_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in other entities &#8211; equity method</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_30b348b0-a626-4d69-aa45-19c85a14f360_negatedLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Carrying value of equity method investment on date of sale</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_7d8f85de-9778-41ff-91e2-619e0f1d3341_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_efd08e5c-bc14-4125-93ca-d1317f896422_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolver loan</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_776a39d3-9df8-4cf5-abbc-e3f4dd6125e1_verboseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolver Loan</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_03d0d7c5-3bd2-4105-9d76-d2ff263f1d45_verboseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entities (VIEs)</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:to="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_APAMHMedicalCorporationMember_9a0f6797-c9f1-4073-a8f3-8de6756d7d14_terseLabel_en-US" xlink:label="lab_ameh_APAMHMedicalCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AP-AMH Medical Corporation</link:label>
    <link:label id="lab_ameh_APAMHMedicalCorporationMember_label_en-US" xlink:label="lab_ameh_APAMHMedicalCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AP-AMH Medical Corporation [Member]</link:label>
    <link:label id="lab_ameh_APAMHMedicalCorporationMember_documentation_en-US" xlink:label="lab_ameh_APAMHMedicalCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AP-AMH Medical Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_APAMHMedicalCorporationMember" xlink:href="ameh-20200630.xsd#ameh_APAMHMedicalCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_APAMHMedicalCorporationMember" xlink:to="lab_ameh_APAMHMedicalCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_WarrantExercisePriceRangeFourMember_c71ccbe9-525a-4648-9594-5cd697ac6546_terseLabel_en-US" xlink:label="lab_ameh_WarrantExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Exercise Price Range Four</link:label>
    <link:label id="lab_ameh_WarrantExercisePriceRangeFourMember_label_en-US" xlink:label="lab_ameh_WarrantExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Exercise Price Range Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeFourMember" xlink:href="ameh-20200630.xsd#ameh_WarrantExercisePriceRangeFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_WarrantExercisePriceRangeFourMember" xlink:to="lab_ameh_WarrantExercisePriceRangeFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_eff30e28-7a54-4e69-bf1f-3474a986d0e5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c28fac3c-cbb9-4258-9bd4-e95715404460_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_531235f4-cbdc-4d77-8095-91418f989a71_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_f9a89b5b-1f2c-41df-8612-3d98eab403b1_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for business acquisition, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_a5b5c6ea-6c79-4ccc-a492-85e881307d63_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_5a8f14ed-fe79-45ee-a9d9-fa868cd487f9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_9e949ed7-5e06-4cad-af0f-580424d5aef1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest acquired</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NumberOfMembersOfFederallyQualifiedHealthPlans_5bc2583c-190e-4fae-9f53-72599679005c_terseLabel_en-US" xlink:label="lab_ameh_NumberOfMembersOfFederallyQualifiedHealthPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of members of federally qualified health plans</link:label>
    <link:label id="lab_ameh_NumberOfMembersOfFederallyQualifiedHealthPlans_label_en-US" xlink:label="lab_ameh_NumberOfMembersOfFederallyQualifiedHealthPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Members Of Federally Qualified Health Plans</link:label>
    <link:label id="lab_ameh_NumberOfMembersOfFederallyQualifiedHealthPlans_documentation_en-US" xlink:label="lab_ameh_NumberOfMembersOfFederallyQualifiedHealthPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Members Of Federally Qualified Health Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfMembersOfFederallyQualifiedHealthPlans" xlink:href="ameh-20200630.xsd#ameh_NumberOfMembersOfFederallyQualifiedHealthPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NumberOfMembersOfFederallyQualifiedHealthPlans" xlink:to="lab_ameh_NumberOfMembersOfFederallyQualifiedHealthPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ConcourseDiagnosticSurgeryCenterLlcMember_48c4decf-6165-4e3e-985e-61069234950c_terseLabel_en-US" xlink:label="lab_ameh_ConcourseDiagnosticSurgeryCenterLlcMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concourse Diagnostic Surgery Center, LLC</link:label>
    <link:label id="lab_ameh_ConcourseDiagnosticSurgeryCenterLlcMember_label_en-US" xlink:label="lab_ameh_ConcourseDiagnosticSurgeryCenterLlcMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concourse Diagnostic Surgery Center, LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ConcourseDiagnosticSurgeryCenterLlcMember" xlink:href="ameh-20200630.xsd#ameh_ConcourseDiagnosticSurgeryCenterLlcMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ConcourseDiagnosticSurgeryCenterLlcMember" xlink:to="lab_ameh_ConcourseDiagnosticSurgeryCenterLlcMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_fcdcda74-07c0-4e00-9fce-e475f4ba3d49_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_9e8769f1-01b8-4c16-8a29-87a20c3dd796_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statements of Operations</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_d04c6c32-1eb5-44a5-896c-26da5d11e5c0_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:to="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayable_298317de-869a-4dba-ac6e-f000dd253c56_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiduciary accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_3efd83a0-4a90-4d55-9a12-7b659cf1c591_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Unamortized financing costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_850803e4-367d-44fb-b7c9-9e76db61f9c2_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CommitmentsAndContingenciesTable_3f25d811-cbeb-4444-bb6f-3f56a4c84d97_terseLabel_en-US" xlink:label="lab_ameh_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:label id="lab_ameh_CommitmentsAndContingenciesTable_label_en-US" xlink:label="lab_ameh_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommitmentsAndContingenciesTable" xlink:href="ameh-20200630.xsd#ameh_CommitmentsAndContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CommitmentsAndContingenciesTable" xlink:to="lab_ameh_CommitmentsAndContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PerMemberPerMonthManagedCareContractMember_27faec50-b12e-4d1b-8a9a-ab00ab2072b3_terseLabel_en-US" xlink:label="lab_ameh_PerMemberPerMonthManagedCareContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PMPM Managed Care Contract</link:label>
    <link:label id="lab_ameh_PerMemberPerMonthManagedCareContractMember_label_en-US" xlink:label="lab_ameh_PerMemberPerMonthManagedCareContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Per-Member-Per-Month Managed Care Contract [Member]</link:label>
    <link:label id="lab_ameh_PerMemberPerMonthManagedCareContractMember_documentation_en-US" xlink:label="lab_ameh_PerMemberPerMonthManagedCareContractMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Per-Member-Per-Month Managed Care Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PerMemberPerMonthManagedCareContractMember" xlink:href="ameh-20200630.xsd#ameh_PerMemberPerMonthManagedCareContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PerMemberPerMonthManagedCareContractMember" xlink:to="lab_ameh_PerMemberPerMonthManagedCareContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Dividends_11ee8195-e404-4215-ba20-ffc83af81fa2_terseLabel_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends declared</link:label>
    <link:label id="lab_us-gaap_Dividends_label_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Dividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Dividends" xlink:to="lab_us-gaap_Dividends" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PaymentPeriodOneMember_3799c526-a0b1-427b-aeb8-c02f7bc82e32_terseLabel_en-US" xlink:label="lab_ameh_PaymentPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Eight Fiscal Quarters</link:label>
    <link:label id="lab_ameh_PaymentPeriodOneMember_label_en-US" xlink:label="lab_ameh_PaymentPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Period One [Member]</link:label>
    <link:label id="lab_ameh_PaymentPeriodOneMember_documentation_en-US" xlink:label="lab_ameh_PaymentPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Period One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentPeriodOneMember" xlink:href="ameh-20200630.xsd#ameh_PaymentPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PaymentPeriodOneMember" xlink:to="lab_ameh_PaymentPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_22f5f455-c3a1-42f6-b2d1-8186f7f83815_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm_2e1c11d5-aa07-40ca-8ab1-8ac012eedfe2_terseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual&#160;Life</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm_label_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Rights Grant In Period Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Rights Grant In Period Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:href="ameh-20200630.xsd#ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:to="lab_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_3718b4cf-6f3f-494b-9848-8586f44fa402_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_78925a25-fe10-4e06-ae48-f60a421201ae_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears_2af409c8-8f06-4287-a246-61ab475e4f46_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of voting common stock, within five years</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Proportion of Ownership Interest in Voting Common Stock, Within Five Years</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Proportion of Ownership Interest in Voting Common Stock, Within Five Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" xlink:href="ameh-20200630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_a9c34dfc-c6dd-47a1-a257-baad1d337258_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement_225fdbb2-0c84-47c8-a114-daaad18fc4dd_terseLabel_en-US" xlink:label="lab_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed term of amended and restated management and administrative services agreement</link:label>
    <link:label id="lab_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement_label_en-US" xlink:label="lab_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Fixed Term Of Amended And Restated Management And Administrative Services Agreement</link:label>
    <link:label id="lab_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement_documentation_en-US" xlink:label="lab_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The initial fixed term of amended and restated management and administrative services agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" xlink:href="ameh-20200630.xsd#ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" xlink:to="lab_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities_e10e9de6-192f-4a04-83d1-e345a6c74111_verboseLabel_en-US" xlink:label="lab_ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities_label_en-US" xlink:label="lab_ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Other Operating Lease Liabilities</link:label>
    <link:label id="lab_ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents increase in lease liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities" xlink:href="ameh-20200630.xsd#ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities" xlink:to="lab_ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NetworkRelationshipsMember_a6a6b979-ed16-4ba6-abe3-0bfa297d1090_terseLabel_en-US" xlink:label="lab_ameh_NetworkRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Network relationships</link:label>
    <link:label id="lab_ameh_NetworkRelationshipsMember_label_en-US" xlink:label="lab_ameh_NetworkRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Network Relationships [Member]</link:label>
    <link:label id="lab_ameh_NetworkRelationshipsMember_documentation_en-US" xlink:label="lab_ameh_NetworkRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Network Relationships</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkRelationshipsMember" xlink:href="ameh-20200630.xsd#ameh_NetworkRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NetworkRelationshipsMember" xlink:to="lab_ameh_NetworkRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NumberOfEnrollees_e096c67f-0174-479b-a9d0-8ac8aa2069a6_terseLabel_en-US" xlink:label="lab_ameh_NumberOfEnrollees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of healthcare enrollees</link:label>
    <link:label id="lab_ameh_NumberOfEnrollees_label_en-US" xlink:label="lab_ameh_NumberOfEnrollees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Enrollees</link:label>
    <link:label id="lab_ameh_NumberOfEnrollees_documentation_en-US" xlink:label="lab_ameh_NumberOfEnrollees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Enrollees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfEnrollees" xlink:href="ameh-20200630.xsd#ameh_NumberOfEnrollees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NumberOfEnrollees" xlink:to="lab_ameh_NumberOfEnrollees" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_179feddd-49b8-4058-9f22-6b36a2e9c70d_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Board Members</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares_b79dba6e-35a7-43aa-91f0-d9e824f28f2e_terseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration, preferred shares</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Sale, Contingent Consideration, Preferred Shares</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Sale, Contingent Consideration, Preferred Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares" xlink:href="ameh-20200630.xsd#ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares" xlink:to="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_06ba6a1a-f7c0-4744-b3c2-c840a490365e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from equity method investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_f251a6dd-daad-4cec-9ebf-406fad24fa33_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Income) loss from equity method investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_b76d9610-3c7a-4c4a-a1fd-46b1101b2b09_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocation of Income (Loss)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_759403a6-8308-4697-a13a-4d98ebbbfc6a_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_0b023920-50f0-473d-866f-a8966226d322_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before benefit from income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_e3f55d68-3e9d-4c61-b659-5765fa006bd9_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantOrRightCancelledInPeriod_50f70faf-8ea2-4e44-a224-5e76d9d0886a_negatedLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightCancelledInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants expired/forfeited (in shares)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightCancelledInPeriod_label_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightCancelledInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Cancelled In Period</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightCancelledInPeriod_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightCancelledInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of warrant or right, cancelled in period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightCancelledInPeriod" xlink:href="ameh-20200630.xsd#ameh_ClassOfWarrantOrRightCancelledInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantOrRightCancelledInPeriod" xlink:to="lab_ameh_ClassOfWarrantOrRightCancelledInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_8f8d14de-d761-4b5a-b535-1cb327d99cf1_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_cbd14394-6391-414e-a440-ed35d299e68e_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities &#8211; equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_4bc0b776-ae86-4438-bd16-876cc2b5b417_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_3207da99-3c28-4785-9866-d40af9c7cd37_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 (excluding the six months ended June 30, 2020)</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion_a15a58c3-83a9-472d-8200-b6e56da000d4_terseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership upon conversion of finance receivable</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Conversion Of Finance Receivable, Ownership Percentage Upon Conversion</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Conversion Of Finance Receivable, Ownership Percentage Upon Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion" xlink:href="ameh-20200630.xsd#ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion" xlink:to="lab_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_7f56b495-c0bb-4f6f-9079-1beb15fcc577_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for vesting of restricted stock awards (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_b62c8558-f085-4b40-8b3f-36229f06fa32_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AffiliatedEntityMember_8c1a4249-198a-41c2-a144-746e6940fe98_terseLabel_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity</link:label>
    <link:label id="lab_srt_AffiliatedEntityMember_label_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AffiliatedEntityMember" xlink:to="lab_srt_AffiliatedEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_ad40806e-b235-425c-b6ff-c5050f170e5d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_be372620-4303-4c17-ad7f-d0477418905a_terseLabel_en-US" xlink:label="lab_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to purchase membership interests</link:label>
    <link:label id="lab_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_label_en-US" xlink:label="lab_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Equity Securities Without Readily Determinable Fair Value Investments</link:label>
    <link:label id="lab_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_documentation_en-US" xlink:label="lab_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Equity Securities Without Readily Determinable Fair Value Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:href="ameh-20200630.xsd#ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:to="lab_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_25bf6c84-7219-4f2c-8908-1ced2c125631_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Liabilities [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_81facb57-c365-4be9-a2c8-f0702cdb44b4_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AdvanceDiagnosticSurgeryCenterMember_16355b0e-e6fd-467d-b2e5-3c935678f698_terseLabel_en-US" xlink:label="lab_ameh_AdvanceDiagnosticSurgeryCenterMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advance Diagnostic Surgery Center</link:label>
    <link:label id="lab_ameh_AdvanceDiagnosticSurgeryCenterMember_label_en-US" xlink:label="lab_ameh_AdvanceDiagnosticSurgeryCenterMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advance Diagnostic Surgery Center [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AdvanceDiagnosticSurgeryCenterMember" xlink:href="ameh-20200630.xsd#ameh_AdvanceDiagnosticSurgeryCenterMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AdvanceDiagnosticSurgeryCenterMember" xlink:to="lab_ameh_AdvanceDiagnosticSurgeryCenterMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal_3a67c10e-2540-498e-ad56-cbbc2b7dc1d6_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal payment on credit agreement</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Periodic Payment, Principal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal" xlink:to="lab_us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_449e855a-bb72-46d8-8ff2-1660326a33d3_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities &#8211; certificates of deposit</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_f328a66d-8e71-49fe-96f2-50a5259d1856_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_074904b8-b9cc-4cfc-b1ce-ac74ee80025d_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock awards</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_OneMSOInc.Member_8bed7066-4234-4179-be72-5b5fed377cbd_terseLabel_en-US" xlink:label="lab_ameh_OneMSOInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One MSO, Inc.</link:label>
    <link:label id="lab_ameh_OneMSOInc.Member_label_en-US" xlink:label="lab_ameh_OneMSOInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One MSO, Inc. [Member]</link:label>
    <link:label id="lab_ameh_OneMSOInc.Member_documentation_en-US" xlink:label="lab_ameh_OneMSOInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One MSO, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOInc.Member" xlink:href="ameh-20200630.xsd#ameh_OneMSOInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_OneMSOInc.Member" xlink:to="lab_ameh_OneMSOInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_23516351-e51c-4555-bea1-4f89e143f89f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_6cd0b4b6-6709-49a6-9be6-2a1f6e6d4cde_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_b2beaa0a-992d-481e-9cb2-94a364e67de4_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_15d46599-e38f-4555-b51b-ada0e0a8d93c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DescriptionOfBusinessTable_0c63acaa-2ce0-495d-acae-8b116d3179e0_terseLabel_en-US" xlink:label="lab_ameh_DescriptionOfBusinessTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description Of Business [Table]</link:label>
    <link:label id="lab_ameh_DescriptionOfBusinessTable_label_en-US" xlink:label="lab_ameh_DescriptionOfBusinessTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description Of Business [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DescriptionOfBusinessTable" xlink:href="ameh-20200630.xsd#ameh_DescriptionOfBusinessTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DescriptionOfBusinessTable" xlink:to="lab_ameh_DescriptionOfBusinessTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities_7793b575-a271-45ae-853f-a654924c059f_negatedTerseLabel_en-US" xlink:label="lab_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical liabilities</link:label>
    <link:label id="lab_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities_label_en-US" xlink:label="lab_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Medical Liabilities</link:label>
    <link:label id="lab_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities_documentation_en-US" xlink:label="lab_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Medical Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities" xlink:href="ameh-20200630.xsd#ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities" xlink:to="lab_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_90aef0b8-2f67-4be7-bf1a-1dbba2e04cf3_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Options, Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice_43ae96a9-e41f-426a-9b54-c62344c8f989_terseLabel_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of warrants exercised (in dollars per share)</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice_label_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share based Payment Award, Warrant Exercised, Exercise Price</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice_documentation_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share based Payment Award, Warrant Exercised, Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" xlink:href="ameh-20200630.xsd#ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" xlink:to="lab_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_20e35569-2afa-4848-ad7f-2217b3fa5b38_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables and Receivables-Related Parties</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_e4292d3c-9a9f-48f9-aebc-ce40ca71f742_negatedLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current period</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_acc4f277-e4f6-4443-82fd-d53ca46b6c60_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityOwnershipPercentage_beb13009-4a29-45d9-8c4e-34d7702f1fbe_verboseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voting rights held (more than)</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:to="lab_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_6f104c97-49f8-49a5-b8c6-c9534ea0030c_terseLabel_en-US" xlink:label="lab_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AHMC &#8211; Risk pool, capitation, claims payment, net</link:label>
    <link:label id="lab_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_label_en-US" xlink:label="lab_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Services Revenue, Capitation, And Claims Payment, Net</link:label>
    <link:label id="lab_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_documentation_en-US" xlink:label="lab_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Services Revenue, Capitation, And Claims Payment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet" xlink:href="ameh-20200630.xsd#ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet" xlink:to="lab_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_7afaed61-1042-40be-9cc9-9ea0c4740dd9_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AlliedPacificofCaliforniaBrokerageAccountMember_1992e472-cf0c-49c0-99d9-97bf253d4507_terseLabel_en-US" xlink:label="lab_ameh_AlliedPacificofCaliforniaBrokerageAccountMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allied Pacific of California Brokerage Account</link:label>
    <link:label id="lab_ameh_AlliedPacificofCaliforniaBrokerageAccountMember_label_en-US" xlink:label="lab_ameh_AlliedPacificofCaliforniaBrokerageAccountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allied Pacific of California Brokerage Account [Member]</link:label>
    <link:label id="lab_ameh_AlliedPacificofCaliforniaBrokerageAccountMember_documentation_en-US" xlink:label="lab_ameh_AlliedPacificofCaliforniaBrokerageAccountMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allied Pacific of California Brokerage Account [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificofCaliforniaBrokerageAccountMember" xlink:href="ameh-20200630.xsd#ameh_AlliedPacificofCaliforniaBrokerageAccountMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AlliedPacificofCaliforniaBrokerageAccountMember" xlink:to="lab_ameh_AlliedPacificofCaliforniaBrokerageAccountMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_c5eef42e-6201-493b-af90-32a7de54a59c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_8ab34cb5-46d9-4055-8c7c-9d29beb19246_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PaymentConsultingFees_70374198-f89b-46ba-a047-6baa329818ea_terseLabel_en-US" xlink:label="lab_ameh_PaymentConsultingFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting services paid</link:label>
    <link:label id="lab_ameh_PaymentConsultingFees_label_en-US" xlink:label="lab_ameh_PaymentConsultingFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Consulting Fees</link:label>
    <link:label id="lab_ameh_PaymentConsultingFees_documentation_en-US" xlink:label="lab_ameh_PaymentConsultingFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Consulting Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentConsultingFees" xlink:href="ameh-20200630.xsd#ameh_PaymentConsultingFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PaymentConsultingFees" xlink:to="lab_ameh_PaymentConsultingFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_8e64e70c-0faf-43e9-be8e-cca06b5809c3_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrent_05685d0b-a505-4806-b7da-acf9c30df023_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total noncurrent assets</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="lab_us-gaap_AssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_eb3912f0-7b08-4315-81ed-f65bb077b846_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_7d0a2522-d529-4cb5-bd89-cb32e9aa0251_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue_5ec50c24-27d0-475b-a5d9-28ce1ea72921_verboseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercised</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue_label_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Exercises In Period, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of warrants or rights exercised in period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" xlink:href="ameh-20200630.xsd#ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" xlink:to="lab_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NMMLineOfCreditAgreementMember_40f4a146-4e9a-4773-a461-b8bbcc6c6e2a_terseLabel_en-US" xlink:label="lab_ameh_NMMLineOfCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NMM Line of Credit Agreement</link:label>
    <link:label id="lab_ameh_NMMLineOfCreditAgreementMember_label_en-US" xlink:label="lab_ameh_NMMLineOfCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NMM Line Of Credit Agreement [Member]</link:label>
    <link:label id="lab_ameh_NMMLineOfCreditAgreementMember_documentation_en-US" xlink:label="lab_ameh_NMMLineOfCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NMM Line Of Credit Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NMMLineOfCreditAgreementMember" xlink:href="ameh-20200630.xsd#ameh_NMMLineOfCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NMMLineOfCreditAgreementMember" xlink:to="lab_ameh_NMMLineOfCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_08516115-c865-488f-b6ce-81eae2952cc6_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_e24f4bd1-2bb4-4d28-9a86-d22fd4f9fafa_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_6db814aa-b636-4cc3-a172-a37953251053_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining lease term, operating</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour_2a2bfcde-2e3f-4966-8ad3-2b9624ab61d8_terseLabel_en-US" xlink:label="lab_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:label id="lab_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:href="ameh-20200630.xsd#ameh_FinanceLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_4c075c6c-9351-43e7-bba8-8bb7e6408ef7_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_147650cb-fd33-4612-ace7-aad0a9d94e49_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, January 1, 2020</link:label>
    <link:label id="lab_us-gaap_Goodwill_4fc57a0b-3342-4393-9fab-2b502c9aa924_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, June 30, 2020</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_84c1718b-5cdd-4405-a378-aa06f6ad1c4c_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_218d98f1-8637-4119-af7a-b15a3d817886_periodStartLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_6b3449ee-9edf-4538-a28b-6d0df01b9dac_periodEndLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_2e31100b-d1e0-4493-bcf5-63d85d11f460_verboseLabel_en-US" xlink:label="lab_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in privately held entities</link:label>
    <link:label id="lab_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_bc2553c1-c7cf-46f3-bd94-640331f2a1f4_terseLabel_en-US" xlink:label="lab_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares in Bright Health, Inc.</link:label>
    <link:label id="lab_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_label_en-US" xlink:label="lab_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment In Privately Held Entity That Does Not Report Net Asset Value</link:label>
    <link:label id="lab_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_documentation_en-US" xlink:label="lab_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total of Investment in privately held entity that does not report net asset value per share .</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" xlink:href="ameh-20200630.xsd#ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" xlink:to="lab_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_2bd10220-5c86-4c18-924f-578772f35a6a_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_68355ce2-6550-4910-8786-78050c3970f6_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LineOfCreditFacilityGuaranteeGivenByRelatedParties_b4d09e2b-34b5-44b3-9c82-e88470381ec0_terseLabel_en-US" xlink:label="lab_ameh_LineOfCreditFacilityGuaranteeGivenByRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of converted loan</link:label>
    <link:label id="lab_ameh_LineOfCreditFacilityGuaranteeGivenByRelatedParties_label_en-US" xlink:label="lab_ameh_LineOfCreditFacilityGuaranteeGivenByRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Guarantee Given By Related Parties</link:label>
    <link:label id="lab_ameh_LineOfCreditFacilityGuaranteeGivenByRelatedParties_documentation_en-US" xlink:label="lab_ameh_LineOfCreditFacilityGuaranteeGivenByRelatedParties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of guarantee given by related parties for line of credit facility.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LineOfCreditFacilityGuaranteeGivenByRelatedParties" xlink:href="ameh-20200630.xsd#ameh_LineOfCreditFacilityGuaranteeGivenByRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LineOfCreditFacilityGuaranteeGivenByRelatedParties" xlink:to="lab_ameh_LineOfCreditFacilityGuaranteeGivenByRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_6eb786ff-623d-45cb-9c2a-f95eaf22125c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred financing costs</link:label>
    <link:label id="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_label_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Line of Credit Arrangements, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:to="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_1edced2e-a060-4ffd-b64b-4a2a52122400_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_OtherReceivablesFinalSettlement2018PerformanceYearMember_09e70bb4-4ef5-4e2e-ae28-d5ce95e209b4_terseLabel_en-US" xlink:label="lab_ameh_OtherReceivablesFinalSettlement2018PerformanceYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables, Final Settlement 2018 Performance Year</link:label>
    <link:label id="lab_ameh_OtherReceivablesFinalSettlement2018PerformanceYearMember_label_en-US" xlink:label="lab_ameh_OtherReceivablesFinalSettlement2018PerformanceYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables, Final Settlement 2018 Performance Year [Member]</link:label>
    <link:label id="lab_ameh_OtherReceivablesFinalSettlement2018PerformanceYearMember_documentation_en-US" xlink:label="lab_ameh_OtherReceivablesFinalSettlement2018PerformanceYearMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables, Final Settlement 2018 Performance Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OtherReceivablesFinalSettlement2018PerformanceYearMember" xlink:href="ameh-20200630.xsd#ameh_OtherReceivablesFinalSettlement2018PerformanceYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_OtherReceivablesFinalSettlement2018PerformanceYearMember" xlink:to="lab_ameh_OtherReceivablesFinalSettlement2018PerformanceYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_bf9bc7bf-021a-4718-86f9-d371988a902d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Change in Carrying Value of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_5c66462d-9aa7-4ffb-b1e5-ee44d8fa6bdd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable_abb8e5f7-2c09-42b8-8830-5049576afd69_terseLabel_en-US" xlink:label="lab_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, termination period, if applicable</link:label>
    <link:label id="lab_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable_label_en-US" xlink:label="lab_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Termination Period, If Applicable</link:label>
    <link:label id="lab_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable_documentation_en-US" xlink:label="lab_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Termination Period, If Applicable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable" xlink:href="ameh-20200630.xsd#ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable" xlink:to="lab_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_ae283b10-dfac-4a3c-ba9d-2a4c9c38e909_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_299e8244-b68f-40ad-a12f-9a342aedb3e0_verboseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosures of non-cash investing and financing activities</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_f4c5ef63-c8a8-43c5-a645-aa975b90dcb3_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_ae650feb-8d9b-404a-8a85-dc183badbd43_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_SummaryOfSignificantAccountingPoliciesLineItems_34ef7b2d-c7d2-40b5-bc9b-e3290135035e_terseLabel_en-US" xlink:label="lab_ameh_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_ameh_SummaryOfSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_ameh_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_ameh_SummaryOfSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_ameh_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems" xlink:href="ameh-20200630.xsd#ameh_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_ameh_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_f7bb7084-5857-4d0d-99b4-629762f97d12_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_985ac73e-1e48-4768-9e6c-990f261da345_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_TemporaryEquityPolicyTextBlock_ac34bee8-9df2-4146-83a7-594346673beb_terseLabel_en-US" xlink:label="lab_ameh_TemporaryEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mezzanine Equity</link:label>
    <link:label id="lab_ameh_TemporaryEquityPolicyTextBlock_label_en-US" xlink:label="lab_ameh_TemporaryEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity [Policy Text Block]</link:label>
    <link:label id="lab_ameh_TemporaryEquityPolicyTextBlock_documentation_en-US" xlink:label="lab_ameh_TemporaryEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_TemporaryEquityPolicyTextBlock" xlink:href="ameh-20200630.xsd#ameh_TemporaryEquityPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_TemporaryEquityPolicyTextBlock" xlink:to="lab_ameh_TemporaryEquityPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3d62ca07-e929-4d8a-9f41-d1393fc7010e_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares of common stock outstanding &#8211; diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6794dc11-cebd-4dea-89b9-ed5cd5fd2bbd_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares of common stock outstanding &#8211; diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_f0bb11eb-7cf6-49eb-b038-f9087de73f6f_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Amortization Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_391528bc-a929-43fc-a0fa-0f8e00635e37_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_85542158-0922-432c-ae2b-964847749b50_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Amounts and Fair Values of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_8e2b5420-b62b-47bc-9107-2710b6857c08_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_7206ca3e-fe63-449e-ad69-08e276af9601_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_085dbd60-fa74-4c7c-99d2-54ec9b6ae06a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_09bf29a4-cfec-4990-ab03-c1d7c0180511_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_a45a043d-70b3-4710-8caa-d95841e9c932_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of term loan</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfDebt_9da1c400-43dd-4a09-95f8-c4a7467bccf2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of indebtedness received</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Repayments of) Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentsOfDebt" xlink:to="lab_us-gaap_ProceedsFromRepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_Dr.ArteagaMember_622ef8a7-5e65-45f0-b95e-4e85c7b07d4a_verboseLabel_en-US" xlink:label="lab_ameh_Dr.ArteagaMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Arteaga</link:label>
    <link:label id="lab_ameh_Dr.ArteagaMember_label_en-US" xlink:label="lab_ameh_Dr.ArteagaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Arteaga [Member]</link:label>
    <link:label id="lab_ameh_Dr.ArteagaMember_documentation_en-US" xlink:label="lab_ameh_Dr.ArteagaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Arteaga [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Dr.ArteagaMember" xlink:href="ameh-20200630.xsd#ameh_Dr.ArteagaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_Dr.ArteagaMember" xlink:to="lab_ameh_Dr.ArteagaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_497c5de2-ab49-4518-96e1-90294ddb6a12_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_609e70f1-c243-4673-b80a-2f86b22ca6fa_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value per share; 100,000,000 shares authorized, 36,309,513 and 35,908,057 shares outstanding, excluding 17,475,707 and 17,458,810 treasury shares, at June&#160;30, 2020, and December&#160;31, 2019, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock_e9cd9c9e-dbf7-4766-b898-32cbacaf3e3f_verboseLabel_en-US" xlink:label="lab_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Other Entities &#8212; Equity Method</link:label>
    <link:label id="lab_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock_label_en-US" xlink:label="lab_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method And Other Equity Investments [Text Block]</link:label>
    <link:label id="lab_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock_documentation_en-US" xlink:label="lab_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method And Other Equity Investments [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock" xlink:href="ameh-20200630.xsd#ameh_EquityMethodAndOtherEquityInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock" xlink:to="lab_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_1c6701a1-02bd-42a2-9b25-5a3e84871dc2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLongTermInvestments_8ddad350-47f9-42a8-895a-1fc76cb2aa32_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in affiliates</link:label>
    <link:label id="lab_us-gaap_OtherLongTermInvestments_label_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLongTermInvestments" xlink:to="lab_us-gaap_OtherLongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1728e238-07dd-40ba-9726-d0ec712eb36e_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_4b4a6d91-9a55-4202-b4a6-f4a4fc3054aa_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent assets</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_81930653-b0cd-4f82-b4a7-3259a4f491f6_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent assets</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_c366a1a3-3562-4d94-93d2-f702f5d8805f_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_c04316ed-873f-438b-8392-8f40ba443ea8_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_998d485c-555b-47f1-99d0-77b1943014c8_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_HealthCareCapitationRevenueMember_ed14d597-8615-4b17-8ea8-470cda3ead68_verboseLabel_en-US" xlink:label="lab_ameh_HealthCareCapitationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitation, net</link:label>
    <link:label id="lab_ameh_HealthCareCapitationRevenueMember_label_en-US" xlink:label="lab_ameh_HealthCareCapitationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Capitation Revenue [Member]</link:label>
    <link:label id="lab_ameh_HealthCareCapitationRevenueMember_documentation_en-US" xlink:label="lab_ameh_HealthCareCapitationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ameh_HealthCareCapitationRevenueMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_HealthCareCapitationRevenueMember" xlink:href="ameh-20200630.xsd#ameh_HealthCareCapitationRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_HealthCareCapitationRevenueMember" xlink:to="lab_ameh_HealthCareCapitationRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_da738d13-51b6-41a9-b069-3e883aa2843f_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_UniversalCareIncMember_b144db23-cf34-4efa-88a0-2db2d4869e15_terseLabel_en-US" xlink:label="lab_ameh_UniversalCareIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Universal Care, Inc.</link:label>
    <link:label id="lab_ameh_UniversalCareIncMember_label_en-US" xlink:label="lab_ameh_UniversalCareIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Universal Care Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareIncMember" xlink:href="ameh-20200630.xsd#ameh_UniversalCareIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_UniversalCareIncMember" xlink:to="lab_ameh_UniversalCareIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_f92af58e-4ccb-4737-be6d-539ed31a7f1a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of equity method investment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_7368af0e-2629-428b-a825-a10ab35e9e02_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash proceeds (excludes proceeds to settle indebtedness owed to APC from UCI)</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_46471416-dc50-4a7b-8893-9aa165e1e0b6_terseLabel_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years)</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_label_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_documentation_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:href="ameh-20200630.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_0704e5e3-01d4-4710-86b3-a5fe6de1578e_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and Diluted Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_d60e6d23-2df1-4871-b45f-a2bd0aacfe01_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:to="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FinanceReceivableStatedInterestRate_e99ce0e8-1b04-4942-aeff-fc9548e9b274_terseLabel_en-US" xlink:label="lab_ameh_FinanceReceivableStatedInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated rate of note of loan receivable</link:label>
    <link:label id="lab_ameh_FinanceReceivableStatedInterestRate_label_en-US" xlink:label="lab_ameh_FinanceReceivableStatedInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Receivable, Stated Interest Rate</link:label>
    <link:label id="lab_ameh_FinanceReceivableStatedInterestRate_documentation_en-US" xlink:label="lab_ameh_FinanceReceivableStatedInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Receivable, Stated Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableStatedInterestRate" xlink:href="ameh-20200630.xsd#ameh_FinanceReceivableStatedInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FinanceReceivableStatedInterestRate" xlink:to="lab_ameh_FinanceReceivableStatedInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_4efa6bb8-0fbb-4555-b53d-07ccbddce7a8_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_5beb4004-bded-475a-b4e7-7d1641340a2d_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_f4456fff-d2d7-433d-ba5c-7c935bd8ac60_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_d9954b6f-5bb3-40c0-8eef-f99b1a748b12_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_569920e1-e7dd-49a6-a0ee-802c10e211b0_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_067672af-0b65-4547-bac3-f4a59a6ab5d2_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of current portion and deferred financing costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_1d553328-d2b8-42ec-bb15-a17735b7a574_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_e91371be-d3cd-44e4-a671-2e73db681a22_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_dfc5628f-c055-4083-bcc6-823f4e7a7b8d_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Business</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_bac3f5e0-eeba-4467-b33a-9e4c1e8834dc_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PreferredBankMember_6122b1a0-1fc4-43bb-98aa-1e57d19c8926_terseLabel_en-US" xlink:label="lab_ameh_PreferredBankMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Bank</link:label>
    <link:label id="lab_ameh_PreferredBankMember_label_en-US" xlink:label="lab_ameh_PreferredBankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Bank [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PreferredBankMember" xlink:href="ameh-20200630.xsd#ameh_PreferredBankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PreferredBankMember" xlink:to="lab_ameh_PreferredBankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_Dr.JayMember_e1b1105e-bb8e-4d55-9e98-67a3271acc97_terseLabel_en-US" xlink:label="lab_ameh_Dr.JayMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Jay</link:label>
    <link:label id="lab_ameh_Dr.JayMember_label_en-US" xlink:label="lab_ameh_Dr.JayMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Jay [Member]</link:label>
    <link:label id="lab_ameh_Dr.JayMember_documentation_en-US" xlink:label="lab_ameh_Dr.JayMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Jay [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Dr.JayMember" xlink:href="ameh-20200630.xsd#ameh_Dr.JayMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_Dr.JayMember" xlink:to="lab_ameh_Dr.JayMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_020da439-035c-4b24-bcbe-ccb4a761a49b_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NumberOfPatients_dc54b721-2c69-471e-a60b-2a56e5a744e6_terseLabel_en-US" xlink:label="lab_ameh_NumberOfPatients" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patients</link:label>
    <link:label id="lab_ameh_NumberOfPatients_label_en-US" xlink:label="lab_ameh_NumberOfPatients" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Patients</link:label>
    <link:label id="lab_ameh_NumberOfPatients_documentation_en-US" xlink:label="lab_ameh_NumberOfPatients" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Patients</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfPatients" xlink:href="ameh-20200630.xsd#ameh_NumberOfPatients"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NumberOfPatients" xlink:to="lab_ameh_NumberOfPatients" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_3ab30904-0ab3-4d53-a3d4-9a9b6f2e3563_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_0fd423fe-15b7-4e4f-8097-01dcbb2e7f74_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock awards</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AccountsReceivableAndNetRevenueTable_9d851c4d-77d5-4644-8b5b-03b8267b5d14_terseLabel_en-US" xlink:label="lab_ameh_AccountsReceivableAndNetRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable And Net Revenue [Table]</link:label>
    <link:label id="lab_ameh_AccountsReceivableAndNetRevenueTable_label_en-US" xlink:label="lab_ameh_AccountsReceivableAndNetRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable And Net Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsReceivableAndNetRevenueTable" xlink:href="ameh-20200630.xsd#ameh_AccountsReceivableAndNetRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueTable" xlink:to="lab_ameh_AccountsReceivableAndNetRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5afecea3-70d1-49de-9457-965c3868489d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_db860959-3d92-4695-8a24-f09f455b3ae6_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AmgIncMember_7fdaae11-38dd-4949-9d2c-2a6d70d31850_terseLabel_en-US" xlink:label="lab_ameh_AmgIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AMG, Inc</link:label>
    <link:label id="lab_ameh_AmgIncMember_label_en-US" xlink:label="lab_ameh_AmgIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AMG, Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AmgIncMember" xlink:href="ameh-20200630.xsd#ameh_AmgIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AmgIncMember" xlink:to="lab_ameh_AmgIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_0aa66204-97cb-4507-a1a0-3a6d7587248a_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">interest rate at end of period</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Interest Rate at Period End</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:to="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividends_a2d28550-21ef-49b6-96d5-5a4eb637b4f6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends paid</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividends_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividends" xlink:to="lab_us-gaap_PaymentsOfDividends" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_6a8c4df5-5731-4164-b86d-9df83d027ce3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_97e095a1-f149-4a78-9c3d-4dae8fbe7801_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_611d5315-fde7-466b-8e05-d11f0f75f78f_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_4ee4a6a6-d3b7-4ed6-a69f-6fd73a159a67_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod_cac3866a-7d1b-418c-a5fa-7038fd62f030_verboseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercised (in dollars per share)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod_label_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants, Exercised In Period</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price per share of warrants or rights exercised during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" xlink:href="ameh-20200630.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" xlink:to="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_52af6d23-1fe0-4a35-83c3-30ab01170f4e_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of warrant</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_8bb3fa91-216c-44c5-bb05-8226668912b2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_362dc761-63ba-4383-b067-7410f34b811f_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_d22d46ae-aae2-4fc6-bd51-4c3f1f7d0377_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_9828cfb3-0f35-441d-8341-f7ba220159a5_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_bdcc8768-2a6a-4178-bf39-caa6d1fa2836_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 (excluding the six months ended June 30, 2020)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_dc3f24ad-6ba9-4494-83c2-6619ab79902e_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MemberRelationshipsMember_3492415e-433b-47f5-b185-52396bf248b6_terseLabel_en-US" xlink:label="lab_ameh_MemberRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Member relationships</link:label>
    <link:label id="lab_ameh_MemberRelationshipsMember_label_en-US" xlink:label="lab_ameh_MemberRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Member Relationships [Member]</link:label>
    <link:label id="lab_ameh_MemberRelationshipsMember_documentation_en-US" xlink:label="lab_ameh_MemberRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Member Relationships</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MemberRelationshipsMember" xlink:href="ameh-20200630.xsd#ameh_MemberRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MemberRelationshipsMember" xlink:to="lab_ameh_MemberRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_e193f2f0-2ef2-48fd-9d04-402a92801e03_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_439a95f5-fc30-4143-9527-2efcffbfa178_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_3a14ec43-f038-4817-acf5-8ba16ef917ef_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_b6c7d0fb-3215-4fe3-84cd-e4ddbc230e71_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock_970d9620-1f3f-4816-8f0f-0e254ee3fa38_verboseLabel_en-US" xlink:label="lab_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables and Receivables &#8211; Related Parties</link:label>
    <link:label id="lab_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock_label_en-US" xlink:label="lab_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables And Related parties Receivables Policy Text Block [Policy Text Block]</link:label>
    <link:label id="lab_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock_documentation_en-US" xlink:label="lab_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Receivables and receivables from related parties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" xlink:href="ameh-20200630.xsd#ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" xlink:to="lab_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_4ec9e795-9269-4299-96da-970dbe3fd9a4_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ShareholdersAndOfficersMember_ea21af24-3847-4c4c-bb7b-f89ae43dd463_terseLabel_en-US" xlink:label="lab_ameh_ShareholdersAndOfficersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC Shareholders and Officers</link:label>
    <link:label id="lab_ameh_ShareholdersAndOfficersMember_label_en-US" xlink:label="lab_ameh_ShareholdersAndOfficersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders And Officers [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareholdersAndOfficersMember" xlink:href="ameh-20200630.xsd#ameh_ShareholdersAndOfficersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ShareholdersAndOfficersMember" xlink:to="lab_ameh_ShareholdersAndOfficersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AccountableHealthCareIPAMember_d85ec4c6-cccd-4eb7-9ee5-878847a1fee6_verboseLabel_en-US" xlink:label="lab_ameh_AccountableHealthCareIPAMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accountable Health Care</link:label>
    <link:label id="lab_ameh_AccountableHealthCareIPAMember_f1cb5760-0bc5-4328-965f-7f75211be016_terseLabel_en-US" xlink:label="lab_ameh_AccountableHealthCareIPAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accountable Health Care, IPA</link:label>
    <link:label id="lab_ameh_AccountableHealthCareIPAMember_label_en-US" xlink:label="lab_ameh_AccountableHealthCareIPAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accountable Health Care IPA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountableHealthCareIPAMember" xlink:href="ameh-20200630.xsd#ameh_AccountableHealthCareIPAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AccountableHealthCareIPAMember" xlink:to="lab_ameh_AccountableHealthCareIPAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDefaultLongtermDebtAmount_64285b3a-a4b3-4e2c-966e-7d97973b1552_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDefaultLongtermDebtAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Default amount of debt instrument</link:label>
    <link:label id="lab_us-gaap_DebtDefaultLongtermDebtAmount_label_en-US" xlink:label="lab_us-gaap_DebtDefaultLongtermDebtAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Debt Default, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDefaultLongtermDebtAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDefaultLongtermDebtAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDefaultLongtermDebtAmount" xlink:to="lab_us-gaap_DebtDefaultLongtermDebtAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_0aa4157f-d6bb-4cc4-85fe-b95908044815_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_e498a61f-2452-4a92-b530-884a07c9f9f3_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_1b03f2f5-12a7-413a-9557-a27d90596162_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common&#160;Stock&#160;Outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_4164c791-c647-4a9b-a296-925b67588d08_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">10% shares held back pursuant to indemnification clause</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_8e1fc337-d696-49ec-bf51-6bbc0cb38a20_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract_657cb81b-3674-46ab-b343-30b1598d2f46_verboseLabel_en-US" xlink:label="lab_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</link:label>
    <link:label id="lab_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract_label_en-US" xlink:label="lab_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid For Lease Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract" xlink:href="ameh-20200630.xsd#ameh_CashPaidForLeaseLiabilitiesAbstractAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract" xlink:to="lab_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_f2c20d39-8c80-45e3-a53f-da84b521ac80_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_63672a70-fb54-48b9-bed6-a163dc7217a9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend received</link:label>
    <link:label id="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_label_en-US" xlink:label="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Equity Method Investment, Distribution, Return of Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:to="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NetworkMedicalManagementMember_78934437-6a9d-4a67-ad11-287c0813c724_terseLabel_en-US" xlink:label="lab_ameh_NetworkMedicalManagementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NMM</link:label>
    <link:label id="lab_ameh_NetworkMedicalManagementMember_label_en-US" xlink:label="lab_ameh_NetworkMedicalManagementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Network Medical Management [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementMember" xlink:href="ameh-20200630.xsd#ameh_NetworkMedicalManagementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NetworkMedicalManagementMember" xlink:to="lab_ameh_NetworkMedicalManagementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_d8bf4161-87cf-409c-814f-55ea0a87135f_verboseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Other Entities - Equity Method and Investments in Privately Held Entities</link:label>
    <link:label id="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_label_en-US" xlink:label="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:to="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_9375e2d0-d9d4-43a0-9e2b-5afebf186e7d_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_6b161497-1c8d-4880-ae1f-05ea547d6f7a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining lease term, finance</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_f79726db-1617-4118-acf9-1e1acc02ac63_verboseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_930c0839-130a-4ad9-9730-092ca5f70006_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_29ffe609-225b-454f-8078-a91d85f91976_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate on loan receivable</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_95552f5f-45e2-40f1-9e22-7a8e4be49eb4_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend payable</link:label>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableCurrent" xlink:to="lab_us-gaap_DividendsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_c634d336-5647-43c4-810c-8d5e5e2f5edb_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining performance obligation, period</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_WarrantExercisePriceRangeOneMember_a8a169f7-e989-44aa-8bd0-ff92a6cb5c78_verboseLabel_en-US" xlink:label="lab_ameh_WarrantExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Exercise Price Range One</link:label>
    <link:label id="lab_ameh_WarrantExercisePriceRangeOneMember_label_en-US" xlink:label="lab_ameh_WarrantExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Exercise Price Range One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeOneMember" xlink:href="ameh-20200630.xsd#ameh_WarrantExercisePriceRangeOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_WarrantExercisePriceRangeOneMember" xlink:to="lab_ameh_WarrantExercisePriceRangeOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1_61fed629-4d37-4402-8aea-9ce9251afacf_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares received from sale of equity method investment</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1_ce2eaeab-ad7d-4ff9-8d32-ff99ce149317_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of non-cash consideration received</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Divestiture, Amount of Consideration Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" xlink:to="lab_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_2d65606d-6885-453c-9161-d6ad427b2912_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fees Incurred and Income Earned from Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PaymentsForMedicalCareCostsAbstract_d47f270d-9ff4-4669-905a-06764acb4b84_terseLabel_en-US" xlink:label="lab_ameh_PaymentsForMedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for medical care costs related to claims incurred:</link:label>
    <link:label id="lab_ameh_PaymentsForMedicalCareCostsAbstract_label_en-US" xlink:label="lab_ameh_PaymentsForMedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Medical Care Costs [Abstract]</link:label>
    <link:label id="lab_ameh_PaymentsForMedicalCareCostsAbstract_documentation_en-US" xlink:label="lab_ameh_PaymentsForMedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Medical Care Costs [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentsForMedicalCareCostsAbstract" xlink:href="ameh-20200630.xsd#ameh_PaymentsForMedicalCareCostsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PaymentsForMedicalCareCostsAbstract" xlink:to="lab_ameh_PaymentsForMedicalCareCostsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange_d7b49e9e-d0df-431f-ab64-7a7885672ca8_terseLabel_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated leverage ratio, annual decrease</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange_label_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio, Incremental Change</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange_documentation_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio, Incremental Change</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange" xlink:href="ameh-20200630.xsd#ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange" xlink:to="lab_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_599e1dfc-cee8-4f0b-9d0a-0e65954d19fc_terseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_label_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember" xlink:to="lab_us-gaap_ProductAndServiceOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_90efc92f-59a1-4731-80f1-abcee06775c0_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b723d33d-1529-4bad-99fb-3f9aa2b8babf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentsPurchaseOfShares_e9504cdb-3610-4e58-8045-eebfff04a181_terseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsPurchaseOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares purchased (in shares)</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentsPurchaseOfShares_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsPurchaseOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Purchase Of Shares</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentsPurchaseOfShares_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsPurchaseOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The number of shares purchased from equity method investment entities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsPurchaseOfShares" xlink:href="ameh-20200630.xsd#ameh_EquityMethodInvestmentsPurchaseOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentsPurchaseOfShares" xlink:to="lab_ameh_EquityMethodInvestmentsPurchaseOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_cee428f1-88a6-4a3e-9128-4372a9a4b110_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_544f89db-c4ca-4735-b073-85bde684db3d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations and Goodwill</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_e35191f8-e2d3-485c-a7a4-8403edba04b0_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EarningsPerShareTable_dc40aeaf-9c3b-41da-aafa-c73fee9feb29_terseLabel_en-US" xlink:label="lab_ameh_EarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Table]</link:label>
    <link:label id="lab_ameh_EarningsPerShareTable_label_en-US" xlink:label="lab_ameh_EarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Table]</link:label>
    <link:label id="lab_ameh_EarningsPerShareTable_documentation_en-US" xlink:label="lab_ameh_EarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EarningsPerShareTable" xlink:href="ameh-20200630.xsd#ameh_EarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EarningsPerShareTable" xlink:to="lab_ameh_EarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_765604f3-5538-400b-bb26-9a20ea28a696_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount_1f3ad452-746f-4eab-9343-e5e0bad7ddec_terseLabel_en-US" xlink:label="lab_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General amount of guarantee (as a percent)</link:label>
    <link:label id="lab_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount_label_en-US" xlink:label="lab_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Financial Guarantee Benchmark Amount</link:label>
    <link:label id="lab_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount_documentation_en-US" xlink:label="lab_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of financial guarantee on benchmark Medicare expenditure amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount" xlink:href="ameh-20200630.xsd#ameh_PercentageOfFinancialGuaranteeBenchmarkAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount" xlink:to="lab_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_17d57950-b262-4a77-88e9-90e38c8e1776_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_f286b79e-014e-42a2-adc1-fbae1bca8476_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable_bedfce0a-155f-4eec-9435-e69c014f01f7_terseLabel_en-US" xlink:label="lab_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease, termination period, if applicable</link:label>
    <link:label id="lab_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable_label_en-US" xlink:label="lab_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Termination Period, If Applicable</link:label>
    <link:label id="lab_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable_documentation_en-US" xlink:label="lab_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Termination Period, If Applicable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable" xlink:href="ameh-20200630.xsd#ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable" xlink:to="lab_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_460db3c5-8c82-4da5-a181-6f1eae274a00_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cd1d14cf-f18b-466e-88a3-8a7fb8302916_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_df6f888b-713b-49ff-a8b4-7662fa21cd0c_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_98f52c0d-4d48-4124-9e85-955452f827c5_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_536d5bd2-e5e5-449b-bd2b-e19fc8bce2eb_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_Pacific6EnterprisesMember_5bf9a502-8a04-40ea-bf16-9d7b02ba8122_terseLabel_en-US" xlink:label="lab_ameh_Pacific6EnterprisesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pacific6 Enterprises</link:label>
    <link:label id="lab_ameh_Pacific6EnterprisesMember_label_en-US" xlink:label="lab_ameh_Pacific6EnterprisesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pacific6 Enterprises [Member]</link:label>
    <link:label id="lab_ameh_Pacific6EnterprisesMember_documentation_en-US" xlink:label="lab_ameh_Pacific6EnterprisesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pacific6 Enterprises [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Pacific6EnterprisesMember" xlink:href="ameh-20200630.xsd#ameh_Pacific6EnterprisesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_Pacific6EnterprisesMember" xlink:to="lab_ameh_Pacific6EnterprisesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_eac1e035-f9c5-41d2-9503-3b761455cb4f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_8f0632f5-4bf5-485e-b4a7-a8b6f7a39132_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current period</link:label>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Year Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_994feffb-b617-4ac6-a090-7f185ce019b6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_718a71b0-06e1-457b-80a2-bb22bf31d4f9_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share &#8211; diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_c2cabccd-363b-4e69-b8bb-159b7951c254_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems" xlink:to="lab_us-gaap_VariableInterestEntityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AccountsAndOtherReceivablesNumberOfAdditionalAgreements_faf67d31-0a6d-4a0d-82d0-0be092beecfa_terseLabel_en-US" xlink:label="lab_ameh_AccountsAndOtherReceivablesNumberOfAdditionalAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional subordinated note receivable agreements</link:label>
    <link:label id="lab_ameh_AccountsAndOtherReceivablesNumberOfAdditionalAgreements_label_en-US" xlink:label="lab_ameh_AccountsAndOtherReceivablesNumberOfAdditionalAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts And Other Receivables, Number Of Additional Agreements</link:label>
    <link:label id="lab_ameh_AccountsAndOtherReceivablesNumberOfAdditionalAgreements_documentation_en-US" xlink:label="lab_ameh_AccountsAndOtherReceivablesNumberOfAdditionalAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts And Other Receivables, Number Of Additional Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsAndOtherReceivablesNumberOfAdditionalAgreements" xlink:href="ameh-20200630.xsd#ameh_AccountsAndOtherReceivablesNumberOfAdditionalAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AccountsAndOtherReceivablesNumberOfAdditionalAgreements" xlink:to="lab_ameh_AccountsAndOtherReceivablesNumberOfAdditionalAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_838dba8f-3c1d-432f-a34e-dc29abaf5b96_verboseLabel_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeiture rate</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_label_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_documentation_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the forfeiture rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:href="ameh-20200630.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:to="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_558c265b-0e5a-45af-b69e-bf741bd72286_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_a3f7b244-552c-4a84-9798-7985ce1a423b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of shares transferred in acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_964c1cd9-b5de-458f-b07e-99891598b56c_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Indefinite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrimeRateMember_e3372067-795f-407d-9731-9eac9871f7ba_terseLabel_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prime Rate</link:label>
    <link:label id="lab_us-gaap_PrimeRateMember_label_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prime Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrimeRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrimeRateMember" xlink:to="lab_us-gaap_PrimeRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_cfd61ade-1f05-4722-8adf-40d64fe88117_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized risk pool revenue</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_6b4cf9cc-a5c9-442c-aee1-7f9b5c1f4469_totalLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net total</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Other Revenues from Transactions with Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants_7df34eec-924d-4170-90a9-054db8fe7f82_verboseLabel_en-US" xlink:label="lab_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for exercise of options and warrants (in shares)</link:label>
    <link:label id="lab_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants_label_en-US" xlink:label="lab_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued during the period shares of exercise of option and warrants</link:label>
    <link:label id="lab_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants_documentation_en-US" xlink:label="lab_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">It represents number of share issued exercise of option and warrants during the period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" xlink:href="ameh-20200630.xsd#ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" xlink:to="lab_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_b72e4f4d-61fc-48be-8a0a-4873a73b78cd_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_5e66a8f6-9000-4507-8375-402526b76ddb_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_47a37f69-4e53-4027-9084-c2845d72a839_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_54a08704-0ed3-4417-acde-a527eb41c65f_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_6195ecff-644d-4d7c-bf79-bc89a3e78312_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_a30846b3-0716-4e99-888d-84fad6ddd358_terseLabel_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_label_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Exercise Price [Abstract]</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_documentation_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xlink:href="ameh-20200630.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xlink:to="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b4703726-e630-47b2-8116-372127837cd0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4efd7190-e791-4917-8ef2-9180714677a1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MedicalCareCostsAbstract_88b8b305-c62c-4618-ad87-314fe25c8c74_terseLabel_en-US" xlink:label="lab_ameh_MedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of medical care costs related to claims incurred:</link:label>
    <link:label id="lab_ameh_MedicalCareCostsAbstract_label_en-US" xlink:label="lab_ameh_MedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Care Costs [Abstract]</link:label>
    <link:label id="lab_ameh_MedicalCareCostsAbstract_documentation_en-US" xlink:label="lab_ameh_MedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Care Costs [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicalCareCostsAbstract" xlink:href="ameh-20200630.xsd#ameh_MedicalCareCostsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MedicalCareCostsAbstract" xlink:to="lab_ameh_MedicalCareCostsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_21ed4aed-bd7a-47dc-bb6c-ae47cc3444bc_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments</link:label>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Other Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:to="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_c0109d57-91d6-4d15-987d-f93b3f97e515_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from related parties</link:label>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromRelatedParties" xlink:to="lab_us-gaap_RevenueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption_bfe88978-b2bb-4b98-b2bf-a0124cca8295_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of option</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investment, Options Issued, Term Of Option</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Options Issued, Term Of Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" xlink:href="ameh-20200630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_4f036953-5505-4982-b27e-21a54c0afc8a_verboseLabel_en-US" xlink:label="lab_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_label_en-US" xlink:label="lab_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation Of Cash Cash Equivalents And Restricted Cash [Abstract]</link:label>
    <link:label id="lab_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_documentation_en-US" xlink:label="lab_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:href="ameh-20200630.xsd#ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:to="lab_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_RepaymentsOfBankLoanAndLinesOfCredit_ea025770-bdbd-4a9e-b078-b229ac36c37f_negatedTerseLabel_en-US" xlink:label="lab_ameh_RepaymentsOfBankLoanAndLinesOfCredit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of bank loan and lines of credit</link:label>
    <link:label id="lab_ameh_RepaymentsOfBankLoanAndLinesOfCredit_label_en-US" xlink:label="lab_ameh_RepaymentsOfBankLoanAndLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments Of Bank Loan And Lines Of Credit</link:label>
    <link:label id="lab_ameh_RepaymentsOfBankLoanAndLinesOfCredit_documentation_en-US" xlink:label="lab_ameh_RepaymentsOfBankLoanAndLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments Of Bank Loan And Lines Of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_RepaymentsOfBankLoanAndLinesOfCredit" xlink:href="ameh-20200630.xsd#ameh_RepaymentsOfBankLoanAndLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_RepaymentsOfBankLoanAndLinesOfCredit" xlink:to="lab_ameh_RepaymentsOfBankLoanAndLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentsRollForward_f9477634-41c1-4f37-9d78-a00ff8ecb342_terseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Roll Forward]</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentsRollForward_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Roll Forward]</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentsRollForward_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsRollForward" xlink:href="ameh-20200630.xsd#ameh_EquityMethodInvestmentsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward" xlink:to="lab_ameh_EquityMethodInvestmentsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9d43119d-6d61-4772-b38e-86462148c73d_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_9f77d298-c02e-4a1f-a934-dcd5b93ecd18_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Medical Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_3efc5023-3d8b-4254-9987-a24a8e89d933_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_08c5b204-f024-4906-a666-f302ce9e4472_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reportable Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity_9b5d2c95-fae3-4929-a38b-909ef397e0ec_terseLabel_en-US" xlink:label="lab_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income</link:label>
    <link:label id="lab_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity_label_en-US" xlink:label="lab_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable To Noncontrolling Interest And Temporary Equity</link:label>
    <link:label id="lab_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity_documentation_en-US" xlink:label="lab_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable To Noncontrolling Interest And Temporary Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" xlink:href="ameh-20200630.xsd#ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" xlink:to="lab_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireRealEstate_fb752555-9827-4d39-a3ec-610d8f180055_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireRealEstate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price of real estate</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireRealEstate_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireRealEstate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Real Estate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireRealEstate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireRealEstate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireRealEstate" xlink:to="lab_us-gaap_PaymentsToAcquireRealEstate" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CreditAgreementMember_41e5740d-5ca7-475e-a232-897511fb1797_terseLabel_en-US" xlink:label="lab_ameh_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement</link:label>
    <link:label id="lab_ameh_CreditAgreementMember_label_en-US" xlink:label="lab_ameh_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement [Member]</link:label>
    <link:label id="lab_ameh_CreditAgreementMember_documentation_en-US" xlink:label="lab_ameh_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CreditAgreementMember" xlink:href="ameh-20200630.xsd#ameh_CreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CreditAgreementMember" xlink:to="lab_ameh_CreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_59d0628b-9912-425a-96be-f2f70542e57d_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ebb1719c-9c2f-47ef-b4ba-b64ba5287711_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_6b472068-18e6-4740-9ab3-755b68a9f22b_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_93d1197a-056c-4288-8dd1-bc665efe96ef_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ManagementServiceMember_320f40fb-cfa8-4567-b025-9779076c1008_terseLabel_en-US" xlink:label="lab_us-gaap_ManagementServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management fee income</link:label>
    <link:label id="lab_us-gaap_ManagementServiceMember_46a56f9d-d3a1-4ac3-a614-da87f9157ed2_verboseLabel_en-US" xlink:label="lab_us-gaap_ManagementServiceMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management Fee Income Contract</link:label>
    <link:label id="lab_us-gaap_ManagementServiceMember_label_en-US" xlink:label="lab_us-gaap_ManagementServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementServiceMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ManagementServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ManagementServiceMember" xlink:to="lab_us-gaap_ManagementServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_ca1afb78-4808-4cd9-99f5-f3747f634d2a_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_9b6e735d-124b-4f33-9414-a37f4a314a57_periodStartLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical liabilities, beginning of period</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_8cf8df89-3b71-4ae0-b68c-b077bfb0d3fd_periodEndLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical liabilities, end of period</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_33fef77c-fa40-4ca6-b40b-042f30022dbe_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceMember_9cf46475-8f9b-4bc2-8b55-5f416ccf8081_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service</link:label>
    <link:label id="lab_us-gaap_ServiceMember_label_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_47ba4fab-e426-4184-a04b-ee2722f9c86c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentGainOnSaleTableTextBlock_ba9dad92-1877-46a6-a2e6-399db98ff761_terseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentGainOnSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Gain On Sale</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentGainOnSaleTableTextBlock_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentGainOnSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Gain On Sale [Table Text Block]</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentGainOnSaleTableTextBlock_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentGainOnSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Gain On Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentGainOnSaleTableTextBlock" xlink:href="ameh-20200630.xsd#ameh_EquityMethodInvestmentGainOnSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentGainOnSaleTableTextBlock" xlink:to="lab_ameh_EquityMethodInvestmentGainOnSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantOrRightExercisable_c85c5c70-5ee8-4abf-875d-c97234861352_terseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightExercisable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Exercisable (in shares)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightExercisable_label_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightExercisable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Exercisable</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightExercisable_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightExercisable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightExercisable" xlink:href="ameh-20200630.xsd#ameh_ClassOfWarrantOrRightExercisable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantOrRightExercisable" xlink:to="lab_ameh_ClassOfWarrantOrRightExercisable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_039014ba-c109-45dd-8d37-02f4894878bf_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_5b401b01-4996-49f4-a790-598fb3e1928f_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_ed55ef9a-5dbc-464e-b672-698e871aed58_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_4fc38c7d-7ffc-4178-99ff-5fce8d110ab1_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_3a9b29f1-9501-4629-b5fe-109235d83641_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_37ae4954-f64b-4fd0-88cf-4029ddeb375b_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_be6b1100-b7c2-466a-b1a4-bd0cc2382688_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade names/trademarks</link:label>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks and Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksAndTradeNamesMember" xlink:to="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_1723d12b-4706-45ab-b936-06eee35a2e4a_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_c1c1ef2b-5867-4231-80bc-7159f0c9e18a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_566a4e2c-2090-47c5-8ee8-2818bacb3c6a_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_bc1434e5-ace3-40d4-b552-7de753f72ff4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_e7a9f2e7-457f-4ac9-80ff-70a5b03c078f_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 11)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_da287890-b426-406b-9401-3eddbe9054fd_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of shares</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f5837aca-d4c0-4276-b955-48886738aac8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentsContribution_9b11f70a-613d-44a4-abfe-3e611bc390fd_terseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsContribution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contribution</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentsContribution_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsContribution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Contribution</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentsContribution_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsContribution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Contribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsContribution" xlink:href="ameh-20200630.xsd#ameh_EquityMethodInvestmentsContribution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentsContribution" xlink:to="lab_ameh_EquityMethodInvestmentsContribution" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_90529702-6b01-4dd8-a5ca-c2129705bb07_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_7e7fc7de-2893-4a49-9c94-563192937ffc_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Support to Nonconsolidated Legal Entity [Domain]</link:label>
    <link:label id="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_label_en-US" xlink:label="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Support to Nonconsolidated Legal Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:to="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_98fd5911-583b-49f6-a866-dee335010a10_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_2aba5b98-0587-4d91-949a-42e88effa2d9_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_ad5b5372-a00a-41e1-8005-a5576eaf339b_negatedLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ApolloMedicalHoldingsIncMember_01da53f8-c4a4-4b55-8f59-68c9b782a8c6_terseLabel_en-US" xlink:label="lab_ameh_ApolloMedicalHoldingsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apollo Medical Holdings, Inc</link:label>
    <link:label id="lab_ameh_ApolloMedicalHoldingsIncMember_label_en-US" xlink:label="lab_ameh_ApolloMedicalHoldingsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apollo Medical Holdings, Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApolloMedicalHoldingsIncMember" xlink:href="ameh-20200630.xsd#ameh_ApolloMedicalHoldingsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ApolloMedicalHoldingsIncMember" xlink:to="lab_ameh_ApolloMedicalHoldingsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PaymentPeriodTwoMember_1401438e-0399-48ec-9f4d-e5aa48e51b1c_terseLabel_en-US" xlink:label="lab_ameh_PaymentPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Following Eight Fiscal Quarters Thereafter</link:label>
    <link:label id="lab_ameh_PaymentPeriodTwoMember_label_en-US" xlink:label="lab_ameh_PaymentPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Period Two [Member]</link:label>
    <link:label id="lab_ameh_PaymentPeriodTwoMember_documentation_en-US" xlink:label="lab_ameh_PaymentPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Period Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentPeriodTwoMember" xlink:href="ameh-20200630.xsd#ameh_PaymentPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PaymentPeriodTwoMember" xlink:to="lab_ameh_PaymentPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_4923b3d9-3fab-4c82-96a3-fe2890e422d6_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DmgMember_2b20a929-2216-4fe8-92d3-2bbbdbe88b00_terseLabel_en-US" xlink:label="lab_ameh_DmgMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DMG</link:label>
    <link:label id="lab_ameh_DmgMember_label_en-US" xlink:label="lab_ameh_DmgMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DMG [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DmgMember" xlink:href="ameh-20200630.xsd#ameh_DmgMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DmgMember" xlink:to="lab_ameh_DmgMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_d770273b-aa0e-4a89-aa39-da2a30c93f0d_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_fef49b73-67bc-4ed1-b44a-cc4a0e2e3e12_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DrJayLoanMember_ca0da2a3-068a-46e5-b3bc-70e16b3ffa01_terseLabel_en-US" xlink:label="lab_ameh_DrJayLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Jay Loan</link:label>
    <link:label id="lab_ameh_DrJayLoanMember_label_en-US" xlink:label="lab_ameh_DrJayLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Jay Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DrJayLoanMember" xlink:href="ameh-20200630.xsd#ameh_DrJayLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DrJayLoanMember" xlink:to="lab_ameh_DrJayLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest_24b0d8f5-111a-4664-ac6a-aa96a1d8d2bf_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Membership interests acquired (in dollars per share)</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Membership Interest Acquired, Per Interest</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Membership Interest Acquired, Per Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" xlink:href="ameh-20200630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_a338d2ab-7568-4949-bacc-cc231eff29c6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_651cb321-d731-4e08-9ac1-2c16cb085f15_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_5e801faa-58aa-45a9-a97f-f0683483f28a_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCreditsAndOtherLiabilities_10bd8175-5086-4e36-998e-f189ea29b053_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCreditsAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount outstanding under agreement</link:label>
    <link:label id="lab_us-gaap_DeferredCreditsAndOtherLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredCreditsAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Credits and Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCreditsAndOtherLiabilities" xlink:to="lab_us-gaap_DeferredCreditsAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_2c0a86c4-ed63-4b0e-b788-c149a6bec415_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_f3f3d831-bab4-4618-8bc9-c644ee0ca229_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_94a24c5a-330a-4c4c-9d83-b869a4668a7c_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total finance lease cost, net</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_2c043519-c57d-4684-b77c-4b67661d57a2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investment &#8211; equity method</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_f913c824-e3b9-4422-8a34-5a4ea2470ec0_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash consideration paid for ownership interest</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_1f30c1bf-fbaa-4257-b192-1f664d531aa8_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_36775b96-34b4-4db4-a812-824f4712ecde_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage_ff14e88a-9dc0-470b-a5e7-3c39dfcdc3da_terseLabel_en-US" xlink:label="lab_ameh_BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares held back in merger to secure indemnification (as a percent)</link:label>
    <link:label id="lab_ameh_BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage_label_en-US" xlink:label="lab_ameh_BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Shares Held Back To Secure Indemnification, Percentage</link:label>
    <link:label id="lab_ameh_BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage_documentation_en-US" xlink:label="lab_ameh_BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Shares Held Back To Secure Indemnification, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage" xlink:href="ameh-20200630.xsd#ameh_BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage" xlink:to="lab_ameh_BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MediPortalLLCMember_1f93a01e-6f58-4447-8bc7-bf1fa68e1996_terseLabel_en-US" xlink:label="lab_ameh_MediPortalLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MediPortal LLC</link:label>
    <link:label id="lab_ameh_MediPortalLLCMember_label_en-US" xlink:label="lab_ameh_MediPortalLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MediPortal LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MediPortalLLCMember" xlink:href="ameh-20200630.xsd#ameh_MediPortalLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MediPortalLLCMember" xlink:to="lab_ameh_MediPortalLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3a499e41-74d7-4d01-9647-ecff63a582c9_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3f3a068d-0ffe-46a3-8251-90cffdea7838_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod_f42df818-5753-47a5-bd20-557639a8336e_verboseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants expired/forfeited (in dollars per share)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod_label_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants, Forfeited In Period</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price per share of warrants or rights forfeited during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" xlink:href="ameh-20200630.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" xlink:to="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_dfc81140-ce48-462d-9be9-1411135037fc_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market value of common stock (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_64cd9e35-ac7a-4fd3-9624-53545c7cb24d_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_6e878f70-ffa0-457f-85c3-fa7d91956615_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_80486d19-fb2b-4459-a028-b75291872179_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue_a35f7461-7f22-4216-8c7e-c2dc13f340d3_verboseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants expired/forfeited</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue_label_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Forfeitures In Period, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of warrants or rights forfeited in period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" xlink:href="ameh-20200630.xsd#ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" xlink:to="lab_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_602f6028-9976-424c-b4f5-0c1955a3d5f9_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss (gain) from investment in equity securities</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ManagementContractsMember_7cce5376-c697-405a-908e-986a6fc2da64_verboseLabel_en-US" xlink:label="lab_ameh_ManagementContractsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management contracts</link:label>
    <link:label id="lab_ameh_ManagementContractsMember_label_en-US" xlink:label="lab_ameh_ManagementContractsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management Contracts [Member]</link:label>
    <link:label id="lab_ameh_ManagementContractsMember_documentation_en-US" xlink:label="lab_ameh_ManagementContractsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management Contracts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ManagementContractsMember" xlink:href="ameh-20200630.xsd#ameh_ManagementContractsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ManagementContractsMember" xlink:to="lab_ameh_ManagementContractsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_18d45cce-261a-4c80-bb6b-a35a4b3b9c25_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings on line of credit</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Long-term Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_a4a46de4-7e8c-49b7-b6c0-e19f40a4fb07_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LasalleMedicalAssociatesIpaMember_276b389e-5898-4d0e-8251-6c543d6d453a_terseLabel_en-US" xlink:label="lab_ameh_LasalleMedicalAssociatesIpaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LaSalle Medical Associates &#8211; IPA Line of Business</link:label>
    <link:label id="lab_ameh_LasalleMedicalAssociatesIpaMember_814c014d-a29a-4555-bcc3-00954fb5a743_verboseLabel_en-US" xlink:label="lab_ameh_LasalleMedicalAssociatesIpaMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LaSalle Medical Associates</link:label>
    <link:label id="lab_ameh_LasalleMedicalAssociatesIpaMember_label_en-US" xlink:label="lab_ameh_LasalleMedicalAssociatesIpaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LaSalle Medical Associates IPA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember" xlink:href="ameh-20200630.xsd#ameh_LasalleMedicalAssociatesIpaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LasalleMedicalAssociatesIpaMember" xlink:to="lab_ameh_LasalleMedicalAssociatesIpaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MWNCommunityHospitalLLCMember_f8832b35-7952-4319-81a9-20ff44d67580_terseLabel_en-US" xlink:label="lab_ameh_MWNCommunityHospitalLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MWN, LLC &#8211; related party</link:label>
    <link:label id="lab_ameh_MWNCommunityHospitalLLCMember_label_en-US" xlink:label="lab_ameh_MWNCommunityHospitalLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MWN Community Hospital LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MWNCommunityHospitalLLCMember" xlink:href="ameh-20200630.xsd#ameh_MWNCommunityHospitalLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MWNCommunityHospitalLLCMember" xlink:to="lab_ameh_MWNCommunityHospitalLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_6ab730df-dcb1-49f8-95b5-ec2152dd69f3_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_bb145065-cbaa-48d0-ae56-c66954493ce9_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_83b0572e-4afa-4090-9332-4c72d705343b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_HSMSOMember_6d40ccd8-db3f-4849-ae4f-059f1f68c0c0_verboseLabel_en-US" xlink:label="lab_ameh_HSMSOMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HSMSO</link:label>
    <link:label id="lab_ameh_HSMSOMember_label_en-US" xlink:label="lab_ameh_HSMSOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HSMSO [Member]</link:label>
    <link:label id="lab_ameh_HSMSOMember_documentation_en-US" xlink:label="lab_ameh_HSMSOMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">xxx_HSMSO Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_HSMSOMember" xlink:href="ameh-20200630.xsd#ameh_HSMSOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_HSMSOMember" xlink:to="lab_ameh_HSMSOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_44e6ad38-b4b1-4579-ab25-4039c24ab7c3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_VotingCommonStockTwoMember_fb109dd3-5511-4f1e-a5c9-3e469d35b962_terseLabel_en-US" xlink:label="lab_ameh_VotingCommonStockTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voting Common Stock A Two</link:label>
    <link:label id="lab_ameh_VotingCommonStockTwoMember_label_en-US" xlink:label="lab_ameh_VotingCommonStockTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voting Common Stock A Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_VotingCommonStockTwoMember" xlink:href="ameh-20200630.xsd#ameh_VotingCommonStockTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_VotingCommonStockTwoMember" xlink:to="lab_ameh_VotingCommonStockTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_SummaryOfSignificantAccountingPoliciesTable_74ed865b-d0b3-4ece-a8ea-43ae17df973d_terseLabel_en-US" xlink:label="lab_ameh_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_ameh_SummaryOfSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_ameh_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_ameh_SummaryOfSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_ameh_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SummaryOfSignificantAccountingPoliciesTable" xlink:href="ameh-20200630.xsd#ameh_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_ameh_SummaryOfSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_745dd20b-6355-437b-89ad-958414f6c325_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from common stock offering</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AurionMember_a8583a18-74ea-4202-8352-bca635f081a0_verboseLabel_en-US" xlink:label="lab_ameh_AurionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aurion</link:label>
    <link:label id="lab_ameh_AurionMember_label_en-US" xlink:label="lab_ameh_AurionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aurion [Member]</link:label>
    <link:label id="lab_ameh_AurionMember_documentation_en-US" xlink:label="lab_ameh_AurionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">xxx_Aurion Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AurionMember" xlink:href="ameh-20200630.xsd#ameh_AurionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AurionMember" xlink:to="lab_ameh_AurionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_54ae09f3-d665-4d12-92c2-c721e8207cbd_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_54ae2ee5-499f-460a-aca9-53d07d5b2abc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share Computations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_4136d24d-e376-42d3-a5ec-9d9782b9831d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NumberOfFamilyPracticeClinics_407dcae8-15c6-4646-9b18-300e615a5dd9_terseLabel_en-US" xlink:label="lab_ameh_NumberOfFamilyPracticeClinics" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of family practice clinics</link:label>
    <link:label id="lab_ameh_NumberOfFamilyPracticeClinics_label_en-US" xlink:label="lab_ameh_NumberOfFamilyPracticeClinics" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Family Practice Clinics</link:label>
    <link:label id="lab_ameh_NumberOfFamilyPracticeClinics_documentation_en-US" xlink:label="lab_ameh_NumberOfFamilyPracticeClinics" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Family Practice Clinics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfFamilyPracticeClinics" xlink:href="ameh-20200630.xsd#ameh_NumberOfFamilyPracticeClinics"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NumberOfFamilyPracticeClinics" xlink:to="lab_ameh_NumberOfFamilyPracticeClinics" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage_b88791c2-4733-427e-925d-43cdac1a6132_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value, Ownership Percentage</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" xlink:href="ameh-20200630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_df7c3fe9-41cf-4fe5-b4dc-d1964f96b186_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Estimated Fair Values of Assets Acquired and Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_19349ec0-0393-47f3-978c-7d1426ad70aa_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_c53d7940-2320-4be2-a8bd-4f540b8c691b_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Support to Nonconsolidated Legal Entity [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_label_en-US" xlink:label="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Support to Nonconsolidated Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:to="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_6b07cfa8-ba9c-42f5-bda1-683a4b212f8b_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_0759217f-ddc1-4501-9b77-b0f647efdb65_totalLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_5d7a05ee-18df-487b-a7ff-67fdc4cfdedc_verboseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount outstanding</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_8673b710-6759-400a-8eb8-c2f0c5aabb8e_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_356e3ca1-1527-4f4e-ac61-a9a852599482_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_f6fbad20-3134-4bbb-84b5-8cc2b901003f_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior periods</link:label>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Year Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_63a133cd-d0a7-48f4-a16b-a434d081020c_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_c40b96c2-6f00-4214-9781-3bca408bb9d2_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of main reporting units</link:label>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_label_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reporting Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportingUnits" xlink:to="lab_us-gaap_NumberOfReportingUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_238cd43a-c80d-4017-b6aa-d92f68b8e1b7_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MezzanineEquityAbstract_f2fe91e7-6026-4666-9f32-672dedc41165_verboseLabel_en-US" xlink:label="lab_ameh_MezzanineEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mezzanine equity</link:label>
    <link:label id="lab_ameh_MezzanineEquityAbstract_label_en-US" xlink:label="lab_ameh_MezzanineEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MEZZANINE EQUITY [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MezzanineEquityAbstract" xlink:href="ameh-20200630.xsd#ameh_MezzanineEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MezzanineEquityAbstract" xlink:to="lab_ameh_MezzanineEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d66fe227-910e-4be1-96fe-020e4e4b841a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FiduciaryAccountsPayableCurrent_6f890e5a-7384-464c-b5c9-df44e63240ae_terseLabel_en-US" xlink:label="lab_ameh_FiduciaryAccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiduciary accounts payable</link:label>
    <link:label id="lab_ameh_FiduciaryAccountsPayableCurrent_label_en-US" xlink:label="lab_ameh_FiduciaryAccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiduciary Accounts Payable Current</link:label>
    <link:label id="lab_ameh_FiduciaryAccountsPayableCurrent_documentation_en-US" xlink:label="lab_ameh_FiduciaryAccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of fiduciary accounts payable, due after one year or beyond the normal operating cycle, if longer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent" xlink:href="ameh-20200630.xsd#ameh_FiduciaryAccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FiduciaryAccountsPayableCurrent" xlink:to="lab_ameh_FiduciaryAccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FinancingReceivableConvertibleToCommonStockPercentageOfOutstandingSharesConvertible_23d07a00-84fe-4985-ba93-65dc5288ce78_terseLabel_en-US" xlink:label="lab_ameh_FinancingReceivableConvertibleToCommonStockPercentageOfOutstandingSharesConvertible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of outstanding stock convertible</link:label>
    <link:label id="lab_ameh_FinancingReceivableConvertibleToCommonStockPercentageOfOutstandingSharesConvertible_label_en-US" xlink:label="lab_ameh_FinancingReceivableConvertibleToCommonStockPercentageOfOutstandingSharesConvertible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Convertible To Common Stock, Percentage Of Outstanding Shares Convertible</link:label>
    <link:label id="lab_ameh_FinancingReceivableConvertibleToCommonStockPercentageOfOutstandingSharesConvertible_documentation_en-US" xlink:label="lab_ameh_FinancingReceivableConvertibleToCommonStockPercentageOfOutstandingSharesConvertible" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Convertible To Common Stock, Percentage Of Outstanding Shares Convertible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinancingReceivableConvertibleToCommonStockPercentageOfOutstandingSharesConvertible" xlink:href="ameh-20200630.xsd#ameh_FinancingReceivableConvertibleToCommonStockPercentageOfOutstandingSharesConvertible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FinancingReceivableConvertibleToCommonStockPercentageOfOutstandingSharesConvertible" xlink:to="lab_ameh_FinancingReceivableConvertibleToCommonStockPercentageOfOutstandingSharesConvertible" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_9a87e4dd-7cfc-464d-831f-142681974887_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MaverickMedicalGroupIncMember_0296c619-e58c-4d15-9ec0-9baa77e8249a_terseLabel_en-US" xlink:label="lab_ameh_MaverickMedicalGroupIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maverick Medical Group, Inc</link:label>
    <link:label id="lab_ameh_MaverickMedicalGroupIncMember_label_en-US" xlink:label="lab_ameh_MaverickMedicalGroupIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maverick Medical Group, Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MaverickMedicalGroupIncMember" xlink:href="ameh-20200630.xsd#ameh_MaverickMedicalGroupIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MaverickMedicalGroupIncMember" xlink:to="lab_ameh_MaverickMedicalGroupIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EscrowDeposit_5283e5fd-24b5-4f49-b13d-0c035edb96bf_terseLabel_en-US" xlink:label="lab_us-gaap_EscrowDeposit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Escrow deposit for potential post-closing adjustments</link:label>
    <link:label id="lab_us-gaap_EscrowDeposit_label_en-US" xlink:label="lab_us-gaap_EscrowDeposit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Escrow Deposit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EscrowDeposit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EscrowDeposit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EscrowDeposit" xlink:to="lab_us-gaap_EscrowDeposit" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum_a412009f-4577-4d5b-b55b-be4e2dda91b7_terseLabel_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum consolidated interest coverage ratio (not less than)</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum_label_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Interest Coverage Ratio, Minimum</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum_documentation_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Interest Coverage Ratio, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:href="ameh-20200630.xsd#ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:to="lab_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_StockIssuedDuringPeriodValueRestrictedStockAwardCancelled_9d218d08-9e37-43c8-8c5e-cebae28789c6_negatedTerseLabel_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodValueRestrictedStockAwardCancelled" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancellation of restricted stock awards</link:label>
    <link:label id="lab_ameh_StockIssuedDuringPeriodValueRestrictedStockAwardCancelled_label_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodValueRestrictedStockAwardCancelled" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Cancelled</link:label>
    <link:label id="lab_ameh_StockIssuedDuringPeriodValueRestrictedStockAwardCancelled_documentation_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodValueRestrictedStockAwardCancelled" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Cancelled</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodValueRestrictedStockAwardCancelled" xlink:href="ameh-20200630.xsd#ameh_StockIssuedDuringPeriodValueRestrictedStockAwardCancelled"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_StockIssuedDuringPeriodValueRestrictedStockAwardCancelled" xlink:to="lab_ameh_StockIssuedDuringPeriodValueRestrictedStockAwardCancelled" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PayorCMember_7654264a-c5cb-4c24-a164-bff9bf183281_terseLabel_en-US" xlink:label="lab_ameh_PayorCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor C</link:label>
    <link:label id="lab_ameh_PayorCMember_label_en-US" xlink:label="lab_ameh_PayorCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor C [Member]</link:label>
    <link:label id="lab_ameh_PayorCMember_documentation_en-US" xlink:label="lab_ameh_PayorCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor C [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorCMember" xlink:href="ameh-20200630.xsd#ameh_PayorCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PayorCMember" xlink:to="lab_ameh_PayorCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AccountsReceivableAndNetRevenueLineItems_7324f709-dffb-4d96-84d3-8a2436159d5e_terseLabel_en-US" xlink:label="lab_ameh_AccountsReceivableAndNetRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable And Net Revenue [Line Items]</link:label>
    <link:label id="lab_ameh_AccountsReceivableAndNetRevenueLineItems_label_en-US" xlink:label="lab_ameh_AccountsReceivableAndNetRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable And Net Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsReceivableAndNetRevenueLineItems" xlink:href="ameh-20200630.xsd#ameh_AccountsReceivableAndNetRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueLineItems" xlink:to="lab_ameh_AccountsReceivableAndNetRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_b9812d30-34ae-4b86-b4aa-c21c793310a9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_47604233-2097-4420-8fca-249e70c3cb2d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_be7ae744-8090-40fd-b35e-514e479c7e62_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Credit Facility</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Line of Credit Facilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:to="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ApcStockOptionMember_dcadf507-d466-430d-9f63-d78636396c41_terseLabel_en-US" xlink:label="lab_ameh_ApcStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC Stock Option</link:label>
    <link:label id="lab_ameh_ApcStockOptionMember_label_en-US" xlink:label="lab_ameh_ApcStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcStockOptionMember" xlink:href="ameh-20200630.xsd#ameh_ApcStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ApcStockOptionMember" xlink:to="lab_ameh_ApcStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_052c8aaa-0461-4696-8d5a-651697747be1_periodStartLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, beginning balance</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_d6fa966f-55b3-4dd0-a0b3-d22d0c3450de_periodEndLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, ending balance</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of warrants or rights outstanding.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" xlink:href="ameh-20200630.xsd#ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" xlink:to="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties_8f04c2d3-9d60-4bea-9402-47ae705b090b_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, net &#8211; related parties</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Due from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:to="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_ebfc1b1a-0995-41a4-98f0-bf877b2363a4_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AHMCMember_372d89fc-44ce-4989-b5cc-2159c69d9760_terseLabel_en-US" xlink:label="lab_ameh_AHMCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AHMC</link:label>
    <link:label id="lab_ameh_AHMCMember_c81580d5-8c40-4a33-90de-1810dd8fe7e7_verboseLabel_en-US" xlink:label="lab_ameh_AHMCMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AHMC</link:label>
    <link:label id="lab_ameh_AHMCMember_label_en-US" xlink:label="lab_ameh_AHMCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AHMC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AHMCMember" xlink:href="ameh-20200630.xsd#ameh_AHMCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AHMCMember" xlink:to="lab_ameh_AHMCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_fbd383cd-4080-4a89-9937-5928602093cd_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_dfe88a86-d5ea-4e89-8c8a-0b40b9bf34d4_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_547b5f1c-93d3-4bb3-b1a3-76b635d51d7d_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_ba743849-0749-41d3-bcfb-1b8bd12d45fa_verboseLabel_en-US" xlink:label="lab_ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for lease liabilities:</link:label>
    <link:label id="lab_ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_label_en-US" xlink:label="lab_ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Right Of Use Assets Obtained In Exchange For Lease Obligations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:href="ameh-20200630.xsd#ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:to="lab_ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilities_e6632365-5b20-419e-b273-faacba1e4d95_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilities_label_en-US" xlink:label="lab_us-gaap_OtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilities" xlink:to="lab_us-gaap_OtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_1d6a4eaf-6d18-41af-bd1f-a9502ace5518_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock subscription</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_1cc6b3bb-9ad9-4db8-890a-c719c3012761_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Payment on Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FinanceReceivableTermOfReceivable_f9037ac1-d674-464c-a709-5de59929555f_terseLabel_en-US" xlink:label="lab_ameh_FinanceReceivableTermOfReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of receivable</link:label>
    <link:label id="lab_ameh_FinanceReceivableTermOfReceivable_label_en-US" xlink:label="lab_ameh_FinanceReceivableTermOfReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Receivable, Term Of Receivable</link:label>
    <link:label id="lab_ameh_FinanceReceivableTermOfReceivable_documentation_en-US" xlink:label="lab_ameh_FinanceReceivableTermOfReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Receivable, Term Of Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableTermOfReceivable" xlink:href="ameh-20200630.xsd#ameh_FinanceReceivableTermOfReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FinanceReceivableTermOfReceivable" xlink:to="lab_ameh_FinanceReceivableTermOfReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfStores_ab9cc72a-2e57-4c9a-b582-b03cedc5205c_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfStores" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of medical centers</link:label>
    <link:label id="lab_us-gaap_NumberOfStores_label_en-US" xlink:label="lab_us-gaap_NumberOfStores" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Stores</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStores" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfStores"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfStores" xlink:to="lab_us-gaap_NumberOfStores" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_a9962102-1d0a-4381-8a15-81c9855d7f5b_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_387858a2-6af8-4362-8cf2-8cf4eb414459_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_InvestmentDeposit_64b3afd7-8486-4ce0-973b-bca3a39f6107_terseLabel_en-US" xlink:label="lab_ameh_InvestmentDeposit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment deposit</link:label>
    <link:label id="lab_ameh_InvestmentDeposit_label_en-US" xlink:label="lab_ameh_InvestmentDeposit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Deposit</link:label>
    <link:label id="lab_ameh_InvestmentDeposit_documentation_en-US" xlink:label="lab_ameh_InvestmentDeposit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Deposit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InvestmentDeposit" xlink:href="ameh-20200630.xsd#ameh_InvestmentDeposit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_InvestmentDeposit" xlink:to="lab_ameh_InvestmentDeposit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_15492fbd-5e20-44f4-9e4d-c6294330a9fa_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_BrightHealthCompanyOfCaliforniaInc.Member_b8ba31ae-1e8a-421c-aae1-1271ae927f07_terseLabel_en-US" xlink:label="lab_ameh_BrightHealthCompanyOfCaliforniaInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bright</link:label>
    <link:label id="lab_ameh_BrightHealthCompanyOfCaliforniaInc.Member_label_en-US" xlink:label="lab_ameh_BrightHealthCompanyOfCaliforniaInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bright Health Company Of California, Inc. [Member]</link:label>
    <link:label id="lab_ameh_BrightHealthCompanyOfCaliforniaInc.Member_documentation_en-US" xlink:label="lab_ameh_BrightHealthCompanyOfCaliforniaInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bright Health Company Of California, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BrightHealthCompanyOfCaliforniaInc.Member" xlink:href="ameh-20200630.xsd#ameh_BrightHealthCompanyOfCaliforniaInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_BrightHealthCompanyOfCaliforniaInc.Member" xlink:to="lab_ameh_BrightHealthCompanyOfCaliforniaInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_9af84e76-5276-479c-808c-8067d9b35475_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_3b902ad1-cbf5-4cc9-a7cf-d920174ff427_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Finance Lease Payments After Adoption of 842</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ContractWithCustomerLiabilityRepaidCapitationReceivedAndNotEarned_d230c413-e695-483a-b6cd-b0c522586c46_terseLabel_en-US" xlink:label="lab_ameh_ContractWithCustomerLiabilityRepaidCapitationReceivedAndNotEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liability repaid, capitation received and not earned</link:label>
    <link:label id="lab_ameh_ContractWithCustomerLiabilityRepaidCapitationReceivedAndNotEarned_label_en-US" xlink:label="lab_ameh_ContractWithCustomerLiabilityRepaidCapitationReceivedAndNotEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Repaid Capitation Received And Not Earned</link:label>
    <link:label id="lab_ameh_ContractWithCustomerLiabilityRepaidCapitationReceivedAndNotEarned_documentation_en-US" xlink:label="lab_ameh_ContractWithCustomerLiabilityRepaidCapitationReceivedAndNotEarned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Repaid, Capitation Received And Not Earned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContractWithCustomerLiabilityRepaidCapitationReceivedAndNotEarned" xlink:href="ameh-20200630.xsd#ameh_ContractWithCustomerLiabilityRepaidCapitationReceivedAndNotEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ContractWithCustomerLiabilityRepaidCapitationReceivedAndNotEarned" xlink:to="lab_ameh_ContractWithCustomerLiabilityRepaidCapitationReceivedAndNotEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReinsuranceRecoverables_5178ff13-868d-4caa-8b3e-a83eebeccbd3_terseLabel_en-US" xlink:label="lab_us-gaap_ReinsuranceRecoverables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recoverable claims paid</link:label>
    <link:label id="lab_us-gaap_ReinsuranceRecoverables_label_en-US" xlink:label="lab_us-gaap_ReinsuranceRecoverables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance Recoverables, Including Reinsurance Premium Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverables" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReinsuranceRecoverables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReinsuranceRecoverables" xlink:to="lab_us-gaap_ReinsuranceRecoverables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_c019a119-ab04-4ea3-96f1-19befb2caee7_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_28fb61de-02a9-4236-9262-a41305dbb953_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_55e6e62d-cae8-4501-829b-bf4a82bde88e_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_632738c8-dfcf-4efb-a011-79d4b22b1732_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_6bf0855b-21fd-444d-9da4-44ed0f08f20a_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AlphaCareMedicalGroupInc.Member_a6dec1e4-f368-4c2d-a73e-9d5bf6a0c2f8_terseLabel_en-US" xlink:label="lab_ameh_AlphaCareMedicalGroupInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alpha Care Medical Group, Inc.</link:label>
    <link:label id="lab_ameh_AlphaCareMedicalGroupInc.Member_label_en-US" xlink:label="lab_ameh_AlphaCareMedicalGroupInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alpha Care Medical Group, Inc. [Member]</link:label>
    <link:label id="lab_ameh_AlphaCareMedicalGroupInc.Member_documentation_en-US" xlink:label="lab_ameh_AlphaCareMedicalGroupInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alpha Care Medical Group, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlphaCareMedicalGroupInc.Member" xlink:href="ameh-20200630.xsd#ameh_AlphaCareMedicalGroupInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AlphaCareMedicalGroupInc.Member" xlink:to="lab_ameh_AlphaCareMedicalGroupInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CollegeStreetInvestmentLpMember_bff73ad8-5fb4-4d71-be8e-6468b85c9cb9_terseLabel_en-US" xlink:label="lab_ameh_CollegeStreetInvestmentLpMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">College Street Investment LP</link:label>
    <link:label id="lab_ameh_CollegeStreetInvestmentLpMember_label_en-US" xlink:label="lab_ameh_CollegeStreetInvestmentLpMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">College Street Investment LP [Member]</link:label>
    <link:label id="lab_ameh_CollegeStreetInvestmentLpMember_documentation_en-US" xlink:label="lab_ameh_CollegeStreetInvestmentLpMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">College Street Investment LP [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CollegeStreetInvestmentLpMember" xlink:href="ameh-20200630.xsd#ameh_CollegeStreetInvestmentLpMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CollegeStreetInvestmentLpMember" xlink:to="lab_ameh_CollegeStreetInvestmentLpMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_3e29fa5e-bdd0-432d-bfcc-cbe12ef72e21_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_335bf063-acf9-4bed-bcc0-fee5764daefb_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued contract liability recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromCollectionOfLoansReceivable_65fec8b9-47ee-4357-b55e-4b7f21b288f8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromCollectionOfLoansReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from repayment of loans receivable &#8211; related parties</link:label>
    <link:label id="lab_us-gaap_ProceedsFromCollectionOfLoansReceivable_label_en-US" xlink:label="lab_us-gaap_ProceedsFromCollectionOfLoansReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Collection of Loans Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfLoansReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollectionOfLoansReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromCollectionOfLoansReceivable" xlink:to="lab_us-gaap_ProceedsFromCollectionOfLoansReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6ad9f21a-bb7c-4f85-972f-87c518c98f83_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_aba6e373-c908-498f-b818-5c771a045b77_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_499ee75f-e751-4651-b5ea-511261a5d496_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related investment balance</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:href="ameh-20200630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2398022d-fb9a-402a-acf8-94760d1bf046_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant date fair value of restricted stock to be recognized straight-line</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares_8a47c7f4-be07-4a00-acc8-af374aa27701_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Membership interests purchased (in shares)</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Purchase Of Shares</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Purchase Of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" xlink:href="ameh-20200630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_IncreaseDecreaseInOperatingLeaseAssets_f1fb2a39-029d-44f3-88e3-0e24f63a63f7_verboseLabel_en-US" xlink:label="lab_ameh_IncreaseDecreaseInOperatingLeaseAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_ameh_IncreaseDecreaseInOperatingLeaseAssets_label_en-US" xlink:label="lab_ameh_IncreaseDecreaseInOperatingLeaseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Assets</link:label>
    <link:label id="lab_ameh_IncreaseDecreaseInOperatingLeaseAssets_documentation_en-US" xlink:label="lab_ameh_IncreaseDecreaseInOperatingLeaseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents increase in operating lease assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInOperatingLeaseAssets" xlink:href="ameh-20200630.xsd#ameh_IncreaseDecreaseInOperatingLeaseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_IncreaseDecreaseInOperatingLeaseAssets" xlink:to="lab_ameh_IncreaseDecreaseInOperatingLeaseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_53e2d5ac-da85-447a-bc0d-57bee86fd3bf_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_d54785bd-cb84-4683-9ad9-790b99e7d438_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_e48e3af1-6435-4e5e-bc4e-3f0e10c9cbce_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_417d1a5d-88fe-4408-bc06-778c49beb72e_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_84b562e8-bc42-4a99-94a8-c50bbd743001_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by (used in) operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue_e9878bb1-e652-45cc-a366-11a91e0f04f2_terseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration, fair value</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Sale, Contingent Consideration, Fair Value</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Sale, Contingent Consideration, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue" xlink:href="ameh-20200630.xsd#ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue" xlink:to="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod_4ce9495f-27f8-411b-a4cb-10e2d755c543_verboseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants granted (in dollars per share)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod_label_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants, Grant In Period</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price per share of warrants or rights granted during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" xlink:href="ameh-20200630.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" xlink:to="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LoanReceivableTextBlock_edbba9ca-25b1-4311-b583-e42989c40efe_verboseLabel_en-US" xlink:label="lab_ameh_LoanReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Receivable and Loan Receivable &#8211; Related Parties</link:label>
    <link:label id="lab_ameh_LoanReceivableTextBlock_label_en-US" xlink:label="lab_ameh_LoanReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Receivable [Text Block]</link:label>
    <link:label id="lab_ameh_LoanReceivableTextBlock_documentation_en-US" xlink:label="lab_ameh_LoanReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LoanReceivableTextBlock" xlink:href="ameh-20200630.xsd#ameh_LoanReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LoanReceivableTextBlock" xlink:to="lab_ameh_LoanReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_ed75e1d7-da55-455a-8c9a-479bf1710cdd_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total paid</link:label>
    <link:label id="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:to="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_HealthSourceMSOInc.Member_8bbf67fd-978c-443a-b4a6-5c90f261bf67_terseLabel_en-US" xlink:label="lab_ameh_HealthSourceMSOInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Source MSO Inc.</link:label>
    <link:label id="lab_ameh_HealthSourceMSOInc.Member_label_en-US" xlink:label="lab_ameh_HealthSourceMSOInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Source MSO Inc. [Member]</link:label>
    <link:label id="lab_ameh_HealthSourceMSOInc.Member_documentation_en-US" xlink:label="lab_ameh_HealthSourceMSOInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Source MSO Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_HealthSourceMSOInc.Member" xlink:href="ameh-20200630.xsd#ameh_HealthSourceMSOInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_HealthSourceMSOInc.Member" xlink:to="lab_ameh_HealthSourceMSOInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NumenLLCMember_5a738745-3d7f-434c-a948-ff1bfd0d5fd2_terseLabel_en-US" xlink:label="lab_ameh_NumenLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numen LLC</link:label>
    <link:label id="lab_ameh_NumenLLCMember_label_en-US" xlink:label="lab_ameh_NumenLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numen LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumenLLCMember" xlink:href="ameh-20200630.xsd#ameh_NumenLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NumenLLCMember" xlink:to="lab_ameh_NumenLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CommitmentsAndContingenciesLineItems_03e68bef-c928-4e86-bf8f-27ce960adc98_terseLabel_en-US" xlink:label="lab_ameh_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:label id="lab_ameh_CommitmentsAndContingenciesLineItems_label_en-US" xlink:label="lab_ameh_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommitmentsAndContingenciesLineItems" xlink:href="ameh-20200630.xsd#ameh_CommitmentsAndContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems" xlink:to="lab_ameh_CommitmentsAndContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_7148fbbf-513f-486b-a1ed-2be03399b110_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount outstanding</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_SCHCMember_c5d4931d-25d4-4a9c-9d11-413ed0a28ae9_terseLabel_en-US" xlink:label="lab_ameh_SCHCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SCHC</link:label>
    <link:label id="lab_ameh_SCHCMember_label_en-US" xlink:label="lab_ameh_SCHCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SCHC [Member]</link:label>
    <link:label id="lab_ameh_SCHCMember_documentation_en-US" xlink:label="lab_ameh_SCHCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SCHC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SCHCMember" xlink:href="ameh-20200630.xsd#ameh_SCHCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_SCHCMember" xlink:to="lab_ameh_SCHCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AntidilutiveSecuritiesExcludedFromEarningsComputationShares_52cbc9f2-af52-4965-88fa-55f29afcb98a_terseLabel_en-US" xlink:label="lab_ameh_AntidilutiveSecuritiesExcludedFromEarningsComputationShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury shares not included in the calculation of earnings per share (in shares)</link:label>
    <link:label id="lab_ameh_AntidilutiveSecuritiesExcludedFromEarningsComputationShares_label_en-US" xlink:label="lab_ameh_AntidilutiveSecuritiesExcludedFromEarningsComputationShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded From Earnings Computation, Shares</link:label>
    <link:label id="lab_ameh_AntidilutiveSecuritiesExcludedFromEarningsComputationShares_documentation_en-US" xlink:label="lab_ameh_AntidilutiveSecuritiesExcludedFromEarningsComputationShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AntidilutiveSecuritiesExcludedFromEarningsComputationShares" xlink:href="ameh-20200630.xsd#ameh_AntidilutiveSecuritiesExcludedFromEarningsComputationShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AntidilutiveSecuritiesExcludedFromEarningsComputationShares" xlink:to="lab_ameh_AntidilutiveSecuritiesExcludedFromEarningsComputationShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LmaMember_6cecad16-c228-44db-b2db-768ef97adc81_terseLabel_en-US" xlink:label="lab_ameh_LmaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LMA</link:label>
    <link:label id="lab_ameh_LmaMember_label_en-US" xlink:label="lab_ameh_LmaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LMA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LmaMember" xlink:href="ameh-20200630.xsd#ameh_LmaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LmaMember" xlink:to="lab_ameh_LmaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_1c39b75f-81f4-48b3-90c5-2196bbb4800a_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets Held-for-use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_6ef49676-c8e0-4b23-98a0-fb1f7007ddb9_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts_0ebc42aa-f139-42ab-b09e-6e7e6f7baec1_terseLabel_en-US" xlink:label="lab_ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts_label_en-US" xlink:label="lab_ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion And Amortization, Excluding Amortization Of Debt Issuance Costs</link:label>
    <link:label id="lab_ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts_documentation_en-US" xlink:label="lab_ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion And Amortization, Excluding Amortization Of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts" xlink:href="ameh-20200630.xsd#ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts" xlink:to="lab_ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_41f910fa-0fc8-42fa-b682-e571803c26f6_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_e69a80ee-be49-4ddc-97fa-062aa6ccef3a_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_fd57601b-f4b1-433e-b1e0-41b087eb5802_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_e2b0b686-92d9-4f02-bdcd-93e167c04c3c_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_291193fd-0124-4eea-bba2-b4db4ced0616_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total medical care costs</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_4e80f8f3-2bb1-4028-a8b8-fd5b694f08c7_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_42e95fd1-5c48-4df2-9bcf-fe6a36bd6338_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_889d0e1c-5a6d-4ac3-b93f-4a2ea5dc295a_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_fe0d8745-c4fe-4547-a808-43bb6b0568e2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_8d14679a-400e-4e41-be6b-2013f31d28d7_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MedicareMember_eeb2116e-9b07-49a6-b066-fb4d3cd5844a_terseLabel_en-US" xlink:label="lab_ameh_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare</link:label>
    <link:label id="lab_ameh_MedicareMember_label_en-US" xlink:label="lab_ameh_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare [Member]</link:label>
    <link:label id="lab_ameh_MedicareMember_documentation_en-US" xlink:label="lab_ameh_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ameh:MedicareMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicareMember" xlink:href="ameh-20200630.xsd#ameh_MedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MedicareMember" xlink:to="lab_ameh_MedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_3ceed119-f3ed-4661-80e0-f3a20c4d13df_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CMSMember_a765521d-2f0c-483f-b07c-f470c18634a0_terseLabel_en-US" xlink:label="lab_ameh_CMSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CMS</link:label>
    <link:label id="lab_ameh_CMSMember_label_en-US" xlink:label="lab_ameh_CMSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CMS [Member]</link:label>
    <link:label id="lab_ameh_CMSMember_documentation_en-US" xlink:label="lab_ameh_CMSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CMS [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CMSMember" xlink:href="ameh-20200630.xsd#ameh_CMSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CMSMember" xlink:to="lab_ameh_CMSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_3ad85e6c-ad38-453c-b133-a056bce7a356_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredParValueMethod_876e0e95-ec23-4a67-a87e-9399f9f2a522_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredParValueMethod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of treasury shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredParValueMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredParValueMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Par Value Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredParValueMethod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredParValueMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredParValueMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredParValueMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_d9087f3a-4c9b-439e-b281-98a4e9db34f4_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">&#160;Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_d23731a4-0efc-4e03-ae3d-b11b304e22f0_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent_fecee954-3857-48ce-8617-d4e79856d567_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, net &#8211; related parties</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent_61479a93-5399-44c5-94ac-43d324f7eab4_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, net &#8211; related party</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:to="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PaymentOfRevenueMonthlyAmount_e0532e6a-8edf-4b6c-b90e-e5f40ac421f4_terseLabel_en-US" xlink:label="lab_ameh_PaymentOfRevenueMonthlyAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments received, monthly</link:label>
    <link:label id="lab_ameh_PaymentOfRevenueMonthlyAmount_label_en-US" xlink:label="lab_ameh_PaymentOfRevenueMonthlyAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Of Revenue, Monthly Amount</link:label>
    <link:label id="lab_ameh_PaymentOfRevenueMonthlyAmount_documentation_en-US" xlink:label="lab_ameh_PaymentOfRevenueMonthlyAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Of Revenue, Monthly Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentOfRevenueMonthlyAmount" xlink:href="ameh-20200630.xsd#ameh_PaymentOfRevenueMonthlyAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PaymentOfRevenueMonthlyAmount" xlink:to="lab_ameh_PaymentOfRevenueMonthlyAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_ad7db84d-5cc7-4740-adfd-48f3f428484d_verboseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Disaggregated Revenue by Each Payor Type</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_a455ab4e-e1f6-42a3-ba14-fcd4176adfee_verboseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets and Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent_76dee310-2a8d-44f4-9194-7bafa2644b8e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of subordinated note receivable agreement</link:label>
    <link:label id="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts and Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AchievaMedInc.Member_02b74ab0-c1ac-4626-9c19-24e91342a7f8_terseLabel_en-US" xlink:label="lab_ameh_AchievaMedInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AchievaMed, Inc.</link:label>
    <link:label id="lab_ameh_AchievaMedInc.Member_label_en-US" xlink:label="lab_ameh_AchievaMedInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AchievaMed, Inc. [Member]</link:label>
    <link:label id="lab_ameh_AchievaMedInc.Member_documentation_en-US" xlink:label="lab_ameh_AchievaMedInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AchievaMed, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AchievaMedInc.Member" xlink:href="ameh-20200630.xsd#ameh_AchievaMedInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AchievaMedInc.Member" xlink:to="lab_ameh_AchievaMedInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_7fa58ac6-1a56-409e-aa5f-cd1b6348400a_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in privately held entities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI and without Readily Determinable Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:to="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_8cf2e90c-1b66-4f31-96a7-5cbfbb8744ea_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_a321e138-9529-4f49-bf2c-586ed994e2c1_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_0fec88db-9b11-4195-b0c3-73c128ad560d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DebtInstrumentApprovedThresholdUseOfFunds_fa7bf2bd-3af0-4abf-8321-bf1f346336f7_terseLabel_en-US" xlink:label="lab_ameh_DebtInstrumentApprovedThresholdUseOfFunds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Approved use of funds (not to exceed)</link:label>
    <link:label id="lab_ameh_DebtInstrumentApprovedThresholdUseOfFunds_label_en-US" xlink:label="lab_ameh_DebtInstrumentApprovedThresholdUseOfFunds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Approved Threshold Use Of Funds</link:label>
    <link:label id="lab_ameh_DebtInstrumentApprovedThresholdUseOfFunds_documentation_en-US" xlink:label="lab_ameh_DebtInstrumentApprovedThresholdUseOfFunds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Approved Threshold Use Of Funds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentApprovedThresholdUseOfFunds" xlink:href="ameh-20200630.xsd#ameh_DebtInstrumentApprovedThresholdUseOfFunds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DebtInstrumentApprovedThresholdUseOfFunds" xlink:to="lab_ameh_DebtInstrumentApprovedThresholdUseOfFunds" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_WeightedaverageremainingcontractualtermyearsAbstract_75d80b10-faa6-4919-922f-407ca6aeeed2_terseLabel_en-US" xlink:label="lab_ameh_WeightedaverageremainingcontractualtermyearsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years)</link:label>
    <link:label id="lab_ameh_WeightedaverageremainingcontractualtermyearsAbstract_label_en-US" xlink:label="lab_ameh_WeightedaverageremainingcontractualtermyearsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term Years [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WeightedaverageremainingcontractualtermyearsAbstract" xlink:href="ameh-20200630.xsd#ameh_WeightedaverageremainingcontractualtermyearsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_WeightedaverageremainingcontractualtermyearsAbstract" xlink:to="lab_ameh_WeightedaverageremainingcontractualtermyearsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_b75bcf94-67f8-48c1-8b8d-1c6bb64d2d38_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_47766962-f025-4d5a-92eb-0d12cc762f33_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesReceivableRelatedPartiesCurrent_deb04ada-c913-4d39-837f-200d6a9f1ada_terseLabel_en-US" xlink:label="lab_us-gaap_NotesReceivableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans receivable &#8211; related parties</link:label>
    <link:label id="lab_us-gaap_NotesReceivableRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_NotesReceivableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Receivable, Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesReceivableRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReceivableRelatedPartiesCurrent" xlink:to="lab_us-gaap_NotesReceivableRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_d837c1c2-999f-4405-9fe7-ffe731654ec5_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_19a1d254-f947-4979-bdeb-cc50f9e72e23_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_c6a68697-2666-458d-979b-99ba55fbdb78_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan proceeds</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_49f91be2-b763-4b8a-bd36-80215f2eb74d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_c9e49884-778f-49c1-ab81-7e017fae2779_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_567854b1-1d84-407f-aa42-7929276ee65a_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of services</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_75cc49e6-c05e-4027-a991-9f08b22e08bb_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_edd663c2-2da4-4e8f-8325-d3f7780a21a9_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_9efd5fde-b310-4c96-ab22-19826eff3a74_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_b01070b2-c08f-474f-923a-845a0fcddfba_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesAbstract_496107b1-5188-4559-8140-24c4b2d1e7e2_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables [Abstract]</link:label>
    <link:label id="lab_us-gaap_ReceivablesAbstract_label_en-US" xlink:label="lab_us-gaap_ReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesAbstract" xlink:to="lab_us-gaap_ReceivablesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_4d2098b0-d014-40f1-a63b-92332e205f8b_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_4fee2732-7be5-48c1-a366-36950a8b8be6_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PayorDMember_c7c2f889-97c9-43f9-a99f-6fc2e4b90570_terseLabel_en-US" xlink:label="lab_ameh_PayorDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor D</link:label>
    <link:label id="lab_ameh_PayorDMember_label_en-US" xlink:label="lab_ameh_PayorDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor D [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorDMember" xlink:href="ameh-20200630.xsd#ameh_PayorDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PayorDMember" xlink:to="lab_ameh_PayorDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_39e6028b-d2dd-44a1-9732-37df7afc12f0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land, property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_66d6f74f-5413-4105-9674-b3754fada212_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_528249b6-f193-4e04-bb11-ce45afe5c9b0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_UniversalCareAcquisitionPartnersLlcMember_5c683396-62df-4786-80a6-d4a746584dcc_terseLabel_en-US" xlink:label="lab_ameh_UniversalCareAcquisitionPartnersLlcMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Universal Care Acquisition Partners, LLC</link:label>
    <link:label id="lab_ameh_UniversalCareAcquisitionPartnersLlcMember_label_en-US" xlink:label="lab_ameh_UniversalCareAcquisitionPartnersLlcMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Universal Care Acquisition Partners, LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareAcquisitionPartnersLlcMember" xlink:href="ameh-20200630.xsd#ameh_UniversalCareAcquisitionPartnersLlcMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_UniversalCareAcquisitionPartnersLlcMember" xlink:to="lab_ameh_UniversalCareAcquisitionPartnersLlcMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NumberOfFederallyQualifiedHealthPlans_8cd900f9-3694-429b-a1fa-2877138b0b3e_terseLabel_en-US" xlink:label="lab_ameh_NumberOfFederallyQualifiedHealthPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number federally qualified health plans</link:label>
    <link:label id="lab_ameh_NumberOfFederallyQualifiedHealthPlans_label_en-US" xlink:label="lab_ameh_NumberOfFederallyQualifiedHealthPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Federally Qualified Health Plans</link:label>
    <link:label id="lab_ameh_NumberOfFederallyQualifiedHealthPlans_documentation_en-US" xlink:label="lab_ameh_NumberOfFederallyQualifiedHealthPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Federally Qualified Health Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfFederallyQualifiedHealthPlans" xlink:href="ameh-20200630.xsd#ameh_NumberOfFederallyQualifiedHealthPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NumberOfFederallyQualifiedHealthPlans" xlink:to="lab_ameh_NumberOfFederallyQualifiedHealthPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_9397913b-05d1-4673-8bf4-29eb89dfa559_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_73e35dcf-e932-4733-ad2b-828c68e4cae6_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d761449d-25e9-4c26-8500-d92ab629b17f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_040ae84b-d39d-4ca7-864d-b79125b21c82_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9457f3bb-32a7-4d43-93e2-e0132cdd121f_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2cb4a0b2-e213-424a-8612-77eaee93fa8c_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mezzanine and Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_44781f61-c396-4f90-8b5c-3dbe23c95f04_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option Transactions Under Stock Option Plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_WarrantExercisePriceRangeThreeMember_81794883-c444-4fe3-9b57-4614c9f817f1_verboseLabel_en-US" xlink:label="lab_ameh_WarrantExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Exercise Price Range Three</link:label>
    <link:label id="lab_ameh_WarrantExercisePriceRangeThreeMember_label_en-US" xlink:label="lab_ameh_WarrantExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Exercise Price Range Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeThreeMember" xlink:href="ameh-20200630.xsd#ameh_WarrantExercisePriceRangeThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_WarrantExercisePriceRangeThreeMember" xlink:to="lab_ameh_WarrantExercisePriceRangeThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_4c0fdad6-9baa-4425-920e-eea7860c4f16_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Required annual facility fee</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantOrRightIssuedInPeriod_fa63480d-63b7-47b7-9bb2-9cf912933686_verboseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Outstanding (in shares)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightIssuedInPeriod_label_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Issued In Period</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightIssuedInPeriod_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightIssuedInPeriod" xlink:href="ameh-20200630.xsd#ameh_ClassOfWarrantOrRightIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantOrRightIssuedInPeriod" xlink:to="lab_ameh_ClassOfWarrantOrRightIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_8d182e14-dfee-43a7-acf2-a5f0d0b658cd_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 (excluding the six months ended June 30, 2020)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_79e61781-b067-488c-a424-b01ab13195a5_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseRenewalTerm1_5a16257c-a296-4fd6-88ca-ddeac5ac95a6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease option to extend (up to)</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseRenewalTerm1_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:to="lab_us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_d609de76-186c-4730-adce-66a06ceb9d8c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ManagementFeeExpense_68f671b2-eb04-4920-90a2-039e92230929_negatedLabel_en-US" xlink:label="lab_us-gaap_ManagementFeeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management fees</link:label>
    <link:label id="lab_us-gaap_ManagementFeeExpense_label_en-US" xlink:label="lab_us-gaap_ManagementFeeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management Fee Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementFeeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ManagementFeeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ManagementFeeExpense" xlink:to="lab_us-gaap_ManagementFeeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_dc747574-754d-4af6-8e5c-636c8ced18eb_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_63c7407f-6702-446c-bdea-57644df110e3_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_c663bf54-0781-4b28-897d-675b53577c75_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_4eb0fff9-9096-446f-833b-aba51cc31b5c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LeaseWeightedAverageDiscountRateAbstract_a1baff95-0949-493e-9c8d-59e3d07f56e7_verboseLabel_en-US" xlink:label="lab_ameh_LeaseWeightedAverageDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Discount Rate</link:label>
    <link:label id="lab_ameh_LeaseWeightedAverageDiscountRateAbstract_label_en-US" xlink:label="lab_ameh_LeaseWeightedAverageDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Weighted Average Discount Rate [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LeaseWeightedAverageDiscountRateAbstract" xlink:href="ameh-20200630.xsd#ameh_LeaseWeightedAverageDiscountRateAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LeaseWeightedAverageDiscountRateAbstract" xlink:to="lab_ameh_LeaseWeightedAverageDiscountRateAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_39700dbe-fc6c-42fa-8747-67bdab51c9c0_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_534ee939-52d2-4e63-8a64-a08f79f229e2_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_47f5b0e6-5bb0-48cd-9cde-6106a0533e08_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_ccdbcb35-c8a8-47c5-a394-52430a9ba30b_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_cb696bec-b305-4c11-abae-55768238d7aa_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod_42fc4ce1-9790-48e4-a180-e828b70bcac7_terseLabel_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in shares)</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod_label_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based Compensation Arrangement By Share based Payment Award Cashless Options Exercises In Period</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod_documentation_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based Compensation Arrangement By Share based Payment Award Cashless Options Exercises In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod" xlink:href="ameh-20200630.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod" xlink:to="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EarningsPerShareLineItems_af344283-738f-43d6-959c-31dd2461b7e9_terseLabel_en-US" xlink:label="lab_ameh_EarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_ameh_EarningsPerShareLineItems_label_en-US" xlink:label="lab_ameh_EarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_ameh_EarningsPerShareLineItems_documentation_en-US" xlink:label="lab_ameh_EarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EarningsPerShareLineItems" xlink:href="ameh-20200630.xsd#ameh_EarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EarningsPerShareLineItems" xlink:to="lab_ameh_EarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_7308ff55-619d-4666-bac4-30efdab153c9_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Contributions to Revenue and Receivables by Payor</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToAffiliateCurrent_641dd4e8-2e3b-452d-92fd-05c94d572587_terseLabel_en-US" xlink:label="lab_us-gaap_DueToAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount due to affiliate</link:label>
    <link:label id="lab_us-gaap_DueToAffiliateCurrent_label_en-US" xlink:label="lab_us-gaap_DueToAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Affiliate, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToAffiliateCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToAffiliateCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToAffiliateCurrent" xlink:to="lab_us-gaap_DueToAffiliateCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_5f3b3786-23b0-4bea-b728-5cc906336c2b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_183058c6-26ee-4829-9cdd-b43642a5e8fd_terseLabel_en-US" xlink:label="lab_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:label id="lab_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:href="ameh-20200630.xsd#ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_0c736956-128f-45bc-902e-85674824576c_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_WorkingCapitalContribution_30d92b0a-f29b-475e-8f45-6257dae0fade_terseLabel_en-US" xlink:label="lab_ameh_WorkingCapitalContribution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working capital contribution</link:label>
    <link:label id="lab_ameh_WorkingCapitalContribution_label_en-US" xlink:label="lab_ameh_WorkingCapitalContribution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working Capital Contribution</link:label>
    <link:label id="lab_ameh_WorkingCapitalContribution_documentation_en-US" xlink:label="lab_ameh_WorkingCapitalContribution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This item represents the working capital contribution in equity method investee.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WorkingCapitalContribution" xlink:href="ameh-20200630.xsd#ameh_WorkingCapitalContribution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_WorkingCapitalContribution" xlink:to="lab_ameh_WorkingCapitalContribution" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_561fa0a5-8ee0-49de-9e66-37fcb865f544_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_cf2d6546-865d-4f95-a4cb-7272e7d2855a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_3c9f6137-69e4-4dad-8d0d-85bff7e87ea7_negatedLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior periods</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_1e669018-ab46-43af-9bd1-267d0a16bdb5_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract term</link:label>
    <link:label id="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_label_en-US" xlink:label="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Description of Timing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfTiming"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:to="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesAndLoansReceivableNetCurrent_fc0cd16c-8fa3-4319-b271-a8619836e68d_terseLabel_en-US" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans receivable</link:label>
    <link:label id="lab_us-gaap_NotesAndLoansReceivableNetCurrent_e4c92394-95a8-43a3-bce2-6a5b8701bfc3_verboseLabel_en-US" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan receivable</link:label>
    <link:label id="lab_us-gaap_NotesAndLoansReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:to="lab_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationCash_d70a04cf-32cb-48ca-9a24-ab7b4cdc1c18_terseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration, cash held in escrow</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationCash_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Sale, Contingent Consideration, Cash</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationCash_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Sale, Contingent Consideration, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationCash" xlink:href="ameh-20200630.xsd#ameh_EquityMethodInvestmentSaleContingentConsiderationCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationCash" xlink:to="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_2f4d1563-a499-4979-bc1d-5db362c56a79_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_cd23d9ee-fb4d-44f1-b166-0958eeecfee1_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share &#8211; basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3e1ba4ea-d0ea-44ec-a089-e24e0e51e802_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_dcd0022c-67f2-41bd-aa92-d02044686302_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract_26f2eb23-efc9-4b9c-81c3-c47d5eb0f955_verboseLabel_en-US" xlink:label="lab_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Lease Term</link:label>
    <link:label id="lab_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract_label_en-US" xlink:label="lab_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Weighted Average Remaining Lease Term [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract" xlink:href="ameh-20200630.xsd#ameh_LeaseWeightedAverageRemainingLeaseTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract" xlink:to="lab_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_f390e555-7d50-437b-aef2-fcac1e2985fd_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NextGenerationACOModelParticipationAgreementMember_ba6a6712-eb0b-4a9f-a34a-b0801a81b255_terseLabel_en-US" xlink:label="lab_ameh_NextGenerationACOModelParticipationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Next Generation ACO Model Participation Agreement</link:label>
    <link:label id="lab_ameh_NextGenerationACOModelParticipationAgreementMember_label_en-US" xlink:label="lab_ameh_NextGenerationACOModelParticipationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Next Generation ACO Model Participation Agreement [Member]</link:label>
    <link:label id="lab_ameh_NextGenerationACOModelParticipationAgreementMember_documentation_en-US" xlink:label="lab_ameh_NextGenerationACOModelParticipationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Next Generation ACO Model Participation Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NextGenerationACOModelParticipationAgreementMember" xlink:href="ameh-20200630.xsd#ameh_NextGenerationACOModelParticipationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NextGenerationACOModelParticipationAgreementMember" xlink:to="lab_ameh_NextGenerationACOModelParticipationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PaymentPeriodThreeMember_0fd63148-1989-433a-9c83-8f953c48336c_terseLabel_en-US" xlink:label="lab_ameh_PaymentPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Following Three Fiscal Quarters Thereafter</link:label>
    <link:label id="lab_ameh_PaymentPeriodThreeMember_label_en-US" xlink:label="lab_ameh_PaymentPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Period Three [Member]</link:label>
    <link:label id="lab_ameh_PaymentPeriodThreeMember_documentation_en-US" xlink:label="lab_ameh_PaymentPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Period Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentPeriodThreeMember" xlink:href="ameh-20200630.xsd#ameh_PaymentPeriodThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PaymentPeriodThreeMember" xlink:to="lab_ameh_PaymentPeriodThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PayorBMember_4c44fe2a-8c2b-4f35-a08b-f6121d8463e5_terseLabel_en-US" xlink:label="lab_ameh_PayorBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor B</link:label>
    <link:label id="lab_ameh_PayorBMember_label_en-US" xlink:label="lab_ameh_PayorBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor B [Member]</link:label>
    <link:label id="lab_ameh_PayorBMember_documentation_en-US" xlink:label="lab_ameh_PayorBMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor B [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorBMember" xlink:href="ameh-20200630.xsd#ameh_PayorBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PayorBMember" xlink:to="lab_ameh_PayorBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_9ce3b9f4-eb7a-482a-85d9-0dc3a8d13172_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants_68c5349f-d67a-45e4-af42-b1c4cae13961_verboseLabel_en-US" xlink:label="lab_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for exercise of options and warrants</link:label>
    <link:label id="lab_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants_label_en-US" xlink:label="lab_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued during the period value of exercise of option and warrants</link:label>
    <link:label id="lab_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants_documentation_en-US" xlink:label="lab_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">It represents value of stock issued during the period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" xlink:href="ameh-20200630.xsd#ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" xlink:to="lab_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NumberOfWarrantsExercised_f87891dd-ce11-467a-b615-dbfb7e9d2f4b_negatedLabel_en-US" xlink:label="lab_ameh_NumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercised (in shares)</link:label>
    <link:label id="lab_ameh_NumberOfWarrantsExercised_label_en-US" xlink:label="lab_ameh_NumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Warrants Exercised</link:label>
    <link:label id="lab_ameh_NumberOfWarrantsExercised_documentation_en-US" xlink:label="lab_ameh_NumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of warrants exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfWarrantsExercised" xlink:href="ameh-20200630.xsd#ameh_NumberOfWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NumberOfWarrantsExercised" xlink:to="lab_ameh_NumberOfWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_38a2865d-729b-4a05-bd6e-b09a0f933d75_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_b1087478-0c94-411e-bdbb-b58ed4534aa7_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of finite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Finite-lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_35ac4645-2513-44ad-8338-5dd8cd1cdd02_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LineOfCreditFacilityExpirationPeriodPeriodOfNotification_8423303e-ee25-4eee-bed8-eb9a1e53c38e_terseLabel_en-US" xlink:label="lab_ameh_LineOfCreditFacilityExpirationPeriodPeriodOfNotification" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of notification of termination</link:label>
    <link:label id="lab_ameh_LineOfCreditFacilityExpirationPeriodPeriodOfNotification_label_en-US" xlink:label="lab_ameh_LineOfCreditFacilityExpirationPeriodPeriodOfNotification" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Expiration Period, Period Of Notification</link:label>
    <link:label id="lab_ameh_LineOfCreditFacilityExpirationPeriodPeriodOfNotification_documentation_en-US" xlink:label="lab_ameh_LineOfCreditFacilityExpirationPeriodPeriodOfNotification" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Expiration Period, Period Of Notification</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LineOfCreditFacilityExpirationPeriodPeriodOfNotification" xlink:href="ameh-20200630.xsd#ameh_LineOfCreditFacilityExpirationPeriodPeriodOfNotification"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LineOfCreditFacilityExpirationPeriodPeriodOfNotification" xlink:to="lab_ameh_LineOfCreditFacilityExpirationPeriodPeriodOfNotification" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_731ed8b9-12cc-42a4-bd7d-057bc14a8417_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_c56cb4b5-227b-4d0e-9d2c-c4dd5960a901_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityExpirationPeriod_78460da9-9b77-4df9-8576-7778e6d2e60f_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of facility</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:to="lab_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_OtherReceivablesMember_04ce3cdd-a747-4739-b563-9f242f83478a_terseLabel_en-US" xlink:label="lab_ameh_OtherReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables</link:label>
    <link:label id="lab_ameh_OtherReceivablesMember_label_en-US" xlink:label="lab_ameh_OtherReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OtherReceivablesMember" xlink:href="ameh-20200630.xsd#ameh_OtherReceivablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_OtherReceivablesMember" xlink:to="lab_ameh_OtherReceivablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_25ffe4b6-4a7a-43e6-9ba6-0a311bcb8b84_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_label_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableTypeDomain" xlink:to="lab_us-gaap_ReceivableTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_SpecialtyCapitationPayableCurrent_45821e79-6b79-42e9-8e55-4e59e919ce18_verboseLabel_en-US" xlink:label="lab_ameh_SpecialtyCapitationPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitation payable</link:label>
    <link:label id="lab_ameh_SpecialtyCapitationPayableCurrent_label_en-US" xlink:label="lab_ameh_SpecialtyCapitationPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Specialty Capitation Payable Current</link:label>
    <link:label id="lab_ameh_SpecialtyCapitationPayableCurrent_documentation_en-US" xlink:label="lab_ameh_SpecialtyCapitationPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the amount of specialty capitation payable current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SpecialtyCapitationPayableCurrent" xlink:href="ameh-20200630.xsd#ameh_SpecialtyCapitationPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_SpecialtyCapitationPayableCurrent" xlink:to="lab_ameh_SpecialtyCapitationPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_52a5285e-b04d-40b2-ab83-120b93b235e7_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_3382eabb-a7d6-4d85-8c9e-dcfb34601c25_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_dc8f806b-3a79-46dd-9adf-590dcd467a1c_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_5a233776-59d6-4d6d-a53c-b9366a3096fa_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bc71e722-792a-4d1c-981e-8211a8408a1c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_71602cb6-3e7b-4806-b65d-569aaf9e6d0c_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_97e27435-e90e-4c1f-a472-3dedfb846854_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest in Allied Physicians of California, a Professional Medical Corporation</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_b71d0e05-5187-461d-a4fa-3afe14a2243f_periodStartLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_4ac75be4-9413-47f0-a7d9-c3195dc87fa0_periodEndLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, ending balance (in dollars per share)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_3e3fbda5-e0c4-4da0-a261-48f2f16cf537_terseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise&#160;Price Per Share (in dollars per share)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_label_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" xlink:href="ameh-20200630.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" xlink:to="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue_a653d0fb-6a5b-4ed3-b660-74f1dd23c675_verboseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants granted</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue_label_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Grant In Period, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of warrants or rights granted in period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" xlink:href="ameh-20200630.xsd#ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" xlink:to="lab_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_127c2709-7dae-4443-9908-c97630781493_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FiveThreeOneW.CollegeLLCMember_8bf4ab10-f9ff-4176-bb63-f4ae6f4dba14_verboseLabel_en-US" xlink:label="lab_ameh_FiveThreeOneW.CollegeLLCMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">531 W. College, LLC &#8211; related party</link:label>
    <link:label id="lab_ameh_FiveThreeOneW.CollegeLLCMember_60c50d00-f761-453a-8a6a-c049dfa352a8_terseLabel_en-US" xlink:label="lab_ameh_FiveThreeOneW.CollegeLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">513 W. College LLC</link:label>
    <link:label id="lab_ameh_FiveThreeOneW.CollegeLLCMember_label_en-US" xlink:label="lab_ameh_FiveThreeOneW.CollegeLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Three One W. College LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiveThreeOneW.CollegeLLCMember" xlink:href="ameh-20200630.xsd#ameh_FiveThreeOneW.CollegeLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FiveThreeOneW.CollegeLLCMember" xlink:to="lab_ameh_FiveThreeOneW.CollegeLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HealthCareOtherMember_0ed58240-21ad-4466-aab9-fe1a05f33569_terseLabel_en-US" xlink:label="lab_us-gaap_HealthCareOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk pool settlements and incentives</link:label>
    <link:label id="lab_us-gaap_HealthCareOtherMember_label_en-US" xlink:label="lab_us-gaap_HealthCareOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOtherMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareOtherMember" xlink:to="lab_us-gaap_HealthCareOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_c347e849-5d0f-430e-a02b-b88a73669403_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities, mezzanine equity and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_38b57ba6-b100-479c-8c1b-9d8213a2a1d4_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_5e9cad00-cb2b-4d57-a1b6-c6b238f023e0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_3548c4ee-5eb1-4921-a081-3305e597e6f6_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_8b81a1ed-de4e-45fa-b8e6-f04e9ed3f5f1_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_13ea6428-3ecc-47e1-b59b-8d651348c1c3_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_ba5dca0a-c730-4e7d-8935-4cd1ade355c4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesReceivableNet_f4e54683-5529-4c65-ad62-ebc9504a796c_terseLabel_en-US" xlink:label="lab_us-gaap_NotesReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of loan</link:label>
    <link:label id="lab_us-gaap_NotesReceivableNet_label_en-US" xlink:label="lab_us-gaap_NotesReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReceivableNet" xlink:to="lab_us-gaap_NotesReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_0bf58fce-9ecd-460b-8430-a6b82131bca9_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_APCAndAPCLSMAMember_d56f1c6b-6a5a-4cba-b791-c46df0519622_terseLabel_en-US" xlink:label="lab_ameh_APCAndAPCLSMAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC and APC-LSMA</link:label>
    <link:label id="lab_ameh_APCAndAPCLSMAMember_label_en-US" xlink:label="lab_ameh_APCAndAPCLSMAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC And APC-LSMA [Member]</link:label>
    <link:label id="lab_ameh_APCAndAPCLSMAMember_documentation_en-US" xlink:label="lab_ameh_APCAndAPCLSMAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC And APC-LSMA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_APCAndAPCLSMAMember" xlink:href="ameh-20200630.xsd#ameh_APCAndAPCLSMAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_APCAndAPCLSMAMember" xlink:to="lab_ameh_APCAndAPCLSMAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_fc16fa6d-5b4b-4001-a6ec-970119724413_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_acbc94b6-ed2c-41d5-b153-3b353b34a7c8_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_8bd2b546-3d1e-4b80-b2b2-e1601dcea68b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful Life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_c53a1a78-24dc-4c55-a92a-0e986e0d4f55_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_4136a221-108a-4920-9c39-f4dac11ce9f5_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Axis]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:to="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DebtInstrumentCovenantLeverageRatioMinimum_a2e3c26f-b52f-41f2-86b4-765cb23f3d0c_terseLabel_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantLeverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated leverage ratio minimum</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantLeverageRatioMinimum_label_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantLeverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio, Minimum</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantLeverageRatioMinimum_documentation_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantLeverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantLeverageRatioMinimum" xlink:href="ameh-20200630.xsd#ameh_DebtInstrumentCovenantLeverageRatioMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DebtInstrumentCovenantLeverageRatioMinimum" xlink:to="lab_ameh_DebtInstrumentCovenantLeverageRatioMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_587397a5-05ab-4a8b-a358-ce56ba2964f0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land, property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_21515ac1-1bb4-4492-bdf6-dc20e16365ca_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_b960f872-26c0-4bc7-aa96-e4f0cae95cba_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Apollo Medical Holdings, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_07e65c1f-ddc1-424e-b412-acc010aaeb48_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities, net of business combinations:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_a82dfd9d-e05f-4272-ab68-b5fa5aa3cd5c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_91fee719-9065-4cd0-a4b2-a57a1bc560eb_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR)</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_c97e7322-d116-4bea-b3a3-81496b5901da_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_5cdd3ab7-ece1-4d81-99e7-686fe07fd630_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_4ca68d1c-2c92-497f-90cf-0cd5988f603f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Network relationship intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_4ca989de-d941-4b62-8e18-14ada2c8b29d_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of warrants received (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7bd187be-4247-496b-a503-4563a2aa7b13_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_0707f01d-f33a-407d-b473-089b246cef2b_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_f59e2e48-13e4-4d18-a3e6-d9baeb00c4df_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for vesting of restricted stock awards</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesReceivableMember_656ce1a4-cef8-4024-832d-04971ab54246_terseLabel_en-US" xlink:label="lab_us-gaap_NotesReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Secured Promissory Note</link:label>
    <link:label id="lab_us-gaap_NotesReceivableMember_label_en-US" xlink:label="lab_us-gaap_NotesReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReceivableMember" xlink:to="lab_us-gaap_NotesReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_44575561-b60a-42e6-a456-244d73804f0a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_7136f17f-e1b9-4d28-b5ff-7b2540c167b4_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_6bc07917-0159-49f5-bd89-54b027d43d2c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_2d2a55d1-8c9a-40d2-97a4-6b19dc4ebb67_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplementary disclosures of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PatientManagementPlatformMember_a4c28b06-722a-4990-bd34-c3cd1326578b_terseLabel_en-US" xlink:label="lab_ameh_PatientManagementPlatformMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient management platform</link:label>
    <link:label id="lab_ameh_PatientManagementPlatformMember_label_en-US" xlink:label="lab_ameh_PatientManagementPlatformMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient Management Platform [Member]</link:label>
    <link:label id="lab_ameh_PatientManagementPlatformMember_documentation_en-US" xlink:label="lab_ameh_PatientManagementPlatformMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient Management Platform</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PatientManagementPlatformMember" xlink:href="ameh-20200630.xsd#ameh_PatientManagementPlatformMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PatientManagementPlatformMember" xlink:to="lab_ameh_PatientManagementPlatformMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_8b1ee71a-c024-47f7-a23f-de979fc2b996_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentAggregateCost_5b3a36cd-d8f3-4806-9707-fe1a703a9180_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount invested for interest</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentAggregateCost_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Aggregate Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentAggregateCost" xlink:to="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PayorFMember_a71c6c98-ad40-417e-bcf4-323f48cf5c99_terseLabel_en-US" xlink:label="lab_ameh_PayorFMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor G</link:label>
    <link:label id="lab_ameh_PayorFMember_label_en-US" xlink:label="lab_ameh_PayorFMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor F [Member]</link:label>
    <link:label id="lab_ameh_PayorFMember_documentation_en-US" xlink:label="lab_ameh_PayorFMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor F [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorFMember" xlink:href="ameh-20200630.xsd#ameh_PayorFMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PayorFMember" xlink:to="lab_ameh_PayorFMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HealthCarePatientServiceMember_89d7b042-870a-4fa4-b92f-00ceefdbdcbb_terseLabel_en-US" xlink:label="lab_us-gaap_HealthCarePatientServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fee-for-service, net</link:label>
    <link:label id="lab_us-gaap_HealthCarePatientServiceMember_label_en-US" xlink:label="lab_us-gaap_HealthCarePatientServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care, Patient Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCarePatientServiceMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCarePatientServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCarePatientServiceMember" xlink:to="lab_us-gaap_HealthCarePatientServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentOwnershipPercentageDisposed_0def3cdd-53c4-4c73-b5aa-8c23e6fce93b_terseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentOwnershipPercentageDisposed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership interest disposed</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentOwnershipPercentageDisposed_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentOwnershipPercentageDisposed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage Disposed</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentOwnershipPercentageDisposed_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentOwnershipPercentageDisposed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage Disposed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentOwnershipPercentageDisposed" xlink:href="ameh-20200630.xsd#ameh_EquityMethodInvestmentOwnershipPercentageDisposed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentOwnershipPercentageDisposed" xlink:to="lab_ameh_EquityMethodInvestmentOwnershipPercentageDisposed" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport_65a352a8-0510-40a8-9bc0-904dcafdc391_terseLabel_en-US" xlink:label="lab_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected period of payment upon termination of agreement</link:label>
    <link:label id="lab_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport_label_en-US" xlink:label="lab_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing Of Satisfaction, Period Of Payment Upon Finalization Of Settlement Report</link:label>
    <link:label id="lab_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport_documentation_en-US" xlink:label="lab_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing Of Satisfaction, Period Of Payment Upon Finalization Of Settlement Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" xlink:href="ameh-20200630.xsd#ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" xlink:to="lab_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_dec9af92-b057-4f2e-8c92-3437a1f8b744_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount available</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fdb21d23-b52d-43ba-9e86-56b559591696_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares purchased by related party</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MezzanineMember_b9acff37-3f79-49d5-b8cb-668fa27ea0f0_terseLabel_en-US" xlink:label="lab_ameh_MezzanineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mezzanine</link:label>
    <link:label id="lab_ameh_MezzanineMember_label_en-US" xlink:label="lab_ameh_MezzanineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mezzanine [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MezzanineMember" xlink:href="ameh-20200630.xsd#ameh_MezzanineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MezzanineMember" xlink:to="lab_ameh_MezzanineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ApcBusinessLoanAgreementMember_25104529-6636-43c2-804e-792d609b7474_terseLabel_en-US" xlink:label="lab_ameh_ApcBusinessLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC Business Loan Agreement</link:label>
    <link:label id="lab_ameh_ApcBusinessLoanAgreementMember_label_en-US" xlink:label="lab_ameh_ApcBusinessLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC Business Loan Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcBusinessLoanAgreementMember" xlink:href="ameh-20200630.xsd#ameh_ApcBusinessLoanAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ApcBusinessLoanAgreementMember" xlink:to="lab_ameh_ApcBusinessLoanAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_ed575a58-4e74-4732-a460-a9868d0b1a5a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized intangible assets, Gross</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PayorGMember_9de42909-ff01-47d4-81d5-c77796b03e8c_terseLabel_en-US" xlink:label="lab_ameh_PayorGMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor G</link:label>
    <link:label id="lab_ameh_PayorGMember_label_en-US" xlink:label="lab_ameh_PayorGMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor G [Member]</link:label>
    <link:label id="lab_ameh_PayorGMember_documentation_en-US" xlink:label="lab_ameh_PayorGMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor G [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorGMember" xlink:href="ameh-20200630.xsd#ameh_PayorGMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PayorGMember" xlink:to="lab_ameh_PayorGMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_91923ed9-878e-45f4-8952-484bf4eb08dd_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_c9b79f47-c3ec-4dcb-bcc9-3be0f717da03_verboseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_9ce0a0f5-5b53-40c2-9229-dff80b573f51_negatedLabel_en-US" xlink:label="lab_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_label_en-US" xlink:label="lab_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Prepaid Expenses And Other Current Assets</link:label>
    <link:label id="lab_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_documentation_en-US" xlink:label="lab_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The increase (decrease) during the reporting period in the value of prepaid expenses and other current assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:href="ameh-20200630.xsd#ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:to="lab_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_a082f388-cd1f-4c7d-930c-3cb3f1ed3947_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_749dd5a8-19b1-42b5-92f6-9a45f85f5b4f_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets recorded under finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_TermLoanAMember_c417075c-afc1-4af6-88b8-d9490817487f_terseLabel_en-US" xlink:label="lab_ameh_TermLoanAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan A</link:label>
    <link:label id="lab_ameh_TermLoanAMember_label_en-US" xlink:label="lab_ameh_TermLoanAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A [Member]</link:label>
    <link:label id="lab_ameh_TermLoanAMember_documentation_en-US" xlink:label="lab_ameh_TermLoanAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_TermLoanAMember" xlink:href="ameh-20200630.xsd#ameh_TermLoanAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_TermLoanAMember" xlink:to="lab_ameh_TermLoanAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_73a03baf-31ee-46d6-901c-7d741310d03f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Operating Lease Payments After Adoption of 842</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_b33230a2-c096-4faf-bc47-f8427c1cf64e_terseLabel_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value (in thousands)</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_label_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_documentation_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:href="ameh-20200630.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_a6a8c426-f3ca-4fc3-8293-7195a3a7e1e4_verboseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_05927d08-b080-4079-825e-c0d05ce2a8d7_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares of common stock outstanding &#8211; basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_c473d9c3-7ce9-47ce-b5c8-5f0b967ad538_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_WarrantExercisePriceRangeTwoMember_7b0771de-09b8-4f91-9913-63f81427332e_verboseLabel_en-US" xlink:label="lab_ameh_WarrantExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Exercise Price Range Two</link:label>
    <link:label id="lab_ameh_WarrantExercisePriceRangeTwoMember_label_en-US" xlink:label="lab_ameh_WarrantExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Exercise Price Range Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeTwoMember" xlink:href="ameh-20200630.xsd#ameh_WarrantExercisePriceRangeTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_WarrantExercisePriceRangeTwoMember" xlink:to="lab_ameh_WarrantExercisePriceRangeTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8031b914-e592-45bd-b9f4-8d8da47302dd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_479e757e-92e7-4d3a-a745-4afc938534f6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_ed02a15c-da85-4381-9068-686f9aa76e5f_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_StockIssuedDuringPeriodProxyVotesPercentage_f5e25737-c546-4f07-b6d1-da7192b12377_terseLabel_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodProxyVotesPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proxy votes</link:label>
    <link:label id="lab_ameh_StockIssuedDuringPeriodProxyVotesPercentage_label_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodProxyVotesPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Proxy Votes, Percentage</link:label>
    <link:label id="lab_ameh_StockIssuedDuringPeriodProxyVotesPercentage_documentation_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodProxyVotesPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Proxy Votes, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodProxyVotesPercentage" xlink:href="ameh-20200630.xsd#ameh_StockIssuedDuringPeriodProxyVotesPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_StockIssuedDuringPeriodProxyVotesPercentage" xlink:to="lab_ameh_StockIssuedDuringPeriodProxyVotesPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ApcLsmaMember_4729b4b1-e2d1-4ff6-961e-598fc8fe06d2_terseLabel_en-US" xlink:label="lab_ameh_ApcLsmaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC LSMA</link:label>
    <link:label id="lab_ameh_ApcLsmaMember_label_en-US" xlink:label="lab_ameh_ApcLsmaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC LSMA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcLsmaMember" xlink:href="ameh-20200630.xsd#ameh_ApcLsmaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ApcLsmaMember" xlink:to="lab_ameh_ApcLsmaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_43217610-e696-4086-9840-34062147bfa3_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury shares (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet_0796c69b-940e-4f9b-86ec-d41b1bf700fd_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of warrants available to purchase, contingent upon the portal completion date (in shares)</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Options Issues, Options To Purchase Additional Interests, If Circumstances Met</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Options Issues, Options To Purchase Additional Interests, If Circumstances Met</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet" xlink:href="ameh-20200630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_eddd0f13-b395-42f9-9c92-4ce7c7581ee4_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, ownership interest</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_e33080f6-ce75-4daf-bb2c-fb816b68cc20_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership interest</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPayableCurrentAndNoncurrent_10ff6f83-d304-434f-a7fd-32bfd500dfe0_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend declared included in dividend payable</link:label>
    <link:label id="lab_us-gaap_DividendsPayableCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_5c7f9dbf-336f-44e7-a1e6-4f67ddcd2d7d_verboseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests_9239a297-7092-4681-a240-94aaae46ad85_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase additional membership interests (in shares)</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Options Issued, Option To Purchase Additional Interests</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Options Issued, Option To Purchase Additional Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" xlink:href="ameh-20200630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_47feafdb-10d2-4ba0-8706-d74d3ea6609c_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 (excluding the six months ended June 30, 2020)</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod_9e0b7669-20ec-4ff4-92aa-9d4a19479bf1_terseLabel_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercised (in shares)</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod_label_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based Compensation Arrangement By Share based Payment Award Warrants Exercises In Period</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod_documentation_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based Compensation Arrangement By Share based Payment Award Warrants Exercises In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" xlink:href="ameh-20200630.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" xlink:to="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_57c872e7-57e2-45da-bb1d-0aedaa70702a_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToFundLongtermLoansToRelatedParties_24041e16-3728-4272-b570-44038340e707_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advances on loans receivable</link:label>
    <link:label id="lab_us-gaap_PaymentsToFundLongtermLoansToRelatedParties_label_en-US" xlink:label="lab_us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Fund Long-term Loans to Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToFundLongtermLoansToRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:to="lab_us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_eddc0909-6842-4731-a219-9016d9237801_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_fab6401b-5364-4407-816a-12b00d0e8635_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit from income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NmmBusinessLoanAgreementMember_728e14a8-5280-4fdd-a75b-2967e4378d22_terseLabel_en-US" xlink:label="lab_ameh_NmmBusinessLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NMM Business Loan Agreement</link:label>
    <link:label id="lab_ameh_NmmBusinessLoanAgreementMember_label_en-US" xlink:label="lab_ameh_NmmBusinessLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NMM Business Loan Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NmmBusinessLoanAgreementMember" xlink:href="ameh-20200630.xsd#ameh_NmmBusinessLoanAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NmmBusinessLoanAgreementMember" xlink:to="lab_ameh_NmmBusinessLoanAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_77a87c10-599f-451b-82b6-3183f0dfea05_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f8c4bd11-da55-4449-92ed-bf227bce18c6_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b7c931f2-bb40-4f5f-a4b7-2f5eba410f42_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents, and restricted cash shown in the statement of cash flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_8cc6fe43-0650-46ea-9558-84759ac125c0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Commitments of Credit Facility</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_53a67c70-f52b-4926-8ae6-b0604ec7a485_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_f559778c-93d1-46ab-92c3-4e79354ce24e_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of equity method investment</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_ae4ac0cb-0bcc-4e5b-ba2f-7766fb16931b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of equity method investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Realized Gain (Loss) on Disposal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:to="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_f01479c4-25d5-417b-855d-a7bffdbdd340_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_3aeadb59-2ac0-446a-b75f-bded8a185a41_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_699ca0e8-3ab6-438a-8a1d-c3f3ec83a3bf_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_2ffcecbe-042f-4e40-a45b-58d3e750cf29_netLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: current portion</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_81f37c20-400f-4412-93ec-8d6a84b6ac4c_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire business</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NumberOfWarrantsGranted_828c3bad-a3f2-4e40-b97f-6cc4152641d5_verboseLabel_en-US" xlink:label="lab_ameh_NumberOfWarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants granted (in shares)</link:label>
    <link:label id="lab_ameh_NumberOfWarrantsGranted_label_en-US" xlink:label="lab_ameh_NumberOfWarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Warrants Granted</link:label>
    <link:label id="lab_ameh_NumberOfWarrantsGranted_documentation_en-US" xlink:label="lab_ameh_NumberOfWarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Warrants Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfWarrantsGranted" xlink:href="ameh-20200630.xsd#ameh_NumberOfWarrantsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NumberOfWarrantsGranted" xlink:to="lab_ameh_NumberOfWarrantsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_203cdee3-6b75-4072-a9d8-d6a5ba691051_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PayorHMember_7921c28f-0fc4-4862-9487-0bbeadac406b_terseLabel_en-US" xlink:label="lab_ameh_PayorHMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor H</link:label>
    <link:label id="lab_ameh_PayorHMember_label_en-US" xlink:label="lab_ameh_PayorHMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor H [Member]</link:label>
    <link:label id="lab_ameh_PayorHMember_documentation_en-US" xlink:label="lab_ameh_PayorHMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor H</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorHMember" xlink:href="ameh-20200630.xsd#ameh_PayorHMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PayorHMember" xlink:to="lab_ameh_PayorHMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_230ba453-7318-4caa-9c67-72d6918251b8_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_e93dd76f-0841-4727-9d98-a15443af8e61_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_b22c54fa-cf6a-4b2f-aabe-7a21834d3d33_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds of options exercised</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_02a54fa3-8f9e-4283-80ee-067f9632b3d7_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e01ba3c9-339a-40e2-9b4a-65e50a4d8505_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_70c64697-27ea-498d-8f05-7b2eac23726a_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum loan availability</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_f1083ac7-cfa6-4239-88f8-c3b9e76bb0ca_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_5bdbedee-7010-4c62-9bc8-fd539d4fda8d_terseLabel_en-US" xlink:label="lab_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_label_en-US" xlink:label="lab_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:label id="lab_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_documentation_en-US" xlink:label="lab_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:href="ameh-20200630.xsd#ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:to="lab_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_ccba4a1a-1151-4d00-8ed1-74234f5ad8a9_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_ff6dfbdf-da17-493b-bf5a-016df862200b_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_65ac6ae9-0918-416c-acc0-5b4c59d8edc9_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost_5c1d74ac-6afa-4881-894f-086676d9e54d_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment amount</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Aggregate Cost</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Aggregate Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" xlink:href="ameh-20200630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_84cf3894-245a-4f02-9aa7-c78f51402968_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_7ceb26e2-775a-44b7-969a-ebd5c3928079_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_56dbb776-7b71-4dce-ac68-77787eb5ee8d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4d525156-838a-4183-a318-aaccbbcd4c39_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_47a134ca-d4f9-4f13-a67a-d485ffa1654c_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_510c3ba1-1816-4012-80d3-c328097a004e_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_16546ff9-5986-4b74-83a7-d0ff11483a28_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c7e71fa8-f8bc-4d50-a4a3-528383459b0e_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of exercises during period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DebtInstrumentCovenantLeverageRatioMaximum_c11285c0-01df-49b9-a775-bcf47e2dafb1_terseLabel_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum consolidated leverage ratio (not greater than)</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantLeverageRatioMaximum_label_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio, Maximum</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantLeverageRatioMaximum_documentation_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantLeverageRatioMaximum" xlink:href="ameh-20200630.xsd#ameh_DebtInstrumentCovenantLeverageRatioMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DebtInstrumentCovenantLeverageRatioMaximum" xlink:to="lab_ameh_DebtInstrumentCovenantLeverageRatioMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_19076593-bbcd-4b8a-b37a-5dab23d4e037_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, value</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_dc901445-6796-4335-ad0b-b32b7d3441c3_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PacificMedicalImagingAndOncologyCenterIncMember_423a093d-e9a4-425c-8cc4-236c58ea9622_terseLabel_en-US" xlink:label="lab_ameh_PacificMedicalImagingAndOncologyCenterIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pacific Medical Imaging &amp; Oncology Center, Inc.</link:label>
    <link:label id="lab_ameh_PacificMedicalImagingAndOncologyCenterIncMember_label_en-US" xlink:label="lab_ameh_PacificMedicalImagingAndOncologyCenterIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pacific Medical Imaging and Oncology Center, Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember" xlink:href="ameh-20200630.xsd#ameh_PacificMedicalImagingAndOncologyCenterIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember" xlink:to="lab_ameh_PacificMedicalImagingAndOncologyCenterIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_5243d847-c8b9-464c-8ec8-f56b95c1d622_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_WeightedAverageExercisePriceWarrantsRollForward_b29a6d1c-09c1-4976-89d0-224271d98edf_terseLabel_en-US" xlink:label="lab_ameh_WeightedAverageExercisePriceWarrantsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_ameh_WeightedAverageExercisePriceWarrantsRollForward_label_en-US" xlink:label="lab_ameh_WeightedAverageExercisePriceWarrantsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants [Roll Forward]</link:label>
    <link:label id="lab_ameh_WeightedAverageExercisePriceWarrantsRollForward_documentation_en-US" xlink:label="lab_ameh_WeightedAverageExercisePriceWarrantsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward" xlink:href="ameh-20200630.xsd#ameh_WeightedAverageExercisePriceWarrantsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward" xlink:to="lab_ameh_WeightedAverageExercisePriceWarrantsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_ffcaeb23-82c2-4c95-9f4a-c4f4f71995a1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ContractTypeAxis_c1288e12-c5da-4296-9b9c-6d9a205c3ba4_terseLabel_en-US" xlink:label="lab_ameh_ContractTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Type [Axis]</link:label>
    <link:label id="lab_ameh_ContractTypeAxis_label_en-US" xlink:label="lab_ameh_ContractTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContractTypeAxis" xlink:href="ameh-20200630.xsd#ameh_ContractTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ContractTypeAxis" xlink:to="lab_ameh_ContractTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1cb4df88-4235-42b4-963b-d488258118ad_verboseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_78d83573-0f9d-450f-9ffc-109bd8adf43a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DescriptionOfBusinessLineItems_91e9d7ce-5894-4bcf-9da3-a67fa3e91216_terseLabel_en-US" xlink:label="lab_ameh_DescriptionOfBusinessLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description Of Business [Line Items]</link:label>
    <link:label id="lab_ameh_DescriptionOfBusinessLineItems_label_en-US" xlink:label="lab_ameh_DescriptionOfBusinessLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description Of Business [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DescriptionOfBusinessLineItems" xlink:href="ameh-20200630.xsd#ameh_DescriptionOfBusinessLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DescriptionOfBusinessLineItems" xlink:to="lab_ameh_DescriptionOfBusinessLineItems" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>16
<FILENAME>ameh-20200630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:b88c77a1-c027-414b-9d80-e41583dc701a,g:39bb5244-cfb0-4a0f-b0d7-a52c48426910-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.apollomed.net/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="ameh-20200630.xsd#DocumentandEntityInformation"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/DocumentandEntityInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_8d98b34f-47a1-41da-a2ad-6e24ab0f1ec5" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_1d61d0f3-cba8-4976-8919-03476eea05ab" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8d98b34f-47a1-41da-a2ad-6e24ab0f1ec5" xlink:to="loc_dei_DocumentType_1d61d0f3-cba8-4976-8919-03476eea05ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_88d0d4ed-758d-4eac-a589-0ee88bcb47e6" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8d98b34f-47a1-41da-a2ad-6e24ab0f1ec5" xlink:to="loc_dei_DocumentQuarterlyReport_88d0d4ed-758d-4eac-a589-0ee88bcb47e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_39cdf62a-8073-4c80-a21f-c1ee05c28782" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8d98b34f-47a1-41da-a2ad-6e24ab0f1ec5" xlink:to="loc_dei_DocumentPeriodEndDate_39cdf62a-8073-4c80-a21f-c1ee05c28782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_bb297422-9cff-44c8-a5dd-b8cd6ddd8537" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8d98b34f-47a1-41da-a2ad-6e24ab0f1ec5" xlink:to="loc_dei_DocumentTransitionReport_bb297422-9cff-44c8-a5dd-b8cd6ddd8537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_07e64bf0-6d5d-4fbd-9a36-37a48d9cea42" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8d98b34f-47a1-41da-a2ad-6e24ab0f1ec5" xlink:to="loc_dei_EntityFileNumber_07e64bf0-6d5d-4fbd-9a36-37a48d9cea42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_b5817eb0-f004-45cb-82cb-86b5da7a4dc9" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8d98b34f-47a1-41da-a2ad-6e24ab0f1ec5" xlink:to="loc_dei_EntityRegistrantName_b5817eb0-f004-45cb-82cb-86b5da7a4dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_09dc7014-6aac-42de-aa30-318275e88b1f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8d98b34f-47a1-41da-a2ad-6e24ab0f1ec5" xlink:to="loc_dei_EntityIncorporationStateCountryCode_09dc7014-6aac-42de-aa30-318275e88b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_bbd8e688-8903-4898-94e1-5bf316483efe" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8d98b34f-47a1-41da-a2ad-6e24ab0f1ec5" xlink:to="loc_dei_EntityTaxIdentificationNumber_bbd8e688-8903-4898-94e1-5bf316483efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_7fb54e22-2b1f-482c-830e-599ba4e687c0" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8d98b34f-47a1-41da-a2ad-6e24ab0f1ec5" xlink:to="loc_dei_EntityAddressAddressLine1_7fb54e22-2b1f-482c-830e-599ba4e687c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_7d499c24-5dc8-4a9c-ad11-28c7da57f2ed" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8d98b34f-47a1-41da-a2ad-6e24ab0f1ec5" xlink:to="loc_dei_EntityAddressAddressLine2_7d499c24-5dc8-4a9c-ad11-28c7da57f2ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_2a78879b-971e-4c5c-a665-c3bbfce70811" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8d98b34f-47a1-41da-a2ad-6e24ab0f1ec5" xlink:to="loc_dei_EntityAddressCityOrTown_2a78879b-971e-4c5c-a665-c3bbfce70811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_fa39102e-8617-4b2c-b382-41041d50b4fa" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8d98b34f-47a1-41da-a2ad-6e24ab0f1ec5" xlink:to="loc_dei_EntityAddressStateOrProvince_fa39102e-8617-4b2c-b382-41041d50b4fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_a8fd52ce-2369-450f-85f6-9ebd0e11ee56" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8d98b34f-47a1-41da-a2ad-6e24ab0f1ec5" xlink:to="loc_dei_EntityAddressPostalZipCode_a8fd52ce-2369-450f-85f6-9ebd0e11ee56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_6d060449-a049-42c7-a24c-43394b3309d1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8d98b34f-47a1-41da-a2ad-6e24ab0f1ec5" xlink:to="loc_dei_CityAreaCode_6d060449-a049-42c7-a24c-43394b3309d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_045d606a-fc7c-4906-bed4-1d6d59900d9d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8d98b34f-47a1-41da-a2ad-6e24ab0f1ec5" xlink:to="loc_dei_LocalPhoneNumber_045d606a-fc7c-4906-bed4-1d6d59900d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_1ffbb083-c42f-47fd-be43-9db7f90a3987" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8d98b34f-47a1-41da-a2ad-6e24ab0f1ec5" xlink:to="loc_dei_EntityCurrentReportingStatus_1ffbb083-c42f-47fd-be43-9db7f90a3987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_8e6167f2-b86e-412c-9110-a254eb17d0df" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8d98b34f-47a1-41da-a2ad-6e24ab0f1ec5" xlink:to="loc_dei_EntityInteractiveDataCurrent_8e6167f2-b86e-412c-9110-a254eb17d0df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_9b1ecbec-d9bf-40a5-b9c5-130d2c5fa404" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8d98b34f-47a1-41da-a2ad-6e24ab0f1ec5" xlink:to="loc_dei_EntityFilerCategory_9b1ecbec-d9bf-40a5-b9c5-130d2c5fa404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_1ff88412-c336-4e60-9015-6e29b8d94637" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8d98b34f-47a1-41da-a2ad-6e24ab0f1ec5" xlink:to="loc_dei_EntitySmallBusiness_1ff88412-c336-4e60-9015-6e29b8d94637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_071bfa47-7034-43b3-8bd8-77ea06ca0e08" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8d98b34f-47a1-41da-a2ad-6e24ab0f1ec5" xlink:to="loc_dei_EntityEmergingGrowthCompany_071bfa47-7034-43b3-8bd8-77ea06ca0e08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_2bc2024a-83db-4b8b-8621-7b8f59a02da4" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8d98b34f-47a1-41da-a2ad-6e24ab0f1ec5" xlink:to="loc_dei_EntityShellCompany_2bc2024a-83db-4b8b-8621-7b8f59a02da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_ea49d624-6917-437c-a611-baaa3c6e0690" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8d98b34f-47a1-41da-a2ad-6e24ab0f1ec5" xlink:to="loc_dei_Security12bTitle_ea49d624-6917-437c-a611-baaa3c6e0690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_1e16aad2-24d5-4c56-8213-8aa31a49817a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8d98b34f-47a1-41da-a2ad-6e24ab0f1ec5" xlink:to="loc_dei_TradingSymbol_1e16aad2-24d5-4c56-8213-8aa31a49817a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_15e299f9-3fb2-453a-b98f-b9c8e342e3b5" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8d98b34f-47a1-41da-a2ad-6e24ab0f1ec5" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_15e299f9-3fb2-453a-b98f-b9c8e342e3b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_a90c061b-a09b-41c2-a43a-8c3b019c2b38" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8d98b34f-47a1-41da-a2ad-6e24ab0f1ec5" xlink:to="loc_dei_AmendmentFlag_a90c061b-a09b-41c2-a43a-8c3b019c2b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_94f4d7dd-025b-4295-ab5f-62476ac74662" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8d98b34f-47a1-41da-a2ad-6e24ab0f1ec5" xlink:to="loc_dei_DocumentFiscalYearFocus_94f4d7dd-025b-4295-ab5f-62476ac74662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_61b60b11-05a9-4008-a600-2dcb2e1f2704" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8d98b34f-47a1-41da-a2ad-6e24ab0f1ec5" xlink:to="loc_dei_DocumentFiscalPeriodFocus_61b60b11-05a9-4008-a600-2dcb2e1f2704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_737714dd-4aa8-417c-9b0d-296d6df41037" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8d98b34f-47a1-41da-a2ad-6e24ab0f1ec5" xlink:to="loc_dei_EntityCentralIndexKey_737714dd-4aa8-417c-9b0d-296d6df41037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_235eafcb-214e-4f68-91a7-b64beae9c413" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8d98b34f-47a1-41da-a2ad-6e24ab0f1ec5" xlink:to="loc_dei_CurrentFiscalYearEndDate_235eafcb-214e-4f68-91a7-b64beae9c413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED" xlink:type="simple" xlink:href="ameh-20200630.xsd#CONSOLIDATEDBALANCESHEETSUNAUDITED"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_6b91c56e-65d3-43fc-b590-6f61a1de2bd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_67f82501-f2a6-4f20-a959-f89c49a9c419" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6b91c56e-65d3-43fc-b590-6f61a1de2bd9" xlink:to="loc_us-gaap_StatementTable_67f82501-f2a6-4f20-a959-f89c49a9c419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_11cefe57-d780-4eb5-bf84-966a43babcde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_67f82501-f2a6-4f20-a959-f89c49a9c419" xlink:to="loc_us-gaap_StatementClassOfStockAxis_11cefe57-d780-4eb5-bf84-966a43babcde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_29885690-50d7-4b34-85ca-011774a08a7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_11cefe57-d780-4eb5-bf84-966a43babcde" xlink:to="loc_us-gaap_ClassOfStockDomain_29885690-50d7-4b34-85ca-011774a08a7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_7bf9f904-f9df-4b61-8353-8fb5efb63929" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_29885690-50d7-4b34-85ca-011774a08a7d" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_7bf9f904-f9df-4b61-8353-8fb5efb63929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_5abff7bf-11da-4592-b9e4-780cc13e3f96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_29885690-50d7-4b34-85ca-011774a08a7d" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_5abff7bf-11da-4592-b9e4-780cc13e3f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4087035e-ac0f-491e-8a0f-89bd5883f7ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_67f82501-f2a6-4f20-a959-f89c49a9c419" xlink:to="loc_us-gaap_StatementLineItems_4087035e-ac0f-491e-8a0f-89bd5883f7ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_2149a2be-57f9-4a10-8b49-777efd1251e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4087035e-ac0f-491e-8a0f-89bd5883f7ac" xlink:to="loc_us-gaap_AssetsAbstract_2149a2be-57f9-4a10-8b49-777efd1251e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_2f77d0d1-79fa-45b4-aad0-f90412e2caa8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2149a2be-57f9-4a10-8b49-777efd1251e6" xlink:to="loc_us-gaap_AssetsCurrentAbstract_2f77d0d1-79fa-45b4-aad0-f90412e2caa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e030d32d-6bac-475a-aa93-bf4750fa6ef6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2f77d0d1-79fa-45b4-aad0-f90412e2caa8" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e030d32d-6bac-475a-aa93-bf4750fa6ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_c9cb2c22-896c-4287-9378-300308143e7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2f77d0d1-79fa-45b4-aad0-f90412e2caa8" xlink:to="loc_us-gaap_RestrictedCashCurrent_c9cb2c22-896c-4287-9378-300308143e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_2861480b-a4eb-4bcf-9831-c0d31b303338" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2f77d0d1-79fa-45b4-aad0-f90412e2caa8" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_2861480b-a4eb-4bcf-9831-c0d31b303338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_a2553d19-15ee-49a8-80b6-1048da549c79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2f77d0d1-79fa-45b4-aad0-f90412e2caa8" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_a2553d19-15ee-49a8-80b6-1048da549c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_e10822cb-b08a-4d17-96c6-c3be62e6d0db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2f77d0d1-79fa-45b4-aad0-f90412e2caa8" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_e10822cb-b08a-4d17-96c6-c3be62e6d0db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_ea942f0b-e028-496f-acb1-a1fb83624f71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2f77d0d1-79fa-45b4-aad0-f90412e2caa8" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_ea942f0b-e028-496f-acb1-a1fb83624f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f56890f8-d8ee-4e92-a0a1-e1ea700e0468" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2f77d0d1-79fa-45b4-aad0-f90412e2caa8" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f56890f8-d8ee-4e92-a0a1-e1ea700e0468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent_25419234-419d-4483-9865-55089962af49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2f77d0d1-79fa-45b4-aad0-f90412e2caa8" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetCurrent_25419234-419d-4483-9865-55089962af49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesCurrent_4c654832-08fa-4bc7-9e0f-a203b71c57ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesReceivableRelatedPartiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2f77d0d1-79fa-45b4-aad0-f90412e2caa8" xlink:to="loc_us-gaap_NotesReceivableRelatedPartiesCurrent_4c654832-08fa-4bc7-9e0f-a203b71c57ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c58325ac-d8a1-4f68-a172-44f16dc522c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2f77d0d1-79fa-45b4-aad0-f90412e2caa8" xlink:to="loc_us-gaap_AssetsCurrent_c58325ac-d8a1-4f68-a172-44f16dc522c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_27fd2b08-4c75-4f02-8794-f4681b0aed37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2149a2be-57f9-4a10-8b49-777efd1251e6" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_27fd2b08-4c75-4f02-8794-f4681b0aed37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_6b24c6fd-9c67-496c-a490-60e93ceb84be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_27fd2b08-4c75-4f02-8794-f4681b0aed37" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_6b24c6fd-9c67-496c-a490-60e93ceb84be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_77a8db26-4e3c-4e51-abc4-9880a6bb2e55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_27fd2b08-4c75-4f02-8794-f4681b0aed37" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_77a8db26-4e3c-4e51-abc4-9880a6bb2e55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_4b6f3337-2cf4-43c5-87eb-9a9430f3279b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_27fd2b08-4c75-4f02-8794-f4681b0aed37" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_4b6f3337-2cf4-43c5-87eb-9a9430f3279b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_09e54724-37a3-4c6f-a298-1bef6aef36fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_27fd2b08-4c75-4f02-8794-f4681b0aed37" xlink:to="loc_us-gaap_Goodwill_09e54724-37a3-4c6f-a298-1bef6aef36fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_ce29eaa6-c064-4016-9338-3202bf906a3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_27fd2b08-4c75-4f02-8794-f4681b0aed37" xlink:to="loc_us-gaap_EquityMethodInvestments_ce29eaa6-c064-4016-9338-3202bf906a3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_8786b4cc-1867-4284-96e3-07b19033d298" xlink:href="ameh-20200630.xsd#ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_27fd2b08-4c75-4f02-8794-f4681b0aed37" xlink:to="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_8786b4cc-1867-4284-96e3-07b19033d298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_d36f0eab-b17c-4609-8af9-d58c715d0768" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_27fd2b08-4c75-4f02-8794-f4681b0aed37" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_d36f0eab-b17c-4609-8af9-d58c715d0768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_1131ef14-68da-4de8-9233-dcb824adb1d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_27fd2b08-4c75-4f02-8794-f4681b0aed37" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_1131ef14-68da-4de8-9233-dcb824adb1d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_1aaa00dd-8dd2-44d6-a6d9-ea27a5b34336" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_27fd2b08-4c75-4f02-8794-f4681b0aed37" xlink:to="loc_us-gaap_AssetsNoncurrent_1aaa00dd-8dd2-44d6-a6d9-ea27a5b34336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_53f9af42-b9fa-403a-81b0-285e5ff74ea0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2149a2be-57f9-4a10-8b49-777efd1251e6" xlink:to="loc_us-gaap_Assets_53f9af42-b9fa-403a-81b0-285e5ff74ea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_563ccede-83ba-4996-9182-c8e4dbfcb55d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4087035e-ac0f-491e-8a0f-89bd5883f7ac" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_563ccede-83ba-4996-9182-c8e4dbfcb55d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_95f81445-d05c-43e0-8969-951120e0a49c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_563ccede-83ba-4996-9182-c8e4dbfcb55d" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_95f81445-d05c-43e0-8969-951120e0a49c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_b8b1078a-78d8-420f-82f8-b5615da1bcef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_95f81445-d05c-43e0-8969-951120e0a49c" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_b8b1078a-78d8-420f-82f8-b5615da1bcef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent_bc07f8fc-2ee4-49eb-9f54-749154ebb7ec" xlink:href="ameh-20200630.xsd#ameh_FiduciaryAccountsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_95f81445-d05c-43e0-8969-951120e0a49c" xlink:to="loc_ameh_FiduciaryAccountsPayableCurrent_bc07f8fc-2ee4-49eb-9f54-749154ebb7ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_d2078514-1294-4c6f-9af8-ed99a71efae0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_95f81445-d05c-43e0-8969-951120e0a49c" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_d2078514-1294-4c6f-9af8-ed99a71efae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_69909967-71fb-4b08-a1ab-8195beb95a54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_95f81445-d05c-43e0-8969-951120e0a49c" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_69909967-71fb-4b08-a1ab-8195beb95a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_9e984967-fce2-40a0-b646-2aad807b76e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_95f81445-d05c-43e0-8969-951120e0a49c" xlink:to="loc_us-gaap_DividendsPayableCurrent_9e984967-fce2-40a0-b646-2aad807b76e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_36e3f616-4d1b-41e4-b6ec-189cdc8d1f03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_95f81445-d05c-43e0-8969-951120e0a49c" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_36e3f616-4d1b-41e4-b6ec-189cdc8d1f03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_798990b4-7f9b-4861-8733-7a3c67872a6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_95f81445-d05c-43e0-8969-951120e0a49c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_798990b4-7f9b-4861-8733-7a3c67872a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_59c6ef8e-3167-492d-93a0-f4336404d7ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_95f81445-d05c-43e0-8969-951120e0a49c" xlink:to="loc_us-gaap_LongTermDebtCurrent_59c6ef8e-3167-492d-93a0-f4336404d7ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f988fa74-e130-4c71-bdc7-060d9d67e84a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_95f81445-d05c-43e0-8969-951120e0a49c" xlink:to="loc_us-gaap_LiabilitiesCurrent_f988fa74-e130-4c71-bdc7-060d9d67e84a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_516b88d3-13d9-4f55-abc3-81552b1a23d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_563ccede-83ba-4996-9182-c8e4dbfcb55d" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_516b88d3-13d9-4f55-abc3-81552b1a23d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_ba27a477-58c4-42a3-9744-b780f66c29a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_516b88d3-13d9-4f55-abc3-81552b1a23d6" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_ba27a477-58c4-42a3-9744-b780f66c29a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_1c048d63-b2ee-4299-b24e-79c0dff9089c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_516b88d3-13d9-4f55-abc3-81552b1a23d6" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_1c048d63-b2ee-4299-b24e-79c0dff9089c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1f40eac3-6c38-4395-aeb2-9dcd622f8ed4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_516b88d3-13d9-4f55-abc3-81552b1a23d6" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1f40eac3-6c38-4395-aeb2-9dcd622f8ed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_76002bf6-90d0-4a23-a40f-faa878e6b157" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_516b88d3-13d9-4f55-abc3-81552b1a23d6" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_76002bf6-90d0-4a23-a40f-faa878e6b157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_398db4ee-2eaf-41c4-a34a-ec626fde957c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_516b88d3-13d9-4f55-abc3-81552b1a23d6" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_398db4ee-2eaf-41c4-a34a-ec626fde957c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_0e3934fb-a9fc-48a4-906a-249447bbed63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_563ccede-83ba-4996-9182-c8e4dbfcb55d" xlink:to="loc_us-gaap_Liabilities_0e3934fb-a9fc-48a4-906a-249447bbed63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_c9c8d99d-7234-40bb-a9a7-b2d531ee01b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_563ccede-83ba-4996-9182-c8e4dbfcb55d" xlink:to="loc_us-gaap_CommitmentsAndContingencies_c9c8d99d-7234-40bb-a9a7-b2d531ee01b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MezzanineEquityAbstract_69d703a7-47c1-405a-808c-4fb92b465164" xlink:href="ameh-20200630.xsd#ameh_MezzanineEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_563ccede-83ba-4996-9182-c8e4dbfcb55d" xlink:to="loc_ameh_MezzanineEquityAbstract_69d703a7-47c1-405a-808c-4fb92b465164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_fa1f259c-9a68-44cd-819c-f03dbc1487dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_MezzanineEquityAbstract_69d703a7-47c1-405a-808c-4fb92b465164" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_fa1f259c-9a68-44cd-819c-f03dbc1487dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_5c696bd1-1b22-4678-8a19-6617a7523bc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_563ccede-83ba-4996-9182-c8e4dbfcb55d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_5c696bd1-1b22-4678-8a19-6617a7523bc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_3cdf6030-cec2-4dcf-bc1d-12dbaf804226" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_5c696bd1-1b22-4678-8a19-6617a7523bc6" xlink:to="loc_us-gaap_PreferredStockValue_3cdf6030-cec2-4dcf-bc1d-12dbaf804226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_3ba9acf7-a7ca-4384-8402-da512b8ab85a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_5c696bd1-1b22-4678-8a19-6617a7523bc6" xlink:to="loc_us-gaap_CommonStockValue_3ba9acf7-a7ca-4384-8402-da512b8ab85a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_c13a10f7-dbe3-4e5d-9b42-096575094530" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_5c696bd1-1b22-4678-8a19-6617a7523bc6" xlink:to="loc_us-gaap_AdditionalPaidInCapital_c13a10f7-dbe3-4e5d-9b42-096575094530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e01fe6a0-387c-408e-9c3b-2e4cb1b6c42c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_5c696bd1-1b22-4678-8a19-6617a7523bc6" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e01fe6a0-387c-408e-9c3b-2e4cb1b6c42c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c2a81856-b468-4634-b8c1-bf835ee547e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_5c696bd1-1b22-4678-8a19-6617a7523bc6" xlink:to="loc_us-gaap_StockholdersEquity_c2a81856-b468-4634-b8c1-bf835ee547e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_9259bdc1-11e8-40ff-a4f2-85e896d7461f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_5c696bd1-1b22-4678-8a19-6617a7523bc6" xlink:to="loc_us-gaap_MinorityInterest_9259bdc1-11e8-40ff-a4f2-85e896d7461f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9138f225-402f-4282-8d6d-c306a04cad21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_5c696bd1-1b22-4678-8a19-6617a7523bc6" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9138f225-402f-4282-8d6d-c306a04cad21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_4bd9d199-f1d7-43bd-9bdb-b7b83bf52525" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_563ccede-83ba-4996-9182-c8e4dbfcb55d" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_4bd9d199-f1d7-43bd-9bdb-b7b83bf52525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" xlink:type="simple" xlink:href="ameh-20200630.xsd#CONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_497d278b-70e8-4171-a012-774349079fee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ff8f5ee8-fd52-4860-a68a-a1cff2992840" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_497d278b-70e8-4171-a012-774349079fee" xlink:to="loc_us-gaap_StatementTable_ff8f5ee8-fd52-4860-a68a-a1cff2992840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3ebb8462-49b7-4e8e-ab47-1ab811b7e9d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ff8f5ee8-fd52-4860-a68a-a1cff2992840" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3ebb8462-49b7-4e8e-ab47-1ab811b7e9d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2e263eac-f3d4-444f-b4cf-52445102e36f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3ebb8462-49b7-4e8e-ab47-1ab811b7e9d0" xlink:to="loc_us-gaap_ClassOfStockDomain_2e263eac-f3d4-444f-b4cf-52445102e36f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_8522d724-2889-4634-ba86-48bbcacbc0e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2e263eac-f3d4-444f-b4cf-52445102e36f" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_8522d724-2889-4634-ba86-48bbcacbc0e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_c8068189-76ef-4ed9-98cf-7e79cab873af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2e263eac-f3d4-444f-b4cf-52445102e36f" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_c8068189-76ef-4ed9-98cf-7e79cab873af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_06845bf4-c959-42f3-a96c-4af25e854795" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ff8f5ee8-fd52-4860-a68a-a1cff2992840" xlink:to="loc_us-gaap_StatementLineItems_06845bf4-c959-42f3-a96c-4af25e854795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_abd532d3-2168-4896-b6c9-7acd623be8f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_06845bf4-c959-42f3-a96c-4af25e854795" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_abd532d3-2168-4896-b6c9-7acd623be8f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_fd9110ba-5a62-4ea1-9707-99387ca04bac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_06845bf4-c959-42f3-a96c-4af25e854795" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_fd9110ba-5a62-4ea1-9707-99387ca04bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_8a5d4edf-c540-42e3-ae5d-b86900ee56c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_06845bf4-c959-42f3-a96c-4af25e854795" xlink:to="loc_us-gaap_PreferredStockSharesIssued_8a5d4edf-c540-42e3-ae5d-b86900ee56c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_01d56683-4cd1-4ec3-84b5-cf1a96cf3b61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_06845bf4-c959-42f3-a96c-4af25e854795" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_01d56683-4cd1-4ec3-84b5-cf1a96cf3b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_b4de3018-3a94-46b3-85c8-c35ce4dfcc09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_06845bf4-c959-42f3-a96c-4af25e854795" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_b4de3018-3a94-46b3-85c8-c35ce4dfcc09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_661c7c28-2d9c-48d8-9e2d-b8fae871452e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_06845bf4-c959-42f3-a96c-4af25e854795" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_661c7c28-2d9c-48d8-9e2d-b8fae871452e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_bc5be01d-4f00-4d36-a689-090bb4631314" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_06845bf4-c959-42f3-a96c-4af25e854795" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_bc5be01d-4f00-4d36-a689-090bb4631314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_f57061dc-e18a-491e-9a48-0f2610198514" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_06845bf4-c959-42f3-a96c-4af25e854795" xlink:to="loc_us-gaap_TreasuryStockCommonShares_f57061dc-e18a-491e-9a48-0f2610198514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" xlink:type="simple" xlink:href="ameh-20200630.xsd#CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_23bd6c3e-c001-48bb-b714-870297506f0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5e1d9878-288b-46a3-a414-5e543cea84c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_23bd6c3e-c001-48bb-b714-870297506f0e" xlink:to="loc_us-gaap_StatementTable_5e1d9878-288b-46a3-a414-5e543cea84c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ee4d422f-b479-4359-bace-8be6e2eda604" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5e1d9878-288b-46a3-a414-5e543cea84c2" xlink:to="loc_srt_ProductOrServiceAxis_ee4d422f-b479-4359-bace-8be6e2eda604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7a8f0124-3823-4e1c-a638-ed2102174d10" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ee4d422f-b479-4359-bace-8be6e2eda604" xlink:to="loc_srt_ProductsAndServicesDomain_7a8f0124-3823-4e1c-a638-ed2102174d10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_HealthCareCapitationRevenueMember_09f7d947-5cc2-45ef-b840-68c127d89792" xlink:href="ameh-20200630.xsd#ameh_HealthCareCapitationRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7a8f0124-3823-4e1c-a638-ed2102174d10" xlink:to="loc_ameh_HealthCareCapitationRevenueMember_09f7d947-5cc2-45ef-b840-68c127d89792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOtherMember_a082bbbe-9ead-489c-bcac-92f98d328569" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7a8f0124-3823-4e1c-a638-ed2102174d10" xlink:to="loc_us-gaap_HealthCareOtherMember_a082bbbe-9ead-489c-bcac-92f98d328569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementServiceMember_c659ab3f-01a8-4b43-80eb-31b425b34f4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ManagementServiceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7a8f0124-3823-4e1c-a638-ed2102174d10" xlink:to="loc_us-gaap_ManagementServiceMember_c659ab3f-01a8-4b43-80eb-31b425b34f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCarePatientServiceMember_a322962a-da0b-41e0-b3d2-b6682283e859" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCarePatientServiceMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7a8f0124-3823-4e1c-a638-ed2102174d10" xlink:to="loc_us-gaap_HealthCarePatientServiceMember_a322962a-da0b-41e0-b3d2-b6682283e859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_6dc7d0e9-375c-4114-8775-5053235166da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7a8f0124-3823-4e1c-a638-ed2102174d10" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_6dc7d0e9-375c-4114-8775-5053235166da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_13f7d2d9-94fb-42d9-a13b-27989c21aa34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5e1d9878-288b-46a3-a414-5e543cea84c2" xlink:to="loc_us-gaap_StatementLineItems_13f7d2d9-94fb-42d9-a13b-27989c21aa34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_1cc21a0f-bf19-4989-becd-155a05aae55a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_13f7d2d9-94fb-42d9-a13b-27989c21aa34" xlink:to="loc_us-gaap_RevenuesAbstract_1cc21a0f-bf19-4989-becd-155a05aae55a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_939e50e8-f8cd-4302-94ee-d0eb687899ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_1cc21a0f-bf19-4989-becd-155a05aae55a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_939e50e8-f8cd-4302-94ee-d0eb687899ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_f3e78016-0ab0-4bfe-ab68-b858079846fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_13f7d2d9-94fb-42d9-a13b-27989c21aa34" xlink:to="loc_us-gaap_OperatingExpensesAbstract_f3e78016-0ab0-4bfe-ab68-b858079846fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_3a6e2996-875f-4955-9bc1-b20a43d5a681" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f3e78016-0ab0-4bfe-ab68-b858079846fb" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_3a6e2996-875f-4955-9bc1-b20a43d5a681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_abeabaec-9553-4492-8386-27cfec84ae6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f3e78016-0ab0-4bfe-ab68-b858079846fb" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_abeabaec-9553-4492-8386-27cfec84ae6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts_bb084039-0936-497e-9a41-2d10572fcbed" xlink:href="ameh-20200630.xsd#ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f3e78016-0ab0-4bfe-ab68-b858079846fb" xlink:to="loc_ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts_bb084039-0936-497e-9a41-2d10572fcbed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_d22287c9-aabd-4f0b-b663-45d3f501fd65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f3e78016-0ab0-4bfe-ab68-b858079846fb" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_d22287c9-aabd-4f0b-b663-45d3f501fd65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_7dffdaf3-d38b-427f-8545-e0fad7b0193e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f3e78016-0ab0-4bfe-ab68-b858079846fb" xlink:to="loc_us-gaap_CostsAndExpenses_7dffdaf3-d38b-427f-8545-e0fad7b0193e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c94f1868-f70c-4041-80c2-9e825546478e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_13f7d2d9-94fb-42d9-a13b-27989c21aa34" xlink:to="loc_us-gaap_OperatingIncomeLoss_c94f1868-f70c-4041-80c2-9e825546478e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_dc6f2aba-397f-4e56-afde-bc09d322bcbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_13f7d2d9-94fb-42d9-a13b-27989c21aa34" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_dc6f2aba-397f-4e56-afde-bc09d322bcbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_0ae109ce-bedb-4ede-8f81-6c6c70be5ff1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_dc6f2aba-397f-4e56-afde-bc09d322bcbf" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_0ae109ce-bedb-4ede-8f81-6c6c70be5ff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_87b0f755-241c-49fe-a1da-4aa91e90f326" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_dc6f2aba-397f-4e56-afde-bc09d322bcbf" xlink:to="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_87b0f755-241c-49fe-a1da-4aa91e90f326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_e4a02435-cf9e-41d9-be73-94b984a75303" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_dc6f2aba-397f-4e56-afde-bc09d322bcbf" xlink:to="loc_us-gaap_InterestExpense_e4a02435-cf9e-41d9-be73-94b984a75303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_86859e2c-f13f-4ffb-bf08-1b6456092d79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_dc6f2aba-397f-4e56-afde-bc09d322bcbf" xlink:to="loc_us-gaap_InvestmentIncomeInterest_86859e2c-f13f-4ffb-bf08-1b6456092d79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_35ed27cc-d39a-4e46-a235-7516838bd0f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_dc6f2aba-397f-4e56-afde-bc09d322bcbf" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_35ed27cc-d39a-4e46-a235-7516838bd0f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_756f1034-76b1-49a4-8189-44473925ceee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_dc6f2aba-397f-4e56-afde-bc09d322bcbf" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_756f1034-76b1-49a4-8189-44473925ceee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_9603c55b-4116-4dd3-9b30-e26ca66f845c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_13f7d2d9-94fb-42d9-a13b-27989c21aa34" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_9603c55b-4116-4dd3-9b30-e26ca66f845c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b1979723-a70e-4fb2-a764-8ca428470d88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_13f7d2d9-94fb-42d9-a13b-27989c21aa34" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b1979723-a70e-4fb2-a764-8ca428470d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_fd19805e-28bf-4eac-b42b-5f9142701c38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_13f7d2d9-94fb-42d9-a13b-27989c21aa34" xlink:to="loc_us-gaap_ProfitLoss_fd19805e-28bf-4eac-b42b-5f9142701c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_3530f6ce-ce73-43bf-aac1-dffcc8e28ad4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_13f7d2d9-94fb-42d9-a13b-27989c21aa34" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_3530f6ce-ce73-43bf-aac1-dffcc8e28ad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_868ae344-b512-4223-bc64-d3a9bb674643" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_13f7d2d9-94fb-42d9-a13b-27989c21aa34" xlink:to="loc_us-gaap_NetIncomeLoss_868ae344-b512-4223-bc64-d3a9bb674643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_3a4d5164-d210-4939-8004-6de0345cfe23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_13f7d2d9-94fb-42d9-a13b-27989c21aa34" xlink:to="loc_us-gaap_EarningsPerShareBasic_3a4d5164-d210-4939-8004-6de0345cfe23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_de446bda-b0fc-4b91-8e31-32250a8b8207" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_13f7d2d9-94fb-42d9-a13b-27989c21aa34" xlink:to="loc_us-gaap_EarningsPerShareDiluted_de446bda-b0fc-4b91-8e31-32250a8b8207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED" xlink:type="simple" xlink:href="ameh-20200630.xsd#CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_7fc12256-c12c-4651-bb64-01773961c952" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_194e6b2d-2646-4ea2-978c-31c6773fb661" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_7fc12256-c12c-4651-bb64-01773961c952" xlink:to="loc_us-gaap_StatementTable_194e6b2d-2646-4ea2-978c-31c6773fb661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_35c154b7-400b-408e-b4c5-045f4d90dc49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_194e6b2d-2646-4ea2-978c-31c6773fb661" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_35c154b7-400b-408e-b4c5-045f4d90dc49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ed5281d5-554f-40ce-b5f1-d1777a919f64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_35c154b7-400b-408e-b4c5-045f4d90dc49" xlink:to="loc_us-gaap_EquityComponentDomain_ed5281d5-554f-40ce-b5f1-d1777a919f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_87a3a393-48a0-4d6f-82cc-b6e6e3bb2ef4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ed5281d5-554f-40ce-b5f1-d1777a919f64" xlink:to="loc_us-gaap_CommonStockMember_87a3a393-48a0-4d6f-82cc-b6e6e3bb2ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_b048999b-e3e6-417b-ac80-54d0e391de70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ed5281d5-554f-40ce-b5f1-d1777a919f64" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_b048999b-e3e6-417b-ac80-54d0e391de70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_28048779-5191-422b-b837-5d73b4faf33b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ed5281d5-554f-40ce-b5f1-d1777a919f64" xlink:to="loc_us-gaap_RetainedEarningsMember_28048779-5191-422b-b837-5d73b4faf33b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_7bdb2bb9-25af-49a2-9906-f65ded1ab708" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ed5281d5-554f-40ce-b5f1-d1777a919f64" xlink:to="loc_us-gaap_NoncontrollingInterestMember_7bdb2bb9-25af-49a2-9906-f65ded1ab708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_9da3acc7-789e-4407-bb8d-f6cbe6e259f3" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_194e6b2d-2646-4ea2-978c-31c6773fb661" xlink:to="loc_dei_LegalEntityAxis_9da3acc7-789e-4407-bb8d-f6cbe6e259f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_751c458c-7dde-4320-bdd7-486638dccb3f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_9da3acc7-789e-4407-bb8d-f6cbe6e259f3" xlink:to="loc_dei_EntityDomain_751c458c-7dde-4320-bdd7-486638dccb3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MezzanineMember_db55625c-2815-4d09-b0fe-b1ca1b593734" xlink:href="ameh-20200630.xsd#ameh_MezzanineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_751c458c-7dde-4320-bdd7-486638dccb3f" xlink:to="loc_ameh_MezzanineMember_db55625c-2815-4d09-b0fe-b1ca1b593734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_18415265-84fc-47a3-8a87-c113e5bf709e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_194e6b2d-2646-4ea2-978c-31c6773fb661" xlink:to="loc_us-gaap_StatementLineItems_18415265-84fc-47a3-8a87-c113e5bf709e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e4e80326-d9a9-4b53-948a-886a06737560" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18415265-84fc-47a3-8a87-c113e5bf709e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e4e80326-d9a9-4b53-948a-886a06737560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_5e0cb546-8834-483c-a9c5-b7952191c859" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18415265-84fc-47a3-8a87-c113e5bf709e" xlink:to="loc_us-gaap_SharesOutstanding_5e0cb546-8834-483c-a9c5-b7952191c859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity_1d4f6d21-a64f-4b3a-8dda-159828b3c09c" xlink:href="ameh-20200630.xsd#ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18415265-84fc-47a3-8a87-c113e5bf709e" xlink:to="loc_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity_1d4f6d21-a64f-4b3a-8dda-159828b3c09c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredParValueMethod_a2809336-7f27-47ee-ae40-9fd93bac17ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredParValueMethod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18415265-84fc-47a3-8a87-c113e5bf709e" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredParValueMethod_a2809336-7f27-47ee-ae40-9fd93bac17ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_d734f21e-1057-47bd-b057-02523d0dd0de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18415265-84fc-47a3-8a87-c113e5bf709e" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_d734f21e-1057-47bd-b057-02523d0dd0de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_59f1fcaf-a3b8-4fd6-b91c-5ce57731df30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18415265-84fc-47a3-8a87-c113e5bf709e" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_59f1fcaf-a3b8-4fd6-b91c-5ce57731df30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_7be7d6c6-930c-4af0-b1e1-d0b65da6b464" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18415265-84fc-47a3-8a87-c113e5bf709e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_7be7d6c6-930c-4af0-b1e1-d0b65da6b464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_13320dac-92c0-490b-afcc-86c405a18cac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18415265-84fc-47a3-8a87-c113e5bf709e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_13320dac-92c0-490b-afcc-86c405a18cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants_a0051437-221b-4960-a578-ea3f6c4038b5" xlink:href="ameh-20200630.xsd#ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18415265-84fc-47a3-8a87-c113e5bf709e" xlink:to="loc_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants_a0051437-221b-4960-a578-ea3f6c4038b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants_c84e2025-deae-4420-8219-5a027fc2898c" xlink:href="ameh-20200630.xsd#ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18415265-84fc-47a3-8a87-c113e5bf709e" xlink:to="loc_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants_c84e2025-deae-4420-8219-5a027fc2898c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_84a84445-1db1-45a4-990b-111b302997f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18415265-84fc-47a3-8a87-c113e5bf709e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_84a84445-1db1-45a4-990b-111b302997f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_d505046f-b3bf-44f7-869e-9a177026940e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18415265-84fc-47a3-8a87-c113e5bf709e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_d505046f-b3bf-44f7-869e-9a177026940e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodValueRestrictedStockAwardCancelled_95bb19b6-f205-4c12-8501-21dbc44cede1" xlink:href="ameh-20200630.xsd#ameh_StockIssuedDuringPeriodValueRestrictedStockAwardCancelled"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18415265-84fc-47a3-8a87-c113e5bf709e" xlink:to="loc_ameh_StockIssuedDuringPeriodValueRestrictedStockAwardCancelled_95bb19b6-f205-4c12-8501-21dbc44cede1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_95096b40-89e2-4f52-83dc-edd2b55a14df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18415265-84fc-47a3-8a87-c113e5bf709e" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_95096b40-89e2-4f52-83dc-edd2b55a14df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_05c6aebb-a393-4530-8b9b-aa30154ff3c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18415265-84fc-47a3-8a87-c113e5bf709e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_05c6aebb-a393-4530-8b9b-aa30154ff3c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_b2904474-b692-450d-80b4-0f13ba416e3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18415265-84fc-47a3-8a87-c113e5bf709e" xlink:to="loc_us-gaap_SharesOutstanding_b2904474-b692-450d-80b4-0f13ba416e3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" xlink:type="simple" xlink:href="ameh-20200630.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_ac38ee8f-1d45-4fbd-addd-3de75a1e8d1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e78f7c8e-8071-45da-89ab-b5265adcd8d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ac38ee8f-1d45-4fbd-addd-3de75a1e8d1a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e78f7c8e-8071-45da-89ab-b5265adcd8d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_813ac3ed-4016-4196-b8b1-b576bfc7a9c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e78f7c8e-8071-45da-89ab-b5265adcd8d7" xlink:to="loc_us-gaap_ProfitLoss_813ac3ed-4016-4196-b8b1-b576bfc7a9c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_30fc37ec-e93e-493a-a5be-1b5702750678" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e78f7c8e-8071-45da-89ab-b5265adcd8d7" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_30fc37ec-e93e-493a-a5be-1b5702750678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_8ce03364-7d1c-4d01-9924-3b85015b0817" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_30fc37ec-e93e-493a-a5be-1b5702750678" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_8ce03364-7d1c-4d01-9924-3b85015b0817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_4abac149-7637-428a-aef2-0d2ba0cc62cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_30fc37ec-e93e-493a-a5be-1b5702750678" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_4abac149-7637-428a-aef2-0d2ba0cc62cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_9d5e6a30-3cb8-4a9b-b8cc-34b1b62541b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_30fc37ec-e93e-493a-a5be-1b5702750678" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_9d5e6a30-3cb8-4a9b-b8cc-34b1b62541b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_7fbc856f-5570-4678-a08c-6dd3d76ffe34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_30fc37ec-e93e-493a-a5be-1b5702750678" xlink:to="loc_us-gaap_ShareBasedCompensation_7fbc856f-5570-4678-a08c-6dd3d76ffe34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_be10d0a4-2d56-4a05-9e09-bfa1acc8e50b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_30fc37ec-e93e-493a-a5be-1b5702750678" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_be10d0a4-2d56-4a05-9e09-bfa1acc8e50b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_1f7bc7a3-d0de-4aef-baf6-9ae8b0dc3e35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_30fc37ec-e93e-493a-a5be-1b5702750678" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_1f7bc7a3-d0de-4aef-baf6-9ae8b0dc3e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_7c8567a5-dff7-4f6c-b59a-f9c94dd86534" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_30fc37ec-e93e-493a-a5be-1b5702750678" xlink:to="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_7c8567a5-dff7-4f6c-b59a-f9c94dd86534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_cefac674-b5f0-40df-96ab-789a648694da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_30fc37ec-e93e-493a-a5be-1b5702750678" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_cefac674-b5f0-40df-96ab-789a648694da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f2ea8fc7-fc5f-4d78-b9f3-f92a4b8ca273" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_30fc37ec-e93e-493a-a5be-1b5702750678" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f2ea8fc7-fc5f-4d78-b9f3-f92a4b8ca273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a51b99ec-4a95-40f3-987a-70f9ad559e25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f2ea8fc7-fc5f-4d78-b9f3-f92a4b8ca273" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a51b99ec-4a95-40f3-987a-70f9ad559e25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_6d6c77e0-7bc3-40ab-ac22-4905ec15191c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f2ea8fc7-fc5f-4d78-b9f3-f92a4b8ca273" xlink:to="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_6d6c77e0-7bc3-40ab-ac22-4905ec15191c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_e1835cb6-31d7-4d11-b545-f9559c99fa3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f2ea8fc7-fc5f-4d78-b9f3-f92a4b8ca273" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_e1835cb6-31d7-4d11-b545-f9559c99fa3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_329ac386-dbd9-431b-8030-d378fc1486a3" xlink:href="ameh-20200630.xsd#ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f2ea8fc7-fc5f-4d78-b9f3-f92a4b8ca273" xlink:to="loc_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_329ac386-dbd9-431b-8030-d378fc1486a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInOperatingLeaseAssets_7d95444b-833b-4812-be2b-1f71318e41cf" xlink:href="ameh-20200630.xsd#ameh_IncreaseDecreaseInOperatingLeaseAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f2ea8fc7-fc5f-4d78-b9f3-f92a4b8ca273" xlink:to="loc_ameh_IncreaseDecreaseInOperatingLeaseAssets_7d95444b-833b-4812-be2b-1f71318e41cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_67605c0d-a4c0-459a-8cf9-fc8a417ca28e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f2ea8fc7-fc5f-4d78-b9f3-f92a4b8ca273" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_67605c0d-a4c0-459a-8cf9-fc8a417ca28e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_e2c2a3b9-dc3e-40af-ab74-b61ddac8323a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f2ea8fc7-fc5f-4d78-b9f3-f92a4b8ca273" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_e2c2a3b9-dc3e-40af-ab74-b61ddac8323a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable_19e8e83b-ff64-451a-ae87-398e499218bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f2ea8fc7-fc5f-4d78-b9f3-f92a4b8ca273" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable_19e8e83b-ff64-451a-ae87-398e499218bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInMedicalLiabilities_6393ef9f-5b70-4c7f-a0dc-5c9db3cc6428" xlink:href="ameh-20200630.xsd#ameh_IncreaseDecreaseInMedicalLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f2ea8fc7-fc5f-4d78-b9f3-f92a4b8ca273" xlink:to="loc_ameh_IncreaseDecreaseInMedicalLiabilities_6393ef9f-5b70-4c7f-a0dc-5c9db3cc6428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_c034bb89-5191-4a46-a43e-2a152b41fd13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f2ea8fc7-fc5f-4d78-b9f3-f92a4b8ca273" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_c034bb89-5191-4a46-a43e-2a152b41fd13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities_c8995af9-53c6-4437-a222-8d81970f6956" xlink:href="ameh-20200630.xsd#ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f2ea8fc7-fc5f-4d78-b9f3-f92a4b8ca273" xlink:to="loc_ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities_c8995af9-53c6-4437-a222-8d81970f6956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2703291b-8c7b-413e-b7b2-091d9c14f901" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e78f7c8e-8071-45da-89ab-b5265adcd8d7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2703291b-8c7b-413e-b7b2-091d9c14f901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fb43503b-4c1e-4c57-8b00-2fa52f4788be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ac38ee8f-1d45-4fbd-addd-3de75a1e8d1a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fb43503b-4c1e-4c57-8b00-2fa52f4788be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_b2321622-6a80-4857-86bc-d3297d9e1794" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fb43503b-4c1e-4c57-8b00-2fa52f4788be" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_b2321622-6a80-4857-86bc-d3297d9e1794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfLoansReceivable_4dbe23cb-0aca-4a50-99a4-6453762b56d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollectionOfLoansReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fb43503b-4c1e-4c57-8b00-2fa52f4788be" xlink:to="loc_us-gaap_ProceedsFromCollectionOfLoansReceivable_4dbe23cb-0aca-4a50-99a4-6453762b56d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToFundLongtermLoansToRelatedParties_71a33548-9c7c-4206-bccd-0840b8a5004f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToFundLongtermLoansToRelatedParties"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fb43503b-4c1e-4c57-8b00-2fa52f4788be" xlink:to="loc_us-gaap_PaymentsToFundLongtermLoansToRelatedParties_71a33548-9c7c-4206-bccd-0840b8a5004f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_a26632dd-8ffb-4e61-8d3f-a274326a3a43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fb43503b-4c1e-4c57-8b00-2fa52f4788be" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_a26632dd-8ffb-4e61-8d3f-a274326a3a43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_d100a706-9088-4ac3-baca-6067505a644b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fb43503b-4c1e-4c57-8b00-2fa52f4788be" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_d100a706-9088-4ac3-baca-6067505a644b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_3455d742-71e7-434a-a573-7738bb1b87ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fb43503b-4c1e-4c57-8b00-2fa52f4788be" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_3455d742-71e7-434a-a573-7738bb1b87ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_089d401a-1828-40f8-8661-ac66bea39b0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fb43503b-4c1e-4c57-8b00-2fa52f4788be" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_089d401a-1828-40f8-8661-ac66bea39b0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_80309994-ad3e-41f0-84c4-e0b9d11be4a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fb43503b-4c1e-4c57-8b00-2fa52f4788be" xlink:to="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_80309994-ad3e-41f0-84c4-e0b9d11be4a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1e14d0c9-e64a-49f3-ad1e-175eef4b6fbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fb43503b-4c1e-4c57-8b00-2fa52f4788be" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1e14d0c9-e64a-49f3-ad1e-175eef4b6fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a6cc142c-7969-429b-bec2-ec9fd1763c78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ac38ee8f-1d45-4fbd-addd-3de75a1e8d1a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a6cc142c-7969-429b-bec2-ec9fd1763c78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_RepaymentsOfBankLoanAndLinesOfCredit_2ecd7c73-eaa0-458f-9794-cb912ff94910" xlink:href="ameh-20200630.xsd#ameh_RepaymentsOfBankLoanAndLinesOfCredit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a6cc142c-7969-429b-bec2-ec9fd1763c78" xlink:to="loc_ameh_RepaymentsOfBankLoanAndLinesOfCredit_2ecd7c73-eaa0-458f-9794-cb912ff94910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_3d957544-3c1a-4fcf-a46e-22a0049f1d73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a6cc142c-7969-429b-bec2-ec9fd1763c78" xlink:to="loc_us-gaap_PaymentsOfDividends_3d957544-3c1a-4fcf-a46e-22a0049f1d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_defe30fe-80e6-4a23-a0ac-46241d23f003" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a6cc142c-7969-429b-bec2-ec9fd1763c78" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_defe30fe-80e6-4a23-a0ac-46241d23f003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_0bc0bc09-201c-4b91-bbab-865b12aa3b58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a6cc142c-7969-429b-bec2-ec9fd1763c78" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_0bc0bc09-201c-4b91-bbab-865b12aa3b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_eeeeed7e-b699-4c7b-b6d8-e7465e0c28be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a6cc142c-7969-429b-bec2-ec9fd1763c78" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_eeeeed7e-b699-4c7b-b6d8-e7465e0c28be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_5979e72d-d024-479e-b1d6-581a1e1d836e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a6cc142c-7969-429b-bec2-ec9fd1763c78" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_5979e72d-d024-479e-b1d6-581a1e1d836e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_c45881e7-80c1-416b-a24f-6384972526cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a6cc142c-7969-429b-bec2-ec9fd1763c78" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_c45881e7-80c1-416b-a24f-6384972526cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_bb4728e8-b4b0-4e0f-8296-4f763e525841" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a6cc142c-7969-429b-bec2-ec9fd1763c78" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_bb4728e8-b4b0-4e0f-8296-4f763e525841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5ef40e6a-a928-4cf6-9c20-7f970ab92c90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a6cc142c-7969-429b-bec2-ec9fd1763c78" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5ef40e6a-a928-4cf6-9c20-7f970ab92c90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a6f31f39-6984-4269-a842-2ffed0ef74d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ac38ee8f-1d45-4fbd-addd-3de75a1e8d1a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a6f31f39-6984-4269-a842-2ffed0ef74d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_42fc885c-9672-4cf7-aa5e-44aeb6a0daec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ac38ee8f-1d45-4fbd-addd-3de75a1e8d1a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_42fc885c-9672-4cf7-aa5e-44aeb6a0daec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_94c3606e-e6ff-47a5-af82-dd8ebac6fb00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ac38ee8f-1d45-4fbd-addd-3de75a1e8d1a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_94c3606e-e6ff-47a5-af82-dd8ebac6fb00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_93935e54-3a31-44bc-84a6-b3cc5de7e6ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ac38ee8f-1d45-4fbd-addd-3de75a1e8d1a" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_93935e54-3a31-44bc-84a6-b3cc5de7e6ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_3c91e3b7-12fd-4808-8273-d3da335a4229" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_93935e54-3a31-44bc-84a6-b3cc5de7e6ed" xlink:to="loc_us-gaap_IncomeTaxesPaid_3c91e3b7-12fd-4808-8273-d3da335a4229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_d45169a6-7f74-4796-8641-d6feb498bcf8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_93935e54-3a31-44bc-84a6-b3cc5de7e6ed" xlink:to="loc_us-gaap_InterestPaidNet_d45169a6-7f74-4796-8641-d6feb498bcf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_46c00cb7-28a3-4bc0-b1be-b216ca248ad3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ac38ee8f-1d45-4fbd-addd-3de75a1e8d1a" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_46c00cb7-28a3-4bc0-b1be-b216ca248ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_18c89a00-6910-4fbb-b503-9c9b2ccd8180" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_46c00cb7-28a3-4bc0-b1be-b216ca248ad3" xlink:to="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_18c89a00-6910-4fbb-b503-9c9b2ccd8180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DeferredTaxLiabilityAdjustedToGoodwill_d2056ba1-5a54-42b5-a603-ddc1af21432e" xlink:href="ameh-20200630.xsd#ameh_DeferredTaxLiabilityAdjustedToGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_46c00cb7-28a3-4bc0-b1be-b216ca248ad3" xlink:to="loc_ameh_DeferredTaxLiabilityAdjustedToGoodwill_d2056ba1-5a54-42b5-a603-ddc1af21432e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1_7df74846-02cd-49d8-98ab-6bcae7045808" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_46c00cb7-28a3-4bc0-b1be-b216ca248ad3" xlink:to="loc_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1_7df74846-02cd-49d8-98ab-6bcae7045808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_fea3d6df-889c-4b6f-b1ad-db969f0cd98c" xlink:href="ameh-20200630.xsd#ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ac38ee8f-1d45-4fbd-addd-3de75a1e8d1a" xlink:to="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_fea3d6df-889c-4b6f-b1ad-db969f0cd98c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f2574393-a6ef-4513-90b4-28f8efee0e61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_fea3d6df-889c-4b6f-b1ad-db969f0cd98c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f2574393-a6ef-4513-90b4-28f8efee0e61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsNoncurrent_11a005d0-6a7a-4eef-891f-6b80a5f9ea35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashEquivalentsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_fea3d6df-889c-4b6f-b1ad-db969f0cd98c" xlink:to="loc_us-gaap_RestrictedCashEquivalentsNoncurrent_11a005d0-6a7a-4eef-891f-6b80a5f9ea35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_114253f7-ed9a-4fc2-9883-69b6af7852de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_fea3d6df-889c-4b6f-b1ad-db969f0cd98c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_114253f7-ed9a-4fc2-9883-69b6af7852de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/DescriptionofBusiness" xlink:type="simple" xlink:href="ameh-20200630.xsd#DescriptionofBusiness"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/DescriptionofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_25b5e44e-7690-4cdb-8198-6c637a602306" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_a577b937-ee08-4719-bcbc-f6a2882adb68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_25b5e44e-7690-4cdb-8198-6c637a602306" xlink:to="loc_us-gaap_NatureOfOperations_a577b937-ee08-4719-bcbc-f6a2882adb68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#DescriptionofBusinessAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_398cd2cf-cbd2-46b5-ad36-efffd73cb24f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DescriptionOfBusinessTable_a8e4cb68-04c2-4cf4-a2a7-a79f081e1f31" xlink:href="ameh-20200630.xsd#ameh_DescriptionOfBusinessTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_398cd2cf-cbd2-46b5-ad36-efffd73cb24f" xlink:to="loc_ameh_DescriptionOfBusinessTable_a8e4cb68-04c2-4cf4-a2a7-a79f081e1f31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_4d6a6ac1-7d67-4ea1-82a1-305b14dcd3c3" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_a8e4cb68-04c2-4cf4-a2a7-a79f081e1f31" xlink:to="loc_dei_LegalEntityAxis_4d6a6ac1-7d67-4ea1-82a1-305b14dcd3c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_bfb82b4f-a5df-4d77-bd59-812f0f287f2e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_4d6a6ac1-7d67-4ea1-82a1-305b14dcd3c3" xlink:to="loc_dei_EntityDomain_bfb82b4f-a5df-4d77-bd59-812f0f287f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_ae343df2-643c-4cee-b9b3-791fa5a5fb41" xlink:href="ameh-20200630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_bfb82b4f-a5df-4d77-bd59-812f0f287f2e" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_ae343df2-643c-4cee-b9b3-791fa5a5fb41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcLsmaMember_2984b013-ce73-46dc-b92a-92e3c17ebe02" xlink:href="ameh-20200630.xsd#ameh_ApcLsmaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_bfb82b4f-a5df-4d77-bd59-812f0f287f2e" xlink:to="loc_ameh_ApcLsmaMember_2984b013-ce73-46dc-b92a-92e3c17ebe02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlphaCareMedicalGroupInc.Member_10a91f0f-8551-48cc-b82b-352085849389" xlink:href="ameh-20200630.xsd#ameh_AlphaCareMedicalGroupInc.Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_bfb82b4f-a5df-4d77-bd59-812f0f287f2e" xlink:to="loc_ameh_AlphaCareMedicalGroupInc.Member_10a91f0f-8551-48cc-b82b-352085849389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountableHealthCareIPAMember_17a0f2ae-0cba-4232-a349-27596a7f6b1e" xlink:href="ameh-20200630.xsd#ameh_AccountableHealthCareIPAMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_bfb82b4f-a5df-4d77-bd59-812f0f287f2e" xlink:to="loc_ameh_AccountableHealthCareIPAMember_17a0f2ae-0cba-4232-a349-27596a7f6b1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AmgIncMember_7a9671a9-ec9c-42af-92cf-b08a0a51bd36" xlink:href="ameh-20200630.xsd#ameh_AmgIncMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_bfb82b4f-a5df-4d77-bd59-812f0f287f2e" xlink:to="loc_ameh_AmgIncMember_7a9671a9-ec9c-42af-92cf-b08a0a51bd36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_45a45bb6-8411-4fde-8f57-152f6fbd2185" xlink:href="ameh-20200630.xsd#ameh_UniversalCareAcquisitionPartnersLlcMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_bfb82b4f-a5df-4d77-bd59-812f0f287f2e" xlink:to="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_45a45bb6-8411-4fde-8f57-152f6fbd2185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2a451f27-a58f-4e97-b1e6-67ace330a8dd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_a8e4cb68-04c2-4cf4-a2a7-a79f081e1f31" xlink:to="loc_srt_CounterpartyNameAxis_2a451f27-a58f-4e97-b1e6-67ace330a8dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5e2e6698-c27b-4803-b9b1-3ea4a152fd45" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_2a451f27-a58f-4e97-b1e6-67ace330a8dd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5e2e6698-c27b-4803-b9b1-3ea4a152fd45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_APAMHMedicalCorporationMember_6191ae44-d080-441f-b21e-2dfd88d934ae" xlink:href="ameh-20200630.xsd#ameh_APAMHMedicalCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5e2e6698-c27b-4803-b9b1-3ea4a152fd45" xlink:to="loc_ameh_APAMHMedicalCorporationMember_6191ae44-d080-441f-b21e-2dfd88d934ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_742e3259-3f54-499f-8440-c6c5f6fa9d37" xlink:href="ameh-20200630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5e2e6698-c27b-4803-b9b1-3ea4a152fd45" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_742e3259-3f54-499f-8440-c6c5f6fa9d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Dr.JayMember_35b0af47-572a-4391-b154-4472dcbd85fe" xlink:href="ameh-20200630.xsd#ameh_Dr.JayMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5e2e6698-c27b-4803-b9b1-3ea4a152fd45" xlink:to="loc_ameh_Dr.JayMember_35b0af47-572a-4391-b154-4472dcbd85fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BrightHealthCompanyOfCaliforniaInc.Member_ce7a170d-8f3a-47e3-b6bd-3a9957ba02ae" xlink:href="ameh-20200630.xsd#ameh_BrightHealthCompanyOfCaliforniaInc.Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5e2e6698-c27b-4803-b9b1-3ea4a152fd45" xlink:to="loc_ameh_BrightHealthCompanyOfCaliforniaInc.Member_ce7a170d-8f3a-47e3-b6bd-3a9957ba02ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_536a226a-5f05-478a-8b72-a13c6d7dd87b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_a8e4cb68-04c2-4cf4-a2a7-a79f081e1f31" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_536a226a-5f05-478a-8b72-a13c6d7dd87b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_56c166c7-e477-4af4-a31c-a6a1a543a3a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_536a226a-5f05-478a-8b72-a13c6d7dd87b" xlink:to="loc_us-gaap_RelatedPartyDomain_56c166c7-e477-4af4-a31c-a6a1a543a3a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_b27ce3aa-6af9-4cc7-863c-7d18742ddc42" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_56c166c7-e477-4af4-a31c-a6a1a543a3a2" xlink:to="loc_srt_AffiliatedEntityMember_b27ce3aa-6af9-4cc7-863c-7d18742ddc42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5870e9a9-a9c1-4643-be35-8b9f47237f8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_a8e4cb68-04c2-4cf4-a2a7-a79f081e1f31" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5870e9a9-a9c1-4643-be35-8b9f47237f8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4ac9544c-8d72-4144-9456-25c8c00821ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5870e9a9-a9c1-4643-be35-8b9f47237f8a" xlink:to="loc_us-gaap_ClassOfStockDomain_4ac9544c-8d72-4144-9456-25c8c00821ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_3dea908f-82b9-4a17-bf51-ec52ac7fd286" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4ac9544c-8d72-4144-9456-25c8c00821ff" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_3dea908f-82b9-4a17-bf51-ec52ac7fd286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_ef84a7c9-3eb2-4c49-a45b-142a35e8b17f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4ac9544c-8d72-4144-9456-25c8c00821ff" xlink:to="loc_us-gaap_PreferredStockMember_ef84a7c9-3eb2-4c49-a45b-142a35e8b17f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a531371f-975d-4d5a-baa7-4006bb8d5576" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_a8e4cb68-04c2-4cf4-a2a7-a79f081e1f31" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a531371f-975d-4d5a-baa7-4006bb8d5576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_8c5bf709-3f0d-489d-8934-193324b0729e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a531371f-975d-4d5a-baa7-4006bb8d5576" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_8c5bf709-3f0d-489d-8934-193324b0729e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApolloMedicalHoldingsIncMember_3f9a1ba5-c733-493f-921f-dd7bfda89a41" xlink:href="ameh-20200630.xsd#ameh_ApolloMedicalHoldingsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_8c5bf709-3f0d-489d-8934-193324b0729e" xlink:to="loc_ameh_ApolloMedicalHoldingsIncMember_3f9a1ba5-c733-493f-921f-dd7bfda89a41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ConcourseDiagnosticSurgeryCenterLlcMember_1e1ae5c8-5e64-4354-8f63-d222e564cbfb" xlink:href="ameh-20200630.xsd#ameh_ConcourseDiagnosticSurgeryCenterLlcMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_8c5bf709-3f0d-489d-8934-193324b0729e" xlink:to="loc_ameh_ConcourseDiagnosticSurgeryCenterLlcMember_1e1ae5c8-5e64-4354-8f63-d222e564cbfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareIncMember_98d537f7-4529-4758-9809-0d2efc878920" xlink:href="ameh-20200630.xsd#ameh_UniversalCareIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_8c5bf709-3f0d-489d-8934-193324b0729e" xlink:to="loc_ameh_UniversalCareIncMember_98d537f7-4529-4758-9809-0d2efc878920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_afab50fb-8385-4fef-aa08-795a759fabad" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_a8e4cb68-04c2-4cf4-a2a7-a79f081e1f31" xlink:to="loc_srt_OwnershipAxis_afab50fb-8385-4fef-aa08-795a759fabad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_8b66fe62-54c0-438c-b435-bd2b15751469" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_afab50fb-8385-4fef-aa08-795a759fabad" xlink:to="loc_srt_OwnershipDomain_8b66fe62-54c0-438c-b435-bd2b15751469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MaverickMedicalGroupIncMember_51f53426-5ba4-4daf-8c9d-1ee7d61ca540" xlink:href="ameh-20200630.xsd#ameh_MaverickMedicalGroupIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_8b66fe62-54c0-438c-b435-bd2b15751469" xlink:to="loc_ameh_MaverickMedicalGroupIncMember_51f53426-5ba4-4daf-8c9d-1ee7d61ca540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_042614e5-4ac8-4aeb-a40f-add020970d9f" xlink:href="ameh-20200630.xsd#ameh_UniversalCareAcquisitionPartnersLlcMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_8b66fe62-54c0-438c-b435-bd2b15751469" xlink:to="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_042614e5-4ac8-4aeb-a40f-add020970d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d840a5f5-7cf4-4908-94d2-e03c69d7c4d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_a8e4cb68-04c2-4cf4-a2a7-a79f081e1f31" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d840a5f5-7cf4-4908-94d2-e03c69d7c4d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_90abe2c3-ff09-4ef8-aaee-4ac848461b84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d840a5f5-7cf4-4908-94d2-e03c69d7c4d1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_90abe2c3-ff09-4ef8-aaee-4ac848461b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountableHealthCareIPAMember_92b9c87a-981d-429d-8e42-b97022de4d7e" xlink:href="ameh-20200630.xsd#ameh_AccountableHealthCareIPAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_90abe2c3-ff09-4ef8-aaee-4ac848461b84" xlink:to="loc_ameh_AccountableHealthCareIPAMember_92b9c87a-981d-429d-8e42-b97022de4d7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AmgIncMember_1ac6b74e-3364-4227-8a0e-a2bcb3af3110" xlink:href="ameh-20200630.xsd#ameh_AmgIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_90abe2c3-ff09-4ef8-aaee-4ac848461b84" xlink:to="loc_ameh_AmgIncMember_1ac6b74e-3364-4227-8a0e-a2bcb3af3110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DescriptionOfBusinessLineItems_3d67e0b3-3bdd-4b7a-8252-70932d161062" xlink:href="ameh-20200630.xsd#ameh_DescriptionOfBusinessLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_a8e4cb68-04c2-4cf4-a2a7-a79f081e1f31" xlink:to="loc_ameh_DescriptionOfBusinessLineItems_3d67e0b3-3bdd-4b7a-8252-70932d161062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement_737ee347-86d6-4139-945d-07af9cd5eb8f" xlink:href="ameh-20200630.xsd#ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_3d67e0b3-3bdd-4b7a-8252-70932d161062" xlink:to="loc_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement_737ee347-86d6-4139-945d-07af9cd5eb8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet_d8c8db4c-5e49-4ad6-b808-1b79fb350d14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesReceivableNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_3d67e0b3-3bdd-4b7a-8252-70932d161062" xlink:to="loc_us-gaap_NotesReceivableNet_d8c8db4c-5e49-4ad6-b808-1b79fb350d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableTermOfReceivable_cfcf20c8-2a22-43bf-9137-f442a3a3c43e" xlink:href="ameh-20200630.xsd#ameh_FinanceReceivableTermOfReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_3d67e0b3-3bdd-4b7a-8252-70932d161062" xlink:to="loc_ameh_FinanceReceivableTermOfReceivable_cfcf20c8-2a22-43bf-9137-f442a3a3c43e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableStatedInterestRate_6939457f-b2b1-4766-aa23-4e0e0a22b202" xlink:href="ameh-20200630.xsd#ameh_FinanceReceivableStatedInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_3d67e0b3-3bdd-4b7a-8252-70932d161062" xlink:to="loc_ameh_FinanceReceivableStatedInterestRate_6939457f-b2b1-4766-aa23-4e0e0a22b202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate_501d127f-2926-4e42-a211-0bfcdedb0944" xlink:href="ameh-20200630.xsd#ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_3d67e0b3-3bdd-4b7a-8252-70932d161062" xlink:to="loc_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate_501d127f-2926-4e42-a211-0bfcdedb0944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f37ee850-1cd7-4264-8af9-da2bf580ca0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_3d67e0b3-3bdd-4b7a-8252-70932d161062" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f37ee850-1cd7-4264-8af9-da2bf580ca0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_31276859-5c88-41df-bbd1-dc2e82a7a2a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_3d67e0b3-3bdd-4b7a-8252-70932d161062" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_31276859-5c88-41df-bbd1-dc2e82a7a2a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodProxyVotesPercentage_fb483f80-eb69-4b26-8bff-285c549081ec" xlink:href="ameh-20200630.xsd#ameh_StockIssuedDuringPeriodProxyVotesPercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_3d67e0b3-3bdd-4b7a-8252-70932d161062" xlink:to="loc_ameh_StockIssuedDuringPeriodProxyVotesPercentage_fb483f80-eb69-4b26-8bff-285c549081ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_4cd35cba-3ce5-465a-a3ff-0cddd1429f79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_3d67e0b3-3bdd-4b7a-8252-70932d161062" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_4cd35cba-3ce5-465a-a3ff-0cddd1429f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentOwnershipPercentageDisposed_6d70d02d-72c3-478a-986c-38a245b5cb96" xlink:href="ameh-20200630.xsd#ameh_EquityMethodInvestmentOwnershipPercentageDisposed"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_3d67e0b3-3bdd-4b7a-8252-70932d161062" xlink:to="loc_ameh_EquityMethodInvestmentOwnershipPercentageDisposed_6d70d02d-72c3-478a-986c-38a245b5cb96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_3e9b3833-3785-43f6-8759-e64da14c82aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_3d67e0b3-3bdd-4b7a-8252-70932d161062" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_3e9b3833-3785-43f6-8759-e64da14c82aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfEnrollees_f3571b0a-c26c-448d-95ba-24a7c76bd1f4" xlink:href="ameh-20200630.xsd#ameh_NumberOfEnrollees"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_3d67e0b3-3bdd-4b7a-8252-70932d161062" xlink:to="loc_ameh_NumberOfEnrollees_f3571b0a-c26c-448d-95ba-24a7c76bd1f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfEmployees_a8127dbc-8f7c-44dd-b3bb-3a13b2842adb" xlink:href="ameh-20200630.xsd#ameh_NumberOfEmployees"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_3d67e0b3-3bdd-4b7a-8252-70932d161062" xlink:to="loc_ameh_NumberOfEmployees_a8127dbc-8f7c-44dd-b3bb-3a13b2842adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStores_b62a82bc-68f6-4765-8dcb-86847737b6fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfStores"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_3d67e0b3-3bdd-4b7a-8252-70932d161062" xlink:to="loc_us-gaap_NumberOfStores_b62a82bc-68f6-4765-8dcb-86847737b6fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfMembersOfFederallyQualifiedHealthPlans_4e8dad7e-2673-4db0-82eb-b3842c2f0725" xlink:href="ameh-20200630.xsd#ameh_NumberOfMembersOfFederallyQualifiedHealthPlans"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_3d67e0b3-3bdd-4b7a-8252-70932d161062" xlink:to="loc_ameh_NumberOfMembersOfFederallyQualifiedHealthPlans_4e8dad7e-2673-4db0-82eb-b3842c2f0725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfFederallyQualifiedHealthPlans_53668b24-c688-4049-b9b1-08f54acb1daf" xlink:href="ameh-20200630.xsd#ameh_NumberOfFederallyQualifiedHealthPlans"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_3d67e0b3-3bdd-4b7a-8252-70932d161062" xlink:to="loc_ameh_NumberOfFederallyQualifiedHealthPlans_53668b24-c688-4049-b9b1-08f54acb1daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_0a79eca8-8e16-4d51-845c-446cf9fbf0be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_3d67e0b3-3bdd-4b7a-8252-70932d161062" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_0a79eca8-8e16-4d51-845c-446cf9fbf0be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_dc0bbc34-0109-4ed7-94f0-e0b2c994e9fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_3d67e0b3-3bdd-4b7a-8252-70932d161062" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_dc0bbc34-0109-4ed7-94f0-e0b2c994e9fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfFamilyPracticeClinics_5d477b90-e296-4925-9202-d18672d57966" xlink:href="ameh-20200630.xsd#ameh_NumberOfFamilyPracticeClinics"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_3d67e0b3-3bdd-4b7a-8252-70932d161062" xlink:to="loc_ameh_NumberOfFamilyPracticeClinics_5d477b90-e296-4925-9202-d18672d57966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_9e29a61d-b8c7-4a63-ab48-058feadaeb51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_3d67e0b3-3bdd-4b7a-8252-70932d161062" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_9e29a61d-b8c7-4a63-ab48-058feadaeb51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_f107a2a7-94e2-4b89-a89e-bef8f55a868d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_3d67e0b3-3bdd-4b7a-8252-70932d161062" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_f107a2a7-94e2-4b89-a89e-bef8f55a868d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_11af16cf-6619-404e-90f4-9863eaf29062" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_3d67e0b3-3bdd-4b7a-8252-70932d161062" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_11af16cf-6619-404e-90f4-9863eaf29062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfDebt_13547f89-f8f0-4da9-a96a-67dbdc34c4c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfDebt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_3d67e0b3-3bdd-4b7a-8252-70932d161062" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfDebt_13547f89-f8f0-4da9-a96a-67dbdc34c4c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1_f0b19838-4102-49b2-8b43-d85948fbf656" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_3d67e0b3-3bdd-4b7a-8252-70932d161062" xlink:to="loc_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1_f0b19838-4102-49b2-8b43-d85948fbf656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet_b439b8bd-8ef0-4776-947d-8c76fb371b17" xlink:href="ameh-20200630.xsd#ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_3d67e0b3-3bdd-4b7a-8252-70932d161062" xlink:to="loc_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet_b439b8bd-8ef0-4776-947d-8c76fb371b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="ameh-20200630.xsd#BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d975507a-13db-4df0-9e15-11525e3295ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_448f10cf-df68-4ce4-ba22-5230edb95d63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d975507a-13db-4df0-9e15-11525e3295ba" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_448f10cf-df68-4ce4-ba22-5230edb95d63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="ameh-20200630.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6bf5167a-42f7-425a-bb85-231a84133432" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_340bcb06-077b-41ec-ae29-e09c02a0d9b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6bf5167a-42f7-425a-bb85-231a84133432" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_340bcb06-077b-41ec-ae29-e09c02a0d9b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_bf6ca0b4-553d-4dc1-a19b-1f0b556f7c69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6bf5167a-42f7-425a-bb85-231a84133432" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_bf6ca0b4-553d-4dc1-a19b-1f0b556f7c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_e05ddc1a-e702-41f6-bca8-dbd3c4b14d8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6bf5167a-42f7-425a-bb85-231a84133432" xlink:to="loc_us-gaap_UseOfEstimates_e05ddc1a-e702-41f6-bca8-dbd3c4b14d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_6771045d-0769-4339-a5ce-478ef6894894" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6bf5167a-42f7-425a-bb85-231a84133432" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_6771045d-0769-4339-a5ce-478ef6894894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_713bdf43-44f1-42ed-ae70-c61eebdf3442" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6bf5167a-42f7-425a-bb85-231a84133432" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_713bdf43-44f1-42ed-ae70-c61eebdf3442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_b12ff2c5-b72b-4e3f-b6d9-0c391c6058c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6bf5167a-42f7-425a-bb85-231a84133432" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_b12ff2c5-b72b-4e3f-b6d9-0c391c6058c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_b107e224-29cd-45a1-a4a7-52ce016bd41a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6bf5167a-42f7-425a-bb85-231a84133432" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_b107e224-29cd-45a1-a4a7-52ce016bd41a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock_7ac9b523-fca3-4fa0-9523-a486972e0cad" xlink:href="ameh-20200630.xsd#ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6bf5167a-42f7-425a-bb85-231a84133432" xlink:to="loc_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock_7ac9b523-fca3-4fa0-9523-a486972e0cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_985c4fef-c2c2-4e23-9993-9bfcfc6d6109" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6bf5167a-42f7-425a-bb85-231a84133432" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_985c4fef-c2c2-4e23-9993-9bfcfc6d6109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_57e204cc-105a-4058-90be-dcf4697f8afb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6bf5167a-42f7-425a-bb85-231a84133432" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_57e204cc-105a-4058-90be-dcf4697f8afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_b7479112-e052-4bbe-b08c-135346111fb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6bf5167a-42f7-425a-bb85-231a84133432" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_b7479112-e052-4bbe-b08c-135346111fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_b13463c6-efa7-437d-94ae-d934887cce3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6bf5167a-42f7-425a-bb85-231a84133432" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_b13463c6-efa7-437d-94ae-d934887cce3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_2d5de8be-2874-4693-bd53-b56190984c30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6bf5167a-42f7-425a-bb85-231a84133432" xlink:to="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_2d5de8be-2874-4693-bd53-b56190984c30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareCostsPolicyPolicyTextBlock_f4b8c7dd-e8b8-415a-a8ea-db4783446195" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareCostsPolicyPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6bf5167a-42f7-425a-bb85-231a84133432" xlink:to="loc_us-gaap_HealthCareCostsPolicyPolicyTextBlock_f4b8c7dd-e8b8-415a-a8ea-db4783446195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_f21c7362-02a0-4af9-9793-d0e5972de5a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6bf5167a-42f7-425a-bb85-231a84133432" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_f21c7362-02a0-4af9-9793-d0e5972de5a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_94755af8-b4df-424b-a4cd-1df49783e446" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6bf5167a-42f7-425a-bb85-231a84133432" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_94755af8-b4df-424b-a4cd-1df49783e446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1589a854-3a5c-4f96-82d7-41c74db0c351" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6bf5167a-42f7-425a-bb85-231a84133432" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1589a854-3a5c-4f96-82d7-41c74db0c351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_047d512b-1bc4-4def-8a48-5464c94d326f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6bf5167a-42f7-425a-bb85-231a84133432" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_047d512b-1bc4-4def-8a48-5464c94d326f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MinorityInterestPolicyPolicyTextBlock_979dbe2f-12e5-492c-87b9-9378c5b3b53e" xlink:href="ameh-20200630.xsd#ameh_MinorityInterestPolicyPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6bf5167a-42f7-425a-bb85-231a84133432" xlink:to="loc_ameh_MinorityInterestPolicyPolicyTextBlock_979dbe2f-12e5-492c-87b9-9378c5b3b53e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_TemporaryEquityPolicyTextBlock_f948a0be-216a-487a-b196-5b82b9590f85" xlink:href="ameh-20200630.xsd#ameh_TemporaryEquityPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6bf5167a-42f7-425a-bb85-231a84133432" xlink:to="loc_ameh_TemporaryEquityPolicyTextBlock_f948a0be-216a-487a-b196-5b82b9590f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0691918a-793c-4f71-b117-73286bb14312" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6bf5167a-42f7-425a-bb85-231a84133432" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0691918a-793c-4f71-b117-73286bb14312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="ameh-20200630.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_207509e9-1088-4744-97f1-9c1e544c5d0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_58937fc9-159a-4628-86e0-73d176481496" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_207509e9-1088-4744-97f1-9c1e544c5d0a" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_58937fc9-159a-4628-86e0-73d176481496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_80c0ae49-c7e4-4cce-96f5-a258273af44a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_207509e9-1088-4744-97f1-9c1e544c5d0a" xlink:to="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_80c0ae49-c7e4-4cce-96f5-a258273af44a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_31ed1302-5ff2-41a8-aa67-43a6f4cb9a01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_207509e9-1088-4744-97f1-9c1e544c5d0a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_31ed1302-5ff2-41a8-aa67-43a6f4cb9a01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_49b13e5e-08a5-4626-9abb-b9a75111f196" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_58c893b5-ebe7-498b-b1e6-f5cb5ae8a11b" xlink:href="ameh-20200630.xsd#ameh_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_49b13e5e-08a5-4626-9abb-b9a75111f196" xlink:to="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_58c893b5-ebe7-498b-b1e6-f5cb5ae8a11b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_4803a6b8-33e5-4952-a360-279279e4c75c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_58c893b5-ebe7-498b-b1e6-f5cb5ae8a11b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_4803a6b8-33e5-4952-a360-279279e4c75c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_7d4a09c9-0232-4796-b9e4-e6ea67d2f013" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_4803a6b8-33e5-4952-a360-279279e4c75c" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_7d4a09c9-0232-4796-b9e4-e6ea67d2f013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_7709dfa3-c5a1-419e-a278-1229098c6e24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_7d4a09c9-0232-4796-b9e4-e6ea67d2f013" xlink:to="loc_us-gaap_CertificatesOfDepositMember_7709dfa3-c5a1-419e-a278-1229098c6e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8899ed92-29f4-46a5-9ea3-f78d2894281f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_58c893b5-ebe7-498b-b1e6-f5cb5ae8a11b" xlink:to="loc_srt_RangeAxis_8899ed92-29f4-46a5-9ea3-f78d2894281f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8b4155a6-3e58-490e-9fa2-fd9b0c010bd5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_8899ed92-29f4-46a5-9ea3-f78d2894281f" xlink:to="loc_srt_RangeMember_8b4155a6-3e58-490e-9fa2-fd9b0c010bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0cb7f315-d072-4cdd-9e44-fedb7caf9d7a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8b4155a6-3e58-490e-9fa2-fd9b0c010bd5" xlink:to="loc_srt_MinimumMember_0cb7f315-d072-4cdd-9e44-fedb7caf9d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_33f10b49-8608-4498-af55-496a485f5ed9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8b4155a6-3e58-490e-9fa2-fd9b0c010bd5" xlink:to="loc_srt_MaximumMember_33f10b49-8608-4498-af55-496a485f5ed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8eeb3bdf-435a-46a2-b2a4-f8e72d5b42c8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_58c893b5-ebe7-498b-b1e6-f5cb5ae8a11b" xlink:to="loc_srt_CounterpartyNameAxis_8eeb3bdf-435a-46a2-b2a4-f8e72d5b42c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b2fa49cf-eef8-425c-86ab-4dc351e5952f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_8eeb3bdf-435a-46a2-b2a4-f8e72d5b42c8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b2fa49cf-eef8-425c-86ab-4dc351e5952f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CMSMember_cb58067e-8798-4cd6-a282-581544d407a7" xlink:href="ameh-20200630.xsd#ameh_CMSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b2fa49cf-eef8-425c-86ab-4dc351e5952f" xlink:to="loc_ameh_CMSMember_cb58067e-8798-4cd6-a282-581544d407a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_4401f483-fa72-43e7-b1bd-281c32c5a76c" xlink:href="ameh-20200630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b2fa49cf-eef8-425c-86ab-4dc351e5952f" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_4401f483-fa72-43e7-b1bd-281c32c5a76c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b651a6a8-2157-463e-a19d-c1c9b7f1b14d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_58c893b5-ebe7-498b-b1e6-f5cb5ae8a11b" xlink:to="loc_srt_ProductOrServiceAxis_b651a6a8-2157-463e-a19d-c1c9b7f1b14d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d7670ccc-80c0-49ff-8233-facfbb23eb4e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_b651a6a8-2157-463e-a19d-c1c9b7f1b14d" xlink:to="loc_srt_ProductsAndServicesDomain_d7670ccc-80c0-49ff-8233-facfbb23eb4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PerMemberPerMonthManagedCareContractMember_2e125aa3-6dfc-4690-986a-8b38b378f0fa" xlink:href="ameh-20200630.xsd#ameh_PerMemberPerMonthManagedCareContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d7670ccc-80c0-49ff-8233-facfbb23eb4e" xlink:to="loc_ameh_PerMemberPerMonthManagedCareContractMember_2e125aa3-6dfc-4690-986a-8b38b378f0fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NextGenerationACOModelParticipationAgreementMember_ed14a2d5-4d6f-49cb-9c62-196d0e22d83d" xlink:href="ameh-20200630.xsd#ameh_NextGenerationACOModelParticipationAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d7670ccc-80c0-49ff-8233-facfbb23eb4e" xlink:to="loc_ameh_NextGenerationACOModelParticipationAgreementMember_ed14a2d5-4d6f-49cb-9c62-196d0e22d83d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementServiceMember_402142be-969d-4e9e-a0f0-668597327449" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ManagementServiceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d7670ccc-80c0-49ff-8233-facfbb23eb4e" xlink:to="loc_us-gaap_ManagementServiceMember_402142be-969d-4e9e-a0f0-668597327449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_ba19b6e8-9dc6-45c6-9eba-8295135bd17d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_58c893b5-ebe7-498b-b1e6-f5cb5ae8a11b" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_ba19b6e8-9dc6-45c6-9eba-8295135bd17d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_e056d302-8445-4e0b-b0bb-2fc3de9638c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_ba19b6e8-9dc6-45c6-9eba-8295135bd17d" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_e056d302-8445-4e0b-b0bb-2fc3de9638c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OtherReceivablesMember_817b83a5-f7f6-4fb7-a3f9-df7c26429d20" xlink:href="ameh-20200630.xsd#ameh_OtherReceivablesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e056d302-8445-4e0b-b0bb-2fc3de9638c6" xlink:to="loc_ameh_OtherReceivablesMember_817b83a5-f7f6-4fb7-a3f9-df7c26429d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsPayableAndAccruedExpensesMember_98d27b1e-58b9-418c-9c61-9ddb6bd5721b" xlink:href="ameh-20200630.xsd#ameh_AccountsPayableAndAccruedExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e056d302-8445-4e0b-b0bb-2fc3de9638c6" xlink:to="loc_ameh_AccountsPayableAndAccruedExpensesMember_98d27b1e-58b9-418c-9c61-9ddb6bd5721b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_8150e164-a3db-4bad-a071-4467c91abdd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_58c893b5-ebe7-498b-b1e6-f5cb5ae8a11b" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_8150e164-a3db-4bad-a071-4467c91abdd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_dc37adfb-7fb4-4447-9e83-0eb54af191b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_8150e164-a3db-4bad-a071-4467c91abdd5" xlink:to="loc_us-gaap_ReceivableTypeDomain_dc37adfb-7fb4-4447-9e83-0eb54af191b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OtherReceivablesFinalSettlement2018PerformanceYearMember_bd9e236d-dca0-4f4c-9f6d-56c3976e8f53" xlink:href="ameh-20200630.xsd#ameh_OtherReceivablesFinalSettlement2018PerformanceYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_dc37adfb-7fb4-4447-9e83-0eb54af191b1" xlink:to="loc_ameh_OtherReceivablesFinalSettlement2018PerformanceYearMember_bd9e236d-dca0-4f4c-9f6d-56c3976e8f53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_50592e17-4de4-46ff-865f-e1b9acc3880a" xlink:href="ameh-20200630.xsd#ameh_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_58c893b5-ebe7-498b-b1e6-f5cb5ae8a11b" xlink:to="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_50592e17-4de4-46ff-865f-e1b9acc3880a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_ee39f2d0-f055-4e3b-95c0-c2cb489b5044" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_50592e17-4de4-46ff-865f-e1b9acc3880a" xlink:to="loc_us-gaap_NumberOfOperatingSegments_ee39f2d0-f055-4e3b-95c0-c2cb489b5044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_57ddb472-5364-4de0-85a0-94c8a7ad3f7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_50592e17-4de4-46ff-865f-e1b9acc3880a" xlink:to="loc_us-gaap_NumberOfReportableSegments_57ddb472-5364-4de0-85a0-94c8a7ad3f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashUninsuredAmount_cfaee711-d0a5-49e4-a419-02ef9056252a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashUninsuredAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_50592e17-4de4-46ff-865f-e1b9acc3880a" xlink:to="loc_us-gaap_CashUninsuredAmount_cfaee711-d0a5-49e4-a419-02ef9056252a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_e702fe7f-e353-42e5-9460-cd62ad9d446b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_50592e17-4de4-46ff-865f-e1b9acc3880a" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_e702fe7f-e353-42e5-9460-cd62ad9d446b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MarketableSecuritiesCurrentMaturityPeriod_ebb2cf45-67a2-4832-80f0-67a75cee90b9" xlink:href="ameh-20200630.xsd#ameh_MarketableSecuritiesCurrentMaturityPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_50592e17-4de4-46ff-865f-e1b9acc3880a" xlink:to="loc_ameh_MarketableSecuritiesCurrentMaturityPeriod_ebb2cf45-67a2-4832-80f0-67a75cee90b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear_ce639a83-6213-4873-9cdb-eca4a74ae059" xlink:href="ameh-20200630.xsd#ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_50592e17-4de4-46ff-865f-e1b9acc3880a" xlink:to="loc_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear_ce639a83-6213-4873-9cdb-eca4a74ae059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_63967148-20cf-4f26-8129-c5412b1884e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_50592e17-4de4-46ff-865f-e1b9acc3880a" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_63967148-20cf-4f26-8129-c5412b1884e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_1827721c-b434-405b-baf3-576e7d212863" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_50592e17-4de4-46ff-865f-e1b9acc3880a" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_1827721c-b434-405b-baf3-576e7d212863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_54157788-0ff5-455c-9892-a3b385624dad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_50592e17-4de4-46ff-865f-e1b9acc3880a" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_54157788-0ff5-455c-9892-a3b385624dad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_95f8843f-778d-4c16-a292-5aef62caeb26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_50592e17-4de4-46ff-865f-e1b9acc3880a" xlink:to="loc_us-gaap_NumberOfReportingUnits_95f8843f-778d-4c16-a292-5aef62caeb26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_943ed1c2-eec6-48d5-8458-0a5e2a57e370" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_50592e17-4de4-46ff-865f-e1b9acc3880a" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_943ed1c2-eec6-48d5-8458-0a5e2a57e370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_7a018f4d-a9d3-408f-a821-c0d17a38fc47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_50592e17-4de4-46ff-865f-e1b9acc3880a" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_7a018f4d-a9d3-408f-a821-c0d17a38fc47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_872ab395-34c2-4361-9f17-406c6a216106" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfTiming"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_50592e17-4de4-46ff-865f-e1b9acc3880a" xlink:to="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_872ab395-34c2-4361-9f17-406c6a216106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport_d48a508d-74d2-4afc-9205-ae1cbeb04486" xlink:href="ameh-20200630.xsd#ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_50592e17-4de4-46ff-865f-e1b9acc3880a" xlink:to="loc_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport_d48a508d-74d2-4afc-9205-ae1cbeb04486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentOfRevenueMonthlyAmount_b58918e5-3a7b-43a3-89fb-4b522f43164d" xlink:href="ameh-20200630.xsd#ameh_PaymentOfRevenueMonthlyAmount"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_50592e17-4de4-46ff-865f-e1b9acc3880a" xlink:to="loc_ameh_PaymentOfRevenueMonthlyAmount_b58918e5-3a7b-43a3-89fb-4b522f43164d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentOfRevenue_9f92a093-8a25-449d-8061-cdfd58cfe54d" xlink:href="ameh-20200630.xsd#ameh_PaymentOfRevenue"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_50592e17-4de4-46ff-865f-e1b9acc3880a" xlink:to="loc_ameh_PaymentOfRevenue_9f92a093-8a25-449d-8061-cdfd58cfe54d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_fc31e847-0739-414b-af66-17b8736e2720" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_50592e17-4de4-46ff-865f-e1b9acc3880a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_fc31e847-0739-414b-af66-17b8736e2720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverables_b80a8b22-0e6b-44a2-98fc-db99d238ceb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReinsuranceRecoverables"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_50592e17-4de4-46ff-865f-e1b9acc3880a" xlink:to="loc_us-gaap_ReinsuranceRecoverables_b80a8b22-0e6b-44a2-98fc-db99d238ceb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_cb756656-8d9f-41e4-8db3-f31ac5c5e4bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_50592e17-4de4-46ff-865f-e1b9acc3880a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_cb756656-8d9f-41e4-8db3-f31ac5c5e4bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContractWithCustomerLiabilityRepaidCapitationReceivedAndNotEarned_17eaf5e8-74a4-41ef-b91e-377782e17d2b" xlink:href="ameh-20200630.xsd#ameh_ContractWithCustomerLiabilityRepaidCapitationReceivedAndNotEarned"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_50592e17-4de4-46ff-865f-e1b9acc3880a" xlink:to="loc_ameh_ContractWithCustomerLiabilityRepaidCapitationReceivedAndNotEarned_17eaf5e8-74a4-41ef-b91e-377782e17d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InvestmentDeposit_8c030df2-d11c-4602-80df-92779225b02f" xlink:href="ameh-20200630.xsd#ameh_InvestmentDeposit"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_50592e17-4de4-46ff-865f-e1b9acc3880a" xlink:to="loc_ameh_InvestmentDeposit_8c030df2-d11c-4602-80df-92779225b02f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityOwnershipPercentage_18e11451-abae-4324-9eb6-a7ad71efdfe3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityOwnershipPercentage"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_50592e17-4de4-46ff-865f-e1b9acc3880a" xlink:to="loc_us-gaap_VariableInterestEntityOwnershipPercentage_18e11451-abae-4324-9eb6-a7ad71efdfe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2b54aae7-e256-48df-bf7e-4e3a21737325" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_b8fca488-4b4d-4f03-8b57-b05ca49d8d60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2b54aae7-e256-48df-bf7e-4e3a21737325" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_b8fca488-4b4d-4f03-8b57-b05ca49d8d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_76573e04-7a6b-4553-a337-7ed243e7ccf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_b8fca488-4b4d-4f03-8b57-b05ca49d8d60" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_76573e04-7a6b-4553-a337-7ed243e7ccf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f322d3e7-5254-445b-86b3-5e7b6ac60e44" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_b8fca488-4b4d-4f03-8b57-b05ca49d8d60" xlink:to="loc_srt_ProductOrServiceAxis_f322d3e7-5254-445b-86b3-5e7b6ac60e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0396e240-9b15-4917-89cd-d0da53020d6e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_f322d3e7-5254-445b-86b3-5e7b6ac60e44" xlink:to="loc_srt_ProductsAndServicesDomain_0396e240-9b15-4917-89cd-d0da53020d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NextGenerationACOModelParticipationAgreementMember_777d8f86-e8de-4f5f-b0eb-389a0dce18b6" xlink:href="ameh-20200630.xsd#ameh_NextGenerationACOModelParticipationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0396e240-9b15-4917-89cd-d0da53020d6e" xlink:to="loc_ameh_NextGenerationACOModelParticipationAgreementMember_777d8f86-e8de-4f5f-b0eb-389a0dce18b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_9712c8d6-9b76-4568-af5f-fa0c052c9f83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_b8fca488-4b4d-4f03-8b57-b05ca49d8d60" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_9712c8d6-9b76-4568-af5f-fa0c052c9f83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_9e7cf63e-e401-4642-b859-6e09093ea5da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_9712c8d6-9b76-4568-af5f-fa0c052c9f83" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_9e7cf63e-e401-4642-b859-6e09093ea5da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails_1" xlink:type="simple" xlink:href="ameh-20200630.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails_1"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_21e25a25-143f-4d69-8051-eb82182c8f2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_b0ceea25-ec2c-4db7-93ee-023a750ce2fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_21e25a25-143f-4d69-8051-eb82182c8f2e" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_b0ceea25-ec2c-4db7-93ee-023a750ce2fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_57967c9d-adeb-4ceb-ba23-8c0e83c31b26" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b0ceea25-ec2c-4db7-93ee-023a750ce2fa" xlink:to="loc_srt_MajorCustomersAxis_57967c9d-adeb-4ceb-ba23-8c0e83c31b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_404b6b6b-f323-44ee-bf8e-c48eb5230df3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_57967c9d-adeb-4ceb-ba23-8c0e83c31b26" xlink:to="loc_srt_NameOfMajorCustomerDomain_404b6b6b-f323-44ee-bf8e-c48eb5230df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommercialMember_abfa0f00-8643-41cd-888f-174485c44f54" xlink:href="ameh-20200630.xsd#ameh_CommercialMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_404b6b6b-f323-44ee-bf8e-c48eb5230df3" xlink:to="loc_ameh_CommercialMember_abfa0f00-8643-41cd-888f-174485c44f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicareMember_8b9c542e-bbb3-4a83-94ea-308c0d1f1433" xlink:href="ameh-20200630.xsd#ameh_MedicareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_404b6b6b-f323-44ee-bf8e-c48eb5230df3" xlink:to="loc_ameh_MedicareMember_8b9c542e-bbb3-4a83-94ea-308c0d1f1433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicaidMember_76500d3b-30fc-47b9-be02-10431fafe4a8" xlink:href="ameh-20200630.xsd#ameh_MedicaidMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_404b6b6b-f323-44ee-bf8e-c48eb5230df3" xlink:to="loc_ameh_MedicaidMember_76500d3b-30fc-47b9-be02-10431fafe4a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OtherThirdPartiesMember_714d3586-a096-4aa7-946f-f79a2f7816ba" xlink:href="ameh-20200630.xsd#ameh_OtherThirdPartiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_404b6b6b-f323-44ee-bf8e-c48eb5230df3" xlink:to="loc_ameh_OtherThirdPartiesMember_714d3586-a096-4aa7-946f-f79a2f7816ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_f5643c46-bef0-403b-b7f0-2445f0420c11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b0ceea25-ec2c-4db7-93ee-023a750ce2fa" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_f5643c46-bef0-403b-b7f0-2445f0420c11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8477a912-d2fc-4bba-b4ad-85b1176d3a58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f5643c46-bef0-403b-b7f0-2445f0420c11" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8477a912-d2fc-4bba-b4ad-85b1176d3a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3d7b0b9d-7d38-4ecb-a279-a2d0aebde99f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsReceivableAndNetRevenueTable_625ee747-e73f-406b-85a5-a6baab4fcd2e" xlink:href="ameh-20200630.xsd#ameh_AccountsReceivableAndNetRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3d7b0b9d-7d38-4ecb-a279-a2d0aebde99f" xlink:to="loc_ameh_AccountsReceivableAndNetRevenueTable_625ee747-e73f-406b-85a5-a6baab4fcd2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7d685d2a-1aa0-44a6-b2b8-eb09d3ba0922" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueTable_625ee747-e73f-406b-85a5-a6baab4fcd2e" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7d685d2a-1aa0-44a6-b2b8-eb09d3ba0922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_16d699a7-fe2c-496a-896e-d7b54f8ef0e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7d685d2a-1aa0-44a6-b2b8-eb09d3ba0922" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_16d699a7-fe2c-496a-896e-d7b54f8ef0e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_976c1417-c3f6-4500-bdf7-3d66c36e73d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_16d699a7-fe2c-496a-896e-d7b54f8ef0e6" xlink:to="loc_us-gaap_SalesRevenueNetMember_976c1417-c3f6-4500-bdf7-3d66c36e73d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_dbe14a0d-f3ea-470e-9cd3-9e172499aa02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_16d699a7-fe2c-496a-896e-d7b54f8ef0e6" xlink:to="loc_us-gaap_AccountsReceivableMember_dbe14a0d-f3ea-470e-9cd3-9e172499aa02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_91be38b8-8d8a-46e0-a5a1-4b887996aed9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueTable_625ee747-e73f-406b-85a5-a6baab4fcd2e" xlink:to="loc_srt_MajorCustomersAxis_91be38b8-8d8a-46e0-a5a1-4b887996aed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_5dbe8e3b-147a-4369-95d8-a6259f88c773" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_91be38b8-8d8a-46e0-a5a1-4b887996aed9" xlink:to="loc_srt_NameOfMajorCustomerDomain_5dbe8e3b-147a-4369-95d8-a6259f88c773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorAMember_f3a49a40-00c0-4216-bae3-1c9b46fc804f" xlink:href="ameh-20200630.xsd#ameh_PayorAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_5dbe8e3b-147a-4369-95d8-a6259f88c773" xlink:to="loc_ameh_PayorAMember_f3a49a40-00c0-4216-bae3-1c9b46fc804f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorBMember_3df6e3e9-15f8-4713-a49b-50ccfdb639d4" xlink:href="ameh-20200630.xsd#ameh_PayorBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_5dbe8e3b-147a-4369-95d8-a6259f88c773" xlink:to="loc_ameh_PayorBMember_3df6e3e9-15f8-4713-a49b-50ccfdb639d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorCMember_59d5374d-7510-4eae-b936-64d8049af3b5" xlink:href="ameh-20200630.xsd#ameh_PayorCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_5dbe8e3b-147a-4369-95d8-a6259f88c773" xlink:to="loc_ameh_PayorCMember_59d5374d-7510-4eae-b936-64d8049af3b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorDMember_2fde087b-f7d2-4788-8d0b-ea3b4ff2c6eb" xlink:href="ameh-20200630.xsd#ameh_PayorDMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_5dbe8e3b-147a-4369-95d8-a6259f88c773" xlink:to="loc_ameh_PayorDMember_2fde087b-f7d2-4788-8d0b-ea3b4ff2c6eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorEMember_d6c70901-3f23-4be3-856d-68b60deac770" xlink:href="ameh-20200630.xsd#ameh_PayorEMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_5dbe8e3b-147a-4369-95d8-a6259f88c773" xlink:to="loc_ameh_PayorEMember_d6c70901-3f23-4be3-856d-68b60deac770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorFMember_65e98dd2-0cb7-411d-a3aa-9027cca440e1" xlink:href="ameh-20200630.xsd#ameh_PayorFMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_5dbe8e3b-147a-4369-95d8-a6259f88c773" xlink:to="loc_ameh_PayorFMember_65e98dd2-0cb7-411d-a3aa-9027cca440e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorGMember_c6b9bb26-1709-4ea0-b6f5-0f4d89ce0a9c" xlink:href="ameh-20200630.xsd#ameh_PayorGMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_5dbe8e3b-147a-4369-95d8-a6259f88c773" xlink:to="loc_ameh_PayorGMember_c6b9bb26-1709-4ea0-b6f5-0f4d89ce0a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorHMember_60577758-03b2-41b7-a7c3-a1549582e97c" xlink:href="ameh-20200630.xsd#ameh_PayorHMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_5dbe8e3b-147a-4369-95d8-a6259f88c773" xlink:to="loc_ameh_PayorHMember_60577758-03b2-41b7-a7c3-a1549582e97c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsReceivableAndNetRevenueLineItems_63f16f50-7a3a-4b40-b703-4964d280f05a" xlink:href="ameh-20200630.xsd#ameh_AccountsReceivableAndNetRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueTable_625ee747-e73f-406b-85a5-a6baab4fcd2e" xlink:to="loc_ameh_AccountsReceivableAndNetRevenueLineItems_63f16f50-7a3a-4b40-b703-4964d280f05a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_ddef5e69-c3d6-425a-b303-2d5ff47395e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueLineItems_63f16f50-7a3a-4b40-b703-4964d280f05a" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_ddef5e69-c3d6-425a-b303-2d5ff47395e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4264a25c-0472-4ec9-9b06-f0a0eb99daa1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_142b226e-adcd-468e-8b14-000abad65dc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4264a25c-0472-4ec9-9b06-f0a0eb99daa1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_142b226e-adcd-468e-8b14-000abad65dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6583259f-c761-4280-a429-5bb49428cd1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_142b226e-adcd-468e-8b14-000abad65dc6" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6583259f-c761-4280-a429-5bb49428cd1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54abd81a-38c8-45b3-bb5b-eabf3b60c036" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6583259f-c761-4280-a429-5bb49428cd1c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54abd81a-38c8-45b3-bb5b-eabf3b60c036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_b17b70e2-c306-4465-912a-38a737f643c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54abd81a-38c8-45b3-bb5b-eabf3b60c036" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_b17b70e2-c306-4465-912a-38a737f643c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_7751ea06-aa67-45f9-9712-5cac9740d02b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54abd81a-38c8-45b3-bb5b-eabf3b60c036" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_7751ea06-aa67-45f9-9712-5cac9740d02b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_46082b5a-9701-45a2-97d1-84828e94d687" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54abd81a-38c8-45b3-bb5b-eabf3b60c036" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_46082b5a-9701-45a2-97d1-84828e94d687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_95a40ac1-5e5f-4377-b5c6-3782c43d3b31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_142b226e-adcd-468e-8b14-000abad65dc6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_95a40ac1-5e5f-4377-b5c6-3782c43d3b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_5054d8f7-99a1-4322-8241-918c7565eb32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_95a40ac1-5e5f-4377-b5c6-3782c43d3b31" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_5054d8f7-99a1-4322-8241-918c7565eb32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ab3746d5-aa58-4059-ba10-6e49fb4628f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_5054d8f7-99a1-4322-8241-918c7565eb32" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ab3746d5-aa58-4059-ba10-6e49fb4628f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_65705ea0-020a-43f3-a547-8316d3860da3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_5054d8f7-99a1-4322-8241-918c7565eb32" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_65705ea0-020a-43f3-a547-8316d3860da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_2f164316-8de2-4bbb-ac6e-1115ea635897" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_5054d8f7-99a1-4322-8241-918c7565eb32" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_2f164316-8de2-4bbb-ac6e-1115ea635897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_04460a35-198c-437e-ba6b-ee219cc2424e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_5054d8f7-99a1-4322-8241-918c7565eb32" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_04460a35-198c-437e-ba6b-ee219cc2424e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwill" xlink:type="simple" xlink:href="ameh-20200630.xsd#BusinessCombinationsandGoodwill"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BusinessCombinationsandGoodwill" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_10e9806d-b047-41f1-80b4-41bfcfee9cdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_e83cae2d-ef81-41ec-872c-ebcb629f0ccd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_10e9806d-b047-41f1-80b4-41bfcfee9cdc" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_e83cae2d-ef81-41ec-872c-ebcb629f0ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwillTables" xlink:type="simple" xlink:href="ameh-20200630.xsd#BusinessCombinationsandGoodwillTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BusinessCombinationsandGoodwillTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_79297b85-c77f-4006-8027-8b72ca89619c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_e54ecd04-fd2c-4bef-b1be-b8cc3e3b7c3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_79297b85-c77f-4006-8027-8b72ca89619c" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_e54ecd04-fd2c-4bef-b1be-b8cc3e3b7c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_c0f36fce-7dad-480f-958e-844a6f82bb24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_79297b85-c77f-4006-8027-8b72ca89619c" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_c0f36fce-7dad-480f-958e-844a6f82bb24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#BusinessCombinationsandGoodwillAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_790d7b69-b1f0-48ce-85e8-135d0d818486" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ee17345d-32a0-4960-9ea2-45f0a195a1d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_790d7b69-b1f0-48ce-85e8-135d0d818486" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ee17345d-32a0-4960-9ea2-45f0a195a1d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_29535d8d-cb1d-4336-aad9-5def29e9c9f9" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ee17345d-32a0-4960-9ea2-45f0a195a1d6" xlink:to="loc_dei_LegalEntityAxis_29535d8d-cb1d-4336-aad9-5def29e9c9f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_d3645b33-82ef-4307-a0b7-4526fdd85f3f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_29535d8d-cb1d-4336-aad9-5def29e9c9f9" xlink:to="loc_dei_EntityDomain_d3645b33-82ef-4307-a0b7-4526fdd85f3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_APCAndAPCLSMAMember_95b1122e-1736-4dbc-9bb1-29d8395e3e18" xlink:href="ameh-20200630.xsd#ameh_APCAndAPCLSMAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_d3645b33-82ef-4307-a0b7-4526fdd85f3f" xlink:to="loc_ameh_APCAndAPCLSMAMember_95b1122e-1736-4dbc-9bb1-29d8395e3e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_47b2ec1b-99b0-4c7b-b4df-e5585cd44148" xlink:href="ameh-20200630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_d3645b33-82ef-4307-a0b7-4526fdd85f3f" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_47b2ec1b-99b0-4c7b-b4df-e5585cd44148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_75ee3c92-734f-4f75-bd43-8c74c5088205" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ee17345d-32a0-4960-9ea2-45f0a195a1d6" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_75ee3c92-734f-4f75-bd43-8c74c5088205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6c500cdc-425c-428a-b044-e89be67d2cec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_75ee3c92-734f-4f75-bd43-8c74c5088205" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6c500cdc-425c-428a-b044-e89be67d2cec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlphaCareMedicalGroupInc.Member_78a8671f-4e2a-4899-b75c-d994c7ba7b7b" xlink:href="ameh-20200630.xsd#ameh_AlphaCareMedicalGroupInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6c500cdc-425c-428a-b044-e89be67d2cec" xlink:to="loc_ameh_AlphaCareMedicalGroupInc.Member_78a8671f-4e2a-4899-b75c-d994c7ba7b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountableHealthCareIPAMember_9de42d08-c1e8-415e-bfbc-02bedfc18307" xlink:href="ameh-20200630.xsd#ameh_AccountableHealthCareIPAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6c500cdc-425c-428a-b044-e89be67d2cec" xlink:to="loc_ameh_AccountableHealthCareIPAMember_9de42d08-c1e8-415e-bfbc-02bedfc18307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AmgIncMember_97154529-50fe-4933-a11c-4e6878395714" xlink:href="ameh-20200630.xsd#ameh_AmgIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6c500cdc-425c-428a-b044-e89be67d2cec" xlink:to="loc_ameh_AmgIncMember_97154529-50fe-4933-a11c-4e6878395714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0f1e3e10-2b3d-4664-93eb-5e2f26c56d7b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ee17345d-32a0-4960-9ea2-45f0a195a1d6" xlink:to="loc_srt_CounterpartyNameAxis_0f1e3e10-2b3d-4664-93eb-5e2f26c56d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f1a0b40f-00c3-4ca7-b668-6d7e7ed8dddc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_0f1e3e10-2b3d-4664-93eb-5e2f26c56d7b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f1a0b40f-00c3-4ca7-b668-6d7e7ed8dddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Dr.JayMember_cc1770e2-c775-4228-a64e-ca688f949c80" xlink:href="ameh-20200630.xsd#ameh_Dr.JayMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f1a0b40f-00c3-4ca7-b668-6d7e7ed8dddc" xlink:to="loc_ameh_Dr.JayMember_cc1770e2-c775-4228-a64e-ca688f949c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_a07c94dd-1831-49f2-a374-b2500c09ebfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ee17345d-32a0-4960-9ea2-45f0a195a1d6" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_a07c94dd-1831-49f2-a374-b2500c09ebfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_6a5bf811-9cae-4240-bba5-26506ace9558" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a07c94dd-1831-49f2-a374-b2500c09ebfe" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_6a5bf811-9cae-4240-bba5-26506ace9558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_01067a0b-68c1-4492-be2e-667d7c749ef8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a07c94dd-1831-49f2-a374-b2500c09ebfe" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_01067a0b-68c1-4492-be2e-667d7c749ef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EscrowDeposit_ba4c6223-6e1a-442a-a281-b3895efeaaf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EscrowDeposit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a07c94dd-1831-49f2-a374-b2500c09ebfe" xlink:to="loc_us-gaap_EscrowDeposit_ba4c6223-6e1a-442a-a281-b3895efeaaf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_0a18b75b-c5b9-4c42-9918-1706216f61ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a07c94dd-1831-49f2-a374-b2500c09ebfe" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_0a18b75b-c5b9-4c42-9918-1706216f61ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_36b4d540-0d81-49e9-a9c6-bc0cf0e18743" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a07c94dd-1831-49f2-a374-b2500c09ebfe" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_36b4d540-0d81-49e9-a9c6-bc0cf0e18743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_5700aefb-3095-4370-817f-83a7ebc35a62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a07c94dd-1831-49f2-a374-b2500c09ebfe" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_5700aefb-3095-4370-817f-83a7ebc35a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_4af8061b-7efb-47a6-8630-994da85319a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a07c94dd-1831-49f2-a374-b2500c09ebfe" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_4af8061b-7efb-47a6-8630-994da85319a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_4947062f-cd5d-4017-8783-82e6bcb0bc57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2365312a-53c5-47f6-b12b-d12c85f6a6f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_4947062f-cd5d-4017-8783-82e6bcb0bc57" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2365312a-53c5-47f6-b12b-d12c85f6a6f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_3d02009b-0972-478f-941e-f2291c5b3bde" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2365312a-53c5-47f6-b12b-d12c85f6a6f5" xlink:to="loc_dei_LegalEntityAxis_3d02009b-0972-478f-941e-f2291c5b3bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_ac31c3a5-51da-4ddf-af5d-0f1fdc04e966" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_3d02009b-0972-478f-941e-f2291c5b3bde" xlink:to="loc_dei_EntityDomain_ac31c3a5-51da-4ddf-af5d-0f1fdc04e966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_APCAndAPCLSMAMember_50b4c823-91ce-422b-9a64-b55d44bfcabc" xlink:href="ameh-20200630.xsd#ameh_APCAndAPCLSMAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_ac31c3a5-51da-4ddf-af5d-0f1fdc04e966" xlink:to="loc_ameh_APCAndAPCLSMAMember_50b4c823-91ce-422b-9a64-b55d44bfcabc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6f2ce3fd-9d96-411d-acab-ccc1fe1eb714" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2365312a-53c5-47f6-b12b-d12c85f6a6f5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6f2ce3fd-9d96-411d-acab-ccc1fe1eb714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_17c4742d-e739-4f51-b025-7f8552fef6ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6f2ce3fd-9d96-411d-acab-ccc1fe1eb714" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_17c4742d-e739-4f51-b025-7f8552fef6ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlphaCareMedicalGroupInc.Member_1fe24088-5419-4b95-8369-0a48c5b5918f" xlink:href="ameh-20200630.xsd#ameh_AlphaCareMedicalGroupInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_17c4742d-e739-4f51-b025-7f8552fef6ff" xlink:to="loc_ameh_AlphaCareMedicalGroupInc.Member_1fe24088-5419-4b95-8369-0a48c5b5918f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountableHealthCareIPAMember_38846186-06eb-428e-ba88-1bc6008dd015" xlink:href="ameh-20200630.xsd#ameh_AccountableHealthCareIPAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_17c4742d-e739-4f51-b025-7f8552fef6ff" xlink:to="loc_ameh_AccountableHealthCareIPAMember_38846186-06eb-428e-ba88-1bc6008dd015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e2f90e15-320d-4807-92b0-225db9a7c662" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2365312a-53c5-47f6-b12b-d12c85f6a6f5" xlink:to="loc_srt_CounterpartyNameAxis_e2f90e15-320d-4807-92b0-225db9a7c662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_029d603a-18c0-4272-be6d-59726f60cea8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_e2f90e15-320d-4807-92b0-225db9a7c662" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_029d603a-18c0-4272-be6d-59726f60cea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Dr.JayMember_da038d2f-a215-4d0c-921e-4f2022a4f0aa" xlink:href="ameh-20200630.xsd#ameh_Dr.JayMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_029d603a-18c0-4272-be6d-59726f60cea8" xlink:to="loc_ameh_Dr.JayMember_da038d2f-a215-4d0c-921e-4f2022a4f0aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_01b697df-0ccd-46cc-9eba-cd4f9d36fe31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2365312a-53c5-47f6-b12b-d12c85f6a6f5" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_01b697df-0ccd-46cc-9eba-cd4f9d36fe31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_e73cc2d0-91fb-4da6-87ad-1d412b015ee7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_01b697df-0ccd-46cc-9eba-cd4f9d36fe31" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_e73cc2d0-91fb-4da6-87ad-1d412b015ee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_501b5237-0abe-4e0a-a69a-a0f29d194452" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_e73cc2d0-91fb-4da6-87ad-1d412b015ee7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_501b5237-0abe-4e0a-a69a-a0f29d194452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_27aff902-b2aa-4f04-9f14-7de1cb49e902" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_e73cc2d0-91fb-4da6-87ad-1d412b015ee7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_27aff902-b2aa-4f04-9f14-7de1cb49e902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_8b3be2a3-f888-4271-a7d7-e350ec796346" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_e73cc2d0-91fb-4da6-87ad-1d412b015ee7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_8b3be2a3-f888-4271-a7d7-e350ec796346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_218398b2-2515-47a1-8c39-0cf578d19c23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_e73cc2d0-91fb-4da6-87ad-1d412b015ee7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_218398b2-2515-47a1-8c39-0cf578d19c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f41aa0f2-bc98-4823-893b-1e491345c72a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_e73cc2d0-91fb-4da6-87ad-1d412b015ee7" xlink:to="loc_us-gaap_Goodwill_f41aa0f2-bc98-4823-893b-1e491345c72a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_04f2a2b0-578e-4db7-b0c7-03462653b48f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_01b697df-0ccd-46cc-9eba-cd4f9d36fe31" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_04f2a2b0-578e-4db7-b0c7-03462653b48f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_92790138-40ac-4e6f-94c5-e425d14e1b09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_01b697df-0ccd-46cc-9eba-cd4f9d36fe31" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_92790138-40ac-4e6f-94c5-e425d14e1b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities_29b72c14-65cc-4366-80b3-8b2c1a4aa3c2" xlink:href="ameh-20200630.xsd#ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_01b697df-0ccd-46cc-9eba-cd4f9d36fe31" xlink:to="loc_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities_29b72c14-65cc-4366-80b3-8b2c1a4aa3c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities_bcfbc688-1641-4374-899b-3ef4a99eaf32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_01b697df-0ccd-46cc-9eba-cd4f9d36fe31" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities_bcfbc688-1641-4374-899b-3ef4a99eaf32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_006aa483-844f-48a9-95bf-6c1d3585140d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_01b697df-0ccd-46cc-9eba-cd4f9d36fe31" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_006aa483-844f-48a9-95bf-6c1d3585140d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_384b101f-8e94-4101-ad07-b17021b9cc79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_01b697df-0ccd-46cc-9eba-cd4f9d36fe31" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_384b101f-8e94-4101-ad07-b17021b9cc79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_8549bd7d-687e-4f4d-beea-052e114851f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_01b697df-0ccd-46cc-9eba-cd4f9d36fe31" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_8549bd7d-687e-4f4d-beea-052e114851f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwillSummaryofGoodwillDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#BusinessCombinationsandGoodwillSummaryofGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BusinessCombinationsandGoodwillSummaryofGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_c9f1b622-51b2-415f-bb25-75a3336db2b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_91b49f53-86cc-49ff-851c-e6c66e4faadd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_c9f1b622-51b2-415f-bb25-75a3336db2b6" xlink:to="loc_us-gaap_GoodwillRollForward_91b49f53-86cc-49ff-851c-e6c66e4faadd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_e7163e3a-de2a-4747-8d38-4d14cf6496d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_91b49f53-86cc-49ff-851c-e6c66e4faadd" xlink:to="loc_us-gaap_Goodwill_e7163e3a-de2a-4747-8d38-4d14cf6496d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_c33bcb21-65fd-420f-a07f-5188cad26070" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_91b49f53-86cc-49ff-851c-e6c66e4faadd" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_c33bcb21-65fd-420f-a07f-5188cad26070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_7ed1c960-f2a6-4c0d-b0c1-14b0a6c06407" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_91b49f53-86cc-49ff-851c-e6c66e4faadd" xlink:to="loc_us-gaap_Goodwill_7ed1c960-f2a6-4c0d-b0c1-14b0a6c06407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNet" xlink:type="simple" xlink:href="ameh-20200630.xsd#IntangibleAssetsNet"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ec1663d5-3a84-4367-a394-a4220f26d24a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_a30dfcb8-a40d-46af-b3f8-ea02dc522006" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ec1663d5-3a84-4367-a394-a4220f26d24a" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_a30dfcb8-a40d-46af-b3f8-ea02dc522006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetTables" xlink:type="simple" xlink:href="ameh-20200630.xsd#IntangibleAssetsNetTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_78982286-f821-4861-89f4-2479795850b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_e2c67f52-8113-4eee-bb53-1a9e24c20cd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_78982286-f821-4861-89f4-2479795850b5" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_e2c67f52-8113-4eee-bb53-1a9e24c20cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_5f4f7997-868e-4360-b7eb-052657abba9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_78982286-f821-4861-89f4-2479795850b5" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_5f4f7997-868e-4360-b7eb-052657abba9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#IntangibleAssetsNetScheduleofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_be8c0145-a9f9-48e7-a860-759b4075feee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_be6e7aeb-b09e-429d-8975-516ec3159ced" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_be8c0145-a9f9-48e7-a860-759b4075feee" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_be6e7aeb-b09e-429d-8975-516ec3159ced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c14acb00-658b-4c23-90c3-5508590099ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_be6e7aeb-b09e-429d-8975-516ec3159ced" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c14acb00-658b-4c23-90c3-5508590099ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_438b9b69-c341-432f-9680-a6de6af602d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c14acb00-658b-4c23-90c3-5508590099ba" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_438b9b69-c341-432f-9680-a6de6af602d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkRelationshipsMember_c1220441-d169-4eb4-8ee4-fb41a488cf53" xlink:href="ameh-20200630.xsd#ameh_NetworkRelationshipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_438b9b69-c341-432f-9680-a6de6af602d7" xlink:to="loc_ameh_NetworkRelationshipsMember_c1220441-d169-4eb4-8ee4-fb41a488cf53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ManagementContractsMember_7b57ddcf-b65b-4412-a9ac-5ec16e53a229" xlink:href="ameh-20200630.xsd#ameh_ManagementContractsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_438b9b69-c341-432f-9680-a6de6af602d7" xlink:to="loc_ameh_ManagementContractsMember_7b57ddcf-b65b-4412-a9ac-5ec16e53a229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MemberRelationshipsMember_89bbc6c0-3322-4b8e-b295-1898aaa1887b" xlink:href="ameh-20200630.xsd#ameh_MemberRelationshipsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_438b9b69-c341-432f-9680-a6de6af602d7" xlink:to="loc_ameh_MemberRelationshipsMember_89bbc6c0-3322-4b8e-b295-1898aaa1887b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PatientManagementPlatformMember_004e5d9c-0001-4a91-8943-50d63419c054" xlink:href="ameh-20200630.xsd#ameh_PatientManagementPlatformMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_438b9b69-c341-432f-9680-a6de6af602d7" xlink:to="loc_ameh_PatientManagementPlatformMember_004e5d9c-0001-4a91-8943-50d63419c054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_728ed596-76d7-46f9-ab05-f14a5467b9b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_438b9b69-c341-432f-9680-a6de6af602d7" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_728ed596-76d7-46f9-ab05-f14a5467b9b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4bb7ce29-8fb4-4925-9d07-b8525f70849c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_be6e7aeb-b09e-429d-8975-516ec3159ced" xlink:to="loc_srt_RangeAxis_4bb7ce29-8fb4-4925-9d07-b8525f70849c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d852824b-18da-406a-b4eb-27595bcc90f8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_4bb7ce29-8fb4-4925-9d07-b8525f70849c" xlink:to="loc_srt_RangeMember_d852824b-18da-406a-b4eb-27595bcc90f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_05cd26ca-0376-4187-9a6e-2558e90f3fd8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d852824b-18da-406a-b4eb-27595bcc90f8" xlink:to="loc_srt_MinimumMember_05cd26ca-0376-4187-9a6e-2558e90f3fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b305ccc4-0c14-4207-99c9-3ae2383ccc08" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d852824b-18da-406a-b4eb-27595bcc90f8" xlink:to="loc_srt_MaximumMember_b305ccc4-0c14-4207-99c9-3ae2383ccc08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_19bf0725-7ef9-4ae6-b8ef-da4fcadcbc6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_be6e7aeb-b09e-429d-8975-516ec3159ced" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_19bf0725-7ef9-4ae6-b8ef-da4fcadcbc6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_95a44f45-7f2a-498a-b501-9cddc86e07c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_19bf0725-7ef9-4ae6-b8ef-da4fcadcbc6f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_95a44f45-7f2a-498a-b501-9cddc86e07c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_b3f8cb00-8672-49da-9bfb-5de997f6b395" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_19bf0725-7ef9-4ae6-b8ef-da4fcadcbc6f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_b3f8cb00-8672-49da-9bfb-5de997f6b395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ad7ba57c-220d-4347-8e4b-ae26d14c1d9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_19bf0725-7ef9-4ae6-b8ef-da4fcadcbc6f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ad7ba57c-220d-4347-8e4b-ae26d14c1d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d63cbc8b-c846-4a4f-b616-e068f0dd879d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_19bf0725-7ef9-4ae6-b8ef-da4fcadcbc6f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d63cbc8b-c846-4a4f-b616-e068f0dd879d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_9cfe0771-3d82-4687-9644-100668947a2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_19bf0725-7ef9-4ae6-b8ef-da4fcadcbc6f" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_9cfe0771-3d82-4687-9644-100668947a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_09207a12-d55b-4828-b2ae-f6d1b217fabe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_19bf0725-7ef9-4ae6-b8ef-da4fcadcbc6f" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_09207a12-d55b-4828-b2ae-f6d1b217fabe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="ameh-20200630.xsd#IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#IntangibleAssetsNetAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8d0935b0-81a2-46bd-853e-39fcc125dbb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_e6f2cf26-9d5d-4bfe-bbb9-ead424c0c3d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8d0935b0-81a2-46bd-853e-39fcc125dbb4" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_e6f2cf26-9d5d-4bfe-bbb9-ead424c0c3d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#IntangibleAssetsNetFutureAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_36f057e1-05cb-42dc-827e-bbdb8e4dce64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_e347bd59-c237-400d-aaa6-5f444e8605b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_36f057e1-05cb-42dc-827e-bbdb8e4dce64" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_e347bd59-c237-400d-aaa6-5f444e8605b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_b70edb98-f8cb-4c72-aab1-845e3fabbce0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_36f057e1-05cb-42dc-827e-bbdb8e4dce64" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_b70edb98-f8cb-4c72-aab1-845e3fabbce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_9408362c-0a0d-4c74-9e26-444babbe1005" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_36f057e1-05cb-42dc-827e-bbdb8e4dce64" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_9408362c-0a0d-4c74-9e26-444babbe1005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_c5ff59d1-181d-4b0e-9394-8722eee22009" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_36f057e1-05cb-42dc-827e-bbdb8e4dce64" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_c5ff59d1-181d-4b0e-9394-8722eee22009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_c8cc0e27-fc0f-42bc-8e0d-66a08f131ed5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_36f057e1-05cb-42dc-827e-bbdb8e4dce64" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_c8cc0e27-fc0f-42bc-8e0d-66a08f131ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_b3473833-541f-4229-a484-4d8f8e4e408e" xlink:href="ameh-20200630.xsd#ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_36f057e1-05cb-42dc-827e-bbdb8e4dce64" xlink:to="loc_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_b3473833-541f-4229-a484-4d8f8e4e408e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_61a6d645-f4ae-4d77-b78e-5fd628e01f42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_36f057e1-05cb-42dc-827e-bbdb8e4dce64" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_61a6d645-f4ae-4d77-b78e-5fd628e01f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethod" xlink:type="simple" xlink:href="ameh-20200630.xsd#InvestmentsinOtherEntitiesEquityMethod"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethod" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_de8efecc-53c0-4ea7-a303-cfa7abe8d33c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock_49fb4be0-bbfb-4586-a302-03c19937032b" xlink:href="ameh-20200630.xsd#ameh_EquityMethodAndOtherEquityInvestmentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_de8efecc-53c0-4ea7-a303-cfa7abe8d33c" xlink:to="loc_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock_49fb4be0-bbfb-4586-a302-03c19937032b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodTables" xlink:type="simple" xlink:href="ameh-20200630.xsd#InvestmentsinOtherEntitiesEquityMethodTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_5da69b3c-02bd-48f4-8833-d5747942fcc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock_f7081006-f504-42c3-91d8-0bf0d7e13c27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_5da69b3c-02bd-48f4-8833-d5747942fcc8" xlink:to="loc_us-gaap_EquityMethodInvestmentsTextBlock_f7081006-f504-42c3-91d8-0bf0d7e13c27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentGainOnSaleTableTextBlock_75e894d2-87f2-4ea1-824d-e48a00edc1c9" xlink:href="ameh-20200630.xsd#ameh_EquityMethodInvestmentGainOnSaleTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_5da69b3c-02bd-48f4-8833-d5747942fcc8" xlink:to="loc_ameh_EquityMethodInvestmentGainOnSaleTableTextBlock_75e894d2-87f2-4ea1-824d-e48a00edc1c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_5e0ac3ef-b6a2-4571-b1e7-e093755e4731" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1e7bb2fe-b239-419d-aaf4-c6249156f22c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_5e0ac3ef-b6a2-4571-b1e7-e093755e4731" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1e7bb2fe-b239-419d-aaf4-c6249156f22c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_946015ce-34f3-45e8-8455-2f9d5d4c1cd6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1e7bb2fe-b239-419d-aaf4-c6249156f22c" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_946015ce-34f3-45e8-8455-2f9d5d4c1cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_bfd95bd5-b8ff-42f6-bfe1-663e6b44b88c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_946015ce-34f3-45e8-8455-2f9d5d4c1cd6" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_bfd95bd5-b8ff-42f6-bfe1-663e6b44b88c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember_8fa83180-6fe4-4141-9fad-5ddc28b002cf" xlink:href="ameh-20200630.xsd#ameh_LasalleMedicalAssociatesIpaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_bfd95bd5-b8ff-42f6-bfe1-663e6b44b88c" xlink:to="loc_ameh_LasalleMedicalAssociatesIpaMember_8fa83180-6fe4-4141-9fad-5ddc28b002cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_128fbbf7-299d-4ef9-9c9b-a3609cb4c204" xlink:href="ameh-20200630.xsd#ameh_PacificMedicalImagingAndOncologyCenterIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_bfd95bd5-b8ff-42f6-bfe1-663e6b44b88c" xlink:to="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_128fbbf7-299d-4ef9-9c9b-a3609cb4c204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareIncMember_be0a1394-6a40-4f5e-a83c-6665d23fc9a6" xlink:href="ameh-20200630.xsd#ameh_UniversalCareIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_bfd95bd5-b8ff-42f6-bfe1-663e6b44b88c" xlink:to="loc_ameh_UniversalCareIncMember_be0a1394-6a40-4f5e-a83c-6665d23fc9a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DiagnosticMedicalGroupMember_a7abd179-4b89-495a-9a86-8d74cfa40703" xlink:href="ameh-20200630.xsd#ameh_DiagnosticMedicalGroupMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_bfd95bd5-b8ff-42f6-bfe1-663e6b44b88c" xlink:to="loc_ameh_DiagnosticMedicalGroupMember_a7abd179-4b89-495a-9a86-8d74cfa40703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiveThreeOneW.CollegeLLCMember_71a7d322-c0b0-48b7-b97c-a870a45ba9d3" xlink:href="ameh-20200630.xsd#ameh_FiveThreeOneW.CollegeLLCMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_bfd95bd5-b8ff-42f6-bfe1-663e6b44b88c" xlink:to="loc_ameh_FiveThreeOneW.CollegeLLCMember_71a7d322-c0b0-48b7-b97c-a870a45ba9d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MWNCommunityHospitalLLCMember_fa587210-6856-4de2-81ef-02d44598e081" xlink:href="ameh-20200630.xsd#ameh_MWNCommunityHospitalLLCMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_bfd95bd5-b8ff-42f6-bfe1-663e6b44b88c" xlink:to="loc_ameh_MWNCommunityHospitalLLCMember_fa587210-6856-4de2-81ef-02d44598e081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a9b0bc9a-538e-4625-abe4-2ead7b177cba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1e7bb2fe-b239-419d-aaf4-c6249156f22c" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a9b0bc9a-538e-4625-abe4-2ead7b177cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsRollForward_df9eee11-dd00-4a31-81ac-145f67c7a4d0" xlink:href="ameh-20200630.xsd#ameh_EquityMethodInvestmentsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a9b0bc9a-538e-4625-abe4-2ead7b177cba" xlink:to="loc_ameh_EquityMethodInvestmentsRollForward_df9eee11-dd00-4a31-81ac-145f67c7a4d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_65e1df79-e3f9-4d50-a7dc-8b1bc02b33ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_df9eee11-dd00-4a31-81ac-145f67c7a4d0" xlink:to="loc_us-gaap_EquityMethodInvestments_65e1df79-e3f9-4d50-a7dc-8b1bc02b33ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_ba26f51e-8c34-469e-9050-aa03b2d586d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_df9eee11-dd00-4a31-81ac-145f67c7a4d0" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_ba26f51e-8c34-469e-9050-aa03b2d586d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsContribution_1def9712-8e83-46f2-b1f1-77fd6cc799e8" xlink:href="ameh-20200630.xsd#ameh_EquityMethodInvestmentsContribution"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_df9eee11-dd00-4a31-81ac-145f67c7a4d0" xlink:to="loc_ameh_EquityMethodInvestmentsContribution_1def9712-8e83-46f2-b1f1-77fd6cc799e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_038c31a9-08bf-4eaf-9ea0-435f6d9dfe4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_df9eee11-dd00-4a31-81ac-145f67c7a4d0" xlink:to="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_038c31a9-08bf-4eaf-9ea0-435f6d9dfe4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_4d4a3481-1c3d-4240-83ea-691f41e10788" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_df9eee11-dd00-4a31-81ac-145f67c7a4d0" xlink:to="loc_us-gaap_EquityMethodInvestments_4d4a3481-1c3d-4240-83ea-691f41e10788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_dc0d08e8-30b6-4e57-8dfa-0e3b898fb588" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_b69374cc-543f-4173-876e-0d36457c3915" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_dc0d08e8-30b6-4e57-8dfa-0e3b898fb588" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_b69374cc-543f-4173-876e-0d36457c3915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_fb3c2411-50a1-491f-836e-af72191756f1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_b69374cc-543f-4173-876e-0d36457c3915" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_fb3c2411-50a1-491f-836e-af72191756f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_1169c703-ca93-42f9-ae1a-d29eb7735f36" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_fb3c2411-50a1-491f-836e-af72191756f1" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_1169c703-ca93-42f9-ae1a-d29eb7735f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember_39978da4-5293-448e-9506-36b71995322a" xlink:href="ameh-20200630.xsd#ameh_LasalleMedicalAssociatesIpaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1169c703-ca93-42f9-ae1a-d29eb7735f36" xlink:to="loc_ameh_LasalleMedicalAssociatesIpaMember_39978da4-5293-448e-9506-36b71995322a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_531ad277-ddf1-48e9-9b0c-387b9172b9c3" xlink:href="ameh-20200630.xsd#ameh_PacificMedicalImagingAndOncologyCenterIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1169c703-ca93-42f9-ae1a-d29eb7735f36" xlink:to="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_531ad277-ddf1-48e9-9b0c-387b9172b9c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareIncMember_5f4a75ee-4fed-4261-8d7a-115c636e9d69" xlink:href="ameh-20200630.xsd#ameh_UniversalCareIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1169c703-ca93-42f9-ae1a-d29eb7735f36" xlink:to="loc_ameh_UniversalCareIncMember_5f4a75ee-4fed-4261-8d7a-115c636e9d69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DiagnosticMedicalGroupMember_5a247bea-59ec-4293-a535-194b97577c43" xlink:href="ameh-20200630.xsd#ameh_DiagnosticMedicalGroupMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1169c703-ca93-42f9-ae1a-d29eb7735f36" xlink:to="loc_ameh_DiagnosticMedicalGroupMember_5a247bea-59ec-4293-a535-194b97577c43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiveThreeOneW.CollegeLLCMember_41c49788-a21f-410f-8d9e-6da98e3bcdb2" xlink:href="ameh-20200630.xsd#ameh_FiveThreeOneW.CollegeLLCMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1169c703-ca93-42f9-ae1a-d29eb7735f36" xlink:to="loc_ameh_FiveThreeOneW.CollegeLLCMember_41c49788-a21f-410f-8d9e-6da98e3bcdb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MWNCommunityHospitalLLCMember_27f7ff4f-09e8-429b-8cb3-8e90557ff37a" xlink:href="ameh-20200630.xsd#ameh_MWNCommunityHospitalLLCMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1169c703-ca93-42f9-ae1a-d29eb7735f36" xlink:to="loc_ameh_MWNCommunityHospitalLLCMember_27f7ff4f-09e8-429b-8cb3-8e90557ff37a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_35dccf57-3f84-4528-b00e-c28b30184662" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_b69374cc-543f-4173-876e-0d36457c3915" xlink:to="loc_dei_LegalEntityAxis_35dccf57-3f84-4528-b00e-c28b30184662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_33b87d7a-2ffb-4408-bde6-52fd27c8dd64" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_35dccf57-3f84-4528-b00e-c28b30184662" xlink:to="loc_dei_EntityDomain_33b87d7a-2ffb-4408-bde6-52fd27c8dd64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcLsmaMember_c660a94c-595b-48a6-8ca9-728b553fba3c" xlink:href="ameh-20200630.xsd#ameh_ApcLsmaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_33b87d7a-2ffb-4408-bde6-52fd27c8dd64" xlink:to="loc_ameh_ApcLsmaMember_c660a94c-595b-48a6-8ca9-728b553fba3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_c3dc959b-958e-486f-8fa8-0393ec70d269" xlink:href="ameh-20200630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_33b87d7a-2ffb-4408-bde6-52fd27c8dd64" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_c3dc959b-958e-486f-8fa8-0393ec70d269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_dbb98ead-ecd4-42ad-915e-ca64af50d2f9" xlink:href="ameh-20200630.xsd#ameh_UniversalCareAcquisitionPartnersLlcMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_33b87d7a-2ffb-4408-bde6-52fd27c8dd64" xlink:to="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_dbb98ead-ecd4-42ad-915e-ca64af50d2f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountableHealthCareIPAMember_b42b5211-3b7f-4691-afd4-d082670489f6" xlink:href="ameh-20200630.xsd#ameh_AccountableHealthCareIPAMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_33b87d7a-2ffb-4408-bde6-52fd27c8dd64" xlink:to="loc_ameh_AccountableHealthCareIPAMember_b42b5211-3b7f-4691-afd4-d082670489f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CollegeStreetInvestmentLpMember_4d317d11-1d3d-4124-ae7f-8b15c0a6beec" xlink:href="ameh-20200630.xsd#ameh_CollegeStreetInvestmentLpMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_33b87d7a-2ffb-4408-bde6-52fd27c8dd64" xlink:to="loc_ameh_CollegeStreetInvestmentLpMember_4d317d11-1d3d-4124-ae7f-8b15c0a6beec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementIncMember_f16ea598-ef9f-4b4a-b95a-ab4d337ac918" xlink:href="ameh-20200630.xsd#ameh_NetworkMedicalManagementIncMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_33b87d7a-2ffb-4408-bde6-52fd27c8dd64" xlink:to="loc_ameh_NetworkMedicalManagementIncMember_f16ea598-ef9f-4b4a-b95a-ab4d337ac918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Pacific6EnterprisesMember_68150018-96a9-4ae1-b8c0-4ad118a07647" xlink:href="ameh-20200630.xsd#ameh_Pacific6EnterprisesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_33b87d7a-2ffb-4408-bde6-52fd27c8dd64" xlink:to="loc_ameh_Pacific6EnterprisesMember_68150018-96a9-4ae1-b8c0-4ad118a07647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_HealthSourceMSOInc.Member_5723388b-b02c-4bb6-9366-8b1f78bcc1dc" xlink:href="ameh-20200630.xsd#ameh_HealthSourceMSOInc.Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_33b87d7a-2ffb-4408-bde6-52fd27c8dd64" xlink:to="loc_ameh_HealthSourceMSOInc.Member_5723388b-b02c-4bb6-9366-8b1f78bcc1dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContractTypeAxis_f683a8da-ca48-40ac-b7ae-36205b4d0cd5" xlink:href="ameh-20200630.xsd#ameh_ContractTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_b69374cc-543f-4173-876e-0d36457c3915" xlink:to="loc_ameh_ContractTypeAxis_f683a8da-ca48-40ac-b7ae-36205b4d0cd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContractTypeDomain_b3c8b1f6-4f6f-487e-aab6-f8f3e7bb0a9e" xlink:href="ameh-20200630.xsd#ameh_ContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ContractTypeAxis_f683a8da-ca48-40ac-b7ae-36205b4d0cd5" xlink:to="loc_ameh_ContractTypeDomain_b3c8b1f6-4f6f-487e-aab6-f8f3e7bb0a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AncillaryServiceContractMember_b6c049b6-13a3-4800-bf46-c2fbb41b762a" xlink:href="ameh-20200630.xsd#ameh_AncillaryServiceContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ContractTypeDomain_b3c8b1f6-4f6f-487e-aab6-f8f3e7bb0a9e" xlink:to="loc_ameh_AncillaryServiceContractMember_b6c049b6-13a3-4800-bf46-c2fbb41b762a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_fb65ab19-9dc8-4bca-8e4a-c6e2c5a15ae4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_b69374cc-543f-4173-876e-0d36457c3915" xlink:to="loc_us-gaap_StatementClassOfStockAxis_fb65ab19-9dc8-4bca-8e4a-c6e2c5a15ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_fae4e07d-eed7-4d4d-b676-627418061811" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_fb65ab19-9dc8-4bca-8e4a-c6e2c5a15ae4" xlink:to="loc_us-gaap_ClassOfStockDomain_fae4e07d-eed7-4d4d-b676-627418061811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_VotingCommonStockTwoMember_60439da5-46a5-42eb-9142-32d63a6f2384" xlink:href="ameh-20200630.xsd#ameh_VotingCommonStockTwoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_fae4e07d-eed7-4d4d-b676-627418061811" xlink:to="loc_ameh_VotingCommonStockTwoMember_60439da5-46a5-42eb-9142-32d63a6f2384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_fa87aa7a-eaee-4904-8f76-6bb888eb6ba9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_fae4e07d-eed7-4d4d-b676-627418061811" xlink:to="loc_us-gaap_PreferredStockMember_fa87aa7a-eaee-4904-8f76-6bb888eb6ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_bb717b7a-375e-4300-a47d-0c7f4f4e02b5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_b69374cc-543f-4173-876e-0d36457c3915" xlink:to="loc_srt_CounterpartyNameAxis_bb717b7a-375e-4300-a47d-0c7f4f4e02b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_829ce20b-53d4-45b1-8ac6-b19b6fea75e1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_bb717b7a-375e-4300-a47d-0c7f4f4e02b5" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_829ce20b-53d4-45b1-8ac6-b19b6fea75e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_e6d37319-4351-4a14-9217-5abd9505b751" xlink:href="ameh-20200630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_829ce20b-53d4-45b1-8ac6-b19b6fea75e1" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_e6d37319-4351-4a14-9217-5abd9505b751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BrightHealthCompanyOfCaliforniaInc.Member_32843415-42db-4039-bc78-0abe5258b305" xlink:href="ameh-20200630.xsd#ameh_BrightHealthCompanyOfCaliforniaInc.Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_829ce20b-53d4-45b1-8ac6-b19b6fea75e1" xlink:to="loc_ameh_BrightHealthCompanyOfCaliforniaInc.Member_32843415-42db-4039-bc78-0abe5258b305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_a93800f3-1d31-49d2-8ba2-87970094c4a4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_b69374cc-543f-4173-876e-0d36457c3915" xlink:to="loc_srt_OwnershipAxis_a93800f3-1d31-49d2-8ba2-87970094c4a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_49b4bb48-0d3b-4ca0-801f-45f7677967e5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_a93800f3-1d31-49d2-8ba2-87970094c4a4" xlink:to="loc_srt_OwnershipDomain_49b4bb48-0d3b-4ca0-801f-45f7677967e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MediPortalLLCMember_fbe3e7d2-ec11-4cc8-9531-87601cab2b47" xlink:href="ameh-20200630.xsd#ameh_MediPortalLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_49b4bb48-0d3b-4ca0-801f-45f7677967e5" xlink:to="loc_ameh_MediPortalLLCMember_fbe3e7d2-ec11-4cc8-9531-87601cab2b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AchievaMedInc.Member_851bf0b7-a7fb-43c1-9277-bef2875ed88b" xlink:href="ameh-20200630.xsd#ameh_AchievaMedInc.Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_49b4bb48-0d3b-4ca0-801f-45f7677967e5" xlink:to="loc_ameh_AchievaMedInc.Member_851bf0b7-a7fb-43c1-9277-bef2875ed88b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_b69374cc-543f-4173-876e-0d36457c3915" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStores_2642b7cd-1390-4080-a0ef-09aedd664350" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfStores"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_us-gaap_NumberOfStores_2642b7cd-1390-4080-a0ef-09aedd664350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfEmployees_731bcccf-f714-478a-9c01-2e84a6640a14" xlink:href="ameh-20200630.xsd#ameh_NumberOfEmployees"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_ameh_NumberOfEmployees_731bcccf-f714-478a-9c01-2e84a6640a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfPatients_2ac9a245-8a74-47ec-8caf-9bb682a823a7" xlink:href="ameh-20200630.xsd#ameh_NumberOfPatients"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_ameh_NumberOfPatients_2ac9a245-8a74-47ec-8caf-9bb682a823a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_df7ddcdf-ffca-4e09-b1ad-5cc536233762" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_df7ddcdf-ffca-4e09-b1ad-5cc536233762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_d8cca888-645c-4ad5-8e64-2635fc918803" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_d8cca888-645c-4ad5-8e64-2635fc918803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_ebe10902-4ab0-4739-a2c5-415a1736c714" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_ebe10902-4ab0-4739-a2c5-415a1736c714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_9ee0acce-7171-403b-9f22-975937b146c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_us-gaap_EquityMethodInvestments_9ee0acce-7171-403b-9f22-975937b146c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForFees_614f4ed7-bd73-4f4c-ab02-34689183f716" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForFees"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_us-gaap_PaymentsForFees_614f4ed7-bd73-4f4c-ab02-34689183f716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsPurchaseOfShares_ee77e19e-88c7-4676-b7a5-4bb1a2aafbe0" xlink:href="ameh-20200630.xsd#ameh_EquityMethodInvestmentsPurchaseOfShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_ameh_EquityMethodInvestmentsPurchaseOfShares_ee77e19e-88c7-4676-b7a5-4bb1a2aafbe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_f2eb8482-1028-4b9b-b1a9-de2bd40a0360" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_f2eb8482-1028-4b9b-b1a9-de2bd40a0360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock_9c4c407f-b3aa-4bd7-9fe8-c93ddcd69548" xlink:href="ameh-20200630.xsd#ameh_EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_ameh_EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock_9c4c407f-b3aa-4bd7-9fe8-c93ddcd69548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentOwnershipPercentageDisposed_64d6e476-2aeb-46f4-8f35-cf4105fadd56" xlink:href="ameh-20200630.xsd#ameh_EquityMethodInvestmentOwnershipPercentageDisposed"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_ameh_EquityMethodInvestmentOwnershipPercentageDisposed_64d6e476-2aeb-46f4-8f35-cf4105fadd56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_3854372a-1330-4cc6-bdad-b235c476812e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_3854372a-1330-4cc6-bdad-b235c476812e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfDebt_36aba422-a343-4f74-83b7-9460c4c632d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfDebt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfDebt_36aba422-a343-4f74-83b7-9460c4c632d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_437e4c02-e548-46c0-9b76-72f1a4da90ad" xlink:href="ameh-20200630.xsd#ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_437e4c02-e548-46c0-9b76-72f1a4da90ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet_578fa8bc-1c81-4281-bfce-5be7a9c53e13" xlink:href="ameh-20200630.xsd#ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet_578fa8bc-1c81-4281-bfce-5be7a9c53e13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationCash_b51637bc-1fd3-4c36-86e1-e1e689a635a0" xlink:href="ameh-20200630.xsd#ameh_EquityMethodInvestmentSaleContingentConsiderationCash"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationCash_b51637bc-1fd3-4c36-86e1-e1e689a635a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares_2f735a77-87e0-4ab7-a4aa-e400d988b8f1" xlink:href="ameh-20200630.xsd#ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares_2f735a77-87e0-4ab7-a4aa-e400d988b8f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue_9ea74678-bd73-468f-b88a-f9fee7a51ad5" xlink:href="ameh-20200630.xsd#ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue_9ea74678-bd73-468f-b88a-f9fee7a51ad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MembersCapital_990db7bf-7238-43a9-a860-151e59463779" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MembersCapital"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_us-gaap_MembersCapital_990db7bf-7238-43a9-a860-151e59463779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireRealEstate_28a4d4ed-e2f0-40e4-9a00-7001254377cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireRealEstate"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_us-gaap_PaymentsToAcquireRealEstate_28a4d4ed-e2f0-40e4-9a00-7001254377cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsContribution_ed6c4f67-3dcf-44c1-a03e-f1b63f32165a" xlink:href="ameh-20200630.xsd#ameh_EquityMethodInvestmentsContribution"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_ameh_EquityMethodInvestmentsContribution_ed6c4f67-3dcf-44c1-a03e-f1b63f32165a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WorkingCapitalContribution_27c32305-6a44-445a-922d-4842f62cc634" xlink:href="ameh-20200630.xsd#ameh_WorkingCapitalContribution"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_ameh_WorkingCapitalContribution_27c32305-6a44-445a-922d-4842f62cc634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares_eb61d87d-501a-4f75-abc6-975157d4c706" xlink:href="ameh-20200630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares_eb61d87d-501a-4f75-abc6-975157d4c706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_a0adc618-7eda-4ee2-a7b0-599bd91a8773" xlink:href="ameh-20200630.xsd#ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_a0adc618-7eda-4ee2-a7b0-599bd91a8773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest_1f3b2570-d08d-4c72-afe9-a48870c70f70" xlink:href="ameh-20200630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest_1f3b2570-d08d-4c72-afe9-a48870c70f70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage_6e38bb5d-9b46-49a7-af13-7e851125ed46" xlink:href="ameh-20200630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage_6e38bb5d-9b46-49a7-af13-7e851125ed46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_44fc1f29-a7bb-4aa4-867e-1a37bd985bf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_44fc1f29-a7bb-4aa4-867e-1a37bd985bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_fd6edebc-35ee-4710-90e7-d1cdd924eeab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_fd6edebc-35ee-4710-90e7-d1cdd924eeab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption_8d0b037d-412e-42e5-a093-8ab1e6e71d6a" xlink:href="ameh-20200630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption_8d0b037d-412e-42e5-a093-8ab1e6e71d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests_acae4a6d-e291-4a3f-92b1-c4b499fed8d3" xlink:href="ameh-20200630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests_acae4a6d-e291-4a3f-92b1-c4b499fed8d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet_7d301c0c-b6af-40bf-ad14-a2792598894b" xlink:href="ameh-20200630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet_7d301c0c-b6af-40bf-ad14-a2792598894b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears_d65ed1c0-b2e4-464e-8c80-b40105838834" xlink:href="ameh-20200630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears_d65ed1c0-b2e4-464e-8c80-b40105838834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment_05bd95ed-0180-4553-a0b8-faeb7797a302" xlink:href="ameh-20200630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment_05bd95ed-0180-4553-a0b8-faeb7797a302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost_f36dd05c-09c7-494b-9fa4-16bedcd17e54" xlink:href="ameh-20200630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost_f36dd05c-09c7-494b-9fa4-16bedcd17e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_54d93dee-6965-41a2-bccf-f9cccf9f97f1" xlink:href="ameh-20200630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_11be0fd5-4a39-4a96-8187-38ab29c7cd93" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_54d93dee-6965-41a2-bccf-f9cccf9f97f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodGainonSaleDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#InvestmentsinOtherEntitiesEquityMethodGainonSaleDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodGainonSaleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_4568c758-3d8a-4b2d-90ba-f8e4c5cc0e3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_7b7c3998-7f65-48d8-a985-3d4248b70393" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_4568c758-3d8a-4b2d-90ba-f8e4c5cc0e3f" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_7b7c3998-7f65-48d8-a985-3d4248b70393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_99b040e7-a741-4f58-b33b-45f33e9988a5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_7b7c3998-7f65-48d8-a985-3d4248b70393" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_99b040e7-a741-4f58-b33b-45f33e9988a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_01a59534-309a-476d-89c0-7d60c3c3147e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_99b040e7-a741-4f58-b33b-45f33e9988a5" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_01a59534-309a-476d-89c0-7d60c3c3147e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareIncMember_475490dc-4f5a-4aaf-bc25-6aff75505510" xlink:href="ameh-20200630.xsd#ameh_UniversalCareIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_01a59534-309a-476d-89c0-7d60c3c3147e" xlink:to="loc_ameh_UniversalCareIncMember_475490dc-4f5a-4aaf-bc25-6aff75505510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_38a0fe9f-22d0-4b31-b9da-2df5023b788c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_7b7c3998-7f65-48d8-a985-3d4248b70393" xlink:to="loc_srt_CounterpartyNameAxis_38a0fe9f-22d0-4b31-b9da-2df5023b788c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e8fe04c1-2108-4c4b-b9be-135182322608" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_38a0fe9f-22d0-4b31-b9da-2df5023b788c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e8fe04c1-2108-4c4b-b9be-135182322608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BrightHealthCompanyOfCaliforniaInc.Member_087490bd-14f8-4210-9c50-74270d87afc2" xlink:href="ameh-20200630.xsd#ameh_BrightHealthCompanyOfCaliforniaInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e8fe04c1-2108-4c4b-b9be-135182322608" xlink:to="loc_ameh_BrightHealthCompanyOfCaliforniaInc.Member_087490bd-14f8-4210-9c50-74270d87afc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f1e9b5a7-f55b-4254-b9a1-260920e4d2a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_7b7c3998-7f65-48d8-a985-3d4248b70393" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f1e9b5a7-f55b-4254-b9a1-260920e4d2a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ba7ee61b-d90e-427f-ac9e-38f7028e2c07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f1e9b5a7-f55b-4254-b9a1-260920e4d2a2" xlink:to="loc_us-gaap_ClassOfStockDomain_ba7ee61b-d90e-427f-ac9e-38f7028e2c07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_f564a6ab-8e50-4b78-9a0a-031358792840" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_ba7ee61b-d90e-427f-ac9e-38f7028e2c07" xlink:to="loc_us-gaap_PreferredStockMember_f564a6ab-8e50-4b78-9a0a-031358792840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_12110f3b-011f-4e3e-a65a-ec52c365f863" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_7b7c3998-7f65-48d8-a985-3d4248b70393" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_12110f3b-011f-4e3e-a65a-ec52c365f863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_46b840c3-8ebb-4027-adb1-e089626228d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_12110f3b-011f-4e3e-a65a-ec52c365f863" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_46b840c3-8ebb-4027-adb1-e089626228d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_4bc7da30-3940-4766-b8b7-0a886efd3bbf" xlink:href="ameh-20200630.xsd#ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_12110f3b-011f-4e3e-a65a-ec52c365f863" xlink:to="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_4bc7da30-3940-4766-b8b7-0a886efd3bbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet_3b416000-8f6e-49b6-8928-01c0610a6f13" xlink:href="ameh-20200630.xsd#ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_12110f3b-011f-4e3e-a65a-ec52c365f863" xlink:to="loc_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet_3b416000-8f6e-49b6-8928-01c0610a6f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_2a51dd6a-c1a4-4eef-ba6d-93f2bca8d95b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_12110f3b-011f-4e3e-a65a-ec52c365f863" xlink:to="loc_us-gaap_EquityMethodInvestments_2a51dd6a-c1a4-4eef-ba6d-93f2bca8d95b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_95cf11a7-c847-4f77-afee-c558a4fbfd8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_12110f3b-011f-4e3e-a65a-ec52c365f863" xlink:to="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_95cf11a7-c847-4f77-afee-c558a4fbfd8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_21893279-484c-4a1b-bb9f-fd7c13f7e829" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_6d140ac8-d7af-4a0e-a701-6aae16e3b136" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_21893279-484c-4a1b-bb9f-fd7c13f7e829" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_6d140ac8-d7af-4a0e-a701-6aae16e3b136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_4754e914-505a-4f06-b81f-f4a312374e6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_6d140ac8-d7af-4a0e-a701-6aae16e3b136" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_4754e914-505a-4f06-b81f-f4a312374e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_1ad333c1-53fc-42e4-aded-817f19af00ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_4754e914-505a-4f06-b81f-f4a312374e6f" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_1ad333c1-53fc-42e4-aded-817f19af00ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember_da83b4e4-e2bd-4799-b8f9-79a6068995f0" xlink:href="ameh-20200630.xsd#ameh_LasalleMedicalAssociatesIpaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_1ad333c1-53fc-42e4-aded-817f19af00ee" xlink:to="loc_ameh_LasalleMedicalAssociatesIpaMember_da83b4e4-e2bd-4799-b8f9-79a6068995f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiveThreeOneW.CollegeLLCMember_a0544ac5-5285-4f7a-8306-752d51e2dce4" xlink:href="ameh-20200630.xsd#ameh_FiveThreeOneW.CollegeLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_1ad333c1-53fc-42e4-aded-817f19af00ee" xlink:to="loc_ameh_FiveThreeOneW.CollegeLLCMember_a0544ac5-5285-4f7a-8306-752d51e2dce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareIncMember_8c1035d1-ea20-449c-8a55-51f44531a3e3" xlink:href="ameh-20200630.xsd#ameh_UniversalCareIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_1ad333c1-53fc-42e4-aded-817f19af00ee" xlink:to="loc_ameh_UniversalCareIncMember_8c1035d1-ea20-449c-8a55-51f44531a3e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_e9385d11-df13-4c1a-8835-d9451621b1c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_6d140ac8-d7af-4a0e-a701-6aae16e3b136" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_e9385d11-df13-4c1a-8835-d9451621b1c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_95d3bbab-2426-4ea7-85f7-3c5c81d4ddf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_e9385d11-df13-4c1a-8835-d9451621b1c7" xlink:to="loc_us-gaap_AssetsAbstract_95d3bbab-2426-4ea7-85f7-3c5c81d4ddf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f2b2d8aa-ffd3-4811-9777-22b37bc2cf77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_95d3bbab-2426-4ea7-85f7-3c5c81d4ddf5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f2b2d8aa-ffd3-4811-9777-22b37bc2cf77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_915f944d-fe62-406d-9482-c20807504967" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_95d3bbab-2426-4ea7-85f7-3c5c81d4ddf5" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_915f944d-fe62-406d-9482-c20807504967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_71165036-3052-437b-84ce-45c558807082" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_95d3bbab-2426-4ea7-85f7-3c5c81d4ddf5" xlink:to="loc_us-gaap_OtherAssetsCurrent_71165036-3052-437b-84ce-45c558807082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent_0148cf4f-de38-43f3-93a4-230fc30be717" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_95d3bbab-2426-4ea7-85f7-3c5c81d4ddf5" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetCurrent_0148cf4f-de38-43f3-93a4-230fc30be717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_3e2ec748-a00d-4eb2-b185-aba85db09117" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_95d3bbab-2426-4ea7-85f7-3c5c81d4ddf5" xlink:to="loc_us-gaap_RestrictedCashCurrent_3e2ec748-a00d-4eb2-b185-aba85db09117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets_07e3f249-023c-40d4-ba40-7c7c79576e14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_95d3bbab-2426-4ea7-85f7-3c5c81d4ddf5" xlink:to="loc_us-gaap_OtherAssets_07e3f249-023c-40d4-ba40-7c7c79576e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_02c1eabd-65c3-4eda-ac82-183d4a00336b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_95d3bbab-2426-4ea7-85f7-3c5c81d4ddf5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_02c1eabd-65c3-4eda-ac82-183d4a00336b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_6151ede4-5655-443d-ad7a-4c03dee2e9c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_95d3bbab-2426-4ea7-85f7-3c5c81d4ddf5" xlink:to="loc_us-gaap_Assets_6151ede4-5655-443d-ad7a-4c03dee2e9c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2eea7f7f-f826-4ae7-9b7e-5388bcf23457" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_e9385d11-df13-4c1a-8835-d9451621b1c7" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2eea7f7f-f826-4ae7-9b7e-5388bcf23457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_04d57844-97e4-4c7b-a95a-b1a6bc1fea2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2eea7f7f-f826-4ae7-9b7e-5388bcf23457" xlink:to="loc_us-gaap_LiabilitiesCurrent_04d57844-97e4-4c7b-a95a-b1a6bc1fea2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilities_7780d4b9-6eda-40ba-976e-a4a1c7901f72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2eea7f7f-f826-4ae7-9b7e-5388bcf23457" xlink:to="loc_us-gaap_OtherLiabilities_7780d4b9-6eda-40ba-976e-a4a1c7901f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8697ce39-e65f-48c6-bae9-f7a2b36cf7a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2eea7f7f-f826-4ae7-9b7e-5388bcf23457" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8697ce39-e65f-48c6-bae9-f7a2b36cf7a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_894c5227-3427-4201-8c69-26220c6c735f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2eea7f7f-f826-4ae7-9b7e-5388bcf23457" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_894c5227-3427-4201-8c69-26220c6c735f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_fb42f509-ff71-4ebc-8c26-32394d4314dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_e9385d11-df13-4c1a-8835-d9451621b1c7" xlink:to="loc_us-gaap_IncomeStatementAbstract_fb42f509-ff71-4ebc-8c26-32394d4314dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_eceaedc9-6cbd-4229-8bdd-ec755cf19f8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fb42f509-ff71-4ebc-8c26-32394d4314dc" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_eceaedc9-6cbd-4229-8bdd-ec755cf19f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_048dcb97-df54-4afc-8908-9fdba33c930e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fb42f509-ff71-4ebc-8c26-32394d4314dc" xlink:to="loc_us-gaap_CostsAndExpenses_048dcb97-df54-4afc-8908-9fdba33c930e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_231bf4d3-a15e-4d08-91fe-bc8f3d1bf159" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fb42f509-ff71-4ebc-8c26-32394d4314dc" xlink:to="loc_us-gaap_OperatingIncomeLoss_231bf4d3-a15e-4d08-91fe-bc8f3d1bf159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_f17a962b-2540-40fd-bb5d-be6355f1a528" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fb42f509-ff71-4ebc-8c26-32394d4314dc" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_f17a962b-2540-40fd-bb5d-be6355f1a528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_dad3bc9d-210f-44ad-9d55-d5010c51d90e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fb42f509-ff71-4ebc-8c26-32394d4314dc" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_dad3bc9d-210f-44ad-9d55-d5010c51d90e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c6a826c8-a614-471a-bd10-b4b9c05123b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fb42f509-ff71-4ebc-8c26-32394d4314dc" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_c6a826c8-a614-471a-bd10-b4b9c05123b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_0e8d6dc8-3b6e-4b93-8ceb-946459e029f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fb42f509-ff71-4ebc-8c26-32394d4314dc" xlink:to="loc_us-gaap_ProfitLoss_0e8d6dc8-3b6e-4b93-8ceb-946459e029f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedParties" xlink:type="simple" xlink:href="ameh-20200630.xsd#LoanReceivableandLoanReceivableRelatedParties"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedParties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_c1a23000-218f-4cf9-a881-8ad1d20c3c04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LoanReceivableTextBlock_8e67d5a0-1cc6-42ec-ac95-9e62ab0176f4" xlink:href="ameh-20200630.xsd#ameh_LoanReceivableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_c1a23000-218f-4cf9-a881-8ad1d20c3c04" xlink:to="loc_ameh_LoanReceivableTextBlock_8e67d5a0-1cc6-42ec-ac95-9e62ab0176f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_380dd86f-3e6e-46a6-b47f-ccfcf542d062" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_be698141-a10c-4b00-95fe-7f58cb7543b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_380dd86f-3e6e-46a6-b47f-ccfcf542d062" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_be698141-a10c-4b00-95fe-7f58cb7543b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_bf66c944-6866-4a7a-954d-afbcbf7dcf33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_be698141-a10c-4b00-95fe-7f58cb7543b1" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_bf66c944-6866-4a7a-954d-afbcbf7dcf33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_56cff6cf-487a-4f55-9cdc-a334bb79fdc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_bf66c944-6866-4a7a-954d-afbcbf7dcf33" xlink:to="loc_us-gaap_ReceivableTypeDomain_56cff6cf-487a-4f55-9cdc-a334bb79fdc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableMember_b5f2f519-2cf8-4440-818a-8cbd53875348" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_56cff6cf-487a-4f55-9cdc-a334bb79fdc8" xlink:to="loc_us-gaap_NotesReceivableMember_b5f2f519-2cf8-4440-818a-8cbd53875348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceReceivablesMember_2410d652-fe83-4d0d-b9f4-e61ad9058176" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceReceivablesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_56cff6cf-487a-4f55-9cdc-a334bb79fdc8" xlink:to="loc_us-gaap_FinanceReceivablesMember_2410d652-fe83-4d0d-b9f4-e61ad9058176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_56deb266-6cd0-4150-97b9-bf193892a0fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_be698141-a10c-4b00-95fe-7f58cb7543b1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_56deb266-6cd0-4150-97b9-bf193892a0fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_bd9665fa-b14a-461a-b814-7240ba430ded" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_56deb266-6cd0-4150-97b9-bf193892a0fb" xlink:to="loc_us-gaap_RelatedPartyDomain_bd9665fa-b14a-461a-b814-7240ba430ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Dr.ArteagaMember_68cf7ab6-2775-4ae4-a3f6-c8fbc52968d1" xlink:href="ameh-20200630.xsd#ameh_Dr.ArteagaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_bd9665fa-b14a-461a-b814-7240ba430ded" xlink:to="loc_ameh_Dr.ArteagaMember_68cf7ab6-2775-4ae4-a3f6-c8fbc52968d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DrJayLoanMember_5b3a136b-ee1d-4d10-8e12-90dcabef549a" xlink:href="ameh-20200630.xsd#ameh_DrJayLoanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_bd9665fa-b14a-461a-b814-7240ba430ded" xlink:to="loc_ameh_DrJayLoanMember_5b3a136b-ee1d-4d10-8e12-90dcabef549a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_e82a7e0e-d8b1-46ba-8514-8852f90cd9eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_be698141-a10c-4b00-95fe-7f58cb7543b1" xlink:to="loc_us-gaap_VariableRateAxis_e82a7e0e-d8b1-46ba-8514-8852f90cd9eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_bcd40099-ec2d-4ada-b727-34a654cd53d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_e82a7e0e-d8b1-46ba-8514-8852f90cd9eb" xlink:to="loc_us-gaap_VariableRateDomain_bcd40099-ec2d-4ada-b727-34a654cd53d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_c93ea068-9d44-414b-b745-8c4b31673d33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrimeRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_bcd40099-ec2d-4ada-b727-34a654cd53d9" xlink:to="loc_us-gaap_PrimeRateMember_c93ea068-9d44-414b-b745-8c4b31673d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_1ddd80fc-9a97-4ae3-972a-f6a889ba7267" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_be698141-a10c-4b00-95fe-7f58cb7543b1" xlink:to="loc_dei_LegalEntityAxis_1ddd80fc-9a97-4ae3-972a-f6a889ba7267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_5b347c55-8a05-4d6b-8c3e-a1d29d8ed9af" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1ddd80fc-9a97-4ae3-972a-f6a889ba7267" xlink:to="loc_dei_EntityDomain_5b347c55-8a05-4d6b-8c3e-a1d29d8ed9af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_869ae1da-327f-4b8e-aabc-48dfbab6998f" xlink:href="ameh-20200630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_5b347c55-8a05-4d6b-8c3e-a1d29d8ed9af" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_869ae1da-327f-4b8e-aabc-48dfbab6998f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_APCAndAPCLSMAMember_5440634c-8dda-437e-94fa-43431fed6e1c" xlink:href="ameh-20200630.xsd#ameh_APCAndAPCLSMAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_5b347c55-8a05-4d6b-8c3e-a1d29d8ed9af" xlink:to="loc_ameh_APCAndAPCLSMAMember_5440634c-8dda-437e-94fa-43431fed6e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Dr.ArteagaMember_0e8f191b-8e29-4c35-b888-b972b977d3bd" xlink:href="ameh-20200630.xsd#ameh_Dr.ArteagaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_5b347c55-8a05-4d6b-8c3e-a1d29d8ed9af" xlink:to="loc_ameh_Dr.ArteagaMember_0e8f191b-8e29-4c35-b888-b972b977d3bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_bb7152de-148a-46b6-bd06-19d899f19229" xlink:href="ameh-20200630.xsd#ameh_UniversalCareAcquisitionPartnersLlcMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_5b347c55-8a05-4d6b-8c3e-a1d29d8ed9af" xlink:to="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_bb7152de-148a-46b6-bd06-19d899f19229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_09564fe7-0f3a-49f8-b5f5-21c5ecaf9e71" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_be698141-a10c-4b00-95fe-7f58cb7543b1" xlink:to="loc_srt_CounterpartyNameAxis_09564fe7-0f3a-49f8-b5f5-21c5ecaf9e71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_db574b7f-4763-4bec-b86f-6aa0b07d2435" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_09564fe7-0f3a-49f8-b5f5-21c5ecaf9e71" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_db574b7f-4763-4bec-b86f-6aa0b07d2435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_16d63104-d097-4e79-9a10-1dc20f8b2594" xlink:href="ameh-20200630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_db574b7f-4763-4bec-b86f-6aa0b07d2435" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_16d63104-d097-4e79-9a10-1dc20f8b2594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_c1cec427-0fd6-4e01-9849-d43a83e3996f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_be698141-a10c-4b00-95fe-7f58cb7543b1" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_c1cec427-0fd6-4e01-9849-d43a83e3996f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_9ecbdb99-fb6a-4f0e-8abd-9e941a1cd0ac" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_c1cec427-0fd6-4e01-9849-d43a83e3996f" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_9ecbdb99-fb6a-4f0e-8abd-9e941a1cd0ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LmaMember_1386c76e-bdfc-4cbc-9e40-4cebbf0ff038" xlink:href="ameh-20200630.xsd#ameh_LmaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_9ecbdb99-fb6a-4f0e-8abd-9e941a1cd0ac" xlink:to="loc_ameh_LmaMember_1386c76e-bdfc-4cbc-9e40-4cebbf0ff038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareIncMember_9be8e69d-c11a-42d9-9ba0-dea01faa3db8" xlink:href="ameh-20200630.xsd#ameh_UniversalCareIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_9ecbdb99-fb6a-4f0e-8abd-9e941a1cd0ac" xlink:to="loc_ameh_UniversalCareIncMember_9be8e69d-c11a-42d9-9ba0-dea01faa3db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_ab3c4536-516f-40d5-a445-2333ec69911f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_be698141-a10c-4b00-95fe-7f58cb7543b1" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_ab3c4536-516f-40d5-a445-2333ec69911f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet_017d43f5-fdaf-46e9-8da5-a68c2c995136" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesReceivableNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_ab3c4536-516f-40d5-a445-2333ec69911f" xlink:to="loc_us-gaap_NotesReceivableNet_017d43f5-fdaf-46e9-8da5-a68c2c995136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_55cdd4df-c66e-4bda-9049-41ef968eed09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_ab3c4536-516f-40d5-a445-2333ec69911f" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_55cdd4df-c66e-4bda-9049-41ef968eed09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_933de066-9974-48a2-944c-d4b71d46ed0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_ab3c4536-516f-40d5-a445-2333ec69911f" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_933de066-9974-48a2-944c-d4b71d46ed0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinancingReceivableConvertibleToCommonStockPercentageOfOutstandingSharesConvertible_0c04c5cc-47a3-4b6b-b8f0-ccf15d9333a2" xlink:href="ameh-20200630.xsd#ameh_FinancingReceivableConvertibleToCommonStockPercentageOfOutstandingSharesConvertible"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_ab3c4536-516f-40d5-a445-2333ec69911f" xlink:to="loc_ameh_FinancingReceivableConvertibleToCommonStockPercentageOfOutstandingSharesConvertible_0c04c5cc-47a3-4b6b-b8f0-ccf15d9333a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion_fa205885-9cb5-4182-a608-6ead0d562088" xlink:href="ameh-20200630.xsd#ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_ab3c4536-516f-40d5-a445-2333ec69911f" xlink:to="loc_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion_fa205885-9cb5-4182-a608-6ead0d562088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4a08820e-c2e5-4c50-bfa0-0259dcd4f11c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_ab3c4536-516f-40d5-a445-2333ec69911f" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4a08820e-c2e5-4c50-bfa0-0259dcd4f11c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AdvancedForWorkingCapital_af295618-f3bb-49c9-9415-ec8400dca400" xlink:href="ameh-20200630.xsd#ameh_AdvancedForWorkingCapital"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_ab3c4536-516f-40d5-a445-2333ec69911f" xlink:to="loc_ameh_AdvancedForWorkingCapital_af295618-f3bb-49c9-9415-ec8400dca400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LineOfCreditFacilityAdditionalAdvances_b303c79e-3578-4f11-ab0b-ea9fc8fafe76" xlink:href="ameh-20200630.xsd#ameh_LineOfCreditFacilityAdditionalAdvances"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_ab3c4536-516f-40d5-a445-2333ec69911f" xlink:to="loc_ameh_LineOfCreditFacilityAdditionalAdvances_b303c79e-3578-4f11-ab0b-ea9fc8fafe76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_61cfde64-c0bc-4ee4-b994-8278944afb5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_ab3c4536-516f-40d5-a445-2333ec69911f" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_61cfde64-c0bc-4ee4-b994-8278944afb5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpenses" xlink:type="simple" xlink:href="ameh-20200630.xsd#AccountsPayableandAccruedExpenses"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/AccountsPayableandAccruedExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_64883c46-a104-4756-bcc1-fda740e91901" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_482472f1-b99c-4f6b-a748-05d2aaab6609" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_64883c46-a104-4756-bcc1-fda740e91901" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_482472f1-b99c-4f6b-a748-05d2aaab6609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesTables" xlink:type="simple" xlink:href="ameh-20200630.xsd#AccountsPayableandAccruedExpensesTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_82cc278e-2c82-4214-bb02-140cd7c5db15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_bb384a96-8e35-457b-9668-c9f9aed3726c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_82cc278e-2c82-4214-bb02-140cd7c5db15" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_bb384a96-8e35-457b-9668-c9f9aed3726c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_06988235-1038-4334-9678-82eece5f8091" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_c84f8474-8c26-4972-be8d-17e2b291e5a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_06988235-1038-4334-9678-82eece5f8091" xlink:to="loc_us-gaap_AccountsPayableCurrent_c84f8474-8c26-4972-be8d-17e2b291e5a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SpecialtyCapitationPayableCurrent_9d8ef23d-ff1b-4f05-9cd9-73432eb318d2" xlink:href="ameh-20200630.xsd#ameh_SpecialtyCapitationPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_06988235-1038-4334-9678-82eece5f8091" xlink:to="loc_ameh_SpecialtyCapitationPayableCurrent_9d8ef23d-ff1b-4f05-9cd9-73432eb318d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SubcontractorIPAPayable_e56f261b-f6e5-4e20-b32b-8baf5f439c85" xlink:href="ameh-20200630.xsd#ameh_SubcontractorIPAPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_06988235-1038-4334-9678-82eece5f8091" xlink:to="loc_ameh_SubcontractorIPAPayable_e56f261b-f6e5-4e20-b32b-8baf5f439c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_548855bb-8538-4a91-90ff-e5cdc6565465" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_06988235-1038-4334-9678-82eece5f8091" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_548855bb-8538-4a91-90ff-e5cdc6565465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_155b8def-88af-4e86-b1e9-bcb3faaf374c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_06988235-1038-4334-9678-82eece5f8091" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_155b8def-88af-4e86-b1e9-bcb3faaf374c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e4cc6fe6-86a9-47ea-970c-0765d4a932a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_06988235-1038-4334-9678-82eece5f8091" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e4cc6fe6-86a9-47ea-970c-0765d4a932a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_30465001-f7ef-4574-ae5d-89fb774f65fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_06988235-1038-4334-9678-82eece5f8091" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_30465001-f7ef-4574-ae5d-89fb774f65fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_8be549f9-41fb-4ba2-97f6-ba362b80c35e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_06988235-1038-4334-9678-82eece5f8091" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_8be549f9-41fb-4ba2-97f6-ba362b80c35e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MedicalLiabilities" xlink:type="simple" xlink:href="ameh-20200630.xsd#MedicalLiabilities"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/MedicalLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_142c885c-fc0e-4eaa-9309-6c8835bd5066" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock_0403f113-a676-4a13-b65c-b3418b416b8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_142c885c-fc0e-4eaa-9309-6c8835bd5066" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock_0403f113-a676-4a13-b65c-b3418b416b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MedicalLiabilitiesTables" xlink:type="simple" xlink:href="ameh-20200630.xsd#MedicalLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/MedicalLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_05975ec1-2180-4d57-abf9-15f81e09e0a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_a95b587c-d469-44e4-b23c-31b9826edbf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_05975ec1-2180-4d57-abf9-15f81e09e0a3" xlink:to="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_a95b587c-d469-44e4-b23c-31b9826edbf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_bbf30de1-0ac3-4a87-874d-4796e1eb14b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_933c0200-6de0-4c17-87db-c55f28231ae1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_bbf30de1-0ac3-4a87-874d-4796e1eb14b1" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_933c0200-6de0-4c17-87db-c55f28231ae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_e707b9c4-ec76-4f80-9b0d-3fa239b4e300" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_933c0200-6de0-4c17-87db-c55f28231ae1" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_e707b9c4-ec76-4f80-9b0d-3fa239b4e300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicalCareCostsAbstract_1a4c566d-ec40-4145-99ed-cce256b3984e" xlink:href="ameh-20200630.xsd#ameh_MedicalCareCostsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_933c0200-6de0-4c17-87db-c55f28231ae1" xlink:to="loc_ameh_MedicalCareCostsAbstract_1a4c566d-ec40-4145-99ed-cce256b3984e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_6700dbe6-12b2-4b98-9628-25f76d9fdebe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_MedicalCareCostsAbstract_1a4c566d-ec40-4145-99ed-cce256b3984e" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_6700dbe6-12b2-4b98-9628-25f76d9fdebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_e4518616-b1cb-49d2-b963-5382c548a11e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_MedicalCareCostsAbstract_1a4c566d-ec40-4145-99ed-cce256b3984e" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_e4518616-b1cb-49d2-b963-5382c548a11e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_d327efa8-d22f-453b-baa1-2b1a372db877" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_MedicalCareCostsAbstract_1a4c566d-ec40-4145-99ed-cce256b3984e" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_d327efa8-d22f-453b-baa1-2b1a372db877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentsForMedicalCareCostsAbstract_2956cab3-7d60-48e6-a4c4-e4939ecacc17" xlink:href="ameh-20200630.xsd#ameh_PaymentsForMedicalCareCostsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_933c0200-6de0-4c17-87db-c55f28231ae1" xlink:to="loc_ameh_PaymentsForMedicalCareCostsAbstract_2956cab3-7d60-48e6-a4c4-e4939ecacc17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_4f96a68e-2d26-4319-8d35-1a76d5f69361" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_PaymentsForMedicalCareCostsAbstract_2956cab3-7d60-48e6-a4c4-e4939ecacc17" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_4f96a68e-2d26-4319-8d35-1a76d5f69361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_032fa4e1-2795-423d-856d-c6890909f966" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_PaymentsForMedicalCareCostsAbstract_2956cab3-7d60-48e6-a4c4-e4939ecacc17" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_032fa4e1-2795-423d-856d-c6890909f966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_6efb31ab-2af0-40c6-9297-0621a7896ddf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_PaymentsForMedicalCareCostsAbstract_2956cab3-7d60-48e6-a4c4-e4939ecacc17" xlink:to="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_6efb31ab-2af0-40c6-9297-0621a7896ddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions_8d1a9b33-ed91-4046-be79-b473c1f1080d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_933c0200-6de0-4c17-87db-c55f28231ae1" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions_8d1a9b33-ed91-4046-be79-b473c1f1080d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_6b86ae78-294b-4643-8b76-b890e4bca122" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_933c0200-6de0-4c17-87db-c55f28231ae1" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_6b86ae78-294b-4643-8b76-b890e4bca122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_331d5793-600b-4c6c-bf41-2e3c9395dad1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_933c0200-6de0-4c17-87db-c55f28231ae1" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_331d5793-600b-4c6c-bf41-2e3c9395dad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCredit" xlink:type="simple" xlink:href="ameh-20200630.xsd#CreditFacilityBankLoanandLinesofCredit"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCredit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_523b6aea-ad25-4ba4-91a9-a4fddf733587" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_737f360b-1191-4051-a161-8b88d52290bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_523b6aea-ad25-4ba4-91a9-a4fddf733587" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_737f360b-1191-4051-a161-8b88d52290bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditTables" xlink:type="simple" xlink:href="ameh-20200630.xsd#CreditFacilityBankLoanandLinesofCreditTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_aa152090-3192-44f4-a1be-74db4d425ac3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_a98dc223-8b6c-4452-b928-d89852ef3b6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_aa152090-3192-44f4-a1be-74db4d425ac3" xlink:to="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_a98dc223-8b6c-4452-b928-d89852ef3b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_ef833789-1d2b-48b2-a1d4-57b9cc9f02d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_aa152090-3192-44f4-a1be-74db4d425ac3" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_ef833789-1d2b-48b2-a1d4-57b9cc9f02d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_9a156b3b-f6e6-4528-99be-a9a7987e2b6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_1fde9e61-1fd5-499e-937c-0c814c9907b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9a156b3b-f6e6-4528-99be-a9a7987e2b6a" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_1fde9e61-1fd5-499e-937c-0c814c9907b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_e4fa655a-b250-4b42-8c3c-81a04bfbc3f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_1fde9e61-1fd5-499e-937c-0c814c9907b4" xlink:to="loc_us-gaap_CreditFacilityAxis_e4fa655a-b250-4b42-8c3c-81a04bfbc3f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_0ada0dd8-7432-4ee3-9448-204bfa5bc34e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_e4fa655a-b250-4b42-8c3c-81a04bfbc3f6" xlink:to="loc_us-gaap_CreditFacilityDomain_0ada0dd8-7432-4ee3-9448-204bfa5bc34e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_TermLoanAMember_6f9b8e65-0a4b-4dcf-a0b2-4de7ae88a75b" xlink:href="ameh-20200630.xsd#ameh_TermLoanAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_0ada0dd8-7432-4ee3-9448-204bfa5bc34e" xlink:to="loc_ameh_TermLoanAMember_6f9b8e65-0a4b-4dcf-a0b2-4de7ae88a75b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_e7670224-623e-4383-94e2-748d6f8320af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_0ada0dd8-7432-4ee3-9448-204bfa5bc34e" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_e7670224-623e-4383-94e2-748d6f8320af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_fabd27e2-cb69-4481-b628-8b1e55d9583c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_1fde9e61-1fd5-499e-937c-0c814c9907b4" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_fabd27e2-cb69-4481-b628-8b1e55d9583c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_b0f9889a-fa71-4732-90ef-ee36e406bf55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_fabd27e2-cb69-4481-b628-8b1e55d9583c" xlink:to="loc_us-gaap_LineOfCredit_b0f9889a-fa71-4732-90ef-ee36e406bf55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LinesOfCreditCurrent_82b4f7fe-cd24-46ad-b114-74cd4bd97091" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LinesOfCreditCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_fabd27e2-cb69-4481-b628-8b1e55d9583c" xlink:to="loc_us-gaap_LinesOfCreditCurrent_82b4f7fe-cd24-46ad-b114-74cd4bd97091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_f3d26b41-4d51-41e3-8da5-259d3ae0f3c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_fabd27e2-cb69-4481-b628-8b1e55d9583c" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_f3d26b41-4d51-41e3-8da5-259d3ae0f3c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_97cbc10f-4fec-4d61-baa6-0d5d5b0b91f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_fabd27e2-cb69-4481-b628-8b1e55d9583c" xlink:to="loc_us-gaap_LongTermDebt_97cbc10f-4fec-4d61-baa6-0d5d5b0b91f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_375d5bbd-9841-41d8-a7a7-a69213eef44a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_bf2baa3c-7105-4b1e-a28c-72c815eecab9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_375d5bbd-9841-41d8-a7a7-a69213eef44a" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_bf2baa3c-7105-4b1e-a28c-72c815eecab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_346b1f23-0b49-4118-8c15-5f3f62566ff6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_375d5bbd-9841-41d8-a7a7-a69213eef44a" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_346b1f23-0b49-4118-8c15-5f3f62566ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_29f62c10-b9fd-4568-b7ac-07aa74baa896" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_375d5bbd-9841-41d8-a7a7-a69213eef44a" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_29f62c10-b9fd-4568-b7ac-07aa74baa896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_e9c171eb-e1d8-49e6-a432-83def27cb18c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_375d5bbd-9841-41d8-a7a7-a69213eef44a" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_e9c171eb-e1d8-49e6-a432-83def27cb18c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_ea4589bc-d7de-412e-8435-48f122f5f9dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_375d5bbd-9841-41d8-a7a7-a69213eef44a" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_ea4589bc-d7de-412e-8435-48f122f5f9dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_d84d3e26-e5ed-4594-8c6f-342a8cc97867" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_375d5bbd-9841-41d8-a7a7-a69213eef44a" xlink:to="loc_us-gaap_LineOfCredit_d84d3e26-e5ed-4594-8c6f-342a8cc97867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_380c3155-a3ca-45e1-8276-47e06a65719a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_0b8be17d-6a87-4cd8-b62a-db0a970ce2f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_380c3155-a3ca-45e1-8276-47e06a65719a" xlink:to="loc_us-gaap_DebtInstrumentTable_0b8be17d-6a87-4cd8-b62a-db0a970ce2f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_48c4ee81-7a9f-4951-ba0f-d124aa8ee849" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0b8be17d-6a87-4cd8-b62a-db0a970ce2f6" xlink:to="loc_us-gaap_CreditFacilityAxis_48c4ee81-7a9f-4951-ba0f-d124aa8ee849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_7a31b5f6-5003-4cf9-8c7d-7a1f22ebecfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_48c4ee81-7a9f-4951-ba0f-d124aa8ee849" xlink:to="loc_us-gaap_CreditFacilityDomain_7a31b5f6-5003-4cf9-8c7d-7a1f22ebecfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_5304cd97-b6b8-4b48-a2bb-b5d35da496c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_7a31b5f6-5003-4cf9-8c7d-7a1f22ebecfb" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_5304cd97-b6b8-4b48-a2bb-b5d35da496c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_9c8948cb-481a-49e6-a71b-b0b354c02512" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_7a31b5f6-5003-4cf9-8c7d-7a1f22ebecfb" xlink:to="loc_us-gaap_LetterOfCreditMember_9c8948cb-481a-49e6-a71b-b0b354c02512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_TermLoanAMember_92c22673-14a6-4070-8fa8-db68687271f7" xlink:href="ameh-20200630.xsd#ameh_TermLoanAMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_7a31b5f6-5003-4cf9-8c7d-7a1f22ebecfb" xlink:to="loc_ameh_TermLoanAMember_92c22673-14a6-4070-8fa8-db68687271f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_f122f7c7-8e56-4fb1-9ed4-4d4cc514c7ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_7a31b5f6-5003-4cf9-8c7d-7a1f22ebecfb" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_f122f7c7-8e56-4fb1-9ed4-4d4cc514c7ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_8c27d64c-eda6-4078-a7d4-5379df782d05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_7a31b5f6-5003-4cf9-8c7d-7a1f22ebecfb" xlink:to="loc_us-gaap_LineOfCreditMember_8c27d64c-eda6-4078-a7d4-5379df782d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e9400177-5f26-499b-b051-f9e3c7364745" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0b8be17d-6a87-4cd8-b62a-db0a970ce2f6" xlink:to="loc_us-gaap_DebtInstrumentAxis_e9400177-5f26-499b-b051-f9e3c7364745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0796d94c-9035-47ce-99e7-dbc058f4223e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_e9400177-5f26-499b-b051-f9e3c7364745" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0796d94c-9035-47ce-99e7-dbc058f4223e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CreditAgreementMember_0834b8e6-5590-462f-ba98-bc12f2ffbfee" xlink:href="ameh-20200630.xsd#ameh_CreditAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0796d94c-9035-47ce-99e7-dbc058f4223e" xlink:to="loc_ameh_CreditAgreementMember_0834b8e6-5590-462f-ba98-bc12f2ffbfee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NMMLineOfCreditAgreementMember_5b4e13e5-5890-47c4-b6e6-6d4a0a23f3c2" xlink:href="ameh-20200630.xsd#ameh_NMMLineOfCreditAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0796d94c-9035-47ce-99e7-dbc058f4223e" xlink:to="loc_ameh_NMMLineOfCreditAgreementMember_5b4e13e5-5890-47c4-b6e6-6d4a0a23f3c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NmmBusinessLoanAgreementMember_57a2125d-60b5-42b6-887b-a210e92dd9d6" xlink:href="ameh-20200630.xsd#ameh_NmmBusinessLoanAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0796d94c-9035-47ce-99e7-dbc058f4223e" xlink:to="loc_ameh_NmmBusinessLoanAgreementMember_57a2125d-60b5-42b6-887b-a210e92dd9d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcBusinessLoanAgreementMember_8af8b26e-7737-4c5a-800d-ee1df3da10d9" xlink:href="ameh-20200630.xsd#ameh_ApcBusinessLoanAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0796d94c-9035-47ce-99e7-dbc058f4223e" xlink:to="loc_ameh_ApcBusinessLoanAgreementMember_8af8b26e-7737-4c5a-800d-ee1df3da10d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_0db45547-1c14-4d13-961a-5a9598a47213" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0b8be17d-6a87-4cd8-b62a-db0a970ce2f6" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_0db45547-1c14-4d13-961a-5a9598a47213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6d6427d0-adcf-47ea-bcd2-623908c2ab21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_0db45547-1c14-4d13-961a-5a9598a47213" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6d6427d0-adcf-47ea-bcd2-623908c2ab21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_5888c30d-2472-4226-8179-770e3a8a9135" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6d6427d0-adcf-47ea-bcd2-623908c2ab21" xlink:to="loc_us-gaap_LineOfCreditMember_5888c30d-2472-4226-8179-770e3a8a9135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_7222d3f3-6393-44a9-a00f-384c0a652a6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0b8be17d-6a87-4cd8-b62a-db0a970ce2f6" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_7222d3f3-6393-44a9-a00f-384c0a652a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_17d4e7c9-b6a6-4c99-b337-a18842abc45f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_7222d3f3-6393-44a9-a00f-384c0a652a6b" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_17d4e7c9-b6a6-4c99-b337-a18842abc45f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentPeriodOneMember_822b72d5-9b58-4f01-a553-d1c24415a04e" xlink:href="ameh-20200630.xsd#ameh_PaymentPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_17d4e7c9-b6a6-4c99-b337-a18842abc45f" xlink:to="loc_ameh_PaymentPeriodOneMember_822b72d5-9b58-4f01-a553-d1c24415a04e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentPeriodTwoMember_59c14da3-8734-4577-86c5-daec0e58ccd1" xlink:href="ameh-20200630.xsd#ameh_PaymentPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_17d4e7c9-b6a6-4c99-b337-a18842abc45f" xlink:to="loc_ameh_PaymentPeriodTwoMember_59c14da3-8734-4577-86c5-daec0e58ccd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentPeriodThreeMember_0569d8b9-d151-410f-a23d-bd83a0dd8a84" xlink:href="ameh-20200630.xsd#ameh_PaymentPeriodThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_17d4e7c9-b6a6-4c99-b337-a18842abc45f" xlink:to="loc_ameh_PaymentPeriodThreeMember_0569d8b9-d151-410f-a23d-bd83a0dd8a84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1d70007f-c03b-4760-9ff6-c2b3a11e47fb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0b8be17d-6a87-4cd8-b62a-db0a970ce2f6" xlink:to="loc_srt_RangeAxis_1d70007f-c03b-4760-9ff6-c2b3a11e47fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_edde8a6d-c3bb-45bb-8511-b30ddc4bb7cb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1d70007f-c03b-4760-9ff6-c2b3a11e47fb" xlink:to="loc_srt_RangeMember_edde8a6d-c3bb-45bb-8511-b30ddc4bb7cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0e2524fd-25bc-46fd-b748-0b4ac9a974d2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_edde8a6d-c3bb-45bb-8511-b30ddc4bb7cb" xlink:to="loc_srt_MinimumMember_0e2524fd-25bc-46fd-b748-0b4ac9a974d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_34e10d20-3375-4190-afad-1d7280090432" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_edde8a6d-c3bb-45bb-8511-b30ddc4bb7cb" xlink:to="loc_srt_MaximumMember_34e10d20-3375-4190-afad-1d7280090432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_0abd1cb8-821e-4a8c-aea3-ed6d42546bb6" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0b8be17d-6a87-4cd8-b62a-db0a970ce2f6" xlink:to="loc_dei_LegalEntityAxis_0abd1cb8-821e-4a8c-aea3-ed6d42546bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_bfbf5e59-c5a0-46ed-8eef-1479c48c77dd" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_0abd1cb8-821e-4a8c-aea3-ed6d42546bb6" xlink:to="loc_dei_EntityDomain_bfbf5e59-c5a0-46ed-8eef-1479c48c77dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementMember_63923ca4-7005-4998-9c97-586745db7efd" xlink:href="ameh-20200630.xsd#ameh_NetworkMedicalManagementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_bfbf5e59-c5a0-46ed-8eef-1479c48c77dd" xlink:to="loc_ameh_NetworkMedicalManagementMember_63923ca4-7005-4998-9c97-586745db7efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_f9feff85-802b-4620-9b5c-1817b03ebfde" xlink:href="ameh-20200630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_bfbf5e59-c5a0-46ed-8eef-1479c48c77dd" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_f9feff85-802b-4620-9b5c-1817b03ebfde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApaacoMember_244b3a44-8812-4ece-bc76-cd9e74772516" xlink:href="ameh-20200630.xsd#ameh_ApaacoMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_bfbf5e59-c5a0-46ed-8eef-1479c48c77dd" xlink:to="loc_ameh_ApaacoMember_244b3a44-8812-4ece-bc76-cd9e74772516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlphaCareMedicalGroupInc.Member_93958bab-6ae3-42f9-a08e-ad1d4e06e553" xlink:href="ameh-20200630.xsd#ameh_AlphaCareMedicalGroupInc.Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_bfbf5e59-c5a0-46ed-8eef-1479c48c77dd" xlink:to="loc_ameh_AlphaCareMedicalGroupInc.Member_93958bab-6ae3-42f9-a08e-ad1d4e06e553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CDSCMember_c4b1861c-493e-4a9e-b5f4-bc875c8beafc" xlink:href="ameh-20200630.xsd#ameh_CDSCMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_bfbf5e59-c5a0-46ed-8eef-1479c48c77dd" xlink:to="loc_ameh_CDSCMember_c4b1861c-493e-4a9e-b5f4-bc875c8beafc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AmgIncMember_122d91dc-3f4b-4310-8ad6-052abf9e1d10" xlink:href="ameh-20200630.xsd#ameh_AmgIncMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_bfbf5e59-c5a0-46ed-8eef-1479c48c77dd" xlink:to="loc_ameh_AmgIncMember_122d91dc-3f4b-4310-8ad6-052abf9e1d10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_adf287af-da3c-4941-a66e-9b9791de4cbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0b8be17d-6a87-4cd8-b62a-db0a970ce2f6" xlink:to="loc_us-gaap_VariableRateAxis_adf287af-da3c-4941-a66e-9b9791de4cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_6592507c-35f3-41b6-8044-b8b56987088d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_adf287af-da3c-4941-a66e-9b9791de4cbb" xlink:to="loc_us-gaap_VariableRateDomain_6592507c-35f3-41b6-8044-b8b56987088d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_5badc0e3-9c82-438a-9529-aff94612e341" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_6592507c-35f3-41b6-8044-b8b56987088d" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_5badc0e3-9c82-438a-9529-aff94612e341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_77bf5788-85a4-4bf2-ba18-6d7e1d58d9c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrimeRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_6592507c-35f3-41b6-8044-b8b56987088d" xlink:to="loc_us-gaap_PrimeRateMember_77bf5788-85a4-4bf2-ba18-6d7e1d58d9c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_4f6d1faf-812f-4b11-a76e-5174d7451d10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0b8be17d-6a87-4cd8-b62a-db0a970ce2f6" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_4f6d1faf-812f-4b11-a76e-5174d7451d10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_b6324546-cb93-452f-9e9d-8574c322187e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_4f6d1faf-812f-4b11-a76e-5174d7451d10" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_b6324546-cb93-452f-9e9d-8574c322187e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PreferredBankMember_8cae379b-920b-47ea-980f-64ef43d94569" xlink:href="ameh-20200630.xsd#ameh_PreferredBankMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_b6324546-cb93-452f-9e9d-8574c322187e" xlink:to="loc_ameh_PreferredBankMember_8cae379b-920b-47ea-980f-64ef43d94569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_aaa7c65b-5229-4310-8d2a-c5e847931035" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0b8be17d-6a87-4cd8-b62a-db0a970ce2f6" xlink:to="loc_us-gaap_DebtInstrumentLineItems_aaa7c65b-5229-4310-8d2a-c5e847931035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_5d8e4fb1-617e-4535-b995-e8ce98ff5d1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aaa7c65b-5229-4310-8d2a-c5e847931035" xlink:to="loc_us-gaap_DebtInstrumentTerm_5d8e4fb1-617e-4535-b995-e8ce98ff5d1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_0902c519-0ad2-438f-b538-5c5a60870196" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aaa7c65b-5229-4310-8d2a-c5e847931035" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_0902c519-0ad2-438f-b538-5c5a60870196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal_038ff918-2671-49b8-b505-d2ff4f7b08e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aaa7c65b-5229-4310-8d2a-c5e847931035" xlink:to="loc_us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal_038ff918-2671-49b8-b505-d2ff4f7b08e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_97d5cd89-03c9-4333-a2b5-6fbe0a2281fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aaa7c65b-5229-4310-8d2a-c5e847931035" xlink:to="loc_us-gaap_LineOfCredit_97d5cd89-03c9-4333-a2b5-6fbe0a2281fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_50212e93-ef34-4424-9435-f5b2f5e0221a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aaa7c65b-5229-4310-8d2a-c5e847931035" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_50212e93-ef34-4424-9435-f5b2f5e0221a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_7bc8cf27-2e8f-458d-b638-cca1312dff60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aaa7c65b-5229-4310-8d2a-c5e847931035" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_7bc8cf27-2e8f-458d-b638-cca1312dff60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_cde3644c-53fb-44e3-85c6-cd494d03d31a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aaa7c65b-5229-4310-8d2a-c5e847931035" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_cde3644c-53fb-44e3-85c6-cd494d03d31a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentNumberOfKeyFinancialRatios_61783f5e-de29-4957-a52a-05e38f618741" xlink:href="ameh-20200630.xsd#ameh_DebtInstrumentNumberOfKeyFinancialRatios"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aaa7c65b-5229-4310-8d2a-c5e847931035" xlink:to="loc_ameh_DebtInstrumentNumberOfKeyFinancialRatios_61783f5e-de29-4957-a52a-05e38f618741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantLeverageRatioMaximum_1c86c206-af4b-44c5-96e2-d42767ec5033" xlink:href="ameh-20200630.xsd#ameh_DebtInstrumentCovenantLeverageRatioMaximum"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aaa7c65b-5229-4310-8d2a-c5e847931035" xlink:to="loc_ameh_DebtInstrumentCovenantLeverageRatioMaximum_1c86c206-af4b-44c5-96e2-d42767ec5033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange_f56bb59d-5785-42cc-b626-e47a7c090346" xlink:href="ameh-20200630.xsd#ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aaa7c65b-5229-4310-8d2a-c5e847931035" xlink:to="loc_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange_f56bb59d-5785-42cc-b626-e47a7c090346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantLeverageRatioMinimum_49109c00-d5d8-4143-8bfb-cdd58d671b56" xlink:href="ameh-20200630.xsd#ameh_DebtInstrumentCovenantLeverageRatioMinimum"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aaa7c65b-5229-4310-8d2a-c5e847931035" xlink:to="loc_ameh_DebtInstrumentCovenantLeverageRatioMinimum_49109c00-d5d8-4143-8bfb-cdd58d671b56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum_1fec12bc-e30a-431c-b1df-7bbc18d99892" xlink:href="ameh-20200630.xsd#ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aaa7c65b-5229-4310-8d2a-c5e847931035" xlink:to="loc_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum_1fec12bc-e30a-431c-b1df-7bbc18d99892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDefaultLongtermDebtAmount_40d58c0c-39ae-4e40-a632-f6b882b91306" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDefaultLongtermDebtAmount"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aaa7c65b-5229-4310-8d2a-c5e847931035" xlink:to="loc_us-gaap_DebtDefaultLongtermDebtAmount_40d58c0c-39ae-4e40-a632-f6b882b91306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentApprovalThresholdOfShareholdersForUseOfFundsPercentage_740d2197-69a0-41e2-ba8b-744e0b2ad6c7" xlink:href="ameh-20200630.xsd#ameh_DebtInstrumentApprovalThresholdOfShareholdersForUseOfFundsPercentage"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aaa7c65b-5229-4310-8d2a-c5e847931035" xlink:to="loc_ameh_DebtInstrumentApprovalThresholdOfShareholdersForUseOfFundsPercentage_740d2197-69a0-41e2-ba8b-744e0b2ad6c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentApprovedThresholdUseOfFunds_420d70ef-de5e-4407-b92b-712e695544a3" xlink:href="ameh-20200630.xsd#ameh_DebtInstrumentApprovedThresholdUseOfFunds"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aaa7c65b-5229-4310-8d2a-c5e847931035" xlink:to="loc_ameh_DebtInstrumentApprovedThresholdUseOfFunds_420d70ef-de5e-4407-b92b-712e695544a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_bdf4e218-ddc0-43cd-99e8-9720913e0350" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aaa7c65b-5229-4310-8d2a-c5e847931035" xlink:to="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_bdf4e218-ddc0-43cd-99e8-9720913e0350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_e56ddf99-5c17-4e7c-9000-486e52816017" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aaa7c65b-5229-4310-8d2a-c5e847931035" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_e56ddf99-5c17-4e7c-9000-486e52816017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_b0a49fd7-b62c-4404-b26d-ab44a710ff33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aaa7c65b-5229-4310-8d2a-c5e847931035" xlink:to="loc_us-gaap_InterestExpense_b0a49fd7-b62c-4404-b26d-ab44a710ff33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LineOfCreditFacilityGuaranteeGivenByRelatedParties_1450b1b9-d552-4a54-8409-69ff50cc1775" xlink:href="ameh-20200630.xsd#ameh_LineOfCreditFacilityGuaranteeGivenByRelatedParties"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aaa7c65b-5229-4310-8d2a-c5e847931035" xlink:to="loc_ameh_LineOfCreditFacilityGuaranteeGivenByRelatedParties_1450b1b9-d552-4a54-8409-69ff50cc1775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_a794741d-bb3d-4acb-8b7d-044e8525e71e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aaa7c65b-5229-4310-8d2a-c5e847931035" xlink:to="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_a794741d-bb3d-4acb-8b7d-044e8525e71e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_e12d79c5-bff0-49b6-bb2e-0a72a53dbe93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aaa7c65b-5229-4310-8d2a-c5e847931035" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_e12d79c5-bff0-49b6-bb2e-0a72a53dbe93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_027c186e-7d5d-40b7-89e7-253e1108083f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aaa7c65b-5229-4310-8d2a-c5e847931035" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_027c186e-7d5d-40b7-89e7-253e1108083f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LineOfCreditFacilityExpirationPeriodPeriodOfNotification_4e79895f-7f4e-480c-8c41-a1c71b54e1ff" xlink:href="ameh-20200630.xsd#ameh_LineOfCreditFacilityExpirationPeriodPeriodOfNotification"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aaa7c65b-5229-4310-8d2a-c5e847931035" xlink:to="loc_ameh_LineOfCreditFacilityExpirationPeriodPeriodOfNotification_4e79895f-7f4e-480c-8c41-a1c71b54e1ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_13ff7009-9299-4581-ab54-999485858b2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aaa7c65b-5229-4310-8d2a-c5e847931035" xlink:to="loc_us-gaap_LongTermDebt_13ff7009-9299-4581-ab54-999485858b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquity" xlink:type="simple" xlink:href="ameh-20200630.xsd#MezzanineandStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/MezzanineandStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_046b164f-05a1-4283-a132-9ef48ed33c07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_424389e7-b9ab-41cb-afc2-4f39855cce7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_046b164f-05a1-4283-a132-9ef48ed33c07" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_424389e7-b9ab-41cb-afc2-4f39855cce7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquityTables" xlink:type="simple" xlink:href="ameh-20200630.xsd#MezzanineandStockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/MezzanineandStockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_94ed194e-3985-4958-bf59-54c4314dfa7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_f71f415d-10f5-4e2e-8865-431bc7e7aeb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_94ed194e-3985-4958-bf59-54c4314dfa7c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_f71f415d-10f5-4e2e-8865-431bc7e7aeb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_f62e31de-9aba-4023-a2d1-f2f4e061c5d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_94ed194e-3985-4958-bf59-54c4314dfa7c" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_f62e31de-9aba-4023-a2d1-f2f4e061c5d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_0f77f0b8-c849-42aa-904e-197ba3cd47d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_94ed194e-3985-4958-bf59-54c4314dfa7c" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_0f77f0b8-c849-42aa-904e-197ba3cd47d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#MezzanineandStockholdersEquityAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_f4fb9ca2-d6b5-467c-baaa-5509b2b15579" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_991baf71-6e85-4ee8-99e4-a29a16d6395d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_f4fb9ca2-d6b5-467c-baaa-5509b2b15579" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_991baf71-6e85-4ee8-99e4-a29a16d6395d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_3acf957a-8161-49c8-9e9e-0630e1b900c2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_991baf71-6e85-4ee8-99e4-a29a16d6395d" xlink:to="loc_srt_TitleOfIndividualAxis_3acf957a-8161-49c8-9e9e-0630e1b900c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_cb7b8ace-09ac-4de9-9068-6fe4f62b8c4b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_3acf957a-8161-49c8-9e9e-0630e1b900c2" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_cb7b8ace-09ac-4de9-9068-6fe4f62b8c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcStockOptionMember_9e6dddc9-34fb-4dac-9eb4-aea7e26e75b5" xlink:href="ameh-20200630.xsd#ameh_ApcStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_cb7b8ace-09ac-4de9-9068-6fe4f62b8c4b" xlink:to="loc_ameh_ApcStockOptionMember_9e6dddc9-34fb-4dac-9eb4-aea7e26e75b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_847d160d-cdf4-4218-9d83-8f8ed2301d20" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_cb7b8ace-09ac-4de9-9068-6fe4f62b8c4b" xlink:to="loc_srt_DirectorMember_847d160d-cdf4-4218-9d83-8f8ed2301d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e6ff421f-83f9-48d3-8af3-743c8f97a052" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_991baf71-6e85-4ee8-99e4-a29a16d6395d" xlink:to="loc_srt_RangeAxis_e6ff421f-83f9-48d3-8af3-743c8f97a052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fa89e49c-180d-4726-965c-f82e21735004" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e6ff421f-83f9-48d3-8af3-743c8f97a052" xlink:to="loc_srt_RangeMember_fa89e49c-180d-4726-965c-f82e21735004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_33bb0146-df75-4987-a882-0a63bb3e5984" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fa89e49c-180d-4726-965c-f82e21735004" xlink:to="loc_srt_MinimumMember_33bb0146-df75-4987-a882-0a63bb3e5984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_71f48824-026d-491c-9bf2-8629e2e2b252" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fa89e49c-180d-4726-965c-f82e21735004" xlink:to="loc_srt_MaximumMember_71f48824-026d-491c-9bf2-8629e2e2b252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b8c7cbe6-6e6e-4c70-9090-40360d9da3c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_991baf71-6e85-4ee8-99e4-a29a16d6395d" xlink:to="loc_us-gaap_AwardTypeAxis_b8c7cbe6-6e6e-4c70-9090-40360d9da3c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f6dbe61a-e5c8-459f-959c-2587ee4d6a44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_b8c7cbe6-6e6e-4c70-9090-40360d9da3c8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f6dbe61a-e5c8-459f-959c-2587ee4d6a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ceaa651e-b314-4b31-a8eb-d48a912d89f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f6dbe61a-e5c8-459f-959c-2587ee4d6a44" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ceaa651e-b314-4b31-a8eb-d48a912d89f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_331fa828-438e-48cd-ad17-d847da8c5d10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f6dbe61a-e5c8-459f-959c-2587ee4d6a44" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_331fa828-438e-48cd-ad17-d847da8c5d10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_528ad604-feb6-458d-a26e-74dc47ec41cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f6dbe61a-e5c8-459f-959c-2587ee4d6a44" xlink:to="loc_us-gaap_RestrictedStockMember_528ad604-feb6-458d-a26e-74dc47ec41cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_71f9e856-2f75-4cf0-8aa7-42dab0e6017a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_991baf71-6e85-4ee8-99e4-a29a16d6395d" xlink:to="loc_dei_LegalEntityAxis_71f9e856-2f75-4cf0-8aa7-42dab0e6017a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a3aed4cc-0df7-4f0f-9a8a-6b4f0dd12612" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_71f9e856-2f75-4cf0-8aa7-42dab0e6017a" xlink:to="loc_dei_EntityDomain_a3aed4cc-0df7-4f0f-9a8a-6b4f0dd12612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_d621ce5e-3bd7-4c92-ab88-9dc8a66cd398" xlink:href="ameh-20200630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_a3aed4cc-0df7-4f0f-9a8a-6b4f0dd12612" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_d621ce5e-3bd7-4c92-ab88-9dc8a66cd398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CDSCMember_87b4fd3b-9927-4d78-93f9-3e8702954553" xlink:href="ameh-20200630.xsd#ameh_CDSCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_a3aed4cc-0df7-4f0f-9a8a-6b4f0dd12612" xlink:to="loc_ameh_CDSCMember_87b4fd3b-9927-4d78-93f9-3e8702954553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d54c3e7a-3533-4843-be95-671dc6b5d4df" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_991baf71-6e85-4ee8-99e4-a29a16d6395d" xlink:to="loc_srt_CounterpartyNameAxis_d54c3e7a-3533-4843-be95-671dc6b5d4df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ac58df24-c8a2-424a-b0e2-7a126330a587" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_d54c3e7a-3533-4843-be95-671dc6b5d4df" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ac58df24-c8a2-424a-b0e2-7a126330a587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificofCaliforniaBrokerageAccountMember_ec0e3668-aac9-48a8-91f1-35fa9934a932" xlink:href="ameh-20200630.xsd#ameh_AlliedPacificofCaliforniaBrokerageAccountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ac58df24-c8a2-424a-b0e2-7a126330a587" xlink:to="loc_ameh_AlliedPacificofCaliforniaBrokerageAccountMember_ec0e3668-aac9-48a8-91f1-35fa9934a932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_33a04ff0-0d30-41f8-b089-7fe127549978" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_991baf71-6e85-4ee8-99e4-a29a16d6395d" xlink:to="loc_us-gaap_ClassOfStockLineItems_33a04ff0-0d30-41f8-b089-7fe127549978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodSharesMerger_edacbdfb-c613-4179-a847-bc7fff2d404a" xlink:href="ameh-20200630.xsd#ameh_StockIssuedDuringPeriodSharesMerger"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_33a04ff0-0d30-41f8-b089-7fe127549978" xlink:to="loc_ameh_StockIssuedDuringPeriodSharesMerger_edacbdfb-c613-4179-a847-bc7fff2d404a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e84a53db-b048-46c3-a753-52977e4a6fdf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_33a04ff0-0d30-41f8-b089-7fe127549978" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e84a53db-b048-46c3-a753-52977e4a6fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_4b4af310-c238-4411-9b3d-543a333c9698" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_33a04ff0-0d30-41f8-b089-7fe127549978" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_4b4af310-c238-4411-9b3d-543a333c9698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_f2c5ce06-72ce-4420-a97c-29ecd8ee53c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_33a04ff0-0d30-41f8-b089-7fe127549978" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_f2c5ce06-72ce-4420-a97c-29ecd8ee53c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod_d15a06fa-0113-4ef1-b78f-1353e36e877a" xlink:href="ameh-20200630.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_33a04ff0-0d30-41f8-b089-7fe127549978" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod_d15a06fa-0113-4ef1-b78f-1353e36e877a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d8233381-0e4d-478a-95bb-23afd7919b65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_33a04ff0-0d30-41f8-b089-7fe127549978" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d8233381-0e4d-478a-95bb-23afd7919b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_51d82311-79e9-4f0f-970d-ae5c7f7353dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_33a04ff0-0d30-41f8-b089-7fe127549978" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_51d82311-79e9-4f0f-970d-ae5c7f7353dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_554fb3de-7cc0-4811-8348-0eb7084916a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_33a04ff0-0d30-41f8-b089-7fe127549978" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_554fb3de-7cc0-4811-8348-0eb7084916a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ae557618-99d1-4ce7-bc19-d5be26adbfde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_33a04ff0-0d30-41f8-b089-7fe127549978" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ae557618-99d1-4ce7-bc19-d5be26adbfde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_34a7fa1f-54d4-4c32-8ad1-57ad4bb015e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_33a04ff0-0d30-41f8-b089-7fe127549978" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_34a7fa1f-54d4-4c32-8ad1-57ad4bb015e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_d8b6cc38-d17d-40cc-bc47-63edcf4b5b3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_33a04ff0-0d30-41f8-b089-7fe127549978" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_d8b6cc38-d17d-40cc-bc47-63edcf4b5b3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_0099ed89-e9c8-4497-b139-4a7288291379" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_33a04ff0-0d30-41f8-b089-7fe127549978" xlink:to="loc_us-gaap_ShareBasedCompensation_0099ed89-e9c8-4497-b139-4a7288291379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_fb36a4e1-edb6-43b7-8b6a-d8e8933615c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_33a04ff0-0d30-41f8-b089-7fe127549978" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_fb36a4e1-edb6-43b7-8b6a-d8e8933615c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod_8ef19753-d7f7-41ba-9732-715fddb82e60" xlink:href="ameh-20200630.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_33a04ff0-0d30-41f8-b089-7fe127549978" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod_8ef19753-d7f7-41ba-9732-715fddb82e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised_c0116c03-3d2e-4e36-9a12-80712a47dc39" xlink:href="ameh-20200630.xsd#ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_33a04ff0-0d30-41f8-b089-7fe127549978" xlink:to="loc_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised_c0116c03-3d2e-4e36-9a12-80712a47dc39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice_dbd7a435-50d9-4c48-93eb-b4503bd79287" xlink:href="ameh-20200630.xsd#ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_33a04ff0-0d30-41f8-b089-7fe127549978" xlink:to="loc_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice_dbd7a435-50d9-4c48-93eb-b4503bd79287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_cdc719a2-222b-444c-897f-1409decf13ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_33a04ff0-0d30-41f8-b089-7fe127549978" xlink:to="loc_us-gaap_TreasuryStockCommonShares_cdc719a2-222b-444c-897f-1409decf13ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_3464ca20-023b-4f58-a694-6aa3b5422a72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_33a04ff0-0d30-41f8-b089-7fe127549978" xlink:to="loc_us-gaap_TreasuryStockValue_3464ca20-023b-4f58-a694-6aa3b5422a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_a09174d0-57c2-4a0e-9b20-ea2ed147aaa7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Dividends"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_33a04ff0-0d30-41f8-b089-7fe127549978" xlink:to="loc_us-gaap_Dividends_a09174d0-57c2-4a0e-9b20-ea2ed147aaa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_9bb0bad3-ab77-4df3-bf56-44d54800cf79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e4e21799-2169-4a45-92b3-eba6106790cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_9bb0bad3-ab77-4df3-bf56-44d54800cf79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e4e21799-2169-4a45-92b3-eba6106790cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_837b32b0-1975-42a2-9777-616dee98da6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e4e21799-2169-4a45-92b3-eba6106790cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_837b32b0-1975-42a2-9777-616dee98da6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c32cc503-bd86-4d21-bf88-e3193a756fe6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e4e21799-2169-4a45-92b3-eba6106790cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c32cc503-bd86-4d21-bf88-e3193a756fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_36841b52-8458-4217-8604-c087a2b285d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e4e21799-2169-4a45-92b3-eba6106790cc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_36841b52-8458-4217-8604-c087a2b285d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_69cca065-0f4a-419a-b722-e7b071861684" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e4e21799-2169-4a45-92b3-eba6106790cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_69cca065-0f4a-419a-b722-e7b071861684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d515080b-5b67-4636-8db3-bf1ecf8e18a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e4e21799-2169-4a45-92b3-eba6106790cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d515080b-5b67-4636-8db3-bf1ecf8e18a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_7c010e9c-2f9e-4f21-8bc8-627101ea94d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_9bb0bad3-ab77-4df3-bf56-44d54800cf79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_7c010e9c-2f9e-4f21-8bc8-627101ea94d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_905740ef-8b1b-450b-847b-b16e42a55745" xlink:href="ameh-20200630.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_9bb0bad3-ab77-4df3-bf56-44d54800cf79" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_905740ef-8b1b-450b-847b-b16e42a55745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_354f9047-e700-46d5-8a18-b75bdf99b0a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_905740ef-8b1b-450b-847b-b16e42a55745" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_354f9047-e700-46d5-8a18-b75bdf99b0a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_25996062-ad24-4c73-9a27-0b3ed3cc718e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_905740ef-8b1b-450b-847b-b16e42a55745" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_25996062-ad24-4c73-9a27-0b3ed3cc718e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_8aa4df99-7b76-41e4-a000-ac1f69b7ef7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_905740ef-8b1b-450b-847b-b16e42a55745" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_8aa4df99-7b76-41e4-a000-ac1f69b7ef7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c6c03708-a5bc-47b4-af9e-fd053b51bbab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_905740ef-8b1b-450b-847b-b16e42a55745" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c6c03708-a5bc-47b4-af9e-fd053b51bbab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_549f6dd9-35a0-4b3b-9730-21ae13d65606" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_905740ef-8b1b-450b-847b-b16e42a55745" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_549f6dd9-35a0-4b3b-9730-21ae13d65606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1cdf5cc3-d562-462a-a1d5-ae2e701f6848" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_9bb0bad3-ab77-4df3-bf56-44d54800cf79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1cdf5cc3-d562-462a-a1d5-ae2e701f6848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_dde6d1dd-f0bc-464f-b064-cef8effb9b6c" xlink:href="ameh-20200630.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_9bb0bad3-ab77-4df3-bf56-44d54800cf79" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_dde6d1dd-f0bc-464f-b064-cef8effb9b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2b14df54-92da-4bc8-8c0d-70e69e65984f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_dde6d1dd-f0bc-464f-b064-cef8effb9b6c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2b14df54-92da-4bc8-8c0d-70e69e65984f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_998d3e20-de10-45e4-93d7-a3982c62a42b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_dde6d1dd-f0bc-464f-b064-cef8effb9b6c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_998d3e20-de10-45e4-93d7-a3982c62a42b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_2899c130-8709-4711-b0b9-4bf86f1f26ed" xlink:href="ameh-20200630.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_9bb0bad3-ab77-4df3-bf56-44d54800cf79" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_2899c130-8709-4711-b0b9-4bf86f1f26ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_5dd148d6-3f77-4ebc-b57c-cd2adbf64851" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_2899c130-8709-4711-b0b9-4bf86f1f26ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_5dd148d6-3f77-4ebc-b57c-cd2adbf64851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_338c0d32-6530-4323-a6a7-5f2b4386c1ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_2899c130-8709-4711-b0b9-4bf86f1f26ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_338c0d32-6530-4323-a6a7-5f2b4386c1ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_d7180e54-33a2-40c4-acb8-1ec0d6c09344" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_2899c130-8709-4711-b0b9-4bf86f1f26ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_d7180e54-33a2-40c4-acb8-1ec0d6c09344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c4c647f8-5994-4eae-8c72-97acd0fb9f39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_9bb0bad3-ab77-4df3-bf56-44d54800cf79" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c4c647f8-5994-4eae-8c72-97acd0fb9f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquityStockOptionActivityUnderBlackScholesOptionPricingModelDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#MezzanineandStockholdersEquityStockOptionActivityUnderBlackScholesOptionPricingModelDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/MezzanineandStockholdersEquityStockOptionActivityUnderBlackScholesOptionPricingModelDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_ac56f09c-df27-4ff1-8089-8d9f0c1d72d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f8dedcf5-cfb7-4c8c-8f30-2f7eaab66720" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_ac56f09c-df27-4ff1-8089-8d9f0c1d72d4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f8dedcf5-cfb7-4c8c-8f30-2f7eaab66720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_ae5b8e2f-6419-45cd-b5ae-d3c334da2678" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f8dedcf5-cfb7-4c8c-8f30-2f7eaab66720" xlink:to="loc_srt_TitleOfIndividualAxis_ae5b8e2f-6419-45cd-b5ae-d3c334da2678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6a0440b4-55f5-41ca-b2d8-126a277e49b3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_ae5b8e2f-6419-45cd-b5ae-d3c334da2678" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6a0440b4-55f5-41ca-b2d8-126a277e49b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_1af9daf4-864d-473d-beb6-b70a4fad1970" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6a0440b4-55f5-41ca-b2d8-126a277e49b3" xlink:to="loc_srt_DirectorMember_1af9daf4-864d-473d-beb6-b70a4fad1970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7b551161-df46-4b1a-9c3e-817e98dbece5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f8dedcf5-cfb7-4c8c-8f30-2f7eaab66720" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7b551161-df46-4b1a-9c3e-817e98dbece5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_11e3a3a3-6c84-42d1-bf58-f0a7d417cca9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7b551161-df46-4b1a-9c3e-817e98dbece5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_11e3a3a3-6c84-42d1-bf58-f0a7d417cca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ef0690db-e001-4689-8f67-27a82928adf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7b551161-df46-4b1a-9c3e-817e98dbece5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ef0690db-e001-4689-8f67-27a82928adf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_07a01ec7-9b71-4ee6-89eb-a62bb10bd48e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7b551161-df46-4b1a-9c3e-817e98dbece5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_07a01ec7-9b71-4ee6-89eb-a62bb10bd48e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_9394e96f-e201-493c-8fdc-50ced18db2be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7b551161-df46-4b1a-9c3e-817e98dbece5" xlink:to="loc_us-gaap_SharePrice_9394e96f-e201-493c-8fdc-50ced18db2be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dbac0dd4-6bba-4e91-8dcb-e0b136f10b9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7b551161-df46-4b1a-9c3e-817e98dbece5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dbac0dd4-6bba-4e91-8dcb-e0b136f10b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_e82a98f6-71dc-4186-818a-da9ce44910b7" xlink:href="ameh-20200630.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7b551161-df46-4b1a-9c3e-817e98dbece5" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_e82a98f6-71dc-4186-818a-da9ce44910b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquitySummaryofWarrantDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#MezzanineandStockholdersEquitySummaryofWarrantDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/MezzanineandStockholdersEquitySummaryofWarrantDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_42f9b74b-626c-43ba-b846-8048910467fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SharesWarrantsRollForward_c1624f0e-d483-43e7-a96e-09757a4092e9" xlink:href="ameh-20200630.xsd#ameh_SharesWarrantsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_42f9b74b-626c-43ba-b846-8048910467fa" xlink:to="loc_ameh_SharesWarrantsRollForward_c1624f0e-d483-43e7-a96e-09757a4092e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_2c1f46ef-427d-48e6-aceb-d9e640a34353" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SharesWarrantsRollForward_c1624f0e-d483-43e7-a96e-09757a4092e9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_2c1f46ef-427d-48e6-aceb-d9e640a34353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfWarrantsGranted_c178a6e0-d9b5-4d5c-9a06-ebcdabd344db" xlink:href="ameh-20200630.xsd#ameh_NumberOfWarrantsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SharesWarrantsRollForward_c1624f0e-d483-43e7-a96e-09757a4092e9" xlink:to="loc_ameh_NumberOfWarrantsGranted_c178a6e0-d9b5-4d5c-9a06-ebcdabd344db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfWarrantsExercised_b12fbc18-5065-4377-a910-5143acaf8a86" xlink:href="ameh-20200630.xsd#ameh_NumberOfWarrantsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SharesWarrantsRollForward_c1624f0e-d483-43e7-a96e-09757a4092e9" xlink:to="loc_ameh_NumberOfWarrantsExercised_b12fbc18-5065-4377-a910-5143acaf8a86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightCancelledInPeriod_82dfe4f2-63d7-4d77-a05e-d0aae8c30ba2" xlink:href="ameh-20200630.xsd#ameh_ClassOfWarrantOrRightCancelledInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SharesWarrantsRollForward_c1624f0e-d483-43e7-a96e-09757a4092e9" xlink:to="loc_ameh_ClassOfWarrantOrRightCancelledInPeriod_82dfe4f2-63d7-4d77-a05e-d0aae8c30ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_0cab7ab9-38f0-431c-b5ea-fea122cb3014" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SharesWarrantsRollForward_c1624f0e-d483-43e7-a96e-09757a4092e9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_0cab7ab9-38f0-431c-b5ea-fea122cb3014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward_6cd01e0c-360e-4a7d-af0f-425d28d5de26" xlink:href="ameh-20200630.xsd#ameh_WeightedAverageExercisePriceWarrantsRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_42f9b74b-626c-43ba-b846-8048910467fa" xlink:to="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward_6cd01e0c-360e-4a7d-af0f-425d28d5de26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_0455fa4b-0380-480d-ab2d-12f493132dcf" xlink:href="ameh-20200630.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward_6cd01e0c-360e-4a7d-af0f-425d28d5de26" xlink:to="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_0455fa4b-0380-480d-ab2d-12f493132dcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod_13562e60-7e1d-4f9d-80c1-6065b5362c52" xlink:href="ameh-20200630.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward_6cd01e0c-360e-4a7d-af0f-425d28d5de26" xlink:to="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod_13562e60-7e1d-4f9d-80c1-6065b5362c52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod_89db2ad8-5aa8-4d66-a4a4-5c86a411b8ac" xlink:href="ameh-20200630.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward_6cd01e0c-360e-4a7d-af0f-425d28d5de26" xlink:to="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod_89db2ad8-5aa8-4d66-a4a4-5c86a411b8ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod_202a0c8a-5bb6-4ed6-9205-719a303106dc" xlink:href="ameh-20200630.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward_6cd01e0c-360e-4a7d-af0f-425d28d5de26" xlink:to="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod_202a0c8a-5bb6-4ed6-9205-719a303106dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_2378b908-cf4e-4de0-80fa-ed99ab806162" xlink:href="ameh-20200630.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward_6cd01e0c-360e-4a7d-af0f-425d28d5de26" xlink:to="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_2378b908-cf4e-4de0-80fa-ed99ab806162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WeightedaverageremainingcontractualtermyearsAbstract_53e1b647-b114-4d99-9dbc-336fcdb8d79e" xlink:href="ameh-20200630.xsd#ameh_WeightedaverageremainingcontractualtermyearsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_42f9b74b-626c-43ba-b846-8048910467fa" xlink:to="loc_ameh_WeightedaverageremainingcontractualtermyearsAbstract_53e1b647-b114-4d99-9dbc-336fcdb8d79e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm_04f2f448-0b12-494e-8e00-edb87f9cf528" xlink:href="ameh-20200630.xsd#ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_WeightedaverageremainingcontractualtermyearsAbstract_53e1b647-b114-4d99-9dbc-336fcdb8d79e" xlink:to="loc_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm_04f2f448-0b12-494e-8e00-edb87f9cf528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AggregateintrinsicvalueAbstract_7a6f6d2a-ac5d-4d9c-8855-fe37f31c1293" xlink:href="ameh-20200630.xsd#ameh_AggregateintrinsicvalueAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_42f9b74b-626c-43ba-b846-8048910467fa" xlink:to="loc_ameh_AggregateintrinsicvalueAbstract_7a6f6d2a-ac5d-4d9c-8855-fe37f31c1293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_37847323-e9b5-4ee3-b533-480d87ba70eb" xlink:href="ameh-20200630.xsd#ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AggregateintrinsicvalueAbstract_7a6f6d2a-ac5d-4d9c-8855-fe37f31c1293" xlink:to="loc_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_37847323-e9b5-4ee3-b533-480d87ba70eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue_05d5cf48-e97b-4679-a067-ce528022dbe2" xlink:href="ameh-20200630.xsd#ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AggregateintrinsicvalueAbstract_7a6f6d2a-ac5d-4d9c-8855-fe37f31c1293" xlink:to="loc_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue_05d5cf48-e97b-4679-a067-ce528022dbe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue_e1b84a2e-cc37-485b-9495-3aa132b79fc4" xlink:href="ameh-20200630.xsd#ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AggregateintrinsicvalueAbstract_7a6f6d2a-ac5d-4d9c-8855-fe37f31c1293" xlink:to="loc_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue_e1b84a2e-cc37-485b-9495-3aa132b79fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue_d5e3245f-99a0-4de8-81b9-13260e098831" xlink:href="ameh-20200630.xsd#ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AggregateintrinsicvalueAbstract_7a6f6d2a-ac5d-4d9c-8855-fe37f31c1293" xlink:to="loc_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue_d5e3245f-99a0-4de8-81b9-13260e098831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_dc0ecd28-8610-4058-8955-e74001314099" xlink:href="ameh-20200630.xsd#ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AggregateintrinsicvalueAbstract_7a6f6d2a-ac5d-4d9c-8855-fe37f31c1293" xlink:to="loc_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_dc0ecd28-8610-4058-8955-e74001314099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquityWarrantsDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#MezzanineandStockholdersEquityWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/MezzanineandStockholdersEquityWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_4e89b180-a500-4300-bc85-65bd67a47d8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_afade0ce-20a0-40bd-8255-0c624b914b7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_4e89b180-a500-4300-bc85-65bd67a47d8d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_afade0ce-20a0-40bd-8255-0c624b914b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_14946b36-ed21-4ecb-b1be-1058aa4fadc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_afade0ce-20a0-40bd-8255-0c624b914b7c" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_14946b36-ed21-4ecb-b1be-1058aa4fadc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_9e9ae659-15cb-42a5-8be6-5c719a0cc017" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_14946b36-ed21-4ecb-b1be-1058aa4fadc9" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_9e9ae659-15cb-42a5-8be6-5c719a0cc017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeOneMember_450dcd17-e7c1-43e0-bd2d-28e46c5fd4cf" xlink:href="ameh-20200630.xsd#ameh_WarrantExercisePriceRangeOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_9e9ae659-15cb-42a5-8be6-5c719a0cc017" xlink:to="loc_ameh_WarrantExercisePriceRangeOneMember_450dcd17-e7c1-43e0-bd2d-28e46c5fd4cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeTwoMember_52586d3f-d1ed-4949-ad1d-29389a407c3b" xlink:href="ameh-20200630.xsd#ameh_WarrantExercisePriceRangeTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_9e9ae659-15cb-42a5-8be6-5c719a0cc017" xlink:to="loc_ameh_WarrantExercisePriceRangeTwoMember_52586d3f-d1ed-4949-ad1d-29389a407c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeThreeMember_afffad95-c3bb-4514-bf57-c378573106dc" xlink:href="ameh-20200630.xsd#ameh_WarrantExercisePriceRangeThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_9e9ae659-15cb-42a5-8be6-5c719a0cc017" xlink:to="loc_ameh_WarrantExercisePriceRangeThreeMember_afffad95-c3bb-4514-bf57-c378573106dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeFourMember_c05d512e-c3f6-4159-8ae7-a56ee8977a9a" xlink:href="ameh-20200630.xsd#ameh_WarrantExercisePriceRangeFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_9e9ae659-15cb-42a5-8be6-5c719a0cc017" xlink:to="loc_ameh_WarrantExercisePriceRangeFourMember_c05d512e-c3f6-4159-8ae7-a56ee8977a9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_51b50ee5-3e66-4a2d-b5da-ec65ba9a999d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_afade0ce-20a0-40bd-8255-0c624b914b7c" xlink:to="loc_srt_RangeAxis_51b50ee5-3e66-4a2d-b5da-ec65ba9a999d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3ea4ff99-815c-4caa-9740-cc5c435e77ac" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_51b50ee5-3e66-4a2d-b5da-ec65ba9a999d" xlink:to="loc_srt_RangeMember_3ea4ff99-815c-4caa-9740-cc5c435e77ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_153e57b1-cf01-4a8c-a4aa-dd6410fabce4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3ea4ff99-815c-4caa-9740-cc5c435e77ac" xlink:to="loc_srt_MinimumMember_153e57b1-cf01-4a8c-a4aa-dd6410fabce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d5e3e5ac-4496-4308-ada2-d9ac323047fa" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3ea4ff99-815c-4caa-9740-cc5c435e77ac" xlink:to="loc_srt_MaximumMember_d5e3e5ac-4496-4308-ada2-d9ac323047fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_24fc618f-eb5b-4e57-8b8b-e035ceaefb56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_afade0ce-20a0-40bd-8255-0c624b914b7c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_24fc618f-eb5b-4e57-8b8b-e035ceaefb56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_b78fdf0b-c77f-49a7-b310-9f6f3d781ad4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_24fc618f-eb5b-4e57-8b8b-e035ceaefb56" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_b78fdf0b-c77f-49a7-b310-9f6f3d781ad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightIssuedInPeriod_2ee51212-e4da-49be-912a-ba3ef0eabeb8" xlink:href="ameh-20200630.xsd#ameh_ClassOfWarrantOrRightIssuedInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_24fc618f-eb5b-4e57-8b8b-e035ceaefb56" xlink:to="loc_ameh_ClassOfWarrantOrRightIssuedInPeriod_2ee51212-e4da-49be-912a-ba3ef0eabeb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm_4870fc01-67ec-4e52-8fae-f1855b5a53b8" xlink:href="ameh-20200630.xsd#ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_24fc618f-eb5b-4e57-8b8b-e035ceaefb56" xlink:to="loc_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm_4870fc01-67ec-4e52-8fae-f1855b5a53b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightExercisable_a75242e4-06ec-4ee2-9e43-716908a1e314" xlink:href="ameh-20200630.xsd#ameh_ClassOfWarrantOrRightExercisable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_24fc618f-eb5b-4e57-8b8b-e035ceaefb56" xlink:to="loc_ameh_ClassOfWarrantOrRightExercisable_a75242e4-06ec-4ee2-9e43-716908a1e314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_80ac58b6-df06-48fe-8d69-5c4ce53afd85" xlink:href="ameh-20200630.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_24fc618f-eb5b-4e57-8b8b-e035ceaefb56" xlink:to="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_80ac58b6-df06-48fe-8d69-5c4ce53afd85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="ameh-20200630.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_db2de07c-cc69-4030-a2ae-c25e25e0cf8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_bbec8cfe-cb90-4940-ae97-b90bba4a849e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_db2de07c-cc69-4030-a2ae-c25e25e0cf8d" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_bbec8cfe-cb90-4940-ae97-b90bba4a849e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a29dfef7-e284-4918-87c0-03b28552f8d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommitmentsAndContingenciesTable_10f89879-23d0-4e3e-a08a-3bbd56282994" xlink:href="ameh-20200630.xsd#ameh_CommitmentsAndContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a29dfef7-e284-4918-87c0-03b28552f8d6" xlink:to="loc_ameh_CommitmentsAndContingenciesTable_10f89879-23d0-4e3e-a08a-3bbd56282994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4bdc94dd-49da-496a-9017-841761cb2a6d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_10f89879-23d0-4e3e-a08a-3bbd56282994" xlink:to="loc_srt_ProductOrServiceAxis_4bdc94dd-49da-496a-9017-841761cb2a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3f81c4a3-dae7-409a-a96b-2dff7c7ad95c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_4bdc94dd-49da-496a-9017-841761cb2a6d" xlink:to="loc_srt_ProductsAndServicesDomain_3f81c4a3-dae7-409a-a96b-2dff7c7ad95c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PreferredBankMember_0e221fb0-1e75-4c74-95d8-faf78bfbebea" xlink:href="ameh-20200630.xsd#ameh_PreferredBankMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3f81c4a3-dae7-409a-a96b-2dff7c7ad95c" xlink:to="loc_ameh_PreferredBankMember_0e221fb0-1e75-4c74-95d8-faf78bfbebea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_55add9d3-4129-4a86-91c0-93c4ffde0f3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_10f89879-23d0-4e3e-a08a-3bbd56282994" xlink:to="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_55add9d3-4129-4a86-91c0-93c4ffde0f3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_808e48ef-c566-4120-97b7-8e2e40ce18a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_55add9d3-4129-4a86-91c0-93c4ffde0f3a" xlink:to="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_808e48ef-c566-4120-97b7-8e2e40ce18a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_0f7396c8-ec10-431f-922e-ff810f507151" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_808e48ef-c566-4120-97b7-8e2e40ce18a6" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_0f7396c8-ec10-431f-922e-ff810f507151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_adea8329-7847-44f1-a2ea-110048a7d227" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_10f89879-23d0-4e3e-a08a-3bbd56282994" xlink:to="loc_dei_LegalEntityAxis_adea8329-7847-44f1-a2ea-110048a7d227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_66c222f5-9321-4459-b9eb-d2a190e62b8a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_adea8329-7847-44f1-a2ea-110048a7d227" xlink:to="loc_dei_EntityDomain_66c222f5-9321-4459-b9eb-d2a190e62b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_ab2fc4c7-34b2-45b6-8843-958607481b4d" xlink:href="ameh-20200630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_66c222f5-9321-4459-b9eb-d2a190e62b8a" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_ab2fc4c7-34b2-45b6-8843-958607481b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlphaCareMedicalGroupInc.Member_90ce1dd3-4afc-484a-bcc4-da55f620caf2" xlink:href="ameh-20200630.xsd#ameh_AlphaCareMedicalGroupInc.Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_66c222f5-9321-4459-b9eb-d2a190e62b8a" xlink:to="loc_ameh_AlphaCareMedicalGroupInc.Member_90ce1dd3-4afc-484a-bcc4-da55f620caf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_c567029e-9b8e-4821-bfdc-7dc086fafdac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_10f89879-23d0-4e3e-a08a-3bbd56282994" xlink:to="loc_us-gaap_CreditFacilityAxis_c567029e-9b8e-4821-bfdc-7dc086fafdac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_4ac11285-4b79-4da4-b83f-76d0b4cc2fed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_c567029e-9b8e-4821-bfdc-7dc086fafdac" xlink:to="loc_us-gaap_CreditFacilityDomain_4ac11285-4b79-4da4-b83f-76d0b4cc2fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_225e59a9-66c0-4fdd-807a-9d627c64c2d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_4ac11285-4b79-4da4-b83f-76d0b4cc2fed" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_225e59a9-66c0-4fdd-807a-9d627c64c2d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommitmentsAndContingenciesLineItems_1bca2b8e-0f36-400d-a965-68d264fe1272" xlink:href="ameh-20200630.xsd#ameh_CommitmentsAndContingenciesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_10f89879-23d0-4e3e-a08a-3bbd56282994" xlink:to="loc_ameh_CommitmentsAndContingenciesLineItems_1bca2b8e-0f36-400d-a965-68d264fe1272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount_69f124a4-3106-43a7-9bae-5783a00c1bc4" xlink:href="ameh-20200630.xsd#ameh_PercentageOfFinancialGuaranteeBenchmarkAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems_1bca2b8e-0f36-400d-a965-68d264fe1272" xlink:to="loc_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount_69f124a4-3106-43a7-9bae-5783a00c1bc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_288b195d-837a-4ab0-8a05-a9c66c244f16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems_1bca2b8e-0f36-400d-a965-68d264fe1272" xlink:to="loc_us-gaap_LineOfCredit_288b195d-837a-4ab0-8a05-a9c66c244f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_075a0027-1484-4c03-812b-0ae8e38b9ec3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems_1bca2b8e-0f36-400d-a965-68d264fe1272" xlink:to="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_075a0027-1484-4c03-812b-0ae8e38b9ec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities_d03e70aa-e7c9-45bb-9adb-6ffed7e5369f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems_1bca2b8e-0f36-400d-a965-68d264fe1272" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities_d03e70aa-e7c9-45bb-9adb-6ffed7e5369f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_2ff171ad-29c4-47fc-9893-cb68e2c80661" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems_1bca2b8e-0f36-400d-a965-68d264fe1272" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_2ff171ad-29c4-47fc-9893-cb68e2c80661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="ameh-20200630.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_2431c35f-6fcc-4953-acbb-cb9ccac17705" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_c60bc301-bafd-495d-a4a5-206a92f3335d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_2431c35f-6fcc-4953-acbb-cb9ccac17705" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_c60bc301-bafd-495d-a4a5-206a92f3335d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsTables" xlink:type="simple" xlink:href="ameh-20200630.xsd#RelatedPartyTransactionsTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_c3d2da33-146d-4816-ab60-a46d41d79791" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_fc69ee7a-faed-4fa8-bfa1-84f9802eb9d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_c3d2da33-146d-4816-ab60-a46d41d79791" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_fc69ee7a-faed-4fa8-bfa1-84f9802eb9d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#RelatedPartyTransactionsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_a7db97e5-35ca-428a-bc73-0de1fe4628b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_938a636c-f7b5-44f2-8e4a-884961b83984" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_a7db97e5-35ca-428a-bc73-0de1fe4628b7" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_938a636c-f7b5-44f2-8e4a-884961b83984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d922d685-d87c-4402-a987-aa794a646e44" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_938a636c-f7b5-44f2-8e4a-884961b83984" xlink:to="loc_srt_CounterpartyNameAxis_d922d685-d87c-4402-a987-aa794a646e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_278a50d4-3b0c-43d5-8a2d-36ec21adfb79" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_d922d685-d87c-4402-a987-aa794a646e44" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_278a50d4-3b0c-43d5-8a2d-36ec21adfb79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_261817ca-474e-4762-a648-6d3e74fc53fa" xlink:href="ameh-20200630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_278a50d4-3b0c-43d5-8a2d-36ec21adfb79" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_261817ca-474e-4762-a648-6d3e74fc53fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0b8cf2dc-d880-4d4c-a89b-e431ca132b6f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_938a636c-f7b5-44f2-8e4a-884961b83984" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0b8cf2dc-d880-4d4c-a89b-e431ca132b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_f4ed4197-9592-49d7-83a8-aa7835078dd8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0b8cf2dc-d880-4d4c-a89b-e431ca132b6f" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_f4ed4197-9592-49d7-83a8-aa7835078dd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareIncMember_cb7d4bbc-3971-407a-8c47-ba1c49ec4faf" xlink:href="ameh-20200630.xsd#ameh_UniversalCareIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f4ed4197-9592-49d7-83a8-aa7835078dd8" xlink:to="loc_ameh_UniversalCareIncMember_cb7d4bbc-3971-407a-8c47-ba1c49ec4faf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LmaMember_cefc5eec-e14f-445e-8928-d388ab6bd457" xlink:href="ameh-20200630.xsd#ameh_LmaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f4ed4197-9592-49d7-83a8-aa7835078dd8" xlink:to="loc_ameh_LmaMember_cefc5eec-e14f-445e-8928-d388ab6bd457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PmiocMember_e2ca8a59-ad9e-4d9c-9062-53269a0d2591" xlink:href="ameh-20200630.xsd#ameh_PmiocMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f4ed4197-9592-49d7-83a8-aa7835078dd8" xlink:to="loc_ameh_PmiocMember_e2ca8a59-ad9e-4d9c-9062-53269a0d2591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DmgMember_9afd658a-7382-4f91-8609-f92707f38cfc" xlink:href="ameh-20200630.xsd#ameh_DmgMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f4ed4197-9592-49d7-83a8-aa7835078dd8" xlink:to="loc_ameh_DmgMember_9afd658a-7382-4f91-8609-f92707f38cfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOInc.Member_701977a3-aad7-489f-8956-3d97f1cbbf9a" xlink:href="ameh-20200630.xsd#ameh_OneMSOInc.Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f4ed4197-9592-49d7-83a8-aa7835078dd8" xlink:to="loc_ameh_OneMSOInc.Member_701977a3-aad7-489f-8956-3d97f1cbbf9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_95b7f1d8-2e2f-4ab3-aff5-223ffddaa571" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_938a636c-f7b5-44f2-8e4a-884961b83984" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_95b7f1d8-2e2f-4ab3-aff5-223ffddaa571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_f24e2d04-0cd7-425d-98e0-efb63425ce40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_95b7f1d8-2e2f-4ab3-aff5-223ffddaa571" xlink:to="loc_us-gaap_RelatedPartyDomain_f24e2d04-0cd7-425d-98e0-efb63425ce40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareIncMember_5995395e-a898-487e-afeb-dbadb45c1234" xlink:href="ameh-20200630.xsd#ameh_UniversalCareIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_f24e2d04-0cd7-425d-98e0-efb63425ce40" xlink:to="loc_ameh_UniversalCareIncMember_5995395e-a898-487e-afeb-dbadb45c1234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_1e84e195-8328-4fdb-a2a7-f298a1012767" xlink:href="ameh-20200630.xsd#ameh_UniversalCareAcquisitionPartnersLlcMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_f24e2d04-0cd7-425d-98e0-efb63425ce40" xlink:to="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_1e84e195-8328-4fdb-a2a7-f298a1012767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcShareholdersMember_2c9ffb6d-782a-4bc9-81c1-302b867cc147" xlink:href="ameh-20200630.xsd#ameh_ApcShareholdersMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_f24e2d04-0cd7-425d-98e0-efb63425ce40" xlink:to="loc_ameh_ApcShareholdersMember_2c9ffb6d-782a-4bc9-81c1-302b867cc147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AdvanceDiagnosticSurgeryCenterMember_0cd217bd-34f8-4dee-8f97-02ac4aee2cf3" xlink:href="ameh-20200630.xsd#ameh_AdvanceDiagnosticSurgeryCenterMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_f24e2d04-0cd7-425d-98e0-efb63425ce40" xlink:to="loc_ameh_AdvanceDiagnosticSurgeryCenterMember_0cd217bd-34f8-4dee-8f97-02ac4aee2cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareholdersAndOfficersMember_07517a80-cf64-4b37-b0d2-5c42e8e3180f" xlink:href="ameh-20200630.xsd#ameh_ShareholdersAndOfficersMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_f24e2d04-0cd7-425d-98e0-efb63425ce40" xlink:to="loc_ameh_ShareholdersAndOfficersMember_07517a80-cf64-4b37-b0d2-5c42e8e3180f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicalPropertyPartnersMember_540c02c3-cd1e-4ff1-a00f-a0a4a14f43db" xlink:href="ameh-20200630.xsd#ameh_MedicalPropertyPartnersMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_f24e2d04-0cd7-425d-98e0-efb63425ce40" xlink:to="loc_ameh_MedicalPropertyPartnersMember_540c02c3-cd1e-4ff1-a00f-a0a4a14f43db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOInc.Member_44d40e46-abc9-409b-987b-ffae47c75a6e" xlink:href="ameh-20200630.xsd#ameh_OneMSOInc.Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_f24e2d04-0cd7-425d-98e0-efb63425ce40" xlink:to="loc_ameh_OneMSOInc.Member_44d40e46-abc9-409b-987b-ffae47c75a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CriticalQualityManagementCorpMember_c16526aa-fd11-4b98-b909-f2c52e91ac7b" xlink:href="ameh-20200630.xsd#ameh_CriticalQualityManagementCorpMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_f24e2d04-0cd7-425d-98e0-efb63425ce40" xlink:to="loc_ameh_CriticalQualityManagementCorpMember_c16526aa-fd11-4b98-b909-f2c52e91ac7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumenLLCMember_c353a65d-5eb9-4caa-a25f-8bd588b296cf" xlink:href="ameh-20200630.xsd#ameh_NumenLLCMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_f24e2d04-0cd7-425d-98e0-efb63425ce40" xlink:to="loc_ameh_NumenLLCMember_c353a65d-5eb9-4caa-a25f-8bd588b296cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AHMCMember_cb1bd554-21ab-4069-a455-4971b77343d1" xlink:href="ameh-20200630.xsd#ameh_AHMCMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_f24e2d04-0cd7-425d-98e0-efb63425ce40" xlink:to="loc_ameh_AHMCMember_cb1bd554-21ab-4069-a455-4971b77343d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_451ae134-0235-4cad-94af-903bb1753749" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_938a636c-f7b5-44f2-8e4a-884961b83984" xlink:to="loc_dei_LegalEntityAxis_451ae134-0235-4cad-94af-903bb1753749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e279b219-7acf-45a4-a1e9-c1dbb54a8ec4" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_451ae134-0235-4cad-94af-903bb1753749" xlink:to="loc_dei_EntityDomain_e279b219-7acf-45a4-a1e9-c1dbb54a8ec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementMember_824ac479-0636-46bb-847e-1479147b2744" xlink:href="ameh-20200630.xsd#ameh_NetworkMedicalManagementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_e279b219-7acf-45a4-a1e9-c1dbb54a8ec4" xlink:to="loc_ameh_NetworkMedicalManagementMember_824ac479-0636-46bb-847e-1479147b2744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_250f09f2-9f7d-475a-ae8b-c9bad5485bd4" xlink:href="ameh-20200630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_e279b219-7acf-45a4-a1e9-c1dbb54a8ec4" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_250f09f2-9f7d-475a-ae8b-c9bad5485bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SCHCMember_f9c6567a-6211-469c-891f-549d22923e92" xlink:href="ameh-20200630.xsd#ameh_SCHCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_e279b219-7acf-45a4-a1e9-c1dbb54a8ec4" xlink:to="loc_ameh_SCHCMember_f9c6567a-6211-469c-891f-549d22923e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_e14d4045-7ef7-4141-8415-64d19838c6c3" xlink:href="ameh-20200630.xsd#ameh_UniversalCareAcquisitionPartnersLlcMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_e279b219-7acf-45a4-a1e9-c1dbb54a8ec4" xlink:to="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_e14d4045-7ef7-4141-8415-64d19838c6c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DrSimAndDrLamMember_e43d0c85-13e9-412f-9145-aab9519ea86e" xlink:href="ameh-20200630.xsd#ameh_DrSimAndDrLamMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_e279b219-7acf-45a4-a1e9-c1dbb54a8ec4" xlink:to="loc_ameh_DrSimAndDrLamMember_e43d0c85-13e9-412f-9145-aab9519ea86e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_b3ca457b-f471-45ed-ab04-37eebd9ddfd8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_938a636c-f7b5-44f2-8e4a-884961b83984" xlink:to="loc_srt_ConsolidatedEntitiesAxis_b3ca457b-f471-45ed-ab04-37eebd9ddfd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_0f65fba9-2d1e-41c1-9561-e66ad320ad81" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_b3ca457b-f471-45ed-ab04-37eebd9ddfd8" xlink:to="loc_srt_ConsolidatedEntitiesDomain_0f65fba9-2d1e-41c1-9561-e66ad320ad81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LmaMember_88d7675d-3fba-41c9-a4ad-ba9e0ca8f53d" xlink:href="ameh-20200630.xsd#ameh_LmaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_0f65fba9-2d1e-41c1-9561-e66ad320ad81" xlink:to="loc_ameh_LmaMember_88d7675d-3fba-41c9-a4ad-ba9e0ca8f53d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PmiocMember_7c42862a-cd68-46b9-ba69-a55390b7824c" xlink:href="ameh-20200630.xsd#ameh_PmiocMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_0f65fba9-2d1e-41c1-9561-e66ad320ad81" xlink:to="loc_ameh_PmiocMember_7c42862a-cd68-46b9-ba69-a55390b7824c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DmgMember_b3385f51-ab4e-4eb9-b64e-0b1f7035e179" xlink:href="ameh-20200630.xsd#ameh_DmgMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_0f65fba9-2d1e-41c1-9561-e66ad320ad81" xlink:to="loc_ameh_DmgMember_b3385f51-ab4e-4eb9-b64e-0b1f7035e179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_6769af41-332d-4787-a9cb-20a4f8c73dc9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_938a636c-f7b5-44f2-8e4a-884961b83984" xlink:to="loc_srt_TitleOfIndividualAxis_6769af41-332d-4787-a9cb-20a4f8c73dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_68900bfd-a5c8-4f3e-bb10-da5427fc710e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_6769af41-332d-4787-a9cb-20a4f8c73dc9" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_68900bfd-a5c8-4f3e-bb10-da5427fc710e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_2c1a637b-6787-4f6b-a27c-7f16a516fdea" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_68900bfd-a5c8-4f3e-bb10-da5427fc710e" xlink:to="loc_srt_DirectorMember_2c1a637b-6787-4f6b-a27c-7f16a516fdea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_6e15827f-f409-4f85-86cb-a1b4a4aadc52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_938a636c-f7b5-44f2-8e4a-884961b83984" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_6e15827f-f409-4f85-86cb-a1b4a4aadc52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1c90053e-8522-4cba-ab41-a64af76bb7f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_6e15827f-f409-4f85-86cb-a1b4a4aadc52" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1c90053e-8522-4cba-ab41-a64af76bb7f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_9b450ce7-eb40-4ec5-b4c5-543196d88542" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1c90053e-8522-4cba-ab41-a64af76bb7f9" xlink:to="loc_us-gaap_ServiceMember_9b450ce7-eb40-4ec5-b4c5-543196d88542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_2fd74bc0-fcec-4d6a-b57f-bde2b66e8817" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_938a636c-f7b5-44f2-8e4a-884961b83984" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_2fd74bc0-fcec-4d6a-b57f-bde2b66e8817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_3515e65c-4a2f-412a-8da8-dd52fc443c22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2fd74bc0-fcec-4d6a-b57f-bde2b66e8817" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_3515e65c-4a2f-412a-8da8-dd52fc443c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_a99afead-f3bc-4133-ae2e-ce9f8f382221" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2fd74bc0-fcec-4d6a-b57f-bde2b66e8817" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_a99afead-f3bc-4133-ae2e-ce9f8f382221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsAndOtherReceivablesNumberOfAdditionalAgreements_1f6b9434-bc13-4241-a79c-345e18b1803b" xlink:href="ameh-20200630.xsd#ameh_AccountsAndOtherReceivablesNumberOfAdditionalAgreements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2fd74bc0-fcec-4d6a-b57f-bde2b66e8817" xlink:to="loc_ameh_AccountsAndOtherReceivablesNumberOfAdditionalAgreements_1f6b9434-bc13-4241-a79c-345e18b1803b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties_7cdf3391-589b-4dcb-8ca9-03e58632c2fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2fd74bc0-fcec-4d6a-b57f-bde2b66e8817" xlink:to="loc_us-gaap_RevenueFromRelatedParties_7cdf3391-589b-4dcb-8ca9-03e58632c2fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentMadeToRelatedParty_13b2f099-2a5e-4f18-9613-bd34d212a270" xlink:href="ameh-20200630.xsd#ameh_PaymentMadeToRelatedParty"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2fd74bc0-fcec-4d6a-b57f-bde2b66e8817" xlink:to="loc_ameh_PaymentMadeToRelatedParty_13b2f099-2a5e-4f18-9613-bd34d212a270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_6a3e97fd-4e58-4ae1-b288-92164dd0680d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2fd74bc0-fcec-4d6a-b57f-bde2b66e8817" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_6a3e97fd-4e58-4ae1-b288-92164dd0680d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_9a8c7e03-4730-42c9-9d27-cba9e78cde3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2fd74bc0-fcec-4d6a-b57f-bde2b66e8817" xlink:to="loc_us-gaap_OperatingLeaseLiability_9a8c7e03-4730-42c9-9d27-cba9e78cde3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_f5b19149-080a-47f1-a602-606fd1b021c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2fd74bc0-fcec-4d6a-b57f-bde2b66e8817" xlink:to="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_f5b19149-080a-47f1-a602-606fd1b021c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilities_804ca932-f67a-4403-85bf-be46d0ca9e52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2fd74bc0-fcec-4d6a-b57f-bde2b66e8817" xlink:to="loc_us-gaap_DeferredCreditsAndOtherLiabilities_804ca932-f67a-4403-85bf-be46d0ca9e52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentConsultingFees_50af5293-2f00-4324-861b-5be0d0d37a74" xlink:href="ameh-20200630.xsd#ameh_PaymentConsultingFees"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2fd74bc0-fcec-4d6a-b57f-bde2b66e8817" xlink:to="loc_ameh_PaymentConsultingFees_50af5293-2f00-4324-861b-5be0d0d37a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_4de80cd8-eb14-434e-9779-a84f788bba3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_41ec71ce-bc3f-4524-80e2-046c9d032f13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_4de80cd8-eb14-434e-9779-a84f788bba3f" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_41ec71ce-bc3f-4524-80e2-046c9d032f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_404066da-6753-4859-893a-0d262e3f046e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_41ec71ce-bc3f-4524-80e2-046c9d032f13" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_404066da-6753-4859-893a-0d262e3f046e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_08df495c-4855-41e8-9537-53a2d2b4a23f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_404066da-6753-4859-893a-0d262e3f046e" xlink:to="loc_us-gaap_RelatedPartyDomain_08df495c-4855-41e8-9537-53a2d2b4a23f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AHMCMember_022045d0-4e9a-4506-b223-1811b23226f9" xlink:href="ameh-20200630.xsd#ameh_AHMCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_08df495c-4855-41e8-9537-53a2d2b4a23f" xlink:to="loc_ameh_AHMCMember_022045d0-4e9a-4506-b223-1811b23226f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_HSMSOMember_aeea9679-6f91-40eb-a847-edff4ef9dc54" xlink:href="ameh-20200630.xsd#ameh_HSMSOMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_08df495c-4855-41e8-9537-53a2d2b4a23f" xlink:to="loc_ameh_HSMSOMember_aeea9679-6f91-40eb-a847-edff4ef9dc54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AurionMember_9ed94950-1dbd-4b52-bc8b-6339bb898ab0" xlink:href="ameh-20200630.xsd#ameh_AurionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_08df495c-4855-41e8-9537-53a2d2b4a23f" xlink:to="loc_ameh_AurionMember_9ed94950-1dbd-4b52-bc8b-6339bb898ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_707a155b-edd8-4440-8f2b-0f2bb6a9a07b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_41ec71ce-bc3f-4524-80e2-046c9d032f13" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_707a155b-edd8-4440-8f2b-0f2bb6a9a07b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_98bc4b99-2028-49b9-8f46-e388dc8dc2a7" xlink:href="ameh-20200630.xsd#ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_707a155b-edd8-4440-8f2b-0f2bb6a9a07b" xlink:to="loc_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_98bc4b99-2028-49b9-8f46-e388dc8dc2a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementFeeExpense_b79d63d9-544e-46da-a917-353f75cd6e20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ManagementFeeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_707a155b-edd8-4440-8f2b-0f2bb6a9a07b" xlink:to="loc_us-gaap_ManagementFeeExpense_b79d63d9-544e-46da-a917-353f75cd6e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_64d495a9-3db8-47ea-aaec-f2feef8f6f7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_707a155b-edd8-4440-8f2b-0f2bb6a9a07b" xlink:to="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_64d495a9-3db8-47ea-aaec-f2feef8f6f7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IncomeTaxes" xlink:type="simple" xlink:href="ameh-20200630.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_5480c14f-cd7b-4dcb-8524-6c2a40067d10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_0a2eb202-8666-4a80-97c2-d465127dcb6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5480c14f-cd7b-4dcb-8524-6c2a40067d10" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_0a2eb202-8666-4a80-97c2-d465127dcb6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShare" xlink:type="simple" xlink:href="ameh-20200630.xsd#EarningsPerShare"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_948b7f98-abda-44f7-ba78-fc369a116559" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_c43322bf-66b2-49a5-9dcd-ecaf95da0164" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_948b7f98-abda-44f7-ba78-fc369a116559" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_c43322bf-66b2-49a5-9dcd-ecaf95da0164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareTables" xlink:type="simple" xlink:href="ameh-20200630.xsd#EarningsPerShareTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0d82aa2e-e172-4179-a416-f17e9d1e4d3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_2ebcbec6-56e6-4627-afb2-7ec9cf15b6a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0d82aa2e-e172-4179-a416-f17e9d1e4d3f" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_2ebcbec6-56e6-4627-afb2-7ec9cf15b6a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_61a777bf-49cc-40a7-a01b-b3b65e96c11b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0d82aa2e-e172-4179-a416-f17e9d1e4d3f" xlink:to="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_61a777bf-49cc-40a7-a01b-b3b65e96c11b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#EarningsPerShareAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_634b2a09-a811-42a7-8bb6-f58651542b6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EarningsPerShareTable_796bcc76-2da1-4a28-ac65-377854d7cedc" xlink:href="ameh-20200630.xsd#ameh_EarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_634b2a09-a811-42a7-8bb6-f58651542b6e" xlink:to="loc_ameh_EarningsPerShareTable_796bcc76-2da1-4a28-ac65-377854d7cedc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_41167a92-3dd3-4949-a0b1-6d2e183afa20" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EarningsPerShareTable_796bcc76-2da1-4a28-ac65-377854d7cedc" xlink:to="loc_dei_LegalEntityAxis_41167a92-3dd3-4949-a0b1-6d2e183afa20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a341af11-265b-43e5-ba7b-f9e0de9bac6f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_41167a92-3dd3-4949-a0b1-6d2e183afa20" xlink:to="loc_dei_EntityDomain_a341af11-265b-43e5-ba7b-f9e0de9bac6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_0dfc8c41-8f91-4957-9230-f10174e19b4a" xlink:href="ameh-20200630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_a341af11-265b-43e5-ba7b-f9e0de9bac6f" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_0dfc8c41-8f91-4957-9230-f10174e19b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EarningsPerShareLineItems_1d8ff331-64ed-4891-8533-1ed3ae28bdd2" xlink:href="ameh-20200630.xsd#ameh_EarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EarningsPerShareTable_796bcc76-2da1-4a28-ac65-377854d7cedc" xlink:to="loc_ameh_EarningsPerShareLineItems_1d8ff331-64ed-4891-8533-1ed3ae28bdd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AntidilutiveSecuritiesExcludedFromEarningsComputationShares_ff39ba98-e22c-41f0-aa22-f15c614b2dda" xlink:href="ameh-20200630.xsd#ameh_AntidilutiveSecuritiesExcludedFromEarningsComputationShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EarningsPerShareLineItems_1d8ff331-64ed-4891-8533-1ed3ae28bdd2" xlink:to="loc_ameh_AntidilutiveSecuritiesExcludedFromEarningsComputationShares_ff39ba98-e22c-41f0-aa22-f15c614b2dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#EarningsPerShareEarningsPerShareComputationsDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a52d177c-c67c-4dfd-bed1-440f7d86932d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_21c15b46-4c5f-4acb-8742-5006f7228cae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a52d177c-c67c-4dfd-bed1-440f7d86932d" xlink:to="loc_us-gaap_EarningsPerShareBasic_21c15b46-4c5f-4acb-8742-5006f7228cae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_443b15cb-617c-4686-baa8-b97582e9f4c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a52d177c-c67c-4dfd-bed1-440f7d86932d" xlink:to="loc_us-gaap_EarningsPerShareDiluted_443b15cb-617c-4686-baa8-b97582e9f4c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ee2210a6-0063-4582-8c29-6d38808e32bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a52d177c-c67c-4dfd-bed1-440f7d86932d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ee2210a6-0063-4582-8c29-6d38808e32bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_abe60ac8-de1a-42fe-a526-4d9b069bdccb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a52d177c-c67c-4dfd-bed1-440f7d86932d" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_abe60ac8-de1a-42fe-a526-4d9b069bdccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_96aec088-1cb5-439a-a44b-ddd3890dae96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EarningsPerShareTable_bd84d6bd-c247-4436-8997-c4320b08d34f" xlink:href="ameh-20200630.xsd#ameh_EarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_96aec088-1cb5-439a-a44b-ddd3890dae96" xlink:to="loc_ameh_EarningsPerShareTable_bd84d6bd-c247-4436-8997-c4320b08d34f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_78a262b9-33aa-4735-8b1c-fe2441d5f335" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EarningsPerShareTable_bd84d6bd-c247-4436-8997-c4320b08d34f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_78a262b9-33aa-4735-8b1c-fe2441d5f335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e63e7bc5-bc72-452c-b308-32fafb02c98f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_78a262b9-33aa-4735-8b1c-fe2441d5f335" xlink:to="loc_us-gaap_EquityComponentDomain_e63e7bc5-bc72-452c-b308-32fafb02c98f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c0917608-4b92-4280-92ca-ffa76fb312e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e63e7bc5-bc72-452c-b308-32fafb02c98f" xlink:to="loc_us-gaap_CommonStockMember_c0917608-4b92-4280-92ca-ffa76fb312e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_458ab023-4563-4f6e-926b-e0330d332492" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e63e7bc5-bc72-452c-b308-32fafb02c98f" xlink:to="loc_us-gaap_WarrantMember_458ab023-4563-4f6e-926b-e0330d332492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8999ec09-6649-4050-8d0f-cba6d2e3c76e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EarningsPerShareTable_bd84d6bd-c247-4436-8997-c4320b08d34f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8999ec09-6649-4050-8d0f-cba6d2e3c76e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3b580ada-5019-481f-80cb-3854d0cca8b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8999ec09-6649-4050-8d0f-cba6d2e3c76e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3b580ada-5019-481f-80cb-3854d0cca8b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_901cd3e3-cc87-4d50-8e2f-132e5e9a5286" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3b580ada-5019-481f-80cb-3854d0cca8b0" xlink:to="loc_us-gaap_EmployeeStockOptionMember_901cd3e3-cc87-4d50-8e2f-132e5e9a5286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_c1db7bdb-ac99-44e0-a562-a2f803bca1a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3b580ada-5019-481f-80cb-3854d0cca8b0" xlink:to="loc_us-gaap_RestrictedStockMember_c1db7bdb-ac99-44e0-a562-a2f803bca1a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EarningsPerShareLineItems_51e4de2e-c2af-4ef3-b062-0fb47bfc9193" xlink:href="ameh-20200630.xsd#ameh_EarningsPerShareLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EarningsPerShareTable_bd84d6bd-c247-4436-8997-c4320b08d34f" xlink:to="loc_ameh_EarningsPerShareLineItems_51e4de2e-c2af-4ef3-b062-0fb47bfc9193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_430c0820-db61-4c66-bd8f-6ffead99a09a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EarningsPerShareLineItems_51e4de2e-c2af-4ef3-b062-0fb47bfc9193" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_430c0820-db61-4c66-bd8f-6ffead99a09a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_180c3140-8f87-41e9-b2a4-ad5661a5ef8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EarningsPerShareLineItems_51e4de2e-c2af-4ef3-b062-0fb47bfc9193" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_180c3140-8f87-41e9-b2a4-ad5661a5ef8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_62aa9f56-5a5e-4f84-85dc-3f2f00749dff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EarningsPerShareLineItems_51e4de2e-c2af-4ef3-b062-0fb47bfc9193" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_62aa9f56-5a5e-4f84-85dc-3f2f00749dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage_3a9c2979-4045-4bf3-af48-d2f8b21666db" xlink:href="ameh-20200630.xsd#ameh_BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EarningsPerShareLineItems_51e4de2e-c2af-4ef3-b062-0fb47bfc9193" xlink:to="loc_ameh_BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage_3a9c2979-4045-4bf3-af48-d2f8b21666db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEs" xlink:type="simple" xlink:href="ameh-20200630.xsd#VariableInterestEntitiesVIEs"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/VariableInterestEntitiesVIEs" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e8a0cc53-f27f-4ae9-8131-efa4d97243b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_89715fb8-8105-4147-9fde-d0e15e03eedf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e8a0cc53-f27f-4ae9-8131-efa4d97243b0" xlink:to="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_89715fb8-8105-4147-9fde-d0e15e03eedf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables" xlink:type="simple" xlink:href="ameh-20200630.xsd#VariableInterestEntitiesVIEsTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e46aaa9f-0a15-4ccb-9063-ea628d8d08bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_58e49a91-7dba-4fdb-8b53-9d67266fad0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e46aaa9f-0a15-4ccb-9063-ea628d8d08bd" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_58e49a91-7dba-4fdb-8b53-9d67266fad0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#VariableInterestEntitiesVIEsDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a9ad8d54-0e2d-4d81-81c1-86d4c0f4ac3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_669e1b9e-bb4e-4ff0-841d-38c787e9c85e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a9ad8d54-0e2d-4d81-81c1-86d4c0f4ac3b" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_669e1b9e-bb4e-4ff0-841d-38c787e9c85e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_a96b5a7b-9df3-4340-8f13-8a8fdc565659" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_669e1b9e-bb4e-4ff0-841d-38c787e9c85e" xlink:to="loc_srt_ConsolidatedEntitiesAxis_a96b5a7b-9df3-4340-8f13-8a8fdc565659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_a1dbc51e-ebf3-46ed-836b-ecee4a687a42" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_a96b5a7b-9df3-4340-8f13-8a8fdc565659" xlink:to="loc_srt_ConsolidatedEntitiesDomain_a1dbc51e-ebf3-46ed-836b-ecee4a687a42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_da9b3767-4ce8-48b6-8ce9-5f03d63db2cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_a1dbc51e-ebf3-46ed-836b-ecee4a687a42" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_da9b3767-4ce8-48b6-8ce9-5f03d63db2cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_d23e5726-5dfa-4fb9-b203-3e5c94e3bfe1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_669e1b9e-bb4e-4ff0-841d-38c787e9c85e" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_d23e5726-5dfa-4fb9-b203-3e5c94e3bfe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_86b36f17-0474-4075-8f3c-16dda4b63996" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_d23e5726-5dfa-4fb9-b203-3e5c94e3bfe1" xlink:to="loc_us-gaap_AssetsAbstract_86b36f17-0474-4075-8f3c-16dda4b63996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_0142a6b7-6189-4712-a44c-8a7c1451df35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_86b36f17-0474-4075-8f3c-16dda4b63996" xlink:to="loc_us-gaap_AssetsCurrentAbstract_0142a6b7-6189-4712-a44c-8a7c1451df35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4a9f686e-c6d0-48cf-abb2-0992018381b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0142a6b7-6189-4712-a44c-8a7c1451df35" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4a9f686e-c6d0-48cf-abb2-0992018381b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_06801b4c-af63-4194-803a-465fb9d47212" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0142a6b7-6189-4712-a44c-8a7c1451df35" xlink:to="loc_us-gaap_RestrictedCashCurrent_06801b4c-af63-4194-803a-465fb9d47212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_763dac75-2524-4ffa-a1bf-d5f29a8c562c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0142a6b7-6189-4712-a44c-8a7c1451df35" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_763dac75-2524-4ffa-a1bf-d5f29a8c562c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_2e23bf66-dcc6-4d21-b0d5-2b7667b55aae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0142a6b7-6189-4712-a44c-8a7c1451df35" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_2e23bf66-dcc6-4d21-b0d5-2b7667b55aae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_1a181eb9-8a26-43f6-9eb4-3aa412eefa50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0142a6b7-6189-4712-a44c-8a7c1451df35" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_1a181eb9-8a26-43f6-9eb4-3aa412eefa50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_22531f3f-9c99-4bb4-9334-13f933aca2f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0142a6b7-6189-4712-a44c-8a7c1451df35" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_22531f3f-9c99-4bb4-9334-13f933aca2f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_eb72f4c4-f5ff-4b84-af9a-9f3f57c0882a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0142a6b7-6189-4712-a44c-8a7c1451df35" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_eb72f4c4-f5ff-4b84-af9a-9f3f57c0882a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent_0034ca05-da42-4ef5-a4a9-baa3bbf34e05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0142a6b7-6189-4712-a44c-8a7c1451df35" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetCurrent_0034ca05-da42-4ef5-a4a9-baa3bbf34e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesCurrent_fcc756a7-589e-41cd-ba35-1363136e4ca8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesReceivableRelatedPartiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0142a6b7-6189-4712-a44c-8a7c1451df35" xlink:to="loc_us-gaap_NotesReceivableRelatedPartiesCurrent_fcc756a7-589e-41cd-ba35-1363136e4ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_dc29cdde-6b2f-4502-a1e9-cabdcd482a53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0142a6b7-6189-4712-a44c-8a7c1451df35" xlink:to="loc_us-gaap_AssetsCurrent_dc29cdde-6b2f-4502-a1e9-cabdcd482a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_8da2914b-f179-4d76-98f1-c59b026a2274" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_86b36f17-0474-4075-8f3c-16dda4b63996" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_8da2914b-f179-4d76-98f1-c59b026a2274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ba9df389-5c45-41c6-bc28-3d61f763568a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8da2914b-f179-4d76-98f1-c59b026a2274" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ba9df389-5c45-41c6-bc28-3d61f763568a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8add0573-c88f-4149-835c-ace86b89808b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8da2914b-f179-4d76-98f1-c59b026a2274" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8add0573-c88f-4149-835c-ace86b89808b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_9e582393-9a07-47d7-855f-d1a9c4add8f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8da2914b-f179-4d76-98f1-c59b026a2274" xlink:to="loc_us-gaap_Goodwill_9e582393-9a07-47d7-855f-d1a9c4add8f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_f984db4a-3aae-4b4d-87b9-63f3039825d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8da2914b-f179-4d76-98f1-c59b026a2274" xlink:to="loc_us-gaap_OtherLongTermInvestments_f984db4a-3aae-4b4d-87b9-63f3039825d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_cb283f0d-41af-45b4-86d5-b3e9fcf52fd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8da2914b-f179-4d76-98f1-c59b026a2274" xlink:to="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_cb283f0d-41af-45b4-86d5-b3e9fcf52fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_45024011-38f5-4ba7-a0be-b9d2ec264776" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8da2914b-f179-4d76-98f1-c59b026a2274" xlink:to="loc_us-gaap_EquityMethodInvestments_45024011-38f5-4ba7-a0be-b9d2ec264776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_207be538-edc3-446f-9c84-5dae01c732ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8da2914b-f179-4d76-98f1-c59b026a2274" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_207be538-edc3-446f-9c84-5dae01c732ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_10e7e7b8-8c46-4a4b-9612-26f96d0aa0ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8da2914b-f179-4d76-98f1-c59b026a2274" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_10e7e7b8-8c46-4a4b-9612-26f96d0aa0ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_3bec4708-5160-4729-a771-e00f02fd3702" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8da2914b-f179-4d76-98f1-c59b026a2274" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_3bec4708-5160-4729-a771-e00f02fd3702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_13d64d5c-516f-433d-a161-a72c4eabd260" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8da2914b-f179-4d76-98f1-c59b026a2274" xlink:to="loc_us-gaap_AssetsNoncurrent_13d64d5c-516f-433d-a161-a72c4eabd260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_0b258a61-3255-4c76-b2dc-f1b38078679d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_86b36f17-0474-4075-8f3c-16dda4b63996" xlink:to="loc_us-gaap_Assets_0b258a61-3255-4c76-b2dc-f1b38078679d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_70e59b62-a6f4-40cf-a22c-809f994d9c44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_d23e5726-5dfa-4fb9-b203-3e5c94e3bfe1" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_70e59b62-a6f4-40cf-a22c-809f994d9c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4c6d3933-6340-4dcb-9e02-ed3bd8191cb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_70e59b62-a6f4-40cf-a22c-809f994d9c44" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4c6d3933-6340-4dcb-9e02-ed3bd8191cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent_cd1f45bf-e53b-4ff7-8e8e-1cf917a1e46a" xlink:href="ameh-20200630.xsd#ameh_FiduciaryAccountsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_70e59b62-a6f4-40cf-a22c-809f994d9c44" xlink:to="loc_ameh_FiduciaryAccountsPayableCurrent_cd1f45bf-e53b-4ff7-8e8e-1cf917a1e46a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_8a7ecd05-7dd4-4e4c-9528-622ea8c675c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_70e59b62-a6f4-40cf-a22c-809f994d9c44" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_8a7ecd05-7dd4-4e4c-9528-622ea8c675c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_a9a200eb-2800-471d-a4cf-fd2de5a7a91e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_70e59b62-a6f4-40cf-a22c-809f994d9c44" xlink:to="loc_us-gaap_TaxesPayableCurrent_a9a200eb-2800-471d-a4cf-fd2de5a7a91e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToAffiliateCurrent_0a8b7232-e4c3-4dd3-a1e5-ac01cbd0acd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToAffiliateCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_70e59b62-a6f4-40cf-a22c-809f994d9c44" xlink:to="loc_us-gaap_DueToAffiliateCurrent_0a8b7232-e4c3-4dd3-a1e5-ac01cbd0acd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_e28221a3-3d2f-479f-9bfb-032f637959be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_70e59b62-a6f4-40cf-a22c-809f994d9c44" xlink:to="loc_us-gaap_DividendsPayableCurrent_e28221a3-3d2f-479f-9bfb-032f637959be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_e6fce027-fc27-4501-857a-2f38724fcbdf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_70e59b62-a6f4-40cf-a22c-809f994d9c44" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_e6fce027-fc27-4501-857a-2f38724fcbdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_98bb068d-ab4c-4c55-b20a-0ba26b6d208b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_70e59b62-a6f4-40cf-a22c-809f994d9c44" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_98bb068d-ab4c-4c55-b20a-0ba26b6d208b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e56b045a-38fd-43a1-a564-2191aa917c85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_70e59b62-a6f4-40cf-a22c-809f994d9c44" xlink:to="loc_us-gaap_LiabilitiesCurrent_e56b045a-38fd-43a1-a564-2191aa917c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_24cb660e-3e17-4713-b0b1-c17ae395da91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_d23e5726-5dfa-4fb9-b203-3e5c94e3bfe1" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_24cb660e-3e17-4713-b0b1-c17ae395da91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_e46151dd-10b7-4392-b1a0-821cc3014853" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_24cb660e-3e17-4713-b0b1-c17ae395da91" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_e46151dd-10b7-4392-b1a0-821cc3014853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_0bff7e27-111d-4ce6-9f03-cc68f36c6c45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_24cb660e-3e17-4713-b0b1-c17ae395da91" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_0bff7e27-111d-4ce6-9f03-cc68f36c6c45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7e92c2ad-90b3-410b-9ba6-0e9c33189ed0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_24cb660e-3e17-4713-b0b1-c17ae395da91" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7e92c2ad-90b3-410b-9ba6-0e9c33189ed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_3276bd1e-73bd-45b1-83cd-ce3799f04e39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_24cb660e-3e17-4713-b0b1-c17ae395da91" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_3276bd1e-73bd-45b1-83cd-ce3799f04e39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_3a8e8dce-acd5-4417-a24d-becb12228ae9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_d23e5726-5dfa-4fb9-b203-3e5c94e3bfe1" xlink:to="loc_us-gaap_Liabilities_3a8e8dce-acd5-4417-a24d-becb12228ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/Leases" xlink:type="simple" xlink:href="ameh-20200630.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_4b2ec3ab-0cdd-4da3-ad98-37f2d7a6c294" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_0a1da953-a79e-4dba-aae2-b2229399ad35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4b2ec3ab-0cdd-4da3-ad98-37f2d7a6c294" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_0a1da953-a79e-4dba-aae2-b2229399ad35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_24d374f7-9dbc-4e2d-af9b-602f8e02aef2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4b2ec3ab-0cdd-4da3-ad98-37f2d7a6c294" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_24d374f7-9dbc-4e2d-af9b-602f8e02aef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesTables" xlink:type="simple" xlink:href="ameh-20200630.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b7e61a03-b6c2-4977-ae54-5ef62e322d73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_1606708b-008b-4cf4-97f5-650198b26e40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b7e61a03-b6c2-4977-ae54-5ef62e322d73" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_1606708b-008b-4cf4-97f5-650198b26e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_0bf83590-9a18-4481-997b-af56f9af05b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b7e61a03-b6c2-4977-ae54-5ef62e322d73" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_0bf83590-9a18-4481-997b-af56f9af05b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_b7c83e1a-66d8-406e-b190-894b4b9879c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b7e61a03-b6c2-4977-ae54-5ef62e322d73" xlink:to="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_b7c83e1a-66d8-406e-b190-894b4b9879c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesAdditionalinformationDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#LeasesAdditionalinformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LeasesAdditionalinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_80f6d153-2a25-4318-afc3-ac586ab0776b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_739c1120-13f1-44bb-a117-4d894f85ba18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_80f6d153-2a25-4318-afc3-ac586ab0776b" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_739c1120-13f1-44bb-a117-4d894f85ba18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8edc7c3e-adeb-41e7-bf02-6e95d1d8e600" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_739c1120-13f1-44bb-a117-4d894f85ba18" xlink:to="loc_srt_RangeAxis_8edc7c3e-adeb-41e7-bf02-6e95d1d8e600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6d1ad470-eb58-49b5-9c24-2e9d4902298e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_8edc7c3e-adeb-41e7-bf02-6e95d1d8e600" xlink:to="loc_srt_RangeMember_6d1ad470-eb58-49b5-9c24-2e9d4902298e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2ddb8b81-bb8d-4139-841e-7198c017a5fa" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6d1ad470-eb58-49b5-9c24-2e9d4902298e" xlink:to="loc_srt_MinimumMember_2ddb8b81-bb8d-4139-841e-7198c017a5fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7c1e4a29-fa67-403a-a73f-48b5dcb4ecba" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6d1ad470-eb58-49b5-9c24-2e9d4902298e" xlink:to="loc_srt_MaximumMember_7c1e4a29-fa67-403a-a73f-48b5dcb4ecba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_716a3d40-e25e-4318-b951-99ac111e607e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_739c1120-13f1-44bb-a117-4d894f85ba18" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_716a3d40-e25e-4318-b951-99ac111e607e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_c5f4afb1-7316-469a-830b-8b38bb72c11a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_716a3d40-e25e-4318-b951-99ac111e607e" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_c5f4afb1-7316-469a-830b-8b38bb72c11a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_9dcd517c-5a8e-4a41-8899-e5309c9c533f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_716a3d40-e25e-4318-b951-99ac111e607e" xlink:to="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_9dcd517c-5a8e-4a41-8899-e5309c9c533f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_acdcf51a-2760-44bc-ac9b-12d652c619bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_716a3d40-e25e-4318-b951-99ac111e607e" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_acdcf51a-2760-44bc-ac9b-12d652c619bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1_33d10598-7aa5-48ba-9539-20a306cda751" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_716a3d40-e25e-4318-b951-99ac111e607e" xlink:to="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1_33d10598-7aa5-48ba-9539-20a306cda751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable_74811453-4922-4cdb-896a-5644dcfef5ad" xlink:href="ameh-20200630.xsd#ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_716a3d40-e25e-4318-b951-99ac111e607e" xlink:to="loc_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable_74811453-4922-4cdb-896a-5644dcfef5ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable_f7fa2cdd-f2b0-4ab8-a443-e8e86bd467d1" xlink:href="ameh-20200630.xsd#ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_716a3d40-e25e-4318-b951-99ac111e607e" xlink:to="loc_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable_f7fa2cdd-f2b0-4ab8-a443-e8e86bd467d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_0392f9a7-8ef6-4194-a319-6a72523bc64b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_716a3d40-e25e-4318-b951-99ac111e607e" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_0392f9a7-8ef6-4194-a319-6a72523bc64b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_a52025a2-6001-43b9-a615-14cc51ce1f13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_716a3d40-e25e-4318-b951-99ac111e607e" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_a52025a2-6001-43b9-a615-14cc51ce1f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#LeasesComponentsofLeaseExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_20c8997a-c489-46dc-98d5-ebec4e2b3af5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_ab81704a-92f1-4505-bb14-a015b29de4e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_20c8997a-c489-46dc-98d5-ebec4e2b3af5" xlink:to="loc_us-gaap_OperatingLeaseCost_ab81704a-92f1-4505-bb14-a015b29de4e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_e0fea5ab-4986-4d83-8f3b-1833ecdcb1e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_20c8997a-c489-46dc-98d5-ebec4e2b3af5" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_e0fea5ab-4986-4d83-8f3b-1833ecdcb1e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_2b53e1e1-c703-4d92-98b5-0df4537f4e43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_20c8997a-c489-46dc-98d5-ebec4e2b3af5" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_2b53e1e1-c703-4d92-98b5-0df4537f4e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_77045193-7f5c-49ce-b0c8-df1c6801c423" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_20c8997a-c489-46dc-98d5-ebec4e2b3af5" xlink:to="loc_us-gaap_SubleaseIncome_77045193-7f5c-49ce-b0c8-df1c6801c423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_c98d0650-3149-4443-8d61-6223abe9bef1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_20c8997a-c489-46dc-98d5-ebec4e2b3af5" xlink:to="loc_us-gaap_LeaseCost_c98d0650-3149-4443-8d61-6223abe9bef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#LeasesOtherInformationRelatedtoLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_8be5f6d0-50f4-47e7-b7aa-a8bc143665af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract_f3a5633a-ea4c-4a3e-b3e1-c41ee102e8ca" xlink:href="ameh-20200630.xsd#ameh_CashPaidForLeaseLiabilitiesAbstractAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8be5f6d0-50f4-47e7-b7aa-a8bc143665af" xlink:to="loc_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract_f3a5633a-ea4c-4a3e-b3e1-c41ee102e8ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_e60e9cae-adfe-46b8-877f-b073ff77edec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract_f3a5633a-ea4c-4a3e-b3e1-c41ee102e8ca" xlink:to="loc_us-gaap_OperatingLeasePayments_e60e9cae-adfe-46b8-877f-b073ff77edec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_e15a9ff9-4e84-4c54-a525-78dc9864b1dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract_f3a5633a-ea4c-4a3e-b3e1-c41ee102e8ca" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_e15a9ff9-4e84-4c54-a525-78dc9864b1dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_1a5c1a8a-c18d-4c91-87ac-689f0b3874a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract_f3a5633a-ea4c-4a3e-b3e1-c41ee102e8ca" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_1a5c1a8a-c18d-4c91-87ac-689f0b3874a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_a52f6180-e095-4d83-a753-4dc1255930e6" xlink:href="ameh-20200630.xsd#ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8be5f6d0-50f4-47e7-b7aa-a8bc143665af" xlink:to="loc_ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_a52f6180-e095-4d83-a753-4dc1255930e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_7206e17a-6f3d-48ef-b55b-7de299bd6691" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_a52f6180-e095-4d83-a753-4dc1255930e6" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_7206e17a-6f3d-48ef-b55b-7de299bd6691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract_90d8f67d-a087-408d-8031-e14b60c2238f" xlink:href="ameh-20200630.xsd#ameh_LeaseWeightedAverageRemainingLeaseTermAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8be5f6d0-50f4-47e7-b7aa-a8bc143665af" xlink:to="loc_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract_90d8f67d-a087-408d-8031-e14b60c2238f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_da9d87f4-5fc1-4bb3-9aff-7329ced52afc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract_90d8f67d-a087-408d-8031-e14b60c2238f" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_da9d87f4-5fc1-4bb3-9aff-7329ced52afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_c46f7b7f-706e-4867-b59a-8a2b4f11fcbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract_90d8f67d-a087-408d-8031-e14b60c2238f" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_c46f7b7f-706e-4867-b59a-8a2b4f11fcbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LeaseWeightedAverageDiscountRateAbstract_23a335b2-3b3f-4e61-890a-e9400b5d4d01" xlink:href="ameh-20200630.xsd#ameh_LeaseWeightedAverageDiscountRateAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8be5f6d0-50f4-47e7-b7aa-a8bc143665af" xlink:to="loc_ameh_LeaseWeightedAverageDiscountRateAbstract_23a335b2-3b3f-4e61-890a-e9400b5d4d01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_9acbc0c8-1d4a-4ce5-bce9-6226c52294c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_LeaseWeightedAverageDiscountRateAbstract_23a335b2-3b3f-4e61-890a-e9400b5d4d01" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_9acbc0c8-1d4a-4ce5-bce9-6226c52294c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_f43ba51c-d3e8-4c5c-8274-989077687127" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_LeaseWeightedAverageDiscountRateAbstract_23a335b2-3b3f-4e61-890a-e9400b5d4d01" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_f43ba51c-d3e8-4c5c-8274-989077687127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails" xlink:type="simple" xlink:href="ameh-20200630.xsd#LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_5393e7f0-c496-4d87-a363-f6e2cd82d00f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_59ca2d64-48f4-4a82-927a-3d6fe5496250" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5393e7f0-c496-4d87-a363-f6e2cd82d00f" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_59ca2d64-48f4-4a82-927a-3d6fe5496250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_1bb8b408-226a-4772-8c7a-10765da2d9aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_59ca2d64-48f4-4a82-927a-3d6fe5496250" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_1bb8b408-226a-4772-8c7a-10765da2d9aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d20396c8-ae35-41a7-8e39-a29b0971a0fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_59ca2d64-48f4-4a82-927a-3d6fe5496250" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d20396c8-ae35-41a7-8e39-a29b0971a0fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_17159095-39ac-4e93-947e-fc68521cd38e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_59ca2d64-48f4-4a82-927a-3d6fe5496250" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_17159095-39ac-4e93-947e-fc68521cd38e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_95a5f681-e03a-435c-bb5e-64d6240468a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_59ca2d64-48f4-4a82-927a-3d6fe5496250" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_95a5f681-e03a-435c-bb5e-64d6240468a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_9b25205a-7e49-409a-b45c-f27626683951" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_59ca2d64-48f4-4a82-927a-3d6fe5496250" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_9b25205a-7e49-409a-b45c-f27626683951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_9e92c111-7da2-4866-86db-e85f128fc50b" xlink:href="ameh-20200630.xsd#ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_59ca2d64-48f4-4a82-927a-3d6fe5496250" xlink:to="loc_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_9e92c111-7da2-4866-86db-e85f128fc50b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_919dd0b0-fb64-4866-9f59-95c54094e07f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_59ca2d64-48f4-4a82-927a-3d6fe5496250" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_919dd0b0-fb64-4866-9f59-95c54094e07f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_87b51290-6c39-41d5-b55f-2ccaa64caef3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_59ca2d64-48f4-4a82-927a-3d6fe5496250" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_87b51290-6c39-41d5-b55f-2ccaa64caef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_87e9388f-9d36-4e5a-b6b8-99e2a40d0856" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_59ca2d64-48f4-4a82-927a-3d6fe5496250" xlink:to="loc_us-gaap_OperatingLeaseLiability_87e9388f-9d36-4e5a-b6b8-99e2a40d0856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_d101f5a0-afae-4139-a336-6ba933987a00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_59ca2d64-48f4-4a82-927a-3d6fe5496250" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_d101f5a0-afae-4139-a336-6ba933987a00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3df59dc0-a26b-4326-a9e6-4c1688fbfa38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_59ca2d64-48f4-4a82-927a-3d6fe5496250" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3df59dc0-a26b-4326-a9e6-4c1688fbfa38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_162c2c72-bc6c-4d7b-85cb-62167ece18aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5393e7f0-c496-4d87-a363-f6e2cd82d00f" xlink:to="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_162c2c72-bc6c-4d7b-85cb-62167ece18aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_fc06822d-6b47-455a-a5dd-814fda7a1bab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_162c2c72-bc6c-4d7b-85cb-62167ece18aa" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_fc06822d-6b47-455a-a5dd-814fda7a1bab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_35dd266e-8ada-4efd-8c2e-0c6d4e774941" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_162c2c72-bc6c-4d7b-85cb-62167ece18aa" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_35dd266e-8ada-4efd-8c2e-0c6d4e774941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_7a8f4025-946a-4fea-ac0b-17b08b84fc7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_162c2c72-bc6c-4d7b-85cb-62167ece18aa" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_7a8f4025-946a-4fea-ac0b-17b08b84fc7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_ed17f60b-4f41-4189-b620-9e2f23811fe0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_162c2c72-bc6c-4d7b-85cb-62167ece18aa" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_ed17f60b-4f41-4189-b620-9e2f23811fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_c693eab5-4eae-455f-bc91-b4a22df0a2c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_162c2c72-bc6c-4d7b-85cb-62167ece18aa" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_c693eab5-4eae-455f-bc91-b4a22df0a2c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour_138bd3be-2870-435f-811b-78622e58fe54" xlink:href="ameh-20200630.xsd#ameh_FinanceLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_162c2c72-bc6c-4d7b-85cb-62167ece18aa" xlink:to="loc_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour_138bd3be-2870-435f-811b-78622e58fe54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_1d738142-7b3c-4136-8b0c-a5987a08f992" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_162c2c72-bc6c-4d7b-85cb-62167ece18aa" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_1d738142-7b3c-4136-8b0c-a5987a08f992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_b47e4718-233b-4b39-af4c-b566aced5a29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_162c2c72-bc6c-4d7b-85cb-62167ece18aa" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_b47e4718-233b-4b39-af4c-b566aced5a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_a8b60587-0550-4092-b815-ae2eedd960d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_162c2c72-bc6c-4d7b-85cb-62167ece18aa" xlink:to="loc_us-gaap_FinanceLeaseLiability_a8b60587-0550-4092-b815-ae2eedd960d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_ee99080c-2896-4170-94b2-ed3aa00c3cc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_162c2c72-bc6c-4d7b-85cb-62167ece18aa" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_ee99080c-2896-4170-94b2-ed3aa00c3cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_598d8e5e-7b07-497b-8c16-14ed11737d36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_162c2c72-bc6c-4d7b-85cb-62167ece18aa" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_598d8e5e-7b07-497b-8c16-14ed11737d36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1" xlink:type="simple" xlink:href="ameh-20200630.xsd#LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>ameh-20200630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:ameh="http://www.apollomed.net/20200630"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ameh-20200630.xsd" xlink:type="simple"/>
    <context id="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if9ce4b07b09648a8b493eae45f76841f_I20200803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <instant>2020-08-03</instant>
        </period>
    </context>
    <context id="i2bce3c5038344323935db8cc2710a157_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i17d58afdf6094c3f9289f4089d3a6678_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia6e2f1d8c41a4e708493e14e80f2e50d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie3ded1fe24c44729a7d30f51269fad23_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i83686cfeea3643b2ab0ba5131ab70154_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ie034b8ac717f4e0f821b2e6846cc21da_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:HealthCareCapitationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i3c020c0256064c2e9f9890db9de73a18_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:HealthCareCapitationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ifb543017186b41428d7d61876f751a53_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:HealthCareCapitationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ibca1f4a0742946218cb28c01d1e69d3a_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:HealthCareCapitationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ie935f35786ac43c595cc0e1bdd2bfa7a_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4e76ce3a79df48a5b2aef434c3026411_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ic9a5e5a435384ed9b47445e91f2e5dbe_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ibfc4299f8823436fac5fd23586298d02_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i86ffd806ab8441679dbed516276b4734_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id2c681dbab0b446cafe1a39de28bedb6_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ic862c6560a614f5abea31e3ad439d0fe_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7276b0b6cad94ed6955187e2affe1b27_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ia03e0ac0e02248b881a5720c0b7bcc62_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i352052d598714a3aa1bc0f6be299be80_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i0a83b91f96d642cb888e655253482c99_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i18eff8c461884069b655593a6463d4b2_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i17c717d9ab9c4c13925e6d4f409d3e67_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic79fc17a0341400e9e62338ca77a93da_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ie229ade0fac144a8a4262469a1176554_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i455aac9cb9b24b88861613f2d5737086_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i5a40c5284da24efa84bc4df89f4f2705_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie4e637eec6484f0786a6ed5c1f6430cb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icdd5d78f45b9441eba8b9eacaa9bf76e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i11c1b7b9b865434fa9576e7784c2dc13_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia43dbbf6ada5449bacec1ab39ed62847_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1f94bdfba2434414a07e834a64442b28_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ie1f8b99761ef4aa3ad4c66bc1cdef075_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i67cb29fa35d447558cebf0c44017ecd8_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib557e6848b8949778b46babd52ad1570_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i691e279196924ed386447cfa2fdb3c0a_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia8c91ec953b9448fb223cb4a034a52d3_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic62aa01d15f74e74b86bfdec19d0c108_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ie5f49e82ee9c46f680d56792f282a687_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i083b9bc8a05048a5840ae066d8501457_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i4b2a896675d04c7d9830d427157f52b0_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i8d951dc1190e45e2ac445202aec7daa9_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="iee021f30ec494988b04ffd293da80842_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="iab3938dc2790442bbae7aab01097fc8b_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id415104b7a1f4a52af19c2f74be0a88d_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ieff7bbd8785d4105a279ebbb1b6569a6_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic6205a2691794f12816d94e2384216d4_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i8f79c810c09544658e32ad8904dcddfb_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i601b184c6fdf4eada4f627de564a12d2_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i56db13635c644c7eb66668022d8f8878_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i5ccf0e9ee2e64a3182ccb11330048327_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="icb7195fbea754ef3b0e02c161fbcbf6c_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i1e6a563a26fa49f79fe7e401bb5fec30_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i88dd112506904c6cb0c741b6ed17ccaf_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i8af5fb33859043a8b3f81453abfe1293_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i86cd437dd5a04045874dddd70078b5dd_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i10e399c42ec54ff9a466cf51bb20fe33_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ic0d5534ac5c5479487b6ae9068ef457e_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i009fc823ec144ee3b772b4396d458c88_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iadd4f63ba5ae42d4ac92cc9136de9da2_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i22c58b4fa0a543509216aa49494d6aba_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="if3adcf989a11491086e545b6aee38fc5_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i5a6c0314826740a281244477bbba6dfa_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i5ee6d5d8a1594010bfbaaec890b48045_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i5148fbc9970c485988d70ba64178db69_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i4974f1b145d14972a8e0b668e4693f24_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i78399cf970d54e8fa6805bb19581eedc_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i24b621b2e16049f5821822f6c6b515c8_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i726581c835934409b022b695e21f02c5_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i949449b3a63b462bb5ac492454d52236_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="idcb813ea894446d389589a68e78f85f8_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i95b98be4bbee40bb905948aa3d1b28ea_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i71a1516b4672496586bb6ad8954b6d32_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i6c10cea2d1d546b486e52aae1b79c77a_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="id43602e4d3ec401c85cc9e362fcdbb4b_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i87ba6bb181b44445a257ca2168e67b6f_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i3af73b22faf94113b2f3aeaf70427a31_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i4bcbf8bc939c4eb8b67d8f9031b07763_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i27980f94484946c1a35649f7381b97d6_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ic610016f8d084d548913bcfa0f781a33_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="iaf1828c07785428dbc2e0059af0c356e_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i2db2c0d074c34657a5d523b0ae1e5784_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i4d3c15f58ae34e5680acaea7c6ae5cd1_D19990701-19990701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>1999-07-01</startDate>
            <endDate>1999-07-01</endDate>
        </period>
    </context>
    <context id="ie580169aa3e849ceb22d709b7d624f59_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:APAMHMedicalCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i1456ec083d5c410eb2ebf5f48f52fd2d_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:APAMHMedicalCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia151a285a5884ae0892fe7f6a0836f46_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:APAMHMedicalCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i15770f5ee2dc453aafa11b7b82d77e5d_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i5a7880e80374477ab2037c274813c2fd_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:ApolloMedicalHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i8449be3fd6d243ea8e51a64ca55d07be_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:ApolloMedicalHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i02112e8965954796a8e1a049bed45005_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:ConcourseDiagnosticSurgeryCenterLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i09e180bcec104dbe8bbc280162a1b502_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:MaverickMedicalGroupIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i1291ccf07b4747d5a674402448bcc8b7_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlphaCareMedicalGroupInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="if0f1246eac284240868626e2943e4052_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ib00db7be80b34cfaa597d79cb3128aff_I20190830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-30</instant>
        </period>
    </context>
    <context id="i26cbf8fca0d84265be9879b3b17db702_D20190830-20190830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:Dr.JayMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:APCAndAPCLSMAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-30</startDate>
            <endDate>2019-08-30</endDate>
        </period>
    </context>
    <context id="if5945e9c877b4ccea72cbc601bc3a9b6_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AmgIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia9f8aa30820f40aaa284eb4906fe92a2_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AmgIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i11b99b377a6a43aa865ba7d01fecd1e5_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AmgIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if3e410ddfdb74a3daeb61a44c92264d8_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AmgIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i5d896ebc98ae47969367089670863233_I20140630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-06-30</instant>
        </period>
    </context>
    <context id="ic4fe11ff13bc463aa7c7d46c9968606e_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i4a23351d6549453987064b1ed4ccd7a5_D20200430-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-30</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="icbe089761e214533973bb396d097bec6_D20200430-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:BrightHealthCompanyOfCaliforniaInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-30</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i9c07037f02c24f758bbadde10f2a6d6b_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib671a237f06845ccacc1a406f5790edd_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i6dab3a2b4fba451e82b3256455eeec2b_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ibcd3d205d526423cbea49810dc2340a8_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0dd8dccc65a74133a54656bd7c8b4677_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:CommercialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2a042bfad69542c1b01c261138a48a66_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:CommercialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i29b931e0f69a45658584dcdb33cccae8_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie5e9ac126c4447a892ae9c1c466ce045_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="iaf70769b3ae24d8bbf5cea51b1569ce3_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i8a6065f0bcd44f40b22cc3dee9debebc_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i9d46920109e94a34afa570bab6edc321_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:OtherThirdPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ifd7a28bbb9224f319f70f1a38371eb43_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:OtherThirdPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i512f416ef63d4ba3abe4a36d380da0b0_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:CommercialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iddb4dfed860740f3a71ee2c530ce3733_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:CommercialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i4ecfacaa79e54b258148a979b14f66f4_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i947f9298713445cea034b7b41f37b6b7_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i7ff9e8dbf4b24be7b22e1054c2cdb0fa_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i04580df691394c6fb1c265641dc8e4fa_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ib2fca4eb23c541db83ecd5805b54ba56_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:OtherThirdPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9b8d4a587e3e4ac684b3f6a5d7d7ffed_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:OtherThirdPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i66d29491233d435a9781fc3960674175_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i8fea9adc9dbd4dfcb6c28fcec10b58ca_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="iba2f1722e182406485b06e7780640a59_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i92d5ad54dc7b46a692cb712060a47f6f_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i100279b65cca403299b145ef5c501434_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i46aa5cd04c64411ca7afff2e510cebe6_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i36fac0be4bce47a8a6f1debf5fb86518_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i8c897dd4206d414da215cddbc7679657_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="icf6775dc61fe4ce084d261017e9ef958_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorFMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ibbe89b583f4b4cac886b6bd1886fc66b_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="icc08a7c3b8514351988c046d7326f98b_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="iea3de6234363414c85c4cadd8273d9a4_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i5fc422ddf26946f9b6595157d37a7e4d_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ia98e92f83fb948a4a5b27c9b21933f87_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i7ad5e28b46a94718807f8ff7283fa384_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id916e080e86746bb89c3cd06f5f75ae6_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i71e3a0e877e1403587f03dd1d16e1041_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorFMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i11b3d315843d44af8440a243a1ec9346_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i84779c02d5604bc6bfe042cc4a70617c_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id6e01a159a3e4416b534f097f6b023a9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1dc8d99226664ef48c410daff8c273d8_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ieb7ca1d55e834afd9682b7e0f9cd250b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iaacb62a7ead1402e943c4985b979a303_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i65e1f17227cc4de2a22981878af26dee_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i34d83ddf3e164119a0619b2f774d028a_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="iee4970fdbd0c4e57965c08b65849a300_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3be99826872a4e079e77a494a475c430_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia5c34ba4f1f24e1e87163828fbf170f9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i86d36b0423244dd6a1ef5fb8fed9dc60_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:PerMemberPerMonthManagedCareContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iaf29becc238d412a85e642e1be07a346_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:NextGenerationACOModelParticipationAgreementMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2017-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5cc5a987a5c04cad931ce456ee204243_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:NextGenerationACOModelParticipationAgreementMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2019-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="id5fbfd0a0b9b4ab3876be59e23e3f101_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:CMSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie8986202564b4172b0aab2302c7971a4_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ameh:OtherReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ie1e6d8b85f4246bf94ae0b52733c146d_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">ameh:OtherReceivablesFinalSettlement2018PerformanceYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i9f4243e46d3647e093788a742f11debf_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ameh:AccountsPayableAndAccruedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iab3766c2a60b42849e233d9acb377205_I20190531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AlphaCareMedicalGroupInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:APCAndAPCLSMAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-31</instant>
        </period>
    </context>
    <context id="i8e2f250049ae44589256e0929aad4803_D20190531-20190531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AlphaCareMedicalGroupInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:APCAndAPCLSMAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-31</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="i9004566cce7c4ef7b4abb21095da7358_I20190830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:Dr.JayMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:APCAndAPCLSMAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-30</instant>
        </period>
    </context>
    <context id="i9efe901318bb4ed08cc6432008f3343c_I20190830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-30</instant>
        </period>
    </context>
    <context id="i460f9923ee7347d6aa697c85d63b74e1_I20190830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-30</instant>
        </period>
    </context>
    <context id="i9519fc3d763e44bba24ad68ede94a1c0_D20190830-20190830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-30</startDate>
            <endDate>2019-08-30</endDate>
        </period>
    </context>
    <context id="i40df6f98654940f690d8f5bfc4d573bc_D20190830-20190830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-30</startDate>
            <endDate>2019-08-30</endDate>
        </period>
    </context>
    <context id="ic772c23a08d84f8da481202e5fe65be4_I20190830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:Dr.JayMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-30</instant>
        </period>
    </context>
    <context id="i38b436d30e5240e3965b3cb5408fc04b_D20190830-20190830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:Dr.JayMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-30</startDate>
            <endDate>2019-08-30</endDate>
        </period>
    </context>
    <context id="i226c14d75f674f3aace656903b7c99e1_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AmgIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i73be6919be5e46b1a06e1ea222b2fdbe_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia02225d6109046c78a438c6a8b4976e7_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9a061ecd0e88428da9167e4c5ef52ac3_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i57bb690a343d4f7d8bad8f8f0b00a299_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i5588309d1fff48048fb83af0ddcb456b_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i7cb7d40948da4beb88d80ee62fb3d330_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic456fd261edf4e6b9386c6e78baefd90_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i0e1880f00d4d4d1e9e8b42e76237839e_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i200a2160c6bc4775ad07f433b5e95e1a_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ic7bfc72f47df49e08bf78786c1c3f3a8_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i5f688ddde99b4f1e907fddc9a3a91b08_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="id11fed723b204eccb39c30a6f9bcb4ec_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0041ee30d491407b91c0d34ee0fd8035_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i80ad21fe7a3a4d959fdd8ebdbe3e6e65_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibf9258f9195d44eebf1af16facb1fb4a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ife724f4c09364f2587ef6b1db0ffb506_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id69c143aef794cd8af6e5723d91edb2c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if0aef9156d514b559b4f1bc502166379_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3fcb4ca5c3c4484fa5efae17077926cd_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i04ee375bba5d426fae0a9eb750e81925_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3ccf5d499e3e4698884b846f6d3df73d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia58b0f57301940558ebd969a25e55261_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic3925100079946168d1204aa44f455d9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4fdfa470671c47fdbbc39c5426a4e251_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie050574270bf4bdba21a2294fe288e97_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i723d471168484995a1f33bc20e25ae83_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie984a2ae967749fbb28bc018191f1448_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i509c376a3e0f41cdbfb08128ed5aff20_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i1d9b625d40984cada77fed26b2662304_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0a335fe94da74cc1b74cfe701830c693_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iadefc20aa4134071bd9a5346e792b746_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i5fd06ba095124e0abdcc0d7f91fc1472_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9c66cc2214574c8e905c03e9a5ac08d7_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i314c4ccc348b436ba49cb07ab3848d81_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i3451c081a11c49aea7b55e24c90e4721_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i357af7bf55294d7b86954b0bf136c8c6_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic39201e9036d43759acb734c62b0b8d4_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i4cd0390dd82a461ebe94ea5eebf97a2a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:MWNCommunityHospitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ied6eb8f6738c4de2bcbeba58131b807b_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:MWNCommunityHospitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ibdc4f73cb093421a92e71951326cfe64_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:MWNCommunityHospitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i82b0e8a55cc14efc8f01a2a693617301_I20121231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-12-31</instant>
        </period>
    </context>
    <context id="i50b118c2801142889220d4c0dfe9842d_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i50bd805f807f463da5c172dec611a78f_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i16e5d9ad68cf4cacbf2ae6fc6a2646a1_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if450a74f42464ca8ac08b054152aac34_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ie1f5324dabcd473b8949ece8d5f9bcbc_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i953f113f807a4b629361138a8c340c45_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i475942101d5b4fb6bf5d97d6d803565f_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i8e6db84cfdcf4e68a45f60ccbfcef795_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ia7524fa990e04653b73c016dce167669_I20150731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-07-31</instant>
        </period>
    </context>
    <context id="id6aa1fa085114394a6e85030a974182f_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ameh:ContractTypeAxis">ameh:AncillaryServiceContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i6c258e6f71044221a1fb158a0d855efb_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ameh:ContractTypeAxis">ameh:AncillaryServiceContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i6610cb295b3947a5b0b3747521ffcc00_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ameh:ContractTypeAxis">ameh:AncillaryServiceContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i5aa2f3de1fe244a09059fe1a984dab17_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ameh:ContractTypeAxis">ameh:AncillaryServiceContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i9b5e25abcace4fa0adbbc4c02841298d_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i36438be782f84c0ab30c9128983e63ae_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i8bec381b83b140e5a9bfeac12bc0b911_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib53dd899d00f4b69a3502812c5cc65dc_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i157f8e47c0564056805baaf2a463ba46_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia85acbdd13224660a5969a4561ebdc1c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5150473a0c7e46868c76e2b4a7a9fc96_I20150831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ameh:VotingCommonStockTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-08-31</instant>
        </period>
    </context>
    <context id="i6176328037a345afb5006679c54758ba_D20150801-20150831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ameh:VotingCommonStockTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-08-01</startDate>
            <endDate>2015-08-31</endDate>
        </period>
    </context>
    <context id="i9e93302086af4602804bb434c398a652_I20150831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ameh:VotingCommonStockTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ameh:ContractTypeAxis">ameh:AncillaryServiceContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-08-31</instant>
        </period>
    </context>
    <context id="i170e72202cdd4b73a7b7a48e85b5dd54_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:BrightHealthCompanyOfCaliforniaInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i19617cb0db6c48aea309f2c2b2bbd2ca_D20200430-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:BrightHealthCompanyOfCaliforniaInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-30</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i2e1d4837a47949caa2ce6ff7a21167cc_D20200430-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-30</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i4d3be425c4e74837aa2e7e572caa5cdc_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:BrightHealthCompanyOfCaliforniaInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i7ca6abb962c644ebad2d7e2afff211f2_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="if482ba97bdb84bda9cf6288b01d207b9_D20200430-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-30</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="idcfb848097a34b5a83ecc1ab0b752557_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:BrightHealthCompanyOfCaliforniaInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i9beb3a18cbe642a8aa4c713b758e5b41_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="ia1f85d23728f488aa706b6728075d6a6_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i371098e379a64f1ab0452b0340ffdcd8_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="icceb687a46d94c0d8314ae9896a926f0_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ibd24a1722d5b442bba297bcc460eb0c0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0e9c10a96719436f9bc86a015712be60_D20200101-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="ie24c440e5f474a2884cc40d10efab865_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ifaefb6ce9ff24e308243a14d1cc7814f_I20160514">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-05-14</instant>
        </period>
    </context>
    <context id="i74f5fd5d4b8a44e882631f206e038bd7_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i61394655c4ad4039984a2f0503f8cb4d_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i0cc11225aa314266a6ef2696d7d4dfad_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id158f4ef37084b119e97ae1e8a41d0c9_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ic80c408963dd4f07a4718bf817b59f78_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:CollegeStreetInvestmentLpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="ib33ce2cceba04d82b64d3b892ada4ad8_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="id2d9c71932034be7bd4932da0626f712_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="id61177debadf4225a858af823bca90d6_D20180601-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="idda53a861d504beea7993e7de2f52ee0_I20190423">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-23</instant>
        </period>
    </context>
    <context id="i74302930c31d45b8a80be7e006522de5_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i051b582accf543bc87134371ea6f7726_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib8b7f2e4ee2a4d2c9a3e1fe33363b2d3_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ia3ac42f4999448a69359a25a83b0f908_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if55f174a731f484e9a8b88ed6a99666e_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="idbb6a15f7620432bb5505e89f3004b9c_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i703c2ff9263240b296697549156a727f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0af7733faffb48348018de02ffdfff6a_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iea1fae3b79a34d86b70cbdfb21ad3dbb_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ifd12b893ddc54a6ead35cdb2bc89c8bc_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:HealthSourceMSOInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i00815df6bd294d36b80661bd7ee807a7_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:Pacific6EnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i4c9caf98dc0642adba42edbbc942a39e_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:MWNCommunityHospitalLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id084b778b0c0437ca9710b2d345a5e1c_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:MWNCommunityHospitalLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:Pacific6EnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i802f55fac88e49498a6b008731c49198_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:MWNCommunityHospitalLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:HealthSourceMSOInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ieb3fd4253957445eb4629822911925ed_I20190831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:MWNCommunityHospitalLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-31</instant>
        </period>
    </context>
    <context id="i1757e23b7dae4837b5c342d3a54fdb9f_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:MWNCommunityHospitalLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9729bda7911148aea82f02fafc542f1e_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:MWNCommunityHospitalLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i21ee88acf5e24e5aa9702c3e569cdb0d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:MWNCommunityHospitalLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifc2b7046e5434c1188649346120d70f7_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:MWNCommunityHospitalLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i3635f2277d854166953f31769a15549d_I20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:MediPortalLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="ia0bdfa92f0584697bf3e23e968030cd7_D20180501-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:MediPortalLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="id2fefe9326624bf8a6e101283a7f761f_I20190701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:AchievaMedInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-01</instant>
        </period>
    </context>
    <context id="ie1f0176357034096b162de4acd821801_D20190701-20190701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:AchievaMedInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-01</endDate>
        </period>
    </context>
    <context id="i4b00da16353446959bec407e221c7666_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:AchievaMedInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i68d3a067d0bf4b79866706938706fb56_I20190628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Dr.ArteagaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="ie7a2683890994e1893345aed93623d96_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Dr.ArteagaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia0ac55575d2248d28bbb2cd6f69b2d1b_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Dr.ArteagaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ie109929786d34e3893f52ead1a5eb485_I20190628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Dr.ArteagaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:APCAndAPCLSMAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="i901365bdd3be4af6a404cf5c6e1a6075_I20190628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:Dr.ArteagaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="i1cce33515e484386a173dc2819744d21_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Dr.ArteagaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i2719e7d006164071b43867d77f417602_I20200228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Dr.ArteagaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-28</instant>
        </period>
    </context>
    <context id="ib85a0e470e8b45179bd029ecf6828423_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Dr.ArteagaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i718197c336244bfaae074a41bf6ba00c_I20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-12-31</instant>
        </period>
    </context>
    <context id="i620d8d9b4ce144e39fd90208e9f296c6_I20180629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-29</instant>
        </period>
    </context>
    <context id="ica83580f8f45424a8053d06ddb0d6b69_I20181128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-28</instant>
        </period>
    </context>
    <context id="i99b8494c9ac5475fb455098946c75db9_I20191213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-13</instant>
        </period>
    </context>
    <context id="i67a0fe9f9fdd46d7b8bf35810922c6aa_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ifaa289066f18409dae39bd6fe0b1bf0a_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i2219841d151045028ba5da60cd719d17_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:DrJayLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i59aea64b29bd441fbc9a872ccf8d6901_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="iff4cb76a3da64b79b6a83acbf4ac62d5_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ameh:TermLoanAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ie8692d3a0d3f43509f73c146da09a16f_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i91da1a2343864108babfdb0d2e98962a_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i8f0dc8ddd67e4b4c8a1d5a71831e1067_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i8ac3810d42dd495ca842271bd91690b0_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i89df1d2e4cc246138d52d9f6d8cd6e7f_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ameh:TermLoanAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="if7490feb65964fa796425290739b321d_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">ameh:PaymentPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i65f643704c1c43d88db131c9dcf5f1c4_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">ameh:PaymentPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7d42642f16854ea2855614113b660e84_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">ameh:PaymentPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i15f80bd5e8b04174974b1f69d1519f06_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ic96d1c4217de472a84ac6f11bbb720c3_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i663b5171da0843d99423875dfcef6e74_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id0e05edf24764d42964dacb1936f8e5f_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1fdcc51ad0fd4793ad2145ddf9d3333f_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9c4c1dc5b0424494b3aa09efc8137c81_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i3b7ff140c5b34302b6867e8581216396_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic1d8ce42602448a88e6e94a295508d62_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i45e40a83e59c4f21b6a684d812a61ca2_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1a435515824f4e14934a70bbffa79e42_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i44c831b5e48a42e88b05d16f1fdb9240_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i6cbb20b8a5374294838553f9c534c7e6_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i7a1baad6dc7444dc9016d658275316ce_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:NMMLineOfCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9a8fc30c8bb8493fa605fcaa4207f068_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:NMMLineOfCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia8ce6e89d9dc47b7a39dd3dd0614631b_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i8c34126de2c140689211bd3a59b45b51_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4bfbe9abbba34f0183c6540bd57fce10_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ib2719f73504548bbae721f92df01a971_I20180614">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:NmmBusinessLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-14</instant>
        </period>
    </context>
    <context id="ibff1604bc099467eb93746f757585546_I20180901">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:NmmBusinessLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-01</instant>
        </period>
    </context>
    <context id="i16eef96539a54340912379d5350ec95c_D20181231-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:NmmBusinessLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ie40c6e5bceac47058b37a4f4c0981530_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:NmmBusinessLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i13403ca944e64582bbcaa0105295fb08_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:NmmBusinessLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i5266cd1d689d4ec2b6a1329887bfa026_I20180905">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:NMMLineOfCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-05</instant>
        </period>
    </context>
    <context id="ia2cd4816f5eb443c93bc954045c6a0d2_I20190417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:NMMLineOfCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-17</instant>
        </period>
    </context>
    <context id="i83420fb7674741a7adf09dd0edce6cb9_I20190729">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:NMMLineOfCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-29</instant>
        </period>
    </context>
    <context id="ifd9d64e834b04bf7b54467b2c29f3db8_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:NMMLineOfCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie9253d136d6c409ea392551405cd59a3_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:NMMLineOfCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i4ceb41120b5c427da8f7a165eb95d2a4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:NMMLineOfCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i889eb6bfb2e4488e843c332fa29a6f88_D20180905-20180905">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:NMMLineOfCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-05</startDate>
            <endDate>2018-09-05</endDate>
        </period>
    </context>
    <context id="i6929d7ef6c724b578ebd614e9aac9b40_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i489c8baa67d6408a868e6bdf3c0b60ea_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i7d75edd516124fbb828f66a694cd578d_I20180614">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ApcBusinessLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-14</instant>
        </period>
    </context>
    <context id="i5c7162ddeee34091b6e14c1103b27d19_I20190611">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ApcBusinessLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-11</instant>
        </period>
    </context>
    <context id="i4b837318f7d8458cb42d750eb8bbe6ef_I20190801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ApcBusinessLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-01</instant>
        </period>
    </context>
    <context id="if65f3f073a4e4926bd996e2b6f3709ca_I20190910">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ApcBusinessLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-10</instant>
        </period>
    </context>
    <context id="i39925af9c158412d82ae7eac78d51ab3_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ApcBusinessLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iadd3b4557abb442c93c1de563072e1bb_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ApcBusinessLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i349ef1b628184659aacbb0718a7d4338_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ApcBusinessLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i256fed6446054355bc000991eae06751_I20181002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApaacoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-02</instant>
        </period>
    </context>
    <context id="i180bcd7578544f3fa0a9e820344d67de_D20181002-20181002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApaacoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-02</startDate>
            <endDate>2018-10-02</endDate>
        </period>
    </context>
    <context id="i65b7438288394c098e39150948dddc7d_I20190814">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApaacoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-14</instant>
        </period>
    </context>
    <context id="i28f48691115042d086bf50c14043181c_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i1cdc831367ff4a8584c4a6fb205fddcd_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i3fc12c8dd5b743488bb6c1675f17858f_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlphaCareMedicalGroupInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i5fcdc1d2217741c292117f4a0d9fff3e_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlphaCareMedicalGroupInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i165dffaa08f24a1888f81cae72742649_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic7bf1ad2136147739b9d3573b799cfb2_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ameh:ApcStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9147cda570b34114b9da7922c7249550_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ameh:ApcStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="if0190ef7dee34fbda65c048ee6b393c7_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i4688143439664825ac968a174665ba3d_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i394a53913abc46b7840e4b3b601af231_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ia7f3c7099ea7466e8c0372573a9eb42b_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i9ec7494ea7af48fda7c1d23e2672ba9d_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9c63f7d7fa16447cb33f1cc3ad14ba3f_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i5c5087d6c84a4583badaea62a58fdd8a_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="id3ba07d0aaff4c4cbfb30aa71876350e_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id5b38446c9f64ce5babcd929b0922482_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="id57bfd29aaf44d4d95e8e561bbe67cf2_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i414264e0cb1e499287a23f8ddf6b9498_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id265c5c2e7f34a2bbb064c838d92d806_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i0652754b1e534a8089d0c0347af659b7_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia1f01a331d6248978588759d09efd270_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i717848bf538848ab855a3a3e35ae4238_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia4f9f7ea8c4f4b079f5fc8ba6a915106_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie1b7b6fb52d049f38e00e0bc30605358_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i8b530cfd9afc42f2a4a14a51d941740c_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i228644db04a54aeea81ac55c214613cf_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i070e64c85f6a46f3abd4745871816551_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i7a07edf9a6d9427cbb8e495a1c38dba1_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i58c8b96e915044a5a2285690f262e2f1_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i5348fddd2d3647eab57aabde18624e3e_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i59b3484b35404c20b3bede5ccbf47667_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i4081b94ec67249e5a1d21eae73e8d25e_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="if21a86c3eed7480aad7e5a1485553c3f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2b03d1915fa54978a6378c9edaa22474_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:AlliedPacificofCaliforniaBrokerageAccountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i255d39881fdb459ba312544c3eb6589e_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i82a52038c4164e77a3f6e20b01157134_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="idf76f2b7860f4f6a97ee09255e45287d_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:CDSCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i5fa3d2acebea43c3a0c0f3e590d02ad4_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:CDSCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i2abd2d27dacd4cf191ac018ca9039a4a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib5bc5df3e2c84bd598e901cd27c8df93_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i43ace250a7394cfe9446cf2a610e1531_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialSupportToNonconsolidatedLegalEntityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="iaebe0c39b9204bfbbf9445aa9abc70d5_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialSupportToNonconsolidatedLegalEntityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id6e276121e9b45228da8ba0bab8f06ba_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlphaCareMedicalGroupInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ic5904f2bef064b47980c2947e43ad5d1_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlphaCareMedicalGroupInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia04e3870deaf4cb7ae407dafc0ffd53d_D20180323-20180403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <startDate>2018-03-23</startDate>
            <endDate>2018-04-03</endDate>
        </period>
    </context>
    <context id="i41ded2bb0c6348508704a83b2f25e6bc_I20151116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-11-16</instant>
        </period>
    </context>
    <context id="i47e9a1771bc24da387426527e858cf9b_I20151116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-11-16</instant>
        </period>
    </context>
    <context id="iac4018695bd347a1a544a3f52b293cce_I20181128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-28</instant>
        </period>
    </context>
    <context id="i122ebc0907a746cd87fa56f04f446654_I20180628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-28</instant>
        </period>
    </context>
    <context id="ia70ec1e9fb224dbcab815eb4726d1011_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:LmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i55654d78599d405eb7c57be43551a331_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:LmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic5c167aa7b744e4890c04342962e5ae7_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:LmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i72f269c8a584404ba65db62cbf5e0711_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i2586f7c4e99c40dabdf57469f68203ca_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i08b5e965334b4ac8b0d2c0c36dd50b77_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:PmiocMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i6d443f60c53b4d9dbf390091cef3b913_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:PmiocMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id80519ef0ba24fdcafbe65246db80663_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:PmiocMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i6e8fcf6df1fc4d238058ca06726c6b36_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:PmiocMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i6ac733b67d504bb484f4fb9e53a73cde_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PmiocMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i8163cedd4bfb49cba3c59247fab38128_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PmiocMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i3b7917e163c9464c858059b5c869b1da_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:DmgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7267113c36ba4c0ca445f3971b88da9e_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:DmgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ide7ed8079ad649bd9de797dff9e87471_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:DmgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i4bafd7f9c77a44129ecb7839f0bf7f38_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:DmgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i0138e45151034c838711c008d2c84fde_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DmgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ibd86a14da8ce4c19b459bfe1b8ee8770_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DmgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i3921017da3f648c8bc7eb46abb24b98e_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AdvanceDiagnosticSurgeryCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0ce5207c08154b16a3abfc694d36072c_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AdvanceDiagnosticSurgeryCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i74b45c805f954374b47abc23fa83e224_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i26a7e7336a074ec58f3aadf344b86686_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i23919fb2bb874604b0836a44a501d87e_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ShareholdersAndOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i6966114f283543be9a6c6ecfb91dcb1a_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ShareholdersAndOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i558c42e47d0740c28d1824777489c673_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0238892dfcac44a1ab11666f4229eff6_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i73ff4025db084040a797fa1c7d3e1949_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ShareholdersAndOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib304e370b0554caf951b8a9f9f09d259_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ShareholdersAndOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i11e982a75af145058c37f804c38acd6b_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:MedicalPropertyPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i974cbc9f20e14ae6bf9611c0590bba01_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:MedicalPropertyPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i232d93f7f5aa4f659c5d32bb1ce43cb7_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:MedicalPropertyPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i4d7d20d05cc44774b777b10316295823_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:MedicalPropertyPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i0a9d069f26ee4fcab93f166f59b290ee_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i6349dc89b0824f79a96623fb0a3f9237_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i725b298255bc442d989d2da38e506475_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:DrSimAndDrLamMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ifa7e8193abcb43cabefbe6e0890b995d_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia52b05b7d3c744de85af06e314bf01e0_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:CriticalQualityManagementCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie772acedf7f24e9c9b7eba3a1c2c4b74_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:CriticalQualityManagementCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ia8b1a37d00a1473aa256f482831880c0_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:NumenLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:SCHCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i40cef4f9cb574f67ae5763a10bf872ae_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:NumenLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:SCHCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="icd17dbf950ae420ba6642ac1f2e76be4_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:NumenLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:SCHCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i3889cb5090e84ede9aeaa5cb4970cb04_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:NumenLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:SCHCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i7badae2658444d349982f8266469914b_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:NumenLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i9b1e96ab04c2463f8f4b975abf5cd0e1_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i8624e665c0b14f12bb96c8f05d6efefc_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i345a15f206fb4db5b7f79fbbfcd4823d_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i297705914c5f4af994b21ae2e9e0dda8_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ia5bc423a58e44f17b75caa9dcd78c5d9_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:HSMSOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib978cd0ae3f8463592332de24798e91f_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:HSMSOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i3e3dd126351d40269ef3b0cff2e2cc12_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:HSMSOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i187e0af77f734ccebbbd27aabf183e43_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:HSMSOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i2c2ea55436e04e569ef824cc8bf38f62_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AurionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i3c92e2a8835d47c094fdb6ae01f4010e_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AurionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ied3ee0af55294b1c90c71dc22ea57f02_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AurionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i07ec194477214462b08c359051ff95f4_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AurionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i11c2bb41ca6348fb8713e36fda662dfe_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="if379bd0a6704484a92b75bcaee392d54_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i83ceffd8ac474d21a39c47ca896605c6_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i94a7e25c8cae461cae1b75c5fa5c6e2b_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ica6dee6dfddc4d1daed02284b5602d0e_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i08491d90fbdd471d983861bcd2288ac8_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i7e330acfd08c4813a18296547a2a33b7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie7d554f31b964866b8df4f6b60c0a919_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i450dc203ab3a40b6a28283cf284bd195_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i8f7252c42eff45858f156999763bf992_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ifced76c7228e456281eecd440fc4200c_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i02765d0185984e60929a5d510dd803fe_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1d2d3cf0b58a46d1835e2032498d600a_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i5ba5a4313e034d9c9d26fa5c9c002ef7_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1acd759fc07341a7815dd2541d1fa444_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="if9d48ee182734c28b3a941a4ea33ad0a_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib7bd39987453433c8655b734992caa99_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i27599a16780e40908fb6bbc9191294f0_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i954924a949ec4f81b4ccce5827b40713_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ife480d762a994b8685aef3f1fd37b377_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7a92fa7d1d5341c18bcd43745c8b8460_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i7f9c10048151448696ea86f0e39c0212_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1fe8e8ce30b4463d841ecdce075f4f3d_D20200630-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <startDate>2020-06-30</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if1ac92c6e4a04bde94c7027334556000_D20191231-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <startDate>2019-12-31</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="enrollee">
        <measure>ameh:enrollee</measure>
    </unit>
    <unit id="primary_care_physician">
        <measure>ameh:primary_care_physician</measure>
    </unit>
    <unit id="specialty_care_physician">
        <measure>ameh:specialty_care_physician</measure>
    </unit>
    <unit id="medical_center">
        <measure>ameh:medical_center</measure>
    </unit>
    <unit id="member">
        <measure>ameh:member</measure>
    </unit>
    <unit id="plan">
        <measure>ameh:plan</measure>
    </unit>
    <unit id="clinic">
        <measure>ameh:clinic</measure>
    </unit>
    <unit id="segment">
        <measure>ameh:segment</measure>
    </unit>
    <unit id="unit">
        <measure>ameh:unit</measure>
    </unit>
    <unit id="provider">
        <measure>ameh:provider</measure>
    </unit>
    <unit id="patient">
        <measure>ameh:patient</measure>
    </unit>
    <unit id="financial_ratio">
        <measure>ameh:financial_ratio</measure>
    </unit>
    <unit id="agreement">
        <measure>ameh:agreement</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80L2ZyYWc6NTBlMDIzMTA5NTM3NDBkNmIxYjI2MTViZmIyMzZhMzIvdGFibGU6MTM1MDJhOGZjNjdjNGUzZjg2YzBkY2Q3YzliNWM4ZGEvdGFibGVyYW5nZToxMzUwMmE4ZmM2N2M0ZTNmODZjMGRjZDdjOWI1YzhkYV8zLTEtMS0xLTA_d2822e06-1413-4a74-82fa-af75c6e0bdd1">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80L2ZyYWc6NTBlMDIzMTA5NTM3NDBkNmIxYjI2MTViZmIyMzZhMzIvdGFibGU6MTM1MDJhOGZjNjdjNGUzZjg2YzBkY2Q3YzliNWM4ZGEvdGFibGVyYW5nZToxMzUwMmE4ZmM2N2M0ZTNmODZjMGRjZDdjOWI1YzhkYV80LTEtMS0xLTA_353fccad-d2ad-4a11-833f-12d1f134c1df">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80L2ZyYWc6NTBlMDIzMTA5NTM3NDBkNmIxYjI2MTViZmIyMzZhMzIvdGFibGU6MTM1MDJhOGZjNjdjNGUzZjg2YzBkY2Q3YzliNWM4ZGEvdGFibGVyYW5nZToxMzUwMmE4ZmM2N2M0ZTNmODZjMGRjZDdjOWI1YzhkYV81LTEtMS0xLTA_1d14d0e7-72c8-41cd-b355-80e56138428c">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80L2ZyYWc6NTBlMDIzMTA5NTM3NDBkNmIxYjI2MTViZmIyMzZhMzIvdGFibGU6MTM1MDJhOGZjNjdjNGUzZjg2YzBkY2Q3YzliNWM4ZGEvdGFibGVyYW5nZToxMzUwMmE4ZmM2N2M0ZTNmODZjMGRjZDdjOWI1YzhkYV82LTEtMS0xLTA_99b3c4a3-c78b-443b-be34-05234f2230d3">0001083446</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80L2ZyYWc6NTBlMDIzMTA5NTM3NDBkNmIxYjI2MTViZmIyMzZhMzIvdGFibGU6MTM1MDJhOGZjNjdjNGUzZjg2YzBkY2Q3YzliNWM4ZGEvdGFibGVyYW5nZToxMzUwMmE4ZmM2N2M0ZTNmODZjMGRjZDdjOWI1YzhkYV83LTEtMS0xLTA_2d5785a8-28cd-41cc-bcd9-0ca31dda9b0d">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="iaf29becc238d412a85e642e1be07a346_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMjY0NTk_5c465777-41e6-4d7a-b713-4cd6abec3b70">P2Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i5cc5a987a5c04cad931ce456ee204243_I20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMjY1MzU_16e36149-7c47-4c0c-bc55-d85a3cf36fbe">P2Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <dei:DocumentType
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xL2ZyYWc6Y2QyMDE0YzgzODNmNDA3MWI5YmRlNzU1NzE0YWM3MTMvdGV4dHJlZ2lvbjpjZDIwMTRjODM4M2Y0MDcxYjliZGU3NTU3MTRhYzcxM18yMDg3_3bfab0a4-0446-437b-aa15-1bcc58fbc15e">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xL2ZyYWc6Y2QyMDE0YzgzODNmNDA3MWI5YmRlNzU1NzE0YWM3MTMvdGFibGU6MjU2MWU5ZWY1ZmFjNGRkMmFhNWJiMWJjZDM0MzEyNGYvdGFibGVyYW5nZToyNTYxZTllZjVmYWM0ZGQyYWE1YmIxYmNkMzQzMTI0Zl8wLTAtMS0xLTA_d79f059b-3b91-4fbd-abdf-b0a8840243b5">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xL2ZyYWc6Y2QyMDE0YzgzODNmNDA3MWI5YmRlNzU1NzE0YWM3MTMvdGV4dHJlZ2lvbjpjZDIwMTRjODM4M2Y0MDcxYjliZGU3NTU3MTRhYzcxM18xMjQ_fb49dd5b-f1f6-44f5-bb5a-2256c8db9e56">2020-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xL2ZyYWc6Y2QyMDE0YzgzODNmNDA3MWI5YmRlNzU1NzE0YWM3MTMvdGFibGU6ZmZlZDZmZWM5MWJkNDMzMjlmNGJmOTU1MzdiMzY5NmUvdGFibGVyYW5nZTpmZmVkNmZlYzkxYmQ0MzMyOWY0YmY5NTUzN2IzNjk2ZV8wLTAtMS0xLTA_269e7f87-8f13-4534-ad5c-7f4e0714a9d7">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xL2ZyYWc6Y2QyMDE0YzgzODNmNDA3MWI5YmRlNzU1NzE0YWM3MTMvdGV4dHJlZ2lvbjpjZDIwMTRjODM4M2Y0MDcxYjliZGU3NTU3MTRhYzcxM18yMDk1_62e594ba-72cb-4d67-9d70-3814cf1b2d1e">001-37392</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xL2ZyYWc6Y2QyMDE0YzgzODNmNDA3MWI5YmRlNzU1NzE0YWM3MTMvdGV4dHJlZ2lvbjpjZDIwMTRjODM4M2Y0MDcxYjliZGU3NTU3MTRhYzcxM18yMDk2_ed98d922-fdb5-4bfc-a1ce-507631d0f41f">Apollo Medical Holdings, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xL2ZyYWc6Y2QyMDE0YzgzODNmNDA3MWI5YmRlNzU1NzE0YWM3MTMvdGFibGU6ODM5OTM0ZGNmMGQ4NGM0ZWIxOTMxZTNkNTIwMmIzMTIvdGFibGVyYW5nZTo4Mzk5MzRkY2YwZDg0YzRlYjE5MzFlM2Q1MjAyYjMxMl8wLTAtMS0xLTA_4941bf5a-b51e-4ec6-a6bb-6d2a0be13e37">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xL2ZyYWc6Y2QyMDE0YzgzODNmNDA3MWI5YmRlNzU1NzE0YWM3MTMvdGFibGU6ODM5OTM0ZGNmMGQ4NGM0ZWIxOTMxZTNkNTIwMmIzMTIvdGFibGVyYW5nZTo4Mzk5MzRkY2YwZDg0YzRlYjE5MzFlM2Q1MjAyYjMxMl8wLTEtMS0xLTA_4372e628-a24c-4e8c-8e0e-b9d1d3590353">95-4472349</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xL2ZyYWc6Y2QyMDE0YzgzODNmNDA3MWI5YmRlNzU1NzE0YWM3MTMvdGV4dHJlZ2lvbjpjZDIwMTRjODM4M2Y0MDcxYjliZGU3NTU3MTRhYzcxM18yMDg4_0bdef1b2-ecea-4711-b30f-accbf0d38e0a">1668 S. Garfield Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xL2ZyYWc6Y2QyMDE0YzgzODNmNDA3MWI5YmRlNzU1NzE0YWM3MTMvdGV4dHJlZ2lvbjpjZDIwMTRjODM4M2Y0MDcxYjliZGU3NTU3MTRhYzcxM18yMDk3_7c6e561e-d862-4ad7-858e-8592c4836921">2nd Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xL2ZyYWc6Y2QyMDE0YzgzODNmNDA3MWI5YmRlNzU1NzE0YWM3MTMvdGV4dHJlZ2lvbjpjZDIwMTRjODM4M2Y0MDcxYjliZGU3NTU3MTRhYzcxM18yMDk4_3d1f9455-eb75-46ff-bf3b-964267f658cd">Alhambra</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xL2ZyYWc6Y2QyMDE0YzgzODNmNDA3MWI5YmRlNzU1NzE0YWM3MTMvdGV4dHJlZ2lvbjpjZDIwMTRjODM4M2Y0MDcxYjliZGU3NTU3MTRhYzcxM18yMDg5_d0f6fc75-268a-453d-8fc2-d0c2d736fe79">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xL2ZyYWc6Y2QyMDE0YzgzODNmNDA3MWI5YmRlNzU1NzE0YWM3MTMvdGV4dHJlZ2lvbjpjZDIwMTRjODM4M2Y0MDcxYjliZGU3NTU3MTRhYzcxM18yMDkx_b2efc840-260f-4d53-aec4-997078f4c5ee">91801</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xL2ZyYWc6Y2QyMDE0YzgzODNmNDA3MWI5YmRlNzU1NzE0YWM3MTMvdGV4dHJlZ2lvbjpjZDIwMTRjODM4M2Y0MDcxYjliZGU3NTU3MTRhYzcxM18yMDky_697e60f8-b799-45a8-bbbf-5567927d3826">626</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xL2ZyYWc6Y2QyMDE0YzgzODNmNDA3MWI5YmRlNzU1NzE0YWM3MTMvdGV4dHJlZ2lvbjpjZDIwMTRjODM4M2Y0MDcxYjliZGU3NTU3MTRhYzcxM18yMDkz_17fcd365-9d50-43e4-95af-8b4e6252ccb3">282-0288</dei:LocalPhoneNumber>
    <dei:EntityCurrentReportingStatus
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xL2ZyYWc6Y2QyMDE0YzgzODNmNDA3MWI5YmRlNzU1NzE0YWM3MTMvdGV4dHJlZ2lvbjpjZDIwMTRjODM4M2Y0MDcxYjliZGU3NTU3MTRhYzcxM18yMDk0_fcb1de85-6c39-4c84-bebc-f13f5707f723">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xL2ZyYWc6Y2QyMDE0YzgzODNmNDA3MWI5YmRlNzU1NzE0YWM3MTMvdGV4dHJlZ2lvbjpjZDIwMTRjODM4M2Y0MDcxYjliZGU3NTU3MTRhYzcxM18yMDkw_6188b07f-0013-4924-8191-6a94316a6073">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xL2ZyYWc6Y2QyMDE0YzgzODNmNDA3MWI5YmRlNzU1NzE0YWM3MTMvdGFibGU6MDA0YmFjZDg3N2Y4NDBhYzg4Mzc5YjJhMGQ0ZWFiYjcvdGFibGVyYW5nZTowMDRiYWNkODc3Zjg0MGFjODgzNzliMmEwZDRlYWJiN18wLTItMS0xLTA_05a3b6be-b3bb-4844-953b-764a850a3a9b">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xL2ZyYWc6Y2QyMDE0YzgzODNmNDA3MWI5YmRlNzU1NzE0YWM3MTMvdGFibGU6MDA0YmFjZDg3N2Y4NDBhYzg4Mzc5YjJhMGQ0ZWFiYjcvdGFibGVyYW5nZTowMDRiYWNkODc3Zjg0MGFjODgzNzliMmEwZDRlYWJiN18xLTMtMS0xLTA_1f7ba652-1635-4204-b4c5-5f96f6814f10">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xL2ZyYWc6Y2QyMDE0YzgzODNmNDA3MWI5YmRlNzU1NzE0YWM3MTMvdGFibGU6MDA0YmFjZDg3N2Y4NDBhYzg4Mzc5YjJhMGQ0ZWFiYjcvdGFibGVyYW5nZTowMDRiYWNkODc3Zjg0MGFjODgzNzliMmEwZDRlYWJiN18yLTMtMS0xLTA_34eac57f-30f6-463c-94d0-1b381a9a2ce3">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xL2ZyYWc6Y2QyMDE0YzgzODNmNDA3MWI5YmRlNzU1NzE0YWM3MTMvdGV4dHJlZ2lvbjpjZDIwMTRjODM4M2Y0MDcxYjliZGU3NTU3MTRhYzcxM18yMDk5_0a3f851d-1654-4909-b669-38be88d62091">false</dei:EntityShellCompany>
    <dei:Security12bTitle
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xL2ZyYWc6Y2QyMDE0YzgzODNmNDA3MWI5YmRlNzU1NzE0YWM3MTMvdGFibGU6ODBkMjcxMTg1MDU2NDFkMjkxZTA5MDY2ZjU0ZDMyZjQvdGFibGVyYW5nZTo4MGQyNzExODUwNTY0MWQyOTFlMDkwNjZmNTRkMzJmNF8xLTAtMS0xLTA_fc9f7f51-62d3-40c8-b502-e7051903d3c8">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xL2ZyYWc6Y2QyMDE0YzgzODNmNDA3MWI5YmRlNzU1NzE0YWM3MTMvdGFibGU6ODBkMjcxMTg1MDU2NDFkMjkxZTA5MDY2ZjU0ZDMyZjQvdGFibGVyYW5nZTo4MGQyNzExODUwNTY0MWQyOTFlMDkwNjZmNTRkMzJmNF8xLTItMS0xLTA_50623908-8c45-48b5-8d11-ea58c1c81146">AMEH</dei:TradingSymbol>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="if9ce4b07b09648a8b493eae45f76841f_I20200803"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xL2ZyYWc6Y2QyMDE0YzgzODNmNDA3MWI5YmRlNzU1NzE0YWM3MTMvdGV4dHJlZ2lvbjpjZDIwMTRjODM4M2Y0MDcxYjliZGU3NTU3MTRhYzcxM18xOTg5_89a2a857-d2f3-43e1-b8a1-2b6336aa788a"
      unitRef="shares">53513655</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNS0xLTEtMS0w_6edd72f1-21b8-4997-ba68-58aa8c48f33b"
      unitRef="usd">152441000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNS0zLTEtMS0w_282a81b4-f840-4fcb-bf74-c7d7f8cb30c6"
      unitRef="usd">103189000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNi0xLTEtMS0w_81906b88-8b55-4c0c-a320-b0d8a5e5eec6"
      unitRef="usd">0</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNi0zLTEtMS0w_b7682186-6225-41f7-a66c-f30e668be383"
      unitRef="usd">75000</us-gaap:RestrictedCashCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNy0xLTEtMS0w_3596a548-f6b4-46cd-aff7-23e2e7c9813e"
      unitRef="usd">117656000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNy0zLTEtMS0w_22aefde5-bb33-454a-8d9e-f3a4a9825456"
      unitRef="usd">116539000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfOC0xLTEtMS0w_7e2dadbc-a962-4ca1-bb3b-2f3fa5f49979"
      unitRef="usd">17588000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfOC0zLTEtMS0w_a9d00f15-5868-4068-85e2-c9d8946a81e8"
      unitRef="usd">11004000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfOS0xLTEtMS0w_ccc7e5af-5075-4f0b-8643-7994419a5580"
      unitRef="usd">59328000</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfOS0zLTEtMS0w_9a3608ed-69e3-40cc-b9d7-f43890376bb1"
      unitRef="usd">48136000</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMTAtMS0xLTEtMA_48b43d83-47a6-4884-8860-a3a38dc4e216"
      unitRef="usd">15919000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMTAtMy0xLTEtMA_3e577a66-beba-468d-a93e-680f545bc814"
      unitRef="usd">16885000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMTEtMS0xLTEtMA_6bd0a703-4094-45ce-8d11-c29194f4ed09"
      unitRef="usd">11188000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMTEtMy0xLTEtMA_8589e04b-f1db-4f19-b367-232c5a616fcb"
      unitRef="usd">10315000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMTItMS0xLTEtMA_f08e4fda-464c-4cc4-bf88-becf261adfea"
      unitRef="usd">6425000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMTItMy0xLTEtMA_9c98caee-1567-4144-9b7c-cf316076ee60"
      unitRef="usd">6425000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:NotesReceivableRelatedPartiesCurrent
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMTMtMS0xLTEtMA_cb4d3ec8-bb2e-4cb5-aeea-1bac37b51aa6"
      unitRef="usd">0</us-gaap:NotesReceivableRelatedPartiesCurrent>
    <us-gaap:NotesReceivableRelatedPartiesCurrent
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMTMtMy0xLTEtMA_9520bc91-82f4-403b-b861-7232cd4ec01f"
      unitRef="usd">16500000</us-gaap:NotesReceivableRelatedPartiesCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMTUtMS0xLTEtMA_fd19c10a-319f-43bc-8876-1635d8b8a8da"
      unitRef="usd">380545000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMTUtMy0xLTEtMA_e0191ce2-1244-4e57-bf3e-24ed03460d67"
      unitRef="usd">329068000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMTgtMS0xLTEtNDUwMw_9e1d1a2f-ed4d-451c-8f3a-322b69a346e2"
      unitRef="usd">746000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMTgtMy0xLTEtNDUwMw_f2686610-e28f-4541-829c-735879d88cec"
      unitRef="usd">746000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMTgtMS0xLTEtMA_d3a29806-9040-4b86-bdbc-9c177dd760da"
      unitRef="usd">11485000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMTgtMy0xLTEtMA_fb441ddd-d935-416c-a520-3e0e83c98c80"
      unitRef="usd">12130000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMTktMS0xLTEtMA_e114b01d-b8b8-43cc-97a5-7f315eb0724d"
      unitRef="usd">94790000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMTktMy0xLTEtMA_0192ae55-de1f-4d08-965c-25eae5beff43"
      unitRef="usd">103012000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMjAtMS0xLTEtMA_d0a7c8ae-b688-4b49-9dd7-1654c7df19c0"
      unitRef="usd">239053000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMjAtMy0xLTEtMA_7f33caa2-45b8-4dbc-bea3-36d44b110751"
      unitRef="usd">238505000</us-gaap:Goodwill>
    <us-gaap:EquityMethodInvestments
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMjEtMS0xLTEtMA_7ce63163-0523-409a-9137-3c675ac305b7"
      unitRef="usd">26817000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMjEtMy0xLTEtMA_1ae9af94-5b98-4c14-a986-2c279f385c17"
      unitRef="usd">28427000</us-gaap:EquityMethodInvestments>
    <ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMjItMS0xLTEtMA_46105ccb-ca08-44d7-b66f-cdf7416fe51e"
      unitRef="usd">37075000</ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue>
    <ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMjItMy0xLTEtMA_d8dd3b0f-f7a7-47e0-8ee5-056752790476"
      unitRef="usd">896000</ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMjQtMS0xLTEtMA_736f5f79-4daf-4dc7-8eb3-3bd9919e2475"
      unitRef="usd">20219000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMjQtMy0xLTEtMA_ba57ac47-927a-4d33-9d78-b7a10df4545f"
      unitRef="usd">14248000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMjUtMS0xLTEtMA_be76bb43-820c-4092-8a2e-3d4b15c82a58"
      unitRef="usd">22487000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMjUtMy0xLTEtMA_f757d017-cbf0-4f08-aaf7-3f70e64f8bbe"
      unitRef="usd">1681000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMjctMS0xLTEtMA_84749817-da11-4057-b97d-d3a398dcdfc3"
      unitRef="usd">452672000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMjctMy0xLTEtMA_828aa1fb-9616-4f06-a87d-85f10e644c5a"
      unitRef="usd">399645000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMjktMS0xLTEtMA_de607d2e-64b4-4591-afba-8d0cfcaf9a0d"
      unitRef="usd">833217000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMjktMy0xLTEtMA_15cc3f68-2e1d-4ffd-87ac-0a35a7fbe37c"
      unitRef="usd">728713000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMzUtMS0xLTEtMA_cfb1aa39-97f4-4283-b406-527078ea9a4b"
      unitRef="usd">24788000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMzUtMy0xLTEtMA_f28f2bf5-3a5d-4028-981f-c302b17fb248"
      unitRef="usd">27279000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <ameh:FiduciaryAccountsPayableCurrent
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMzYtMS0xLTEtMA_0caeaf10-a402-408b-98ee-157dbed2b8bf"
      unitRef="usd">1853000</ameh:FiduciaryAccountsPayableCurrent>
    <ameh:FiduciaryAccountsPayableCurrent
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMzYtMy0xLTEtMA_e2975118-986c-4d1d-8dc1-587acc2e1901"
      unitRef="usd">2027000</ameh:FiduciaryAccountsPayableCurrent>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMzctMS0xLTEtMA_db12b7c6-5f9a-4217-8585-3ebd38064794"
      unitRef="usd">70273000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMzctMy0xLTEtMA_f97f6b9d-2eb9-46c9-a0e7-052ff583e7c5"
      unitRef="usd">58725000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMzgtMS0xLTEtMA_1d885fa1-08b9-4ad1-9f24-9c9d2cf49073"
      unitRef="usd">42210000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMzgtMy0xLTEtMA_d940dd9c-4899-4296-9e2a-8d49f24078cd"
      unitRef="usd">4529000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMzktMS0xLTEtMA_9d64e104-2585-4ee2-8c19-599a3f2a03d5"
      unitRef="usd">431000</us-gaap:DividendsPayableCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfMzktMy0xLTEtMA_8966119f-578a-4882-92a9-0a15478dc3bf"
      unitRef="usd">271000</us-gaap:DividendsPayableCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNDAtMS0xLTEtMA_3543bac5-b3b4-4edb-8320-006176b9bd90"
      unitRef="usd">102000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNDAtMy0xLTEtMA_c27016a3-bb8c-481a-96dd-3562d2d3e31d"
      unitRef="usd">102000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNDEtMS0xLTEtMA_b330bd29-c9c5-46da-9c53-c54b6d09f889"
      unitRef="usd">3350000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNDEtMy0xLTEtMA_40fbb7d5-1855-488c-87d9-c8810201921b"
      unitRef="usd">2990000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNDItMS0xLTEtMA_e669f042-c0e0-4feb-9d00-590e371bc8cd"
      unitRef="usd">9500000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNDItMy0xLTEtMA_e3723f96-460d-430a-9211-2361b9462d90"
      unitRef="usd">9500000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNDMtMS0xLTEtMA_ea56551f-0e74-4a8d-a78b-eaf01c5e7a7a"
      unitRef="usd">152507000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNDMtMy0xLTEtMA_a04edb83-130d-4cba-a918-9609ad77eeeb"
      unitRef="usd">105423000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNDYtMS0xLTEtMA_af022b49-12a7-4003-bcd4-c49ff42c3805"
      unitRef="usd">13654000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNDYtMy0xLTEtMA_498a72b3-b7eb-4b8b-a005-73740ba9dfbc"
      unitRef="usd">18269000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNDctMS0xLTEtMA_71085c89-2b48-4973-8d21-01fecced1351"
      unitRef="usd">355000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNDctMy0xLTEtMA_f7418b6b-5fdd-4e40-8623-b936be6656b6"
      unitRef="usd">416000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNDgtMS0xLTEtMA_27934e3b-0ac6-4cc2-ac17-b35a80065384"
      unitRef="usd">17418000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNDgtMy0xLTEtMA_af37b674-6cc0-47f2-9929-34eb2c7c7d7d"
      unitRef="usd">11373000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNDktMS0xLTEtMA_0d11b7d8-aaab-4709-b905-a301359adad0"
      unitRef="usd">230455000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNDktMy0xLTEtMA_f9715e78-099a-42c1-837d-5f4d0f66b65a"
      unitRef="usd">232172000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNTEtMS0xLTEtMA_12287908-1efe-4e2c-86fc-9332cfd1abf9"
      unitRef="usd">261882000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNTEtMy0xLTEtMA_a5db1b61-8fbc-45f0-a615-f9d7ebe17a28"
      unitRef="usd">262230000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNTMtMS0xLTEtMA_25e8bbc6-563d-4d97-873e-bc97931db998"
      unitRef="usd">414389000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNTMtMy0xLTEtMA_424b3360-eb5e-400c-8578-4777911f95a1"
      unitRef="usd">367653000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNTUtMS0xLTEtMA_de59835b-9119-43eb-b328-4c04ed0eb277"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNTUtMy0xLTEtMA_0c65a926-cbe6-4f67-a0d0-b5771e50c49b"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNTgtMS0xLTEtMA_8854dda4-dc76-4d8a-9d1d-8b66fd576d2f"
      unitRef="usd">210980000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNTgtMy0xLTEtMA_2c6a23bf-c839-4277-ac87-95ffc8d4be44"
      unitRef="usd">168725000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i17d58afdf6094c3f9289f4089d3a6678_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjEtMC0xLTEtMC90ZXh0cmVnaW9uOjk5ZGJiNjkyZmM4YzRjYjBhODhlMTZmM2Q0YjQ0NGEyXzQ5NDc4MDIzMjUxOTM_2f35f76e-38e9-4d12-af1a-4671fb87c1a6"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ia6e2f1d8c41a4e708493e14e80f2e50d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjEtMC0xLTEtMC90ZXh0cmVnaW9uOjk5ZGJiNjkyZmM4YzRjYjBhODhlMTZmM2Q0YjQ0NGEyXzQ5NDc4MDIzMjUxOTM_ce4f8501-6143-4bed-8b22-6a9bd75137e6"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i17d58afdf6094c3f9289f4089d3a6678_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjEtMC0xLTEtMC90ZXh0cmVnaW9uOjk5ZGJiNjkyZmM4YzRjYjBhODhlMTZmM2Q0YjQ0NGEyXzQ5NDc4MDIzMjUyMDQ_7e6bbdac-b2a9-43f3-b67e-4673e305b8d0"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ia6e2f1d8c41a4e708493e14e80f2e50d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjEtMC0xLTEtMC90ZXh0cmVnaW9uOjk5ZGJiNjkyZmM4YzRjYjBhODhlMTZmM2Q0YjQ0NGEyXzQ5NDc4MDIzMjUyMDQ_889ebddb-ebf7-4d74-8a9b-ec0f983ce4ef"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ia6e2f1d8c41a4e708493e14e80f2e50d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjEtMC0xLTEtMC90ZXh0cmVnaW9uOjk5ZGJiNjkyZmM4YzRjYjBhODhlMTZmM2Q0YjQ0NGEyXzQ5NDc4MDIzMjUyMTU_1873fe2b-4373-43c6-80b1-453b3041cd29"
      unitRef="shares">1111111</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i17d58afdf6094c3f9289f4089d3a6678_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjEtMC0xLTEtMC90ZXh0cmVnaW9uOjk5ZGJiNjkyZmM4YzRjYjBhODhlMTZmM2Q0YjQ0NGEyXzQ5NDc4MDIzMjUyMTU_ff089cdb-b18f-4c4a-b5c6-379fed919527"
      unitRef="shares">1111111</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ia6e2f1d8c41a4e708493e14e80f2e50d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjEtMC0xLTEtMC90ZXh0cmVnaW9uOjk5ZGJiNjkyZmM4YzRjYjBhODhlMTZmM2Q0YjQ0NGEyXzU0OTc1NTgxMzkxMDk_425db5b1-e87e-44f4-906b-c518ffe6b269"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i17d58afdf6094c3f9289f4089d3a6678_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjEtMC0xLTEtMC90ZXh0cmVnaW9uOjk5ZGJiNjkyZmM4YzRjYjBhODhlMTZmM2Q0YjQ0NGEyXzU0OTc1NTgxMzkxMDk_7efede2f-b976-4b57-8fb7-e35bedfa6275"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i17d58afdf6094c3f9289f4089d3a6678_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjEtMS0xLTEtMA_7f317f74-4eba-45b8-9fa5-0b6d4fad49d3"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="ia6e2f1d8c41a4e708493e14e80f2e50d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjEtMy0xLTEtMA_9509b1e7-1f3f-4a8e-88f5-63aa179354fb"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ie3ded1fe24c44729a7d30f51269fad23_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjItMC0xLTEtMC90ZXh0cmVnaW9uOjdkYWIwNzVlMWQ3NDQ2ZDM4NGU4NjA3M2ZiNzcyMDU4XzQ5NDc4MDIzMjUxOTE_224c8eb8-f38a-4b6f-86a4-ed7b2f0d01f0"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i83686cfeea3643b2ab0ba5131ab70154_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjItMC0xLTEtMC90ZXh0cmVnaW9uOjdkYWIwNzVlMWQ3NDQ2ZDM4NGU4NjA3M2ZiNzcyMDU4XzQ5NDc4MDIzMjUxOTE_5ede97e5-c9e9-48b7-bda3-7a62340b7d66"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ie3ded1fe24c44729a7d30f51269fad23_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjItMC0xLTEtMC90ZXh0cmVnaW9uOjdkYWIwNzVlMWQ3NDQ2ZDM4NGU4NjA3M2ZiNzcyMDU4XzQ5NDc4MDIzMjUyMDI_f6ed8215-1d99-4d22-8b22-444e88aac3cc"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i83686cfeea3643b2ab0ba5131ab70154_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjItMC0xLTEtMC90ZXh0cmVnaW9uOjdkYWIwNzVlMWQ3NDQ2ZDM4NGU4NjA3M2ZiNzcyMDU4XzQ5NDc4MDIzMjUyMDI_fd2b1cc2-954b-43f5-ac6c-ded45891e2bf"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ie3ded1fe24c44729a7d30f51269fad23_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjItMC0xLTEtMC90ZXh0cmVnaW9uOjdkYWIwNzVlMWQ3NDQ2ZDM4NGU4NjA3M2ZiNzcyMDU4XzQ5NDc4MDIzMjUyMTE_413928ae-1334-46e3-aa2a-34157990e5ef"
      unitRef="shares">555555</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i83686cfeea3643b2ab0ba5131ab70154_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjItMC0xLTEtMC90ZXh0cmVnaW9uOjdkYWIwNzVlMWQ3NDQ2ZDM4NGU4NjA3M2ZiNzcyMDU4XzQ5NDc4MDIzMjUyMTE_e2a73fde-fd30-4148-996a-b4f2f00f6f1a"
      unitRef="shares">555555</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i83686cfeea3643b2ab0ba5131ab70154_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjItMC0xLTEtMC90ZXh0cmVnaW9uOjdkYWIwNzVlMWQ3NDQ2ZDM4NGU4NjA3M2ZiNzcyMDU4XzU0OTc1NTgxMzkxMDU_4770ca18-092c-4d21-a29a-487f3749d7af"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ie3ded1fe24c44729a7d30f51269fad23_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjItMC0xLTEtMC90ZXh0cmVnaW9uOjdkYWIwNzVlMWQ3NDQ2ZDM4NGU4NjA3M2ZiNzcyMDU4XzU0OTc1NTgxMzkxMDU_d958523d-3f68-482b-b947-e725a7988e51"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i83686cfeea3643b2ab0ba5131ab70154_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjItMS0xLTEtMA_2807f1bd-2ee2-4679-8beb-2e4f71b92df5"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="ie3ded1fe24c44729a7d30f51269fad23_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjItMy0xLTEtMA_d5a497ce-6e82-4e62-b866-9f45f0552eb7"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOjBiOWI0NzFiOWJmNjQ1MTI5Y2RjNzI4ZDczOWJiYTgzXzQ5NDc4MDIzMjUyMjg_7bc90250-a8b3-438b-b25a-516fa47bd8b9"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOjBiOWI0NzFiOWJmNjQ1MTI5Y2RjNzI4ZDczOWJiYTgzXzQ5NDc4MDIzMjUyMjg_f72c9da6-eab2-488b-a7d9-e59ef6f82502"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOjBiOWI0NzFiOWJmNjQ1MTI5Y2RjNzI4ZDczOWJiYTgzXzQ5NDc4MDIzMjUyNDE_618b7c34-cc1e-4c5d-b861-c6f7aa7c7107"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOjBiOWI0NzFiOWJmNjQ1MTI5Y2RjNzI4ZDczOWJiYTgzXzQ5NDc4MDIzMjUyNDE_701f08b0-0b22-4aaa-a2f8-aa408776ca18"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOjBiOWI0NzFiOWJmNjQ1MTI5Y2RjNzI4ZDczOWJiYTgzXzQ5NDc4MDIzMjUyNTM_02a75fd9-43b9-422e-b278-3499c13dcc05"
      unitRef="shares">36309513</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOjBiOWI0NzFiOWJmNjQ1MTI5Y2RjNzI4ZDczOWJiYTgzXzQ5NDc4MDIzMjUyNzc_3897cb08-92aa-46aa-a0ce-c9da59049540"
      unitRef="shares">35908057</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOjBiOWI0NzFiOWJmNjQ1MTI5Y2RjNzI4ZDczOWJiYTgzXzQ5NDc4MDIzMjUyNjU_e445687c-0246-44cc-a7d3-e3bc99a871bf"
      unitRef="shares">17475707</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOjBiOWI0NzFiOWJmNjQ1MTI5Y2RjNzI4ZDczOWJiYTgzXzQ5NDc4MDIzMjUyODk_bdcf3d19-9980-4b9a-9ffa-5eb2251e8bc6"
      unitRef="shares">17458810</us-gaap:TreasuryStockCommonShares>
    <us-gaap:CommonStockValue
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjMtMS0xLTEtMA_09d9837f-727b-403f-a3f4-058865e15627"
      unitRef="usd">36000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjMtMy0xLTEtMA_27810675-ab1e-4423-baf3-cf5178b7fd7a"
      unitRef="usd">36000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjQtMS0xLTEtMA_eeec4fa0-0ea5-46a7-a77c-18a6b2f2090f"
      unitRef="usd">163986000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjQtMy0xLTEtMA_476114e0-721f-4de5-899b-2cec91c6dbf1"
      unitRef="usd">159608000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjUtMS0xLTEtMA_fe8fccfa-12f7-43f9-a54f-784f3f334b71"
      unitRef="usd">43001000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjUtMy0xLTEtMA_5a6b8202-5294-400e-b4be-5a7884ca0dc0"
      unitRef="usd">31905000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjYtMS0xLTEtMA_8806087c-e3ba-4ec7-a3ed-e74c170f17a6"
      unitRef="usd">207023000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjYtMy0xLTEtMA_df481ba0-4803-4af3-b814-1cd1d9f78b28"
      unitRef="usd">191549000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjgtMS0xLTEtMA_5135b126-667b-456d-b5fc-cfd565a89157"
      unitRef="usd">825000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNjgtMy0xLTEtMA_b6008e89-bf65-4246-a71c-26e15726fce0"
      unitRef="usd">786000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNzAtMS0xLTEtMA_1a97eb45-9c61-45a2-80cb-f3dd2275a665"
      unitRef="usd">207848000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNzAtMy0xLTEtMA_98b4ecff-c3c2-4fa6-8c11-458790c7bffd"
      unitRef="usd">192335000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNzItMS0xLTEtMA_424d3a14-a024-4485-94b1-f3a365ff065e"
      unitRef="usd">833217000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yMi9mcmFnOjhiZjQ4MmEyZmJkNzQ0NTE5YTc2NWEzZmMxZmMzNGMzL3RhYmxlOjEyNjM3ODk5Mzg0MzRmOGQ5MmIzMWFiOTJhNzk1OTdjL3RhYmxlcmFuZ2U6MTI2Mzc4OTkzODQzNGY4ZDkyYjMxYWI5MmE3OTU5N2NfNzItMy0xLTEtMA_b30e474e-888c-4cd0-8d54-cdd1be8bd20f"
      unitRef="usd">728713000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie034b8ac717f4e0f821b2e6846cc21da_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMy0xLTEtMS0w_5da20b73-8158-43fd-9a1b-bd6cbe37df90"
      unitRef="usd">140949000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3c020c0256064c2e9f9890db9de73a18_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMy0zLTEtMS0w_cf7b599f-6e03-4139-8a44-3542eb1f2dd5"
      unitRef="usd">103224000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifb543017186b41428d7d61876f751a53_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMy01LTEtMS0w_22715171-f108-4be3-a13b-6cc557b452f4"
      unitRef="usd">281370000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibca1f4a0742946218cb28c01d1e69d3a_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMy03LTEtMS0w_43d8bc96-ada9-4adf-8da1-774061992d5d"
      unitRef="usd">174740000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie935f35786ac43c595cc0e1bdd2bfa7a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfNC0xLTEtMS0w_82f8b0fc-1f8f-49b2-927b-6921e37dc1e1"
      unitRef="usd">12003000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4e76ce3a79df48a5b2aef434c3026411_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfNC0zLTEtMS0w_a46a1f25-8ded-49bb-ba42-404aa3efdf0d"
      unitRef="usd">11191000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic9a5e5a435384ed9b47445e91f2e5dbe_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfNC01LTEtMS0w_4ffc2d1a-ccd7-45e2-b6f4-7f8b1ba28331"
      unitRef="usd">23239000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibfc4299f8823436fac5fd23586298d02_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfNC03LTEtMS0w_b02b0047-2912-4228-b2be-18d1afb9ea87"
      unitRef="usd">21285000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i86ffd806ab8441679dbed516276b4734_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfNS0xLTEtMS0w_1385fafd-de9f-4505-80e2-84fc14bd8ff8"
      unitRef="usd">8690000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id2c681dbab0b446cafe1a39de28bedb6_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfNS0zLTEtMS0w_99a8e15a-3a96-41e2-85ba-3bab043b83f3"
      unitRef="usd">10353000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic862c6560a614f5abea31e3ad439d0fe_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfNS01LTEtMS0w_995f2bbb-19f6-4229-8114-d3e8a2a38831"
      unitRef="usd">17505000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7276b0b6cad94ed6955187e2affe1b27_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfNS03LTEtMS0w_de114b5c-5dc3-46a2-b956-a4116210baac"
      unitRef="usd">19349000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia03e0ac0e02248b881a5720c0b7bcc62_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfNi0xLTEtMS0w_8b5dd0fc-f889-4d97-979c-b49d42c7220a"
      unitRef="usd">2270000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i352052d598714a3aa1bc0f6be299be80_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfNi0zLTEtMS0w_01e717a7-81d1-423a-898d-44e20a540a9c"
      unitRef="usd">3878000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0a83b91f96d642cb888e655253482c99_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfNi01LTEtMS0w_d83cef79-ba82-44a9-ba4c-dcd4a6156a28"
      unitRef="usd">5697000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i18eff8c461884069b655593a6463d4b2_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfNi03LTEtMS0w_a034639c-816a-401f-ad6b-f22cca4cb925"
      unitRef="usd">7959000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i17c717d9ab9c4c13925e6d4f409d3e67_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfNy0xLTEtMS0w_6c04fdcd-c5db-4e26-8b67-301afe308d0b"
      unitRef="usd">1257000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic79fc17a0341400e9e62338ca77a93da_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfNy0zLTEtMS0w_6a60e569-c7d8-4aab-94e5-54a75b980ff0"
      unitRef="usd">1404000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie229ade0fac144a8a4262469a1176554_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfNy01LTEtMS0w_5bea77d3-0c23-42a5-aa0d-8282e465ea1e"
      unitRef="usd">2463000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i455aac9cb9b24b88861613f2d5737086_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfNy03LTEtMS0w_967b6c3a-848c-41b2-bc95-ee34cbd29217"
      unitRef="usd">2473000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfOS0xLTEtMS0w_5d3535ba-d6b4-4168-adf1-d54a6eac714d"
      unitRef="usd">165169000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfOS0zLTEtMS0w_aa2860f1-bc83-4f33-bb17-f092c8d29e0f"
      unitRef="usd">130050000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfOS01LTEtMS0w_d2596615-d805-480a-bdea-ccefaab9a10f"
      unitRef="usd">330274000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfOS03LTEtMS0w_09dc5492-f168-4883-96f9-33829bed8dca"
      unitRef="usd">225806000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMTItMS0xLTEtMA_5989a382-b948-4db5-8a76-ff2f84c65baf"
      unitRef="usd">136079000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMTItMy0xLTEtMA_e6385b30-13bb-45a2-b868-b5fe2bff2a8d"
      unitRef="usd">101363000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMTItNS0xLTEtMA_57b21d26-1efd-4ac8-bf20-faa9a5a69da9"
      unitRef="usd">280283000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMTItNy0xLTEtMA_7aecc9fc-7600-4f12-a6a4-21b26f09532c"
      unitRef="usd">184795000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMTMtMS0xLTEtMA_f728ca89-9dbd-4cd8-8e10-f5a2c0f8daab"
      unitRef="usd">11556000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMTMtMy0xLTEtMA_4c779172-ec1d-4f41-84bf-27ae7c532e20"
      unitRef="usd">11818000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMTMtNS0xLTEtMA_0970f1fa-de7e-48c9-a4fc-9b95a2839b28"
      unitRef="usd">23390000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMTMtNy0xLTEtMA_25071ea2-cc24-4986-8e88-8c4d43ced9e6"
      unitRef="usd">22081000</us-gaap:GeneralAndAdministrativeExpense>
    <ameh:DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts
      contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMTQtMS0xLTEtMA_6089377a-1ca1-46dc-8274-b78c4380294e"
      unitRef="usd">4628000</ameh:DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts>
    <ameh:DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts
      contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMTQtMy0xLTEtMA_6646c139-f579-4a92-9237-77fbd93287c9"
      unitRef="usd">4455000</ameh:DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts>
    <ameh:DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMTQtNS0xLTEtMA_8f2003c0-a98f-4d23-9446-7b853e47faa2"
      unitRef="usd">9330000</ameh:DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts>
    <ameh:DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMTQtNy0xLTEtMA_3bef738b-e9d3-45ed-a07c-f6b1ae1b3de8"
      unitRef="usd">8872000</ameh:DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMTUtMS0xLTEtMA_5b22a78a-f1de-48ff-83a0-ab2e19c7c181"
      unitRef="usd">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMTUtMy0xLTEtMA_83e67198-1059-4984-be97-fd51a31bca3f"
      unitRef="usd">-2314000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMTUtNS0xLTEtMA_a5d5b29a-99bb-4502-b0dd-b2359f903eb3"
      unitRef="usd">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMTUtNy0xLTEtMA_c0e92b84-984e-4693-ad9b-4ae1494cfb7c"
      unitRef="usd">-1363000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:CostsAndExpenses
      contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMTctMS0xLTEtMA_7251e682-4991-4f66-b227-43dcf50ab787"
      unitRef="usd">152263000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMTctMy0xLTEtMA_148c2ccd-d182-4518-a1e6-2b0163e60e2a"
      unitRef="usd">115322000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMTctNS0xLTEtMA_992a0454-6168-4d9e-bd10-bb718e476e24"
      unitRef="usd">313003000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMTctNy0xLTEtMA_e14bfbaa-2dc6-44ef-9833-1b5c004be596"
      unitRef="usd">214385000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMTktMS0xLTEtMA_fbbfc034-c9fc-4671-9271-4b29c8fcf8c1"
      unitRef="usd">12906000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMTktMy0xLTEtMA_30db1792-0549-4d85-a21c-7c3bf03921ca"
      unitRef="usd">14728000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMTktNS0xLTEtMA_dd6f0232-3e87-472a-907f-023c21990e1e"
      unitRef="usd">17271000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMTktNy0xLTEtMA_5a4d37ee-8845-410e-a513-821498049655"
      unitRef="usd">11421000</us-gaap:OperatingIncomeLoss>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMjItMS0xLTEtMA_efbd1a10-12d3-4988-af1f-26adcf493d62"
      unitRef="usd">834000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMjItMy0xLTEtMA_d01745ce-c26a-499b-ab88-3d99a5f46950"
      unitRef="usd">-42000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMjItNS0xLTEtMA_3ced0138-a8cd-489c-a647-6052e89f3771"
      unitRef="usd">2888000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMjItNy0xLTEtMA_d50be0a6-2261-4c81-b02e-0321a28a35a4"
      unitRef="usd">-892000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMjMtMS0xLTEtNDY2NQ_43919e66-e477-433c-bf80-14cad4f285ab"
      unitRef="usd">99647000</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMjMtMy0xLTEtNDY2NQ_ccfd3c82-dafb-46a0-bf9e-1177b40c465b"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMjMtNS0xLTEtNDY1Ng_cf72bea9-56c0-4a97-87ab-bd88c02c02b7"
      unitRef="usd">99647000</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMjMtNy0xLTEtNDY1Ng_6ebb2f4e-859a-4049-9a9e-3d200c1e48aa"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:InterestExpense
      contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMjMtMS0xLTEtMA_b0f1f2c0-d5ad-470b-bf6b-bc7a55f4b14c"
      unitRef="usd">2673000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMjMtMy0xLTEtMA_d887ed17-0ca4-4038-962f-22da7605f57e"
      unitRef="usd">311000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMjMtNS0xLTEtMA_0e2d19d9-594c-4b33-810a-43296988c2a5"
      unitRef="usd">5541000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMjMtNy0xLTEtMA_aa25b86e-95e0-4d2a-90ac-b3450236f71e"
      unitRef="usd">522000</us-gaap:InterestExpense>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMjQtMS0xLTEtMA_2a51ee15-2f60-4099-a3fe-d17a3da93774"
      unitRef="usd">863000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMjQtMy0xLTEtMA_311700c1-09fc-4728-a421-e642d39d5b8f"
      unitRef="usd">474000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMjQtNS0xLTEtMA_10467c00-f6cd-4067-ac5f-71586a6cf4b0"
      unitRef="usd">1792000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMjQtNy0xLTEtMA_b580cbb7-8db0-4d03-a73b-6f1ed48973f2"
      unitRef="usd">797000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMjUtMS0xLTEtMA_b7c4406b-5d46-4073-8d20-a5f03bcee5fb"
      unitRef="usd">1282000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMjUtMy0xLTEtMA_69ae0bd6-0f94-4ade-b732-96739b932ad1"
      unitRef="usd">24000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMjUtNS0xLTEtMA_e4804f13-e926-4611-81a9-122ff3456a85"
      unitRef="usd">1384000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMjUtNy0xLTEtMA_51f2c305-bef7-4abe-9cac-e7a558027e2c"
      unitRef="usd">211000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMjctMS0xLTEtMA_831dafaf-ed9b-4186-97e7-bdec8ba20ea1"
      unitRef="usd">99953000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMjctMy0xLTEtMA_57cf0609-636e-4488-9079-7e87170555c1"
      unitRef="usd">145000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMjctNS0xLTEtMA_4d35274a-f319-4043-b08f-397304b9f19e"
      unitRef="usd">100170000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMjctNy0xLTEtMA_341a9f79-1c9b-4326-a69d-eaf86bb87e7b"
      unitRef="usd">-406000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMjktMS0xLTEtMA_49472043-6af7-4bdc-9717-fa9a642be35c"
      unitRef="usd">112859000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMjktMy0xLTEtMA_0fa05167-e78c-4c06-8198-81d67451cf70"
      unitRef="usd">14873000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMjktNS0xLTEtMA_1f78f550-39e1-46ee-aa73-0650ceb5625e"
      unitRef="usd">117441000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMjktNy0xLTEtMA_a083a1c8-360c-4b4d-9a5b-8cc1b0d78e37"
      unitRef="usd">11015000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMzEtMS0xLTEtMA_ece16360-802d-4179-8f93-2a0b0a94ebe4"
      unitRef="usd">31858000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMzEtMy0xLTEtMA_debc947b-b6e8-4b79-b00c-0a7a9eb5d7af"
      unitRef="usd">4209000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMzEtNS0xLTEtMA_637af34b-2cac-447c-9148-4020f57a9191"
      unitRef="usd">33453000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMzEtNy0xLTEtMA_769e3301-4783-4780-824c-549ed89c988c"
      unitRef="usd">2801000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMzMtMS0xLTEtMA_5b1dca2d-1204-41a2-94c8-cc017856b230"
      unitRef="usd">81001000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMzMtMy0xLTEtMA_8f836eb1-7c56-416c-94b3-58bdf265f1e8"
      unitRef="usd">10664000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMzMtNS0xLTEtMA_b288b949-86f1-4dce-8fc0-88c06427704d"
      unitRef="usd">83988000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMzMtNy0xLTEtMA_2ca7c156-a661-4130-b7fc-bbd53264c908"
      unitRef="usd">8214000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMzUtMS0xLTEtMA_d8e51332-62ff-4fcf-8f08-aabfdb4fb3cb"
      unitRef="usd">73957000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMzUtMy0xLTEtMA_87764573-783e-4e8a-aee6-98dbcece5beb"
      unitRef="usd">7119000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMzUtNS0xLTEtMA_4f3d1f19-3b9f-44c6-a610-155906e92b67"
      unitRef="usd">72892000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMzUtNy0xLTEtMA_823bba58-509a-447e-96da-a2e1013f76b9"
      unitRef="usd">4529000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMzctMS0xLTEtMA_5831b659-bf12-4b2e-b4fd-5c8f2980496d"
      unitRef="usd">7044000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMzctMy0xLTEtMA_df803b84-dd90-4789-8359-d7354d1fc671"
      unitRef="usd">3545000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMzctNS0xLTEtMA_07716871-df75-41f4-b38d-4365ae339408"
      unitRef="usd">11096000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMzctNy0xLTEtMA_2ef2f23f-3398-4440-a33f-059bbdcd8581"
      unitRef="usd">3685000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMzktMS0xLTEtMA_4fb6f628-b2a4-44fd-a7e2-590f4981f882"
      unitRef="usdPerShare">0.20</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMzktMy0xLTEtMA_dbd8a9ae-140c-442c-91ba-2725d7c793be"
      unitRef="usdPerShare">0.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMzktNS0xLTEtMA_cbbd260a-3d0d-44eb-81ad-b754fcd24444"
      unitRef="usdPerShare">0.31</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfMzktNy0xLTEtMA_95e22dfa-f9e1-462d-bff1-86aff196ec78"
      unitRef="usdPerShare">0.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfNDEtMS0xLTEtMA_a17485a0-7ae8-49d2-9321-d790a6918a36"
      unitRef="usdPerShare">0.19</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfNDEtMy0xLTEtMA_5bcb12ba-9526-4824-9690-e91eb8aaeeef"
      unitRef="usdPerShare">0.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfNDEtNS0xLTEtMA_7ca6d738-8e56-4b1a-b68b-ffa8d54d1cfe"
      unitRef="usdPerShare">0.30</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8yOC9mcmFnOjg0N2U3MzcwNWM1YTRkY2U4M2U3ZDU3OThlNGI0MDA2L3RhYmxlOmNlYzUzOTYxMTUzMjRkY2Y4ZDAwNzE4MGZjYWY3N2RkL3RhYmxlcmFuZ2U6Y2VjNTM5NjExNTMyNGRjZjhkMDA3MTgwZmNhZjc3ZGRfNDEtNy0xLTEtMA_f0b5ac02-dd61-4965-b97f-6dca282bbf00"
      unitRef="usdPerShare">0.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5a40c5284da24efa84bc4df89f4f2705_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMy0xLTEtMS0w_f3c9e6a2-bf1e-4bbc-a75c-993174fcef2f"
      unitRef="usd">168725000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="ie4e637eec6484f0786a6ed5c1f6430cb_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMy0zLTEtMS0w_3a34964b-8084-408d-a262-6b72744f045c"
      unitRef="shares">35908057</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie4e637eec6484f0786a6ed5c1f6430cb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMy01LTEtMS0w_4a52da8b-bf23-4f4c-8a16-083aceb38bdb"
      unitRef="usd">36000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icdd5d78f45b9441eba8b9eacaa9bf76e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMy03LTEtMS0w_ecd77eab-5716-4765-99df-5834c02dea0a"
      unitRef="usd">159608000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i11c1b7b9b865434fa9576e7784c2dc13_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMy05LTEtMS0w_80921506-d627-4934-b351-681f6cb65357"
      unitRef="usd">31905000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia43dbbf6ada5449bacec1ab39ed62847_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMy0xMS0xLTEtMA_9bd7eecf-15e9-4bd0-a24a-12136ca85177"
      unitRef="usd">786000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMy0xMy0xLTEtMA_a1c057e5-482f-4f01-906d-e1f30d751a3a"
      unitRef="usd">192335000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i1f94bdfba2434414a07e834a64442b28_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfNC0xLTEtMS0w_5f66d351-de75-4d8f-bd5b-2c6fefce9671"
      unitRef="usd">-1161000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="ie1f8b99761ef4aa3ad4c66bc1cdef075_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfNC05LTEtMS0w_48d26366-c300-44c3-b54a-643ebde6626e"
      unitRef="usd">4052000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i67cb29fa35d447558cebf0c44017ecd8_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfNC0xMS0xLTEtMA_ee1ddf9f-5f90-4687-83ca-fb4d0d9a3094"
      unitRef="usd">95000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="ib557e6848b8949778b46babd52ad1570_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfNC0xMy0xLTEtMA_48f727a1-e088-4863-922a-2c350259e56a"
      unitRef="usd">4147000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i691e279196924ed386447cfa2fdb3c0a_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfNS0zLTEtMS0w_7125d8c3-6552-48d1-aee1-eb540a6403b1"
      unitRef="shares">16897</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredParValueMethod
      contextRef="ia8c91ec953b9448fb223cb4a034a52d3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfNS03LTEtMS0w_df7a7e61-971d-430e-9481-26656c004cdb"
      unitRef="usd">301000</us-gaap:TreasuryStockValueAcquiredParValueMethod>
    <us-gaap:TreasuryStockValueAcquiredParValueMethod
      contextRef="ib557e6848b8949778b46babd52ad1570_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfNS0xMy0xLTEtMA_630c56b4-bf51-4349-977a-91484f730537"
      unitRef="usd">301000</us-gaap:TreasuryStockValueAcquiredParValueMethod>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i1f94bdfba2434414a07e834a64442b28_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfNi0xLTEtMS0w_232e7578-1971-49ef-bf0a-5c7793b189aa"
      unitRef="usd">125000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="ib557e6848b8949778b46babd52ad1570_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfNi0xMy0xLTEtMA_8972df85-252a-4e67-8780-89519fa80d5e"
      unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants
      contextRef="i691e279196924ed386447cfa2fdb3c0a_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfNy0zLTEtMS0w_d413d8e3-89d4-4942-8a8e-87ac4ecae54a"
      unitRef="shares">151601</ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="ia8c91ec953b9448fb223cb4a034a52d3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfNy03LTEtMS0w_2ed91917-19c6-49d2-97fb-2f951389bed5"
      unitRef="usd">722000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="ib557e6848b8949778b46babd52ad1570_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfNy0xMy0xLTEtMA_022a2f9d-084f-4a9b-ad76-cc36f5eb880a"
      unitRef="usd">722000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ia8c91ec953b9448fb223cb4a034a52d3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfOC03LTEtMS0w_f9400ec5-1d16-48eb-89e2-e0013228ed4c"
      unitRef="usd">1058000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ib557e6848b8949778b46babd52ad1570_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfOC0xMy0xLTEtMA_282ebb0f-bb7f-4aaf-bf5d-05cb33c7569e"
      unitRef="usd">1058000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i1f94bdfba2434414a07e834a64442b28_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfOS0xLTEtMS0w_57fde2fd-9c7c-49c7-8f39-2adb739a617d"
      unitRef="usd">10000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ib557e6848b8949778b46babd52ad1570_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfOS0xMy0xLTEtMA_7bad001d-7bfe-44a7-a818-a644afe2eb06"
      unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic62aa01d15f74e74b86bfdec19d0c108_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTAtMS0xLTEtMA_2344661f-97a2-4413-b90c-7690765a4275"
      unitRef="usd">157439000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="ie5f49e82ee9c46f680d56792f282a687_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTAtMy0xLTEtMA_374d4d6e-f049-4384-be1e-e4408095c9e1"
      unitRef="shares">36042761</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie5f49e82ee9c46f680d56792f282a687_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTAtNS0xLTEtMA_6b6acb6f-4fb8-40de-bfca-f1eb9427c108"
      unitRef="usd">36000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i083b9bc8a05048a5840ae066d8501457_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTAtNy0xLTEtMA_baaac71e-4aa0-4a8d-9dd5-9ecf46521ec0"
      unitRef="usd">161087000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4b2a896675d04c7d9830d427157f52b0_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTAtOS0xLTEtMA_933ec953-2c34-4a7f-91f6-92260016b38b"
      unitRef="usd">35957000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8d951dc1190e45e2ac445202aec7daa9_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTAtMTEtMS0xLTA_ab0c2b1a-d685-4b3d-9482-589813e90803"
      unitRef="usd">881000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iee021f30ec494988b04ffd293da80842_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTAtMTMtMS0xLTA_7f3cad1b-b4ff-400e-bc39-17073a50f000"
      unitRef="usd">197961000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="iab3938dc2790442bbae7aab01097fc8b_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTEtMS0xLTEtMzI5_4b3c4492-6315-4295-89d2-80d889e734b0"
      unitRef="usd">73667000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="id415104b7a1f4a52af19c2f74be0a88d_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTEtOS0xLTEtMzMy_4e80b50b-a90b-43e5-af07-f654e192ffc8"
      unitRef="usd">7044000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="ieff7bbd8785d4105a279ebbb1b6569a6_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTEtMTEtMS0xLTMzNQ_475ea1c7-6308-4010-9fe0-572df4ead85f"
      unitRef="usd">291000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTEtMTMtMS0xLTMzNQ_7479533f-c7a3-4a09-8c06-d178ffd804e6"
      unitRef="usd">7335000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="iab3938dc2790442bbae7aab01097fc8b_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTItMS0xLTEtMzI5_a92bbc49-bd29-4751-a0f1-979e39b4e22f"
      unitRef="usd">126000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTItMTMtMS0xLTMzNQ_e1b74a2f-1ae5-40f9-bffa-146fa3f7030e"
      unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="ic6205a2691794f12816d94e2384216d4_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTMtMy0xLTEtNjE4Mg_9f14d54b-af84-43b8-ae69-f5271f6c52d3"
      unitRef="shares">24453</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTMtMTMtMS0xLTYxODI_7794de50-1950-4f96-82f7-8523528eee62"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants
      contextRef="ic6205a2691794f12816d94e2384216d4_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTQtMy0xLTEtMzMy_0431ad45-260b-4349-a2ef-517a7d6ba555"
      unitRef="shares">242299</ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="i8f79c810c09544658e32ad8904dcddfb_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTQtNy0xLTEtMzMy_233ccb38-42f8-4272-bbf4-c3bdb1dbeb94"
      unitRef="usd">2283000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTQtMTMtMS0xLTMzNQ_15ba9d5d-ff93-4dac-a744-3758503a61ea"
      unitRef="usd">2283000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i8f79c810c09544658e32ad8904dcddfb_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTUtNy0xLTEtMzMy_c0a9a1eb-f945-4a21-888f-2f3d1951702b"
      unitRef="usd">852000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTUtMTMtMS0xLTMzNQ_7660e9e1-980b-402a-a529-18193328e7e9"
      unitRef="usd">852000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <ameh:StockIssuedDuringPeriodValueRestrictedStockAwardCancelled
      contextRef="i8f79c810c09544658e32ad8904dcddfb_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTYtNy0xLTEtMjUyMQ_b29674f8-33d6-400c-b400-9dcab0d34c9a"
      unitRef="usd">236000</ameh:StockIssuedDuringPeriodValueRestrictedStockAwardCancelled>
    <ameh:StockIssuedDuringPeriodValueRestrictedStockAwardCancelled
      contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTYtMTMtMS0xLTI1MjE_96cafed5-f08c-4de7-8708-8eac6e9ed418"
      unitRef="usd">236000</ameh:StockIssuedDuringPeriodValueRestrictedStockAwardCancelled>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="iab3938dc2790442bbae7aab01097fc8b_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTYtMS0xLTEtMzI5_fbef340d-f832-43a1-991e-b56777061a38"
      unitRef="usd">20000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ieff7bbd8785d4105a279ebbb1b6569a6_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTYtMTEtMS0xLTMzNQ_7ffef991-8a8d-46cf-9616-6320095a3014"
      unitRef="usd">347000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTYtMTMtMS0xLTMzNQ_dbfa385d-334b-4c60-887f-4fccc8175ee7"
      unitRef="usd">347000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i601b184c6fdf4eada4f627de564a12d2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTctMS0xLTEtMzM4_0101bb62-f03b-412a-b740-7ee1cf3271f0"
      unitRef="usd">210980000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i56db13635c644c7eb66668022d8f8878_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTctMy0xLTEtMzM4_12b1dd22-fa00-4dc5-8b95-5cadfd559fff"
      unitRef="shares">36309513</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i56db13635c644c7eb66668022d8f8878_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTctNS0xLTEtMzM4_61d0e5c3-d13e-477b-9509-0e83122f3f0c"
      unitRef="usd">36000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5ccf0e9ee2e64a3182ccb11330048327_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTctNy0xLTEtMzM4_6104da0a-1819-458a-a6be-62acd254623d"
      unitRef="usd">163986000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icb7195fbea754ef3b0e02c161fbcbf6c_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTctOS0xLTEtMzM4_9da9da57-b10e-48d8-9d2a-ea16d5b681ca"
      unitRef="usd">43001000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1e6a563a26fa49f79fe7e401bb5fec30_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTctMTEtMS0xLTMzOA_a7631b1e-dc3d-4b12-8983-d4ab960f411a"
      unitRef="usd">825000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjM3OTEwYWZhODdkNjRlZGJiZjRlMmYwOTNiMDZkYmE0L3RhYmxlcmFuZ2U6Mzc5MTBhZmE4N2Q2NGVkYmJmNGUyZjA5M2IwNmRiYTRfMTctMTMtMS0xLTMzOA_541bb140-5a04-4131-a227-298747bdfae5"
      unitRef="usd">207848000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i88dd112506904c6cb0c741b6ed17ccaf_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfMy0xLTEtMS0w_9974f4e7-38ff-452c-9d69-7843a3363f33"
      unitRef="usd">225117000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i8af5fb33859043a8b3f81453abfe1293_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfMy0zLTEtMS0w_f84ac32d-1182-4923-8420-8ff9342ce9cc"
      unitRef="shares">34578040</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8af5fb33859043a8b3f81453abfe1293_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfMy01LTEtMS0w_a6f9ad07-4074-4a7b-83b5-a7fe67af3095"
      unitRef="usd">35000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i86cd437dd5a04045874dddd70078b5dd_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfMy03LTEtMS0w_b16fe0fc-21f7-4649-979e-4e92b53a68b5"
      unitRef="usd">162723000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i10e399c42ec54ff9a466cf51bb20fe33_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfMy05LTEtMS0w_193f3dc8-d359-41a6-8bfb-f30c0a03c3f4"
      unitRef="usd">17788000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic0d5534ac5c5479487b6ae9068ef457e_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfMy0xMS0xLTEtMA_ca33b389-29fb-4aea-bc97-50a86da31c08"
      unitRef="usd">998000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i009fc823ec144ee3b772b4396d458c88_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfMy0xMy0xLTEtMA_35d1fe1a-3335-4f19-9dc1-9177a36de0e2"
      unitRef="usd">181544000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="iadd4f63ba5ae42d4ac92cc9136de9da2_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfNC0xLTEtMS0w_bb7168d9-b066-4e65-9e2c-abc87e66024a"
      unitRef="usd">-3000000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i22c58b4fa0a543509216aa49494d6aba_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfNC05LTEtMS0w_299e248e-156a-4a61-9aa3-a765a73bcc4a"
      unitRef="usd">140000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="if3adcf989a11491086e545b6aee38fc5_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfNC0xMS0xLTEtMA_2da3d164-fc67-455f-8b93-bd60d0d6dc58"
      unitRef="usd">410000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i5a6c0314826740a281244477bbba6dfa_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfNC0xMy0xLTEtMA_08a70558-7bc6-40d3-9345-e56a965da456"
      unitRef="usd">550000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <us-gaap:TreasuryStockValueAcquiredParValueMethod
      contextRef="iadd4f63ba5ae42d4ac92cc9136de9da2_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfNS0xLTEtMS0w_c6b29ff1-c46e-4608-8f1d-1923825213e4"
      unitRef="usd">40000</us-gaap:TreasuryStockValueAcquiredParValueMethod>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i5ee6d5d8a1594010bfbaaec890b48045_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfNS0zLTEtMS0w_53bd66ef-418d-43e4-a77b-0a083a5add62"
      unitRef="shares">93451</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredParValueMethod
      contextRef="i5a6c0314826740a281244477bbba6dfa_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfNS0xMy0xLTEtMA_b89d4715-1ea3-4619-af51-5c27c05bd496"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredParValueMethod>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="iadd4f63ba5ae42d4ac92cc9136de9da2_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfNi0xLTEtMS0w_8a626e55-2b45-4133-9632-a31bd8720749"
      unitRef="usd">155000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants
      contextRef="i5ee6d5d8a1594010bfbaaec890b48045_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfNi0zLTEtMS0w_252515f6-c4d7-467f-96bb-5ff87a440c66"
      unitRef="shares">17516</ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="i5148fbc9970c485988d70ba64178db69_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfNi03LTEtMS0w_2a06c02d-bd70-4efe-969e-28697b3f1f80"
      unitRef="usd">140000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="i5a6c0314826740a281244477bbba6dfa_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfNi0xMy0xLTEtMA_0926e5bf-6542-4f3a-9983-c4457a9b7908"
      unitRef="usd">140000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="iadd4f63ba5ae42d4ac92cc9136de9da2_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfNy0xLTEtMS0w_7fb59235-3856-4420-98b0-0bc93178e742"
      unitRef="usd">202000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i5ee6d5d8a1594010bfbaaec890b48045_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfNy0zLTEtMS0w_dd7dff1e-1c5f-4987-ba14-f8191542306d"
      unitRef="shares">1599</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i5148fbc9970c485988d70ba64178db69_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfNy03LTEtMS0w_208ffeb6-e836-4934-b71e-f48668d51dfc"
      unitRef="usd">143000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i5a6c0314826740a281244477bbba6dfa_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfNy0xMy0xLTEtMA_ee68fa7d-4078-4d78-b9cd-368ab5b392b5"
      unitRef="usd">143000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="iadd4f63ba5ae42d4ac92cc9136de9da2_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfOC0xLTEtMS0w_2dc7d4e1-7af7-4fea-88a5-18814a7665bc"
      unitRef="usd">10000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i5a6c0314826740a281244477bbba6dfa_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfOC0xMy0xLTEtMA_777b293c-aebe-4a9d-8b37-30cc401c75dc"
      unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4974f1b145d14972a8e0b668e4693f24_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfOS0xLTEtMS0w_012c15d8-0958-4f01-8fe0-ddb76a16752a"
      unitRef="usd">212434000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i78399cf970d54e8fa6805bb19581eedc_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfOS0zLTEtMS0w_d9bf2451-1ca4-4870-a65e-665d3266fe3d"
      unitRef="shares">34503704</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i78399cf970d54e8fa6805bb19581eedc_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfOS01LTEtMS0w_66577327-fe13-443c-a8de-645c6124986b"
      unitRef="usd">35000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i24b621b2e16049f5821822f6c6b515c8_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfOS03LTEtMS0w_2c851046-2ce5-43a8-9749-7ff1cdd738dc"
      unitRef="usd">163006000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i726581c835934409b022b695e21f02c5_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfOS05LTEtMS0w_3894680e-b6de-4e25-81ca-d74c173bcd59"
      unitRef="usd">17928000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i949449b3a63b462bb5ac492454d52236_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfOS0xMS0xLTEtMA_5a25fc58-3c44-43ae-ae94-5b170bfcbc4d"
      unitRef="usd">1408000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idcb813ea894446d389589a68e78f85f8_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfOS0xMy0xLTEtMA_81aefb7c-24d6-4821-bb33-6b9cf01092ba"
      unitRef="usd">182377000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i95b98be4bbee40bb905948aa3d1b28ea_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfMTAtMS0xLTEtMA_6d77beaf-1a6f-461a-9114-0179a3df08c6"
      unitRef="usd">6896000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i71a1516b4672496586bb6ad8954b6d32_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfMTAtOS0xLTEtMA_9302f270-588f-46e4-8890-c0be16e3010d"
      unitRef="usd">3545000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i6c10cea2d1d546b486e52aae1b79c77a_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfMTAtMTEtMS0xLTA_c9208382-76d9-41f3-a533-ed96cdb1bfa1"
      unitRef="usd">223000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfMTAtMTMtMS0xLTA_4b4e1288-918d-4d2a-9a3f-f74fb1af3595"
      unitRef="usd">3768000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="i95b98be4bbee40bb905948aa3d1b28ea_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfMTItMS0xLTEtMA_4cfe9ce2-78b4-4d64-ac46-7cbf9e1c39ad"
      unitRef="usd">50000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants
      contextRef="id43602e4d3ec401c85cc9e362fcdbb4b_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfMTItMy0xLTEtMA_cd221cfc-c563-4e2f-8d2d-be640dc4ae01"
      unitRef="shares">135108</ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="i87ba6bb181b44445a257ca2168e67b6f_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfMTItNy0xLTEtMA_ec2340c9-cdae-46c9-8464-70e3e67d4426"
      unitRef="usd">758000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfMTItMTMtMS0xLTA_07f9dae3-2aa2-43a9-8438-0d4a5eb96708"
      unitRef="usd">758000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i95b98be4bbee40bb905948aa3d1b28ea_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfMTMtMS0xLTEtMA_13fec2d4-f18b-4532-a503-e53c57e55be9"
      unitRef="usd">203000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i87ba6bb181b44445a257ca2168e67b6f_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfMTMtNy0xLTEtMA_e680ee91-f874-47e0-bee4-eba88d21e15c"
      unitRef="usd">128000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfMTMtMTMtMS0xLTA_ab971074-6bd5-4dc9-b80e-c0b14a51d4ba"
      unitRef="usd">128000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i6c10cea2d1d546b486e52aae1b79c77a_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfMTQtMTEtMS0xLTA_3b97b59a-f627-45cb-aee6-4c9c4db24ef0"
      unitRef="usd">942000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfMTQtMTMtMS0xLTA_44f632f0-c42c-47a7-8ec4-8b6411b691ea"
      unitRef="usd">942000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3af73b22faf94113b2f3aeaf70427a31_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfMTUtMS0xLTEtMA_21a40ce7-4cec-47ca-9cf0-03c2b2f526f7"
      unitRef="usd">219583000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i4bcbf8bc939c4eb8b67d8f9031b07763_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfMTUtMy0xLTEtMA_d875cdd4-f295-4fcd-adc6-1b2e61ac54df"
      unitRef="shares">34638812</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4bcbf8bc939c4eb8b67d8f9031b07763_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfMTUtNS0xLTEtMA_7fd105c3-5d56-49fb-a6f5-f029eab2e905"
      unitRef="usd">35000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i27980f94484946c1a35649f7381b97d6_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfMTUtNy0xLTEtMA_76c034d7-6074-442f-aa05-bb276bfd990f"
      unitRef="usd">163892000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic610016f8d084d548913bcfa0f781a33_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfMTUtOS0xLTEtMA_3f6ba190-ddde-4e87-9dac-7c3508e85fb0"
      unitRef="usd">21473000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaf1828c07785428dbc2e0059af0c356e_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfMTUtMTEtMS0xLTA_c895aea0-52a7-4d77-84d9-c2e214b0db34"
      unitRef="usd">689000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2db2c0d074c34657a5d523b0ae1e5784_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zMS9mcmFnOmZkMWIyY2IxNDFlMTQzNWE5MjA3NGVjYTdmZmRkYjYzL3RhYmxlOjE1ZWFkZDM4ZWJiYzRlY2RhODlmMTk4M2EzYjk4OGRkL3RhYmxlcmFuZ2U6MTVlYWRkMzhlYmJjNGVjZGE4OWYxOTgzYTNiOTg4ZGRfMTUtMTMtMS0xLTA_27e74325-b64a-4f61-b6c3-fa04d14b6315"
      unitRef="usd">186089000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMy0xLTEtMS0w_0faf176b-4372-4656-86cc-180d0d862bc0"
      unitRef="usd">83988000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMy0zLTEtMS0w_513b24b5-6988-429d-a7bc-ae5dfcedad31"
      unitRef="usd">8214000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNS0xLTEtMS0w_d4c3e027-8641-4a65-a218-7c769d86152b"
      unitRef="usd">9330000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNS0zLTEtMS0w_b1d6de7f-75fc-490b-b2cd-f8e70007b9e8"
      unitRef="usd">8872000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNi0xLTEtMS02MjQx_e3cda71e-d4e1-45cb-bcfd-8ee4afe50133"
      unitRef="usd">658000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNi0zLTEtMS02MjQx_36feeccb-acf9-4932-a67b-9f8e0170d46d"
      unitRef="usd">0</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNi0xLTEtMS0w_086382ba-69b5-42dc-952e-9fb2f2b731a3"
      unitRef="usd">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNi0zLTEtMS0w_bbc84301-ad97-488d-bc88-233cb0a2132c"
      unitRef="usd">-1363000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ShareBasedCompensation
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNy0xLTEtMS0w_c9addc21-763d-4f3d-a150-7b3333eb5d80"
      unitRef="usd">1910000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNy0zLTEtMS0w_0c50ec21-01a7-4312-b266-73fd18b9bdd4"
      unitRef="usd">676000</us-gaap:ShareBasedCompensation>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfOC0xLTEtMS0w_a817ffc0-2bbd-4687-8b1f-f87953b4bd02"
      unitRef="usd">-25000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfOC0zLTEtMS0w_78b9b440-5614-44f3-9c87-4943605db9e8"
      unitRef="usd">15000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfOS0xLTEtMS0w_0416d9a7-ed56-40b4-a10c-dba943ba4a3b"
      unitRef="usd">2888000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfOS0zLTEtMS0w_419b164d-6ff0-49d0-b03c-a0c81b18e9e1"
      unitRef="usd">-892000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMTAtMS0xLTEtNTE2Ng_4c6cb799-4a6c-4402-aeaf-dac73885f27a"
      unitRef="usd">99647000</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMTAtMy0xLTEtNTE2Ng_884b953e-25ef-4831-aa0a-7b442ce91f90"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMTAtMS0xLTEtMA_6e0bc33b-824d-4031-8a20-0cd2d0fe1a09"
      unitRef="usd">-4473000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMTAtMy0xLTEtMA_ddbc9e91-a5d3-43ff-83c5-3cce82dd5242"
      unitRef="usd">-549000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMTItMS0xLTEtMA_7521bdb4-f497-4f7f-b1c4-1156811a6bbd"
      unitRef="usd">6284000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMTItMy0xLTEtMA_e4a682c3-75ee-46bd-90b2-de1e7475193d"
      unitRef="usd">-588000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMTMtMS0xLTEtMA_432361dc-5ccc-4502-aed0-b86c803b0ee5"
      unitRef="usd">11191000</us-gaap:IncreaseDecreaseInDueFromRelatedParties>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMTMtMy0xLTEtMA_6ff37162-1082-48b3-ba32-bf7bcb040358"
      unitRef="usd">12665000</us-gaap:IncreaseDecreaseInDueFromRelatedParties>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMTQtMS0xLTEtMA_4bc08974-f374-41e2-b229-a11a2fa88d26"
      unitRef="usd">-966000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMTQtMy0xLTEtMA_726bd3d8-a14f-4779-971e-dac29b47685f"
      unitRef="usd">11897000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <ameh:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMTUtMS0xLTEtMA_d91c10f0-8e77-4edb-895c-098d2347a362"
      unitRef="usd">873000</ameh:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets>
    <ameh:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMTUtMy0xLTEtMA_d6d3e0b2-5a94-435e-a5ef-ee39b31f04be"
      unitRef="usd">2740000</ameh:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets>
    <ameh:IncreaseDecreaseInOperatingLeaseAssets
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMTYtMS0xLTEtMA_8e69f5a0-533a-4411-94c3-5e65d3e90eef"
      unitRef="usd">1680000</ameh:IncreaseDecreaseInOperatingLeaseAssets>
    <ameh:IncreaseDecreaseInOperatingLeaseAssets
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMTYtMy0xLTEtMA_251b9c7a-c22a-46bd-84a7-c041663b34cb"
      unitRef="usd">1098000</ameh:IncreaseDecreaseInOperatingLeaseAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMTctMS0xLTEtMA_47d880d4-b165-43cd-95c1-887f4130bb0d"
      unitRef="usd">5095000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMTctMy0xLTEtMA_99a8cbf7-a946-401c-9109-b62a24d29ba6"
      unitRef="usd">243000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMTgtMS0xLTEtMA_65f60531-135d-41fb-9065-cd0a82275a68"
      unitRef="usd">-3043000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMTgtMy0xLTEtMA_50beef5c-e3d3-4b44-ad7f-81db0a3c86a7"
      unitRef="usd">3340000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMTktMS0xLTEtMA_e2ff4cf2-555d-47f0-859e-522eda1e2d02"
      unitRef="usd">-174000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMTktMy0xLTEtMA_dd4485f9-b510-4d17-bd88-b1a12af5a8ad"
      unitRef="usd">260000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <ameh:IncreaseDecreaseInMedicalLiabilities
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMjAtMS0xLTEtMA_9fd8907f-de5f-4704-9f01-9de1fba2aaf5"
      unitRef="usd">11252000</ameh:IncreaseDecreaseInMedicalLiabilities>
    <ameh:IncreaseDecreaseInMedicalLiabilities
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMjAtMy0xLTEtMA_5249e5b6-bd18-41ad-b18f-53b73cbcb49a"
      unitRef="usd">-3819000</ameh:IncreaseDecreaseInMedicalLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMjEtMS0xLTEtMA_a77710d5-8b61-4886-a77e-ad6e2bd721d1"
      unitRef="usd">37681000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMjEtMy0xLTEtMA_c5ec535e-18db-492c-830c-44ebc2ee97b8"
      unitRef="usd">-11622000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <ameh:IncreaseDecreaseInOtherOperatingLeaseLiabilities
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMjItMS0xLTEtMA_93812867-0f75-4fb8-9707-641bb308723a"
      unitRef="usd">-1247000</ameh:IncreaseDecreaseInOtherOperatingLeaseLiabilities>
    <ameh:IncreaseDecreaseInOtherOperatingLeaseLiabilities
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMjItMy0xLTEtMA_573d89b4-53e5-40cd-9bd6-118489d95f34"
      unitRef="usd">-1044000</ameh:IncreaseDecreaseInOtherOperatingLeaseLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMjMtMS0xLTEtMA_f475d976-866f-4711-80de-b979d8d438eb"
      unitRef="usd">12575000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMjMtMy0xLTEtMA_5f80029c-cdaa-4279-a299-db8d92ba6916"
      unitRef="usd">-22017000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMjYtMS0xLTEtMA_302b1c2d-fb17-4a49-9f16-59694c95ac3e"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMjYtMy0xLTEtMA_391f116d-87af-40a8-803b-6e35651a480e"
      unitRef="usd">41518000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:ProceedsFromCollectionOfLoansReceivable
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMjctMS0xLTEtMzY5Mg_08733376-4874-43d9-ad28-91f6ab2a4716"
      unitRef="usd">16500000</us-gaap:ProceedsFromCollectionOfLoansReceivable>
    <us-gaap:ProceedsFromCollectionOfLoansReceivable
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMjctMy0xLTEtMzY5Mg_c1d7d5a7-90b0-47ce-a025-878078e0d87e"
      unitRef="usd">0</us-gaap:ProceedsFromCollectionOfLoansReceivable>
    <us-gaap:PaymentsToFundLongtermLoansToRelatedParties
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMjctMS0xLTEtMA_408a5f75-9e1e-4b81-a823-e852037fa154"
      unitRef="usd">0</us-gaap:PaymentsToFundLongtermLoansToRelatedParties>
    <us-gaap:PaymentsToFundLongtermLoansToRelatedParties
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMjctMy0xLTEtMA_64932490-2a06-4a0c-b176-f64189dedb53"
      unitRef="usd">6425000</us-gaap:PaymentsToFundLongtermLoansToRelatedParties>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMjgtMS0xLTEtMA_9153f74a-4539-436e-a51d-6588a85b454f"
      unitRef="usd">1142000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMjgtMy0xLTEtMA_3f27b198-2edb-4973-8b64-99af212098a9"
      unitRef="usd">8000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMjktMS0xLTEtMA_79f37ad1-8f19-4619-893a-68ef41c695d5"
      unitRef="usd">500000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMjktMy0xLTEtMA_b75afe45-8a68-4f8c-ad86-44e7fc5c6c7c"
      unitRef="usd">2158000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMzAtMS0xLTEtMjg5OA_df64875b-01a8-4a9a-be6b-82cd710c03fa"
      unitRef="usd">52743000</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMzAtMy0xLTEtMjg5OA_a1913515-8846-4d0e-bc7b-736d516a1348"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMzAtMS0xLTEtMA_28f60ca0-7d33-4a53-9f33-e736963d832c"
      unitRef="usd">451000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMzAtMy0xLTEtMA_04472926-13b0-4db8-bdb3-a6fadb5f64ca"
      unitRef="usd">378000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMzEtMS0xLTEtMA_7a7ef576-40fe-433d-849d-a6d2a6c7bba0"
      unitRef="usd">0</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMzEtMy0xLTEtMA_677b59b8-9def-4812-9ebf-111209ba11bc"
      unitRef="usd">240000</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMzItMS0xLTEtMA_0cbb7989-d009-4077-a8b7-e6c811dd5678"
      unitRef="usd">67150000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMzItMy0xLTEtMA_cfbf7577-63d6-4c55-a616-cb46f58528d6"
      unitRef="usd">-50247000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <ameh:RepaymentsOfBankLoanAndLinesOfCredit
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMzUtMS0xLTEtMA_fb2082a5-40e1-4057-a377-cbe90a2f89f7"
      unitRef="usd">0</ameh:RepaymentsOfBankLoanAndLinesOfCredit>
    <ameh:RepaymentsOfBankLoanAndLinesOfCredit
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMzUtMy0xLTEtMA_bda122ff-f23d-4d07-8b1e-e59ee410cb70"
      unitRef="usd">8040000</ameh:RepaymentsOfBankLoanAndLinesOfCredit>
    <us-gaap:PaymentsOfDividends
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMzYtMS0xLTEtMA_4d5d9647-b22e-4f9c-aa57-630bc424d9c7"
      unitRef="usd">30187000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMzYtMy0xLTEtMA_960a0477-ceb9-4e66-9c03-c5a1a445013a"
      unitRef="usd">10942000</us-gaap:PaymentsOfDividends>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMzctMS0xLTEtMA_732c2b2f-aad6-49c0-b6d7-966f4e1ee472"
      unitRef="usd">2375000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMzctMy0xLTEtMA_03851c64-33da-41a8-bf92-f3b1d41d1be3"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMzgtMS0xLTEtMA_0df2336f-08f9-4d6a-884d-e9dc9ca167c3"
      unitRef="usd">61000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMzgtMy0xLTEtMA_bdbdf4a1-9260-4753-8a6c-4d4da83f9904"
      unitRef="usd">50000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMzktMS0xLTEtMA_30ca354c-02a0-4b2d-9d39-84f7270fdb8b"
      unitRef="usd">2863000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfMzktMy0xLTEtMA_3c1d6da1-da3c-4039-a159-08c89e679d4d"
      unitRef="usd">898000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNDAtMS0xLTEtMA_70165d20-4d4e-4be0-8693-ccd9d868d87a"
      unitRef="usd">788000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNDAtMy0xLTEtMA_9beac94f-5d15-4b75-926f-fca857cadf13"
      unitRef="usd">40000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNDEtMS0xLTEtMA_cc871881-ef41-45f8-8b60-fd723f15a195"
      unitRef="usd">0</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNDEtMy0xLTEtMA_57a1940c-c55d-437f-a3c6-db0a7faf7452"
      unitRef="usd">39600000</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNDItMS0xLTEtMA_0df53bff-4900-42c3-999b-3ca5f2323d67"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNDItMy0xLTEtMA_ea2ff132-b8c5-4d05-ab15-fffb78939b92"
      unitRef="usd">205000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNDMtMS0xLTEtMA_ca2e015e-b9d9-4357-ace2-ef0f7006f6bb"
      unitRef="usd">-30548000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNDMtMy0xLTEtMA_fffba940-84a3-480a-893c-f28717595303"
      unitRef="usd">21631000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNDUtMS0xLTEtMA_7a708173-c0d4-4ea7-8331-f5e65aabe654"
      unitRef="usd">49177000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNDUtMy0xLTEtMA_92d45720-dd16-4e3e-bb30-efcbbdfe5f46"
      unitRef="usd">-50633000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNDctMS0xLTEtMA_b288ac55-b568-41d0-9002-d5de63658f5a"
      unitRef="usd">104010000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i009fc823ec144ee3b772b4396d458c88_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNDctMy0xLTEtMA_c7bacdac-9adb-4273-8988-b070fd28f05e"
      unitRef="usd">107637000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNDktMS0xLTEtMA_b8d1a9b7-4ae6-46a5-b140-84a3bfaadbed"
      unitRef="usd">153187000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2db2c0d074c34657a5d523b0ae1e5784_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNDktMy0xLTEtMA_bf53373d-faa7-400b-b040-24c3ccb044e9"
      unitRef="usd">57004000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaid
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNTItMS0xLTEtMA_d7986e27-266d-4526-9ccf-d5b0a3ed7c7e"
      unitRef="usd">0</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNTItMy0xLTEtMA_6d243534-52dc-421f-bd00-889220784990"
      unitRef="usd">16700000</us-gaap:IncomeTaxesPaid>
    <us-gaap:InterestPaidNet
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNTMtMS0xLTEtMA_be70c43e-9779-490c-b9bb-39ccaac57553"
      unitRef="usd">2623000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNTMtMy0xLTEtMA_824990a4-b742-49e4-ab81-fdadd428a8d6"
      unitRef="usd">439000</us-gaap:InterestPaidNet>
    <us-gaap:DividendsPayableCurrentAndNoncurrent
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNTYtMS0xLTEtMA_704549d5-1521-4cca-a0c8-387f96dea5fd"
      unitRef="usd">160000</us-gaap:DividendsPayableCurrentAndNoncurrent>
    <us-gaap:DividendsPayableCurrentAndNoncurrent
      contextRef="i2db2c0d074c34657a5d523b0ae1e5784_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNTYtMy0xLTEtMA_82486f9d-6650-4841-9748-a36c1bab2061"
      unitRef="usd">0</us-gaap:DividendsPayableCurrentAndNoncurrent>
    <ameh:DeferredTaxLiabilityAdjustedToGoodwill
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNTctMS0xLTEtODQx_8f3db34e-3cf4-45d1-8910-8fccd848c10f"
      unitRef="usd">0</ameh:DeferredTaxLiabilityAdjustedToGoodwill>
    <ameh:DeferredTaxLiabilityAdjustedToGoodwill
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNTctMy0xLTEtMTMzMQ_8a7e3372-2281-44d1-952c-b6c1a6e84fd1"
      unitRef="usd">8355000</ameh:DeferredTaxLiabilityAdjustedToGoodwill>
    <us-gaap:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNjAtMS0xLTEtMzY4Mg_75a6b307-8791-4a16-ba30-6f5717d73132"
      unitRef="usd">36179000</us-gaap:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1>
    <us-gaap:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjUzMmNhZjk5MjE4NzQyMTJhNTM0ZGUxYzFlNTkxZDIwL3RhYmxlcmFuZ2U6NTMyY2FmOTkyMTg3NDIxMmE1MzRkZTFjMWU1OTFkMjBfNjAtMy0xLTEtMzY4Mg_a13ce764-6e94-484b-8614-61b72212f1dd"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjdhYTNmMDFlNGIyZTRiYjJiNjlkZTBlNGFkY2I1NTdkL3RhYmxlcmFuZ2U6N2FhM2YwMWU0YjJlNGJiMmI2OWRlMGU0YWRjYjU1N2RfMi0xLTEtMS0w_946e0bff-00f6-4388-ab15-cb9c9071ea77"
      unitRef="usd">152441000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2db2c0d074c34657a5d523b0ae1e5784_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjdhYTNmMDFlNGIyZTRiYjJiNjlkZTBlNGFkY2I1NTdkL3RhYmxlcmFuZ2U6N2FhM2YwMWU0YjJlNGJiMmI2OWRlMGU0YWRjYjU1N2RfMi0zLTEtMS0w_8ca55293-e343-4d7e-b94f-585c624d1f55"
      unitRef="usd">52726000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashEquivalentsNoncurrent
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjdhYTNmMDFlNGIyZTRiYjJiNjlkZTBlNGFkY2I1NTdkL3RhYmxlcmFuZ2U6N2FhM2YwMWU0YjJlNGJiMmI2OWRlMGU0YWRjYjU1N2RfNC0xLTEtMS0w_0419b237-aa7b-4b9d-aba5-b0c7440ac06e"
      unitRef="usd">746000</us-gaap:RestrictedCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashEquivalentsNoncurrent
      contextRef="i2db2c0d074c34657a5d523b0ae1e5784_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjdhYTNmMDFlNGIyZTRiYjJiNjlkZTBlNGFkY2I1NTdkL3RhYmxlcmFuZ2U6N2FhM2YwMWU0YjJlNGJiMmI2OWRlMGU0YWRjYjU1N2RfNC0zLTEtMS0w_fd71779e-14fe-4e08-884a-f533dfd51d83"
      unitRef="usd">4278000</us-gaap:RestrictedCashEquivalentsNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjdhYTNmMDFlNGIyZTRiYjJiNjlkZTBlNGFkY2I1NTdkL3RhYmxlcmFuZ2U6N2FhM2YwMWU0YjJlNGJiMmI2OWRlMGU0YWRjYjU1N2RfNS0xLTEtMS0w_8d505800-7500-4c20-8135-5af5f7baf94c"
      unitRef="usd">153187000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2db2c0d074c34657a5d523b0ae1e5784_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8zNC9mcmFnOmJkN2Q1YzcxNDgyNzQ2ZWU5OTRmMzhlZWYxMTE1MzBlL3RhYmxlOjdhYTNmMDFlNGIyZTRiYjJiNjlkZTBlNGFkY2I1NTdkL3RhYmxlcmFuZ2U6N2FhM2YwMWU0YjJlNGJiMmI2OWRlMGU0YWRjYjU1N2RfNS0zLTEtMS0w_4f3024d7-6633-466f-8c8c-d9d3fc39f451"
      unitRef="usd">57004000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NatureOfOperations
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfMTMzMTY_68cf7095-41ff-411a-881f-d3a84253e54b">Description of Business&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Overview&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Apollo Medical Holdings, Inc. (&#x201c;ApolloMed&#x201d;), together with its affiliated physician groups and consolidated entities (collectively, the &#x201c;Company&#x201d;) is a physician-centric integrated population health management company working to provide coordinated, outcome-based medical care in a cost-effective manner to patients in California, the majority of whom are covered by private or public insurance such as Medicare, Medicaid and health maintenance organization (&#x201c;HMO&#x201d;) plans, with a portion of the Company&#x2019;s revenue coming from non-insured patients. The Company provides care coordination services to each major constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups and health plans. The Company&#x2019;s physician network consists of primary care physicians, specialist physicians, and hospitalists. The Company operates primarily through the following subsidiaries of ApolloMed: Network Medical Management, Inc. (&#x201c;NMM&#x201d;), Apollo Medical Management, Inc. (&#x201c;AMM&#x201d;), APA ACO, Inc. ("APAACO"), Apollo Care Connect, Inc. (&#x201c;Apollo Care Connect&#x201d;), and their consolidated entities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;NMM was formed in 1994 as a management service organization (&#x201c;MSO&#x201d;) for the purposes of providing management services to medical companies and independent practice associations (&#x201c;IPAs&#x201d;). The management services primarily include billing, collection, accounting, administration, quality assurance, marketing, compliance, and education. Following a business combination, NMM became a wholly-owned subsidiary of ApolloMed in December 2017. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Allied Physicians of California IPA, a Professional Medical Corporation d.b.a. Allied Pacific of California IPA (&#x201c;APC&#x201d;) was incorporated in 1992, for the purpose of arranging healthcare services as an IPA. APC has contracts with various HMOs and other licensed healthcare service plans as defined in the California Knox-Keene Health Care Service Plan Act of 1975. Each HMO negotiates a fixed amount per member per month (&#x201c;PMPM&#x201d;) that is to be paid to APC. In return, APC arranges for the delivery of healthcare services by contracting with physicians or professional medical corporations for primary care and specialty care services. APC assumes the financial risk of the cost of delivering healthcare services in excess of the fixed amounts received. Some of the risk is transferred to the contracted physicians or professional corporations. The risk is also minimized by stop-loss provisions in contracts with HMOs.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In July 1999, APC entered into an amended and restated management and administrative services agreement with NMM (the initial management services agreement was entered into in 1997) for an initial fixed term of 30 years. In accordance with relevant accounting guidance, APC is determined to be a variable interest entity ("VIE") of the Company as NMM is the primary beneficiary with the ability to direct the activities (excluding clinical decisions) that most significantly affect APC&#x2019;s economic performance through its majority representation on the APC Joint Planning Board; therefore APC is consolidated by NMM.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;AP-AMH Medical Corporation (&#x201c;AP-AMH&#x201d;) was formed in May 2019, as a designated shareholder professional corporation. Dr. Thomas Lam, a shareholder, and the Chief Executive Officer and Chief Financial Officer of APC and Co-Chief Executive Officer of ApolloMed, is the sole shareholder of AP-AMH. ApolloMed makes all the decisions on behalf of AP-AMH and funds and receives all the distributions from its operations. ApolloMed has the rights to receive benefits from the operations of AP-AMH and has the option, but not the obligation, to cover losses. Therefore, AP-AMH is controlled and consolidated by ApolloMed as the primary beneficiary of this VIE.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In September 2019, ApolloMed completed the following series of transactions with its affiliates, AP-AMH and APC;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;1.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;"&gt;ApolloMed loaned AP-AMH $545.0 million pursuant to a 10-year secured loan agreement (the &#x201c;AP-AMH Loan&#x201d;). The loan bears interest at a rate of 10% per annum simple interest, is not prepayable (except in certain limited circumstances), requires quarterly payments of interest only in arrears, and is secured by a first priority security interest in all of AP-AMH&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;&#x2019;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;s assets, including the shares of APC Series A Preferred Stock purchased by AP-AMH, as described below. To the extent that AP-AMH is unable to make any interest payment when due because it has received dividends on the APC Series A Preferred Stock insufficient to pay in full such interest payment, then the outstanding principal amount of the loan will be increased by the amount of any such accrued but unpaid interest, and any such increased principal amounts will bear interest at the rate of 10.75% per annum simple interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;2.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;"&gt;AP-AMH purchased 1,000,000 shares of APC Series A Preferred Stock for aggregate consideration of $545.0 million in a private placement. Under the terms of the APC Certificate of Determination of Preferences of Series A Preferred &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Stock (the &#x201c;Certificate of Determination&#x201d;), AP-AMH is entitled to receive preferential, cumulative dividends that accrue on a daily basis and that are equal to the sum of (i) APC&#x2019;s net income from healthcare services (as defined in the Certificate of Determination), plus (ii) any dividends received by APC from certain of APC&#x2019;s affiliated entities, less (iii) any Retained Amounts (as defined in the Certificate of Determination).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;3.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;"&gt;APC purchased 15,015,015 shares of ApolloMed&#x2019;s common stock for total consideration of $300.0 million in private placement. In connection therewith, ApolloMed granted APC certain registration rights with respect to ApolloMed&#x2019;s common stock that APC purchased, and APC agreed that APC votes in excess of 9.99% of ApolloMed&#x2019;s then outstanding shares will be voted by proxy given to ApolloMed&#x2019;s management, and that those proxy holders will cast the excess votes in the same proportion as all other votes cast on any specific proposal coming before ApolloMed&#x2019;s stockholders.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;4.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;"&gt;ApolloMed licensed to AP-AMH the right to use certain trade names for certain specified purposes for a fee equal to a percentage of the aggregate gross revenues of AP-AMH. The license fee is payable out of any Series A Preferred Stock dividends received by AP-AMH from APC.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;5.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;"&gt;Through its subsidiary, NMM, the Company agreed to provide certain administrative services to AP-AMH for a fee equal to a percentage of the aggregate gross revenues of AP-AMH. The administrative fee also is payable out of any APC Series A Preferred Stock dividends received by AP-AMH from APC.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;APC's ownership in ApolloMed was 32.28% at June&#160;30, 2020 and 32.50% at December&#160;31, 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Concourse Diagnostic Surgery Center, LLC (&#x201c;CDSC&#x201d;) was formed in March&#160;2010 in the state of California. CDSC is an ambulatory surgery center in City of Industry, California organized by a group of highly qualified physicians, which utilizes some of the most advanced equipment in the eastern part of Los Angeles County and the San Gabriel Valley. The facility is Medicare certified and accredited by the Accreditation Association for Ambulatory Healthcare, Inc. As of June&#160;30, 2020, APC owned 45.01% of CDSC&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;&#x2019;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;s capital stock. CDSC is determined to be a VIE and APC is determined to be the primary beneficiary. APC has the ability to direct the activities that most significantly affect CDSC&#x2019;s economic performance and receives the most economic benefits; therefore CDSC is consolidated by APC.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;APC-LSMA Designated Shareholder Medical Corporation (&#x201c;APC-LSMA&#x201d;) was formed in October&#160;2012 as a designated shareholder professional corporation. Dr. Thomas Lam, a stockholder and the Chief Executive Officer and Chief Financial Officer of APC and Co-Chief Executive Officer of ApolloMed, is a nominee shareholder of APC. APC makes all investment decisions on behalf of APC-LSMA, funds all investments and receives all distributions from the investments. APC has the obligation to absorb losses and right to receive benefits from all investments made by APC-LSMA. APC-LSMA&#x2019;s sole function is to act as the nominee shareholder for APC in other California medical professional corporations. Therefore, APC-LSMA is controlled and consolidated by APC as the primary beneficiary of this VIE. The only activity of APC-LSMA is to hold the investments in medical corporations, including the IPA lines of business of LaSalle Medical Associates (&#x201c;LMA&#x201d;), Pacific Medical Imaging and Oncology Center, Inc. (&#x201c;PMIOC&#x201d;), Diagnostic Medical Group (&#x201c;DMG&#x201d;) and AHMC International Cancer Center, a Medical Corporation (&#x201c;ICC&#x201d;). APC-LSMA also holds a 100% ownership interest in Maverick Medical Group, Inc. (&#x201c;MMG&#x201d;), Alpha Care Medical Group, Inc. (&#x201c;Alpha Care&#x201d;), Accountable Health Care IPA, a Professional Medical Corporation (&#x201c;Accountable Health Care&#x201d;), and AMG, a Professional Medical Corporation (&#x201c;AMG&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Alpha Care, an IPA acquired by the Company in May 2019, has been operating in California since 1993 as a risk bearing organization engaged in providing professional services under capitation arrangements with its contracted health plans through a provider network consisting of primary care and specialty care physicians. Alpha Care specializes in delivering high-quality healthcare to approximately 170,000 enrollees, as of June&#160;30, 2020, and focuses on Medi-Cal/Medicaid, Commercial, and Medicare and Dual Eligible members in the Riverside and San Bernardino counties of Southern California.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Accountable Health Care is a California-based IPA that has served the local community in the greater Los Angeles County area through a network of physicians and health care providers for more than 20 years. Accountable Health Care currently has a network of over 400 primary care physicians and 700 specialty care physicians, and four community and regional hospital medical centers that provide quality health care services to approximately 80,000 members of three federally qualified health plans and multiple product lines, including Medi-Cal, Commercial, Medicare and the California Healthy Families program. In August 2019, APC and APC-LSMA acquired the remaining outstanding shares of Accountable Health Care&#x2019;s capital stock that they did not already own (comprising 75%) for&#160;$7.3 million&#160;in cash (see Note 3).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;AMG is a network of family practice clinics operating out of three main locations in Southern California. AMG provides professional and post-acute care services to Medicare, Medi-Cal/Medicaid, and Commercial patients through its network of &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;doctors and nurse practitioners. In September 2019, APC-LSMA purchased 100% of the shares of capital stock of AMG for $1.2 million in cash and $0.4 million of APC common stock (see Note 3).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Universal Care Acquisition Partners, LLC (&#x201c;UCAP&#x201d;), a 100% owned subsidiary of APC, was formed in June&#160;2014, for the purpose of holding an investment in Universal Care, Inc. (&#x201c;UCI&#x201d;). On April 30, 2020, UCAP completed the sale of its 48.9% ownership interest in UCI to Bright Health Company of California, Inc. ("Bright") for approximately $69.2 million in cash proceeds (including $16.5 million as repayment of indebtedness owed to APC), plus non-cash consideration consisting of shares of Bright Health, Inc.'s preferred stock having an estimated fair value of approximately $36.2 million on the date of sale. In addition, pursuant to the terms of the stock purchase agreement, APC has a beneficial interest in the equity method investment sold. The estimated fair value of such interest on April 30, 2020 was&#160;$15.7 million (see Note 5). As set forth in the Company&#x2019;s definitive proxy statement filed with the SEC on July 31, 2019 (the &#x201c;Proxy Statement&#x201d;), the 48.9% interest in UCI is an &#x201c;Excluded Asset&#x201d; that remains solely for the benefit of APC and its shareholders. As such, any proceeds or gain on the sale of APC&#x2019;s indirect ownership interest in UCI has no impact on the Series A Dividend payable by APC to AP-AMH Medical Corporation as described in the Proxy Statement and consequently the sale did not affect net income attributable to ApolloMed.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;APAACO, jointly owned by NMM and AMM, began participating in the Next Generation Accountable Care Organization (&#x201c;NGACO") Model of the Centers for Medicare &amp;amp; Medicaid Services (&#x201c;CMS&#x201d;) in January 2017. The NGACO Model is a CMS program that allows provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participating in this new attribution-based risk sharing model. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;AMM, a wholly-owned subsidiary of ApolloMed, manages affiliated medical groups, ApolloMed Hospitalists, a Medical Corporation (&#x201c;AMH&#x201d;) and Southern California Heart Centers, a Medical Corporation (&#x201c;SCHC&#x201d;). AMH provides hospitalist, intensivist, and physician advisory services. SCHC is a specialty clinic that focuses on cardiac care and diagnostic testing. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Apollo Care Connect, Inc. ("Apollo Care Connect"), a wholly-owned subsidiary of ApolloMed, provides a cloud and mobile-based population health management platform that includes digital care plans, a case management module, connectivity with multiple healthcare tracking devices and the ability to integrate with multiple electronic health records to capture clinical data.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <ameh:InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement
      contextRef="i4d3c15f58ae34e5680acaea7c6ae5cd1_D19990701-19990701"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfMjc5Mg_01364458-1894-44e2-9d23-a7b0d54f5c5b">P30Y</ameh:InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement>
    <us-gaap:NotesReceivableNet
      contextRef="ie580169aa3e849ceb22d709b7d624f59_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfMzk0Mg_f560a751-e343-4452-8b8f-2e36a3494931"
      unitRef="usd">545000000.0</us-gaap:NotesReceivableNet>
    <ameh:FinanceReceivableTermOfReceivable
      contextRef="i1456ec083d5c410eb2ebf5f48f52fd2d_D20190901-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfMzk1OQ_5edec8c0-6f12-4205-87d3-a9b821ed403a">P10Y</ameh:FinanceReceivableTermOfReceivable>
    <ameh:FinanceReceivableStatedInterestRate
      contextRef="ie580169aa3e849ceb22d709b7d624f59_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfNDA0OA_645d48e5-80ed-404f-80ee-18d8326194f4"
      unitRef="number">0.10</ameh:FinanceReceivableStatedInterestRate>
    <ameh:FinanceReceivableModificationsSubsequentDefaultInterestRate
      contextRef="ie580169aa3e849ceb22d709b7d624f59_I20190930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfNDc0OQ_b7bc8f94-b0e9-43a7-946c-b18600cae312"
      unitRef="number">0.1075</ameh:FinanceReceivableModificationsSubsequentDefaultInterestRate>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ia151a285a5884ae0892fe7f6a0836f46_D20190901-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfNDc5Ng_f9a1fca9-1511-47a9-bd31-3995ce22333d"
      unitRef="shares">1000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:NotesReceivableNet
      contextRef="ie580169aa3e849ceb22d709b7d624f59_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfNDg2OQ_a05e5a92-f1ce-491f-b014-3fe08c9529f9"
      unitRef="usd">545000000.0</us-gaap:NotesReceivableNet>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i15770f5ee2dc453aafa11b7b82d77e5d_D20190901-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfNTQzNQ_424fc16f-dfe0-416f-bd58-f5bd42a6d59b"
      unitRef="shares">15015015</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i15770f5ee2dc453aafa11b7b82d77e5d_D20190901-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfNTUwMA_05c88208-354c-4999-9d61-357975ed4e11"
      unitRef="usd">300000000.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <ameh:StockIssuedDuringPeriodProxyVotesPercentage
      contextRef="i15770f5ee2dc453aafa11b7b82d77e5d_D20190901-20190930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfNTcwNA_cf67d3ea-fdee-489f-a12e-05bef55d922f"
      unitRef="number">0.0999</ameh:StockIssuedDuringPeriodProxyVotesPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i5a7880e80374477ab2037c274813c2fd_I20200630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfNjU3OA_7da44c33-8af2-479f-a2a7-78247f8249af"
      unitRef="number">0.3228</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i8449be3fd6d243ea8e51a64ca55d07be_I20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfNjU5MQ_2345d1a0-d9ba-428b-a6d2-cb89924493ba"
      unitRef="number">0.3250</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i02112e8965954796a8e1a049bed45005_I20200630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfNzEwOA_9cf95944-6f13-489e-be63-69147cdbd0a4"
      unitRef="number">0.4501</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i09e180bcec104dbe8bbc280162a1b502_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfODUzMw_07a54916-f608-4c61-87b2-e311ac5165ad"
      unitRef="number">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <ameh:NumberOfEnrollees
      contextRef="i1291ccf07b4747d5a674402448bcc8b7_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfOTE4MA_edcd2b4e-880b-4079-b211-55884b453e2e"
      unitRef="enrollee">170000</ameh:NumberOfEnrollees>
    <ameh:NumberOfEmployees
      contextRef="if0f1246eac284240868626e2943e4052_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfOTYyMA_471bbc90-4af5-4265-bb2b-894803beeb02"
      unitRef="primary_care_physician">400</ameh:NumberOfEmployees>
    <ameh:NumberOfEmployees
      contextRef="if0f1246eac284240868626e2943e4052_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfOTY1MQ_73c03f5f-3e9a-48c3-8cfd-610b135a9db7"
      unitRef="specialty_care_physician">700</ameh:NumberOfEmployees>
    <us-gaap:NumberOfStores
      contextRef="if0f1246eac284240868626e2943e4052_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfOTY4NQ_5c7f75da-93b0-46df-8476-ae4cc0cad1db"
      unitRef="medical_center">4</us-gaap:NumberOfStores>
    <ameh:NumberOfMembersOfFederallyQualifiedHealthPlans
      contextRef="if0f1246eac284240868626e2943e4052_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfOTc5MQ_eda093cc-32bd-4c09-b879-1e9a1e21fccf"
      unitRef="member">80000</ameh:NumberOfMembersOfFederallyQualifiedHealthPlans>
    <ameh:NumberOfFederallyQualifiedHealthPlans
      contextRef="if0f1246eac284240868626e2943e4052_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfOTgwNQ_d7e16a6d-1f1b-4b3c-8b96-022afeb2b22e"
      unitRef="plan">3</ameh:NumberOfFederallyQualifiedHealthPlans>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="ib00db7be80b34cfaa597d79cb3128aff_I20190830"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfMTAxMTY_7778e2f8-5bb6-43dc-bccf-c28f609caf45"
      unitRef="number">0.75</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i26cbf8fca0d84265be9879b3b17db702_D20190830-20190830"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfMTAxMjQ_5fce0098-5058-4e58-9db4-cee3d9b5e35b"
      unitRef="usd">7300000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <ameh:NumberOfFamilyPracticeClinics
      contextRef="if5945e9c877b4ccea72cbc601bc3a9b6_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfMTAyMTA_acbfc486-f958-4d0d-bc5a-59a074f446f9"
      unitRef="clinic">3</ameh:NumberOfFamilyPracticeClinics>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="ia9f8aa30820f40aaa284eb4906fe92a2_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfMTA0NTc_4ddf2a15-ba22-49d8-b8de-dc1268302e2a"
      unitRef="number">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i11b99b377a6a43aa865ba7d01fecd1e5_D20190901-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfMTA1MDI_6725d1c5-acd9-4212-9c56-53a30b142125"
      unitRef="usd">1200000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="if3e410ddfdb74a3daeb61a44c92264d8_D20190901-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfMTA1MTc_bc539e34-d49a-401f-bf2d-e29a9d6d2732"
      unitRef="usd">400000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i5d896ebc98ae47969367089670863233_I20140630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfMTA2MDc_156852b2-2504-484f-bad2-78d3b8f54a72"
      unitRef="number">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <ameh:EquityMethodInvestmentOwnershipPercentageDisposed
      contextRef="ic4fe11ff13bc463aa7c7d46c9968606e_I20200430"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfMTA3OTE_87cf25c4-edc9-48de-ada1-ce761de1a085"
      unitRef="number">0.489</ameh:EquityMethodInvestmentOwnershipPercentageDisposed>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="i4a23351d6549453987064b1ed4ccd7a5_D20200430-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfMTA4OTQ_048b7b12-6af2-46a6-9cf4-2256e523f3c0"
      unitRef="usd">69200000</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:ProceedsFromRepaymentsOfDebt
      contextRef="i4a23351d6549453987064b1ed4ccd7a5_D20200430-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfMTA5MjU_ec9be68b-d815-463a-b35c-090a13d742a6"
      unitRef="usd">16500000</us-gaap:ProceedsFromRepaymentsOfDebt>
    <us-gaap:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1
      contextRef="icbe089761e214533973bb396d097bec6_D20200430-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfMTExOTk_7c75d161-1bf5-4c34-8d68-1671e05e18aa"
      unitRef="usd">36200000</us-gaap:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1>
    <ameh:AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet
      contextRef="i9c07037f02c24f758bbadde10f2a6d6b_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfMTE0ODA_9dba054a-58c2-469e-a92e-4de5641d3f05"
      unitRef="usd">15700000</ameh:AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet>
    <ameh:EquityMethodInvestmentOwnershipPercentageDisposed
      contextRef="ic4fe11ff13bc463aa7c7d46c9968606e_I20200430"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80MC9mcmFnOjhlMjhhZDdlNzY1ZDQzZjk5OTQ1OGRlNWYzMDMxYTczL3RleHRyZWdpb246OGUyOGFkN2U3NjVkNDNmOTk5NDU4ZGU1ZjMwMzFhNzNfMTE3NjI_611f4642-2294-4a7a-a17a-c167e059c485"
      unitRef="number">0.489</ameh:EquityMethodInvestmentOwnershipPercentageDisposed>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMTI2NDQzODM3Njg0MzM_0d699ecb-380e-4006-bc28-657a0b9b8f45">Basis of Presentation and Summary of Significant Accounting Policies&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The accompanying consolidated balance sheets at December&#160;31, 2019, has been derived from the Company&#x2019;s audited consolidated financial statements, but does not include all disclosures required by generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;). The accompanying unaudited consolidated financial statements as of June&#160;30, 2020, and for the three and six months ended June&#160;30, 2020 and 2019, have been prepared in accordance with U.S. GAAP for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements, and should be read in conjunction with the audited consolidated financial statements and related notes to the financial statements included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2019 as filed with the SEC on March 16, 2020. In the opinion of management, all material adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been made to make the consolidated financial statements not misleading as required by Regulation S-X, Rule 10-01. Operating results for the three and six months ended June&#160;30, 2020, are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2020, or any future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;The consolidated balance sheets as of June&#160;30, 2020 and December&#160;31, 2019, and the consolidated statements of income for the three and six months ended June&#160;30, 2020 and 2019, &#160;include the accounts of ApolloMed, its consolidated subsidiaries, NMM, AMM, APAACO, and Apollo Care Connect, its consolidated VIE, AP-AMH, NMM's consolidated subsidiaries, and consolidated VIE, APC, APC&#x2019;s subsidiary, UCAP, and APC&#x2019;s consolidated VIEs, CDSC, APC-LSMA, ICC, and APC-LSMA&#x2019;s consolidated subsidiaries Alpha Care and Accountable Health Care.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;All material intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The preparation of the consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.&#160;Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combination and goodwill valuation and impairment, accrual of medical liabilities (incurred, but not reported (&#x201c;IBNR&#x201d;) claims), determination of full-risk and shared-risk revenue and receivables (including constraints and completion factors, including historical medical loss ratios (&#x201c;MLR&#x201d;)), income taxes, valuation of share-based compensation and right-of-use ("ROU") assets and lease liabilities. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Reportable Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company operates as one reportable segment, the healthcare delivery segment, and implements and operates innovative health care models to create a patient-centered, physician-centric experience. The Company reports its consolidated financial statements in the aggregate, including all activities in one reportable segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s cash and cash equivalents primarily consist of money market funds and certificates of deposit. The Company considers all highly liquid investments that are both readily convertible into known amounts of cash and mature within 90 days from their date of purchase to be cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company maintains its cash in deposit accounts with several banks, which at times may&#160;exceed the insured limits of the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;). The Company believes it is not exposed to any significant credit risk with respect to its cash, cash equivalents and restricted cash. As of June&#160;30, 2020, the Company&#x2019;s deposit accounts with banks exceeded the FDIC&#x2019;s insured limit by approximately $290.9 million, including approximately $117.6 million in certificates of deposit that were recognized as investments in marketable securities. The Company has not experienced any losses to date and performs ongoing evaluations of these financial institutions to limit the Company&#x2019;s concentration of risk exposure.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Restricted cash consists of cash held as collateral to secure standby letters of credits as required by certain contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Investments in Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The appropriate classification of investments is determined at the time of purchase and such designation is reevaluated at each balance sheet date. As of June&#160;30, 2020 and December&#160;31, 2019, investments in marketable securities amounted to approximately $117.7 million and $116.5 million, respectively, and consisted of equity securities and certificates of deposit with various financial institutions, reported at par value, plus accrued interest, with maturity dates from four months to 24 months (see fair value measurements of financial instruments below). Investments in certificates of deposits are classified as Level 1 investments in the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Receivables and Receivables &#x2013; Related Parties&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s receivables are comprised of accounts receivable, capitation and claims receivable, risk pool settlements and incentive receivables, management fee income and other receivables. Accounts receivable are recorded and stated at the amount expected to be collected.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s receivables &#x2013; related parties are comprised of risk pool settlements, management fee income and incentive receivables, and other receivables. Receivables &#x2013; related parties are recorded and stated at the amount expected to be collected.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Capitation and claims receivable relate to each health plan&#x2019;s capitation and is received by the Company in the month following the month of service. Risk pool settlements and incentive receivables mainly consist of the Company&#x2019;s full risk pool receivable that is recorded quarterly based on reports received from the Company&#x2019;s hospital partners and management&#x2019;s estimate of the Company&#x2019;s portion of the estimated risk pool surplus for open performance years. Settlement of risk pool surplus or deficits occurs approximately 18 months after the risk pool performance year is completed. Other receivables consists of recoverable claims paid related to the 2019 APAACO performance year to be administered following instructions from CMS, fee-for-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;services (&#x201c;FFS&#x201d;) reimbursement for patient care, certain expense reimbursements, transportation reimbursements from the hospitals, and stop loss insurance premium reimbursements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company maintains reserves for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends and changes in customer payment patterns to evaluate the adequacy of these reserves. The Company also regularly analyzes the ultimate collectability of accounts receivable after certain stages of the collection cycle using a look-back analysis to determine the amount of receivables subsequently collected and adjustments are recorded when necessary. Reserves are recorded primarily on a specific identification basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Receivables are recorded when the Company is able to determine amounts receivable under applicable contracts and agreements based on information provided and collection is reasonably likely to occur. In regards to the credit loss standard, the Company continuously monitors its collections of receivables and our expectation is that the historical credit loss experienced across our receivable portfolio is materially similar to any current expected credit losses that would be estimated under the current expected credit losses (CECL) model. As of June 30, 2020 and December 31, 2019 the Company had $1.3&#160;million and  $2.9&#160;million of allowance for doubtful accounts, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Concentrations of Risks&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company disaggregates revenue from contracts by service type and payor type. This level of detail provides useful information pertaining to how the Company generates revenue by significant revenue stream and by type of direct contracts. The consolidated statements of income present disaggregated revenue by service type. The following table presents disaggregated revenue generated by payor type for the three and six months ended June&#160;30, 2020 and 2019 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.792%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.739%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Commercial&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Medicare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;62,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;57,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Medicaid&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;68,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Other third parties&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;165,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;130,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.792%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.739%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Commercial&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;50,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;50,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Medicare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;126,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;95,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Medicaid&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;134,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;61,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Other third parties&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;330,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;225,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company had major payors that contributed the following percentages of net revenue:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.792%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.739%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Payor A&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Payor B&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Payor C&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Payor D&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Payor E&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Payor F&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.792%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.739%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Payor A&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Payor B&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Payor C&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Payor D&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Payor E&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Payor F&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;*&#160;Less than 10% of total net revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company had major payors that contributed to the following percentages of receivables and receivables &#x2013; related parties:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:62.181%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.543%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.546%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Payor D&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Payor G&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;30.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Payor H&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;35.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:18pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;*&#160;Less than 10% of total receivables and receivables &#x2014; related parties, net&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Fair Value Measurements of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s financial instruments consist of cash and cash equivalents, fiduciary cash, restricted cash, investment in marketable securities, receivables, loans receivable, accounts payable, certain accrued expenses, finance lease obligations, and long-term debt. The carrying values of the financial instruments classified as current in the accompanying consolidated balance sheets are considered to be at their fair values, due to the short maturity of these instruments. The carrying amounts of finance lease obligations and long-term debt approximate fair value as they bear interest at rates that approximate current market rates for debt with similar maturities and credit quality.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 820, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (&#x201c;ASC 820&#x201d;), applies to all financial assets and financial liabilities that are measured and reported on a fair value basis and requires disclosure that establishes a framework for measuring fair value and expands disclosure about fair value measurements. ASC&#160;820 establishes a fair value hierarchy for disclosure of the inputs to valuations used to measure fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;This hierarchy prioritizes the inputs into three broad levels as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Level&#160;1&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &#x2014; Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that can be accessed at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Level&#160;2&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &#x2014; Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;asset or liability (i.e., interest rates and yield curves), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Level&#160;3&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &#x2014; Unobservable inputs that reflect assumptions about what market participants would use in pricing the asset or liability. These inputs would be based on the best information available, including the Company&#x2019;s own data.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The carrying amounts and fair values of the Company&#x2019;s financial instruments as of June&#160;30, 2020, are presented below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.852%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.741%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Level 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Money market funds*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;108,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;108,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Marketable securities &#x2013; certificates of deposit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;117,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;117,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Marketable securities &#x2013; equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;225,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;225,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The carrying amounts and fair values of the Company&#x2019;s financial instruments as of December&#160;31, 2019, are presented below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.852%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.741%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds*&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;50,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;50,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Marketable securities &#x2013; certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;116,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;116,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Marketable securities &#x2013; equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;167,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;167,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;*&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Included in cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;There have been no changes in Level 1, Level 2, or Level 3 classification and no changes in valuation techniques for these assets for the six months ended June&#160;30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Intangible Assets and Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Intangible assets with finite lives include network-payor relationships, management contracts and member relationships and are stated at cost, less accumulated amortization and impairment losses. These intangible assets are amortized on the accelerated method using the discounted cash flow rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Intangible assets with finite lives also include a patient management platform, as well as trade names and trademarks, whose valuations were determined using the cost to recreate method and the relief from royalty method, respectively. These assets are stated at cost, less accumulated amortization and impairment losses, and are amortized using the straight-line method.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Finite-lived intangibles and long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may&#160;not be recoverable. If the expected future cash flows from the use of such assets (undiscounted and without interest charges) are less than the carrying value, a write-down would be recorded to reduce the carrying value of the asset to its estimated fair value. Fair value is determined based on appropriate valuation techniques. The Company determined that there was no impairment of its finite-lived intangible or long-lived assets during the six months ended June&#160;30, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Goodwill and Indefinite-Lived Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Under ASC 350, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Intangibles &#x2013; Goodwill and Other&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;, goodwill and indefinite-lived intangible assets are reviewed at least annually for impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;At least annually, at the Company&#x2019;s fiscal year-end, or sooner if events or changes in circumstances indicate that an impairment has occurred, the Company performs a qualitative assessment to determine whether it is more likely than not that the fair value of each reporting unit is less than its carrying amount as a basis for determining whether it is necessary to complete quantitative impairment assessments for each of the Company&#x2019;s three main reporting units (1) management services, (2) IPAs, and (3) ACOs. The Company is required to perform a quantitative goodwill impairment test only if the conclusion from the qualitative assessment is that it is more likely than not that a reporting unit&#x2019;s fair value is less than the carrying value of its assets. Should this be the case, a quantitative analysis is performed to identify whether a potential impairment exists by comparing the estimated fair values of the reporting units with their respective carrying values, including goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;An impairment loss is recognized if the implied fair value of the asset being tested is less than its carrying value. In this event, the asset is written down accordingly. The fair values of goodwill are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;At least annually, indefinite-lived intangible assets are tested for impairment. Impairment for intangible assets with indefinite lives exists if the carrying value of the intangible asset exceeds its fair value. The fair values of indefinite-lived intangible assets are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company had no impairment of its goodwill or indefinite-lived intangible assets during the six months ended June&#160;30, 2020 and 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Investments in Other Entities &#x2014; Equity Method&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company accounts for certain investments using the equity method of accounting when it is determined that the investment provides the Company with the ability to exercise significant influence, but not control, over the investee. Significant influence is generally deemed to exist if the Company has an ownership interest in the voting stock of the investee of between 20% and 50%, although other factors, such as representation on the investee&#x2019;s board of directors, are considered in determining whether the equity method of accounting is appropriate. Under the equity method of accounting, the investment, originally recorded at cost, is adjusted to recognize the Company&#x2019;s share of net earnings or losses of the investee and is recognized in the accompanying consolidated statements of income under &#x201c;Income (loss) from equity method investments&#x201d; and also is adjusted by contributions to and distributions from the investee. Equity method investments are subject to impairment evaluation. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Investments in Privately Held Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company accounts for certain investments using the cost method of accounting when it is determined that the investment provides the Company with little or no influence over the investee. Under the cost method of accounting, the investment is measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income. The investments in privately held entities that do not report NAV are subject to qualitative assessment for indicators of impairments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Medical Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;APC, Alpha Care, Accountable Health Care, APAACO and MMG are responsible for integrated care that the associated physicians and contracted hospitals provide to their enrollees. APC, Alpha Care, Accountable Health Care, APAACO and MMG provide integrated care to HMOs, Medicare and Medi-Cal enrollees through a network of contracted providers under sub-capitation and direct patient service arrangements. Medical costs for professional and institutional services rendered by contracted providers are recorded as cost of services expenses in the accompanying consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;An estimate of amounts due to contracted physicians, hospitals, and other professional providers is included in medical liabilities in the accompanying consolidated balance sheets. Medical liabilities include claims reported as of the balance sheet date and estimates IBNR claims. Such estimates are developed using actuarial methods and are based on numerous variables, including the utilization of health care services, historical payment patterns, cost trends, product mix, seasonality, changes in membership, and other factors. The estimation methods and the resulting reserves are periodically reviewed and updated. Many of the medical contracts are complex in nature and may&#160;be subject to differing interpretations regarding amounts due for the provision of various services. Such differing interpretations may&#160;not come to light until a substantial period of time has passed following the contract implementation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company receives payments from the following sources for services rendered: (i) commercial insurers; (ii) the federal government under the Medicare program administered by CMS; (iii) state governments under the Medicaid and other programs; (iv) other third-party payors (e.g., hospitals and IPAs); and (v) individual patients and clients.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Nature of Services and Revenue Streams&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenue primarily consists of capitation revenue, risk pool settlements and incentives, NGACO All-Inclusive Population-Based Payments (&#x201c;AIPBP&#x201d;), management fee income, and FFS revenue. Revenue is recorded in the period in which services are rendered or the period in which the Company is obligated to provide services. The form of billing and related risk of collection for such services may&#160;vary by type of revenue and the customer. The following is a summary of the principal forms of the Company&#x2019;s billing arrangements and how revenue is recognized for each.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Capitation, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Managed care revenues of the Company consist primarily of capitated fees for medical services provided by the Company under a capitated arrangement directly made with various managed care providers including HMOs. Capitation revenue is typically prepaid monthly to the Company based on the number of enrollees selecting the Company as their healthcare provider. Capitation revenue is recognized in the month in which the Company is obligated to provide services to plan enrollees under contracts with various health plans. Minor ongoing adjustments to prior months&#x2019; capitation, primarily arising from contracted HMOs finalizing their monthly patient eligibility data for additions or subtractions of enrollees, are recognized in the month they are communicated to the Company. Additionally, Medicare pays capitation using a &#x201c;Risk Adjustment&#x201d; model, which compensates managed care organizations and providers based on the health status (acuity) of each individual enrollee. Health plans and providers with higher acuity enrollees will receive more and those with lower acuity enrollees will receive less. Under Risk Adjustment, capitation is determined based on health severity, measured using patient encounter data. Capitation is paid on a monthly basis based on data submitted for the enrollee for the preceding year and is adjusted in subsequent periods after the final data is compiled. Positive or negative capitation adjustments are made for Medicare enrollees with conditions requiring more or less healthcare services than assumed in the interim payments. Since the Company cannot reliably predict these adjustments, periodic changes in capitation amounts earned as a result of Risk Adjustment are recognized when those changes are communicated by the health plans to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;PMPM managed care contracts generally have a term of one year or longer. All managed care contracts have a single performance obligation that constitutes a series for the provision of managed healthcare services for a population of enrolled members for the duration of the contract. The transaction price for PMPM contracts is variable as it primarily includes PMPM fees associated with unspecified membership that fluctuates throughout the contract. In certain contracts, PMPM fees also include adjustments for items such as performance incentives, performance guarantees and risk shares. The Company generally estimates the transaction price using the most likely amount methodology and amounts are only included in the net transaction price to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The majority of the Company&#x2019;s net PMPM transaction price relates specifically to the Company&#x2019;s efforts to transfer the service for a distinct increment of the series (e.g., day or month) and is recognized as revenue in the month in which members are entitled to service.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Risk Pool Settlements and Incentives&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;APC enters into full risk capitation arrangements with certain health plans and local hospitals, which are administered by a third party, where the hospital is responsible for providing, arranging and paying for institutional risk and APC is responsible for providing, arranging and paying for professional risk. Under a full risk pool sharing agreement, APC generally receives a percentage of the net surplus from the affiliated hospital&#x2019;s risk pools with HMOs after deductions for the affiliated hospitals costs. Advance settlement payments are typically made quarterly in arrears if there is a surplus. The Company&#x2019;s risk pool settlements under arrangements with health plans and hospitals are recognized using the most likely amount methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The assumptions for historical MLR, IBNR completion factors and constraint percentages were used by management in applying the most likely amount methodology.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Under capitated arrangements with certain HMOs, APC participates in one or more shared risk arrangements relating to the provision of institutional services to enrollees (shared risk arrangements) and thus can earn additional revenue or incur losses based upon the enrollee utilization of institutional services. Shared risk capitation arrangements are entered into with certain health plans, which are administered by the health plan, where APC is responsible for rendering professional services, but the health plan does not enter into a capitation arrangement with a hospital and therefore the health plan retains the institutional risk. Shared risk deficits, if any, are not payable until and unless (and only to the extent of any) risk-sharing surpluses are generated. At the termination of the HMO contract, any accumulated deficit will be extinguished.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s risk pool settlements under arrangements with HMOs are recognized, using the most likely methodology, and only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur. Given &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;the lack of access to the health plans&#x2019; data and control over the members assigned to APC, the adjustments and/or the withheld amounts are unpredictable and as such APC&#x2019;s risk share revenue is deemed to be fully constrained until APC is notified of the amount by the health plan. Risk pools for the prior contract years are generally final settled in the third or fourth quarter of the following year.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In addition to risk-sharing revenues, the Company also receives incentives under &#x201c;pay-for-performance&#x201d; programs for quality medical care, based on various criteria. As an incentive to control enrollee utilization and to promote quality care, certain HMOs have designed quality incentive programs and commercial generic pharmacy incentive programs to compensate the Company for its efforts to improve the quality of services and efficient and effective use of pharmacy supplemental benefits provided to HMO members. The incentive programs track specific performance measures and calculate payments to the Company based on the performance measures. The Company&#x2019;s incentives under &#x201c;pay-for-performance&#x201d; programs are recognized using the most likely methodology. However, as the Company does not have sufficient insight from the health plans on the amount and timing of the shared risk pool and incentive payments these amounts are considered to be fully constrained and only recorded when such payments are known and/or received.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Generally, for the foregoing arrangements, the final settlement is dependent on each distinct day&#x2019;s performance within the annual measurement period but cannot be allocated to specific days until the full measurement period has occurred and performance can be assessed. As such, this is a form of variable consideration estimated at contract inception and updated through the measurement period (i.e., the contract year), to the extent the risk of reversal does not exist and the consideration is not constrained.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;NGACO AIPBP Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;APAACO and CMS entered into a NGACO Model Participation Agreement (the &#x201c;Participation Agreement&#x201d;) with an initial term of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMjY0NTk_5c465777-41e6-4d7a-b713-4cd6abec3b70"&gt;two&lt;/span&gt; performance years through December&#160;31, 2018, which term was extended for &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMjY1MzU_16e36149-7c47-4c0c-bc55-d85a3cf36fbe"&gt;two&lt;/span&gt; additional renewal years.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For each performance year, the Company must submit to CMS its selections for risk arrangement; the amount of the profit/loss cap; alternative payment mechanism; benefits enhancements, if any; and its decision regarding voluntary alignment under the NGACO Model. The Company must obtain CMS consent before voluntarily discontinuing any benefit enhancement during a performance year.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the NGACO Model, CMS aligns beneficiaries to the Company to manage (direct care and pay providers) based on a budgetary benchmark established with CMS. The Company is responsible for managing medical costs for these beneficiaries. The beneficiaries will receive services from physicians and other medical service providers that are both in-network and out-of-network. The Company receives capitation from CMS on a monthly basis to pay claims from in-network providers. The Company records such capitation received from CMS as revenue as the Company is primarily responsible and liable for managing the patient care and for satisfying provider obligations, is assuming the credit risk for the services provided by in-network providers through its arrangement with CMS, and has control of the funds, the services provided and the process by which the providers are ultimately paid. Claims from out-of-network providers are processed and paid by CMS and the Company&#x2019;s shared savings or losses in managing the services provided by out-of-network providers are generally determined on an annual basis after reconciliation with CMS. Pursuant to the Company&#x2019;s risk share agreement with CMS, the Company will be eligible to receive the savings or be liable for the deficit according to the budget established by CMS based on the Company&#x2019;s efficiency in managing how the beneficiaries aligned to the Company by CMS are served by in-network and out-of-network providers. The Company&#x2019;s savings or losses on providing such services are both capped by CMS, and are subject to significant estimation risk, whereby payments can vary significantly depending upon certain patient characteristics and other variable factors. Accordingly, the Company recognizes such surplus or deficit upon substantial completion of reconciliation and determination of the amounts. The Company records NGACO capitation revenues monthly. Excess over claims paid, plus an estimate for the related IBNR claims (see Note 8), and monthly capitation received are deferred and recorded as a liability until actual claims are paid or incurred. CMS will determine if there were any excess capitation paid for the performance year and the excess is refunded to CMS.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For each performance year, CMS pays the Company in accordance with the alternative payment mechanism, if any, for which CMS has approved the Company; the risk arrangement for which the Company has been approved by CMS; and as otherwise provided in the Participation Agreement. Following the end of each performance year and at such other times as may be required under the Participation Agreement, CMS will issue a settlement report to the Company setting forth the amount of any shared savings or shared losses and the amount of other monies. If CMS owes the Company shared savings or other monies, CMS will pay the Company in full within 30 days after the date on which the relevant settlement report is deemed final, except as provided in the Participation Agreement. If the Company owes CMS shared losses or other monies owed as a result of a final settlement, the Company will pay CMS in full within 30 days after the relevant settlement report is deemed final. If the &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Company fails to pay the amounts due to CMS in full within 30 days after the date of a demand letter or settlement report, CMS will assess simple interest on the unpaid balance at the rate applicable to other Medicare debts under current provisions of law and applicable regulations. In addition, CMS and the U.S. Department of the Treasury may use any applicable debt collection tools available to collect any amounts owed by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company participates in the AIPBP track of the NGACO Model. Under the AIPBP track, CMS estimates the total annual expenditures for APAACO&#x2019;s assigned patients and pays that projected amount to the Company in monthly installments, and the Company is responsible for all Part A and Part B costs for in-network participating providers and preferred providers contracted by the Company to provide services to the assigned patients.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As APAACO does not have sufficient insight into the financial performance of the shared risk pool with CMS because of unknown factors related to IBNR claims, risk adjustment factors, and stop loss provisions, among other factors, an estimate cannot be developed. Due to these limitations, APAACO cannot determine the amount of surplus or deficit that will likely be recognized in the future and therefore this shared risk pool revenue is considered fully constrained.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For performance year 2020, the Company continues to receive monthly AIPBP payments at a rate of approximately $7.6 million per month from CMS, and will need to continue to comply with all terms and conditions in the Participation Agreement and various regulatory requirements to be eligible to participate in the AIPBP mechanism and/or NGACO Model. The Company has received approximately $22.9&#160;million and $45.5 million in total AIPBP payments for the three and six months ended June&#160;30, 2020, respectively, of which $20.5&#160;million and $42.4 million has been recognized as revenue for the three and six months ended June 30, 2020, respectively. The Company also recorded assets of approximately $8.5 million related to IBNR claims as of June&#160;30, 2020, and $3.2 million related to final settlement of the 2018 performance year. These balances are included in &#x201c;Other receivables&#x201d; in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Management Fee Income&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Management fee income encompasses fees paid for management, physician advisory, healthcare staffing, administrative and other non-medical services provided by the Company to IPAs, hospitals and other healthcare providers. Such fees may be in the form of billings at agreed-upon hourly rates, percentages of revenue or fee collections, or amounts fixed on a monthly, quarterly or annual basis. The revenue may include variable arrangements measuring factors such as hours staffed, patient visits or collections per visit against benchmarks, and, in certain cases, may be subject to achieving quality metrics or fee collections. The Company recognizes such variable supplemental revenues in the period when such amounts are determined to be fixed and therefore contractually obligated as payable by the customer under the terms of the applicable agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company provides a significant service of integrating the services selected by the Company&#x2019;s clients into one overall output for which the client has contracted. Therefore, such management contracts generally contain a single performance obligation. The nature of the Company&#x2019;s performance obligation is to stand ready to provide services over the contractual period. Also, the Company&#x2019;s performance obligation forms a series of distinct periods of time over which the Company stands ready to perform. The Company&#x2019;s performance obligation is satisfied as the Company completes each period&#x2019;s obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Consideration from management contracts is variable in nature because the majority of the fees are generally based on revenue or collections, which can vary from period to period. The Company has control over pricing. Contractual fees are invoiced to the Company&#x2019;s clients generally monthly and payment terms are typically due within 30 days. The variable consideration in the Company&#x2019;s management contracts meets the criteria to be allocated to the distinct period of time to which it relates because (i) it is due to the activities performed to satisfy the performance obligation during that period and (ii) it represents the consideration to which the Company expects to be entitled.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s management contracts generally have long terms (e.g., 10 years), although they may be terminated earlier under the terms of the applicable contracts. Since the remaining variable consideration will be allocated to a wholly unsatisfied promise that forms part of a single performance obligation recognized under the series guidance, the Company has applied the optional exemption to exclude disclosure of the allocation of the transaction price to remaining performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Fee-for-Service Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;FFS revenue represents revenue earned under contracts in which the Company bills and collects the professional component of charges for medical services rendered by the Company&#x2019;s contracted physicians and employed physicians. Under the FFS arrangements, the Company bills the hospitals and third-party payors for the physician staffing and further bills patients or their third-party payors for patient care services provided and receives payment. FFS revenue related to the patient care services is reported net of contractual allowances and policy discounts and are recognized in the period in which the services are rendered to specific patients. All services provided are expected to result in cash flows and are therefore reflected as net revenue in the &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;consolidated financial statements. The recognition of net revenue (gross charges less contractual allowances) from such services is dependent on such factors as proper completion of medical charts following a patient visit, the forwarding of such charts to the Company&#x2019;s billing center for medical coding and entering into the Company&#x2019;s billing system and the verification of each patient&#x2019;s submission or representation at the time services are rendered as to the payor(s) responsible for payment of such services. Revenue is recorded based on the information known at the time of entering of such information into the Company&#x2019;s billing systems, as well as an estimate of the revenue associated with medical services.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company is responsible for confirming member eligibility, performing program utilization review, potentially directing payment to the provider and accepting the financial risk of loss associated with services rendered, as specified within the Company&#x2019;s client contracts. The Company has the ability to adjust contractual fees with clients and possess the financial risk of loss in certain contractual obligations. These factors indicate the Company is the principal and, as such, the Company records gross fees contracted with clients in revenues.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Consideration from FFS arrangements is variable in nature because fees are based on patient encounters, credits due to clients and reimbursement of provider costs, all of which can vary from period to period.&#160;Patient encounters and related episodes of care and procedures qualify as distinct goods and services, provided simultaneously together with other readily available resources, in a single instance of service, and thereby constitute a single performance obligation for each patient encounter and, in most instances, occur at readily determinable transaction prices. As a practical expedient, the Company adopted a portfolio approach for the FFS revenue stream to group together contracts with similar characteristics and analyze historical cash collections trends. The contracts within the portfolio share the characteristics conducive to ensuring that the results do not materially differ under the new standard if it were to be applied to individual patient contracts related to each patient encounter. Accordingly, there was no change in the Company&#x2019;s method to recognize revenue under ASC 606 &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; from the previous accounting guidance.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Estimating net FFS revenue is a complex process, largely due to the volume of transactions, the number and complexity of contracts with payors, the limited availability at times of certain patient and payor information at the time services are provided, and the length of time it takes for collections to fully mature. These expected collections are based on fees and negotiated payment rates in the case of third-party payors, the specific benefits provided for under each patient&#x2019;s healthcare plans, mandated payment rates in the case of Medicare and Medicaid programs, and historical cash collections (net of recoveries) in combination with expected collections from third-party payors.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The relationship between gross charges and the transaction price recognized is significantly influenced by payor mix, as collections on gross charges may vary significantly, depending on whether and with whom the patients the Company provides services to in the period are insured and the Company&#x2019;s contractual relationships with those payors. Payor mix is subject to change as additional patient and payor information is obtained after the period services are provided. The Company periodically assesses the estimates of unbilled revenue, contractual adjustments and discounts, and payor mix by analyzing actual results, including cash collections, against estimates. Changes in these estimates are charged or credited to the consolidated statements of income in the period that the assessment is made. Significant changes in payor mix, contractual arrangements with payors, specialty mix, acuity, general economic conditions and health care coverage provided by federal or state governments or private insurers may have a significant impact on estimates and significantly affect the results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Contract Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Typically, revenues and receivables are recognized once the Company has satisfied its performance obligation. Accordingly, the Company&#x2019;s contract assets are comprised of receivables and receivables &#x2013; related parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2019;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;s billing and accounting systems provide historical trends of cash collections and contractual write-offs, accounts receivable agings and established fee adjustments from third-party payors. These estimates are recorded and monitored monthly as revenues are recognized.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; The principal exposure for uncollectible fee for service visits is from self-pay patients and, to a lesser extent, for co-payments and deductibles from patients with insurance.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Contract Liabilities (Deferred Revenue&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Contract liabilities are recorded when cash payments are received in advance of the Company&#x2019;s performance, or in the case of the Company&#x2019;s NGACO, the excess of AIPBP capitation received and the actual claims paid or incurred. The Company&#x2019;s contract liability balance was $3.1 million and $8.9 million as of June&#160;30, 2020, and December&#160;31, 2019, respectively, and is presented within &#x201c;Accounts payable and accrued expenses&#x201d; in the accompanying consolidated balance sheets. During the six months ended June&#160;30, 2020, $0.4 million of the Company&#x2019;s contract liability accrued in 2019 has been recognized as revenue and $8.5 million was repaid back to CMS for AIPBP capitation received and not earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Other Financial Information&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In March 2020, the Company made a deposit of $4.0 million for future investment opportunities. The investment was made with cash strictly related to the APC excluded assets that was generated from the series of transactions with AP-AMH. The deposit is included in &#x201c;Other assets&#x201d; in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Federal and state income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the consolidated financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company maintains a stock-based compensation program for employees, non-employees, directors and consultants. The value of share-based awards such as options is recognized as compensation expense on a cumulative straight-line basis over the vesting period of the awards, adjusted for expected forfeitures. From time to time, the Company issues shares of its common stock to its employees, directors and consultants, which shares may be subject to the Company&#x2019;s repurchase right (but not obligation) that lapses based on time-based and performance-based vesting schedules.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Basic and Diluted Earnings Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Basic earnings per share is computed by dividing net income attributable to holders of the Company&#x2019;s common stock by the weighted average number of shares of common stock outstanding during the periods presented. Diluted earnings per share is computed using the weighted average number of shares of common stock outstanding, plus the effect of dilutive securities outstanding during the periods presented, using the treasury stock method. Refer to Note 14 for a discussion of shares treated as treasury shares for accounting purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Noncontrolling Interests&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company consolidates entities in which the Company has a controlling financial interest. The Company consolidates subsidiaries in which the Company holds, directly or indirectly, more than 50% of the voting rights, and VIEs in which the Company is the primary beneficiary. Noncontrolling interests represent third-party equity ownership interests (including equity ownership interests held by certain VIEs) in the Company&#x2019;s consolidated entities. Net income attributable to noncontrolling interests is disclosed in the consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Mezzanine Equity&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Pursuant to APC&#x2019;s shareholder agreements, in the event of a disqualifying event, as defined in the agreements, APC could be required to repurchase the shares from the respective shareholders based on certain triggers outlined in the shareholder agreements. As the redemption feature of the shares is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as mezzanine or temporary equity. Accordingly, the Company recognizes &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;noncontrolling interests in APC as mezzanine equity in the consolidated financial statements. As of June&#160;30, 2020 and December&#160;31, 2019, APC's shares were not redeemable, nor was it probable the shares would become redeemable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2016, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-13, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Financial Instruments-Credit Losses (Topic 326)-Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (&#x201c;ASU 2016-13&#x201d;). The new standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. ASU 2016-13 became effective for fiscal years beginning after December 15, 2019, with early adoption permitted. The Company adopted ASU 2016-13 on January 1, 2020. The adoption of ASU 2016-13 did not have a material impact on the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In October 2018, the FASB issued ASU No. 2018-17, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Consolidation (Topic 810): Targeted Improvements to Related Party Guidance for Variable Interest Entities&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (&#x201c;ASU 2018-17&#x201d;). This ASU reduces the cost and complexity of financial reporting associated with consolidation of VIEs. A VIE is an organization in which consolidation is not based on a majority of voting rights. The new guidance supersedes the private company alternative for common control leasing arrangements issued in 2014 and expands it to all qualifying common control arrangements. The amendments in this ASU became effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The Company adopted ASU 2018-17 on January 1, 2020. The adoption of ASU 2018-17 did not have a material impact on the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In December 2019, the FASB issued ASU No. 2019-12, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (&#x201c;ASU 2019-12&#x201d;). This ASU simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740 &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Income Taxes &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The amendments in this ASU are effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company is currently assessing the impact that the adoption of ASU 2019-12 will have on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In January 2020, the FASB issued ASU No. 2020-01, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Investments - Equity Securities (Topic 321), Investments - Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;(&#x201c;ASU 2020-01&#x201d;). This ASU clarifies the interaction between accounting for equity securities, equity method investments and certain derivative instruments. The amendments in this ASU are effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company is currently assessing the impact that the adoption of ASU 2020-01 will have on the Company's consolidation financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Other than the standards discussed above, there have been no other new accounting pronouncements that have significance, or potential significance, to the Company&#x2019;s financial position, results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDg5MDA_c34e3db4-f6e4-4472-b6fe-523d53b2fb94">Basis of PresentationThe accompanying consolidated balance sheets at December&#160;31, 2019, has been derived from the Company&#x2019;s audited consolidated financial statements, but does not include all disclosures required by generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;). The accompanying unaudited consolidated financial statements as of June&#160;30, 2020, and for the three and six months ended June&#160;30, 2020 and 2019, have been prepared in accordance with U.S. GAAP for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements, and should be read in conjunction with the audited consolidated financial statements and related notes to the financial statements included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2019 as filed with the SEC on March 16, 2020. In the opinion of management, all material adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been made to make the consolidated financial statements not misleading as required by Regulation S-X, Rule 10-01.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDg4ODQ_2d6c2f51-b9cf-40ea-adf1-3951d7943542">&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;The consolidated balance sheets as of June&#160;30, 2020 and December&#160;31, 2019, and the consolidated statements of income for the three and six months ended June&#160;30, 2020 and 2019, &#160;include the accounts of ApolloMed, its consolidated subsidiaries, NMM, AMM, APAACO, and Apollo Care Connect, its consolidated VIE, AP-AMH, NMM's consolidated subsidiaries, and consolidated VIE, APC, APC&#x2019;s subsidiary, UCAP, and APC&#x2019;s consolidated VIEs, CDSC, APC-LSMA, ICC, and APC-LSMA&#x2019;s consolidated subsidiaries Alpha Care and Accountable Health Care.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;All material intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDg4NzE_61729d7c-7832-4fff-90c5-8ce4bfe0b4d4">&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The preparation of the consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.&#160;Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combination and goodwill valuation and impairment, accrual of medical liabilities (incurred, but not reported (&#x201c;IBNR&#x201d;) claims), determination of full-risk and shared-risk revenue and receivables (including constraints and completion factors, including historical medical loss ratios (&#x201c;MLR&#x201d;)), income taxes, valuation of share-based compensation and right-of-use ("ROU") assets and lease liabilities. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDg4OTI_27a6c3a5-3bc9-43e0-943e-f598dd26e0d6">&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Reportable Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company operates as one reportable segment, the healthcare delivery segment, and implements and operates innovative health care models to create a patient-centered, physician-centric experience. The Company reports its consolidated financial statements in the aggregate, including all activities in one reportable segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMzQzMA_671aedb3-5086-4b8a-ae64-682c13581997"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMzcwOA_b59621d3-65bd-4c20-899e-b28025193a76"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDg4NDE_86df3749-0f31-4318-9d84-0dbcaeaebc7b">&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s cash and cash equivalents primarily consist of money market funds and certificates of deposit. The Company considers all highly liquid investments that are both readily convertible into known amounts of cash and mature within 90 days from their date of purchase to be cash equivalents.&lt;/span&gt;&lt;/div&gt;The Company maintains its cash in deposit accounts with several banks, which at times may&#160;exceed the insured limits of the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;). The Company believes it is not exposed to any significant credit risk with respect to its cash, cash equivalents and restricted cash.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashUninsuredAmount
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDc0Mg_30bcac89-fe83-429f-bff3-46a7f1c05546"
      unitRef="usd">290900000</us-gaap:CashUninsuredAmount>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ib671a237f06845ccacc1a406f5790edd_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDc3MA_b531b04b-bacf-40b7-850f-712429eec60a"
      unitRef="usd">117600000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDg4Nzg_c3aa5b80-5dea-4e04-9716-0edeb1b41fb5">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Restricted cash consists of cash held as collateral to secure standby letters of credits as required by certain contracts.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDg4NjU_587a7520-a802-458f-bab5-84dda6b4b134">&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Investments in Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The appropriate classification of investments is determined at the time of purchase and such designation is reevaluated at each balance sheet date. As of June&#160;30, 2020 and December&#160;31, 2019, investments in marketable securities amounted to approximately $117.7 million and $116.5 million, respectively, and consisted of equity securities and certificates of deposit with various financial institutions, reported at par value, plus accrued interest, with maturity dates from four months to 24 months (see fair value measurements of financial instruments below). Investments in certificates of deposits are classified as Level 1 investments in the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNTQ0MA_c541c4cc-91b4-4403-b34f-31a10589a35f"
      unitRef="usd">117700000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNTQ0Nw_8fb01d40-bb97-4fbf-aa27-f404e237424e"
      unitRef="usd">116500000</us-gaap:MarketableSecuritiesCurrent>
    <ameh:MarketableSecuritiesCurrentMaturityPeriod
      contextRef="i6dab3a2b4fba451e82b3256455eeec2b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMTA5OTUxMTY4NDgxMA_b473a9c4-9b15-4b68-b3de-a5ab5efebe63">P4M</ameh:MarketableSecuritiesCurrentMaturityPeriod>
    <ameh:MarketableSecuritiesCurrentMaturityPeriod
      contextRef="ibcd3d205d526423cbea49810dc2340a8_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMTA5OTUxMTY4NDgxMQ_6b9814d2-8bb5-404f-ad89-d810006d98a4">P24M</ameh:MarketableSecuritiesCurrentMaturityPeriod>
    <ameh:ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDg5MTk_996c8d9d-039a-4a00-88a8-a48eefdbcee2">&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Receivables and Receivables &#x2013; Related Parties&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s receivables are comprised of accounts receivable, capitation and claims receivable, risk pool settlements and incentive receivables, management fee income and other receivables. Accounts receivable are recorded and stated at the amount expected to be collected.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s receivables &#x2013; related parties are comprised of risk pool settlements, management fee income and incentive receivables, and other receivables. Receivables &#x2013; related parties are recorded and stated at the amount expected to be collected.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Capitation and claims receivable relate to each health plan&#x2019;s capitation and is received by the Company in the month following the month of service. Risk pool settlements and incentive receivables mainly consist of the Company&#x2019;s full risk pool receivable that is recorded quarterly based on reports received from the Company&#x2019;s hospital partners and management&#x2019;s estimate of the Company&#x2019;s portion of the estimated risk pool surplus for open performance years. Settlement of risk pool surplus or deficits occurs approximately 18 months after the risk pool performance year is completed. Other receivables consists of recoverable claims paid related to the 2019 APAACO performance year to be administered following instructions from CMS, fee-for-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;services (&#x201c;FFS&#x201d;) reimbursement for patient care, certain expense reimbursements, transportation reimbursements from the hospitals, and stop loss insurance premium reimbursements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company maintains reserves for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends and changes in customer payment patterns to evaluate the adequacy of these reserves. The Company also regularly analyzes the ultimate collectability of accounts receivable after certain stages of the collection cycle using a look-back analysis to determine the amount of receivables subsequently collected and adjustments are recorded when necessary. Reserves are recorded primarily on a specific identification basis.&lt;/span&gt;&lt;/div&gt;Receivables are recorded when the Company is able to determine amounts receivable under applicable contracts and agreements based on information provided and collection is reasonably likely to occur. In regards to the credit loss standard, the Company continuously monitors its collections of receivables and our expectation is that the historical credit loss experienced across our receivable portfolio is materially similar to any current expected credit losses that would be estimated under the current expected credit losses (CECL) model. As of June 30, 2020 and December 31, 2019 the Company had</ameh:ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock>
    <ameh:RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNjkxNQ_09d7a3dc-514d-4bb2-a8e8-ecdb9f15503c">P18M</ameh:RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMTY0OTI2NzQ5ODkwNA_87c5f388-283f-492a-94f8-17fed5ce1363"
      unitRef="usd">1300000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMTA5OTUxMTYzMzQ3OTc_9a788a73-9c49-4938-a85a-96b6e83c6070"
      unitRef="usd">2900000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDg4ODk_ab80f52c-fb2e-4014-9794-3840ce8b05ce">Concentrations of RisksThe Company disaggregates revenue from contracts by service type and payor type. This level of detail provides useful information pertaining to how the Company generates revenue by significant revenue stream and by type of direct contracts. The consolidated statements of income present disaggregated revenue by service type.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDg4NTI_e3bd7759-8f94-47c5-80cf-2c5755466d55">The following table presents disaggregated revenue generated by payor type for the three and six months ended June&#160;30, 2020 and 2019 (in thousands):&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.792%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.739%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Commercial&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Medicare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;62,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;57,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Medicaid&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;68,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Other third parties&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;165,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;130,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.792%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.739%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Commercial&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;50,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;50,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Medicare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;126,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;95,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Medicaid&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;134,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;61,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Other third parties&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;330,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;225,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0dd8dccc65a74133a54656bd7c8b4677_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjllNmE4YWQ0NjRlMDRlYzRhYTc1MTkyNTc4YWEzNjQwL3RhYmxlcmFuZ2U6OWU2YThhZDQ2NGUwNGVjNGFhNzUxOTI1NzhhYTM2NDBfMy0xLTEtMS0w_4996f3fb-f909-48cc-a168-7716827e019d"
      unitRef="usd">25479000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2a042bfad69542c1b01c261138a48a66_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjllNmE4YWQ0NjRlMDRlYzRhYTc1MTkyNTc4YWEzNjQwL3RhYmxlcmFuZ2U6OWU2YThhZDQ2NGUwNGVjNGFhNzUxOTI1NzhhYTM2NDBfMy0zLTEtMS0w_ac2b3830-56c5-4ed2-a235-bc7b605d4204"
      unitRef="usd">25365000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i29b931e0f69a45658584dcdb33cccae8_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjllNmE4YWQ0NjRlMDRlYzRhYTc1MTkyNTc4YWEzNjQwL3RhYmxlcmFuZ2U6OWU2YThhZDQ2NGUwNGVjNGFhNzUxOTI1NzhhYTM2NDBfNC0xLTEtMS0w_3c4cd76f-f729-4b9c-8a4b-47d57019abb5"
      unitRef="usd">62038000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie5e9ac126c4447a892ae9c1c466ce045_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjllNmE4YWQ0NjRlMDRlYzRhYTc1MTkyNTc4YWEzNjQwL3RhYmxlcmFuZ2U6OWU2YThhZDQ2NGUwNGVjNGFhNzUxOTI1NzhhYTM2NDBfNC0zLTEtMS0w_b8c439bf-0fad-4aa8-8943-818968d0f5e5"
      unitRef="usd">57965000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaf70769b3ae24d8bbf5cea51b1569ce3_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjllNmE4YWQ0NjRlMDRlYzRhYTc1MTkyNTc4YWEzNjQwL3RhYmxlcmFuZ2U6OWU2YThhZDQ2NGUwNGVjNGFhNzUxOTI1NzhhYTM2NDBfNS0xLTEtMS0w_3de50eab-2702-46e6-b92f-4bce52f8555c"
      unitRef="usd">68450000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8a6065f0bcd44f40b22cc3dee9debebc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjllNmE4YWQ0NjRlMDRlYzRhYTc1MTkyNTc4YWEzNjQwL3RhYmxlcmFuZ2U6OWU2YThhZDQ2NGUwNGVjNGFhNzUxOTI1NzhhYTM2NDBfNS0zLTEtMS0w_1c4e35c9-e248-455a-882a-cb68de9e8acf"
      unitRef="usd">36277000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9d46920109e94a34afa570bab6edc321_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjllNmE4YWQ0NjRlMDRlYzRhYTc1MTkyNTc4YWEzNjQwL3RhYmxlcmFuZ2U6OWU2YThhZDQ2NGUwNGVjNGFhNzUxOTI1NzhhYTM2NDBfNi0xLTEtMS0w_a4f0a64b-e543-4d3b-8d38-3cf739cc376b"
      unitRef="usd">9202000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifd7a28bbb9224f319f70f1a38371eb43_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjllNmE4YWQ0NjRlMDRlYzRhYTc1MTkyNTc4YWEzNjQwL3RhYmxlcmFuZ2U6OWU2YThhZDQ2NGUwNGVjNGFhNzUxOTI1NzhhYTM2NDBfNi0zLTEtMS0w_af653245-ce05-4b9c-9290-4dd00cb49440"
      unitRef="usd">10443000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjllNmE4YWQ0NjRlMDRlYzRhYTc1MTkyNTc4YWEzNjQwL3RhYmxlcmFuZ2U6OWU2YThhZDQ2NGUwNGVjNGFhNzUxOTI1NzhhYTM2NDBfNy0xLTEtMS0w_3f3f4321-e66c-473d-a4e9-7520fa01d50d"
      unitRef="usd">165169000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjllNmE4YWQ0NjRlMDRlYzRhYTc1MTkyNTc4YWEzNjQwL3RhYmxlcmFuZ2U6OWU2YThhZDQ2NGUwNGVjNGFhNzUxOTI1NzhhYTM2NDBfNy0zLTEtMS0w_ea75a4aa-bc13-45d5-beb7-2b759ff973f6"
      unitRef="usd">130050000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i512f416ef63d4ba3abe4a36d380da0b0_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOmNmZDExMmJmZDc2MzQ3NGY4MmY0N2JiMTEzNDJhM2M2L3RhYmxlcmFuZ2U6Y2ZkMTEyYmZkNzYzNDc0ZjgyZjQ3YmIxMTM0MmEzYzZfMy0xLTEtMS0w_6875cbcc-1cc3-4d5f-b557-ffc0c88e583a"
      unitRef="usd">50192000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iddb4dfed860740f3a71ee2c530ce3733_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOmNmZDExMmJmZDc2MzQ3NGY4MmY0N2JiMTEzNDJhM2M2L3RhYmxlcmFuZ2U6Y2ZkMTEyYmZkNzYzNDc0ZjgyZjQ3YmIxMTM0MmEzYzZfMy0zLTEtMS0w_d5745076-fa54-4a1b-b46e-c0cf9764b963"
      unitRef="usd">50383000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4ecfacaa79e54b258148a979b14f66f4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOmNmZDExMmJmZDc2MzQ3NGY4MmY0N2JiMTEzNDJhM2M2L3RhYmxlcmFuZ2U6Y2ZkMTEyYmZkNzYzNDc0ZjgyZjQ3YmIxMTM0MmEzYzZfNC0xLTEtMS0w_08cc88ed-f9e8-41ee-b410-6517baf84496"
      unitRef="usd">126918000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i947f9298713445cea034b7b41f37b6b7_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOmNmZDExMmJmZDc2MzQ3NGY4MmY0N2JiMTEzNDJhM2M2L3RhYmxlcmFuZ2U6Y2ZkMTEyYmZkNzYzNDc0ZjgyZjQ3YmIxMTM0MmEzYzZfNC0zLTEtMS0w_5e5f025c-8df6-40b1-a89b-6dacca0be508"
      unitRef="usd">95063000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7ff9e8dbf4b24be7b22e1054c2cdb0fa_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOmNmZDExMmJmZDc2MzQ3NGY4MmY0N2JiMTEzNDJhM2M2L3RhYmxlcmFuZ2U6Y2ZkMTEyYmZkNzYzNDc0ZjgyZjQ3YmIxMTM0MmEzYzZfNS0xLTEtMS0w_809e0c8f-39df-4770-8b1d-e2597be45093"
      unitRef="usd">134897000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i04580df691394c6fb1c265641dc8e4fa_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOmNmZDExMmJmZDc2MzQ3NGY4MmY0N2JiMTEzNDJhM2M2L3RhYmxlcmFuZ2U6Y2ZkMTEyYmZkNzYzNDc0ZjgyZjQ3YmIxMTM0MmEzYzZfNS0zLTEtMS0w_d78a3128-1b13-4972-ad12-d23bb938ecd1"
      unitRef="usd">61647000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib2fca4eb23c541db83ecd5805b54ba56_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOmNmZDExMmJmZDc2MzQ3NGY4MmY0N2JiMTEzNDJhM2M2L3RhYmxlcmFuZ2U6Y2ZkMTEyYmZkNzYzNDc0ZjgyZjQ3YmIxMTM0MmEzYzZfNi0xLTEtMS0w_b7498d55-883d-459a-ad6e-10b34965daeb"
      unitRef="usd">18267000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9b8d4a587e3e4ac684b3f6a5d7d7ffed_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOmNmZDExMmJmZDc2MzQ3NGY4MmY0N2JiMTEzNDJhM2M2L3RhYmxlcmFuZ2U6Y2ZkMTEyYmZkNzYzNDc0ZjgyZjQ3YmIxMTM0MmEzYzZfNi0zLTEtMS0w_0801c54a-489d-44ea-8b52-3403171b0a6c"
      unitRef="usd">18713000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOmNmZDExMmJmZDc2MzQ3NGY4MmY0N2JiMTEzNDJhM2M2L3RhYmxlcmFuZ2U6Y2ZkMTEyYmZkNzYzNDc0ZjgyZjQ3YmIxMTM0MmEzYzZfNy0xLTEtMS0w_e862c3e9-9171-48b3-a42f-12962403536f"
      unitRef="usd">330274000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOmNmZDExMmJmZDc2MzQ3NGY4MmY0N2JiMTEzNDJhM2M2L3RhYmxlcmFuZ2U6Y2ZkMTEyYmZkNzYzNDc0ZjgyZjQ3YmIxMTM0MmEzYzZfNy0zLTEtMS0w_f093188b-e25a-43dc-807e-997cdd13d111"
      unitRef="usd">225806000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDg4OTQ_024647b2-849a-45f1-8701-5a23688cabe8">The Company had major payors that contributed the following percentages of net revenue:&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.792%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.739%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Payor A&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Payor B&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Payor C&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Payor D&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Payor E&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Payor F&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.792%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.739%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Payor A&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Payor B&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Payor C&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Payor D&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Payor E&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Payor F&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;*&#160;Less than 10% of total net revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company had major payors that contributed to the following percentages of receivables and receivables &#x2013; related parties:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:62.181%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.543%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.546%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Payor D&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Payor G&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;30.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Payor H&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;35.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:18pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;*&#160;Less than 10% of total receivables and receivables &#x2014; related parties, net&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i66d29491233d435a9781fc3960674175_D20200401-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjg3NTFlMDhkNmQ3NTQzZDNhZTExNWNjZmZmNjRhZDQ0L3RhYmxlcmFuZ2U6ODc1MWUwOGQ2ZDc1NDNkM2FlMTE1Y2NmZmY2NGFkNDRfMy0xLTEtMS0w_3da85f2e-a7f8-4c91-9f55-c062b2d9810e"
      unitRef="number">0.119</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i8fea9adc9dbd4dfcb6c28fcec10b58ca_D20190401-20190630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjg3NTFlMDhkNmQ3NTQzZDNhZTExNWNjZmZmNjRhZDQ0L3RhYmxlcmFuZ2U6ODc1MWUwOGQ2ZDc1NDNkM2FlMTE1Y2NmZmY2NGFkNDRfMy0zLTEtMS0w_fe95cf88-d482-4694-9d48-9fec1917b0d1"
      unitRef="number">0.137</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iba2f1722e182406485b06e7780640a59_D20200401-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjg3NTFlMDhkNmQ3NTQzZDNhZTExNWNjZmZmNjRhZDQ0L3RhYmxlcmFuZ2U6ODc1MWUwOGQ2ZDc1NDNkM2FlMTE1Y2NmZmY2NGFkNDRfNC0xLTEtMS0w_81b436e8-e6d6-46a8-9488-24f8ae185dae"
      unitRef="number">0.103</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i92d5ad54dc7b46a692cb712060a47f6f_D20190401-20190630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjg3NTFlMDhkNmQ3NTQzZDNhZTExNWNjZmZmNjRhZDQ0L3RhYmxlcmFuZ2U6ODc1MWUwOGQ2ZDc1NDNkM2FlMTE1Y2NmZmY2NGFkNDRfNC0zLTEtMS0w_eb5c1c28-80f3-4f14-a33f-5c38a11ab6ad"
      unitRef="number">0.126</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i100279b65cca403299b145ef5c501434_D20190401-20190630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjg3NTFlMDhkNmQ3NTQzZDNhZTExNWNjZmZmNjRhZDQ0L3RhYmxlcmFuZ2U6ODc1MWUwOGQ2ZDc1NDNkM2FlMTE1Y2NmZmY2NGFkNDRfNS0zLTEtMS0w_7034c7d1-93a0-4f69-9fe3-74de5a2fe884"
      unitRef="number">0.105</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i46aa5cd04c64411ca7afff2e510cebe6_D20200401-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjg3NTFlMDhkNmQ3NTQzZDNhZTExNWNjZmZmNjRhZDQ0L3RhYmxlcmFuZ2U6ODc1MWUwOGQ2ZDc1NDNkM2FlMTE1Y2NmZmY2NGFkNDRfNi0xLTEtMS0w_409656d7-0e7c-45c9-9852-7b41ddc9dbc1"
      unitRef="number">0.175</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i36fac0be4bce47a8a6f1debf5fb86518_D20190401-20190630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjg3NTFlMDhkNmQ3NTQzZDNhZTExNWNjZmZmNjRhZDQ0L3RhYmxlcmFuZ2U6ODc1MWUwOGQ2ZDc1NDNkM2FlMTE1Y2NmZmY2NGFkNDRfNi0zLTEtMS0w_14e17950-d3dd-418c-b6d7-89020a43919d"
      unitRef="number">0.137</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i8c897dd4206d414da215cddbc7679657_D20200401-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjg3NTFlMDhkNmQ3NTQzZDNhZTExNWNjZmZmNjRhZDQ0L3RhYmxlcmFuZ2U6ODc1MWUwOGQ2ZDc1NDNkM2FlMTE1Y2NmZmY2NGFkNDRfNy0xLTEtMS0w_c034b211-f649-4ef7-9b3b-2d5925a69b3f"
      unitRef="number">0.124</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="icf6775dc61fe4ce084d261017e9ef958_D20200401-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjg3NTFlMDhkNmQ3NTQzZDNhZTExNWNjZmZmNjRhZDQ0L3RhYmxlcmFuZ2U6ODc1MWUwOGQ2ZDc1NDNkM2FlMTE1Y2NmZmY2NGFkNDRfOC0xLTEtMS0zNjUw_32afc7d2-3dbb-437b-8421-0a9303d68916"
      unitRef="number">0.101</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ibbe89b583f4b4cac886b6bd1886fc66b_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjI3YmEyZThiMWQ5YzRkNDBiYmExMGQxNDVhZDU2NmI3L3RhYmxlcmFuZ2U6MjdiYTJlOGIxZDljNGQ0MGJiYTEwZDE0NWFkNTY2YjdfMy0xLTEtMS0xNjYy_9b7ede9e-f672-439b-bb71-a47ba9e674c5"
      unitRef="number">0.119</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="icc08a7c3b8514351988c046d7326f98b_D20190101-20190630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjI3YmEyZThiMWQ5YzRkNDBiYmExMGQxNDVhZDU2NmI3L3RhYmxlcmFuZ2U6MjdiYTJlOGIxZDljNGQ0MGJiYTEwZDE0NWFkNTY2YjdfMy0zLTEtMS0w_123209c5-eb68-4517-ac8b-399ec440f578"
      unitRef="number">0.158</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iea3de6234363414c85c4cadd8273d9a4_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjI3YmEyZThiMWQ5YzRkNDBiYmExMGQxNDVhZDU2NmI3L3RhYmxlcmFuZ2U6MjdiYTJlOGIxZDljNGQ0MGJiYTEwZDE0NWFkNTY2YjdfNC0xLTEtMS0xNjYy_a488ba3a-bb69-4436-a090-55a285bfcdcb"
      unitRef="number">0.103</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i5fc422ddf26946f9b6595157d37a7e4d_D20190101-20190630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjI3YmEyZThiMWQ5YzRkNDBiYmExMGQxNDVhZDU2NmI3L3RhYmxlcmFuZ2U6MjdiYTJlOGIxZDljNGQ0MGJiYTEwZDE0NWFkNTY2YjdfNC0zLTEtMS0w_7e902dda-027b-4256-a602-c93e15b573a2"
      unitRef="number">0.143</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia98e92f83fb948a4a5b27c9b21933f87_D20190101-20190630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjI3YmEyZThiMWQ5YzRkNDBiYmExMGQxNDVhZDU2NmI3L3RhYmxlcmFuZ2U6MjdiYTJlOGIxZDljNGQ0MGJiYTEwZDE0NWFkNTY2YjdfNS0zLTEtMS0w_c7cf1fea-926e-4663-8e40-70e7696af7bb"
      unitRef="number">0.117</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i7ad5e28b46a94718807f8ff7283fa384_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjI3YmEyZThiMWQ5YzRkNDBiYmExMGQxNDVhZDU2NmI3L3RhYmxlcmFuZ2U6MjdiYTJlOGIxZDljNGQ0MGJiYTEwZDE0NWFkNTY2YjdfNi0xLTEtMS0xNjYy_30e7c5de-9a7f-4d91-a7fc-507d89abbbc9"
      unitRef="number">0.175</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id916e080e86746bb89c3cd06f5f75ae6_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjI3YmEyZThiMWQ5YzRkNDBiYmExMGQxNDVhZDU2NmI3L3RhYmxlcmFuZ2U6MjdiYTJlOGIxZDljNGQ0MGJiYTEwZDE0NWFkNTY2YjdfNy0xLTEtMS0xNjYy_347a4a62-c847-4a21-84c1-12cc6f52b5ac"
      unitRef="number">0.129</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i71e3a0e877e1403587f03dd1d16e1041_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjI3YmEyZThiMWQ5YzRkNDBiYmExMGQxNDVhZDU2NmI3L3RhYmxlcmFuZ2U6MjdiYTJlOGIxZDljNGQ0MGJiYTEwZDE0NWFkNTY2YjdfOC0xLTEtMS0zNjYx_588a119d-6edf-4a72-a7d0-55e99478a0cc"
      unitRef="number">0.103</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i11b3d315843d44af8440a243a1ec9346_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjg0ODc5NDlkYTg1MDRjM2ZiZDM1OTlmNDVhODVmMjg0L3RhYmxlcmFuZ2U6ODQ4Nzk0OWRhODUwNGMzZmJkMzU5OWY0NWE4NWYyODRfMi0xLTEtMS0w_a2120ed6-17fe-4456-b3d8-f2e7f59279dc"
      unitRef="number">0.124</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i84779c02d5604bc6bfe042cc4a70617c_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjg0ODc5NDlkYTg1MDRjM2ZiZDM1OTlmNDVhODVmMjg0L3RhYmxlcmFuZ2U6ODQ4Nzk0OWRhODUwNGMzZmJkMzU5OWY0NWE4NWYyODRfMy0xLTEtMS0w_5b7a9c17-7691-45d6-a9ad-f11d68ae2a64"
      unitRef="number">0.335</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id6e01a159a3e4416b534f097f6b023a9_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjg0ODc5NDlkYTg1MDRjM2ZiZDM1OTlmNDVhODVmMjg0L3RhYmxlcmFuZ2U6ODQ4Nzk0OWRhODUwNGMzZmJkMzU5OWY0NWE4NWYyODRfMy0zLTEtMS0w_44108c81-eef0-4feb-b115-ca0f2efda33a"
      unitRef="number">0.304</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i1dc8d99226664ef48c410daff8c273d8_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjg0ODc5NDlkYTg1MDRjM2ZiZDM1OTlmNDVhODVmMjg0L3RhYmxlcmFuZ2U6ODQ4Nzk0OWRhODUwNGMzZmJkMzU5OWY0NWE4NWYyODRfNC0xLTEtMS0w_34f58804-e92e-4ff5-82a9-0060df1429ce"
      unitRef="number">0.351</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ieb7ca1d55e834afd9682b7e0f9cd250b_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjg0ODc5NDlkYTg1MDRjM2ZiZDM1OTlmNDVhODVmMjg0L3RhYmxlcmFuZ2U6ODQ4Nzk0OWRhODUwNGMzZmJkMzU5OWY0NWE4NWYyODRfNC0zLTEtMS0w_d982b59c-43c5-40d4-965c-68a9c7b0797e"
      unitRef="number">0.360</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDg4NzY_ec2ddf0d-50a3-425e-8362-c570e1f21648">&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Fair Value Measurements of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s financial instruments consist of cash and cash equivalents, fiduciary cash, restricted cash, investment in marketable securities, receivables, loans receivable, accounts payable, certain accrued expenses, finance lease obligations, and long-term debt. The carrying values of the financial instruments classified as current in the accompanying consolidated balance sheets are considered to be at their fair values, due to the short maturity of these instruments. The carrying amounts of finance lease obligations and long-term debt approximate fair value as they bear interest at rates that approximate current market rates for debt with similar maturities and credit quality.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 820, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (&#x201c;ASC 820&#x201d;), applies to all financial assets and financial liabilities that are measured and reported on a fair value basis and requires disclosure that establishes a framework for measuring fair value and expands disclosure about fair value measurements. ASC&#160;820 establishes a fair value hierarchy for disclosure of the inputs to valuations used to measure fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;This hierarchy prioritizes the inputs into three broad levels as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Level&#160;1&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &#x2014; Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that can be accessed at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Level&#160;2&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &#x2014; Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;asset or liability (i.e., interest rates and yield curves), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Level&#160;3&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &#x2014; Unobservable inputs that reflect assumptions about what market participants would use in pricing the asset or liability. These inputs would be based on the best information available, including the Company&#x2019;s own data.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDg4OTA_70c4e1b3-5355-405a-a5b8-8eebd3f2715d">&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The carrying amounts and fair values of the Company&#x2019;s financial instruments as of June&#160;30, 2020, are presented below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.852%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.741%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Level 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Money market funds*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;108,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;108,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Marketable securities &#x2013; certificates of deposit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;117,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;117,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Marketable securities &#x2013; equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;225,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;225,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The carrying amounts and fair values of the Company&#x2019;s financial instruments as of December&#160;31, 2019, are presented below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.852%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.741%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds*&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;50,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;50,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Marketable securities &#x2013; certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;116,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;116,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Marketable securities &#x2013; equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;167,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;167,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;*&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Included in cash and cash equivalents&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iaacb62a7ead1402e943c4985b979a303_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjhiZDlhYjhjMTljNTQ4MTc4YjRiYmZkMWYxYjMyNDI5L3RhYmxlcmFuZ2U6OGJkOWFiOGMxOWM1NDgxNzhiNGJiZmQxZjFiMzI0MjlfMy0xLTEtMS0w_72c9166c-82ca-4c5c-8c58-2ed6cb66d9d5"
      unitRef="usd">108195000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i65e1f17227cc4de2a22981878af26dee_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjhiZDlhYjhjMTljNTQ4MTc4YjRiYmZkMWYxYjMyNDI5L3RhYmxlcmFuZ2U6OGJkOWFiOGMxOWM1NDgxNzhiNGJiZmQxZjFiMzI0MjlfMy0zLTEtMS0w_603cd667-17b2-44b3-adf2-18b2c6ec4b64"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i34d83ddf3e164119a0619b2f774d028a_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjhiZDlhYjhjMTljNTQ4MTc4YjRiYmZkMWYxYjMyNDI5L3RhYmxlcmFuZ2U6OGJkOWFiOGMxOWM1NDgxNzhiNGJiZmQxZjFiMzI0MjlfMy01LTEtMS0w_7e54fba9-4ae5-4993-976a-e30925f1f921"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjhiZDlhYjhjMTljNTQ4MTc4YjRiYmZkMWYxYjMyNDI5L3RhYmxlcmFuZ2U6OGJkOWFiOGMxOWM1NDgxNzhiNGJiZmQxZjFiMzI0MjlfMy03LTEtMS0w_46d4a248-0b9f-47e3-b1f9-250ce4dd7221"
      unitRef="usd">108195000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iaacb62a7ead1402e943c4985b979a303_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjhiZDlhYjhjMTljNTQ4MTc4YjRiYmZkMWYxYjMyNDI5L3RhYmxlcmFuZ2U6OGJkOWFiOGMxOWM1NDgxNzhiNGJiZmQxZjFiMzI0MjlfNC0xLTEtMS0w_da6361ca-a4db-40b6-9564-0dbffd74c9ba"
      unitRef="usd">117611000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i65e1f17227cc4de2a22981878af26dee_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjhiZDlhYjhjMTljNTQ4MTc4YjRiYmZkMWYxYjMyNDI5L3RhYmxlcmFuZ2U6OGJkOWFiOGMxOWM1NDgxNzhiNGJiZmQxZjFiMzI0MjlfNC0zLTEtMS0w_409b0170-1f45-438f-9928-0f8bdb077d98"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i34d83ddf3e164119a0619b2f774d028a_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjhiZDlhYjhjMTljNTQ4MTc4YjRiYmZkMWYxYjMyNDI5L3RhYmxlcmFuZ2U6OGJkOWFiOGMxOWM1NDgxNzhiNGJiZmQxZjFiMzI0MjlfNC01LTEtMS0w_5c2175c3-6191-4953-9735-c9b23dd61d95"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjhiZDlhYjhjMTljNTQ4MTc4YjRiYmZkMWYxYjMyNDI5L3RhYmxlcmFuZ2U6OGJkOWFiOGMxOWM1NDgxNzhiNGJiZmQxZjFiMzI0MjlfNC03LTEtMS0w_b8fdadab-a1b9-463f-a8da-06305722a026"
      unitRef="usd">117611000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="iaacb62a7ead1402e943c4985b979a303_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjhiZDlhYjhjMTljNTQ4MTc4YjRiYmZkMWYxYjMyNDI5L3RhYmxlcmFuZ2U6OGJkOWFiOGMxOWM1NDgxNzhiNGJiZmQxZjFiMzI0MjlfNS0xLTEtMS0w_2daacbd3-6bcb-430c-b751-cf5d618f0e49"
      unitRef="usd">45000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i65e1f17227cc4de2a22981878af26dee_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjhiZDlhYjhjMTljNTQ4MTc4YjRiYmZkMWYxYjMyNDI5L3RhYmxlcmFuZ2U6OGJkOWFiOGMxOWM1NDgxNzhiNGJiZmQxZjFiMzI0MjlfNS0zLTEtMS0w_81b21ec5-d6d2-4bbb-8f65-f82664da60ce"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i34d83ddf3e164119a0619b2f774d028a_I20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjhiZDlhYjhjMTljNTQ4MTc4YjRiYmZkMWYxYjMyNDI5L3RhYmxlcmFuZ2U6OGJkOWFiOGMxOWM1NDgxNzhiNGJiZmQxZjFiMzI0MjlfNS01LTEtMS0w_066ff469-00bd-4db4-9ee1-a982de5f5789"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjhiZDlhYjhjMTljNTQ4MTc4YjRiYmZkMWYxYjMyNDI5L3RhYmxlcmFuZ2U6OGJkOWFiOGMxOWM1NDgxNzhiNGJiZmQxZjFiMzI0MjlfNS03LTEtMS0w_f51cf8e1-a75b-4a78-9cbe-bcce1d7a719b"
      unitRef="usd">45000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iaacb62a7ead1402e943c4985b979a303_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjhiZDlhYjhjMTljNTQ4MTc4YjRiYmZkMWYxYjMyNDI5L3RhYmxlcmFuZ2U6OGJkOWFiOGMxOWM1NDgxNzhiNGJiZmQxZjFiMzI0MjlfNy0xLTEtMS0w_bf776450-6393-4c20-93ab-52aaa872a332"
      unitRef="usd">225851000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i65e1f17227cc4de2a22981878af26dee_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjhiZDlhYjhjMTljNTQ4MTc4YjRiYmZkMWYxYjMyNDI5L3RhYmxlcmFuZ2U6OGJkOWFiOGMxOWM1NDgxNzhiNGJiZmQxZjFiMzI0MjlfNy0zLTEtMS0w_b98a82fd-3b9a-4e0c-8867-d21bedfce5e9"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i34d83ddf3e164119a0619b2f774d028a_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjhiZDlhYjhjMTljNTQ4MTc4YjRiYmZkMWYxYjMyNDI5L3RhYmxlcmFuZ2U6OGJkOWFiOGMxOWM1NDgxNzhiNGJiZmQxZjFiMzI0MjlfNy01LTEtMS0w_90a88adc-530d-4fbe-a868-9c86dae53dc1"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOjhiZDlhYjhjMTljNTQ4MTc4YjRiYmZkMWYxYjMyNDI5L3RhYmxlcmFuZ2U6OGJkOWFiOGMxOWM1NDgxNzhiNGJiZmQxZjFiMzI0MjlfNy03LTEtMS0w_7f4ca79b-3c63-462d-8b0b-e256145712ac"
      unitRef="usd">225851000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iee4970fdbd0c4e57965c08b65849a300_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOmEyOWFmNjE2MjMxZTRlOThhMjUyNWNmZDdlN2FmNWE1L3RhYmxlcmFuZ2U6YTI5YWY2MTYyMzFlNGU5OGEyNTI1Y2ZkN2U3YWY1YTVfMy0xLTEtMS0w_1732e754-8f16-4a77-9a4a-34d31b848789"
      unitRef="usd">50731000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3be99826872a4e079e77a494a475c430_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOmEyOWFmNjE2MjMxZTRlOThhMjUyNWNmZDdlN2FmNWE1L3RhYmxlcmFuZ2U6YTI5YWY2MTYyMzFlNGU5OGEyNTI1Y2ZkN2U3YWY1YTVfMy0zLTEtMS0w_6acfe4ee-d142-42fa-ab0d-1c9e9a4de80d"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia5c34ba4f1f24e1e87163828fbf170f9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOmEyOWFmNjE2MjMxZTRlOThhMjUyNWNmZDdlN2FmNWE1L3RhYmxlcmFuZ2U6YTI5YWY2MTYyMzFlNGU5OGEyNTI1Y2ZkN2U3YWY1YTVfMy01LTEtMS0w_078feaa0-9696-4808-bc2e-702360276705"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOmEyOWFmNjE2MjMxZTRlOThhMjUyNWNmZDdlN2FmNWE1L3RhYmxlcmFuZ2U6YTI5YWY2MTYyMzFlNGU5OGEyNTI1Y2ZkN2U3YWY1YTVfMy03LTEtMS0w_d5858050-0e72-4175-a7d6-dc35dcab9564"
      unitRef="usd">50731000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iee4970fdbd0c4e57965c08b65849a300_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOmEyOWFmNjE2MjMxZTRlOThhMjUyNWNmZDdlN2FmNWE1L3RhYmxlcmFuZ2U6YTI5YWY2MTYyMzFlNGU5OGEyNTI1Y2ZkN2U3YWY1YTVfNC0xLTEtMS0w_6f8a3a94-bc07-4fc6-82d6-cad0496d7982"
      unitRef="usd">116469000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3be99826872a4e079e77a494a475c430_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOmEyOWFmNjE2MjMxZTRlOThhMjUyNWNmZDdlN2FmNWE1L3RhYmxlcmFuZ2U6YTI5YWY2MTYyMzFlNGU5OGEyNTI1Y2ZkN2U3YWY1YTVfNC0zLTEtMS0w_0c5fc19f-1145-412b-8a94-685cd3779401"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia5c34ba4f1f24e1e87163828fbf170f9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOmEyOWFmNjE2MjMxZTRlOThhMjUyNWNmZDdlN2FmNWE1L3RhYmxlcmFuZ2U6YTI5YWY2MTYyMzFlNGU5OGEyNTI1Y2ZkN2U3YWY1YTVfNC01LTEtMS0w_a64d750b-32fa-420e-94bd-2e242ad3c9d0"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOmEyOWFmNjE2MjMxZTRlOThhMjUyNWNmZDdlN2FmNWE1L3RhYmxlcmFuZ2U6YTI5YWY2MTYyMzFlNGU5OGEyNTI1Y2ZkN2U3YWY1YTVfNC03LTEtMS0w_1a3979a6-983c-4d1d-a301-46af5b909812"
      unitRef="usd">116469000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="iee4970fdbd0c4e57965c08b65849a300_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOmEyOWFmNjE2MjMxZTRlOThhMjUyNWNmZDdlN2FmNWE1L3RhYmxlcmFuZ2U6YTI5YWY2MTYyMzFlNGU5OGEyNTI1Y2ZkN2U3YWY1YTVfNS0xLTEtMS0w_0c68b18d-f284-40d1-94b9-d0f96f01335f"
      unitRef="usd">70000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i3be99826872a4e079e77a494a475c430_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOmEyOWFmNjE2MjMxZTRlOThhMjUyNWNmZDdlN2FmNWE1L3RhYmxlcmFuZ2U6YTI5YWY2MTYyMzFlNGU5OGEyNTI1Y2ZkN2U3YWY1YTVfNS0zLTEtMS0w_6d5cb8a8-662f-45e3-b6e5-84730daaff2d"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ia5c34ba4f1f24e1e87163828fbf170f9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOmEyOWFmNjE2MjMxZTRlOThhMjUyNWNmZDdlN2FmNWE1L3RhYmxlcmFuZ2U6YTI5YWY2MTYyMzFlNGU5OGEyNTI1Y2ZkN2U3YWY1YTVfNS01LTEtMS0w_8d83359a-f121-4468-82d2-546df3275751"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOmEyOWFmNjE2MjMxZTRlOThhMjUyNWNmZDdlN2FmNWE1L3RhYmxlcmFuZ2U6YTI5YWY2MTYyMzFlNGU5OGEyNTI1Y2ZkN2U3YWY1YTVfNS03LTEtMS0w_6c59c0ae-95cc-494c-b956-d502da31cbbc"
      unitRef="usd">70000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iee4970fdbd0c4e57965c08b65849a300_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOmEyOWFmNjE2MjMxZTRlOThhMjUyNWNmZDdlN2FmNWE1L3RhYmxlcmFuZ2U6YTI5YWY2MTYyMzFlNGU5OGEyNTI1Y2ZkN2U3YWY1YTVfNy0xLTEtMS0w_c4eebd13-7d40-46a2-a8fd-c96b8c982e55"
      unitRef="usd">167270000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3be99826872a4e079e77a494a475c430_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOmEyOWFmNjE2MjMxZTRlOThhMjUyNWNmZDdlN2FmNWE1L3RhYmxlcmFuZ2U6YTI5YWY2MTYyMzFlNGU5OGEyNTI1Y2ZkN2U3YWY1YTVfNy0zLTEtMS0w_37c9a63e-7a97-48e8-8eb4-b50460c1a6bb"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia5c34ba4f1f24e1e87163828fbf170f9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOmEyOWFmNjE2MjMxZTRlOThhMjUyNWNmZDdlN2FmNWE1L3RhYmxlcmFuZ2U6YTI5YWY2MTYyMzFlNGU5OGEyNTI1Y2ZkN2U3YWY1YTVfNy01LTEtMS0w_20d7a409-e1f8-4e72-9c13-e28b809261f9"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RhYmxlOmEyOWFmNjE2MjMxZTRlOThhMjUyNWNmZDdlN2FmNWE1L3RhYmxlcmFuZ2U6YTI5YWY2MTYyMzFlNGU5OGEyNTI1Y2ZkN2U3YWY1YTVfNy03LTEtMS0w_e24cfc2d-d44a-41b3-92d4-04ef5b57782c"
      unitRef="usd">167270000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDg4OTY_2e042819-64fd-42fa-977b-bc40180b39e7">&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Intangible Assets and Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Intangible assets with finite lives include network-payor relationships, management contracts and member relationships and are stated at cost, less accumulated amortization and impairment losses. These intangible assets are amortized on the accelerated method using the discounted cash flow rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Intangible assets with finite lives also include a patient management platform, as well as trade names and trademarks, whose valuations were determined using the cost to recreate method and the relief from royalty method, respectively. These assets are stated at cost, less accumulated amortization and impairment losses, and are amortized using the straight-line method.&lt;/span&gt;&lt;/div&gt;Finite-lived intangibles and long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may&#160;not be recoverable. If the expected future cash flows from the use of such assets (undiscounted and without interest charges) are less than the carrying value, a write-down would be recorded to reduce the carrying value of the asset to its estimated fair value. Fair value is determined based on appropriate valuation techniques.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMTM0ODc_37af8660-072f-4710-b14a-ded2d39c03d0"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMTM0ODc_ad64d65b-5aa9-4e08-9cee-69db8cc5453d"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMTM0ODc_c9720230-a084-4f06-b080-6225da4deccf"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMTM0ODc_e1562270-19c0-4ed0-bc29-7a5251b33119"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDg4OTE_352cfb8c-1c1a-482c-8d26-1196f90225eb">&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Goodwill and Indefinite-Lived Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Under ASC 350, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Intangibles &#x2013; Goodwill and Other&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;, goodwill and indefinite-lived intangible assets are reviewed at least annually for impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;At least annually, at the Company&#x2019;s fiscal year-end, or sooner if events or changes in circumstances indicate that an impairment has occurred, the Company performs a qualitative assessment to determine whether it is more likely than not that the fair value of each reporting unit is less than its carrying amount as a basis for determining whether it is necessary to complete quantitative impairment assessments for each of the Company&#x2019;s three main reporting units (1) management services, (2) IPAs, and (3) ACOs. The Company is required to perform a quantitative goodwill impairment test only if the conclusion from the qualitative assessment is that it is more likely than not that a reporting unit&#x2019;s fair value is less than the carrying value of its assets. Should this be the case, a quantitative analysis is performed to identify whether a potential impairment exists by comparing the estimated fair values of the reporting units with their respective carrying values, including goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;An impairment loss is recognized if the implied fair value of the asset being tested is less than its carrying value. In this event, the asset is written down accordingly. The fair values of goodwill are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;At least annually, indefinite-lived intangible assets are tested for impairment. Impairment for intangible assets with indefinite lives exists if the carrying value of the intangible asset exceeds its fair value. The fair values of indefinite-lived intangible assets are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:NumberOfReportingUnits
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMTQyMjE_4ba2571d-cd3e-40c0-9a4a-2a88a42c8fe8"
      unitRef="unit">3</us-gaap:NumberOfReportingUnits>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMTU1NDk_7e35bbeb-6678-40df-bb8a-8baf30955897"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMTU1NDk_9ba01974-ff13-4d74-81db-2477f79d2ad5"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMTU1NDk_9c53e393-d987-4e09-8429-1d8b04fe753d"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMTU1NDk_a279a16d-e208-4350-95b1-b598bdeec617"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMTA5OTUxMTY4NDgyNg_0d9ecbf8-30ec-43d6-bb7b-62d1a9f6c685">&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Investments in Other Entities &#x2014; Equity Method&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company accounts for certain investments using the equity method of accounting when it is determined that the investment provides the Company with the ability to exercise significant influence, but not control, over the investee. Significant influence is generally deemed to exist if the Company has an ownership interest in the voting stock of the investee of between 20% and 50%, although other factors, such as representation on the investee&#x2019;s board of directors, are considered in determining whether the equity method of accounting is appropriate. Under the equity method of accounting, the investment, originally recorded at cost, is adjusted to recognize the Company&#x2019;s share of net earnings or losses of the investee and is recognized in the accompanying consolidated statements of income under &#x201c;Income (loss) from equity method investments&#x201d; and also is adjusted by contributions to and distributions from the investee. Equity method investments are subject to impairment evaluation. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Investments in Privately Held Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company accounts for certain investments using the cost method of accounting when it is determined that the investment provides the Company with little or no influence over the investee. Under the cost method of accounting, the investment is measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income. The investments in privately held entities that do not report NAV are subject to qualitative assessment for indicators of impairments.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy>
    <us-gaap:HealthCareCostsPolicyPolicyTextBlock
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDg4NTM_205e2ea6-2bb6-463f-a875-b477bbc1dcc7">&lt;div style="text-align:justify;margin-top:10pt;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Medical Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;APC, Alpha Care, Accountable Health Care, APAACO and MMG are responsible for integrated care that the associated physicians and contracted hospitals provide to their enrollees. APC, Alpha Care, Accountable Health Care, APAACO and MMG provide integrated care to HMOs, Medicare and Medi-Cal enrollees through a network of contracted providers under sub-capitation and direct patient service arrangements. Medical costs for professional and institutional services rendered by contracted providers are recorded as cost of services expenses in the accompanying consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;An estimate of amounts due to contracted physicians, hospitals, and other professional providers is included in medical liabilities in the accompanying consolidated balance sheets. Medical liabilities include claims reported as of the balance sheet date and estimates IBNR claims. Such estimates are developed using actuarial methods and are based on numerous variables, including the utilization of health care services, historical payment patterns, cost trends, product mix, seasonality, changes in membership, and other factors. The estimation methods and the resulting reserves are periodically reviewed and updated. Many of the medical contracts are complex in nature and may&#160;be subject to differing interpretations regarding amounts due for the provision of various services. Such differing interpretations may&#160;not come to light until a substantial period of time has passed following the contract implementation.&lt;/span&gt;&lt;/div&gt;</us-gaap:HealthCareCostsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDg4NjQ_7c3e15a3-5331-459b-ad6f-ffd71026b8b9">&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company receives payments from the following sources for services rendered: (i) commercial insurers; (ii) the federal government under the Medicare program administered by CMS; (iii) state governments under the Medicaid and other programs; (iv) other third-party payors (e.g., hospitals and IPAs); and (v) individual patients and clients.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Nature of Services and Revenue Streams&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenue primarily consists of capitation revenue, risk pool settlements and incentives, NGACO All-Inclusive Population-Based Payments (&#x201c;AIPBP&#x201d;), management fee income, and FFS revenue. Revenue is recorded in the period in which services are rendered or the period in which the Company is obligated to provide services. The form of billing and related risk of collection for such services may&#160;vary by type of revenue and the customer. The following is a summary of the principal forms of the Company&#x2019;s billing arrangements and how revenue is recognized for each.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Capitation, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Managed care revenues of the Company consist primarily of capitated fees for medical services provided by the Company under a capitated arrangement directly made with various managed care providers including HMOs. Capitation revenue is typically prepaid monthly to the Company based on the number of enrollees selecting the Company as their healthcare provider. Capitation revenue is recognized in the month in which the Company is obligated to provide services to plan enrollees under contracts with various health plans. Minor ongoing adjustments to prior months&#x2019; capitation, primarily arising from contracted HMOs finalizing their monthly patient eligibility data for additions or subtractions of enrollees, are recognized in the month they are communicated to the Company. Additionally, Medicare pays capitation using a &#x201c;Risk Adjustment&#x201d; model, which compensates managed care organizations and providers based on the health status (acuity) of each individual enrollee. Health plans and providers with higher acuity enrollees will receive more and those with lower acuity enrollees will receive less. Under Risk Adjustment, capitation is determined based on health severity, measured using patient encounter data. Capitation is paid on a monthly basis based on data submitted for the enrollee for the preceding year and is adjusted in subsequent periods after the final data is compiled. Positive or negative capitation adjustments are made for Medicare enrollees with conditions requiring more or less healthcare services than assumed in the interim payments. Since the Company cannot reliably predict these adjustments, periodic changes in capitation amounts earned as a result of Risk Adjustment are recognized when those changes are communicated by the health plans to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;PMPM managed care contracts generally have a term of one year or longer. All managed care contracts have a single performance obligation that constitutes a series for the provision of managed healthcare services for a population of enrolled members for the duration of the contract. The transaction price for PMPM contracts is variable as it primarily includes PMPM fees associated with unspecified membership that fluctuates throughout the contract. In certain contracts, PMPM fees also include adjustments for items such as performance incentives, performance guarantees and risk shares. The Company generally estimates the transaction price using the most likely amount methodology and amounts are only included in the net transaction price to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The majority of the Company&#x2019;s net PMPM transaction price relates specifically to the Company&#x2019;s efforts to transfer the service for a distinct increment of the series (e.g., day or month) and is recognized as revenue in the month in which members are entitled to service.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Risk Pool Settlements and Incentives&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;APC enters into full risk capitation arrangements with certain health plans and local hospitals, which are administered by a third party, where the hospital is responsible for providing, arranging and paying for institutional risk and APC is responsible for providing, arranging and paying for professional risk. Under a full risk pool sharing agreement, APC generally receives a percentage of the net surplus from the affiliated hospital&#x2019;s risk pools with HMOs after deductions for the affiliated hospitals costs. Advance settlement payments are typically made quarterly in arrears if there is a surplus. The Company&#x2019;s risk pool settlements under arrangements with health plans and hospitals are recognized using the most likely amount methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The assumptions for historical MLR, IBNR completion factors and constraint percentages were used by management in applying the most likely amount methodology.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Under capitated arrangements with certain HMOs, APC participates in one or more shared risk arrangements relating to the provision of institutional services to enrollees (shared risk arrangements) and thus can earn additional revenue or incur losses based upon the enrollee utilization of institutional services. Shared risk capitation arrangements are entered into with certain health plans, which are administered by the health plan, where APC is responsible for rendering professional services, but the health plan does not enter into a capitation arrangement with a hospital and therefore the health plan retains the institutional risk. Shared risk deficits, if any, are not payable until and unless (and only to the extent of any) risk-sharing surpluses are generated. At the termination of the HMO contract, any accumulated deficit will be extinguished.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s risk pool settlements under arrangements with HMOs are recognized, using the most likely methodology, and only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur. Given &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;the lack of access to the health plans&#x2019; data and control over the members assigned to APC, the adjustments and/or the withheld amounts are unpredictable and as such APC&#x2019;s risk share revenue is deemed to be fully constrained until APC is notified of the amount by the health plan. Risk pools for the prior contract years are generally final settled in the third or fourth quarter of the following year.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In addition to risk-sharing revenues, the Company also receives incentives under &#x201c;pay-for-performance&#x201d; programs for quality medical care, based on various criteria. As an incentive to control enrollee utilization and to promote quality care, certain HMOs have designed quality incentive programs and commercial generic pharmacy incentive programs to compensate the Company for its efforts to improve the quality of services and efficient and effective use of pharmacy supplemental benefits provided to HMO members. The incentive programs track specific performance measures and calculate payments to the Company based on the performance measures. The Company&#x2019;s incentives under &#x201c;pay-for-performance&#x201d; programs are recognized using the most likely methodology. However, as the Company does not have sufficient insight from the health plans on the amount and timing of the shared risk pool and incentive payments these amounts are considered to be fully constrained and only recorded when such payments are known and/or received.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Generally, for the foregoing arrangements, the final settlement is dependent on each distinct day&#x2019;s performance within the annual measurement period but cannot be allocated to specific days until the full measurement period has occurred and performance can be assessed. As such, this is a form of variable consideration estimated at contract inception and updated through the measurement period (i.e., the contract year), to the extent the risk of reversal does not exist and the consideration is not constrained.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;NGACO AIPBP Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;APAACO and CMS entered into a NGACO Model Participation Agreement (the &#x201c;Participation Agreement&#x201d;) with an initial term of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMjY0NTk_5c465777-41e6-4d7a-b713-4cd6abec3b70"&gt;two&lt;/span&gt; performance years through December&#160;31, 2018, which term was extended for &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMjY1MzU_16e36149-7c47-4c0c-bc55-d85a3cf36fbe"&gt;two&lt;/span&gt; additional renewal years.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For each performance year, the Company must submit to CMS its selections for risk arrangement; the amount of the profit/loss cap; alternative payment mechanism; benefits enhancements, if any; and its decision regarding voluntary alignment under the NGACO Model. The Company must obtain CMS consent before voluntarily discontinuing any benefit enhancement during a performance year.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the NGACO Model, CMS aligns beneficiaries to the Company to manage (direct care and pay providers) based on a budgetary benchmark established with CMS. The Company is responsible for managing medical costs for these beneficiaries. The beneficiaries will receive services from physicians and other medical service providers that are both in-network and out-of-network. The Company receives capitation from CMS on a monthly basis to pay claims from in-network providers. The Company records such capitation received from CMS as revenue as the Company is primarily responsible and liable for managing the patient care and for satisfying provider obligations, is assuming the credit risk for the services provided by in-network providers through its arrangement with CMS, and has control of the funds, the services provided and the process by which the providers are ultimately paid. Claims from out-of-network providers are processed and paid by CMS and the Company&#x2019;s shared savings or losses in managing the services provided by out-of-network providers are generally determined on an annual basis after reconciliation with CMS. Pursuant to the Company&#x2019;s risk share agreement with CMS, the Company will be eligible to receive the savings or be liable for the deficit according to the budget established by CMS based on the Company&#x2019;s efficiency in managing how the beneficiaries aligned to the Company by CMS are served by in-network and out-of-network providers. The Company&#x2019;s savings or losses on providing such services are both capped by CMS, and are subject to significant estimation risk, whereby payments can vary significantly depending upon certain patient characteristics and other variable factors. Accordingly, the Company recognizes such surplus or deficit upon substantial completion of reconciliation and determination of the amounts. The Company records NGACO capitation revenues monthly. Excess over claims paid, plus an estimate for the related IBNR claims (see Note 8), and monthly capitation received are deferred and recorded as a liability until actual claims are paid or incurred. CMS will determine if there were any excess capitation paid for the performance year and the excess is refunded to CMS.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For each performance year, CMS pays the Company in accordance with the alternative payment mechanism, if any, for which CMS has approved the Company; the risk arrangement for which the Company has been approved by CMS; and as otherwise provided in the Participation Agreement. Following the end of each performance year and at such other times as may be required under the Participation Agreement, CMS will issue a settlement report to the Company setting forth the amount of any shared savings or shared losses and the amount of other monies. If CMS owes the Company shared savings or other monies, CMS will pay the Company in full within 30 days after the date on which the relevant settlement report is deemed final, except as provided in the Participation Agreement. If the Company owes CMS shared losses or other monies owed as a result of a final settlement, the Company will pay CMS in full within 30 days after the relevant settlement report is deemed final. If the &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Company fails to pay the amounts due to CMS in full within 30 days after the date of a demand letter or settlement report, CMS will assess simple interest on the unpaid balance at the rate applicable to other Medicare debts under current provisions of law and applicable regulations. In addition, CMS and the U.S. Department of the Treasury may use any applicable debt collection tools available to collect any amounts owed by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company participates in the AIPBP track of the NGACO Model. Under the AIPBP track, CMS estimates the total annual expenditures for APAACO&#x2019;s assigned patients and pays that projected amount to the Company in monthly installments, and the Company is responsible for all Part A and Part B costs for in-network participating providers and preferred providers contracted by the Company to provide services to the assigned patients.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As APAACO does not have sufficient insight into the financial performance of the shared risk pool with CMS because of unknown factors related to IBNR claims, risk adjustment factors, and stop loss provisions, among other factors, an estimate cannot be developed. Due to these limitations, APAACO cannot determine the amount of surplus or deficit that will likely be recognized in the future and therefore this shared risk pool revenue is considered fully constrained.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For performance year 2020, the Company continues to receive monthly AIPBP payments at a rate of approximately $7.6 million per month from CMS, and will need to continue to comply with all terms and conditions in the Participation Agreement and various regulatory requirements to be eligible to participate in the AIPBP mechanism and/or NGACO Model. The Company has received approximately $22.9&#160;million and $45.5 million in total AIPBP payments for the three and six months ended June&#160;30, 2020, respectively, of which $20.5&#160;million and $42.4 million has been recognized as revenue for the three and six months ended June 30, 2020, respectively. The Company also recorded assets of approximately $8.5 million related to IBNR claims as of June&#160;30, 2020, and $3.2 million related to final settlement of the 2018 performance year. These balances are included in &#x201c;Other receivables&#x201d; in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Management Fee Income&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Management fee income encompasses fees paid for management, physician advisory, healthcare staffing, administrative and other non-medical services provided by the Company to IPAs, hospitals and other healthcare providers. Such fees may be in the form of billings at agreed-upon hourly rates, percentages of revenue or fee collections, or amounts fixed on a monthly, quarterly or annual basis. The revenue may include variable arrangements measuring factors such as hours staffed, patient visits or collections per visit against benchmarks, and, in certain cases, may be subject to achieving quality metrics or fee collections. The Company recognizes such variable supplemental revenues in the period when such amounts are determined to be fixed and therefore contractually obligated as payable by the customer under the terms of the applicable agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company provides a significant service of integrating the services selected by the Company&#x2019;s clients into one overall output for which the client has contracted. Therefore, such management contracts generally contain a single performance obligation. The nature of the Company&#x2019;s performance obligation is to stand ready to provide services over the contractual period. Also, the Company&#x2019;s performance obligation forms a series of distinct periods of time over which the Company stands ready to perform. The Company&#x2019;s performance obligation is satisfied as the Company completes each period&#x2019;s obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Consideration from management contracts is variable in nature because the majority of the fees are generally based on revenue or collections, which can vary from period to period. The Company has control over pricing. Contractual fees are invoiced to the Company&#x2019;s clients generally monthly and payment terms are typically due within 30 days. The variable consideration in the Company&#x2019;s management contracts meets the criteria to be allocated to the distinct period of time to which it relates because (i) it is due to the activities performed to satisfy the performance obligation during that period and (ii) it represents the consideration to which the Company expects to be entitled.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s management contracts generally have long terms (e.g., 10 years), although they may be terminated earlier under the terms of the applicable contracts. Since the remaining variable consideration will be allocated to a wholly unsatisfied promise that forms part of a single performance obligation recognized under the series guidance, the Company has applied the optional exemption to exclude disclosure of the allocation of the transaction price to remaining performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Fee-for-Service Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;FFS revenue represents revenue earned under contracts in which the Company bills and collects the professional component of charges for medical services rendered by the Company&#x2019;s contracted physicians and employed physicians. Under the FFS arrangements, the Company bills the hospitals and third-party payors for the physician staffing and further bills patients or their third-party payors for patient care services provided and receives payment. FFS revenue related to the patient care services is reported net of contractual allowances and policy discounts and are recognized in the period in which the services are rendered to specific patients. All services provided are expected to result in cash flows and are therefore reflected as net revenue in the &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;consolidated financial statements. The recognition of net revenue (gross charges less contractual allowances) from such services is dependent on such factors as proper completion of medical charts following a patient visit, the forwarding of such charts to the Company&#x2019;s billing center for medical coding and entering into the Company&#x2019;s billing system and the verification of each patient&#x2019;s submission or representation at the time services are rendered as to the payor(s) responsible for payment of such services. Revenue is recorded based on the information known at the time of entering of such information into the Company&#x2019;s billing systems, as well as an estimate of the revenue associated with medical services.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company is responsible for confirming member eligibility, performing program utilization review, potentially directing payment to the provider and accepting the financial risk of loss associated with services rendered, as specified within the Company&#x2019;s client contracts. The Company has the ability to adjust contractual fees with clients and possess the financial risk of loss in certain contractual obligations. These factors indicate the Company is the principal and, as such, the Company records gross fees contracted with clients in revenues.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Consideration from FFS arrangements is variable in nature because fees are based on patient encounters, credits due to clients and reimbursement of provider costs, all of which can vary from period to period.&#160;Patient encounters and related episodes of care and procedures qualify as distinct goods and services, provided simultaneously together with other readily available resources, in a single instance of service, and thereby constitute a single performance obligation for each patient encounter and, in most instances, occur at readily determinable transaction prices. As a practical expedient, the Company adopted a portfolio approach for the FFS revenue stream to group together contracts with similar characteristics and analyze historical cash collections trends. The contracts within the portfolio share the characteristics conducive to ensuring that the results do not materially differ under the new standard if it were to be applied to individual patient contracts related to each patient encounter. Accordingly, there was no change in the Company&#x2019;s method to recognize revenue under ASC 606 &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; from the previous accounting guidance.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Estimating net FFS revenue is a complex process, largely due to the volume of transactions, the number and complexity of contracts with payors, the limited availability at times of certain patient and payor information at the time services are provided, and the length of time it takes for collections to fully mature. These expected collections are based on fees and negotiated payment rates in the case of third-party payors, the specific benefits provided for under each patient&#x2019;s healthcare plans, mandated payment rates in the case of Medicare and Medicaid programs, and historical cash collections (net of recoveries) in combination with expected collections from third-party payors.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The relationship between gross charges and the transaction price recognized is significantly influenced by payor mix, as collections on gross charges may vary significantly, depending on whether and with whom the patients the Company provides services to in the period are insured and the Company&#x2019;s contractual relationships with those payors. Payor mix is subject to change as additional patient and payor information is obtained after the period services are provided. The Company periodically assesses the estimates of unbilled revenue, contractual adjustments and discounts, and payor mix by analyzing actual results, including cash collections, against estimates. Changes in these estimates are charged or credited to the consolidated statements of income in the period that the assessment is made. Significant changes in payor mix, contractual arrangements with payors, specialty mix, acuity, general economic conditions and health care coverage provided by federal or state governments or private insurers may have a significant impact on estimates and significantly affect the results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Contract Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Typically, revenues and receivables are recognized once the Company has satisfied its performance obligation. Accordingly, the Company&#x2019;s contract assets are comprised of receivables and receivables &#x2013; related parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2019;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;s billing and accounting systems provide historical trends of cash collections and contractual write-offs, accounts receivable agings and established fee adjustments from third-party payors. These estimates are recorded and monitored monthly as revenues are recognized.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; The principal exposure for uncollectible fee for service visits is from self-pay patients and, to a lesser extent, for co-payments and deductibles from patients with insurance.&lt;/span&gt;&lt;/div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Contract Liabilities (Deferred Revenue&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;)&lt;/span&gt;Contract liabilities are recorded when cash payments are received in advance of the Company&#x2019;s performance, or in the case of the Company&#x2019;s NGACO, the excess of AIPBP capitation received and the actual claims paid or incurred.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:RevenuePerformanceObligationDescriptionOfTiming
      contextRef="i86d36b0423244dd6a1ef5fb8fed9dc60_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMjEwNTA_8389bca6-0e1f-4dac-b73d-0b2b47d9142b">one year</us-gaap:RevenuePerformanceObligationDescriptionOfTiming>
    <ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport
      contextRef="id5fbfd0a0b9b4ab3876be59e23e3f101_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMjk4MDM_fd2673ad-4165-4ac9-b2d0-fda96b9bba54">P30D</ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport>
    <ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport
      contextRef="id5fbfd0a0b9b4ab3876be59e23e3f101_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMzAwNjQ_dddebf36-3e02-449e-9d95-0db761f21827">P30D</ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport>
    <ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport
      contextRef="id5fbfd0a0b9b4ab3876be59e23e3f101_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMzAxODc_dddebf36-3e02-449e-9d95-0db761f21827">P30D</ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport>
    <ameh:PaymentOfRevenueMonthlyAmount
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMzE1NjI_397fab6e-73a3-4055-82fc-ecb297ad278d"
      unitRef="usd">7600000</ameh:PaymentOfRevenueMonthlyAmount>
    <ameh:PaymentOfRevenue
      contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMTA5OTUxMTY5MDg4OQ_8b15ea4f-1d2e-44d9-a435-40a4652c6856"
      unitRef="usd">22900000</ameh:PaymentOfRevenue>
    <ameh:PaymentOfRevenue
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMzE4MzA_ee5fdb5e-ed8f-4cd3-8a8b-59045b18e569"
      unitRef="usd">45500000</ameh:PaymentOfRevenue>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNjA0NzMxNDAwNzg0NQ_68398c18-80f3-4b85-bc2e-678ffde5072a"
      unitRef="usd">20500000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMzE4OTM_0f9a88bc-2ca7-403a-b5cc-0ac17a4779fa"
      unitRef="usd">42400000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ReinsuranceRecoverables
      contextRef="ie8986202564b4172b0aab2302c7971a4_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMzE5Nzg_061f15c6-3398-4412-998e-2350afcfe193"
      unitRef="usd">8500000</us-gaap:ReinsuranceRecoverables>
    <us-gaap:ReinsuranceRecoverables
      contextRef="ie1e6d8b85f4246bf94ae0b52733c146d_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMzIwMzE_8353eb79-b28a-4343-8fec-3578663dcf76"
      unitRef="usd">3200000</us-gaap:ReinsuranceRecoverables>
    <us-gaap:RevenuePerformanceObligationDescriptionOfTiming
      contextRef="ic862c6560a614f5abea31e3ad439d0fe_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMzQ0Mjc_e6e3e166-dd9a-4fe4-ad62-79f81e20fb04">10 years</us-gaap:RevenuePerformanceObligationDescriptionOfTiming>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDA5MTM_08178166-5653-4ac3-b703-a05b43766b45"
      unitRef="usd">3100000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDA5MjA_107dd19b-c59c-4815-99d4-d2c58696506e"
      unitRef="usd">8900000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i9f4243e46d3647e093788a742f11debf_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDEwOTg_ee4f2a2e-87a2-4538-8076-2b1bf6ea5fb4"
      unitRef="usd">400000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <ameh:ContractWithCustomerLiabilityRepaidCapitationReceivedAndNotEarned
      contextRef="i9f4243e46d3647e093788a742f11debf_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDExODY_a81f7997-e460-40e8-b894-2396c0904fa9"
      unitRef="usd">8500000</ameh:ContractWithCustomerLiabilityRepaidCapitationReceivedAndNotEarned>
    <ameh:InvestmentDeposit
      contextRef="iee021f30ec494988b04ffd293da80842_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDEzMzE_126b316e-8f93-4363-9d63-afb1761f820b"
      unitRef="usd">4000000.0</ameh:InvestmentDeposit>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDg4OTk_58c76831-0a13-4ffe-a0aa-889ee77aa40c">&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Federal and state income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the consolidated financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDg5MTg_ebdca82c-0e7d-4918-ab48-e91dac7f3343">&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company maintains a stock-based compensation program for employees, non-employees, directors and consultants. The value of share-based awards such as options is recognized as compensation expense on a cumulative straight-line basis over the vesting period of the awards, adjusted for expected forfeitures. From time to time, the Company issues shares of its common stock to its employees, directors and consultants, which shares may be subject to the Company&#x2019;s repurchase right (but not obligation) that lapses based on time-based and performance-based vesting schedules.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDg4NDM_71f71d48-4eae-4f2c-887d-920b478613c0">&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Basic and Diluted Earnings Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Basic earnings per share is computed by dividing net income attributable to holders of the Company&#x2019;s common stock by the weighted average number of shares of common stock outstanding during the periods presented. Diluted earnings per share is computed using the weighted average number of shares of common stock outstanding, plus the effect of dilutive securities outstanding during the periods presented, using the treasury stock method. Refer to Note 14 for a discussion of shares treated as treasury shares for accounting purposes.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <ameh:MinorityInterestPolicyPolicyTextBlock
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDg4NjE_d8d27765-cf20-4080-908a-f80a584536c3">&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Noncontrolling Interests&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company consolidates entities in which the Company has a controlling financial interest. The Company consolidates subsidiaries in which the Company holds, directly or indirectly, more than 50% of the voting rights, and VIEs in which the Company is the primary beneficiary. Noncontrolling interests represent third-party equity ownership interests (including equity ownership interests held by certain VIEs) in the Company&#x2019;s consolidated entities. Net income attributable to noncontrolling interests is disclosed in the consolidated statements of income.&lt;/span&gt;&lt;/div&gt;</ameh:MinorityInterestPolicyPolicyTextBlock>
    <us-gaap:VariableInterestEntityOwnershipPercentage
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDQ2Mzk_26e19047-cf31-4802-9d92-16e87243cc4b"
      unitRef="number">0.50</us-gaap:VariableInterestEntityOwnershipPercentage>
    <ameh:TemporaryEquityPolicyTextBlock
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDg5MDU_af42b10d-e478-4064-946a-6cabe8ce1fda">&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Mezzanine Equity&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Pursuant to APC&#x2019;s shareholder agreements, in the event of a disqualifying event, as defined in the agreements, APC could be required to repurchase the shares from the respective shareholders based on certain triggers outlined in the shareholder agreements. As the redemption feature of the shares is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as mezzanine or temporary equity. Accordingly, the Company recognizes &lt;/span&gt;&lt;/div&gt;noncontrolling interests in APC as mezzanine equity in the consolidated financial statements.</ameh:TemporaryEquityPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfNDg4NTQ_da34dd7e-9bae-4efb-a238-e7a78af60990">&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2016, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-13, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Financial Instruments-Credit Losses (Topic 326)-Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (&#x201c;ASU 2016-13&#x201d;). The new standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. ASU 2016-13 became effective for fiscal years beginning after December 15, 2019, with early adoption permitted. The Company adopted ASU 2016-13 on January 1, 2020. The adoption of ASU 2016-13 did not have a material impact on the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In October 2018, the FASB issued ASU No. 2018-17, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Consolidation (Topic 810): Targeted Improvements to Related Party Guidance for Variable Interest Entities&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (&#x201c;ASU 2018-17&#x201d;). This ASU reduces the cost and complexity of financial reporting associated with consolidation of VIEs. A VIE is an organization in which consolidation is not based on a majority of voting rights. The new guidance supersedes the private company alternative for common control leasing arrangements issued in 2014 and expands it to all qualifying common control arrangements. The amendments in this ASU became effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The Company adopted ASU 2018-17 on January 1, 2020. The adoption of ASU 2018-17 did not have a material impact on the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In December 2019, the FASB issued ASU No. 2019-12, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (&#x201c;ASU 2019-12&#x201d;). This ASU simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740 &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Income Taxes &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The amendments in this ASU are effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company is currently assessing the impact that the adoption of ASU 2019-12 will have on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In January 2020, the FASB issued ASU No. 2020-01, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Investments - Equity Securities (Topic 321), Investments - Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;(&#x201c;ASU 2020-01&#x201d;). This ASU clarifies the interaction between accounting for equity securities, equity method investments and certain derivative instruments. The amendments in this ASU are effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company is currently assessing the impact that the adoption of ASU 2020-01 will have on the Company's consolidation financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Other than the standards discussed above, there have been no other new accounting pronouncements that have significance, or potential significance, to the Company&#x2019;s financial position, results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RleHRyZWdpb246MjJkNDk5OGM1YmExNDc0OGIxODUyMjQ3ZGMzYThmYzNfMzA5Mw_e558478a-2842-4cf8-b520-9cf70917e1bc">Business Combinations and Goodwill&lt;div style="text-indent:-18pt;padding-left:18pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Alpha Care Medical Group, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On May 31, 2019, APC and APC-LSMA completed their acquisition of 100% of the capital stock of Alpha Care from Dr. Kevin Tyson for an aggregate purchase price of approximately $45.1 million in cash, subject to post-closing adjustments. As part of the transaction the Company deposited $2.0 million into an escrow account for potential post-closing adjustments. As of June&#160;30, 2020, no post-closing adjustment is expected to be paid to Dr. Tyson and the full amount of the escrow account is expected to be returned to the Company. As such, the escrow amount is presented within prepaid expenses and other current assets in the accompanying consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the estimated fair values of the assets acquired and liabilities assumed, as of the acquisition date (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:78.498%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.502%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance Sheet&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;Assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Network relationship intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,795)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(6,334)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Medical liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(15,616)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;45,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash paid&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;45,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Accountable Health Care, IPA, a Professional Medical Corporation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On August 30, 2019, APC and APC-LSMA acquired the remaining outstanding shares of capital stock (comprising 75%) in Accountable Health Care in exchange for $7.3 million. In addition to the payment of $7.3 million, APC assumed all assets and liabilities of Accountable Health Care, including loans payable to NMM and APC of $15.4 million, which have been eliminated upon consolidation and contributed the 25% investment totaling $2.4 million, total purchase price was $25.1 million (see Note 5). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the estimated fair values of the assets acquired and liabilities assumed, as of the acquisition date (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:78.498%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.502%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance Sheet&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;Assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Network relationship intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3,759)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Medical liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(12,154)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Subordinated loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(15,327)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net asset acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Equity investment contributed&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash paid&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;AMG, a Professional Medical Corporation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company acquired AMG in September 2019, for total consideration of $1.6 million, of which $0.4 million was in the form of APC common stock. The business combination did not meet the quantitative thresholds to require separate disclosures based on the Company&#x2019;s consolidated net assets, investments and net income.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The acquisitions were accounted for under the acquisition method of accounting. The fair value of the consideration for the acquired company was allocated to acquired tangible and intangible assets and liabilities based upon their fair values. The excess of the purchase consideration over the fair value of the net tangible and identifiable intangible assets acquired was recorded as goodwill. The determination of the fair value of assets and liabilities acquired requires the Company to make estimates and use valuation techniques when market value is not readily available. The results of operations of the company &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;acquired have been included in the Company&#x2019;s financial statements from the date of acquisition. Transaction costs associated with business acquisitions are expensed as they are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;At the time of acquisition, the Company estimates the amount of the identifiable intangible assets based on a valuation and the facts and circumstances available at the time. The Company determines the final value of the identifiable intangible assets as soon as information is available, but not more than one year from the date of acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Goodwill is not deductible for tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The change in the carrying value of goodwill for the six months ended June&#160;30, 2020, was as follows (in thousands);&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:78.498%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.502%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance, January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;238,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance, June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;239,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="iab3766c2a60b42849e233d9acb377205_I20190531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RleHRyZWdpb246MjJkNDk5OGM1YmExNDc0OGIxODUyMjQ3ZGMzYThmYzNfMTMy_3d5d0ceb-d803-4ee5-bcf5-54919a55da78"
      unitRef="number">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i8e2f250049ae44589256e0929aad4803_D20190531-20190531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RleHRyZWdpb246MjJkNDk5OGM1YmExNDc0OGIxODUyMjQ3ZGMzYThmYzNfMjQw_ca5fe5b1-cc6a-4867-b3d7-d10512a68c41"
      unitRef="usd">45100000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:EscrowDeposit
      contextRef="iab3766c2a60b42849e233d9acb377205_I20190531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RleHRyZWdpb246MjJkNDk5OGM1YmExNDc0OGIxODUyMjQ3ZGMzYThmYzNfMzM4_0a4aa14b-bad4-4d20-9a8a-3ed3939c0fc3"
      unitRef="usd">2000000.0</us-gaap:EscrowDeposit>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RleHRyZWdpb246MjJkNDk5OGM1YmExNDc0OGIxODUyMjQ3ZGMzYThmYzNfMzA5NA_c75fb1a2-835b-4c58-85e1-948b8f33b8d1">The following table summarizes the estimated fair values of the assets acquired and liabilities assumed, as of the acquisition date (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:78.498%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.502%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance Sheet&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;Assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Network relationship intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,795)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(6,334)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Medical liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(15,616)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;45,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash paid&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;45,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the estimated fair values of the assets acquired and liabilities assumed, as of the acquisition date (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:78.498%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.502%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance Sheet&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;Assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Network relationship intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3,759)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Medical liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(12,154)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Subordinated loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(15,327)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net asset acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Equity investment contributed&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash paid&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="iab3766c2a60b42849e233d9acb377205_I20190531"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RhYmxlOjFkZjA4MzcwZGRiOTQzOTVhNjQ4NzI0NGI1YTc1ZTU4L3RhYmxlcmFuZ2U6MWRmMDgzNzBkZGI5NDM5NWE2NDg3MjQ0YjVhNzVlNThfMi0xLTEtMS0w_d1914f96-4915-4af1-aafb-986b194f93b7"
      unitRef="usd">3569000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="iab3766c2a60b42849e233d9acb377205_I20190531"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RhYmxlOjFkZjA4MzcwZGRiOTQzOTVhNjQ4NzI0NGI1YTc1ZTU4L3RhYmxlcmFuZ2U6MWRmMDgzNzBkZGI5NDM5NWE2NDg3MjQ0YjVhNzVlNThfMy0xLTEtMS0w_4d45e629-b8fc-4717-b606-5c7ee9708f5e"
      unitRef="usd">10336000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther
      contextRef="iab3766c2a60b42849e233d9acb377205_I20190531"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RhYmxlOjFkZjA4MzcwZGRiOTQzOTVhNjQ4NzI0NGI1YTc1ZTU4L3RhYmxlcmFuZ2U6MWRmMDgzNzBkZGI5NDM5NWE2NDg3MjQ0YjVhNzVlNThfNC0xLTEtMS0w_b6068264-ee7d-432f-b8c9-6c0371cae0d2"
      unitRef="usd">4675000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="iab3766c2a60b42849e233d9acb377205_I20190531"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RhYmxlOjFkZjA4MzcwZGRiOTQzOTVhNjQ4NzI0NGI1YTc1ZTU4L3RhYmxlcmFuZ2U6MWRmMDgzNzBkZGI5NDM5NWE2NDg3MjQ0YjVhNzVlNThfNS0xLTEtMS0w_d89891ec-ebb7-4328-a661-056c83d89793"
      unitRef="usd">22636000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:Goodwill
      contextRef="iab3766c2a60b42849e233d9acb377205_I20190531"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RhYmxlOjFkZjA4MzcwZGRiOTQzOTVhNjQ4NzI0NGI1YTc1ZTU4L3RhYmxlcmFuZ2U6MWRmMDgzNzBkZGI5NDM5NWE2NDg3MjQ0YjVhNzVlNThfNi0xLTEtMS0w_0f9a3b8d-92cf-4455-b50c-d7e8974a95a1"
      unitRef="usd">28585000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="iab3766c2a60b42849e233d9acb377205_I20190531"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RhYmxlOjFkZjA4MzcwZGRiOTQzOTVhNjQ4NzI0NGI1YTc1ZTU4L3RhYmxlcmFuZ2U6MWRmMDgzNzBkZGI5NDM5NWE2NDg3MjQ0YjVhNzVlNThfNy0xLTEtMS0w_c9b7a623-92f0-4e37-a07e-4b888513014f"
      unitRef="usd">2795000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="iab3766c2a60b42849e233d9acb377205_I20190531"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RhYmxlOjFkZjA4MzcwZGRiOTQzOTVhNjQ4NzI0NGI1YTc1ZTU4L3RhYmxlcmFuZ2U6MWRmMDgzNzBkZGI5NDM5NWE2NDg3MjQ0YjVhNzVlNThfOC0xLTEtMS0w_1e7aedff-0bde-45f5-8771-6a5bc0912fc2"
      unitRef="usd">6334000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <ameh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities
      contextRef="iab3766c2a60b42849e233d9acb377205_I20190531"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RhYmxlOjFkZjA4MzcwZGRiOTQzOTVhNjQ4NzI0NGI1YTc1ZTU4L3RhYmxlcmFuZ2U6MWRmMDgzNzBkZGI5NDM5NWE2NDg3MjQ0YjVhNzVlNThfOS0xLTEtMS0w_a16d79e2-cdb8-419a-a698-f6c7165b4c14"
      unitRef="usd">15616000</ameh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="iab3766c2a60b42849e233d9acb377205_I20190531"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RhYmxlOjFkZjA4MzcwZGRiOTQzOTVhNjQ4NzI0NGI1YTc1ZTU4L3RhYmxlcmFuZ2U6MWRmMDgzNzBkZGI5NDM5NWE2NDg3MjQ0YjVhNzVlNThfMTAtMS0xLTEtMA_6789f35d-73ee-4c39-b8c8-2e0c8886f32d"
      unitRef="usd">45056000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i8e2f250049ae44589256e0929aad4803_D20190531-20190531"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RhYmxlOjFkZjA4MzcwZGRiOTQzOTVhNjQ4NzI0NGI1YTc1ZTU4L3RhYmxlcmFuZ2U6MWRmMDgzNzBkZGI5NDM5NWE2NDg3MjQ0YjVhNzVlNThfMTItMS0xLTEtMA_dc10f8db-074b-4466-a3c2-f995693b92cd"
      unitRef="usd">45056000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i9004566cce7c4ef7b4abb21095da7358_I20190830"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RleHRyZWdpb246MjJkNDk5OGM1YmExNDc0OGIxODUyMjQ3ZGMzYThmYzNfMTAwMg_2d1e9341-0e8c-4adb-bd68-807e6d27ebf9"
      unitRef="number">0.75</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i26cbf8fca0d84265be9879b3b17db702_D20190830-20190830"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RleHRyZWdpb246MjJkNDk5OGM1YmExNDc0OGIxODUyMjQ3ZGMzYThmYzNfMTA0OQ_5fce0098-5058-4e58-9db4-cee3d9b5e35b"
      unitRef="usd">7300000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i26cbf8fca0d84265be9879b3b17db702_D20190830-20190830"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RleHRyZWdpb246MjJkNDk5OGM1YmExNDc0OGIxODUyMjQ3ZGMzYThmYzNfMTA4Mw_5fce0098-5058-4e58-9db4-cee3d9b5e35b"
      unitRef="usd">7300000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="i9efe901318bb4ed08cc6432008f3343c_I20190830"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RleHRyZWdpb246MjJkNDk5OGM1YmExNDc0OGIxODUyMjQ3ZGMzYThmYzNfMTE5NQ_319bf01c-4cac-49bb-bb5a-8c5012520c5d"
      unitRef="usd">15400000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i460f9923ee7347d6aa697c85d63b74e1_I20190830"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RleHRyZWdpb246MjJkNDk5OGM1YmExNDc0OGIxODUyMjQ3ZGMzYThmYzNfMTI2NQ_2350ca72-05f9-42f5-9844-fd4f558ff805"
      unitRef="number">0.25</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i9519fc3d763e44bba24ad68ede94a1c0_D20190830-20190830"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RleHRyZWdpb246MjJkNDk5OGM1YmExNDc0OGIxODUyMjQ3ZGMzYThmYzNfMTI4OA_90fd2050-a2ec-4cec-9fa7-ca5d2072fc16"
      unitRef="usd">2400000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i40df6f98654940f690d8f5bfc4d573bc_D20190830-20190830"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RleHRyZWdpb246MjJkNDk5OGM1YmExNDc0OGIxODUyMjQ3ZGMzYThmYzNfMTMxNw_6e56cb74-706c-4df5-b6e6-1d241e615ecf"
      unitRef="usd">25100000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="ic772c23a08d84f8da481202e5fe65be4_I20190830"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RhYmxlOjY2NTc3ODA5NmMwYzRiNjA5ZTVlOTQ0NzEyYjg1MzFhL3RhYmxlcmFuZ2U6NjY1Nzc4MDk2YzBjNGI2MDllNWU5NDQ3MTJiODUzMWFfMi0xLTEtMS0w_05bde798-191d-4b01-903e-06b0bb65c8f7"
      unitRef="usd">582000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="ic772c23a08d84f8da481202e5fe65be4_I20190830"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RhYmxlOjY2NTc3ODA5NmMwYzRiNjA5ZTVlOTQ0NzEyYjg1MzFhL3RhYmxlcmFuZ2U6NjY1Nzc4MDk2YzBjNGI2MDllNWU5NDQ3MTJiODUzMWFfMy0xLTEtMS0w_56a05fda-9a84-4aa8-99e6-f3a29415c160"
      unitRef="usd">5150000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther
      contextRef="ic772c23a08d84f8da481202e5fe65be4_I20190830"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RhYmxlOjY2NTc3ODA5NmMwYzRiNjA5ZTVlOTQ0NzEyYjg1MzFhL3RhYmxlcmFuZ2U6NjY1Nzc4MDk2YzBjNGI2MDllNWU5NDQ3MTJiODUzMWFfNC0xLTEtMS0w_7c4a65c3-3fa3-4178-a572-1fbcd22b6fa8"
      unitRef="usd">198000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="ic772c23a08d84f8da481202e5fe65be4_I20190830"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RhYmxlOjY2NTc3ODA5NmMwYzRiNjA5ZTVlOTQ0NzEyYjg1MzFhL3RhYmxlcmFuZ2U6NjY1Nzc4MDk2YzBjNGI2MDllNWU5NDQ3MTJiODUzMWFfNS0xLTEtMS0w_b380570d-6d1b-47ae-a7c4-e7a3b728b415"
      unitRef="usd">11411000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:Goodwill
      contextRef="ic772c23a08d84f8da481202e5fe65be4_I20190830"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RhYmxlOjY2NTc3ODA5NmMwYzRiNjA5ZTVlOTQ0NzEyYjg1MzFhL3RhYmxlcmFuZ2U6NjY1Nzc4MDk2YzBjNGI2MDllNWU5NDQ3MTJiODUzMWFfNi0xLTEtMS0w_59a1e4ea-2e98-4990-beb2-ce776aefb0a1"
      unitRef="usd">23566000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="ic772c23a08d84f8da481202e5fe65be4_I20190830"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RhYmxlOjY2NTc3ODA5NmMwYzRiNjA5ZTVlOTQ0NzEyYjg1MzFhL3RhYmxlcmFuZ2U6NjY1Nzc4MDk2YzBjNGI2MDllNWU5NDQ3MTJiODUzMWFfNy0xLTEtMS0w_a9e6f6d5-c3a5-4ca8-b361-f4872d55f147"
      unitRef="usd">3759000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <ameh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities
      contextRef="ic772c23a08d84f8da481202e5fe65be4_I20190830"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RhYmxlOjY2NTc3ODA5NmMwYzRiNjA5ZTVlOTQ0NzEyYjg1MzFhL3RhYmxlcmFuZ2U6NjY1Nzc4MDk2YzBjNGI2MDllNWU5NDQ3MTJiODUzMWFfOC0xLTEtMS0w_06849f3d-c943-41a5-a96c-7d825b9e71f4"
      unitRef="usd">12154000</ameh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities
      contextRef="ic772c23a08d84f8da481202e5fe65be4_I20190830"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RhYmxlOjY2NTc3ODA5NmMwYzRiNjA5ZTVlOTQ0NzEyYjg1MzFhL3RhYmxlcmFuZ2U6NjY1Nzc4MDk2YzBjNGI2MDllNWU5NDQ3MTJiODUzMWFfOS0xLTEtMS0w_5f9ceb62-32ce-44b1-b583-0bbd88ef31eb"
      unitRef="usd">15327000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="ic772c23a08d84f8da481202e5fe65be4_I20190830"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RhYmxlOjY2NTc3ODA5NmMwYzRiNjA5ZTVlOTQ0NzEyYjg1MzFhL3RhYmxlcmFuZ2U6NjY1Nzc4MDk2YzBjNGI2MDllNWU5NDQ3MTJiODUzMWFfMTAtMS0xLTEtMA_a2367db8-3593-4432-afce-faf438274cff"
      unitRef="usd">9667000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned
      contextRef="ic772c23a08d84f8da481202e5fe65be4_I20190830"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RhYmxlOjY2NTc3ODA5NmMwYzRiNjA5ZTVlOTQ0NzEyYjg1MzFhL3RhYmxlcmFuZ2U6NjY1Nzc4MDk2YzBjNGI2MDllNWU5NDQ3MTJiODUzMWFfMTItMS0xLTEtMA_72f77e28-39c6-4598-aaf3-735984977aa3"
      unitRef="usd">2417000</us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i38b436d30e5240e3965b3cb5408fc04b_D20190830-20190830"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RhYmxlOjY2NTc3ODA5NmMwYzRiNjA5ZTVlOTQ0NzEyYjg1MzFhL3RhYmxlcmFuZ2U6NjY1Nzc4MDk2YzBjNGI2MDllNWU5NDQ3MTJiODUzMWFfMTMtMS0xLTEtMA_5dec2212-9d5d-441d-8fef-58da97f9f487"
      unitRef="usd">7250000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i226c14d75f674f3aace656903b7c99e1_D20190901-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RleHRyZWdpb246MjJkNDk5OGM1YmExNDc0OGIxODUyMjQ3ZGMzYThmYzNfMTU1NQ_e9779405-7c98-49f5-a758-4e79351592d9"
      unitRef="usd">1600000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="if3e410ddfdb74a3daeb61a44c92264d8_D20190901-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RleHRyZWdpb246MjJkNDk5OGM1YmExNDc0OGIxODUyMjQ3ZGMzYThmYzNfMTU2OA_d57c651c-a319-441b-bf09-230b79c75ad7"
      unitRef="usd">400000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RleHRyZWdpb246MjJkNDk5OGM1YmExNDc0OGIxODUyMjQ3ZGMzYThmYzNfMzA4OA_d417fd97-db18-4f21-8b09-6c6af202007d">&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The change in the carrying value of goodwill for the six months ended June&#160;30, 2020, was as follows (in thousands);&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:78.498%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.502%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance, January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;238,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance, June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;239,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RhYmxlOjU2ZWZjYzVlMTM3ZTQ1ZWY4NGU5N2Y5MjIwOWZhNWVkL3RhYmxlcmFuZ2U6NTZlZmNjNWUxMzdlNDVlZjg0ZTk3ZjkyMjA5ZmE1ZWRfMC0xLTEtMS0w_ff8f85a7-2298-4864-8b54-1969c1a5db3b"
      unitRef="usd">238505000</us-gaap:Goodwill>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RhYmxlOjU2ZWZjYzVlMTM3ZTQ1ZWY4NGU5N2Y5MjIwOWZhNWVkL3RhYmxlcmFuZ2U6NTZlZmNjNWUxMzdlNDVlZjg0ZTk3ZjkyMjA5ZmE1ZWRfMS0xLTEtMS0w_83b52057-97e6-4531-933a-a0d5bc1ade4a"
      unitRef="usd">548000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:Goodwill
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80OS9mcmFnOjIyZDQ5OThjNWJhMTQ3NDhiMTg1MjI0N2RjM2E4ZmMzL3RhYmxlOjU2ZWZjYzVlMTM3ZTQ1ZWY4NGU5N2Y5MjIwOWZhNWVkL3RhYmxlcmFuZ2U6NTZlZmNjNWUxMzdlNDVlZjg0ZTk3ZjkyMjA5ZmE1ZWRfMy0xLTEtMS0w_3c4385ac-f704-4948-bc70-4f7cc15bdf63"
      unitRef="usd">239053000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RleHRyZWdpb246YzU4NjQ0ZjNjZDg3NDQ1Nzk1ZWZhYmJhZGNiN2Q2ZGVfNDg2_9c98e441-4b21-409c-889d-d4ccd29cfdc9">Intangible Assets, Net&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;At June&#160;30, 2020, the Company&#x2019;s intangible assets, net, consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:42.199%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.544%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.684%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.684%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.687%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Useful&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Life&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Amortized intangible assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Network relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;11-15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;143,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(67,015)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;76,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Management contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(10,736)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Member relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,793)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Patient management platform&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,064)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Trade names/trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(131)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;176,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(81,739)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;94,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;At December&#160;31, 2019, the Company&#x2019;s intangible assets, net, consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:38.789%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.426%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.888%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.234%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Useful&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Life&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Amortized intangible assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Network relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;11-15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;143,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(60,526)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;83,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Management contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(9,676)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Member relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,352)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Patient management platform&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(858)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Trade names/trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(105)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;176,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(73,517)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;103,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Included in depreciation and amortization on the accompanying consolidated statements of income is amortization expense of $4.1 million and $3.9 million for the three months ended June&#160;30, 2020 and 2019, respectively, and $8.2 million and $7.7 million for the six months ended June&#160;30, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Future amortization expense is estimated to be as follows for the following years ending December&#160;31 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:85.262%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.738%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020 (excluding the six months ended June 30, 2020)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;39,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;94,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RleHRyZWdpb246YzU4NjQ0ZjNjZDg3NDQ1Nzk1ZWZhYmJhZGNiN2Q2ZGVfNDgy_22c08c94-ea59-480c-ad41-97c4ce883deb">&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;At June&#160;30, 2020, the Company&#x2019;s intangible assets, net, consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:42.199%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.544%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.684%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.684%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.687%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Useful&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Life&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Amortized intangible assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Network relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;11-15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;143,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(67,015)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;76,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Management contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(10,736)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Member relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,793)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Patient management platform&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,064)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Trade names/trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(131)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;176,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(81,739)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;94,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;At December&#160;31, 2019, the Company&#x2019;s intangible assets, net, consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:38.789%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.426%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.888%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.234%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Useful&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Life&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Amortized intangible assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Network relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;11-15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;143,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(60,526)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;83,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Management contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(9,676)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Member relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,352)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Patient management platform&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(858)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Trade names/trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(105)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;176,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(73,517)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;103,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i73be6919be5e46b1a06e1ea222b2fdbe_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmMzNTFhMmEyMWJhOTQ0Yzc5OTliZjRlM2I3YWUxZDUwL3RhYmxlcmFuZ2U6YzM1MWEyYTIxYmE5NDRjNzk5OWJmNGUzYjdhZTFkNTBfMi0xLTEtMS0wL3RleHRyZWdpb246NmRhNjVmNjA0Njk4NGQ0NDkyMGUxOGZkMTZmYzRjYThfNjU5NzA2OTc2NjY2Nw_9a1940d4-9773-4d3a-a31f-dbd236d64418">P11Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ia02225d6109046c78a438c6a8b4976e7_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmMzNTFhMmEyMWJhOTQ0Yzc5OTliZjRlM2I3YWUxZDUwL3RhYmxlcmFuZ2U6YzM1MWEyYTIxYmE5NDRjNzk5OWJmNGUzYjdhZTFkNTBfMi0xLTEtMS0wL3RleHRyZWdpb246NmRhNjVmNjA0Njk4NGQ0NDkyMGUxOGZkMTZmYzRjYThfNjU5NzA2OTc2NjY3OQ_095467a6-f25d-4281-8a1f-0e72e1e0f400">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i9a061ecd0e88428da9167e4c5ef52ac3_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmMzNTFhMmEyMWJhOTQ0Yzc5OTliZjRlM2I3YWUxZDUwL3RhYmxlcmFuZ2U6YzM1MWEyYTIxYmE5NDRjNzk5OWJmNGUzYjdhZTFkNTBfMi0zLTEtMS0w_8f67b307-44a3-46cf-8183-17e3f14031e6"
      unitRef="usd">143930000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i9a061ecd0e88428da9167e4c5ef52ac3_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmMzNTFhMmEyMWJhOTQ0Yzc5OTliZjRlM2I3YWUxZDUwL3RhYmxlcmFuZ2U6YzM1MWEyYTIxYmE5NDRjNzk5OWJmNGUzYjdhZTFkNTBfMi01LTEtMS0w_371a16f3-0375-48a5-8577-86256aac52bd"
      unitRef="usd">67015000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i9a061ecd0e88428da9167e4c5ef52ac3_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmMzNTFhMmEyMWJhOTQ0Yzc5OTliZjRlM2I3YWUxZDUwL3RhYmxlcmFuZ2U6YzM1MWEyYTIxYmE5NDRjNzk5OWJmNGUzYjdhZTFkNTBfMi03LTEtMS0w_e119aa6a-6056-443b-88f6-a01c2be66c49"
      unitRef="usd">76915000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i57bb690a343d4f7d8bad8f8f0b00a299_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmMzNTFhMmEyMWJhOTQ0Yzc5OTliZjRlM2I3YWUxZDUwL3RhYmxlcmFuZ2U6YzM1MWEyYTIxYmE5NDRjNzk5OWJmNGUzYjdhZTFkNTBfMy0xLTEtMS0w_14ec078a-5d2e-4fc8-b795-09f6fb4fdce6">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i5588309d1fff48048fb83af0ddcb456b_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmMzNTFhMmEyMWJhOTQ0Yzc5OTliZjRlM2I3YWUxZDUwL3RhYmxlcmFuZ2U6YzM1MWEyYTIxYmE5NDRjNzk5OWJmNGUzYjdhZTFkNTBfMy0zLTEtMS0w_c527ac6c-8920-420f-a725-6b343953b3da"
      unitRef="usd">22832000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i5588309d1fff48048fb83af0ddcb456b_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmMzNTFhMmEyMWJhOTQ0Yzc5OTliZjRlM2I3YWUxZDUwL3RhYmxlcmFuZ2U6YzM1MWEyYTIxYmE5NDRjNzk5OWJmNGUzYjdhZTFkNTBfMy01LTEtMS0w_1ffed547-3bc3-4241-a511-0300442573a0"
      unitRef="usd">10736000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i5588309d1fff48048fb83af0ddcb456b_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmMzNTFhMmEyMWJhOTQ0Yzc5OTliZjRlM2I3YWUxZDUwL3RhYmxlcmFuZ2U6YzM1MWEyYTIxYmE5NDRjNzk5OWJmNGUzYjdhZTFkNTBfMy03LTEtMS0w_9a1ed65d-b205-4598-903b-07ba721e927b"
      unitRef="usd">12096000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i7cb7d40948da4beb88d80ee62fb3d330_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmMzNTFhMmEyMWJhOTQ0Yzc5OTliZjRlM2I3YWUxZDUwL3RhYmxlcmFuZ2U6YzM1MWEyYTIxYmE5NDRjNzk5OWJmNGUzYjdhZTFkNTBfNC0xLTEtMS0w_c4155a5c-14aa-40ad-8caf-c743c3b1ce49">P12Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ic456fd261edf4e6b9386c6e78baefd90_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmMzNTFhMmEyMWJhOTQ0Yzc5OTliZjRlM2I3YWUxZDUwL3RhYmxlcmFuZ2U6YzM1MWEyYTIxYmE5NDRjNzk5OWJmNGUzYjdhZTFkNTBfNC0zLTEtMS0w_c874e5c7-c86e-4109-b551-57acbbe6cdc1"
      unitRef="usd">6696000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ic456fd261edf4e6b9386c6e78baefd90_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmMzNTFhMmEyMWJhOTQ0Yzc5OTliZjRlM2I3YWUxZDUwL3RhYmxlcmFuZ2U6YzM1MWEyYTIxYmE5NDRjNzk5OWJmNGUzYjdhZTFkNTBfNC01LTEtMS0w_8c5d1a55-7fb1-49a9-9407-18f1123cfaf6"
      unitRef="usd">2793000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ic456fd261edf4e6b9386c6e78baefd90_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmMzNTFhMmEyMWJhOTQ0Yzc5OTliZjRlM2I3YWUxZDUwL3RhYmxlcmFuZ2U6YzM1MWEyYTIxYmE5NDRjNzk5OWJmNGUzYjdhZTFkNTBfNC03LTEtMS0w_03123459-a163-4f32-9caf-5ec53a2aca14"
      unitRef="usd">3903000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i0e1880f00d4d4d1e9e8b42e76237839e_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmMzNTFhMmEyMWJhOTQ0Yzc5OTliZjRlM2I3YWUxZDUwL3RhYmxlcmFuZ2U6YzM1MWEyYTIxYmE5NDRjNzk5OWJmNGUzYjdhZTFkNTBfNS0xLTEtMS0w_09a4f188-75c1-4c20-96c1-167a4d452ac9">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i200a2160c6bc4775ad07f433b5e95e1a_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmMzNTFhMmEyMWJhOTQ0Yzc5OTliZjRlM2I3YWUxZDUwL3RhYmxlcmFuZ2U6YzM1MWEyYTIxYmE5NDRjNzk5OWJmNGUzYjdhZTFkNTBfNS0zLTEtMS0w_2cb719d1-d051-4833-81e7-bfa7d2b8bd54"
      unitRef="usd">2060000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i200a2160c6bc4775ad07f433b5e95e1a_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmMzNTFhMmEyMWJhOTQ0Yzc5OTliZjRlM2I3YWUxZDUwL3RhYmxlcmFuZ2U6YzM1MWEyYTIxYmE5NDRjNzk5OWJmNGUzYjdhZTFkNTBfNS01LTEtMS0w_677d3093-d690-45a3-9274-6a88dc04fe2f"
      unitRef="usd">1064000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i200a2160c6bc4775ad07f433b5e95e1a_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmMzNTFhMmEyMWJhOTQ0Yzc5OTliZjRlM2I3YWUxZDUwL3RhYmxlcmFuZ2U6YzM1MWEyYTIxYmE5NDRjNzk5OWJmNGUzYjdhZTFkNTBfNS03LTEtMS0w_d6ab8319-79a0-4efd-bbb6-5019cef577a0"
      unitRef="usd">996000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ic7bfc72f47df49e08bf78786c1c3f3a8_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmMzNTFhMmEyMWJhOTQ0Yzc5OTliZjRlM2I3YWUxZDUwL3RhYmxlcmFuZ2U6YzM1MWEyYTIxYmE5NDRjNzk5OWJmNGUzYjdhZTFkNTBfNi0xLTEtMS0w_12cf94f9-d3de-4646-b251-cacd9b6a1043">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i5f688ddde99b4f1e907fddc9a3a91b08_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmMzNTFhMmEyMWJhOTQ0Yzc5OTliZjRlM2I3YWUxZDUwL3RhYmxlcmFuZ2U6YzM1MWEyYTIxYmE5NDRjNzk5OWJmNGUzYjdhZTFkNTBfNi0zLTEtMS0w_d34a51f8-931f-4ece-819f-a5ec494d9c3c"
      unitRef="usd">1011000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i5f688ddde99b4f1e907fddc9a3a91b08_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmMzNTFhMmEyMWJhOTQ0Yzc5OTliZjRlM2I3YWUxZDUwL3RhYmxlcmFuZ2U6YzM1MWEyYTIxYmE5NDRjNzk5OWJmNGUzYjdhZTFkNTBfNi01LTEtMS0w_ea4bd6c4-af9e-491c-a713-6b56b6016ac1"
      unitRef="usd">131000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i5f688ddde99b4f1e907fddc9a3a91b08_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmMzNTFhMmEyMWJhOTQ0Yzc5OTliZjRlM2I3YWUxZDUwL3RhYmxlcmFuZ2U6YzM1MWEyYTIxYmE5NDRjNzk5OWJmNGUzYjdhZTFkNTBfNi03LTEtMS0w_250542e1-f2f5-484d-888a-cf4c25db1dae"
      unitRef="usd">880000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmMzNTFhMmEyMWJhOTQ0Yzc5OTliZjRlM2I3YWUxZDUwL3RhYmxlcmFuZ2U6YzM1MWEyYTIxYmE5NDRjNzk5OWJmNGUzYjdhZTFkNTBfNy0zLTEtMS0w_b77d448c-a2b6-42bc-be0b-3f12ff26d6f0"
      unitRef="usd">176529000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmMzNTFhMmEyMWJhOTQ0Yzc5OTliZjRlM2I3YWUxZDUwL3RhYmxlcmFuZ2U6YzM1MWEyYTIxYmE5NDRjNzk5OWJmNGUzYjdhZTFkNTBfNy01LTEtMS0w_90215bd4-3c29-4d3a-bc45-2a6b8d094744"
      unitRef="usd">81739000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmMzNTFhMmEyMWJhOTQ0Yzc5OTliZjRlM2I3YWUxZDUwL3RhYmxlcmFuZ2U6YzM1MWEyYTIxYmE5NDRjNzk5OWJmNGUzYjdhZTFkNTBfNy03LTEtMS0w_3ccea650-870e-4992-9858-e98dcbf1d264"
      unitRef="usd">94790000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="id11fed723b204eccb39c30a6f9bcb4ec_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmVhN2FjM2FmNzhjNDQzZmM4MDExMDdlMzc0ZTA1NjFhL3RhYmxlcmFuZ2U6ZWE3YWMzYWY3OGM0NDNmYzgwMTEwN2UzNzRlMDU2MWFfMi0xLTEtMS0wL3RleHRyZWdpb246YWNiZGFmMzUxZmRlNGViODkwMTg2MjI1MTFjMWNhNDRfNjU5NzA2OTc2NjY2Nw_afa00b1c-4607-4408-9130-60e7139576a8">P11Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i0041ee30d491407b91c0d34ee0fd8035_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmVhN2FjM2FmNzhjNDQzZmM4MDExMDdlMzc0ZTA1NjFhL3RhYmxlcmFuZ2U6ZWE3YWMzYWY3OGM0NDNmYzgwMTEwN2UzNzRlMDU2MWFfMi0xLTEtMS0wL3RleHRyZWdpb246YWNiZGFmMzUxZmRlNGViODkwMTg2MjI1MTFjMWNhNDRfNjU5NzA2OTc2NjY3MQ_306475a5-1e1f-4f8e-8d54-23ec14cabf2c">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i80ad21fe7a3a4d959fdd8ebdbe3e6e65_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmVhN2FjM2FmNzhjNDQzZmM4MDExMDdlMzc0ZTA1NjFhL3RhYmxlcmFuZ2U6ZWE3YWMzYWY3OGM0NDNmYzgwMTEwN2UzNzRlMDU2MWFfMi0zLTEtMS0w_95ebba82-05a3-4444-bf22-7335ea7e47b4"
      unitRef="usd">143930000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i80ad21fe7a3a4d959fdd8ebdbe3e6e65_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmVhN2FjM2FmNzhjNDQzZmM4MDExMDdlMzc0ZTA1NjFhL3RhYmxlcmFuZ2U6ZWE3YWMzYWY3OGM0NDNmYzgwMTEwN2UzNzRlMDU2MWFfMi01LTEtMS0w_575e910d-eba8-46a3-a38a-5a557ddf4526"
      unitRef="usd">60526000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i80ad21fe7a3a4d959fdd8ebdbe3e6e65_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmVhN2FjM2FmNzhjNDQzZmM4MDExMDdlMzc0ZTA1NjFhL3RhYmxlcmFuZ2U6ZWE3YWMzYWY3OGM0NDNmYzgwMTEwN2UzNzRlMDU2MWFfMi03LTEtMS0w_3ff66919-e430-4d2d-980b-c6a94c6c2366"
      unitRef="usd">83404000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ibf9258f9195d44eebf1af16facb1fb4a_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmVhN2FjM2FmNzhjNDQzZmM4MDExMDdlMzc0ZTA1NjFhL3RhYmxlcmFuZ2U6ZWE3YWMzYWY3OGM0NDNmYzgwMTEwN2UzNzRlMDU2MWFfMy0xLTEtMS0w_d74bbf97-783f-4651-8554-2f5a1e999aaf">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ife724f4c09364f2587ef6b1db0ffb506_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmVhN2FjM2FmNzhjNDQzZmM4MDExMDdlMzc0ZTA1NjFhL3RhYmxlcmFuZ2U6ZWE3YWMzYWY3OGM0NDNmYzgwMTEwN2UzNzRlMDU2MWFfMy0zLTEtMS0w_e3998fba-0627-481d-b8e8-dad055aa92c8"
      unitRef="usd">22832000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ife724f4c09364f2587ef6b1db0ffb506_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmVhN2FjM2FmNzhjNDQzZmM4MDExMDdlMzc0ZTA1NjFhL3RhYmxlcmFuZ2U6ZWE3YWMzYWY3OGM0NDNmYzgwMTEwN2UzNzRlMDU2MWFfMy01LTEtMS0w_ea4fa135-c81e-40ef-b8d8-9f6842ee7e00"
      unitRef="usd">9676000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ife724f4c09364f2587ef6b1db0ffb506_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmVhN2FjM2FmNzhjNDQzZmM4MDExMDdlMzc0ZTA1NjFhL3RhYmxlcmFuZ2U6ZWE3YWMzYWY3OGM0NDNmYzgwMTEwN2UzNzRlMDU2MWFfMy03LTEtMS0w_6b3489f2-6b1c-4ea6-bc6a-740ffeaad649"
      unitRef="usd">13156000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="id69c143aef794cd8af6e5723d91edb2c_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmVhN2FjM2FmNzhjNDQzZmM4MDExMDdlMzc0ZTA1NjFhL3RhYmxlcmFuZ2U6ZWE3YWMzYWY3OGM0NDNmYzgwMTEwN2UzNzRlMDU2MWFfNC0xLTEtMS0w_e4c0fdcf-c1b5-4e09-934a-f06294151aee">P12Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="if0aef9156d514b559b4f1bc502166379_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmVhN2FjM2FmNzhjNDQzZmM4MDExMDdlMzc0ZTA1NjFhL3RhYmxlcmFuZ2U6ZWE3YWMzYWY3OGM0NDNmYzgwMTEwN2UzNzRlMDU2MWFfNC0zLTEtMS0w_b0e37c3d-5e9e-4db9-af13-0a00300da2ef"
      unitRef="usd">6696000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="if0aef9156d514b559b4f1bc502166379_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmVhN2FjM2FmNzhjNDQzZmM4MDExMDdlMzc0ZTA1NjFhL3RhYmxlcmFuZ2U6ZWE3YWMzYWY3OGM0NDNmYzgwMTEwN2UzNzRlMDU2MWFfNC01LTEtMS0w_867c2086-f575-4926-a2fb-e3dba36d9471"
      unitRef="usd">2352000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="if0aef9156d514b559b4f1bc502166379_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmVhN2FjM2FmNzhjNDQzZmM4MDExMDdlMzc0ZTA1NjFhL3RhYmxlcmFuZ2U6ZWE3YWMzYWY3OGM0NDNmYzgwMTEwN2UzNzRlMDU2MWFfNC03LTEtMS0w_7942f76a-bfd8-4126-ac72-233bc9499377"
      unitRef="usd">4344000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i3fcb4ca5c3c4484fa5efae17077926cd_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmVhN2FjM2FmNzhjNDQzZmM4MDExMDdlMzc0ZTA1NjFhL3RhYmxlcmFuZ2U6ZWE3YWMzYWY3OGM0NDNmYzgwMTEwN2UzNzRlMDU2MWFfNS0xLTEtMS0w_51fb747e-b457-4f9c-b552-2a0dfafc6f8f">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i04ee375bba5d426fae0a9eb750e81925_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmVhN2FjM2FmNzhjNDQzZmM4MDExMDdlMzc0ZTA1NjFhL3RhYmxlcmFuZ2U6ZWE3YWMzYWY3OGM0NDNmYzgwMTEwN2UzNzRlMDU2MWFfNS0zLTEtMS0w_ecc53a49-f05c-4c5f-8cfd-4b56c4c55e90"
      unitRef="usd">2060000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i04ee375bba5d426fae0a9eb750e81925_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmVhN2FjM2FmNzhjNDQzZmM4MDExMDdlMzc0ZTA1NjFhL3RhYmxlcmFuZ2U6ZWE3YWMzYWY3OGM0NDNmYzgwMTEwN2UzNzRlMDU2MWFfNS01LTEtMS0w_dc6fa25b-adde-44f0-bb7b-011fd7553207"
      unitRef="usd">858000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i04ee375bba5d426fae0a9eb750e81925_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmVhN2FjM2FmNzhjNDQzZmM4MDExMDdlMzc0ZTA1NjFhL3RhYmxlcmFuZ2U6ZWE3YWMzYWY3OGM0NDNmYzgwMTEwN2UzNzRlMDU2MWFfNS03LTEtMS0w_a9f07c8c-ed5b-4f93-8fa0-ddcda9e876e7"
      unitRef="usd">1202000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i3ccf5d499e3e4698884b846f6d3df73d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmVhN2FjM2FmNzhjNDQzZmM4MDExMDdlMzc0ZTA1NjFhL3RhYmxlcmFuZ2U6ZWE3YWMzYWY3OGM0NDNmYzgwMTEwN2UzNzRlMDU2MWFfNi0xLTEtMS0w_a68f15e5-34e3-4cb3-b532-75768efa89ba">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ia58b0f57301940558ebd969a25e55261_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmVhN2FjM2FmNzhjNDQzZmM4MDExMDdlMzc0ZTA1NjFhL3RhYmxlcmFuZ2U6ZWE3YWMzYWY3OGM0NDNmYzgwMTEwN2UzNzRlMDU2MWFfNi0zLTEtMS0w_65384037-38cd-42d8-8599-48540a8b35ca"
      unitRef="usd">1011000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ia58b0f57301940558ebd969a25e55261_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmVhN2FjM2FmNzhjNDQzZmM4MDExMDdlMzc0ZTA1NjFhL3RhYmxlcmFuZ2U6ZWE3YWMzYWY3OGM0NDNmYzgwMTEwN2UzNzRlMDU2MWFfNi01LTEtMS0w_1ad07427-0b6d-4893-bac2-7a8383048bb8"
      unitRef="usd">105000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ia58b0f57301940558ebd969a25e55261_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmVhN2FjM2FmNzhjNDQzZmM4MDExMDdlMzc0ZTA1NjFhL3RhYmxlcmFuZ2U6ZWE3YWMzYWY3OGM0NDNmYzgwMTEwN2UzNzRlMDU2MWFfNi03LTEtMS0w_101fceb3-d353-4801-81b7-c130f2d7e985"
      unitRef="usd">906000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmVhN2FjM2FmNzhjNDQzZmM4MDExMDdlMzc0ZTA1NjFhL3RhYmxlcmFuZ2U6ZWE3YWMzYWY3OGM0NDNmYzgwMTEwN2UzNzRlMDU2MWFfNy0zLTEtMS0w_c5f3a9e6-ce98-4a3e-aef4-0fc2dd493753"
      unitRef="usd">176529000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmVhN2FjM2FmNzhjNDQzZmM4MDExMDdlMzc0ZTA1NjFhL3RhYmxlcmFuZ2U6ZWE3YWMzYWY3OGM0NDNmYzgwMTEwN2UzNzRlMDU2MWFfNy01LTEtMS0w_4d1b444d-0fbc-46c6-a43e-7fd21fd4e818"
      unitRef="usd">73517000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOmVhN2FjM2FmNzhjNDQzZmM4MDExMDdlMzc0ZTA1NjFhL3RhYmxlcmFuZ2U6ZWE3YWMzYWY3OGM0NDNmYzgwMTEwN2UzNzRlMDU2MWFfNy03LTEtMS0w_424ad924-b447-4b42-8bc1-617b9f7c6065"
      unitRef="usd">103012000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RleHRyZWdpb246YzU4NjQ0ZjNjZDg3NDQ1Nzk1ZWZhYmJhZGNiN2Q2ZGVfMjM2_dbd09770-1a3f-4776-be15-c407524786a2"
      unitRef="usd">4100000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RleHRyZWdpb246YzU4NjQ0ZjNjZDg3NDQ1Nzk1ZWZhYmJhZGNiN2Q2ZGVfMjQz_484b69b2-1073-4c5c-b179-338c364cca28"
      unitRef="usd">3900000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RleHRyZWdpb246YzU4NjQ0ZjNjZDg3NDQ1Nzk1ZWZhYmJhZGNiN2Q2ZGVfMzIw_80725e4a-e127-42ae-88e0-3499d1a678eb"
      unitRef="usd">8200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RleHRyZWdpb246YzU4NjQ0ZjNjZDg3NDQ1Nzk1ZWZhYmJhZGNiN2Q2ZGVfMzI3_a6ad3e11-920e-49fa-970a-bd4b59f4946b"
      unitRef="usd">7700000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RleHRyZWdpb246YzU4NjQ0ZjNjZDg3NDQ1Nzk1ZWZhYmJhZGNiN2Q2ZGVfNDgw_fd5e1304-4831-462a-8784-ea8591f4d489">Future amortization expense is estimated to be as follows for the following years ending December&#160;31 (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:85.262%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.738%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020 (excluding the six months ended June 30, 2020)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;39,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;94,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOjZmOGRlNDdiYmVmODQyNzVhMWFkNjA1Mjk5Zjc0NmI4L3RhYmxlcmFuZ2U6NmY4ZGU0N2JiZWY4NDI3NWExYWQ2MDUyOTlmNzQ2YjhfMi0xLTEtMS0w_2ac6aae8-fab7-49f3-aac7-55ba2d6e820b"
      unitRef="usd">7807000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOjZmOGRlNDdiYmVmODQyNzVhMWFkNjA1Mjk5Zjc0NmI4L3RhYmxlcmFuZ2U6NmY4ZGU0N2JiZWY4NDI3NWExYWQ2MDUyOTlmNzQ2YjhfMy0xLTEtMS0w_5c2912ec-a338-4367-8943-b454e66710be"
      unitRef="usd">14524000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOjZmOGRlNDdiYmVmODQyNzVhMWFkNjA1Mjk5Zjc0NmI4L3RhYmxlcmFuZ2U6NmY4ZGU0N2JiZWY4NDI3NWExYWQ2MDUyOTlmNzQ2YjhfNC0xLTEtMS0w_1c57244b-b80d-4d69-a86e-57b2037ed797"
      unitRef="usd">12673000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOjZmOGRlNDdiYmVmODQyNzVhMWFkNjA1Mjk5Zjc0NmI4L3RhYmxlcmFuZ2U6NmY4ZGU0N2JiZWY4NDI3NWExYWQ2MDUyOTlmNzQ2YjhfNS0xLTEtMS0w_4fb5d1bc-8b65-4cfa-8472-d83df83e9831"
      unitRef="usd">10842000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOjZmOGRlNDdiYmVmODQyNzVhMWFkNjA1Mjk5Zjc0NmI4L3RhYmxlcmFuZ2U6NmY4ZGU0N2JiZWY4NDI3NWExYWQ2MDUyOTlmNzQ2YjhfNi0xLTEtMS0w_22e26c1d-67ec-41ff-a7d9-d51cd50295bc"
      unitRef="usd">9830000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <ameh:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOjZmOGRlNDdiYmVmODQyNzVhMWFkNjA1Mjk5Zjc0NmI4L3RhYmxlcmFuZ2U6NmY4ZGU0N2JiZWY4NDI3NWExYWQ2MDUyOTlmNzQ2YjhfNy0xLTEtMS0w_cadaa91c-0392-4ed4-920a-3c93dcb106c2"
      unitRef="usd">39114000</ameh:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81Mi9mcmFnOmM1ODY0NGYzY2Q4NzQ0NTc5NWVmYWJiYWRjYjdkNmRlL3RhYmxlOjZmOGRlNDdiYmVmODQyNzVhMWFkNjA1Mjk5Zjc0NmI4L3RhYmxlcmFuZ2U6NmY4ZGU0N2JiZWY4NDI3NWExYWQ2MDUyOTlmNzQ2YjhfOS0xLTEtMS0w_65a2ae31-4728-459c-912f-0aee7668dcd2"
      unitRef="usd">94790000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <ameh:EquityMethodAndOtherEquityInvestmentsTextBlock
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMTE1NDQ4NzIxMDUyMjQ_dfd5d988-5fed-4072-b4fa-79277d20b0ba">Investments in Other Entities &#x2014; Equity Method&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Rollforward of Equity Method Investment (in thousands)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:39.374%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.964%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.011%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.134%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.549%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.632%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Allocation of Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Contribution&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;LaSalle Medical Associates &#x2013; IPA Line of Business&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(428)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Pacific Medical Imaging &amp;amp; Oncology Center, Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Universal Care, Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,998)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Diagnostic Medical Group&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(102)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;531 W. College, LLC &#x2013; related party&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(231)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;MWN, LLC &#x2013; related party&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,998)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;LaSalle Medical Associates &#x2014; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;IPA Line of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;LMA was founded by Dr. Albert Arteaga in 1996 and currently operates six neighborhood medical centers through its network of approximately 2,300 PCP and Specialists providers, treating children, adults and seniors in San Bernardino County, California. LMA&#x2019;s patients are primarily served by Medi-Cal. LMA also accepts Blue Cross, Blue Shield, Molina, Care 1st, Health Net and Inland Empire Health Plan. LMA is also an IPA of independently contracted doctors, hospitals and clinics, delivering high-quality care to approximately 290,000 patients in Fresno, Kings, Los Angeles, Madera, Riverside, San Bernardino and Tulare Counties. During 2012, APC-LSMA and LMA entered into a share purchase agreement whereby APC-LSMA invested $5.0 million for a 25% interest in LMA&#x2019;s IPA line of business. NMM has a management services agreement with LMA. APC accounts for its investment in LMA under the equity method as APC has the ability to exercise significant influence, but not control over LMA&#x2019;s operations. For the three months ended June&#160;30, 2020, APC recognized income from this investment of $0.2 million. For the three months ended June&#160;30, 2019, APC recognized a loss from this investment of $1.3 million. For the six months ended June&#160;30, 2020 and 2019, APC recognized losses of $0.4 million and $2.4 million, respectively, in the accompanying consolidated statements of income. The accompanying consolidated balance sheets include the related investment balance of $6.0 million and $6.4 million at June&#160;30, 2020 and December&#160;31, 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;LMA&#x2019;s summarized balance sheets at June&#160;30, 2020 and December&#160;31, 2019, and summarized statements of operations for the six months ended June&#160;30, 2020 and 2019, with respect to its IPA line of business are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Balance Sheets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:70.620%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.909%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.739%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Receivables, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Loan receivable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Restricted cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Liabilities and Stockholders&#x2019; (Deficit) Equity&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Stockholders&#x2019; deficit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(7,314)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(5,602)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total liabilities and stockholders&#x2019; deficit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Statements of Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:69.114%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.809%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.344%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;92,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;93,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;93,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;102,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Net loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,567)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(9,411)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Pacific Medical Imaging and Oncology Center, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Incorporated in California in 2004, PMIOC provides comprehensive diagnostic imaging services using state-of-the-art technology. PMIOC offers high-quality diagnostic services, such as MRI/MRA, PET/CT, CT, nuclear medicine, ultrasound, digital x-rays, bone densitometry and digital mammography, at its facilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In July&#160;2015, APC-LSMA and PMIOC entered into a share purchase agreement whereby APC-LSMA invested $1.2 million for a 40% ownership interest in PMIOC.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;APC and PMIOC have an Ancillary Service Contract together whereby PMIOC provides covered services on behalf of APC to enrollees of the plans of APC. Under the Ancillary Service Contract, APC paid PMIOC fees of approximately $0.4 million and $0.6 million, for the three months ended June&#160;30, 2020 and 2019, respectively, and fees of approximately $1.0&#160;million and $1.4 million for the six months ended June&#160;30, 2020 and 2019. APC accounts for its investment in PMIOC under the equity method of accounting as APC has the ability to exercise significant influence, but not control over PMIOC&#x2019;s operations. For the three months ended June&#160;30, 2020, APC recognized a loss from this investment of $10,200. For the three months ended June&#160;30, 2019, APC recognized income from this investment of $0.1 million. For the six months ended June&#160;30, 2020 and 2019, APC recognized income of $0.1&#160;million and $0.2 million, respectively, in the accompanying consolidated statements of income. The accompanying consolidated balance sheets include the related investment balance of $1.5 million and $1.4 million at June&#160;30, 2020 and December&#160;31, 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Universal Care, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;UCI is a privately held health plan that has been in operation since 1985. UCI holds a license under the California Knox-Keene Health Care Services Plan Act to operate as a full-service health plan. UCI contracts with CMS under the Medicare Advantage Prescription Drug Program.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In August 2015, UCAP purchased 100,000 shares of UCI class A-2 voting common stock from UCI for $10.0 million, which shares comprise 48.9% of UCI&#x2019;s total outstanding shares and 50% of UCI&#x2019;s voting common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On April 30, 2020, UCAP completed the sale of its 48.9% ownership interest in UCI to Bright for approximately $69.2 million in cash proceeds (including $16.5 million as repayment of indebtedness owed to APC), plus non-cash consideration consisting of shares of Bright Health, Inc.&#x2019;s preferred stock having an estimated fair value of approximately $36.2 million on the date of sale, included in investments in privately held entities. The fair value of the preferred shares was determined utilizing a market approach which includes significant unobservable inputs (Level 3) including forecasted revenue along with estimates of revenue multiples, volatility and time-to-liquidity. In addition, pursuant to the terms of the stock purchase agreement, APC has a beneficial interest in the equity method investment sold. The estimated fair value of such interest on April 30, 2020 was&#160;$15.7 million and is included in "Other assets" in the accompanying consolidated balance sheets. The beneficial interest is the result of a gross margin provision in the stock purchase agreement which entitles UCAP to potentially receive additional cash and preferred shares (currently held in an escrow account with cash of $15.6&#160;million and preferred shares with an estimated fair value of $6.4&#160;million, total estimated fair value of $22.0&#160;million on the date of sale) based on the gross margin of UCI for calendar year 2020 as measured against a target. The amount to be received varies dependent upon the gross margin as compared to the target but cannot exceed the amounts that are in the escrow account. Additionally, the stock purchase agreement includes a tangible net equity provision that may result in the receipt or payment of additional amounts based on a comparison of final tangible net equity of UCI on the date of sale (determined with the benefit of one year of hindsight) as compared to the estimated tangible net equity at the time of sale. It is expected that settlement of the beneficial interest will begin in the second half of 2021. The Company determined the fair value of the beneficial interest using an income approach which includes significant unobservable inputs (Level 3). Specifically, the Company utilized a probability weighted discounted cash flow model using a risk-free treasury rate to estimate fair value which considered various scenarios of gross margin adjustment and the impact of each adjustment to the expected proceeds from the escrow account and assigned probabilities to each such scenario in determining fair value. The gross margin adjustment is defined as three times any deficit in actual gross margin of UCI for the year ended December 31, 2020 below a target gross margin unless such deficit is within a specific collar amount.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The gain on sale of equity method investment recognized in connection with this transaction was determined as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:78.116%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.884%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amount (in '000s)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash proceeds (excludes proceeds to settle indebtedness owed to APC from UCI)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;52,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Preferred shares in Bright Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Beneficial interest in UCI&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: Carrying value of equity method investment on date of sale&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,998)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gain on sale of equity method investment&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;99,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For the three months ended June 30, 2020 and June&#160;30, 2019 APC recorded income from this investment of approximately $0.9&#160;million and $4.5 million. For the six months ended June 30, 2020 and June 30, 2019 APC recorded income from this investment of approximately $3.6&#160;million  and $5.5 million in the accompanying consolidated statements of income, respectively. As a result of the sale, there was no investment balance as of June&#160;30, 2020 as compared to an investment balance of $1.4 million as of December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;UCI's balance sheet at December 31, 2019 and statements of income for the four months ended April 30, 2020 and six months ended June 30, 2019 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Balance Sheets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:83.526%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.474%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Receivables, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;63,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;38,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Loan receivable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Restricted cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;140,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Liabilities and Stockholders&#x2019; (Deficit) Equity&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;128,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Stockholders&#x2019; deficit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(20,547)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total liabilities and stockholders&#x2019; deficit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;140,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Statements of Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:59.549%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:16.859%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:16.862%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Four Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;April 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;195,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;247,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;189,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;239,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Income before benefit from income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Benefit from income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3,167)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Diagnostic Medical Group&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In May 2016, David C.P. Chen M.D., individually, and APC-LSMA, entered into a share purchase agreement whereby APC-LSMA acquired a 40% ownership interest in DMG.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;APC accounts for its investment in DMG under the equity method of accounting as APC has the ability to exercise significant influence, but not control over DMG&#x2019;s operations. For the three months ended June&#160;30, 2020 and 2019, APC recognized loss and income from this investment of $0.1&#160;million and $0.2 million, respectively, in the consolidated statements of income. For the six months ended  June&#160;30, 2020 and 2019, APC recognized loss and income from investment of $0.1&#160;million and $0.4 million, respectively, in the consolidated statements of income. The accompanying consolidated balance sheets include the related investment balances of $2.2 million and $2.3 million as of June&#160;30, 2020 and December&#160;31, 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;531 W. College LLC &#x2013; Related Party&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2018, College Street Investment LP, a California limited partnership (&#x201c;CSI&#x201d;), APC and NMM entered into an operating agreement to govern the limited liability company, 531 W. College, LLC and the conduct of its business, and to specify their relative rights and obligations. CSI, APC and NMM, each owns 50%, 25% and 25%, respectively, of member units based on initial capital contributions of $16.7 million, $8.3 million, and $8.3 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2018, 531 W. College, LLC closed its purchase of a non-operational hospital located in Los Angeles from Societe Francaise De Bienfaisance Mutuelle De Los Angeles, a California nonprofit corporation, for a total purchase price of $33.3 million. On April 23, 2019, NMM and APC entered into an agreement whereby NMM assigned and APC assumed NMM&#x2019;s 25% membership interest in 531 W. College, LLC for approximately $8.3 million. Subsequently, APC has a 50% ownership in 531 W. College LLC with a total investment balance of approximately $17.0 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;APC accounts for its investment in 531 W. College, LLC under the equity method of accounting as APC has the ability to exercise significant influence, but not control over the operations of this joint venture. For the three months ended June&#160;30, 2020 and 2019, APC recognized loss and income of $0.1 million and $12,649, respectively. For the six months ended June&#160;30, 2020 and 2019, APC recorded losses of $0.2 million and $34,319 in the accompanying consolidated statements of income, respectively. During the period ended June&#160;30, 2020, the Company contributed $0.5 million to 531 W. College LLC as part of its 50% interest and had investment balances of $17.0 million and $16.7 million, respectively, at June&#160;30, 2020 and December&#160;31, 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;531 W. College LLC&#x2019;s balance sheets at June&#160;30, 2020 and December&#160;31, 2019, and statements of operations for the six months ended June&#160;30, 2020 and 2019, are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Balance sheets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.206%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.323%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.739%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Other assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Property and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Liabilities and Members&#x2019; Equity&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Stockholders&#x2019; equity&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;32,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;32,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total liabilities and members&#x2019; equity&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Statements of Operation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:69.114%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.929%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.224%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Loss from operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(579)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(538)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Other income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Net loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(558)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(153)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;MWN LLC &#x2013; Related Party&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In December 2018, NMM, 6 Founders LLC, a California limited liability company doing business as Pacific6 Enterprises (&#x201c;Pacific6&#x201d;), and Health Source MSO Inc., a California corporation (&#x201c;HSMSO&#x201d;) entered into an operating agreement to govern &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;MWN Community Hospital, LLC and the conduct of its business and to specify their relative rights and obligations. NMM, Pacific6, and HSMSO each own 33.3% of the membership shares based on each member&#x2019;s initial capital contributions of $3,000 and working capital contributions of $30,000. NMM invested an additional $0.3 million for working capital purposes in August 2019. For the three and six months ended June&#160;30, 2020, NMM recorded loss and income from its investment in MWN LLC of $43,000 and $12,000, respectively, in the accompanying consolidated statements of income and had an investment balance of $0.2 million as of June&#160;30, 2020 and December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Investments in privately held entities that do not report net asset value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;MediPortal, LLC&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In May 2018, APC purchased 270,000 membership interests of MediPortal LLC, a New York limited liability company, for $0.4 million or $1.50 per membership interest, which represented an approximately 2.8% ownership interest. In connection with the initial purchase, APC received a five-year warrant to purchase an additional 270,000 membership interests. Additionally, APC received a five-year option to purchase an additional 380,000 membership interests and a five-year warrant to purchase 480,000 membership interests, which MediPortal LLC will grant APC upon completion of its health portal. As of June&#160;30, 2020, the health portal has not been completed. As APC does not have the ability to exercise significant influence, and lacks control, over the investee, this investment is accounted for using a measurement alternative which allows the investment to be measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;AchievaMed&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On July 1, 2019, NMM and AchievaMed, Inc., a California corporation (&#x201c;AchievaMed&#x201d;), entered into an agreement in which NMM would purchase 50% of the aggregate shares of capital stock of AchievaMed over a period of time not to exceed five years. As a result of this transaction NMM invested $0.5 million for a 10% interest. The related investment balance of $0.5 million is included in &#x201c;Investment in privately held entities&#x201d; in the accompanying consolidated balance sheets as of June&#160;30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Bright Health, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In April 2020, UCAP completed the sale of its 48.9% ownership interest in UCI to Bright for approximately $69.2 million in cash proceeds (including $16.5 million as repayment of indebtedness owed to APC), plus non-cash consideration consisting of shares of Bright Health, Inc.&#x2019;s preferred stock having an estimated fair value of approximately $36.2 million on the date of sale. The related investment balance of $36.2 million is included in &#x201c;Investment in privately held entities&#x201d; in the accompanying consolidated balance sheets as of June&#160;30, 2020.&lt;/span&gt;&lt;/div&gt;</ameh:EquityMethodAndOtherEquityInvestmentsTextBlock>
    <us-gaap:EquityMethodInvestmentsTextBlock
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfOTcyMA_fb1e7085-1ffc-416a-b238-5d99fe81c32e">&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Rollforward of Equity Method Investment (in thousands)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:39.374%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.964%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.011%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.134%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.549%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.632%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Allocation of Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Contribution&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;LaSalle Medical Associates &#x2013; IPA Line of Business&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(428)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Pacific Medical Imaging &amp;amp; Oncology Center, Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Universal Care, Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,998)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Diagnostic Medical Group&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(102)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;531 W. College, LLC &#x2013; related party&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(231)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;MWN, LLC &#x2013; related party&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,998)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;LMA&#x2019;s summarized balance sheets at June&#160;30, 2020 and December&#160;31, 2019, and summarized statements of operations for the six months ended June&#160;30, 2020 and 2019, with respect to its IPA line of business are as follows (in thousands):&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Balance Sheets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:70.620%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.909%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.739%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Receivables, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Loan receivable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Restricted cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Liabilities and Stockholders&#x2019; (Deficit) Equity&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Stockholders&#x2019; deficit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(7,314)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(5,602)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total liabilities and stockholders&#x2019; deficit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Statements of Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:69.114%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.809%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.344%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;92,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;93,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;93,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;102,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Net loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,567)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(9,411)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;UCI's balance sheet at December 31, 2019 and statements of income for the four months ended April 30, 2020 and six months ended June 30, 2019 are as follows (in thousands):&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Balance Sheets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:83.526%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.474%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Receivables, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;63,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;38,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Loan receivable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Restricted cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;140,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Liabilities and Stockholders&#x2019; (Deficit) Equity&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;128,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Stockholders&#x2019; deficit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(20,547)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total liabilities and stockholders&#x2019; deficit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;140,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Statements of Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:59.549%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:16.859%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:16.862%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Four Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;April 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;195,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;247,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;189,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;239,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Income before benefit from income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Benefit from income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3,167)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;531 W. College LLC&#x2019;s balance sheets at June&#160;30, 2020 and December&#160;31, 2019, and statements of operations for the six months ended June&#160;30, 2020 and 2019, are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Balance sheets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.206%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.323%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.739%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Other assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Property and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Liabilities and Members&#x2019; Equity&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Stockholders&#x2019; equity&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;32,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;32,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total liabilities and members&#x2019; equity&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Statements of Operation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:69.114%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.929%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.224%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Loss from operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(579)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(538)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Other income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Net loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(558)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(153)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsTextBlock>
    <us-gaap:EquityMethodInvestments
      contextRef="ic3925100079946168d1204aa44f455d9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU4NDZlOWI2OTNmMzQyNjM5NzdhZmE2NGQ0YjA0NThhL3RhYmxlcmFuZ2U6ZTg0NmU5YjY5M2YzNDI2Mzk3N2FmYTY0ZDRiMDQ1OGFfMS0xLTEtMS0w_3ecf0756-e5ae-4922-9c9c-34a92fe628b5"
      unitRef="usd">6397000</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i4fdfa470671c47fdbbc39c5426a4e251_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU4NDZlOWI2OTNmMzQyNjM5NzdhZmE2NGQ0YjA0NThhL3RhYmxlcmFuZ2U6ZTg0NmU5YjY5M2YzNDI2Mzk3N2FmYTY0ZDRiMDQ1OGFfMS0yLTEtMS0w_57ef8131-c352-45b2-965c-ddb3e775aa07"
      unitRef="usd">-428000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <ameh:EquityMethodInvestmentsContribution
      contextRef="i4fdfa470671c47fdbbc39c5426a4e251_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU4NDZlOWI2OTNmMzQyNjM5NzdhZmE2NGQ0YjA0NThhL3RhYmxlcmFuZ2U6ZTg0NmU5YjY5M2YzNDI2Mzk3N2FmYTY0ZDRiMDQ1OGFfMS0zLTEtMS0w_6aa46588-b5f4-49e4-996a-709b606069eb"
      unitRef="usd">0</ameh:EquityMethodInvestmentsContribution>
    <us-gaap:EquityMethodInvestments
      contextRef="ie050574270bf4bdba21a2294fe288e97_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU4NDZlOWI2OTNmMzQyNjM5NzdhZmE2NGQ0YjA0NThhL3RhYmxlcmFuZ2U6ZTg0NmU5YjY5M2YzNDI2Mzk3N2FmYTY0ZDRiMDQ1OGFfMS00LTEtMS0w_00784414-a073-4a7d-85d2-d77c24978482"
      unitRef="usd">5969000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i723d471168484995a1f33bc20e25ae83_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU4NDZlOWI2OTNmMzQyNjM5NzdhZmE2NGQ0YjA0NThhL3RhYmxlcmFuZ2U6ZTg0NmU5YjY5M2YzNDI2Mzk3N2FmYTY0ZDRiMDQ1OGFfMi0xLTEtMS0w_70183375-14db-48c1-aa3c-40f8c27ea6fc"
      unitRef="usd">1396000</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ie984a2ae967749fbb28bc018191f1448_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU4NDZlOWI2OTNmMzQyNjM5NzdhZmE2NGQ0YjA0NThhL3RhYmxlcmFuZ2U6ZTg0NmU5YjY5M2YzNDI2Mzk3N2FmYTY0ZDRiMDQ1OGFfMi0yLTEtMS0w_411ec138-8a0b-4bb9-90de-c1e76076428f"
      unitRef="usd">77000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <ameh:EquityMethodInvestmentsContribution
      contextRef="ie984a2ae967749fbb28bc018191f1448_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU4NDZlOWI2OTNmMzQyNjM5NzdhZmE2NGQ0YjA0NThhL3RhYmxlcmFuZ2U6ZTg0NmU5YjY5M2YzNDI2Mzk3N2FmYTY0ZDRiMDQ1OGFfMi0zLTEtMS0w_3bd790a2-35be-4edd-ad15-b351da92a695"
      unitRef="usd">0</ameh:EquityMethodInvestmentsContribution>
    <us-gaap:EquityMethodInvestments
      contextRef="i509c376a3e0f41cdbfb08128ed5aff20_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU4NDZlOWI2OTNmMzQyNjM5NzdhZmE2NGQ0YjA0NThhL3RhYmxlcmFuZ2U6ZTg0NmU5YjY5M2YzNDI2Mzk3N2FmYTY0ZDRiMDQ1OGFfMi00LTEtMS0w_877c9966-388c-4af3-899d-fcbc7c4af2e5"
      unitRef="usd">1473000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i1d9b625d40984cada77fed26b2662304_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU4NDZlOWI2OTNmMzQyNjM5NzdhZmE2NGQ0YjA0NThhL3RhYmxlcmFuZ2U6ZTg0NmU5YjY5M2YzNDI2Mzk3N2FmYTY0ZDRiMDQ1OGFfMy0xLTEtMS0w_8b75ff87-f2a8-4d98-a69c-66896034ddb4"
      unitRef="usd">1438000</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i0a335fe94da74cc1b74cfe701830c693_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU4NDZlOWI2OTNmMzQyNjM5NzdhZmE2NGQ0YjA0NThhL3RhYmxlcmFuZ2U6ZTg0NmU5YjY5M2YzNDI2Mzk3N2FmYTY0ZDRiMDQ1OGFfMy0yLTEtMS0w_e56c4853-8dbe-42b6-92e0-a477c08b2924"
      unitRef="usd">3560000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <ameh:EquityMethodInvestmentsContribution
      contextRef="i0a335fe94da74cc1b74cfe701830c693_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU4NDZlOWI2OTNmMzQyNjM5NzdhZmE2NGQ0YjA0NThhL3RhYmxlcmFuZ2U6ZTg0NmU5YjY5M2YzNDI2Mzk3N2FmYTY0ZDRiMDQ1OGFfMy0zLTEtMS0w_8ced4641-3c59-4180-9021-d2919383d095"
      unitRef="usd">0</ameh:EquityMethodInvestmentsContribution>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount
      contextRef="i0a335fe94da74cc1b74cfe701830c693_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU4NDZlOWI2OTNmMzQyNjM5NzdhZmE2NGQ0YjA0NThhL3RhYmxlcmFuZ2U6ZTg0NmU5YjY5M2YzNDI2Mzk3N2FmYTY0ZDRiMDQ1OGFfMy00LTEtMS0xOTI1_5ef6e9c9-b1d9-4090-a715-5a7d65e60c7c"
      unitRef="usd">4998000</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:EquityMethodInvestments
      contextRef="iadefc20aa4134071bd9a5346e792b746_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU4NDZlOWI2OTNmMzQyNjM5NzdhZmE2NGQ0YjA0NThhL3RhYmxlcmFuZ2U6ZTg0NmU5YjY5M2YzNDI2Mzk3N2FmYTY0ZDRiMDQ1OGFfMy00LTEtMS0w_030a07b1-9f5b-4f8f-a587-d6ae8cc91070"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i5fd06ba095124e0abdcc0d7f91fc1472_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU4NDZlOWI2OTNmMzQyNjM5NzdhZmE2NGQ0YjA0NThhL3RhYmxlcmFuZ2U6ZTg0NmU5YjY5M2YzNDI2Mzk3N2FmYTY0ZDRiMDQ1OGFfNC0xLTEtMS0w_4c41870a-b973-47cd-a0f6-7bef34f9172c"
      unitRef="usd">2334000</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i9c66cc2214574c8e905c03e9a5ac08d7_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU4NDZlOWI2OTNmMzQyNjM5NzdhZmE2NGQ0YjA0NThhL3RhYmxlcmFuZ2U6ZTg0NmU5YjY5M2YzNDI2Mzk3N2FmYTY0ZDRiMDQ1OGFfNC0yLTEtMS0w_d8034608-0f27-4f66-a4e1-95fe2c15948e"
      unitRef="usd">-102000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <ameh:EquityMethodInvestmentsContribution
      contextRef="i9c66cc2214574c8e905c03e9a5ac08d7_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU4NDZlOWI2OTNmMzQyNjM5NzdhZmE2NGQ0YjA0NThhL3RhYmxlcmFuZ2U6ZTg0NmU5YjY5M2YzNDI2Mzk3N2FmYTY0ZDRiMDQ1OGFfNC0zLTEtMS0w_485330ea-b7ca-439f-9a00-29bdeba475f7"
      unitRef="usd">0</ameh:EquityMethodInvestmentsContribution>
    <us-gaap:EquityMethodInvestments
      contextRef="i314c4ccc348b436ba49cb07ab3848d81_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU4NDZlOWI2OTNmMzQyNjM5NzdhZmE2NGQ0YjA0NThhL3RhYmxlcmFuZ2U6ZTg0NmU5YjY5M2YzNDI2Mzk3N2FmYTY0ZDRiMDQ1OGFfNC00LTEtMS0w_a222d992-7555-4429-ba57-30f256448321"
      unitRef="usd">2232000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i3451c081a11c49aea7b55e24c90e4721_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU4NDZlOWI2OTNmMzQyNjM5NzdhZmE2NGQ0YjA0NThhL3RhYmxlcmFuZ2U6ZTg0NmU5YjY5M2YzNDI2Mzk3N2FmYTY0ZDRiMDQ1OGFfNS0xLTEtMS0w_c7005ad7-d94b-44ef-8c5f-74476f1b85fa"
      unitRef="usd">16698000</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i357af7bf55294d7b86954b0bf136c8c6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU4NDZlOWI2OTNmMzQyNjM5NzdhZmE2NGQ0YjA0NThhL3RhYmxlcmFuZ2U6ZTg0NmU5YjY5M2YzNDI2Mzk3N2FmYTY0ZDRiMDQ1OGFfNS0yLTEtMS0w_afe0583d-538d-4ed4-b91c-158714ec4b44"
      unitRef="usd">-231000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <ameh:EquityMethodInvestmentsContribution
      contextRef="i357af7bf55294d7b86954b0bf136c8c6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU4NDZlOWI2OTNmMzQyNjM5NzdhZmE2NGQ0YjA0NThhL3RhYmxlcmFuZ2U6ZTg0NmU5YjY5M2YzNDI2Mzk3N2FmYTY0ZDRiMDQ1OGFfNS0zLTEtMS0w_a0c60975-3e99-402b-9306-63fca8606b6e"
      unitRef="usd">500000</ameh:EquityMethodInvestmentsContribution>
    <us-gaap:EquityMethodInvestments
      contextRef="ic39201e9036d43759acb734c62b0b8d4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU4NDZlOWI2OTNmMzQyNjM5NzdhZmE2NGQ0YjA0NThhL3RhYmxlcmFuZ2U6ZTg0NmU5YjY5M2YzNDI2Mzk3N2FmYTY0ZDRiMDQ1OGFfNS00LTEtMS0w_f8bc12df-36b6-406e-a2e1-41063a089f74"
      unitRef="usd">16967000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i4cd0390dd82a461ebe94ea5eebf97a2a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU4NDZlOWI2OTNmMzQyNjM5NzdhZmE2NGQ0YjA0NThhL3RhYmxlcmFuZ2U6ZTg0NmU5YjY5M2YzNDI2Mzk3N2FmYTY0ZDRiMDQ1OGFfNi0xLTEtMS0w_409a902d-cb99-4a32-9ad1-9b41ddc828fa"
      unitRef="usd">164000</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ied6eb8f6738c4de2bcbeba58131b807b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU4NDZlOWI2OTNmMzQyNjM5NzdhZmE2NGQ0YjA0NThhL3RhYmxlcmFuZ2U6ZTg0NmU5YjY5M2YzNDI2Mzk3N2FmYTY0ZDRiMDQ1OGFfNi0yLTEtMS0w_ea5173db-5503-4186-aea0-a3d695caedf1"
      unitRef="usd">12000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <ameh:EquityMethodInvestmentsContribution
      contextRef="ied6eb8f6738c4de2bcbeba58131b807b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU4NDZlOWI2OTNmMzQyNjM5NzdhZmE2NGQ0YjA0NThhL3RhYmxlcmFuZ2U6ZTg0NmU5YjY5M2YzNDI2Mzk3N2FmYTY0ZDRiMDQ1OGFfNi0zLTEtMS0w_d4ebdd07-50a3-4a47-9a76-43510bf4ee03"
      unitRef="usd">0</ameh:EquityMethodInvestmentsContribution>
    <us-gaap:EquityMethodInvestments
      contextRef="ibdc4f73cb093421a92e71951326cfe64_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU4NDZlOWI2OTNmMzQyNjM5NzdhZmE2NGQ0YjA0NThhL3RhYmxlcmFuZ2U6ZTg0NmU5YjY5M2YzNDI2Mzk3N2FmYTY0ZDRiMDQ1OGFfNi00LTEtMS0w_2ac44869-e530-4b0d-a5bb-f193a0c074a1"
      unitRef="usd">176000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU4NDZlOWI2OTNmMzQyNjM5NzdhZmE2NGQ0YjA0NThhL3RhYmxlcmFuZ2U6ZTg0NmU5YjY5M2YzNDI2Mzk3N2FmYTY0ZDRiMDQ1OGFfNy0xLTEtMS0w_2748d750-c468-40b7-97ea-35f70bc18f58"
      unitRef="usd">28427000</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU4NDZlOWI2OTNmMzQyNjM5NzdhZmE2NGQ0YjA0NThhL3RhYmxlcmFuZ2U6ZTg0NmU5YjY5M2YzNDI2Mzk3N2FmYTY0ZDRiMDQ1OGFfNy0yLTEtMS0w_59b667a3-e29b-4743-a6d2-4a6cdb8baf1f"
      unitRef="usd">2888000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <ameh:EquityMethodInvestmentsContribution
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU4NDZlOWI2OTNmMzQyNjM5NzdhZmE2NGQ0YjA0NThhL3RhYmxlcmFuZ2U6ZTg0NmU5YjY5M2YzNDI2Mzk3N2FmYTY0ZDRiMDQ1OGFfNy0zLTEtMS0w_2c10d732-ca0c-46e1-a5dd-8521be57049d"
      unitRef="usd">500000</ameh:EquityMethodInvestmentsContribution>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU4NDZlOWI2OTNmMzQyNjM5NzdhZmE2NGQ0YjA0NThhL3RhYmxlcmFuZ2U6ZTg0NmU5YjY5M2YzNDI2Mzk3N2FmYTY0ZDRiMDQ1OGFfNy00LTEtMS0xOTQx_1b0d7b3d-43af-4d06-afe2-47fde756aaa8"
      unitRef="usd">4998000</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:EquityMethodInvestments
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU4NDZlOWI2OTNmMzQyNjM5NzdhZmE2NGQ0YjA0NThhL3RhYmxlcmFuZ2U6ZTg0NmU5YjY5M2YzNDI2Mzk3N2FmYTY0ZDRiMDQ1OGFfNy00LTEtMS0w_7d91137f-ad10-489b-bfad-c17d4176198e"
      unitRef="usd">26817000</us-gaap:EquityMethodInvestments>
    <us-gaap:NumberOfStores
      contextRef="ie050574270bf4bdba21a2294fe288e97_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMjMw_4f6c530b-c84e-4496-8624-d91429fe5005"
      unitRef="medical_center">6</us-gaap:NumberOfStores>
    <ameh:NumberOfEmployees
      contextRef="ie050574270bf4bdba21a2294fe288e97_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMjk1_3d6ddb8d-f7f8-4b3d-905c-dc134c9916d2"
      unitRef="provider">2300</ameh:NumberOfEmployees>
    <ameh:NumberOfPatients
      contextRef="ie050574270bf4bdba21a2294fe288e97_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNjgw_dddb1ee0-ae07-40ae-91e0-a91c3fb40689"
      unitRef="patient">290000</ameh:NumberOfPatients>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="i82b0e8a55cc14efc8f01a2a693617301_I20121231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfODc0_57b5780f-a5b5-47d9-9ce6-d718e583db35"
      unitRef="usd">5000000.0</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i82b0e8a55cc14efc8f01a2a693617301_I20121231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfODgz_d398be11-6c57-4f5d-bcdf-71183d545b11"
      unitRef="number">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i50b118c2801142889220d4c0dfe9842d_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMTIxNQ_e81cf6f7-87bb-4ea4-9323-7fa603e65838"
      unitRef="usd">200000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i50bd805f807f463da5c172dec611a78f_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMTIyMg_352ea7d8-7fad-4cf0-aed0-50147fab1fdd"
      unitRef="usd">-1300000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i16e5d9ad68cf4cacbf2ae6fc6a2646a1_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMTM3NA_5d09ed83-6131-4f01-ace9-63113719d907"
      unitRef="usd">-400000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="if450a74f42464ca8ac08b054152aac34_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMTM4MQ_a080b934-b056-43ff-a6a2-6400f5c2f90d"
      unitRef="usd">-2400000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="ie050574270bf4bdba21a2294fe288e97_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMTU0MA_c041b801-d086-4a6b-a85c-3e403ea9770d"
      unitRef="usd">6000000.0</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="ic3925100079946168d1204aa44f455d9_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMTU0Nw_07cc7a4e-b50e-4600-9e1b-c0de426dbda5"
      unitRef="usd">6400000</us-gaap:EquityMethodInvestments>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie1f5324dabcd473b8949ece8d5f9bcbc_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU3ZWYyNmFkMmM1OTQwZmU4ZDhkNGViOWVmNDRiZGQ3L3RhYmxlcmFuZ2U6ZTdlZjI2YWQyYzU5NDBmZThkOGQ0ZWI5ZWY0NGJkZDdfMy0xLTEtMS0w_eb36d7da-cd96-49b8-9adb-250323eb2dd7"
      unitRef="usd">2852000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i953f113f807a4b629361138a8c340c45_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU3ZWYyNmFkMmM1OTQwZmU4ZDhkNGViOWVmNDRiZGQ3L3RhYmxlcmFuZ2U6ZTdlZjI2YWQyYzU5NDBmZThkOGQ0ZWI5ZWY0NGJkZDdfMy0zLTEtMS0w_70040bd0-d725-401b-be33-9fd7a8384f71"
      unitRef="usd">6345000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ie1f5324dabcd473b8949ece8d5f9bcbc_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU3ZWYyNmFkMmM1OTQwZmU4ZDhkNGViOWVmNDRiZGQ3L3RhYmxlcmFuZ2U6ZTdlZjI2YWQyYzU5NDBmZThkOGQ0ZWI5ZWY0NGJkZDdfNC0xLTEtMS0w_a3887c70-e309-4140-9cca-5b340410c83a"
      unitRef="usd">6751000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i953f113f807a4b629361138a8c340c45_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU3ZWYyNmFkMmM1OTQwZmU4ZDhkNGViOWVmNDRiZGQ3L3RhYmxlcmFuZ2U6ZTdlZjI2YWQyYzU5NDBmZThkOGQ0ZWI5ZWY0NGJkZDdfNC0zLTEtMS0w_8c1ace17-16ff-49f4-8186-d71419cb7562"
      unitRef="usd">5124000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="ie1f5324dabcd473b8949ece8d5f9bcbc_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU3ZWYyNmFkMmM1OTQwZmU4ZDhkNGViOWVmNDRiZGQ3L3RhYmxlcmFuZ2U6ZTdlZjI2YWQyYzU5NDBmZThkOGQ0ZWI5ZWY0NGJkZDdfNS0xLTEtMS0w_382c4cd5-a5cf-4ef8-89ce-a2e1877e552c"
      unitRef="usd">880000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i953f113f807a4b629361138a8c340c45_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU3ZWYyNmFkMmM1OTQwZmU4ZDhkNGViOWVmNDRiZGQ3L3RhYmxlcmFuZ2U6ZTdlZjI2YWQyYzU5NDBmZThkOGQ0ZWI5ZWY0NGJkZDdfNS0zLTEtMS0w_95cd63e5-ff81-4148-99e0-882891531ed2"
      unitRef="usd">3526000</us-gaap:OtherAssetsCurrent>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="ie1f5324dabcd473b8949ece8d5f9bcbc_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU3ZWYyNmFkMmM1OTQwZmU4ZDhkNGViOWVmNDRiZGQ3L3RhYmxlcmFuZ2U6ZTdlZjI2YWQyYzU5NDBmZThkOGQ0ZWI5ZWY0NGJkZDdfNi0xLTEtMS0w_59b7f13c-3d62-412e-937e-c4be967accdd"
      unitRef="usd">2250000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="i953f113f807a4b629361138a8c340c45_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU3ZWYyNmFkMmM1OTQwZmU4ZDhkNGViOWVmNDRiZGQ3L3RhYmxlcmFuZ2U6ZTdlZjI2YWQyYzU5NDBmZThkOGQ0ZWI5ZWY0NGJkZDdfNi0zLTEtMS0w_45855ee1-c578-4d23-98fa-f677887328d0"
      unitRef="usd">2250000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="ie1f5324dabcd473b8949ece8d5f9bcbc_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU3ZWYyNmFkMmM1OTQwZmU4ZDhkNGViOWVmNDRiZGQ3L3RhYmxlcmFuZ2U6ZTdlZjI2YWQyYzU5NDBmZThkOGQ0ZWI5ZWY0NGJkZDdfNy0xLTEtMS0w_4f031162-3bc8-418b-b9b6-90e177b62e7b"
      unitRef="usd">688000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i953f113f807a4b629361138a8c340c45_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU3ZWYyNmFkMmM1OTQwZmU4ZDhkNGViOWVmNDRiZGQ3L3RhYmxlcmFuZ2U6ZTdlZjI2YWQyYzU5NDBmZThkOGQ0ZWI5ZWY0NGJkZDdfNy0zLTEtMS0w_202f9059-f785-4a41-adb1-07501eb3f22b"
      unitRef="usd">683000</us-gaap:RestrictedCashCurrent>
    <us-gaap:Assets
      contextRef="ie1f5324dabcd473b8949ece8d5f9bcbc_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU3ZWYyNmFkMmM1OTQwZmU4ZDhkNGViOWVmNDRiZGQ3L3RhYmxlcmFuZ2U6ZTdlZjI2YWQyYzU5NDBmZThkOGQ0ZWI5ZWY0NGJkZDdfOS0xLTEtMS0w_4dc16231-1092-4dac-8b5c-1e7f160968a3"
      unitRef="usd">13421000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i953f113f807a4b629361138a8c340c45_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU3ZWYyNmFkMmM1OTQwZmU4ZDhkNGViOWVmNDRiZGQ3L3RhYmxlcmFuZ2U6ZTdlZjI2YWQyYzU5NDBmZThkOGQ0ZWI5ZWY0NGJkZDdfOS0zLTEtMS0w_2b9a6ad8-f09e-42e2-a31e-60da32032d79"
      unitRef="usd">17928000</us-gaap:Assets>
    <us-gaap:LiabilitiesCurrent
      contextRef="ie1f5324dabcd473b8949ece8d5f9bcbc_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU3ZWYyNmFkMmM1OTQwZmU4ZDhkNGViOWVmNDRiZGQ3L3RhYmxlcmFuZ2U6ZTdlZjI2YWQyYzU5NDBmZThkOGQ0ZWI5ZWY0NGJkZDdfMTItMS0xLTEtMA_36f89004-f3cc-4f51-89fe-5a8bc925dc11"
      unitRef="usd">20735000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i953f113f807a4b629361138a8c340c45_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU3ZWYyNmFkMmM1OTQwZmU4ZDhkNGViOWVmNDRiZGQ3L3RhYmxlcmFuZ2U6ZTdlZjI2YWQyYzU5NDBmZThkOGQ0ZWI5ZWY0NGJkZDdfMTItMy0xLTEtMA_88ab8750-0538-4f5f-b11d-349ee855ee5b"
      unitRef="usd">23530000</us-gaap:LiabilitiesCurrent>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie1f5324dabcd473b8949ece8d5f9bcbc_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU3ZWYyNmFkMmM1OTQwZmU4ZDhkNGViOWVmNDRiZGQ3L3RhYmxlcmFuZ2U6ZTdlZjI2YWQyYzU5NDBmZThkOGQ0ZWI5ZWY0NGJkZDdfMTMtMS0xLTEtMA_2d4b87af-3394-4c46-b22c-1326e525303c"
      unitRef="usd">-7314000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i953f113f807a4b629361138a8c340c45_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU3ZWYyNmFkMmM1OTQwZmU4ZDhkNGViOWVmNDRiZGQ3L3RhYmxlcmFuZ2U6ZTdlZjI2YWQyYzU5NDBmZThkOGQ0ZWI5ZWY0NGJkZDdfMTMtMy0xLTEtMA_549be60c-c7c6-440f-83e7-3b50a6a3da05"
      unitRef="usd">-5602000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ie1f5324dabcd473b8949ece8d5f9bcbc_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU3ZWYyNmFkMmM1OTQwZmU4ZDhkNGViOWVmNDRiZGQ3L3RhYmxlcmFuZ2U6ZTdlZjI2YWQyYzU5NDBmZThkOGQ0ZWI5ZWY0NGJkZDdfMTUtMS0xLTEtMA_59cbfc9b-95ff-4fed-8882-8cef9f77a2e6"
      unitRef="usd">13421000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i953f113f807a4b629361138a8c340c45_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmU3ZWYyNmFkMmM1OTQwZmU4ZDhkNGViOWVmNDRiZGQ3L3RhYmxlcmFuZ2U6ZTdlZjI2YWQyYzU5NDBmZThkOGQ0ZWI5ZWY0NGJkZDdfMTUtMy0xLTEtMA_f8e6f5e3-16e6-4fe7-b200-f8d1d411f0c2"
      unitRef="usd">17928000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i475942101d5b4fb6bf5d97d6d803565f_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmE4ODM5YmVmZTVjYjQ4Njg4YTQ0ZjE3NDliYWY2ODZkL3RhYmxlcmFuZ2U6YTg4MzliZWZlNWNiNDg2ODhhNDRmMTc0OWJhZjY4NmRfMy0xLTEtMS0w_21ba569d-e176-446e-a2ad-f039df518178"
      unitRef="usd">92113000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8e6db84cfdcf4e68a45f60ccbfcef795_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmE4ODM5YmVmZTVjYjQ4Njg4YTQ0ZjE3NDliYWY2ODZkL3RhYmxlcmFuZ2U6YTg4MzliZWZlNWNiNDg2ODhhNDRmMTc0OWJhZjY4NmRfMy0zLTEtMS0w_c9d5f448-aa93-4c74-b16f-ad755189ba5a"
      unitRef="usd">93434000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostsAndExpenses
      contextRef="i475942101d5b4fb6bf5d97d6d803565f_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmE4ODM5YmVmZTVjYjQ4Njg4YTQ0ZjE3NDliYWY2ODZkL3RhYmxlcmFuZ2U6YTg4MzliZWZlNWNiNDg2ODhhNDRmMTc0OWJhZjY4NmRfNC0xLTEtMS0w_1459f77d-0ac4-484b-ba27-b3bd4dafc9c5"
      unitRef="usd">93680000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i8e6db84cfdcf4e68a45f60ccbfcef795_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmE4ODM5YmVmZTVjYjQ4Njg4YTQ0ZjE3NDliYWY2ODZkL3RhYmxlcmFuZ2U6YTg4MzliZWZlNWNiNDg2ODhhNDRmMTc0OWJhZjY4NmRfNC0zLTEtMS0w_5514fd06-401b-4773-ade9-81de1e530ed4"
      unitRef="usd">102845000</us-gaap:CostsAndExpenses>
    <us-gaap:ProfitLoss
      contextRef="i475942101d5b4fb6bf5d97d6d803565f_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmE4ODM5YmVmZTVjYjQ4Njg4YTQ0ZjE3NDliYWY2ODZkL3RhYmxlcmFuZ2U6YTg4MzliZWZlNWNiNDg2ODhhNDRmMTc0OWJhZjY4NmRfNi0xLTEtMS0w_a4c86c90-f067-4850-9693-7c6cc94f5535"
      unitRef="usd">-1567000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i8e6db84cfdcf4e68a45f60ccbfcef795_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmE4ODM5YmVmZTVjYjQ4Njg4YTQ0ZjE3NDliYWY2ODZkL3RhYmxlcmFuZ2U6YTg4MzliZWZlNWNiNDg2ODhhNDRmMTc0OWJhZjY4NmRfNi0zLTEtMS0w_dcdfdda9-5518-414e-919f-b967376328c2"
      unitRef="usd">-9411000</us-gaap:ProfitLoss>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="ia7524fa990e04653b73c016dce167669_I20150731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMjI3Nw_3d545968-0c8f-4a4e-96e3-951386daba71"
      unitRef="usd">1200000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ia7524fa990e04653b73c016dce167669_I20150731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMjI4Ng_b968784e-1405-4109-a265-a80eed3f122a"
      unitRef="number">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PaymentsForFees
      contextRef="id6aa1fa085114394a6e85030a974182f_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMjU0Mw_4c62628b-9364-42f1-9488-a4c0f644af8a"
      unitRef="usd">400000</us-gaap:PaymentsForFees>
    <us-gaap:PaymentsForFees
      contextRef="i6c258e6f71044221a1fb158a0d855efb_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMjU1MA_ebe6b8cb-23d3-4324-aa93-10449dcd4d18"
      unitRef="usd">600000</us-gaap:PaymentsForFees>
    <us-gaap:PaymentsForFees
      contextRef="i6610cb295b3947a5b0b3747521ffcc00_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMjYyOQ_50080cf3-ac12-4822-a537-94a739ef15d0"
      unitRef="usd">1000000.0</us-gaap:PaymentsForFees>
    <us-gaap:PaymentsForFees
      contextRef="i5aa2f3de1fe244a09059fe1a984dab17_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMjYzNg_ecc195bc-b845-4a1a-9b8d-ded222251d42"
      unitRef="usd">1400000</us-gaap:PaymentsForFees>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i9b5e25abcace4fa0adbbc4c02841298d_D20200401-20200630"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMjk1Nw_9865f8c5-3c22-4ca6-b34a-d403461aa7c5"
      unitRef="usd">-10200</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i36438be782f84c0ab30c9128983e63ae_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMjk2NA_409bc36d-af9a-4cd8-9e20-67e76635059e"
      unitRef="usd">100000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i8bec381b83b140e5a9bfeac12bc0b911_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMjk4Ng_0240e2e5-21e5-4435-8450-0769f16e77cc"
      unitRef="usd">100000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ib53dd899d00f4b69a3502812c5cc65dc_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMjk5Mw_c301daf0-72a9-49b0-b837-a35b189bd4ed"
      unitRef="usd">200000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i157f8e47c0564056805baaf2a463ba46_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMzA5Ng_bd8183e2-c092-4d80-9165-6aac929b41e4"
      unitRef="usd">1500000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="ia85acbdd13224660a5969a4561ebdc1c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMzEwMw_fea899fb-6d5b-49f9-9bc5-f4b07f5cf870"
      unitRef="usd">1400000</us-gaap:EquityMethodInvestments>
    <ameh:EquityMethodInvestmentsPurchaseOfShares
      contextRef="i5150473a0c7e46868c76e2b4a7a9fc96_I20150831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMzQ2OA_39a48ee8-0cf8-4f2e-8098-498b7cc68fdd"
      unitRef="shares">100000</ameh:EquityMethodInvestmentsPurchaseOfShares>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i6176328037a345afb5006679c54758ba_D20150801-20150831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMzUyOA_f4b7796e-5392-42e7-bbaa-ed67d1f6e633"
      unitRef="usd">10000000.0</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i9e93302086af4602804bb434c398a652_I20150831"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMzU1NA_9dff0d51-6557-42d2-9404-c655abbd19a2"
      unitRef="number">0.489</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <ameh:EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock
      contextRef="i5150473a0c7e46868c76e2b4a7a9fc96_I20150831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMzU5NQ_31123b42-63f9-41a8-9fe3-e55ca5b88f17"
      unitRef="number">0.50</ameh:EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock>
    <ameh:EquityMethodInvestmentOwnershipPercentageDisposed
      contextRef="i170e72202cdd4b73a7b7a48e85b5dd54_I20200430"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNDE0Nw_39e04407-d5c5-47a6-aee8-da0d1338461e"
      unitRef="number">0.489</ameh:EquityMethodInvestmentOwnershipPercentageDisposed>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="i19617cb0db6c48aea309f2c2b2bbd2ca_D20200430-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNDIwNA_1aa9125f-972d-4547-b7a4-4d8b1b93b0a2"
      unitRef="usd">69200000</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:ProceedsFromRepaymentsOfDebt
      contextRef="i2e1d4837a47949caa2ce6ff7a21167cc_D20200430-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNDIzNQ_490179b7-d72e-416b-b587-1adec34d4052"
      unitRef="usd">16500000</us-gaap:ProceedsFromRepaymentsOfDebt>
    <ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue
      contextRef="i4d3be425c4e74837aa2e7e572caa5cdc_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNDQxNA_ca8c7077-106b-424d-bd42-42576007b30a"
      unitRef="usd">36200000</ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue>
    <ameh:AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet
      contextRef="i4a23351d6549453987064b1ed4ccd7a5_D20200430-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNDY2Mg_c54e1764-b51d-44b7-b69d-3727973f83df"
      unitRef="usd">15700000</ameh:AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet>
    <ameh:EquityMethodInvestmentSaleContingentConsiderationCash
      contextRef="i7ca6abb962c644ebad2d7e2afff211f2_I20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMTA5OTUxMTY0NjU5Mg_79b848e1-8b86-4b13-b2b7-e8d139a7a030"
      unitRef="usd">15600000</ameh:EquityMethodInvestmentSaleContingentConsiderationCash>
    <ameh:EquityMethodInvestmentSaleContingentConsiderationPreferredShares
      contextRef="i7ca6abb962c644ebad2d7e2afff211f2_I20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMTA5OTUxMTY0NjYwNw_ac207a06-b774-4d2c-aadf-9b692fbe782f"
      unitRef="usd">6400000</ameh:EquityMethodInvestmentSaleContingentConsiderationPreferredShares>
    <ameh:EquityMethodInvestmentSaleContingentConsiderationFairValue
      contextRef="i7ca6abb962c644ebad2d7e2afff211f2_I20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMTA5OTUxMTY0NjYyMQ_c5986bfa-5b8c-4aa2-b810-3d701a30c7a8"
      unitRef="usd">22000000.0</ameh:EquityMethodInvestmentSaleContingentConsiderationFairValue>
    <ameh:EquityMethodInvestmentGainOnSaleTableTextBlock
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMTA5OTUxMTY0NjYzNQ_94a2a8aa-938d-408a-aafb-87558a6b0e49">&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The gain on sale of equity method investment recognized in connection with this transaction was determined as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:78.116%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.884%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amount (in '000s)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash proceeds (excludes proceeds to settle indebtedness owed to APC from UCI)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;52,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Preferred shares in Bright Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Beneficial interest in UCI&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: Carrying value of equity method investment on date of sale&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,998)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gain on sale of equity method investment&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;99,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ameh:EquityMethodInvestmentGainOnSaleTableTextBlock>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="if482ba97bdb84bda9cf6288b01d207b9_D20200430-20200430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjQ1ZTZmY2ZjZmI0MzRlNjlhOTJjMGMwMDgzMDUzMTJiL3RhYmxlcmFuZ2U6NDVlNmZjZmNmYjQzNGU2OWE5MmMwYzAwODMwNTMxMmJfMi0xLTEtMS02NzI0_3cbb46b3-32c9-4804-b299-7d941a00adfc"
      unitRef="usd">52743000</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue
      contextRef="idcfb848097a34b5a83ecc1ab0b752557_I20200430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjQ1ZTZmY2ZjZmI0MzRlNjlhOTJjMGMwMDgzMDUzMTJiL3RhYmxlcmFuZ2U6NDVlNmZjZmNmYjQzNGU2OWE5MmMwYzAwODMwNTMxMmJfMy0xLTEtMS02NzI0_873ab673-ad44-474b-888d-01fed296b150"
      unitRef="usd">36179000</ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue>
    <ameh:AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet
      contextRef="if482ba97bdb84bda9cf6288b01d207b9_D20200430-20200430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjQ1ZTZmY2ZjZmI0MzRlNjlhOTJjMGMwMDgzMDUzMTJiL3RhYmxlcmFuZ2U6NDVlNmZjZmNmYjQzNGU2OWE5MmMwYzAwODMwNTMxMmJfNC0xLTEtMS02NzI0_63f4831f-4179-4d44-9ef7-a669817e2d15"
      unitRef="usd">15723000</ameh:AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet>
    <us-gaap:EquityMethodInvestments
      contextRef="i9beb3a18cbe642a8aa4c713b758e5b41_I20200430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjQ1ZTZmY2ZjZmI0MzRlNjlhOTJjMGMwMDgzMDUzMTJiL3RhYmxlcmFuZ2U6NDVlNmZjZmNmYjQzNGU2OWE5MmMwYzAwODMwNTMxMmJfNS0xLTEtMS02NzI0_dcd30e6b-fd13-4541-86a7-948259a916dd"
      unitRef="usd">4998000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="if482ba97bdb84bda9cf6288b01d207b9_D20200430-20200430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjQ1ZTZmY2ZjZmI0MzRlNjlhOTJjMGMwMDgzMDUzMTJiL3RhYmxlcmFuZ2U6NDVlNmZjZmNmYjQzNGU2OWE5MmMwYzAwODMwNTMxMmJfNy0xLTEtMS02NzI2_e52f0457-1e12-42d7-b66c-f0e441906dc4"
      unitRef="usd">99647000</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ia1f85d23728f488aa706b6728075d6a6_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMTA5OTUxMTY0NjYzOA_649dad1e-f343-4cf7-b558-5355fbef63d1"
      unitRef="usd">900000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i371098e379a64f1ab0452b0340ffdcd8_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNDk0NzgwMjMzNTQyMA_031c1551-b580-4aa3-a1d2-c0474f1ca919"
      unitRef="usd">4500000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i0a335fe94da74cc1b74cfe701830c693_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMTA5OTUxMTY0NjY1Mg_7adb48c5-34a4-4b37-8eab-52d64de25641"
      unitRef="usd">3600000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="icceb687a46d94c0d8314ae9896a926f0_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNDk0NzgwMjMzNTQ0OQ_d7ad20e4-9b4c-4fd7-8775-fcbea77f0101"
      unitRef="usd">5500000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="iadefc20aa4134071bd9a5346e792b746_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMTA5OTUxMTY0MjU2MQ_0d4099db-d941-40ec-be2a-52d51c96a9c2"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i1d9b625d40984cada77fed26b2662304_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNDk0NzgwMjMzNTY1NA_39915b5d-2fdb-44f9-a1bd-af0ee766ab98"
      unitRef="usd">1400000</us-gaap:EquityMethodInvestments>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ibd24a1722d5b442bba297bcc460eb0c0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmMzZGQ1MmM1OWRhNDRiZmM4YjAzMzkyZDk1M2Q5MDk1L3RhYmxlcmFuZ2U6YzNkZDUyYzU5ZGE0NGJmYzhiMDMzOTJkOTUzZDkwOTVfMy0zLTEtMS02Mzc1_a6ba49b4-9527-4001-a8d6-2d9ec467533e"
      unitRef="usd">33890000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ibd24a1722d5b442bba297bcc460eb0c0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmMzZGQ1MmM1OWRhNDRiZmM4YjAzMzkyZDk1M2Q5MDk1L3RhYmxlcmFuZ2U6YzNkZDUyYzU5ZGE0NGJmYzhiMDMzOTJkOTUzZDkwOTVfNC0zLTEtMS02Mzc1_4f252e2e-8159-4dc3-b3e6-843c2b1d2eba"
      unitRef="usd">63843000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="ibd24a1722d5b442bba297bcc460eb0c0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmMzZGQ1MmM1OWRhNDRiZmM4YjAzMzkyZDk1M2Q5MDk1L3RhYmxlcmFuZ2U6YzNkZDUyYzU5ZGE0NGJmYzhiMDMzOTJkOTUzZDkwOTVfNS0zLTEtMS02Mzc1_446a6ca7-dae7-4b2e-b5f5-99d347997bfb"
      unitRef="usd">38280000</us-gaap:OtherAssetsCurrent>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="ibd24a1722d5b442bba297bcc460eb0c0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmMzZGQ1MmM1OWRhNDRiZmM4YjAzMzkyZDk1M2Q5MDk1L3RhYmxlcmFuZ2U6YzNkZDUyYzU5ZGE0NGJmYzhiMDMzOTJkOTUzZDkwOTVfNi0zLTEtMS02Mzc1_1355d7d5-a6a3-4a87-bb3c-68d8de4268c1"
      unitRef="usd">882000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="ibd24a1722d5b442bba297bcc460eb0c0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmMzZGQ1MmM1OWRhNDRiZmM4YjAzMzkyZDk1M2Q5MDk1L3RhYmxlcmFuZ2U6YzNkZDUyYzU5ZGE0NGJmYzhiMDMzOTJkOTUzZDkwOTVfNy0zLTEtMS02Mzc1_6bc78e0a-4756-45d4-9a15-ba5cfe282471"
      unitRef="usd">4021000</us-gaap:RestrictedCashCurrent>
    <us-gaap:Assets
      contextRef="ibd24a1722d5b442bba297bcc460eb0c0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmMzZGQ1MmM1OWRhNDRiZmM4YjAzMzkyZDk1M2Q5MDk1L3RhYmxlcmFuZ2U6YzNkZDUyYzU5ZGE0NGJmYzhiMDMzOTJkOTUzZDkwOTVfOS0zLTEtMS02Mzc1_045a4916-3c9b-4c7d-b8a6-382417f692f5"
      unitRef="usd">140916000</us-gaap:Assets>
    <us-gaap:LiabilitiesCurrent
      contextRef="ibd24a1722d5b442bba297bcc460eb0c0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmMzZGQ1MmM1OWRhNDRiZmM4YjAzMzkyZDk1M2Q5MDk1L3RhYmxlcmFuZ2U6YzNkZDUyYzU5ZGE0NGJmYzhiMDMzOTJkOTUzZDkwOTVfMTItMy0xLTEtNjM3NQ_5d8df3ef-e5f8-4e87-83cc-66dbd83cb30e"
      unitRef="usd">128330000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OtherLiabilities
      contextRef="ibd24a1722d5b442bba297bcc460eb0c0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmMzZGQ1MmM1OWRhNDRiZmM4YjAzMzkyZDk1M2Q5MDk1L3RhYmxlcmFuZ2U6YzNkZDUyYzU5ZGE0NGJmYzhiMDMzOTJkOTUzZDkwOTVfMTMtMS0xLTEtNjQyNA_a59f5fbe-c8e5-48db-b779-4da88e523706"
      unitRef="usd">33133000</us-gaap:OtherLiabilities>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibd24a1722d5b442bba297bcc460eb0c0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmMzZGQ1MmM1OWRhNDRiZmM4YjAzMzkyZDk1M2Q5MDk1L3RhYmxlcmFuZ2U6YzNkZDUyYzU5ZGE0NGJmYzhiMDMzOTJkOTUzZDkwOTVfMTMtMy0xLTEtNjM3NQ_44fcf966-0ca8-4727-8757-684b2152561e"
      unitRef="usd">-20547000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ibd24a1722d5b442bba297bcc460eb0c0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmMzZGQ1MmM1OWRhNDRiZmM4YjAzMzkyZDk1M2Q5MDk1L3RhYmxlcmFuZ2U6YzNkZDUyYzU5ZGE0NGJmYzhiMDMzOTJkOTUzZDkwOTVfMTUtMy0xLTEtNjM3NQ_f89cae62-617d-4ca3-a05b-e7a2db8fac63"
      unitRef="usd">140916000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0e9c10a96719436f9bc86a015712be60_D20200101-20200430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjc2NjgwOTg3M2QzODQ1ZGJiYzEwODA0NDI3MTJlMTA2L3RhYmxlcmFuZ2U6NzY2ODA5ODczZDM4NDVkYmJjMTA4MDQ0MjcxMmUxMDZfMy0xLTEtMS02Mzc1_0aa4c80d-b750-4bf0-b9c1-6e184654e357"
      unitRef="usd">195308000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie24c440e5f474a2884cc40d10efab865_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjc2NjgwOTg3M2QzODQ1ZGJiYzEwODA0NDI3MTJlMTA2L3RhYmxlcmFuZ2U6NzY2ODA5ODczZDM4NDVkYmJjMTA4MDQ0MjcxMmUxMDZfMy0zLTEtMS02Mzc1_bbf18ccb-2570-4be3-a660-586b6f533866"
      unitRef="usd">247517000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostsAndExpenses
      contextRef="i0e9c10a96719436f9bc86a015712be60_D20200101-20200430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjc2NjgwOTg3M2QzODQ1ZGJiYzEwODA0NDI3MTJlMTA2L3RhYmxlcmFuZ2U6NzY2ODA5ODczZDM4NDVkYmJjMTA4MDQ0MjcxMmUxMDZfNC0xLTEtMS02Mzc1_28475de5-0b83-4d52-9e26-81a2eca127cc"
      unitRef="usd">189028000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ie24c440e5f474a2884cc40d10efab865_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjc2NjgwOTg3M2QzODQ1ZGJiYzEwODA0NDI3MTJlMTA2L3RhYmxlcmFuZ2U6NzY2ODA5ODczZDM4NDVkYmJjMTA4MDQ0MjcxMmUxMDZfNC0zLTEtMS02Mzc1_c2dc681c-d0a6-4bd0-b8db-217584922819"
      unitRef="usd">239389000</us-gaap:CostsAndExpenses>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i0e9c10a96719436f9bc86a015712be60_D20200101-20200430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjc2NjgwOTg3M2QzODQ1ZGJiYzEwODA0NDI3MTJlMTA2L3RhYmxlcmFuZ2U6NzY2ODA5ODczZDM4NDVkYmJjMTA4MDQ0MjcxMmUxMDZfNi0xLTEtMS02NDc1_994b798e-80c3-49f4-87f0-bd62371bb7d9"
      unitRef="usd">6280000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ie24c440e5f474a2884cc40d10efab865_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjc2NjgwOTg3M2QzODQ1ZGJiYzEwODA0NDI3MTJlMTA2L3RhYmxlcmFuZ2U6NzY2ODA5ODczZDM4NDVkYmJjMTA4MDQ0MjcxMmUxMDZfNi0zLTEtMS02NDY5_d7890d36-a2b3-44dd-9f55-0643b83a020c"
      unitRef="usd">8128000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0e9c10a96719436f9bc86a015712be60_D20200101-20200430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjc2NjgwOTg3M2QzODQ1ZGJiYzEwODA0NDI3MTJlMTA2L3RhYmxlcmFuZ2U6NzY2ODA5ODczZDM4NDVkYmJjMTA4MDQ0MjcxMmUxMDZfNy0xLTEtMS02NDc1_87046e36-736e-4363-8728-64f9b1914c5d"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie24c440e5f474a2884cc40d10efab865_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjc2NjgwOTg3M2QzODQ1ZGJiYzEwODA0NDI3MTJlMTA2L3RhYmxlcmFuZ2U6NzY2ODA5ODczZDM4NDVkYmJjMTA4MDQ0MjcxMmUxMDZfNy0zLTEtMS02NDY5_25b75adb-1e87-44c1-b399-e4447145fd3e"
      unitRef="usd">-3167000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="i0e9c10a96719436f9bc86a015712be60_D20200101-20200430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjc2NjgwOTg3M2QzODQ1ZGJiYzEwODA0NDI3MTJlMTA2L3RhYmxlcmFuZ2U6NzY2ODA5ODczZDM4NDVkYmJjMTA4MDQ0MjcxMmUxMDZfNi0xLTEtMS02Mzc1_be5c82b1-a5be-4f7f-87a0-68940ff6caa6"
      unitRef="usd">6280000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ie24c440e5f474a2884cc40d10efab865_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjc2NjgwOTg3M2QzODQ1ZGJiYzEwODA0NDI3MTJlMTA2L3RhYmxlcmFuZ2U6NzY2ODA5ODczZDM4NDVkYmJjMTA4MDQ0MjcxMmUxMDZfNi0zLTEtMS02Mzc1_35e292c0-7901-432f-aced-0c7460908373"
      unitRef="usd">11295000</us-gaap:ProfitLoss>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ifaefb6ce9ff24e308243a14d1cc7814f_I20160514"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNTE0Ng_f6a360ca-b8ae-410a-9b58-6284c121c92b"
      unitRef="number">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i74f5fd5d4b8a44e882631f206e038bd7_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNTQ0Nw_cd4e87dd-532a-4388-ab1e-eb8f7a2842e6"
      unitRef="usd">-100000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i61394655c4ad4039984a2f0503f8cb4d_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNTQ1NA_917feed2-2b5f-4eb6-9fb9-fbd228b78af1"
      unitRef="usd">200000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i0cc11225aa314266a6ef2696d7d4dfad_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNTQ3Ng_9febc6df-35b3-49fb-9124-3a925df57a31"
      unitRef="usd">-100000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="id158f4ef37084b119e97ae1e8a41d0c9_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNTQ4Mw_7efd087a-8599-47c7-9fef-9b8625e3e069"
      unitRef="usd">400000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i314c4ccc348b436ba49cb07ab3848d81_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNTYzMQ_9d78110e-fb79-4fae-9392-0b0f2f13be6f"
      unitRef="usd">2200000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i5fd06ba095124e0abdcc0d7f91fc1472_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNjA0NzMxMzk2NzQ5OA_8010972d-e5e0-4efc-b4cb-8041b7685593"
      unitRef="usd">2300000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ic80c408963dd4f07a4718bf817b59f78_I20180630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNjAxMA_96a8e288-46b6-4da6-bf81-32983abcbbda"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ib33ce2cceba04d82b64d3b892ada4ad8_I20180630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNjAxNA_d3c6e4c5-9f69-4497-968f-3b68646edf18"
      unitRef="number">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="id2d9c71932034be7bd4932da0626f712_I20180630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNjAyMQ_9f158626-d6d4-4e50-b385-57324f398ae0"
      unitRef="number">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:MembersCapital
      contextRef="ic80c408963dd4f07a4718bf817b59f78_I20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNjA5Nw_dc228c4f-7e60-4b7b-862c-6a78a43015bd"
      unitRef="usd">16700000</us-gaap:MembersCapital>
    <us-gaap:MembersCapital
      contextRef="ib33ce2cceba04d82b64d3b892ada4ad8_I20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNjEwMQ_43f9585b-57c5-4a46-aad4-ecc01c8c51f3"
      unitRef="usd">8300000</us-gaap:MembersCapital>
    <us-gaap:MembersCapital
      contextRef="id2d9c71932034be7bd4932da0626f712_I20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNjEwOQ_fcfc97d3-05f5-4633-a59d-5d65c9fbf5d7"
      unitRef="usd">8300000</us-gaap:MembersCapital>
    <us-gaap:PaymentsToAcquireRealEstate
      contextRef="id61177debadf4225a858af823bca90d6_D20180601-20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNjM2OA_8b3175c5-2594-48e3-8752-61dedf39190d"
      unitRef="usd">33300000</us-gaap:PaymentsToAcquireRealEstate>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="idda53a861d504beea7993e7de2f52ee0_I20190423"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNjQ3Mg_5781b0ed-049b-4f38-98cb-fd42ee6bd021"
      unitRef="number">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="idda53a861d504beea7993e7de2f52ee0_I20190423"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNjUzNg_e489a574-7402-48f2-be8b-2bd3cd24ead3"
      unitRef="usd">8300000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i74302930c31d45b8a80be7e006522de5_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNjU2NA_0038b376-cf7e-428d-9313-192425b1f984"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestments
      contextRef="ic39201e9036d43759acb734c62b0b8d4_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNjY0OA_8037cf08-60ae-4760-baf8-8abc1ee5e94d"
      unitRef="usd">17000000.0</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i051b582accf543bc87134371ea6f7726_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNjkyOA_0e2f4b87-33e6-4737-b2e1-74f265d8ed47"
      unitRef="usd">-100000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ib8b7f2e4ee2a4d2c9a3e1fe33363b2d3_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNjkzNg_c16adb51-47c4-4ce2-85e0-74b8b0d091bf"
      unitRef="usd">12649</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ia3ac42f4999448a69359a25a83b0f908_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNjk1OA_62bf6f55-abbd-481a-91a6-cc657368a689"
      unitRef="usd">-200000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="if55f174a731f484e9a8b88ed6a99666e_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNjk2NQ_ef99054e-6bc7-4632-91dc-212ab364299d"
      unitRef="usd">-34319</us-gaap:IncomeLossFromEquityMethodInvestments>
    <ameh:EquityMethodInvestmentsContribution
      contextRef="i357af7bf55294d7b86954b0bf136c8c6_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNzA3NQ_6277d5d3-8d65-4ad2-be33-e7751edc73b6"
      unitRef="usd">500000</ameh:EquityMethodInvestmentsContribution>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i74302930c31d45b8a80be7e006522de5_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNzExNQ_20ae1a4d-f05e-45fb-a43f-5f2effc2fdc0"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestments
      contextRef="ic39201e9036d43759acb734c62b0b8d4_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNzE1OA_8037cf08-60ae-4760-baf8-8abc1ee5e94d"
      unitRef="usd">17000000.0</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i3451c081a11c49aea7b55e24c90e4721_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNzE2NQ_dbccce6f-a3a5-426c-be72-68cca3ad2990"
      unitRef="usd">16700000</us-gaap:EquityMethodInvestments>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="idbb6a15f7620432bb5505e89f3004b9c_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjU1OTk2ZDRjYTk4ZjQ1ZWFiOWY4ZGEzMmIwZDBlNjU0L3RhYmxlcmFuZ2U6NTU5OTZkNGNhOThmNDVlYWI5ZjhkYTMyYjBkMGU2NTRfMy0xLTEtMS0w_94e0ea12-3055-4177-9bbd-bf1736abdc61"
      unitRef="usd">126000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i703c2ff9263240b296697549156a727f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjU1OTk2ZDRjYTk4ZjQ1ZWFiOWY4ZGEzMmIwZDBlNjU0L3RhYmxlcmFuZ2U6NTU5OTZkNGNhOThmNDVlYWI5ZjhkYTMyYjBkMGU2NTRfMy0zLTEtMS0w_fc709e81-0cd9-4799-baf9-39d6c40dca80"
      unitRef="usd">139000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OtherAssetsCurrent
      contextRef="idbb6a15f7620432bb5505e89f3004b9c_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjU1OTk2ZDRjYTk4ZjQ1ZWFiOWY4ZGEzMmIwZDBlNjU0L3RhYmxlcmFuZ2U6NTU5OTZkNGNhOThmNDVlYWI5ZjhkYTMyYjBkMGU2NTRfNC0xLTEtMS0w_576edcf0-a11e-4806-8354-a8a1388aca75"
      unitRef="usd">0</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i703c2ff9263240b296697549156a727f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjU1OTk2ZDRjYTk4ZjQ1ZWFiOWY4ZGEzMmIwZDBlNjU0L3RhYmxlcmFuZ2U6NTU5OTZkNGNhOThmNDVlYWI5ZjhkYTMyYjBkMGU2NTRfNC0zLTEtMS0w_23aa6b45-4def-4d52-9042-b26a83555766"
      unitRef="usd">17000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssets
      contextRef="idbb6a15f7620432bb5505e89f3004b9c_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjU1OTk2ZDRjYTk4ZjQ1ZWFiOWY4ZGEzMmIwZDBlNjU0L3RhYmxlcmFuZ2U6NTU5OTZkNGNhOThmNDVlYWI5ZjhkYTMyYjBkMGU2NTRfNS0xLTEtMS0w_1dceeeed-e993-4949-ad25-5dac321be9f3"
      unitRef="usd">70000</us-gaap:OtherAssets>
    <us-gaap:OtherAssets
      contextRef="i703c2ff9263240b296697549156a727f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjU1OTk2ZDRjYTk4ZjQ1ZWFiOWY4ZGEzMmIwZDBlNjU0L3RhYmxlcmFuZ2U6NTU5OTZkNGNhOThmNDVlYWI5ZjhkYTMyYjBkMGU2NTRfNS0zLTEtMS0w_8e6e74ab-7bcf-45c0-a045-85176f5127b8"
      unitRef="usd">70000</us-gaap:OtherAssets>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="idbb6a15f7620432bb5505e89f3004b9c_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjU1OTk2ZDRjYTk4ZjQ1ZWFiOWY4ZGEzMmIwZDBlNjU0L3RhYmxlcmFuZ2U6NTU5OTZkNGNhOThmNDVlYWI5ZjhkYTMyYjBkMGU2NTRfNi0xLTEtMS0w_ecd2c046-35b1-4d18-bea5-284cd5470c56"
      unitRef="usd">33697000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i703c2ff9263240b296697549156a727f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjU1OTk2ZDRjYTk4ZjQ1ZWFiOWY4ZGEzMmIwZDBlNjU0L3RhYmxlcmFuZ2U6NTU5OTZkNGNhOThmNDVlYWI5ZjhkYTMyYjBkMGU2NTRfNi0zLTEtMS0w_2059e63e-c808-485f-930b-7d9516434ee5"
      unitRef="usd">33581000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:Assets
      contextRef="idbb6a15f7620432bb5505e89f3004b9c_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjU1OTk2ZDRjYTk4ZjQ1ZWFiOWY4ZGEzMmIwZDBlNjU0L3RhYmxlcmFuZ2U6NTU5OTZkNGNhOThmNDVlYWI5ZjhkYTMyYjBkMGU2NTRfOC0xLTEtMS0w_f3b8ad1f-c84e-4190-82ff-ee6d2356bf38"
      unitRef="usd">33893000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i703c2ff9263240b296697549156a727f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjU1OTk2ZDRjYTk4ZjQ1ZWFiOWY4ZGEzMmIwZDBlNjU0L3RhYmxlcmFuZ2U6NTU5OTZkNGNhOThmNDVlYWI5ZjhkYTMyYjBkMGU2NTRfOC0zLTEtMS0w_eb86d1c3-1500-42ed-bfe9-782ae7f87a4f"
      unitRef="usd">33807000</us-gaap:Assets>
    <us-gaap:LiabilitiesCurrent
      contextRef="idbb6a15f7620432bb5505e89f3004b9c_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjU1OTk2ZDRjYTk4ZjQ1ZWFiOWY4ZGEzMmIwZDBlNjU0L3RhYmxlcmFuZ2U6NTU5OTZkNGNhOThmNDVlYWI5ZjhkYTMyYjBkMGU2NTRfMTItMS0xLTEtMA_73357363-790e-4b7f-9228-17de7f5c897d"
      unitRef="usd">1109000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i703c2ff9263240b296697549156a727f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjU1OTk2ZDRjYTk4ZjQ1ZWFiOWY4ZGEzMmIwZDBlNjU0L3RhYmxlcmFuZ2U6NTU5OTZkNGNhOThmNDVlYWI5ZjhkYTMyYjBkMGU2NTRfMTItMy0xLTEtMA_6110eb05-1c10-496c-928f-043653a539b9"
      unitRef="usd">1062000</us-gaap:LiabilitiesCurrent>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idbb6a15f7620432bb5505e89f3004b9c_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjU1OTk2ZDRjYTk4ZjQ1ZWFiOWY4ZGEzMmIwZDBlNjU0L3RhYmxlcmFuZ2U6NTU5OTZkNGNhOThmNDVlYWI5ZjhkYTMyYjBkMGU2NTRfMTMtMS0xLTEtMA_e5614c4a-cf77-4d7e-813d-d8ecc1da2802"
      unitRef="usd">32784000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i703c2ff9263240b296697549156a727f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjU1OTk2ZDRjYTk4ZjQ1ZWFiOWY4ZGEzMmIwZDBlNjU0L3RhYmxlcmFuZ2U6NTU5OTZkNGNhOThmNDVlYWI5ZjhkYTMyYjBkMGU2NTRfMTMtMy0xLTEtMA_b24eaeef-add1-48f8-aa2d-c58182064491"
      unitRef="usd">32745000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="idbb6a15f7620432bb5505e89f3004b9c_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjU1OTk2ZDRjYTk4ZjQ1ZWFiOWY4ZGEzMmIwZDBlNjU0L3RhYmxlcmFuZ2U6NTU5OTZkNGNhOThmNDVlYWI5ZjhkYTMyYjBkMGU2NTRfMTUtMS0xLTEtMA_6f8851fc-8759-4bdd-a7ba-4e888a71ab0b"
      unitRef="usd">33893000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i703c2ff9263240b296697549156a727f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOjU1OTk2ZDRjYTk4ZjQ1ZWFiOWY4ZGEzMmIwZDBlNjU0L3RhYmxlcmFuZ2U6NTU5OTZkNGNhOThmNDVlYWI5ZjhkYTMyYjBkMGU2NTRfMTUtMy0xLTEtMA_4584def1-c6cc-4000-adcc-afb673e25f9f"
      unitRef="usd">33807000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0af7733faffb48348018de02ffdfff6a_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmIyMTdmOWRiMTFlOTQxMGI5NWU2MjlmMDA1MDYyOWM5L3RhYmxlcmFuZ2U6YjIxN2Y5ZGIxMWU5NDEwYjk1ZTYyOWYwMDUwNjI5YzlfMi0xLTEtMS0w_1aa01449-1a96-4b9a-a0e8-0aba66d2d45d"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iea1fae3b79a34d86b70cbdfb21ad3dbb_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmIyMTdmOWRiMTFlOTQxMGI5NWU2MjlmMDA1MDYyOWM5L3RhYmxlcmFuZ2U6YjIxN2Y5ZGIxMWU5NDEwYjk1ZTYyOWYwMDUwNjI5YzlfMi0zLTEtMS0w_d0afceaf-1e10-4abc-8e6f-23620ffc6da4"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostsAndExpenses
      contextRef="i0af7733faffb48348018de02ffdfff6a_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmIyMTdmOWRiMTFlOTQxMGI5NWU2MjlmMDA1MDYyOWM5L3RhYmxlcmFuZ2U6YjIxN2Y5ZGIxMWU5NDEwYjk1ZTYyOWYwMDUwNjI5YzlfMy0xLTEtMS0w_726322a4-27ec-4a98-a3a5-05f070df9cea"
      unitRef="usd">579000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="iea1fae3b79a34d86b70cbdfb21ad3dbb_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmIyMTdmOWRiMTFlOTQxMGI5NWU2MjlmMDA1MDYyOWM5L3RhYmxlcmFuZ2U6YjIxN2Y5ZGIxMWU5NDEwYjk1ZTYyOWYwMDUwNjI5YzlfMy0zLTEtMS0w_2a58741e-c5cb-4e61-960f-fed736f164ee"
      unitRef="usd">538000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0af7733faffb48348018de02ffdfff6a_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmIyMTdmOWRiMTFlOTQxMGI5NWU2MjlmMDA1MDYyOWM5L3RhYmxlcmFuZ2U6YjIxN2Y5ZGIxMWU5NDEwYjk1ZTYyOWYwMDUwNjI5YzlfNC0xLTEtMS0w_5b4224b4-d865-49ae-b2f2-7b14579f1824"
      unitRef="usd">-579000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iea1fae3b79a34d86b70cbdfb21ad3dbb_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmIyMTdmOWRiMTFlOTQxMGI5NWU2MjlmMDA1MDYyOWM5L3RhYmxlcmFuZ2U6YjIxN2Y5ZGIxMWU5NDEwYjk1ZTYyOWYwMDUwNjI5YzlfNC0zLTEtMS0w_ed29c86c-5d7c-461c-859c-cc9cf58ed1bb"
      unitRef="usd">-538000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i0af7733faffb48348018de02ffdfff6a_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmIyMTdmOWRiMTFlOTQxMGI5NWU2MjlmMDA1MDYyOWM5L3RhYmxlcmFuZ2U6YjIxN2Y5ZGIxMWU5NDEwYjk1ZTYyOWYwMDUwNjI5YzlfNi0xLTEtMS0w_f068ca9e-096e-4637-bfb3-07b318180197"
      unitRef="usd">21000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="iea1fae3b79a34d86b70cbdfb21ad3dbb_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmIyMTdmOWRiMTFlOTQxMGI5NWU2MjlmMDA1MDYyOWM5L3RhYmxlcmFuZ2U6YjIxN2Y5ZGIxMWU5NDEwYjk1ZTYyOWYwMDUwNjI5YzlfNi0zLTEtMS0w_7ffc3212-f640-4a69-aaee-c8b459fd04d5"
      unitRef="usd">385000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:ProfitLoss
      contextRef="i0af7733faffb48348018de02ffdfff6a_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmIyMTdmOWRiMTFlOTQxMGI5NWU2MjlmMDA1MDYyOWM5L3RhYmxlcmFuZ2U6YjIxN2Y5ZGIxMWU5NDEwYjk1ZTYyOWYwMDUwNjI5YzlfOC0xLTEtMS0w_69caeb49-e554-4080-b2f6-42591cec6834"
      unitRef="usd">-558000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iea1fae3b79a34d86b70cbdfb21ad3dbb_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RhYmxlOmIyMTdmOWRiMTFlOTQxMGI5NWU2MjlmMDA1MDYyOWM5L3RhYmxlcmFuZ2U6YjIxN2Y5ZGIxMWU5NDEwYjk1ZTYyOWYwMDUwNjI5YzlfOC0zLTEtMS0w_4ad34d77-4667-48eb-a716-9ba0e0c99d68"
      unitRef="usd">-153000</us-gaap:ProfitLoss>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ifd12b893ddc54a6ead35cdb2bc89c8bc_I20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNzgwMA_6cb19339-f6dc-4970-8a28-1cc036b1e5f8"
      unitRef="number">0.333</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i00815df6bd294d36b80661bd7ee807a7_I20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNzgwMA_876beef1-2df1-49f4-b32a-dbae1cbe9656"
      unitRef="number">0.333</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i4c9caf98dc0642adba42edbbc942a39e_I20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNzgwMA_a30ce0c9-38c6-45c1-b8f7-fb218fd291b1"
      unitRef="number">0.333</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:MembersCapital
      contextRef="id084b778b0c0437ca9710b2d345a5e1c_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNzg4NA_2d6b5afb-f778-4962-a1f2-014e5cae1b37"
      unitRef="usd">3000</us-gaap:MembersCapital>
    <us-gaap:MembersCapital
      contextRef="i802f55fac88e49498a6b008731c49198_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNzg4NA_2f71a6f8-b040-4045-be4e-54b2a6091967"
      unitRef="usd">3000</us-gaap:MembersCapital>
    <us-gaap:MembersCapital
      contextRef="i4c9caf98dc0642adba42edbbc942a39e_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNzg4NA_4b686c55-e882-4c34-930c-69d44db68e13"
      unitRef="usd">3000</us-gaap:MembersCapital>
    <ameh:WorkingCapitalContribution
      contextRef="i802f55fac88e49498a6b008731c49198_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNzkyNA_021c1a3f-d951-4131-a786-ed08c5d06126"
      unitRef="usd">30000</ameh:WorkingCapitalContribution>
    <ameh:WorkingCapitalContribution
      contextRef="id084b778b0c0437ca9710b2d345a5e1c_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNzkyNA_1b986eb2-1d54-4465-9c3d-b3397ba438e0"
      unitRef="usd">30000</ameh:WorkingCapitalContribution>
    <ameh:WorkingCapitalContribution
      contextRef="i4c9caf98dc0642adba42edbbc942a39e_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNzkyNA_4f40d14c-f741-4309-b771-d27939926eac"
      unitRef="usd">30000</ameh:WorkingCapitalContribution>
    <ameh:WorkingCapitalContribution
      contextRef="ieb3fd4253957445eb4629822911925ed_I20190831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNzk1NQ_ca899772-59f5-487b-a755-f5550b21bd36"
      unitRef="usd">300000</ameh:WorkingCapitalContribution>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i1757e23b7dae4837b5c342d3a54fdb9f_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfODA5Mw_964770e4-b8a5-4243-9e7f-5670e5564633"
      unitRef="usd">-43000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i9729bda7911148aea82f02fafc542f1e_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfODEwMA_7396cf1a-00f4-4108-a001-e46ec75e3796"
      unitRef="usd">12000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i21ee88acf5e24e5aa9702c3e569cdb0d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfODIwNQ_907b262a-10a5-4bb5-a36e-d1c2be49ad5e"
      unitRef="usd">200000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="ifc2b7046e5434c1188649346120d70f7_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfODIwNQ_e9cb671d-f6d7-499b-80a6-172719a1b62d"
      unitRef="usd">200000</us-gaap:EquityMethodInvestments>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares
      contextRef="i3635f2277d854166953f31769a15549d_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfODM1OA_745334b5-fa91-4012-b6b1-65addca4a36e"
      unitRef="shares">270000</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares>
    <ameh:PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments
      contextRef="ia0bdfa92f0584697bf3e23e968030cd7_D20180501-20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfODQ0Mw_a4897824-4bdb-466c-ac05-6339fb8fd350"
      unitRef="usd">400000</ameh:PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest
      contextRef="i3635f2277d854166953f31769a15549d_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfODQ0OQ_dcf3c5c2-d026-4c31-9775-c5e1354373f1"
      unitRef="shares">1.50</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage
      contextRef="i3635f2277d854166953f31769a15549d_I20180531"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfODUxMg_d3b84e0e-f0d2-4be1-af50-13f24c2a661b"
      unitRef="number">0.028</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i3635f2277d854166953f31769a15549d_I20180531"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMTA5OTUxMTY0MjU2OQ_62844435-4ffe-469b-ab2d-76e2726b9e8d">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i3635f2277d854166953f31769a15549d_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfODYzMw_3f67ab55-40da-4ea0-8db5-18c0e1840872"
      unitRef="shares">270000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption
      contextRef="ia0bdfa92f0584697bf3e23e968030cd7_D20180501-20180531"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMTA5OTUxMTY0MjU3MA_71835439-1478-4dde-b5ab-805eb3ccc6a0">P5Y</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests
      contextRef="ia0bdfa92f0584697bf3e23e968030cd7_D20180501-20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfODcyOA_15bbf5f1-ea3a-4f09-b656-f5c7ef311b5e"
      unitRef="shares">380000</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i3635f2277d854166953f31769a15549d_I20180531"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfMTA5OTUxMTY0MjU3MQ_625b6317-c0ac-4d03-aa78-2a5e1a48f2f5">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet
      contextRef="i3635f2277d854166953f31769a15549d_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfODc4Ng_06c2b11d-7497-4637-91a5-a7ae536cf993"
      unitRef="shares">480000</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears
      contextRef="id2fefe9326624bf8a6e101283a7f761f_I20190701"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfOTQwMw_e1e80f95-f0b8-4ed5-82a7-f911cb8bd1e1"
      unitRef="number">0.50</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment
      contextRef="ie1f0176357034096b162de4acd821801_D20190701-20190701"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfOTQ5Nw_f9c2edbe-2544-4260-aa1b-2ceffe049e34">P5Y</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost
      contextRef="id2fefe9326624bf8a6e101283a7f761f_I20190701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfOTU0Ng_6a8f6c5f-c3c2-49a1-8d29-36ea4bd8e8f7"
      unitRef="usd">500000</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage
      contextRef="id2fefe9326624bf8a6e101283a7f761f_I20190701"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfOTU1NQ_d8598246-9820-4b07-a10b-1b735afac8b9"
      unitRef="number">0.10</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments
      contextRef="i4b00da16353446959bec407e221c7666_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfOTYwMg_7e07e491-e9fe-42ec-a242-6f892b82a149"
      unitRef="usd">500000</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments>
    <ameh:EquityMethodInvestmentOwnershipPercentageDisposed
      contextRef="i170e72202cdd4b73a7b7a48e85b5dd54_I20200430"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNzY5NjU4MTQwNjU1NA_39e04407-d5c5-47a6-aee8-da0d1338461e"
      unitRef="number">0.489</ameh:EquityMethodInvestmentOwnershipPercentageDisposed>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="i19617cb0db6c48aea309f2c2b2bbd2ca_D20200430-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNzY5NjU4MTQwNjYxMQ_1aa9125f-972d-4547-b7a4-4d8b1b93b0a2"
      unitRef="usd">69200000</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:ProceedsFromRepaymentsOfDebt
      contextRef="i2e1d4837a47949caa2ce6ff7a21167cc_D20200430-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNzY5NjU4MTQwNjY0Mg_490179b7-d72e-416b-b587-1adec34d4052"
      unitRef="usd">16500000</us-gaap:ProceedsFromRepaymentsOfDebt>
    <ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue
      contextRef="i4d3be425c4e74837aa2e7e572caa5cdc_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNzY5NjU4MTQwNjgyMQ_ca8c7077-106b-424d-bd42-42576007b30a"
      unitRef="usd">36200000</ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue>
    <ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue
      contextRef="i4d3be425c4e74837aa2e7e572caa5cdc_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV81OC9mcmFnOmMxNTBjYWY1NDZiNjQ4ZTU4ODIzYTU2NzJjMDk3MjVmL3RleHRyZWdpb246YzE1MGNhZjU0NmI2NDhlNTg4MjNhNTY3MmMwOTcyNWZfNzY5NjU4MTQwNzczOA_ca8c7077-106b-424d-bd42-42576007b30a"
      unitRef="usd">36200000</ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue>
    <ameh:LoanReceivableTextBlock
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV82NC9mcmFnOmQ4NDJlMDllZDY2NTQzNGZiZTJmZDc5Y2Q1YjYzNGRiL3RleHRyZWdpb246ZDg0MmUwOWVkNjY1NDM0ZmJlMmZkNzljZDViNjM0ZGJfMzQyMA_9ea5c5e6-775e-4c7e-8a4a-2ac27c2a80c8">Loan Receivable and Loan Receivable &#x2013; Related Parties&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Loan receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Dr. Albert Arteaga&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On June 28, 2019, APC entered into a convertible secured promissory note with Dr. Albert H. Arteaga, M.D. (&#x201c;Dr. Arteaga&#x201d;), Chief Executive Officer of LMA, to loan $6.4 million to Dr. Arteaga.  Interest on the loan accrues at a rate that is equal to the prime rate, plus 1% (4.25% as of June&#160;30, 2020) and payable in monthly installments of interest only on the first day of each month until the maturity date of December 31, 2020, at which time, all outstanding principal and accrued interest thereon shall be due and payable in full. The note is secured by certain shares of LMA common stock held by Dr. Arteaga. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;At any time on or before December&#160;31, 2020, and upon written notice by APC to Dr. Arteaga, APC has the right, but not the obligation, to convert the entire outstanding principal amount of this note into shares of LMA common stock, which equal 21.25% of the aggregate then-issued and outstanding shares of LMA common stock to be held by APC&#x2019;s designee, which may include APC-LSMA. If converted, APC-LSMA and APC&#x2019;s designee will collectively own 46.25% of the equity of LMA with the remaining 53.75% to be owned by Dr. Arteaga. The entire note receivable has been classified under loans receivable on the consolidated balance sheets in the amount of $6.4 million as of June&#160;30, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On February 28, 2020, the Company entered into an agreement to advance Dr. Arteaga $2.2 million related to claims that were overpaid in the ordinary course of business. The advanced amount is repaid as the overpaid claims are recovered. As of June&#160;30, 2020, the outstanding amount due was $0.9 million and included in the &#x201c;Prepaid expenses and other current assets&#x201d; in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company assessed the loan receivables under the CECL model by assessing the party's ability to pay by reviewing their interest payment history quarterly, financial history annually and reassessing any insolvency risk that is identified. If a failure to pay occurs, the Company assesses the terms of the notes and estimates an expected credit loss based on the remittance schedule of the note.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Loan receivable &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;&#x2013;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt; related parties&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Universal Care, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In 2015, APC advanced $5.0 million on behalf of UCAP to UCI for working capital purposes. On June 29, 2018, November 28, 2018, and December 13, 2019, APC advanced an additional $2.5 million, $5.0 million and $4.0 million, respectively. The loans accrue interest at the prime rate, plus 1.00%, or 4.25%, as of March 31, 2020, and 5.75% as of December&#160;31, 2019, with interest to be paid monthly. On April 30, 2020, the outstanding balance was fully repaid as part of UCAP's disposition of its 48.9% ownership interest in UCI to Bright.&lt;/span&gt;&lt;/div&gt;</ameh:LoanReceivableTextBlock>
    <us-gaap:NotesReceivableNet
      contextRef="i68d3a067d0bf4b79866706938706fb56_I20190628"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV82NC9mcmFnOmQ4NDJlMDllZDY2NTQzNGZiZTJmZDc5Y2Q1YjYzNGRiL3RleHRyZWdpb246ZDg0MmUwOWVkNjY1NDM0ZmJlMmZkNzljZDViNjM0ZGJfMjYw_3aeb4506-5c1c-42b2-a22d-95335acef8de"
      unitRef="usd">6400000</us-gaap:NotesReceivableNet>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ie7a2683890994e1893345aed93623d96_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV82NC9mcmFnOmQ4NDJlMDllZDY2NTQzNGZiZTJmZDc5Y2Q1YjYzNGRiL3RleHRyZWdpb246ZDg0MmUwOWVkNjY1NDM0ZmJlMmZkNzljZDViNjM0ZGJfMzU3_6b64e03d-2a3c-45f3-a9e9-d24ea3430750"
      unitRef="number">0.01</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia0ac55575d2248d28bbb2cd6f69b2d1b_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV82NC9mcmFnOmQ4NDJlMDllZDY2NTQzNGZiZTJmZDc5Y2Q1YjYzNGRiL3RleHRyZWdpb246ZDg0MmUwOWVkNjY1NDM0ZmJlMmZkNzljZDViNjM0ZGJfMzYx_b772b48e-7abe-4500-8c56-68ec9af80543"
      unitRef="number">0.0425</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <ameh:FinancingReceivableConvertibleToCommonStockPercentageOfOutstandingSharesConvertible
      contextRef="i68d3a067d0bf4b79866706938706fb56_I20190628"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV82NC9mcmFnOmQ4NDJlMDllZDY2NTQzNGZiZTJmZDc5Y2Q1YjYzNGRiL3RleHRyZWdpb246ZDg0MmUwOWVkNjY1NDM0ZmJlMmZkNzljZDViNjM0ZGJfOTIy_aff93fc0-c6bb-4f9a-aae8-2bdb215296b5"
      unitRef="number">0.2125</ameh:FinancingReceivableConvertibleToCommonStockPercentageOfOutstandingSharesConvertible>
    <ameh:EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion
      contextRef="ie109929786d34e3893f52ead1a5eb485_I20190628"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV82NC9mcmFnOmQ4NDJlMDllZDY2NTQzNGZiZTJmZDc5Y2Q1YjYzNGRiL3RleHRyZWdpb246ZDg0MmUwOWVkNjY1NDM0ZmJlMmZkNzljZDViNjM0ZGJfMTExOQ_1c82001b-953a-44ed-b269-f499ceac50c3"
      unitRef="number">0.4625</ameh:EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion>
    <ameh:EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion
      contextRef="i901365bdd3be4af6a404cf5c6e1a6075_I20190628"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV82NC9mcmFnOmQ4NDJlMDllZDY2NTQzNGZiZTJmZDc5Y2Q1YjYzNGRiL3RleHRyZWdpb246ZDg0MmUwOWVkNjY1NDM0ZmJlMmZkNzljZDViNjM0ZGJfMTE2Mg_ea4d4fe3-4f95-4276-85a8-87966538c518"
      unitRef="number">0.5375</ameh:EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion>
    <us-gaap:NotesReceivableNet
      contextRef="i1cce33515e484386a173dc2819744d21_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV82NC9mcmFnOmQ4NDJlMDllZDY2NTQzNGZiZTJmZDc5Y2Q1YjYzNGRiL3RleHRyZWdpb246ZDg0MmUwOWVkNjY1NDM0ZmJlMmZkNzljZDViNjM0ZGJfMTMzMw_96b8b9b6-5b5c-4ccf-91c3-d0f15ed81a09"
      unitRef="usd">6400000</us-gaap:NotesReceivableNet>
    <us-gaap:NotesReceivableNet
      contextRef="i2719e7d006164071b43867d77f417602_I20200228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV82NC9mcmFnOmQ4NDJlMDllZDY2NTQzNGZiZTJmZDc5Y2Q1YjYzNGRiL3RleHRyZWdpb246ZDg0MmUwOWVkNjY1NDM0ZmJlMmZkNzljZDViNjM0ZGJfMTQ0Nw_422bc936-09e9-4d7a-b0b3-8c9fb8719279"
      unitRef="usd">2200000</us-gaap:NotesReceivableNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ib85a0e470e8b45179bd029ecf6828423_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV82NC9mcmFnOmQ4NDJlMDllZDY2NTQzNGZiZTJmZDc5Y2Q1YjYzNGRiL3RleHRyZWdpb246ZDg0MmUwOWVkNjY1NDM0ZmJlMmZkNzljZDViNjM0ZGJfMTY0Mw_49f9f412-d4eb-48ec-bc90-5b83d6b2118f"
      unitRef="usd">900000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <ameh:AdvancedForWorkingCapital
      contextRef="i718197c336244bfaae074a41bf6ba00c_I20151231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV82NC9mcmFnOmQ4NDJlMDllZDY2NTQzNGZiZTJmZDc5Y2Q1YjYzNGRiL3RleHRyZWdpb246ZDg0MmUwOWVkNjY1NDM0ZmJlMmZkNzljZDViNjM0ZGJfMTgzNg_44bebf88-6d82-4a8b-b012-ce1db9abf390"
      unitRef="usd">5000000.0</ameh:AdvancedForWorkingCapital>
    <ameh:LineOfCreditFacilityAdditionalAdvances
      contextRef="i620d8d9b4ce144e39fd90208e9f296c6_I20180629"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV82NC9mcmFnOmQ4NDJlMDllZDY2NTQzNGZiZTJmZDc5Y2Q1YjYzNGRiL3RleHRyZWdpb246ZDg0MmUwOWVkNjY1NDM0ZmJlMmZkNzljZDViNjM0ZGJfMTk3OQ_5375b1c1-be4c-49a9-b344-89145850355f"
      unitRef="usd">2500000</ameh:LineOfCreditFacilityAdditionalAdvances>
    <ameh:LineOfCreditFacilityAdditionalAdvances
      contextRef="ica83580f8f45424a8053d06ddb0d6b69_I20181128"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV82NC9mcmFnOmQ4NDJlMDllZDY2NTQzNGZiZTJmZDc5Y2Q1YjYzNGRiL3RleHRyZWdpb246ZDg0MmUwOWVkNjY1NDM0ZmJlMmZkNzljZDViNjM0ZGJfMTk4Mw_d575fc29-7d79-4cbd-8bac-2be8543fcaf4"
      unitRef="usd">5000000.0</ameh:LineOfCreditFacilityAdditionalAdvances>
    <ameh:LineOfCreditFacilityAdditionalAdvances
      contextRef="i99b8494c9ac5475fb455098946c75db9_I20191213"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV82NC9mcmFnOmQ4NDJlMDllZDY2NTQzNGZiZTJmZDc5Y2Q1YjYzNGRiL3RleHRyZWdpb246ZDg0MmUwOWVkNjY1NDM0ZmJlMmZkNzljZDViNjM0ZGJfMTk5MA_a9fb025d-d225-460d-a89c-2d04277945ed"
      unitRef="usd">4000000.0</ameh:LineOfCreditFacilityAdditionalAdvances>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i67a0fe9f9fdd46d7b8bf35810922c6aa_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV82NC9mcmFnOmQ4NDJlMDllZDY2NTQzNGZiZTJmZDc5Y2Q1YjYzNGRiL3RleHRyZWdpb246ZDg0MmUwOWVkNjY1NDM0ZmJlMmZkNzljZDViNjM0ZGJfMjA1OA_36b0c219-c17e-4b2f-a9df-134553ef375d"
      unitRef="number">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ifaa289066f18409dae39bd6fe0b1bf0a_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV82NC9mcmFnOmQ4NDJlMDllZDY2NTQzNGZiZTJmZDc5Y2Q1YjYzNGRiL3RleHRyZWdpb246ZDg0MmUwOWVkNjY1NDM0ZmJlMmZkNzljZDViNjM0ZGJfNjU5NzA2OTc3MDEzMw_6c6b533e-2579-40cb-b1b1-3c3725d466b8"
      unitRef="number">0.0425</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2219841d151045028ba5da60cd719d17_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV82NC9mcmFnOmQ4NDJlMDllZDY2NTQzNGZiZTJmZDc5Y2Q1YjYzNGRiL3RleHRyZWdpb246ZDg0MmUwOWVkNjY1NDM0ZmJlMmZkNzljZDViNjM0ZGJfMjA4Mg_6bfee4bf-bd0a-495b-bdcd-6f5efcb377a8"
      unitRef="number">0.0575</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i59aea64b29bd441fbc9a872ccf8d6901_I20200430"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV82NC9mcmFnOmQ4NDJlMDllZDY2NTQzNGZiZTJmZDc5Y2Q1YjYzNGRiL3RleHRyZWdpb246ZDg0MmUwOWVkNjY1NDM0ZmJlMmZkNzljZDViNjM0ZGJfMjM1MA_8fa61189-1e93-4051-b62c-3f4f2b274523"
      unitRef="number">0.489</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83MC9mcmFnOmZjNDFkMWE3NzgzMzRlYWRhOTgxNGQ1YzViNzNlMWUzL3RleHRyZWdpb246ZmM0MWQxYTc3ODMzNGVhZGE5ODE0ZDVjNWI3M2UxZTNfMTQ0_b4c9c568-485c-47a3-8f20-cb5ffd31a9f3">Accounts Payable and Accrued Expenses&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s accounts payable and accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.206%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.323%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.739%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Accounts payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Capitation payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Subcontractor IPA payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Professional fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Due to related parties&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Accrued compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Contract liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total accounts payable and accrued expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83MC9mcmFnOmZjNDFkMWE3NzgzMzRlYWRhOTgxNGQ1YzViNzNlMWUzL3RleHRyZWdpb246ZmM0MWQxYTc3ODMzNGVhZGE5ODE0ZDVjNWI3M2UxZTNfMTQ3_49cca6b8-df2a-49c3-a486-b5fbda9d2131">&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s accounts payable and accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.206%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.323%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.739%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Accounts payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Capitation payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Subcontractor IPA payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Professional fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Due to related parties&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Accrued compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Contract liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total accounts payable and accrued expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableCurrent
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83MC9mcmFnOmZjNDFkMWE3NzgzMzRlYWRhOTgxNGQ1YzViNzNlMWUzL3RhYmxlOmI4Zjk2ZGMwNzViNTRjNjBiNmY1ZDQxODVhZTgyODU1L3RhYmxlcmFuZ2U6YjhmOTZkYzA3NWI1NGM2MGI2ZjVkNDE4NWFlODI4NTVfMS0xLTEtMS0w_e9b7414f-4e60-425a-a060-b48ad9579dfc"
      unitRef="usd">10425000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83MC9mcmFnOmZjNDFkMWE3NzgzMzRlYWRhOTgxNGQ1YzViNzNlMWUzL3RhYmxlOmI4Zjk2ZGMwNzViNTRjNjBiNmY1ZDQxODVhZTgyODU1L3RhYmxlcmFuZ2U6YjhmOTZkYzA3NWI1NGM2MGI2ZjVkNDE4NWFlODI4NTVfMS0zLTEtMS0w_c8981c3a-6d56-4210-aedb-eb4977d40d40"
      unitRef="usd">6914000</us-gaap:AccountsPayableCurrent>
    <ameh:SpecialtyCapitationPayableCurrent
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83MC9mcmFnOmZjNDFkMWE3NzgzMzRlYWRhOTgxNGQ1YzViNzNlMWUzL3RhYmxlOmI4Zjk2ZGMwNzViNTRjNjBiNmY1ZDQxODVhZTgyODU1L3RhYmxlcmFuZ2U6YjhmOTZkYzA3NWI1NGM2MGI2ZjVkNDE4NWFlODI4NTVfMi0xLTEtMS0w_eebf5457-e785-48ca-ac83-2c36932e13f3"
      unitRef="usd">2754000</ameh:SpecialtyCapitationPayableCurrent>
    <ameh:SpecialtyCapitationPayableCurrent
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83MC9mcmFnOmZjNDFkMWE3NzgzMzRlYWRhOTgxNGQ1YzViNzNlMWUzL3RhYmxlOmI4Zjk2ZGMwNzViNTRjNjBiNmY1ZDQxODVhZTgyODU1L3RhYmxlcmFuZ2U6YjhmOTZkYzA3NWI1NGM2MGI2ZjVkNDE4NWFlODI4NTVfMi0zLTEtMS0w_4d947fa0-2cd3-4b97-b74d-aac2c2cf91ea"
      unitRef="usd">2813000</ameh:SpecialtyCapitationPayableCurrent>
    <ameh:SubcontractorIPAPayable
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83MC9mcmFnOmZjNDFkMWE3NzgzMzRlYWRhOTgxNGQ1YzViNzNlMWUzL3RhYmxlOmI4Zjk2ZGMwNzViNTRjNjBiNmY1ZDQxODVhZTgyODU1L3RhYmxlcmFuZ2U6YjhmOTZkYzA3NWI1NGM2MGI2ZjVkNDE4NWFlODI4NTVfMy0xLTEtMS0w_af57f3a7-3309-4104-a904-d9da331df0cd"
      unitRef="usd">3083000</ameh:SubcontractorIPAPayable>
    <ameh:SubcontractorIPAPayable
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83MC9mcmFnOmZjNDFkMWE3NzgzMzRlYWRhOTgxNGQ1YzViNzNlMWUzL3RhYmxlOmI4Zjk2ZGMwNzViNTRjNjBiNmY1ZDQxODVhZTgyODU1L3RhYmxlcmFuZ2U6YjhmOTZkYzA3NWI1NGM2MGI2ZjVkNDE4NWFlODI4NTVfMy0zLTEtMS0w_08640de4-814c-4a18-8289-bd52f63ba8ae"
      unitRef="usd">3360000</ameh:SubcontractorIPAPayable>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83MC9mcmFnOmZjNDFkMWE3NzgzMzRlYWRhOTgxNGQ1YzViNzNlMWUzL3RhYmxlOmI4Zjk2ZGMwNzViNTRjNjBiNmY1ZDQxODVhZTgyODU1L3RhYmxlcmFuZ2U6YjhmOTZkYzA3NWI1NGM2MGI2ZjVkNDE4NWFlODI4NTVfNC0xLTEtMS0w_bcda705c-188c-4d29-b329-9d70f5cfdceb"
      unitRef="usd">2325000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83MC9mcmFnOmZjNDFkMWE3NzgzMzRlYWRhOTgxNGQ1YzViNzNlMWUzL3RhYmxlOmI4Zjk2ZGMwNzViNTRjNjBiNmY1ZDQxODVhZTgyODU1L3RhYmxlcmFuZ2U6YjhmOTZkYzA3NWI1NGM2MGI2ZjVkNDE4NWFlODI4NTVfNC0zLTEtMS0w_d3758d53-75af-458d-ab24-81699f15bbc8"
      unitRef="usd">1837000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83MC9mcmFnOmZjNDFkMWE3NzgzMzRlYWRhOTgxNGQ1YzViNzNlMWUzL3RhYmxlOmI4Zjk2ZGMwNzViNTRjNjBiNmY1ZDQxODVhZTgyODU1L3RhYmxlcmFuZ2U6YjhmOTZkYzA3NWI1NGM2MGI2ZjVkNDE4NWFlODI4NTVfNS0xLTEtMS0w_38c76362-ded3-4e83-be7b-491ffcfb74eb"
      unitRef="usd">80000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83MC9mcmFnOmZjNDFkMWE3NzgzMzRlYWRhOTgxNGQ1YzViNzNlMWUzL3RhYmxlOmI4Zjk2ZGMwNzViNTRjNjBiNmY1ZDQxODVhZTgyODU1L3RhYmxlcmFuZ2U6YjhmOTZkYzA3NWI1NGM2MGI2ZjVkNDE4NWFlODI4NTVfNS0zLTEtMS0w_f355ee1c-f464-423c-8ab2-33dfe96ac409"
      unitRef="usd">225000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83MC9mcmFnOmZjNDFkMWE3NzgzMzRlYWRhOTgxNGQ1YzViNzNlMWUzL3RhYmxlOmI4Zjk2ZGMwNzViNTRjNjBiNmY1ZDQxODVhZTgyODU1L3RhYmxlcmFuZ2U6YjhmOTZkYzA3NWI1NGM2MGI2ZjVkNDE4NWFlODI4NTVfNi0xLTEtMS0w_18146a14-8cd3-4f4e-9c0d-60bdc6922270"
      unitRef="usd">3060000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83MC9mcmFnOmZjNDFkMWE3NzgzMzRlYWRhOTgxNGQ1YzViNzNlMWUzL3RhYmxlOmI4Zjk2ZGMwNzViNTRjNjBiNmY1ZDQxODVhZTgyODU1L3RhYmxlcmFuZ2U6YjhmOTZkYzA3NWI1NGM2MGI2ZjVkNDE4NWFlODI4NTVfNi0zLTEtMS0w_d3a43bc3-e4cf-4c41-a0a3-873d0e077d14"
      unitRef="usd">3238000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83MC9mcmFnOmZjNDFkMWE3NzgzMzRlYWRhOTgxNGQ1YzViNzNlMWUzL3RhYmxlOmI4Zjk2ZGMwNzViNTRjNjBiNmY1ZDQxODVhZTgyODU1L3RhYmxlcmFuZ2U6YjhmOTZkYzA3NWI1NGM2MGI2ZjVkNDE4NWFlODI4NTVfNy0xLTEtMS0w_5df695ae-221e-4961-a129-fa2cd7347b70"
      unitRef="usd">3061000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83MC9mcmFnOmZjNDFkMWE3NzgzMzRlYWRhOTgxNGQ1YzViNzNlMWUzL3RhYmxlOmI4Zjk2ZGMwNzViNTRjNjBiNmY1ZDQxODVhZTgyODU1L3RhYmxlcmFuZ2U6YjhmOTZkYzA3NWI1NGM2MGI2ZjVkNDE4NWFlODI4NTVfNy0zLTEtMS0w_a91a7257-7a30-4c9b-beb8-0b013758ce21"
      unitRef="usd">8892000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83MC9mcmFnOmZjNDFkMWE3NzgzMzRlYWRhOTgxNGQ1YzViNzNlMWUzL3RhYmxlOmI4Zjk2ZGMwNzViNTRjNjBiNmY1ZDQxODVhZTgyODU1L3RhYmxlcmFuZ2U6YjhmOTZkYzA3NWI1NGM2MGI2ZjVkNDE4NWFlODI4NTVfOS0xLTEtMS0w_c437b2bd-2304-49eb-ba44-f7a3f029bea5"
      unitRef="usd">24788000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83MC9mcmFnOmZjNDFkMWE3NzgzMzRlYWRhOTgxNGQ1YzViNzNlMWUzL3RhYmxlOmI4Zjk2ZGMwNzViNTRjNjBiNmY1ZDQxODVhZTgyODU1L3RhYmxlcmFuZ2U6YjhmOTZkYzA3NWI1NGM2MGI2ZjVkNDE4NWFlODI4NTVfOS0zLTEtMS0w_50eb7ca3-0493-463d-aef9-c0822b7df2ae"
      unitRef="usd">27279000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83My9mcmFnOjEzZDQzMjA0MTY1MDRjMjdhMmMzOGZlZjgwOGE1MTEwL3RleHRyZWdpb246MTNkNDMyMDQxNjUwNGMyN2EyYzM4ZmVmODA4YTUxMTBfMTA3_ce3ee496-9070-4624-8c58-1f0fc38ca6e7">Medical Liabilities&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s medical liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.206%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.323%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.739%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Medical liabilities, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;58,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Components of medical care costs related to claims incurred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;165,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;93,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total medical care costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;165,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;96,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Payments for medical care costs related to claims incurred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(97,112)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(60,440)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(57,470)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(39,744)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(154,582)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(100,184)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Acquired from Alpha Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(156)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Medical liabilities, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;70,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;42,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock>
    <us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83My9mcmFnOjEzZDQzMjA0MTY1MDRjMjdhMmMzOGZlZjgwOGE1MTEwL3RleHRyZWdpb246MTNkNDMyMDQxNjUwNGMyN2EyYzM4ZmVmODA4YTUxMTBfMTEw_5191ba6a-4b49-4602-afe8-16c13ff570c7">&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s medical liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.206%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.323%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.739%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Medical liabilities, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;58,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Components of medical care costs related to claims incurred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;165,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;93,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total medical care costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;165,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;96,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Payments for medical care costs related to claims incurred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(97,112)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(60,440)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(57,470)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(39,744)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(154,582)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(100,184)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Acquired from Alpha Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(156)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Medical liabilities, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;70,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;42,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83My9mcmFnOjEzZDQzMjA0MTY1MDRjMjdhMmMzOGZlZjgwOGE1MTEwL3RhYmxlOjQyOWQyMzM0NGYzZDQzNzc5OTgxNzg3MjU3YmMxZjk3L3RhYmxlcmFuZ2U6NDI5ZDIzMzQ0ZjNkNDM3Nzk5ODE3ODcyNTdiYzFmOTdfMS0xLTEtMS0w_7c4a6be6-7f29-4483-a49a-1906a5a58aee"
      unitRef="usd">58725000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i009fc823ec144ee3b772b4396d458c88_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83My9mcmFnOjEzZDQzMjA0MTY1MDRjMjdhMmMzOGZlZjgwOGE1MTEwL3RhYmxlOjQyOWQyMzM0NGYzZDQzNzc5OTgxNzg3MjU3YmMxZjk3L3RhYmxlcmFuZ2U6NDI5ZDIzMzQ0ZjNkNDM3Nzk5ODE3ODcyNTdiYzFmOTdfMS0zLTEtMS0w_5ee7c0bf-3c99-4b8c-8a70-13adc36d75d2"
      unitRef="usd">33642000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83My9mcmFnOjEzZDQzMjA0MTY1MDRjMjdhMmMzOGZlZjgwOGE1MTEwL3RhYmxlOjQyOWQyMzM0NGYzZDQzNzc5OTgxNzg3MjU3YmMxZjk3L3RhYmxlcmFuZ2U6NDI5ZDIzMzQ0ZjNkNDM3Nzk5ODE3ODcyNTdiYzFmOTdfMy0xLTEtMS0w_5a46b8e7-5633-4ca9-b75b-850a979c8490"
      unitRef="usd">165571000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83My9mcmFnOjEzZDQzMjA0MTY1MDRjMjdhMmMzOGZlZjgwOGE1MTEwL3RhYmxlOjQyOWQyMzM0NGYzZDQzNzc5OTgxNzg3MjU3YmMxZjk3L3RhYmxlcmFuZ2U6NDI5ZDIzMzQ0ZjNkNDM3Nzk5ODE3ODcyNTdiYzFmOTdfMy0zLTEtMS0w_4d8af9bf-6bcb-431c-ae60-b5417684d1a2"
      unitRef="usd">93833000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83My9mcmFnOjEzZDQzMjA0MTY1MDRjMjdhMmMzOGZlZjgwOGE1MTEwL3RhYmxlOjQyOWQyMzM0NGYzZDQzNzc5OTgxNzg3MjU3YmMxZjk3L3RhYmxlcmFuZ2U6NDI5ZDIzMzQ0ZjNkNDM3Nzk5ODE3ODcyNTdiYzFmOTdfNC0xLTEtMS0w_f926b86f-b4fa-48d8-a520-68b97fbfa679"
      unitRef="usd">233000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83My9mcmFnOjEzZDQzMjA0MTY1MDRjMjdhMmMzOGZlZjgwOGE1MTEwL3RhYmxlOjQyOWQyMzM0NGYzZDQzNzc5OTgxNzg3MjU3YmMxZjk3L3RhYmxlcmFuZ2U6NDI5ZDIzMzQ0ZjNkNDM3Nzk5ODE3ODcyNTdiYzFmOTdfNC0zLTEtMS0w_5b6d86b0-be98-4083-8ac0-6ad9cd0b279d"
      unitRef="usd">2688000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83My9mcmFnOjEzZDQzMjA0MTY1MDRjMjdhMmMzOGZlZjgwOGE1MTEwL3RhYmxlOjQyOWQyMzM0NGYzZDQzNzc5OTgxNzg3MjU3YmMxZjk3L3RhYmxlcmFuZ2U6NDI5ZDIzMzQ0ZjNkNDM3Nzk5ODE3ODcyNTdiYzFmOTdfNS0xLTEtMS0w_fef131f7-5ad9-4c7f-8e41-13d1774c8c07"
      unitRef="usd">165804000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83My9mcmFnOjEzZDQzMjA0MTY1MDRjMjdhMmMzOGZlZjgwOGE1MTEwL3RhYmxlOjQyOWQyMzM0NGYzZDQzNzc5OTgxNzg3MjU3YmMxZjk3L3RhYmxlcmFuZ2U6NDI5ZDIzMzQ0ZjNkNDM3Nzk5ODE3ODcyNTdiYzFmOTdfNS0zLTEtMS0w_9d576534-6308-4859-872d-dbd677bafb09"
      unitRef="usd">96521000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83My9mcmFnOjEzZDQzMjA0MTY1MDRjMjdhMmMzOGZlZjgwOGE1MTEwL3RhYmxlOjQyOWQyMzM0NGYzZDQzNzc5OTgxNzg3MjU3YmMxZjk3L3RhYmxlcmFuZ2U6NDI5ZDIzMzQ0ZjNkNDM3Nzk5ODE3ODcyNTdiYzFmOTdfNy0xLTEtMS0w_ca49e32f-43b5-41fa-96a5-c87294141bb5"
      unitRef="usd">97112000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83My9mcmFnOjEzZDQzMjA0MTY1MDRjMjdhMmMzOGZlZjgwOGE1MTEwL3RhYmxlOjQyOWQyMzM0NGYzZDQzNzc5OTgxNzg3MjU3YmMxZjk3L3RhYmxlcmFuZ2U6NDI5ZDIzMzQ0ZjNkNDM3Nzk5ODE3ODcyNTdiYzFmOTdfNy0zLTEtMS0w_05f08340-cad0-4f9e-94d4-800ae5c4d7f1"
      unitRef="usd">60440000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83My9mcmFnOjEzZDQzMjA0MTY1MDRjMjdhMmMzOGZlZjgwOGE1MTEwL3RhYmxlOjQyOWQyMzM0NGYzZDQzNzc5OTgxNzg3MjU3YmMxZjk3L3RhYmxlcmFuZ2U6NDI5ZDIzMzQ0ZjNkNDM3Nzk5ODE3ODcyNTdiYzFmOTdfOC0xLTEtMS0w_c6771e63-7584-464c-b031-6726c897194a"
      unitRef="usd">57470000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83My9mcmFnOjEzZDQzMjA0MTY1MDRjMjdhMmMzOGZlZjgwOGE1MTEwL3RhYmxlOjQyOWQyMzM0NGYzZDQzNzc5OTgxNzg3MjU3YmMxZjk3L3RhYmxlcmFuZ2U6NDI5ZDIzMzQ0ZjNkNDM3Nzk5ODE3ODcyNTdiYzFmOTdfOC0zLTEtMS0w_1fd759f4-cf22-4690-bcd6-578f7a1fc511"
      unitRef="usd">39744000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83My9mcmFnOjEzZDQzMjA0MTY1MDRjMjdhMmMzOGZlZjgwOGE1MTEwL3RhYmxlOjQyOWQyMzM0NGYzZDQzNzc5OTgxNzg3MjU3YmMxZjk3L3RhYmxlcmFuZ2U6NDI5ZDIzMzQ0ZjNkNDM3Nzk5ODE3ODcyNTdiYzFmOTdfOS0xLTEtMS0w_b027518d-6862-45d1-b414-8d321c559ea5"
      unitRef="usd">154582000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83My9mcmFnOjEzZDQzMjA0MTY1MDRjMjdhMmMzOGZlZjgwOGE1MTEwL3RhYmxlOjQyOWQyMzM0NGYzZDQzNzc5OTgxNzg3MjU3YmMxZjk3L3RhYmxlcmFuZ2U6NDI5ZDIzMzQ0ZjNkNDM3Nzk5ODE3ODcyNTdiYzFmOTdfOS0zLTEtMS0w_41a02e54-b9e3-46f9-ba5f-7ed39e57399b"
      unitRef="usd">100184000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83My9mcmFnOjEzZDQzMjA0MTY1MDRjMjdhMmMzOGZlZjgwOGE1MTEwL3RhYmxlOjQyOWQyMzM0NGYzZDQzNzc5OTgxNzg3MjU3YmMxZjk3L3RhYmxlcmFuZ2U6NDI5ZDIzMzQ0ZjNkNDM3Nzk5ODE3ODcyNTdiYzFmOTdfMTAtMS0xLTEtMTY4OA_591309af-9733-41f7-92a7-0cdbbcaa34d7"
      unitRef="usd">0</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83My9mcmFnOjEzZDQzMjA0MTY1MDRjMjdhMmMzOGZlZjgwOGE1MTEwL3RhYmxlOjQyOWQyMzM0NGYzZDQzNzc5OTgxNzg3MjU3YmMxZjk3L3RhYmxlcmFuZ2U6NDI5ZDIzMzQ0ZjNkNDM3Nzk5ODE3ODcyNTdiYzFmOTdfMTAtMy0xLTEtODA0_48e490b2-4390-4f18-a122-f83b6ffcb2ba"
      unitRef="usd">13120000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83My9mcmFnOjEzZDQzMjA0MTY1MDRjMjdhMmMzOGZlZjgwOGE1MTEwL3RhYmxlOjQyOWQyMzM0NGYzZDQzNzc5OTgxNzg3MjU3YmMxZjk3L3RhYmxlcmFuZ2U6NDI5ZDIzMzQ0ZjNkNDM3Nzk5ODE3ODcyNTdiYzFmOTdfMTAtMS0xLTEtMA_5ed746ee-dd41-4c19-9e0e-f8be9db08197"
      unitRef="usd">326000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83My9mcmFnOjEzZDQzMjA0MTY1MDRjMjdhMmMzOGZlZjgwOGE1MTEwL3RhYmxlOjQyOWQyMzM0NGYzZDQzNzc5OTgxNzg3MjU3YmMxZjk3L3RhYmxlcmFuZ2U6NDI5ZDIzMzQ0ZjNkNDM3Nzk5ODE3ODcyNTdiYzFmOTdfMTAtMy0xLTEtMA_01481170-958b-4bdf-ae93-bbde7249806b"
      unitRef="usd">-156000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83My9mcmFnOjEzZDQzMjA0MTY1MDRjMjdhMmMzOGZlZjgwOGE1MTEwL3RhYmxlOjQyOWQyMzM0NGYzZDQzNzc5OTgxNzg3MjU3YmMxZjk3L3RhYmxlcmFuZ2U6NDI5ZDIzMzQ0ZjNkNDM3Nzk5ODE3ODcyNTdiYzFmOTdfMTItMS0xLTEtMA_6c9e9830-d42e-48b8-a2fb-f02ba83df8c8"
      unitRef="usd">70273000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i2db2c0d074c34657a5d523b0ae1e5784_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83My9mcmFnOjEzZDQzMjA0MTY1MDRjMjdhMmMzOGZlZjgwOGE1MTEwL3RhYmxlOjQyOWQyMzM0NGYzZDQzNzc5OTgxNzg3MjU3YmMxZjk3L3RhYmxlcmFuZ2U6NDI5ZDIzMzQ0ZjNkNDM3Nzk5ODE3ODcyNTdiYzFmOTdfMTItMy0xLTEtMA_31d3b140-d7cb-4007-9021-2f74e52703f2"
      unitRef="usd">42943000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTA5OTUxMTY0Njg1NA_d8278731-14f2-49b6-9a34-3b538cf59631">Credit Facility, Bank Loan and Lines of Credit&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Credit Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s credit facility consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:82.017%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.983%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Term loan A&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;185,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revolver loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;60,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;245,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: Current portion of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(9,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: Unamortized financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(5,295)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;230,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Future commitments of the Company&#x2019;s credit facility is to be as follows for the years ending December&#160;31 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:82.017%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.983%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020 (excluding the six months ended June 30, 2020)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;197,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;245,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In September 2019, the Company entered into a secured credit agreement (the &#x201c;Credit Agreement,&#x201d; and the credit facility thereunder, the "Credit Facility") with Truist Bank (formerly known as SunTrust Bank), in its capacity as administrative agent for the lenders (in such capacity, the &#x201c;Agent&#x201d;), as a lender, an issuer of letters of credit and as swingline lender, and Preferred Bank, JPMorgan Chase Bank, N.A., MUFG Union Bank, N.A., Royal Bank of Canada, Fifth Third Bank and City National Bank, as lenders (the &#x201c;Lenders&#x201d;). In connection with the closing of the Credit Agreement, the Company, its subsidiary, NMM, and the Agent entered into a Guaranty and Security Agreement (the &#x201c;Guaranty and Security Agreement&#x201d;), pursuant to which, among other things, NMM guaranteed the obligations of the Company under the Credit Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Credit Agreement provides for a five-year revolving credit facility to the Company of $100.0 million (&#x201c;Revolver Loan&#x201d;), which includes a letter of credit subfacility of up to $25.0 million. The Credit Agreement also provides for a term loan of $190.0 million, (&#x201c;Term Loan A&#x201d;). The unpaid principal amount of the term loan is payable in quarterly installments on the last day of each fiscal quarter commencing on December 31, 2019. The principal payment for each of the first eight fiscal quarters is $2.4 million, for the following eight fiscal quarters thereafter is $3.6 million and for the following three fiscal quarters thereafter is $4.8 million. The remaining principal payment on the term loan is due on September&#160;11, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The proceeds of the term loan and up to $60.0 million of the revolving credit facility were used to (i) finance a portion of the AP-AMH Loan, (ii) refinance certain indebtedness of the Company and its subsidiaries and, indirectly, APC, (iii) pay transaction costs and expenses arising in connection with the Credit Agreement, the AP-AMH Loan and certain other related transactions and (iv) provide for working capital, capital expenditures and other general corporate purposes. The remainder of the revolving credit facility will be used to finance future acquisitions and investments and to provide for working capital needs, capital expenditures and other general corporate purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company is required to pay an annual facility fee of 0.20% to 0.35% on the available commitments under the Credit Agreement, regardless of usage, with the applicable fee determined on a quarterly basis based on the Company&#x2019;s leverage ratio. The Company is also required to pay customary fees as specified in a separate fee agreement between the Company and SunTrust Robinson Humphrey, Inc., the lead arranger of the Credit Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Amounts borrowed under the Credit Agreement will bear interest at an annual rate equal to either, at the Company&#x2019;s option, (a) the rate for Eurocurrency deposits for the corresponding deposits of U.S. dollars appearing on Reuters Screen LIBOR01 Page (&#x201c;LIBOR&#x201d;), adjusted for any reserve requirement in effect, plus a spread of between 2.00% and 3.00%, as determined on a quarterly basis based on the Company&#x2019;s leverage ratio, or (b) a base rate, plus a spread between 1.00% and 2.00%, as determined on a quarterly basis based on the Company&#x2019;s leverage ratio. As of June&#160;30, 2020, the interest rate on Term Loan A and Revolver Loan was 3.57% and 3.24%, respectively. The base rate is defined in a manner such that it will not be less than LIBOR. The Company will pay fees for standby letters of credit at an annual rate of between 2.00% and 3.00%, as determined on a quarterly basis based on the Company&#x2019;s leverage ratio, plus facing fees and standard fees payable to the issuing bank on the respective letter of credit. Loans outstanding under the Credit Agreement may be prepaid at any time without penalty, except for LIBOR breakage costs and expenses. If LIBOR ceases to be reported, the Credit Agreement requires the Company and the Agent to endeavor to establish a commercially reasonable alternative rate of interest and until they are able to do so, all borrowings must be at the base rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Credit Agreement requires the Company and its subsidiaries to comply with various affirmative covenants, including, without limitation, furnishing updated financial and other information, preserving existence and entitlements, maintaining properties and insurance, complying with laws, maintaining books and records, requiring any new domestic subsidiary meeting a materiality threshold specified in the Credit Agreement to become a guarantor thereunder and paying obligations. The Credit Agreement requires the Company and its subsidiaries to comply with, and to use commercially reasonable efforts to the extent permitted by law to cause certain material associated practices of the Company, including APC, to comply with, restrictions on liens, indebtedness and investments (including restrictions on acquisitions by the Company), subject to specified exceptions. The Credit Agreement also contains various other negative covenants binding the Company and its subsidiaries, including, without limitation, restrictions on fundamental changes, dividends and distributions, sales and leasebacks, transactions with affiliates, burdensome agreements, use of proceeds, maintenance of business, amendments of organizational documents, accounting changes and prepayments and modifications of subordinated debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Credit Agreement requires the Company to comply with two key financial ratios, each calculated on a consolidated basis. The Company must maintain a maximum consolidated leverage ratio of not greater than 3.75 to 1.00 as of the last day of each fiscal quarter. The maximum consolidated leverage ratio decreases by 0.25 each year, until it is reduced to 3.00 to 1.00 for each fiscal quarter ending after September 30, 2022. The Company must maintain a minimum consolidated interest coverage ratio of not less than 3.25 to 1.00 as of the last day of each fiscal quarter. As of June&#160;30, 2020, the Company was in compliance with the covenants relating to its credit facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Pursuant to the Guaranty and Security Agreement, the Company and NMM have granted the Lenders a security interest in all of their assets, including, without limitation, all stock and other equity issued by their subsidiaries (including NMM) and all rights with respect to the AP-AMH Loan. The Guaranty and Security Agreement requires the Company and NMM to comply with various affirmative and negative covenants, including, without limitation, covenants relating to maintaining perfected security interests, providing information and documentation to the Agent, complying with contractual obligations relating to the collateral, restricting the sale and issuance of securities by their respective subsidiaries and providing the Agent access to the collateral.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Credit Agreement contains events of default, including, without limitation, failure to make a payment when due, default on various covenants in the Credit Agreement, breach of representations or warranties, cross-default on other material indebtedness, bankruptcy or insolvency, occurrence of certain judgments and certain events under the Employee Retirement Income Security Act of 1974 aggregating more than $10.0 million, invalidity of the loan documents, any lien under the Guaranty and Security Agreement ceasing to be valid and perfected, any change in control, as defined in the Credit Agreement, an event of default under the AP-AMH Loan, failure by APC to pay dividends in cash for any period of two consecutive fiscal quarters, failure by AP-AMH to pay cash interest to the Company, or if any modification is made to the Certificate of Determination or the Special Purpose Shareholder Agreement that directly or indirectly restricts, conditions, impairs, reduces or otherwise limits the payment of the Series A Preferred dividend by APC to AP-AMH. In addition, it will constitute an event of default under the Credit Agreement if APC uses all or any portion of the consideration received by APC from AP-AMH on account of AP-AMH&#x2019;s purchase of Series A Preferred Stock for any purpose other than certain specific approved uses described in the following sentence, unless not less than 50.01% of all holders of common stock of APC at such time approve such use; provided that APC may use up to $50.0 million in the aggregate of such consideration for any purpose without any requirement to obtain such approval of the holders of common stock of APC. The approved uses include (i) any permitted investment, (ii) any dividend or distribution to the holders of the common stock of APC, (iii) any repurchase of common stock of APC, (iv) paying taxes relating to or arising from certain assets and transactions, or (v) funding losses, deficits or working capital support on account of certain non-healthcare assets in an amount not to exceed $125.0 million. If any event of default occurs and is continuing under the Credit Agreement, the Lenders may terminate their commitments, and may require the Company and its guarantors to repay outstanding debt and/or to provide a cash deposit as additional security for outstanding letters of credit. In &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;addition, the Agent, on behalf of the Lenders, may pursue remedies under the Guaranty and Security Agreement, including, without limitation, transferring pledged securities of the Company&#x2019;s subsidiaries in the name of the Agent and exercising all rights with respect thereto (including the right to vote and to receive dividends), collect on pledged accounts, instruments and other receivables (including the AP-AMH Loan), and all other rights provided by law or under the loan documents and the AP-AMH Loan.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In the ordinary course of business, certain of the Lenders under the Credit Agreement and their affiliates have provided to the Company and its subsidiaries and the associated practices, and may in the future provide, (i) investment banking, commercial banking (including pursuant to certain existing business loan and credit agreements being terminated in connection with entering into the Credit Agreement), cash management, foreign exchange or other financial services, and (ii) services as a bond trustee and other trust and fiduciary services, for which they have received compensation and may receive compensation in the future.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Deferred Financing Costs&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In September 2019, the Company recorded deferred financing costs of $6.5 million related to the issuance of the Credit Facility. This amount was recorded as a direct reduction of the carrying amount of the related debt liability. The deferred financing costs will be amortized over the life of the Credit Facility using the effective interest rate method. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Effective Interest Rate&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s average effective interest rate on its total debt during the six months ended June&#160;30, 2020 and 2019, was 3.93% and 4.71%, respectively. Interest expense in the consolidated statements of income included amortization of deferred debt issuance costs for the three and six months ended June&#160;30, 2020 and 2019, of $0.3 million and $0, respectively, and $0.7 million and $0, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Lines of Credit &#x2013; Related Party&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;NMM Business Loan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On June&#160;14, 2018, NMM amended its promissory note agreement with Preferred Bank (&#x201c;NMM Business Loan Agreement&#x201d;), which provides for loan availability of up to $20.0 million with a maturity date of June&#160;22, 2020. One of the Company&#x2019;s board members is the chairman and CEO of Preferred Bank. The NMM Business Loan Agreement was subsequently amended on September&#160;1, 2018, to temporarily increase the loan availability from $20.0 million to $27.0 million for the period from September 1, 2018 through January 31, 2019, further extended to October&#160;31, 2019, to facilitate the issuance of an additional standby letter of credit for the benefit of CMS. The interest rate is based on the Wall Street Journal &#x201c;prime rate,&#x201d; plus 0.125%, or 5.625% as of December&#160;31, 2018. The loan was guaranteed by Apollo Medical Holdings, Inc. and is collateralized by substantially all of the assets of NMM. The amounts outstanding as of June&#160;30, 2019, of $5.0 million was fully repaid on September&#160;11, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On September&#160;5, 2018, NMM entered into a non-revolving line of credit agreement with Preferred Bank, which provides for loan availability of up to $20.0 million with a maturity date of September&#160;5, 2019. This credit facility was subsequently amended on April&#160;17, 2019, and July&#160;29, 2019, to reduce the loan availability from $20.0 million to $16.0 million and from $16.0 million to $2.2 million, respectively. The interest rate is based on the Wall Street Journal &#x201c;prime rate,&#x201d; plus 0.125%, or 3.375% as of June&#160;30, 2020, and 4.875% as of December&#160;31, 2019. The line of credit is guaranteed by Apollo Medical Holdings, Inc. and is collateralized by substantially all assets of NMM. NMM obtained this line of credit to finance potential acquisitions. Each drawdown from the line of credit is converted into a five-year term loan with monthly principal payments, plus interest based on a five-year amortization schedule.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On September 11, 2019, the NMM Business Loan Agreement, dated as of June&#160;14, 2018, between NMM and Preferred Bank, as amended, and the Line of Credit Agreement, dated as of September&#160;5, 2018, between NMM and Preferred Bank, as amended, were terminated in connection with the closing of the credit facility.&#160;Certain letters of credit issued by Preferred Bank under the Line of Credit Agreement were terminated and reissued under the Credit Agreement. As of June&#160;30, 2020,  outstanding letters of credit totaled $14.8 million and the Company has $10.2 million available under the revolving credit facility for letters of credit.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;APC Business Loan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On June&#160;14, 2018, APC amended its promissory note agreement with Preferred Bank, which provides for loan availability of up to $10.0 million with a maturity date of June&#160;22, 2020. This credit facility was subsequently amended on April&#160;17, 2019, and June&#160;11, 2019, to increase the loan availability from $10.0 million to $40.0 million and extend the maturity date through December&#160;31, 2020. On August&#160;1, 2019, and September&#160;10, 2019, this credit facility was further amended to increase loan availability from $40.0 million to $43.8 million, and decrease loan availability from $43.8 million to $4.1 million, respectively. This decrease further limited the purpose of the indebtedness under APC Business Loan Agreement to the issuance of standby letters of credit, and added as a permitted lien the security interest in all of its assets granted by APC in favor of NMM under a Security Agreement dated on or about September 11, 2019, securing APC&#x2019;s obligations to NMM under, and as required pursuant to, the APC management services agreement dated as of July 1, 1999, as amended. The interest rate is based on the Wall Street Journal &#x201c;prime rate,&#x201d; plus 0.125%, or 3.375% and 4.875% as of June&#160;30, 2020, and December&#160;31, 2019, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of June&#160;30, 2020 and December&#160;31, 2019, there was no availability under this line of credit.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Standby Letters of Credit&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On October&#160;2, 2018, APAACO established a second irrevocable standby letter of credit with Preferred Bank (through the NMM Business Loan Agreement) for $6.6 million for the benefit of CMS. The letter of credit expires on December&#160;31, 2020, and is automatically extended without amendment for additional one-year periods from the present or any future expiration date, unless notified by the institution to terminate prior to 90 days from any expiration date. APAACO may continue to draw from the letter of credit for one year following the bank&#x2019;s notification of non-renewal. This standby letter of credit was subsequently amended on August&#160;14, 2019, to increase amount from $6.6 million to $14.8 million and extended expiration date on December&#160;31, 2020, with all other terms and conditions remain unchanged. In connection with the closing of the Credit Facility,&#160;this letter of credit was terminated and reissued under the Credit Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;APC established irrevocable standby letters of credit with Preferred Bank under the APC Business Loan Agreement for a total of $0.3 million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional one-year periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Alpha Care established irrevocable standby letters of credit with Preferred Bank under the APC Business Loan Agreement for a total of $3.8 million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional one-year periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTYxNzY_2853c32a-e870-4e87-90ac-3f8458b0aa33">&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s credit facility consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:82.017%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.983%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Term loan A&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;185,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revolver loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;60,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;245,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: Current portion of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(9,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: Unamortized financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(5,295)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;230,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock>
    <us-gaap:LineOfCredit
      contextRef="iff4cb76a3da64b79b6a83acbf4ac62d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RhYmxlOmY3MmIyN2Q1ZjVjYzRiOWI5YTFkNjdlM2ZiODFkNjI3L3RhYmxlcmFuZ2U6ZjcyYjI3ZDVmNWNjNGI5YjlhMWQ2N2UzZmI4MWQ2MjdfMi0xLTEtMS0w_c161c39b-41b0-45f4-93bb-9a8f865d5a95"
      unitRef="usd">185250000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="ie8692d3a0d3f43509f73c146da09a16f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RhYmxlOmY3MmIyN2Q1ZjVjYzRiOWI5YTFkNjdlM2ZiODFkNjI3L3RhYmxlcmFuZ2U6ZjcyYjI3ZDVmNWNjNGI5YjlhMWQ2N2UzZmI4MWQ2MjdfMy0xLTEtMS0w_3ec35e04-7f96-4b65-9c11-a89267722f50"
      unitRef="usd">60000000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RhYmxlOmY3MmIyN2Q1ZjVjYzRiOWI5YTFkNjdlM2ZiODFkNjI3L3RhYmxlcmFuZ2U6ZjcyYjI3ZDVmNWNjNGI5YjlhMWQ2N2UzZmI4MWQ2MjdfNC0xLTEtMS0w_d4f88a58-76e7-4500-9ac4-faa07cb1eb75"
      unitRef="usd">245250000</us-gaap:LineOfCredit>
    <us-gaap:LinesOfCreditCurrent
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RhYmxlOmY3MmIyN2Q1ZjVjYzRiOWI5YTFkNjdlM2ZiODFkNjI3L3RhYmxlcmFuZ2U6ZjcyYjI3ZDVmNWNjNGI5YjlhMWQ2N2UzZmI4MWQ2MjdfNi0xLTEtMS0w_189e7e6b-7baa-4329-931f-5af3430c9b17"
      unitRef="usd">9500000</us-gaap:LinesOfCreditCurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RhYmxlOmY3MmIyN2Q1ZjVjYzRiOWI5YTFkNjdlM2ZiODFkNjI3L3RhYmxlcmFuZ2U6ZjcyYjI3ZDVmNWNjNGI5YjlhMWQ2N2UzZmI4MWQ2MjdfNy0xLTEtMS0w_bc309f99-0763-469b-aa91-081d0999d773"
      unitRef="usd">5295000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RhYmxlOmY3MmIyN2Q1ZjVjYzRiOWI5YTFkNjdlM2ZiODFkNjI3L3RhYmxlcmFuZ2U6ZjcyYjI3ZDVmNWNjNGI5YjlhMWQ2N2UzZmI4MWQ2MjdfOS0xLTEtMS0w_78d32e1d-2594-411d-b85d-aad4155a6a7e"
      unitRef="usd">230455000</us-gaap:LongTermDebt>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTYxNzc_477304ae-37bc-4286-b073-55447ef524ad">&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Future commitments of the Company&#x2019;s credit facility is to be as follows for the years ending December&#160;31 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:82.017%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.983%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020 (excluding the six months ended June 30, 2020)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;197,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;245,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RhYmxlOjA0OTY4NTE3NDI1ZTQ4ZDdiOGY2M2M1NDU5YzlhZGEzL3RhYmxlcmFuZ2U6MDQ5Njg1MTc0MjVlNDhkN2I4ZjYzYzU0NTljOWFkYTNfMS0xLTEtMS0w_5eef840a-6c9d-424c-9c4b-8d27930c149c"
      unitRef="usd">7125000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RhYmxlOjA0OTY4NTE3NDI1ZTQ4ZDdiOGY2M2M1NDU5YzlhZGEzL3RhYmxlcmFuZ2U6MDQ5Njg1MTc0MjVlNDhkN2I4ZjYzYzU0NTljOWFkYTNfMi0xLTEtMS0w_7064f553-dd62-4af9-8652-0a409690e49f"
      unitRef="usd">10688000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RhYmxlOjA0OTY4NTE3NDI1ZTQ4ZDdiOGY2M2M1NDU5YzlhZGEzL3RhYmxlcmFuZ2U6MDQ5Njg1MTc0MjVlNDhkN2I4ZjYzYzU0NTljOWFkYTNfMy0xLTEtMS0w_be0b4b6a-b0b9-455c-9d5b-3ac75a835e63"
      unitRef="usd">14250000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RhYmxlOjA0OTY4NTE3NDI1ZTQ4ZDdiOGY2M2M1NDU5YzlhZGEzL3RhYmxlcmFuZ2U6MDQ5Njg1MTc0MjVlNDhkN2I4ZjYzYzU0NTljOWFkYTNfNC0xLTEtMS0w_3ad2dc20-14b0-41e5-b1d9-d4d32668fcf2"
      unitRef="usd">15437000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RhYmxlOjA0OTY4NTE3NDI1ZTQ4ZDdiOGY2M2M1NDU5YzlhZGEzL3RhYmxlcmFuZ2U6MDQ5Njg1MTc0MjVlNDhkN2I4ZjYzYzU0NTljOWFkYTNfNS0xLTEtMS0w_d1a7dae5-5217-4396-a54a-48bb64b3951d"
      unitRef="usd">197750000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LineOfCredit
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RhYmxlOjA0OTY4NTE3NDI1ZTQ4ZDdiOGY2M2M1NDU5YzlhZGEzL3RhYmxlcmFuZ2U6MDQ5Njg1MTc0MjVlNDhkN2I4ZjYzYzU0NTljOWFkYTNfNy0xLTEtMS0w_22e720fe-38c8-403f-89fa-24357bf84d16"
      unitRef="usd">245250000</us-gaap:LineOfCredit>
    <us-gaap:DebtInstrumentTerm
      contextRef="i91da1a2343864108babfdb0d2e98962a_D20190901-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTA5OTUxMTY0Njg1Nw_5c1894b0-aae3-4090-849d-6e1a87366009">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i8f0dc8ddd67e4b4c8a1d5a71831e1067_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTIwMg_e9173348-6543-4743-9987-e3cc4d58d74e"
      unitRef="usd">100000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i8ac3810d42dd495ca842271bd91690b0_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTI3OQ_92294399-b03a-4c1b-85d3-2aa3e2c22ada"
      unitRef="usd">25000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i89df1d2e4cc246138d52d9f6d8cd6e7f_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTMzNw_7983fb9b-86a3-4c06-8e12-da5322720510"
      unitRef="usd">190000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityPeriodicPaymentPrincipal
      contextRef="if7490feb65964fa796425290739b321d_D20190901-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTU4MQ_076a4a3b-a5dd-40da-a4dc-20e7d75c3264"
      unitRef="usd">2400000</us-gaap:LineOfCreditFacilityPeriodicPaymentPrincipal>
    <us-gaap:LineOfCreditFacilityPeriodicPaymentPrincipal
      contextRef="i65f643704c1c43d88db131c9dcf5f1c4_D20190901-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTYzOQ_a902ddaf-89cb-46a4-bae2-de11c807aa10"
      unitRef="usd">3600000</us-gaap:LineOfCreditFacilityPeriodicPaymentPrincipal>
    <us-gaap:LineOfCreditFacilityPeriodicPaymentPrincipal
      contextRef="i7d42642f16854ea2855614113b660e84_D20190901-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTcwMA_7377d865-55d2-4740-8b8a-0c30803a5664"
      unitRef="usd">4800000</us-gaap:LineOfCreditFacilityPeriodicPaymentPrincipal>
    <us-gaap:LineOfCredit
      contextRef="i15f80bd5e8b04174974b1f69d1519f06_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTgyMw_b226f5e5-474d-49e6-8053-b45f082bdbf0"
      unitRef="usd">60000000.0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="ic96d1c4217de472a84ac6f11bbb720c3_D20190901-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMjUxNQ_ed03a3fa-1a52-4238-aa27-e28d5c2545a4"
      unitRef="number">0.0020</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i663b5171da0843d99423875dfcef6e74_D20190901-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMjUyMQ_5a8caf00-7e1f-49fc-901d-d04379a38ec8"
      unitRef="number">0.0035</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="id0e05edf24764d42964dacb1936f8e5f_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMzIyNA_f439a0d6-10f2-4e78-8ec6-e612c226e231"
      unitRef="number">0.0200</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i1fdcc51ad0fd4793ad2145ddf9d3333f_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMzIzMQ_606a6898-c2d7-44de-a108-267ae13ebde6"
      unitRef="number">0.0300</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i9c4c1dc5b0424494b3aa09efc8137c81_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMzM1MQ_493cc899-529c-42e7-adc5-cb9a86f3bcdd"
      unitRef="number">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i3b7ff140c5b34302b6867e8581216396_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMzM1OA_d17b2c22-d86e-4a7f-8413-a48509c0f2b7"
      unitRef="number">0.0200</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd
      contextRef="iff4cb76a3da64b79b6a83acbf4ac62d5_I20200630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMzUwMQ_3ee91e49-6d17-480f-83b0-2d33dc5f7c41"
      unitRef="number">0.0357</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd
      contextRef="ie8692d3a0d3f43509f73c146da09a16f_I20200630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMzUwOA_3beab100-359b-4b94-b5ff-fae9cddc94b0"
      unitRef="number">0.0324</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="ic1d8ce42602448a88e6e94a295508d62_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMzY5MA_e1febb26-c227-4a5f-b6df-097a1da972a2"
      unitRef="number">0.0200</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i45e40a83e59c4f21b6a684d812a61ca2_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMzY5Nw_eac7e0fd-a2e3-4db9-a3e9-1789f626d7b0"
      unitRef="number">0.0300</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <ameh:DebtInstrumentNumberOfKeyFinancialRatios
      contextRef="i1a435515824f4e14934a70bbffa79e42_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfNTYxOQ_035c4c0e-ad44-4225-95b9-354272dbde52"
      unitRef="financial_ratio">2</ameh:DebtInstrumentNumberOfKeyFinancialRatios>
    <ameh:DebtInstrumentCovenantLeverageRatioMaximum
      contextRef="i1a435515824f4e14934a70bbffa79e42_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfNTc2OQ_9a775326-5610-47cd-b61d-3557f0ea0bc5"
      unitRef="number">0.0375</ameh:DebtInstrumentCovenantLeverageRatioMaximum>
    <ameh:DebtInstrumentCovenantLeverageRatioIncrementalChange
      contextRef="i1a435515824f4e14934a70bbffa79e42_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfNTg3Ng_ff2527b6-c3fb-4d7a-94ff-2fc7985abca5"
      unitRef="number">0.0025</ameh:DebtInstrumentCovenantLeverageRatioIncrementalChange>
    <ameh:DebtInstrumentCovenantLeverageRatioMinimum
      contextRef="i1a435515824f4e14934a70bbffa79e42_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfNTkxMw_2b54f7f1-9f36-47d5-9d00-88f0f6160174"
      unitRef="number">0.0300</ameh:DebtInstrumentCovenantLeverageRatioMinimum>
    <ameh:DebtInstrumentCovenantInterestCoverageRatioMinimum
      contextRef="i44c831b5e48a42e88b05d16f1fdb9240_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfNjA1NQ_721e5bee-e047-42f5-87a2-f9c3f455d39c"
      unitRef="number">0.0325</ameh:DebtInstrumentCovenantInterestCoverageRatioMinimum>
    <us-gaap:DebtDefaultLongtermDebtAmount
      contextRef="i6cbb20b8a5374294838553f9c534c7e6_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfNzM3NQ_54fcc5f2-47af-4ad1-a0be-7f8bb7a8b0c6"
      unitRef="usd">10000000.0</us-gaap:DebtDefaultLongtermDebtAmount>
    <ameh:DebtInstrumentApprovalThresholdOfShareholdersForUseOfFundsPercentage
      contextRef="i7a1baad6dc7444dc9016d658275316ce_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfODM0Ng_62187253-d7db-4e8c-8053-5a6f3b215b6e"
      unitRef="number">0.5001</ameh:DebtInstrumentApprovalThresholdOfShareholdersForUseOfFundsPercentage>
    <us-gaap:DebtDefaultLongtermDebtAmount
      contextRef="i9a8fc30c8bb8493fa605fcaa4207f068_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfODQ1MA_91008923-7a1d-494f-8d4d-b05a19e403f4"
      unitRef="usd">50000000.0</us-gaap:DebtDefaultLongtermDebtAmount>
    <ameh:DebtInstrumentApprovedThresholdUseOfFunds
      contextRef="i9a8fc30c8bb8493fa605fcaa4207f068_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfODk4Mg_dc7f5786-0ced-42c3-82b1-27dbc95c2566"
      unitRef="usd">125000000.0</ameh:DebtInstrumentApprovedThresholdUseOfFunds>
    <us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet
      contextRef="i15f80bd5e8b04174974b1f69d1519f06_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTA0OTU_08f51240-f659-4788-9f41-5497de4c6ce6"
      unitRef="usd">6500000</us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="i44c831b5e48a42e88b05d16f1fdb9240_D20200101-20200630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTA5MDU_9c9e8185-c679-44d3-b295-729c87f65295"
      unitRef="number">0.0393</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="ia8ce6e89d9dc47b7a39dd3dd0614631b_D20190101-20190630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTA5MTI_ab327d82-9195-4409-accc-ed7f32251e01"
      unitRef="number">0.0471</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:InterestExpense
      contextRef="i8c34126de2c140689211bd3a59b45b51_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTEwODI_1099b081-9bfe-4d49-99a9-30d579be904d"
      unitRef="usd">300000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i44c831b5e48a42e88b05d16f1fdb9240_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTEwODk_cca36c67-01f5-4133-a316-7fb4044ff331"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i4bfbe9abbba34f0183c6540bd57fce10_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTY0OTI2NzQ2MDIyOQ_e98ccf0a-e614-4807-a9e8-652f2eb4e270"
      unitRef="usd">700000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ia8ce6e89d9dc47b7a39dd3dd0614631b_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTI2NDQzODM3MzYxMTc_83a07477-b914-443c-9271-9ab1f1103596"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ib2719f73504548bbae721f92df01a971_I20180614"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTEzMDU_ce1eb367-233b-414d-adc6-5eb9a98cead9"
      unitRef="usd">20000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ib2719f73504548bbae721f92df01a971_I20180614"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTE1Mjg_ce1eb367-233b-414d-adc6-5eb9a98cead9"
      unitRef="usd">20000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ibff1604bc099467eb93746f757585546_I20180901"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTE1MzQ_f484c018-7ff5-4db1-a040-9f762aa1d9da"
      unitRef="usd">27000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i16eef96539a54340912379d5350ec95c_D20181231-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTE3NTA_d8f9daac-ff42-4bdd-970d-c7e6b767e549"
      unitRef="number">0.00125</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd
      contextRef="ie40c6e5bceac47058b37a4f4c0981530_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTE3NTc_27c36f12-998d-4673-b615-f7512672ab98"
      unitRef="number">0.05625</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:LineOfCredit
      contextRef="i13403ca944e64582bbcaa0105295fb08_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTE5NDM_07aca5a1-12c2-47a3-99fb-8ce93f2aa8b2"
      unitRef="usd">5000000.0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i5266cd1d689d4ec2b6a1329887bfa026_I20180905"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTIxMDI_b50a8f86-2800-42d0-9de2-6229a41599ed"
      unitRef="usd">20000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i5266cd1d689d4ec2b6a1329887bfa026_I20180905"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTIyMjk_b50a8f86-2800-42d0-9de2-6229a41599ed"
      unitRef="usd">20000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ia2cd4816f5eb443c93bc954045c6a0d2_I20190417"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTIyMzU_69441358-c317-4e3b-a702-763be09b477f"
      unitRef="usd">16000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ia2cd4816f5eb443c93bc954045c6a0d2_I20190417"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTIyNDc_69441358-c317-4e3b-a702-763be09b477f"
      unitRef="usd">16000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i83420fb7674741a7adf09dd0edce6cb9_I20190729"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTIyNTM_02d0c1a3-4679-4909-a487-4b85c41e208d"
      unitRef="usd">2200000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ifd9d64e834b04bf7b54467b2c29f3db8_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTIzNDQ_a70a19ea-0e67-481e-824c-9f5ddddf9126"
      unitRef="number">0.00125</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd
      contextRef="ie9253d136d6c409ea392551405cd59a3_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTIzNTE_e24d29b8-c646-4eff-bdd1-d357e3ffb76f"
      unitRef="number">0.03375</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd
      contextRef="i4ceb41120b5c427da8f7a165eb95d2a4_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTIzNjc_a021843c-bec8-42fe-ac00-0d3b98148ead"
      unitRef="number">0.04875</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <ameh:LineOfCreditFacilityGuaranteeGivenByRelatedParties
      contextRef="i889eb6bfb2e4488e843c332fa29a6f88_D20180905-20180905"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTA5OTUxMTY0Njg1Ng_8d524dd3-b2b2-4068-b94a-1ce9e061c294">P5Y</ameh:LineOfCreditFacilityGuaranteeGivenByRelatedParties>
    <us-gaap:LineOfCreditFacilityExpirationPeriod
      contextRef="i889eb6bfb2e4488e843c332fa29a6f88_D20180905-20180905"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTA5OTUxMTY0Njg1NQ_35c4bf1a-0173-4937-93dd-c70224fc38af">P5Y</us-gaap:LineOfCreditFacilityExpirationPeriod>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i6929d7ef6c724b578ebd614e9aac9b40_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTMyMDM_e5847cee-b952-4972-9b42-2f68212e530e"
      unitRef="usd">14800000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="i489c8baa67d6408a868e6bdf3c0b60ea_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTMyMzU_267af3ec-cccd-4502-82f5-b68d538409e7"
      unitRef="usd">10200000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i7d75edd516124fbb828f66a694cd578d_I20180614"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTM0NDA_1f7adc99-9d4f-4503-a6b2-90cfe1f87797"
      unitRef="usd">10000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i7d75edd516124fbb828f66a694cd578d_I20180614"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTM1Njk_1f7adc99-9d4f-4503-a6b2-90cfe1f87797"
      unitRef="usd">10000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i5c7162ddeee34091b6e14c1103b27d19_I20190611"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTM1NzU_33fb39cb-979f-4ef7-a5af-724210aa5dd5"
      unitRef="usd">40000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i5c7162ddeee34091b6e14c1103b27d19_I20190611"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTM3MDk_33fb39cb-979f-4ef7-a5af-724210aa5dd5"
      unitRef="usd">40000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i4b837318f7d8458cb42d750eb8bbe6ef_I20190801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTM3MTU_fdc7cfb2-bbee-4cab-bc6a-d856f97ae262"
      unitRef="usd">43800000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i4b837318f7d8458cb42d750eb8bbe6ef_I20190801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTM3NTU_fdc7cfb2-bbee-4cab-bc6a-d856f97ae262"
      unitRef="usd">43800000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="if65f3f073a4e4926bd996e2b6f3709ca_I20190910"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTM3NjE_acb0714c-a0bd-48fe-85a8-8212a416e7d4"
      unitRef="usd">4100000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i39925af9c158412d82ae7eac78d51ab3_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTQzMDg_2231597a-eab4-4af2-873f-2272236f551d"
      unitRef="number">0.00125</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd
      contextRef="iadd3b4557abb442c93c1de563072e1bb_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTQzMTU_baf2beeb-d3b5-4d83-af6c-5b08b63664d2"
      unitRef="number">0.03375</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd
      contextRef="i349ef1b628184659aacbb0718a7d4338_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTQzMjI_6ab2cd13-33e1-4032-9b69-8204f1edb2ba"
      unitRef="number">0.04875</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="iadd3b4557abb442c93c1de563072e1bb_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTQzODQ_27edeb5f-4dc8-4010-a280-dabc69d91c3e"
      unitRef="usd">0</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="i349ef1b628184659aacbb0718a7d4338_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTQzODQ_c6cdcd0f-64a0-42ca-9a92-a1d50a472c1d"
      unitRef="usd">0</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i256fed6446054355bc000991eae06751_I20181002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTQ1OTE_6863a786-3e46-4203-a978-6bdb898fdc1e"
      unitRef="usd">6600000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityExpirationPeriod
      contextRef="i180bcd7578544f3fa0a9e820344d67de_D20181002-20181002"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTA5OTUxMTY0Njg1MQ_e99db0b1-efd0-404c-ab26-6c01b3cccb2a">P1Y</us-gaap:LineOfCreditFacilityExpirationPeriod>
    <ameh:LineOfCreditFacilityExpirationPeriodPeriodOfNotification
      contextRef="i180bcd7578544f3fa0a9e820344d67de_D20181002-20181002"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTQ4Mzc_4f6c5935-6631-4d72-b626-90f35226f12a">P90D</ameh:LineOfCreditFacilityExpirationPeriodPeriodOfNotification>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i256fed6446054355bc000991eae06751_I20181002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTUwNzM_6863a786-3e46-4203-a978-6bdb898fdc1e"
      unitRef="usd">6600000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i65b7438288394c098e39150948dddc7d_I20190814"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTUwNzk_66de7e36-39c9-4b1f-a013-39a993ab0ccf"
      unitRef="usd">14800000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i28f48691115042d086bf50c14043181c_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTU0MzE_9e972a18-e146-4d5f-9240-e1f15138f947"
      unitRef="usd">300000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityExpirationPeriod
      contextRef="i1cdc831367ff4a8584c4a6fb205fddcd_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTA5OTUxMTY0Njg1Mw_389b5c9b-950a-49f9-bcfd-b03c9c789628">P1Y</us-gaap:LineOfCreditFacilityExpirationPeriod>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i3fc12c8dd5b743488bb6c1675f17858f_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTU4Njg_3b321c93-6459-491f-a79c-f475ad12681f"
      unitRef="usd">3800000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityExpirationPeriod
      contextRef="i5fcdc1d2217741c292117f4a0d9fff3e_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV83Ni9mcmFnOjg1OTUzYzliNjI5NjRiMTM4OTEyNWJiYmIyZDlmYjJjL3RleHRyZWdpb246ODU5NTNjOWI2Mjk2NGIxMzg5MTI1YmJiYjJkOWZiMmNfMTA5OTUxMTY0Njg1Mg_adb09bb3-a249-4d81-b889-d4a8ecc90142">P1Y</us-gaap:LineOfCreditFacilityExpirationPeriod>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfMTI2NDQzODM3MzM4MTg_ffe89571-8152-44a7-8012-1bfd14794c18">Mezzanine and Stockholders&#x2019; Equity&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Mezzanine&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As the redemption feature (see Note 2) of the shares is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as noncontrolling interest in APC as mezzanine or temporary equity. APC&#x2019;s shares are not redeemable and it is not probable that the shares will become redeemable as of June&#160;30, 2020 and December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Stockholders&#x2019; Equity&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of June&#160;30, 2020, 302,732 holdback shares have not been issued to certain former NMM shareholders who were NMM shareholders at the time of closing of the merger between NMM and ApolloMed in December 2017 (the "Merger"), as they have yet to submit properly completed letters of transmittal to ApolloMed in order to receive their pro rata portion of ApolloMed common stock and warrants as contemplated under the merger agreement. Pending such receipt, such former NMM shareholders have the right to receive, without interest, their pro rata share of dividends or distributions with a record date after the effectiveness of the Merger. The consolidated financial statements have treated such shares of common stock as outstanding, given the receipt of the letter of transmittal is considered perfunctory and the Company is legally obligated to issue these shares in connection with the Merger.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;See options and warrants section below for common stock issued upon exercise of stock options and stock purchase warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s outstanding stock options consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.920%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.756%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.756%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.639%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Options outstanding at January&#160;1, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;607,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.42&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Options granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Options exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(120,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Options forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(12,228)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options outstanding at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;486,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.70&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options exercisable at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;380,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.74&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During the six months ended June&#160;30, 2020 and 2019, stock options were exercised for 120,000 and 111,000 shares, respectively, of the Company&#x2019;s common stock, which resulted in proceeds of approximately $0.3 million and $0.5 million, respectively. The exercise price ranged from $2.10 to $5.00 per share for the exercises during the six months ended June&#160;30, 2020, and ranged from $1.50 to $5.79 per share for the exercises during the six months ended June&#160;30, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During the six months ended June&#160;30, 2020 and 2019, no stock options were exercised pursuant to the cashless exercise provision.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During the six months ended June&#160;30, 2020, the Company granted 11,742 stock options with a vesting period of five-years to certain ApolloMed board members with an exercise price of $18.41, which were recognized at fair value, as determined using the Black-Scholes option pricing model and the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:80.258%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.742%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;June 30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Board Members&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Expected term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;90.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Market value of common stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Annual dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Forfeiture rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Restricted Stock Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company grants restricted stock awards to employees which are earned based on service conditions. The grant date fair value of the restricted stock awards is that day&#x2019;s closing market price of the Company&#x2019;s common stock. During the six months ended June&#160;30, 2020, the Company granted restricted stock awards totaling 97,447 shares with a weighted average grant date fair value of $17.58. The grant date fair value of the restricted stock was $1.6 million to be recognized on a straight-line basis over the awards&#x2019; vesting period of three years. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During the three and six months ended June&#160;30, 2020, the Company recorded approximately $0.9 million and $1.6 million of share-based compensation expense associated with the issuance of restricted shares of common stock and vesting of stock options which is included in general and administrative expenses in the accompanying consolidated statements of income, respectively. Unrecognized compensation expense related to total share-based payments outstanding as of June&#160;30, 2020, was $3.8 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s outstanding warrants consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:43.680%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.913%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Warrants outstanding at January&#160;1, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,154,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Warrants granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Warrants exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(273,900)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Warrants expired/forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Warrants outstanding at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,880,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.61&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:19.637%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.152%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:16.567%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.982%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.742%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Exercise&#160;Price&#160;Per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Warrants&#x2028;Outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Contractual&#160;Life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Exercisable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Exercise&#160;Price&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;754,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.29&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;754,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,313,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.85&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,313,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;812,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.44&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;812,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:right;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;$                                              $                     9.00 &#x2013;11.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,880,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.61&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,880,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During the six months ended June&#160;30, 2020 and 2019, common stock warrants were exercised for 273,900 and 41,624 shares, respectively, of the Company&#x2019;s common stock, which resulted in proceeds of approximately $2.6 million and $0.4 million, respectively. The exercise price ranged from $9.00 to $11.00 per share for the exercises during the six months ended June&#160;30, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Treasury Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;APC owned 17,307,214 and 17,290,317 shares of ApolloMed&#x2019;s common stock as of June&#160;30, 2020 and December&#160;31, 2019, which are legally issued and outstanding but excluded from shares of common stock outstanding in the consolidated financial statements, as such shares are treated as treasury shares for accounting purposes (see Note 1).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During the year ended December 31, 2019, APC established a brokerage account to invest excess capital in the equity market. The brokerage account is managed directly by an independent investment committee of the APC board of directors, from which Dr. Kenneth Sim and Dr. Thomas Lam have been excluded. As of June&#160;30, 2020, the brokerage account only held shares of ApolloMed totaling&#160;$7.6 million, and as such the ApolloMed shares in the brokerage account&#160;have been recorded as treasury shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Dividends&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During the six months ended June&#160;30, 2020 and 2019, APC paid dividends of $29.6 million and $10.0 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During the six months ended  June&#160;30, 2020 and 2019, CDSC paid dividends of $0.6 million and $1.2 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <ameh:StockIssuedDuringPeriodSharesMerger
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfNDM4_809c83cd-6696-4b45-9946-5e72be872680"
      unitRef="shares">302732</ameh:StockIssuedDuringPeriodSharesMerger>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfNDY2Nw_886e6fd4-c52d-4aae-8dbf-bf465f3b1a64">&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s outstanding stock options consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.920%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.756%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.756%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.639%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Options outstanding at January&#160;1, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;607,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.42&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Options granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Options exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(120,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Options forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(12,228)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options outstanding at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;486,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.70&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options exercisable at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;380,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.74&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmE1M2M2OGE3MjEwZDRkZjQ4NWQyNTRmNDIyNTQ0MjU4L3RhYmxlcmFuZ2U6YTUzYzY4YTcyMTBkNGRmNDg1ZDI1NGY0MjI1NDQyNThfMS0xLTEtMS0w_b3436d6e-ee89-4f9e-9672-ad9d39f7bed0"
      unitRef="shares">607346</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmE1M2M2OGE3MjEwZDRkZjQ4NWQyNTRmNDIyNTQ0MjU4L3RhYmxlcmFuZ2U6YTUzYzY4YTcyMTBkNGRmNDg1ZDI1NGY0MjI1NDQyNThfMS0zLTEtMS0w_f4ffc20b-a562-4253-95e0-a2f787ac79da"
      unitRef="usdPerShare">9.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i165dffaa08f24a1888f81cae72742649_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmE1M2M2OGE3MjEwZDRkZjQ4NWQyNTRmNDIyNTQ0MjU4L3RhYmxlcmFuZ2U6YTUzYzY4YTcyMTBkNGRmNDg1ZDI1NGY0MjI1NDQyNThfMS01LTEtMS0w_265b4f34-2ec7-458a-947d-40d2e9159bff">P3Y5M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmE1M2M2OGE3MjEwZDRkZjQ4NWQyNTRmNDIyNTQ0MjU4L3RhYmxlcmFuZ2U6YTUzYzY4YTcyMTBkNGRmNDg1ZDI1NGY0MjI1NDQyNThfMS03LTEtMS0w_dfd8a11e-42c3-4c15-9007-26a311e2d6f7"
      unitRef="usd">5600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmE1M2M2OGE3MjEwZDRkZjQ4NWQyNTRmNDIyNTQ0MjU4L3RhYmxlcmFuZ2U6YTUzYzY4YTcyMTBkNGRmNDg1ZDI1NGY0MjI1NDQyNThfMi0xLTEtMS0w_8eb67be5-453c-448c-800f-7c65b771307f"
      unitRef="shares">11742</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmE1M2M2OGE3MjEwZDRkZjQ4NWQyNTRmNDIyNTQ0MjU4L3RhYmxlcmFuZ2U6YTUzYzY4YTcyMTBkNGRmNDg1ZDI1NGY0MjI1NDQyNThfMi0zLTEtMS0w_8b81c057-71d0-44b1-b506-099df21b812d"
      unitRef="usdPerShare">18.41</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmE1M2M2OGE3MjEwZDRkZjQ4NWQyNTRmNDIyNTQ0MjU4L3RhYmxlcmFuZ2U6YTUzYzY4YTcyMTBkNGRmNDg1ZDI1NGY0MjI1NDQyNThfMy0xLTEtMS0w_d5ae6563-7e65-4ff1-9274-7dc690a1e616"
      unitRef="shares">120000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmE1M2M2OGE3MjEwZDRkZjQ4NWQyNTRmNDIyNTQ0MjU4L3RhYmxlcmFuZ2U6YTUzYzY4YTcyMTBkNGRmNDg1ZDI1NGY0MjI1NDQyNThfMy0zLTEtMS0w_61d6699b-3931-482d-b42d-49c04a37657c"
      unitRef="usdPerShare">2.58</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmE1M2M2OGE3MjEwZDRkZjQ4NWQyNTRmNDIyNTQ0MjU4L3RhYmxlcmFuZ2U6YTUzYzY4YTcyMTBkNGRmNDg1ZDI1NGY0MjI1NDQyNThfMy03LTEtMS0w_c6cd3339-3cf9-44be-93ab-65589414f59d"
      unitRef="usd">1800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmE1M2M2OGE3MjEwZDRkZjQ4NWQyNTRmNDIyNTQ0MjU4L3RhYmxlcmFuZ2U6YTUzYzY4YTcyMTBkNGRmNDg1ZDI1NGY0MjI1NDQyNThfNC0xLTEtMS0w_6bf88d05-b4f2-4308-91d2-8064b4f01aec"
      unitRef="shares">12228</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmE1M2M2OGE3MjEwZDRkZjQ4NWQyNTRmNDIyNTQ0MjU4L3RhYmxlcmFuZ2U6YTUzYzY4YTcyMTBkNGRmNDg1ZDI1NGY0MjI1NDQyNThfNC0zLTEtMS0w_8889b858-a64f-44f3-a9ba-0731a2af700c"
      unitRef="usdPerShare">17.57</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmE1M2M2OGE3MjEwZDRkZjQ4NWQyNTRmNDIyNTQ0MjU4L3RhYmxlcmFuZ2U6YTUzYzY4YTcyMTBkNGRmNDg1ZDI1NGY0MjI1NDQyNThfNi0xLTEtMS0w_02b764f5-ec5a-4aef-9265-2b8341a3d18f"
      unitRef="shares">486860</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmE1M2M2OGE3MjEwZDRkZjQ4NWQyNTRmNDIyNTQ0MjU4L3RhYmxlcmFuZ2U6YTUzYzY4YTcyMTBkNGRmNDg1ZDI1NGY0MjI1NDQyNThfNi0zLTEtMS0w_866e81d5-879d-40d9-b39a-6875b7e4b835"
      unitRef="usdPerShare">10.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmE1M2M2OGE3MjEwZDRkZjQ4NWQyNTRmNDIyNTQ0MjU4L3RhYmxlcmFuZ2U6YTUzYzY4YTcyMTBkNGRmNDg1ZDI1NGY0MjI1NDQyNThfNi01LTEtMS0w_dfd39206-1a8e-418d-be8b-8e79fbdffcc7">P3Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmE1M2M2OGE3MjEwZDRkZjQ4NWQyNTRmNDIyNTQ0MjU4L3RhYmxlcmFuZ2U6YTUzYzY4YTcyMTBkNGRmNDg1ZDI1NGY0MjI1NDQyNThfNi03LTEtMS0w_fc3f321f-7ea3-403b-8364-e8bccdc6ec36"
      unitRef="usd">2900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmE1M2M2OGE3MjEwZDRkZjQ4NWQyNTRmNDIyNTQ0MjU4L3RhYmxlcmFuZ2U6YTUzYzY4YTcyMTBkNGRmNDg1ZDI1NGY0MjI1NDQyNThfOC0xLTEtMS0w_1d4e8e00-6010-47fa-aae1-947664d1b464"
      unitRef="shares">380894</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmE1M2M2OGE3MjEwZDRkZjQ4NWQyNTRmNDIyNTQ0MjU4L3RhYmxlcmFuZ2U6YTUzYzY4YTcyMTBkNGRmNDg1ZDI1NGY0MjI1NDQyNThfOC0zLTEtMS0w_0669ddae-3d1c-4a96-9272-3298be21725d"
      unitRef="usdPerShare">7.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmE1M2M2OGE3MjEwZDRkZjQ4NWQyNTRmNDIyNTQ0MjU4L3RhYmxlcmFuZ2U6YTUzYzY4YTcyMTBkNGRmNDg1ZDI1NGY0MjI1NDQyNThfOC01LTEtMS0w_0517f912-d875-4f3c-be26-2ccdf5cd21de">P2Y8M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmE1M2M2OGE3MjEwZDRkZjQ4NWQyNTRmNDIyNTQ0MjU4L3RhYmxlcmFuZ2U6YTUzYzY4YTcyMTBkNGRmNDg1ZDI1NGY0MjI1NDQyNThfOC03LTEtMS0w_27c4e9b8-c056-42d1-aa4e-1048cc9faed6"
      unitRef="usd">3000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfMTU3OA_b8e13237-5729-43b0-9d0f-08586426c2fe"
      unitRef="shares">120000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfMTU4NQ_aa69d218-891e-4845-9336-51378218dbcc"
      unitRef="shares">111000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ic7bf1ad2136147739b9d3573b799cfb2_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfMTY4NQ_51d16f18-26bb-4b98-a7d6-be02919651ae"
      unitRef="usd">300000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i9147cda570b34114b9da7922c7249550_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfMTY5Mg_48c60c61-e690-4c80-bb15-78c014c9ebe1"
      unitRef="usd">500000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="if0190ef7dee34fbda65c048ee6b393c7_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfMTczMw_66e38a4f-8334-40df-9f44-710c09348cd2"
      unitRef="usdPerShare">2.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i4688143439664825ac968a174665ba3d_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfNjA0NzMxMzk1NzU0NA_504c48bb-24cf-4024-9d0a-b81e8aa32cba"
      unitRef="usdPerShare">5.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i394a53913abc46b7840e4b3b601af231_I20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfMTgxNA_222f54de-c363-4f59-81fe-a1ac70773557"
      unitRef="usdPerShare">1.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ia7f3c7099ea7466e8c0372573a9eb42b_I20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfMTgyMA_c61c5a5e-9385-4024-bc0e-8cc8c7f1ac28"
      unitRef="usdPerShare">5.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfMTkyMA_a4bc79cc-5078-463e-a17f-d0e479a7d366"
      unitRef="shares">0</ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod>
    <ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfMTkyMA_d0d23550-8452-48d5-80bc-47bb0627ccd5"
      unitRef="shares">0</ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfNDY3MA_44698fb0-f5be-4936-8a35-11246e0e97c3">&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During the six months ended June&#160;30, 2020, the Company granted 11,742 stock options with a vesting period of five-years to certain ApolloMed board members with an exercise price of $18.41, which were recognized at fair value, as determined using the Black-Scholes option pricing model and the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:80.258%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.742%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;June 30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Board Members&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Expected term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;90.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Market value of common stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Annual dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Forfeiture rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i9ec7494ea7af48fda7c1d23e2672ba9d_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfMjA0OA_cf05f023-dcf9-402e-8311-a474cdd5e6a8"
      unitRef="shares">11742</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i9c63f7d7fa16447cb33f1cc3ad14ba3f_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfMTE1NDQ4NzIxMDYxMzI_fcff4f97-de4e-48db-a2a7-ac86c3dca671">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i5c5087d6c84a4583badaea62a58fdd8a_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfMjEzNA_ff170517-fc55-4b30-ab41-e5a43a85093e"
      unitRef="usdPerShare">18.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i9ec7494ea7af48fda7c1d23e2672ba9d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOjBmMGU1ZDA2NWJiMTRjMDRiNDcxZjExNjMyZDkxYjUxL3RhYmxlcmFuZ2U6MGYwZTVkMDY1YmIxNGMwNGI0NzFmMTE2MzJkOTFiNTFfMS0xLTEtMS0w_a05273e8-cb28-4bf8-ad89-5e2144562e0a">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i9ec7494ea7af48fda7c1d23e2672ba9d_D20200101-20200630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOjBmMGU1ZDA2NWJiMTRjMDRiNDcxZjExNjMyZDkxYjUxL3RhYmxlcmFuZ2U6MGYwZTVkMDY1YmIxNGMwNGI0NzFmMTE2MzJkOTFiNTFfMi0xLTEtMS0w_16e3f3a3-8de8-4acf-8f50-6dc285197c58"
      unitRef="number">0.9001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i9ec7494ea7af48fda7c1d23e2672ba9d_D20200101-20200630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOjBmMGU1ZDA2NWJiMTRjMDRiNDcxZjExNjMyZDkxYjUxL3RhYmxlcmFuZ2U6MGYwZTVkMDY1YmIxNGMwNGI0NzFmMTE2MzJkOTFiNTFfMy0xLTEtMS0w_cc928c49-17db-4287-a623-b6da135bb882"
      unitRef="number">0.0143</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharePrice
      contextRef="i5c5087d6c84a4583badaea62a58fdd8a_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOjBmMGU1ZDA2NWJiMTRjMDRiNDcxZjExNjMyZDkxYjUxL3RhYmxlcmFuZ2U6MGYwZTVkMDY1YmIxNGMwNGI0NzFmMTE2MzJkOTFiNTFfNC0xLTEtMS0w_0d9d2c42-7735-41c0-9897-2142daae47f9"
      unitRef="usdPerShare">10.56</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i9ec7494ea7af48fda7c1d23e2672ba9d_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOjBmMGU1ZDA2NWJiMTRjMDRiNDcxZjExNjMyZDkxYjUxL3RhYmxlcmFuZ2U6MGYwZTVkMDY1YmIxNGMwNGI0NzFmMTE2MzJkOTFiNTFfNS0xLTEtMS0w_663f82b5-4e42-40ef-aa3c-1fd653bbdf11"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate
      contextRef="i9ec7494ea7af48fda7c1d23e2672ba9d_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOjBmMGU1ZDA2NWJiMTRjMDRiNDcxZjExNjMyZDkxYjUxL3RhYmxlcmFuZ2U6MGYwZTVkMDY1YmIxNGMwNGI0NzFmMTE2MzJkOTFiNTFfNi0xLTEtMS0w_e11c0777-a047-4457-a45e-27979169c9f7"
      unitRef="number">0</ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="id3ba07d0aaff4c4cbfb30aa71876350e_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfMjYwMA_548ea2be-d890-49aa-aabe-6f35ba9aa600"
      unitRef="shares">97447</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="id3ba07d0aaff4c4cbfb30aa71876350e_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfMjY1OQ_21d12861-ec59-4dbe-8302-bf18368c5086"
      unitRef="usdPerShare">17.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="id5b38446c9f64ce5babcd929b0922482_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfMjcxNw_0556f658-cba2-4ef1-b191-1d20d37514ce"
      unitRef="usd">1600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="id3ba07d0aaff4c4cbfb30aa71876350e_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfMjc5Nw_2fc37294-390c-490c-9712-4ae0963496be">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensation
      contextRef="id57bfd29aaf44d4d95e8e561bbe67cf2_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfMjg2OA_4151a5ce-5083-4541-a915-ea9feb9af840"
      unitRef="usd">900000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i414264e0cb1e499287a23f8ddf6b9498_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfNjA0NzMxMzk1NzU1OA_313a8fb0-6a14-46ee-8124-a29659131f83"
      unitRef="usd">1600000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="id265c5c2e7f34a2bbb064c838d92d806_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfNjU5NzA2OTc3OTUyNA_9880e5bc-a51c-4212-b9ac-906ae93706d7"
      unitRef="usd">3800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfNDY3Nw_a7cffe42-efd0-41bd-8903-b11a5f0f5131">&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s outstanding warrants consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:43.680%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.913%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Warrants outstanding at January&#160;1, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,154,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Warrants granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Warrants exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(273,900)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Warrants expired/forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Warrants outstanding at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,880,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.61&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:19.637%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.152%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:16.567%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.982%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.742%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Exercise&#160;Price&#160;Per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Warrants&#x2028;Outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Contractual&#160;Life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Exercisable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Exercise&#160;Price&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;754,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.29&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;754,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,313,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.85&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,313,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;812,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.44&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;812,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:right;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;$                                              $                     9.00 &#x2013;11.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,880,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.61&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,880,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmFhYWI2YTAzYWFjMTRlOGRiNzA4Y2VlNzU3MTBkNzYzL3RhYmxlcmFuZ2U6YWFhYjZhMDNhYWMxNGU4ZGI3MDhjZWU3NTcxMGQ3NjNfMS0xLTEtMS0w_86f3b48e-d2ba-43fc-b7b3-da29ce7a3a3a"
      unitRef="shares">3154590</us-gaap:ClassOfWarrantOrRightOutstanding>
    <ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmFhYWI2YTAzYWFjMTRlOGRiNzA4Y2VlNzU3MTBkNzYzL3RhYmxlcmFuZ2U6YWFhYjZhMDNhYWMxNGU4ZGI3MDhjZWU3NTcxMGQ3NjNfMS0zLTEtMS0w_cf5978d8-250c-4570-9aea-d9eff0ca63f1"
      unitRef="usdPerShare">9.96</ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants>
    <ameh:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm
      contextRef="i165dffaa08f24a1888f81cae72742649_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmFhYWI2YTAzYWFjMTRlOGRiNzA4Y2VlNzU3MTBkNzYzL3RhYmxlcmFuZ2U6YWFhYjZhMDNhYWMxNGU4ZGI3MDhjZWU3NTcxMGQ3NjNfMS01LTEtMS0w_131ecd7f-aaa9-4d9a-bfab-43d28adf28c2">P2Y3D</ameh:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm>
    <ameh:ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmFhYWI2YTAzYWFjMTRlOGRiNzA4Y2VlNzU3MTBkNzYzL3RhYmxlcmFuZ2U6YWFhYjZhMDNhYWMxNGU4ZGI3MDhjZWU3NTcxMGQ3NjNfMS03LTEtMS0w_b9b33f9e-9b32-452c-bae5-e61d9080c548"
      unitRef="usd">26700000</ameh:ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue>
    <ameh:NumberOfWarrantsGranted
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmFhYWI2YTAzYWFjMTRlOGRiNzA4Y2VlNzU3MTBkNzYzL3RhYmxlcmFuZ2U6YWFhYjZhMDNhYWMxNGU4ZGI3MDhjZWU3NTcxMGQ3NjNfMi0xLTEtMS0w_4aa4dec6-f8df-4578-9f6a-029e315def1c"
      unitRef="shares">0</ameh:NumberOfWarrantsGranted>
    <ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmFhYWI2YTAzYWFjMTRlOGRiNzA4Y2VlNzU3MTBkNzYzL3RhYmxlcmFuZ2U6YWFhYjZhMDNhYWMxNGU4ZGI3MDhjZWU3NTcxMGQ3NjNfMi0zLTEtMS0w_ecf3330f-a62b-4b16-b501-3e56a79682e9"
      unitRef="usdPerShare">0</ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod>
    <ameh:ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmFhYWI2YTAzYWFjMTRlOGRiNzA4Y2VlNzU3MTBkNzYzL3RhYmxlcmFuZ2U6YWFhYjZhMDNhYWMxNGU4ZGI3MDhjZWU3NTcxMGQ3NjNfMi03LTEtMS0w_1e279de5-84d9-4e8f-9217-9517616505cf"
      unitRef="usd">0</ameh:ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue>
    <ameh:NumberOfWarrantsExercised
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmFhYWI2YTAzYWFjMTRlOGRiNzA4Y2VlNzU3MTBkNzYzL3RhYmxlcmFuZ2U6YWFhYjZhMDNhYWMxNGU4ZGI3MDhjZWU3NTcxMGQ3NjNfMy0xLTEtMS0w_7ff0e31d-f531-44c8-a63f-42d13753b4e3"
      unitRef="shares">273900</ameh:NumberOfWarrantsExercised>
    <ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmFhYWI2YTAzYWFjMTRlOGRiNzA4Y2VlNzU3MTBkNzYzL3RhYmxlcmFuZ2U6YWFhYjZhMDNhYWMxNGU4ZGI3MDhjZWU3NTcxMGQ3NjNfMy0zLTEtMS0w_cbfedb90-9773-42be-8cbd-a9fab8c3bd86"
      unitRef="usdPerShare">9.32</ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod>
    <ameh:ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmFhYWI2YTAzYWFjMTRlOGRiNzA4Y2VlNzU3MTBkNzYzL3RhYmxlcmFuZ2U6YWFhYjZhMDNhYWMxNGU4ZGI3MDhjZWU3NTcxMGQ3NjNfMy03LTEtMS0w_d091eb1e-1e58-4064-8f82-3c2fc3de477b"
      unitRef="usd">2000000</ameh:ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue>
    <ameh:ClassOfWarrantOrRightCancelledInPeriod
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmFhYWI2YTAzYWFjMTRlOGRiNzA4Y2VlNzU3MTBkNzYzL3RhYmxlcmFuZ2U6YWFhYjZhMDNhYWMxNGU4ZGI3MDhjZWU3NTcxMGQ3NjNfNC0xLTEtMS0w_15fde319-351f-4be1-ab6f-d3a7260cb406"
      unitRef="shares">0</ameh:ClassOfWarrantOrRightCancelledInPeriod>
    <ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmFhYWI2YTAzYWFjMTRlOGRiNzA4Y2VlNzU3MTBkNzYzL3RhYmxlcmFuZ2U6YWFhYjZhMDNhYWMxNGU4ZGI3MDhjZWU3NTcxMGQ3NjNfNC0zLTEtMS0w_6e1445fb-281b-432d-83b4-d62badd0cf09"
      unitRef="usdPerShare">0</ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod>
    <ameh:ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmFhYWI2YTAzYWFjMTRlOGRiNzA4Y2VlNzU3MTBkNzYzL3RhYmxlcmFuZ2U6YWFhYjZhMDNhYWMxNGU4ZGI3MDhjZWU3NTcxMGQ3NjNfNC03LTEtMS0w_5976f2e8-20c0-45f4-8dda-42ea00b95525"
      unitRef="usd">0</ameh:ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmFhYWI2YTAzYWFjMTRlOGRiNzA4Y2VlNzU3MTBkNzYzL3RhYmxlcmFuZ2U6YWFhYjZhMDNhYWMxNGU4ZGI3MDhjZWU3NTcxMGQ3NjNfNi0xLTEtMS0w_fabd2713-41f0-4326-9b03-43de647277b3"
      unitRef="shares">2880690</us-gaap:ClassOfWarrantOrRightOutstanding>
    <ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmFhYWI2YTAzYWFjMTRlOGRiNzA4Y2VlNzU3MTBkNzYzL3RhYmxlcmFuZ2U6YWFhYjZhMDNhYWMxNGU4ZGI3MDhjZWU3NTcxMGQ3NjNfNi0zLTEtMS0w_3f9348a9-c94f-4fd4-acc3-273ff21fa5f4"
      unitRef="usdPerShare">10.02</ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants>
    <ameh:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmFhYWI2YTAzYWFjMTRlOGRiNzA4Y2VlNzU3MTBkNzYzL3RhYmxlcmFuZ2U6YWFhYjZhMDNhYWMxNGU4ZGI3MDhjZWU3NTcxMGQ3NjNfNi01LTEtMS0w_c49ee2a7-7047-459a-9ab1-d378f7a4275e">P1Y7M9D</ameh:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm>
    <ameh:ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOmFhYWI2YTAzYWFjMTRlOGRiNzA4Y2VlNzU3MTBkNzYzL3RhYmxlcmFuZ2U6YWFhYjZhMDNhYWMxNGU4ZGI3MDhjZWU3NTcxMGQ3NjNfNi03LTEtMS0w_520ce50c-2baf-4e10-8d29-48d9af89bdb3"
      unitRef="usd">18700000</ameh:ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i0652754b1e534a8089d0c0347af659b7_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOjRjYWJiYWJiNGZiZTQ2NWJiMGIwM2ZjMzE1YzdhNjA2L3RhYmxlcmFuZ2U6NGNhYmJhYmI0ZmJlNDY1YmIwYjAzZmMzMTVjN2E2MDZfMS0wLTEtMS0w_19cf193d-00e9-4f6e-a9a8-dc5334280da2"
      unitRef="usdPerShare">9.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ameh:ClassOfWarrantOrRightIssuedInPeriod
      contextRef="ia1f01a331d6248978588759d09efd270_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOjRjYWJiYWJiNGZiZTQ2NWJiMGIwM2ZjMzE1YzdhNjA2L3RhYmxlcmFuZ2U6NGNhYmJhYmI0ZmJlNDY1YmIwYjAzZmMzMTVjN2E2MDZfMS0yLTEtMS0w_42db0101-d0bb-4a7d-936f-1036f30ccb57"
      unitRef="shares">754870</ameh:ClassOfWarrantOrRightIssuedInPeriod>
    <ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm
      contextRef="ia1f01a331d6248978588759d09efd270_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOjRjYWJiYWJiNGZiZTQ2NWJiMGIwM2ZjMzE1YzdhNjA2L3RhYmxlcmFuZ2U6NGNhYmJhYmI0ZmJlNDY1YmIwYjAzZmMzMTVjN2E2MDZfMS00LTEtMS0w_d05a9c12-0384-4cb3-884f-57c79ba95436">P0Y3M14D</ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm>
    <ameh:ClassOfWarrantOrRightExercisable
      contextRef="i0652754b1e534a8089d0c0347af659b7_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOjRjYWJiYWJiNGZiZTQ2NWJiMGIwM2ZjMzE1YzdhNjA2L3RhYmxlcmFuZ2U6NGNhYmJhYmI0ZmJlNDY1YmIwYjAzZmMzMTVjN2E2MDZfMS02LTEtMS0w_2791d46d-f54e-45e8-9cba-7073e42afd5d"
      unitRef="shares">754870</ameh:ClassOfWarrantOrRightExercisable>
    <ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants
      contextRef="i0652754b1e534a8089d0c0347af659b7_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOjRjYWJiYWJiNGZiZTQ2NWJiMGIwM2ZjMzE1YzdhNjA2L3RhYmxlcmFuZ2U6NGNhYmJhYmI0ZmJlNDY1YmIwYjAzZmMzMTVjN2E2MDZfMS04LTEtMS0w_f1c663ad-9c25-436e-8673-5321ab96ff7a"
      unitRef="usdPerShare">9.00</ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i717848bf538848ab855a3a3e35ae4238_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOjRjYWJiYWJiNGZiZTQ2NWJiMGIwM2ZjMzE1YzdhNjA2L3RhYmxlcmFuZ2U6NGNhYmJhYmI0ZmJlNDY1YmIwYjAzZmMzMTVjN2E2MDZfMi0wLTEtMS0w_42a14ac5-8e51-474d-ba8f-bdf23b0ae972"
      unitRef="usdPerShare">10.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ameh:ClassOfWarrantOrRightIssuedInPeriod
      contextRef="ia4f9f7ea8c4f4b079f5fc8ba6a915106_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOjRjYWJiYWJiNGZiZTQ2NWJiMGIwM2ZjMzE1YzdhNjA2L3RhYmxlcmFuZ2U6NGNhYmJhYmI0ZmJlNDY1YmIwYjAzZmMzMTVjN2E2MDZfMi0yLTEtMS0w_2df13e91-f9a4-43f6-8c95-ebeb20f825ac"
      unitRef="shares">1313345</ameh:ClassOfWarrantOrRightIssuedInPeriod>
    <ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm
      contextRef="ia4f9f7ea8c4f4b079f5fc8ba6a915106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOjRjYWJiYWJiNGZiZTQ2NWJiMGIwM2ZjMzE1YzdhNjA2L3RhYmxlcmFuZ2U6NGNhYmJhYmI0ZmJlNDY1YmIwYjAzZmMzMTVjN2E2MDZfMi00LTEtMS0w_3e131efa-4f80-4b42-84fe-45d682fc1f92">P1Y10M6D</ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm>
    <ameh:ClassOfWarrantOrRightExercisable
      contextRef="i717848bf538848ab855a3a3e35ae4238_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOjRjYWJiYWJiNGZiZTQ2NWJiMGIwM2ZjMzE1YzdhNjA2L3RhYmxlcmFuZ2U6NGNhYmJhYmI0ZmJlNDY1YmIwYjAzZmMzMTVjN2E2MDZfMi02LTEtMS0w_15490aab-ebbc-4ebe-bd6b-a2efe15a6f60"
      unitRef="shares">1313345</ameh:ClassOfWarrantOrRightExercisable>
    <ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants
      contextRef="i717848bf538848ab855a3a3e35ae4238_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOjRjYWJiYWJiNGZiZTQ2NWJiMGIwM2ZjMzE1YzdhNjA2L3RhYmxlcmFuZ2U6NGNhYmJhYmI0ZmJlNDY1YmIwYjAzZmMzMTVjN2E2MDZfMi04LTEtMS0w_3efb2152-7544-48fd-9314-9c7a9120039c"
      unitRef="usdPerShare">10.00</ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ie1b7b6fb52d049f38e00e0bc30605358_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOjRjYWJiYWJiNGZiZTQ2NWJiMGIwM2ZjMzE1YzdhNjA2L3RhYmxlcmFuZ2U6NGNhYmJhYmI0ZmJlNDY1YmIwYjAzZmMzMTVjN2E2MDZfMy0wLTEtMS0w_e6039dcc-b3c0-49ee-a611-cd43d03149b4"
      unitRef="usdPerShare">11.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ameh:ClassOfWarrantOrRightIssuedInPeriod
      contextRef="i8b530cfd9afc42f2a4a14a51d941740c_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOjRjYWJiYWJiNGZiZTQ2NWJiMGIwM2ZjMzE1YzdhNjA2L3RhYmxlcmFuZ2U6NGNhYmJhYmI0ZmJlNDY1YmIwYjAzZmMzMTVjN2E2MDZfMy0yLTEtMS0w_1255cb25-f1de-4c0a-9cbe-527045e4f9d7"
      unitRef="shares">812475</ameh:ClassOfWarrantOrRightIssuedInPeriod>
    <ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm
      contextRef="i8b530cfd9afc42f2a4a14a51d941740c_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOjRjYWJiYWJiNGZiZTQ2NWJiMGIwM2ZjMzE1YzdhNjA2L3RhYmxlcmFuZ2U6NGNhYmJhYmI0ZmJlNDY1YmIwYjAzZmMzMTVjN2E2MDZfMy00LTEtMS0w_54210ce7-ff7e-4375-8b85-159df73dfb0e">P2Y5M8D</ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm>
    <ameh:ClassOfWarrantOrRightExercisable
      contextRef="ie1b7b6fb52d049f38e00e0bc30605358_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOjRjYWJiYWJiNGZiZTQ2NWJiMGIwM2ZjMzE1YzdhNjA2L3RhYmxlcmFuZ2U6NGNhYmJhYmI0ZmJlNDY1YmIwYjAzZmMzMTVjN2E2MDZfMy02LTEtMS0w_159b3a97-1a22-4f78-9061-93c0e9c523d9"
      unitRef="shares">812475</ameh:ClassOfWarrantOrRightExercisable>
    <ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants
      contextRef="ie1b7b6fb52d049f38e00e0bc30605358_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOjRjYWJiYWJiNGZiZTQ2NWJiMGIwM2ZjMzE1YzdhNjA2L3RhYmxlcmFuZ2U6NGNhYmJhYmI0ZmJlNDY1YmIwYjAzZmMzMTVjN2E2MDZfMy04LTEtMS0w_fccb7180-1300-49fa-9d3a-5b5d3ea22729"
      unitRef="usdPerShare">11.00</ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i228644db04a54aeea81ac55c214613cf_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOjRjYWJiYWJiNGZiZTQ2NWJiMGIwM2ZjMzE1YzdhNjA2L3RhYmxlcmFuZ2U6NGNhYmJhYmI0ZmJlNDY1YmIwYjAzZmMzMTVjN2E2MDZfNS0wLTEtMS0wL3RleHRyZWdpb246ODVhMGRhZTMyYWVlNGQyOThkZTllZmRjYjEzZjYyMGVfNjA0NzMxMzk1Mjk3Ng_da7d116c-5f06-4182-8295-67e5ba4ba9d0"
      unitRef="usdPerShare">9.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i070e64c85f6a46f3abd4745871816551_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOjRjYWJiYWJiNGZiZTQ2NWJiMGIwM2ZjMzE1YzdhNjA2L3RhYmxlcmFuZ2U6NGNhYmJhYmI0ZmJlNDY1YmIwYjAzZmMzMTVjN2E2MDZfNS0wLTEtMS0wL3RleHRyZWdpb246ODVhMGRhZTMyYWVlNGQyOThkZTllZmRjYjEzZjYyMGVfNjA0NzMxMzk1Mjk3OQ_734d3030-6c1c-4013-8f05-7bb9e30664a6"
      unitRef="usdPerShare">11.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ameh:ClassOfWarrantOrRightIssuedInPeriod
      contextRef="i7a07edf9a6d9427cbb8e495a1c38dba1_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOjRjYWJiYWJiNGZiZTQ2NWJiMGIwM2ZjMzE1YzdhNjA2L3RhYmxlcmFuZ2U6NGNhYmJhYmI0ZmJlNDY1YmIwYjAzZmMzMTVjN2E2MDZfNS0yLTEtMS0w_68e45002-f374-4a6a-ab51-9f576c44800c"
      unitRef="shares">2880690</ameh:ClassOfWarrantOrRightIssuedInPeriod>
    <ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm
      contextRef="i7a07edf9a6d9427cbb8e495a1c38dba1_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOjRjYWJiYWJiNGZiZTQ2NWJiMGIwM2ZjMzE1YzdhNjA2L3RhYmxlcmFuZ2U6NGNhYmJhYmI0ZmJlNDY1YmIwYjAzZmMzMTVjN2E2MDZfNS00LTEtMS0w_72bcca86-9f85-4f07-aeb5-33dd55aaf324">P1Y7M9D</ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm>
    <ameh:ClassOfWarrantOrRightExercisable
      contextRef="i58c8b96e915044a5a2285690f262e2f1_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOjRjYWJiYWJiNGZiZTQ2NWJiMGIwM2ZjMzE1YzdhNjA2L3RhYmxlcmFuZ2U6NGNhYmJhYmI0ZmJlNDY1YmIwYjAzZmMzMTVjN2E2MDZfNS02LTEtMS0w_158d5b2c-a94f-4999-9df1-e654a38c4834"
      unitRef="shares">2880690</ameh:ClassOfWarrantOrRightExercisable>
    <ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants
      contextRef="i58c8b96e915044a5a2285690f262e2f1_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RhYmxlOjRjYWJiYWJiNGZiZTQ2NWJiMGIwM2ZjMzE1YzdhNjA2L3RhYmxlcmFuZ2U6NGNhYmJhYmI0ZmJlNDY1YmIwYjAzZmMzMTVjN2E2MDZfNS04LTEtMS0w_367529e8-287c-45e9-b3ca-3cb34b881fe4"
      unitRef="usdPerShare">10.02</ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants>
    <ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfMzUyOQ_fe88c3f6-9a6c-49b2-a2c4-1136dba7e45f"
      unitRef="shares">273900</ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod>
    <ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfMzUzNg_4730dad2-a8d0-4002-a5c0-624fc11e063d"
      unitRef="shares">41624</ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod>
    <ameh:WarrantIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfMzYzNg_e3ab2bb9-1e9d-4ce7-bcc7-8e51a62e1fb8"
      unitRef="usd">2600000</ameh:WarrantIssuedDuringPeriodValueStockOptionsExercised>
    <ameh:WarrantIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfMzY0Mw_1c3ac901-cf8c-49b7-9ed8-74e4b55198b0"
      unitRef="usd">400000</ameh:WarrantIssuedDuringPeriodValueStockOptionsExercised>
    <ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice
      contextRef="i5348fddd2d3647eab57aabde18624e3e_D20190101-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfMzY5Mg_67660db8-14a8-438b-bb76-43ff4bb0aee1"
      unitRef="usdPerShare">9.00</ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice>
    <ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice
      contextRef="i6dab3a2b4fba451e82b3256455eeec2b_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfMzY5Mg_f3f953fe-dc28-494a-8e25-225dc8bd38ad"
      unitRef="usdPerShare">9.00</ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice>
    <ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice
      contextRef="i59b3484b35404c20b3bede5ccbf47667_D20190101-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfMzY5OA_0c3fafb6-4255-4288-9136-02c30e9c850c"
      unitRef="usdPerShare">11.00</ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice>
    <ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice
      contextRef="ibcd3d205d526423cbea49810dc2340a8_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfMzY5OA_c8193134-a7b7-4ee1-9300-b44f853a77fe"
      unitRef="usdPerShare">11.00</ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i4081b94ec67249e5a1d21eae73e8d25e_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfMzgwNg_f5f7fd67-e20f-4273-a8bc-5252c5c2fd43"
      unitRef="shares">17307214</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="if21a86c3eed7480aad7e5a1485553c3f_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfMzgxMw_ed90941c-3a81-4ec4-85b1-4398454caea3"
      unitRef="shares">17290317</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockValue
      contextRef="i2b03d1915fa54978a6378c9edaa22474_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfNDQ3OA_d84c1ea9-ddae-4cad-b199-c0e23c18db88"
      unitRef="usd">7600000</us-gaap:TreasuryStockValue>
    <us-gaap:Dividends
      contextRef="i255d39881fdb459ba312544c3eb6589e_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfNjU5NzA2OTc3MTM1NQ_b12357ce-b152-44f5-a0d1-f56385847248"
      unitRef="usd">29600000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="i82a52038c4164e77a3f6e20b01157134_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfNjU5NzA2OTc3MTM2Mw_6dcccbff-6fe8-403c-b3aa-fe9485f6324f"
      unitRef="usd">10000000.0</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="idf76f2b7860f4f6a97ee09255e45287d_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfNjU5NzA2OTc4MDk5Mw_89100edf-ea22-402c-a569-3f45c02bba1b"
      unitRef="usd">600000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="i5fa3d2acebea43c3a0c0f3e590d02ad4_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84Mi9mcmFnOjdiZTQ3MmVlZmZlMzQ3MTJiNTc3YmJhMWMwZjQxOTg1L3RleHRyZWdpb246N2JlNDcyZWVmZmUzNDcxMmI1NzdiYmExYzBmNDE5ODVfNjU5NzA2OTc4MDk4Mw_f276a30d-3b7c-4976-a98c-1149ce6fb610"
      unitRef="usd">1200000</us-gaap:Dividends>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84OC9mcmFnOmY1NTNmMDg5OWEzYjRlMzBiZDNlNDNjZGZjNjhiOGU3L3RleHRyZWdpb246ZjU1M2YwODk5YTNiNGUzMGJkM2U0M2NkZmM2OGI4ZTdfMTA5OTUxMTYzMzgyMg_af3cadb5-92a3-49c7-863b-264793ed127a">Commitments and Contingencies&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Regulatory Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Laws and regulations governing the Medicare program and healthcare generally are complex and subject to interpretation. The Company believes that it is in compliance with all applicable laws and regulations and is not aware of any pending or &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;threatened investigations involving allegations of potential wrongdoing. While no regulatory inquiries have been made, compliance with such laws and regulations can be subject to future government review and interpretation, as well as significant regulatory action, including fines, penalties, and exclusion from the Medicare and Medi-Cal programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As risk-bearing organizations, APC, Alpha Care and Accountable Health Care are required to comply with California DMHC regulations, including maintenance of minimum working capital, tangible net equity (&#x201c;TNE&#x201d;), cash-to-claims ratio and claims payment requirements prescribed by the California DMHC. TNE is defined as net equity less intangibles, less non-allowable assets (which include unsecured amounts due from affiliates), plus subordinated obligations. At&#160;June&#160;30, 2020 and December&#160;31, 2019, APC, Alpha Care and Accountable Health Care were in compliance with these regulations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Many of the Company&#x2019;s payor and provider contracts are complex in nature and may be subject to differing interpretations regarding amounts due for the provision of medical services. Such differing interpretations may not come to light until a substantial period of time has passed following contract implementation. Liabilities for claims disputes are recorded when the loss is probable and can be estimated. Any adjustments to reserves are reflected in current operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Standby Letters of Credit&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As part of the APAACO participation with CMS, the Company must provide a financial guarantee to CMS, the guarantee generally must be in an amount equal to 2% of the Company&#x2019;s benchmark Medicare Part A and Part B expenditures. The Company has established an irrevocable standby letter of credit with Preferred Bank of $8.2 million and $6.6 million for the 2019 and 2018 performance years (see Note 9).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;APC established irrevocable standby letters of credit with a financial institution for a total of $0.3 million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional one-year periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated (see Note 9).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Alpha Care established irrevocable standby letters of credit with a financial institution for a total of $3.8 million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional one-year periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated (see Note 9). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;From time to time, the Company is involved in various legal proceedings and other matters arising in the normal course of its business. The resolution of any claim or litigation is subject to inherent uncertainty and could have a material adverse effect on the Company&#x2019;s financial condition, cash flows or results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Prospect Medical Systems&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On or about March 23, 2018, and April 3, 2018, a Demand for Arbitration and an Amended Demand for Arbitration were filed by Prospect Medical Group, Inc. and Prospect Medical Systems, Inc. (collectively, &#x201c;Prospect&#x201d;) against MMG, ApolloMed and AMM with Judicial Arbitration Mediation Services in California, arising out of MMG&#x2019;s purported business plans, seeking damages in excess of $5.0 million, and alleging breach of contract, violation of unfair competition laws, and tortious interference with Prospect&#x2019;s current and future economic relationships with its health plans and their members. By stipulation and order dated April 28, 2020, ApolloMed and AMM were dismissed without prejudice from the arbitration for lack of jurisdiction on the basis that neither of them were a party to any arbitration agreement with Prospect, subject, however, to Prospect reserving its rights against ApolloMed and AMM and tolling of applicable statute of limitation. MMG disputes the allegations and intends to vigorously defend against this matter. The resolution of this matter and any potential range of loss in excess of any current accrual cannot be reasonably determined or estimated at this time primarily because the matter has not been fully arbitrated and presents unique regulatory and contractual interpretation issues. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Liability Insurance&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company believes that its insurance coverage is appropriate based upon the Company&#x2019;s claims experience and the nature and risks of the Company&#x2019;s business. In addition to the known incidents that have resulted in the assertion of claims, the Company cannot be certain that its insurance coverage will be adequate to cover liabilities arising out of claims asserted against the Company, the Company&#x2019;s affiliated professional organizations or the Company&#x2019;s affiliated hospitalists in the future where the outcomes of such claims are unfavorable. The Company believes that the ultimate resolution of all pending claims, including liabilities in excess of the Company&#x2019;s insurance coverage, will not have a material adverse effect on the Company&#x2019;s financial position, results of operations or cash flows; however, there can be no assurance that future claims will not have such &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;a material adverse effect on the Company&#x2019;s business. Contracted physicians are required to obtain their own insurance coverage.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Although the Company currently maintains liability insurance policies on a claims-made basis, which are intended to cover malpractice liability and certain other claims, the coverage must be renewed annually, and may&#160;not continue to be available to the Company in future years at acceptable costs, and on favorable terms.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <ameh:PercentageOfFinancialGuaranteeBenchmarkAmount
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84OC9mcmFnOmY1NTNmMDg5OWEzYjRlMzBiZDNlNDNjZGZjNjhiOGU3L3RleHRyZWdpb246ZjU1M2YwODk5YTNiNGUzMGJkM2U0M2NkZmM2OGI4ZTdfMTg3OA_ebef6d8d-46f6-41da-8462-7b3e11b796bb"
      unitRef="number">0.02</ameh:PercentageOfFinancialGuaranteeBenchmarkAmount>
    <us-gaap:LineOfCredit
      contextRef="i2abd2d27dacd4cf191ac018ca9039a4a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84OC9mcmFnOmY1NTNmMDg5OWEzYjRlMzBiZDNlNDNjZGZjNjhiOGU3L3RleHRyZWdpb246ZjU1M2YwODk5YTNiNGUzMGJkM2U0M2NkZmM2OGI4ZTdfMjA0MA_390009f1-c4ea-4e79-8ee1-7603855725b4"
      unitRef="usd">8200000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="ib5bc5df3e2c84bd598e901cd27c8df93_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84OC9mcmFnOmY1NTNmMDg5OWEzYjRlMzBiZDNlNDNjZGZjNjhiOGU3L3RleHRyZWdpb246ZjU1M2YwODk5YTNiNGUzMGJkM2U0M2NkZmM2OGI4ZTdfMjA0Nw_3c172ae6-2d1e-4b78-ad17-363eb42d9228"
      unitRef="usd">6600000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="i43ace250a7394cfe9446cf2a610e1531_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84OC9mcmFnOmY1NTNmMDg5OWEzYjRlMzBiZDNlNDNjZGZjNjhiOGU3L3RleHRyZWdpb246ZjU1M2YwODk5YTNiNGUzMGJkM2U0M2NkZmM2OGI4ZTdfMjIwMg_f7820e4b-2003-4c94-b9ac-dd2f315c0089"
      unitRef="usd">300000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityExpirationPeriod
      contextRef="iaebe0c39b9204bfbbf9445aa9abc70d5_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84OC9mcmFnOmY1NTNmMDg5OWEzYjRlMzBiZDNlNDNjZGZjNjhiOGU3L3RleHRyZWdpb246ZjU1M2YwODk5YTNiNGUzMGJkM2U0M2NkZmM2OGI4ZTdfMTA5OTUxMTYyODM4MjA_d023bb69-cd4e-4422-aba4-59d6ea4f535b">P1Y</us-gaap:LineOfCreditFacilityExpirationPeriod>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities
      contextRef="id6e276121e9b45228da8ba0bab8f06ba_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84OC9mcmFnOmY1NTNmMDg5OWEzYjRlMzBiZDNlNDNjZGZjNjhiOGU3L3RleHRyZWdpb246ZjU1M2YwODk5YTNiNGUzMGJkM2U0M2NkZmM2OGI4ZTdfMjYyMw_4074acc3-ffba-4e65-8b7e-e5a813b30dad"
      unitRef="usd">3800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities>
    <us-gaap:LineOfCreditFacilityExpirationPeriod
      contextRef="ic5904f2bef064b47980c2947e43ad5d1_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84OC9mcmFnOmY1NTNmMDg5OWEzYjRlMzBiZDNlNDNjZGZjNjhiOGU3L3RleHRyZWdpb246ZjU1M2YwODk5YTNiNGUzMGJkM2U0M2NkZmM2OGI4ZTdfMTA5OTUxMTYzMzgxOA_c634ffba-5773-4dfd-af40-8d5d2d682fa4">P1Y</us-gaap:LineOfCreditFacilityExpirationPeriod>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="ia04e3870deaf4cb7ae407dafc0ffd53d_D20180323-20180403"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV84OC9mcmFnOmY1NTNmMDg5OWEzYjRlMzBiZDNlNDNjZGZjNjhiOGU3L3RleHRyZWdpb246ZjU1M2YwODk5YTNiNGUzMGJkM2U0M2NkZmM2OGI4ZTdfMzY3Mw_60682176-303a-42b6-9014-53ceff1fd6bc"
      unitRef="usd">5000000.0</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMTA5OTUxMTYzMjY4OA_b9810fd9-375e-4379-92a5-aa1a5190cbe8">Related-Party Transactions&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On November 16, 2015, UCAP entered into a subordinated note receivable agreement with UCI, a 48.9% owned equity method investee (see Note 5), in the amount of $5.0 million. On June 28, 2018 and November 28, 2018, UCAP entered into two additional subordinated note receivable agreements with UCI in the amount of $2.5 million and $5.0 million, respectively. On April 30, 2020, the outstanding balance was fully repaid as part of UCAP's disposition of its 48.9% ownership interest in UCI to Bright (see Note 6).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During the three and six months ended June&#160;30, 2020 and 2019, NMM earned approximately $4.2&#160;million and $5.2 million, respectively, and $8.4&#160;million, respectively, in management fees from LMA, which is accounted for under the equity method based on 25% equity ownership interest held by APC in LMA&#x2019;s IPA line of business (see Note 5).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During the three and six months ended June&#160;30, 2020 and 2019, APC paid approximately $0.4&#160;million and $0.6 million, respectively, and $1.0 million and $1.4 million, respectively, to PMIOC for provider services, which is accounted for under the equity method based on 40% equity ownership interest held by APC (see Note 5).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During the three and six months ended June&#160;30, 2020 and 2019, APC paid approximately $0.9&#160;million and $1.8 million, respectively, and $2.6 million and $3.8 million, respectively, to DMG for provider services, which is accounted for under the equity method based on 40% equity ownership interest held by APC (see Note 5).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During the three and six months ended June&#160;30, 2020 and 2019, APC paid approximately $0.1&#160;million, respectively, and $0.1&#160;million, respectively, to Advanced Diagnostic Surgery Center for services as a provider. Advanced Diagnostic Surgery Center shares common ownership with certain board members of APC.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During the three months ended June&#160;30, 2020 and 2019, APC paid an aggregate of approximately $9.0&#160;million and $7.1 million, respectively,  which include approximately $3.0&#160;million and $1.9 million, respectively, to shareholders who are also officers of APC. During the six months ended June&#160;30, 2020 and 2019, APC paid an aggregate of approximately of $16.3 million and $16.4 million, respectively, to shareholders of APC for provider services, which include approximately $4.8 million and $5.1 million, respectively, to shareholders who are also officers of APC.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During the three and six months ended June&#160;30, 2020 and 2019, NMM paid approximately $0.3 million, respectively and $0.5 million, respectively, to Medical Property Partners (&#x201c;MPP&#x201d;) for an office lease. MPP shares common ownership with certain board members of NMM.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During the three and six months ended June&#160;30, 2020, NMM paid approximately $0.4&#160;million and $0.7 million, respectively, to One MSO, Inc. ("One MSO") for an office lease. One MSO is indirectly 50% owned by Drs. Sim and Lam.  As of June 30, 2020, the Company had $10.6&#160;million of ROU assets and lease liabilities, respectively, related to its office lease with One MSO to be amortized over the remaining life of the lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During the three and six months ended June&#160;30, 2020 and 2019, the Company paid approximately $0.1&#160;million, respectively, and $0.2 million, respectively, to Critical Quality Management Corporation (&#x201c;CQMC&#x201d;) for an office lease. CQMC shares common ownership with certain board members of APC.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During the three and six months ended June&#160;30, 2020 and 2019, SCHC paid approximately $0.1&#160;million, respectively, and $0.2 million, respectively, to Numen, LLC (&#x201c;Numen&#x201d;) for an office lease. Numen is owned by a shareholder of APC. As of June 30, 2020, the Company had $1.4&#160;million of ROU assets and lease liabilities, respectively, related to its office lease with One MSO to be amortized over the remaining life of the lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has agreements with HSMSO, Aurion Corporation (&#x201c;Aurion&#x201d;), and AHMC Healthcare (&#x201c;AHMC&#x201d;) for services provided to the Company. One of the Company&#x2019;s board members is an officer of AHMC, HSMSO and Aurion. Aurion is also partially owned by one of the Company&#x2019;s board members. The following table sets forth fees incurred and income earned related to AHMC, HSMSO and Aurion (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:40.606%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.323%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.323%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.909%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.643%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;AHMC &#x2013; Risk pool, capitation, claims payment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;HSMSO &#x2013; Management fees, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(189)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(265)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(321)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(915)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Aurion &#x2013; Management fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(128)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(200)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Net total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company and AHMC have a risk sharing agreement with certain AHMC hospitals to share the surplus and deficits of each of the hospital pools. During the three and six months ended June&#160;30, 2020 and 2019, the Company has recognized risk pool revenue under this agreement of $10.2 million and $10.2 million, respectively, and $21.0 million and $25.0 million, respectively, for which $53.7 million and $40.4 million remain outstanding as of June&#160;30, 2020 and December&#160;31, 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During the three and six months ended June&#160;30, 2020 and 2019, NMM paid approximately&#160;$0 and $0.1 million, respectively, and $27,000&#160;and $0.1 million, respectively, to ApolloMed board member, Matthew Mazdyasni, for consulting services. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In addition, affiliates wholly owned by the Company&#x2019;s officers, including the Company's Co-CEOs, Dr. Sim and Dr. Lam, are reported in the accompanying consolidated statements of income on a consolidated basis, together with the Company&#x2019;s subsidiaries, and therefore, the Company does not separately disclose transactions between such affiliates and the Company&#x2019;s subsidiaries as related-party transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For equity method investments, loans receivable and line of credits from related parties, see Notes 5, 6 and 9, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i41ded2bb0c6348508704a83b2f25e6bc_I20151116"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMTI5_b0ab0af8-c269-4c56-a6ec-e868d8e4dd30"
      unitRef="number">0.489</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="i47e9a1771bc24da387426527e858cf9b_I20151116"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMTky_5a5480ff-a765-4b14-9763-e4f2040a4bf4"
      unitRef="usd">5000000.0</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <ameh:AccountsAndOtherReceivablesNumberOfAdditionalAgreements
      contextRef="iac4018695bd347a1a544a3f52b293cce_I20181128"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMjU0_63d6f967-61ee-462f-9055-7663f7f19852"
      unitRef="agreement">2</ameh:AccountsAndOtherReceivablesNumberOfAdditionalAgreements>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="i122ebc0907a746cd87fa56f04f446654_I20180628"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMzM0_89a7661c-b050-4896-b5e9-ae50fb2d5923"
      unitRef="usd">2500000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="iac4018695bd347a1a544a3f52b293cce_I20181128"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMzQx_ef2eb74e-9812-457b-af43-c1efda167f48"
      unitRef="usd">5000000.0</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i59aea64b29bd441fbc9a872ccf8d6901_I20200430"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfNDk0NzgwMjMyOTQ3Mw_8fa61189-1e93-4051-b62c-3f4f2b274523"
      unitRef="number">0.489</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:RevenueFromRelatedParties
      contextRef="ia70ec1e9fb224dbcab815eb4726d1011_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfNDQy_66bc4a2a-76ae-4dc3-a87d-3c38269451a6"
      unitRef="usd">4200000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="i55654d78599d405eb7c57be43551a331_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfNDQ5_60312b30-f230-4426-9ed2-7dc1e90f1d69"
      unitRef="usd">5200000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="ic5c167aa7b744e4890c04342962e5ae7_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfNDcx_f76fb01f-333b-40f4-8390-54657642b02a"
      unitRef="usd">8400000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i72f269c8a584404ba65db62cbf5e0711_I20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfNTgx_0d47f285-1645-4746-8184-8329fd2147a9"
      unitRef="number">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i2586f7c4e99c40dabdf57469f68203ca_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfNTgx_8a9e39b4-625f-44f1-b5f9-3deb8a4161b5"
      unitRef="number">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i08b5e965334b4ac8b0d2c0c36dd50b77_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfNzM0_221c52a5-6d9b-48d0-9df5-fa5a83fdfc85"
      unitRef="usd">400000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i6d443f60c53b4d9dbf390091cef3b913_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfNzQx_4a44aaf3-dbcf-4cb7-942b-b63544f62029"
      unitRef="usd">600000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="id80519ef0ba24fdcafbe65246db80663_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfNzYz_7e8f0ff6-5b15-4b02-bf1e-310aead51f34"
      unitRef="usd">1000000.0</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i6e8fcf6df1fc4d238058ca06726c6b36_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfNzcw_0379b340-8aa8-492b-9f50-fcf1f429527a"
      unitRef="usd">1400000</ameh:PaymentMadeToRelatedParty>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i6ac733b67d504bb484f4fb9e53a73cde_I20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfODc2_7302b3e9-95e4-4446-acbf-e33ca542d8ea"
      unitRef="number">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i8163cedd4bfb49cba3c59247fab38128_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfODc2_a9c243a5-6c1e-43c9-b638-d5968fed196b"
      unitRef="number">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i3b7917e163c9464c858059b5c869b1da_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfOTk5_7f7dcf23-b83b-49a1-b3ac-078691c71ae7"
      unitRef="usd">900000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i7267113c36ba4c0ca445f3971b88da9e_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMTAwNg_541463a2-78d0-40cb-a432-9083a9ba0d62"
      unitRef="usd">1800000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="ide7ed8079ad649bd9de797dff9e87471_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMTAyOA_0ed5f6f1-9492-4f36-bdfe-ce86575358e9"
      unitRef="usd">2600000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i4bafd7f9c77a44129ecb7839f0bf7f38_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMTAzNQ_73a355ba-b1fa-4b06-8658-72f1de08177b"
      unitRef="usd">3800000</ameh:PaymentMadeToRelatedParty>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i0138e45151034c838711c008d2c84fde_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMTEzOQ_b80cc574-ce96-41f4-af75-bcd994612933"
      unitRef="number">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ibd86a14da8ce4c19b459bfe1b8ee8770_I20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMTEzOQ_be078422-2ea3-48ab-8cf7-bbc3b0caa558"
      unitRef="number">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i3921017da3f648c8bc7eb46abb24b98e_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMTI2Mg_3368e79a-2a9a-428c-8fce-0254e209477f"
      unitRef="usd">100000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i0ce5207c08154b16a3abfc694d36072c_D20190401-20190630"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMTI5Mg_005b682a-64f1-4a17-a628-e953e4e0f3a3"
      unitRef="usd">100000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i74b45c805f954374b47abc23fa83e224_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfNjA0NzMxMzk1ODM1OA_215b2d41-66a7-46e6-8d26-64ec2520fa21"
      unitRef="usd">9000000.0</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i26a7e7336a074ec58f3aadf344b86686_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfNjA0NzMxMzk1ODM2NQ_66799aef-cb07-467a-a91f-0ba108eac6b7"
      unitRef="usd">7100000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i23919fb2bb874604b0836a44a501d87e_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfNjA0NzMxMzk1ODQxMg_3308eefb-015b-4a85-ba76-8bcbc5179c53"
      unitRef="usd">3000000.0</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i6966114f283543be9a6c6ecfb91dcb1a_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfNjA0NzMxMzk1ODQxOQ_06df191e-7493-4ad0-9156-46c072a64573"
      unitRef="usd">1900000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i558c42e47d0740c28d1824777489c673_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMTU5MA_0c6e3a59-f702-408f-a130-0aec8a5f1b38"
      unitRef="usd">16300000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i0238892dfcac44a1ab11666f4229eff6_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMTU5Nw_ea916c72-f48c-4eeb-b490-70ed46db7d16"
      unitRef="usd">16400000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i73ff4025db084040a797fa1c7d3e1949_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMTcxOA_64434bda-7972-48dd-ae97-968f3a82d03d"
      unitRef="usd">4800000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="ib304e370b0554caf951b8a9f9f09d259_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMTcyNQ_9895c0cb-1930-4e58-91bb-89bd9c781854"
      unitRef="usd">5100000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i11e982a75af145058c37f804c38acd6b_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfNTQ5NzU1ODE0NDA1Nw_41c15b3b-04ab-4ca9-8ea9-2b26d9bef8b8"
      unitRef="usd">300000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i974cbc9f20e14ae6bf9611c0590bba01_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfNTQ5NzU1ODE0NDA1Nw_f028d819-3b6c-451c-b47f-a8c0e9042888"
      unitRef="usd">300000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i232d93f7f5aa4f659c5d32bb1ce43cb7_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfNTQ5NzU1ODE0NDA4Mw_351e9034-14c5-495c-a685-948f3827bb15"
      unitRef="usd">500000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i4d7d20d05cc44774b777b10316295823_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfNTQ5NzU1ODE0NDA4Mw_e8f47d9d-1659-43cb-bdc0-9e4bbe4a7492"
      unitRef="usd">500000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i0a9d069f26ee4fcab93f166f59b290ee_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMjA2NA_67d04cdb-67c1-44a7-b6fd-5f24ab666dd8"
      unitRef="usd">400000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i6349dc89b0824f79a96623fb0a3f9237_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMjA3MQ_3b772a45-54fa-47bb-80a0-174e8ba15e1e"
      unitRef="usd">700000</ameh:PaymentMadeToRelatedParty>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i725b298255bc442d989d2da38e506475_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMTA5OTUxMTYzMjY4NA_e0d56e04-8ab8-4148-b1e5-1220d624485c"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:OperatingLeaseLiability
      contextRef="ifa7e8193abcb43cabefbe6e0890b995d_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfNTQ5NzU1ODE0NDE2Mg_59ab0d77-357d-4880-8713-4b3a1977a8f4"
      unitRef="usd">10600000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ifa7e8193abcb43cabefbe6e0890b995d_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfNTQ5NzU1ODE0NDE2Mg_7b0a1c36-878c-4fac-8b12-004f0736a811"
      unitRef="usd">10600000</us-gaap:OperatingLeaseRightOfUseAsset>
    <ameh:PaymentMadeToRelatedParty
      contextRef="ia52b05b7d3c744de85af06e314bf01e0_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMjQ2OA_2bb5c4af-2e38-4c64-9fb1-ace03062dc64"
      unitRef="usd">100000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="ie772acedf7f24e9c9b7eba3a1c2c4b74_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMjQ5OQ_c2bda6fd-8fed-4609-b2d9-026e406aff0d"
      unitRef="usd">200000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="ia8b1a37d00a1473aa256f482831880c0_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMjczMA_1b9ca716-f05e-4566-af97-027a2c5d63d1"
      unitRef="usd">100000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i40cef4f9cb574f67ae5763a10bf872ae_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMjczMA_af77be0f-6eb0-4088-8a3c-b72efbf6fbb6"
      unitRef="usd">100000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="icd17dbf950ae420ba6642ac1f2e76be4_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMjc1OQ_6c76d965-a2e8-49e7-877f-304666965118"
      unitRef="usd">200000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i3889cb5090e84ede9aeaa5cb4970cb04_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMjc1OQ_c14cc9c1-86f6-4c2f-870f-f9b462408679"
      unitRef="usd">200000</ameh:PaymentMadeToRelatedParty>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i7badae2658444d349982f8266469914b_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfNTQ5NzU1ODE0NDE1OQ_689f803d-1f30-4d36-96c6-b76ff046db18"
      unitRef="usd">1400000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="i7badae2658444d349982f8266469914b_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfNTQ5NzU1ODE0NDE1OQ_eec35e87-5bb9-4fa3-9c4f-d8ed177d4ff4"
      unitRef="usd">1400000</us-gaap:OperatingLeaseLiability>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfNDMwOQ_787b2f99-1f7a-4eaf-9991-0957af01f77c">The following table sets forth fees incurred and income earned related to AHMC, HSMSO and Aurion (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:40.606%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.323%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.323%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.909%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.643%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;AHMC &#x2013; Risk pool, capitation, claims payment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;HSMSO &#x2013; Management fees, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(189)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(265)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(321)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(915)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Aurion &#x2013; Management fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(128)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(200)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Net total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet
      contextRef="i9b1e96ab04c2463f8f4b975abf5cd0e1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RhYmxlOjQyYWI5ZmM5ZTI1NjQ4MjBiM2I2Zjg1YjM0MDA5MTk5L3RhYmxlcmFuZ2U6NDJhYjlmYzllMjU2NDgyMGIzYjZmODViMzQwMDkxOTlfMi0xLTEtMS0w_15d567fb-46e9-40ec-9e68-4d746075df2a"
      unitRef="usd">6057000</ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet>
    <ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet
      contextRef="i8624e665c0b14f12bb96c8f05d6efefc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RhYmxlOjQyYWI5ZmM5ZTI1NjQ4MjBiM2I2Zjg1YjM0MDA5MTk5L3RhYmxlcmFuZ2U6NDJhYjlmYzllMjU2NDgyMGIzYjZmODViMzQwMDkxOTlfMi0zLTEtMS0w_bfc10901-5aa5-4c6d-9f6f-4546e2a400f1"
      unitRef="usd">16350000</ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet>
    <ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet
      contextRef="i345a15f206fb4db5b7f79fbbfcd4823d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RhYmxlOjQyYWI5ZmM5ZTI1NjQ4MjBiM2I2Zjg1YjM0MDA5MTk5L3RhYmxlcmFuZ2U6NDJhYjlmYzllMjU2NDgyMGIzYjZmODViMzQwMDkxOTlfMi01LTEtMS0w_a073c263-4702-4061-b834-05d72dc5a02e"
      unitRef="usd">18056000</ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet>
    <ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet
      contextRef="i297705914c5f4af994b21ae2e9e0dda8_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RhYmxlOjQyYWI5ZmM5ZTI1NjQ4MjBiM2I2Zjg1YjM0MDA5MTk5L3RhYmxlcmFuZ2U6NDJhYjlmYzllMjU2NDgyMGIzYjZmODViMzQwMDkxOTlfMi03LTEtMS0w_07250312-5b2c-49d9-90eb-2d484ae69d73"
      unitRef="usd">27950000</ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet>
    <us-gaap:ManagementFeeExpense
      contextRef="ia5bc423a58e44f17b75caa9dcd78c5d9_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RhYmxlOjQyYWI5ZmM5ZTI1NjQ4MjBiM2I2Zjg1YjM0MDA5MTk5L3RhYmxlcmFuZ2U6NDJhYjlmYzllMjU2NDgyMGIzYjZmODViMzQwMDkxOTlfMy0xLTEtMS0w_0bcdb4a6-110f-434e-a052-62a5895390ad"
      unitRef="usd">189000</us-gaap:ManagementFeeExpense>
    <us-gaap:ManagementFeeExpense
      contextRef="ib978cd0ae3f8463592332de24798e91f_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RhYmxlOjQyYWI5ZmM5ZTI1NjQ4MjBiM2I2Zjg1YjM0MDA5MTk5L3RhYmxlcmFuZ2U6NDJhYjlmYzllMjU2NDgyMGIzYjZmODViMzQwMDkxOTlfMy0zLTEtMS0w_97e2c9f2-bb5c-4408-9715-d92a2ae57ce9"
      unitRef="usd">265000</us-gaap:ManagementFeeExpense>
    <us-gaap:ManagementFeeExpense
      contextRef="i3e3dd126351d40269ef3b0cff2e2cc12_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RhYmxlOjQyYWI5ZmM5ZTI1NjQ4MjBiM2I2Zjg1YjM0MDA5MTk5L3RhYmxlcmFuZ2U6NDJhYjlmYzllMjU2NDgyMGIzYjZmODViMzQwMDkxOTlfMy01LTEtMS0w_2e1bdba0-b8a5-49cd-a9f3-ab8e9ffa3874"
      unitRef="usd">321000</us-gaap:ManagementFeeExpense>
    <us-gaap:ManagementFeeExpense
      contextRef="i187e0af77f734ccebbbd27aabf183e43_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RhYmxlOjQyYWI5ZmM5ZTI1NjQ4MjBiM2I2Zjg1YjM0MDA5MTk5L3RhYmxlcmFuZ2U6NDJhYjlmYzllMjU2NDgyMGIzYjZmODViMzQwMDkxOTlfMy03LTEtMS0w_cb7b07e3-6a06-4eeb-a2b6-71528f600b6b"
      unitRef="usd">915000</us-gaap:ManagementFeeExpense>
    <us-gaap:ManagementFeeExpense
      contextRef="i2c2ea55436e04e569ef824cc8bf38f62_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RhYmxlOjQyYWI5ZmM5ZTI1NjQ4MjBiM2I2Zjg1YjM0MDA5MTk5L3RhYmxlcmFuZ2U6NDJhYjlmYzllMjU2NDgyMGIzYjZmODViMzQwMDkxOTlfNC0xLTEtMS0w_11d7a59b-0254-4e44-86a5-d629d1ce37ce"
      unitRef="usd">53000</us-gaap:ManagementFeeExpense>
    <us-gaap:ManagementFeeExpense
      contextRef="i3c92e2a8835d47c094fdb6ae01f4010e_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RhYmxlOjQyYWI5ZmM5ZTI1NjQ4MjBiM2I2Zjg1YjM0MDA5MTk5L3RhYmxlcmFuZ2U6NDJhYjlmYzllMjU2NDgyMGIzYjZmODViMzQwMDkxOTlfNC0zLTEtMS0w_9aa4a101-3f83-45b1-8c6a-b6ea0f2c33d4"
      unitRef="usd">100000</us-gaap:ManagementFeeExpense>
    <us-gaap:ManagementFeeExpense
      contextRef="ied3ee0af55294b1c90c71dc22ea57f02_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RhYmxlOjQyYWI5ZmM5ZTI1NjQ4MjBiM2I2Zjg1YjM0MDA5MTk5L3RhYmxlcmFuZ2U6NDJhYjlmYzllMjU2NDgyMGIzYjZmODViMzQwMDkxOTlfNC01LTEtMS0w_b195c6ec-cf32-4221-97a8-3a325e102d89"
      unitRef="usd">128000</us-gaap:ManagementFeeExpense>
    <us-gaap:ManagementFeeExpense
      contextRef="i07ec194477214462b08c359051ff95f4_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RhYmxlOjQyYWI5ZmM5ZTI1NjQ4MjBiM2I2Zjg1YjM0MDA5MTk5L3RhYmxlcmFuZ2U6NDJhYjlmYzllMjU2NDgyMGIzYjZmODViMzQwMDkxOTlfNC03LTEtMS0w_9815cdcc-1566-4810-a6a4-859419c1d57f"
      unitRef="usd">200000</us-gaap:ManagementFeeExpense>
    <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
      contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RhYmxlOjQyYWI5ZmM5ZTI1NjQ4MjBiM2I2Zjg1YjM0MDA5MTk5L3RhYmxlcmFuZ2U6NDJhYjlmYzllMjU2NDgyMGIzYjZmODViMzQwMDkxOTlfNi0xLTEtMS0w_6a8a1ae4-c5f5-4f4c-b6cb-96fa2ddff5e4"
      unitRef="usd">5815000</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
      contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RhYmxlOjQyYWI5ZmM5ZTI1NjQ4MjBiM2I2Zjg1YjM0MDA5MTk5L3RhYmxlcmFuZ2U6NDJhYjlmYzllMjU2NDgyMGIzYjZmODViMzQwMDkxOTlfNi0zLTEtMS0w_c0689eec-2d5d-419c-a875-8e54da3743e7"
      unitRef="usd">15985000</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RhYmxlOjQyYWI5ZmM5ZTI1NjQ4MjBiM2I2Zjg1YjM0MDA5MTk5L3RhYmxlcmFuZ2U6NDJhYjlmYzllMjU2NDgyMGIzYjZmODViMzQwMDkxOTlfNi01LTEtMS0w_6adb7b6b-54a6-41c3-93af-13491c45add3"
      unitRef="usd">17607000</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RhYmxlOjQyYWI5ZmM5ZTI1NjQ4MjBiM2I2Zjg1YjM0MDA5MTk5L3RhYmxlcmFuZ2U6NDJhYjlmYzllMjU2NDgyMGIzYjZmODViMzQwMDkxOTlfNi03LTEtMS0w_b3533367-1b80-4206-94c4-2dcb3574f39a"
      unitRef="usd">26835000</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
      contextRef="i9b1e96ab04c2463f8f4b975abf5cd0e1_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMzUyNg_e48e9d91-c66c-4dd4-8916-a9abc2419a86"
      unitRef="usd">10200000</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
      contextRef="i345a15f206fb4db5b7f79fbbfcd4823d_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMzUzMw_0d7b5ec7-c583-47da-b408-c607870b0e29"
      unitRef="usd">10200000</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
      contextRef="i8624e665c0b14f12bb96c8f05d6efefc_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMzU1NQ_5652df1c-d63f-45f0-b3c6-6fc0a3e7f1e4"
      unitRef="usd">21000000.0</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
      contextRef="i297705914c5f4af994b21ae2e9e0dda8_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMzU2Mg_89d47592-e9ad-46a2-9a98-09fb3c401b8b"
      unitRef="usd">25000000.0</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
    <us-gaap:DeferredCreditsAndOtherLiabilities
      contextRef="i11c2bb41ca6348fb8713e36fda662dfe_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMzU5MA_516b8209-bcd4-4855-95d9-aed8d0b60d1a"
      unitRef="usd">53700000</us-gaap:DeferredCreditsAndOtherLiabilities>
    <us-gaap:DeferredCreditsAndOtherLiabilities
      contextRef="if379bd0a6704484a92b75bcaee392d54_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMzU5Nw_1c227ad6-fe3b-4e2d-903e-a5919ff2fe7b"
      unitRef="usd">40400000</us-gaap:DeferredCreditsAndOtherLiabilities>
    <ameh:PaymentConsultingFees
      contextRef="i83ceffd8ac474d21a39c47ca896605c6_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMjE5OTAyMzI2MDg4Mw_8b0e8e72-373c-4dcb-a9ab-c41e162d4efb"
      unitRef="usd">0</ameh:PaymentConsultingFees>
    <ameh:PaymentConsultingFees
      contextRef="i94a7e25c8cae461cae1b75c5fa5c6e2b_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMjE5OTAyMzI2MDg5MA_ee7b1779-6cdf-422d-a0eb-e81a4e5a09c5"
      unitRef="usd">100000</ameh:PaymentConsultingFees>
    <ameh:PaymentConsultingFees
      contextRef="ica6dee6dfddc4d1daed02284b5602d0e_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMzcyMA_0eb60ad7-420d-4ad2-970d-6ba07cd1052a"
      unitRef="usd">27000</ameh:PaymentConsultingFees>
    <ameh:PaymentConsultingFees
      contextRef="i08491d90fbdd471d983861bcd2288ac8_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85MS9mcmFnOjllNmNkN2QyNjVkZTRlZWU4YzBlMTIzNmI1YzA3NWZmL3RleHRyZWdpb246OWU2Y2Q3ZDI2NWRlNGVlZThjMGUxMjM2YjVjMDc1ZmZfMjE5OTAyMzI2MDkxNg_bf6f4e54-0dbc-4c05-9e81-f21140ad90b8"
      unitRef="usd">100000</ameh:PaymentConsultingFees>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV85Ny9mcmFnOmEwMjA5ZTcxYTJmZjQyMzA5MGU2ZGJkNjdkMmJkOGJjL3RleHRyZWdpb246YTAyMDllNzFhMmZmNDIzMDkwZTZkYmQ2N2QyYmQ4YmNfMjc2MA_b8385088-7520-47a3-9ecb-b613b496c06c">Income Taxes&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company uses the liability method of accounting for income taxes as set forth in ASC 740. Under the liability method, deferred taxes are determined based on differences between the financial statement and tax bases of assets and liabilities using enacted tax rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On an interim basis, the Company estimates what its anticipated annual effective tax rate will be and records a quarterly income tax provision (benefit) in accordance with the estimated annual rate, plus the tax effect of certain discrete items that arise during the quarter. As the fiscal year progresses, the Company refines its estimates based on actual events and financial results during the quarter. This process can result in significant changes to the Company&#x2019;s estimated effective tax rate. When this occurs, the income tax provision (benefit) is adjusted during the quarter in which the estimates are refined so that the year-to-date provision reflects the estimated annual effective tax rate. These changes, along with adjustments to the Company&#x2019;s deferred taxes and related valuation allowance, may create fluctuations in the overall effective tax rate from quarter to quarter.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of June&#160;30, 2020, due to the overall cumulative losses incurred in recent years, the Company maintained a full valuation allowance against its deferred tax assets related to loss entities the Company cannot consolidate under the federal consolidation rules, as realization of these assets is uncertain.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s effective tax rate for the six months ended June&#160;30, 2020, differed from the U.S. federal statutory rate primarily due to state income taxes, income from flow through entities, nondeductible permanent items, and change in valuation allowance.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of June&#160;30, 2020, the Company does not have any unrecognized tax benefits related to various federal and state income tax matters. The Company will recognize accrued interest and penalties related to unrecognized tax benefits in income tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company is subject to U.S. federal income tax as well as income tax in California. The Company and its subsidiaries&#x2019; state and Federal income tax returns are open to audit under the statute of limitations for the years ended December 31, 2015 through December&#160;31, 2018, and for the years ended December 31, 2016 through December&#160;31, 2018, respectively. The Company does not anticipate material unrecognized tax benefits within the next 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On March 27, 2020, the Coronavirus Aid, Relief and Economic Security Act ("CARES Act") was signed into law. The CARES Act includes various income and payroll tax provisions that we are in the process of analyzing to determine the tax impacts. &lt;/span&gt;&lt;/div&gt;However, we do not expect the benefits of the CARES Act to impact the Company&#x2019;s annual estimated tax rate for the period June 30, 2020.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90ZXh0cmVnaW9uOmYwMTk0MGEzYTc5ZDQyZjA4OWM1MDA3YjRlNmE1ZDdlXzExMzQ_e13ff807-2dca-48ea-824c-f55e9fd07008">Earnings Per Share&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Basic earnings per share is calculated using the weighted average number of shares of the Company&#x2019;s common stock issued and outstanding during a certain period, and is calculated by dividing net income attributable to ApolloMed by the weighted average number of shares of the Company&#x2019;s common stock issued and outstanding during such period. Diluted earnings per share is calculated using the weighted average number of shares of common stock and potentially dilutive shares of common stock outstanding during the period, using the as-if converted method for secured convertible notes, preferred stock, and the treasury stock method for options and common stock warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of June&#160;30, 2020 and December&#160;31, 2019, APC held 17,307,214 and 17,290,317 shares of ApolloMed&#x2019;s common stock, respectively, which are treated as treasury shares for accounting purposes and not included in the number of shares of common stock outstanding used to calculate earnings per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Below is a summary of the earnings per share computations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.060%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.739%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Earnings per share &#x2013; basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Earnings per share &#x2013; diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Weighted average shares of common stock outstanding &#x2013; basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,071,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,540,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Weighted average shares of common stock outstanding &#x2013; diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37,285,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37,962,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:70.941%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.794%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.795%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Earnings per share &#x2013; basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Earnings per share &#x2013; diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Weighted average shares of common stock outstanding &#x2013; basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,040,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,518,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Weighted average shares of common stock outstanding &#x2013; diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37,296,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37,896,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Below is a summary of the shares included in the diluted earnings per share computations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.060%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.739%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Weighted average shares of common stock outstanding &#x2013; basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,071,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,540,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;10% shares held back pursuant to indemnification clause&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,519,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;169,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;363,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,041,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,539,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Weighted average shares of common stock outstanding &#x2013; diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37,285,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37,962,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.060%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.739%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Weighted average shares of common stock outstanding &#x2013; basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,040,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,518,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;10% shares held back pursuant to indemnification clause&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,519,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;173,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;368,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,076,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,490,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Weighted average shares of common stock outstanding &#x2013; diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37,296,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37,896,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <ameh:AntidilutiveSecuritiesExcludedFromEarningsComputationShares
      contextRef="i255d39881fdb459ba312544c3eb6589e_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90ZXh0cmVnaW9uOmYwMTk0MGEzYTc5ZDQyZjA4OWM1MDA3YjRlNmE1ZDdlXzc0NQ_79d5667c-a0d1-4f3c-a223-75bf139e2e8b"
      unitRef="shares">17307214</ameh:AntidilutiveSecuritiesExcludedFromEarningsComputationShares>
    <ameh:AntidilutiveSecuritiesExcludedFromEarningsComputationShares
      contextRef="i7e330acfd08c4813a18296547a2a33b7_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90ZXh0cmVnaW9uOmYwMTk0MGEzYTc5ZDQyZjA4OWM1MDA3YjRlNmE1ZDdlXzc1Mg_fb814010-6199-47e2-9f3e-ee463b8c0dbb"
      unitRef="shares">17290317</ameh:AntidilutiveSecuritiesExcludedFromEarningsComputationShares>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90ZXh0cmVnaW9uOmYwMTk0MGEzYTc5ZDQyZjA4OWM1MDA3YjRlNmE1ZDdlXzExNDM_44f57ca1-8665-4e45-8a96-1f9cc08b37c0">&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Below is a summary of the earnings per share computations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.060%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.739%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Earnings per share &#x2013; basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Earnings per share &#x2013; diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Weighted average shares of common stock outstanding &#x2013; basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,071,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,540,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Weighted average shares of common stock outstanding &#x2013; diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37,285,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37,962,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:70.941%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.794%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.795%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Earnings per share &#x2013; basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Earnings per share &#x2013; diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Weighted average shares of common stock outstanding &#x2013; basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,040,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,518,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Weighted average shares of common stock outstanding &#x2013; diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37,296,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37,896,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:EarningsPerShareBasic
      contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTo0MDgyNzkwZjQ5MjY0M2YzYTY3NjI0YWM4ODc4OTVhOS90YWJsZXJhbmdlOjQwODI3OTBmNDkyNjQzZjNhNjc2MjRhYzg4Nzg5NWE5XzEtMi0xLTEtMA_e7f01d97-07fa-4110-9178-70cc273505fd"
      unitRef="usdPerShare">0.20</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTo0MDgyNzkwZjQ5MjY0M2YzYTY3NjI0YWM4ODc4OTVhOS90YWJsZXJhbmdlOjQwODI3OTBmNDkyNjQzZjNhNjc2MjRhYzg4Nzg5NWE5XzEtNC0xLTEtMA_91f3706a-f9be-4c8a-b85b-ee8e32699ae4"
      unitRef="usdPerShare">0.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTo0MDgyNzkwZjQ5MjY0M2YzYTY3NjI0YWM4ODc4OTVhOS90YWJsZXJhbmdlOjQwODI3OTBmNDkyNjQzZjNhNjc2MjRhYzg4Nzg5NWE5XzItMi0xLTEtMA_2b829f91-357f-4faf-97a7-c273cbe84760"
      unitRef="usdPerShare">0.19</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTo0MDgyNzkwZjQ5MjY0M2YzYTY3NjI0YWM4ODc4OTVhOS90YWJsZXJhbmdlOjQwODI3OTBmNDkyNjQzZjNhNjc2MjRhYzg4Nzg5NWE5XzItNC0xLTEtMA_264f2e7d-bd0d-4ce3-9678-678ea77cad7a"
      unitRef="usdPerShare">0.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTo0MDgyNzkwZjQ5MjY0M2YzYTY3NjI0YWM4ODc4OTVhOS90YWJsZXJhbmdlOjQwODI3OTBmNDkyNjQzZjNhNjc2MjRhYzg4Nzg5NWE5XzMtMi0xLTEtMA_025495ef-c3e4-4301-a46f-5f7af3b46390"
      unitRef="shares">36071604</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTo0MDgyNzkwZjQ5MjY0M2YzYTY3NjI0YWM4ODc4OTVhOS90YWJsZXJhbmdlOjQwODI3OTBmNDkyNjQzZjNhNjc2MjRhYzg4Nzg5NWE5XzMtNC0xLTEtMA_b5b26335-1ff8-4512-82d2-28a96441d30d"
      unitRef="shares">34540059</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTo0MDgyNzkwZjQ5MjY0M2YzYTY3NjI0YWM4ODc4OTVhOS90YWJsZXJhbmdlOjQwODI3OTBmNDkyNjQzZjNhNjc2MjRhYzg4Nzg5NWE5XzQtMi0xLTEtMA_7db6ee84-8362-41cc-81f5-bf19f953cb16"
      unitRef="shares">37285585</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTo0MDgyNzkwZjQ5MjY0M2YzYTY3NjI0YWM4ODc4OTVhOS90YWJsZXJhbmdlOjQwODI3OTBmNDkyNjQzZjNhNjc2MjRhYzg4Nzg5NWE5XzQtNC0xLTEtMA_eec87c7b-8a23-475a-8355-698b1fd6d0b8"
      unitRef="shares">37962555</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTplNWYzNWE3YWNiNDY0Y2JkYWJiYjgyNzJlOTdiNzYyNi90YWJsZXJhbmdlOmU1ZjM1YTdhY2I0NjRjYmRhYmJiODI3MmU5N2I3NjI2XzEtMi0xLTEtMA_40ac7536-ff39-4a49-a39e-ffab8e05c019"
      unitRef="usdPerShare">0.31</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTplNWYzNWE3YWNiNDY0Y2JkYWJiYjgyNzJlOTdiNzYyNi90YWJsZXJhbmdlOmU1ZjM1YTdhY2I0NjRjYmRhYmJiODI3MmU5N2I3NjI2XzEtNC0xLTEtMA_a0a030f0-27d2-402a-848f-ccb4ad3b51de"
      unitRef="usdPerShare">0.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTplNWYzNWE3YWNiNDY0Y2JkYWJiYjgyNzJlOTdiNzYyNi90YWJsZXJhbmdlOmU1ZjM1YTdhY2I0NjRjYmRhYmJiODI3MmU5N2I3NjI2XzItMi0xLTEtMA_3d4e5615-e194-4c0c-9a82-6b9e74984d05"
      unitRef="usdPerShare">0.30</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTplNWYzNWE3YWNiNDY0Y2JkYWJiYjgyNzJlOTdiNzYyNi90YWJsZXJhbmdlOmU1ZjM1YTdhY2I0NjRjYmRhYmJiODI3MmU5N2I3NjI2XzItNC0xLTEtMA_e7cec0aa-a6c5-49e8-b519-4ee457f07d79"
      unitRef="usdPerShare">0.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTplNWYzNWE3YWNiNDY0Y2JkYWJiYjgyNzJlOTdiNzYyNi90YWJsZXJhbmdlOmU1ZjM1YTdhY2I0NjRjYmRhYmJiODI3MmU5N2I3NjI2XzMtMi0xLTEtMA_476fcac9-9303-48e5-86c4-c7628290a34a"
      unitRef="shares">36040936</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTplNWYzNWE3YWNiNDY0Y2JkYWJiYjgyNzJlOTdiNzYyNi90YWJsZXJhbmdlOmU1ZjM1YTdhY2I0NjRjYmRhYmJiODI3MmU5N2I3NjI2XzMtNC0xLTEtMA_4dfc4378-da45-4d11-8259-f388eeb4ef01"
      unitRef="shares">34518461</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTplNWYzNWE3YWNiNDY0Y2JkYWJiYjgyNzJlOTdiNzYyNi90YWJsZXJhbmdlOmU1ZjM1YTdhY2I0NjRjYmRhYmJiODI3MmU5N2I3NjI2XzQtMi0xLTEtMA_28fc127d-32f9-436c-8015-15de76ac6f15"
      unitRef="shares">37296913</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTplNWYzNWE3YWNiNDY0Y2JkYWJiYjgyNzJlOTdiNzYyNi90YWJsZXJhbmdlOmU1ZjM1YTdhY2I0NjRjYmRhYmJiODI3MmU5N2I3NjI2XzQtNC0xLTEtMA_823b259f-e36c-4a91-a650-09862e7c00c6"
      unitRef="shares">37896837</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90ZXh0cmVnaW9uOmYwMTk0MGEzYTc5ZDQyZjA4OWM1MDA3YjRlNmE1ZDdlXzEyNjQ0MzgzNzIwNTcx_ab0e329e-05be-466d-9ff0-413c269214e2">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Below is a summary of the shares included in the diluted earnings per share computations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.060%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.739%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Weighted average shares of common stock outstanding &#x2013; basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,071,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,540,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;10% shares held back pursuant to indemnification clause&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,519,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;169,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;363,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,041,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,539,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Weighted average shares of common stock outstanding &#x2013; diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37,285,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37,962,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.060%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.739%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Weighted average shares of common stock outstanding &#x2013; basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,040,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,518,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;10% shares held back pursuant to indemnification clause&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,519,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;173,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;368,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,076,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,490,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Weighted average shares of common stock outstanding &#x2013; diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37,296,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37,896,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTpmMWFmMDI2MzljNzM0OTIyYTYxZGRiZTQ3ZTM2ZDQ4Ni90YWJsZXJhbmdlOmYxYWYwMjYzOWM3MzQ5MjJhNjFkZGJlNDdlMzZkNDg2XzEtMi0xLTEtMA_146ef7b9-3cbc-49b4-bcff-b6b62e1f9ad1"
      unitRef="shares">36071604</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTpmMWFmMDI2MzljNzM0OTIyYTYxZGRiZTQ3ZTM2ZDQ4Ni90YWJsZXJhbmdlOmYxYWYwMjYzOWM3MzQ5MjJhNjFkZGJlNDdlMzZkNDg2XzEtNC0xLTEtMA_6d5df357-4416-41cc-8064-2a75028adec1"
      unitRef="shares">34540059</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <ameh:BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage
      contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTpmMWFmMDI2MzljNzM0OTIyYTYxZGRiZTQ3ZTM2ZDQ4Ni90YWJsZXJhbmdlOmYxYWYwMjYzOWM3MzQ5MjJhNjFkZGJlNDdlMzZkNDg2XzItMC0xLTEtMC90ZXh0cmVnaW9uOmY2NDQwNzZhZDA0NDQyMjc5MTg0ZDc2MzczYjBkMDA0XzY1OTcwNjk3NjY3MTk_0251292d-5e21-453f-b8a2-12857fdc5285"
      unitRef="number">0.10</ameh:BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage>
    <ameh:BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage
      contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTpmMWFmMDI2MzljNzM0OTIyYTYxZGRiZTQ3ZTM2ZDQ4Ni90YWJsZXJhbmdlOmYxYWYwMjYzOWM3MzQ5MjJhNjFkZGJlNDdlMzZkNDg2XzItMC0xLTEtMC90ZXh0cmVnaW9uOmY2NDQwNzZhZDA0NDQyMjc5MTg0ZDc2MzczYjBkMDA0XzY1OTcwNjk3NjY3MTk_11093073-f1f9-4f83-be56-ec936b8a714c"
      unitRef="number">0.10</ameh:BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ic6205a2691794f12816d94e2384216d4_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTpmMWFmMDI2MzljNzM0OTIyYTYxZGRiZTQ3ZTM2ZDQ4Ni90YWJsZXJhbmdlOmYxYWYwMjYzOWM3MzQ5MjJhNjFkZGJlNDdlMzZkNDg2XzItMi0xLTEtMA_2a6e206e-eed1-42c1-89f8-bf2d70af9c9c"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="id43602e4d3ec401c85cc9e362fcdbb4b_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTpmMWFmMDI2MzljNzM0OTIyYTYxZGRiZTQ3ZTM2ZDQ4Ni90YWJsZXJhbmdlOmYxYWYwMjYzOWM3MzQ5MjJhNjFkZGJlNDdlMzZkNDg2XzItNC0xLTEtMA_1ce7bc13-a107-44c6-9387-ab0f312f0c8a"
      unitRef="shares">1519805</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ie7d554f31b964866b8df4f6b60c0a919_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTpmMWFmMDI2MzljNzM0OTIyYTYxZGRiZTQ3ZTM2ZDQ4Ni90YWJsZXJhbmdlOmYxYWYwMjYzOWM3MzQ5MjJhNjFkZGJlNDdlMzZkNDg2XzMtMi0xLTEtMA_548517f0-2ccc-4344-9677-f00ffcd607d4"
      unitRef="shares">169402</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i450dc203ab3a40b6a28283cf284bd195_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTpmMWFmMDI2MzljNzM0OTIyYTYxZGRiZTQ3ZTM2ZDQ4Ni90YWJsZXJhbmdlOmYxYWYwMjYzOWM3MzQ5MjJhNjFkZGJlNDdlMzZkNDg2XzMtNC0xLTEtMA_ea0ba48f-1e6f-4680-b73d-463440b469af"
      unitRef="shares">363593</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i8f7252c42eff45858f156999763bf992_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTpmMWFmMDI2MzljNzM0OTIyYTYxZGRiZTQ3ZTM2ZDQ4Ni90YWJsZXJhbmdlOmYxYWYwMjYzOWM3MzQ5MjJhNjFkZGJlNDdlMzZkNDg2XzQtMi0xLTEtMA_dea9faea-2968-4651-b4e6-cba05d6edd9d"
      unitRef="shares">1041784</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ifced76c7228e456281eecd440fc4200c_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTpmMWFmMDI2MzljNzM0OTIyYTYxZGRiZTQ3ZTM2ZDQ4Ni90YWJsZXJhbmdlOmYxYWYwMjYzOWM3MzQ5MjJhNjFkZGJlNDdlMzZkNDg2XzQtNC0xLTEtMA_32b75090-2ba9-4ddf-ad56-303a86242add"
      unitRef="shares">1539098</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i02765d0185984e60929a5d510dd803fe_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTpmMWFmMDI2MzljNzM0OTIyYTYxZGRiZTQ3ZTM2ZDQ4Ni90YWJsZXJhbmdlOmYxYWYwMjYzOWM3MzQ5MjJhNjFkZGJlNDdlMzZkNDg2XzUtMi0xLTEtMA_d4234444-e358-4531-8082-9410f6266a5e"
      unitRef="shares">2795</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i1d2d3cf0b58a46d1835e2032498d600a_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTpmMWFmMDI2MzljNzM0OTIyYTYxZGRiZTQ3ZTM2ZDQ4Ni90YWJsZXJhbmdlOmYxYWYwMjYzOWM3MzQ5MjJhNjFkZGJlNDdlMzZkNDg2XzUtNC0xLTEtMA_d22dc237-c810-4b48-9ff8-052317276243"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTpmMWFmMDI2MzljNzM0OTIyYTYxZGRiZTQ3ZTM2ZDQ4Ni90YWJsZXJhbmdlOmYxYWYwMjYzOWM3MzQ5MjJhNjFkZGJlNDdlMzZkNDg2XzYtMi0xLTEtMA_cf6c176d-ceb8-4bce-9c55-b299a557d4d9"
      unitRef="shares">37285585</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTpmMWFmMDI2MzljNzM0OTIyYTYxZGRiZTQ3ZTM2ZDQ4Ni90YWJsZXJhbmdlOmYxYWYwMjYzOWM3MzQ5MjJhNjFkZGJlNDdlMzZkNDg2XzYtNC0xLTEtMA_89b821c3-f58d-4e26-b4ae-0209d80257a4"
      unitRef="shares">37962555</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTplMjNiNDkwYTAxNWU0MmRiOTViMDYyOTJlNTU5NGFiMi90YWJsZXJhbmdlOmUyM2I0OTBhMDE1ZTQyZGI5NWIwNjI5MmU1NTk0YWIyXzEtMi0xLTEtMA_a7c6031a-c573-4147-b141-3f9a65236890"
      unitRef="shares">36040936</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTplMjNiNDkwYTAxNWU0MmRiOTViMDYyOTJlNTU5NGFiMi90YWJsZXJhbmdlOmUyM2I0OTBhMDE1ZTQyZGI5NWIwNjI5MmU1NTk0YWIyXzEtNC0xLTEtMA_9c23d042-593d-4cf6-975d-b6fa164ecd1f"
      unitRef="shares">34518461</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <ameh:BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTplMjNiNDkwYTAxNWU0MmRiOTViMDYyOTJlNTU5NGFiMi90YWJsZXJhbmdlOmUyM2I0OTBhMDE1ZTQyZGI5NWIwNjI5MmU1NTk0YWIyXzItMC0xLTEtMjM0NS90ZXh0cmVnaW9uOjIxN2ZmZTdmMzY2YzQ5Njc5NDFhY2E4ZGM5NTY4ZjY2XzY1OTcwNjk3NjY3Mjc_378abe6f-27de-4d79-97d9-0e1e024a61d7"
      unitRef="number">0.10</ameh:BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage>
    <ameh:BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTplMjNiNDkwYTAxNWU0MmRiOTViMDYyOTJlNTU5NGFiMi90YWJsZXJhbmdlOmUyM2I0OTBhMDE1ZTQyZGI5NWIwNjI5MmU1NTk0YWIyXzItMC0xLTEtMjM0NS90ZXh0cmVnaW9uOjIxN2ZmZTdmMzY2YzQ5Njc5NDFhY2E4ZGM5NTY4ZjY2XzY1OTcwNjk3NjY3Mjc_551d3715-2d08-464c-b0ff-f77ab39c12fe"
      unitRef="number">0.10</ameh:BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i5ba5a4313e034d9c9d26fa5c9c002ef7_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTplMjNiNDkwYTAxNWU0MmRiOTViMDYyOTJlNTU5NGFiMi90YWJsZXJhbmdlOmUyM2I0OTBhMDE1ZTQyZGI5NWIwNjI5MmU1NTk0YWIyXzItMi0xLTEtMA_b92e1092-cc96-41b3-bea1-effea91b1294"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i1acd759fc07341a7815dd2541d1fa444_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTplMjNiNDkwYTAxNWU0MmRiOTViMDYyOTJlNTU5NGFiMi90YWJsZXJhbmdlOmUyM2I0OTBhMDE1ZTQyZGI5NWIwNjI5MmU1NTk0YWIyXzItNC0xLTEtMA_31b32752-c2df-4c97-a4ca-dc3ee584e713"
      unitRef="shares">1519805</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="if9d48ee182734c28b3a941a4ea33ad0a_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTplMjNiNDkwYTAxNWU0MmRiOTViMDYyOTJlNTU5NGFiMi90YWJsZXJhbmdlOmUyM2I0OTBhMDE1ZTQyZGI5NWIwNjI5MmU1NTk0YWIyXzMtMi0xLTEtMA_a3123ae6-74ef-4189-873e-28a871e479b0"
      unitRef="shares">173299</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ib7bd39987453433c8655b734992caa99_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTplMjNiNDkwYTAxNWU0MmRiOTViMDYyOTJlNTU5NGFiMi90YWJsZXJhbmdlOmUyM2I0OTBhMDE1ZTQyZGI5NWIwNjI5MmU1NTk0YWIyXzMtNC0xLTEtMA_b87135ec-aa7a-48df-aff7-362eb91fa1d8"
      unitRef="shares">368273</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i27599a16780e40908fb6bbc9191294f0_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTplMjNiNDkwYTAxNWU0MmRiOTViMDYyOTJlNTU5NGFiMi90YWJsZXJhbmdlOmUyM2I0OTBhMDE1ZTQyZGI5NWIwNjI5MmU1NTk0YWIyXzQtMi0xLTEtMA_8df6b833-22a3-40ec-866d-2007e80882e4"
      unitRef="shares">1076802</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i954924a949ec4f81b4ccce5827b40713_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTplMjNiNDkwYTAxNWU0MmRiOTViMDYyOTJlNTU5NGFiMi90YWJsZXJhbmdlOmUyM2I0OTBhMDE1ZTQyZGI5NWIwNjI5MmU1NTk0YWIyXzQtNC0xLTEtMA_9b9e3460-4815-4b11-b9ed-79479ea621d6"
      unitRef="shares">1490298</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ife480d762a994b8685aef3f1fd37b377_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTplMjNiNDkwYTAxNWU0MmRiOTViMDYyOTJlNTU5NGFiMi90YWJsZXJhbmdlOmUyM2I0OTBhMDE1ZTQyZGI5NWIwNjI5MmU1NTk0YWIyXzUtMi0xLTEtMA_0e2e540d-79a1-4249-a6fd-587216ee6568"
      unitRef="shares">5876</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i7a92fa7d1d5341c18bcd43745c8b8460_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTplMjNiNDkwYTAxNWU0MmRiOTViMDYyOTJlNTU5NGFiMi90YWJsZXJhbmdlOmUyM2I0OTBhMDE1ZTQyZGI5NWIwNjI5MmU1NTk0YWIyXzUtNC0xLTEtMA_845cd327-d13e-401c-96cb-0546100d50be"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTplMjNiNDkwYTAxNWU0MmRiOTViMDYyOTJlNTU5NGFiMi90YWJsZXJhbmdlOmUyM2I0OTBhMDE1ZTQyZGI5NWIwNjI5MmU1NTk0YWIyXzYtMi0xLTEtMA_80f3a933-2c7c-4bb5-b7b3-d3fccab9ac8e"
      unitRef="shares">37296913</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDAvZnJhZzpmMDE5NDBhM2E3OWQ0MmYwODljNTAwN2I0ZTZhNWQ3ZS90YWJsZTplMjNiNDkwYTAxNWU0MmRiOTViMDYyOTJlNTU5NGFiMi90YWJsZXJhbmdlOmUyM2I0OTBhMDE1ZTQyZGI5NWIwNjI5MmU1NTk0YWIyXzYtNC0xLTEtMA_142011d9-ee4e-4c1c-a5ce-2885e3aedfda"
      unitRef="shares">37896837</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:VariableInterestEntityDisclosureTextBlock
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90ZXh0cmVnaW9uOjFjMzZhNDJhYTJjNTQwYzM5Y2MzOTM2YTdmODFjMjQ4XzE4NTY_4a6d3aee-0e91-4ff0-91ae-68996e75c02f">Variable Interest Entities (VIEs)&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A VIE is defined as a legal entity whose equity owners do not have sufficient equity at risk, or, as a group, the holders of the equity investment at risk lack any of the following three characteristics: decision-making rights, the obligation to absorb losses, or the right to receive the expected residual returns of the entity. The primary beneficiary is identified as the variable interest holder that has both the power to direct the activities of the VIE that most significantly affect the entity&#x2019;s economic performance and the obligation to absorb expected losses or the right to receive benefits from the entity that could potentially be significant to the VIE.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company follows guidance on the consolidation of VIEs that requires companies to utilize a qualitative approach to determine whether it is the primary beneficiary of a VIE. See Note 2 &#x2013; &#x201c;Basis of Presentation and Summary of Significant Accounting Policies&#x201d; to the accompanying consolidated financial statements for information on how the Company determines VIEs and its treatment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table includes assets that can only be used to settle the liabilities of APC and its VIEs, including Alpha Care and Accountable Health Care, and to which the creditors of APC, including Alpha Care and Accountable Health Care, have no recourse to the Company, nor do creditors of the Company have recourse against the assets of APC, including Alpha Care and Accountable Health Care. These assets and liabilities, with the exception of the investment in a privately held entity that does not report net asset value per share and amounts due to affiliates, which are eliminated upon consolidation with NMM, are included in the accompanying consolidated balance sheets (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:70.873%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.636%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.758%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;113,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;87,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Investment in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;117,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;123,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Receivables, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Receivables, net &#x2013; related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;55,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;42,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Loan receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Loan receivable &#x2013; related parties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;317,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;294,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Land, property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;75,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;81,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;109,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;108,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Investment in affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;285,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;318,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Investment in privately held entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Investments in other entities &#x2013; equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total noncurrent assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;571,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;554,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;889,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;849,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fiduciary accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Medical liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;47,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;49,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;42,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amount due to affiliate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Dividends payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;126,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;96,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finance lease liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:14pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:70.873%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.636%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.758%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Total liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;142,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;114,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The assets of the Company&#x2019;s other consolidated VIEs were not considered significant.&lt;/span&gt;&lt;/div&gt;</us-gaap:VariableInterestEntityDisclosureTextBlock>
    <us-gaap:ScheduleOfVariableInterestEntitiesTextBlock
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90ZXh0cmVnaW9uOjFjMzZhNDJhYTJjNTQwYzM5Y2MzOTM2YTdmODFjMjQ4XzE4NTk_5d2f1c2d-f790-4a0f-87e1-8eca0a1068db">The following table includes assets that can only be used to settle the liabilities of APC and its VIEs, including Alpha Care and Accountable Health Care, and to which the creditors of APC, including Alpha Care and Accountable Health Care, have no recourse to the Company, nor do creditors of the Company have recourse against the assets of APC, including Alpha Care and Accountable Health Care. These assets and liabilities, with the exception of the investment in a privately held entity that does not report net asset value per share and amounts due to affiliates, which are eliminated upon consolidation with NMM, are included in the accompanying consolidated balance sheets (in thousands).&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:70.873%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.636%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.758%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;113,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;87,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Investment in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;117,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;123,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Receivables, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Receivables, net &#x2013; related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;55,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;42,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Loan receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Loan receivable &#x2013; related parties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;317,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;294,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Land, property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;75,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;81,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;109,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;108,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Investment in affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;285,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;318,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Investment in privately held entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Investments in other entities &#x2013; equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total noncurrent assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;571,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;554,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;889,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;849,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fiduciary accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Medical liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;47,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;49,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;42,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amount due to affiliate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Dividends payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;126,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;96,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finance lease liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:70.873%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.636%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.758%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Total liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;142,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;114,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfVariableInterestEntitiesTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzQtMS0xLTEtMA_5c440102-c1eb-446e-a638-9c3535230a46"
      unitRef="usd">113790000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzQtMy0xLTEtMA_e2da8ef0-7c1c-4752-962b-95ff286dd00e"
      unitRef="usd">87110000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzUtMS0xLTEtMA_a54f4c51-c9e2-4405-89fa-3474987832eb"
      unitRef="usd">0</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzUtMy0xLTEtMA_3e76e1df-378f-4068-9f67-fa72ba92bf74"
      unitRef="usd">75000</us-gaap:RestrictedCashCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzYtMS0xLTEtMA_a01bdd06-92be-4413-a07a-b8bf7b38fcde"
      unitRef="usd">117611000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzYtMy0xLTEtMA_f7b0036c-6c80-4a20-9f36-6761c102a8e0"
      unitRef="usd">123948000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzctMS0xLTEtMA_1473e046-c030-4ea3-98d6-ac145a7dce52"
      unitRef="usd">15687000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzctMy0xLTEtMA_4aa02dd5-d75a-43ef-b833-5b9118095d81"
      unitRef="usd">9300000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzgtMS0xLTEtMA_1c83201e-dc2a-4688-ae93-c457ea63fcc7"
      unitRef="usd">55889000</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzgtMy0xLTEtMA_0808ce69-da50-4e8e-bab7-4eb0fe23667e"
      unitRef="usd">42976000</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzktMS0xLTEtMA_97bbf984-a102-4d41-ae3d-71045a7e3678"
      unitRef="usd">734000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzktMy0xLTEtMA_a48bd1ee-5811-4b26-8565-c967b2648fe9"
      unitRef="usd">744000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzEwLTEtMS0xLTA_98272b1d-dcca-43f7-b6c1-be5467049157"
      unitRef="usd">7752000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzEwLTMtMS0xLTA_5df7fbf1-87e5-468d-9d11-5ad451239b36"
      unitRef="usd">7403000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzExLTEtMS0xLTA_70a63daf-1a6c-434d-801c-7ae7d37f3f42"
      unitRef="usd">6425000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzExLTMtMS0xLTA_7e8fb237-15cd-4cb0-a18d-22c81a0a8f2e"
      unitRef="usd">6425000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:NotesReceivableRelatedPartiesCurrent
      contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzEyLTEtMS0xLTA_4e818b42-9a69-427d-b547-83f7e8247384"
      unitRef="usd">0</us-gaap:NotesReceivableRelatedPartiesCurrent>
    <us-gaap:NotesReceivableRelatedPartiesCurrent
      contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzEyLTMtMS0xLTA_03786dc7-eb70-4191-a48f-8984bff155fb"
      unitRef="usd">16500000</us-gaap:NotesReceivableRelatedPartiesCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzEzLTEtMS0xLTA_2ae687ed-f1e0-4f80-947d-7f2812338896"
      unitRef="usd">317888000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzEzLTMtMS0xLTA_bc619732-6262-429c-bd51-63678b0b4d56"
      unitRef="usd">294481000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzE2LTEtMS0xLTA_79570d7b-0dea-4336-aa51-306ed80fffd2"
      unitRef="usd">9085000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzE2LTMtMS0xLTA_c1ae854f-5475-4ae5-958c-acc4c59ea540"
      unitRef="usd">9547000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzE3LTEtMS0xLTA_bf5a86be-1c65-4140-8585-b7d2aefbbd06"
      unitRef="usd">75177000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzE3LTMtMS0xLTA_b3c3956f-e120-48de-ab09-5c39ce6c3978"
      unitRef="usd">81439000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzE4LTEtMS0xLTA_59d143b0-089f-4ff6-b576-621d02d6cfbb"
      unitRef="usd">109460000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzE4LTMtMS0xLTA_448ba43a-2234-4035-b1c1-ceacc40a1ad8"
      unitRef="usd">108913000</us-gaap:Goodwill>
    <us-gaap:OtherLongTermInvestments
      contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzE5LTEtMS0xLTA_ec85057d-a50f-4e2d-8c15-b8cb2f2aee04"
      unitRef="usd">285569000</us-gaap:OtherLongTermInvestments>
    <us-gaap:OtherLongTermInvestments
      contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzE5LTMtMS0xLTA_99ac6b8d-c493-4124-aacf-45ecd1540481"
      unitRef="usd">318315000</us-gaap:OtherLongTermInvestments>
    <us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue
      contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzIwLTEtMS0xLTY4NTQ_f38dcc31-b48e-4bb0-b339-26eb329178cf"
      unitRef="usd">36584000</us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue>
    <us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue
      contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzIwLTMtMS0xLTY4NTQ_8aafda03-0a22-4430-ae77-87f52a9a0fc9"
      unitRef="usd">1615000</us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue>
    <us-gaap:EquityMethodInvestments
      contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzIwLTEtMS0xLTA_debc4d33-ed88-4032-94f3-8522fa3f816c"
      unitRef="usd">26864000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzIwLTMtMS0xLTA_089d6aea-9cfc-4d02-a6fb-db5cf8fb87ba"
      unitRef="usd">28427000</us-gaap:EquityMethodInvestments>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzIxLTEtMS0xLTA_b31df2ac-24a4-41ca-b0d5-4937fce3b0a2"
      unitRef="usd">746000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzIxLTMtMS0xLTA_fc10ff25-e9ea-4a06-bfc5-3bea69c29459"
      unitRef="usd">746000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzIyLTEtMS0xLTA_76340143-46b5-4cf4-b419-6e4c79f5a369"
      unitRef="usd">7017000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzIyLTMtMS0xLTA_2045e4b6-6b5a-4f8a-84ab-5853baa57f97"
      unitRef="usd">4751000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzIzLTEtMS0xLTA_29fb1189-c86d-4de3-a9f9-48d871a6ef0a"
      unitRef="usd">20750000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzIzLTMtMS0xLTA_ca2dfa1b-d373-4ee4-9c7b-49b2b8546baa"
      unitRef="usd">1057000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzI1LTEtMS0xLTA_2254a941-6a2f-4d2f-8195-14a3bae96698"
      unitRef="usd">571252000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzI1LTMtMS0xLTA_caba7537-4be4-4349-8bde-0b3496860644"
      unitRef="usd">554810000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzI3LTEtMS0xLTA_4762f591-1b9c-4f32-9b31-bf8bed6ca3f3"
      unitRef="usd">889140000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzI3LTMtMS0xLTA_d3a034a8-53ee-4790-a8a7-91870d546590"
      unitRef="usd">849291000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzMwLTEtMS0xLTA_22ff8567-921a-4169-937a-4a413fe83503"
      unitRef="usd">11822000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzMwLTMtMS0xLTA_1f60d2d6-11e7-4dad-a96d-3c27e2d55e61"
      unitRef="usd">11187000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <ameh:FiduciaryAccountsPayableCurrent
      contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzMxLTEtMS0xLTA_fcc5ffe7-94f0-4aec-b3bc-3e80360dbd8c"
      unitRef="usd">1853000</ameh:FiduciaryAccountsPayableCurrent>
    <ameh:FiduciaryAccountsPayableCurrent
      contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzMxLTMtMS0xLTA_1a5ae52c-3778-4deb-bfe9-aa20fad2b302"
      unitRef="usd">2027000</ameh:FiduciaryAccountsPayableCurrent>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzMyLTEtMS0xLTA_b9bc6b74-618b-4b22-8c14-aa25936ee23b"
      unitRef="usd">47304000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzMyLTMtMS0xLTA_7e355f00-1ab5-483d-822c-643cf4f47234"
      unitRef="usd">49019000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:TaxesPayableCurrent
      contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzMzLTEtMS0xLTA_bf000c36-a0c9-46f0-b55f-774a8b667b04"
      unitRef="usd">42211000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzMzLTMtMS0xLTA_3fc42c92-1f48-4eb0-bfa1-0f04fd1a289e"
      unitRef="usd">4530000</us-gaap:TaxesPayableCurrent>
    <us-gaap:DueToAffiliateCurrent
      contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzM0LTEtMS0xLTA_8a8d1528-ef1f-4f45-9fe2-94bb3da663d3"
      unitRef="usd">21533000</us-gaap:DueToAffiliateCurrent>
    <us-gaap:DueToAffiliateCurrent
      contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzM0LTMtMS0xLTA_18403430-fc63-4c9a-b0af-094083050194"
      unitRef="usd">28058000</us-gaap:DueToAffiliateCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzM1LTEtMS0xLTA_5d7f5ed4-c185-4e5b-bb5f-395e85f4feea"
      unitRef="usd">431000</us-gaap:DividendsPayableCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzM1LTMtMS0xLTA_f4f5dc79-8cb3-4e27-b8f6-d0ef1054ca0b"
      unitRef="usd">271000</us-gaap:DividendsPayableCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzM2LTEtMS0xLTA_f4f8a03f-35ef-4bb7-884a-b310470c6836"
      unitRef="usd">102000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzM2LTMtMS0xLTA_eb3b8564-82a2-4e2a-a51d-e79f60069a52"
      unitRef="usd">102000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzM3LTEtMS0xLTA_481c5649-5be9-4e76-b2fe-ad3e5afd0128"
      unitRef="usd">1319000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzM3LTMtMS0xLTA_798e5d92-4581-41a9-86a5-76a8cd85e063"
      unitRef="usd">1088000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzM5LTEtMS0xLTA_805cbeed-4bde-48d6-b8ef-49dd77a2b644"
      unitRef="usd">126575000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzM5LTMtMS0xLTA_6b90eee9-c8b9-490c-8fb3-f3f8547f4ac6"
      unitRef="usd">96282000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzQyLTEtMS0xLTA_9c2f884a-6d4c-4812-9eee-479e53f91131"
      unitRef="usd">9490000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzQyLTMtMS0xLTA_2601c9f2-c86b-4347-8b2a-85051c7e49c0"
      unitRef="usd">14059000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzQzLTEtMS0xLTA_447ec8e5-d0aa-4f77-abe5-d6ce225642e8"
      unitRef="usd">355000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzQzLTMtMS0xLTA_4cb9594f-74d3-409e-a02f-3d11b8bcd1a2"
      unitRef="usd">416000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzQ0LTEtMS0xLTA_8ba8c26a-5891-40e5-9195-fc861879508a"
      unitRef="usd">5833000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzQ0LTMtMS0xLTA_5cd2a252-177b-4748-b3cc-461a1bb95942"
      unitRef="usd">3742000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzQ2LTEtMS0xLTA_1a395672-1072-497a-adbf-0c8637568d44"
      unitRef="usd">15678000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzQ2LTMtMS0xLTA_7a5b375d-fe8d-41f6-a073-55c2f61531c3"
      unitRef="usd">18217000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i7f9c10048151448696ea86f0e39c0212_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzQ4LTEtMS0xLTA_fe893408-fdd5-489f-a158-bf6f20bd3519"
      unitRef="usd">142253000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i66d4b89ccc8c4ee1ae626eeb6ade4690_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDMvZnJhZzoxYzM2YTQyYWEyYzU0MGMzOWNjMzkzNmE3ZjgxYzI0OC90YWJsZTo3ZTg0ODZhYWEwYWQ0ZDE5OWM0OThiYzUwOGE5M2FiMi90YWJsZXJhbmdlOjdlODQ4NmFhYTBhZDRkMTk5YzQ5OGJjNTA4YTkzYWIyXzQ4LTMtMS0xLTA_549aa2c9-de56-46e2-bb6b-8d27a3779d2d"
      unitRef="usd">114499000</us-gaap:Liabilities>
    <us-gaap:LesseeFinanceLeasesTextBlock
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90ZXh0cmVnaW9uOjBiNjNjZGMyNTJlYzQ3Y2E4YjQ3MWY3YzIyOTIzYmJjXzEwMzk_b0053f62-6184-4137-b8e9-5c6f5ea0168f">Leases&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has operating and finance leases for corporate offices, doctors&#x2019; offices, and certain equipment. These leases have remaining lease terms of 1 month to 5 years, some of which may include options to extend the leases for up to 10 years, and some of which may include options to terminate the leases within one year. As of June&#160;30, 2020 and December&#160;31, 2019, assets recorded under finance leases were $0.4 million and $0.5 million, respectively, and accumulated depreciation associated with finance leases was $0.3 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Also, the Company rents or subleases certain real estate to third parties, which are accounted for as operating leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Leases with an initial term of 12 months or less are not recorded on the balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The components of lease expense were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:77.824%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.941%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.505%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Finance lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Amortization of lease expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Sublease income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(226)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(106)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total finance lease cost, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:77.678%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.380%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.212%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Finance lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Amortization of lease expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Sublease income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(360)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(206)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total finance lease cost, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Other information related to leases was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:77.295%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.425%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.546%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Supplemental Cash Flows Information&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Right-of-use assets obtained in exchange for lease liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Supplemental Cash Flows Information&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Right-of-use assets obtained in exchange for lease liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Weighted Average Remaining Lease Term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.06 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.87 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4.17 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.00 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Weighted Average Discount Rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Future minimum lease payments under non-cancellable leases as of June&#160;30, 2020 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:70.620%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.323%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.325%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Finance Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020 (excluding the six months ended June 30, 2020)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Less: imputed interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Less: current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Long-term lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of June&#160;30, 2020, the Company does not have additional operating and finance leases that have not yet commenced.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeFinanceLeasesTextBlock>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90ZXh0cmVnaW9uOjBiNjNjZGMyNTJlYzQ3Y2E4YjQ3MWY3YzIyOTIzYmJjXzEwNTE_24fb3dd3-04c2-4abc-898c-de16abfc9f12">Leases&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has operating and finance leases for corporate offices, doctors&#x2019; offices, and certain equipment. These leases have remaining lease terms of 1 month to 5 years, some of which may include options to extend the leases for up to 10 years, and some of which may include options to terminate the leases within one year. As of June&#160;30, 2020 and December&#160;31, 2019, assets recorded under finance leases were $0.4 million and $0.5 million, respectively, and accumulated depreciation associated with finance leases was $0.3 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Also, the Company rents or subleases certain real estate to third parties, which are accounted for as operating leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Leases with an initial term of 12 months or less are not recorded on the balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The components of lease expense were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:77.824%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.941%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.505%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Finance lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Amortization of lease expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Sublease income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(226)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(106)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total finance lease cost, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:77.678%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.380%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.212%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Finance lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Amortization of lease expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Sublease income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(360)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(206)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total finance lease cost, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Other information related to leases was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:77.295%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.425%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.546%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Supplemental Cash Flows Information&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Right-of-use assets obtained in exchange for lease liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Supplemental Cash Flows Information&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Right-of-use assets obtained in exchange for lease liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Weighted Average Remaining Lease Term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.06 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.87 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4.17 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.00 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Weighted Average Discount Rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Future minimum lease payments under non-cancellable leases as of June&#160;30, 2020 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:70.620%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.323%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.325%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Finance Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020 (excluding the six months ended June 30, 2020)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Less: imputed interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Less: current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Long-term lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of June&#160;30, 2020, the Company does not have additional operating and finance leases that have not yet commenced.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeFinanceLeaseRemainingLeaseTerm
      contextRef="if0190ef7dee34fbda65c048ee6b393c7_I20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90ZXh0cmVnaW9uOjBiNjNjZGMyNTJlYzQ3Y2E4YjQ3MWY3YzIyOTIzYmJjXzE2OA_04912863-ca76-4c45-a7ac-ce874c1ac538">P1M</us-gaap:LesseeFinanceLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="if0190ef7dee34fbda65c048ee6b393c7_I20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90ZXh0cmVnaW9uOjBiNjNjZGMyNTJlYzQ3Y2E4YjQ3MWY3YzIyOTIzYmJjXzE2OA_33d1608a-4757-441c-9d81-95e80ae62683">P1M</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="i4688143439664825ac968a174665ba3d_I20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90ZXh0cmVnaW9uOjBiNjNjZGMyNTJlYzQ3Y2E4YjQ3MWY3YzIyOTIzYmJjXzE3NA_3711b51c-b000-4a07-833f-6731a5a6c793">P5Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeFinanceLeaseRemainingLeaseTerm
      contextRef="i4688143439664825ac968a174665ba3d_I20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90ZXh0cmVnaW9uOjBiNjNjZGMyNTJlYzQ3Y2E4YjQ3MWY3YzIyOTIzYmJjXzE3NA_8fcbd946-4eb1-4ae4-9368-6725d0c5577d">P5Y</us-gaap:LesseeFinanceLeaseRemainingLeaseTerm>
    <us-gaap:LesseeFinanceLeaseRenewalTerm1
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90ZXh0cmVnaW9uOjBiNjNjZGMyNTJlYzQ3Y2E4YjQ3MWY3YzIyOTIzYmJjXzI0Mw_4588fa0f-017f-42c6-bd12-6d082b3bbb79">P10Y</us-gaap:LesseeFinanceLeaseRenewalTerm1>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90ZXh0cmVnaW9uOjBiNjNjZGMyNTJlYzQ3Y2E4YjQ3MWY3YzIyOTIzYmJjXzI0Mw_8b73e392-1280-49ed-8831-6aaa67ba863f">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <ameh:LesseeOperatingLeaseTerminationPeriodIfApplicable
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90ZXh0cmVnaW9uOjBiNjNjZGMyNTJlYzQ3Y2E4YjQ3MWY3YzIyOTIzYmJjXzMyMg_43c94f91-457c-4768-bc1d-82eccc038087">P1Y</ameh:LesseeOperatingLeaseTerminationPeriodIfApplicable>
    <ameh:LesseeFinanceLeaseTerminationPeriodIfApplicable
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90ZXh0cmVnaW9uOjBiNjNjZGMyNTJlYzQ3Y2E4YjQ3MWY3YzIyOTIzYmJjXzMyMg_ebac538c-ca16-4bd3-b851-40ab07a5325e">P1Y</ameh:LesseeFinanceLeaseTerminationPeriodIfApplicable>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90ZXh0cmVnaW9uOjBiNjNjZGMyNTJlYzQ3Y2E4YjQ3MWY3YzIyOTIzYmJjXzYwNDczMTM5NTM4NzU_fd64d504-2a24-4086-b1f6-1f33a454c5c6"
      unitRef="usd">400000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90ZXh0cmVnaW9uOjBiNjNjZGMyNTJlYzQ3Y2E4YjQ3MWY3YzIyOTIzYmJjXzE2NDkyNjc0NDI3MzI_6c373589-cff8-4e08-aaef-74d0dfffaaf0"
      unitRef="usd">500000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i1fe8e8ce30b4463d841ecdce075f4f3d_D20200630-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90ZXh0cmVnaW9uOjBiNjNjZGMyNTJlYzQ3Y2E4YjQ3MWY3YzIyOTIzYmJjXzQ2Nw_47b9a24c-72b8-4e4c-9226-f57296997208"
      unitRef="usd">300000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="if1ac92c6e4a04bde94c7027334556000_D20191231-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90ZXh0cmVnaW9uOjBiNjNjZGMyNTJlYzQ3Y2E4YjQ3MWY3YzIyOTIzYmJjXzQ2Nw_6dfbd64a-5700-489f-8e1c-f5fa87a33a3b"
      unitRef="usd">300000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90ZXh0cmVnaW9uOjBiNjNjZGMyNTJlYzQ3Y2E4YjQ3MWY3YzIyOTIzYmJjXzEwNDA_b916327d-37f8-4245-9813-b8bc157cfb0c">&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The components of lease expense were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:77.824%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.941%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.505%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Finance lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Amortization of lease expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Sublease income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(226)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(106)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total finance lease cost, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:77.678%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.380%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.212%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Finance lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Amortization of lease expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Sublease income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(360)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(206)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total finance lease cost, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Other information related to leases was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:77.295%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.425%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.546%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Supplemental Cash Flows Information&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Right-of-use assets obtained in exchange for lease liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Supplemental Cash Flows Information&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Right-of-use assets obtained in exchange for lease liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Weighted Average Remaining Lease Term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.06 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.87 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4.17 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.00 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Weighted Average Discount Rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo4ODRkY2U0ZWJlZjY0YzQ5YThkOGQzYjE5NWYxNDdmZi90YWJsZXJhbmdlOjg4NGRjZTRlYmVmNjRjNDlhOGQ4ZDNiMTk1ZjE0N2ZmXzMtMS0xLTEtMA_8850d94c-0758-448f-85f1-c190148658d7"
      unitRef="usd">1446000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo4ODRkY2U0ZWJlZjY0YzQ5YThkOGQzYjE5NWYxNDdmZi90YWJsZXJhbmdlOjg4NGRjZTRlYmVmNjRjNDlhOGQ4ZDNiMTk1ZjE0N2ZmXzMtMy0xLTEtMA_7967a334-3b84-4136-83d2-2a02682edfc2"
      unitRef="usd">1240000</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo4ODRkY2U0ZWJlZjY0YzQ5YThkOGQzYjE5NWYxNDdmZi90YWJsZXJhbmdlOjg4NGRjZTRlYmVmNjRjNDlhOGQ4ZDNiMTk1ZjE0N2ZmXzYtMS0xLTEtMA_4834bb62-e820-4db5-8ad0-c5f0e74f20a1"
      unitRef="usd">35000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo4ODRkY2U0ZWJlZjY0YzQ5YThkOGQzYjE5NWYxNDdmZi90YWJsZXJhbmdlOjg4NGRjZTRlYmVmNjRjNDlhOGQ4ZDNiMTk1ZjE0N2ZmXzYtMy0xLTEtMA_fa5d84af-f116-4fe2-b7d4-ee8ea4d3673e"
      unitRef="usd">25000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo4ODRkY2U0ZWJlZjY0YzQ5YThkOGQzYjE5NWYxNDdmZi90YWJsZXJhbmdlOjg4NGRjZTRlYmVmNjRjNDlhOGQ4ZDNiMTk1ZjE0N2ZmXzctMS0xLTEtMA_665a2716-6408-4e24-8495-cc1c50a1d8f1"
      unitRef="usd">4000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo4ODRkY2U0ZWJlZjY0YzQ5YThkOGQzYjE5NWYxNDdmZi90YWJsZXJhbmdlOjg4NGRjZTRlYmVmNjRjNDlhOGQ4ZDNiMTk1ZjE0N2ZmXzctMy0xLTEtMA_a6cbbc4d-7eb3-4cd1-8214-8b83af853b26"
      unitRef="usd">4000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:SubleaseIncome
      contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo4ODRkY2U0ZWJlZjY0YzQ5YThkOGQzYjE5NWYxNDdmZi90YWJsZXJhbmdlOjg4NGRjZTRlYmVmNjRjNDlhOGQ4ZDNiMTk1ZjE0N2ZmXzktMS0xLTEtMA_b570bb95-8ec5-47e3-8144-51010167f07c"
      unitRef="usd">226000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo4ODRkY2U0ZWJlZjY0YzQ5YThkOGQzYjE5NWYxNDdmZi90YWJsZXJhbmdlOjg4NGRjZTRlYmVmNjRjNDlhOGQ4ZDNiMTk1ZjE0N2ZmXzktMy0xLTEtMA_0a381ae5-ede2-4863-825f-765825ab522f"
      unitRef="usd">106000</us-gaap:SubleaseIncome>
    <us-gaap:LeaseCost
      contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo4ODRkY2U0ZWJlZjY0YzQ5YThkOGQzYjE5NWYxNDdmZi90YWJsZXJhbmdlOjg4NGRjZTRlYmVmNjRjNDlhOGQ4ZDNiMTk1ZjE0N2ZmXzExLTEtMS0xLTA_9f7ef088-5f88-42ac-b640-d87b0b0a1f61"
      unitRef="usd">1259000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo4ODRkY2U0ZWJlZjY0YzQ5YThkOGQzYjE5NWYxNDdmZi90YWJsZXJhbmdlOjg4NGRjZTRlYmVmNjRjNDlhOGQ4ZDNiMTk1ZjE0N2ZmXzExLTMtMS0xLTA_436345f7-a1d9-4cbb-811e-325496ef72a6"
      unitRef="usd">1163000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTpmODZjMjI3MjVjN2Y0MTE1OGFkNmYzYTU3NjdkMzQ5MS90YWJsZXJhbmdlOmY4NmMyMjcyNWM3ZjQxMTU4YWQ2ZjNhNTc2N2QzNDkxXzMtMS0xLTEtMA_8f278a3e-9605-43aa-8b5c-a05813e60f2f"
      unitRef="usd">3388000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTpmODZjMjI3MjVjN2Y0MTE1OGFkNmYzYTU3NjdkMzQ5MS90YWJsZXJhbmdlOmY4NmMyMjcyNWM3ZjQxMTU4YWQ2ZjNhNTc2N2QzNDkxXzMtMy0xLTEtMA_861a260d-b26d-4a24-8e14-b988fb427bae"
      unitRef="usd">2343000</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTpmODZjMjI3MjVjN2Y0MTE1OGFkNmYzYTU3NjdkMzQ5MS90YWJsZXJhbmdlOmY4NmMyMjcyNWM3ZjQxMTU4YWQ2ZjNhNTc2N2QzNDkxXzYtMS0xLTEtMA_2411e97b-0a82-473f-816a-b179706925f0"
      unitRef="usd">61000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTpmODZjMjI3MjVjN2Y0MTE1OGFkNmYzYTU3NjdkMzQ5MS90YWJsZXJhbmdlOmY4NmMyMjcyNWM3ZjQxMTU4YWQ2ZjNhNTc2N2QzNDkxXzYtMy0xLTEtMA_eb8fabef-d085-42c8-86c9-80f7af0d0837"
      unitRef="usd">50000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTpmODZjMjI3MjVjN2Y0MTE1OGFkNmYzYTU3NjdkMzQ5MS90YWJsZXJhbmdlOmY4NmMyMjcyNWM3ZjQxMTU4YWQ2ZjNhNTc2N2QzNDkxXzctMS0xLTEtMA_6c5901c0-61a2-4c37-8448-37e68ce3268a"
      unitRef="usd">7000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTpmODZjMjI3MjVjN2Y0MTE1OGFkNmYzYTU3NjdkMzQ5MS90YWJsZXJhbmdlOmY4NmMyMjcyNWM3ZjQxMTU4YWQ2ZjNhNTc2N2QzNDkxXzctMy0xLTEtMA_0e45df20-e11d-40c2-ace5-073d2f82f2ef"
      unitRef="usd">9000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:SubleaseIncome
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTpmODZjMjI3MjVjN2Y0MTE1OGFkNmYzYTU3NjdkMzQ5MS90YWJsZXJhbmdlOmY4NmMyMjcyNWM3ZjQxMTU4YWQ2ZjNhNTc2N2QzNDkxXzktMS0xLTEtMA_1259e6dc-9763-42d2-a748-8fab26692725"
      unitRef="usd">360000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTpmODZjMjI3MjVjN2Y0MTE1OGFkNmYzYTU3NjdkMzQ5MS90YWJsZXJhbmdlOmY4NmMyMjcyNWM3ZjQxMTU4YWQ2ZjNhNTc2N2QzNDkxXzktMy0xLTEtMA_4e89d8ae-551b-4a0f-81ce-385e3c9411c1"
      unitRef="usd">206000</us-gaap:SubleaseIncome>
    <us-gaap:LeaseCost
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTpmODZjMjI3MjVjN2Y0MTE1OGFkNmYzYTU3NjdkMzQ5MS90YWJsZXJhbmdlOmY4NmMyMjcyNWM3ZjQxMTU4YWQ2ZjNhNTc2N2QzNDkxXzExLTEtMS0xLTA_72a20949-89ed-4f9a-8276-3cf2710c7800"
      unitRef="usd">3096000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTpmODZjMjI3MjVjN2Y0MTE1OGFkNmYzYTU3NjdkMzQ5MS90YWJsZXJhbmdlOmY4NmMyMjcyNWM3ZjQxMTU4YWQ2ZjNhNTc2N2QzNDkxXzExLTMtMS0xLTA_87b7f0c3-9601-4842-a59f-026fd507f9e8"
      unitRef="usd">2196000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo3NTkwMjUxOGI4OGI0OTZmOWEzY2FlNTBjODIyM2JjNC90YWJsZXJhbmdlOjc1OTAyNTE4Yjg4YjQ5NmY5YTNjYWU1MGM4MjIzYmM0XzYtMS0xLTEtMA_4439e785-86c0-4d9f-8cc3-d9d52ab2b8fb"
      unitRef="usd">1333000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo3NTkwMjUxOGI4OGI0OTZmOWEzY2FlNTBjODIyM2JjNC90YWJsZXJhbmdlOjc1OTAyNTE4Yjg4YjQ5NmY5YTNjYWU1MGM4MjIzYmM0XzYtMy0xLTEtMA_4572027f-b509-4159-9318-d3bfa8ea15c2"
      unitRef="usd">1239000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo3NTkwMjUxOGI4OGI0OTZmOWEzY2FlNTBjODIyM2JjNC90YWJsZXJhbmdlOjc1OTAyNTE4Yjg4YjQ5NmY5YTNjYWU1MGM4MjIzYmM0XzctMS0xLTEtMA_e43d33fd-d953-4837-8147-3d59064ceba5"
      unitRef="usd">4000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo3NTkwMjUxOGI4OGI0OTZmOWEzY2FlNTBjODIyM2JjNC90YWJsZXJhbmdlOjc1OTAyNTE4Yjg4YjQ5NmY5YTNjYWU1MGM4MjIzYmM0XzctMy0xLTEtMA_6c4e47b4-eb54-4254-b625-38e43e0ebe2f"
      unitRef="usd">4000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo3NTkwMjUxOGI4OGI0OTZmOWEzY2FlNTBjODIyM2JjNC90YWJsZXJhbmdlOjc1OTAyNTE4Yjg4YjQ5NmY5YTNjYWU1MGM4MjIzYmM0XzgtMS0xLTEtMA_5f22802f-d78b-4990-b0dd-1c3c1804cd95"
      unitRef="usd">35000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo3NTkwMjUxOGI4OGI0OTZmOWEzY2FlNTBjODIyM2JjNC90YWJsZXJhbmdlOjc1OTAyNTE4Yjg4YjQ5NmY5YTNjYWU1MGM4MjIzYmM0XzgtMy0xLTEtMA_fee018c8-d36b-4891-bcb7-5a75da997a7f"
      unitRef="usd">25000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo3NTkwMjUxOGI4OGI0OTZmOWEzY2FlNTBjODIyM2JjNC90YWJsZXJhbmdlOjc1OTAyNTE4Yjg4YjQ5NmY5YTNjYWU1MGM4MjIzYmM0XzExLTEtMS0xLTA_9526b316-02a5-4e4f-93f2-ddb71781a00d"
      unitRef="usd">2907000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i67e9837ac1b44e17bd318afc5f3f872b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo3NTkwMjUxOGI4OGI0OTZmOWEzY2FlNTBjODIyM2JjNC90YWJsZXJhbmdlOjc1OTAyNTE4Yjg4YjQ5NmY5YTNjYWU1MGM4MjIzYmM0XzExLTMtMS0xLTA_bee49540-5525-424b-a5e5-b63919456d80"
      unitRef="usd">6441000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeasePayments
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo3NTkwMjUxOGI4OGI0OTZmOWEzY2FlNTBjODIyM2JjNC90YWJsZXJhbmdlOjc1OTAyNTE4Yjg4YjQ5NmY5YTNjYWU1MGM4MjIzYmM0XzE5LTEtMS0xLTA_10f1f1bc-2e90-452a-819f-40e2ece91f4d"
      unitRef="usd">2880000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo3NTkwMjUxOGI4OGI0OTZmOWEzY2FlNTBjODIyM2JjNC90YWJsZXJhbmdlOjc1OTAyNTE4Yjg4YjQ5NmY5YTNjYWU1MGM4MjIzYmM0XzE5LTMtMS0xLTA_fe843cbf-cfd2-4ec5-a09c-be1279ebb3a6"
      unitRef="usd">2273000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo3NTkwMjUxOGI4OGI0OTZmOWEzY2FlNTBjODIyM2JjNC90YWJsZXJhbmdlOjc1OTAyNTE4Yjg4YjQ5NmY5YTNjYWU1MGM4MjIzYmM0XzIwLTEtMS0xLTA_db30a1ff-4d1d-4983-b6c3-281fee74f8f0"
      unitRef="usd">7000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo3NTkwMjUxOGI4OGI0OTZmOWEzY2FlNTBjODIyM2JjNC90YWJsZXJhbmdlOjc1OTAyNTE4Yjg4YjQ5NmY5YTNjYWU1MGM4MjIzYmM0XzIwLTMtMS0xLTA_0def8882-804b-441a-9793-0b2f47569dc1"
      unitRef="usd">9000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo3NTkwMjUxOGI4OGI0OTZmOWEzY2FlNTBjODIyM2JjNC90YWJsZXJhbmdlOjc1OTAyNTE4Yjg4YjQ5NmY5YTNjYWU1MGM4MjIzYmM0XzIxLTEtMS0xLTA_25a09864-526e-4c5a-994f-ce19ee625460"
      unitRef="usd">61000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo3NTkwMjUxOGI4OGI0OTZmOWEzY2FlNTBjODIyM2JjNC90YWJsZXJhbmdlOjc1OTAyNTE4Yjg4YjQ5NmY5YTNjYWU1MGM4MjIzYmM0XzIxLTMtMS0xLTA_ce59f52d-be12-4d48-9558-598c02a4d6f3"
      unitRef="usd">50000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo3NTkwMjUxOGI4OGI0OTZmOWEzY2FlNTBjODIyM2JjNC90YWJsZXJhbmdlOjc1OTAyNTE4Yjg4YjQ5NmY5YTNjYWU1MGM4MjIzYmM0XzI0LTEtMS0xLTA_04c8cdec-ada9-49c3-be31-4669e87ee4d4"
      unitRef="usd">7652000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i6572bdcc7f6745a2892fd69a1d6a4248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo3NTkwMjUxOGI4OGI0OTZmOWEzY2FlNTBjODIyM2JjNC90YWJsZXJhbmdlOjc1OTAyNTE4Yjg4YjQ5NmY5YTNjYWU1MGM4MjIzYmM0XzI0LTMtMS0xLTA_772ab570-7826-4184-b99c-e1aa3264a678"
      unitRef="usd">15417000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo3NTkwMjUxOGI4OGI0OTZmOWEzY2FlNTBjODIyM2JjNC90YWJsZXJhbmdlOjc1OTAyNTE4Yjg4YjQ5NmY5YTNjYWU1MGM4MjIzYmM0XzMxLTEtMS0xLTA_4222f497-0d48-4507-a9ff-10534c879d2b">P7Y21D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i2db2c0d074c34657a5d523b0ae1e5784_I20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo3NTkwMjUxOGI4OGI0OTZmOWEzY2FlNTBjODIyM2JjNC90YWJsZXJhbmdlOjc1OTAyNTE4Yjg4YjQ5NmY5YTNjYWU1MGM4MjIzYmM0XzMxLTMtMS0xLTA_a4a5e2e9-df75-4e84-9e6c-bf8a9c3108e5">P6Y10M13D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo3NTkwMjUxOGI4OGI0OTZmOWEzY2FlNTBjODIyM2JjNC90YWJsZXJhbmdlOjc1OTAyNTE4Yjg4YjQ5NmY5YTNjYWU1MGM4MjIzYmM0XzMyLTEtMS0xLTA_66175ec0-0598-40ab-b0d8-7493fcae60c0">P4Y2M1D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i2db2c0d074c34657a5d523b0ae1e5784_I20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo3NTkwMjUxOGI4OGI0OTZmOWEzY2FlNTBjODIyM2JjNC90YWJsZXJhbmdlOjc1OTAyNTE4Yjg4YjQ5NmY5YTNjYWU1MGM4MjIzYmM0XzMyLTMtMS0xLTA_77b8ea9a-ce20-4edf-998b-3976aac40450">P5Y</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo3NTkwMjUxOGI4OGI0OTZmOWEzY2FlNTBjODIyM2JjNC90YWJsZXJhbmdlOjc1OTAyNTE4Yjg4YjQ5NmY5YTNjYWU1MGM4MjIzYmM0XzM2LTEtMS0xLTA_fe0ef567-0a3c-48b2-9e47-5349492f5bdd"
      unitRef="number">0.0610</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i2db2c0d074c34657a5d523b0ae1e5784_I20190630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo3NTkwMjUxOGI4OGI0OTZmOWEzY2FlNTBjODIyM2JjNC90YWJsZXJhbmdlOjc1OTAyNTE4Yjg4YjQ5NmY5YTNjYWU1MGM4MjIzYmM0XzM2LTMtMS0xLTA_75dffe4f-6e74-414f-aaa8-e9a4970516e8"
      unitRef="number">0.0618</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo3NTkwMjUxOGI4OGI0OTZmOWEzY2FlNTBjODIyM2JjNC90YWJsZXJhbmdlOjc1OTAyNTE4Yjg4YjQ5NmY5YTNjYWU1MGM4MjIzYmM0XzM3LTEtMS0xLTA_ca6cedfa-197d-42da-8965-87b44c58352c"
      unitRef="number">0.0300</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="i2db2c0d074c34657a5d523b0ae1e5784_I20190630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZTo3NTkwMjUxOGI4OGI0OTZmOWEzY2FlNTBjODIyM2JjNC90YWJsZXJhbmdlOjc1OTAyNTE4Yjg4YjQ5NmY5YTNjYWU1MGM4MjIzYmM0XzM3LTMtMS0xLTA_064ca8f8-e88d-489c-9872-a34e1b494584"
      unitRef="number">0.0300</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90ZXh0cmVnaW9uOjBiNjNjZGMyNTJlYzQ3Y2E4YjQ3MWY3YzIyOTIzYmJjXzEwMzc_98db1a1e-d15b-4c21-b289-18edb9e9f0b3">&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Future minimum lease payments under non-cancellable leases as of June&#160;30, 2020 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:70.620%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.323%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.325%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Finance Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020 (excluding the six months ended June 30, 2020)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Less: imputed interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Less: current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Long-term lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock
      contextRef="i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90ZXh0cmVnaW9uOjBiNjNjZGMyNTJlYzQ3Y2E4YjQ3MWY3YzIyOTIzYmJjXzEwNDM_68ff79b1-4b18-4379-8733-803f4b6f99a5">&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Future minimum lease payments under non-cancellable leases as of June&#160;30, 2020 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:70.620%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.323%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.325%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Finance Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020 (excluding the six months ended June 30, 2020)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Less: imputed interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Less: current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Long-term lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZToxYjc0YmUxZWExMWI0OTU0YTBjNzQ5OGQxY2M3YjQ2Yi90YWJsZXJhbmdlOjFiNzRiZTFlYTExYjQ5NTRhMGM3NDk4ZDFjYzdiNDZiXzEtMS0xLTEtMA_6fb64b63-18b2-457d-8f87-d5e79c5823a0"
      unitRef="usd">2337000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZToxYjc0YmUxZWExMWI0OTU0YTBjNzQ5OGQxY2M3YjQ2Yi90YWJsZXJhbmdlOjFiNzRiZTFlYTExYjQ5NTRhMGM3NDk4ZDFjYzdiNDZiXzEtMy0xLTEtMA_54cad65b-53e2-4cb4-9d2a-1d9cd47ed83f"
      unitRef="usd">59000</us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZToxYjc0YmUxZWExMWI0OTU0YTBjNzQ5OGQxY2M3YjQ2Yi90YWJsZXJhbmdlOjFiNzRiZTFlYTExYjQ5NTRhMGM3NDk4ZDFjYzdiNDZiXzItMS0xLTEtMA_2763262d-d623-47fe-a87d-63f050d0bf12"
      unitRef="usd">4297000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZToxYjc0YmUxZWExMWI0OTU0YTBjNzQ5OGQxY2M3YjQ2Yi90YWJsZXJhbmdlOjFiNzRiZTFlYTExYjQ5NTRhMGM3NDk4ZDFjYzdiNDZiXzItMy0xLTEtMA_7da4f434-978d-4939-86c8-ba65a6e5702b"
      unitRef="usd">119000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZToxYjc0YmUxZWExMWI0OTU0YTBjNzQ5OGQxY2M3YjQ2Yi90YWJsZXJhbmdlOjFiNzRiZTFlYTExYjQ5NTRhMGM3NDk4ZDFjYzdiNDZiXzMtMS0xLTEtMA_59d4f026-93b0-4e7c-a7d3-3cd2498add14"
      unitRef="usd">3529000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZToxYjc0YmUxZWExMWI0OTU0YTBjNzQ5OGQxY2M3YjQ2Yi90YWJsZXJhbmdlOjFiNzRiZTFlYTExYjQ5NTRhMGM3NDk4ZDFjYzdiNDZiXzMtMy0xLTEtMA_5ef13070-4428-4071-a054-794425d808e3"
      unitRef="usd">119000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZToxYjc0YmUxZWExMWI0OTU0YTBjNzQ5OGQxY2M3YjQ2Yi90YWJsZXJhbmdlOjFiNzRiZTFlYTExYjQ5NTRhMGM3NDk4ZDFjYzdiNDZiXzQtMS0xLTEtMA_e8f72467-8375-49dc-bf22-028f0f43c74f"
      unitRef="usd">3303000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZToxYjc0YmUxZWExMWI0OTU0YTBjNzQ5OGQxY2M3YjQ2Yi90YWJsZXJhbmdlOjFiNzRiZTFlYTExYjQ5NTRhMGM3NDk4ZDFjYzdiNDZiXzQtMy0xLTEtMA_e584c192-4838-4d71-babf-5d224b33c198"
      unitRef="usd">119000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZToxYjc0YmUxZWExMWI0OTU0YTBjNzQ5OGQxY2M3YjQ2Yi90YWJsZXJhbmdlOjFiNzRiZTFlYTExYjQ5NTRhMGM3NDk4ZDFjYzdiNDZiXzUtMS0xLTEtMA_4842817c-749a-4056-a806-95e9bd20a890"
      unitRef="usd">2940000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZToxYjc0YmUxZWExMWI0OTU0YTBjNzQ5OGQxY2M3YjQ2Yi90YWJsZXJhbmdlOjFiNzRiZTFlYTExYjQ5NTRhMGM3NDk4ZDFjYzdiNDZiXzUtMy0xLTEtMA_22f161aa-6034-467e-8c90-6c060bd70bd3"
      unitRef="usd">79000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <ameh:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZToxYjc0YmUxZWExMWI0OTU0YTBjNzQ5OGQxY2M3YjQ2Yi90YWJsZXJhbmdlOjFiNzRiZTFlYTExYjQ5NTRhMGM3NDk4ZDFjYzdiNDZiXzYtMS0xLTEtMA_84e38a34-c18a-450e-baf6-801f91c67b04"
      unitRef="usd">9459000</ameh:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <ameh:FinanceLeaseLiabilityToBePaidAfterYearFour
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZToxYjc0YmUxZWExMWI0OTU0YTBjNzQ5OGQxY2M3YjQ2Yi90YWJsZXJhbmdlOjFiNzRiZTFlYTExYjQ5NTRhMGM3NDk4ZDFjYzdiNDZiXzYtMy0xLTEtMA_dfd99f5c-64ad-4598-b5eb-6c12d66c8899"
      unitRef="usd">0</ameh:FinanceLeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZToxYjc0YmUxZWExMWI0OTU0YTBjNzQ5OGQxY2M3YjQ2Yi90YWJsZXJhbmdlOjFiNzRiZTFlYTExYjQ5NTRhMGM3NDk4ZDFjYzdiNDZiXzgtMS0xLTEtMA_e75ebab3-f137-498e-a748-99082057113a"
      unitRef="usd">25865000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZToxYjc0YmUxZWExMWI0OTU0YTBjNzQ5OGQxY2M3YjQ2Yi90YWJsZXJhbmdlOjFiNzRiZTFlYTExYjQ5NTRhMGM3NDk4ZDFjYzdiNDZiXzgtMy0xLTEtMA_f8a56121-c0cc-4686-b707-a4c44ac38242"
      unitRef="usd">495000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZToxYjc0YmUxZWExMWI0OTU0YTBjNzQ5OGQxY2M3YjQ2Yi90YWJsZXJhbmdlOjFiNzRiZTFlYTExYjQ5NTRhMGM3NDk4ZDFjYzdiNDZiXzktMS0xLTEtMA_10435b48-5360-451b-bbae-8d89cacfaffa"
      unitRef="usd">5097000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZToxYjc0YmUxZWExMWI0OTU0YTBjNzQ5OGQxY2M3YjQ2Yi90YWJsZXJhbmdlOjFiNzRiZTFlYTExYjQ5NTRhMGM3NDk4ZDFjYzdiNDZiXzktMy0xLTEtMA_f20025f9-cd39-439c-8785-5a361ef68939"
      unitRef="usd">38000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZToxYjc0YmUxZWExMWI0OTU0YTBjNzQ5OGQxY2M3YjQ2Yi90YWJsZXJhbmdlOjFiNzRiZTFlYTExYjQ5NTRhMGM3NDk4ZDFjYzdiNDZiXzEwLTEtMS0xLTA_5fe9a787-dbc0-4096-bb79-492b6cb204ff"
      unitRef="usd">20768000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZToxYjc0YmUxZWExMWI0OTU0YTBjNzQ5OGQxY2M3YjQ2Yi90YWJsZXJhbmdlOjFiNzRiZTFlYTExYjQ5NTRhMGM3NDk4ZDFjYzdiNDZiXzEwLTMtMS0xLTA_4265d6df-86bd-4f62-a1ef-6e2418fb732d"
      unitRef="usd">457000</us-gaap:FinanceLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZToxYjc0YmUxZWExMWI0OTU0YTBjNzQ5OGQxY2M3YjQ2Yi90YWJsZXJhbmdlOjFiNzRiZTFlYTExYjQ5NTRhMGM3NDk4ZDFjYzdiNDZiXzExLTEtMS0xLTA_fba17a9b-ec62-49cc-baa1-bd92494c7bed"
      unitRef="usd">3350000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZToxYjc0YmUxZWExMWI0OTU0YTBjNzQ5OGQxY2M3YjQ2Yi90YWJsZXJhbmdlOjFiNzRiZTFlYTExYjQ5NTRhMGM3NDk4ZDFjYzdiNDZiXzExLTMtMS0xLTA_cb52c3d3-df40-4052-ba28-281fab8a552f"
      unitRef="usd">102000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZToxYjc0YmUxZWExMWI0OTU0YTBjNzQ5OGQxY2M3YjQ2Yi90YWJsZXJhbmdlOjFiNzRiZTFlYTExYjQ5NTRhMGM3NDk4ZDFjYzdiNDZiXzEyLTEtMS0xLTA_5c96e86c-40a6-4a38-ad95-e8a5c33502cf"
      unitRef="usd">17418000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i2bce3c5038344323935db8cc2710a157_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV8xMDYvZnJhZzowYjYzY2RjMjUyZWM0N2NhOGI0NzFmN2MyMjkyM2JiYy90YWJsZToxYjc0YmUxZWExMWI0OTU0YTBjNzQ5OGQxY2M3YjQ2Yi90YWJsZXJhbmdlOjFiNzRiZTFlYTExYjQ5NTRhMGM3NDk4ZDFjYzdiNDZiXzEyLTMtMS0xLTA_b9d838d4-fbaa-451f-9428-abd2a5a4cdf0"
      unitRef="usd">355000</us-gaap:FinanceLeaseLiabilityNoncurrent>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619861346792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Aug. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Apollo Medical Holdings, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">95-4472349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1668 S. Garfield Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">2nd Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Alhambra<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">91801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">282-0288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AMEH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,513,655<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001083446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619854705912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 152,441<span></span>
</td>
<td class="nump">$ 103,189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investment in marketable securities</a></td>
<td class="nump">117,656<span></span>
</td>
<td class="nump">116,539<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables, net</a></td>
<td class="nump">17,588<span></span>
</td>
<td class="nump">11,004<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedPartiesCurrent', window );">Receivables, net &#8211; related parties</a></td>
<td class="nump">59,328<span></span>
</td>
<td class="nump">48,136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">15,919<span></span>
</td>
<td class="nump">16,885<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">11,188<span></span>
</td>
<td class="nump">10,315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetCurrent', window );">Loans receivable</a></td>
<td class="nump">6,425<span></span>
</td>
<td class="nump">6,425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableRelatedPartiesCurrent', window );">Loans receivable &#8211; related parties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,500<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">380,545<span></span>
</td>
<td class="nump">329,068<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Noncurrent assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">746<span></span>
</td>
<td class="nump">746<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Land, property and equipment, net</a></td>
<td class="nump">11,485<span></span>
</td>
<td class="nump">12,130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">94,790<span></span>
</td>
<td class="nump">103,012<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">239,053<span></span>
</td>
<td class="nump">238,505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in other entities &#8211; equity method</a></td>
<td class="nump">26,817<span></span>
</td>
<td class="nump">28,427<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue', window );">Investments in privately held entities</a></td>
<td class="nump">37,075<span></span>
</td>
<td class="nump">896<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">20,219<span></span>
</td>
<td class="nump">14,248<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">22,487<span></span>
</td>
<td class="nump">1,681<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total noncurrent assets</a></td>
<td class="nump">452,672<span></span>
</td>
<td class="nump">399,645<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">833,217<span></span>
</td>
<td class="nump">728,713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">24,788<span></span>
</td>
<td class="nump">27,279<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FiduciaryAccountsPayableCurrent', window );">Fiduciary accounts payable</a></td>
<td class="nump">1,853<span></span>
</td>
<td class="nump">2,027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical liabilities</a></td>
<td class="nump">70,273<span></span>
</td>
<td class="nump">58,725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="nump">42,210<span></span>
</td>
<td class="nump">4,529<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Dividend payable</a></td>
<td class="nump">431<span></span>
</td>
<td class="nump">271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">3,350<span></span>
</td>
<td class="nump">2,990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">9,500<span></span>
</td>
<td class="nump">9,500<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">152,507<span></span>
</td>
<td class="nump">105,423<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Noncurrent liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">13,654<span></span>
</td>
<td class="nump">18,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities, net of current portion</a></td>
<td class="nump">355<span></span>
</td>
<td class="nump">416<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">17,418<span></span>
</td>
<td class="nump">11,373<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of current portion and deferred financing costs</a></td>
<td class="nump">230,455<span></span>
</td>
<td class="nump">232,172<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total noncurrent liabilities</a></td>
<td class="nump">261,882<span></span>
</td>
<td class="nump">262,230<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">414,389<span></span>
</td>
<td class="nump">367,653<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 11)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_MezzanineEquityAbstract', window );"><strong>Mezzanine equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Noncontrolling interest in Allied Physicians of California, a Professional Medical Corporation</a></td>
<td class="nump">210,980<span></span>
</td>
<td class="nump">168,725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value per share; 100,000,000 shares authorized, 36,309,513 and 35,908,057 shares outstanding, excluding 17,475,707 and 17,458,810 treasury shares, at June&#160;30, 2020, and December&#160;31, 2019, respectively</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">163,986<span></span>
</td>
<td class="nump">159,608<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">43,001<span></span>
</td>
<td class="nump">31,905<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Retained earnings</a></td>
<td class="nump">207,023<span></span>
</td>
<td class="nump">191,549<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="nump">825<span></span>
</td>
<td class="nump">786<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">207,848<span></span>
</td>
<td class="nump">192,335<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, mezzanine equity and stockholders&#8217; equity</a></td>
<td class="nump">833,217<span></span>
</td>
<td class="nump">728,713<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FiduciaryAccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of fiduciary accounts payable, due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FiduciaryAccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of Investment in privately held entity that does not report net asset value per share .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_MezzanineEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_MezzanineEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of financing receivable, classified as current. Includes, but is not limited to, notes and loan receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts due from parties associated with the reporting entity as evidenced by a written promise to pay, due within 1 year (or 1 business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619859630424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">36,309,513<span></span>
</td>
<td class="nump">35,908,057<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury shares (in shares)</a></td>
<td class="nump">17,475,707<span></span>
</td>
<td class="nump">17,458,810<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">1,111,111<span></span>
</td>
<td class="nump">1,111,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">555,555<span></span>
</td>
<td class="nump">555,555<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619859286504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 165,169<span></span>
</td>
<td class="nump">$ 130,050<span></span>
</td>
<td class="nump">$ 330,274<span></span>
</td>
<td class="nump">$ 225,806<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of services</a></td>
<td class="nump">136,079<span></span>
</td>
<td class="nump">101,363<span></span>
</td>
<td class="nump">280,283<span></span>
</td>
<td class="nump">184,795<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">11,556<span></span>
</td>
<td class="nump">11,818<span></span>
</td>
<td class="nump">23,390<span></span>
</td>
<td class="nump">22,081<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts', window );">Depreciation and amortization</a></td>
<td class="nump">4,628<span></span>
</td>
<td class="nump">4,455<span></span>
</td>
<td class="nump">9,330<span></span>
</td>
<td class="nump">8,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for doubtful accounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,314)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,363)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total expenses</a></td>
<td class="nump">152,263<span></span>
</td>
<td class="nump">115,322<span></span>
</td>
<td class="nump">313,003<span></span>
</td>
<td class="nump">214,385<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">12,906<span></span>
</td>
<td class="nump">14,728<span></span>
</td>
<td class="nump">17,271<span></span>
</td>
<td class="nump">11,421<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="nump">834<span></span>
</td>
<td class="num">(42)<span></span>
</td>
<td class="nump">2,888<span></span>
</td>
<td class="num">(892)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal', window );">Gain on sale of equity method investment</a></td>
<td class="nump">99,647<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">99,647<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(2,673)<span></span>
</td>
<td class="num">(311)<span></span>
</td>
<td class="num">(5,541)<span></span>
</td>
<td class="num">(522)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">863<span></span>
</td>
<td class="nump">474<span></span>
</td>
<td class="nump">1,792<span></span>
</td>
<td class="nump">797<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">1,282<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="nump">1,384<span></span>
</td>
<td class="nump">211<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">99,953<span></span>
</td>
<td class="nump">145<span></span>
</td>
<td class="nump">100,170<span></span>
</td>
<td class="num">(406)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before provision for income taxes</a></td>
<td class="nump">112,859<span></span>
</td>
<td class="nump">14,873<span></span>
</td>
<td class="nump">117,441<span></span>
</td>
<td class="nump">11,015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">31,858<span></span>
</td>
<td class="nump">4,209<span></span>
</td>
<td class="nump">33,453<span></span>
</td>
<td class="nump">2,801<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">&#160;Net income</a></td>
<td class="nump">81,001<span></span>
</td>
<td class="nump">10,664<span></span>
</td>
<td class="nump">83,988<span></span>
</td>
<td class="nump">8,214<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income attributable to noncontrolling interests</a></td>
<td class="nump">73,957<span></span>
</td>
<td class="nump">7,119<span></span>
</td>
<td class="nump">72,892<span></span>
</td>
<td class="nump">4,529<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Apollo Medical Holdings, Inc.</a></td>
<td class="nump">$ 7,044<span></span>
</td>
<td class="nump">$ 3,545<span></span>
</td>
<td class="nump">$ 11,096<span></span>
</td>
<td class="nump">$ 3,685<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per share &#8211; basic (in dollars per share)</a></td>
<td class="nump">$ 0.20<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="nump">$ 0.31<span></span>
</td>
<td class="nump">$ 0.11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per share &#8211; diluted (in dollars per share)</a></td>
<td class="nump">$ 0.19<span></span>
</td>
<td class="nump">$ 0.09<span></span>
</td>
<td class="nump">$ 0.30<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ameh_HealthCareCapitationRevenueMember', window );">Capitation, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 140,949<span></span>
</td>
<td class="nump">$ 103,224<span></span>
</td>
<td class="nump">$ 281,370<span></span>
</td>
<td class="nump">$ 174,740<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_HealthCareOtherMember', window );">Risk pool settlements and incentives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">12,003<span></span>
</td>
<td class="nump">11,191<span></span>
</td>
<td class="nump">23,239<span></span>
</td>
<td class="nump">21,285<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ManagementServiceMember', window );">Management fee income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">8,690<span></span>
</td>
<td class="nump">10,353<span></span>
</td>
<td class="nump">17,505<span></span>
</td>
<td class="nump">19,349<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_HealthCarePatientServiceMember', window );">Fee-for-service, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">2,270<span></span>
</td>
<td class="nump">3,878<span></span>
</td>
<td class="nump">5,697<span></span>
</td>
<td class="nump">7,959<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 1,257<span></span>
</td>
<td class="nump">$ 1,404<span></span>
</td>
<td class="nump">$ 2,463<span></span>
</td>
<td class="nump">$ 2,473<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Depreciation, Depletion And Amortization, Excluding Amortization Of Debt Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of an equity method investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(7)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(9)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ameh_HealthCareCapitationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ameh_HealthCareCapitationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_HealthCareOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_HealthCareOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ManagementServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ManagementServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_HealthCarePatientServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_HealthCarePatientServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619858697592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS' EQUITY (UNAUDITED) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common&#160;Stock&#160;Outstanding</div></th>
<th class="th"><div>Additional Paid-in&#160;Capital</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Noncontrolling Interest</div></th>
<th class="th">
<div>Noncontrolling Interest </div>
<div>Mezzanine</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, beginning balance at Dec. 31, 2018</a></td>
<td class="nump">$ 181,544<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 162,723<span></span>
</td>
<td class="nump">$ 17,788<span></span>
</td>
<td class="nump">$ 998<span></span>
</td>
<td class="nump">$ 225,117<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,578,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity', window );">Net (loss) income</a></td>
<td class="nump">550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="nump">410<span></span>
</td>
<td class="num">(3,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredParValueMethod', window );">Purchase of treasury shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchase of treasury shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(93,451)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants', window );">Shares issued for exercise of options and warrants</a></td>
<td class="nump">140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants', window );">Shares issued for exercise of options and warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">202<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Dividends</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance at Mar. 31, 2019</a></td>
<td class="nump">182,377<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">163,006<span></span>
</td>
<td class="nump">17,928<span></span>
</td>
<td class="nump">1,408<span></span>
</td>
<td class="nump">212,434<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, ending balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,503,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity', window );">Net (loss) income</a></td>
<td class="nump">3,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,545<span></span>
</td>
<td class="nump">223<span></span>
</td>
<td class="nump">6,896<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants', window );">Shares issued for exercise of options and warrants</a></td>
<td class="nump">758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants', window );">Shares issued for exercise of options and warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Dividends</a></td>
<td class="num">(942)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(942)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance at Jun. 30, 2019</a></td>
<td class="nump">186,089<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">163,892<span></span>
</td>
<td class="nump">21,473<span></span>
</td>
<td class="nump">689<span></span>
</td>
<td class="nump">219,583<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, ending balance (in shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,638,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, beginning balance at Dec. 31, 2019</a></td>
<td class="nump">192,335<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">159,608<span></span>
</td>
<td class="nump">31,905<span></span>
</td>
<td class="nump">786<span></span>
</td>
<td class="nump">168,725<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,908,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity', window );">Net (loss) income</a></td>
<td class="nump">4,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,052<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="num">(1,161)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredParValueMethod', window );">Purchase of treasury shares</a></td>
<td class="num">(301)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(301)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchase of treasury shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,897)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Purchase of noncontrolling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(125)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants', window );">Shares issued for exercise of options and warrants</a></td>
<td class="nump">722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants', window );">Shares issued for exercise of options and warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151,601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">1,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Dividends</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance at Mar. 31, 2020</a></td>
<td class="nump">197,961<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">161,087<span></span>
</td>
<td class="nump">35,957<span></span>
</td>
<td class="nump">881<span></span>
</td>
<td class="nump">157,439<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, ending balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,042,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity', window );">Net (loss) income</a></td>
<td class="nump">7,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,044<span></span>
</td>
<td class="nump">291<span></span>
</td>
<td class="nump">73,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Purchase of noncontrolling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(126)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Shares issued for vesting of restricted stock awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Shares issued for vesting of restricted stock awards</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants', window );">Shares issued for exercise of options and warrants</a></td>
<td class="nump">2,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants', window );">Shares issued for exercise of options and warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">242,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringPeriodValueRestrictedStockAwardCancelled', window );">Cancellation of restricted stock awards</a></td>
<td class="num">(236)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(236)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Dividends</a></td>
<td class="num">(347)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(347)<span></span>
</td>
<td class="num">(20,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance at Jun. 30, 2020</a></td>
<td class="nump">$ 207,848<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">$ 163,986<span></span>
</td>
<td class="nump">$ 43,001<span></span>
</td>
<td class="nump">$ 825<span></span>
</td>
<td class="nump">$ 210,980<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,309,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Income (Loss), Including Portion Attributable To Noncontrolling Interest And Temporary Equity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_StockIssuedDuringPeriodValueRestrictedStockAwardCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Restricted Stock Award, Cancelled</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_StockIssuedDuringPeriodValueRestrictedStockAwardCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents number of share issued exercise of option and warrants during the period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents value of stock issued during the period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromRedemptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569655-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4616395-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromRedemptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredParValueMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the par value method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredParValueMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619859195640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 83,988<span></span>
</td>
<td class="nump">$ 8,214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">9,330<span></span>
</td>
<td class="nump">8,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">658<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for doubtful accounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,363)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">1,910<span></span>
</td>
<td class="nump">676<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized loss (gain) from investment in equity securities</a></td>
<td class="nump">25<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Income) loss from equity method investments</a></td>
<td class="num">(2,888)<span></span>
</td>
<td class="nump">892<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal', window );">Gain on sale of equity method investments</a></td>
<td class="num">(99,647)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred tax</a></td>
<td class="num">(4,473)<span></span>
</td>
<td class="num">(549)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net of business combinations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Receivables, net</a></td>
<td class="num">(6,284)<span></span>
</td>
<td class="nump">588<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueFromRelatedParties', window );">Receivables, net &#8211; related parties</a></td>
<td class="num">(11,191)<span></span>
</td>
<td class="num">(12,665)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other receivables</a></td>
<td class="nump">966<span></span>
</td>
<td class="num">(11,897)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(873)<span></span>
</td>
<td class="num">(2,740)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_IncreaseDecreaseInOperatingLeaseAssets', window );">Right-of-use assets</a></td>
<td class="nump">1,680<span></span>
</td>
<td class="nump">1,098<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(5,095)<span></span>
</td>
<td class="num">(243)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(3,043)<span></span>
</td>
<td class="nump">3,340<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable', window );">Fiduciary accounts payable</a></td>
<td class="num">(174)<span></span>
</td>
<td class="nump">260<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_IncreaseDecreaseInMedicalLiabilities', window );">Medical liabilities</a></td>
<td class="nump">11,252<span></span>
</td>
<td class="num">(3,819)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes payable</a></td>
<td class="nump">37,681<span></span>
</td>
<td class="num">(11,622)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="num">(1,247)<span></span>
</td>
<td class="num">(1,044)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="nump">12,575<span></span>
</td>
<td class="num">(22,017)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Payments for business acquisition, net of cash acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(41,518)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollectionOfLoansReceivable', window );">Proceeds from repayment of loans receivable &#8211; related parties</a></td>
<td class="nump">16,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToFundLongtermLoansToRelatedParties', window );">Advances on loans receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,425)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(1,142)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Purchases of investment &#8211; equity method</a></td>
<td class="num">(500)<span></span>
</td>
<td class="num">(2,158)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Proceeds from sale of equity method investment</a></td>
<td class="nump">52,743<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(451)<span></span>
</td>
<td class="num">(378)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital', window );">Dividend received</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">240<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">67,150<span></span>
</td>
<td class="num">(50,247)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_RepaymentsOfBankLoanAndLinesOfCredit', window );">Repayment of bank loan and lines of credit</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(8,040)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Dividends paid</a></td>
<td class="num">(30,187)<span></span>
</td>
<td class="num">(10,942)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of term loan</a></td>
<td class="num">(2,375)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payment of finance lease obligations</a></td>
<td class="num">(61)<span></span>
</td>
<td class="num">(50)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from the exercise of stock options and warrants</a></td>
<td class="nump">2,863<span></span>
</td>
<td class="nump">898<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of shares</a></td>
<td class="num">(788)<span></span>
</td>
<td class="num">(40)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Borrowings on line of credit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">39,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from common stock offering</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">205<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(30,548)<span></span>
</td>
<td class="nump">21,631<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">49,177<span></span>
</td>
<td class="num">(50,633)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">104,010<span></span>
</td>
<td class="nump">107,637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">153,187<span></span>
</td>
<td class="nump">57,004<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplementary disclosures of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">2,623<span></span>
</td>
<td class="nump">439<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosures of non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DeferredTaxLiabilityAdjustedToGoodwill', window );">Deferred tax liability adjustment to goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,355<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1', window );">Preferred shares received from sale of equity method investment</a></td>
<td class="nump">36,179<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract', window );"><strong>Reconciliation of cash, cash equivalents, and restricted cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">152,441<span></span>
</td>
<td class="nump">52,726<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashEquivalentsNoncurrent', window );">Restricted cash &#8211; non-current</a></td>
<td class="nump">746<span></span>
</td>
<td class="nump">4,278<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents, and restricted cash shown in the statement of cash flows</a></td>
<td class="nump">$ 153,187<span></span>
</td>
<td class="nump">$ 57,004<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DeferredTaxLiabilityAdjustedToGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liability Adjusted To Goodwill</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DeferredTaxLiabilityAdjustedToGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_IncreaseDecreaseInMedicalLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of medical liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_IncreaseDecreaseInMedicalLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_IncreaseDecreaseInOperatingLeaseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents increase in operating lease assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_IncreaseDecreaseInOperatingLeaseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents increase in lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the value of prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_RepaymentsOfBankLoanAndLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repayments Of Bank Loan And Lines Of Credit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_RepaymentsOfBankLoanAndLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of an equity method investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(7)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(9)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash consideration received for selling an asset or business through a noncash (or part noncash) transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToFundLongtermLoansToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with extending a long-term loan to a related party. Alternate caption: Payments for Advances to Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToFundLongtermLoansToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollectionOfLoansReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the collection, including prepayments, of loans receivable issued for financing of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollectionOfLoansReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=SL94080555-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619981004472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Description of Business</a></td>
<td class="text">Description of Business<div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Overview</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Apollo Medical Holdings, Inc. (&#8220;ApolloMed&#8221;), together with its affiliated physician groups and consolidated entities (collectively, the &#8220;Company&#8221;) is a physician-centric integrated population health management company working to provide coordinated, outcome-based medical care in a cost-effective manner to patients in California, the majority of whom are covered by private or public insurance such as Medicare, Medicaid and health maintenance organization (&#8220;HMO&#8221;) plans, with a portion of the Company&#8217;s revenue coming from non-insured patients. The Company provides care coordination services to each major constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups and health plans. The Company&#8217;s physician network consists of primary care physicians, specialist physicians, and hospitalists. The Company operates primarily through the following subsidiaries of ApolloMed: Network Medical Management, Inc. (&#8220;NMM&#8221;), Apollo Medical Management, Inc. (&#8220;AMM&#8221;), APA ACO, Inc. ("APAACO"), Apollo Care Connect, Inc. (&#8220;Apollo Care Connect&#8221;), and their consolidated entities.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">NMM was formed in 1994 as a management service organization (&#8220;MSO&#8221;) for the purposes of providing management services to medical companies and independent practice associations (&#8220;IPAs&#8221;). The management services primarily include billing, collection, accounting, administration, quality assurance, marketing, compliance, and education. Following a business combination, NMM became a wholly-owned subsidiary of ApolloMed in December 2017. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Allied Physicians of California IPA, a Professional Medical Corporation d.b.a. Allied Pacific of California IPA (&#8220;APC&#8221;) was incorporated in 1992, for the purpose of arranging healthcare services as an IPA. APC has contracts with various HMOs and other licensed healthcare service plans as defined in the California Knox-Keene Health Care Service Plan Act of 1975. Each HMO negotiates a fixed amount per member per month (&#8220;PMPM&#8221;) that is to be paid to APC. In return, APC arranges for the delivery of healthcare services by contracting with physicians or professional medical corporations for primary care and specialty care services. APC assumes the financial risk of the cost of delivering healthcare services in excess of the fixed amounts received. Some of the risk is transferred to the contracted physicians or professional corporations. The risk is also minimized by stop-loss provisions in contracts with HMOs.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In July 1999, APC entered into an amended and restated management and administrative services agreement with NMM (the initial management services agreement was entered into in 1997) for an initial fixed term of 30 years. In accordance with relevant accounting guidance, APC is determined to be a variable interest entity ("VIE") of the Company as NMM is the primary beneficiary with the ability to direct the activities (excluding clinical decisions) that most significantly affect APC&#8217;s economic performance through its majority representation on the APC Joint Planning Board; therefore APC is consolidated by NMM.  </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">AP-AMH Medical Corporation (&#8220;AP-AMH&#8221;) was formed in May 2019, as a designated shareholder professional corporation. Dr. Thomas Lam, a shareholder, and the Chief Executive Officer and Chief Financial Officer of APC and Co-Chief Executive Officer of ApolloMed, is the sole shareholder of AP-AMH. ApolloMed makes all the decisions on behalf of AP-AMH and funds and receives all the distributions from its operations. ApolloMed has the rights to receive benefits from the operations of AP-AMH and has the option, but not the obligation, to cover losses. Therefore, AP-AMH is controlled and consolidated by ApolloMed as the primary beneficiary of this VIE.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In September 2019, ApolloMed completed the following series of transactions with its affiliates, AP-AMH and APC;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">1.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">ApolloMed loaned AP-AMH $545.0 million pursuant to a 10-year secured loan agreement (the &#8220;AP-AMH Loan&#8221;). The loan bears interest at a rate of 10% per annum simple interest, is not prepayable (except in certain limited circumstances), requires quarterly payments of interest only in arrears, and is secured by a first priority security interest in all of AP-AMH</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">&#8217;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">s assets, including the shares of APC Series A Preferred Stock purchased by AP-AMH, as described below. To the extent that AP-AMH is unable to make any interest payment when due because it has received dividends on the APC Series A Preferred Stock insufficient to pay in full such interest payment, then the outstanding principal amount of the loan will be increased by the amount of any such accrued but unpaid interest, and any such increased principal amounts will bear interest at the rate of 10.75% per annum simple interest.</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">2.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">AP-AMH purchased 1,000,000 shares of APC Series A Preferred Stock for aggregate consideration of $545.0 million in a private placement. Under the terms of the APC Certificate of Determination of Preferences of Series A Preferred </span></div><div style="padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Stock (the &#8220;Certificate of Determination&#8221;), AP-AMH is entitled to receive preferential, cumulative dividends that accrue on a daily basis and that are equal to the sum of (i) APC&#8217;s net income from healthcare services (as defined in the Certificate of Determination), plus (ii) any dividends received by APC from certain of APC&#8217;s affiliated entities, less (iii) any Retained Amounts (as defined in the Certificate of Determination).</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">3.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">APC purchased 15,015,015 shares of ApolloMed&#8217;s common stock for total consideration of $300.0 million in private placement. In connection therewith, ApolloMed granted APC certain registration rights with respect to ApolloMed&#8217;s common stock that APC purchased, and APC agreed that APC votes in excess of 9.99% of ApolloMed&#8217;s then outstanding shares will be voted by proxy given to ApolloMed&#8217;s management, and that those proxy holders will cast the excess votes in the same proportion as all other votes cast on any specific proposal coming before ApolloMed&#8217;s stockholders.</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">4.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">ApolloMed licensed to AP-AMH the right to use certain trade names for certain specified purposes for a fee equal to a percentage of the aggregate gross revenues of AP-AMH. The license fee is payable out of any Series A Preferred Stock dividends received by AP-AMH from APC.</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">5.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Through its subsidiary, NMM, the Company agreed to provide certain administrative services to AP-AMH for a fee equal to a percentage of the aggregate gross revenues of AP-AMH. The administrative fee also is payable out of any APC Series A Preferred Stock dividends received by AP-AMH from APC.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">APC's ownership in ApolloMed was 32.28% at June&#160;30, 2020 and 32.50% at December&#160;31, 2019. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Concourse Diagnostic Surgery Center, LLC (&#8220;CDSC&#8221;) was formed in March&#160;2010 in the state of California. CDSC is an ambulatory surgery center in City of Industry, California organized by a group of highly qualified physicians, which utilizes some of the most advanced equipment in the eastern part of Los Angeles County and the San Gabriel Valley. The facility is Medicare certified and accredited by the Accreditation Association for Ambulatory Healthcare, Inc. As of June&#160;30, 2020, APC owned 45.01% of CDSC</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">&#8217;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">s capital stock. CDSC is determined to be a VIE and APC is determined to be the primary beneficiary. APC has the ability to direct the activities that most significantly affect CDSC&#8217;s economic performance and receives the most economic benefits; therefore CDSC is consolidated by APC.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">APC-LSMA Designated Shareholder Medical Corporation (&#8220;APC-LSMA&#8221;) was formed in October&#160;2012 as a designated shareholder professional corporation. Dr. Thomas Lam, a stockholder and the Chief Executive Officer and Chief Financial Officer of APC and Co-Chief Executive Officer of ApolloMed, is a nominee shareholder of APC. APC makes all investment decisions on behalf of APC-LSMA, funds all investments and receives all distributions from the investments. APC has the obligation to absorb losses and right to receive benefits from all investments made by APC-LSMA. APC-LSMA&#8217;s sole function is to act as the nominee shareholder for APC in other California medical professional corporations. Therefore, APC-LSMA is controlled and consolidated by APC as the primary beneficiary of this VIE. The only activity of APC-LSMA is to hold the investments in medical corporations, including the IPA lines of business of LaSalle Medical Associates (&#8220;LMA&#8221;), Pacific Medical Imaging and Oncology Center, Inc. (&#8220;PMIOC&#8221;), Diagnostic Medical Group (&#8220;DMG&#8221;) and AHMC International Cancer Center, a Medical Corporation (&#8220;ICC&#8221;). APC-LSMA also holds a 100% ownership interest in Maverick Medical Group, Inc. (&#8220;MMG&#8221;), Alpha Care Medical Group, Inc. (&#8220;Alpha Care&#8221;), Accountable Health Care IPA, a Professional Medical Corporation (&#8220;Accountable Health Care&#8221;), and AMG, a Professional Medical Corporation (&#8220;AMG&#8221;).</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Alpha Care, an IPA acquired by the Company in May 2019, has been operating in California since 1993 as a risk bearing organization engaged in providing professional services under capitation arrangements with its contracted health plans through a provider network consisting of primary care and specialty care physicians. Alpha Care specializes in delivering high-quality healthcare to approximately 170,000 enrollees, as of June&#160;30, 2020, and focuses on Medi-Cal/Medicaid, Commercial, and Medicare and Dual Eligible members in the Riverside and San Bernardino counties of Southern California.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accountable Health Care is a California-based IPA that has served the local community in the greater Los Angeles County area through a network of physicians and health care providers for more than 20 years. Accountable Health Care currently has a network of over 400 primary care physicians and 700 specialty care physicians, and four community and regional hospital medical centers that provide quality health care services to approximately 80,000 members of three federally qualified health plans and multiple product lines, including Medi-Cal, Commercial, Medicare and the California Healthy Families program. In August 2019, APC and APC-LSMA acquired the remaining outstanding shares of Accountable Health Care&#8217;s capital stock that they did not already own (comprising 75%) for&#160;$7.3 million&#160;in cash (see Note 3).</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">AMG is a network of family practice clinics operating out of three main locations in Southern California. AMG provides professional and post-acute care services to Medicare, Medi-Cal/Medicaid, and Commercial patients through its network of </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">doctors and nurse practitioners. In September 2019, APC-LSMA purchased 100% of the shares of capital stock of AMG for $1.2 million in cash and $0.4 million of APC common stock (see Note 3).</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Universal Care Acquisition Partners, LLC (&#8220;UCAP&#8221;), a 100% owned subsidiary of APC, was formed in June&#160;2014, for the purpose of holding an investment in Universal Care, Inc. (&#8220;UCI&#8221;). On April 30, 2020, UCAP completed the sale of its 48.9% ownership interest in UCI to Bright Health Company of California, Inc. ("Bright") for approximately $69.2 million in cash proceeds (including $16.5 million as repayment of indebtedness owed to APC), plus non-cash consideration consisting of shares of Bright Health, Inc.'s preferred stock having an estimated fair value of approximately $36.2 million on the date of sale. In addition, pursuant to the terms of the stock purchase agreement, APC has a beneficial interest in the equity method investment sold. The estimated fair value of such interest on April 30, 2020 was&#160;$15.7 million (see Note 5). As set forth in the Company&#8217;s definitive proxy statement filed with the SEC on July 31, 2019 (the &#8220;Proxy Statement&#8221;), the 48.9% interest in UCI is an &#8220;Excluded Asset&#8221; that remains solely for the benefit of APC and its shareholders. As such, any proceeds or gain on the sale of APC&#8217;s indirect ownership interest in UCI has no impact on the Series A Dividend payable by APC to AP-AMH Medical Corporation as described in the Proxy Statement and consequently the sale did not affect net income attributable to ApolloMed.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">APAACO, jointly owned by NMM and AMM, began participating in the Next Generation Accountable Care Organization (&#8220;NGACO") Model of the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) in January 2017. The NGACO Model is a CMS program that allows provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participating in this new attribution-based risk sharing model. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">AMM, a wholly-owned subsidiary of ApolloMed, manages affiliated medical groups, ApolloMed Hospitalists, a Medical Corporation (&#8220;AMH&#8221;) and Southern California Heart Centers, a Medical Corporation (&#8220;SCHC&#8221;). AMH provides hospitalist, intensivist, and physician advisory services. SCHC is a specialty clinic that focuses on cardiac care and diagnostic testing. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Apollo Care Connect, Inc. ("Apollo Care Connect"), a wholly-owned subsidiary of ApolloMed, provides a cloud and mobile-based population health management platform that includes digital care plans, a case management module, connectivity with multiple healthcare tracking devices and the ability to integrate with multiple electronic health records to capture clinical data.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619851998472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text">Basis of Presentation and Summary of Significant Accounting Policies<div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of Presentation</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying consolidated balance sheets at December&#160;31, 2019, has been derived from the Company&#8217;s audited consolidated financial statements, but does not include all disclosures required by generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;). The accompanying unaudited consolidated financial statements as of June&#160;30, 2020, and for the three and six months ended June&#160;30, 2020 and 2019, have been prepared in accordance with U.S. GAAP for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements, and should be read in conjunction with the audited consolidated financial statements and related notes to the financial statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2019 as filed with the SEC on March 16, 2020. In the opinion of management, all material adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been made to make the consolidated financial statements not misleading as required by Regulation S-X, Rule 10-01. Operating results for the three and six months ended June&#160;30, 2020, are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2020, or any future periods.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Principles of Consolidation</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The consolidated balance sheets as of June&#160;30, 2020 and December&#160;31, 2019, and the consolidated statements of income for the three and six months ended June&#160;30, 2020 and 2019, &#160;include the accounts of ApolloMed, its consolidated subsidiaries, NMM, AMM, APAACO, and Apollo Care Connect, its consolidated VIE, AP-AMH, NMM's consolidated subsidiaries, and consolidated VIE, APC, APC&#8217;s subsidiary, UCAP, and APC&#8217;s consolidated VIEs, CDSC, APC-LSMA, ICC, and APC-LSMA&#8217;s consolidated subsidiaries Alpha Care and Accountable Health Care.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">All material intercompany balances and transactions have been eliminated in consolidation.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of the consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.&#160;Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combination and goodwill valuation and impairment, accrual of medical liabilities (incurred, but not reported (&#8220;IBNR&#8221;) claims), determination of full-risk and shared-risk revenue and receivables (including constraints and completion factors, including historical medical loss ratios (&#8220;MLR&#8221;)), income taxes, valuation of share-based compensation and right-of-use ("ROU") assets and lease liabilities. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Reportable Segments</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company operates as one reportable segment, the healthcare delivery segment, and implements and operates innovative health care models to create a patient-centered, physician-centric experience. The Company reports its consolidated financial statements in the aggregate, including all activities in one reportable segment.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash and Cash Equivalents</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s cash and cash equivalents primarily consist of money market funds and certificates of deposit. The Company considers all highly liquid investments that are both readily convertible into known amounts of cash and mature within 90 days from their date of purchase to be cash equivalents.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company maintains its cash in deposit accounts with several banks, which at times may&#160;exceed the insured limits of the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;). The Company believes it is not exposed to any significant credit risk with respect to its cash, cash equivalents and restricted cash. As of June&#160;30, 2020, the Company&#8217;s deposit accounts with banks exceeded the FDIC&#8217;s insured limit by approximately $290.9 million, including approximately $117.6 million in certificates of deposit that were recognized as investments in marketable securities. The Company has not experienced any losses to date and performs ongoing evaluations of these financial institutions to limit the Company&#8217;s concentration of risk exposure.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Restricted Cash</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Restricted cash consists of cash held as collateral to secure standby letters of credits as required by certain contracts.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Investments in Marketable Securities</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The appropriate classification of investments is determined at the time of purchase and such designation is reevaluated at each balance sheet date. As of June&#160;30, 2020 and December&#160;31, 2019, investments in marketable securities amounted to approximately $117.7 million and $116.5 million, respectively, and consisted of equity securities and certificates of deposit with various financial institutions, reported at par value, plus accrued interest, with maturity dates from four months to 24 months (see fair value measurements of financial instruments below). Investments in certificates of deposits are classified as Level 1 investments in the fair value hierarchy.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Receivables and Receivables &#8211; Related Parties</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s receivables are comprised of accounts receivable, capitation and claims receivable, risk pool settlements and incentive receivables, management fee income and other receivables. Accounts receivable are recorded and stated at the amount expected to be collected.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s receivables &#8211; related parties are comprised of risk pool settlements, management fee income and incentive receivables, and other receivables. Receivables &#8211; related parties are recorded and stated at the amount expected to be collected.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Capitation and claims receivable relate to each health plan&#8217;s capitation and is received by the Company in the month following the month of service. Risk pool settlements and incentive receivables mainly consist of the Company&#8217;s full risk pool receivable that is recorded quarterly based on reports received from the Company&#8217;s hospital partners and management&#8217;s estimate of the Company&#8217;s portion of the estimated risk pool surplus for open performance years. Settlement of risk pool surplus or deficits occurs approximately 18 months after the risk pool performance year is completed. Other receivables consists of recoverable claims paid related to the 2019 APAACO performance year to be administered following instructions from CMS, fee-for-</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">services (&#8220;FFS&#8221;) reimbursement for patient care, certain expense reimbursements, transportation reimbursements from the hospitals, and stop loss insurance premium reimbursements.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company maintains reserves for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends and changes in customer payment patterns to evaluate the adequacy of these reserves. The Company also regularly analyzes the ultimate collectability of accounts receivable after certain stages of the collection cycle using a look-back analysis to determine the amount of receivables subsequently collected and adjustments are recorded when necessary. Reserves are recorded primarily on a specific identification basis.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Receivables are recorded when the Company is able to determine amounts receivable under applicable contracts and agreements based on information provided and collection is reasonably likely to occur. In regards to the credit loss standard, the Company continuously monitors its collections of receivables and our expectation is that the historical credit loss experienced across our receivable portfolio is materially similar to any current expected credit losses that would be estimated under the current expected credit losses (CECL) model. As of June 30, 2020 and December 31, 2019 the Company had $1.3&#160;million and  $2.9&#160;million of allowance for doubtful accounts, respectively. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Concentrations of Risks</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company disaggregates revenue from contracts by service type and payor type. This level of detail provides useful information pertaining to how the Company generates revenue by significant revenue stream and by type of direct contracts. The consolidated statements of income present disaggregated revenue by service type. The following table presents disaggregated revenue generated by payor type for the three and six months ended June&#160;30, 2020 and 2019 (in thousands):</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:71.792%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.739%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Commercial</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,479&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,365&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Medicare</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">62,038&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">57,965&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Medicaid</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">68,450&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,277&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other third parties</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,202&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,443&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenue</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">165,169&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">130,050&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:71.792%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.739%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Commercial</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50,192&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50,383&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Medicare</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">126,918&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">95,063&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Medicaid</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">134,897&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">61,647&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other third parties</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,267&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,713&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenue</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">330,274&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">225,806&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company had major payors that contributed the following percentages of net revenue:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:71.792%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.739%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Payor A</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Payor B</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Payor C</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Payor D</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Payor E</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payor F</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td></tr></table></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:71.792%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.739%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Payor A</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Payor B</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Payor C</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Payor D</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Payor E</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payor F</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">*&#160;Less than 10% of total net revenues</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company had major payors that contributed to the following percentages of receivables and receivables &#8211; related parties:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:62.181%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.543%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.546%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Payor D</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payor G</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payor H</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-indent:-18pt;padding-left:18pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">*&#160;Less than 10% of total receivables and receivables &#8212; related parties, net</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Fair Value Measurements of Financial Instruments</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s financial instruments consist of cash and cash equivalents, fiduciary cash, restricted cash, investment in marketable securities, receivables, loans receivable, accounts payable, certain accrued expenses, finance lease obligations, and long-term debt. The carrying values of the financial instruments classified as current in the accompanying consolidated balance sheets are considered to be at their fair values, due to the short maturity of these instruments. The carrying amounts of finance lease obligations and long-term debt approximate fair value as they bear interest at rates that approximate current market rates for debt with similar maturities and credit quality.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 820, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Fair Value Measurement</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASC 820&#8221;), applies to all financial assets and financial liabilities that are measured and reported on a fair value basis and requires disclosure that establishes a framework for measuring fair value and expands disclosure about fair value measurements. ASC&#160;820 establishes a fair value hierarchy for disclosure of the inputs to valuations used to measure fair value.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This hierarchy prioritizes the inputs into three broad levels as follows:</span></div><div style="padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Level&#160;1</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> &#8212; Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that can be accessed at the measurement date.</span></div><div style="padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Level&#160;2</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> &#8212; Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the </span></div><div style="padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">asset or liability (i.e., interest rates and yield curves), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).</span></div><div style="padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Level&#160;3</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> &#8212; Unobservable inputs that reflect assumptions about what market participants would use in pricing the asset or liability. These inputs would be based on the best information available, including the Company&#8217;s own data.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The carrying amounts and fair values of the Company&#8217;s financial instruments as of June&#160;30, 2020, are presented below (in thousands):</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:44.852%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.741%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Fair Value Measurements</span></div></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Level 1</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Level 2</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Level 3</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Total</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Money market funds*</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">108,195&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">108,195&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Marketable securities &#8211; certificates of deposit</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">117,611&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">117,611&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Marketable securities &#8211; equity securities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">225,851&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">225,851&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The carrying amounts and fair values of the Company&#8217;s financial instruments as of December&#160;31, 2019, are presented below (in thousands):</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:44.852%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.741%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Measurements</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds*</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50,731&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50,731&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities &#8211; certificates of deposit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">116,469&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">116,469&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities &#8211; equity securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">70&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">70&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">167,270&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">167,270&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="padding-left:18pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">*&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Included in cash and cash equivalents</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There have been no changes in Level 1, Level 2, or Level 3 classification and no changes in valuation techniques for these assets for the six months ended June&#160;30, 2020.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Intangible Assets and Long-Lived Assets</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Intangible assets with finite lives include network-payor relationships, management contracts and member relationships and are stated at cost, less accumulated amortization and impairment losses. These intangible assets are amortized on the accelerated method using the discounted cash flow rate.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Intangible assets with finite lives also include a patient management platform, as well as trade names and trademarks, whose valuations were determined using the cost to recreate method and the relief from royalty method, respectively. These assets are stated at cost, less accumulated amortization and impairment losses, and are amortized using the straight-line method.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Finite-lived intangibles and long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may&#160;not be recoverable. If the expected future cash flows from the use of such assets (undiscounted and without interest charges) are less than the carrying value, a write-down would be recorded to reduce the carrying value of the asset to its estimated fair value. Fair value is determined based on appropriate valuation techniques. The Company determined that there was no impairment of its finite-lived intangible or long-lived assets during the six months ended June&#160;30, 2020 and 2019.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Goodwill and Indefinite-Lived Intangible Assets</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under ASC 350, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Intangibles &#8211; Goodwill and Other</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, goodwill and indefinite-lived intangible assets are reviewed at least annually for impairment.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At least annually, at the Company&#8217;s fiscal year-end, or sooner if events or changes in circumstances indicate that an impairment has occurred, the Company performs a qualitative assessment to determine whether it is more likely than not that the fair value of each reporting unit is less than its carrying amount as a basis for determining whether it is necessary to complete quantitative impairment assessments for each of the Company&#8217;s three main reporting units (1) management services, (2) IPAs, and (3) ACOs. The Company is required to perform a quantitative goodwill impairment test only if the conclusion from the qualitative assessment is that it is more likely than not that a reporting unit&#8217;s fair value is less than the carrying value of its assets. Should this be the case, a quantitative analysis is performed to identify whether a potential impairment exists by comparing the estimated fair values of the reporting units with their respective carrying values, including goodwill.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">An impairment loss is recognized if the implied fair value of the asset being tested is less than its carrying value. In this event, the asset is written down accordingly. The fair values of goodwill are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At least annually, indefinite-lived intangible assets are tested for impairment. Impairment for intangible assets with indefinite lives exists if the carrying value of the intangible asset exceeds its fair value. The fair values of indefinite-lived intangible assets are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company had no impairment of its goodwill or indefinite-lived intangible assets during the six months ended June&#160;30, 2020 and 2019. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Investments in Other Entities &#8212; Equity Method</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accounts for certain investments using the equity method of accounting when it is determined that the investment provides the Company with the ability to exercise significant influence, but not control, over the investee. Significant influence is generally deemed to exist if the Company has an ownership interest in the voting stock of the investee of between 20% and 50%, although other factors, such as representation on the investee&#8217;s board of directors, are considered in determining whether the equity method of accounting is appropriate. Under the equity method of accounting, the investment, originally recorded at cost, is adjusted to recognize the Company&#8217;s share of net earnings or losses of the investee and is recognized in the accompanying consolidated statements of income under &#8220;Income (loss) from equity method investments&#8221; and also is adjusted by contributions to and distributions from the investee. Equity method investments are subject to impairment evaluation. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Investments in Privately Held Entities</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accounts for certain investments using the cost method of accounting when it is determined that the investment provides the Company with little or no influence over the investee. Under the cost method of accounting, the investment is measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income. The investments in privately held entities that do not report NAV are subject to qualitative assessment for indicators of impairments.</span></div><div style="text-align:justify;margin-top:10pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Medical Liabilities</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">APC, Alpha Care, Accountable Health Care, APAACO and MMG are responsible for integrated care that the associated physicians and contracted hospitals provide to their enrollees. APC, Alpha Care, Accountable Health Care, APAACO and MMG provide integrated care to HMOs, Medicare and Medi-Cal enrollees through a network of contracted providers under sub-capitation and direct patient service arrangements. Medical costs for professional and institutional services rendered by contracted providers are recorded as cost of services expenses in the accompanying consolidated statements of income.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">An estimate of amounts due to contracted physicians, hospitals, and other professional providers is included in medical liabilities in the accompanying consolidated balance sheets. Medical liabilities include claims reported as of the balance sheet date and estimates IBNR claims. Such estimates are developed using actuarial methods and are based on numerous variables, including the utilization of health care services, historical payment patterns, cost trends, product mix, seasonality, changes in membership, and other factors. The estimation methods and the resulting reserves are periodically reviewed and updated. Many of the medical contracts are complex in nature and may&#160;be subject to differing interpretations regarding amounts due for the provision of various services. Such differing interpretations may&#160;not come to light until a substantial period of time has passed following the contract implementation.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue Recognition</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company receives payments from the following sources for services rendered: (i) commercial insurers; (ii) the federal government under the Medicare program administered by CMS; (iii) state governments under the Medicaid and other programs; (iv) other third-party payors (e.g., hospitals and IPAs); and (v) individual patients and clients.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Nature of Services and Revenue Streams</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenue primarily consists of capitation revenue, risk pool settlements and incentives, NGACO All-Inclusive Population-Based Payments (&#8220;AIPBP&#8221;), management fee income, and FFS revenue. Revenue is recorded in the period in which services are rendered or the period in which the Company is obligated to provide services. The form of billing and related risk of collection for such services may&#160;vary by type of revenue and the customer. The following is a summary of the principal forms of the Company&#8217;s billing arrangements and how revenue is recognized for each.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Capitation, Net</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Managed care revenues of the Company consist primarily of capitated fees for medical services provided by the Company under a capitated arrangement directly made with various managed care providers including HMOs. Capitation revenue is typically prepaid monthly to the Company based on the number of enrollees selecting the Company as their healthcare provider. Capitation revenue is recognized in the month in which the Company is obligated to provide services to plan enrollees under contracts with various health plans. Minor ongoing adjustments to prior months&#8217; capitation, primarily arising from contracted HMOs finalizing their monthly patient eligibility data for additions or subtractions of enrollees, are recognized in the month they are communicated to the Company. Additionally, Medicare pays capitation using a &#8220;Risk Adjustment&#8221; model, which compensates managed care organizations and providers based on the health status (acuity) of each individual enrollee. Health plans and providers with higher acuity enrollees will receive more and those with lower acuity enrollees will receive less. Under Risk Adjustment, capitation is determined based on health severity, measured using patient encounter data. Capitation is paid on a monthly basis based on data submitted for the enrollee for the preceding year and is adjusted in subsequent periods after the final data is compiled. Positive or negative capitation adjustments are made for Medicare enrollees with conditions requiring more or less healthcare services than assumed in the interim payments. Since the Company cannot reliably predict these adjustments, periodic changes in capitation amounts earned as a result of Risk Adjustment are recognized when those changes are communicated by the health plans to the Company.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">PMPM managed care contracts generally have a term of one year or longer. All managed care contracts have a single performance obligation that constitutes a series for the provision of managed healthcare services for a population of enrolled members for the duration of the contract. The transaction price for PMPM contracts is variable as it primarily includes PMPM fees associated with unspecified membership that fluctuates throughout the contract. In certain contracts, PMPM fees also include adjustments for items such as performance incentives, performance guarantees and risk shares. The Company generally estimates the transaction price using the most likely amount methodology and amounts are only included in the net transaction price to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The majority of the Company&#8217;s net PMPM transaction price relates specifically to the Company&#8217;s efforts to transfer the service for a distinct increment of the series (e.g., day or month) and is recognized as revenue in the month in which members are entitled to service.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Risk Pool Settlements and Incentives</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">APC enters into full risk capitation arrangements with certain health plans and local hospitals, which are administered by a third party, where the hospital is responsible for providing, arranging and paying for institutional risk and APC is responsible for providing, arranging and paying for professional risk. Under a full risk pool sharing agreement, APC generally receives a percentage of the net surplus from the affiliated hospital&#8217;s risk pools with HMOs after deductions for the affiliated hospitals costs. Advance settlement payments are typically made quarterly in arrears if there is a surplus. The Company&#8217;s risk pool settlements under arrangements with health plans and hospitals are recognized using the most likely amount methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The assumptions for historical MLR, IBNR completion factors and constraint percentages were used by management in applying the most likely amount methodology.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under capitated arrangements with certain HMOs, APC participates in one or more shared risk arrangements relating to the provision of institutional services to enrollees (shared risk arrangements) and thus can earn additional revenue or incur losses based upon the enrollee utilization of institutional services. Shared risk capitation arrangements are entered into with certain health plans, which are administered by the health plan, where APC is responsible for rendering professional services, but the health plan does not enter into a capitation arrangement with a hospital and therefore the health plan retains the institutional risk. Shared risk deficits, if any, are not payable until and unless (and only to the extent of any) risk-sharing surpluses are generated. At the termination of the HMO contract, any accumulated deficit will be extinguished.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s risk pool settlements under arrangements with HMOs are recognized, using the most likely methodology, and only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur. Given </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">the lack of access to the health plans&#8217; data and control over the members assigned to APC, the adjustments and/or the withheld amounts are unpredictable and as such APC&#8217;s risk share revenue is deemed to be fully constrained until APC is notified of the amount by the health plan. Risk pools for the prior contract years are generally final settled in the third or fourth quarter of the following year.</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to risk-sharing revenues, the Company also receives incentives under &#8220;pay-for-performance&#8221; programs for quality medical care, based on various criteria. As an incentive to control enrollee utilization and to promote quality care, certain HMOs have designed quality incentive programs and commercial generic pharmacy incentive programs to compensate the Company for its efforts to improve the quality of services and efficient and effective use of pharmacy supplemental benefits provided to HMO members. The incentive programs track specific performance measures and calculate payments to the Company based on the performance measures. The Company&#8217;s incentives under &#8220;pay-for-performance&#8221; programs are recognized using the most likely methodology. However, as the Company does not have sufficient insight from the health plans on the amount and timing of the shared risk pool and incentive payments these amounts are considered to be fully constrained and only recorded when such payments are known and/or received.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Generally, for the foregoing arrangements, the final settlement is dependent on each distinct day&#8217;s performance within the annual measurement period but cannot be allocated to specific days until the full measurement period has occurred and performance can be assessed. As such, this is a form of variable consideration estimated at contract inception and updated through the measurement period (i.e., the contract year), to the extent the risk of reversal does not exist and the consideration is not constrained.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">NGACO AIPBP Revenue</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">APAACO and CMS entered into a NGACO Model Participation Agreement (the &#8220;Participation Agreement&#8221;) with an initial term of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMjY0NTk_5c465777-41e6-4d7a-b713-4cd6abec3b70">two</span> performance years through December&#160;31, 2018, which term was extended for <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMjY1MzU_16e36149-7c47-4c0c-bc55-d85a3cf36fbe">two</span> additional renewal years.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For each performance year, the Company must submit to CMS its selections for risk arrangement; the amount of the profit/loss cap; alternative payment mechanism; benefits enhancements, if any; and its decision regarding voluntary alignment under the NGACO Model. The Company must obtain CMS consent before voluntarily discontinuing any benefit enhancement during a performance year.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the NGACO Model, CMS aligns beneficiaries to the Company to manage (direct care and pay providers) based on a budgetary benchmark established with CMS. The Company is responsible for managing medical costs for these beneficiaries. The beneficiaries will receive services from physicians and other medical service providers that are both in-network and out-of-network. The Company receives capitation from CMS on a monthly basis to pay claims from in-network providers. The Company records such capitation received from CMS as revenue as the Company is primarily responsible and liable for managing the patient care and for satisfying provider obligations, is assuming the credit risk for the services provided by in-network providers through its arrangement with CMS, and has control of the funds, the services provided and the process by which the providers are ultimately paid. Claims from out-of-network providers are processed and paid by CMS and the Company&#8217;s shared savings or losses in managing the services provided by out-of-network providers are generally determined on an annual basis after reconciliation with CMS. Pursuant to the Company&#8217;s risk share agreement with CMS, the Company will be eligible to receive the savings or be liable for the deficit according to the budget established by CMS based on the Company&#8217;s efficiency in managing how the beneficiaries aligned to the Company by CMS are served by in-network and out-of-network providers. The Company&#8217;s savings or losses on providing such services are both capped by CMS, and are subject to significant estimation risk, whereby payments can vary significantly depending upon certain patient characteristics and other variable factors. Accordingly, the Company recognizes such surplus or deficit upon substantial completion of reconciliation and determination of the amounts. The Company records NGACO capitation revenues monthly. Excess over claims paid, plus an estimate for the related IBNR claims (see Note 8), and monthly capitation received are deferred and recorded as a liability until actual claims are paid or incurred. CMS will determine if there were any excess capitation paid for the performance year and the excess is refunded to CMS.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For each performance year, CMS pays the Company in accordance with the alternative payment mechanism, if any, for which CMS has approved the Company; the risk arrangement for which the Company has been approved by CMS; and as otherwise provided in the Participation Agreement. Following the end of each performance year and at such other times as may be required under the Participation Agreement, CMS will issue a settlement report to the Company setting forth the amount of any shared savings or shared losses and the amount of other monies. If CMS owes the Company shared savings or other monies, CMS will pay the Company in full within 30 days after the date on which the relevant settlement report is deemed final, except as provided in the Participation Agreement. If the Company owes CMS shared losses or other monies owed as a result of a final settlement, the Company will pay CMS in full within 30 days after the relevant settlement report is deemed final. If the </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Company fails to pay the amounts due to CMS in full within 30 days after the date of a demand letter or settlement report, CMS will assess simple interest on the unpaid balance at the rate applicable to other Medicare debts under current provisions of law and applicable regulations. In addition, CMS and the U.S. Department of the Treasury may use any applicable debt collection tools available to collect any amounts owed by the Company.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company participates in the AIPBP track of the NGACO Model. Under the AIPBP track, CMS estimates the total annual expenditures for APAACO&#8217;s assigned patients and pays that projected amount to the Company in monthly installments, and the Company is responsible for all Part A and Part B costs for in-network participating providers and preferred providers contracted by the Company to provide services to the assigned patients.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As APAACO does not have sufficient insight into the financial performance of the shared risk pool with CMS because of unknown factors related to IBNR claims, risk adjustment factors, and stop loss provisions, among other factors, an estimate cannot be developed. Due to these limitations, APAACO cannot determine the amount of surplus or deficit that will likely be recognized in the future and therefore this shared risk pool revenue is considered fully constrained.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For performance year 2020, the Company continues to receive monthly AIPBP payments at a rate of approximately $7.6 million per month from CMS, and will need to continue to comply with all terms and conditions in the Participation Agreement and various regulatory requirements to be eligible to participate in the AIPBP mechanism and/or NGACO Model. The Company has received approximately $22.9&#160;million and $45.5 million in total AIPBP payments for the three and six months ended June&#160;30, 2020, respectively, of which $20.5&#160;million and $42.4 million has been recognized as revenue for the three and six months ended June 30, 2020, respectively. The Company also recorded assets of approximately $8.5 million related to IBNR claims as of June&#160;30, 2020, and $3.2 million related to final settlement of the 2018 performance year. These balances are included in &#8220;Other receivables&#8221; in the accompanying consolidated balance sheets.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Management Fee Income</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Management fee income encompasses fees paid for management, physician advisory, healthcare staffing, administrative and other non-medical services provided by the Company to IPAs, hospitals and other healthcare providers. Such fees may be in the form of billings at agreed-upon hourly rates, percentages of revenue or fee collections, or amounts fixed on a monthly, quarterly or annual basis. The revenue may include variable arrangements measuring factors such as hours staffed, patient visits or collections per visit against benchmarks, and, in certain cases, may be subject to achieving quality metrics or fee collections. The Company recognizes such variable supplemental revenues in the period when such amounts are determined to be fixed and therefore contractually obligated as payable by the customer under the terms of the applicable agreement.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company provides a significant service of integrating the services selected by the Company&#8217;s clients into one overall output for which the client has contracted. Therefore, such management contracts generally contain a single performance obligation. The nature of the Company&#8217;s performance obligation is to stand ready to provide services over the contractual period. Also, the Company&#8217;s performance obligation forms a series of distinct periods of time over which the Company stands ready to perform. The Company&#8217;s performance obligation is satisfied as the Company completes each period&#8217;s obligations.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Consideration from management contracts is variable in nature because the majority of the fees are generally based on revenue or collections, which can vary from period to period. The Company has control over pricing. Contractual fees are invoiced to the Company&#8217;s clients generally monthly and payment terms are typically due within 30 days. The variable consideration in the Company&#8217;s management contracts meets the criteria to be allocated to the distinct period of time to which it relates because (i) it is due to the activities performed to satisfy the performance obligation during that period and (ii) it represents the consideration to which the Company expects to be entitled.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s management contracts generally have long terms (e.g., 10 years), although they may be terminated earlier under the terms of the applicable contracts. Since the remaining variable consideration will be allocated to a wholly unsatisfied promise that forms part of a single performance obligation recognized under the series guidance, the Company has applied the optional exemption to exclude disclosure of the allocation of the transaction price to remaining performance obligations.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Fee-for-Service Revenue</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">FFS revenue represents revenue earned under contracts in which the Company bills and collects the professional component of charges for medical services rendered by the Company&#8217;s contracted physicians and employed physicians. Under the FFS arrangements, the Company bills the hospitals and third-party payors for the physician staffing and further bills patients or their third-party payors for patient care services provided and receives payment. FFS revenue related to the patient care services is reported net of contractual allowances and policy discounts and are recognized in the period in which the services are rendered to specific patients. All services provided are expected to result in cash flows and are therefore reflected as net revenue in the </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">consolidated financial statements. The recognition of net revenue (gross charges less contractual allowances) from such services is dependent on such factors as proper completion of medical charts following a patient visit, the forwarding of such charts to the Company&#8217;s billing center for medical coding and entering into the Company&#8217;s billing system and the verification of each patient&#8217;s submission or representation at the time services are rendered as to the payor(s) responsible for payment of such services. Revenue is recorded based on the information known at the time of entering of such information into the Company&#8217;s billing systems, as well as an estimate of the revenue associated with medical services.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is responsible for confirming member eligibility, performing program utilization review, potentially directing payment to the provider and accepting the financial risk of loss associated with services rendered, as specified within the Company&#8217;s client contracts. The Company has the ability to adjust contractual fees with clients and possess the financial risk of loss in certain contractual obligations. These factors indicate the Company is the principal and, as such, the Company records gross fees contracted with clients in revenues.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Consideration from FFS arrangements is variable in nature because fees are based on patient encounters, credits due to clients and reimbursement of provider costs, all of which can vary from period to period.&#160;Patient encounters and related episodes of care and procedures qualify as distinct goods and services, provided simultaneously together with other readily available resources, in a single instance of service, and thereby constitute a single performance obligation for each patient encounter and, in most instances, occur at readily determinable transaction prices. As a practical expedient, the Company adopted a portfolio approach for the FFS revenue stream to group together contracts with similar characteristics and analyze historical cash collections trends. The contracts within the portfolio share the characteristics conducive to ensuring that the results do not materially differ under the new standard if it were to be applied to individual patient contracts related to each patient encounter. Accordingly, there was no change in the Company&#8217;s method to recognize revenue under ASC 606 </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue from Contracts with Customers</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> from the previous accounting guidance.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Estimating net FFS revenue is a complex process, largely due to the volume of transactions, the number and complexity of contracts with payors, the limited availability at times of certain patient and payor information at the time services are provided, and the length of time it takes for collections to fully mature. These expected collections are based on fees and negotiated payment rates in the case of third-party payors, the specific benefits provided for under each patient&#8217;s healthcare plans, mandated payment rates in the case of Medicare and Medicaid programs, and historical cash collections (net of recoveries) in combination with expected collections from third-party payors.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The relationship between gross charges and the transaction price recognized is significantly influenced by payor mix, as collections on gross charges may vary significantly, depending on whether and with whom the patients the Company provides services to in the period are insured and the Company&#8217;s contractual relationships with those payors. Payor mix is subject to change as additional patient and payor information is obtained after the period services are provided. The Company periodically assesses the estimates of unbilled revenue, contractual adjustments and discounts, and payor mix by analyzing actual results, including cash collections, against estimates. Changes in these estimates are charged or credited to the consolidated statements of income in the period that the assessment is made. Significant changes in payor mix, contractual arrangements with payors, specialty mix, acuity, general economic conditions and health care coverage provided by federal or state governments or private insurers may have a significant impact on estimates and significantly affect the results of operations and cash flows.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Contract Assets</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Typically, revenues and receivables are recognized once the Company has satisfied its performance obligation. Accordingly, the Company&#8217;s contract assets are comprised of receivables and receivables &#8211; related parties.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8217;</span><span style="background-color:rgb(255,255,255, 0.0);color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">s billing and accounting systems provide historical trends of cash collections and contractual write-offs, accounts receivable agings and established fee adjustments from third-party payors. These estimates are recorded and monitored monthly as revenues are recognized.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The principal exposure for uncollectible fee for service visits is from self-pay patients and, to a lesser extent, for co-payments and deductibles from patients with insurance.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Contract Liabilities (Deferred Revenue</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">)</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Contract liabilities are recorded when cash payments are received in advance of the Company&#8217;s performance, or in the case of the Company&#8217;s NGACO, the excess of AIPBP capitation received and the actual claims paid or incurred. The Company&#8217;s contract liability balance was $3.1 million and $8.9 million as of June&#160;30, 2020, and December&#160;31, 2019, respectively, and is presented within &#8220;Accounts payable and accrued expenses&#8221; in the accompanying consolidated balance sheets. During the six months ended June&#160;30, 2020, $0.4 million of the Company&#8217;s contract liability accrued in 2019 has been recognized as revenue and $8.5 million was repaid back to CMS for AIPBP capitation received and not earned.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other Financial Information</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2020, the Company made a deposit of $4.0 million for future investment opportunities. The investment was made with cash strictly related to the APC excluded assets that was generated from the series of transactions with AP-AMH. The deposit is included in &#8220;Other assets&#8221; in the accompanying consolidated balance sheets.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Income Taxes</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Federal and state income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the consolidated financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the consolidated financial statements.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Share-Based Compensation</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company maintains a stock-based compensation program for employees, non-employees, directors and consultants. The value of share-based awards such as options is recognized as compensation expense on a cumulative straight-line basis over the vesting period of the awards, adjusted for expected forfeitures. From time to time, the Company issues shares of its common stock to its employees, directors and consultants, which shares may be subject to the Company&#8217;s repurchase right (but not obligation) that lapses based on time-based and performance-based vesting schedules.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basic and Diluted Earnings Per Share</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Basic earnings per share is computed by dividing net income attributable to holders of the Company&#8217;s common stock by the weighted average number of shares of common stock outstanding during the periods presented. Diluted earnings per share is computed using the weighted average number of shares of common stock outstanding, plus the effect of dilutive securities outstanding during the periods presented, using the treasury stock method. Refer to Note 14 for a discussion of shares treated as treasury shares for accounting purposes.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Noncontrolling Interests</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company consolidates entities in which the Company has a controlling financial interest. The Company consolidates subsidiaries in which the Company holds, directly or indirectly, more than 50% of the voting rights, and VIEs in which the Company is the primary beneficiary. Noncontrolling interests represent third-party equity ownership interests (including equity ownership interests held by certain VIEs) in the Company&#8217;s consolidated entities. Net income attributable to noncontrolling interests is disclosed in the consolidated statements of income.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Mezzanine Equity</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to APC&#8217;s shareholder agreements, in the event of a disqualifying event, as defined in the agreements, APC could be required to repurchase the shares from the respective shareholders based on certain triggers outlined in the shareholder agreements. As the redemption feature of the shares is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as mezzanine or temporary equity. Accordingly, the Company recognizes </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">noncontrolling interests in APC as mezzanine equity in the consolidated financial statements. As of June&#160;30, 2020 and December&#160;31, 2019, APC's shares were not redeemable, nor was it probable the shares would become redeemable.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Accounting Pronouncements</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financial Instruments-Credit Losses (Topic 326)-Measurement of Credit Losses on Financial Instruments</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASU 2016-13&#8221;). The new standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. ASU 2016-13 became effective for fiscal years beginning after December 15, 2019, with early adoption permitted. The Company adopted ASU 2016-13 on January 1, 2020. The adoption of ASU 2016-13 did not have a material impact on the consolidated financial statements.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In October 2018, the FASB issued ASU No. 2018-17, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Consolidation (Topic 810): Targeted Improvements to Related Party Guidance for Variable Interest Entities</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASU 2018-17&#8221;). This ASU reduces the cost and complexity of financial reporting associated with consolidation of VIEs. A VIE is an organization in which consolidation is not based on a majority of voting rights. The new guidance supersedes the private company alternative for common control leasing arrangements issued in 2014 and expands it to all qualifying common control arrangements. The amendments in this ASU became effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The Company adopted ASU 2018-17 on January 1, 2020. The adoption of ASU 2018-17 did not have a material impact on the consolidated financial statements.</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASU 2019-12&#8221;). This ASU simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740 </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Income Taxes </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The amendments in this ASU are effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company is currently assessing the impact that the adoption of ASU 2019-12 will have on the Company's consolidated financial statements.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2020, the FASB issued ASU No. 2020-01, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Investments - Equity Securities (Topic 321), Investments - Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(&#8220;ASU 2020-01&#8221;). This ASU clarifies the interaction between accounting for equity securities, equity method investments and certain derivative instruments. The amendments in this ASU are effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company is currently assessing the impact that the adoption of ASU 2020-01 will have on the Company's consolidation financial statements.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other than the standards discussed above, there have been no other new accounting pronouncements that have significance, or potential significance, to the Company&#8217;s financial position, results of operations and cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619852013752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations and Goodwill<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Business Combinations and Goodwill</a></td>
<td class="text">Business Combinations and Goodwill<div style="text-indent:-18pt;padding-left:18pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Alpha Care Medical Group, Inc.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On May 31, 2019, APC and APC-LSMA completed their acquisition of 100% of the capital stock of Alpha Care from Dr. Kevin Tyson for an aggregate purchase price of approximately $45.1 million in cash, subject to post-closing adjustments. As part of the transaction the Company deposited $2.0 million into an escrow account for potential post-closing adjustments. As of June&#160;30, 2020, no post-closing adjustment is expected to be paid to Dr. Tyson and the full amount of the escrow account is expected to be returned to the Company. As such, the escrow amount is presented within prepaid expenses and other current assets in the accompanying consolidated balance sheets. </span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the estimated fair values of the assets acquired and liabilities assumed, as of the acquisition date (in thousands):</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:78.498%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:17.502%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance Sheet</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Assets acquired</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,569&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,336&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,675&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Network relationship intangible assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,636&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28,585&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,795)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6,334)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Medical liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(15,616)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;Net assets acquired</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45,056&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45,056&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accountable Health Care, IPA, a Professional Medical Corporation</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On August 30, 2019, APC and APC-LSMA acquired the remaining outstanding shares of capital stock (comprising 75%) in Accountable Health Care in exchange for $7.3 million. In addition to the payment of $7.3 million, APC assumed all assets and liabilities of Accountable Health Care, including loans payable to NMM and APC of $15.4 million, which have been eliminated upon consolidation and contributed the 25% investment totaling $2.4 million, total purchase price was $25.1 million (see Note 5). </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the estimated fair values of the assets acquired and liabilities assumed, as of the acquisition date (in thousands):</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:78.498%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:17.502%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance Sheet</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Assets acquired</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">582&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,150&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">198&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Network relationship intangible assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,411&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,566&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,759)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Medical liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(12,154)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Subordinated loan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(15,327)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net asset acquired</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,667&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity investment contributed</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,417&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,250&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">AMG, a Professional Medical Corporation</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company acquired AMG in September 2019, for total consideration of $1.6 million, of which $0.4 million was in the form of APC common stock. The business combination did not meet the quantitative thresholds to require separate disclosures based on the Company&#8217;s consolidated net assets, investments and net income.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The acquisitions were accounted for under the acquisition method of accounting. The fair value of the consideration for the acquired company was allocated to acquired tangible and intangible assets and liabilities based upon their fair values. The excess of the purchase consideration over the fair value of the net tangible and identifiable intangible assets acquired was recorded as goodwill. The determination of the fair value of assets and liabilities acquired requires the Company to make estimates and use valuation techniques when market value is not readily available. The results of operations of the company </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">acquired have been included in the Company&#8217;s financial statements from the date of acquisition. Transaction costs associated with business acquisitions are expensed as they are incurred.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At the time of acquisition, the Company estimates the amount of the identifiable intangible assets based on a valuation and the facts and circumstances available at the time. The Company determines the final value of the identifiable intangible assets as soon as information is available, but not more than one year from the date of acquisition.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Goodwill is not deductible for tax purposes.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The change in the carrying value of goodwill for the six months ended June&#160;30, 2020, was as follows (in thousands);</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:78.498%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:17.502%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, January 1, 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">238,505&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">548&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, June 30, 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">239,053&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619853723464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets, Net</a></td>
<td class="text">Intangible Assets, Net<div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At June&#160;30, 2020, the Company&#8217;s intangible assets, net, consisted of the following (in thousands):</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:42.199%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:7.544%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.684%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.684%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.687%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Useful</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Life</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Years)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Amortization</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net June 30,<br/>2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Amortized intangible assets:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Network relationships</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">11-15</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">143,930&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(67,015)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">76,915&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Management contracts</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,832&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10,736)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,096&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Member relationships</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,696&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,793)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,903&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Patient management platform</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,060&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,064)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">996&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Trade names/trademarks</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,011&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(131)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">880&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">176,529&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(81,739)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">94,790&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At December&#160;31, 2019, the Company&#8217;s intangible assets, net, consisted of the following (in thousands):</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:38.789%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.426%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.888%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.234%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Useful</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Life</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Years)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross December 31,<br/>2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Amortization</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Amortized intangible assets:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Network relationships</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">11-15</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">143,930&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(60,526)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">83,404&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Management contracts</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,832&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9,676)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,156&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Member relationships</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,696&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,352)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,344&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Patient management platform</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,060&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(858)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,202&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Trade names/trademarks</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,011&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(105)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">906&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">176,529&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(73,517)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">103,012&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Included in depreciation and amortization on the accompanying consolidated statements of income is amortization expense of $4.1 million and $3.9 million for the three months ended June&#160;30, 2020 and 2019, respectively, and $8.2 million and $7.7 million for the six months ended June&#160;30, 2020 and 2019, respectively.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Future amortization expense is estimated to be as follows for the following years ending December&#160;31 (in thousands):</span></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:85.262%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.738%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020 (excluding the six months ended June 30, 2020)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,807&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,524&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,673&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,842&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,830&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39,114&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">94,790&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619852041720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Other Entities &#8212; Equity Method<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock', window );">Investments in Other Entities &#8212; Equity Method</a></td>
<td class="text">Investments in Other Entities &#8212; Equity Method<div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Rollforward of Equity Method Investment (in thousands)</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:39.374%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.964%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.011%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.134%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.549%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.632%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Allocation of Income (Loss)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Contribution</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sale</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">LaSalle Medical Associates &#8211; IPA Line of Business</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,397&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(428)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,969&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pacific Medical Imaging &amp; Oncology Center, Inc.</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,396&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">77&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,473&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Universal Care, Inc.</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,438&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,560&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,998)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Diagnostic Medical Group</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,334&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(102)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,232&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">531 W. College, LLC &#8211; related party</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,698&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(231)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,967&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">MWN, LLC &#8211; related party</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">164&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">176&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28,427&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,888&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,998)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,817&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">LaSalle Medical Associates &#8212; </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">IPA Line of Business</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">LMA was founded by Dr. Albert Arteaga in 1996 and currently operates six neighborhood medical centers through its network of approximately 2,300 PCP and Specialists providers, treating children, adults and seniors in San Bernardino County, California. LMA&#8217;s patients are primarily served by Medi-Cal. LMA also accepts Blue Cross, Blue Shield, Molina, Care 1st, Health Net and Inland Empire Health Plan. LMA is also an IPA of independently contracted doctors, hospitals and clinics, delivering high-quality care to approximately 290,000 patients in Fresno, Kings, Los Angeles, Madera, Riverside, San Bernardino and Tulare Counties. During 2012, APC-LSMA and LMA entered into a share purchase agreement whereby APC-LSMA invested $5.0 million for a 25% interest in LMA&#8217;s IPA line of business. NMM has a management services agreement with LMA. APC accounts for its investment in LMA under the equity method as APC has the ability to exercise significant influence, but not control over LMA&#8217;s operations. For the three months ended June&#160;30, 2020, APC recognized income from this investment of $0.2 million. For the three months ended June&#160;30, 2019, APC recognized a loss from this investment of $1.3 million. For the six months ended June&#160;30, 2020 and 2019, APC recognized losses of $0.4 million and $2.4 million, respectively, in the accompanying consolidated statements of income. The accompanying consolidated balance sheets include the related investment balance of $6.0 million and $6.4 million at June&#160;30, 2020 and December&#160;31, 2019, respectively.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">LMA&#8217;s summarized balance sheets at June&#160;30, 2020 and December&#160;31, 2019, and summarized statements of operations for the six months ended June&#160;30, 2020 and 2019, with respect to its IPA line of business are as follows (in thousands):</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Balance Sheets</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:70.620%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.909%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.739%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash and cash equivalents</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,852&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,345&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Receivables, net</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,751&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,124&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other current assets</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">880&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,526&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Loan receivable</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,250&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,250&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Restricted cash</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">688&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">683&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total assets</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,421&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,928&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Liabilities and Stockholders&#8217; (Deficit) Equity</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Current liabilities</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,735&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,530&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Stockholders&#8217; deficit</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7,314)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5,602)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total liabilities and stockholders&#8217; deficit</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,421&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,928&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:10pt;"><span><br/></span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Statements of Operations</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:69.114%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.809%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.344%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">92,113&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">93,434&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Expenses</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">93,680&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">102,845&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net loss</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,567)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9,411)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:10pt;"><span><br/></span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Pacific Medical Imaging and Oncology Center, Inc.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Incorporated in California in 2004, PMIOC provides comprehensive diagnostic imaging services using state-of-the-art technology. PMIOC offers high-quality diagnostic services, such as MRI/MRA, PET/CT, CT, nuclear medicine, ultrasound, digital x-rays, bone densitometry and digital mammography, at its facilities.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In July&#160;2015, APC-LSMA and PMIOC entered into a share purchase agreement whereby APC-LSMA invested $1.2 million for a 40% ownership interest in PMIOC.</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">APC and PMIOC have an Ancillary Service Contract together whereby PMIOC provides covered services on behalf of APC to enrollees of the plans of APC. Under the Ancillary Service Contract, APC paid PMIOC fees of approximately $0.4 million and $0.6 million, for the three months ended June&#160;30, 2020 and 2019, respectively, and fees of approximately $1.0&#160;million and $1.4 million for the six months ended June&#160;30, 2020 and 2019. APC accounts for its investment in PMIOC under the equity method of accounting as APC has the ability to exercise significant influence, but not control over PMIOC&#8217;s operations. For the three months ended June&#160;30, 2020, APC recognized a loss from this investment of $10,200. For the three months ended June&#160;30, 2019, APC recognized income from this investment of $0.1 million. For the six months ended June&#160;30, 2020 and 2019, APC recognized income of $0.1&#160;million and $0.2 million, respectively, in the accompanying consolidated statements of income. The accompanying consolidated balance sheets include the related investment balance of $1.5 million and $1.4 million at June&#160;30, 2020 and December&#160;31, 2019, respectively.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Universal Care, Inc.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">UCI is a privately held health plan that has been in operation since 1985. UCI holds a license under the California Knox-Keene Health Care Services Plan Act to operate as a full-service health plan. UCI contracts with CMS under the Medicare Advantage Prescription Drug Program.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2015, UCAP purchased 100,000 shares of UCI class A-2 voting common stock from UCI for $10.0 million, which shares comprise 48.9% of UCI&#8217;s total outstanding shares and 50% of UCI&#8217;s voting common stock. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On April 30, 2020, UCAP completed the sale of its 48.9% ownership interest in UCI to Bright for approximately $69.2 million in cash proceeds (including $16.5 million as repayment of indebtedness owed to APC), plus non-cash consideration consisting of shares of Bright Health, Inc.&#8217;s preferred stock having an estimated fair value of approximately $36.2 million on the date of sale, included in investments in privately held entities. The fair value of the preferred shares was determined utilizing a market approach which includes significant unobservable inputs (Level 3) including forecasted revenue along with estimates of revenue multiples, volatility and time-to-liquidity. In addition, pursuant to the terms of the stock purchase agreement, APC has a beneficial interest in the equity method investment sold. The estimated fair value of such interest on April 30, 2020 was&#160;$15.7 million and is included in "Other assets" in the accompanying consolidated balance sheets. The beneficial interest is the result of a gross margin provision in the stock purchase agreement which entitles UCAP to potentially receive additional cash and preferred shares (currently held in an escrow account with cash of $15.6&#160;million and preferred shares with an estimated fair value of $6.4&#160;million, total estimated fair value of $22.0&#160;million on the date of sale) based on the gross margin of UCI for calendar year 2020 as measured against a target. The amount to be received varies dependent upon the gross margin as compared to the target but cannot exceed the amounts that are in the escrow account. Additionally, the stock purchase agreement includes a tangible net equity provision that may result in the receipt or payment of additional amounts based on a comparison of final tangible net equity of UCI on the date of sale (determined with the benefit of one year of hindsight) as compared to the estimated tangible net equity at the time of sale. It is expected that settlement of the beneficial interest will begin in the second half of 2021. The Company determined the fair value of the beneficial interest using an income approach which includes significant unobservable inputs (Level 3). Specifically, the Company utilized a probability weighted discounted cash flow model using a risk-free treasury rate to estimate fair value which considered various scenarios of gross margin adjustment and the impact of each adjustment to the expected proceeds from the escrow account and assigned probabilities to each such scenario in determining fair value. The gross margin adjustment is defined as three times any deficit in actual gross margin of UCI for the year ended December 31, 2020 below a target gross margin unless such deficit is within a specific collar amount.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The gain on sale of equity method investment recognized in connection with this transaction was determined as follows:</span></div><div style="text-align:justify;margin-top:10pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:78.116%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:17.884%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount (in '000s)</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash proceeds (excludes proceeds to settle indebtedness owed to APC from UCI)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">52,743&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Preferred shares in Bright Health, Inc.</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,179&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Beneficial interest in UCI</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,723&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Carrying value of equity method investment on date of sale</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,998)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gain on sale of equity method investment</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">99,647&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three months ended June 30, 2020 and June&#160;30, 2019 APC recorded income from this investment of approximately $0.9&#160;million and $4.5 million. For the six months ended June 30, 2020 and June 30, 2019 APC recorded income from this investment of approximately $3.6&#160;million  and $5.5 million in the accompanying consolidated statements of income, respectively. As a result of the sale, there was no investment balance as of June&#160;30, 2020 as compared to an investment balance of $1.4 million as of December&#160;31, 2019.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">UCI's balance sheet at December 31, 2019 and statements of income for the four months ended April 30, 2020 and six months ended June 30, 2019 are as follows (in thousands):</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Balance Sheets</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:83.526%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.474%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash and cash equivalents</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33,890&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Receivables, net</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63,843&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other current assets</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38,280&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Loan receivable</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">882&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Restricted cash</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,021&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total assets</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">140,916&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Liabilities and Stockholders&#8217; (Deficit) Equity</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Current liabilities</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">128,330&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33,133&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Stockholders&#8217; deficit</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(20,547)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total liabilities and stockholders&#8217; deficit</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">140,916&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Statements of Operations</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:59.549%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:16.859%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:16.862%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Four Months Ended</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">April 30,<br/>2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2019</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">195,308&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">247,517&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Expenses</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">189,028&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">239,389&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income before benefit from income taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,280&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,128&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Benefit from income taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,167)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,280&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,295&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Diagnostic Medical Group</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May 2016, David C.P. Chen M.D., individually, and APC-LSMA, entered into a share purchase agreement whereby APC-LSMA acquired a 40% ownership interest in DMG.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">APC accounts for its investment in DMG under the equity method of accounting as APC has the ability to exercise significant influence, but not control over DMG&#8217;s operations. For the three months ended June&#160;30, 2020 and 2019, APC recognized loss and income from this investment of $0.1&#160;million and $0.2 million, respectively, in the consolidated statements of income. For the six months ended  June&#160;30, 2020 and 2019, APC recognized loss and income from investment of $0.1&#160;million and $0.4 million, respectively, in the consolidated statements of income. The accompanying consolidated balance sheets include the related investment balances of $2.2 million and $2.3 million as of June&#160;30, 2020 and December&#160;31, 2019, respectively.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">531 W. College LLC &#8211; Related Party</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2018, College Street Investment LP, a California limited partnership (&#8220;CSI&#8221;), APC and NMM entered into an operating agreement to govern the limited liability company, 531 W. College, LLC and the conduct of its business, and to specify their relative rights and obligations. CSI, APC and NMM, each owns 50%, 25% and 25%, respectively, of member units based on initial capital contributions of $16.7 million, $8.3 million, and $8.3 million, respectively.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2018, 531 W. College, LLC closed its purchase of a non-operational hospital located in Los Angeles from Societe Francaise De Bienfaisance Mutuelle De Los Angeles, a California nonprofit corporation, for a total purchase price of $33.3 million. On April 23, 2019, NMM and APC entered into an agreement whereby NMM assigned and APC assumed NMM&#8217;s 25% membership interest in 531 W. College, LLC for approximately $8.3 million. Subsequently, APC has a 50% ownership in 531 W. College LLC with a total investment balance of approximately $17.0 million. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">APC accounts for its investment in 531 W. College, LLC under the equity method of accounting as APC has the ability to exercise significant influence, but not control over the operations of this joint venture. For the three months ended June&#160;30, 2020 and 2019, APC recognized loss and income of $0.1 million and $12,649, respectively. For the six months ended June&#160;30, 2020 and 2019, APC recorded losses of $0.2 million and $34,319 in the accompanying consolidated statements of income, respectively. During the period ended June&#160;30, 2020, the Company contributed $0.5 million to 531 W. College LLC as part of its 50% interest and had investment balances of $17.0 million and $16.7 million, respectively, at June&#160;30, 2020 and December&#160;31, 2019. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">531 W. College LLC&#8217;s balance sheets at June&#160;30, 2020 and December&#160;31, 2019, and statements of operations for the six months ended June&#160;30, 2020 and 2019, are as follows (in thousands):</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Balance sheets</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:71.206%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.323%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.739%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">126&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">139&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other current assets</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other assets</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">70&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">70&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Property and equipment, net</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33,697&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33,581&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total assets</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33,893&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33,807&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Liabilities and Members&#8217; Equity</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Current liabilities</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,109&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,062&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Stockholders&#8217; equity</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32,784&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32,745&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total liabilities and members&#8217; equity</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33,893&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33,807&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Statements of Operation</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:69.114%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.929%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.224%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Expenses</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">579&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">538&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Loss from operations</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(579)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(538)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other income</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">385&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net loss</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(558)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(153)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:10pt;"><span><br/></span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">MWN LLC &#8211; Related Party</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2018, NMM, 6 Founders LLC, a California limited liability company doing business as Pacific6 Enterprises (&#8220;Pacific6&#8221;), and Health Source MSO Inc., a California corporation (&#8220;HSMSO&#8221;) entered into an operating agreement to govern </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">MWN Community Hospital, LLC and the conduct of its business and to specify their relative rights and obligations. NMM, Pacific6, and HSMSO each own 33.3% of the membership shares based on each member&#8217;s initial capital contributions of $3,000 and working capital contributions of $30,000. NMM invested an additional $0.3 million for working capital purposes in August 2019. For the three and six months ended June&#160;30, 2020, NMM recorded loss and income from its investment in MWN LLC of $43,000 and $12,000, respectively, in the accompanying consolidated statements of income and had an investment balance of $0.2 million as of June&#160;30, 2020 and December&#160;31, 2019.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Investments in privately held entities that do not report net asset value</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">MediPortal, LLC</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May 2018, APC purchased 270,000 membership interests of MediPortal LLC, a New York limited liability company, for $0.4 million or $1.50 per membership interest, which represented an approximately 2.8% ownership interest. In connection with the initial purchase, APC received a five-year warrant to purchase an additional 270,000 membership interests. Additionally, APC received a five-year option to purchase an additional 380,000 membership interests and a five-year warrant to purchase 480,000 membership interests, which MediPortal LLC will grant APC upon completion of its health portal. As of June&#160;30, 2020, the health portal has not been completed. As APC does not have the ability to exercise significant influence, and lacks control, over the investee, this investment is accounted for using a measurement alternative which allows the investment to be measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">AchievaMed</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On July 1, 2019, NMM and AchievaMed, Inc., a California corporation (&#8220;AchievaMed&#8221;), entered into an agreement in which NMM would purchase 50% of the aggregate shares of capital stock of AchievaMed over a period of time not to exceed five years. As a result of this transaction NMM invested $0.5 million for a 10% interest. The related investment balance of $0.5 million is included in &#8220;Investment in privately held entities&#8221; in the accompanying consolidated balance sheets as of June&#160;30, 2020.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Bright Health, Inc.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2020, UCAP completed the sale of its 48.9% ownership interest in UCI to Bright for approximately $69.2 million in cash proceeds (including $16.5 million as repayment of indebtedness owed to APC), plus non-cash consideration consisting of shares of Bright Health, Inc.&#8217;s preferred stock having an estimated fair value of approximately $36.2 million on the date of sale. The related investment balance of $36.2 million is included in &#8220;Investment in privately held entities&#8221; in the accompanying consolidated balance sheets as of June&#160;30, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method And Other Equity Investments [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodAndOtherEquityInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619853362184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loan Receivable and Loan Receivable &#8211; Related Parties<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LoanReceivableTextBlock', window );">Loan Receivable and Loan Receivable &#8211; Related Parties</a></td>
<td class="text">Loan Receivable and Loan Receivable &#8211; Related Parties<div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Loan receivable</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Dr. Albert Arteaga</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On June 28, 2019, APC entered into a convertible secured promissory note with Dr. Albert H. Arteaga, M.D. (&#8220;Dr. Arteaga&#8221;), Chief Executive Officer of LMA, to loan $6.4 million to Dr. Arteaga.  Interest on the loan accrues at a rate that is equal to the prime rate, plus 1% (4.25% as of June&#160;30, 2020) and payable in monthly installments of interest only on the first day of each month until the maturity date of December 31, 2020, at which time, all outstanding principal and accrued interest thereon shall be due and payable in full. The note is secured by certain shares of LMA common stock held by Dr. Arteaga. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At any time on or before December&#160;31, 2020, and upon written notice by APC to Dr. Arteaga, APC has the right, but not the obligation, to convert the entire outstanding principal amount of this note into shares of LMA common stock, which equal 21.25% of the aggregate then-issued and outstanding shares of LMA common stock to be held by APC&#8217;s designee, which may include APC-LSMA. If converted, APC-LSMA and APC&#8217;s designee will collectively own 46.25% of the equity of LMA with the remaining 53.75% to be owned by Dr. Arteaga. The entire note receivable has been classified under loans receivable on the consolidated balance sheets in the amount of $6.4 million as of June&#160;30, 2020. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On February 28, 2020, the Company entered into an agreement to advance Dr. Arteaga $2.2 million related to claims that were overpaid in the ordinary course of business. The advanced amount is repaid as the overpaid claims are recovered. As of June&#160;30, 2020, the outstanding amount due was $0.9 million and included in the &#8220;Prepaid expenses and other current assets&#8221; in the accompanying consolidated balance sheets.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company assessed the loan receivables under the CECL model by assessing the party's ability to pay by reviewing their interest payment history quarterly, financial history annually and reassessing any insolvency risk that is identified. If a failure to pay occurs, the Company assesses the terms of the notes and estimates an expected credit loss based on the remittance schedule of the note.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Loan receivable </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#8211;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"> related parties</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Universal Care, Inc.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In 2015, APC advanced $5.0 million on behalf of UCAP to UCI for working capital purposes. On June 29, 2018, November 28, 2018, and December 13, 2019, APC advanced an additional $2.5 million, $5.0 million and $4.0 million, respectively. The loans accrue interest at the prime rate, plus 1.00%, or 4.25%, as of March 31, 2020, and 5.75% as of December&#160;31, 2019, with interest to be paid monthly. On April 30, 2020, the outstanding balance was fully repaid as part of UCAP's disposition of its 48.9% ownership interest in UCI to Bright.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LoanReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loan Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LoanReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619852281992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Expenses</a></td>
<td class="text">Accounts Payable and Accrued Expenses<div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s accounts payable and accrued expenses consisted of the following (in thousands):</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:71.206%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.323%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.739%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accounts payable</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,425&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,914&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Capitation payable</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,754&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,813&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Subcontractor IPA payable</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,083&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,360&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Professional fees</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,325&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,837&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Due to related parties</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">80&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">225&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accrued compensation</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,060&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,238&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Contract liabilities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,061&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,892&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total accounts payable and accrued expenses</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,788&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27,279&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619979874888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medical Liabilities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract', window );"><strong>Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock', window );">Medical Liabilities</a></td>
<td class="text">Medical Liabilities<div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s medical liabilities consisted of the following (in thousands):</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:71.206%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.323%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.739%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Medical liabilities, beginning of period</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">58,725&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33,642&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Components of medical care costs related to claims incurred:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current period</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">165,571&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">93,833&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prior periods</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">233&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,688&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total medical care costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">165,804&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">96,521&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments for medical care costs related to claims incurred:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current period</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(97,112)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(60,440)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prior periods</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(57,470)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(39,744)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total paid</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(154,582)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(100,184)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acquired from Alpha Care</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,120&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">326&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(156)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Medical liabilities, end of period</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">70,273&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42,943&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for liabilities related to future policy benefits and unpaid claims and claim adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -URI http://asc.fasb.org/subtopic&amp;trid=2560295<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619948420712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Facility, Bank Loan and Lines of Credit<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Credit Facility, Bank Loan and Lines of Credit</a></td>
<td class="text">Credit Facility, Bank Loan and Lines of Credit<div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Credit Facility</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s credit facility consisted of the following (in thousands):</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:82.017%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:13.983%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Term loan A</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">185,250&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revolver loan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">60,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total debt</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">245,250&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Current portion of debt</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9,500)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Unamortized financing costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5,295)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term debt</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">230,455&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Future commitments of the Company&#8217;s credit facility is to be as follows for the years ending December&#160;31 (in thousands):</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:82.017%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:13.983%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020 (excluding the six months ended June 30, 2020)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,125&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,688&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,250&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,437&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">197,750&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">245,250&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Credit Agreement</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In September 2019, the Company entered into a secured credit agreement (the &#8220;Credit Agreement,&#8221; and the credit facility thereunder, the "Credit Facility") with Truist Bank (formerly known as SunTrust Bank), in its capacity as administrative agent for the lenders (in such capacity, the &#8220;Agent&#8221;), as a lender, an issuer of letters of credit and as swingline lender, and Preferred Bank, JPMorgan Chase Bank, N.A., MUFG Union Bank, N.A., Royal Bank of Canada, Fifth Third Bank and City National Bank, as lenders (the &#8220;Lenders&#8221;). In connection with the closing of the Credit Agreement, the Company, its subsidiary, NMM, and the Agent entered into a Guaranty and Security Agreement (the &#8220;Guaranty and Security Agreement&#8221;), pursuant to which, among other things, NMM guaranteed the obligations of the Company under the Credit Agreement. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Credit Agreement provides for a five-year revolving credit facility to the Company of $100.0 million (&#8220;Revolver Loan&#8221;), which includes a letter of credit subfacility of up to $25.0 million. The Credit Agreement also provides for a term loan of $190.0 million, (&#8220;Term Loan A&#8221;). The unpaid principal amount of the term loan is payable in quarterly installments on the last day of each fiscal quarter commencing on December 31, 2019. The principal payment for each of the first eight fiscal quarters is $2.4 million, for the following eight fiscal quarters thereafter is $3.6 million and for the following three fiscal quarters thereafter is $4.8 million. The remaining principal payment on the term loan is due on September&#160;11, 2024.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The proceeds of the term loan and up to $60.0 million of the revolving credit facility were used to (i) finance a portion of the AP-AMH Loan, (ii) refinance certain indebtedness of the Company and its subsidiaries and, indirectly, APC, (iii) pay transaction costs and expenses arising in connection with the Credit Agreement, the AP-AMH Loan and certain other related transactions and (iv) provide for working capital, capital expenditures and other general corporate purposes. The remainder of the revolving credit facility will be used to finance future acquisitions and investments and to provide for working capital needs, capital expenditures and other general corporate purposes.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is required to pay an annual facility fee of 0.20% to 0.35% on the available commitments under the Credit Agreement, regardless of usage, with the applicable fee determined on a quarterly basis based on the Company&#8217;s leverage ratio. The Company is also required to pay customary fees as specified in a separate fee agreement between the Company and SunTrust Robinson Humphrey, Inc., the lead arranger of the Credit Agreement.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Amounts borrowed under the Credit Agreement will bear interest at an annual rate equal to either, at the Company&#8217;s option, (a) the rate for Eurocurrency deposits for the corresponding deposits of U.S. dollars appearing on Reuters Screen LIBOR01 Page (&#8220;LIBOR&#8221;), adjusted for any reserve requirement in effect, plus a spread of between 2.00% and 3.00%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio, or (b) a base rate, plus a spread between 1.00% and 2.00%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio. As of June&#160;30, 2020, the interest rate on Term Loan A and Revolver Loan was 3.57% and 3.24%, respectively. The base rate is defined in a manner such that it will not be less than LIBOR. The Company will pay fees for standby letters of credit at an annual rate of between 2.00% and 3.00%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio, plus facing fees and standard fees payable to the issuing bank on the respective letter of credit. Loans outstanding under the Credit Agreement may be prepaid at any time without penalty, except for LIBOR breakage costs and expenses. If LIBOR ceases to be reported, the Credit Agreement requires the Company and the Agent to endeavor to establish a commercially reasonable alternative rate of interest and until they are able to do so, all borrowings must be at the base rate.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Credit Agreement requires the Company and its subsidiaries to comply with various affirmative covenants, including, without limitation, furnishing updated financial and other information, preserving existence and entitlements, maintaining properties and insurance, complying with laws, maintaining books and records, requiring any new domestic subsidiary meeting a materiality threshold specified in the Credit Agreement to become a guarantor thereunder and paying obligations. The Credit Agreement requires the Company and its subsidiaries to comply with, and to use commercially reasonable efforts to the extent permitted by law to cause certain material associated practices of the Company, including APC, to comply with, restrictions on liens, indebtedness and investments (including restrictions on acquisitions by the Company), subject to specified exceptions. The Credit Agreement also contains various other negative covenants binding the Company and its subsidiaries, including, without limitation, restrictions on fundamental changes, dividends and distributions, sales and leasebacks, transactions with affiliates, burdensome agreements, use of proceeds, maintenance of business, amendments of organizational documents, accounting changes and prepayments and modifications of subordinated debt.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Credit Agreement requires the Company to comply with two key financial ratios, each calculated on a consolidated basis. The Company must maintain a maximum consolidated leverage ratio of not greater than 3.75 to 1.00 as of the last day of each fiscal quarter. The maximum consolidated leverage ratio decreases by 0.25 each year, until it is reduced to 3.00 to 1.00 for each fiscal quarter ending after September 30, 2022. The Company must maintain a minimum consolidated interest coverage ratio of not less than 3.25 to 1.00 as of the last day of each fiscal quarter. As of June&#160;30, 2020, the Company was in compliance with the covenants relating to its credit facility.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the Guaranty and Security Agreement, the Company and NMM have granted the Lenders a security interest in all of their assets, including, without limitation, all stock and other equity issued by their subsidiaries (including NMM) and all rights with respect to the AP-AMH Loan. The Guaranty and Security Agreement requires the Company and NMM to comply with various affirmative and negative covenants, including, without limitation, covenants relating to maintaining perfected security interests, providing information and documentation to the Agent, complying with contractual obligations relating to the collateral, restricting the sale and issuance of securities by their respective subsidiaries and providing the Agent access to the collateral.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Credit Agreement contains events of default, including, without limitation, failure to make a payment when due, default on various covenants in the Credit Agreement, breach of representations or warranties, cross-default on other material indebtedness, bankruptcy or insolvency, occurrence of certain judgments and certain events under the Employee Retirement Income Security Act of 1974 aggregating more than $10.0 million, invalidity of the loan documents, any lien under the Guaranty and Security Agreement ceasing to be valid and perfected, any change in control, as defined in the Credit Agreement, an event of default under the AP-AMH Loan, failure by APC to pay dividends in cash for any period of two consecutive fiscal quarters, failure by AP-AMH to pay cash interest to the Company, or if any modification is made to the Certificate of Determination or the Special Purpose Shareholder Agreement that directly or indirectly restricts, conditions, impairs, reduces or otherwise limits the payment of the Series A Preferred dividend by APC to AP-AMH. In addition, it will constitute an event of default under the Credit Agreement if APC uses all or any portion of the consideration received by APC from AP-AMH on account of AP-AMH&#8217;s purchase of Series A Preferred Stock for any purpose other than certain specific approved uses described in the following sentence, unless not less than 50.01% of all holders of common stock of APC at such time approve such use; provided that APC may use up to $50.0 million in the aggregate of such consideration for any purpose without any requirement to obtain such approval of the holders of common stock of APC. The approved uses include (i) any permitted investment, (ii) any dividend or distribution to the holders of the common stock of APC, (iii) any repurchase of common stock of APC, (iv) paying taxes relating to or arising from certain assets and transactions, or (v) funding losses, deficits or working capital support on account of certain non-healthcare assets in an amount not to exceed $125.0 million. If any event of default occurs and is continuing under the Credit Agreement, the Lenders may terminate their commitments, and may require the Company and its guarantors to repay outstanding debt and/or to provide a cash deposit as additional security for outstanding letters of credit. In </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">addition, the Agent, on behalf of the Lenders, may pursue remedies under the Guaranty and Security Agreement, including, without limitation, transferring pledged securities of the Company&#8217;s subsidiaries in the name of the Agent and exercising all rights with respect thereto (including the right to vote and to receive dividends), collect on pledged accounts, instruments and other receivables (including the AP-AMH Loan), and all other rights provided by law or under the loan documents and the AP-AMH Loan.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the ordinary course of business, certain of the Lenders under the Credit Agreement and their affiliates have provided to the Company and its subsidiaries and the associated practices, and may in the future provide, (i) investment banking, commercial banking (including pursuant to certain existing business loan and credit agreements being terminated in connection with entering into the Credit Agreement), cash management, foreign exchange or other financial services, and (ii) services as a bond trustee and other trust and fiduciary services, for which they have received compensation and may receive compensation in the future.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Deferred Financing Costs</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In September 2019, the Company recorded deferred financing costs of $6.5 million related to the issuance of the Credit Facility. This amount was recorded as a direct reduction of the carrying amount of the related debt liability. The deferred financing costs will be amortized over the life of the Credit Facility using the effective interest rate method. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Effective Interest Rate</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s average effective interest rate on its total debt during the six months ended June&#160;30, 2020 and 2019, was 3.93% and 4.71%, respectively. Interest expense in the consolidated statements of income included amortization of deferred debt issuance costs for the three and six months ended June&#160;30, 2020 and 2019, of $0.3 million and $0, respectively, and $0.7 million and $0, respectively.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Lines of Credit &#8211; Related Party</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">NMM Business Loan</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On June&#160;14, 2018, NMM amended its promissory note agreement with Preferred Bank (&#8220;NMM Business Loan Agreement&#8221;), which provides for loan availability of up to $20.0 million with a maturity date of June&#160;22, 2020. One of the Company&#8217;s board members is the chairman and CEO of Preferred Bank. The NMM Business Loan Agreement was subsequently amended on September&#160;1, 2018, to temporarily increase the loan availability from $20.0 million to $27.0 million for the period from September 1, 2018 through January 31, 2019, further extended to October&#160;31, 2019, to facilitate the issuance of an additional standby letter of credit for the benefit of CMS. The interest rate is based on the Wall Street Journal &#8220;prime rate,&#8221; plus 0.125%, or 5.625% as of December&#160;31, 2018. The loan was guaranteed by Apollo Medical Holdings, Inc. and is collateralized by substantially all of the assets of NMM. The amounts outstanding as of June&#160;30, 2019, of $5.0 million was fully repaid on September&#160;11, 2019.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On September&#160;5, 2018, NMM entered into a non-revolving line of credit agreement with Preferred Bank, which provides for loan availability of up to $20.0 million with a maturity date of September&#160;5, 2019. This credit facility was subsequently amended on April&#160;17, 2019, and July&#160;29, 2019, to reduce the loan availability from $20.0 million to $16.0 million and from $16.0 million to $2.2 million, respectively. The interest rate is based on the Wall Street Journal &#8220;prime rate,&#8221; plus 0.125%, or 3.375% as of June&#160;30, 2020, and 4.875% as of December&#160;31, 2019. The line of credit is guaranteed by Apollo Medical Holdings, Inc. and is collateralized by substantially all assets of NMM. NMM obtained this line of credit to finance potential acquisitions. Each drawdown from the line of credit is converted into a five-year term loan with monthly principal payments, plus interest based on a five-year amortization schedule.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On September 11, 2019, the NMM Business Loan Agreement, dated as of June&#160;14, 2018, between NMM and Preferred Bank, as amended, and the Line of Credit Agreement, dated as of September&#160;5, 2018, between NMM and Preferred Bank, as amended, were terminated in connection with the closing of the credit facility.&#160;Certain letters of credit issued by Preferred Bank under the Line of Credit Agreement were terminated and reissued under the Credit Agreement. As of June&#160;30, 2020,  outstanding letters of credit totaled $14.8 million and the Company has $10.2 million available under the revolving credit facility for letters of credit.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">APC Business Loan</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On June&#160;14, 2018, APC amended its promissory note agreement with Preferred Bank, which provides for loan availability of up to $10.0 million with a maturity date of June&#160;22, 2020. This credit facility was subsequently amended on April&#160;17, 2019, and June&#160;11, 2019, to increase the loan availability from $10.0 million to $40.0 million and extend the maturity date through December&#160;31, 2020. On August&#160;1, 2019, and September&#160;10, 2019, this credit facility was further amended to increase loan availability from $40.0 million to $43.8 million, and decrease loan availability from $43.8 million to $4.1 million, respectively. This decrease further limited the purpose of the indebtedness under APC Business Loan Agreement to the issuance of standby letters of credit, and added as a permitted lien the security interest in all of its assets granted by APC in favor of NMM under a Security Agreement dated on or about September 11, 2019, securing APC&#8217;s obligations to NMM under, and as required pursuant to, the APC management services agreement dated as of July 1, 1999, as amended. The interest rate is based on the Wall Street Journal &#8220;prime rate,&#8221; plus 0.125%, or 3.375% and 4.875% as of June&#160;30, 2020, and December&#160;31, 2019, respectively. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020 and December&#160;31, 2019, there was no availability under this line of credit.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Standby Letters of Credit</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On October&#160;2, 2018, APAACO established a second irrevocable standby letter of credit with Preferred Bank (through the NMM Business Loan Agreement) for $6.6 million for the benefit of CMS. The letter of credit expires on December&#160;31, 2020, and is automatically extended without amendment for additional one-year periods from the present or any future expiration date, unless notified by the institution to terminate prior to 90 days from any expiration date. APAACO may continue to draw from the letter of credit for one year following the bank&#8217;s notification of non-renewal. This standby letter of credit was subsequently amended on August&#160;14, 2019, to increase amount from $6.6 million to $14.8 million and extended expiration date on December&#160;31, 2020, with all other terms and conditions remain unchanged. In connection with the closing of the Credit Facility,&#160;this letter of credit was terminated and reissued under the Credit Agreement.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">APC established irrevocable standby letters of credit with Preferred Bank under the APC Business Loan Agreement for a total of $0.3 million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional one-year periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Alpha Care established irrevocable standby letters of credit with Preferred Bank under the APC Business Loan Agreement for a total of $3.8 million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional one-year periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619852266408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Mezzanine and Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Mezzanine and Stockholders' Equity</a></td>
<td class="text">Mezzanine and Stockholders&#8217; Equity<div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Mezzanine</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As the redemption feature (see Note 2) of the shares is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as noncontrolling interest in APC as mezzanine or temporary equity. APC&#8217;s shares are not redeemable and it is not probable that the shares will become redeemable as of June&#160;30, 2020 and December&#160;31, 2019.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stockholders&#8217; Equity</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, 302,732 holdback shares have not been issued to certain former NMM shareholders who were NMM shareholders at the time of closing of the merger between NMM and ApolloMed in December 2017 (the "Merger"), as they have yet to submit properly completed letters of transmittal to ApolloMed in order to receive their pro rata portion of ApolloMed common stock and warrants as contemplated under the merger agreement. Pending such receipt, such former NMM shareholders have the right to receive, without interest, their pro rata share of dividends or distributions with a record date after the effectiveness of the Merger. The consolidated financial statements have treated such shares of common stock as outstanding, given the receipt of the letter of transmittal is considered perfunctory and the Company is legally obligated to issue these shares in connection with the Merger.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See options and warrants section below for common stock issued upon exercise of stock options and stock purchase warrants.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Options</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s outstanding stock options consisted of the following:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:44.920%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.756%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.756%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.639%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Shares</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Weighted</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exercise Price</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Weighted</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Remaining</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Contractual</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Term</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Years)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Aggregate</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Intrinsic</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Value</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(in thousands)</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Options outstanding at January&#160;1, 2020</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">607,346&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.22&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.42</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,600&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Options granted</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,742&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.41&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Options exercised</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(120,000)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.58&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,800&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Options forfeited</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(12,228)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17.57&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options outstanding at June 30, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">486,860&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.86&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.70</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,900&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options exercisable at June 30, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">380,894&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.11&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.74</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the six months ended June&#160;30, 2020 and 2019, stock options were exercised for 120,000 and 111,000 shares, respectively, of the Company&#8217;s common stock, which resulted in proceeds of approximately $0.3 million and $0.5 million, respectively. The exercise price ranged from $2.10 to $5.00 per share for the exercises during the six months ended June&#160;30, 2020, and ranged from $1.50 to $5.79 per share for the exercises during the six months ended June&#160;30, 2019.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the six months ended June&#160;30, 2020 and 2019, no stock options were exercised pursuant to the cashless exercise provision.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the six months ended June&#160;30, 2020, the Company granted 11,742 stock options with a vesting period of five-years to certain ApolloMed board members with an exercise price of $18.41, which were recognized at fair value, as determined using the Black-Scholes option pricing model and the following assumptions:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:80.258%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.742%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">June 30, 2020</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Board Members</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Expected term</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.0 years</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Expected volatility</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">90.01&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Risk-free interest rate</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.43&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Market value of common stock</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.56&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Annual dividend yield</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Forfeiture rate</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Restricted Stock Awards</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company grants restricted stock awards to employees which are earned based on service conditions. The grant date fair value of the restricted stock awards is that day&#8217;s closing market price of the Company&#8217;s common stock. During the six months ended June&#160;30, 2020, the Company granted restricted stock awards totaling 97,447 shares with a weighted average grant date fair value of $17.58. The grant date fair value of the restricted stock was $1.6 million to be recognized on a straight-line basis over the awards&#8217; vesting period of three years. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three and six months ended June&#160;30, 2020, the Company recorded approximately $0.9 million and $1.6 million of share-based compensation expense associated with the issuance of restricted shares of common stock and vesting of stock options which is included in general and administrative expenses in the accompanying consolidated statements of income, respectively. Unrecognized compensation expense related to total share-based payments outstanding as of June&#160;30, 2020, was $3.8 million. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Warrants</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s outstanding warrants consisted of the following:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:43.680%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.913%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Shares</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Weighted</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exercise Price</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Weighted</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Remaining</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Contractual</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Term</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Years)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Aggregate</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Intrinsic</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Value</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(in thousands)</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Warrants outstanding at January&#160;1, 2020</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,154,590&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.96&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.01</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,700&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Warrants granted</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Warrants exercised</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(273,900)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.32&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Warrants expired/forfeited</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Warrants outstanding at June 30, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,880,690&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.02&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.61</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,700&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:19.637%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.152%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:16.567%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.982%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.742%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exercise&#160;Price&#160;Per Share</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Warrants&#8232;Outstanding</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Weighted</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Remaining</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Contractual&#160;Life</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Warrants</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exercisable</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Weighted</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exercise&#160;Price</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Per Share</span></div></td></tr><tr><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.00&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">754,870&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.29</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">754,870&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.00&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.00&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,313,345&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.85</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,313,345&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.00&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.00&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">812,475&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.44</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">812,475&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.00&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">$                                              $                     9.00 &#8211;11.00</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,880,690&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.61</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,880,690&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.02&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the six months ended June&#160;30, 2020 and 2019, common stock warrants were exercised for 273,900 and 41,624 shares, respectively, of the Company&#8217;s common stock, which resulted in proceeds of approximately $2.6 million and $0.4 million, respectively. The exercise price ranged from $9.00 to $11.00 per share for the exercises during the six months ended June&#160;30, 2020 and 2019, respectively.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Treasury Stock</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">APC owned 17,307,214 and 17,290,317 shares of ApolloMed&#8217;s common stock as of June&#160;30, 2020 and December&#160;31, 2019, which are legally issued and outstanding but excluded from shares of common stock outstanding in the consolidated financial statements, as such shares are treated as treasury shares for accounting purposes (see Note 1).</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the year ended December 31, 2019, APC established a brokerage account to invest excess capital in the equity market. The brokerage account is managed directly by an independent investment committee of the APC board of directors, from which Dr. Kenneth Sim and Dr. Thomas Lam have been excluded. As of June&#160;30, 2020, the brokerage account only held shares of ApolloMed totaling&#160;$7.6 million, and as such the ApolloMed shares in the brokerage account&#160;have been recorded as treasury shares.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Dividends</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the six months ended June&#160;30, 2020 and 2019, APC paid dividends of $29.6 million and $10.0 million, respectively.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the six months ended  June&#160;30, 2020 and 2019, CDSC paid dividends of $0.6 million and $1.2 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619853694504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Regulatory Matters</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Laws and regulations governing the Medicare program and healthcare generally are complex and subject to interpretation. The Company believes that it is in compliance with all applicable laws and regulations and is not aware of any pending or </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">threatened investigations involving allegations of potential wrongdoing. While no regulatory inquiries have been made, compliance with such laws and regulations can be subject to future government review and interpretation, as well as significant regulatory action, including fines, penalties, and exclusion from the Medicare and Medi-Cal programs.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As risk-bearing organizations, APC, Alpha Care and Accountable Health Care are required to comply with California DMHC regulations, including maintenance of minimum working capital, tangible net equity (&#8220;TNE&#8221;), cash-to-claims ratio and claims payment requirements prescribed by the California DMHC. TNE is defined as net equity less intangibles, less non-allowable assets (which include unsecured amounts due from affiliates), plus subordinated obligations. At&#160;June&#160;30, 2020 and December&#160;31, 2019, APC, Alpha Care and Accountable Health Care were in compliance with these regulations.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Many of the Company&#8217;s payor and provider contracts are complex in nature and may be subject to differing interpretations regarding amounts due for the provision of medical services. Such differing interpretations may not come to light until a substantial period of time has passed following contract implementation. Liabilities for claims disputes are recorded when the loss is probable and can be estimated. Any adjustments to reserves are reflected in current operations.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Standby Letters of Credit</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As part of the APAACO participation with CMS, the Company must provide a financial guarantee to CMS, the guarantee generally must be in an amount equal to 2% of the Company&#8217;s benchmark Medicare Part A and Part B expenditures. The Company has established an irrevocable standby letter of credit with Preferred Bank of $8.2 million and $6.6 million for the 2019 and 2018 performance years (see Note 9).</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">APC established irrevocable standby letters of credit with a financial institution for a total of $0.3 million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional one-year periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated (see Note 9).</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Alpha Care established irrevocable standby letters of credit with a financial institution for a total of $3.8 million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional one-year periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated (see Note 9). </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Litigation</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">From time to time, the Company is involved in various legal proceedings and other matters arising in the normal course of its business. The resolution of any claim or litigation is subject to inherent uncertainty and could have a material adverse effect on the Company&#8217;s financial condition, cash flows or results of operations.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Prospect Medical Systems</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On or about March 23, 2018, and April 3, 2018, a Demand for Arbitration and an Amended Demand for Arbitration were filed by Prospect Medical Group, Inc. and Prospect Medical Systems, Inc. (collectively, &#8220;Prospect&#8221;) against MMG, ApolloMed and AMM with Judicial Arbitration Mediation Services in California, arising out of MMG&#8217;s purported business plans, seeking damages in excess of $5.0 million, and alleging breach of contract, violation of unfair competition laws, and tortious interference with Prospect&#8217;s current and future economic relationships with its health plans and their members. By stipulation and order dated April 28, 2020, ApolloMed and AMM were dismissed without prejudice from the arbitration for lack of jurisdiction on the basis that neither of them were a party to any arbitration agreement with Prospect, subject, however, to Prospect reserving its rights against ApolloMed and AMM and tolling of applicable statute of limitation. MMG disputes the allegations and intends to vigorously defend against this matter. The resolution of this matter and any potential range of loss in excess of any current accrual cannot be reasonably determined or estimated at this time primarily because the matter has not been fully arbitrated and presents unique regulatory and contractual interpretation issues. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Liability Insurance</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company believes that its insurance coverage is appropriate based upon the Company&#8217;s claims experience and the nature and risks of the Company&#8217;s business. In addition to the known incidents that have resulted in the assertion of claims, the Company cannot be certain that its insurance coverage will be adequate to cover liabilities arising out of claims asserted against the Company, the Company&#8217;s affiliated professional organizations or the Company&#8217;s affiliated hospitalists in the future where the outcomes of such claims are unfavorable. The Company believes that the ultimate resolution of all pending claims, including liabilities in excess of the Company&#8217;s insurance coverage, will not have a material adverse effect on the Company&#8217;s financial position, results of operations or cash flows; however, there can be no assurance that future claims will not have such </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a material adverse effect on the Company&#8217;s business. Contracted physicians are required to obtain their own insurance coverage.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Although the Company currently maintains liability insurance policies on a claims-made basis, which are intended to cover malpractice liability and certain other claims, the coverage must be renewed annually, and may&#160;not continue to be available to the Company in future years at acceptable costs, and on favorable terms.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619852340776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related-Party Transactions</a></td>
<td class="text">Related-Party Transactions<div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On November 16, 2015, UCAP entered into a subordinated note receivable agreement with UCI, a 48.9% owned equity method investee (see Note 5), in the amount of $5.0 million. On June 28, 2018 and November 28, 2018, UCAP entered into two additional subordinated note receivable agreements with UCI in the amount of $2.5 million and $5.0 million, respectively. On April 30, 2020, the outstanding balance was fully repaid as part of UCAP's disposition of its 48.9% ownership interest in UCI to Bright (see Note 6).</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three and six months ended June&#160;30, 2020 and 2019, NMM earned approximately $4.2&#160;million and $5.2 million, respectively, and $8.4&#160;million, respectively, in management fees from LMA, which is accounted for under the equity method based on 25% equity ownership interest held by APC in LMA&#8217;s IPA line of business (see Note 5).</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three and six months ended June&#160;30, 2020 and 2019, APC paid approximately $0.4&#160;million and $0.6 million, respectively, and $1.0 million and $1.4 million, respectively, to PMIOC for provider services, which is accounted for under the equity method based on 40% equity ownership interest held by APC (see Note 5).</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three and six months ended June&#160;30, 2020 and 2019, APC paid approximately $0.9&#160;million and $1.8 million, respectively, and $2.6 million and $3.8 million, respectively, to DMG for provider services, which is accounted for under the equity method based on 40% equity ownership interest held by APC (see Note 5).</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three and six months ended June&#160;30, 2020 and 2019, APC paid approximately $0.1&#160;million, respectively, and $0.1&#160;million, respectively, to Advanced Diagnostic Surgery Center for services as a provider. Advanced Diagnostic Surgery Center shares common ownership with certain board members of APC.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three months ended June&#160;30, 2020 and 2019, APC paid an aggregate of approximately $9.0&#160;million and $7.1 million, respectively,  which include approximately $3.0&#160;million and $1.9 million, respectively, to shareholders who are also officers of APC. During the six months ended June&#160;30, 2020 and 2019, APC paid an aggregate of approximately of $16.3 million and $16.4 million, respectively, to shareholders of APC for provider services, which include approximately $4.8 million and $5.1 million, respectively, to shareholders who are also officers of APC.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three and six months ended June&#160;30, 2020 and 2019, NMM paid approximately $0.3 million, respectively and $0.5 million, respectively, to Medical Property Partners (&#8220;MPP&#8221;) for an office lease. MPP shares common ownership with certain board members of NMM.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three and six months ended June&#160;30, 2020, NMM paid approximately $0.4&#160;million and $0.7 million, respectively, to One MSO, Inc. ("One MSO") for an office lease. One MSO is indirectly 50% owned by Drs. Sim and Lam.  As of June 30, 2020, the Company had $10.6&#160;million of ROU assets and lease liabilities, respectively, related to its office lease with One MSO to be amortized over the remaining life of the lease.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three and six months ended June&#160;30, 2020 and 2019, the Company paid approximately $0.1&#160;million, respectively, and $0.2 million, respectively, to Critical Quality Management Corporation (&#8220;CQMC&#8221;) for an office lease. CQMC shares common ownership with certain board members of APC.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three and six months ended June&#160;30, 2020 and 2019, SCHC paid approximately $0.1&#160;million, respectively, and $0.2 million, respectively, to Numen, LLC (&#8220;Numen&#8221;) for an office lease. Numen is owned by a shareholder of APC. As of June 30, 2020, the Company had $1.4&#160;million of ROU assets and lease liabilities, respectively, related to its office lease with One MSO to be amortized over the remaining life of the lease.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has agreements with HSMSO, Aurion Corporation (&#8220;Aurion&#8221;), and AHMC Healthcare (&#8220;AHMC&#8221;) for services provided to the Company. One of the Company&#8217;s board members is an officer of AHMC, HSMSO and Aurion. Aurion is also partially owned by one of the Company&#8217;s board members. The following table sets forth fees incurred and income earned related to AHMC, HSMSO and Aurion (in thousands):</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:40.606%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.323%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.323%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.909%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.643%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Six Months Ended June 30,</span></div></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">AHMC &#8211; Risk pool, capitation, claims payment, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,057&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,350&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,056&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27,950&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">HSMSO &#8211; Management fees, net</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(189)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(265)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(321)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(915)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Aurion &#8211; Management fees</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(53)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(100)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(128)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(200)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net total</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,815&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,985&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,607&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,835&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company and AHMC have a risk sharing agreement with certain AHMC hospitals to share the surplus and deficits of each of the hospital pools. During the three and six months ended June&#160;30, 2020 and 2019, the Company has recognized risk pool revenue under this agreement of $10.2 million and $10.2 million, respectively, and $21.0 million and $25.0 million, respectively, for which $53.7 million and $40.4 million remain outstanding as of June&#160;30, 2020 and December&#160;31, 2019, respectively.</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three and six months ended June&#160;30, 2020 and 2019, NMM paid approximately&#160;$0 and $0.1 million, respectively, and $27,000&#160;and $0.1 million, respectively, to ApolloMed board member, Matthew Mazdyasni, for consulting services. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, affiliates wholly owned by the Company&#8217;s officers, including the Company's Co-CEOs, Dr. Sim and Dr. Lam, are reported in the accompanying consolidated statements of income on a consolidated basis, together with the Company&#8217;s subsidiaries, and therefore, the Company does not separately disclose transactions between such affiliates and the Company&#8217;s subsidiaries as related-party transactions.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For equity method investments, loans receivable and line of credits from related parties, see Notes 5, 6 and 9, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619852361896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company uses the liability method of accounting for income taxes as set forth in ASC 740. Under the liability method, deferred taxes are determined based on differences between the financial statement and tax bases of assets and liabilities using enacted tax rates.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On an interim basis, the Company estimates what its anticipated annual effective tax rate will be and records a quarterly income tax provision (benefit) in accordance with the estimated annual rate, plus the tax effect of certain discrete items that arise during the quarter. As the fiscal year progresses, the Company refines its estimates based on actual events and financial results during the quarter. This process can result in significant changes to the Company&#8217;s estimated effective tax rate. When this occurs, the income tax provision (benefit) is adjusted during the quarter in which the estimates are refined so that the year-to-date provision reflects the estimated annual effective tax rate. These changes, along with adjustments to the Company&#8217;s deferred taxes and related valuation allowance, may create fluctuations in the overall effective tax rate from quarter to quarter.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, due to the overall cumulative losses incurred in recent years, the Company maintained a full valuation allowance against its deferred tax assets related to loss entities the Company cannot consolidate under the federal consolidation rules, as realization of these assets is uncertain.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s effective tax rate for the six months ended June&#160;30, 2020, differed from the U.S. federal statutory rate primarily due to state income taxes, income from flow through entities, nondeductible permanent items, and change in valuation allowance.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, the Company does not have any unrecognized tax benefits related to various federal and state income tax matters. The Company will recognize accrued interest and penalties related to unrecognized tax benefits in income tax expense.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is subject to U.S. federal income tax as well as income tax in California. The Company and its subsidiaries&#8217; state and Federal income tax returns are open to audit under the statute of limitations for the years ended December 31, 2015 through December&#160;31, 2018, and for the years ended December 31, 2016 through December&#160;31, 2018, respectively. The Company does not anticipate material unrecognized tax benefits within the next 12 months.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On March 27, 2020, the Coronavirus Aid, Relief and Economic Security Act ("CARES Act") was signed into law. The CARES Act includes various income and payroll tax provisions that we are in the process of analyzing to determine the tax impacts. </span></div>However, we do not expect the benefits of the CARES Act to impact the Company&#8217;s annual estimated tax rate for the period June 30, 2020.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619852340776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share</a></td>
<td class="text">Earnings Per Share<div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Basic earnings per share is calculated using the weighted average number of shares of the Company&#8217;s common stock issued and outstanding during a certain period, and is calculated by dividing net income attributable to ApolloMed by the weighted average number of shares of the Company&#8217;s common stock issued and outstanding during such period. Diluted earnings per share is calculated using the weighted average number of shares of common stock and potentially dilutive shares of common stock outstanding during the period, using the as-if converted method for secured convertible notes, preferred stock, and the treasury stock method for options and common stock warrants.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020 and December&#160;31, 2019, APC held 17,307,214 and 17,290,317 shares of ApolloMed&#8217;s common stock, respectively, which are treated as treasury shares for accounting purposes and not included in the number of shares of common stock outstanding used to calculate earnings per share.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Below is a summary of the earnings per share computations:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:71.060%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.739%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Earnings per share &#8211; basic</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.20&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.10&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Earnings per share &#8211; diluted</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.19&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.09&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Weighted average shares of common stock outstanding &#8211; basic</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,071,604&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34,540,059&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Weighted average shares of common stock outstanding &#8211; diluted</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,285,585&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,962,555&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"><tr><td style="width:1.0%;"/><td style="width:70.941%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.794%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.795%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Earnings per share &#8211; basic</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.31&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.11&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Earnings per share &#8211; diluted</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.30&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.10&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Weighted average shares of common stock outstanding &#8211; basic</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,040,936&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34,518,461&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Weighted average shares of common stock outstanding &#8211; diluted</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,296,913&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,896,837&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Below is a summary of the shares included in the diluted earnings per share computations:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:71.060%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.739%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Weighted average shares of common stock outstanding &#8211; basic</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,071,604&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34,540,059&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">10% shares held back pursuant to indemnification clause</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,519,805&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Stock options</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">169,402&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">363,593&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Warrants</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,041,784&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,539,098&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock awards</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,795&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Weighted average shares of common stock outstanding &#8211; diluted</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,285,585&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,962,555&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:71.060%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.739%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Weighted average shares of common stock outstanding &#8211; basic</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,040,936&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34,518,461&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">10% shares held back pursuant to indemnification clause</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,519,805&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Stock options</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">173,299&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">368,273&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Warrants</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,076,802&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,490,298&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock awards</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,876&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Weighted average shares of common stock outstanding &#8211; diluted</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,296,913&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,896,837&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619853668632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Variable Interest Entities (VIEs)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityDisclosureTextBlock', window );">Variable Interest Entities (VIEs)</a></td>
<td class="text">Variable Interest Entities (VIEs)<div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A VIE is defined as a legal entity whose equity owners do not have sufficient equity at risk, or, as a group, the holders of the equity investment at risk lack any of the following three characteristics: decision-making rights, the obligation to absorb losses, or the right to receive the expected residual returns of the entity. The primary beneficiary is identified as the variable interest holder that has both the power to direct the activities of the VIE that most significantly affect the entity&#8217;s economic performance and the obligation to absorb expected losses or the right to receive benefits from the entity that could potentially be significant to the VIE.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company follows guidance on the consolidation of VIEs that requires companies to utilize a qualitative approach to determine whether it is the primary beneficiary of a VIE. See Note 2 &#8211; &#8220;Basis of Presentation and Summary of Significant Accounting Policies&#8221; to the accompanying consolidated financial statements for information on how the Company determines VIEs and its treatment.</span></div><div style="text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table includes assets that can only be used to settle the liabilities of APC and its VIEs, including Alpha Care and Accountable Health Care, and to which the creditors of APC, including Alpha Care and Accountable Health Care, have no recourse to the Company, nor do creditors of the Company have recourse against the assets of APC, including Alpha Care and Accountable Health Care. These assets and liabilities, with the exception of the investment in a privately held entity that does not report net asset value per share and amounts due to affiliates, which are eliminated upon consolidation with NMM, are included in the accompanying consolidated balance sheets (in thousands).</span></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:70.873%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.636%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.758%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Assets</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current assets</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">113,790&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">87,110&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investment in marketable securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">117,611&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">123,948&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Receivables, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,687&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,300&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Receivables, net &#8211; related party</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">55,889&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42,976&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other receivables</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">734&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">744&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses and other current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,752&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,403&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loan receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,425&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,425&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loan receivable &#8211; related parties</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total current assets</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">317,888&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">294,481&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Land, property and equipment, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,085&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,547&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intangible assets, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75,177&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">81,439&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">109,460&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">108,913&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investment in affiliates</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">285,569&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">318,315&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investment in privately held entities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,584&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,615&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investments in other entities &#8211; equity method</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,864&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28,427&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">746&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">746&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease right-of-use assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,017&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,751&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,750&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,057&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total noncurrent assets</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">571,252&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">554,810&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Total assets</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">889,140&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">849,291&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable and accrued expenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,822&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,187&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fiduciary accounts payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,853&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,027&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Medical liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">47,304&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49,019&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income taxes payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42,211&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,530&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount due to affiliate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,533&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28,058&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dividends payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">431&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">271&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance lease liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">102&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">102&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,319&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,088&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total current liabilities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">126,575&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">96,282&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Noncurrent liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,490&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,059&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance lease liabilities, net of current portion</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">355&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">416&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities, net of current portion</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,833&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,742&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total noncurrent liabilities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,678&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,217&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr></table><div style="margin-top:14pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:70.873%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.636%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.758%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Total liabilities</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">142,253&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">114,499&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The assets of the Company&#8217;s other consolidated VIEs were not considered significant.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619852288216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has operating and finance leases for corporate offices, doctors&#8217; offices, and certain equipment. These leases have remaining lease terms of 1 month to 5 years, some of which may include options to extend the leases for up to 10 years, and some of which may include options to terminate the leases within one year. As of June&#160;30, 2020 and December&#160;31, 2019, assets recorded under finance leases were $0.4 million and $0.5 million, respectively, and accumulated depreciation associated with finance leases was $0.3 million, respectively. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Also, the Company rents or subleases certain real estate to third parties, which are accounted for as operating leases.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Leases with an initial term of 12 months or less are not recorded on the balance sheet.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The components of lease expense were as follows (in thousands):</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:77.824%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:7.941%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.505%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating lease cost</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,446&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,240&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Finance lease cost</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Amortization of lease expense</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Interest on lease liabilities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Sublease income</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(226)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(106)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total finance lease cost, net</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,259&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,163&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:77.678%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.380%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.212%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating lease cost</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,388&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,343&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Finance lease cost</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Amortization of lease expense</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">61&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Interest on lease liabilities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Sublease income</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(360)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(206)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total finance lease cost, net</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,096&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,196&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other information related to leases was as follows (in thousands):</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:77.295%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.425%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.546%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Supplemental Cash Flows Information</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash paid for amounts included in the measurement of lease liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating cash flows from operating leases</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,333&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,239&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating cash flows from finance leases</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Financing cash flows from finance leases</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Right-of-use assets obtained in exchange for lease liabilities:</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating leases</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,907&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,441&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Supplemental Cash Flows Information</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash paid for amounts included in the measurement of lease liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating cash flows from operating leases</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,880&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,273&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating cash flows from finance leases</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Financing cash flows from finance leases</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">61&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Right-of-use assets obtained in exchange for lease liabilities:</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating leases</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,652&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,417&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Weighted Average Remaining Lease Term</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating leases</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.06 years</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.87 years</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Finance leases</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.17 years</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.00 years</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Weighted Average Discount Rate</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating leases</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.10&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.18&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Finance leases</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.00&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.00&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Future minimum lease payments under non-cancellable leases as of June&#160;30, 2020 is as follows (in thousands):</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:70.620%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.323%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.325%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Operating Leases</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Finance Leases</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020 (excluding the six months ended June 30, 2020)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,337&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">59&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,297&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">119&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,529&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">119&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,303&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">119&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,940&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">79&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Thereafter</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,459&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total future minimum lease payments</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,865&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">495&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Less: imputed interest</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,097&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total lease liabilities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,768&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">457&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Less: current portion</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,350&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">102&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Long-term lease liabilities</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,418&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">355&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, the Company does not have additional operating and finance leases that have not yet commenced.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has operating and finance leases for corporate offices, doctors&#8217; offices, and certain equipment. These leases have remaining lease terms of 1 month to 5 years, some of which may include options to extend the leases for up to 10 years, and some of which may include options to terminate the leases within one year. As of June&#160;30, 2020 and December&#160;31, 2019, assets recorded under finance leases were $0.4 million and $0.5 million, respectively, and accumulated depreciation associated with finance leases was $0.3 million, respectively. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Also, the Company rents or subleases certain real estate to third parties, which are accounted for as operating leases.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Leases with an initial term of 12 months or less are not recorded on the balance sheet.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The components of lease expense were as follows (in thousands):</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:77.824%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:7.941%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.505%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating lease cost</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,446&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,240&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Finance lease cost</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Amortization of lease expense</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Interest on lease liabilities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Sublease income</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(226)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(106)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total finance lease cost, net</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,259&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,163&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:77.678%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.380%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.212%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating lease cost</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,388&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,343&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Finance lease cost</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Amortization of lease expense</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">61&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Interest on lease liabilities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Sublease income</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(360)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(206)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total finance lease cost, net</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,096&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,196&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other information related to leases was as follows (in thousands):</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:77.295%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.425%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.546%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Supplemental Cash Flows Information</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash paid for amounts included in the measurement of lease liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating cash flows from operating leases</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,333&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,239&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating cash flows from finance leases</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Financing cash flows from finance leases</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Right-of-use assets obtained in exchange for lease liabilities:</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating leases</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,907&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,441&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Supplemental Cash Flows Information</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash paid for amounts included in the measurement of lease liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating cash flows from operating leases</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,880&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,273&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating cash flows from finance leases</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Financing cash flows from finance leases</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">61&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Right-of-use assets obtained in exchange for lease liabilities:</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating leases</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,652&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,417&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Weighted Average Remaining Lease Term</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating leases</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.06 years</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.87 years</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Finance leases</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.17 years</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.00 years</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Weighted Average Discount Rate</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating leases</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.10&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.18&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Finance leases</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.00&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.00&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Future minimum lease payments under non-cancellable leases as of June&#160;30, 2020 is as follows (in thousands):</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:70.620%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.323%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.325%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Operating Leases</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Finance Leases</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020 (excluding the six months ended June 30, 2020)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,337&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">59&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,297&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">119&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,529&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">119&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,303&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">119&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,940&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">79&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Thereafter</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,459&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total future minimum lease payments</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,865&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">495&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Less: imputed interest</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,097&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total lease liabilities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,768&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">457&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Less: current portion</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,350&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">102&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Long-term lease liabilities</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,418&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">355&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, the Company does not have additional operating and finance leases that have not yet commenced.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619860473096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of PresentationThe accompanying consolidated balance sheets at December&#160;31, 2019, has been derived from the Company&#8217;s audited consolidated financial statements, but does not include all disclosures required by generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;). The accompanying unaudited consolidated financial statements as of June&#160;30, 2020, and for the three and six months ended June&#160;30, 2020 and 2019, have been prepared in accordance with U.S. GAAP for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements, and should be read in conjunction with the audited consolidated financial statements and related notes to the financial statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2019 as filed with the SEC on March 16, 2020. In the opinion of management, all material adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been made to make the consolidated financial statements not misleading as required by Regulation S-X, Rule 10-01.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Principles of Consolidation</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The consolidated balance sheets as of June&#160;30, 2020 and December&#160;31, 2019, and the consolidated statements of income for the three and six months ended June&#160;30, 2020 and 2019, &#160;include the accounts of ApolloMed, its consolidated subsidiaries, NMM, AMM, APAACO, and Apollo Care Connect, its consolidated VIE, AP-AMH, NMM's consolidated subsidiaries, and consolidated VIE, APC, APC&#8217;s subsidiary, UCAP, and APC&#8217;s consolidated VIEs, CDSC, APC-LSMA, ICC, and APC-LSMA&#8217;s consolidated subsidiaries Alpha Care and Accountable Health Care.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">All material intercompany balances and transactions have been eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of the consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.&#160;Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combination and goodwill valuation and impairment, accrual of medical liabilities (incurred, but not reported (&#8220;IBNR&#8221;) claims), determination of full-risk and shared-risk revenue and receivables (including constraints and completion factors, including historical medical loss ratios (&#8220;MLR&#8221;)), income taxes, valuation of share-based compensation and right-of-use ("ROU") assets and lease liabilities. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Reportable Segments</a></td>
<td class="text"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Reportable Segments</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company operates as one reportable segment, the healthcare delivery segment, and implements and operates innovative health care models to create a patient-centered, physician-centric experience. The Company reports its consolidated financial statements in the aggregate, including all activities in one reportable segment.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash and Cash Equivalents</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s cash and cash equivalents primarily consist of money market funds and certificates of deposit. The Company considers all highly liquid investments that are both readily convertible into known amounts of cash and mature within 90 days from their date of purchase to be cash equivalents.</span></div>The Company maintains its cash in deposit accounts with several banks, which at times may&#160;exceed the insured limits of the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;). The Company believes it is not exposed to any significant credit risk with respect to its cash, cash equivalents and restricted cash.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Restricted Cash</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Restricted cash consists of cash held as collateral to secure standby letters of credits as required by certain contracts.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Investments in Marketable Securities</a></td>
<td class="text"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Investments in Marketable Securities</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The appropriate classification of investments is determined at the time of purchase and such designation is reevaluated at each balance sheet date. As of June&#160;30, 2020 and December&#160;31, 2019, investments in marketable securities amounted to approximately $117.7 million and $116.5 million, respectively, and consisted of equity securities and certificates of deposit with various financial institutions, reported at par value, plus accrued interest, with maturity dates from four months to 24 months (see fair value measurements of financial instruments below). Investments in certificates of deposits are classified as Level 1 investments in the fair value hierarchy.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock', window );">Receivables and Receivables &#8211; Related Parties</a></td>
<td class="text"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Receivables and Receivables &#8211; Related Parties</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s receivables are comprised of accounts receivable, capitation and claims receivable, risk pool settlements and incentive receivables, management fee income and other receivables. Accounts receivable are recorded and stated at the amount expected to be collected.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s receivables &#8211; related parties are comprised of risk pool settlements, management fee income and incentive receivables, and other receivables. Receivables &#8211; related parties are recorded and stated at the amount expected to be collected.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Capitation and claims receivable relate to each health plan&#8217;s capitation and is received by the Company in the month following the month of service. Risk pool settlements and incentive receivables mainly consist of the Company&#8217;s full risk pool receivable that is recorded quarterly based on reports received from the Company&#8217;s hospital partners and management&#8217;s estimate of the Company&#8217;s portion of the estimated risk pool surplus for open performance years. Settlement of risk pool surplus or deficits occurs approximately 18 months after the risk pool performance year is completed. Other receivables consists of recoverable claims paid related to the 2019 APAACO performance year to be administered following instructions from CMS, fee-for-</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">services (&#8220;FFS&#8221;) reimbursement for patient care, certain expense reimbursements, transportation reimbursements from the hospitals, and stop loss insurance premium reimbursements.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company maintains reserves for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends and changes in customer payment patterns to evaluate the adequacy of these reserves. The Company also regularly analyzes the ultimate collectability of accounts receivable after certain stages of the collection cycle using a look-back analysis to determine the amount of receivables subsequently collected and adjustments are recorded when necessary. Reserves are recorded primarily on a specific identification basis.</span></div>Receivables are recorded when the Company is able to determine amounts receivable under applicable contracts and agreements based on information provided and collection is reasonably likely to occur. In regards to the credit loss standard, the Company continuously monitors its collections of receivables and our expectation is that the historical credit loss experienced across our receivable portfolio is materially similar to any current expected credit losses that would be estimated under the current expected credit losses (CECL) model. As of June 30, 2020 and December 31, 2019 the Company had<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Risks</a></td>
<td class="text">Concentrations of RisksThe Company disaggregates revenue from contracts by service type and payor type. This level of detail provides useful information pertaining to how the Company generates revenue by significant revenue stream and by type of direct contracts. The consolidated statements of income present disaggregated revenue by service type.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements of Financial Instruments</a></td>
<td class="text"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Fair Value Measurements of Financial Instruments</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s financial instruments consist of cash and cash equivalents, fiduciary cash, restricted cash, investment in marketable securities, receivables, loans receivable, accounts payable, certain accrued expenses, finance lease obligations, and long-term debt. The carrying values of the financial instruments classified as current in the accompanying consolidated balance sheets are considered to be at their fair values, due to the short maturity of these instruments. The carrying amounts of finance lease obligations and long-term debt approximate fair value as they bear interest at rates that approximate current market rates for debt with similar maturities and credit quality.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 820, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Fair Value Measurement</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASC 820&#8221;), applies to all financial assets and financial liabilities that are measured and reported on a fair value basis and requires disclosure that establishes a framework for measuring fair value and expands disclosure about fair value measurements. ASC&#160;820 establishes a fair value hierarchy for disclosure of the inputs to valuations used to measure fair value.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This hierarchy prioritizes the inputs into three broad levels as follows:</span></div><div style="padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Level&#160;1</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> &#8212; Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that can be accessed at the measurement date.</span></div><div style="padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Level&#160;2</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> &#8212; Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the </span></div><div style="padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">asset or liability (i.e., interest rates and yield curves), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).</span></div><div style="padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Level&#160;3</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> &#8212; Unobservable inputs that reflect assumptions about what market participants would use in pricing the asset or liability. These inputs would be based on the best information available, including the Company&#8217;s own data.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Intangible Assets and Long-Lived Assets</a></td>
<td class="text"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Intangible Assets and Long-Lived Assets</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Intangible assets with finite lives include network-payor relationships, management contracts and member relationships and are stated at cost, less accumulated amortization and impairment losses. These intangible assets are amortized on the accelerated method using the discounted cash flow rate.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Intangible assets with finite lives also include a patient management platform, as well as trade names and trademarks, whose valuations were determined using the cost to recreate method and the relief from royalty method, respectively. These assets are stated at cost, less accumulated amortization and impairment losses, and are amortized using the straight-line method.</span></div>Finite-lived intangibles and long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may&#160;not be recoverable. If the expected future cash flows from the use of such assets (undiscounted and without interest charges) are less than the carrying value, a write-down would be recorded to reduce the carrying value of the asset to its estimated fair value. Fair value is determined based on appropriate valuation techniques.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Indefinite-Lived Intangible Assets</a></td>
<td class="text"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Goodwill and Indefinite-Lived Intangible Assets</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under ASC 350, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Intangibles &#8211; Goodwill and Other</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, goodwill and indefinite-lived intangible assets are reviewed at least annually for impairment.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At least annually, at the Company&#8217;s fiscal year-end, or sooner if events or changes in circumstances indicate that an impairment has occurred, the Company performs a qualitative assessment to determine whether it is more likely than not that the fair value of each reporting unit is less than its carrying amount as a basis for determining whether it is necessary to complete quantitative impairment assessments for each of the Company&#8217;s three main reporting units (1) management services, (2) IPAs, and (3) ACOs. The Company is required to perform a quantitative goodwill impairment test only if the conclusion from the qualitative assessment is that it is more likely than not that a reporting unit&#8217;s fair value is less than the carrying value of its assets. Should this be the case, a quantitative analysis is performed to identify whether a potential impairment exists by comparing the estimated fair values of the reporting units with their respective carrying values, including goodwill.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">An impairment loss is recognized if the implied fair value of the asset being tested is less than its carrying value. In this event, the asset is written down accordingly. The fair values of goodwill are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At least annually, indefinite-lived intangible assets are tested for impairment. Impairment for intangible assets with indefinite lives exists if the carrying value of the intangible asset exceeds its fair value. The fair values of indefinite-lived intangible assets are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy', window );">Investments in Other Entities - Equity Method and Investments in Privately Held Entities</a></td>
<td class="text"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Investments in Other Entities &#8212; Equity Method</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accounts for certain investments using the equity method of accounting when it is determined that the investment provides the Company with the ability to exercise significant influence, but not control, over the investee. Significant influence is generally deemed to exist if the Company has an ownership interest in the voting stock of the investee of between 20% and 50%, although other factors, such as representation on the investee&#8217;s board of directors, are considered in determining whether the equity method of accounting is appropriate. Under the equity method of accounting, the investment, originally recorded at cost, is adjusted to recognize the Company&#8217;s share of net earnings or losses of the investee and is recognized in the accompanying consolidated statements of income under &#8220;Income (loss) from equity method investments&#8221; and also is adjusted by contributions to and distributions from the investee. Equity method investments are subject to impairment evaluation. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Investments in Privately Held Entities</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accounts for certain investments using the cost method of accounting when it is determined that the investment provides the Company with little or no influence over the investee. Under the cost method of accounting, the investment is measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income. The investments in privately held entities that do not report NAV are subject to qualitative assessment for indicators of impairments.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareCostsPolicyPolicyTextBlock', window );">Medical Liabilities</a></td>
<td class="text"><div style="text-align:justify;margin-top:10pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Medical Liabilities</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">APC, Alpha Care, Accountable Health Care, APAACO and MMG are responsible for integrated care that the associated physicians and contracted hospitals provide to their enrollees. APC, Alpha Care, Accountable Health Care, APAACO and MMG provide integrated care to HMOs, Medicare and Medi-Cal enrollees through a network of contracted providers under sub-capitation and direct patient service arrangements. Medical costs for professional and institutional services rendered by contracted providers are recorded as cost of services expenses in the accompanying consolidated statements of income.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">An estimate of amounts due to contracted physicians, hospitals, and other professional providers is included in medical liabilities in the accompanying consolidated balance sheets. Medical liabilities include claims reported as of the balance sheet date and estimates IBNR claims. Such estimates are developed using actuarial methods and are based on numerous variables, including the utilization of health care services, historical payment patterns, cost trends, product mix, seasonality, changes in membership, and other factors. The estimation methods and the resulting reserves are periodically reviewed and updated. Many of the medical contracts are complex in nature and may&#160;be subject to differing interpretations regarding amounts due for the provision of various services. Such differing interpretations may&#160;not come to light until a substantial period of time has passed following the contract implementation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue Recognition</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company receives payments from the following sources for services rendered: (i) commercial insurers; (ii) the federal government under the Medicare program administered by CMS; (iii) state governments under the Medicaid and other programs; (iv) other third-party payors (e.g., hospitals and IPAs); and (v) individual patients and clients.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Nature of Services and Revenue Streams</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenue primarily consists of capitation revenue, risk pool settlements and incentives, NGACO All-Inclusive Population-Based Payments (&#8220;AIPBP&#8221;), management fee income, and FFS revenue. Revenue is recorded in the period in which services are rendered or the period in which the Company is obligated to provide services. The form of billing and related risk of collection for such services may&#160;vary by type of revenue and the customer. The following is a summary of the principal forms of the Company&#8217;s billing arrangements and how revenue is recognized for each.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Capitation, Net</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Managed care revenues of the Company consist primarily of capitated fees for medical services provided by the Company under a capitated arrangement directly made with various managed care providers including HMOs. Capitation revenue is typically prepaid monthly to the Company based on the number of enrollees selecting the Company as their healthcare provider. Capitation revenue is recognized in the month in which the Company is obligated to provide services to plan enrollees under contracts with various health plans. Minor ongoing adjustments to prior months&#8217; capitation, primarily arising from contracted HMOs finalizing their monthly patient eligibility data for additions or subtractions of enrollees, are recognized in the month they are communicated to the Company. Additionally, Medicare pays capitation using a &#8220;Risk Adjustment&#8221; model, which compensates managed care organizations and providers based on the health status (acuity) of each individual enrollee. Health plans and providers with higher acuity enrollees will receive more and those with lower acuity enrollees will receive less. Under Risk Adjustment, capitation is determined based on health severity, measured using patient encounter data. Capitation is paid on a monthly basis based on data submitted for the enrollee for the preceding year and is adjusted in subsequent periods after the final data is compiled. Positive or negative capitation adjustments are made for Medicare enrollees with conditions requiring more or less healthcare services than assumed in the interim payments. Since the Company cannot reliably predict these adjustments, periodic changes in capitation amounts earned as a result of Risk Adjustment are recognized when those changes are communicated by the health plans to the Company.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">PMPM managed care contracts generally have a term of one year or longer. All managed care contracts have a single performance obligation that constitutes a series for the provision of managed healthcare services for a population of enrolled members for the duration of the contract. The transaction price for PMPM contracts is variable as it primarily includes PMPM fees associated with unspecified membership that fluctuates throughout the contract. In certain contracts, PMPM fees also include adjustments for items such as performance incentives, performance guarantees and risk shares. The Company generally estimates the transaction price using the most likely amount methodology and amounts are only included in the net transaction price to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The majority of the Company&#8217;s net PMPM transaction price relates specifically to the Company&#8217;s efforts to transfer the service for a distinct increment of the series (e.g., day or month) and is recognized as revenue in the month in which members are entitled to service.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Risk Pool Settlements and Incentives</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">APC enters into full risk capitation arrangements with certain health plans and local hospitals, which are administered by a third party, where the hospital is responsible for providing, arranging and paying for institutional risk and APC is responsible for providing, arranging and paying for professional risk. Under a full risk pool sharing agreement, APC generally receives a percentage of the net surplus from the affiliated hospital&#8217;s risk pools with HMOs after deductions for the affiliated hospitals costs. Advance settlement payments are typically made quarterly in arrears if there is a surplus. The Company&#8217;s risk pool settlements under arrangements with health plans and hospitals are recognized using the most likely amount methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The assumptions for historical MLR, IBNR completion factors and constraint percentages were used by management in applying the most likely amount methodology.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under capitated arrangements with certain HMOs, APC participates in one or more shared risk arrangements relating to the provision of institutional services to enrollees (shared risk arrangements) and thus can earn additional revenue or incur losses based upon the enrollee utilization of institutional services. Shared risk capitation arrangements are entered into with certain health plans, which are administered by the health plan, where APC is responsible for rendering professional services, but the health plan does not enter into a capitation arrangement with a hospital and therefore the health plan retains the institutional risk. Shared risk deficits, if any, are not payable until and unless (and only to the extent of any) risk-sharing surpluses are generated. At the termination of the HMO contract, any accumulated deficit will be extinguished.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s risk pool settlements under arrangements with HMOs are recognized, using the most likely methodology, and only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur. Given </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">the lack of access to the health plans&#8217; data and control over the members assigned to APC, the adjustments and/or the withheld amounts are unpredictable and as such APC&#8217;s risk share revenue is deemed to be fully constrained until APC is notified of the amount by the health plan. Risk pools for the prior contract years are generally final settled in the third or fourth quarter of the following year.</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to risk-sharing revenues, the Company also receives incentives under &#8220;pay-for-performance&#8221; programs for quality medical care, based on various criteria. As an incentive to control enrollee utilization and to promote quality care, certain HMOs have designed quality incentive programs and commercial generic pharmacy incentive programs to compensate the Company for its efforts to improve the quality of services and efficient and effective use of pharmacy supplemental benefits provided to HMO members. The incentive programs track specific performance measures and calculate payments to the Company based on the performance measures. The Company&#8217;s incentives under &#8220;pay-for-performance&#8221; programs are recognized using the most likely methodology. However, as the Company does not have sufficient insight from the health plans on the amount and timing of the shared risk pool and incentive payments these amounts are considered to be fully constrained and only recorded when such payments are known and/or received.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Generally, for the foregoing arrangements, the final settlement is dependent on each distinct day&#8217;s performance within the annual measurement period but cannot be allocated to specific days until the full measurement period has occurred and performance can be assessed. As such, this is a form of variable consideration estimated at contract inception and updated through the measurement period (i.e., the contract year), to the extent the risk of reversal does not exist and the consideration is not constrained.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">NGACO AIPBP Revenue</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">APAACO and CMS entered into a NGACO Model Participation Agreement (the &#8220;Participation Agreement&#8221;) with an initial term of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMjY0NTk_5c465777-41e6-4d7a-b713-4cd6abec3b70">two</span> performance years through December&#160;31, 2018, which term was extended for <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmNjNWQ2NzgzYzE0OTRhMWY4ODZjMDNjOTNlMzk4Y2VlL3NlYzpjYzVkNjc4M2MxNDk0YTFmODg2YzAzYzkzZTM5OGNlZV80My9mcmFnOjY4OTU0YjY4NTc5NTRhZTY4YTkzMzA2Mzc4YjM2MjdhL3RleHRyZWdpb246Njg5NTRiNjg1Nzk1NGFlNjhhOTMzMDYzNzhiMzYyN2FfMjY1MzU_16e36149-7c47-4c0c-bc55-d85a3cf36fbe">two</span> additional renewal years.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For each performance year, the Company must submit to CMS its selections for risk arrangement; the amount of the profit/loss cap; alternative payment mechanism; benefits enhancements, if any; and its decision regarding voluntary alignment under the NGACO Model. The Company must obtain CMS consent before voluntarily discontinuing any benefit enhancement during a performance year.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the NGACO Model, CMS aligns beneficiaries to the Company to manage (direct care and pay providers) based on a budgetary benchmark established with CMS. The Company is responsible for managing medical costs for these beneficiaries. The beneficiaries will receive services from physicians and other medical service providers that are both in-network and out-of-network. The Company receives capitation from CMS on a monthly basis to pay claims from in-network providers. The Company records such capitation received from CMS as revenue as the Company is primarily responsible and liable for managing the patient care and for satisfying provider obligations, is assuming the credit risk for the services provided by in-network providers through its arrangement with CMS, and has control of the funds, the services provided and the process by which the providers are ultimately paid. Claims from out-of-network providers are processed and paid by CMS and the Company&#8217;s shared savings or losses in managing the services provided by out-of-network providers are generally determined on an annual basis after reconciliation with CMS. Pursuant to the Company&#8217;s risk share agreement with CMS, the Company will be eligible to receive the savings or be liable for the deficit according to the budget established by CMS based on the Company&#8217;s efficiency in managing how the beneficiaries aligned to the Company by CMS are served by in-network and out-of-network providers. The Company&#8217;s savings or losses on providing such services are both capped by CMS, and are subject to significant estimation risk, whereby payments can vary significantly depending upon certain patient characteristics and other variable factors. Accordingly, the Company recognizes such surplus or deficit upon substantial completion of reconciliation and determination of the amounts. The Company records NGACO capitation revenues monthly. Excess over claims paid, plus an estimate for the related IBNR claims (see Note 8), and monthly capitation received are deferred and recorded as a liability until actual claims are paid or incurred. CMS will determine if there were any excess capitation paid for the performance year and the excess is refunded to CMS.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For each performance year, CMS pays the Company in accordance with the alternative payment mechanism, if any, for which CMS has approved the Company; the risk arrangement for which the Company has been approved by CMS; and as otherwise provided in the Participation Agreement. Following the end of each performance year and at such other times as may be required under the Participation Agreement, CMS will issue a settlement report to the Company setting forth the amount of any shared savings or shared losses and the amount of other monies. If CMS owes the Company shared savings or other monies, CMS will pay the Company in full within 30 days after the date on which the relevant settlement report is deemed final, except as provided in the Participation Agreement. If the Company owes CMS shared losses or other monies owed as a result of a final settlement, the Company will pay CMS in full within 30 days after the relevant settlement report is deemed final. If the </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Company fails to pay the amounts due to CMS in full within 30 days after the date of a demand letter or settlement report, CMS will assess simple interest on the unpaid balance at the rate applicable to other Medicare debts under current provisions of law and applicable regulations. In addition, CMS and the U.S. Department of the Treasury may use any applicable debt collection tools available to collect any amounts owed by the Company.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company participates in the AIPBP track of the NGACO Model. Under the AIPBP track, CMS estimates the total annual expenditures for APAACO&#8217;s assigned patients and pays that projected amount to the Company in monthly installments, and the Company is responsible for all Part A and Part B costs for in-network participating providers and preferred providers contracted by the Company to provide services to the assigned patients.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As APAACO does not have sufficient insight into the financial performance of the shared risk pool with CMS because of unknown factors related to IBNR claims, risk adjustment factors, and stop loss provisions, among other factors, an estimate cannot be developed. Due to these limitations, APAACO cannot determine the amount of surplus or deficit that will likely be recognized in the future and therefore this shared risk pool revenue is considered fully constrained.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For performance year 2020, the Company continues to receive monthly AIPBP payments at a rate of approximately $7.6 million per month from CMS, and will need to continue to comply with all terms and conditions in the Participation Agreement and various regulatory requirements to be eligible to participate in the AIPBP mechanism and/or NGACO Model. The Company has received approximately $22.9&#160;million and $45.5 million in total AIPBP payments for the three and six months ended June&#160;30, 2020, respectively, of which $20.5&#160;million and $42.4 million has been recognized as revenue for the three and six months ended June 30, 2020, respectively. The Company also recorded assets of approximately $8.5 million related to IBNR claims as of June&#160;30, 2020, and $3.2 million related to final settlement of the 2018 performance year. These balances are included in &#8220;Other receivables&#8221; in the accompanying consolidated balance sheets.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Management Fee Income</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Management fee income encompasses fees paid for management, physician advisory, healthcare staffing, administrative and other non-medical services provided by the Company to IPAs, hospitals and other healthcare providers. Such fees may be in the form of billings at agreed-upon hourly rates, percentages of revenue or fee collections, or amounts fixed on a monthly, quarterly or annual basis. The revenue may include variable arrangements measuring factors such as hours staffed, patient visits or collections per visit against benchmarks, and, in certain cases, may be subject to achieving quality metrics or fee collections. The Company recognizes such variable supplemental revenues in the period when such amounts are determined to be fixed and therefore contractually obligated as payable by the customer under the terms of the applicable agreement.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company provides a significant service of integrating the services selected by the Company&#8217;s clients into one overall output for which the client has contracted. Therefore, such management contracts generally contain a single performance obligation. The nature of the Company&#8217;s performance obligation is to stand ready to provide services over the contractual period. Also, the Company&#8217;s performance obligation forms a series of distinct periods of time over which the Company stands ready to perform. The Company&#8217;s performance obligation is satisfied as the Company completes each period&#8217;s obligations.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Consideration from management contracts is variable in nature because the majority of the fees are generally based on revenue or collections, which can vary from period to period. The Company has control over pricing. Contractual fees are invoiced to the Company&#8217;s clients generally monthly and payment terms are typically due within 30 days. The variable consideration in the Company&#8217;s management contracts meets the criteria to be allocated to the distinct period of time to which it relates because (i) it is due to the activities performed to satisfy the performance obligation during that period and (ii) it represents the consideration to which the Company expects to be entitled.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s management contracts generally have long terms (e.g., 10 years), although they may be terminated earlier under the terms of the applicable contracts. Since the remaining variable consideration will be allocated to a wholly unsatisfied promise that forms part of a single performance obligation recognized under the series guidance, the Company has applied the optional exemption to exclude disclosure of the allocation of the transaction price to remaining performance obligations.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Fee-for-Service Revenue</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">FFS revenue represents revenue earned under contracts in which the Company bills and collects the professional component of charges for medical services rendered by the Company&#8217;s contracted physicians and employed physicians. Under the FFS arrangements, the Company bills the hospitals and third-party payors for the physician staffing and further bills patients or their third-party payors for patient care services provided and receives payment. FFS revenue related to the patient care services is reported net of contractual allowances and policy discounts and are recognized in the period in which the services are rendered to specific patients. All services provided are expected to result in cash flows and are therefore reflected as net revenue in the </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">consolidated financial statements. The recognition of net revenue (gross charges less contractual allowances) from such services is dependent on such factors as proper completion of medical charts following a patient visit, the forwarding of such charts to the Company&#8217;s billing center for medical coding and entering into the Company&#8217;s billing system and the verification of each patient&#8217;s submission or representation at the time services are rendered as to the payor(s) responsible for payment of such services. Revenue is recorded based on the information known at the time of entering of such information into the Company&#8217;s billing systems, as well as an estimate of the revenue associated with medical services.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is responsible for confirming member eligibility, performing program utilization review, potentially directing payment to the provider and accepting the financial risk of loss associated with services rendered, as specified within the Company&#8217;s client contracts. The Company has the ability to adjust contractual fees with clients and possess the financial risk of loss in certain contractual obligations. These factors indicate the Company is the principal and, as such, the Company records gross fees contracted with clients in revenues.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Consideration from FFS arrangements is variable in nature because fees are based on patient encounters, credits due to clients and reimbursement of provider costs, all of which can vary from period to period.&#160;Patient encounters and related episodes of care and procedures qualify as distinct goods and services, provided simultaneously together with other readily available resources, in a single instance of service, and thereby constitute a single performance obligation for each patient encounter and, in most instances, occur at readily determinable transaction prices. As a practical expedient, the Company adopted a portfolio approach for the FFS revenue stream to group together contracts with similar characteristics and analyze historical cash collections trends. The contracts within the portfolio share the characteristics conducive to ensuring that the results do not materially differ under the new standard if it were to be applied to individual patient contracts related to each patient encounter. Accordingly, there was no change in the Company&#8217;s method to recognize revenue under ASC 606 </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue from Contracts with Customers</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> from the previous accounting guidance.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Estimating net FFS revenue is a complex process, largely due to the volume of transactions, the number and complexity of contracts with payors, the limited availability at times of certain patient and payor information at the time services are provided, and the length of time it takes for collections to fully mature. These expected collections are based on fees and negotiated payment rates in the case of third-party payors, the specific benefits provided for under each patient&#8217;s healthcare plans, mandated payment rates in the case of Medicare and Medicaid programs, and historical cash collections (net of recoveries) in combination with expected collections from third-party payors.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The relationship between gross charges and the transaction price recognized is significantly influenced by payor mix, as collections on gross charges may vary significantly, depending on whether and with whom the patients the Company provides services to in the period are insured and the Company&#8217;s contractual relationships with those payors. Payor mix is subject to change as additional patient and payor information is obtained after the period services are provided. The Company periodically assesses the estimates of unbilled revenue, contractual adjustments and discounts, and payor mix by analyzing actual results, including cash collections, against estimates. Changes in these estimates are charged or credited to the consolidated statements of income in the period that the assessment is made. Significant changes in payor mix, contractual arrangements with payors, specialty mix, acuity, general economic conditions and health care coverage provided by federal or state governments or private insurers may have a significant impact on estimates and significantly affect the results of operations and cash flows.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Contract Assets</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Typically, revenues and receivables are recognized once the Company has satisfied its performance obligation. Accordingly, the Company&#8217;s contract assets are comprised of receivables and receivables &#8211; related parties.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8217;</span><span style="background-color:rgb(255,255,255, 0.0);color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">s billing and accounting systems provide historical trends of cash collections and contractual write-offs, accounts receivable agings and established fee adjustments from third-party payors. These estimates are recorded and monitored monthly as revenues are recognized.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The principal exposure for uncollectible fee for service visits is from self-pay patients and, to a lesser extent, for co-payments and deductibles from patients with insurance.</span></div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Contract Liabilities (Deferred Revenue</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">)</span>Contract liabilities are recorded when cash payments are received in advance of the Company&#8217;s performance, or in the case of the Company&#8217;s NGACO, the excess of AIPBP capitation received and the actual claims paid or incurred.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Income Taxes</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Federal and state income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the consolidated financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Share-Based Compensation</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company maintains a stock-based compensation program for employees, non-employees, directors and consultants. The value of share-based awards such as options is recognized as compensation expense on a cumulative straight-line basis over the vesting period of the awards, adjusted for expected forfeitures. From time to time, the Company issues shares of its common stock to its employees, directors and consultants, which shares may be subject to the Company&#8217;s repurchase right (but not obligation) that lapses based on time-based and performance-based vesting schedules.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Earnings Per Share</a></td>
<td class="text"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basic and Diluted Earnings Per Share</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Basic earnings per share is computed by dividing net income attributable to holders of the Company&#8217;s common stock by the weighted average number of shares of common stock outstanding during the periods presented. Diluted earnings per share is computed using the weighted average number of shares of common stock outstanding, plus the effect of dilutive securities outstanding during the periods presented, using the treasury stock method. Refer to Note 14 for a discussion of shares treated as treasury shares for accounting purposes.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_MinorityInterestPolicyPolicyTextBlock', window );">Noncontrolling Interests</a></td>
<td class="text"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Noncontrolling Interests</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company consolidates entities in which the Company has a controlling financial interest. The Company consolidates subsidiaries in which the Company holds, directly or indirectly, more than 50% of the voting rights, and VIEs in which the Company is the primary beneficiary. Noncontrolling interests represent third-party equity ownership interests (including equity ownership interests held by certain VIEs) in the Company&#8217;s consolidated entities. Net income attributable to noncontrolling interests is disclosed in the consolidated statements of income.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_TemporaryEquityPolicyTextBlock', window );">Mezzanine Equity</a></td>
<td class="text"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Mezzanine Equity</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to APC&#8217;s shareholder agreements, in the event of a disqualifying event, as defined in the agreements, APC could be required to repurchase the shares from the respective shareholders based on certain triggers outlined in the shareholder agreements. As the redemption feature of the shares is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as mezzanine or temporary equity. Accordingly, the Company recognizes </span></div>noncontrolling interests in APC as mezzanine equity in the consolidated financial statements.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Accounting Pronouncements</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financial Instruments-Credit Losses (Topic 326)-Measurement of Credit Losses on Financial Instruments</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASU 2016-13&#8221;). The new standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. ASU 2016-13 became effective for fiscal years beginning after December 15, 2019, with early adoption permitted. The Company adopted ASU 2016-13 on January 1, 2020. The adoption of ASU 2016-13 did not have a material impact on the consolidated financial statements.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In October 2018, the FASB issued ASU No. 2018-17, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Consolidation (Topic 810): Targeted Improvements to Related Party Guidance for Variable Interest Entities</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASU 2018-17&#8221;). This ASU reduces the cost and complexity of financial reporting associated with consolidation of VIEs. A VIE is an organization in which consolidation is not based on a majority of voting rights. The new guidance supersedes the private company alternative for common control leasing arrangements issued in 2014 and expands it to all qualifying common control arrangements. The amendments in this ASU became effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The Company adopted ASU 2018-17 on January 1, 2020. The adoption of ASU 2018-17 did not have a material impact on the consolidated financial statements.</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASU 2019-12&#8221;). This ASU simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740 </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Income Taxes </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The amendments in this ASU are effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company is currently assessing the impact that the adoption of ASU 2019-12 will have on the Company's consolidated financial statements.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2020, the FASB issued ASU No. 2020-01, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Investments - Equity Securities (Topic 321), Investments - Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(&#8220;ASU 2020-01&#8221;). This ASU clarifies the interaction between accounting for equity securities, equity method investments and certain derivative instruments. The amendments in this ASU are effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company is currently assessing the impact that the adoption of ASU 2020-01 will have on the Company's consolidation financial statements.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other than the standards discussed above, there have been no other new accounting pronouncements that have significance, or potential significance, to the Company&#8217;s financial position, results of operations and cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_MinorityInterestPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minority Interest Policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_MinorityInterestPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Receivables and receivables from related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_TemporaryEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_TemporaryEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions and any noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareCostsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for  accruing health care costs for a prepaid health care service provider.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 405<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6491204&amp;loc=d3e4879-115612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareCostsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619853657448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregated Revenue by Each Payor Type</a></td>
<td class="text">The following table presents disaggregated revenue generated by payor type for the three and six months ended June&#160;30, 2020 and 2019 (in thousands):<div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:71.792%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.739%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Commercial</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,479&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,365&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Medicare</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">62,038&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">57,965&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Medicaid</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">68,450&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,277&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other third parties</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,202&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,443&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenue</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">165,169&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">130,050&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:71.792%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.739%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Commercial</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50,192&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50,383&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Medicare</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">126,918&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">95,063&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Medicaid</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">134,897&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">61,647&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other third parties</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,267&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,713&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenue</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">330,274&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">225,806&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock', window );">Schedule of Contributions to Revenue and Receivables by Payor</a></td>
<td class="text">The Company had major payors that contributed the following percentages of net revenue:<div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:71.792%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.739%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Payor A</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Payor B</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Payor C</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Payor D</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Payor E</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payor F</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td></tr></table></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:71.792%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.739%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Payor A</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Payor B</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Payor C</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Payor D</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Payor E</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payor F</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">*&#160;Less than 10% of total net revenues</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company had major payors that contributed to the following percentages of receivables and receivables &#8211; related parties:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:62.181%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.543%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.546%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Payor D</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payor G</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payor H</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-indent:-18pt;padding-left:18pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">*&#160;Less than 10% of total receivables and receivables &#8212; related parties, net</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of Carrying Amounts and Fair Values of Financial Instruments</a></td>
<td class="text"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The carrying amounts and fair values of the Company&#8217;s financial instruments as of June&#160;30, 2020, are presented below (in thousands):</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:44.852%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.741%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Fair Value Measurements</span></div></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Level 1</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Level 2</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Level 3</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Total</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Money market funds*</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">108,195&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">108,195&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Marketable securities &#8211; certificates of deposit</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">117,611&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">117,611&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Marketable securities &#8211; equity securities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">225,851&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">225,851&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The carrying amounts and fair values of the Company&#8217;s financial instruments as of December&#160;31, 2019, are presented below (in thousands):</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:44.852%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.741%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Measurements</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds*</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50,731&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50,731&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities &#8211; certificates of deposit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">116,469&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">116,469&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities &#8211; equity securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">70&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">70&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">167,270&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">167,270&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="padding-left:18pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">*&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Included in cash and cash equivalents</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619852361896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations and Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Summary of Estimated Fair Values of Assets Acquired and Liabilities Assumed</a></td>
<td class="text">The following table summarizes the estimated fair values of the assets acquired and liabilities assumed, as of the acquisition date (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:78.498%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:17.502%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance Sheet</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Assets acquired</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,569&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,336&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,675&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Network relationship intangible assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,636&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28,585&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,795)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6,334)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Medical liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(15,616)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;Net assets acquired</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45,056&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45,056&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the estimated fair values of the assets acquired and liabilities assumed, as of the acquisition date (in thousands):</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:78.498%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:17.502%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance Sheet</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Assets acquired</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">582&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,150&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">198&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Network relationship intangible assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,411&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,566&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,759)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Medical liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(12,154)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Subordinated loan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(15,327)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net asset acquired</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,667&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity investment contributed</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,417&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,250&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Change in Carrying Value of Goodwill</a></td>
<td class="text"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The change in the carrying value of goodwill for the six months ended June&#160;30, 2020, was as follows (in thousands);</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:78.498%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:17.502%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, January 1, 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">238,505&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">548&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, June 30, 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">239,053&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140620040760552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Intangible Assets, Net</a></td>
<td class="text"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At June&#160;30, 2020, the Company&#8217;s intangible assets, net, consisted of the following (in thousands):</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:42.199%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:7.544%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.684%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.684%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.687%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Useful</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Life</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Years)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Amortization</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net June 30,<br/>2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Amortized intangible assets:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Network relationships</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">11-15</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">143,930&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(67,015)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">76,915&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Management contracts</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,832&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10,736)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,096&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Member relationships</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,696&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,793)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,903&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Patient management platform</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,060&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,064)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">996&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Trade names/trademarks</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,011&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(131)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">880&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">176,529&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(81,739)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">94,790&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At December&#160;31, 2019, the Company&#8217;s intangible assets, net, consisted of the following (in thousands):</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:38.789%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.426%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.888%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.234%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Useful</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Life</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Years)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross December 31,<br/>2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Amortization</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Amortized intangible assets:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Network relationships</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">11-15</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">143,930&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(60,526)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">83,404&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Management contracts</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,832&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9,676)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,156&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Member relationships</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,696&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,352)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,344&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Patient management platform</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,060&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(858)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,202&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Trade names/trademarks</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,011&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(105)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">906&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">176,529&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(73,517)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">103,012&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Future Amortization Expense</a></td>
<td class="text">Future amortization expense is estimated to be as follows for the following years ending December&#160;31 (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:85.262%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.738%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020 (excluding the six months ended June 30, 2020)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,807&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,524&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,673&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,842&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,830&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39,114&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">94,790&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619852315576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Other Entities &#8212; Equity Method (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsTextBlock', window );">Equity Method Investments</a></td>
<td class="text"><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Rollforward of Equity Method Investment (in thousands)</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:39.374%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.964%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.011%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.134%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.549%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.632%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Allocation of Income (Loss)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Contribution</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sale</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">LaSalle Medical Associates &#8211; IPA Line of Business</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,397&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(428)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,969&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pacific Medical Imaging &amp; Oncology Center, Inc.</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,396&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">77&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,473&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Universal Care, Inc.</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,438&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,560&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,998)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Diagnostic Medical Group</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,334&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(102)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,232&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">531 W. College, LLC &#8211; related party</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,698&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(231)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,967&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">MWN, LLC &#8211; related party</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">164&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">176&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28,427&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,888&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,998)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,817&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div>LMA&#8217;s summarized balance sheets at June&#160;30, 2020 and December&#160;31, 2019, and summarized statements of operations for the six months ended June&#160;30, 2020 and 2019, with respect to its IPA line of business are as follows (in thousands):<div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Balance Sheets</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:70.620%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.909%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.739%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash and cash equivalents</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,852&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,345&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Receivables, net</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,751&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,124&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other current assets</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">880&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,526&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Loan receivable</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,250&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,250&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Restricted cash</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">688&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">683&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total assets</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,421&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,928&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Liabilities and Stockholders&#8217; (Deficit) Equity</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Current liabilities</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,735&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,530&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Stockholders&#8217; deficit</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7,314)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5,602)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total liabilities and stockholders&#8217; deficit</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,421&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,928&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:10pt;"><span><br/></span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Statements of Operations</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:69.114%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.809%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.344%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">92,113&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">93,434&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Expenses</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">93,680&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">102,845&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net loss</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,567)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9,411)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div>UCI's balance sheet at December 31, 2019 and statements of income for the four months ended April 30, 2020 and six months ended June 30, 2019 are as follows (in thousands):<div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Balance Sheets</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:83.526%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.474%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash and cash equivalents</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33,890&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Receivables, net</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63,843&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other current assets</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38,280&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Loan receivable</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">882&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Restricted cash</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,021&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total assets</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">140,916&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Liabilities and Stockholders&#8217; (Deficit) Equity</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Current liabilities</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">128,330&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33,133&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Stockholders&#8217; deficit</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(20,547)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total liabilities and stockholders&#8217; deficit</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">140,916&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Statements of Operations</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:59.549%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:16.859%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:16.862%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Four Months Ended</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">April 30,<br/>2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2019</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">195,308&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">247,517&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Expenses</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">189,028&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">239,389&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income before benefit from income taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,280&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,128&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Benefit from income taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,167)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,280&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,295&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">531 W. College LLC&#8217;s balance sheets at June&#160;30, 2020 and December&#160;31, 2019, and statements of operations for the six months ended June&#160;30, 2020 and 2019, are as follows (in thousands):</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Balance sheets</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:71.206%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.323%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.739%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">126&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">139&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other current assets</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other assets</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">70&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">70&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Property and equipment, net</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33,697&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33,581&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total assets</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33,893&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33,807&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Liabilities and Members&#8217; Equity</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Current liabilities</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,109&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,062&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Stockholders&#8217; equity</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32,784&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32,745&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total liabilities and members&#8217; equity</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33,893&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33,807&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Statements of Operation</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:69.114%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.929%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.224%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Expenses</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">579&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">538&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Loss from operations</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(579)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(538)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other income</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">385&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net loss</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(558)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(153)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentGainOnSaleTableTextBlock', window );">Equity Method Investment, Gain On Sale</a></td>
<td class="text"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The gain on sale of equity method investment recognized in connection with this transaction was determined as follows:</span></div><div style="text-align:justify;margin-top:10pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:78.116%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:17.884%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount (in '000s)</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash proceeds (excludes proceeds to settle indebtedness owed to APC from UCI)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">52,743&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Preferred shares in Bright Health, Inc.</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,179&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Beneficial interest in UCI</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,723&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Carrying value of equity method investment on date of sale</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,998)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gain on sale of equity method investment</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">99,647&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentGainOnSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Gain On Sale</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentGainOnSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619853422824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Expenses</a></td>
<td class="text"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s accounts payable and accrued expenses consisted of the following (in thousands):</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:71.206%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.323%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.739%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accounts payable</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,425&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,914&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Capitation payable</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,754&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,813&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Subcontractor IPA payable</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,083&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,360&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Professional fees</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,325&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,837&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Due to related parties</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">80&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">225&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accrued compensation</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,060&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,238&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Contract liabilities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,061&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,892&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total accounts payable and accrued expenses</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,788&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27,279&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619854209528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medical Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract', window );"><strong>Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense', window );">Schedule of Medical Liabilities</a></td>
<td class="text"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s medical liabilities consisted of the following (in thousands):</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:71.206%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.323%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.739%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Medical liabilities, beginning of period</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">58,725&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33,642&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Components of medical care costs related to claims incurred:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current period</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">165,571&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">93,833&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prior periods</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">233&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,688&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total medical care costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">165,804&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">96,521&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments for medical care costs related to claims incurred:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current period</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(97,112)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(60,440)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prior periods</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(57,470)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(39,744)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total paid</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(154,582)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(100,184)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acquired from Alpha Care</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,120&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">326&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(156)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Medical liabilities, end of period</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">70,273&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42,943&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619852274184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Facility, Bank Loan and Lines of Credit (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock', window );">Schedule of Credit Facility</a></td>
<td class="text"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s credit facility consisted of the following (in thousands):</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:82.017%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:13.983%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Term loan A</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">185,250&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revolver loan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">60,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total debt</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">245,250&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Current portion of debt</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9,500)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Unamortized financing costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5,295)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term debt</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">230,455&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Future Commitments of Credit Facility</a></td>
<td class="text"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Future commitments of the Company&#8217;s credit facility is to be as follows for the years ending December&#160;31 (in thousands):</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:82.017%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:13.983%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020 (excluding the six months ended June 30, 2020)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,125&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,688&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,250&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,437&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">197,750&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">245,250&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(e),(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619853578152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Mezzanine and Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock Option Transactions Under Stock Option Plans</a></td>
<td class="text"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s outstanding stock options consisted of the following:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:44.920%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.756%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.756%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.639%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Shares</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Weighted</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exercise Price</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Weighted</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Remaining</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Contractual</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Term</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Years)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Aggregate</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Intrinsic</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Value</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(in thousands)</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Options outstanding at January&#160;1, 2020</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">607,346&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.22&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.42</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,600&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Options granted</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,742&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.41&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Options exercised</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(120,000)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.58&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,800&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Options forfeited</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(12,228)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17.57&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options outstanding at June 30, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">486,860&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.86&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.70</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,900&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options exercisable at June 30, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">380,894&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.11&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.74</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Stock Options, Valuation Assumptions</a></td>
<td class="text"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the six months ended June&#160;30, 2020, the Company granted 11,742 stock options with a vesting period of five-years to certain ApolloMed board members with an exercise price of $18.41, which were recognized at fair value, as determined using the Black-Scholes option pricing model and the following assumptions:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:80.258%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.742%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">June 30, 2020</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Board Members</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Expected term</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.0 years</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Expected volatility</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">90.01&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Risk-free interest rate</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.43&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Market value of common stock</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.56&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Annual dividend yield</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Forfeiture rate</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Outstanding Warrants</a></td>
<td class="text"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s outstanding warrants consisted of the following:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:43.680%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.913%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Shares</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Weighted</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exercise Price</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Weighted</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Remaining</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Contractual</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Term</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Years)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Aggregate</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Intrinsic</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Value</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(in thousands)</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Warrants outstanding at January&#160;1, 2020</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,154,590&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.96&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.01</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,700&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Warrants granted</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Warrants exercised</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(273,900)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.32&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Warrants expired/forfeited</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Warrants outstanding at June 30, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,880,690&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.02&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.61</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,700&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:19.637%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.152%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:16.567%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.982%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.742%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exercise&#160;Price&#160;Per Share</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Warrants&#8232;Outstanding</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Weighted</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Remaining</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Contractual&#160;Life</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Warrants</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exercisable</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Weighted</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exercise&#160;Price</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Per Share</span></div></td></tr><tr><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.00&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">754,870&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.29</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">754,870&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.00&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.00&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,313,345&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.85</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,313,345&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.00&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.00&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">812,475&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.44</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">812,475&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.00&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">$                                              $                     9.00 &#8211;11.00</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,880,690&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.61</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,880,690&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.02&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619853587608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of Fees Incurred and Income Earned from Related Party Transactions</a></td>
<td class="text">The following table sets forth fees incurred and income earned related to AHMC, HSMSO and Aurion (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:40.606%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.323%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.323%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.909%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.643%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Six Months Ended June 30,</span></div></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">AHMC &#8211; Risk pool, capitation, claims payment, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,057&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,350&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,056&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27,950&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">HSMSO &#8211; Management fees, net</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(189)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(265)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(321)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(915)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Aurion &#8211; Management fees</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(53)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(100)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(128)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(200)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net total</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,815&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,985&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,607&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,835&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619975160872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share Computations</a></td>
<td class="text"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Below is a summary of the earnings per share computations:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:71.060%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.739%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Earnings per share &#8211; basic</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.20&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.10&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Earnings per share &#8211; diluted</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.19&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.09&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Weighted average shares of common stock outstanding &#8211; basic</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,071,604&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34,540,059&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Weighted average shares of common stock outstanding &#8211; diluted</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,285,585&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,962,555&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"><tr><td style="width:1.0%;"/><td style="width:70.941%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.794%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.795%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Earnings per share &#8211; basic</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.31&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.11&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Earnings per share &#8211; diluted</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.30&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.10&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Weighted average shares of common stock outstanding &#8211; basic</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,040,936&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34,518,461&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Weighted average shares of common stock outstanding &#8211; diluted</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,296,913&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,896,837&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Schedule of Shares Included in the Diluted Earnings Per Share Computations</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Below is a summary of the shares included in the diluted earnings per share computations:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:71.060%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.739%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Weighted average shares of common stock outstanding &#8211; basic</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,071,604&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34,540,059&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">10% shares held back pursuant to indemnification clause</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,519,805&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Stock options</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">169,402&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">363,593&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Warrants</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,041,784&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,539,098&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock awards</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,795&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Weighted average shares of common stock outstanding &#8211; diluted</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,285,585&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,962,555&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:71.060%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.739%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Weighted average shares of common stock outstanding &#8211; basic</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,040,936&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34,518,461&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">10% shares held back pursuant to indemnification clause</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,519,805&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Stock options</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">173,299&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">368,273&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Warrants</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,076,802&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,490,298&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock awards</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,876&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Weighted average shares of common stock outstanding &#8211; diluted</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,296,913&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,896,837&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619853694504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Variable Interest Entities (VIEs) (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock', window );">Schedule of Variable Interest Entities</a></td>
<td class="text">The following table includes assets that can only be used to settle the liabilities of APC and its VIEs, including Alpha Care and Accountable Health Care, and to which the creditors of APC, including Alpha Care and Accountable Health Care, have no recourse to the Company, nor do creditors of the Company have recourse against the assets of APC, including Alpha Care and Accountable Health Care. These assets and liabilities, with the exception of the investment in a privately held entity that does not report net asset value per share and amounts due to affiliates, which are eliminated upon consolidation with NMM, are included in the accompanying consolidated balance sheets (in thousands).<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:70.873%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.636%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.758%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Assets</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current assets</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">113,790&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">87,110&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investment in marketable securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">117,611&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">123,948&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Receivables, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,687&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,300&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Receivables, net &#8211; related party</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">55,889&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42,976&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other receivables</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">734&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">744&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses and other current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,752&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,403&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loan receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,425&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,425&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loan receivable &#8211; related parties</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total current assets</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">317,888&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">294,481&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Land, property and equipment, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,085&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,547&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intangible assets, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75,177&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">81,439&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">109,460&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">108,913&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investment in affiliates</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">285,569&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">318,315&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investment in privately held entities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,584&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,615&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investments in other entities &#8211; equity method</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,864&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28,427&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">746&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">746&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease right-of-use assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,017&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,751&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,750&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,057&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total noncurrent assets</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">571,252&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">554,810&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Total assets</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">889,140&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">849,291&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable and accrued expenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,822&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,187&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fiduciary accounts payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,853&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,027&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Medical liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">47,304&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49,019&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income taxes payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42,211&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,530&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount due to affiliate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,533&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28,058&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dividends payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">431&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">271&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance lease liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">102&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">102&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,319&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,088&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total current liabilities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">126,575&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">96,282&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Noncurrent liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,490&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,059&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance lease liabilities, net of current portion</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">355&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">416&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities, net of current portion</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,833&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,742&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total noncurrent liabilities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,678&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,217&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr></table><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:70.873%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.636%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.758%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Total liabilities</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">142,253&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">114,499&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=SL6759159-111685<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5747-111685<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=SL6228884-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5728-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfVariableInterestEntitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619853604136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Information Related to Lease Costs</a></td>
<td class="text"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The components of lease expense were as follows (in thousands):</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:77.824%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:7.941%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.505%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating lease cost</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,446&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,240&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Finance lease cost</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Amortization of lease expense</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Interest on lease liabilities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Sublease income</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(226)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(106)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total finance lease cost, net</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,259&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,163&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:77.678%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.380%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.212%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating lease cost</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,388&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,343&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Finance lease cost</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Amortization of lease expense</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">61&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Interest on lease liabilities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Sublease income</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(360)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(206)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total finance lease cost, net</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,096&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,196&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other information related to leases was as follows (in thousands):</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:77.295%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.425%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.546%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Supplemental Cash Flows Information</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash paid for amounts included in the measurement of lease liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating cash flows from operating leases</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,333&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,239&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating cash flows from finance leases</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Financing cash flows from finance leases</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Right-of-use assets obtained in exchange for lease liabilities:</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating leases</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,907&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,441&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Supplemental Cash Flows Information</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash paid for amounts included in the measurement of lease liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating cash flows from operating leases</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,880&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,273&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating cash flows from finance leases</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Financing cash flows from finance leases</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">61&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Right-of-use assets obtained in exchange for lease liabilities:</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating leases</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,652&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,417&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Weighted Average Remaining Lease Term</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating leases</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.06 years</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.87 years</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Finance leases</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.17 years</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.00 years</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Weighted Average Discount Rate</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating leases</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.10&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.18&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Finance leases</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.00&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.00&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Operating Lease Payments After Adoption of 842</a></td>
<td class="text"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Future minimum lease payments under non-cancellable leases as of June&#160;30, 2020 is as follows (in thousands):</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:70.620%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.323%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.325%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Operating Leases</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Finance Leases</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020 (excluding the six months ended June 30, 2020)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,337&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">59&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,297&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">119&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,529&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">119&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,303&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">119&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,940&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">79&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Thereafter</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,459&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total future minimum lease payments</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,865&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">495&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Less: imputed interest</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,097&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total lease liabilities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,768&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">457&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Less: current portion</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,350&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">102&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Long-term lease liabilities</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,418&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">355&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Finance Lease Payments After Adoption of 842</a></td>
<td class="text"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Future minimum lease payments under non-cancellable leases as of June&#160;30, 2020 is as follows (in thousands):</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:70.620%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.323%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.325%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Operating Leases</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Finance Leases</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020 (excluding the six months ended June 30, 2020)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,337&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">59&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,297&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">119&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,529&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">119&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,303&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">119&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,940&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">79&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Thereafter</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,459&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total future minimum lease payments</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,865&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">495&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Less: imputed interest</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,097&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total lease liabilities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,768&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">457&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Less: current portion</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,350&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">102&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Long-term lease liabilities</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,418&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">355&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619855002760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business - Additional Information (Details)<br> member in Thousands, enrollee in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="7"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jul. 01, 1999</div></th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>enrollee</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>primary_care_physician</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>specialty_care_physician</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>medical_center</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>member</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>plan</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>clinic</div>
</th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Nov. 16, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Proceeds from sale of equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,743<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1', window );">Value of non-cash consideration received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,179<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ameh_AccountableHealthCareIPAMember', window );">Accountable Health Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ameh_AmgIncMember', window );">AMG, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember', window );">Universal Care, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Investment, ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Proceeds from sale of equity method investment</a></td>
<td class="nump">$ 52,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet', window );">Additional cash consideration entitled to be received</a></td>
<td class="nump">$ 15,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ameh_APAMHMedicalCorporationMember', window );">AP-AMH Medical Corporation | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableNet', window );">Amount of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 545,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FinanceReceivableTermOfReceivable', window );">Term of receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FinanceReceivableStatedInterestRate', window );">Stated rate of note of loan receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate', window );">Interest rate in the event of default</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares purchased by related party | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,015,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock subscription</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringPeriodProxyVotesPercentage', window );">Proxy votes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement', window );">Fixed term of amended and restated management and administrative services agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | Accountable Health Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Interest acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | AMG, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Value of shares transferred in acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | Apollo Medical Holdings, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Investment, ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.28%<span></span>
</td>
<td class="nump">32.28%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | Concourse Diagnostic Surgery Center, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Investment, ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.01%<span></span>
</td>
<td class="nump">45.01%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | Universal Care, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentOwnershipPercentageDisposed', window );">Ownership interest disposed</a></td>
<td class="nump">48.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Proceeds from sale of equity method investment</a></td>
<td class="nump">$ 69,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfDebt', window );">Repayment of indebtedness received</a></td>
<td class="nump">16,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet', window );">Additional cash consideration entitled to be received</a></td>
<td class="nump">15,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | AP-AMH Medical Corporation | Affiliated Entity | Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares purchased by related party | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | Bright | Preferred Stock | Universal Care, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1', window );">Value of non-cash consideration received</a></td>
<td class="nump">$ 36,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_ApcLsmaMember', window );">APC LSMA | Accountable Health Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Interest acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_ApcLsmaMember', window );">APC LSMA | AMG, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Interest acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_ApcLsmaMember', window );">APC LSMA | Maverick Medical Group, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_ApcLsmaMember', window );">APC LSMA | Universal Care Acquisition Partners, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlphaCareMedicalGroupInc.Member', window );">Alpha Care Medical Group, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NumberOfEnrollees', window );">Number of healthcare enrollees | enrollee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AccountableHealthCareIPAMember', window );">Accountable Health Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NumberOfEmployees', window );">Number of employees (over)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfStores', window );">Number of medical centers | medical_center</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NumberOfMembersOfFederallyQualifiedHealthPlans', window );">Number of members of federally qualified health plans | member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NumberOfFederallyQualifiedHealthPlans', window );">Number federally qualified health plans | plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AmgIncMember', window );">AMG, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NumberOfFamilyPracticeClinics', window );">Number of family practice clinics | clinic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_UniversalCareAcquisitionPartnersLlcMember', window );">Universal Care Acquisition Partners, LLC | APC | Universal Care, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Investment, ownership interest</a></td>
<td class="nump">48.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfDebt', window );">Repayment of indebtedness received</a></td>
<td class="nump">$ 16,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_UniversalCareAcquisitionPartnersLlcMember', window );">Universal Care Acquisition Partners, LLC | Bright | Universal Care, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentOwnershipPercentageDisposed', window );">Ownership interest disposed</a></td>
<td class="nump">48.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Proceeds from sale of equity method investment</a></td>
<td class="nump">$ 69,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional Proceeds To Be Received From Sale Of Equity Method Investments, If Circumstances Met</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DescriptionOfBusinessLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DescriptionOfBusinessLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentOwnershipPercentageDisposed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Ownership Percentage Disposed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentOwnershipPercentageDisposed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Receivable, Modifications, Subsequent Default, Interest Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FinanceReceivableStatedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Receivable, Stated Interest Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FinanceReceivableStatedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FinanceReceivableTermOfReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Receivable, Term Of Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FinanceReceivableTermOfReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The initial fixed term of amended and restated management and administrative services agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_NumberOfEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Employees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_NumberOfEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_NumberOfEnrollees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Enrollees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_NumberOfEnrollees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_NumberOfFamilyPracticeClinics">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Family Practice Clinics</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_NumberOfFamilyPracticeClinics</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_NumberOfFederallyQualifiedHealthPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Federally Qualified Health Plans</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_NumberOfFederallyQualifiedHealthPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_NumberOfMembersOfFederallyQualifiedHealthPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Members Of Federally Qualified Health Plans</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_NumberOfMembersOfFederallyQualifiedHealthPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_StockIssuedDuringPeriodProxyVotesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Proxy Votes, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_StockIssuedDuringPeriodProxyVotesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash consideration received for selling an asset or business through a noncash (or part noncash) transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919230-210447<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfStores">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of stores.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfStores</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow in aggregate debt due to repayments and proceeds from additional borrowings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ameh_AccountableHealthCareIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ameh_AccountableHealthCareIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ameh_AmgIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ameh_AmgIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ameh_APAMHMedicalCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ameh_APAMHMedicalCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_ApolloMedicalHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_ApolloMedicalHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_ConcourseDiagnosticSurgeryCenterLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_ConcourseDiagnosticSurgeryCenterLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ameh_BrightHealthCompanyOfCaliforniaInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ameh_BrightHealthCompanyOfCaliforniaInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_ApcLsmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_ApcLsmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ameh_MaverickMedicalGroupIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ameh_MaverickMedicalGroupIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ameh_UniversalCareAcquisitionPartnersLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ameh_UniversalCareAcquisitionPartnersLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlphaCareMedicalGroupInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlphaCareMedicalGroupInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AccountableHealthCareIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AccountableHealthCareIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AmgIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AmgIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_UniversalCareAcquisitionPartnersLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_UniversalCareAcquisitionPartnersLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619859011384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>segment </div>
<div>unit</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">Amount deposit accounts exceeded FDIC insured limit</a></td>
<td class="nump">$ 290,900,000<span></span>
</td>
<td class="nump">$ 290,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Amount of short-term marketable securities</a></td>
<td class="nump">117,656,000<span></span>
</td>
<td class="nump">$ 117,656,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 116,539,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear', window );">Risk pool surplus or deficits, settlement period after risk pool performance year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts</a></td>
<td class="nump">1,300,000<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of finite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of main reporting units | unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of indefinite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentOfRevenueMonthlyAmount', window );">Payments received, monthly</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentOfRevenue', window );">Payments received</a></td>
<td class="nump">22,900,000<span></span>
</td>
<td class="nump">45,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Accrued contract liability recognized</a></td>
<td class="nump">20,500,000<span></span>
</td>
<td class="nump">42,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="nump">3,061,000<span></span>
</td>
<td class="nump">$ 3,061,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,892,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_InvestmentDeposit', window );">Investment deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityOwnershipPercentage', window );">Voting rights held (more than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=ameh_OtherReceivablesFinalSettlement2018PerformanceYearMember', window );">Other Receivables, Final Settlement 2018 Performance Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverables', window );">Recoverable claims paid</a></td>
<td class="nump">3,200,000<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=ameh_OtherReceivablesMember', window );">Other Receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverables', window );">Recoverable claims paid</a></td>
<td class="nump">8,500,000<span></span>
</td>
<td class="nump">8,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=ameh_AccountsPayableAndAccruedExpensesMember', window );">Accounts Payable and Accrued Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Accrued contract liability recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ContractWithCustomerLiabilityRepaidCapitationReceivedAndNotEarned', window );">Contract liability repaid, capitation received and not earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ameh_PerMemberPerMonthManagedCareContractMember', window );">PMPM Managed Care Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuePerformanceObligationDescriptionOfTiming', window );">Contract term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ManagementServiceMember', window );">Management Fee Income Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuePerformanceObligationDescriptionOfTiming', window );">Contract term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ameh_CMSMember', window );">CMS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport', window );">Expected period of payment upon termination of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_MarketableSecuritiesCurrentMaturityPeriod', window );">Short-term marketable securities, maturity period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_MarketableSecuritiesCurrentMaturityPeriod', window );">Short-term marketable securities, maturity period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Amount of short-term marketable securities</a></td>
<td class="nump">$ 117,600,000<span></span>
</td>
<td class="nump">$ 117,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ContractWithCustomerLiabilityRepaidCapitationReceivedAndNotEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Liability, Repaid, Capitation Received And Not Earned</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ContractWithCustomerLiabilityRepaidCapitationReceivedAndNotEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_InvestmentDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment Deposit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_InvestmentDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_MarketableSecuritiesCurrentMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Marketable Securities, Current, Maturity Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_MarketableSecuritiesCurrentMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_PaymentOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment Of Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_PaymentOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_PaymentOfRevenueMonthlyAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment Of Revenue, Monthly Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_PaymentOfRevenueMonthlyAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Remaining Performance Obligation, Expected Timing Of Satisfaction, Period Of Payment Upon Finalization Of Settlement Report</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk Pool Surplus Or Deficits, Settlement Period After Performance Year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121599878&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashUninsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReinsuranceRecoverables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after valuation allowance, recoverable under reinsurance contracts including premium paid under reinsurance contracts. Examples include, but are not limited to, settled and unsettled claims, incurred but not reported losses, loss adjustment expense, premium paid, policy benefits and policy reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=99397103&amp;loc=d3e6824-158387<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 310<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=99404803&amp;loc=d3e21409-158489<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReinsuranceRecoverables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuePerformanceObligationDescriptionOfTiming">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of timing for satisfying performance obligation in contract with customer. Includes, but is not limited to, as services are rendered, and upon shipment, delivery or completion of service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuePerformanceObligationDescriptionOfTiming</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=SL6759159-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=ameh_OtherReceivablesFinalSettlement2018PerformanceYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=ameh_OtherReceivablesFinalSettlement2018PerformanceYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=ameh_OtherReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=ameh_OtherReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=ameh_AccountsPayableAndAccruedExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=ameh_AccountsPayableAndAccruedExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ameh_PerMemberPerMonthManagedCareContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ameh_PerMemberPerMonthManagedCareContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ManagementServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ManagementServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ameh_CMSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ameh_CMSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619852055656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Additional Information, Performance Obligation (Details) - Next Generation ACO Model Participation Agreement<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2017-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2017-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Remaining performance obligation, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2019-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Remaining performance obligation, period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2017-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2017-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ameh_NextGenerationACOModelParticipationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ameh_NextGenerationACOModelParticipationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2019-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2019-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619859903336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Disaggregation of Revenue by Each Payor Type (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 165,169<span></span>
</td>
<td class="nump">$ 130,050<span></span>
</td>
<td class="nump">$ 330,274<span></span>
</td>
<td class="nump">$ 225,806<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ameh_CommercialMember', window );">Commercial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">25,479<span></span>
</td>
<td class="nump">25,365<span></span>
</td>
<td class="nump">50,192<span></span>
</td>
<td class="nump">50,383<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ameh_MedicareMember', window );">Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">62,038<span></span>
</td>
<td class="nump">57,965<span></span>
</td>
<td class="nump">126,918<span></span>
</td>
<td class="nump">95,063<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ameh_MedicaidMember', window );">Medicaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">68,450<span></span>
</td>
<td class="nump">36,277<span></span>
</td>
<td class="nump">134,897<span></span>
</td>
<td class="nump">61,647<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ameh_OtherThirdPartiesMember', window );">Other third parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 9,202<span></span>
</td>
<td class="nump">$ 10,443<span></span>
</td>
<td class="nump">$ 18,267<span></span>
</td>
<td class="nump">$ 18,713<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_CommercialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_CommercialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_MedicaidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_MedicaidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_OtherThirdPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_OtherThirdPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619857996376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Contributions to Revenue and Receivables by Payor (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Net Revenue | Payor A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AccountsReceivableAndNetRevenueLineItems', window );"><strong>Accounts Receivable And Net Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">11.90%<span></span>
</td>
<td class="nump">13.70%<span></span>
</td>
<td class="nump">11.90%<span></span>
</td>
<td class="nump">15.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Net Revenue | Payor B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AccountsReceivableAndNetRevenueLineItems', window );"><strong>Accounts Receivable And Net Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">10.30%<span></span>
</td>
<td class="nump">12.60%<span></span>
</td>
<td class="nump">10.30%<span></span>
</td>
<td class="nump">14.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Net Revenue | Payor C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AccountsReceivableAndNetRevenueLineItems', window );"><strong>Accounts Receivable And Net Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Net Revenue | Payor D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AccountsReceivableAndNetRevenueLineItems', window );"><strong>Accounts Receivable And Net Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">17.50%<span></span>
</td>
<td class="nump">13.70%<span></span>
</td>
<td class="nump">17.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Net Revenue | Payor E</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AccountsReceivableAndNetRevenueLineItems', window );"><strong>Accounts Receivable And Net Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">12.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Net Revenue | Payor G</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AccountsReceivableAndNetRevenueLineItems', window );"><strong>Accounts Receivable And Net Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">10.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Receivables and Receivables-Related Parties | Payor D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AccountsReceivableAndNetRevenueLineItems', window );"><strong>Accounts Receivable And Net Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Receivables and Receivables-Related Parties | Payor G</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AccountsReceivableAndNetRevenueLineItems', window );"><strong>Accounts Receivable And Net Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Receivables and Receivables-Related Parties | Payor H</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AccountsReceivableAndNetRevenueLineItems', window );"><strong>Accounts Receivable And Net Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_AccountsReceivableAndNetRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_AccountsReceivableAndNetRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_PayorAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_PayorAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_PayorBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_PayorBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_PayorCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_PayorCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_PayorDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_PayorDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_PayorEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_PayorEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_PayorFMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_PayorFMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_PayorGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_PayorGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_PayorHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_PayorHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619855618040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Carrying Amounts and Fair Values of Financial Instruments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">$ 108,195<span></span>
</td>
<td class="nump">$ 50,731<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities &#8211; certificates of deposit</a></td>
<td class="nump">117,611<span></span>
</td>
<td class="nump">116,469<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable securities &#8211; equity securities</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">225,851<span></span>
</td>
<td class="nump">167,270<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">108,195<span></span>
</td>
<td class="nump">50,731<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities &#8211; certificates of deposit</a></td>
<td class="nump">117,611<span></span>
</td>
<td class="nump">116,469<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable securities &#8211; equity securities</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">225,851<span></span>
</td>
<td class="nump">167,270<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities &#8211; certificates of deposit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable securities &#8211; equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities &#8211; certificates of deposit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable securities &#8211; equity securities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=99377092&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619860675960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations and Goodwill - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 30, 2019</div></th>
<th class="th"><div>May 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 41,518<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ameh_AccountableHealthCareIPAMember', window );">Accountable Health Care, IPA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="nump">$ 25,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Liabilities assumed</a></td>
<td class="nump">15,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ameh_AccountableHealthCareIPAMember', window );">Accountable Health Care, IPA | Dr. Jay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid</a></td>
<td class="nump">$ 7,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ameh_AmgIncMember', window );">AMG, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_APCAndAPCLSMAMember', window );">APC and APC-LSMA | Alpha Care Medical Group, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Interest acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EscrowDeposit', window );">Escrow deposit for potential post-closing adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_APCAndAPCLSMAMember', window );">APC and APC-LSMA | Accountable Health Care, IPA | Dr. Jay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Interest acquired</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="nump">$ 7,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | Accountable Health Care, IPA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Interest acquired</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Payments to acquire investments</a></td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | AMG, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Value of shares transferred in acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EscrowDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EscrowDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ameh_AccountableHealthCareIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ameh_AccountableHealthCareIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ameh_Dr.JayMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ameh_Dr.JayMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ameh_AmgIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ameh_AmgIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_APCAndAPCLSMAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_APCAndAPCLSMAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ameh_AlphaCareMedicalGroupInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ameh_AlphaCareMedicalGroupInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619860915384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations and Goodwill - Identifiable Assets Acquired and Liabilities Assumed (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 30, 2019</div></th>
<th class="th"><div>May 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract', window );"><strong>Assets acquired</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 239,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 238,505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 41,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ameh_AccountableHealthCareIPAMember', window );">Accountable Health Care, IPA | Dr. Jay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract', window );"><strong>Assets acquired</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable, net</a></td>
<td class="nump">5,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther', window );">Other current assets</a></td>
<td class="nump">198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Network relationship intangible assets</a></td>
<td class="nump">11,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">23,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(3,759)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities', window );">Medical liabilities</a></td>
<td class="num">(12,154)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities', window );">Subordinated loan</a></td>
<td class="num">(15,327)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Net assets acquired</a></td>
<td class="nump">9,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned', window );">Equity investment contributed</a></td>
<td class="nump">2,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid</a></td>
<td class="nump">$ 7,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_APCAndAPCLSMAMember', window );">APC and APC-LSMA | Alpha Care Medical Group, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract', window );"><strong>Assets acquired</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther', window );">Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Network relationship intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,795)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,334)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities', window );">Medical liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,616)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Net assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Medical Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities assumed (as defined) which have been recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ameh_AccountableHealthCareIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ameh_AccountableHealthCareIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ameh_Dr.JayMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ameh_Dr.JayMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_APCAndAPCLSMAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_APCAndAPCLSMAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ameh_AlphaCareMedicalGroupInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ameh_AlphaCareMedicalGroupInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619854301672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations and Goodwill - Summary of Goodwill (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance, January 1, 2020</a></td>
<td class="nump">$ 238,505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Adjustments</a></td>
<td class="nump">548<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance, June 30, 2020</a></td>
<td class="nump">$ 239,053<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillOtherIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillOtherIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619850304520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net - Schedule of Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">$ (81,739)<span></span>
</td>
<td class="num">$ (73,517)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">94,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Intangible Assets, Gross</a></td>
<td class="nump">176,529<span></span>
</td>
<td class="nump">176,529<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible Assets, Net</a></td>
<td class="nump">94,790<span></span>
</td>
<td class="nump">103,012<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_NetworkRelationshipsMember', window );">Network relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Amortized intangible assets, Gross</a></td>
<td class="nump">143,930<span></span>
</td>
<td class="nump">143,930<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(67,015)<span></span>
</td>
<td class="num">(60,526)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 76,915<span></span>
</td>
<td class="nump">$ 83,404<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_NetworkRelationshipsMember', window );">Network relationships | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life</a></td>
<td class="text">11 years<span></span>
</td>
<td class="text">11 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_NetworkRelationshipsMember', window );">Network relationships | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_ManagementContractsMember', window );">Management contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Amortized intangible assets, Gross</a></td>
<td class="nump">$ 22,832<span></span>
</td>
<td class="nump">$ 22,832<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(10,736)<span></span>
</td>
<td class="num">(9,676)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 12,096<span></span>
</td>
<td class="nump">$ 13,156<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_MemberRelationshipsMember', window );">Member relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">12 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Amortized intangible assets, Gross</a></td>
<td class="nump">$ 6,696<span></span>
</td>
<td class="nump">$ 6,696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(2,793)<span></span>
</td>
<td class="num">(2,352)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 3,903<span></span>
</td>
<td class="nump">$ 4,344<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_PatientManagementPlatformMember', window );">Patient management platform</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Amortized intangible assets, Gross</a></td>
<td class="nump">$ 2,060<span></span>
</td>
<td class="nump">$ 2,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(1,064)<span></span>
</td>
<td class="num">(858)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 996<span></span>
</td>
<td class="nump">$ 1,202<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember', window );">Trade names/trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Amortized intangible assets, Gross</a></td>
<td class="nump">$ 1,011<span></span>
</td>
<td class="nump">$ 1,011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(131)<span></span>
</td>
<td class="num">(105)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 880<span></span>
</td>
<td class="nump">$ 906<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_NetworkRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_NetworkRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_ManagementContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_ManagementContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_MemberRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_MemberRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_PatientManagementPlatformMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_PatientManagementPlatformMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619852127176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 4.1<span></span>
</td>
<td class="nump">$ 3.9<span></span>
</td>
<td class="nump">$ 8.2<span></span>
</td>
<td class="nump">$ 7.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619852030696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets, Net - Future Amortization Expense (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">2020 (excluding the six months ended June 30, 2020)</a></td>
<td class="nump">$ 7,807<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2021</a></td>
<td class="nump">14,524<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2022</a></td>
<td class="nump">12,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2023</a></td>
<td class="nump">10,842<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2024</a></td>
<td class="nump">9,830<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour', window );">Thereafter</a></td>
<td class="nump">39,114<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 94,790<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Asset, Expected Amortization, After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619860688968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Other Entities &#8212; Equity Method - Equity Method Investments (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,427,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Income (Loss)</a></td>
<td class="nump">$ 834,000<span></span>
</td>
<td class="num">$ (42,000)<span></span>
</td>
<td class="nump">2,888,000<span></span>
</td>
<td class="num">$ (892,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,998,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="nump">26,817,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,817,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember', window );">LaSalle Medical Associates &#8211; IPA Line of Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,397,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(428,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="nump">5,969,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,969,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember', window );">Pacific Medical Imaging &amp; Oncology Center, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,396,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="nump">1,473,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,473,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember', window );">Universal Care, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,438,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Income (Loss)</a></td>
<td class="nump">900,000<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="nump">3,560,000<span></span>
</td>
<td class="nump">$ 5,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,998,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DiagnosticMedicalGroupMember', window );">Diagnostic Medical Group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,334,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(102,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="nump">2,232,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,232,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_FiveThreeOneW.CollegeLLCMember', window );">531 W. College, LLC &#8211; related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,698,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(231,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="nump">16,967,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,967,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_MWNCommunityHospitalLLCMember', window );">MWN, LLC &#8211; related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="nump">$ 176,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 176,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentsContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments, Contribution</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentsContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the entity's equity method investment which has been sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentSoldCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DiagnosticMedicalGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DiagnosticMedicalGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_FiveThreeOneW.CollegeLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_FiveThreeOneW.CollegeLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_MWNCommunityHospitalLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_MWNCommunityHospitalLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619837053160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Other Entities &#8212; Equity Method - Additional Information (Details)<br> patient in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="6"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2015 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>primary_care_physician</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>specialty_care_physician</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>medical_center</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>provider</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>patient</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 23, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>May 14, 2016</div></th>
<th class="th"><div>Nov. 16, 2015</div></th>
<th class="th">
<div>Jul. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2012 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 834,000<span></span>
</td>
<td class="num">$ (42,000)<span></span>
</td>
<td class="nump">$ 2,888,000<span></span>
</td>
<td class="num">$ (892,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,817,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,817,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,427,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Cash consideration paid for ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">2,158,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Proceeds from sale of equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,743,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue', window );">Investments in privately held entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,075,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,075,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">896,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | MediPortal LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares', window );">Membership interests purchased (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments', window );">Payments to purchase membership interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest', window );">Membership interests acquired (in dollars per share) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants received (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption', window );">Term of option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests', window );">Options to purchase additional membership interests (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">380,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet', window );">Number of warrants available to purchase, contingent upon the portal completion date (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">480,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AccountableHealthCareIPAMember', window );">Accountable Health Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfStores', window );">Number of medical centers | medical_center</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NumberOfEmployees', window );">Number of employees (more than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_NetworkMedicalManagementIncMember', window );">Network Medical Management, Inc. | AchievaMed, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears', window );">Percentage of voting common stock, within five years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment', window );">Duration of investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost', window );">Investment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments', window );">Related investment balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_Pacific6EnterprisesMember', window );">Pacific6 Enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_HealthSourceMSOInc.Member', window );">Health Source MSO Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember', window );">LaSalle Medical Associates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfStores', window );">Number of medical centers | medical_center</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NumberOfEmployees', window );">Number of employees (more than) | provider</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NumberOfPatients', window );">Number of patients | patient</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(428,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,969,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,969,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,397,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember', window );">LaSalle Medical Associates | APC LSMA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Amount invested for interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember', window );">LaSalle Medical Associates | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="num">(1,300,000)<span></span>
</td>
<td class="num">(400,000)<span></span>
</td>
<td class="num">(2,400,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember', window );">Pacific Medical Imaging &amp; Oncology Center, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,473,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,473,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,396,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember', window );">Pacific Medical Imaging &amp; Oncology Center, Inc. | APC LSMA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Amount invested for interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember', window );">Pacific Medical Imaging &amp; Oncology Center, Inc. | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,200)<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember', window );">Pacific Medical Imaging &amp; Oncology Center, Inc. | APC | Ancillary Service Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Fees paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember', window );">Universal Care, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="nump">3,560,000<span></span>
</td>
<td class="nump">5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="nump">$ 4,998,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,438,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Proceeds from sale of equity method investment</a></td>
<td class="nump">52,743,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet', window );">Additional cash and non-cash consideration entitled to be received</a></td>
<td class="nump">15,723,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember', window );">Universal Care, Inc. | Preferred Stock | Bright</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue', window );">Investments in privately held entities</a></td>
<td class="nump">$ 36,179,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember', window );">Universal Care, Inc. | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentOwnershipPercentageDisposed', window );">Ownership interest disposed</a></td>
<td class="nump">48.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Proceeds from sale of equity method investment</a></td>
<td class="nump">$ 69,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfDebt', window );">Repayment of indebtedness received</a></td>
<td class="nump">16,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet', window );">Additional cash and non-cash consideration entitled to be received</a></td>
<td class="nump">15,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember', window );">Universal Care, Inc. | APC | Preferred Stock | Bright</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue', window );">Investments in privately held entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember', window );">Universal Care, Inc. | Universal Care Acquisition Partners, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentSaleContingentConsiderationCash', window );">Contingent consideration, cash held in escrow</a></td>
<td class="nump">15,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares', window );">Contingent consideration, preferred shares</a></td>
<td class="nump">6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue', window );">Contingent consideration, fair value</a></td>
<td class="nump">$ 22,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember', window );">Universal Care, Inc. | Universal Care Acquisition Partners, LLC | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="nump">48.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfDebt', window );">Repayment of indebtedness received</a></td>
<td class="nump">$ 16,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember', window );">Universal Care, Inc. | Universal Care Acquisition Partners, LLC | Bright</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentOwnershipPercentageDisposed', window );">Ownership interest disposed</a></td>
<td class="nump">48.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Proceeds from sale of equity method investment</a></td>
<td class="nump">$ 69,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember', window );">Universal Care, Inc. | Universal Care Acquisition Partners, LLC | Voting Common Stock A Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsPurchaseOfShares', window );">Shares purchased (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Cash consideration paid for ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock', window );">Percentage of voting common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember', window );">Universal Care, Inc. | Universal Care Acquisition Partners, LLC | Ancillary Service Contract | Voting Common Stock A Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DiagnosticMedicalGroupMember', window );">Diagnostic Medical Group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(102,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,232,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,232,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,334,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DiagnosticMedicalGroupMember', window );">Diagnostic Medical Group | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_FiveThreeOneW.CollegeLLCMember', window );">513 W. College LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(231,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,967,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,967,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,698,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireRealEstate', window );">Purchase price of real estate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_FiveThreeOneW.CollegeLLCMember', window );">513 W. College LLC | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
<td class="nump">$ 12,649<span></span>
</td>
<td class="num">(200,000)<span></span>
</td>
<td class="num">$ (34,319)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MembersCapital', window );">Initial capital contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_FiveThreeOneW.CollegeLLCMember', window );">513 W. College LLC | College Street Investment LP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MembersCapital', window );">Initial capital contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_FiveThreeOneW.CollegeLLCMember', window );">513 W. College LLC | Network Medical Management, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Amount invested for interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MembersCapital', window );">Initial capital contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_MWNCommunityHospitalLLCMember', window );">MWN, LLC &#8211; related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_MWNCommunityHospitalLLCMember', window );">MWN, LLC &#8211; related party | Network Medical Management, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MembersCapital', window );">Initial capital contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_WorkingCapitalContribution', window );">Working capital contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_MWNCommunityHospitalLLCMember', window );">MWN, LLC &#8211; related party | Pacific6 Enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MembersCapital', window );">Initial capital contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_WorkingCapitalContribution', window );">Working capital contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_MWNCommunityHospitalLLCMember', window );">MWN, LLC &#8211; related party | Health Source MSO Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MembersCapital', window );">Initial capital contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_WorkingCapitalContribution', window );">Working capital contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional Proceeds To Be Received From Sale Of Equity Method Investments, If Circumstances Met</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentOwnershipPercentageDisposed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Ownership Percentage Disposed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentOwnershipPercentageDisposed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentSaleContingentConsiderationCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Sale, Contingent Consideration, Cash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentSaleContingentConsiderationCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Sale, Contingent Consideration, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Sale, Contingent Consideration, Preferred Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentsContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments, Contribution</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentsContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The proportion of investment in Voting common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentsPurchaseOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares purchased from equity method investment entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentsPurchaseOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value Investments, Options Issued, Term Of Option</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value Investments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value Investments, Aggregate Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value Investments, Duration Of Investment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value Investments, Membership Interest Acquired, Per Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value Investments, Options Issued, Option To Purchase Additional Interests</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value Investments, Options Issues, Options To Purchase Additional Interests, If Circumstances Met</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value Investments, Proportion of Ownership Interest in Voting Common Stock, Within Five Years</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value Investments, Purchase Of Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities without Readily Determinable Fair Value, Ownership Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of Investment in privately held entity that does not report net asset value per share .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_NumberOfEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Employees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_NumberOfEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_NumberOfPatients">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Patients</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_NumberOfPatients</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments To Acquire Equity Securities Without Readily Determinable Fair Value Investments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_WorkingCapitalContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the working capital contribution in equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_WorkingCapitalContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MembersCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of member capital in limited liability company (LLC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MembersCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfStores">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of stores.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfStores</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for fees classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireRealEstate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the acquisition of a piece of land, anything permanently fixed to it, including buildings, structures on it and so forth; includes real estate intended to generate income for the owner; excludes real estate acquired for use by the owner.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireRealEstate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow in aggregate debt due to repayments and proceeds from additional borrowings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ameh_MediPortalLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ameh_MediPortalLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AccountableHealthCareIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AccountableHealthCareIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_NetworkMedicalManagementIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_NetworkMedicalManagementIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ameh_AchievaMedInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ameh_AchievaMedInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_Pacific6EnterprisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_Pacific6EnterprisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_HealthSourceMSOInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_HealthSourceMSOInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_ApcLsmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_ApcLsmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ContractTypeAxis=ameh_AncillaryServiceContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ContractTypeAxis=ameh_AncillaryServiceContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ameh_BrightHealthCompanyOfCaliforniaInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ameh_BrightHealthCompanyOfCaliforniaInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_UniversalCareAcquisitionPartnersLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_UniversalCareAcquisitionPartnersLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ameh_VotingCommonStockTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ameh_VotingCommonStockTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DiagnosticMedicalGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DiagnosticMedicalGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_FiveThreeOneW.CollegeLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_FiveThreeOneW.CollegeLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_CollegeStreetInvestmentLpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_CollegeStreetInvestmentLpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_MWNCommunityHospitalLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_MWNCommunityHospitalLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619857959080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Other Entities &#8212; Equity Method - Gain on Sale (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Cash proceeds (excludes proceeds to settle indebtedness owed to APC from UCI)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,743,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue', window );">Preferred shares in Bright Health, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,075,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,075,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 896,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Less: Carrying value of equity method investment on date of sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,817,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,817,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,427,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal', window );">Gain on sale of equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,647,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">99,647,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember', window );">Universal Care, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Cash proceeds (excludes proceeds to settle indebtedness owed to APC from UCI)</a></td>
<td class="nump">$ 52,743,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet', window );">Beneficial interest in UCI</a></td>
<td class="nump">15,723,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Less: Carrying value of equity method investment on date of sale</a></td>
<td class="num">(4,998,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,438,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal', window );">Gain on sale of equity method investment</a></td>
<td class="nump">99,647,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember', window );">Universal Care, Inc. | Bright | Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue', window );">Preferred shares in Bright Health, Inc.</a></td>
<td class="nump">$ 36,179,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional Proceeds To Be Received From Sale Of Equity Method Investments, If Circumstances Met</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of Investment in privately held entity that does not report net asset value per share .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of an equity method investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(7)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(9)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ameh_BrightHealthCompanyOfCaliforniaInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ameh_BrightHealthCompanyOfCaliforniaInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619943097896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Other Entities &#8212; Equity Method - Summarized Balance Sheets and Statements of Income (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 152,441<span></span>
</td>
<td class="nump">$ 52,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 152,441<span></span>
</td>
<td class="nump">$ 52,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 103,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables, net</a></td>
<td class="nump">17,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetCurrent', window );">Loan receivable</a></td>
<td class="nump">6,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">11,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">833,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">833,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">728,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>Liabilities and Stockholders&#8217; (Deficit) Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="nump">152,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">152,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Stockholders&#8217; deficit</a></td>
<td class="nump">207,848<span></span>
</td>
<td class="nump">186,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">207,848<span></span>
</td>
<td class="nump">186,089<span></span>
</td>
<td class="nump">$ 197,961<span></span>
</td>
<td class="nump">192,335<span></span>
</td>
<td class="nump">$ 182,377<span></span>
</td>
<td class="nump">$ 181,544<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; deficit</a></td>
<td class="nump">833,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">833,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">728,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">165,169<span></span>
</td>
<td class="nump">130,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">330,274<span></span>
</td>
<td class="nump">225,806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Expenses</a></td>
<td class="nump">152,263<span></span>
</td>
<td class="nump">115,322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">313,003<span></span>
</td>
<td class="nump">214,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">12,906<span></span>
</td>
<td class="nump">14,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,271<span></span>
</td>
<td class="nump">11,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">1,282<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,384<span></span>
</td>
<td class="nump">211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before benefit from income taxes</a></td>
<td class="nump">112,859<span></span>
</td>
<td class="nump">14,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,441<span></span>
</td>
<td class="nump">11,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit from income taxes</a></td>
<td class="nump">31,858<span></span>
</td>
<td class="nump">4,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,453<span></span>
</td>
<td class="nump">2,801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">&#160;Net income</a></td>
<td class="nump">81,001<span></span>
</td>
<td class="nump">$ 10,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,988<span></span>
</td>
<td class="nump">8,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=ameh_LasalleMedicalAssociatesIpaMember', window );">LaSalle Medical Associates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">2,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables, net</a></td>
<td class="nump">6,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetCurrent', window );">Loan receivable</a></td>
<td class="nump">2,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">13,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>Liabilities and Stockholders&#8217; (Deficit) Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="nump">20,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Stockholders&#8217; deficit</a></td>
<td class="num">(7,314)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,314)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,602)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; deficit</a></td>
<td class="nump">13,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,113<span></span>
</td>
<td class="nump">93,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,680<span></span>
</td>
<td class="nump">102,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">&#160;Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,567)<span></span>
</td>
<td class="num">(9,411)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=ameh_FiveThreeOneW.CollegeLLCMember', window );">513 W. College LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other assets</a></td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">33,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">33,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>Liabilities and Stockholders&#8217; (Deficit) Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="nump">1,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Stockholders&#8217; deficit</a></td>
<td class="nump">32,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; deficit</a></td>
<td class="nump">$ 33,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">579<span></span>
</td>
<td class="nump">538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(579)<span></span>
</td>
<td class="num">(538)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">&#160;Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (558)<span></span>
</td>
<td class="num">(153)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=ameh_UniversalCareIncMember', window );">Universal Care, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetCurrent', window );">Loan receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>Liabilities and Stockholders&#8217; (Deficit) Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Stockholders&#8217; deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,547)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 195,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">247,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">239,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before benefit from income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit from income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,167)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">&#160;Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of financing receivable, classified as current. Includes, but is not limited to, notes and loan receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=ameh_LasalleMedicalAssociatesIpaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=ameh_LasalleMedicalAssociatesIpaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=ameh_FiveThreeOneW.CollegeLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=ameh_FiveThreeOneW.CollegeLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=ameh_UniversalCareIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=ameh_UniversalCareIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619860094776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loan Receivable and Loan Receivable &#8211; Related Parties - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Feb. 28, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 13, 2019</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Nov. 28, 2018</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Nov. 16, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember', window );">Universal Care, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_UniversalCareAcquisitionPartnersLlcMember', window );">Universal Care Acquisition Partners, LLC | APC | Universal Care, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember', window );">Convertible Secured Promissory Note | Dr. Arteaga | LMA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion', window );">Ownership upon conversion of finance receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember', window );">Convertible Secured Promissory Note | Dr. Arteaga</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableNet', window );">Amount of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember', window );">Convertible Secured Promissory Note | Dr. Arteaga | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableNet', window );">Amount of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on loan receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FinancingReceivableConvertibleToCommonStockPercentageOfOutstandingSharesConvertible', window );">Percentage of outstanding stock convertible</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember', window );">Convertible Secured Promissory Note | Dr. Arteaga | APC and APC-LSMA | LMA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion', window );">Ownership upon conversion of finance receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember', window );">Convertible Secured Promissory Note | Dr. Arteaga | Prime Rate | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_FinanceReceivablesMember', window );">Financing Receivable | APC | Universal Care, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on loan receivable</a></td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AdvancedForWorkingCapital', window );">Advance for working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LineOfCreditFacilityAdditionalAdvances', window );">Additional advances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_FinanceReceivablesMember', window );">Financing Receivable | Prime Rate | APC | Universal Care, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_FinanceReceivablesMember', window );">Financing Receivable | Dr. Arteaga</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableNet', window );">Amount of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_FinanceReceivablesMember', window );">Financing Receivable | Dr. Jay Loan | APC | Universal Care, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on loan receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_AdvancedForWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount advanced for working capital purposes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_AdvancedForWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Conversion Of Finance Receivable, Ownership Percentage Upon Conversion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FinancingReceivableConvertibleToCommonStockPercentageOfOutstandingSharesConvertible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financing Receivable, Convertible To Common Stock, Percentage Of Outstanding Shares Convertible</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FinancingReceivableConvertibleToCommonStockPercentageOfOutstandingSharesConvertible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LineOfCreditFacilityAdditionalAdvances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of line of credit facility additional amount advances as a loan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LineOfCreditFacilityAdditionalAdvances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919230-210447<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_UniversalCareAcquisitionPartnersLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_UniversalCareAcquisitionPartnersLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_Dr.ArteagaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_Dr.ArteagaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_Dr.ArteagaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_Dr.ArteagaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_APCAndAPCLSMAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_APCAndAPCLSMAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_FinanceReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_FinanceReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_DrJayLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_DrJayLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619861325112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">$ 10,425<span></span>
</td>
<td class="nump">$ 6,914<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SpecialtyCapitationPayableCurrent', window );">Capitation payable</a></td>
<td class="nump">2,754<span></span>
</td>
<td class="nump">2,813<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SubcontractorIPAPayable', window );">Subcontractor IPA payable</a></td>
<td class="nump">3,083<span></span>
</td>
<td class="nump">3,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">2,325<span></span>
</td>
<td class="nump">1,837<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to related parties</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">3,060<span></span>
</td>
<td class="nump">3,238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="nump">3,061<span></span>
</td>
<td class="nump">8,892<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Total accounts payable and accrued expenses</a></td>
<td class="nump">$ 24,788<span></span>
</td>
<td class="nump">$ 27,279<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_SpecialtyCapitationPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of specialty capitation payable current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_SpecialtyCapitationPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_SubcontractorIPAPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subcontractor IPA Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_SubcontractorIPAPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619860842568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medical Liabilities - Schedule of Medical Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract', window );"><strong>Medical Liabilities [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical liabilities, beginning of period</a></td>
<td class="nump">$ 58,725<span></span>
</td>
<td class="nump">$ 33,642<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_MedicalCareCostsAbstract', window );"><strong>Components of medical care costs related to claims incurred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense', window );">Current period</a></td>
<td class="nump">165,571<span></span>
</td>
<td class="nump">93,833<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Prior periods</a></td>
<td class="nump">233<span></span>
</td>
<td class="nump">2,688<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1', window );">Total medical care costs</a></td>
<td class="nump">165,804<span></span>
</td>
<td class="nump">96,521<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentsForMedicalCareCostsAbstract', window );"><strong>Payments for medical care costs related to claims incurred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1', window );">Current period</a></td>
<td class="num">(97,112)<span></span>
</td>
<td class="num">(60,440)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1', window );">Prior periods</a></td>
<td class="num">(57,470)<span></span>
</td>
<td class="num">(39,744)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense', window );">Total paid</a></td>
<td class="num">(154,582)<span></span>
</td>
<td class="num">(100,184)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions', window );">Acquired from Alpha Care</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease', window );">Adjustments</a></td>
<td class="nump">326<span></span>
</td>
<td class="num">(156)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical liabilities, end of period</a></td>
<td class="nump">$ 70,273<span></span>
</td>
<td class="nump">$ 42,943<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_MedicalCareCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Medical Care Costs [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_MedicalCareCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_PaymentsForMedicalCareCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For Medical Care Costs [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_PaymentsForMedicalCareCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the cost of settling unpaid claims after deduction of reinsurance recoveries related to the acquisition of a business. Includes, but is not limited to, claims which have been incurred but not reported.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of increase (decrease) in the liability for unpaid claims and claims adjustment expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle insured claims and pay costs incurred in the claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLossesAndLossAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619858677992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Credit Facility, Bank Loan and Lines of Credit - Credit Facility (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Total debt</a></td>
<td class="nump">$ 245,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LinesOfCreditCurrent', window );">Less: Current portion of debt</a></td>
<td class="num">(9,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: Unamortized financing costs</a></td>
<td class="num">(5,295)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">230,455<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=ameh_TermLoanAMember', window );">Term loan A</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Total debt</a></td>
<td class="nump">185,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolver loan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Total debt</a></td>
<td class="nump">$ 60,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LinesOfCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LinesOfCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=ameh_TermLoanAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=ameh_TermLoanAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619848971704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Credit Facility, Bank Loan and Lines of Credit - Schedule of Maturities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">2020 (excluding the six months ended June 30, 2020)</a></td>
<td class="nump">$ 7,125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2021</a></td>
<td class="nump">10,688<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2022</a></td>
<td class="nump">14,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2023</a></td>
<td class="nump">15,437<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2024</a></td>
<td class="nump">197,750<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Total</a></td>
<td class="nump">$ 245,250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619835715080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Facility, Bank Loan and Lines of Credit - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th">
<div>Oct. 02, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 05, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>financial_ratio</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>financial_ratio</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 10, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 14, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 29, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 11, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 17, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 01, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 14, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amount outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 245,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 245,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,673,000<span></span>
</td>
<td class="nump">$ 311,000<span></span>
</td>
<td class="nump">5,541,000<span></span>
</td>
<td class="nump">$ 522,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Loan proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 230,455,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 230,455,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_CreditAgreementMember', window );">Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DebtInstrumentNumberOfKeyFinancialRatios', window );">Number of key financial ratios | financial_ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DebtInstrumentCovenantLeverageRatioMaximum', window );">Maximum consolidated leverage ratio (not greater than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange', window );">Consolidated leverage ratio, annual decrease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DebtInstrumentCovenantLeverageRatioMinimum', window );">Consolidated leverage ratio minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum', window );">Minimum consolidated interest coverage ratio (not less than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDefaultLongtermDebtAmount', window );">Default amount of debt instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Average effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.93%<span></span>
</td>
<td class="nump">4.71%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_CreditAgreementMember', window );">Credit Agreement | Preferred Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Amount outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_CreditAgreementMember', window );">Credit Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Required annual facility fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_CreditAgreementMember', window );">Credit Agreement | Minimum | London Interbank Offered Rate (LIBOR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_CreditAgreementMember', window );">Credit Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Required annual facility fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_CreditAgreementMember', window );">Credit Agreement | Maximum | London Interbank Offered Rate (LIBOR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_CreditAgreementMember', window );">Credit Agreement | First Eight Fiscal Quarters</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal', window );">Principal payment on credit agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_CreditAgreementMember', window );">Credit Agreement | Following Eight Fiscal Quarters Thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal', window );">Principal payment on credit agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_CreditAgreementMember', window );">Credit Agreement | Following Three Fiscal Quarters Thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal', window );">Principal payment on credit agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_NMMLineOfCreditAgreementMember', window );">NMM Line of Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDefaultLongtermDebtAmount', window );">Default amount of debt instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DebtInstrumentApprovalThresholdOfShareholdersForUseOfFundsPercentage', window );">Shareholder approval percentage (not less than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.01%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DebtInstrumentApprovedThresholdUseOfFunds', window );">Approved use of funds (not to exceed)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolver Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amount outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">interest rate at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.24%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.24%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolver Loan | Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Revolving credit facility term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amount outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet', window );">Deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolver Loan | Credit Agreement | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit | Credit Agreement | Preferred Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Amount available</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit | Credit Agreement | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=ameh_TermLoanAMember', window );">Term loan A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amount outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 185,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 185,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">interest rate at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.57%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.57%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=ameh_TermLoanAMember', window );">Term loan A | Credit Agreement | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 190,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationPeriod', window );">Term of facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit | APAACO | Preferred Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationPeriod', window );">Term of facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LineOfCreditFacilityExpirationPeriodPeriodOfNotification', window );">Period of notification of termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit | Alpha Care Medical Group, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationPeriod', window );">Term of facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit | Alpha Care Medical Group, Inc. | Preferred Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationPeriod', window );">Term of facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit | Credit Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Required annual facility fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit | Credit Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Required annual facility fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | NMM Line of Credit Agreement | NMM | Preferred Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">interest rate at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LineOfCreditFacilityGuaranteeGivenByRelatedParties', window );">Term of converted loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationPeriod', window );">Term of facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | NMM Line of Credit Agreement | NMM | Prime Rate | Preferred Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | NMM Business Loan Agreement | NMM | Preferred Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,000,000.0<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amount outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">interest rate at end of period</a></td>
<td class="nump">5.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | NMM Business Loan Agreement | NMM | Prime Rate | Preferred Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">0.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | APC Business Loan Agreement | APC | Preferred Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">interest rate at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Amount available</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | APC Business Loan Agreement | APC | Prime Rate | Preferred Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DebtInstrumentApprovalThresholdOfShareholdersForUseOfFundsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Approval Threshold Of Shareholders For Use Of Funds, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DebtInstrumentApprovalThresholdOfShareholdersForUseOfFundsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DebtInstrumentApprovedThresholdUseOfFunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Approved Threshold Use Of Funds</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DebtInstrumentApprovedThresholdUseOfFunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Interest Coverage Ratio, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Leverage Ratio, Incremental Change</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DebtInstrumentCovenantLeverageRatioMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Leverage Ratio, Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DebtInstrumentCovenantLeverageRatioMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DebtInstrumentCovenantLeverageRatioMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Leverage Ratio, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DebtInstrumentCovenantLeverageRatioMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DebtInstrumentNumberOfKeyFinancialRatios">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Number Of Key Financial Ratios</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DebtInstrumentNumberOfKeyFinancialRatios</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LineOfCreditFacilityExpirationPeriodPeriodOfNotification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Expiration Period, Period Of Notification</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LineOfCreditFacilityExpirationPeriodPeriodOfNotification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LineOfCreditFacilityGuaranteeGivenByRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of guarantee given by related parties for line of credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LineOfCreditFacilityGuaranteeGivenByRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDefaultLongtermDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of outstanding long-term debt or borrowing associated with any securities or credit agreement for which there has been a default in principal, interest, sinking fund, or redemption provisions, or any breach of covenant that existed at the end of the period and subsequently has not been cured.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDefaultLongtermDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section S45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68176171&amp;loc=SL68176184-208336<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payment applied to principal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ameh_CreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ameh_CreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=ameh_PreferredBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=ameh_PreferredBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=ameh_PaymentPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=ameh_PaymentPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=ameh_PaymentPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=ameh_PaymentPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=ameh_PaymentPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=ameh_PaymentPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ameh_NMMLineOfCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ameh_NMMLineOfCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=ameh_TermLoanAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=ameh_TermLoanAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_ApaacoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_ApaacoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlphaCareMedicalGroupInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlphaCareMedicalGroupInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_NetworkMedicalManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_NetworkMedicalManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ameh_NmmBusinessLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ameh_NmmBusinessLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ameh_ApcBusinessLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ameh_ApcBusinessLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619861144360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Mezzanine and Stockholders' Equity - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringPeriodSharesMerger', window );">Holdback shares not issued to former shareholders (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">302,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="nump">111,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod', window );">Options exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding exercise price (in dollars per share)</a></td>
<td class="nump">$ 10.86<span></span>
</td>
<td class="nump">$ 10.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,910<span></span>
</td>
<td class="nump">$ 676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod', window );">Warrants exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">273,900<span></span>
</td>
<td class="nump">41,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised', window );">Proceeds from warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury shares (in shares)</a></td>
<td class="nump">17,475,707<span></span>
</td>
<td class="nump">17,475,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,458,810<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ameh_AlliedPacificofCaliforniaBrokerageAccountMember', window );">Allied Pacific of California Brokerage Account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, value</a></td>
<td class="nump">$ 7,600<span></span>
</td>
<td class="nump">$ 7,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury shares (in shares)</a></td>
<td class="nump">17,307,214<span></span>
</td>
<td class="nump">17,307,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,290,317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends declared</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,600<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_CDSCMember', window );">CDSC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends declared</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">$ 900<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expense</a></td>
<td class="nump">3,800<span></span>
</td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock awards granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Grant date fair value of restricted stock to be recognized straight-line</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercise price of exercises during period (in dollars per share)</a></td>
<td class="nump">$ 2.10<span></span>
</td>
<td class="nump">$ 2.10<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice', window );">Exercise price of warrants exercised (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00<span></span>
</td>
<td class="nump">9.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercise price of exercises during period (in dollars per share)</a></td>
<td class="nump">5.00<span></span>
</td>
<td class="nump">5.00<span></span>
</td>
<td class="nump">5.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice', window );">Exercise price of warrants exercised (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.00<span></span>
</td>
<td class="nump">$ 11.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ameh_ApcStockOptionMember', window );">APC Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Proceeds of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Board Members</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding exercise price (in dollars per share)</a></td>
<td class="nump">$ 18.41<span></span>
</td>
<td class="nump">$ 18.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Board Members | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based Compensation Arrangement By Share based Payment Award Cashless Options Exercises In Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based Compensation Arrangement By Share based Payment Award Warrants Exercises In Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share based Payment Award, Warrant Exercised, Exercise Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_StockIssuedDuringPeriodSharesMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_StockIssuedDuringPeriodSharesMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant Issued During Period Value Stock Options Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ameh_AlliedPacificofCaliforniaBrokerageAccountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ameh_AlliedPacificofCaliforniaBrokerageAccountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_CDSCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_CDSCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ameh_ApcStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ameh_ApcStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619850474456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Mezzanine and Stockholders' Equity - Schedule of Stock Options Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, beginning balance (in shares)</a></td>
<td class="nump">607,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options granted (in shares)</a></td>
<td class="nump">11,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares)</a></td>
<td class="num">(120,000)<span></span>
</td>
<td class="num">(111,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options forfeited (in shares)</a></td>
<td class="num">(12,228)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending balance (in shares)</a></td>
<td class="nump">486,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">607,346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable (in shares)</a></td>
<td class="nump">380,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 9.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted (in dollars per share)</a></td>
<td class="nump">18.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised (in dollars per share)</a></td>
<td class="nump">2.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options forfeited (in dollars per share)</a></td>
<td class="nump">17.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, ending balance (in dollars per share)</a></td>
<td class="nump">10.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options exercisable (in dollars per share)</a></td>
<td class="nump">$ 7.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted Average Remaining Contractual Term (Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding</a></td>
<td class="text">3 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 5 months 1 day<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable</a></td>
<td class="text">2 years 8 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value (in thousands)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Beginning balance</a></td>
<td class="nump">$ 5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Options exercised</a></td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Ending balance</a></td>
<td class="nump">2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Exercise Price [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619848806184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Mezzanine and Stockholders' Equity - Stock Option Activity Under Black-Scholes Option Pricing Model (Details) - Board Members<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2020 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">90.01%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.43%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Market value of common stock (in dollars per share)</a></td>
<td class="nump">$ 10.56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Annual dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate', window );">Forfeiture rate</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the forfeiture rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619854343496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Mezzanine and Stockholders' Equity - Summary of Warrant (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SharesWarrantsRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, beginning balance (in shares)</a></td>
<td class="nump">3,154,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NumberOfWarrantsGranted', window );">Warrants granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NumberOfWarrantsExercised', window );">Warrants exercised (in shares)</a></td>
<td class="num">(273,900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightCancelledInPeriod', window );">Warrants expired/forfeited (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, ending balance (in shares)</a></td>
<td class="nump">2,880,690<span></span>
</td>
<td class="nump">3,154,590<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_WeightedAverageExercisePriceWarrantsRollForward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants', window );">Warrants outstanding, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 9.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod', window );">Warrants granted (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod', window );">Warrants exercised (in dollars per share)</a></td>
<td class="nump">9.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod', window );">Warrants expired/forfeited (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants', window );">Warrants outstanding, ending balance (in dollars per share)</a></td>
<td class="nump">$ 10.02<span></span>
</td>
<td class="nump">$ 9.96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_WeightedaverageremainingcontractualtermyearsAbstract', window );"><strong>Weighted Average Remaining Contractual Term (Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm', window );">Warrants outstanding</a></td>
<td class="text">1 year 7 months 9 days<span></span>
</td>
<td class="text">2 years 3 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AggregateintrinsicvalueAbstract', window );"><strong>Aggregate Intrinsic Value (in thousands)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue', window );">Warrants outstanding, beginning balance</a></td>
<td class="nump">$ 26,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue', window );">Warrants granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue', window );">Warrants exercised</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue', window );">Warrants expired/forfeited</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue', window );">Warrants outstanding, ending balance</a></td>
<td class="nump">$ 18,700<span></span>
</td>
<td class="nump">$ 26,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_AggregateintrinsicvalueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_AggregateintrinsicvalueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantOrRightCancelledInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right, cancelled in period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantOrRightCancelledInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Rights outstanding Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of warrants or rights exercised in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of warrants or rights forfeited in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of warrants or rights granted in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share of warrants or rights exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share of warrants or rights forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share of warrants or rights granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_NumberOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_NumberOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_NumberOfWarrantsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Warrants Granted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_NumberOfWarrantsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_SharesWarrantsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares, Warrants [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_SharesWarrantsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_WeightedAverageExercisePriceWarrantsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_WeightedAverageExercisePriceWarrantsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_WeightedaverageremainingcontractualtermyearsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_WeightedaverageremainingcontractualtermyearsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619855830216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Mezzanine and Stockholders' Equity - Warrants (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants', window );">Weighted Average Exercise&#160;Price Per Share (in dollars per share)</a></td>
<td class="nump">$ 10.02<span></span>
</td>
<td class="nump">$ 9.96<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeOneMember', window );">Warrant Exercise Price Range One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise&#160;Price&#160;Per Share (in dollars per share)</a></td>
<td class="nump">$ 9.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightIssuedInPeriod', window );">Warrants Outstanding (in shares)</a></td>
<td class="nump">754,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual&#160;Life</a></td>
<td class="text">3 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightExercisable', window );">Warrants Exercisable (in shares)</a></td>
<td class="nump">754,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants', window );">Weighted Average Exercise&#160;Price Per Share (in dollars per share)</a></td>
<td class="nump">$ 9.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeTwoMember', window );">Warrant Exercise Price Range Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise&#160;Price&#160;Per Share (in dollars per share)</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightIssuedInPeriod', window );">Warrants Outstanding (in shares)</a></td>
<td class="nump">1,313,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual&#160;Life</a></td>
<td class="text">1 year 10 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightExercisable', window );">Warrants Exercisable (in shares)</a></td>
<td class="nump">1,313,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants', window );">Weighted Average Exercise&#160;Price Per Share (in dollars per share)</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeThreeMember', window );">Warrant Exercise Price Range Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise&#160;Price&#160;Per Share (in dollars per share)</a></td>
<td class="nump">$ 11.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightIssuedInPeriod', window );">Warrants Outstanding (in shares)</a></td>
<td class="nump">812,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual&#160;Life</a></td>
<td class="text">2 years 5 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightExercisable', window );">Warrants Exercisable (in shares)</a></td>
<td class="nump">812,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants', window );">Weighted Average Exercise&#160;Price Per Share (in dollars per share)</a></td>
<td class="nump">$ 11.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeFourMember', window );">Warrant Exercise Price Range Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightIssuedInPeriod', window );">Warrants Outstanding (in shares)</a></td>
<td class="nump">2,880,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual&#160;Life</a></td>
<td class="text">1 year 7 months 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightExercisable', window );">Warrants Exercisable (in shares)</a></td>
<td class="nump">2,880,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants', window );">Weighted Average Exercise&#160;Price Per Share (in dollars per share)</a></td>
<td class="nump">$ 10.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeFourMember', window );">Warrant Exercise Price Range Four | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise&#160;Price&#160;Per Share (in dollars per share)</a></td>
<td class="nump">9.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeFourMember', window );">Warrant Exercise Price Range Four | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise&#160;Price&#160;Per Share (in dollars per share)</a></td>
<td class="nump">$ 11.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantOrRightExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Exercisable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantOrRightExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantOrRightIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Issued in Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantOrRightIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Rights Grant In Period Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619849310728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 03, 2018</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount', window );">General amount of guarantee (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amount outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 245,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Damages sought</a></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | Standby Letters of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationPeriod', window );">Term of facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlphaCareMedicalGroupInc.Member', window );">Alpha Care Medical Group, Inc. | Standby Letters of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationPeriod', window );">Term of facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities', window );">Standby letters of credit assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amount outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationPeriod', window );">Term of facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ameh_PreferredBankMember', window );">Preferred Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amount outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,200,000<span></span>
</td>
<td class="nump">$ 6,600,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of financial guarantee on benchmark Medicare expenditure amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_PercentageOfFinancialGuaranteeBenchmarkAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities assumed (as defined) which have been recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlphaCareMedicalGroupInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlphaCareMedicalGroupInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis=us-gaap_StandbyLettersOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis=us-gaap_StandbyLettersOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ameh_PreferredBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ameh_PreferredBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619858352104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 28, 2018 </div>
<div>USD ($) </div>
<div>agreement</div>
</th>
<th class="th">
<div>Jun. 28, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 16, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 20,219,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,219,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,248,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="nump">20,768,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,768,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty', window );">Recognized risk pool revenue</a></td>
<td class="nump">5,815,000<span></span>
</td>
<td class="nump">$ 15,985,000<span></span>
</td>
<td class="nump">17,607,000<span></span>
</td>
<td class="nump">$ 26,835,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_NetworkMedicalManagementMember', window );">NMM | Board Members</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentConsultingFees', window );">Consulting services paid</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">27,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_NetworkMedicalManagementMember', window );">NMM | LMA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Revenue from related parties</a></td>
<td class="nump">4,200,000<span></span>
</td>
<td class="nump">8,400,000<span></span>
</td>
<td class="nump">5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | PMIOC | Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related parties</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | DMG | Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related parties</a></td>
<td class="nump">900,000<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="nump">3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_UniversalCareIncMember', window );">Universal Care, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Amount of subordinated note receivable agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_UniversalCareAcquisitionPartnersLlcMember', window );">Universal Care Acquisition Partners, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Amount of subordinated note receivable agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AccountsAndOtherReceivablesNumberOfAdditionalAgreements', window );">Number of additional subordinated note receivable agreements | agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_ApcShareholdersMember', window );">APC Shareholders | APC | Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related parties</a></td>
<td class="nump">9,000,000.0<span></span>
</td>
<td class="nump">7,100,000<span></span>
</td>
<td class="nump">16,300,000<span></span>
</td>
<td class="nump">16,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AdvanceDiagnosticSurgeryCenterMember', window );">Advance Diagnostic Surgery Center | APC | Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related parties</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_ShareholdersAndOfficersMember', window );">APC Shareholders and Officers | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related parties</a></td>
<td class="nump">3,000,000.0<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="nump">4,800,000<span></span>
</td>
<td class="nump">5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_MedicalPropertyPartnersMember', window );">Medical Property Partners | NMM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related parties</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_OneMSOInc.Member', window );">One MSO, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">10,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="nump">10,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_OneMSOInc.Member', window );">One MSO, Inc. | NMM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related parties</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_CriticalQualityManagementCorpMember', window );">Critical Quality Management Corp</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related parties</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_NumenLLCMember', window );">Numen LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_NumenLLCMember', window );">Numen LLC | SCHC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related parties</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AHMCMember', window );">AHMC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty', window );">Recognized risk pool revenue</a></td>
<td class="nump">10,200,000<span></span>
</td>
<td class="nump">$ 21,000,000.0<span></span>
</td>
<td class="nump">10,200,000<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCreditsAndOtherLiabilities', window );">Amount outstanding under agreement</a></td>
<td class="nump">$ 53,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember', window );">Universal Care, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LmaMember', window );">LMA | NMM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PmiocMember', window );">PMIOC | APC Shareholders | APC | Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DmgMember', window );">DMG | APC Shareholders | APC | Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_OneMSOInc.Member', window );">One MSO, Inc. | Dr. Sim And Dr. Lam</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | Universal Care, Inc. | Universal Care Acquisition Partners, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_AccountsAndOtherReceivablesNumberOfAdditionalAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts And Other Receivables, Number Of Additional Agreements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_AccountsAndOtherReceivablesNumberOfAdditionalAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_PaymentConsultingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment Consulting Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_PaymentConsultingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_PaymentMadeToRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Credit/Duration (Amount paid to related party in relation to providing services</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_PaymentMadeToRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndOtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndOtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCreditsAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income in future periods and obligations not separately disclosed in the balance sheet (other liabilities).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCreditsAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the sum of all other revenue and income realized from sales and other transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_NetworkMedicalManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_NetworkMedicalManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=ameh_LmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=ameh_LmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=ameh_PmiocMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=ameh_PmiocMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=ameh_DmgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=ameh_DmgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_UniversalCareIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_UniversalCareIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_UniversalCareAcquisitionPartnersLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_UniversalCareAcquisitionPartnersLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_ApcShareholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_ApcShareholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AdvanceDiagnosticSurgeryCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AdvanceDiagnosticSurgeryCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_ShareholdersAndOfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_ShareholdersAndOfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_MedicalPropertyPartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_MedicalPropertyPartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_OneMSOInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_OneMSOInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_CriticalQualityManagementCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_CriticalQualityManagementCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_NumenLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_NumenLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_SCHCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_SCHCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AHMCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AHMCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PmiocMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PmiocMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DmgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DmgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_OneMSOInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_OneMSOInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_DrSimAndDrLamMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_DrSimAndDrLamMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_UniversalCareAcquisitionPartnersLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_UniversalCareAcquisitionPartnersLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619860536648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions - Fees Incurred and Income Received (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty', window );">Net total</a></td>
<td class="nump">$ 5,815<span></span>
</td>
<td class="nump">$ 15,985<span></span>
</td>
<td class="nump">$ 17,607<span></span>
</td>
<td class="nump">$ 26,835<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AHMCMember', window );">AHMC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet', window );">AHMC &#8211; Risk pool, capitation, claims payment, net</a></td>
<td class="nump">6,057<span></span>
</td>
<td class="nump">16,350<span></span>
</td>
<td class="nump">18,056<span></span>
</td>
<td class="nump">27,950<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty', window );">Net total</a></td>
<td class="nump">10,200<span></span>
</td>
<td class="nump">21,000<span></span>
</td>
<td class="nump">10,200<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_HSMSOMember', window );">HSMSO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ManagementFeeExpense', window );">Management fees</a></td>
<td class="num">(189)<span></span>
</td>
<td class="num">(265)<span></span>
</td>
<td class="num">(321)<span></span>
</td>
<td class="num">(915)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AurionMember', window );">Aurion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ManagementFeeExpense', window );">Management fees</a></td>
<td class="num">$ (53)<span></span>
</td>
<td class="num">$ (100)<span></span>
</td>
<td class="num">$ (128)<span></span>
</td>
<td class="num">$ (200)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Insurance Services Revenue, Capitation, And Claims Payment, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ManagementFeeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses related to the managing member or general partner for management of the day-to-day business functions of the limited liability company (LLC) or limited partnership (LP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ManagementFeeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the sum of all other revenue and income realized from sales and other transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AHMCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AHMCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_HSMSOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_HSMSOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AurionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AurionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619965094088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Additional Information (Details) - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EarningsPerShareLineItems', window );"><strong>Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AntidilutiveSecuritiesExcludedFromEarningsComputationShares', window );">Treasury shares not included in the calculation of earnings per share (in shares)</a></td>
<td class="nump">17,307,214<span></span>
</td>
<td class="nump">17,290,317<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_AntidilutiveSecuritiesExcludedFromEarningsComputationShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_AntidilutiveSecuritiesExcludedFromEarningsComputationShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Earnings Per Share [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619853401752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Earnings Per Share Computations (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per share &#8211; basic (in dollars per share)</a></td>
<td class="nump">$ 0.20<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="nump">$ 0.31<span></span>
</td>
<td class="nump">$ 0.11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per share &#8211; diluted (in dollars per share)</a></td>
<td class="nump">$ 0.19<span></span>
</td>
<td class="nump">$ 0.09<span></span>
</td>
<td class="nump">$ 0.30<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares of common stock outstanding &#8211; basic (in shares)</a></td>
<td class="nump">36,071,604<span></span>
</td>
<td class="nump">34,540,059<span></span>
</td>
<td class="nump">36,040,936<span></span>
</td>
<td class="nump">34,518,461<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares of common stock outstanding &#8211; diluted (in shares)</a></td>
<td class="nump">37,285,585<span></span>
</td>
<td class="nump">37,962,555<span></span>
</td>
<td class="nump">37,296,913<span></span>
</td>
<td class="nump">37,896,837<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619855840040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Shares Included in Diluted Earnings Per Share Computations (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EarningsPerShareLineItems', window );"><strong>Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares of common stock outstanding &#8211; basic (in shares)</a></td>
<td class="nump">36,071,604<span></span>
</td>
<td class="nump">34,540,059<span></span>
</td>
<td class="nump">36,040,936<span></span>
</td>
<td class="nump">34,518,461<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares of common stock outstanding &#8211; diluted (in shares)</a></td>
<td class="nump">37,285,585<span></span>
</td>
<td class="nump">37,962,555<span></span>
</td>
<td class="nump">37,296,913<span></span>
</td>
<td class="nump">37,896,837<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage', window );">Shares held back in merger to secure indemnification (as a percent)</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EarningsPerShareLineItems', window );"><strong>Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Adjustments to weighted average shares of common stock (in shares)</a></td>
<td class="nump">169,402<span></span>
</td>
<td class="nump">363,593<span></span>
</td>
<td class="nump">173,299<span></span>
</td>
<td class="nump">368,273<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EarningsPerShareLineItems', window );"><strong>Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Adjustments to weighted average shares of common stock (in shares)</a></td>
<td class="nump">2,795<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,876<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">10% shares held back pursuant to indemnification clause</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EarningsPerShareLineItems', window );"><strong>Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Adjustments to weighted average shares of common stock (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,519,805<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,519,805<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EarningsPerShareLineItems', window );"><strong>Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Adjustments to weighted average shares of common stock (in shares)</a></td>
<td class="nump">1,041,784<span></span>
</td>
<td class="nump">1,539,098<span></span>
</td>
<td class="nump">1,076,802<span></span>
</td>
<td class="nump">1,490,298<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Shares Held Back To Secure Indemnification, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Earnings Per Share [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619859007224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Variable Interest Entities (VIEs) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 152,441<span></span>
</td>
<td class="nump">$ 103,189<span></span>
</td>
<td class="nump">$ 52,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investment in marketable securities</a></td>
<td class="nump">117,656<span></span>
</td>
<td class="nump">116,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables, net</a></td>
<td class="nump">17,588<span></span>
</td>
<td class="nump">11,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedPartiesCurrent', window );">Receivables, net &#8211; related party</a></td>
<td class="nump">59,328<span></span>
</td>
<td class="nump">48,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">15,919<span></span>
</td>
<td class="nump">16,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">11,188<span></span>
</td>
<td class="nump">10,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetCurrent', window );">Loans receivable</a></td>
<td class="nump">6,425<span></span>
</td>
<td class="nump">6,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableRelatedPartiesCurrent', window );">Loans receivable &#8211; related parties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">380,545<span></span>
</td>
<td class="nump">329,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Noncurrent assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">94,790<span></span>
</td>
<td class="nump">103,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">239,053<span></span>
</td>
<td class="nump">238,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="nump">26,817<span></span>
</td>
<td class="nump">28,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">746<span></span>
</td>
<td class="nump">746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">20,219<span></span>
</td>
<td class="nump">14,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">22,487<span></span>
</td>
<td class="nump">1,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total noncurrent assets</a></td>
<td class="nump">452,672<span></span>
</td>
<td class="nump">399,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">833,217<span></span>
</td>
<td class="nump">728,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">24,788<span></span>
</td>
<td class="nump">27,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FiduciaryAccountsPayableCurrent', window );">Fiduciary accounts payable</a></td>
<td class="nump">1,853<span></span>
</td>
<td class="nump">2,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical liabilities</a></td>
<td class="nump">70,273<span></span>
</td>
<td class="nump">58,725<span></span>
</td>
<td class="nump">$ 42,943<span></span>
</td>
<td class="nump">$ 33,642<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Dividend payable</a></td>
<td class="nump">431<span></span>
</td>
<td class="nump">271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">3,350<span></span>
</td>
<td class="nump">2,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">152,507<span></span>
</td>
<td class="nump">105,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Noncurrent liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">13,654<span></span>
</td>
<td class="nump">18,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term lease liabilities</a></td>
<td class="nump">355<span></span>
</td>
<td class="nump">416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">17,418<span></span>
</td>
<td class="nump">11,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total noncurrent liabilities</a></td>
<td class="nump">261,882<span></span>
</td>
<td class="nump">262,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">414,389<span></span>
</td>
<td class="nump">367,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember', window );">Variable Interest Entity, Primary Beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">113,790<span></span>
</td>
<td class="nump">87,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investment in marketable securities</a></td>
<td class="nump">117,611<span></span>
</td>
<td class="nump">123,948<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables, net</a></td>
<td class="nump">15,687<span></span>
</td>
<td class="nump">9,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedPartiesCurrent', window );">Receivables, net &#8211; related party</a></td>
<td class="nump">55,889<span></span>
</td>
<td class="nump">42,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">734<span></span>
</td>
<td class="nump">744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">7,752<span></span>
</td>
<td class="nump">7,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetCurrent', window );">Loans receivable</a></td>
<td class="nump">6,425<span></span>
</td>
<td class="nump">6,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableRelatedPartiesCurrent', window );">Loans receivable &#8211; related parties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">317,888<span></span>
</td>
<td class="nump">294,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Noncurrent assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Land, property and equipment, net</a></td>
<td class="nump">9,085<span></span>
</td>
<td class="nump">9,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">75,177<span></span>
</td>
<td class="nump">81,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">109,460<span></span>
</td>
<td class="nump">108,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLongTermInvestments', window );">Investment in affiliates</a></td>
<td class="nump">285,569<span></span>
</td>
<td class="nump">318,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue', window );">Investment in privately held entities</a></td>
<td class="nump">36,584<span></span>
</td>
<td class="nump">1,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="nump">26,864<span></span>
</td>
<td class="nump">28,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">746<span></span>
</td>
<td class="nump">746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">7,017<span></span>
</td>
<td class="nump">4,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">20,750<span></span>
</td>
<td class="nump">1,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total noncurrent assets</a></td>
<td class="nump">571,252<span></span>
</td>
<td class="nump">554,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">889,140<span></span>
</td>
<td class="nump">849,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">11,822<span></span>
</td>
<td class="nump">11,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FiduciaryAccountsPayableCurrent', window );">Fiduciary accounts payable</a></td>
<td class="nump">1,853<span></span>
</td>
<td class="nump">2,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical liabilities</a></td>
<td class="nump">47,304<span></span>
</td>
<td class="nump">49,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income taxes payable</a></td>
<td class="nump">42,211<span></span>
</td>
<td class="nump">4,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToAffiliateCurrent', window );">Amount due to affiliate</a></td>
<td class="nump">21,533<span></span>
</td>
<td class="nump">28,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Dividend payable</a></td>
<td class="nump">431<span></span>
</td>
<td class="nump">271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">1,319<span></span>
</td>
<td class="nump">1,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">126,575<span></span>
</td>
<td class="nump">96,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Noncurrent liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">9,490<span></span>
</td>
<td class="nump">14,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term lease liabilities</a></td>
<td class="nump">355<span></span>
</td>
<td class="nump">416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">5,833<span></span>
</td>
<td class="nump">3,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total noncurrent liabilities</a></td>
<td class="nump">15,678<span></span>
</td>
<td class="nump">18,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">$ 142,253<span></span>
</td>
<td class="nump">$ 114,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FiduciaryAccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of fiduciary accounts payable, due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FiduciaryAccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToAffiliateCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payable due to an entity that is affiliated with the reporting entity by means of direct or indirect ownership. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToAffiliateCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI) and investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=99377092&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of financing receivable, classified as current. Includes, but is not limited to, notes and loan receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts due from parties associated with the reporting entity as evidenced by a written promise to pay, due within 1 year (or 1 business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619861002216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease option to extend (up to)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseRenewalTerm1', window );">Finance lease option to extend (up to)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable', window );">Operating lease, termination period, if applicable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable', window );">Finance lease, termination period, if applicable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Assets recorded under finance leases</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Accumulated depreciation associated with finance leases</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">$ 61<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease term, operating</a></td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm', window );">Remaining lease term, finance</a></td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease term, operating</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm', window );">Remaining lease term, finance</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Finance Lease, Termination Period, If Applicable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Termination Period, If Applicable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseRenewalTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's finance lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseRenewalTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619860177272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Lease Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,446<span></span>
</td>
<td class="nump">$ 1,240<span></span>
</td>
<td class="nump">$ 3,388<span></span>
</td>
<td class="nump">$ 2,343<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of lease expense</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(226)<span></span>
</td>
<td class="num">(106)<span></span>
</td>
<td class="num">(360)<span></span>
</td>
<td class="num">(206)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total finance lease cost, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,259<span></span>
</td>
<td class="nump">$ 1,163<span></span>
</td>
<td class="nump">$ 3,096<span></span>
</td>
<td class="nump">$ 2,196<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619861076584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Other Information Related to Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 1,333<span></span>
</td>
<td class="nump">$ 1,239<span></span>
</td>
<td class="nump">$ 2,880<span></span>
</td>
<td class="nump">$ 2,273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Operating cash flows from finance leases</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash flows from finance leases</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract', window );"><strong>Right-of-use assets obtained in exchange for lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating leases</a></td>
<td class="nump">$ 2,907<span></span>
</td>
<td class="nump">$ 6,441<span></span>
</td>
<td class="nump">$ 7,652<span></span>
</td>
<td class="nump">$ 15,417<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract', window );"><strong>Weighted Average Remaining Lease Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases</a></td>
<td class="text">7 years 21 days<span></span>
</td>
<td class="text">6 years 10 months 13 days<span></span>
</td>
<td class="text">7 years 21 days<span></span>
</td>
<td class="text">6 years 10 months 13 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance leases</a></td>
<td class="text">4 years 2 months 1 day<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">4 years 2 months 1 day<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LeaseWeightedAverageDiscountRateAbstract', window );"><strong>Weighted Average Discount Rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases</a></td>
<td class="nump">6.10%<span></span>
</td>
<td class="nump">6.18%<span></span>
</td>
<td class="nump">6.10%<span></span>
</td>
<td class="nump">6.18%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance leases</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_CashPaidForLeaseLiabilitiesAbstractAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LeaseWeightedAverageDiscountRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LeaseWeightedAverageDiscountRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LeaseWeightedAverageRemainingLeaseTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619849549496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Future Minimum Payments Under Non-cancelable Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2020 (excluding the six months ended June 30, 2020)</a></td>
<td class="nump">$ 2,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">4,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">3,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">3,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">2,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">9,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">25,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="nump">5,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">20,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="nump">3,350<span></span>
</td>
<td class="nump">$ 2,990<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term lease liabilities</a></td>
<td class="nump">17,418<span></span>
</td>
<td class="nump">11,373<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2020 (excluding the six months ended June 30, 2020)</a></td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term lease liabilities</a></td>
<td class="nump">$ 355<span></span>
</td>
<td class="nump">$ 416<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Liability, To Be Paid, After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FinanceLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, To Be Paid, After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R9999.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140619852037880">
<tr>
<th class="tl" colspan="1">Label</th>
<th class="tl"><strong>Element</strong></th>
<th class="th" colspan="1">Value</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrentAndNoncurrent', window );">Dividends Payable</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_DividendsPayableCurrentAndNoncurrent</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrentAndNoncurrent', window );">Dividends Payable</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_DividendsPayableCurrentAndNoncurrent</td>
<td class="nump">$ 160,000<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>92
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MKUH]LNK/**R &KP"55B%.?!!,7Q(I@J.-!RULG!;Z4^#4$V#4#7^ZL>"P()
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MR[=9LPG6L%":8%W+;0!KK\[:HKKO@K=H"]%X'L.&QS#]&.9XS"=8[$65RZW
MIJ"[-M;7JC7]<)G219I>S!_&CD&L2,0&HR-=?-#%O<._6OT/XA>6?-L$K80U
MG\LJ+TH15(-@];WZE"M/[6KY4$ @!,NGX'S?P!]%]0)UVFN/U^)!7>SUVHV
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MGY(=)3_I0[Z\Y!\N6E=:NU_WQ6_C;R/'[B>!W7+WP\JIK)<48 JUP*MT0^7
M=6S#'XU9\P\$YZ9I3,D?P3J @A;@^<+ ]?T?M$'\Q>B[?P)02P,$%     @
MW$0*45!":*UR*0  \H8  !@   !X;"]W;W)K<VAE971S+W-H965T."YX;6S-
M??USVT:RX+^"TNW>22F(%B5;LF/'5;)B)[JS$CTKV;NJJ_L!)(8B8A#@XD,R
M]Z]__3G3 X#^R+Z]]ZIV8Q'$S/3T]'?W-%\]ULW'=NU<EWS:E%7[P\&ZZ[;?
M/WG2+M=ND[6S>NLJ^&95-YNL@X_-_9-VV[@LIT&;\LGIR<GYDTU65 >O7]&S
MV^;UJ[KORJ)RMTW2]IM-UNS>N+)^_.%@?J //A3WZPX?/'G]:IO=NSO7_;Z]
M;>#3$S]+7FQ<U19UE31N]</!Y?S[-T_Q?7KA;X5[;,W?">YD4=<?\<-U_L/!
M"0+D2K?L<(8,_GEP5ZXL<2( X^\RYX%?$@?:OW7V=[1WV,LB:]U57?[O(N_6
M/QP\/TARM\KZLOM0/_[L9#_/<+YE7;;TW^21WSU_<9 L^[:K-S(8(-@4%?^;
M?1(\F '/3_8,.)4!IP0W+T10_IAUV>M73?V8-/@VS(9_T%9I- !75'@H=UT#
MWQ8PKGO])FN+-JE7R6WC6E=U&>.JRI,[/B;\[JZXKXI5L<RJ+KE<+NN^ZHKJ
M/KFMRV)9N/;5DPX@P?F>+&75-[SJZ9Y5SY.;NNK6;?*VRET>CW\"._#;.-5M
MO#G][(3_LZ]FR=E)FIR>G)Y\9KXSCY8SFN]LSWP3NTS^[^6B[1H@H__WF06>
M^@6>T@)/_S_C_5^_:C(]R6]K!RRVK#?;K-KA^\NZ:F%(GG4N!\8ILVKI$B+4
M-LFZY$>W=)N%:Y*S.9[:_$6:K+,V63A7 5<UP*IYLFKJ3=+!Q%<\[7__;\]/
MYQ<O87R?%SAMM,:JJ&"-(BN3%F!R(#FZ-DT6?9?D-8!=U5U25,NRSP'0LDSR
MHEV6==O#)D"Z_+TO&H1SE]R[RC7PP@ZWX[8X<Q:PL&U@CF);PJ"B(MA^KPB4
M.UR3T'*Y ?"767*(X)Z>O/Q]=C=+?KJ\O*7/\Y='LS&R^NJKMY1DM I0O/,4
MG](9@H@FB+IUXQP]:8M/R88YS2&GQ:/H%47]@V/<@VC?9HB*HB(0FYP.[K'H
MUHG?"2U55!UL=&. +"K6$DI4- @A*BK@G)[D<)MT=8("-9F?'/\;O7;9=,6R
M=,ESW-<'=]^7/,7=\?^9$04V.>"HW*4XUPY.<W26,(Z7B==?U74'KPX..-X%
M'D+I.K>'? B+Z[HO8:A+4.TA8N"0_N@KUBM^D]]P@C!IXTIZ@>$#G. 4DV_+
M1G,EN"$S7%95#R,^N&W== E I-C]7YXB=BYKA )&?(?TM"I*9X[K[NT5SG.3
M-<MU,C]G:IDEU[Q^O2TJW#@@?9-5H+D1S)3. 7 /) ' 9/D?H+L8_D-$2-$2
M^\"8"H^HA/TO^Z;!9^;=(T)> ?R/F %(VQ:%$FXC2U99T2!Y!ID3J':3 24
M$C?91T= ?OD0D(8V15O"D1(4,9'$9)@F'WH@4,#IR7R6_+H% 4'; 6! ^[??
MS'F K<81!+K) N1-4>4@-]!*48+6^;LU2,Q-MD,:=)^V8-&X?'2X"-#@='$E
MQ%T%..P[$'4)@%[4>3L#X>T%&2QVY=&ELORSXGLL@6C3$S(='X_.PYP"S -P
MU!OWST@O%06=B-5>9K[<UF59W[@<7H$G,0S] @BM ,P[8/-?;F[2Y)+^<WMY
M>?4K \[CDRL\+, 0G%4W,=/?KM_BL./+FY]IHO_QV95PWJGA5_0?S]1^$$B]
MWZ\N;P4@\\9P$IC[ZL<[GN;X_=W-99I<7UWY<?1H>K %,+DLM^N,MTPC&9W9
M LC_9Y>5("'P.Y#+EMU)%8@Z4V)A,0<&4]5F(OD#O[JR &.65F=Q&JAOEOS>
M$@.\!9&Q(:6*],AZB>E3N./;!*W5][PF*HNBVPUUFXB!UD@W+UJ<APFGSEKP
M9;:BU9!%L]4*:$18%\4Q&@\;3X_POA.HRB);%&71%3)5@ Y?!.!0ON#*^\;P
M*KCW;T/'/M@:]^"J7J!!&5.U\"'O242'060#D0R9188B:+X-4>T?A( :_@3=
ML1]=RK+@OZ"#QAO;,2!+5SP@P0%%PX?Z :1M^+JLJ_OCDLQ#G!,H+ZON"R1/
MQA1:?"V8O2T2^6:!1*;FP'U=YX\%T.U#5O;A<0%D6S2BQ);+!I4IZC:'TKB,
ML'X(8(/60H&"=B4*<(]+-?>NW_SR02V]9%EFQ:8]2L&D!0[9*#0P_:HOR^.F
M:#^*B8$V%W^6DQ#B]<B@Q0%G:EL#9Q5ZJ&+$X-0K8+:Z:54HXMMK4+YU0YOQ
MFZH!/\1-K0?\YKV'^RA5J=QEG_ < L8 = +V&'UA7AE()6"S03?XN%X=]\#%
MAP<??OW]X"@B8@?C+%)G8&=X/G.\$+(HO+^??&@Q^.]]C1M<D$>"QQYM%JD8
M9!HJ+AQ? Q4W4_@AYL%C10  M?6F6(+&>2B:NA*R@.'(_VUDV#RN'>-;#J%H
MEOT&V(V$'^ 9&0\$9:NZ%\\U<"$8,X[$!1!J5B$I@7)7,E%K#*3>LL  "))F
MUY/=Q";!DFS2O( I&B^(P8@0GZEN/R.L9F(LDE2_<_>\G=^";0DV'IHXCE5]
MI<Q/[[?\/AGCR9I4PA*U1>Z0*\%:\R\(<Y5&^OAY"]CQ ]LZ/$="DVQJF(;,
MX278VB#;LF0+;\'XXZ5#)8.LMUWO6G!%LXJ>-7A8_J1GT388[':LL_<8VFQ!
MW-\W[AZ>6AI!ZY8B2"P(BFH/6F:@'MLU[97^> NZ!&AZB."@B/5M^L.9M\'3
MW+!=*/8S"258=0?'W7QT'9!5E0OI.9#,*(G%!<T!KK;H8F2H:=W29M; IS!W
M6<"2*$8?G)(U:S(XC 5P#+D\ L0#KH)[!;E3)Q^K^K&R&L1O!6@.R1T)&/#T
MX@2TU*[USCS0O6JM;0\.!HH#F Z(?XB"&'R,,';P?SE-?+>H=*?![".V:1TJ
MC1($0_416/UQ78 R0I59;$BO[X!BEL[EZISV:/6C2<([P:?O7$Y3_"@+7.-;
M9 1?U0V<.DL\E9WO?KR^BMU[!7L!; '0(-1)P5X'4&N-LA-VC6^T1HT"U8,3
MF9 >H)T NV]%H^JVTS&ML*IHD1?( X7O2?",XP13#N0T#@EW@B?!E.Z21D5H
M0Y<IVVZ;^A-)'*"7OYR^.)F]  ^K+$E\&5:*WYO/+V;G^AY99M/$S'3Y""*
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M. \Z[/+.IZ:2YY@#FN8N^SZ^IV-2=A,X+X*9PT! )JT?'MIZ"9]*E,AP+F)
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M*B["IKG,BS9-4:$G(WTB[ 4Q6JJH]1*]4**1.*DA#?@OV2;1C1B %T^&RE#
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M2^UHZH3MFL8\&N] [VNMW>[@!88?Q^PW4$L#!!0    ( -Q$"E'$*S:0*P,
M /4&   9    >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;*55;8_;-@S^*X0W
M# E@G&W9CI,T"9#+.FS##@CZLGT8]D&QF5BK+;F2TMS]^U&RXZ;;]3"@7VR*
M(A\^%"EJ=5'Z@ZD1+3RVC33KH+:V6T:1*6MLN;E3'4K:.2K=<DM+?8I,IY%7
MWJEM(A;'LZCE0@:;E=?M]6:ESK81$O<:S+EMN7ZZQT9=UD$27!5OQ*FV3A%M
M5AT_X5NT[[N]IE4THE2B16F$DJ#QN ZVR?(^<_;>X'>!%W,C@\ODH-0'M_BE
M6@>Q(X0-EM8A</I]PATVC0,B&A\'S& ,Z1QOY2OZ3SYWRN7 #>Y4\X>H;+T.
MY@%4>.3GQKY1EY]QR"=W>*5JC/_"9;"- RC/QJIV<"8&K9#]GS\.Y_!_'-C@
MP#SO/I!G^2.W?+/2Z@+:61.:$WRJWIO(">F*\M9JVA7D9S</6(F2-_";X ?1
M""O0K")+P&X[*@>0^QZ$?05D!@]*VMK :UEA]:5_1(1&5NS*ZIZ]"/CK6=Y!
M&H? 8A:_@)>.6:8>+_T*WC6[)Z VAO>RXZ*"7<-%:X#+4=Q6?].)4\M9>/U(
M;6\PA*UK&^<I)'R&^7-[,%932_WU KML9)=Y=MFWU>!%$'=YEZ;C):X#NIT&
M]2<,GD.&=S7"3K4=ET\_?#=G2?'*0#O8-3=VI:*;9RQ6H(Y@R>FH&KK"0IY@
M0F=A:W4V='9FN@0J%_IRC<+#?P%#..!)2.D "+%#+50%WT,^#PN6DY"FX2QC
MGIN25 /CS*[,2JZ1*!G2:FRXHV45E'W=A"S/6F.UA)W[4_D&]&26AWF1P"(-
MYVD*>U+J8<\ (PT+9_,YO%.60CP3ROG/XPP6LS!G">SY4^N)N2[Z-F:311$F
M"9O"9!:'619/_T5NDA=A5I!ZDB["(LNF TG?N9,DS\)\[KR3. Z3.6UORX]G
M09'@J%4+VZ:K.>P<-5]D]@J2-$Q8?-/C!E(V<UBSZ?/U0EE]4:DB#EF1DI"Q
M<)&E\%SK1S>CJ$5]\@/7-=-9VGXJC=IQIF_[4?;9O'\0'KBF?C'0X)%<X[LB
M#T#W0[9?6-7YP790EL:D%VMZEU [ ]H_*F6O"Q=@?.DV_P!02P,$%     @
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MH3XB6L"V9U\16<0#408I5R$AQ)$DRI?"*]VX AG59QP%\@14?.NO##)1(9I
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M90=Q>UY3%SW4V>M5B%H5/*E+4R +8(]X]>%&>-QW(<,VA'\0TKEI*GH1ZB=
M$MK&*=^NHN21FTY\USHW)4PG@/]?<1ZRF+S 1U>?'_:%OI3]<]_U$74-4U*^
MH\17?0#]5'SY$4F7-!A3EU.7,OC2([MF3".-:*ATQ]>?747<9RWX!J5R6:)K
M?XKQN1[>#W@?LHBM@EYM:.5^E;L=]G1R4MOKQ_CQ(C;]0<,V95A=#R#WNT=]
M)H^Y@K_&O(=47[A0/.I.?,0&+Z$?N9J=>R:2R'YJ,69^$>FVU)E^GQ7.7D0/
M&"KQN-YC/NIDWA4[QRU$?Z7BGTY.SX/B#VZ;)*J^/#]H&*YA>J &]B^SD(%I
MD'Y* 88+0%AD0$G4AKHKJ8N NP.BJWB@&JJM9Y6^R^B%$Y9/L_=(0 P -4UG
M"EU'?]?SS&K*T1X4C_JK:]<,%>09Y!BOUL,;]!)GUN9F8**SSNL^'GP2)1 G
MDF\7VGT+&(?X/6^K$'85,^E>XWCO&#,N=\0;[7$FOV<S[@!_/"'BX-Q_.V5T
MMWGELK%Q1UQW8SC *UV&>NB@(^*DG<>M^-AK(GMO=!\MN0A YCI5U,<?9.'3
MFPUX1S<F\VY$:$[N"#K<NLV>>%SNH6KJ4^B02[1_%!W^[I P^P.([T\*!W3J
M&.I\$2R;#0/"V700$ 12\2+]@W@T-G"Y@F'59;NF['L6TQAYAVGG'0X<WD,Z
M?^[X1(=.<S8ZS6FGE$*#;^ XO$8T1=:8S Z'/NZ8=2MZBKD Z-H,PJW%RC7P
M1LU9HOAC'>ZUQ U1ZL$>6E=,RT)*WY7F^=J1\]9'6AW(-EST\GT2[CX'8U;<
MV2E1S=&M]]U89K[CARKM2ZJ&[HL(0H;TM75][-'-/,X=-DK\^XOA=8"HG.7?
M3;F*BDI1<6A EP\QL";0,KNXN(B=^K\.R0Q!RQY0,\(Q0]7;XZH/3>0",-M4
M4?8UWKO>$2Z9X)"B9^\[/7/Q L;M4ZMYYV0O+Z\^=GV_Q&P2,Q7F;$5^7=X;
M.9A5[<W,O8=Y D$<LU=^]B)Z'>VQ)&VTM[G?<6O,^'T[+PVJG+7T[DE#\!#J
M$_+,</'F6_?D:J[+(\O"@29);>L.P+E."7_%ZDJ]3(P@JXS?0>@N**7ITK5F
M6G?#ZR_3PLT-]% N5RZFU+WE-N0[H_[2$R\UJFVZ"R/IL ;6C'#FO@08I^*>
MM]Z[?H9KS\&@A>(T5*4D,2O,G32W@*>'M>&QX.<"R]F^4.>JE.+)8X7@V#Q$
M*$&* \X<T 0)Y^&V@ECN6DW"K;]['0U"DW)V]CO?6^[^S((8Y3[&_"%@!P\9
M&^=AFZR?,,JX0^1PX'*OWW+Q=%@UW&.;_E)";D;A-[5O*7[DE1&Z/OT_;)04
M6;/;N"0_U#)N"(A,S-?'.P%#</ENH]45'?9_4WXQ)OI_^7VY_/;]@9>3Z$_I
M;$VUYC\81-D[/)?\59WP-/Q-HDOY4SS=</F#1A]TM:9FP-RL,'4Z.5\<R26J
M_]*4._[#/,NR :?Y(V0$#: !^'U5(@5R7VB#\)>:7O\W4$L#!!0    ( -Q$
M"E''9^,;> H  !0>   9    >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;,U9
M:V_CN!7]*X2;;2> 1I'D][R 3&86W>UF-YCL T71#[1$VT0DT2-2<;*_ON=>
M2K+L.)G9=%'T2R)1Y'V<>WGO(?UF:ZH;NU;*B;LB+^W;P=JYS:NS,YNN52%M
M:#:JQ)>EJ0KI\%JMSNRF4C+C145^ED31Y*R0NAR\>\-C5]6[-Z9VN2[5525L
M712RNG^O<K-].X@'[< GO5H[&CA[]V8C5^I:N5\V5Q7>SCHIF2Y4:;4I1:66
M;P?G\:OW(YK/$W[5:FM[SX(\61AS0R_?96\'$1FD<I4ZDB#Q[U9=J#PG03#C
M<R-ST*FDA?WG5OJW[#M\64BK+DS^F\[<^NU@-A"96LHZ=Y_,]N^J\6=,\E*3
M6_XKMG[N<#H0:6V=*9K%L*#0I?\O[QH<>@MFT2,+DF9!PG9[16SE!^GDNS>5
MV8J*9D,:/;"KO!K&Z9*"<NTJ?-58Y]Y=JM]_ER4&A2PS<>U,>K,V>:8J^S?Q
M\7.MW?V;,P<]-/LL;62^]S*31V1.Q*4IW=J*CV6FLOWU9["O,S)IC7R?/"GP
M^[H,Q3 *1!(ET1/RAIW30Y8W?$3>,3?%C\8I\:_SA7454N7?3Z@9=6I&K&;T
MIV+[7)E__<LLB:>O6W=V$\^M<&N%'92I8L-;8:FDJRLE7EBEO-_)J3!+GF;7
MLE)6:"M*XX0UN<KOD9-NK4O^GB*T%=(4T\^O+@(>4UZE'Q*947[QYUKF>GDO
MI!4;A1U4JM*U<\GZ-3XLE"I%FDMK]5*KC.:6IFR4P/F5T*53L,CA@<5C1M'Y
M9BKAX)6I4% :T2'-:L"PK3OXPR81"*AJB]SCIUWKZ*8R"QYV:^GZ0&QUGL/*
MU!1J;[4E=Y&8JDM,EOA!I:I8J$H,8QJ-Y^%303I_*"7 4Q),AXF@)0N9WK26
MK.6M=X(QT];6P,L9D:K*H?H*JM!0_./EI5_1J!3;M1%;0/CP2^.I0Y4E.]+<
M6$*\R00(6T'>0KDM*:35Y.'Y!H$QE] -G9V[<'4J7M"RP26O&YP&!!)&[KWE
M]^@PL-;6BT(SWL@)I!: W>3*01S^.K**U%>RM)CF9$YK]E2:"K;3: 7=J.BD
M0E<D4%2H@ +)P$E.V=BM@Y8"8Y9"P5YL904=SI*-E&U(HER2%77)XG?^RU6%
MH"-U0W&ERHP LG6Z]NHW+O!OCX'/KO/VH_;0,SO@384VV25X<.@)"R(_,GVK
M,^BVE.^91H72BYJ<M"Q$2!(*7$0&%X1<NL8#M5PJ[GJELK8-JP]/*'[VFQD[
M7&?L^5*7LDPU(+<. ^1R:S_:/<U@3YMLI'S9 Q5#M<-*AB@0*U+;%!X&JM7O
MPWP89<UAL' 3FXS*Q;(N4V<J7REHW04219;W-#-7*YDC=\PBURNV#+CRAJ"9
M=E?$2A):-@2 H>HC<(WJ9S8>Q[V<L,V*!7$6"NV^J\W6JS<847>J2K7E,/FO
M?8E^9%-7*6J=ZA2$XJ=FTL\[Q[J2U8/Q0"0C9,G?!LLEY?<6$U^):^_R;TQ#
M,./\5E5@5>)C:^!5I5/U\/LG1=2-=%U0T47K0]46/Z->BQ?_5+*RI^)\A2U
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MIN#'M9*9JF@"OB\-MF3S0@JZ'X+?_0=02P,$%     @ W$0*44,^:;W@"@
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M<?3G5AW=$7"ECEG6<N\?'EQ0ZWU+Q+4[6.Q1D'SKN!D^=;5#WNCFY72=@0)
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MQHQ"4,(!\'XI 7_Q@ M4G\RN_@=02P,$%     @ W$0*4:%AJ2H:!@  X X
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M)R@YWH#WE;6A>^  _4?M^;]02P,$%     @ W$0*41P 'WZ1!   2PX  !D
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M*M&Z!NE8K\>) >S?_E(D<?[.,EGI5N]4Q3IIO+:WE?35_RIE!SH"=Z]2%QA
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MMU( )QE@?*UQ$AUN:('#/SWG_P502P,$%     @ W$0*4;K9ES,:!@  +1P
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M#*.:%N#W7$HSO!"#]0WA^=]02P,$%     @ W$0*44TT8D:\-P  =,   !D
M  !X;"]W;W)K<VAE971S+W-H965T,C,N>&ULW7UK<QM'DN!?Z=#.[)(1($12
M#\O/"(J6;,V9-E>T?1=Q<1\:Z )85J,;TP]2F%]_^:S*ZFZ E.R-V[B(&8L
MNJNRLK+RG5G?W-?-A_;6N2[[N"FK]MLGMUVW_>KITW9YZS9Y.Z^WKH)?5G6S
MR3OXV*R?MMO&Y06]M"F?GI^>OGRZR7WUY+MOZ+OKYKMOZKXK?>6NFZSM-YN\
MV;UV97W_[9.S)_K%>[^^[?"+I]]]L\W7[L9UOVVO&_CT-(Q2^(VK6E]76>-6
MWSZY./OJ]?ES?(&>^-V[^];\G>%2%G7] 3^\*[Y]<HH0N=(M.QPBAW_NW*4K
M2QP)X/BG#/HDS(DOVK]U]+>T>%C,(F_=95W^3U]TM]\^>?4D*]PJ[\ON?7W_
MHY,%O<#QEG79TG^S>WGV]$FV[-NNWLC+ ,'&5_QO_E$0\9@7SN6%<X*;)R(H
MO\^[_+MOFOH^:_!I& W_H*72VP"<KW!7;KH&?O7P7O?=Z[SU;5:OLNO&M:[J
M<L95560WO$_XVXU?5W[EEWG591?+9=U7G:_6V75=^J5W;7:D?QU_\[0#H'#H
MITL!X#4#<+X'@)?955UUMVWVIBI<D;[_%!835G2N*WI]?G# ?_35/'MV.LO.
M3\]/#XSW+&#H&8WW;,]X4PO^WQ>+MFN HO[/@0F>APF>TP3//V4+IA#Y&</\
M>NN \)?U9IM7.US"LJY:6$61=ZX <B[S:NDR(I\VR[OL>[=TFX5K_OW?SEZ>
M?OWL#+%X]N4LN\W;;.%<!03?P"DJLE53;[(.1K_DL?_]WUZ=GWWQ-0S2%Q['
M3B9:^0HF\GF9M0"7@U/=M;-LT7=940,ZJ[K+?+4L^P*@+<NL\.VRK-L>%@(G
M_Y^];Q#87;9VE6O@@1VNR6UQY#SNSK:!,?RVA)=\1;#]5A$H-S@GH>9B ^ O
M\^P(P3T__?JW^<T\^^'BXIH^GWU]/,]&&.NK1R\IRVD6H$ G"!0RG-&) AY*
M8'6WC7/T3>L_9ALF?X?D/_$J/:>;<.=X%X !;W-$BJ\(V*:@?;SWW6T6UD3S
M^:J#)6\,N+YB7J[GG%Y"L'P%--T3LVRSKLZ0ZV5GIR?_28]=-)U?EBY[A2M\
M[]9]R4/<G/RO.3&%I@!LE;L9CK6#?1WM*KS'TZ3SK^JZ@T<'6YVN K>C=)W;
M0TB$RMNZ+^%5EZ%P0L3 =OW15\S\PR(_82]AT,:5] ##!SC!(2:?EH462GK#
M8W%153V\\=YMZZ;+ "+%[O\(9+%S>2-D,'T,D;Q6OG1FSV[>7.)@5WFSO,W.
M7C+)S+-W#$2]]16N'C"_R2L0L@CKC#8#-@#H B#*BS] RO BCA KOJ73!.]4
MN$\E(&'9-PU^9YX])@QZ8 >('@"W;5%8X%KR;)7[!FDT"I1(NIL<R $PN<D_
M. +RX9U 0MKXMH1])2A22DEI<9:][X%* ;&G9_,#S/E%8,XO#G+5Z\A4 ".7
M =8]+/JS!R.^<Y Y!]:2):Q!226+S!J_'F'6X!/& 3CJC7LL1\HFF)&>[$[X
M92\C7VSKLJRO7 &/P#<I#/T"2,;G#<C06?;SU=4LNZ#_7%]<7/["@//[V26P
M-\00D%8W,=+O[][@:R<75S_20/]Q<"8<=^KU2_I/.*/A)6!BOUU>7 M YHGA
M(##VY?<W/,S)3S=7%[/LW>5E>(^^FG[9 IA=E-O;G)=,;S(Z\P40\H\N+^&L
MXV_ 9NW!)<XN<DJ)A;D6:"95FPLCCR?/E1X42)J=N6.DOD,GY64X*2\/$O=O
MK</]?P/L V%LIX['IXU 9X)%'9\1D2"?QKNM,L'K1OGCN]U07 I3:0VO#(S*
M!9APZ+P%(V8K@O(6U*9\M0(Z)> :XO"HF6S"F8#GG4!5^GSA2]]Y&2I"AP\"
M<,A\<>9][_ LN/9/0\<^V!IWYZI>H'$?P=IKX4/1$\./+Y&"!817%_/$' !A
MNJ&3\P<AH(8_01+M1Y>R#;!;T##CA>T8D*7S=TCT<*K@0WT'NE[\N:RK]4E)
MNB>."=2?5VN/1X0QA>ID"P35XD';+)#05<-8UW5Q[^'LW.5E'[_V<'1\(R)Q
MN6Q0/J.D= 4LK4RP?@1@@PQ$IH9**PJD@$O5)=^]_OF]JI'9LLS]ICV>@;X,
MIW2CT,#PJ[XL3QK??A"M!=4X_BP[(<0;D$&3 \Y4>X?3[75312_"H5=PX.NF
M5<:,3]^"**\;6DQ85 WXH=/4!L"O?@IP'\]4,G3Y1]R'B#$ G8 ]01N89P92
MB=ALT/P]J5<G/9SBHR?O?_GMR7%"Q [>LTB=@]82SIGCB?"(PO/[R8<F@_^N
M:US@@DP>W/9DL4C%P%=1>.+[-5!Q,X4?.CRXK0@ H+;>^"5(O3O?U)60!;R.
MY[]-U*3[6\?XEDWPS;+?P'$C!@QXQH,'S!J4M;[#@XW[&D\AJ$:.V 40:EXA
M*8'.JF2BNAUPO:5'SP>29M>3%M;V)8E!5',+#T,T01B 120&6=T>8%:'V/P7
M@<U_<9!)LP9+LNG&K0DA4YS^DP<A9B]:,RBN</9I ;CERH/H^9:?)S,CNR7I
MN$3!63AD#J""A@?DC)>&"89Q/2#^+D>'D(R1T2";&H8A17\)5@2PV#S;PE/P
M_LG2H;Q%#K"]W;4>6&Q%WS5(,X'@YLDR&.QVK+[L,2%8F5JO&[>&;RVIHLI.
M#BSF1[[:@Y9#._PJ[/"K@YMSF;>WA"WZXPT(13B<^_;Y,X>R:(H*DCY-?SCS
M-)CV&U"5@,S%0B%&#2C8P1%H/K@.CEI5R'%T(*U0.HG-7P"26M^E.Z/&2TN8
MO07>!6.7'J9$T7+G]*BS= ?*6  7(<M2@+C#61#QP(OK[$-5WU=6JH:EP#E$
M%H"'&C;MRU.0W+LV>$^ %Z@DW_9@PB&+A.& (0Q1<&ACOPP;^^4#IZY%<D4"
MQ/V8VLY/&B SGPE>V9R(@5M7(@,B:8^L"@@>500T*!V2?E6  0<"K,.=P)?@
M@'DV=JR)AUN:L^Y&7K>#V#@[C:[/TX/+>6<VVI,1#90D3 D@I*,VZ=#\\\.R
MFVF[;6H@;:0 4!C:ELE6I*TE0Y!R1D*(#@A,/J4<4BA0_2I<"RH:C^01E2I>
MZ5V7PR.)=4E$2!+KL2:F3]>XB6MLXQKY/,"DL.>TUH\DEN  _>WL[(OY%V#4
MEZ7J#_#5R_D+_0HUP';KR&6//B6UX("Z8#R $JFCVR6S[3_[+%/O@(/4?9NX
MPD!2=CW)QIG1CCO@^@WI/L"$MR6\0_HA&4XH!%J0+C0DG6Z$HZ 9Z5BOZKY1
M$QH6?OY</QRU8&.3:X1&!ITL1[T_V.0I7$W//RPP<'*,+IT$XWM6VA*S4F)R
M=/A^ OVCS,Z&>T:NK C-K8?C"82T.WBV3%CA[ %6$158W!G[F1C^V=?P'5MH
MUWFS]ZC]Y;-,2AZK;A,"X7?0R9G4@G<C/C4#]K;U)EC"^G[R!.GTV[H&&0\,
MSFHA(-;A;]0]$IO'F)TKYU01CQJL>7BN/@([)4&.AE-3B)%$RD7@%WP<25E9
MRJE<!$/,%?,',:,85<MZ*Q@=86QRZ8<6N <C>]8^M<M3,/T97%P^L+\R(;Y(
M_%2TR"UP5://)&-X?9^%FO$2ZW$D1@$,I(0CKP8*?X?6EVON/&J8[S^-L#*,
MS:::TY2#&NU2LW%FI:0#,?",SG_V@&37E+N,;4&*S[*F&Q:X-SX$%@IBI:2=
MJD@#(S5)22,\J%;,/H#)*Q&=0OIX8:FO;XA[HYL3X]CHP:#@ TH^=+<#,=T$
M' XH5]Z%5PL'C!9Y:[T$:=,.9-G9*V7P^0JPPCZ3,,QP1D2D1C. S'X94G>B
M0P4O2.F4 K>YCZXM"4A0;(!]J./YF++S E0'%)ZH444"2T(^M&675S<S/)TG
M,,J)TEST%;Q]>Q-\'(WSFP7@0TXT($IL);*E9D%K$Z=2^CR<;G)3D@'3<8C?
M_AP)2 E&XSQ=O64W!@#?-[10L)8WOM\,AD@U?CP%" [2*"[+,5ELZPZ/#- C
MZYXTM&-'PYC%)CZ+QMUACH#XX#8D?X4@)UYE6[S*R]V_8'CCK5CD8,Z[!6*$
MX_T.XUUTDMGMF?S 0-X#UF[)V34;>S Z^*BVT&U>K<7OJ4-L\QV!#YL%Y,"A
M/M4/F3<6H%SERYV<+-HYQEB*4=B2&G["Z OR@K V'*,OY?"._7R3N*&3HP0#
MK'K-6@VCMM04CN4.(Y#L[\EAI^H/)XM\^8&G1E<0+"7HR9;/I^Y%<K[#&@$+
MQ!>%Z?,.&3]/(D/(Z1,"72B$A(J2IZ*AB@24H0J+6EH&MF;51?6>'%<'%:WS
MJ&B='S:Q$U*AX"PPGVEEZK-&LEM>^#:X)]K@L*2C&FPSE&W"-[)NMV7"!Z+#
M4!-\1!J"G2I)*27%%?8<^&13WP&2T)OG0!0E4>(MTP5)Q!KXP7TB.SDIP,*#
M !@7M7X-K,[E&P('Q2^"AO.#D;GLC&DYCL1-ALXDO)F@I$A ,#@XN-4Q$>7L
MV<$->HO:^N^DK5\-;(>WP79X%VV'21KX:Z>8U!FG#1FC?^QU](#H\46_Q! <
M_49FH'4Q6,MSK^$Y2[7(LLZK5#4/+ C(4M1Y83UJYVD@9":+<>*_KA>E7RM7
M)K<VAB60XQ /%^+)FX921\BR"HQL#UH26TV9N?H"'YVZTS@;D!>AWXF/*9IY
M '71.U4<VEM,1@A&;.#W!K[!BHR+:R]B)O!B529K=.8M9XLL2#,2VQKAY@/-
MWC?SJJ)'G'[\U(I4M(58^:W?>!!(NJK@&6#!"8(-Y=#<4+/)[[I!CU3>@/!\
M7<,_4>NYN'D=U)[)YR_K(G)W?>WBYC*\]0J3@*9/EWT>G]-W9KCTTG/B";HI
M(P&9N$K\T@:L@M]2G R%1)7$PT'"R>P#!U+X$0F"FL D#08; T?% [VU^&Z3
M;QSF6Q+V>1+$B-U;CB?FJ(N8P?)%W7?[W"!@US(.AM--^"EXWY/P*:<7;?N.
M4!9B5R14Z%#(7&8\$4=Q5)#@-=*-:C(R'KEY.4UBT=1YP0*,/)6L3K=?!4<+
M,<+SKX%/TJNX#7W%B@593W7'FL*2-3-.3!6:9G)F=6$9=QJ^&VTO"#<ZY4O4
M2:)I:_ I?CV&ZWP(EX9B4X!P>CU#>V+0(YAG$V/$)8P''*PF\'%#MQ@7XTEF
MN@7L"8 GJL%TX:5Z@4*7I(%FMM",=L)==N3G;CZ+[*8)H;*=1W\U,!D0,<<2
M0!)RTBDT_U&2#6/HC;+4FJ9>U TSZ)T%1Q@6[$=.#FUXTDG2$MJFM#+8."#5
M(WDT&8RA.-:M?!:V\K?*3&)A;=P*M=HD>,I'[QY_EDG(6X++H+ F119[XO^$
M6G5!C'%(4J$-,]YKZEWP!^!K"T1NDNUW!YH>R]LT"#M4(#"8@J@ZJ#;%]-JS
MPXFQ[V*JP$4DZ)]00/U$>\G?3FI+?\G(V;MAL@*+*F#=OL.8^)V+I[%R'?+5
M$]:8E4K:6[]-/6A1WR;_"3OHD\?9GN% B[B^EC6ZKDM,D@"VT6]Z]B. 5 <Z
M^-=4:H38PW'#ARNAI"5^/VX]\J32,>UN7'=;%V*U4>X*\&P)#)#^MRIQ1XE3
M/0919':&O-+@<S"HV<*JD.IFR)WO'89.6_0V('9!;(4DJ<+A,0"TWE/8W,B+
M>]<D,?D(/&(0)0FHDQPAEN7%%!N0V"MF"4V]RTM@./Q(&M)0A!HL_@7;- M[
M'K<DPDZI(YBE@70L4!T\8C%)\NQP8N,/FF&#T[^KT&&&.R:G8'1,)H_:7SH#
M,$;@U*1-/'L!FE=\(+J,DR'9$3>+N4+,_,,\G'DT3?[L".*M0VT8N"YE^Y:L
MH\1= O5F^,1,Q?;8B&I1>*(/[\150#TH1NL:;-W,KS2E!(6.<?$DB2@ /(6'
M1'95EEHPG9^<F9308*UI\1^BTL6Z,B=)X&K;5E/BHH_E_M81XCQYB('F\)1^
M0+<HR6F4XC3](-B$ 3STFL?<LK[B(8CHZ5U*FDCM#CS'N2BKK/4S'/A$"DG,
M2,9<#LT>AQ6!3B)+,NB(J^-Q";8];F?6 =&;.( >1/?9L65#ZCR=94?GQ]F[
MZPLYGD?/P(BX_&7@3?,FY TPRS[P-D2@ WD:Z#N4LS6Z^'U(" 3N2'53P8NZ
M9S.]J L/[5\^6&PDT[BIR>YU(SN8?"<4V\>#,\]N.&&_0_5[(:G@H#[,ADL.
MSCWXGV"%420^M5W8^MQX<PU^W$?RIY/:!=^&Q,88,3#VL6[[<&\UX]XWAHT/
M+7VKU^A.P9FOAHQ:HRGKBCBT;!OF*OD$&@6&%;"%(\@=61'[CXJ8-50" $\1
MIYB98>"[>S!P.BSFH:R56+O!%#G 1N2(4S(Q)@AV;GE;^7_B6T$-#)EHL^R/
MOEC'2)552\V16:#T5*>J38\0?TC"X2:YZ2-9MF!QR)[?Q7V2XIDI=23.(2J)
M4)@>OQ'9LQV9C@4O+9TK.#DLM4='6_#(1?VWVIQ#>D5,*3\[G!$^2'I@(?T&
M>0/:C2>4408*UE74P09O7(.UQF&Z']&TTU<G%9 _ XK:8RE 2;1$?8Y4SR3N
M1IN2$?4TR6T1S3*&3$3,5<*MS78'&6N\H\&C;L5[K(,28QB#/Q]=L_2@BUJG
M.=AM0'VPDS'CF2R.N@1-Y$["G#R;<X.4<'T5@8PE>X5SPKCIN.AI4<A0)<'4
MWGN,"8/Y$NUS(:^[FA#0=O7R0SQ4# !^7H#AA&4.YZ=_)TIX<?IW+'4"'/;K
MVV$2,*5)49994J8DYHL.&Z3<@MR!(5I 0PQ<KKZ:5$<>VD_?VJ,T%[WU@;=F
M@[U&Y="O?45XCED/:DAX35]F] ?),ZG?4)(W57\AC\H;7 U[;"0P.L!\S&P(
MXNPAW_5D/*6GA6LN/7]WA',>LQ*3HL,<''&7,N<BV] LEX0^)NDN^E#7*&47
MYLN@)46"?K-O.C;58KV#530"OQVE:^WA0Y_+(<@*_2_C#\ 8.I L $55F],\
M<>PCM>Z%:$BKI&<&I[22:-@P2M6(+BWR\ 4;)[5Y6TG"TU]3$D3R9=)BD3K(
M?MN&#:$<5:<;0IB2XE76 ;.?+WX?;OH>;9IU!C*[:DYH-= >E(@Q^_[L<.;\
ME11R_!3]IY/"[)-'D7*X4(DVVU>&IN5ZM!M75S^("=QND1>JZQ69]YK]/Y18
M'P@0L%4O/:=J:1Z]UK*P0PM^"2D?2J02L,+2B:K!>#UI?Y\+L XZ K+.?KSZ
M!<B*T2/5>/CAY!++2G1JM %)J.3JK=/:+8%?)@ 28*X&E',R2 :3L+-ZKS18
M#*HC$K,$0W2;\(Q(NDI3KX#:8)1<710AA16K"31?!U- 7&,8X!"P-#^NY?,;
ML\S:6 KV6>R<K!Z;P:6!0XD^6I@"&<R&N3XLM),UQQ7XM.AZJFSK$Z.H$>'I
M(%*QIBF FB4<9.$XEYJ#7Z$,!TO#Y'U0E08%<J2XW[FRW@:]G4I^J,B3.6IT
MY0;EO>HWKL%L9LQJED!WZE0'FBC560B VC*7Z)DP>4C#O*"9^#HIFVB&B"_Z
M)19B?P3U"1@X;@>(R)GU0+$;&M4WNX&B=3$?EI4C5'9Q;'-CB1/"W]CD&BX[
M1!A)NU%?&[S4;VD;*2M+P]>!$(R#7/)32_>1) .79'#:(<:>+6?GPBK.C0,T
M@';8B4\84SR:P@;!D98USD1TV0JN-=-<\2R;OG]LA(-5[ T=CQ+=M!D*T!*S
MB/H%6E7DUV!DT%HQ_1^UYFU.X;\T;517'RN@'BST/8L%0F>'RWK>2Y;+>Y:X
M^XKA/WV40?44Y9*V2IE&3XMK;>N^"6'+(??[*CORV*A@LT$+AQ,O8.N;]FOX
M 7ZAH5Q!=2EK5&^H[$^8-OX8! %L+TB*39I'";SU\NJ&QH+!B V:8=K1.+Y(
MN1J.2*#<'8?@IF^*$XS*[3AEJLV.W'P]-YR1K=SKB_:85=XC>!EU#N"*/9UB
M$B@B4DO/@N1G)GELY:,XXG1YWH$;RHQJP^=1N954] 0))FE.CTIRQTK_'U#\
M7I3ER3OV3(+:=%UOI6W#R6MB:M>ZRR$=XMWUZ^N8##&9/<YLYNW;&P5I'A9A
M,Y9%$,CA@4_WMQX.9" 8EH8B,O5$#QY.\K5;37@1;ZUH%/' DQ<'';AHF6)-
M"_(-4Y5.B".M(60W$@GW%BQD"W?HQ#;Y:K9*F ZZY'7JE"&UMR7.$7HX,9.2
MH'7&/OX]+NX KU%&:#Y,O6M2](K"K5YSFS@/^P[BD!-F1<,*Q>;IS"$WS*1/
M!GK#T9V<<.7M 4."^%%"/1^]W(QA%B/*5[GC9B1)<=#&@FN4C2!:44-,R@,,
M0F"/1$Q1UP(X[Y097NXTX4K!2^+D(,HQ=HLQD:!A2MNR-#XNZ5*@!9NZ5X5Q
M'TQCPYPK"CZ+KND[4'8,I(SI*&P3;)JJ"-2N?(76G11OVTQ;FLK76C<EE&@X
MSLR0!OR7M*0D[13@Q9VA="A0>P1SO@D[H)JV@^5Y<7Y1.@:UK"D*+UFOI*W3
MD)H%&]8Z"UKS%$(ID4U4C4U?4>RM&&P\J,4R$WNKHWS!JE##8#7'65@AE7Q<
M!(2IRX/*E6>RCZ$BWPVHN&[6>26:()_C2-<)(<INH2"#O3O*E^@".0[!.B-E
M%"5SM;-HAP=C$R5@:2V>1!K+D U%%$3"<]R)&1H&XMD)4=\_^!Y&0-0),4!1
M4J&5.D/"FG6]<%@:TF2#7X+1'TBFXGR%AI-2[$'S4I%!"75*:AR@#-,0E0%1
M;3#H$KN Z9J,"@G+(AY#A1OB6 N>$4R,#WGK(IULS0E1/D\F-2;8*FH.@A;K
M$N[8GX-IRARXBM;H(..=>"+"%(C38K^C*E\]+1RQ1)!I"]%+B$$IPYXBY\!
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M*.]TXG5FW8."#@R56ET@8$AC),^T=9B&1DRXU,\<,?%/XH"JDN3#HEH\MC3
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M+88[!KLQ/ZSERI0F&_2@M+?[3I-6WD;JAX-UU!Z/Z]9$)U&<Q**2J?8H2;Z
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MVS_NVJ%N*,K(USG1UT;UE719#@,<TF7(ZSY413D !5*(FL,L)9Q7^%'0.2]
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M@B$<:2W)KK4D;VXM[UOK6M?V_+NXX=T=7>$&7^HO1PV_W%^V'L2A!^P]@#2
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MQ2DC'Z5!A#I6KXC/8+QO!PG-@A2PY-.R:NNAU?_.R/SK0E8%L.'<E@ !;P3
M5YJC35Y-.@6K'6+8Z=&$178 ;9FWEU71<B+#A#(_/"+#B,86+ZV6U1-E] $.
MSTVY,T! 6\Z09Q^60KEDUN2N?'A4F;>AM'45/WX&]]V+9N7LR +J^\P.( "(
M?ON 'D%C"_,8L0# :8I(_HG@5=)E\M!'RB06.\.,ACXP^P0\/XH9QFB:>7O
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M=YP 5*I];+<3(Y?N@3N5!L]E-UP(CG)@#V!_)J793*R _C\>Y_\"4$L#!!0
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MB2/;"WL[T**VE^2YT'3EMI\Y_>.@- *TOA!T*^P&1D'_US3]%U!+ P04
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M3@5G:5+2'UK75ZIMB4<E2Q<1_@M6\N1.,F\KF^(B8]FB!-R")?QNUK_76IZ
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M"F%L0 >DL=XE#TF O+5)F[1>LFX?AJ&@9=H6*HDJ*2<UL!\_4J)%RQ9).XV
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M!Q<>!:/ _%3XB@C:M-R+9%!%,F@3"615K2&I'S65&="K?*3;!">Y!&:CJBF
M03VQX:#?Z]<#&-0".-!RVM2RWXM&!T,=5J$.O:'>,?6(-@(4!H9ED^; ^M)H
M,$P<K<X@4JU3:DH(0:DSL4!D"=E LC*#QY;9>4+1*R6RJ=3\$,(ARBPI>Z;F
MJ IGY!^Y%!9%%LO2Q"'R![W,TZH6FX9K5!^NJ*G:1O4A:&HWK?O#OIH, Z?)
M@3>VVVQ#F+1C 96Y9" ,]&,**[ %3"I-^(J9VB0*QJPIT''I?A?9&^R3LDF_
ML<D^[)VE1/@.V*G@JQ*T!VGH@5$B#3W!["/%#BEN2:9F\5TRJB%WH\&&30]H
M\;CTNPLF.@#&J5L8O2-M*R$6SRQ-&WN/CF<K:ITM)X*A7P7W 3)N2./=)5D7
MQ!KTN'5).M$,_:HY)Z^%0$J:4(/VK&"@]+419%TI!WW?C':"&?H5LX:C<4'<
MKQ/*6T8I@=9;QKV>#ZD3Q/"((B:)S&%4$TB3A'T?R#=Y8"G3KP:[@.777P?0
MU]40![U&]/66,8Y]Z)W&A7Z%&;]%?4"Y2S=[\SCHAPU8A[6B;&PX;6@X'([P
MX9B<T(5^I;OE3U1I._W*%5?3^CZLJU:1T@/]8Z=&V*]&WX2E1FGVZ JM:;I
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M$U#D["6RT-4O.#38P /)7AM9-F2[@I*+^DE_-HDX(5@[_034$%"7$%X@X(:
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M2JGJ[KX>&+FKVM=':6PS7+WF]D;$E /8[ULIS<O .6CO6+/_ %!+ P04
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MIKDP'^3V'2LG%%A[H12Z^$7;<JS?0F&NC4Q*,$20\'3W3[^71.P!<+<!0$H
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MD8O'F%%8QW8 O%]+T/6R82_*U;>:X7]02P,$%     @ W$0*44$[YG>H!
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M 6$<]/F<<[7>F #]IRO] U!+ P04    " #<1 I186TB[I$"  "W!@  &0
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M>Q;)C.F22VW]_;B<:U3F;OQ\ QOWV-AADP-8:X*<P*;D;<7$DF -1+,-::3
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M-,\R1,8]^A^+?5I8JZ8D:LY(:. *\;LJKU#?]]SDTU 6NC%[N X* Y6"#_S
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MLJZ_ZX[072?LD5GH\L4N')*T6+3AVUJPT.J+W0%?VH6%;EJL::?=W&=<.1
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MZ.5/+V:JV?=%5<Q%W:SE4/2QTS*W^2QOWPW"R)%HT9800^Y4>U_7<OZ#0G4
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M,Z$3V0B8]SLA]-.B<=#/_,O_ %!+ P04    " #<1 I1"]Q:F:4"  #2!P
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M(\&&+#[HE&PJ*CCGP&FF7A=H>[DC^.<,DGXZ@F$.S+!>7NY(#@V ^8TC4.;
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M803T^P7G:GMC!J@/WB_^!5!+ P04    " #<1 I16:ZLFGP$  "X$0  &0
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M> /ZOM3:'28^0/-BC_\ 4$L#!!0    ( -Q$"E'$P;M)% 0  .$/   9
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M[U=7</+I%#Z!"RIF$A7P#.XSKM69F33C;['8*K.!FKG:@+9;NT$)\+( 2(\
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M4DV.9KE3GP^$:X!ZOF%,OFRT@NJ#9/H34$L#!!0    ( -Q$"E&:TPOV8@(
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M80+Y SN,T<QN1)T;T5$W[O3V+FN&.\3D:=5N,(!N0$K+4IXO<E],[X$\][B
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M' 3[<P,<I>B><,&R1+'2+!YO,4O'PHOVSB3H3 %&3F_#^0XA;HWNT^V$\;!
M&J3@(+H&$3\*A]UD%.B0F+Z](_>-;?]AM_B^+E8UXS4NA:)J6 ^3'-><C 6E
M;_S(.U?@^T:)QCOEF0)_W*+@,.K'(LA'<02';?%MK.4)6(?T]!T1C5?]1\R8
M#/3H1NX+/PK/%<^^&:#H>\0S.B88>BB,AD=$DZ#OQC".AE$U(89!-*S_2Y.@
M%T-G#[&ARMZ[]NE3B[IO<[G,NA3->;Z;[>[TU_HF.YB_05=S9)A?J&\ ^IK9
MPS<?$+YBML[D=2\G*VD*7H;26];<R9N!H)6^=#Y1(:^P^G5#<$J8$I#_KR@5
MNX$RT'T9F?T+4$L#!!0    ( -Q$"E&BKWO@:PD  &\S   9    >&PO=V]R
M:W-H965T<R]S:&5E=#8Y+GAM;+V;;V_;.!+&OXK@6QRZ0%N+_ZF])$ ;IWM=
M=/>"=K?W6K7I6*@L>24Y:;[]4;)CVIHAI;3&O4GLY"'U4*3F1\[8%P]E];5>
M&=-$W]9Y45].5DVS^64ZK><KLT[KU^7&%/8_R[):IXU]6]U-ZTUETD77:)U/
M:1S+Z3K-BLG51?>WV^KJHMPV>5:8VRJJM^MU6CV^-7GY<#DADZ<_?,SN5DW[
MA^G5Q2:],Y],\]?FMK+OIH=>%MG:%'56%E%EEI>3-^27&R7:!IWB<V8>ZJ/7
M43N4+V7YM7WS?G$YB5M')C?SINTBM;_NS;7)\[8GZ^/O?:>3PS7;AL>OGWI_
MUPW>#N9+6IOK,O]OMFA6EQ,]B19FF6[SYF/Y\&^S'U!G<%[F=?<S>MAI93*)
MYMNZ*=?[QM;!.BMVO]-O^QMQU(!P3P.Z;T#'-F#[!FQL [YOP,<V$/L&W="G
MN[%W-VZ6-NG5154^1%6KMKVU+[J[W[6V]RLKVH7RJ:GL?S/;KKGZG%99^B4W
MT?NB,96IF^BF:+(F,W7TXO/[F_KGZ,7,-&F6VU>OHK\^S:(7/_T<_11E1?3G
MJMS6:;&H+Z:-==+V-YWOK_IV=U7JN>IOV^)UQ.*7$8UIC#2_#C>?F;EM3MKF
M)$&:ST9?'6U^,_[J^K3YU-[]PQ30PQ30KC_FZ>]Z6U6F:**TKDU3!SIDAPY9
MUR'W=9C6J\A.3#1O7YB_M]E]FMLKH!.UZTIV7;51Y?Z*",HYN9C>'T\((HL9
MT<FI; 9E@BHJ#ZJ3\?##>'AP/!_MLJRR>6-V(\)&L>M '%TW[@T *I3 ;8F#
M+1&T];ZXM\;6[=39I\&&V:_V06D?I=K,MU7W#&%6!3!"B))"]OQB,BE8@GN6
M!\]RX%;.C5T-UF7],BI,@QF4\,I*:-WSAZA(''/<GCK84\^R%_WS'YH2\B^+
MI#QMYW^35LTC9EH!.R)AM&\:JK@FS+,\]<&T#IK^3[,RE75XL([YT_!VB83T
M'I]K1"6U]JS3Y. O"?J[K<PFS1:1^69W%[4-[&UH*#O3\T#HV?E.D&DF8#$@
M*AL=/+Y)[-@4!YU_*-.B/KJS*&AB<&W)J>@9'%*=&CR")WF6072]>N+ ONM0
MS$(D-@;$L<>V PZA0=M_EDV:CYC\?3?'UV<Z%AS<741'DUAJCU$',L*":/RC
M+$(N3WMU."%AGMBM3EK<9>U\[7KUAD("J9%PE8!Y@C*[_F-"/>-WA"%AQ/Q:
MEHN'+,]1;Y 0E"6Q8'USF$Z+V+?X'4I(F"6.?W4+P%U$,4^[QZ<GH=U^-(_1
MVC2K<H&. Y*$2DU4?QB(3'.J/*-PQ"%#R!G<7!"(#<7[O!X0G;IS:"$#;-F8
M*FVRXB[*C3T.155[[GE5+E]M:Q-Z<"%([$X;X :1$4ZY[[%UP"%AXNR(&+ '
M>4'M9<&4(UBQ*P-W1QU5:)@JN^A7A$/+SBB%V.""2D5[3A$=2Q+)/<\8=8"A
M8<#LO 8,0D)HQBAX>A"=HEH1YC%X='89=WC)[2DRRY%-[VF_+O+3\!GFS7Q>
M;MO(LDD?.[*VFY9T/J^VQNUDT#O"X-KB"NQ8,)FBRK.]IHXM-,R6=]EB.\_2
MZK$U>S("U"P"#@TB.**R3[,G\E$'%QJ&R^]FD<WMZO).W=XCY(>R5P<FH4QH
MU=^(S?:RXQ,BIPGO]7:#R!BS.S;/F!VS:)A9L^P^6YAB$9P42!K.^N=A1$25
M+S0Y&-$PC-YE15K,S3[8#TT,) Z)060*BTY].BS1YV%IR"GD#&.BOXM"5#1)
M/)M=ZF!$PS ZW>P..460(ZB(03S%3CR"4T\\90Y.+!Z[XQT74IEC"0NS9&:6
MQO:\B)KTVZ%S]##-D','DX+W;@(FTU1Z8BAS3&'AX\F'LKA[U9AJ/6YU,>3T
M(?I'%$3$B6=[QHX2;6%*!9Z#7?ZB7!Y6WJ:LVM0X.@(((Z(XZ3,+DQ&F?&O.
M,8N%F04V1$,W'.&1)%KW8P^JHY1Y'FGFR,7"Y-H9'G()@<0)9_V4Y36B8U))
MX;NMCC4LS!I/:OWQ971;96U5)GIK"K/,NNU"Z EW^&#J3)ED%^E9.-(_+Y>,
MG"?L @7G941G]Z+$MRY<J&?A4#_B+,=@X ;NH,27*N8NKO/PH>,[D\4<'BS:
M;#'I;T<P'66)[RC''31X&!IC$L8<X8"0X#B'R!+F2V9Q1PL>IL7WYXPY9((0
M&@0(1&:WK,I7U'#PX /P&),WYC#F*]8',2;BGE0\/ZJZA+'P0WECCM1;E.@3
M E/QV!-YN>,##_-A3-Z8P["/Y(V'5*<&'1IX& T_DC?F\.0!:EU(<<:?-^:.
M+SQ\/!F;-^;PT,&(/8/W-S2(SIX%N2_%PQVUN#Y;WI@[O/ P7C[8!^!EM*E*
MN^MK'KO'H07BIHWJ_N (:9+$&JPS1"6XYX@O''7$$'7&9KH%!(@21/5C."+3
M=E/EV?(+AQD1QDPHT2T0O,0)E_U5C^ITXLMQ"4<8$2;,*;O3Y=+N.NU3BE=W
M(2RH%D+VH8+H&-'>FIEP5!%AJIR:W50VP#0F?XQ6)E\<LO.H<P@1>^;3?=8@
M,B*]MAULQ%!-YBS%!($=.;0$@T!D_F*"./I$0!@\(S:@ DFG@6+"@.C4G:..
M"%/G.XL) M)$Q2##C*BXC2 >SPXY(HR<H5*"0! 2*Y!;0F0D%K[Y=IP1X=/1
M,TH) IYYA"(4;(DPG;!(],!;.'J),7FP@$&((+L7)AS<2D3'$YIXIEHZ6,EP
MZNMYI03IV"+#;/GN4H)$@$(T[<\8*B/:L[BDPXX,8^=YI00)@8*4$A"5OY0@
M'71D&#HC2PD2LH,K%O>C,R9+8N+[Z)-CC!QBS+Q<FS;]:<*W$M*!4PK.W)A,
M^));TC%$AAGR9MW.=;386J>EVVV@1I'2/A$,3#HBT['PY ;DT6?)?KR8(L<4
M4Q"1MY@B'3KD&8LI<DPQ94!TZM-!1)ZUF"*1)!L#I7U,%6O?E#N(R#,64R12
M)*%2J/[A!]$EDFK/C54.*.K,M13EF*+.54M12-:+@XPHHK+D%9Z0IQQ#U%E+
M*6I,*041>4LIRB%$_5]**0JR0V@0$1$54[[JLG* 4><MI"BD_"^D I]:Q3XE
M</P9CU.[CC3J#&44!2OQQ-(0["PP'>$\Z2_AZ=%W%=JOHOR>5G=94=M97]J&
M\>NVGVKW[8[=FZ;<=%]?^%(V3;GN7JY,NC!5*[#_7Y9E\_2F_4;$X3LV5_\#
M4$L#!!0    ( -Q$"E'1T Z6K0,  !D1   9    >&PO=V]R:W-H965T<R]S
M:&5E=#<P+GAM;+5847.;.!#^*QJF#\F,+R!L<-*Q/9.&DFNGF<LDU[N'FWM0
M8&TT!8F31)S^^Y. 8+O&*J73%QO!?M^NOEVD%8LM%U]D!J#02Y$SN70RI<JW
MKBN3# HB+W@)3#]9<U$0I8=BX\I2 $EK4)&[ON>%;D$H<U:+^MZ]6"UXI7+*
MX%X@614%$5_?0<ZW2P<[KS<>Z"93YH:[6I1D X^@/I?W0H_<CB6E!3!).4,"
MUDOG&K^]Q:$!U!9_4=C*O6MDIO+$^1<S^) N'<]$!#DDRE 0_?<,-Y#GADG'
M\5]+ZG0^#7#_^I4]KB>O)_-$)-SP_&^:JFSI7#HHA36I<O7 M[]#.Z' \"4\
ME_4OVC:VX=Q!2245+UJPCJ"@K/DG+ZT0>P \.P'P6X _%#!M =.A@%D+F T%
M!"T@& H(6T X%#!O ?,Z68VZ=6HBHLAJ(?@6"6.MV<Q%G=\:K3-"F2G%1R7T
M4ZIQ:O4)=!XE^@U=IRDUQ4%R1%E3XJ94SB)0A.;R7)M\?HS0V9MS]$9;H#\S
M7DG"4KEPE8[#L+E)Z_-=X],_X?-CQ2[0U)L@W_.]'OB-'1Y!HN'8P/%5#SSZ
M.>_O!\-[O<<_Y_UVM'=79[Y+O]^EWZ_YIB?3+R7 !-5E,$$1R$30LL[\/Y^T
M+?J@H)#_6CQ-.T_3VM/LA*<_2A"ZI-@&Y<87XHT7Q1&\*& I.JM*/3KO*R<[
M,_;05R"BKQ"CT<AX#/) F%DGS,Q*%5-&6 (C9+'SVF09C8S'( ]D"3I9@A^I
MEPE2(/3ZUZQ*^AGEZ031-2)EF=.$/.70%Z[=!ZZCM00;=L&&PW,X,E2[A^^&
M.N]"G5N)KO4+KZ3N(A(N4DA1Q5(0:+T_@=XEO6$-:U;3WSRO9IY>P)[WU^UC
MF^!;FV@ 3VRW.9CV93?M2_NTDZ0JJIPH/>44=->6T"8_1$INKO7]+579 "4N
MCZ*;'BDQP";JL0D.3=X?F_C?F,3')B$^-+D]-@E.J'G5J7EE5?..,EI4A:4<
ML;=K0+Q?O 7AO68'6^-^ -.=[S8A\Z).])K;+C6]K8R=$:.",Y7UMB%CD?$8
MY*$BN_T?^R,4:5^"7CWL?#8]QB+C,<A#/79="K9O['?DY7N5O=O8\>Q75_9N
MM\3VK6Q,9=L9@]/MPVAD/ 9YJ,AN2\;V'?/'*]O.9]-C+#(>@VST</?.?.:C
MP1T1&\JDGNQ:4WD7<ZVT:,[AS4#QLCX&/G&E#Y7U909$;_[&0#]?<ZY>!^9D
MV7T-6?T/4$L#!!0    ( -Q$"E&=R;)X$0,  &D*   9    >&PO=V]R:W-H
M965T<R]S:&5E=#<Q+GAM;*5674_;,!3]*U:T!Y" ?"<4M96@H1W3IB$*V\.T
M!S=U6PO'SFR7LOWZV4Z(0F*Z:KPDL7/.N3[W^FNX8_Q1;!"2X+D@5(R<C93E
MA>N*?(,**,Y8B:CZLV*\@%(U^=H5)4=P:4@%<0//2]P"8NJ,AZ;OEH^';"L)
MINB6 [$M"LA_7R'"=B/'=UXZ[O!Z(W6'.QZ6<(WF2#Z4MURUW$9EB0M$!684
M<+0:.9?^Q2S5> /XAM%.M+Z!=K)@[%$W;I8CQ],#0@3E4BM ]7I"$T2(%E+#
M^%5K.DU(36Q_OZA/C7?E90$%FC#R'2_E9N2<.V")5G!+Y!W;?42UGUCKY8P(
M\P2["IL&#LBW0K*B)JL1%)A6;_A<YZ%%\*,W"$%-" XEA#4A/)00U83H4$)<
M$^)#"4E-2 XEI#7!5-^MLFM*DT$)QT/.=H!KM%+3'Z:^AJTJ@JF>B7/)U5^L
M>'+\&:DZ"G *)JPH&454"L!6P'2#ZV<UX=7[*$,28B*.%>YAGH&C#\?@ \ 4
MW&_85D"Z%$-7JL%H23>O U]5@8,W G_:TC,0>B<@\ +/0I_LIV<H5W1?T_V!
MA9Z]+_KUP71K].G[HL_^.[JKRM_,@:"9 X'1"_?/@1^7"R&YVAM^[M$,&\W0
M:$9O:'XM$8<2TS4@9BKE3$A;F2J5Q*CH7?-I[$=1,G2?VL6P@(+(>PV:]D%A
M>'[^&C3K@X(P"AO0*ZM18S7::_6R8%SB/]!LK6KM5(91M79L"R/JC]3KN)D<
M@,DJ3-S&Q)W,]2%!!S+M0Q*_D[4^)/;L.8N;G,5[<W9#)>)(2*!25N6+8+C
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MO(:#83MH&/A.P^9VD.U[]K#;Z7&M<]SK]"^]CY"NWCU)P=+1)5*;*R5<?_+
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M[B?N6==;-T&*;* =/(!]'+8:([*J-$R -$S)0$.;AS?Q=9FZ?)_PQ& R!^/
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MQ]Q*&[ NC;"^:EVCGH=FZZKB '(/@=PCAGQI,C;2U:U4384:\IO6Q2. _(I
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M&D[\+-9E.?)E%\J'X<7K[P)>?]-P]!M02P,$%     @ W$0*4<?7<T]' @
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M;;\Y?GJ6O6V'UWPV_:'UYAE02P$"% ,4    " #<1 I1!T%-8H$   "Q
M$               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (
M -Q$"E%LU'Y2[@   "L"   1              "  :\   !D;V-0<F]P<R]C
M;W)E+GAM;%!+ 0(4 Q0    ( -Q$"E&97)PC$ 8  )PG   3
M  "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ W$0*45X^
MP)I'!0  F14  !@              ("!#0@  'AL+W=O<FMS:&5E=',O<VAE
M970Q+GAM;%!+ 0(4 Q0    ( -Q$"E'@X;I_\0@  '8G   8
M  " @8H-  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " #<
M1 I1[H<SCD<#   4#0  &               @(&Q%@  >&PO=V]R:W-H965T
M<R]S:&5E=#,N>&UL4$L! A0#%     @ W$0*4:<]O'N+!P  [B$  !@
M         ("!+AH  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0
M   ( -Q$"E$>9O 2<@<  ,TF   8              " @>\A  !X;"]W;W)K
M<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " #<1 I1/.2D]+$)  "L*@
M&               @(&7*0  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L!
M A0#%     @ W$0*403G=4*N%   /3H  !@              ("!?C,  'AL
M+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( -Q$"E%00FBM<BD
M /*&   8              " @6)(  !X;"]W;W)K<VAE971S+W-H965T."YX
M;6Q02P$"% ,4    " #<1 I1I,A82>@'   N%   &               @($*
M<@  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ W$0*46A=
M3FE-!   ?PH  !D              ("!*'H  'AL+W=O<FMS:&5E=',O<VAE
M970Q,"YX;6Q02P$"% ,4    " #<1 I1;Q'6YL<4  #01   &0
M    @(&L?@  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    (
M -Q$"E'LESA:J@8  )T/   9              " @:J3  !X;"]W;W)K<VAE
M971S+W-H965T,3(N>&UL4$L! A0#%     @ W$0*4=V$NZ36 @  1 8  !D
M             ("!BYH  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"
M% ,4    " #<1 I1Q"LVD"L#  #U!@  &0              @(&8G0  >&PO
M=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( -Q$"E$**B- SA8
M +5)   9              " @?J@  !X;"]W;W)K<VAE971S+W-H965T,34N
M>&UL4$L! A0#%     @ W$0*4<=GXQMX"@  %!X  !D              ("!
M_[<  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " #<1 I1
M0SYIO> *  !)'   &0              @(&NP@  >&PO=V]R:W-H965T<R]S
M:&5E=#$W+GAM;%!+ 0(4 Q0    ( -Q$"E%PGZO57P@  #X;   9
M      " @<7-  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%
M  @ W$0*4:%AJ2H:!@  X X  !D              ("!6]8  'AL+W=O<FMS
M:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " #<1 I1'  ??I$$  !+#@
M&0              @(&LW   >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+
M 0(4 Q0    ( -Q$"E'KMI<WK <  /41   9              " @73A  !X
M;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ W$0*4;K9ES,:
M!@  +1P  !D              ("!5^D  'AL+W=O<FMS:&5E=',O<VAE970R
M,BYX;6Q02P$"% ,4    " #<1 I1331B1KPW  !TP   &0
M@(&H[P  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( -Q$
M"E$O2M4=4 4  ,<.   9              " @9LG 0!X;"]W;W)K<VAE971S
M+W-H965T,C0N>&UL4$L! A0#%     @ W$0*41;L_4GM P  [@D  !D
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M=#(Y+GAM;%!+ 0(4 Q0    ( -Q$"E$:M*M800,  $0'   9
M  " @2!# 0!X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @
MW$0*4;"SDA,V!0  00T  !D              ("!F$8! 'AL+W=O<FMS:&5E
M=',O<VAE970S,2YX;6Q02P$"% ,4    " #<1 I1;T&5^OP"  !=!@  &0
M            @($%3 $ >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4
M Q0    ( -Q$"E&C>9E[@0,  %0+   9              " @3A/ 0!X;"]W
M;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ W$0*40C][G[T!0
M9@T  !D              ("!\%(! 'AL+W=O<FMS:&5E=',O<VAE970S-"YX
M;6Q02P$"% ,4    " #<1 I1>ERE3/ $   I$   &0              @($;
M60$ >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( -Q$"E&H
M)2+MA@D  .,U   9              " @4)> 0!X;"]W;W)K<VAE971S+W-H
M965T,S8N>&UL4$L! A0#%     @ W$0*4?;6N(#9!@  .B   !D
M     ("!_V<! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -Q$"E&Q1W/_.@0  +<1   9              "
M@01^ 0!X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ W$0*
M44$[YG>H!   <Q(  !D              ("!=8(! 'AL+W=O<FMS:&5E=',O
M<VAE970T,RYX;6Q02P$"% ,4    " #<1 I1EL-U%U4"  !O!0  &0
M        @(%4AP$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0
M   ( -Q$"E'2[?\[.P4  # ;   9              " @>") 0!X;"]W;W)K
M<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ W$0*4;"[T].* @  Q@8
M !D              ("!4H\! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q0
M2P$"% ,4    " #<1 I186TB[I$"  "W!@  &0              @($3D@$
M>&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( -Q$"E&"X5U
M=P4  (D;   9              " @=N4 0!X;"]W;W)K<VAE971S+W-H965T
M-#@N>&UL4$L! A0#%     @ W$0*49ZNGCY\#P  &&D  !D
M ("!B9H! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    " #<
M1 I1\38LYMH#  "^#@  &0              @($\J@$ >&PO=V]R:W-H965T
M<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( -Q$"E'B.B [O@D  +\W   9
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M970U-2YX;6Q02P$"% ,4    " #<1 I1MVW0/'L"  ! !@  &0
M    @($9R $ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    (
M -Q$"E&._TMZ50L  +E*   9              " @<O* 0!X;"]W;W)K<VAE
M971S+W-H965T-3<N>&UL4$L! A0#%     @ W$0*47J!TN>4!@  A!\  !D
M             ("!5]8! 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"
M% ,4    " #<1 I16:ZLFGP$  "X$0  &0              @($BW0$ >&PO
M=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( -Q$"E&G%)2@_@(
M +T'   9              " @=7A 0!X;"]W;W)K<VAE971S+W-H965T-C N
M>&UL4$L! A0#%     @ W$0*4<3!NTD4!   X0\  !D              ("!
M"N4! 'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q02P$"% ,4    " #<1 I1
M5*JK(X,$  !U%P  &0              @(%5Z0$ >&PO=V]R:W-H965T<R]S
M:&5E=#8R+GAM;%!+ 0(4 Q0    ( -Q$"E$WH)))<@,   \-   9
M      " @0_N 0!X;"]W;W)K<VAE971S+W-H965T-C,N>&UL4$L! A0#%
M  @ W$0*48%];1PP"   7#(  !D              ("!N/$! 'AL+W=O<FMS
M:&5E=',O<VAE970V-"YX;6Q02P$"% ,4    " #<1 I1S4C#L88#  "<#
M&0              @($?^@$ >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+
M 0(4 Q0    ( -Q$"E&:TPOV8@(  ,8%   9              " @=S] 0!X
M;"]W;W)K<VAE971S+W-H965T-C8N>&UL4$L! A0#%     @ W$0*42C%M<,5
M P  . H  !D              ("!=0 " 'AL+W=O<FMS:&5E=',O<VAE970V
M-RYX;6Q02P$"% ,4    " #<1 I1X[:B:30$   E$0  &0
M@('! P( >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+ 0(4 Q0    ( -Q$
M"E&BKWO@:PD  &\S   9              " @2P( @!X;"]W;W)K<VAE971S
M+W-H965T-CDN>&UL4$L! A0#%     @ W$0*4='0#I:M P  &1$  !D
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M=#<T+GAM;%!+ 0(4 Q0    ( -Q$"E&VKH?150(  &(,   -
M  "  5XC @!X;"]S='EL97,N>&UL4$L! A0#%     @ W$0*49>*NQS
M$P(   L              ( !WB4" %]R96QS+RYR96QS4$L! A0#%     @
MW$0*44^,,4JI!0  5S$   \              ( !QR8" 'AL+W=O<FMB;V]K
M+GAM;%!+ 0(4 Q0    ( -Q$"E''UW-/1P(  -4K   :              "
M 9TL @!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( -Q$
M"E$?G85O"0(  -@J   3              "  1PO @!;0V]N=&5N=%]4>7!E
<<UTN>&UL4$L%!@    !2 %( =18  %8Q @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>478</ContextCount>
  <ElementCount>550</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>143</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>17</UnitCount>
  <MyReports>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONSOLIDATED BALANCE SHEETS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS' EQUITY (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS' EQUITY (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/DescriptionofBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2111103 - Disclosure - Business Combinations and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BusinessCombinationsandGoodwill</Role>
      <ShortName>Business Combinations and Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2116104 - Disclosure - Intangible Assets, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IntangibleAssetsNet</Role>
      <ShortName>Intangible Assets, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2121105 - Disclosure - Investments in Other Entities ??? Equity Method</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethod</Role>
      <ShortName>Investments in Other Entities ??? Equity Method</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2127106 - Disclosure - Loan Receivable and Loan Receivable ??? Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedParties</Role>
      <ShortName>Loan Receivable and Loan Receivable ??? Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2129107 - Disclosure - Accounts Payable and Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/AccountsPayableandAccruedExpenses</Role>
      <ShortName>Accounts Payable and Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2132108 - Disclosure - Medical Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/MedicalLiabilities</Role>
      <ShortName>Medical Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2135109 - Disclosure - Credit Facility, Bank Loan and Lines of Credit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCredit</Role>
      <ShortName>Credit Facility, Bank Loan and Lines of Credit</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2140110 - Disclosure - Mezzanine and Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/MezzanineandStockholdersEquity</Role>
      <ShortName>Mezzanine and Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2147111 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2149112 - Disclosure - Related-Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/RelatedPartyTransactions</Role>
      <ShortName>Related-Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2153113 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2154114 - Disclosure - Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/EarningsPerShare</Role>
      <ShortName>Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2159115 - Disclosure - Variable Interest Entities (VIEs)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/VariableInterestEntitiesVIEs</Role>
      <ShortName>Variable Interest Entities (VIEs)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2162116 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2312302 - Disclosure - Business Combinations and Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BusinessCombinationsandGoodwillTables</Role>
      <ShortName>Business Combinations and Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/BusinessCombinationsandGoodwill</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2317303 - Disclosure - Intangible Assets, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IntangibleAssetsNetTables</Role>
      <ShortName>Intangible Assets, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/IntangibleAssetsNet</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2322304 - Disclosure - Investments in Other Entities ??? Equity Method (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodTables</Role>
      <ShortName>Investments in Other Entities ??? Equity Method (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethod</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2330305 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/AccountsPayableandAccruedExpensesTables</Role>
      <ShortName>Accounts Payable and Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/AccountsPayableandAccruedExpenses</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2333306 - Disclosure - Medical Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/MedicalLiabilitiesTables</Role>
      <ShortName>Medical Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/MedicalLiabilities</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2336307 - Disclosure - Credit Facility, Bank Loan and Lines of Credit (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditTables</Role>
      <ShortName>Credit Facility, Bank Loan and Lines of Credit (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCredit</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2341308 - Disclosure - Mezzanine and Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/MezzanineandStockholdersEquityTables</Role>
      <ShortName>Mezzanine and Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/MezzanineandStockholdersEquity</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2350309 - Disclosure - Related-Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/RelatedPartyTransactionsTables</Role>
      <ShortName>Related-Party Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/RelatedPartyTransactions</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2355310 - Disclosure - Earnings Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/EarningsPerShareTables</Role>
      <ShortName>Earnings Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/EarningsPerShare</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2360311 - Disclosure - Variable Interest Entities (VIEs) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables</Role>
      <ShortName>Variable Interest Entities (VIEs) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/VariableInterestEntitiesVIEs</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2363312 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/Leases</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Description of Business - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails</Role>
      <ShortName>Description of Business - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information, Performance Obligation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Additional Information, Performance Obligation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Disaggregation of Revenue by Each Payor Type (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Disaggregation of Revenue by Each Payor Type (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Contributions to Revenue and Receivables by Payor (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Contributions to Revenue and Receivables by Payor (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2410406 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Carrying Amounts and Fair Values of Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Carrying Amounts and Fair Values of Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2413407 - Disclosure - Business Combinations and Goodwill - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails</Role>
      <ShortName>Business Combinations and Goodwill - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2414408 - Disclosure - Business Combinations and Goodwill - Identifiable Assets Acquired and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails</Role>
      <ShortName>Business Combinations and Goodwill - Identifiable Assets Acquired and Liabilities Assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2415409 - Disclosure - Business Combinations and Goodwill - Summary of Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BusinessCombinationsandGoodwillSummaryofGoodwillDetails</Role>
      <ShortName>Business Combinations and Goodwill - Summary of Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2418410 - Disclosure - Intangible Assets, Net - Schedule of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets, Net - Schedule of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2419411 - Disclosure - Intangible Assets, Net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails</Role>
      <ShortName>Intangible Assets, Net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2420412 - Disclosure - Intangible Assets, Net - Future Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails</Role>
      <ShortName>Intangible Assets, Net - Future Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2423413 - Disclosure - Investments in Other Entities ??? Equity Method - Equity Method Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails</Role>
      <ShortName>Investments in Other Entities ??? Equity Method - Equity Method Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2424414 - Disclosure - Investments in Other Entities ??? Equity Method - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails</Role>
      <ShortName>Investments in Other Entities ??? Equity Method - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2425415 - Disclosure - Investments in Other Entities ??? Equity Method - Gain on Sale (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodGainonSaleDetails</Role>
      <ShortName>Investments in Other Entities ??? Equity Method - Gain on Sale (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2426416 - Disclosure - Investments in Other Entities ??? Equity Method - Summarized Balance Sheets and Statements of Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails</Role>
      <ShortName>Investments in Other Entities ??? Equity Method - Summarized Balance Sheets and Statements of Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2428417 - Disclosure - Loan Receivable and Loan Receivable ??? Related Parties - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails</Role>
      <ShortName>Loan Receivable and Loan Receivable ??? Related Parties - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2431418 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails</Role>
      <ShortName>Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2434419 - Disclosure - Medical Liabilities - Schedule of Medical Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails</Role>
      <ShortName>Medical Liabilities - Schedule of Medical Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2437420 - Disclosure - Credit Facility, Bank Loan and Lines of Credit - Credit Facility (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails</Role>
      <ShortName>Credit Facility, Bank Loan and Lines of Credit - Credit Facility (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2438421 - Disclosure - Credit Facility, Bank Loan and Lines of Credit - Schedule of Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails</Role>
      <ShortName>Credit Facility, Bank Loan and Lines of Credit - Schedule of Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2439422 - Disclosure - Credit Facility, Bank Loan and Lines of Credit - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails</Role>
      <ShortName>Credit Facility, Bank Loan and Lines of Credit - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2442423 - Disclosure - Mezzanine and Stockholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Mezzanine and Stockholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2443424 - Disclosure - Mezzanine and Stockholders' Equity - Schedule of Stock Options Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails</Role>
      <ShortName>Mezzanine and Stockholders' Equity - Schedule of Stock Options Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2444425 - Disclosure - Mezzanine and Stockholders' Equity - Stock Option Activity Under Black-Scholes Option Pricing Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/MezzanineandStockholdersEquityStockOptionActivityUnderBlackScholesOptionPricingModelDetails</Role>
      <ShortName>Mezzanine and Stockholders' Equity - Stock Option Activity Under Black-Scholes Option Pricing Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2445426 - Disclosure - Mezzanine and Stockholders' Equity - Summary of Warrant (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/MezzanineandStockholdersEquitySummaryofWarrantDetails</Role>
      <ShortName>Mezzanine and Stockholders' Equity - Summary of Warrant (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2446427 - Disclosure - Mezzanine and Stockholders' Equity - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/MezzanineandStockholdersEquityWarrantsDetails</Role>
      <ShortName>Mezzanine and Stockholders' Equity - Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2448428 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2451429 - Disclosure - Related-Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related-Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2452430 - Disclosure - Related-Party Transactions - Fees Incurred and Income Received (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails</Role>
      <ShortName>Related-Party Transactions - Fees Incurred and Income Received (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2456431 - Disclosure - Earnings Per Share - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails</Role>
      <ShortName>Earnings Per Share - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2457432 - Disclosure - Earnings Per Share - Earnings Per Share Computations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails</Role>
      <ShortName>Earnings Per Share - Earnings Per Share Computations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2458433 - Disclosure - Earnings Per Share - Shares Included in Diluted Earnings Per Share Computations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails</Role>
      <ShortName>Earnings Per Share - Shares Included in Diluted Earnings Per Share Computations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2461434 - Disclosure - Variable Interest Entities (VIEs) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails</Role>
      <ShortName>Variable Interest Entities (VIEs) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2464435 - Disclosure - Leases - Additional information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LeasesAdditionalinformationDetails</Role>
      <ShortName>Leases - Additional information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2465436 - Disclosure - Leases - Components of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails</Role>
      <ShortName>Leases - Components of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2466437 - Disclosure - Leases - Other Information Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails</Role>
      <ShortName>Leases - Other Information Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2467438 - Disclosure - Leases - Future Minimum Payments Under Non-cancelable Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails</Role>
      <ShortName>Leases - Future Minimum Payments Under Non-cancelable Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="ameh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9999.htm</HtmlFileName>
      <LongName>Uncategorized Items - ameh-20200630.htm</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/role/uncategorizedFacts</Role>
      <ShortName>Uncategorized Items - ameh-20200630.htm</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="ameh-20200630.htm">ameh-20200630.htm</File>
    <File>ameh-20200630.xsd</File>
    <File>ameh-20200630_cal.xml</File>
    <File>ameh-20200630_def.xml</File>
    <File>ameh-20200630_lab.xml</File>
    <File>ameh-20200630_pre.xml</File>
    <File>ex1012020063010-qngksim.htm</File>
    <File>ex1022020063010qngtlam.htm</File>
    <File>ex1032020063010qngechin.htm</File>
    <File>ex1042020063010qngavaz.htm</File>
    <File>ex1052020063010qngayou.htm</File>
    <File>ex1062020063010qngbsim.htm</File>
    <File>ex3112020063010-qng.htm</File>
    <File>ex3122020063010-qng.htm</File>
    <File>ex3132020063010-qng.htm</File>
    <File>ex322020063010-qng.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>98
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ameh-20200630.htm": {
   "axisCustom": 1,
   "axisStandard": 32,
   "contextCount": 478,
   "dts": {
    "calculationLink": {
     "local": [
      "ameh-20200630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ameh-20200630_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "ameh-20200630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ameh-20200630_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ameh-20200630_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "ameh-20200630.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 773,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 2,
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 7
   },
   "keyCustom": 106,
   "keyStandard": 444,
   "memberCustom": 86,
   "memberStandard": 37,
   "nsprefix": "ameh",
   "nsuri": "http://www.apollomed.net/20200630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Document and Entity Information",
     "role": "http://www.apollomed.net/role/DocumentandEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116104 - Disclosure - Intangible Assets, Net",
     "role": "http://www.apollomed.net/role/IntangibleAssetsNet",
     "shortName": "Intangible Assets, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ameh:EquityMethodAndOtherEquityInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121105 - Disclosure - Investments in Other Entities \u2014 Equity Method",
     "role": "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethod",
     "shortName": "Investments in Other Entities \u2014 Equity Method",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ameh:EquityMethodAndOtherEquityInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ameh:LoanReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2127106 - Disclosure - Loan Receivable and Loan Receivable \u2013 Related Parties",
     "role": "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedParties",
     "shortName": "Loan Receivable and Loan Receivable \u2013 Related Parties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ameh:LoanReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129107 - Disclosure - Accounts Payable and Accrued Expenses",
     "role": "http://www.apollomed.net/role/AccountsPayableandAccruedExpenses",
     "shortName": "Accounts Payable and Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132108 - Disclosure - Medical Liabilities",
     "role": "http://www.apollomed.net/role/MedicalLiabilities",
     "shortName": "Medical Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135109 - Disclosure - Credit Facility, Bank Loan and Lines of Credit",
     "role": "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCredit",
     "shortName": "Credit Facility, Bank Loan and Lines of Credit",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2140110 - Disclosure - Mezzanine and Stockholders' Equity",
     "role": "http://www.apollomed.net/role/MezzanineandStockholdersEquity",
     "shortName": "Mezzanine and Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2147111 - Disclosure - Commitments and Contingencies",
     "role": "http://www.apollomed.net/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2149112 - Disclosure - Related-Party Transactions",
     "role": "http://www.apollomed.net/role/RelatedPartyTransactions",
     "shortName": "Related-Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2153113 - Disclosure - Income Taxes",
     "role": "http://www.apollomed.net/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i2bce3c5038344323935db8cc2710a157_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONSOLIDATED BALANCE SHEETS (UNAUDITED)",
     "role": "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
     "shortName": "CONSOLIDATED BALANCE SHEETS (UNAUDITED)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i2bce3c5038344323935db8cc2710a157_I20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AccruedIncomeTaxesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2154114 - Disclosure - Earnings Per Share",
     "role": "http://www.apollomed.net/role/EarningsPerShare",
     "shortName": "Earnings Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2159115 - Disclosure - Variable Interest Entities (VIEs)",
     "role": "http://www.apollomed.net/role/VariableInterestEntitiesVIEs",
     "shortName": "Variable Interest Entities (VIEs)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2162116 - Disclosure - Leases",
     "role": "http://www.apollomed.net/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312302 - Disclosure - Business Combinations and Goodwill (Tables)",
     "role": "http://www.apollomed.net/role/BusinessCombinationsandGoodwillTables",
     "shortName": "Business Combinations and Goodwill (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317303 - Disclosure - Intangible Assets, Net (Tables)",
     "role": "http://www.apollomed.net/role/IntangibleAssetsNetTables",
     "shortName": "Intangible Assets, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322304 - Disclosure - Investments in Other Entities \u2014 Equity Method (Tables)",
     "role": "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodTables",
     "shortName": "Investments in Other Entities \u2014 Equity Method (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2330305 - Disclosure - Accounts Payable and Accrued Expenses (Tables)",
     "role": "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesTables",
     "shortName": "Accounts Payable and Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2333306 - Disclosure - Medical Liabilities (Tables)",
     "role": "http://www.apollomed.net/role/MedicalLiabilitiesTables",
     "shortName": "Medical Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i2bce3c5038344323935db8cc2710a157_I20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)",
     "role": "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i2bce3c5038344323935db8cc2710a157_I20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2336307 - Disclosure - Credit Facility, Bank Loan and Lines of Credit (Tables)",
     "role": "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditTables",
     "shortName": "Credit Facility, Bank Loan and Lines of Credit (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2341308 - Disclosure - Mezzanine and Stockholders' Equity (Tables)",
     "role": "http://www.apollomed.net/role/MezzanineandStockholdersEquityTables",
     "shortName": "Mezzanine and Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2350309 - Disclosure - Related-Party Transactions (Tables)",
     "role": "http://www.apollomed.net/role/RelatedPartyTransactionsTables",
     "shortName": "Related-Party Transactions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2355310 - Disclosure - Earnings Per Share (Tables)",
     "role": "http://www.apollomed.net/role/EarningsPerShareTables",
     "shortName": "Earnings Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2360311 - Disclosure - Variable Interest Entities (VIEs) (Tables)",
     "role": "http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables",
     "shortName": "Variable Interest Entities (VIEs) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2363312 - Disclosure - Leases (Tables)",
     "role": "http://www.apollomed.net/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromSaleOfEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Description of Business - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
     "shortName": "Description of Business - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "ie580169aa3e849ceb22d709b7d624f59_I20190930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:NotesReceivableNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": null,
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information, Performance Obligation (Details)",
     "role": "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Additional Information, Performance Obligation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Disaggregation of Revenue by Each Payor Type (Details)",
     "role": "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Disaggregation of Revenue by Each Payor Type (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i0dd8dccc65a74133a54656bd7c8b4677_D20200401-20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)",
     "role": "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
     "shortName": "CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i66d29491233d435a9781fc3960674175_D20200401-20200630",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Contributions to Revenue and Receivables by Payor (Details)",
     "role": "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Contributions to Revenue and Receivables by Payor (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i66d29491233d435a9781fc3960674175_D20200401-20200630",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i2bce3c5038344323935db8cc2710a157_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410406 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Carrying Amounts and Fair Values of Financial Instruments (Details)",
     "role": "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Carrying Amounts and Fair Values of Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i2bce3c5038344323935db8cc2710a157_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413407 - Disclosure - Business Combinations and Goodwill - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
     "shortName": "Business Combinations and Goodwill - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i9efe901318bb4ed08cc6432008f3343c_I20190830",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i2bce3c5038344323935db8cc2710a157_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414408 - Disclosure - Business Combinations and Goodwill - Identifiable Assets Acquired and Liabilities Assumed (Details)",
     "role": "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails",
     "shortName": "Business Combinations and Goodwill - Identifiable Assets Acquired and Liabilities Assumed (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "ic772c23a08d84f8da481202e5fe65be4_I20190830",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415409 - Disclosure - Business Combinations and Goodwill - Summary of Goodwill (Details)",
     "role": "http://www.apollomed.net/role/BusinessCombinationsandGoodwillSummaryofGoodwillDetails",
     "shortName": "Business Combinations and Goodwill - Summary of Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:GoodwillOtherIncreaseDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i2bce3c5038344323935db8cc2710a157_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418410 - Disclosure - Intangible Assets, Net - Schedule of Intangible Assets (Details)",
     "role": "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails",
     "shortName": "Intangible Assets, Net - Schedule of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i2bce3c5038344323935db8cc2710a157_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419411 - Disclosure - Intangible Assets, Net - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails",
     "shortName": "Intangible Assets, Net - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i2bce3c5038344323935db8cc2710a157_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420412 - Disclosure - Intangible Assets, Net - Future Amortization Expense (Details)",
     "role": "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails",
     "shortName": "Intangible Assets, Net - Future Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i2bce3c5038344323935db8cc2710a157_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:EquityMethodInvestmentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423413 - Disclosure - Investments in Other Entities \u2014 Equity Method - Equity Method Investments (Details)",
     "role": "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails",
     "shortName": "Investments in Other Entities \u2014 Equity Method - Equity Method Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:EquityMethodInvestmentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentSoldCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424414 - Disclosure - Investments in Other Entities \u2014 Equity Method - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
     "shortName": "Investments in Other Entities \u2014 Equity Method - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i3635f2277d854166953f31769a15549d_I20180531",
      "decimals": "INF",
      "lang": "en-US",
      "name": "ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i009fc823ec144ee3b772b4396d458c88_I20181231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS' EQUITY (UNAUDITED)",
     "role": "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED",
     "shortName": "CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS' EQUITY (UNAUDITED)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i8af5fb33859043a8b3f81453abfe1293_I20181231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromSaleOfEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425415 - Disclosure - Investments in Other Entities \u2014 Equity Method - Gain on Sale (Details)",
     "role": "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodGainonSaleDetails",
     "shortName": "Investments in Other Entities \u2014 Equity Method - Gain on Sale (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ameh:EquityMethodInvestmentGainOnSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "if482ba97bdb84bda9cf6288b01d207b9_D20200430-20200430",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i2bce3c5038344323935db8cc2710a157_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426416 - Disclosure - Investments in Other Entities \u2014 Equity Method - Summarized Balance Sheets and Statements of Income (Details)",
     "role": "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails",
     "shortName": "Investments in Other Entities \u2014 Equity Method - Summarized Balance Sheets and Statements of Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i953f113f807a4b629361138a8c340c45_I20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i2bce3c5038344323935db8cc2710a157_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428417 - Disclosure - Loan Receivable and Loan Receivable \u2013 Related Parties - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
     "shortName": "Loan Receivable and Loan Receivable \u2013 Related Parties - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i901365bdd3be4af6a404cf5c6e1a6075_I20190628",
      "decimals": "4",
      "lang": "en-US",
      "name": "ameh:EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i2bce3c5038344323935db8cc2710a157_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431418 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details)",
     "role": "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails",
     "shortName": "Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i2bce3c5038344323935db8cc2710a157_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434419 - Disclosure - Medical Liabilities - Schedule of Medical Liabilities (Details)",
     "role": "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails",
     "shortName": "Medical Liabilities - Schedule of Medical Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i2bce3c5038344323935db8cc2710a157_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCredit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437420 - Disclosure - Credit Facility, Bank Loan and Lines of Credit - Credit Facility (Details)",
     "role": "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails",
     "shortName": "Credit Facility, Bank Loan and Lines of Credit - Credit Facility (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i2bce3c5038344323935db8cc2710a157_I20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:LinesOfCreditCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i2bce3c5038344323935db8cc2710a157_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438421 - Disclosure - Credit Facility, Bank Loan and Lines of Credit - Schedule of Maturities (Details)",
     "role": "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails",
     "shortName": "Credit Facility, Bank Loan and Lines of Credit - Schedule of Maturities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i2bce3c5038344323935db8cc2710a157_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i2bce3c5038344323935db8cc2710a157_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCredit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439422 - Disclosure - Credit Facility, Bank Loan and Lines of Credit - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
     "shortName": "Credit Facility, Bank Loan and Lines of Credit - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i44c831b5e48a42e88b05d16f1fdb9240_D20200101-20200630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "ameh:DebtInstrumentCovenantInterestCoverageRatioMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ameh:StockIssuedDuringPeriodSharesMerger",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442423 - Disclosure - Mezzanine and Stockholders' Equity - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
     "shortName": "Mezzanine and Stockholders' Equity - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ameh:StockIssuedDuringPeriodSharesMerger",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443424 - Disclosure - Mezzanine and Stockholders' Equity - Schedule of Stock Options Activity (Details)",
     "role": "http://www.apollomed.net/role/MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails",
     "shortName": "Mezzanine and Stockholders' Equity - Schedule of Stock Options Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)",
     "role": "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i9ec7494ea7af48fda7c1d23e2672ba9d_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444425 - Disclosure - Mezzanine and Stockholders' Equity - Stock Option Activity Under Black-Scholes Option Pricing Model (Details)",
     "role": "http://www.apollomed.net/role/MezzanineandStockholdersEquityStockOptionActivityUnderBlackScholesOptionPricingModelDetails",
     "shortName": "Mezzanine and Stockholders' Equity - Stock Option Activity Under Black-Scholes Option Pricing Model (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i9ec7494ea7af48fda7c1d23e2672ba9d_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "ie16ac4200d1c48e7ba401f9883c0c3a5_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445426 - Disclosure - Mezzanine and Stockholders' Equity - Summary of Warrant (Details)",
     "role": "http://www.apollomed.net/role/MezzanineandStockholdersEquitySummaryofWarrantDetails",
     "shortName": "Mezzanine and Stockholders' Equity - Summary of Warrant (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "ameh:NumberOfWarrantsGranted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i2bce3c5038344323935db8cc2710a157_I20200630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446427 - Disclosure - Mezzanine and Stockholders' Equity - Warrants (Details)",
     "role": "http://www.apollomed.net/role/MezzanineandStockholdersEquityWarrantsDetails",
     "shortName": "Mezzanine and Stockholders' Equity - Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i0652754b1e534a8089d0c0347af659b7_I20200630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "ameh:PercentageOfFinancialGuaranteeBenchmarkAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448428 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "ameh:PercentageOfFinancialGuaranteeBenchmarkAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i2bce3c5038344323935db8cc2710a157_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451429 - Disclosure - Related-Party Transactions - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
     "shortName": "Related-Party Transactions - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i83ceffd8ac474d21a39c47ca896605c6_D20200401-20200630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "ameh:PaymentConsultingFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452430 - Disclosure - Related-Party Transactions - Fees Incurred and Income Received (Details)",
     "role": "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails",
     "shortName": "Related-Party Transactions - Fees Incurred and Income Received (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i9b1e96ab04c2463f8f4b975abf5cd0e1_D20200401-20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i255d39881fdb459ba312544c3eb6589e_D20200101-20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ameh:AntidilutiveSecuritiesExcludedFromEarningsComputationShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2456431 - Disclosure - Earnings Per Share - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails",
     "shortName": "Earnings Per Share - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i255d39881fdb459ba312544c3eb6589e_D20200101-20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ameh:AntidilutiveSecuritiesExcludedFromEarningsComputationShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareBasic",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2457432 - Disclosure - Earnings Per Share - Earnings Per Share Computations (Details)",
     "role": "http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails",
     "shortName": "Earnings Per Share - Earnings Per Share Computations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2458433 - Disclosure - Earnings Per Share - Shares Included in Diluted Earnings Per Share Computations (Details)",
     "role": "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails",
     "shortName": "Earnings Per Share - Shares Included in Diluted Earnings Per Share Computations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "ameh:BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i2bce3c5038344323935db8cc2710a157_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2461434 - Disclosure - Variable Interest Entities (VIEs) (Details)",
     "role": "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails",
     "shortName": "Variable Interest Entities (VIEs) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i7f9c10048151448696ea86f0e39c0212_I20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Description of Business",
     "role": "http://www.apollomed.net/role/DescriptionofBusiness",
     "shortName": "Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeFinanceLeaseRenewalTerm1",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i2bce3c5038344323935db8cc2710a157_I20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2464435 - Disclosure - Leases - Additional information (Details)",
     "role": "http://www.apollomed.net/role/LeasesAdditionalinformationDetails",
     "shortName": "Leases - Additional information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": null,
      "lang": "en-US",
      "name": "ameh:LesseeOperatingLeaseTerminationPeriodIfApplicable",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2465436 - Disclosure - Leases - Components of Lease Expense (Details)",
     "role": "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails",
     "shortName": "Leases - Components of Lease Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2466437 - Disclosure - Leases - Other Information Related to Leases (Details)",
     "role": "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails",
     "shortName": "Leases - Other Information Related to Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i60123cb9befa425e88fa680fc988f0e1_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i2bce3c5038344323935db8cc2710a157_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2467438 - Disclosure - Leases - Future Minimum Payments Under Non-cancelable Leases (Details)",
     "role": "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails",
     "shortName": "Leases - Future Minimum Payments Under Non-cancelable Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i2bce3c5038344323935db8cc2710a157_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies",
     "role": "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111103 - Disclosure - Business Combinations and Goodwill",
     "role": "http://www.apollomed.net/role/BusinessCombinationsandGoodwill",
     "shortName": "Business Combinations and Goodwill",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i371a8b160e6c464ebe642f2928a09a83_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9999": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i2db2c0d074c34657a5d523b0ae1e5784_I20190630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DividendsPayableCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "",
     "isDefault": "false",
     "longName": "Uncategorized Items - ameh-20200630.htm",
     "role": "http://xbrl.sec.gov/role/uncategorizedFacts",
     "shortName": "Uncategorized Items - ameh-20200630.htm",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200630.htm",
      "contextRef": "i2db2c0d074c34657a5d523b0ae1e5784_I20190630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DividendsPayableCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 143,
   "tag": {
    "ameh_AHMCMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "AHMC [Member]",
        "terseLabel": "AHMC",
        "verboseLabel": "AHMC"
       }
      }
     },
     "localname": "AHMCMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_APAMHMedicalCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "AP-AMH Medical Corporation [Member]",
        "label": "AP-AMH Medical Corporation [Member]",
        "terseLabel": "AP-AMH Medical Corporation"
       }
      }
     },
     "localname": "APAMHMedicalCorporationMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_APCAndAPCLSMAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "APC And APC-LSMA [Member]",
        "label": "APC And APC-LSMA [Member]",
        "terseLabel": "APC and APC-LSMA"
       }
      }
     },
     "localname": "APCAndAPCLSMAMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AccountableHealthCareIPAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accountable Health Care IPA [Member]",
        "terseLabel": "Accountable Health Care, IPA",
        "verboseLabel": "Accountable Health Care"
       }
      }
     },
     "localname": "AccountableHealthCareIPAMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AccountsAndOtherReceivablesNumberOfAdditionalAgreements": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounts And Other Receivables, Number Of Additional Agreements",
        "label": "Accounts And Other Receivables, Number Of Additional Agreements",
        "terseLabel": "Number of additional subordinated note receivable agreements"
       }
      }
     },
     "localname": "AccountsAndOtherReceivablesNumberOfAdditionalAgreements",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ameh_AccountsPayableAndAccruedExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounts Payable And Accrued Expenses [Member]",
        "terseLabel": "Accounts Payable and Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedExpensesMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AccountsReceivableAndNetRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounts Receivable And Net Revenue [Line Items]",
        "terseLabel": "Accounts Receivable And Net Revenue [Line Items]"
       }
      }
     },
     "localname": "AccountsReceivableAndNetRevenueLineItems",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_AccountsReceivableAndNetRevenueTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounts Receivable And Net Revenue [Table]",
        "terseLabel": "Accounts Receivable And Net Revenue [Table]"
       }
      }
     },
     "localname": "AccountsReceivableAndNetRevenueTable",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_AchievaMedInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "AchievaMed, Inc. [Member]",
        "label": "AchievaMed, Inc. [Member]",
        "terseLabel": "AchievaMed, Inc."
       }
      }
     },
     "localname": "AchievaMedInc.Member",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional Proceeds To Be Received From Sale Of Equity Method Investments, If Circumstances Met",
        "label": "Additional Proceeds To Be Received From Sale Of Equity Method Investments, If Circumstances Met",
        "netLabel": "Beneficial interest in UCI",
        "terseLabel": "Additional cash consideration entitled to be received",
        "verboseLabel": "Additional cash and non-cash consideration entitled to be received"
       }
      }
     },
     "localname": "AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodGainonSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_AdvanceDiagnosticSurgeryCenterMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Advance Diagnostic Surgery Center [Member]",
        "terseLabel": "Advance Diagnostic Surgery Center"
       }
      }
     },
     "localname": "AdvanceDiagnosticSurgeryCenterMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AdvancedForWorkingCapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount advanced for working capital purposes.",
        "label": "Advanced For Working Capital",
        "terseLabel": "Advance for working capital"
       }
      }
     },
     "localname": "AdvancedForWorkingCapital",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_AggregateintrinsicvalueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value (in thousands)"
       }
      }
     },
     "localname": "AggregateintrinsicvalueAbstract",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquitySummaryofWarrantDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_AlliedPacificOfCaliforniaIPAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Allied Pacific Of California IPA",
        "label": "Allied Pacific Of California IPA [Member]",
        "verboseLabel": "APC"
       }
      }
     },
     "localname": "AlliedPacificOfCaliforniaIPAMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AlliedPacificofCaliforniaBrokerageAccountMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Allied Pacific of California Brokerage Account [Member]",
        "label": "Allied Pacific of California Brokerage Account [Member]",
        "terseLabel": "Allied Pacific of California Brokerage Account"
       }
      }
     },
     "localname": "AlliedPacificofCaliforniaBrokerageAccountMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AlphaCareMedicalGroupInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Alpha Care Medical Group, Inc. [Member]",
        "label": "Alpha Care Medical Group, Inc. [Member]",
        "terseLabel": "Alpha Care Medical Group, Inc."
       }
      }
     },
     "localname": "AlphaCareMedicalGroupInc.Member",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AmgIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "AMG, Inc [Member]",
        "terseLabel": "AMG, Inc"
       }
      }
     },
     "localname": "AmgIncMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AncillaryServiceContractMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Ancillary Service Contract [Member]",
        "terseLabel": "Ancillary Service Contract"
       }
      }
     },
     "localname": "AncillaryServiceContractMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AntidilutiveSecuritiesExcludedFromEarningsComputationShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU",
        "label": "Antidilutive Securities Excluded From Earnings Computation, Shares",
        "terseLabel": "Treasury shares not included in the calculation of earnings per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromEarningsComputationShares",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_ApaacoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "APAACO [Member]",
        "terseLabel": "APAACO"
       }
      }
     },
     "localname": "ApaacoMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ApcBusinessLoanAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "APC Business Loan Agreement [Member]",
        "terseLabel": "APC Business Loan Agreement"
       }
      }
     },
     "localname": "ApcBusinessLoanAgreementMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ApcLsmaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "APC LSMA [Member]",
        "terseLabel": "APC LSMA"
       }
      }
     },
     "localname": "ApcLsmaMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ApcShareholdersMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "APC Shareholders [Member]",
        "terseLabel": "APC Shareholders"
       }
      }
     },
     "localname": "ApcShareholdersMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ApcStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "APC Stock Option [Member]",
        "terseLabel": "APC Stock Option"
       }
      }
     },
     "localname": "ApcStockOptionMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ApolloMedicalHoldingsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Apollo Medical Holdings, Inc [Member]",
        "terseLabel": "Apollo Medical Holdings, Inc"
       }
      }
     },
     "localname": "ApolloMedicalHoldingsIncMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AurionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "xxx_Aurion Member",
        "label": "Aurion [Member]",
        "verboseLabel": "Aurion"
       }
      }
     },
     "localname": "AurionMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_BrightHealthCompanyOfCaliforniaInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bright Health Company Of California, Inc.",
        "label": "Bright Health Company Of California, Inc. [Member]",
        "terseLabel": "Bright"
       }
      }
     },
     "localname": "BrightHealthCompanyOfCaliforniaInc.Member",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodGainonSaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Medical Liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Medical Liabilities",
        "negatedTerseLabel": "Medical liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Shares Held Back To Secure Indemnification, Percentage",
        "label": "Business Combination, Shares Held Back To Secure Indemnification, Percentage",
        "terseLabel": "Shares held back in merger to secure indemnification (as a percent)"
       }
      }
     },
     "localname": "BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_CDSCMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "CDSC",
        "label": "CDSC [Member]",
        "terseLabel": "CDSC"
       }
      }
     },
     "localname": "CDSCMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_CMSMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "CMS [Member]",
        "label": "CMS [Member]",
        "terseLabel": "CMS"
       }
      }
     },
     "localname": "CMSMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_CashPaidForLeaseLiabilitiesAbstractAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash Paid For Lease Liabilities [Abstract]",
        "verboseLabel": "Cash paid for amounts included in the measurement of lease liabilities:"
       }
      }
     },
     "localname": "CashPaidForLeaseLiabilitiesAbstractAbstract",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_ClassOfWarrantOrRightCancelledInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Class of warrant or right, cancelled in period",
        "label": "Class Of Warrant Or Right Cancelled In Period",
        "negatedLabel": "Warrants expired/forfeited (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightCancelledInPeriod",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquitySummaryofWarrantDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_ClassOfWarrantOrRightExercisable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Class of Warrant or Right, Exercisable",
        "label": "Class Of Warrant Or Right Exercisable",
        "terseLabel": "Warrants Exercisable (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisable",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_ClassOfWarrantOrRightIssuedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Class of Warrant or Right, Issued in Period",
        "label": "Class Of Warrant Or Right Issued In Period",
        "verboseLabel": "Warrants Outstanding (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightIssuedInPeriod",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Class Of Warrant Or Rights Grant In Period Weighted Average Remaining Contractual Term",
        "label": "Class Of Warrant Or Rights Grant In Period Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual\u00a0Life"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Class Of Warrant Or Rights outstanding Weighted Average Remaining Contractual Term",
        "label": "Class Of Warrant Or Rights Outstanding Weighted Average Remaining Contractual Term",
        "verboseLabel": "Warrants outstanding"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquitySummaryofWarrantDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Intrinsic value of warrants or rights exercised in period.",
        "label": "Class Of Warrants Or Right, Exercises In Period, Aggregate Intrinsic Value",
        "verboseLabel": "Warrants exercised"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquitySummaryofWarrantDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Intrinsic value of warrants or rights forfeited in period.",
        "label": "Class Of Warrants Or Right, Forfeitures In Period, Aggregate Intrinsic Value",
        "verboseLabel": "Warrants expired/forfeited"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquitySummaryofWarrantDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Intrinsic value of warrants or rights granted in period.",
        "label": "Class Of Warrants Or Right, Grant In Period, Aggregate Intrinsic Value",
        "verboseLabel": "Warrants granted"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquitySummaryofWarrantDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Intrinsic value of warrants or rights outstanding.",
        "label": "Class Of Warrants Or Right, Outstanding, Aggregate Intrinsic Value",
        "periodEndLabel": "Warrants outstanding, ending balance",
        "periodStartLabel": "Warrants outstanding, beginning balance"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquitySummaryofWarrantDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants",
        "label": "Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants",
        "periodEndLabel": "Warrants outstanding, ending balance (in dollars per share)",
        "periodStartLabel": "Warrants outstanding, beginning balance (in dollars per share)",
        "terseLabel": "Weighted Average Exercise\u00a0Price Per Share (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquitySummaryofWarrantDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exercise price per share of warrants or rights exercised during the period.",
        "label": "Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants, Exercised In Period",
        "verboseLabel": "Warrants exercised (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquitySummaryofWarrantDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exercise price per share of warrants or rights forfeited during the period.",
        "label": "Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants, Forfeited In Period",
        "verboseLabel": "Warrants expired/forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquitySummaryofWarrantDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exercise price per share of warrants or rights granted during the period.",
        "label": "Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants, Grant In Period",
        "verboseLabel": "Warrants granted (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquitySummaryofWarrantDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ameh_CollegeStreetInvestmentLpMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "College Street Investment LP [Member].",
        "label": "College Street Investment LP [Member]",
        "terseLabel": "College Street Investment LP"
       }
      }
     },
     "localname": "CollegeStreetInvestmentLpMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_CommercialMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ameh:CommercialMember",
        "label": "Commercial [Member]",
        "terseLabel": "Commercial"
       }
      }
     },
     "localname": "CommercialMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_CommitmentsAndContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments And Contingencies [Line Items]",
        "terseLabel": "Commitments And Contingencies [Line Items]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesLineItems",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_CommitmentsAndContingenciesTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments And Contingencies [Table]",
        "terseLabel": "Commitments And Contingencies [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesTable",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_ConcourseDiagnosticSurgeryCenterLlcMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Concourse Diagnostic Surgery Center, LLC [Member]",
        "terseLabel": "Concourse Diagnostic Surgery Center, LLC"
       }
      }
     },
     "localname": "ConcourseDiagnosticSurgeryCenterLlcMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ContractTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Contract Type [Axis]",
        "terseLabel": "Contract Type [Axis]"
       }
      }
     },
     "localname": "ContractTypeAxis",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_ContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Contract Type [Domain]",
        "terseLabel": "Contract Type [Domain]"
       }
      }
     },
     "localname": "ContractTypeDomain",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ContractWithCustomerLiabilityRepaidCapitationReceivedAndNotEarned": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contract with Customer, Liability, Repaid, Capitation Received And Not Earned",
        "label": "Contract With Customer, Liability, Repaid Capitation Received And Not Earned",
        "terseLabel": "Contract liability repaid, capitation received and not earned"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRepaidCapitationReceivedAndNotEarned",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_CreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Credit Agreement [Member]",
        "label": "Credit Agreement [Member]",
        "terseLabel": "Credit Agreement"
       }
      }
     },
     "localname": "CreditAgreementMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_CriticalQualityManagementCorpMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "xxx_Critical Quality Management Corp Member",
        "label": "Critical Quality Management Corp [Member]",
        "terseLabel": "Critical Quality Management Corp"
       }
      }
     },
     "localname": "CriticalQualityManagementCorpMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_DebtInstrumentApprovalThresholdOfShareholdersForUseOfFundsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Approval Threshold Of Shareholders For Use Of Funds, Percentage",
        "label": "Debt Instrument, Approval Threshold Of Shareholders For Use Of Funds, Percentage",
        "terseLabel": "Shareholder approval percentage (not less than)"
       }
      }
     },
     "localname": "DebtInstrumentApprovalThresholdOfShareholdersForUseOfFundsPercentage",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_DebtInstrumentApprovedThresholdUseOfFunds": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Approved Threshold Use Of Funds",
        "label": "Debt Instrument, Approved Threshold Use Of Funds",
        "terseLabel": "Approved use of funds (not to exceed)"
       }
      }
     },
     "localname": "DebtInstrumentApprovedThresholdUseOfFunds",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Interest Coverage Ratio, Minimum",
        "label": "Debt Instrument, Covenant, Interest Coverage Ratio, Minimum",
        "terseLabel": "Minimum consolidated interest coverage ratio (not less than)"
       }
      }
     },
     "localname": "DebtInstrumentCovenantInterestCoverageRatioMinimum",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Leverage Ratio, Incremental Change",
        "label": "Debt Instrument, Covenant, Leverage Ratio, Incremental Change",
        "terseLabel": "Consolidated leverage ratio, annual decrease"
       }
      }
     },
     "localname": "DebtInstrumentCovenantLeverageRatioIncrementalChange",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ameh_DebtInstrumentCovenantLeverageRatioMaximum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Leverage Ratio, Maximum",
        "label": "Debt Instrument, Covenant, Leverage Ratio, Maximum",
        "terseLabel": "Maximum consolidated leverage ratio (not greater than)"
       }
      }
     },
     "localname": "DebtInstrumentCovenantLeverageRatioMaximum",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ameh_DebtInstrumentCovenantLeverageRatioMinimum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Leverage Ratio, Minimum",
        "label": "Debt Instrument, Covenant, Leverage Ratio, Minimum",
        "terseLabel": "Consolidated leverage ratio minimum"
       }
      }
     },
     "localname": "DebtInstrumentCovenantLeverageRatioMinimum",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ameh_DebtInstrumentNumberOfKeyFinancialRatios": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Number Of Key Financial Ratios",
        "label": "Debt Instrument, Number Of Key Financial Ratios",
        "terseLabel": "Number of key financial ratios"
       }
      }
     },
     "localname": "DebtInstrumentNumberOfKeyFinancialRatios",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ameh_DeferredTaxLiabilityAdjustedToGoodwill": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Tax Liability Adjusted To Goodwill",
        "label": "Deferred Tax Liability Adjusted To Goodwill",
        "terseLabel": "Deferred tax liability adjustment to goodwill"
       }
      }
     },
     "localname": "DeferredTaxLiabilityAdjustedToGoodwill",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Depreciation, Depletion And Amortization, Excluding Amortization Of Debt Issuance Costs",
        "label": "Depreciation, Depletion And Amortization, Excluding Amortization Of Debt Issuance Costs",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_DescriptionOfBusinessLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Description Of Business [Line Items]",
        "terseLabel": "Description Of Business [Line Items]"
       }
      }
     },
     "localname": "DescriptionOfBusinessLineItems",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_DescriptionOfBusinessTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Description Of Business [Table]",
        "terseLabel": "Description Of Business [Table]"
       }
      }
     },
     "localname": "DescriptionOfBusinessTable",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_DiagnosticMedicalGroupMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Diagnostic Medical Group [Member]",
        "terseLabel": "Diagnostic Medical Group"
       }
      }
     },
     "localname": "DiagnosticMedicalGroupMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_DmgMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "DMG [Member]",
        "terseLabel": "DMG"
       }
      }
     },
     "localname": "DmgMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_Dr.ArteagaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Dr. Arteaga [Member]",
        "label": "Dr. Arteaga [Member]",
        "verboseLabel": "Dr. Arteaga"
       }
      }
     },
     "localname": "Dr.ArteagaMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_Dr.JayMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Dr. Jay [Member]",
        "label": "Dr. Jay [Member]",
        "terseLabel": "Dr. Jay"
       }
      }
     },
     "localname": "Dr.JayMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_DrJayLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Dr. Jay Loan [Member]",
        "terseLabel": "Dr. Jay Loan"
       }
      }
     },
     "localname": "DrJayLoanMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_DrSimAndDrLamMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Dr. Sim And Dr. Lam",
        "label": "Dr. Sim And Dr. Lam [Member]",
        "terseLabel": "Dr. Sim And Dr. Lam"
       }
      }
     },
     "localname": "DrSimAndDrLamMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_EarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Line Items] for Earnings Per Share [Table]",
        "label": "Earnings Per Share [Line Items]",
        "terseLabel": "Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "EarningsPerShareLineItems",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails",
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_EarningsPerShareTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Earnings Per Share [Table]",
        "label": "Earnings Per Share [Table]",
        "terseLabel": "Earnings Per Share [Table]"
       }
      }
     },
     "localname": "EarningsPerShareTable",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails",
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_EquityMethodAndOtherEquityInvestmentsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Method And Other Equity Investments [Text Block]",
        "label": "Equity Method And Other Equity Investments [Text Block]",
        "verboseLabel": "Investments in Other Entities \u2014 Equity Method"
       }
      }
     },
     "localname": "EquityMethodAndOtherEquityInvestmentsTextBlock",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethod"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Method Investment, Conversion Of Finance Receivable, Ownership Percentage Upon Conversion",
        "label": "Equity Method Investment, Conversion Of Finance Receivable, Ownership Percentage Upon Conversion",
        "terseLabel": "Ownership upon conversion of finance receivable"
       }
      }
     },
     "localname": "EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_EquityMethodInvestmentGainOnSaleTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Method Investment, Gain On Sale",
        "label": "Equity Method Investment, Gain On Sale [Table Text Block]",
        "terseLabel": "Equity Method Investment, Gain On Sale"
       }
      }
     },
     "localname": "EquityMethodInvestmentGainOnSaleTableTextBlock",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ameh_EquityMethodInvestmentOwnershipPercentageDisposed": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Method Investment, Ownership Percentage Disposed",
        "label": "Equity Method Investment, Ownership Percentage Disposed",
        "terseLabel": "Ownership interest disposed"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentageDisposed",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_EquityMethodInvestmentSaleContingentConsiderationCash": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Method Investment, Sale, Contingent Consideration, Cash",
        "label": "Equity Method Investment, Sale, Contingent Consideration, Cash",
        "terseLabel": "Contingent consideration, cash held in escrow"
       }
      }
     },
     "localname": "EquityMethodInvestmentSaleContingentConsiderationCash",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Method Investment, Sale, Contingent Consideration, Fair Value",
        "label": "Equity Method Investment, Sale, Contingent Consideration, Fair Value",
        "terseLabel": "Contingent consideration, fair value"
       }
      }
     },
     "localname": "EquityMethodInvestmentSaleContingentConsiderationFairValue",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Method Investment, Sale, Contingent Consideration, Preferred Shares",
        "label": "Equity Method Investment, Sale, Contingent Consideration, Preferred Shares",
        "terseLabel": "Contingent consideration, preferred shares"
       }
      }
     },
     "localname": "EquityMethodInvestmentSaleContingentConsiderationPreferredShares",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_EquityMethodInvestmentsContribution": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Method Investments, Contribution",
        "label": "Equity Method Investments, Contribution",
        "terseLabel": "Contribution"
       }
      }
     },
     "localname": "EquityMethodInvestmentsContribution",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The proportion of investment in Voting common stock.",
        "label": "Equity Method Investments, Proportion of Ownership Interest in Voting Common Stock",
        "terseLabel": "Percentage of voting common stock"
       }
      }
     },
     "localname": "EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_EquityMethodInvestmentsPurchaseOfShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares purchased from equity method investment entities.",
        "label": "Equity Method Investments, Purchase Of Shares",
        "terseLabel": "Shares purchased (in shares)"
       }
      }
     },
     "localname": "EquityMethodInvestmentsPurchaseOfShares",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_EquityMethodInvestmentsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Method Investments [Roll Forward]",
        "label": "Equity Method Investments [Roll Forward]",
        "terseLabel": "Equity Method Investments [Roll Forward]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsRollForward",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value Investments, Options Issued, Term Of Option",
        "label": "Equity Securities Without Readily Determinable Fair Value Investment, Options Issued, Term Of Option",
        "terseLabel": "Term of option"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value Investments",
        "label": "Equity Securities Without Readily Determinable Fair Value Investments",
        "terseLabel": "Related investment balance"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value Investments, Aggregate Cost",
        "label": "Equity Securities Without Readily Determinable Fair Value Investments, Aggregate Cost",
        "terseLabel": "Investment amount"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value Investments, Duration Of Investment",
        "label": "Equity Securities Without Readily Determinable Fair Value Investments, Duration Of Investment",
        "terseLabel": "Duration of investment"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value Investments, Membership Interest Acquired, Per Interest",
        "label": "Equity Securities Without Readily Determinable Fair Value Investments, Membership Interest Acquired, Per Interest",
        "terseLabel": "Membership interests acquired (in dollars per share)"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value Investments, Options Issued, Option To Purchase Additional Interests",
        "label": "Equity Securities Without Readily Determinable Fair Value Investments, Options Issued, Option To Purchase Additional Interests",
        "terseLabel": "Options to purchase additional membership interests (in shares)"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value Investments, Options Issues, Options To Purchase Additional Interests, If Circumstances Met",
        "label": "Equity Securities Without Readily Determinable Fair Value Investments, Options Issues, Options To Purchase Additional Interests, If Circumstances Met",
        "terseLabel": "Number of warrants available to purchase, contingent upon the portal completion date (in shares)"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value Investments, Proportion of Ownership Interest in Voting Common Stock, Within Five Years",
        "label": "Equity Securities Without Readily Determinable Fair Value Investments, Proportion of Ownership Interest in Voting Common Stock, Within Five Years",
        "terseLabel": "Percentage of voting common stock, within five years"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value Investments, Purchase Of Shares",
        "label": "Equity Securities Without Readily Determinable Fair Value Investments, Purchase Of Shares",
        "terseLabel": "Membership interests purchased (in shares)"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Securities without Readily Determinable Fair Value, Ownership Percentage",
        "label": "Equity Securities Without Readily Determinable Fair Value, Ownership Percentage",
        "terseLabel": "Ownership percentage"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_FiduciaryAccountsPayableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of fiduciary accounts payable, due after one year or beyond the normal operating cycle, if longer.",
        "label": "Fiduciary Accounts Payable Current",
        "terseLabel": "Fiduciary accounts payable"
       }
      }
     },
     "localname": "FiduciaryAccountsPayableCurrent",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_FinanceLeaseLiabilityToBePaidAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Finance Lease, Liability, To Be Paid, After Year Four",
        "label": "Finance Lease, Liability, To Be Paid, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityToBePaidAfterYearFour",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Finance Receivable, Modifications, Subsequent Default, Interest Rate",
        "label": "Finance Receivable, Modifications, Subsequent Default, Interest Rate",
        "terseLabel": "Interest rate in the event of default"
       }
      }
     },
     "localname": "FinanceReceivableModificationsSubsequentDefaultInterestRate",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_FinanceReceivableStatedInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Finance Receivable, Stated Interest Rate",
        "label": "Finance Receivable, Stated Interest Rate",
        "terseLabel": "Stated rate of note of loan receivable"
       }
      }
     },
     "localname": "FinanceReceivableStatedInterestRate",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_FinanceReceivableTermOfReceivable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Finance Receivable, Term Of Receivable",
        "label": "Finance Receivable, Term Of Receivable",
        "terseLabel": "Term of receivable"
       }
      }
     },
     "localname": "FinanceReceivableTermOfReceivable",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_FinancingReceivableConvertibleToCommonStockPercentageOfOutstandingSharesConvertible": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Financing Receivable, Convertible To Common Stock, Percentage Of Outstanding Shares Convertible",
        "label": "Financing Receivable, Convertible To Common Stock, Percentage Of Outstanding Shares Convertible",
        "terseLabel": "Percentage of outstanding stock convertible"
       }
      }
     },
     "localname": "FinancingReceivableConvertibleToCommonStockPercentageOfOutstandingSharesConvertible",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_FiveThreeOneW.CollegeLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Five Three One W. College LLC [Member]",
        "terseLabel": "513 W. College LLC",
        "verboseLabel": "531 W. College, LLC \u2013 related party"
       }
      }
     },
     "localname": "FiveThreeOneW.CollegeLLCMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_HSMSOMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "xxx_HSMSO Member",
        "label": "HSMSO [Member]",
        "verboseLabel": "HSMSO"
       }
      }
     },
     "localname": "HSMSOMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_HealthCareCapitationRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ameh_HealthCareCapitationRevenueMember",
        "label": "Health Care Capitation Revenue [Member]",
        "verboseLabel": "Capitation, net"
       }
      }
     },
     "localname": "HealthCareCapitationRevenueMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_HealthSourceMSOInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Health Source MSO Inc. [Member]",
        "label": "Health Source MSO Inc. [Member]",
        "terseLabel": "Health Source MSO Inc."
       }
      }
     },
     "localname": "HealthSourceMSOInc.Member",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_IncreaseDecreaseInMedicalLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of medical liabilities.",
        "label": "Increase (Decrease) In Medical Liabilities",
        "verboseLabel": "Medical liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInMedicalLiabilities",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_IncreaseDecreaseInOperatingLeaseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents increase in operating lease assets.",
        "label": "Increase (Decrease) In Operating Lease Assets",
        "verboseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseAssets",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents increase in lease liabilities.",
        "label": "Increase (Decrease) In Other Operating Lease Liabilities",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLeaseLiabilities",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the value of prepaid expenses and other current assets.",
        "label": "Increase (Decrease) In Prepaid Expenses And Other Current Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The initial fixed term of amended and restated management and administrative services agreement.",
        "label": "Initial Fixed Term Of Amended And Restated Management And Administrative Services Agreement",
        "terseLabel": "Fixed term of amended and restated management and administrative services agreement"
       }
      }
     },
     "localname": "InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Insurance Services Revenue, Capitation, And Claims Payment, Net",
        "label": "Insurance Services Revenue, Capitation, And Claims Payment, Net",
        "terseLabel": "AHMC \u2013 Risk pool, capitation, claims payment, net"
       }
      }
     },
     "localname": "InsuranceServicesRevenueCapitationAndClaimsPaymentNet",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_InvestmentDeposit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investment Deposit",
        "label": "Investment Deposit",
        "terseLabel": "Investment deposit"
       }
      }
     },
     "localname": "InvestmentDeposit",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of Investment in privately held entity that does not report net asset value per share .",
        "label": "Investment In Privately Held Entity That Does Not Report Net Asset Value",
        "terseLabel": "Preferred shares in Bright Health, Inc.",
        "verboseLabel": "Investments in privately held entities"
       }
      }
     },
     "localname": "InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodGainonSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_LasalleMedicalAssociatesIpaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "LaSalle Medical Associates IPA [Member]",
        "terseLabel": "LaSalle Medical Associates \u2013 IPA Line of Business",
        "verboseLabel": "LaSalle Medical Associates"
       }
      }
     },
     "localname": "LasalleMedicalAssociatesIpaMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Lease Right Of Use Assets Obtained In Exchange For Lease Obligations [Abstract]",
        "verboseLabel": "Right-of-use assets obtained in exchange for lease liabilities:"
       }
      }
     },
     "localname": "LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_LeaseWeightedAverageDiscountRateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Lease Weighted Average Discount Rate [Abstract]",
        "verboseLabel": "Weighted Average Discount Rate"
       }
      }
     },
     "localname": "LeaseWeightedAverageDiscountRateAbstract",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_LeaseWeightedAverageRemainingLeaseTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Lease Weighted Average Remaining Lease Term [Abstract]",
        "verboseLabel": "Weighted Average Remaining Lease Term"
       }
      }
     },
     "localname": "LeaseWeightedAverageRemainingLeaseTermAbstract",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Finance Lease, Termination Period, If Applicable",
        "label": "Lessee, Finance Lease, Termination Period, If Applicable",
        "terseLabel": "Finance lease, termination period, if applicable"
       }
      }
     },
     "localname": "LesseeFinanceLeaseTerminationPeriodIfApplicable",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
        "label": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Termination Period, If Applicable",
        "label": "Lessee, Operating Lease, Termination Period, If Applicable",
        "terseLabel": "Operating lease, termination period, if applicable"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTerminationPeriodIfApplicable",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_LineOfCreditFacilityAdditionalAdvances": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of line of credit facility additional amount advances as a loan.",
        "label": "Line of Credit Facility Additional Advances",
        "terseLabel": "Additional advances"
       }
      }
     },
     "localname": "LineOfCreditFacilityAdditionalAdvances",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_LineOfCreditFacilityExpirationPeriodPeriodOfNotification": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line Of Credit Facility, Expiration Period, Period Of Notification",
        "label": "Line Of Credit Facility, Expiration Period, Period Of Notification",
        "terseLabel": "Period of notification of termination"
       }
      }
     },
     "localname": "LineOfCreditFacilityExpirationPeriodPeriodOfNotification",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_LineOfCreditFacilityGuaranteeGivenByRelatedParties": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of guarantee given by related parties for line of credit facility.",
        "label": "Line Of Credit Facility, Guarantee Given By Related Parties",
        "terseLabel": "Term of converted loan"
       }
      }
     },
     "localname": "LineOfCreditFacilityGuaranteeGivenByRelatedParties",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_LmaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "LMA [Member]",
        "terseLabel": "LMA"
       }
      }
     },
     "localname": "LmaMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_LoanReceivableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Loan Receivable",
        "label": "Loan Receivable [Text Block]",
        "verboseLabel": "Loan Receivable and Loan Receivable \u2013 Related Parties"
       }
      }
     },
     "localname": "LoanReceivableTextBlock",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedParties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ameh_MWNCommunityHospitalLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "MWN Community Hospital LLC [Member]",
        "terseLabel": "MWN, LLC \u2013 related party"
       }
      }
     },
     "localname": "MWNCommunityHospitalLLCMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ManagementContractsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Management Contracts",
        "label": "Management Contracts [Member]",
        "verboseLabel": "Management contracts"
       }
      }
     },
     "localname": "ManagementContractsMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_MarketableSecuritiesCurrentMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Marketable Securities, Current, Maturity Period",
        "label": "Marketable Securities, Current, Maturity Period",
        "terseLabel": "Short-term marketable securities, maturity period"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrentMaturityPeriod",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_MaverickMedicalGroupIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maverick Medical Group, Inc [Member]",
        "terseLabel": "Maverick Medical Group, Inc"
       }
      }
     },
     "localname": "MaverickMedicalGroupIncMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_MediPortalLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "MediPortal LLC [Member]",
        "terseLabel": "MediPortal LLC"
       }
      }
     },
     "localname": "MediPortalLLCMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_MedicaidMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ameh:MedicaidMember",
        "label": "Medicaid [Member]",
        "terseLabel": "Medicaid"
       }
      }
     },
     "localname": "MedicaidMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_MedicalCareCostsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Medical Care Costs [Abstract]",
        "label": "Medical Care Costs [Abstract]",
        "terseLabel": "Components of medical care costs related to claims incurred:"
       }
      }
     },
     "localname": "MedicalCareCostsAbstract",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_MedicalPropertyPartnersMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Medical Property Partners [Member]",
        "terseLabel": "Medical Property Partners"
       }
      }
     },
     "localname": "MedicalPropertyPartnersMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_MedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ameh:MedicareMember",
        "label": "Medicare [Member]",
        "terseLabel": "Medicare"
       }
      }
     },
     "localname": "MedicareMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_MemberRelationshipsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Member Relationships",
        "label": "Member Relationships [Member]",
        "terseLabel": "Member relationships"
       }
      }
     },
     "localname": "MemberRelationshipsMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_MezzanineEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "MEZZANINE EQUITY [Abstract]",
        "verboseLabel": "Mezzanine equity"
       }
      }
     },
     "localname": "MezzanineEquityAbstract",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_MezzanineMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Mezzanine [Member]",
        "terseLabel": "Mezzanine"
       }
      }
     },
     "localname": "MezzanineMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_MinorityInterestPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minority Interest Policy.",
        "label": "Minority Interest Policy [Policy Text Block]",
        "terseLabel": "Noncontrolling Interests"
       }
      }
     },
     "localname": "MinorityInterestPolicyPolicyTextBlock",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ameh_NMMLineOfCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "NMM Line Of Credit Agreement [Member]",
        "label": "NMM Line Of Credit Agreement [Member]",
        "terseLabel": "NMM Line of Credit Agreement"
       }
      }
     },
     "localname": "NMMLineOfCreditAgreementMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net Income (Loss), Including Portion Attributable To Noncontrolling Interest And Temporary Equity",
        "label": "Net Income (Loss), Including Portion Attributable To Noncontrolling Interest And Temporary Equity",
        "terseLabel": "Net (loss) income"
       }
      }
     },
     "localname": "NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_NetworkMedicalManagementIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Network Medical Management, Inc. [Member]",
        "terseLabel": "Network Medical Management, Inc."
       }
      }
     },
     "localname": "NetworkMedicalManagementIncMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_NetworkMedicalManagementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Network Medical Management [Member]",
        "terseLabel": "NMM"
       }
      }
     },
     "localname": "NetworkMedicalManagementMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_NetworkRelationshipsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Network Relationships",
        "label": "Network Relationships [Member]",
        "terseLabel": "Network relationships"
       }
      }
     },
     "localname": "NetworkRelationshipsMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_NextGenerationACOModelParticipationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Next Generation ACO Model Participation Agreement [Member]",
        "label": "Next Generation ACO Model Participation Agreement [Member]",
        "terseLabel": "Next Generation ACO Model Participation Agreement"
       }
      }
     },
     "localname": "NextGenerationACOModelParticipationAgreementMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_NmmBusinessLoanAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "NMM Business Loan Agreement [Member]",
        "terseLabel": "NMM Business Loan Agreement"
       }
      }
     },
     "localname": "NmmBusinessLoanAgreementMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_NumberOfEmployees": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number Of Employees",
        "label": "Number Of Employees",
        "terseLabel": "Number of employees (more than)",
        "verboseLabel": "Number of employees (over)"
       }
      }
     },
     "localname": "NumberOfEmployees",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ameh_NumberOfEnrollees": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number Of Enrollees",
        "label": "Number Of Enrollees",
        "terseLabel": "Number of healthcare enrollees"
       }
      }
     },
     "localname": "NumberOfEnrollees",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ameh_NumberOfFamilyPracticeClinics": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of Family Practice Clinics",
        "label": "Number Of Family Practice Clinics",
        "terseLabel": "Number of family practice clinics"
       }
      }
     },
     "localname": "NumberOfFamilyPracticeClinics",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ameh_NumberOfFederallyQualifiedHealthPlans": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number Of Federally Qualified Health Plans",
        "label": "Number Of Federally Qualified Health Plans",
        "terseLabel": "Number federally qualified health plans"
       }
      }
     },
     "localname": "NumberOfFederallyQualifiedHealthPlans",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ameh_NumberOfMembersOfFederallyQualifiedHealthPlans": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number Of Members Of Federally Qualified Health Plans",
        "label": "Number Of Members Of Federally Qualified Health Plans",
        "terseLabel": "Number of members of federally qualified health plans"
       }
      }
     },
     "localname": "NumberOfMembersOfFederallyQualifiedHealthPlans",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ameh_NumberOfPatients": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number Of Patients",
        "label": "Number Of Patients",
        "terseLabel": "Number of patients"
       }
      }
     },
     "localname": "NumberOfPatients",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ameh_NumberOfWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of warrants exercised",
        "label": "Number Of Warrants Exercised",
        "negatedLabel": "Warrants exercised (in shares)"
       }
      }
     },
     "localname": "NumberOfWarrantsExercised",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquitySummaryofWarrantDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_NumberOfWarrantsGranted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number Of Warrants Granted",
        "label": "Number Of Warrants Granted",
        "verboseLabel": "Warrants granted (in shares)"
       }
      }
     },
     "localname": "NumberOfWarrantsGranted",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquitySummaryofWarrantDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_NumenLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Numen LLC [Member]",
        "terseLabel": "Numen LLC"
       }
      }
     },
     "localname": "NumenLLCMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_OneMSOInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "One MSO, Inc. [Member]",
        "label": "One MSO, Inc. [Member]",
        "terseLabel": "One MSO, Inc."
       }
      }
     },
     "localname": "OneMSOInc.Member",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_OtherReceivablesFinalSettlement2018PerformanceYearMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Receivables, Final Settlement 2018 Performance Year",
        "label": "Other Receivables, Final Settlement 2018 Performance Year [Member]",
        "terseLabel": "Other Receivables, Final Settlement 2018 Performance Year"
       }
      }
     },
     "localname": "OtherReceivablesFinalSettlement2018PerformanceYearMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_OtherReceivablesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Receivables [Member]",
        "terseLabel": "Other Receivables"
       }
      }
     },
     "localname": "OtherReceivablesMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_OtherThirdPartiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ameh:OtherThirdPartiesMember",
        "label": "Other Third Parties [Member]",
        "terseLabel": "Other third parties"
       }
      }
     },
     "localname": "OtherThirdPartiesMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_Pacific6EnterprisesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pacific6 Enterprises [Member]",
        "label": "Pacific6 Enterprises [Member]",
        "terseLabel": "Pacific6 Enterprises"
       }
      }
     },
     "localname": "Pacific6EnterprisesMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PacificMedicalImagingAndOncologyCenterIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Pacific Medical Imaging and Oncology Center, Inc [Member]",
        "terseLabel": "Pacific Medical Imaging &amp; Oncology Center, Inc."
       }
      }
     },
     "localname": "PacificMedicalImagingAndOncologyCenterIncMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PatientManagementPlatformMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Patient Management Platform",
        "label": "Patient Management Platform [Member]",
        "terseLabel": "Patient management platform"
       }
      }
     },
     "localname": "PatientManagementPlatformMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PaymentConsultingFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payment Consulting Fees",
        "label": "Payment Consulting Fees",
        "terseLabel": "Consulting services paid"
       }
      }
     },
     "localname": "PaymentConsultingFees",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_PaymentMadeToRelatedParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Credit/Duration (Amount paid to related party in relation to providing services",
        "label": "Payment Made To Related Party",
        "terseLabel": "Payments to related parties"
       }
      }
     },
     "localname": "PaymentMadeToRelatedParty",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_PaymentOfRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payment Of Revenue",
        "label": "Payment Of Revenue",
        "terseLabel": "Payments received"
       }
      }
     },
     "localname": "PaymentOfRevenue",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_PaymentOfRevenueMonthlyAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payment Of Revenue, Monthly Amount",
        "label": "Payment Of Revenue, Monthly Amount",
        "terseLabel": "Payments received, monthly"
       }
      }
     },
     "localname": "PaymentOfRevenueMonthlyAmount",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_PaymentPeriodOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payment Period One [Member]",
        "label": "Payment Period One [Member]",
        "terseLabel": "First Eight Fiscal Quarters"
       }
      }
     },
     "localname": "PaymentPeriodOneMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PaymentPeriodThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payment Period Three [Member]",
        "label": "Payment Period Three [Member]",
        "terseLabel": "Following Three Fiscal Quarters Thereafter"
       }
      }
     },
     "localname": "PaymentPeriodThreeMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PaymentPeriodTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payment Period Two [Member]",
        "label": "Payment Period Two [Member]",
        "terseLabel": "Following Eight Fiscal Quarters Thereafter"
       }
      }
     },
     "localname": "PaymentPeriodTwoMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PaymentsForMedicalCareCostsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments For Medical Care Costs [Abstract]",
        "label": "Payments For Medical Care Costs [Abstract]",
        "terseLabel": "Payments for medical care costs related to claims incurred:"
       }
      }
     },
     "localname": "PaymentsForMedicalCareCostsAbstract",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments To Acquire Equity Securities Without Readily Determinable Fair Value Investments",
        "label": "Payments To Acquire Equity Securities Without Readily Determinable Fair Value Investments",
        "terseLabel": "Payments to purchase membership interests"
       }
      }
     },
     "localname": "PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_PayorAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payor A [Member]",
        "label": "Payor A [Member]",
        "terseLabel": "Payor A"
       }
      }
     },
     "localname": "PayorAMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PayorBMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payor B [Member]",
        "label": "Payor B [Member]",
        "terseLabel": "Payor B"
       }
      }
     },
     "localname": "PayorBMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PayorCMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payor C [Member]",
        "label": "Payor C [Member]",
        "terseLabel": "Payor C"
       }
      }
     },
     "localname": "PayorCMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PayorDMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Payor D [Member]",
        "terseLabel": "Payor D"
       }
      }
     },
     "localname": "PayorDMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PayorEMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Payor E [Member]",
        "terseLabel": "Payor E"
       }
      }
     },
     "localname": "PayorEMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PayorFMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payor F [Member]",
        "label": "Payor F [Member]",
        "terseLabel": "Payor G"
       }
      }
     },
     "localname": "PayorFMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PayorGMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payor G [Member]",
        "label": "Payor G [Member]",
        "terseLabel": "Payor G"
       }
      }
     },
     "localname": "PayorGMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PayorHMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payor H",
        "label": "Payor H [Member]",
        "terseLabel": "Payor H"
       }
      }
     },
     "localname": "PayorHMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PerMemberPerMonthManagedCareContractMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per-Member-Per-Month Managed Care Contract [Member]",
        "label": "Per-Member-Per-Month Managed Care Contract [Member]",
        "terseLabel": "PMPM Managed Care Contract"
       }
      }
     },
     "localname": "PerMemberPerMonthManagedCareContractMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PercentageOfFinancialGuaranteeBenchmarkAmount": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of financial guarantee on benchmark Medicare expenditure amount.",
        "label": "Percentage Of Financial Guarantee Benchmark Amount",
        "terseLabel": "General amount of guarantee (as a percent)"
       }
      }
     },
     "localname": "PercentageOfFinancialGuaranteeBenchmarkAmount",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_PmiocMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "PMIOC [Member]",
        "terseLabel": "PMIOC"
       }
      }
     },
     "localname": "PmiocMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PreferredBankMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Preferred Bank [Member]",
        "terseLabel": "Preferred Bank"
       }
      }
     },
     "localname": "PreferredBankMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Receivables and receivables from related parties.",
        "label": "Receivables And Related parties Receivables Policy Text Block [Policy Text Block]",
        "verboseLabel": "Receivables and Receivables \u2013 Related Parties"
       }
      }
     },
     "localname": "ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract",
        "label": "Reconciliation Of Cash Cash Equivalents And Restricted Cash [Abstract]",
        "verboseLabel": "Reconciliation of cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_RepaymentsOfBankLoanAndLinesOfCredit": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Repayments Of Bank Loan And Lines Of Credit",
        "label": "Repayments Of Bank Loan And Lines Of Credit",
        "negatedTerseLabel": "Repayment of bank loan and lines of credit"
       }
      }
     },
     "localname": "RepaymentsOfBankLoanAndLinesOfCredit",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue, Remaining Performance Obligation, Expected Timing Of Satisfaction, Period Of Payment Upon Finalization Of Settlement Report",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing Of Satisfaction, Period Of Payment Upon Finalization Of Settlement Report",
        "terseLabel": "Expected period of payment upon termination of agreement"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Risk Pool Surplus Or Deficits, Settlement Period After Performance Year",
        "label": "Risk Pool Surplus Or Deficits, Settlement Period After Performance Year",
        "terseLabel": "Risk pool surplus or deficits, settlement period after risk pool performance year"
       }
      }
     },
     "localname": "RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_SCHCMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "SCHC [Member]",
        "label": "SCHC [Member]",
        "terseLabel": "SCHC"
       }
      }
     },
     "localname": "SCHCMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share based Compensation Arrangement By Share based Payment Award Cashless Options Exercises In Period",
        "label": "Share based Compensation Arrangement By Share based Payment Award Cashless Options Exercises In Period",
        "terseLabel": "Options exercised (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the forfeiture rate.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate",
        "verboseLabel": "Forfeiture rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityStockOptionActivityUnderBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value (in thousands)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Exercise Price [Abstract]",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Term (Years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share based Compensation Arrangement By Share based Payment Award Warrants Exercises In Period",
        "label": "Share based Compensation Arrangement By Share based Payment Award Warrants Exercises In Period",
        "terseLabel": "Warrants exercised (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share based Payment Award, Warrant Exercised, Exercise Price",
        "label": "Share-Based Compensation Arrangement By Share based Payment Award, Warrant Exercised, Exercise Price",
        "terseLabel": "Exercise price of warrants exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ameh_ShareholdersAndOfficersMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Shareholders And Officers [Member]",
        "terseLabel": "APC Shareholders and Officers"
       }
      }
     },
     "localname": "ShareholdersAndOfficersMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_SharesWarrantsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shares, Warrants [Roll Forward]",
        "label": "Shares, Warrants [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "SharesWarrantsRollForward",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquitySummaryofWarrantDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_SpecialtyCapitationPayableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the amount of specialty capitation payable current.",
        "label": "Specialty Capitation Payable Current",
        "verboseLabel": "Capitation payable"
       }
      }
     },
     "localname": "SpecialtyCapitationPayableCurrent",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_StockIssuedDuringPeriodProxyVotesPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issued During Period, Proxy Votes, Percentage",
        "label": "Stock Issued During Period, Proxy Votes, Percentage",
        "terseLabel": "Proxy votes"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodProxyVotesPercentage",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_StockIssuedDuringPeriodSharesMerger": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to merger.",
        "label": "Stock Issued During Period, Shares, Merger",
        "terseLabel": "Holdback shares not issued to former shareholders (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesMerger",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_StockIssuedDuringPeriodValueRestrictedStockAwardCancelled": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Restricted Stock Award, Cancelled",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Cancelled",
        "negatedTerseLabel": "Cancellation of restricted stock awards"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardCancelled",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "It represents number of share issued exercise of option and warrants during the period",
        "label": "Stock issued during the period shares of exercise of option and warrants",
        "verboseLabel": "Shares issued for exercise of options and warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "It represents value of stock issued during the period",
        "label": "Stock issued during the period value of exercise of option and warrants",
        "verboseLabel": "Shares issued for exercise of options and warrants"
       }
      }
     },
     "localname": "StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_SubcontractorIPAPayable": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Subcontractor IPA Payable",
        "label": "Subcontractor IPA Payable",
        "verboseLabel": "Subcontractor IPA payable"
       }
      }
     },
     "localname": "SubcontractorIPAPayable",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summary Of Significant Accounting Policies [Line Items]",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summary Of Significant Accounting Policies [Table]",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_TemporaryEquityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Temporary Equity [Policy Text Block]",
        "label": "Temporary Equity [Policy Text Block]",
        "terseLabel": "Mezzanine Equity"
       }
      }
     },
     "localname": "TemporaryEquityPolicyTextBlock",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ameh_TermLoanAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term Loan A [Member]",
        "label": "Term Loan A [Member]",
        "terseLabel": "Term loan A"
       }
      }
     },
     "localname": "TermLoanAMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_UniversalCareAcquisitionPartnersLlcMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Universal Care Acquisition Partners, LLC [Member]",
        "terseLabel": "Universal Care Acquisition Partners, LLC"
       }
      }
     },
     "localname": "UniversalCareAcquisitionPartnersLlcMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_UniversalCareIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Universal Care Inc [Member]",
        "terseLabel": "Universal Care, Inc."
       }
      }
     },
     "localname": "UniversalCareIncMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodGainonSaleDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_VotingCommonStockTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Voting Common Stock A Two [Member]",
        "terseLabel": "Voting Common Stock A Two"
       }
      }
     },
     "localname": "VotingCommonStockTwoMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_WarrantExercisePriceRangeFourMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Warrant Exercise Price Range Four [Member]",
        "terseLabel": "Warrant Exercise Price Range Four"
       }
      }
     },
     "localname": "WarrantExercisePriceRangeFourMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_WarrantExercisePriceRangeOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Warrant Exercise Price Range One [Member]",
        "verboseLabel": "Warrant Exercise Price Range One"
       }
      }
     },
     "localname": "WarrantExercisePriceRangeOneMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_WarrantExercisePriceRangeThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Warrant Exercise Price Range Three [Member]",
        "verboseLabel": "Warrant Exercise Price Range Three"
       }
      }
     },
     "localname": "WarrantExercisePriceRangeThreeMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_WarrantExercisePriceRangeTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Warrant Exercise Price Range Two [Member]",
        "verboseLabel": "Warrant Exercise Price Range Two"
       }
      }
     },
     "localname": "WarrantExercisePriceRangeTwoMember",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Warrant Issued During Period Value Stock Options Exercised",
        "label": "Warrant Issued During Period Value Stock Options Exercised",
        "terseLabel": "Proceeds from warrants exercised"
       }
      }
     },
     "localname": "WarrantIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_WeightedAverageExercisePriceWarrantsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted Average Exercise Price, Warrants [Roll Forward]",
        "label": "Weighted Average Exercise Price, Warrants [Roll Forward]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceWarrantsRollForward",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquitySummaryofWarrantDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_WeightedaverageremainingcontractualtermyearsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted Average Remaining Contractual Term Years [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Term (Years)"
       }
      }
     },
     "localname": "WeightedaverageremainingcontractualtermyearsAbstract",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquitySummaryofWarrantDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_WorkingCapitalContribution": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents the working capital contribution in equity method investee.",
        "label": "Working Capital Contribution",
        "terseLabel": "Working capital contribution"
       }
      }
     },
     "localname": "WorkingCapitalContribution",
     "nsuri": "http://www.apollomed.net/20200630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r557"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r558"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED",
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r560"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED",
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r556"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_AffiliatedEntityMember": {
     "auth_ref": [
      "r308",
      "r455",
      "r456",
      "r459",
      "r555"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Affiliated Entity [Member]",
        "terseLabel": "Affiliated Entity"
       }
      }
     },
     "localname": "AffiliatedEntityMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r388",
      "r389",
      "r394",
      "r395",
      "r555"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r388",
      "r389",
      "r394",
      "r395"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r66",
      "r121"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodGainonSaleDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Board Members"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityStockOptionActivityUnderBlackScholesOptionPricingModelDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodGainonSaleDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r202",
      "r289",
      "r294",
      "r540"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r311",
      "r313",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r538",
      "r541"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails",
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r311",
      "r313",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r538",
      "r541"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails",
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r202",
      "r289",
      "r294",
      "r540"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r200",
      "r289",
      "r292",
      "r472",
      "r537",
      "r539"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r200",
      "r289",
      "r292",
      "r472",
      "r537",
      "r539"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r300",
      "r311",
      "r313",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r538",
      "r541"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails",
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r300",
      "r311",
      "r313",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r538",
      "r541"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails",
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodGainonSaleDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodGainonSaleDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r203",
      "r458"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityStockOptionActivityUnderBlackScholesOptionPricingModelDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityStockOptionActivityUnderBlackScholesOptionPricingModelDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsAndOtherReceivablesNetCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.",
        "label": "Accounts and Other Receivables, Net, Current",
        "terseLabel": "Amount of subordinated note receivable agreement"
       }
      }
     },
     "localname": "AccountsAndOtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]"
       }
      }
     },
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of receivable.",
        "label": "Receivable Type [Axis]",
        "terseLabel": "Receivable Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued expenses",
        "totalLabel": "Total accounts payable and accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accounts Payable and Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "verboseLabel": "Receivables and Receivables-Related Parties"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r3",
      "r33",
      "r204",
      "r205"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Receivables, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableRelatedPartiesCurrent": {
     "auth_ref": [
      "r60",
      "r125",
      "r456",
      "r459"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.",
        "label": "Accounts Receivable, Related Parties, Current",
        "terseLabel": "Receivables, net \u2013 related parties",
        "verboseLabel": "Receivables, net \u2013 related party"
       }
      }
     },
     "localname": "AccountsReceivableRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r25",
      "r492",
      "r518"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "verboseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r51"
     ],
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "verboseLabel": "Professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r34",
      "r346"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r129",
      "r130",
      "r131",
      "r343",
      "r344",
      "r345"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "verboseLabel": "Additional Paid-in\u00a0Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by (used in) operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r39",
      "r206",
      "r217"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "terseLabel": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r75",
      "r104",
      "r430"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r104",
      "r230",
      "r237"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r117",
      "r182",
      "r192",
      "r198",
      "r214",
      "r388",
      "r394",
      "r419",
      "r490",
      "r516"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets",
        "verboseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r64",
      "r117",
      "r214",
      "r388",
      "r394",
      "r419"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r408"
     ],
     "calculation": {
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r15",
      "r16",
      "r17",
      "r18",
      "r19",
      "r20",
      "r21",
      "r22",
      "r117",
      "r214",
      "r388",
      "r394",
      "r419"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "Total noncurrent assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "Noncurrent assets",
        "verboseLabel": "Noncurrent assets"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r208",
      "r210",
      "r220",
      "r497"
     ],
     "calculation": {
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Marketable securities \u2013 certificates of deposit"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r316",
      "r342"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r406",
      "r407"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "verboseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r310",
      "r312"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r310",
      "r312",
      "r369",
      "r370"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned": {
     "auth_ref": [
      "r379"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Value Assigned",
        "terseLabel": "Equity investment contributed"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Interest acquired"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r375",
      "r376",
      "r377"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "auth_ref": [
      "r375",
      "r376"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "terseLabel": "Value of shares transferred in acquisition"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Business Combinations and Goodwill"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]",
        "terseLabel": "Assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r372"
     ],
     "calculation": {
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": {
     "auth_ref": [
      "r372"
     ],
     "calculation": {
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "auth_ref": [
      "r372"
     ],
     "calculation": {
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "auth_ref": [
      "r372"
     ],
     "calculation": {
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "negatedLabel": "Accounts payable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r372"
     ],
     "calculation": {
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "negatedLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities": {
     "auth_ref": [
      "r371",
      "r372"
     ],
     "calculation": {
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of financial liabilities assumed (as defined) which have been recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Financial Liabilities",
        "negatedTerseLabel": "Subordinated loan",
        "terseLabel": "Standby letters of credit assumed"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r372"
     ],
     "calculation": {
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Network relationship intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "auth_ref": [
      "r372"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "terseLabel": "Liabilities assumed"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r372"
     ],
     "calculation": {
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "totalLabel": "Net assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r1",
      "r128",
      "r173"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "verboseLabel": "Basis of Presentation and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r42",
      "r106"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and cash equivalents",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r14",
      "r107",
      "r113"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r14",
      "r107",
      "r113",
      "r487"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r98",
      "r106",
      "r112"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period",
        "totalLabel": "Total cash, cash equivalents, and restricted cash shown in the statement of cash flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r98",
      "r420"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "verboseLabel": "Supplemental disclosures of non-cash investing and financing activities"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashUninsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.",
        "label": "Cash, Uninsured Amount",
        "terseLabel": "Amount deposit accounts exceeded FDIC insured limit"
       }
      }
     },
     "localname": "CashUninsuredAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of Deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r115",
      "r117",
      "r144",
      "r145",
      "r146",
      "r148",
      "r150",
      "r159",
      "r160",
      "r161",
      "r214",
      "r419"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodGainonSaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise\u00a0Price\u00a0Per Share (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "verboseLabel": "Number of warrants received (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "periodEndLabel": "Warrants outstanding, ending balance (in shares)",
        "periodStartLabel": "Warrants outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquitySummaryofWarrantDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r274",
      "r314"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r55",
      "r250",
      "r501",
      "r525"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "verboseLabel": "Commitments and contingencies (Note 11)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r247",
      "r248",
      "r249",
      "r253"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r129",
      "r130"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "10% shares held back pursuant to indemnification clause",
        "verboseLabel": "Common\u00a0Stock\u00a0Outstanding"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED",
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common Stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r31",
      "r264"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "verboseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value per share; 100,000,000 shares authorized, 36,309,513 and 35,908,057 shares outstanding, excluding 17,475,707 and 17,458,810 treasury shares, at June\u00a030, 2020, and December\u00a031, 2019, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r168",
      "r169",
      "r202",
      "r417",
      "r418"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r168",
      "r169",
      "r202",
      "r417",
      "r418",
      "r548"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r165",
      "r512"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Risks"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r168",
      "r169",
      "r202",
      "r417",
      "r418"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r113",
      "r390"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy": {
     "auth_ref": [
      "r113",
      "r390"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions and any noncontrolling interest.",
        "label": "Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]",
        "verboseLabel": "Investments in Other Entities - Equity Method and Investments in Privately Held Entities"
       }
      }
     },
     "localname": "ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r276",
      "r277",
      "r290"
     ],
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "verboseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r291"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Accrued contract liability recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r80",
      "r472"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of services"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "terseLabel": "Expenses",
        "totalLabel": "Total expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDefaultLongtermDebtAmount": {
     "auth_ref": [
      "r122"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of outstanding long-term debt or borrowing associated with any securities or credit agreement for which there has been a default in principal, interest, sinking fund, or redemption provisions, or any breach of covenant that existed at the end of the period and subsequently has not been cured.",
        "label": "Debt Instrument, Debt Default, Amount",
        "terseLabel": "Default amount of debt instrument"
       }
      }
     },
     "localname": "DebtDefaultLongtermDebtAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Credit Facility, Bank Loan and Lines of Credit"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCredit"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r24",
      "r25",
      "r26",
      "r491",
      "r494",
      "r514"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "auth_ref": [
      "r53",
      "r429"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The average effective interest rate during the reporting period.",
        "label": "Debt Instrument, Interest Rate During Period",
        "terseLabel": "Average effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate on loan receivable"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r54",
      "r123",
      "r265",
      "r268",
      "r269",
      "r270",
      "r428",
      "r429",
      "r431",
      "r511"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Revolving credit facility term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r258",
      "r430"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedTerseLabel": "Less: Unamortized financing costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet": {
     "auth_ref": [
      "r432"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Line of Credit Arrangements, Net",
        "terseLabel": "Deferred financing costs"
       }
      }
     },
     "localname": "DebtIssuanceCostsLineOfCreditArrangementsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCreditsAndOtherLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income in future periods and obligations not separately disclosed in the balance sheet (other liabilities).",
        "label": "Deferred Credits and Other Liabilities",
        "terseLabel": "Amount outstanding under agreement"
       }
      }
     },
     "localname": "DeferredCreditsAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r350",
      "r351"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liability",
        "verboseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.",
        "label": "Deferred Income Taxes and Tax Credits",
        "verboseLabel": "Deferred tax"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r104",
      "r179"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r289",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "verboseLabel": "Schedule of Disaggregated Revenue by Each Payor Type"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Dividends": {
     "auth_ref": [
      "r271",
      "r508"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.",
        "label": "Dividends",
        "terseLabel": "Dividends declared"
       }
      }
     },
     "localname": "Dividends",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsPayableCurrent": {
     "auth_ref": [
      "r10",
      "r51"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Dividends Payable, Current",
        "terseLabel": "Dividend payable"
       }
      }
     },
     "localname": "DividendsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r25",
      "r28",
      "r493",
      "r517"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.",
        "label": "Dividends Payable",
        "terseLabel": "Dividend declared included in dividend payable"
       }
      }
     },
     "localname": "DividendsPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToAffiliateCurrent": {
     "auth_ref": [
      "r23",
      "r119",
      "r456",
      "r550"
     ],
     "calculation": {
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of payable due to an entity that is affiliated with the reporting entity by means of direct or indirect ownership. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Affiliate, Current",
        "terseLabel": "Amount due to affiliate"
       }
      }
     },
     "localname": "DueToAffiliateCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r45",
      "r125",
      "r456"
     ],
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Related Parties, Current",
        "verboseLabel": "Due to related parties"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r73",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r142",
      "r144",
      "r148",
      "r149",
      "r150",
      "r155",
      "r156",
      "r504",
      "r529"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Earnings per share \u2013 basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
      "http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r73",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r144",
      "r148",
      "r149",
      "r150",
      "r155",
      "r156",
      "r504",
      "r529"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Earnings per share \u2013 diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
      "http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r113",
      "r151",
      "r153"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "verboseLabel": "Basic and Diluted Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r151",
      "r153",
      "r154",
      "r157"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "verboseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r341"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "verboseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r129",
      "r130",
      "r131",
      "r133",
      "r139",
      "r141",
      "r158",
      "r216",
      "r264",
      "r271",
      "r343",
      "r344",
      "r345",
      "r359",
      "r360",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r542",
      "r543",
      "r544"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED",
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentAggregateCost": {
     "auth_ref": [
      "r43"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents the aggregate cost of investments accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Aggregate Cost",
        "terseLabel": "Amount invested for interest"
       }
      }
     },
     "localname": "EquityMethodInvestmentAggregateCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis": {
     "auth_ref": [
      "r0",
      "r117",
      "r214",
      "r419"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by nonconsolidated equity method investee. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment, Nonconsolidated Investee [Axis]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Axis]"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain": {
     "auth_ref": [
      "r0",
      "r117",
      "r214",
      "r419"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nonconsolidated equity method investee. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment, Nonconsolidated Investee [Domain]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Ownership interest",
        "verboseLabel": "Investment, ownership interest"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal": {
     "auth_ref": [
      "r76",
      "r77",
      "r104"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of an equity method investment.",
        "label": "Equity Method Investment, Realized Gain (Loss) on Disposal",
        "negatedTerseLabel": "Gain on sale of equity method investments",
        "terseLabel": "Gain on sale of equity method investment"
       }
      }
     },
     "localname": "EquityMethodInvestmentRealizedGainLossOnDisposal",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodGainonSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentSoldCarryingAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the entity's equity method investment which has been sold.",
        "label": "Equity Method Investment, Amount Sold",
        "negatedTerseLabel": "Sale"
       }
      }
     },
     "localname": "EquityMethodInvestmentSoldCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r43",
      "r183",
      "r211"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "negatedLabel": "Less: Carrying value of equity method investment on date of sale",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "terseLabel": "Investments in other entities \u2013 equity method",
        "verboseLabel": "Investment in other entities \u2013 equity method"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodGainonSaleDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity Method Investments and Joint Ventures [Abstract]",
        "terseLabel": "Equity Method Investments and Joint Ventures [Abstract]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentsTextBlock": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.",
        "label": "Equity Method Investments [Table Text Block]",
        "verboseLabel": "Equity Method Investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r415"
     ],
     "calculation": {
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI",
        "terseLabel": "Marketable securities \u2013 equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue": {
     "auth_ref": [
      "r415"
     ],
     "calculation": {
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI) and investment in equity security without readily determinable fair value.",
        "label": "Equity Securities, FV-NI and without Readily Determinable Fair Value",
        "verboseLabel": "Investment in privately held entities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EscrowDeposit": {
     "auth_ref": [
      "r499"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.",
        "label": "Escrow Deposit",
        "terseLabel": "Escrow deposit for potential post-closing adjustments"
       }
      }
     },
     "localname": "EscrowDeposit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r408",
      "r409",
      "r410",
      "r413"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r408",
      "r409",
      "r410",
      "r412",
      "r413"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "verboseLabel": "Schedule of Carrying Amounts and Fair Values of Financial Instruments"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r309",
      "r409",
      "r462",
      "r463",
      "r464"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r301",
      "r302",
      "r307",
      "r309",
      "r409",
      "r462"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r301",
      "r302",
      "r307",
      "r309",
      "r409",
      "r463"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r309",
      "r409",
      "r464"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r309",
      "r462",
      "r463",
      "r464"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r113",
      "r414",
      "r416"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r435",
      "r442",
      "r451"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense",
        "verboseLabel": "Interest on lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "auth_ref": [
      "r437",
      "r445"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of interest paid on finance lease liability.",
        "label": "Finance Lease, Interest Payment on Liability",
        "verboseLabel": "Operating cash flows from finance leases"
       }
      }
     },
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Finance Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Finance Leases"
       }
      }
     },
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r434",
      "r450"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "totalLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r434"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "netLabel": "Less: current portion",
        "terseLabel": "Finance lease liabilities",
        "verboseLabel": "Finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.",
        "label": "Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Finance Lease Payments After Adoption of 842"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r434"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Long-term lease liabilities",
        "verboseLabel": "Finance lease liabilities, net of current portion"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r450"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Payment, Due",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r450"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r450"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r450"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r450"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r450"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.",
        "label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2020 (excluding the six months ended June 30, 2020)"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r450"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r436",
      "r445"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedTerseLabel": "Payment of finance lease obligations",
        "verboseLabel": "Financing cash flows from finance leases"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED",
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r433"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "Assets recorded under finance leases"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r435",
      "r442",
      "r451"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Accumulated depreciation associated with finance leases",
        "verboseLabel": "Amortization of lease expense"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails",
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r448",
      "r451"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "verboseLabel": "Finance leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r447",
      "r451"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "verboseLabel": "Finance leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FinanceReceivablesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amounts due the Company from customers, clients, lessees, borrowers, or others under the terms of its agreements therewith. Such amount may include accrued interest receivable in accordance with the terms of the agreements. The agreements also may contain provisions and related items including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.",
        "label": "Financing Receivable [Member]",
        "terseLabel": "Financing Receivable"
       }
      }
     },
     "localname": "FinanceReceivablesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis": {
     "auth_ref": [
      "r381",
      "r549"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by financial support arrangement provided to a nonconsolidated legal entity that is required to comply with or operate in accordance with requirements that are similar to those included in Rule 2a-7 of the Investment Company Act of 1940 for registered money market funds.",
        "label": "Financial Support to Nonconsolidated Legal Entity [Axis]",
        "terseLabel": "Financial Support to Nonconsolidated Legal Entity [Axis]"
       }
      }
     },
     "localname": "FinancialSupportToNonconsolidatedLegalEntityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain": {
     "auth_ref": [
      "r381",
      "r549"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Financial support arrangement provided to a nonconsolidated legal entity that is required to comply with or operate in accordance with requirements that are similar to those included in Rule 2a-7 of the Investment Company Act of 1940 for registered money market funds.",
        "label": "Financial Support to Nonconsolidated Legal Entity [Domain]",
        "terseLabel": "Financial Support to Nonconsolidated Legal Entity [Domain]"
       }
      }
     },
     "localname": "FinancialSupportToNonconsolidatedLegalEntityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Useful Life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r236"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      },
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r238"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "2020 (excluding the six months ended June 30, 2020)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r238"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r238"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r238"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "verboseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r231",
      "r232",
      "r236",
      "r239",
      "r473",
      "r474"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r236",
      "r474"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Amortized intangible assets, Gross"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r231",
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r236",
      "r473"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails",
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "verboseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r221",
      "r223",
      "r488"
     ],
     "calculation": {
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Balance, June 30, 2020",
        "periodStartLabel": "Balance, January 1, 2020",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillSummaryofGoodwillDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r113",
      "r226",
      "r233"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "verboseLabel": "Goodwill and Indefinite-Lived Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r104",
      "r222",
      "r224",
      "r227"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Impairment of goodwill"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillOtherIncreaseDecrease": {
     "auth_ref": [
      "r225"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Other Increase (Decrease)",
        "terseLabel": "Adjustments"
       }
      }
     },
     "localname": "GoodwillOtherIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillSummaryofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillSummaryofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HealthCareCostsPolicyPolicyTextBlock": {
     "auth_ref": [
      "r553"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for  accruing health care costs for a prepaid health care service provider.",
        "label": "Health Care Costs, Policy [Policy Text Block]",
        "verboseLabel": "Medical Liabilities"
       }
      }
     },
     "localname": "HealthCareCostsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_HealthCareOtherMember": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Service provided for maintenance, diagnosis and treatment of physical and mental health, classified as other.",
        "label": "Health Care, Other [Member]",
        "terseLabel": "Risk pool settlements and incentives"
       }
      }
     },
     "localname": "HealthCareOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HealthCarePatientServiceMember": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Service provided to patient for maintenance, diagnosis and treatment of physical and mental health. Excludes service to resident in health care facility.",
        "label": "Health Care, Patient Service [Member]",
        "terseLabel": "Fee-for-service, net"
       }
      }
     },
     "localname": "HealthCarePatientServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r104",
      "r240"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Impairment of Intangible Assets, Finite-lived",
        "terseLabel": "Impairment of finite-lived intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "auth_ref": [
      "r104",
      "r240"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.",
        "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)",
        "terseLabel": "Impairment of indefinite-lived intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r104",
      "r243",
      "r245"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment of Long-Lived Assets Held-for-use",
        "terseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r113",
      "r242",
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "verboseLabel": "Intangible Assets and Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r124",
      "r182",
      "r191",
      "r194",
      "r197",
      "r199"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "terseLabel": "Income before benefit from income taxes",
        "totalLabel": "Income before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r71",
      "r104",
      "r180",
      "r211",
      "r502",
      "r527"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedLabel": "(Income) loss from equity method investments",
        "terseLabel": "Income (loss) from equity method investments",
        "verboseLabel": "Allocation of Income (Loss)"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]",
        "verboseLabel": "Statements of Operations"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r353",
      "r354",
      "r357",
      "r361",
      "r363",
      "r365",
      "r366",
      "r367"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r118",
      "r140",
      "r141",
      "r181",
      "r352",
      "r362",
      "r364",
      "r530"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for income taxes",
        "verboseLabel": "Benefit from income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r69",
      "r113",
      "r348",
      "r349",
      "r354",
      "r355",
      "r356",
      "r358",
      "r554"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r100",
      "r108"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Receivables, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "verboseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDueFromRelatedParties": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity.",
        "label": "Increase (Decrease) in Due from Related Parties",
        "negatedLabel": "Receivables, net \u2013 related parties"
       }
      }
     },
     "localname": "IncreaseDecreaseInDueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities, net of business combinations:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayable": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Increase (Decrease) in Other Accounts Payable",
        "verboseLabel": "Fiduciary accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedTerseLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in receivables classified as other.",
        "label": "Increase (Decrease) in Other Receivables",
        "negatedLabel": "Other receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangible Assets, Net"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "totalLabel": "Intangible Assets, Gross"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r229",
      "r234"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Intangible Assets, Net",
        "verboseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r70",
      "r178",
      "r427",
      "r430",
      "r505"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r95",
      "r99",
      "r108"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r82",
      "r177"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r449",
      "r451"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total finance lease cost, net"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r449"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Information Related to Lease Costs"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeFinanceLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Remaining lease term of finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Finance Lease, Remaining Lease Term",
        "terseLabel": "Remaining lease term, finance"
       }
      }
     },
     "localname": "LesseeFinanceLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeFinanceLeaseRenewalTerm1": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's finance lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Finance Lease, Renewal Term",
        "terseLabel": "Finance lease option to extend (up to)"
       }
      }
     },
     "localname": "LesseeFinanceLeaseRenewalTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "auth_ref": [
      "r452"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.",
        "label": "Lessee, Finance Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeFinanceLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Operating Lease Payments After Adoption of 842"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r450"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r450"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r450"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r450"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r450"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r450"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2020 (excluding the six months ended June 30, 2020)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r450"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Remaining lease term, operating"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Operating lease option to extend (up to)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r452"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Amount outstanding"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r49",
      "r117",
      "r193",
      "r214",
      "r389",
      "r394",
      "r395",
      "r419"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r38",
      "r117",
      "r214",
      "r419",
      "r496",
      "r522"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "terseLabel": "Total liabilities and stockholders\u2019 deficit",
        "totalLabel": "Total liabilities, mezzanine equity and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 (Deficit) Equity",
        "verboseLabel": "Liabilities, mezzanine equity and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r52",
      "r117",
      "r214",
      "r389",
      "r394",
      "r395",
      "r419"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "terseLabel": "Current liabilities",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r11",
      "r12",
      "r13",
      "r26",
      "r27",
      "r117",
      "r214",
      "r389",
      "r394",
      "r395",
      "r419"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total noncurrent liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Noncurrent liabilities",
        "verboseLabel": "Noncurrent liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r532",
      "r535"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.",
        "label": "Liability for Claims and Claims Adjustment Expense",
        "periodEndLabel": "Medical liabilities, end of period",
        "periodStartLabel": "Medical liabilities, beginning of period",
        "terseLabel": "Medical liabilities"
       }
      }
     },
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock": {
     "auth_ref": [
      "r547"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for liabilities related to future policy benefits and unpaid claims and claim adjustments.",
        "label": "Liability for Future Policy Benefits and Unpaid Claims Disclosure [Text Block]",
        "terseLabel": "Medical Liabilities"
       }
      }
     },
     "localname": "LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in the cost of settling unpaid claims after deduction of reinsurance recoveries related to the acquisition of a business. Includes, but is not limited to, claims which have been incurred but not reported.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Business Acquisitions",
        "terseLabel": "Acquired from Alpha Care"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1": {
     "auth_ref": [
      "r534"
     ],
     "calculation": {
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year",
        "negatedLabel": "Current period"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1": {
     "auth_ref": [
      "r534"
     ],
     "calculation": {
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years",
        "negatedLabel": "Prior periods"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1": {
     "auth_ref": [
      "r533"
     ],
     "calculation": {
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims",
        "totalLabel": "Total medical care costs"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]",
        "terseLabel": "Medical Liabilities [Roll Forward]"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of increase (decrease) in the liability for unpaid claims and claims adjustment expense.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Period Increase (Decrease)",
        "terseLabel": "Adjustments"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r26",
      "r494",
      "r514"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-term Line of Credit",
        "terseLabel": "Total debt",
        "totalLabel": "Total",
        "verboseLabel": "Amount outstanding"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r47",
      "r123"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]",
        "terseLabel": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.",
        "label": "Line of Credit Facility, Commitment Fee Percentage",
        "terseLabel": "Required annual facility fee"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Line of Credit Facility, Expiration Period",
        "terseLabel": "Term of facility"
       }
      }
     },
     "localname": "LineOfCreditFacilityExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The effective interest rate at the end of the reporting period.",
        "label": "Line of Credit Facility, Interest Rate at Period End",
        "terseLabel": "interest rate at end of period"
       }
      }
     },
     "localname": "LineOfCreditFacilityInterestRateAtPeriodEnd",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]",
        "terseLabel": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]",
        "terseLabel": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r47"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum loan availability"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal": {
     "auth_ref": [
      "r47"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the required periodic payment applied to principal.",
        "label": "Line of Credit Facility, Periodic Payment, Principal",
        "terseLabel": "Principal payment on credit agreement"
       }
      }
     },
     "localname": "LineOfCreditFacilityPeriodicPaymentPrincipal",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "auth_ref": [
      "r47"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "terseLabel": "Amount available"
       }
      }
     },
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r47",
      "r123"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]",
        "terseLabel": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LinesOfCreditCurrent": {
     "auth_ref": [
      "r24",
      "r491"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Line of Credit, Current",
        "negatedTerseLabel": "Less: Current portion of debt"
       }
      }
     },
     "localname": "LinesOfCreditCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "London Interbank Offered Rate (LIBOR)"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r26",
      "r259",
      "r494",
      "r519"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Total",
        "verboseLabel": "Loan proceeds"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 8.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "terseLabel": "Current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r127",
      "r256"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LineOfCredit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r127",
      "r256"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LineOfCredit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r127",
      "r256"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LineOfCredit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r127",
      "r256"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LineOfCredit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LineOfCredit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.",
        "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year",
        "terseLabel": "2020 (excluding the six months ended June 30, 2020)"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt, net of current portion and deferred financing costs"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r54",
      "r257"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "auth_ref": [
      "r250",
      "r251",
      "r252"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.",
        "label": "Loss Contingency, Damages Sought, Value",
        "terseLabel": "Damages sought"
       }
      }
     },
     "localname": "LossContingencyDamagesSoughtValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ManagementFeeExpense": {
     "auth_ref": [
      "r457"
     ],
     "calculation": {
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses related to the managing member or general partner for management of the day-to-day business functions of the limited liability company (LLC) or limited partnership (LP).",
        "label": "Management Fee Expense",
        "negatedLabel": "Management fees"
       }
      }
     },
     "localname": "ManagementFeeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ManagementServiceMember": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractually stipulated right to receive compensation for operating and managing business.",
        "label": "Management Service [Member]",
        "terseLabel": "Management fee income",
        "verboseLabel": "Management Fee Income Contract"
       }
      }
     },
     "localname": "ManagementServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r5",
      "r50"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Amount of short-term marketable securities",
        "verboseLabel": "Investment in marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "verboseLabel": "Investments in Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MembersCapital": {
     "auth_ref": [
      "r271"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of member capital in limited liability company (LLC).",
        "label": "Members' Capital",
        "terseLabel": "Initial capital contributions"
       }
      }
     },
     "localname": "MembersCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r62",
      "r117",
      "r214",
      "r419",
      "r495",
      "r521"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": {
     "auth_ref": [
      "r271"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders",
        "negatedTerseLabel": "Dividends"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromRedemptions": {
     "auth_ref": [
      "r271",
      "r386",
      "r387"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).",
        "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests",
        "negatedTerseLabel": "Purchase of noncontrolling interest"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromRedemptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent",
        "terseLabel": "Ownership interest"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r162",
      "r173"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Description of Business"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r98",
      "r102",
      "r105"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r67",
      "r68",
      "r72",
      "r105",
      "r117",
      "r132",
      "r134",
      "r135",
      "r136",
      "r137",
      "r140",
      "r141",
      "r147",
      "r182",
      "r191",
      "r194",
      "r197",
      "r199",
      "r214",
      "r419",
      "r503",
      "r528"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net income attributable to Apollo Medical Holdings, Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r67",
      "r68",
      "r140",
      "r141",
      "r392",
      "r403"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "verboseLabel": "Net income attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "verboseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1": {
     "auth_ref": [
      "r109",
      "r110",
      "r111"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash consideration received for selling an asset or business through a noncash (or part noncash) transaction.",
        "label": "Noncash or Part Noncash Divestiture, Amount of Consideration Received",
        "terseLabel": "Value of non-cash consideration received",
        "verboseLabel": "Preferred shares received from sale of equity method investment"
       }
      }
     },
     "localname": "NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r129",
      "r130",
      "r131",
      "r271",
      "r383"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "verboseLabel": "Noncontrolling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesAndLoansReceivableNetCurrent": {
     "auth_ref": [
      "r3",
      "r4",
      "r32",
      "r204",
      "r205",
      "r498"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 8.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of financing receivable, classified as current. Includes, but is not limited to, notes and loan receivable.",
        "label": "Financing Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Loans receivable",
        "verboseLabel": "Loan receivable"
       }
      }
     },
     "localname": "NotesAndLoansReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An amount representing an agreement for an unconditional promise by the maker to pay the Entity (holder) a definite sum of money at a future date(s) within one year of the balance sheet date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.",
        "label": "Notes Receivable [Member]",
        "terseLabel": "Convertible Secured Promissory Note"
       }
      }
     },
     "localname": "NotesReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NotesReceivableNet": {
     "auth_ref": [
      "r33",
      "r204",
      "r219"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement.",
        "label": "Financing Receivable, after Allowance for Credit Loss",
        "terseLabel": "Amount of loan"
       }
      }
     },
     "localname": "NotesReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesReceivableRelatedPartiesCurrent": {
     "auth_ref": [
      "r60",
      "r125",
      "r456"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 9.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amounts due from parties associated with the reporting entity as evidenced by a written promise to pay, due within 1 year (or 1 business cycle).",
        "label": "Notes Receivable, Related Parties, Current",
        "terseLabel": "Loans receivable \u2013 related parties"
       }
      }
     },
     "localname": "NotesReceivableRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportingUnits": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.",
        "label": "Number of Reporting Units",
        "terseLabel": "Number of main reporting units"
       }
      }
     },
     "localname": "NumberOfReportingUnits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfStores": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the number of stores.",
        "label": "Number of Stores",
        "terseLabel": "Number of medical centers"
       }
      }
     },
     "localname": "NumberOfStores",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r182",
      "r191",
      "r194",
      "r197",
      "r199"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r443",
      "r451"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "verboseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r434"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Lease liabilities",
        "totalLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r434"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Less: current portion",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r434"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term lease liabilities",
        "verboseLabel": "Operating lease liabilities, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r438",
      "r445"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "verboseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets",
        "verboseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r448",
      "r451"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "verboseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r447",
      "r451"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "verboseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssets": {
     "auth_ref": [
      "r22",
      "r489",
      "r515"
     ],
     "calculation": {
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of assets classified as other.",
        "label": "Other Assets",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 8.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilities": {
     "auth_ref": [
      "r500"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other.",
        "label": "Other Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLongTermInvestments": {
     "auth_ref": [
      "r43",
      "r526"
     ],
     "calculation": {
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term investments classified as other.",
        "label": "Other Long-term Investments",
        "terseLabel": "Investment in affiliates"
       }
      }
     },
     "localname": "OtherLongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "verboseLabel": "Other income"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Net, Current",
        "terseLabel": "Other receivables",
        "verboseLabel": "Other receivables"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForFees": {
     "auth_ref": [
      "r101"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for fees classified as other.",
        "label": "Payments for Other Fees",
        "terseLabel": "Fees paid"
       }
      }
     },
     "localname": "PaymentsForFees",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForLossesAndLossAdjustmentExpense": {
     "auth_ref": [
      "r101",
      "r534"
     ],
     "calculation": {
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle insured claims and pay costs incurred in the claims settlement process.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid",
        "negatedTotalLabel": "Total paid"
       }
      }
     },
     "localname": "PaymentsForLossesAndLossAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchase of shares"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividends": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.",
        "label": "Payments of Dividends",
        "negatedTerseLabel": "Dividends paid"
       }
      }
     },
     "localname": "PaymentsOfDividends",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r88",
      "r378"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Payments to acquire business"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Payments for business acquisition, net of cash acquired",
        "terseLabel": "Cash paid"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Payments to Acquire Equity Method Investments",
        "negatedTerseLabel": "Purchases of investment \u2013 equity method",
        "verboseLabel": "Cash consideration paid for ownership interest"
       }
      }
     },
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r90"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "terseLabel": "Payments to acquire investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r209"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedTerseLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireRealEstate": {
     "auth_ref": [
      "r89"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow from the acquisition of a piece of land, anything permanently fixed to it, including buildings, structures on it and so forth; includes real estate intended to generate income for the owner; excludes real estate acquired for use by the owner.",
        "label": "Payments to Acquire Real Estate",
        "terseLabel": "Purchase price of real estate"
       }
      }
     },
     "localname": "PaymentsToAcquireRealEstate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToFundLongtermLoansToRelatedParties": {
     "auth_ref": [
      "r87",
      "r455"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with extending a long-term loan to a related party. Alternate caption: Payments for Advances to Affiliates.",
        "label": "Payments to Fund Long-term Loans to Related Parties",
        "negatedTerseLabel": "Advances on loans receivable"
       }
      }
     },
     "localname": "PaymentsToFundLongtermLoansToRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodGainonSaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "verboseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "verboseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r6",
      "r40",
      "r41"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "verboseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrimeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.",
        "label": "Prime Rate [Member]",
        "terseLabel": "Prime Rate"
       }
      }
     },
     "localname": "PrimeRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromCollectionOfLoansReceivable": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the collection, including prepayments, of loans receivable issued for financing of goods and services.",
        "label": "Proceeds from Collection of Loans Receivable",
        "terseLabel": "Proceeds from repayment of loans receivable \u2013 related parties"
       }
      }
     },
     "localname": "ProceedsFromCollectionOfLoansReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital": {
     "auth_ref": [
      "r86",
      "r97"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities.",
        "label": "Proceeds from Equity Method Investment, Distribution, Return of Capital",
        "terseLabel": "Dividend received"
       }
      }
     },
     "localname": "ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from common stock offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLongTermLinesOfCredit": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.",
        "label": "Proceeds from Long-term Lines of Credit",
        "terseLabel": "Borrowings on line of credit"
       }
      }
     },
     "localname": "ProceedsFromLongTermLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfDebt": {
     "auth_ref": [
      "r126"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net cash inflow or outflow in aggregate debt due to repayments and proceeds from additional borrowings.",
        "label": "Proceeds from (Repayments of) Debt",
        "terseLabel": "Repayment of indebtedness received"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfEquityMethodInvestments": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Proceeds from Sale of Equity Method Investments",
        "terseLabel": "Proceeds from sale of equity method investment",
        "verboseLabel": "Cash proceeds (excludes proceeds to settle indebtedness owed to APC from UCI)"
       }
      }
     },
     "localname": "ProceedsFromSaleOfEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodGainonSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from the exercise of stock options and warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.",
        "label": "Product and Service, Other [Member]",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "ProductAndServiceOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r0",
      "r67",
      "r68",
      "r96",
      "r117",
      "r132",
      "r140",
      "r141",
      "r182",
      "r191",
      "r194",
      "r197",
      "r199",
      "r214",
      "r385",
      "r391",
      "r393",
      "r403",
      "r404",
      "r419",
      "r506"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income",
        "totalLabel": "Net income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r65",
      "r244",
      "r442"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "terseLabel": "Land, property and equipment, net",
        "verboseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r18",
      "r19",
      "r244",
      "r524"
     ],
     "calculation": {
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Land, property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r74",
      "r218"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Provision for doubtful accounts",
        "verboseLabel": "Provision for doubtful accounts"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivableTypeDomain": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.",
        "label": "Receivable [Domain]",
        "terseLabel": "Receivable [Domain]"
       }
      }
     },
     "localname": "ReceivableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Receivables [Abstract]",
        "terseLabel": "Receivables [Abstract]"
       }
      }
     },
     "localname": "ReceivablesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReinsuranceRecoverables": {
     "auth_ref": [
      "r513",
      "r523",
      "r531"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after valuation allowance, recoverable under reinsurance contracts including premium paid under reinsurance contracts. Examples include, but are not limited to, settled and unsettled claims, incurred but not reported losses, loss adjustment expense, premium paid, policy benefits and policy reserves.",
        "label": "Reinsurance Recoverables, Including Reinsurance Premium Paid",
        "terseLabel": "Recoverable claims paid"
       }
      }
     },
     "localname": "ReinsuranceRecoverables",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r308",
      "r455",
      "r456"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r308",
      "r455",
      "r456",
      "r459"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the sum of all other revenue and income realized from sales and other transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party during the period.",
        "label": "Related Party Transaction, Other Revenues from Transactions with Related Party",
        "totalLabel": "Net total",
        "verboseLabel": "Recognized risk pool revenue"
       }
      }
     },
     "localname": "RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r308",
      "r455",
      "r459",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r453",
      "r454",
      "r456",
      "r460",
      "r461"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "verboseLabel": "Related-Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedTerseLabel": "Repayment of term loan"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r2",
      "r14",
      "r112"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r8",
      "r22",
      "r112",
      "r552"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash Equivalents, Noncurrent",
        "periodEndLabel": "Restricted cash \u2013 non-current"
       }
      }
     },
     "localname": "RestrictedCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r8",
      "r22",
      "r112",
      "r552"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash",
        "verboseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted stock awards"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock awards"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r35",
      "r271",
      "r346",
      "r520",
      "r545",
      "r546"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r129",
      "r130",
      "r131",
      "r133",
      "r139",
      "r141",
      "r216",
      "r343",
      "r344",
      "r345",
      "r359",
      "r360",
      "r542",
      "r544"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "verboseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r175",
      "r176",
      "r190",
      "r195",
      "r196",
      "r200",
      "r201",
      "r202",
      "r288",
      "r289",
      "r472"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue",
        "verboseLabel": "Total revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r114",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromRelatedParties": {
     "auth_ref": [
      "r79",
      "r551"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.",
        "label": "Revenue from Related Parties",
        "terseLabel": "Revenue from related parties"
       }
      }
     },
     "localname": "RevenueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuePerformanceObligationDescriptionOfTiming": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description of timing for satisfying performance obligation in contract with customer. Includes, but is not limited to, as services are rendered, and upon shipment, delivery or completion of service.",
        "label": "Revenue, Performance Obligation, Description of Timing",
        "terseLabel": "Contract term"
       }
      }
     },
     "localname": "RevenuePerformanceObligationDescriptionOfTiming",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "terseLabel": "Remaining performance obligation, period"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in CCYY-MM-DD format.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenues [Abstract]",
        "verboseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolver loan",
        "verboseLabel": "Revolver Loan"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r446",
      "r451"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "verboseLabel": "Operating leases"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract]",
        "terseLabel": "Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract]"
       }
      }
     },
     "localname": "RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r168",
      "r202"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "verboseLabel": "Net Revenue"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accounts Payable and Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r369",
      "r370"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Earnings Per Share Computations"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodGainonSaleDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r0",
      "r117",
      "r213",
      "r214",
      "r419"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodGainonSaleDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r231",
      "r235",
      "r473"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r231",
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Intangible Assets, Net"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r226",
      "r228"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Change in Carrying Value of Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.",
        "label": "Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]",
        "terseLabel": "Schedule of Medical Liabilities"
       }
      }
     },
     "localname": "ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock": {
     "auth_ref": [
      "r47",
      "r123"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Schedule of Line of Credit Facilities [Table Text Block]",
        "terseLabel": "Schedule of Credit Facility"
       }
      }
     },
     "localname": "ScheduleOfLineOfCreditFacilitiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of Future Commitments of Credit Facility"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Summary of Estimated Fair Values of Assets Acquired and Liabilities Assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r120",
      "r457",
      "r459"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.",
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "verboseLabel": "Schedule of Fees Incurred and Income Earned from Related Party Transactions"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.",
        "label": "Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]",
        "verboseLabel": "Schedule of Contributions to Revenue and Receivables by Payor"
       }
      }
     },
     "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r316",
      "r342"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityStockOptionActivityUnderBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r320",
      "r328",
      "r331"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Stock Option Transactions Under Stock Option Plans"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "verboseLabel": "Schedule of Stock Options, Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r57",
      "r115",
      "r159",
      "r160",
      "r261",
      "r262",
      "r263",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r274",
      "r314"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of Outstanding Warrants"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTable": {
     "auth_ref": [
      "r388",
      "r389",
      "r394",
      "r395",
      "r396",
      "r397",
      "r399",
      "r400",
      "r401"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table]",
        "terseLabel": "Schedule of Variable Interest Entities [Table]"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTextBlock": {
     "auth_ref": [
      "r396",
      "r397",
      "r399",
      "r400",
      "r401"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table Text Block]",
        "verboseLabel": "Schedule of Variable Interest Entities"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).",
        "label": "Schedule of Weighted Average Number of Shares [Table Text Block]",
        "verboseLabel": "Schedule of Shares Included in the Diluted Earnings Per Share Computations"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "verboseLabel": "Schedule of Future Amortization Expense"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r113",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r201"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "verboseLabel": "Reportable Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A Preferred Stock"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Outstanding nonredeemable series B preferred stock or outstanding series B preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series B Preferred Stock [Member]",
        "terseLabel": "Series B Preferred Stock"
       }
      }
     },
     "localname": "SeriesBPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ServiceMember": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.",
        "label": "Service [Member]",
        "terseLabel": "Service"
       }
      }
     },
     "localname": "ServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Restricted stock awards granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Annual dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityStockOptionActivityUnderBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityStockOptionActivityUnderBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityStockOptionActivityUnderBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityStockOptionActivityUnderBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "verboseLabel": "Exercise price of exercises during period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r330"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Options forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r342"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r322",
      "r342"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options outstanding, ending balance (in shares)",
        "periodStartLabel": "Options outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Options outstanding, ending balance (in dollars per share)",
        "periodStartLabel": "Options outstanding, beginning balance (in dollars per share)",
        "terseLabel": "Options outstanding exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Options exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r314",
      "r318"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Options forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r113",
      "r316",
      "r319"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "verboseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]",
        "terseLabel": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Exercise Price Range [Domain]",
        "terseLabel": "Exercise Price Range [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Market value of common stock (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityStockOptionActivityUnderBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "terseLabel": "Grant date fair value of restricted stock to be recognized straight-line"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r336",
      "r347"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "verboseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityStockOptionActivityUnderBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r342"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Equity, ending balance (in shares)",
        "periodStartLabel": "Equity, beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StandbyLettersOfCreditMember": {
     "auth_ref": [
      "r254",
      "r255",
      "r382",
      "r549"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An irrevocable undertaking (typically by a financial institution) to guarantee payment of a specified financial obligation.",
        "label": "Standby Letters of Credit [Member]",
        "terseLabel": "Standby Letters of Credit"
       }
      }
     },
     "localname": "StandbyLettersOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r29",
      "r30",
      "r31",
      "r115",
      "r117",
      "r144",
      "r145",
      "r146",
      "r148",
      "r150",
      "r159",
      "r160",
      "r161",
      "r214",
      "r264",
      "r419"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodGainonSaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r59",
      "r129",
      "r130",
      "r131",
      "r133",
      "r139",
      "r141",
      "r158",
      "r216",
      "r264",
      "r271",
      "r343",
      "r344",
      "r345",
      "r359",
      "r360",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r542",
      "r543",
      "r544"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED",
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r129",
      "r130",
      "r131",
      "r158",
      "r472"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r30",
      "r31",
      "r264",
      "r271"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Number of shares purchased by related party"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r264",
      "r271"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Shares issued for vesting of restricted stock awards (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r30",
      "r31",
      "r264",
      "r271"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "verboseLabel": "Share-based compensation (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r30",
      "r31",
      "r264",
      "r271",
      "r325"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Options exercised (in shares)",
        "terseLabel": "Stock options exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r30",
      "r31",
      "r264",
      "r271"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Stock subscription"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r30",
      "r31",
      "r264",
      "r271"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "terseLabel": "Shares issued for vesting of restricted stock awards"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r30",
      "r31",
      "r271",
      "r315",
      "r329"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r59",
      "r264",
      "r271"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Proceeds of options exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r31",
      "r36",
      "r37",
      "r117",
      "r207",
      "r214",
      "r419"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Retained earnings"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r117",
      "r129",
      "r130",
      "r131",
      "r133",
      "r139",
      "r214",
      "r216",
      "r271",
      "r343",
      "r344",
      "r345",
      "r359",
      "r360",
      "r383",
      "r384",
      "r402",
      "r419",
      "r421",
      "r422",
      "r426",
      "r543",
      "r544"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Equity, ending balance",
        "periodStartLabel": "Equity, beginning balance",
        "terseLabel": "Stockholders\u2019 deficit",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "verboseLabel": "Stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]",
        "terseLabel": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r116",
      "r271",
      "r275"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Mezzanine and Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r444",
      "r451"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "negatedLabel": "Sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplementary disclosures of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r533"
     ],
     "calculation": {
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs.",
        "label": "Current Year Claims and Claims Adjustment Expense",
        "terseLabel": "Current period"
       }
      }
     },
     "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r533"
     ],
     "calculation": {
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.",
        "label": "Prior Year Claims and Claims Adjustment Expense",
        "terseLabel": "Prior periods"
       }
      }
     },
     "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests": {
     "auth_ref": [
      "r56",
      "r117",
      "r214",
      "r419"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests",
        "terseLabel": "Noncontrolling interest in Allied Physicians of California, a Professional Medical Corporation"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TrademarksAndTradeNamesMember": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trademarks and Trade Names [Member]",
        "terseLabel": "Trade names/trademarks"
       }
      }
     },
     "localname": "TrademarksAndTradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonShares": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Shares",
        "terseLabel": "Treasury shares (in shares)"
       }
      }
     },
     "localname": "TreasuryStockCommonShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r31",
      "r264",
      "r271"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "negatedLabel": "Purchase of treasury shares (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r58",
      "r272",
      "r273"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "terseLabel": "Treasury stock, value"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredParValueMethod": {
     "auth_ref": [
      "r264",
      "r271",
      "r272"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the par value method.",
        "label": "Treasury Stock, Value, Acquired, Par Value Method",
        "negatedLabel": "Purchase of treasury shares"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredParValueMethod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Unrealized Gain (Loss) on Investments",
        "negatedLabel": "Unrealized loss (gain) from investment in equity securities"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r163",
      "r164",
      "r166",
      "r167",
      "r170",
      "r171",
      "r172"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableInterestEntityDisclosureTextBlock": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.",
        "label": "Variable Interest Entity Disclosure [Text Block]",
        "verboseLabel": "Variable Interest Entities (VIEs)"
       }
      }
     },
     "localname": "VariableInterestEntityDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEs"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableInterestEntityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Variable Interest Entity [Line Items]",
        "terseLabel": "Variable Interest Entity [Line Items]"
       }
      }
     },
     "localname": "VariableInterestEntityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableInterestEntityOwnershipPercentage": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).",
        "label": "Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage",
        "verboseLabel": "Voting rights held (more than)"
       }
      }
     },
     "localname": "VariableInterestEntityOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": {
     "auth_ref": [
      "r388",
      "r389",
      "r394",
      "r395",
      "r396"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity.",
        "label": "Variable Interest Entity, Primary Beneficiary [Member]",
        "terseLabel": "Variable Interest Entity, Primary Beneficiary"
       }
      }
     },
     "localname": "VariableInterestEntityPrimaryBeneficiaryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Term of warrant"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r150"
     ],
     "calculation": {
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "terseLabel": "Adjustments to weighted average shares of common stock (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r143",
      "r150"
     ],
     "calculation": {
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Weighted average shares of common stock outstanding \u2013 diluted (in shares)",
        "verboseLabel": "Weighted average shares of common stock outstanding \u2013 diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails",
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r142",
      "r150"
     ],
     "calculation": {
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "verboseLabel": "Weighted average shares of common stock outstanding \u2013 basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails",
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 17
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04.(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(11))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121596127&loc=d3e12803-110250"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121600890&loc=d3e2207-128464"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5263-128473"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(4)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116873149&loc=d3e923-111674"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116873149&loc=d3e923-111674"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569655-111683"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4616395-111683"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5728-111685"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=SL6759159-111685"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=SL6759159-111685"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5747-111685"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=SL6228884-111685"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL7498348-110258"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=68176171&loc=SL68176184-208336"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(7))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62652-112803"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99397103&loc=d3e6824-158387"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(6))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(f))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99404803&loc=d3e21409-158489"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(cc)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/subtopic&trid=2560295"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=66023616&loc=SL35737432-115832"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.1(c))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491204&loc=d3e4879-115612"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r556": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r557": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r558": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r559": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.27(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(7)(c))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(9)(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=SL94080555-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>99
<FILENAME>0001628280-20-012247-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-20-012247-xbrl.zip
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MW5SJ\I2S*_[CVX]^T-L']_9^AA),C.*:K9G!(D@RN2MZ"Y)-<Q),79]@;A-
M5],;ES6GKU)M$P<,D%S!5+UIP;I8&E;GMPB@VZ,$*/N8(S<1]!$\.21#&*RW
MJ$&6#;!%*FZ- *W2]S >*",GFQJ(:=E9<J)N;%0/S%8\CRE@C3'%ER*UF)]\
M]V@^JZ=\\G"N6+R<L)P!U,.P[_XE>'AR<$<-^1T\GIPLP^GSF'OU&'T8[, Z
M@IW+02+KU?3_(9H([*2H(UE,I5(E>;2Y VK+.:#ZRP[0SP:TK]!_)J#]U!4!
MVBB -S;9' DLN%Q3C3:GV%*P&(:(^K<%T+6E(RX!2HRV 9H$KD!T-C.YS,96
M*[&[_N<2:G<2^K<D]#,!7:&$2O&A^9!R#^,]AQ*8C5BJU5'#-&X;>N'DO,/T
MX<F!S+?1=&J(%UD\IE(;9 SJKDH#KZ&Y<1&L';7I' 3'82PF%PP2$'SP&:06
M@@00I-@>M5>245O,P>1Q $/96$UD:3D[#SXVY- TJ \YNI*K<:,VE(/)X_KM
M8XZMU6PB4@:P4=4K20TVNJ0>;?*P%?9Q'Z?X?)DH.#^\C1:R.H[95NII''VR
MC$TL>@TM759(*6Z%A5PSD@/92%6B'$,T&"VT@"3HK?H^%11.T[;#1@X@D^NW
MDJFK44.Q%YVHMQ-+"#8G<=A4.,FEK;"2 \CD^NTD&B\&-70TSD&FG"V&U)-Y
ME(@YNJVPD^_\G4=X,MEN<^F#,\'54'*R@![1$IL62=2K)<EF*\SE,( .8S4-
M9D\:1Y98(SA6$<T20W#!0W9<RE98S>$D=/W&TV9I+3-$FS.86$C1#,5CA.@K
MT+:%F.N6T/7;4)OZ4F8M2(6!K2\N2*S0P)3J)::ML*'G1V]-Z_GAK4W)<BJ-
M;5+/""P8(T6B\SXSIH3%5]P*"SH$G,/83W&N8!73D"T 9@07'<2"UB;5O+ 5
M]G,HZ5R_]800$+DP%7+0G:%HH_6M;YGQR>2X%=9S*.E<O^V,QCK?P92F@ADD
MYX8QF\9%?S-B!["=HS!2,4G)/JE.(P"QB:JW&1N'YEM.C@8P4J.P!C'HPZG,
MJ<4$ 5TNKM5N#&I4_D$>0'V,0DX#@N'@,E1TH+*:@1AJZ\7CS26SQOT"7ZIM
M_U!4^</_G/8]R+.CX]E4_UQ<5KT/9M/^Q>>SP\/)]/D]?01S69Q\0O5^\B;Z
MYMC[\AP/?U@^E/?J5O;ES1N<3J;7$!E=3_DS2/1)A"-D:*87H$2I@6V+X W3
MUA!!7S^:3<=4^,RUAIIR@T %P IAIB+(B(5:BK(UT-RJ==+KN_#P$4[JO>E9
MQ=?A2&"R5HUV4I<GQP >&I:@X*24@5UE.Z8-!'\-TV,Y055L]0><]TW&BY'@
M@^ K48M8,0 40A:V2+Y(C6H T];@\[=,W::@9%L!JHW4'=''9WMMJ^B#Q @
MCES^,*SW-Q.NS?1,KI!&\._1YRI9(=O4.)84K31 [$4('".QY2KJU83MH\_U
M:^/A48V)R96&/E2 %$)FH688- Q.PG6G%$:,+860^B:Q3+E 47>)(!)2#0ZK
M#<D,@.THGELL5EPJML2BD7OU62UDXH:N5?)L</MDXEHCM^$!Q<P**9?@>YB7
M&[F>086^7H7!U3]LSAH_H&N+]X8'EZ-#[/NR0DL@"31(I%8U "G5L")POGEY
M_)AND3=[>9.T7U&>+30HDIU(88@M9E-#3,4UEQW&G+:&"&O*LZT0&M,+LH@S
MFF#ZGJT,!L7$6',P%L+V0#- GFV%, $YS"7&%*H!3K5D;RJXI,YB"X[,UL"T
MSCS;"O')M01;V=IB!((XU#@MZ">@*%B(96OP67^>;95V2(RSS1MAT+ K9S+0
M6G6]$"J;#&Y]* WU!'KJU^?*&D29GELDE(1(>JLE-<XT@O*^F^N;#5^I4<$&
M:X#2L@-#<-AL8:?>/8G!G.OVT6?]F<;UHRJM):*:4PX*L FHVD&(R%(,L6#<
M/E2'RC0.4  <70<T%IL*-.NRC7V;F^L=\_77,>P=WJ08;'A <TN%LS5L2M '
M'+)XAS6K.:]<:]M""SY8QFR 2DACR6;@V&H#P8K0HDM50@2TKKH1M?N[,5[9
MM;05#+&2]=$'CJ#QOE#4_[)QKN:6\ZA:VVY,QFQ5T#"WOI%&G*A4>IL=,UGK
MO2K=[-T:^VUOB]Z]%IB8DBVAD6 *(,U3WQ;.-MI&3"WRUL"T[HS9BO"Q$C%$
MKZYI0RCJU#1)HEX+46C"WFP-/L-DS%:$DL;TU5H73%0'DR.3X00:%TJUB1F7
MHQILOJGU@YOND-B\ND;4V%29>I^#$L%C)M^RA>"1FEA7_-8085VE\BN$)G(%
MGVH-J&$?A)R@ZG_)F)0IU+HUT Q1*K\ZF*P17PJ#$P[06D&(D5M0@^=,$[\]
M$K364OG5X<.FAN !.2@^J4!.%%&*B5D:A"1;@\\ I?*K0\F8TC@[+WT#O(BG
ME!R!+[&JXN.<UX?24$\ :X46/6%  5>5L$4CT&)]K%(J_J'ER@U=<]Y,W^P*
MFU]75)3G'(=,T-!@ !],<38B]O5PZ.,;_] ]??ST6>\2WC"H-H^5^Z0*M!:*
M/NLH 4(W8.)SX[!]J ZQA#<,M@$C&V\ANYC H%/K!@ I$1'&VH:0V'$\-Y%8
M0\UH0P']-M0(43@70Y U3MH^F5C;TN= @-J^0X!+288AAY*S!KDJ V!3KA3+
M]@$ZR-+G,.!"2= L60A5+5ARF,50U. +8O'-P=E.Y2W =(N\V4N;H5=5HIAR
M3Y,T%?(:0,Y:* 4B6T*V(I6WA@CK:\JQ*F@<4%S.M[/10&DA.YN=:Y$C!1LX
M;PTTPS3E6)D$N:BRPMF'HL_/%#+.J7D,XFPS&OYM#4QK;LJQ*GQZK V%/$9/
M$!U10(;B($ -SOFX-?@,TI1C52A5IFR]8%:P(%:?U0 5-4:2<LNAK5'9#<;3
M0"63 )$(&*)B-)#*B+ZJ#<@RAN:Q-]<W^]"C7W][PF0U\K9155QR4-0D1:+8
M2U6#NA'5N^VCS_HSC0,TG61K6-!5J^ZY@MLSC0Y1+*7"*>V4PHBQK>"C<0+5
M"RN G -S$1]=XTH$0S1B'7,,-CR@.1&JUK6Y=]:%WB,V)$9GU8N)B6+;/D '
MRYBM'UR/+7G2^!M; 6OUU^91]$4#+J&WYP[J^#'=(J_LLI^^HB)-Z!7-F;CX
MPB"4*:::FX8FEDQ*T6\-$=:8,5L1-"Z5;%IO;:0QO[I.Z$/LU<Y>-7))-6X-
M- -ES%:U62!:?7BQY6HRJ%^;BZI3;FA:RHK9]DC0NC-F*\('F\TNLVJS',#E
M2NS$F%"P&5:)DJW!9YB,V:J4727'IIH$["&&A*$&Y\EH<"@A95@?2H-9XNK9
MAA8RB@<),1MD=<D21Y3 U?[GKBVEF*3^]L4OFT;8/W>+;BDGI3Y"UBOSPW8'
M#R=MIFH$[SVZ=9W^=7]2>R9]CG_]QU.OTA8A9+4)!=&+6F\6=;5K,H74;#MH
MH9S3N6R>TNE#>>[,3KOV.-8G]?J!XO<^D(K7O_:E3A@/[\SFQ[,Y=M-]58?Z
MG8TYU">N1-%/?CK'Z0*Y7WYQ^_7[1\[NI]_IK=8FAY-^X(QRUZWMRHHVL($:
M'E;0:F"P1NDAU$*#W()KU=7SV+I<Q-8[GFP\3SZ,Z<OGQ_3E;\?TI]/)&:.F
MI_W&WW+D2'!Q.I?OSZ^AOUY<X.+(Q=_]"A]WFVRPZ'+ D#.@F#X@2%*+J!2*
M#>*.HNLT@E_N*]XYQ,7B85L&O)?]Q"=**5G<>C27)O.YU,^)B7>">96YJ"$E
MTX*(J]RW/6)#VR>?9/4)DH0Q:/LUP7MED1[(S1R*60%3SD:R\:E7=2,Y_8U=
M@FP]JR>QN1OAA]&2G3Y/]'O6TT-YV,["Z7TY.9C5>].7&BR_"[+??U7D0YH=
M:XP].S<=_YKI9TZ?+^Y-^3J]SU5NS.\51.);C=5!KU(1-?41&$/0 )PV>#[6
MCC5?'K.L;/>DL]9)+C&4OL<U*FTLFLZD"L&<33[<Z9J5L^9.S^J=SA=R=X+/
MI[/%R82?G,Z?R_SU'>EF\/[A6-2.*6*SH3Y%S$ ER43L>IK$H:5@-KA!68?R
MX>]3F2\.)L?O+_;A2_WZW7E>RO1/\]GI\:<%^BI\/>;[BR/<7,#?!J0R[7EH
MD3^$I,OO<7'TBZ-2ZXKM/;0208)4 T9U?(P#R,2<:8,;:/V5$CH^P#LXEP]H
M],T(8#Z>3XYP_OH_K+?_G^.#UPN]09Q^'/2/G_O%%&BF60=14)4'.# YYNBB
MN**N#)BPP6KD+RC W(,:I$/YE^#AR4&GP[7$+"MGP.)8%,;#D\_CP)^=_3DL
M>/N11V=R\A]>&L"/?]#E<[[P\A_-I9U?]AT@GWFYX\,_%8C#OT%_,J:2.NEJ
M23UP0PPEU528O'496SM?6<BCHO]GF;5/?L!%DN+VZ6(RE<7B%JM[M5B6%@PL
M:SWDSRM:*(V]8*<QFJKJ+P:2DE,A3S8I+\Q%9;3BOS="(CRZ<VM:]>?])_LK
M<<#_(E=T=_[-?^&5$U*;QKD/<U+OL^X3.:E\]64(/IQ,)_QQ;7=V[,O-?2@0
MI'!.ZO,Q"R;'Q+W9,7LL%$=I[H^>CR=;A*7U?3LF.]/ (**Z74)03&Q2'+K-
M7<K>%(-S[6BO<F7:4E%KDA)&!(^8U<)@JL8VX6HEC&"M8LMA'W[5H6F@94VM
M31T.0%]1*%H$X.)<A+/IPN/ER!H6:6\J<4+-)0IQR2@]A5Q\3$9?TA_1N_-2
M6=A$6_YG&<"?IY.7^B(>=H?N/3C[,F@_^]/9V6M79U>S++"Z.FEH8FUKO3H:
MHIJ6Q*E"Y%)BCN:L#K</']D\\$>]?G")H6OP.F%%U;"H^B#8&@.H_^\UQC41
MR$K5&* F#!>C:I9A[HXV(Z3-^^;H0^+\A3GZ\-2KS+>B7M:6HA77VY'[DCQ1
M;P=K2B+AN./8W\NLW)Y/GA^<G"<Z9D?'.'U]Z08^O;3QV9[49Y2[K;;.;2=>
MG]\"A$TR/O6V00Y:"ID(:Q5KFL-8XQBFC>U4^!=R; U#S]ZM/)W=Z9\L-)T=
M_/+EE9BLNA[*VI@A,".SAK8FMI"*D;K!%75O-[KBXN#6M/9_.DE>XJ'\<3.L
MS/O'L#YU59IWY7BVN+CDQN<C8T7RZ @:(00KV9%W(4(((L+N0JW8#58K7< ?
MX_2YO"N4W9],)T>G1]<OHY_9G7.%@PF)JZ_.] U]$9Q7KPNA9&LJ.P\&\T@!
MPU?;"IBI-5=FC@$36.\Q0 R1:N+<&S*E$1CN,X1^F\WOG"Y.9D=J!B^5U!WI
M*[T.84M,XN4%8C3@J&&-)8!C2\:RB];ZC) QQA'T;=D(](9IS.(*%6_%M%C4
MNL600^[#><E[%4B4/';9.ZMQFV_EA'L)4I"MB]Q[[&,N#J6PY3ZL2=XUC1^M
MY*T'NV'DKK<^2K$W5A4'54/5%E@P6+(A%A:_'7(WJ=LH=VK53 S-J*,)T,"0
M<\R^BI0J),3;(7?7C=TP<E<JQ*)7-$4*H =L&/I@ACXFE+VS8Y>[AR<',G]Z
M,)DO=T9.Y)K[>@XC@*TF=*HSJ3@'S=NBRK19]-DG*P1^[ *X9A"'D<1@70,;
MI45?@= CB0ID;UYM*AHR(PG3!X\;AHG9:R6H36J.)H%I'E7RQ''P1IV7Y/V'
M\VUVZ*UD@,V*T /AAHR8B@0@%[+54+VD0A9:C W&+GOKB_K6+WD%4BNNY&3U
M4?:@P7B@1&";3Q0IC5WRUA?UK5_N4FM%<J6F0@<D22,'L28 .ZYDSL;CC5_N
MUA'U#9"EAJ">28O%^@(<&_4T9XA@*V>!/XXVW&&W.7)'KC&"D/,<%##*7KB&
M/JM+S1^&.':Y&R#J&\#P4:Z (2?Q&BEPS$"^10PU5=6K4L<N@ -$?>N7Q!BK
M*]";O6C4YX,ZG=DV]B6:F,"F,/;\RR-\/9NOK'"_-^/0FSIK%/=XLGAQ^_5M
MF?+!$<X_;+*&A[)X+"]E>BH/Y!IJ*X;/^N0F6+!RJ50U]F2*[');MO>@D'D,
MTUQVU!DFUT3HFDW=V<X.3(0<R$1)*>OO!D/9"JUS>\NI,XS6*:X&K $J:XP=
M,1;'E*PST: &XJ,82[.CSC!:QQKC4J'8RSK!>%=Z?BU("QR,!0\CH,YUX[H"
M[M[91NJHIL' U0!' &L9$[;6G(0^T(XD;H7!NKOE6F<8@^5C0S9]%"I+KPK"
MV&Q=MGNG'(/-(] Z.^H,-(*/<TFU@GHW%2Q4=%:54"5.,9481E^(NZ3.#UM.
MG6&T#K>84J@<;1-@Z:.I7+3&)BG22AA#'>D(?)T?MY$Z1)(+A>P;$#!RSI$B
M5:O_-HYQ+!ML;G9>9Y@E 6:3,;&G'#2@"K;DS 9B3=[%5C*-?4G@1E!GF(4(
M05\E.@\^>O5U^OQH53ZU9I=\+3CZ$I@;D=<91NN$QN!<K<W% JIGJ+>HMR%5
MGS )C'XA\D909QBM@R5+<4U]'2J0$3"02US(V>)]RV,HWAJ!F[R&E.  M6-8
M@[B^(Q8+)/6.36JYM>243.CS=ABL;<_K#%2L76S4D-Q(C@DB42[LN?8F$RT%
ME-&7/]V8O,[ZJ9.L>%3BI"06C \Y->-KM54990W8$5!G! 9K#7F=]5/'6O+5
MVY#!5P!L&<"@ X]6N'C8#JTS@,$Z;^ZN!&69O.P]WK>1/1E2*FQ<#=$ <:0F
M!APS8#+1)AX!>]8 [0H8_-,VLJ>JOV/1AH)> &RDX*&9DEHDXSR6#^*L39P]
MN&//%X=:ET8/7L5R5<ZU].[B,8(TR'UH>L76,O?LX!@Z2(V#/?_:1MTCE!AM
M#4%R[R]02\R.DIA6N+I@/ER4V.F>#67/,+H'D2DZ3()5 RXG!3Q#R8%*4F-F
M_.8WA/P1)_-_X^&IW'[]]M=_Z15QS@>O[VM4=7B9.F]/NC<]/CU9+,^PJX?V
M>II#!K'+RO*DGFD5A\Z5;'/*V%RL(C<#+3<2M#S4[&MM7FP$:PMJ)%'(M92@
M&I?Q9J#E1X*6")1D6J5J&"3T"C0VF6+(T#6AV=RQX:/1A"L<U^U)2LDNYN00
MQ*0B*2$40$B!P=\0M*Y5$ZX0+0SL@1":;0[$2DXV^NQR([5FZJG>#+2N51->
M#:VW7<?[+Q]O.=Z/7+S[L_N-YUA]) /..X!:(UI95H8WJ:5R'$O7I4?S63WE
MDX?S)S)_.>'WV] _DOG9>_HO^M4/]G&*SZ7VKO0:SV@PPUNY4J,>9R%A=CY7
ML YSD A.+*DRQIYNWUB1_@2@#_0K_B13.8M";]UYN#^K<KC<(\^3X[,7G\]E
M.9;C\X+.D]?'4O]<M9RO_#R6(YQ,)]/G2J0VFQ^AQL(/Z7#R?/F1/[PZ%CZ1
M^G1RI*<\;$_TU453;NFQ)Q> GWV+?US/A;^ILWZ=KFK2!>&N]Y/>/M?W'N#F
MV+3 '+#DI+;-]%*^XBT+A"CB5-_!!D?..P&XJ@"4T0K "@.FJH:\58.&"@&2
MSRF2A"+.BV]JT4=BV_]BTM.=_2?;:+HEEQSUBB$"@4V.#"(Y;QRGDBS"YFJN
MMQ-&\;"+UI,#D9/[,\8/1HPN6]N\2PU?0V>;Z\E 6(DU4PY-[4>DIM&L& HN
M><\6X@B&\URDY1_,3F1Q?X;3Q:UI_7$R5;!4X[U#Y/;K=[\_5=WV%]CU=Q\^
MD9.3PZ7!4>6;WU.NSP3G(T&W=%2]0(^(((DI/N6,"5RSRPVS(U"7GRE^%RQX
MA*\[A$H!?65^*K4;P.EB.]N%J0%,,;+#: A<AFX'^\X.[M/&G0GG<^3#YL5#
MGSFV^?#X .\L&V7VQGV'/\UGI\>KF'7X%T/H'MWIW'ETY_Z3_4_M2KIJ5&#"
M:J*"+*ZY8 P4%("0BUI9E757$"MD<]&H6&FPM^/#9O'AP\78]QGQB9K[L)K%
MV**\":I$6!*#M-3=:G+6E% Q^9#/=4C>/,NP&M"NZJ_?G7_S7_AZ5262G^#_
MF9'K!NY\%&P?0_G)Z9A7UE-Y1=Z(-"G&>IN)0*K)S!&\NAVY>0^>-Y=J-P(>
MB*:5HI&T) ^I1L18$N=0HZ<$8C<7GF%FRMX(4I1@2V-?4^Q5ID3H &O,4OML
M&<OFW+?(RX'>.W9L+CL^]#3>Y\<G/(V\HH9?O;5X*SD&*-"G\9F:6Z#&4$/R
M;V=*;3*5=J!^""IKH,G.H\DU0\L5(5N-<24TB8$$-M=H[/RZ5=D(GPGZ5",C
MP8$17Q1YSQ1 '3LV0",0[!M)AN&UAW.1+=046DS0/"*KUE##H XGER+VG#GE
MHE= V3SF?":H1\_O3?GZ(2R?OV>_K&CWK">)Q1:2(!#)HHEB!9USY%HE&5&*
M^<?)='(B]R<OI=Y3 9P^G_1,\F(A)XO;K\_J] ]QL;BT;'WR^VS^XK$<+O/1
MBX/)\:<2S9^EBF[.)'LTRA0-,:T*.41.&<%GCJ@FI:0H:03T^=N3[#>+F*.D
MS[*^7;@:R1F<NI_%QB3 O06U0][@@IA-Q_9:UB-#(E+SCK[OEV^I9D*- 7,S
M9 RZ4D8@[7\?M[,BS?XQ%S6:6RF2(61U\$NUK37(!G*C[+&96ID@1-I&D5P+
MM-<BD8DI53 %>NA.0EGC>",27>N=+?P8BJ6O -OR6EMO)%G%KO5>Q5(;2*3B
M<V3UK53[2JO%;*5$K@/::Y%(([WQ63.F@O[/2A'UA9VDZ'S*OFQW0/5(X=+/
M>*=/'RF O?!J&^72=:?'1L.1&%(*6$UJX#T%*4'L&/9J;C+ UR*=G*AQ<@V2
MZM(B)E-+.:D^M>R;QS'US?@B\"[>]'2.57IOA%YEN?RCITJWTFR&%M4;JE5*
M(6BJB%4ZU8DMZ#7*)).W3#S7CO#U;!"PMDE-SI,S(,SD"WN#O86QAA_"(^I,
M<K/3D<.T)C$&K(A7WZM8,(F*95,]B)BF<9$/(Z#/+ATY''VRP>I4 26U$5!+
M*&HPLE E\1(EALW=H+KIV%[+=DIJQ87<BBVA@@HY-8O-]N%B9!O!A_/NMPNW
MM:<CAQ%)%48'#=@4'Z&Y/EN]1;*53&L4S ;O&=]P:*]%(FLL;,&CM%2 :\86
M):@W5XN52FZ[W;>UIR,'DDBC\!8;8@T6*(1E=$4<C+,Q^C2&QBR;">WU-#UJ
MW$>6!?8,D*%AD(9BDTFIN,@?3H+9+M@&2D<.%/NH!^13($+UAIQZ06*P"*5@
M)%MUE+91+@=)1ZY2.IF;HE6*]%V^)><,E"&V6'UMR6^M= Z:CARH:VK(ZK.&
MY/6B8$+H<66)!5V0$%RT6R:> Z8C5RB?[%5Q6GV<J12(-N9JG0%$T) DA+K!
MOD[/&SW13ZRGA_*P_? _IWI3^W)R,%/L7LKBI%_FCZ^*?% Y?1\7>'AXL6%7
MP9[Q1 5@<>\81P(AM-H0DHG),J16B114#FHA$43!'<&*SQBQ''[]1TPP(8%+
MAAI0)72V]SZ&)BYG*6ESUW_&B/?U5#<Y7R%9U;L:NI02T#;OB9U1P47)?NO5
M[_G>QG,([QWA\\GTN1K2AU.>'<Z>O[XC?<O+M6Q-N!9E+"4#.I024X+2B%PF
M-E;C$]NLQJ<W1QD/B.SPJCF8PCY%]&(:6*[4R&3KLM2 K;D-KF@;/_K7HJAM
M+11=Z)6HN3>VQ)2:5!?)Q>B\@:U7U#]/-2R:J[U=[O8;C3XVZ'UH4D 1 V9+
M^K-)4HWL#<?B;XX^OGX AU>[&GPW=9XT?+4>3+)4"P8/45)QBGS<>K6[3BE=
MY;:;5DTD-"58!V*0*K.IJ:G3Q!:2VWKM>G>"SZ>SQ<E;B[GL'#82'5NXM^=R
MSH)&HZR1IPELO*CH(9M<Q[)%<D0P#J]IO056>\H>EKT5"*$PF=0['D.NV6Z]
MIEV_Q*YT"%.P*IH6K>7>E!$3A2 .N!A1=;O!J?H5H?>CFLFG!W.1AU/YY9L[
ML\-#>2[W[]\9B<;U(6%+U$)PZMDFRK$$($/-^LB9QS+6>51 #J]S^UJ-Z67^
M/E;P*?0^NLD#1Z?0Y[K!+<I'!_:U:%W@:GPQM6:'$*V0AJ6"H9=UEH0.MU[K
M[O_RX,[LZ*@/1GK]K]GB>'*"A^-1NE*C4&XQ^;R<,TE,0ABR]9:R271SE.[:
M<!Q>YVHD"BUY]6V+!V>Q.$E6PU3O(C>)VZ]S!Y#9JZG<MU/;CN>SE_H YQ^?
MW'9Q].(J?S6][=TESZJQ_N2*9P<_YX*7]V2H^9:,(3!;D,:Y&:O6(!8?;2^F
M69H%M\5FX>\OXW[R#O^BM>HQWU\<76^-AUO=7"U#UF9VV5@++N?BG*G IK:^
MX.CJN>V![;<]PY#E[_?A78'5@P&6+ZEF$UKN^_VCKQC8)E>%H[68<CNOVH2+
MMH<[NFT)W7KEZ&?2K9^Z(KK9**&6WK:;&[!&M<VAQ,81782(NPJV;:7;,#Y]
M@V PP7*@F-(M]U4*,@%L<(CLX8.:]!W=MH5N7U87O[(R3=N"=U"1N$+RE L4
M8<DU+'L^\.:&D!<E[A_GUX/95+_G8G8XJ?IDWE)LJ^HS2_#-6M\=(02*KL=D
MUF?,JB8,PPBV'(T,NU76Q:=0P*D6KX&@4:2F3D:J<=DG(X8QS18<!8C#&_8L
ML5(&;I5['\&,$%HTK/XD]_W:'S9'V2$^>MN**3AH6(H1 S%X2IZ-C97%QA3C
MV?:E8-+FZ><-J[.]BC^WADQ:V#-I50T<$&U#DX.UX M@E!R,-U@2V.S:"#)I
MP\R+&AMASX:5G[<7^6">\JTI3PX/<?[ZB<Q?3E@N3MO&7%YD%]0PMF0-@'-6
MV4\V9#0UAR"-1I#+VQ%^G(0?)IL8HS5,K@12]9XPD"&?-!APMC5F,X:.X3O"
MCY/P VTV0W3-5[%-' ":8D)I8K'DGG2R:01ASX[PXR3\,%%?H=#W1Q,CBT9_
M!GO/ V#C,EA7\@U:#=^$\.^&K8W["#Z3)(T5LW(.R1LNUN62O42/,@)_>D>^
ML?JV2CSVV5+V9,%(P$)-D*TC-E3L#5HIO]'D&Z@6-OA:<RG5F 84"_J@)M<Z
M#LPQU ][G^[(MYWD&\;GLR&U+)#8A CZ_VP"(;:^D\(3WH"MW3>.<]>RH(\Y
M(%.MUCL',1H,O44AA+X=I[+ES5W0W]%H@VH+@@T&DD?#22#FF#E%<028L#0N
M\7S=,6\>C?X<EDN](]Z;$OY(U?M4#]P_O#(GANER\<G;NEAT?W*BQJG?P[+-
MY\/VY&3&+][[W'_/3E18^G:8V71Y[.GOL^M>]LRK(6RT*7J7C4_H(6"?+&!B
M3+U/9 J9SB9)*&'/?+<=<W?,O:J7N.3NYWF)']#\*IE!*=ZKOY C-H@:G1@@
M @_L2\88W.;JY6O([>XD:O02=2VVP"8CR:E;S;4"J1>3*"%DR8%"K>%B3RML
M9BAU9W;:/=1C9>+K#[AP>SYY?G#R+\'#DP-%YABGKR^YEU/^9B<RZV\2!BMJ
MP5C4B6$RE2)#1D%O2G/LR!%5QWBQZN/-WHZ_._ZN=I7I'8,_D6N%U:2[G-@*
M6;UU2 4*(SJ6V%I"9VU,S",@^PVDVE45P-!KJ>MF.51/ BXP2%JR'9VD/D]-
M"1^X;O#6J.$*5H:U'Y_A'E^<\F@N3>9SJ<MCXQ3H34E;)\:(1"4ZC@!"6%U-
MXK"UI@:AN<UUV6^@%=@4A[E!=H0E4=\4114+M^AR)F.KZZ.C1^!#C ; X6UI
MY:8P9U-ZAI<"9B_,%LE0"BZ$M+DJ8F?5-I_?UZ*@"@EYM)E)(CC,B,#)>B5L
MED!@-YNR-Q<WM"V'ZGQR66V,PI9,I*A_F11JQ'ASZF^',"QK+WA-UI0L/A6,
MT+I%@>#(>#"M5:[YYA2\KA?M82I,F85B3@BQEMY@+GL+*"67B,7%9FY.D=_Z
MT5Y_51U5!VB3<[U'!C@B=!HO,$,T0H;-YI9#7;51PECG&4EA:[#$9 OXV#L(
MY8C&AF2=>E%_V-RX@;[3YB-WA5+K%05S?18#] +_!@E0@W90F335&FE(.=Z$
M3B8W0?TVE$:1I;3F0+S)#C0>@FJ94[;0ENHWFF!AT] =<HK*)V]N TM/XYX)
M>Q96D0J&%EH-%2@C@.3LHK?-F2C&9WH[;>D&!%_;39[A []H?8$8 @-6,+XL
M1]LV$XQOF0GJS0G\;@[3A@DZ#;.US@5$C39=C!BEN5AB315JPWISMC7>'*8-
MLX>QVI ;2//)9"!KBY2$8D5MJ:V&RP@<ZQW31N';<S8:LN42?:W0>O_89#.U
M;!.%TE)>^O9YBPGV-Z=U78%BYY_QY$0_].3=O=Z_WD&J>655'N0]B^L96#10
MLZ/8"Z1R<5A1?; -ILRH^_<,,@QR=:RIKA9.MGAG/) DJJ"_5S31]:Y_;G-9
M,UI%\T!.?I_-7YP;SGV<XO-EV<!UYY%72)IH;4JU5Y(UZ)YW#AE;=IX8BZG+
M)=Q.FC,_:,>>E?LD2R@_SR?)J_-^*P:/.=H:C*H*P52*%Z6!:\&)G"_W&'!^
M!_;(5<4RCG=^)0E';USQAKVM$"AC-FIE1*/PX%R5L"O2WB2J7HDU*ZQ8-L%2
MR Z96P"U*CE9#SY9075*DAM#C="./B-)5%.FU)R B$.HC@OZW@S5>Q\]N>I'
MD*C><6TDJ6KTR. :E%( <I_2&@IV_]F3:<7D$:2J=UP;2;*ZA=!L DS>-L@@
M!3/E+#5B*3%&&4&R>L>UD:2K*U%$&UJ*SH!W1"&8(+DTKTX:E0W>BGG50J.1
M.]K)>':M%1>] T-.-4-) 8H-$9-+;7M+. ?)VZZPE!,U$/*^86L$^E"SL;F*
M42QK:RWB"#R)\2 XO#&7/G9*/"6-3J#F2,DPU4;.8O6J?4=@S,<)]T"EG=4Z
MRL77RJ$/&5.0 U=RQ+EP/IOZ:O,FJN4_=]G.]F ^F9W.6?:?//R,G9=77>Y8
MF:XUV8;:(E57H/I(V<1HJ2:1/MHUC1&-<]<Y_K#<.#N?+&0Q$C2 "V,KN;+I
M^SXK(3CI,SR*_N6+;"X:*PHL]G]YT#O'G4[UQ'_-%L>3$SS<RE6(U7&F]GJM
ME'+?E00^,99D34_N0< @=I3Z],LE>+,)NBE<R>I$A]"0<Q8HT%M_DEJ Y"UK
M7%3R&+GRY;9WQY7/<LO)MPHN^!(20!""Z$IVKEA;7)!ZOB2^@1UC=[;HBU?$
M5]9 -21Q&LI5E-ZVC )[4%.$ 5JE,H89PCORC&)ELR17J&)2;627/4^S:VK<
ML&E0Z9J5$>2(=DP;17K*60V%,W(+XD "JG]M''L)L7 E4S<WC;PCV% 9[,:.
MDH$HH;?8MS;G",5#M,[49%K:W#6C'6>&6J[RT8?F7$HU![ QEN";MRD6M"%
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M2C\MAA;!)P-L&7S-N9+UEDOE%IJ^-%H>?2ZN3W^?;9@R&R6/DOI:L;?3BSF
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M<72<7V'=9.!DHZM51)959!3% EMK/&E,9B_2WM&.* K;<7X;.;]<RK>KB,2
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M;-N/I]%"LB17G"-$ Y8DFGOCE>:6>QN,0LX:I!> )3.XYI6Y&).68D^%@^E
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ML'8ZOKFW,YOZUL^PL$"H<E8J R6F02BM.,<D&*A)4)B(K-<7%4NSE^@"LTA
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MABA3GG392ZN_Q:LR*HA6=_4I(Y;#I>)TIWAUXZN%I.>?B5I^1I\X]DQ1HX'
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M[B#M=2%;E[5"]9$'[;J@45U"/T=JEU/@[@X'^>UPC#/=/X+N)].%K;7",QT
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M#=.&D+/8^[KT0;WGUFG9$F1+L&A+-]D2/)TEF-A*AF7 )C 01\T!"K$$2J(
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M(*45NIXK*X)7"Z$:!0R%"JQ:?EK; %H6V-J63G25Y40(1 A$"$0(%6!#1%$
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MP8ATU?ETU;]N]'8/H42N@$UF>8"Q@GE9'R!('UV)Q46QM2UDMYH7I*J2A4[
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M%QC?_5HF<RLL5@4I"Q9?$;,^+0IS_24':5&)B\G<#VDS3I.Y5TB3+V=+^J1
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MD6#Q:Z]3FV@OK*-'NS@141I14OTP=] ,\VQ_<[/)N=>3N;KBKXJAO,21',)
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M13&L>EZJH$ =6E]&$!V86<EYT%F#@CVN??+MYR(Q+:@&+&0@;N7]RITZ+>^
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MT>C5/:<Q&M+H?)"7QY]XP<1CK2JP$LM8(FR>!J/Z9?#KW%'YR$]#--RI+XX
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M3O7W ]@?9"_*QS_?P*6#PQ=\;_O(.^MBPSV1H.X(CU)%3$PI$9AL8[A@/O:
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MSM>J/M!.57D4;D*"%,T7^)N/Z6YLW#D *Z#JO_.R%"L>$A=L]41_*34K;/@
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M:S.$>6)QS=?:V'I9@LUA )N] F1>U""#/HH:,18GNEGV:N<"SOBE:W+%I8]
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M*ZX,A7\+S;FZIC'%3^F<>YF\&S^_>']\6A[^]4?Z[NN;3T<'OY7PW9?#W_^
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MJ72>,L GN]'7 =/!R]^.WH3[P9!%P[#YS4=B/]O1]*P.Q,+"+.4,<TF\HM2
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MB:8??!4.Q65=[2[@&T!TZO#J>K26+.O(L=!3JJJ^\H6MGNMZ G"TN.K[[X#
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M=&-O4S3UJT0*I^C,:[B:&E<?%5&P-;P##HO(3RYK/%LW?K[,?&ER!5?P0.!
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MD;/'YI9;NI@=?#C9]5:D*!Q!WDN+N)8*.184"@0+T#92>TY6UKBXC?NY,V9
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M<R&0$]BCH")@-;=&6 )XK9M"%Q._IGC]O$W\\_. 2=_E8LS?919_J1=P/T#
M9_Z#B<C\-9:8HAT6T0[S)P+>.&4E9: =$D8\,H4L5A%QI[46A&'"$VB'IC)7
ME<.OQ8XO=OP#3N+&#6Q.Q:XO^N&"?I@*RI;]-O=A40H+*(7-^4,!$I6-(26$
M70!5()) 6BF"I!7.8T-H\G1E3389XP^K%(JS4)R%2Y,X9;=8@CXH_L(2]$'5
M/.\^E<%$0(HBN*,BF(_U6R*#@L5&/CB-.#$666DT2M(K(H7CGO"5-2*:DER-
M]1?WX+$UP?-V#\:3>/7/W&S4WEY?L[1)7:SLIE[S^XAU&#\T;375J_50JS_I
M9DV/7:[5L+#!BDI=) 5W:SVKT[%:7=^52IM<G8P4B^!=>9;3<;U&-&*OM9:)
MT9#9A9I8+., _<%V9OT0;7&U.RW"S\7F2_&T;JD O<>QS*TB@U4,_>.<2E7*
M09=5#IH9C![;)IG<L)@E"X/?=V?NZ5LF/\M+N(B)<B=>PF)W_(C=\7[>[@B>
MX*2#0UAQASB7$EGF*4K&"&F8,]37WN[XP:U7/]2ZR?3XK:*(N8[ZZC:NWHN4
M5#>0C3\V7]7"%,;C,_V*9^=_HNV.]BM6UF;C_5_KS8;-;5I3[@_0/[3=<Y+C
MU_W!T81AXWF3'*\?[\'8&V,NQVMYCL]YVL:-<7JV4[5MR&UO<C> _/.D77,_
M7:+!_253) XZ%2?D8GS(!G2$ !_61^5Y3,IQZQPEV&0N7B;TQ(75F49PIA]H
M84/^63;D]9/6WBX-)!K&"<)1>\0M@+L+4B.-592!JNB265F[IG3G__Q:M<NZ
M?L<UQGVV]G,#OXIT=!&R62J]2SIYBX/F5 H7C5;&,4=4< K3B>4  H&NDXR%
M6&>O"6[D3IB=,.D@L95I=,='P^3EDM)NK>/-#[LB^8BQT4A@H1&/\(<)CB-P
M&UDP3D0F'(C**KN1EG:U\?ZPD=7LF)9X3.-Z-#;>,J04*7G:4L);)_<@)1/%
M-(X45DU"I['X2^RAF7K])HW?.?3=XTIC=?NP.-/$T"QT[59KJO86%3H34S28
M,**=XS%@[;WDC&*<"5<Y\]?KJI^5M3L?9%YW@OGRQ/*-:'_89<2XA FH.&_A
M#^- SSEAD?8"$RHH]B+D<\C5J_DH,[D<M]V=-3Z:MI<$,3T^&K>NG>L6->X&
M?#@:=-SQI'?$@J81EQA<*\IB5(RK(*V51GDM@F1.\4B*:?1 (O.>@LA0)K"W
MBB(LDD&<)H&,YAREP),0.B6-Q<H:O<8TFFNN!H"3W1? H85P1A"3/ M*LLBY
M<Y:"929U##'SLGI\G\KM2O!DKC/?"T:-]WQS?=?@%"@6&%D:,W3 'R99A;P5
M\'M%DR<R,_'?!AJ5 %QN^7%BAPL)!,<AR62T%-QPG*0!JR<)ESP/0C'GB[6S
M_&8RW]HGNS(*L$,51PI+$)  &.%DE(@$RDF41$2?D]]O[?/QRS#&1KL_B@WQ
MZ^46 M=R$_\ U_"SBEW4DH7^^Y&B!2BH"S5TH88NU-#/)HNY4$,7:NA"#5W.
M_I\K-;17BGK*+-9!\Z2#Y1I,-1I%BCD0RV\(@['"_WR'D_YMVM[R;'-C7;1[
MK9/MLX^=]L&ZV-GZN[NY]0&WS]Z<;A_ ]6=O]R^?]+</MDG[#,:X\17&]9^#
M]KOWM+71[;:_?!;MC0^LM?5'!WR;L]:7MQ?YG[%P(2JC$3$D(.XP00:SB+!T
MV#DIO$YJ94UH6KM#_KKC=2G@*NS/-9O-I>#^X[-\/C_VYR4IAGFN!R$M%BG8
MW(^4(VZM1L9$B1*SU' B/* ;*(8F$5=[DQ;BMEJHAN?M#Q7RYR>E%@K#<TU1
M_P+#L_+<@M'/$$N6(4Z41E8HBDAR/E#J9+)Z98T87=R!>F+^\W8'"K_S$]<"
MA=_YZ>N+><X'QS06"@<D W&(*QN1!1V"HK+,*:H=> J@+TB3DZO'XL5-J(7*
M>-YN0N%W?CY*H>#U7?!Z/MPOC"611XMH-!IQ8S!RT5'DHU+2QN1PQ>^<^SW6
MKZRO[E!33/S"[UR365R$K^V)6?,OA=]Y2=IA/N9O391)!H$\LR*73VCDF"0H
M<:UH$"(17C4#5N)J,^!"X/;8>N%YV_%+I/)\WB9]351#H?*LER*XP.F,I>8F
M,1 EP_,Q &@#:Z1'*F@JG(F*I$SE29M$%%+G^FF"Y^TA?#K.2<B38LQ<\EM<
MA">L!Q["17@+-SCTG:(,[JP,YF/\(AD?G:2(41\1YXX@)S1#V+F@=4R,1%?Q
M.C.JBEM0.V7P$VX!?0+:X)S N? W/]%BB1?"WUQ?'?I"^)N7E$1[D;_94B95
M[H? A %/BC.*; (UFFSB3%/%?4HK:Z8IY57=^=CG+86^N= WEY+-GY#!7*$V
M.IVGB)DC"2IEF[6S1(JQ<0=C8XYJ:BSO4WJI]V! Q+ YR']GH^/OS-0!5@5,
M^+/A9EZ637&!FUG1I%2D8%,8+Q$71B-K$T,*; S-C5+6LMR&E9/ZV11UA^P2
MH:UKVX*[&#VE;<'"4;.7T[: :<>9# Q'03F.S(!F9-X)CG7RF+OO$:V5M@6U
M4(VM>=4H8/XI)129( *XVR0@G6)" DP@HY+)F2PK:PI$IGY5J\^^:T%%H':U
M=\$3([!;N%-!Z]T+;TB02?U>]WLPPM,9,Q],2Z:._Q2/1C'SX4X:%60&^3&-
MII\GHER8,IQ*3WA0(DG%$[/6@]\C#69.>6,BF6"[P9.6-*:0:#XTB>9GTOZP
M&\$[,1P+!,N0\\^30%95Y.'*,$&$H<&LK)'5J\GG,Y95$(4Q._,B I%8Y 2'
MD()3W+)@HY/$<NX-B H/^I$$XJ+'/!R[S.N'8>HSOV1YH9OKNT$H+P7QR#)B
MLCYWR"5L$&78*>.5L 'T.;Z%E;?BWZT8/:OV%+V*2OZOUR =O5[_<-S29+61
M(<I-EBU_-%VW1@ %?-@?-7HQCJI[_.^Q!>4U@D__B? +6+;]?C<,,]O\(%;8
MUAC&(SO(3**A,_3=_O XMU%Q=@BHUQ\/9(*&__TO38GZ?3C')@[?.3QO2=N<
M"QV..?'S9YU#&&!<?>8*8XZ6==@X@>T!OZG2O#/Q*RB)B@7Q"H%K+X[V^R&O
M\>3;8#"-5W=&%CLE?KVH8"K%,[U;5E!^HK&R_-ANM^^KQ8%EGK7..2\[AI6Y
M4H5\A7MV+ $5>SP\"$8SQU\['F/\YK/\3<9WSB-]21/^,WGOJV^4I>/BH.;.
M_*X;X?1-\CL.,L5DR)RYP\;>Y$1P/*P0 9YZTQTQ>=;%I]_PRN</F&R-X;ST
MY[GLV:\S1M_Q]<?PQOF^XZ>-HM\_[/QOIO@]V8^PP';P%=YR_.#.L-J;@V@#
M2&'#_F,[W?RJXV'#XXZ[HVHZ^T>3V1O.%G\\AHN[Z%;C]*@_%K)7X^KS?^*$
M?9=@$-J) '.ZJB9$O]==:1UL\^-1_'UBY./Y6]S(Y7RQ@5==-VUFQ[\PEW-_
M[@]F?M1>1 Y6["NR"=[JE>V>V-/ARF\77AZ$#5V:T1LGZB++,E7W 6\I/=Q,
MW<KG^F_[] ;= "4()M:_.MZ+()5F8'GGW@5):^DQ\X9%9C2XPKN@JK<J*()-
M^#I;9Q5[J5V[3G"NI4,78-,;K%-2(G+LC8O!68(%8THQS-ASHT,_Q\]9(Y)Q
MMYL8IC;-95,B37,?X9T 4\>F0QKT>]6W*X+S2CN>ZTP RVR/3DQHWQ^.*IKT
M/MPC*[R3SFA_9AI=T,JY^U?\=A0/AV.M 0\X;8Q;@E6T3.$YVRCK8W,0--?E
M"6U>4'(SY599%[ULE$R5T'?4\[G):.<48E:18_WK)PK7=P;^N)?;]OFL0J=*
ML&%G(QPKQ.F0IOI\,J8L,=V+AL3W[(9A8]C/8\F6]=@MJK;HW-.;(#.CL>7<
M'V1#&5:R?Q@;I]$.;A?'9RPSTT2KJ>$"V_@8MEV>V<K\M-^RT0?6 AB$5YI#
M@'/3/N[!D_VE,+8B5CLB<92>2QY=E)PF:JBVV%A===^E&)/*LX4?9/9L+SJL
MG_P^C*0;-]-TA%MP^_^ S?OUI;F=9^NY&4S@1*5@% J.:,03)4@[<#NEES95
MLZC""FQM;X^R8 Z.XW/3/!DO)DT=)XK&V\'@%-RI&5),O81SWVG8^0;;_7"T
M/VS$PZRC_C@^C..P\+@5*84_*W]J..GR,;S4;>/W']G]I=O& W?;N,MAQ\,W
MY*C14<>DNT6S\8<%^W1PVB!CZ;['PZ-[G<]ZS=Y]GFY_=YI>1KY7)-)Z#GHI
M$,]U5,YR3)+1X(SA7,P_SO<BE)%"OC,^GOY,=[[LY.=U6ULMMK/U@>S V-KO
M/HLVW19PW<GFEYW]]I>_OUXYGM[:Z>Y4[_;Y6^LL=-L;?W=W#O;PSM97MG/P
M%6R*=;'3>P/W^YA:\U6U*>FDA56(TGSXH24'JT)P1(PTGE@1''.9?$<W!;[:
M:O#>CZ?O<>O4#V-*'M=]</&$;+WVKFLR4VIL[SL;Z2YNW&T4RU.\KM@NWQ_Z
M0;3#N!''?Q<07P3$YZMA-7."8J&043$GWS*"#&,661R$ Q0/D=N5-<&7P9#\
MTNMA;Z^2>8#:DCM7[#S46(I.N[OK=GP8&].PQ&,G*E]?8W<Q(_!'JK?J-=>/
MG\;\D_/Z],T*ZGQD7F"F62X^98:!FZ&]IXI@2X3*CN'UUD1Q#!_4IICGW6.>
M,W ,/4H*<\0-U\AYA1%/RGLB7$@R%_0PT\2"U<ZNN,^M5C\,^_&LYMD!S4V)
M)-6N^.XIN: K-\6_.X?Y8.X5(GI.TX[!7\]"X)?/&-;^[0:_K=T>6;_;G1_]
M].*&G&N^.EFVASTWN]Q88.,\WZ\FYV>DU9E 8:]%-C>V<?O=]MDV_<#;9Q]P
M>\L+@+'>]I<_.MM?/AYL'X2O[=['[N7SL^VSS[Q]\ 'O'+0/=C;V $(_D/;9
M5X"Q'8"_/_9WWK4[;?J![KS[.[5A'+O&&QTY)X@["G]@XY'6)J# O0_4^!2\
M&:LIV!XQK&<EXVRDTF&="(D\2*$CS+@CS"4F \'F\FG;;.H;ZY-<R79N"WAY
M'UXZ1+V:4O+]!U\<*)<2L#E)K9C@+'D'ZC4*F;R(U"E-5I9W6/NV WH__MGY
MYVJ+BRK-Y@4+X>DNI1YK;SB*5AC$-?;(!I!)HSSW46L6HGO>1[CKHVO/7Z]+
M&KJ2XE$UV6R.,T^'.0UHFO59G=KF4^"+Y[:O;M0NCWA**R2YVRDMIZO$F(<X
MI56K@O,[7HM7R6T?"G;+C6^]]O;7H:M2ER$O8\CJ?D[O'^%H_I:XV*.??5\[
MX">1:'V#<?MY&--Q=X%$F9J_SY^=%)_/V_RR'>U@^.NEE.:;]\<+V*V3A5M"
M %DMHZ'4H#\<GD>/*]?ZN@AR6>JGO]3KWA_WCKLY#[Y:Y_5>'][K[&*]=EGO
M9[/>F4OV]HW]1,[;*J53"RUYDV\ZWDGQFKK)5W=7G?=X]/;3V^VQ&23+Y)3)
M>=*3\T3H1N?+?"]<0%:IJ'^0\+J.VL,?1N :+D)]'<8K*S"I9;[EN$ Q%Z4A
MQD41N73$8AE)M)121U-P\=KC@KF#>QB4?Q6.![GJ[O(YPLVG!^, 0W;+G^;!
MP?@@O]<Z:V^]W6_UWIRVOORQGTG'ML^\V-SJ=G8./G9;]#W;_O+YV\[&YY/+
M!_G;9RW2^O+F='OK_;?MWAO1WOAXT#[[*C:__-%KO_M\!L_:W]EZ^[6]]9_4
MFFNO>OG0 L:SWS[X&V9I';</OO+V.QCWQM?3UKO/WS;?[7QM;>WTML]@[%O[
MJ7WP6;3/UNGFEJ?M3)YVLFLL,1P'CHQ2#/&0LPP922BX0)D,DG.B<W/MRZ=>
MZ#:1LABD1P1)L,%<>J4M9]I+JQTW2D951.JYBA3;_+"+C>!268D2S?QX5!.D
M+8@4CHH"LN $()5[N=Q^D+J0\?" :9B/IX7JE:-2*+/O(5/.@'(ET0<<M8:-
M$:PA4D7N14R"6L_N(5/NE@/[*JI8EPRZIX*29[.L_"258U@ASBVH2ND3TD0S
M1%1DB7#,2)2 :YPU#5L&\^>S)\4NZ%^;U2GH?Q\M#A\7_N=.&N8/&8I"6$PA
MD%E*M2*6R,009DH@KJU 6BB%M*1"6NL%=6%E3:HF)E=+;4L'VZ(*BBIX5JK@
MR6B"&O7;>RJHS\Y1/Q)BK)4622QD[K;GD ;7 %E,/'512L_-RIJ237,-ZA<O
MX+E2*CSQ,YJ6/;1[<=8_+C/_/>P1S=4U6%ZBQQ*UP;4!<J&<DP9;QEG@207M
M;-!))^PPMM28$B!_?,R?+YXD/'JLM$4BT(AX\AHY903")LGD> J^"OW<'-*N
MVTE\852Y'SM."*T9-H& #N8:<YV<9C;A$+SC0KH2T*W=KIX%=,%!5]9+C[2A
M&'&*$[**"B0=X+(1S+%@5]8H;6I&:U<177?U]Q-.? ' )Q33?%P$+#'->\'$
M64P3EC$&P15BSC/ 1$Z0%80@S##FG K%;#Z\QTW%KO9/NM>89H'# H?U6+LG
M@X8EKK<P\LWB>L:2&*0(R%$LQAVO<R\_A)4#JY!$0Y4#Y*--;*XB7[$&:Q'7
M*[G75^)ZX\:7CYIZ_7+B>LH[%3@V7 ?+771:!XUCE#2!+\D8+G&]1\?\]CQ;
MMN=$""L\(MQ:Q+$-2'N;D%><>>:(C_DLA]![B>LM@ROT)^VXNQTF/4,[SH.Q
ME@*58!(D'J4S3$LOH]+.QA0,+G&]VNWJN;B>5CP*KY#7,B).L$%."(*$LMZY
M*'WP9&5--N52#+EG?T!;\.^)X-\B8;W'!< 2UKL72)R%];07@5@AD$J.(&ZL
M089CA4CF)*3,)YODRAIM*G.5^[5D*A8T?(9H^&3 L$3U%@:^650/,X W+@RR
M1#+$$Z/(9 ]/1"^8I=9;PE?66-/@99!>/WOT*\EZRPCJ_0764,[4Z\V2]H[
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M3]M?=E+KH'6RRY/T@F&'O.81<6XDTI)R!(J&4Y.BP%BLK T[WZZHD\9A%AK
M[?U^/S0FJ]H8K^JP,=H'@=[;;W1&0_CB"%;B:]X]]NAHT/\&RS:*("PWR@A\
MZ9].>"#IN-YFJ<+%4\EXTSOJ]D_CBQ:.KV27!1G )@PHJ:01SPYR;E"!@B>,
M>V.(#+1J:W5-B+?QU^N_*FSX= 03#7@X!$F8KNNPV1@-HAV!0F_X_4XW 'HT
M&S8<=^%+^2+8M9T^B!& S"< RO_$P:$=@/[O-U[G:,=IL_$:;@F+>MBQJPT
MK$J=J-_A$7#7;&0V["#"\V")!P"1<,/!/V,HR[H(P=7590V0D'[#@B%S!)?\
MIWL<&Z\'_2&,K_KYTWXG=D.ST0);Y=#FA\)-R7#4;/Q/M-W1/D#NJ!KO^\-N
M_@ODI@/?F'SX%_QN_)3.</*@PT;6); 1.H"L1Q'^J% S2WF>.!AAZ'N )1C
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MQF%_--;2_6ZC#SAZX0W'3@_, KS7V_[XX6  Q]CHP27[PT:L_*@_C@_C.$S
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M^^Q#&R6L^_P < F6;P' >P; F2',A18B1H*\4!KQ0!DR.EF4I%):*T9UP 4
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M8<P26V$ CKB0)+K@B;^B*FVSV-^SV*]. ') \X,&2 [)(!Q 3C)@> )G!H6
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M6I5OE2O'Y[O!9.<CI>?<D.<2I?Y?K_\5_3^X5ZS^53\F3_4DO#JL7N>';I1
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M)3;T#H1B)S4$:U9FMD] S1)K#:$B(:-H0!RH+LI;-7OI'7&&.9S5K#37'0$
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M/NG5A#B6)<31R%8C6T\I?/;LK?1V'(V-\X=5EDV9L8>@&2^HS-ACQA=?#_I
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M>Z.-7G@U66?X]Q^=7C[Q\%>TP_@VS\].>C^,14]LY.JO&]X?'QZ7YBE;\6@
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MN:-OXG?)7KX<>WLZYU',%HZ)[O/_#%NAE&;IS)?UO1W]"6.CE0!V@#V<D^1
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M?@S+Y8.>M]7#JM74<QM6T[":%6(UCU]SL6$U]\=J9L8"@:-3WC*$>>Y5)5E
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MP.2'T[-3$7DO'BP<GY;K]*8]9*[:LFO/V>+<$A"0S2/*H4N'V=<,SP"4ZP3
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M](IR)Y2.+DC"H['6&\?Q<EW@=A[*:J 3Z-N=S>&%%YJ$9YZVM]O[46BN?(S
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MTMJ;$\?#-=&[/Q:G_&W,.E3(%(/D7&+!F1#.P\(90Z*-6"I1EQ$D&-/&K//
M4 7O>;TOM60VMQ1F,6>#T>S&-$HCZ8+31J?@2<Q-D.3U!>26%62[0&TQ)QKD
M4L&]2YQ:ZY,4(#L>P;D9Y22A[NFLNMRT)WFV.Q3S1.E:/BL<=U5F!='8^:"$
MTH+SQ)+%N7(W3)KS(%6(=8$VH#XT(\,FL^(>,RO:N7ZZ"0X[@F(*P!UQMBDZ
M*I'TF#CFO7<4M(M^[Y+$BJI.X7"6G74,]%1:65?-Z^M&BG&Z[L5^M0Z@U,T
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M11A6N4XO65?\,>P>=SN/3XA+W%1C>0#D;[#S@2W%WPB@MS<9#V\%DHW9^/X
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M;O_X!MT!1@VP^S^]&%72QHK(I),>]*C5D8KH1!;.QIRW83=6E;D0Z+'1&NJ
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MA&TC, \'IWH+$1@@N4SZJ(C-BA%I9"+!VT)"*EP$ZK,SO#YY_?!.P3Q"+'H
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M'7?R(.74^6,Z:'JB";K2003I^$&"%\RM /[LP9?AL8;Q<^>@P8'.01[E3FY
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M*8M5PAM3\OF9>:<Q8C^/:K.G\JI,%@C'N).NZ\4YP6(NT_3^P;JYJAO_TIO
M,.,)QY=9[OC:&F4_GHX..Q5#?M2/?K&';^VO%YWAP2!?U;DBJ67!R1RUX=)E
M!98+9]EG([)-7.7O"5[/$H]GBU"MP8O*3'_7C.6'A8Z= S!8BRH&S$5#,J<%
MU(81Q-L0B>**1Q7!E)0"H,.L"&I6.%MBJ%S=FU8X\U9'D7,RTE+OD\%5EU8I
M)4"-X8(SQ[A@[8+?Z()_!9,T)T>=9)$(;QGHBBB)50%>"6>EDM%G7R\X=W1%
M,'.>2PQ]6&O[PWY_V,UIJ0>LXZLOG:,6UG/,>R&/FH_82J,H:J\9:I]^WO']
M_F&G5SD<JA\-IY/Q!%Z@#@K3"2BFV)^FF?%[/+ 3PUC\46]0Z2X0Q^H,ED?'
M7.D-_"#V?!^^#V\@Y1BOX.#'4QA)<U$<T 1D"G\ 'TUFH-Y\C)K2QPA@/,';
M[$]'^T/4ES^-<^YL#">YP_YU5NW5>/[\WV'T\_-S/GRH8+\0SL$TPH8"S!:U
M<[R>J!7R&.-<O?$N3EXGC(:?JQCO;,;0*ND-OL"W<$'S&,3([Z."G2U7_N^T
M-SGL@#[\G">U#^3L17IC^,+ HRLD]4; -4!TPB&(#5PEY7T<('ZKN@^N<24D
MO<D$%JAQY^)0PQ#()KY17V,X E&HA*N6R_71:N?_RX-!GNQVWO7V:DD>X9!@
M3L>=/_U>9]=_@>'E/)A+YVIG[9R=L%+=]^RS# <P^-W<3\LV&TP7DH_!3GVM
MJ_@*>: B ;2JXI5TQGHMC(TN)^\YET8N5[67<A$N!=[*,_C#.@$WUM\(8.?)
MR@A\QI&4/-:D\XD$YAR)-(,YQ6P*UCY[;B[P":]4<C9#I$I4Y\+0"$BS4\Z(
M4BTCQS()0HW!]&4@]F/1\O7>EQX@0AH_ZJ>^I9@[(N&^[R&2-K.$"'0EI%$J
M :.PK*0@E0M>,*ZD!-(7M+(NWT20:@8Y\Z7\<9'FTWNU<;3&-^&ZW:TNVWBS
M'8 _*Q,S8(WB1,JBB*>)D:*TL,I*L+4P$N5N,A1EN5><8M(JTS(;XT718%<$
MRI@R3,B;"$6UBW[.HG,@]SI%],D6HDNV1%*!5:&])R4[B:=W!9>E3O*Z;,#I
MB7+6,W!X,1Z^6'_WO8"8BM&%!V,U+;)H[TS.U,$L9*FX-:D%Q%O:&[*[_EG!
MWK".49I3(;FJFT<QY5YI1T21*E(>@F<!8[$WB(= LT7B/F;TF8LH/(VTB*P<
M393[U.+A;:ZYA#4OW&@O:"(B8-*K,YIX9R-A3+J8=0F:8<.BU;,IKY>"0_P1
M+GAO,/6U,QWI8S7I,:JDC05^CQ$[5JS5$>#8B0RL*.:\C9S_',[9JTS57PBS
M"Z<$ZO1[?.<<$GH.)-_ E>\=S\^A\(RM-HFU%QR6O%:VU*FJ%96CH/(+K0W2
MBVK!=_(@]O)XO3>._2$847D+[OA;'VS>>]YUFR^:7;?W@6UL;>QUUW?4YC\O
MCSY\>@O7_:WW<7T#=M3&IX^O/G[:^+3;VWSU7IS>=1\_O6==_N%@$Y#SP]9&
M;^/5^Z/NJS\^=_E[VN4;GS_N=?GFJ]?RXU8JW:TUM;GU_FMWZ\-1]VCGL+NS
M[8L (S<HXK@7L.LP_TF+0+B6!C9 8MSX&BEAX^2TAO#&J:59)@8*,DD:@X=?
M\:PM=44 @X7O9X"U?13DT30_>[ZP)A4LGUB5<\](5IOBU*:ME^O;]S\Y7N<T
M\"D6F?=,BA LIZ7(Q%5**CC+SBUR]&!-R:L:T&_SSK3O)\/18:?K)Y,\>LJ6
M])_^H):S4?W4F.76V1E^R:/!C%)V<^I%=!/OCX8[(U_[!G>S[T]VJ[=!-O.H
M<FCCO^)P;[^?OU9?&D_#)] PM1L4)G)_E"?5+6I79Y-EV@FYW\M?X*$FNW[2
MZ54>S]Z@OE+/#V+N'/0FNQVX!2:7PBKBV8).?]G(\=_PZ\%PTO$'.!Q,2(5;
MH)<4GP>SZ2^AZ68G0(;C'K[YRRCC#;[D7P]Z:;);5\QJYE'R5:/.%/^:_]*'
M\; _G>1?FS,>=/$2Y^ZEF'&Z'KKL"'=J+A?^W!T='Z/9 5M]E/UGX@L\U2^^
M?^ /Q\]^/O'P>[!G3LWHN1/5;+'9.1QS$[NLE-N;J6IA$_HG*Q'[!9AURB/\
M&H[;/[Y!=W9'2$'^Y]MDT#Q[OE7M5MB'J,E0K?W[9W^Z;-+YZNN;ZNBT^E(Z
ME\*\-#3)H$H01EE1A,5 0.'B\:FOB_?@9+>*W0VJ/'R, /5V&BB$?P[[7Q#T
M #CS[%U8A_TA+@.&!0]&P\%.&L)W5CO_[/9@F0;#&9RB^NL-_COMC8!W+,1^
M]GS**V>PN?+?+T7D"',7\J(J*-/)%-5&I62J@-4H?^G!?%3@?4)/5-'*@XS
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M&/JS';_:66NB8E?,3+C*:E?'$Y>0,YBN<5Y<WZ>\>[I(*<\Y*@6BA2D3,(6
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M!57*+-=B<8?4Q2F:&':U91MZ!O<<[@$_KU-7017L]O;']>]1SRU:"_7] %=
M558)(J#]?CL$Q.OM-]D<M3+%6N6=NK1$#2O<SD[[+]F6"!6I-][K53D!,[,"
MR.0GW*OYF%_ZA2V+@-/WL0I!?9K"[H2OUM/5' /WXUZ3)SS(O4J[UTQRK[ZA
MKZ*XAZB'45LO7MKOC'*5@G!R$E=FNGNELSL\R*",5_#7<^BJ,P<JVC#!I"EL
M'#6'I+./72]=OU^A2EG,5\8:'--)133ZO;W>+!,",.<X[:&:CH5LO5E&'![+
M@T%]Z>T, 6+'8*^E7#(*6S.0R6Y5)0)YSC+FLO!Q@_2'"VF 58VR:EQ5?L4B
MG%649R9=,8XP2AW] #-$ M[$C\$F#-5X:HJ.*4FCXV2,CF_&5A$Z$!I0KSVL
M7Y&CGXYS]<#-N#" 65\W@QQ,ZWSR>OF:^6T,D3%BZG^G^4028,6OYIVZ3J6U
MU)56QC^<M5![7@Y!VXZG(S2['O7S7TR$+CI0@$+=S !(2=V' UE[5:H:A!(M
MSZHP7V>Z?PX!;Q*4,/X^ZE50W(#F8A(7IE2.SXWOSRV+UX.Y/Z6R<>#+GP?#
M [2/(QYUG#0#KTR%Q3+;%3P G(YF^[H>U4D#Z7A[SCQ#%\W"S,#V"5-0)KG.
MX(0/ :2.4[1.\:1F,NJAY$44F@]C9>D<S),9J^RX K-1^Y1.I)]V&A_7!3_>
M!7"N-L)X,J\0TBB^ [2^JC=@L)C%5BU(E9\\&_8H5ZKWRW"$P'S1612\#,Q^
MA66GC<%^?WZJ9+8,QQFMBY-W E"7/=C995FIUP77\7OMQ=E)E)7E!B).]K$=
M^>N"#JSFL4FN&PQQL9M!5C/3S'8SI2='6TUV>\SFII!-TO:837O,YI:/V?Q@
MQV:N#*C'VGO6$!9UV.[A&-T.@_&94Q##T*A>M*IJW7X:Y!^W;^Y;(50T]W9V
M3S*3VI# '%CTBB)GF"O*PX4) J.JAZ>=<2U\HV((GCNJS;_%4HJU<30[>/*E
M<O;V]RO#'"YT?/'*/FCH4.T47J1.<S8TR\V%8>:#RNJ 7=)'YU23HU\?G:@3
MY.MC9WAGY$]??*]?;<&&T<W]U8.9KJP3KGQE2.7]^FA%'(XGC<&/UN^,DU3Q
MCM/.V^\IRN!86Y3A>XLR\+LIRO 621#6"!]-#K=@0XQK+]/#J\B@NN]F=5#Z
M_8V]C<\;_,WAQJ>_/W_<>MO_^,][^>'HMWYWZ_71QMYK!K\7&_]\W#OMJ-O\
MYSW_P-^(C^NO^<8_;_L;K_[N?]S:_=1]]?YK]U.7?_CT-XPULH]['T_&.C_!
M<ZQMXQ%06I(CH*\RD<(XK,V@B/?,*^9H#-F>/B)JDS F9YXT;!;EM?4\!Q$5
M8T:ZH,]49&@6A%0KTEE<DFN48_CVS4\.UA0O)0LE15-DU,)&'ZU(%C0S]DZ0
M3TTQ;PXZ&X#&5:U5IJNP!8SA_8NUOSH56:\,8?3NG3P&-QA6!EK,O2_UP:"3
MSK[W+UYC[.-JARLD \7"0Z 84+>*6D,E;.$ ^UEE'6*5] P+Q_2B5UZ<WL\O
MJ].!W0P*,;V>%VG=/!@ Z]CM[1^?NG@P1RKN86._5MN!>OC_8DGDVA$9E29>
MYTBRU3;9+%,"K'PN[:I;=J:B*L\^*Z=;S75S'CKGA8P!]:^5N1^E/GASU<1=
MDYUGQK 0N4Q>6".Y5MQDJVPL+BR7B2ME834G+[$BSR8RE;=SJ1YOY,F+FD,]
ME&#-/8C*Y\-MY96T8)81;[0B,C!)G-&"9%DXE=3+4.3%H9K5#@ -'I-M8AC,
M5AQL#CVS=Y=!S[GB,@>=TW&^*.%2VJF0A#2HF:3THB@>N!/ !9O3$XS;B\)[
M56X42,ZIW*CJZ-9%,E-!VV99FV=PK<V&^6!*QM^]%'UZ3[>U2+HX;8AF&;B#
MYH4XJA0Q6HMB"G-6\6?/)P?#):T!CM/A+J>&QG,]]'WXPSC0A4@=-=Y('9,%
M?J!TH;)(J;62M2A1?5*46ORY.<DYZM)MZP!X-(LD4$6)M$Z3@'VG?5:T!)Z4
M0X\)7U4W=P+K>AC2+OP-+OR;K]NYP/8S,A,P.SB1R@1,K10DLER29QHXNOU6
MCL#)MH>@AIH4G1.5\T_T@_#]NLZ"'S=QT5&N2K;ZXV/,J*7^;WU^OG&)SQ+:
MKL9YE?/9:PE"%1+8'25$L%H-C['8I!V='4R2)[/,6\Y[=7G"\<"S',#[AYM8
M1/1@VQ:O&;-5CU5!)%6,!,TC%G(ML,^-5 @K%S#@:G+KV#?VG !-@PH'*,MO
M5=[" A'63_H QT(]9*R/5 =GKU8H?J/;[60_JJJ\7+NAL3<T S0XT E@+83H
M@V4J!VFX3HRR63J\O(G2R&_SESR89LR>7? @/:!3%_>PP]X<;FLPU*7G'E@=
M]JA($=M F41$%!;L3(G=BV%/+3DL78O&M2LD*V!CR5CE7(*=#%HC@K;(4BBX
MHQ#+3T*T2W]S2Z^V-16,!T%)X?"'!$,=>Q1S8A+N25H8:#14UI>MD;QR92&(
M*@(G\-B\4,H,/)%&4)V2.\VS\GG6753>1)GL5@C."D'\NHW%Z0-EA0@A NC4
M(HD5CA(EM3):\D"YQV()9_N_G=C_IR6A-VAZ,M4GI')NSLO\V5V;A:<POZAF
MU+E.I*XBNR?:/M5^JCKS""3I:E3-\ ( %JU75DHJ@]<J(5T(165J&*NK;IQ;
M\J6E:I<7I*V=K]LT25.X581IJ8@$ZYM89E&:N"N),S#*W 5M:)<N(5=6%Q-E
M=@[,N^1#*@HN[(JVG(IXSIG.RC'4+N)U%M%ZEX4+DFBN"O:. 8:MBB,BY6"]
M9)H%!8;[6;M]">%N-O$2WEWU-PN'5;,A  K A'D:P>N_UCI(6-$ZFY\K6/1/
MM[3\<OV;KD_*J45?C59"R"!]M($F'FD4.B5%@S$W0<KK>EIUD<FN3WEKN!C5
M_7$U,CK/.&=188Q6)P<:V29*'. >R)SR5I14HE58C.,;&OG*9$PG*471-"H1
M9'(I%"RDY%C,103'OE4KK5WW[UGW-U^WI9?2^R((&,* O3$8XH!_D:"% B36
M,.GNXC8UWTO'DZ6*N5QH\%R6%'T)62MXEA0LU5K<!!UO)> <"?APM&VR+;04
M351@&+:CG(3",A&,^NR38D5(;%ISOO?TZIL>;AF+3H65*!,7( $V>JH-UU$'
MH6^B45&[Y.<L>3S8IL*X(+#X@/>62 ?[W14%)GF$%0%#6&''%%CR)>VWS]GT
M>#:K^WKS1652S4OLSNK;WI7QI7TT8%!J YQ!AB"M++($EY7P1L246^/KIL1H
M<SWR;2,H#R([XE26P-O!^/)@Z)(LP$I2DB>;_56-+\NTB#DE+)<E70Q>1.4X
M&'D^",NX76Y\M4MXS27T+G(ID/9%K&DHHD/-;TE23MN2$W,ZU&<=;LKT:LVJ
MNS2K1#".F8R;RDDM@<2#KG5!1:M=8,FW9M7M[:^MSVK;%)-BX8($BXY.YQEV
M2(V$&E@ %@WSV2"]/AL[_#ZS"IB484R _1R\!#L:6+X"R\JP8&WR-],/N5WW
M\_*A#S9VMI5D4@O/B4%;&GN\$2\%)XY:X5WP-&F.'.O\LF+?;5AED\&X,LYC
M6G, XSH;9U(I+ELC#6L-J]N4@</-M6V:DRJZ,#"I'2>R"$U"*IG$;+4R2BB;
M'68DW6 /6!E\2::X: RFJ'.7P:2WPH%Y74P1MC6M;G/1CS;> "OV0JG@26#%
MHSVM":RV)887EC*US)AP<3W!)<;5>O?5_9I6E F;I6**40$T0EA0+UBA-V'M
M\5*;5BTOOQDQ>GFT^68[6!JC,A+ PF$G@R*)+T:1$),#*@<[6XBK&E<A6>V9
M3-[&+"/#DJ4NE RD((-*,+2UCV]Z$3,0/2PXS#.VIK4^$!N+(2%$$8"5>:5L
M:UX]8O/*<="D)GE1M+31AFARD-H'D)?@;/Z6>25:;?L=IY-X=V=;"&V!UGK"
MO</Z8#826V(FE"N9.772F((&%KM:)LE5:1>-67%J(JAW)0/37OA0HG8R"4T-
MC]_BVKP5A.\YI@:"0*D*VG)/-.8/2,\,\9I;DIT2669:@)9=0Q" >ZW5Q7%3
M9[WG=P9#@,O8>3<=[>318>=%=0:I(EPS1H8)X'Y.U%8O\_/QKH>[8LFY/4P1
MGR-\=3IE=D ^#/THS4K!8:8"X-</A?#7078L,+>#G?GJ$F_71WHC@2Q%2U5Q
M2@K\E_$A<E&\%9ESV3K2;B]DA>UWCKI?8<QL<[W+P+#F3 6>)"-:>T.DSF!C
M):YA[^?( 8B+Y^S9<[<D9OE];C4.M\L&=(ZG!FZE+*"*3T5(&:S65K<NE;N2
M @Z6MM;&.9\+B8&B%!A/O&.%T. 9M=E''<RSYV8)Y)]G:7=.-H"]/EQPX1@>
M, C!&JFI#-2"T$CI%67)FF\2PU90;DA0WGRM2"*(0RZ!4, -X 86S&AO #-"
M#%$QXZ(2Z)*Y:;C03FO&9.%6@-((V7D==8XE.)9B8+Z%BSN3 C#&*2:<.):)
MD7B0RV.*&U,:@","1?=:*B/0(W\V%G.!8ZZB;KO#?D)2=K [K)MX],=#H!L%
MZ. Q5>LL$)KK&JH7TIDK'EI6RD;)LS0)=!F-W"9F.9A+1EH7M6DS[V[39'FO
MNFO;%,! >.5(,90326TAG@E*J,]X@*"P("P(I+ZH ]J5#54NK'4\E>@CJ"/F
M V-:ZR(Y=[F4-O7J=E=]XV [ T?1T7!2I(U$YAQ(D(X20W/"I$>3F*Y6_4K9
M5R=PJ$:<;P0,OIOC&%&*I%PE(#<2"WP89XIGT221F9.N!9!;%*6(/86TE$*&
MY G,/,>D[41\=H9@[H[PEB<J$AZCO*!UU95[S@ILCV!HH$K)Z,$:9L%Z5URA
M+G'E6ORXS44_!*O'6:<BIA,PAP<HL[) 8T(@%D/\T5AF555FY_)6SY5HS(_D
M<;K> ?7OC"DPEIWEWBA?F%28&2U,L51&87U,.K2P>HNGT=ZHC:/W8#"\I!OK
M:PRTM601;$8!IJ/T8#I&CVV]X0\>.)Z4R<4&>T$8]NSR.B/!Z'2%T\RDSSH4
MIS&4KAP-P=,;J3[0+N]EE[=0L'LL<T0$#61,8?4@:8"'VT@S6.;<6KN\!_$E
MT?7J+D;!D\-*5\I[6;1R427!0V Q2Q'#C9Q.;^7C,O(ANP?;0F%1 B$)DU$1
M"9J7>&T5<1(8EN4&UD5=:?O+9!*GB:H(YA?8V@$,[L"H8)H[9;EH^=-=+F^V
M19KD$F&PT3#]'6RQ%"EQ68:0I3?2<=S^ESAZ? &YFO59^VN$'1XFAQU<!XSQ
M=7YJNJMU__IKWEBM:NPZ:'A7IY_].*]VX O7C!("(VDYVUG.=B-4C7J7J 9=
MKG.6)?H P,VT+LH%[FANO?RW62MRC6^ !6P2,.,4B#:1$0D[E@1=$E&% U_3
M6J=D;^78LI N13"YJ.6R&.>=UER40+THC@O3DO3;7'G1?;,M0'-R+Q51$M-L
M#5K U%/"C,PV>*8RR[CRYBI(O3G(G>Z[S5DGS&?-OY^=@\K-QW7WV]0;P;4
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M$7/N?'%;[^V29<TY"I6M(2H$APX^05R4A22;0<V;)$N1RXM>MOZ]!V,%;IW
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M*D2?LW \*8D+SQSC@K4+?SL+OW&P#9N/&Y\T*5D$(C-/Q%&1B0<H=Z7PD@W
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MJ@M.K70L.5I" L(/KZRPF@'-@U4'I+\1NZS=_-_8_)^_;NQLAZ(+;')): J
M]Y$"QX:-3PIG3()4.!KLU3;_9-A9VQ_V^\,N4(0P]*/4V:N8U4JGZR= *0[@
M[Z-TZ,>#7FV>Q?GJ=,9-=Y#5SE78U",+*KP&LR0!]:\FSY<"K!_(T1C,5)BV
MP\[P8( S=[CHJ:_*D)E?D< 6F)_1>*73&\3^-,UH6O.]_SN&5^3%RTWXPOIH
MM?.NMU>S6WC]I]^#VXTRK-?^<#2!>P _QM_Z&.M?X\5P,?#8%/HD8 +A+]Q
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M2F)LUHR&/HQ/YF&#>-(?C!J].)H\$/A%9QRS59]LVE;/M]W<4.!NXZJ?@!5
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MO:*B&:>@%69ZR]2><TW[%HW-$5B(\QF1O-RQM \=.#Q81G2/&5?RDWX\YE^
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MZFBJUE2]];+*=3H'+$!5<MIN]\U^JWOH^D&:NJO3;Z9JU;3;?8W=]_@Q*^K
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MU=E_QXMO(R=7+'5$!L#Q[#74)L+Q&(X?)U@],Q]B:RZ<._YRII^1ZM9FOQ<
M_,CV!S-=0FC$'/3GLO&8BSBDL[_906I'@*M"]AP7CMZ^,CXP=@I'<BK@F3'I
M123M+3)IB6\NFQ(R)<30@"_<H%^(&\6<G4T82D;^#8I56_A/,T;VY7\OWY^"
MT S3A&S/XSH%. 2U0?L"Y%5+80%V^8/RT,CUP44=\N"(W%EQ.IOY1"$D9SBW
M/RH0KS+GMHXNM<%8:Z^WY5JMKJ+ ;#WZ*DO.:G94I1F&ZO2T*?<<IIS5["D,
MKB*V7+>](,]?MCHJIN[.ENNLLN6V(*#=6G(=Y8@V+L)8:<-M;\#AE]J(>Y 1
MU\IU1&W$:2.N/JB_M1$W6&/$$7+NV)#K+!ER] Z-#WQ>XJ,'4@;@CF'/71ER
M[3S795L>K,VX\IAQK5P_6#3C@.;A/RDH#5+<,6W4[3!\?1[&!)MK@?#U@L9F
M#+T Z1V@F%'L4T? (V, #XVS 8/ 2%IO0^X?Z/76*H:U59YF)_=9D2W6[@A;
M#%.6;=\OIJA(EQV\V%)D@6JW344JB>/;WC0V5:V7] 7R ?!DFAPJ3(#.7)L#
MM]XP,==:(62A7'T4P@,$PW#EBD&KP)I6=%8Q;@]=":"@B-R[(/& Q;C28!"$
M/TICP(!X@X=!9VILSM1HZ4P-G:FA,S5V+UJV<%E(P=(:;/3Z68/.*J_?-H)E
MV%UP\G5;VPF6X5#1WIY7L#Q0KBQYFW)G 1<EY%OBOI6ELY$ O,^?(VRK%3!_
MFG-'"D75R-J=4"QX<R4X".5R\\LFUT=FFR'2#!3_"JQA% 9IG!O]4]NE#5/S
M>!<U]$?XQP3 [AT:; 3,8U\#^R/7\C^2L>MS0G!!^H(-'O$; 9)3U0M F[FS
M"@Z[" [)?QZI]RL!R17<V=J:.1?)K*EF[6$JG>#,>9P\7HX.C!FLB4?9/!)$
MP#9Q);"J)2,8>#-Y/56/#>;;KS*^X2?@ODRFA]]GA,?'=?GH(:BU5:R/BWW%
MP;4JUK<B;7,KH6^IR@2\N!S76X%8N9B(T"\FMG6OR(%%N&Q&UQY< ['.Y7((
M/3GAC''%LVX!X(<RZO=L%C%Q]X-SZREZWO]#7]0+-)OI: D0M@*(1W)I04QJ
MP&Z1E#K;W9\5?FH1% *"\%.7H=]:633GG_!>,J<-(/^=D2=97F\J; D>]T!U
M#6X\U%[M&)2NNA'#3D]\>^:IVB>+YSU07$SZO ]]X[+05OY]F(Z2<>I+J^ZH
M--0/VUU'7DS=N:-<*RF<T:A><$$ =MI>L!!)BQ'-BT'NI73U=C&EPU+UD87+
MFTABO@]?V"//QTPO86R"L@GF;N#2=6,^$WH2@M#PP^"&$LVH0DI".DC,\AT0
M'2O;N 5])$1S$+0(U1LP@B.W<X_S!F\ C9C/'# 'K&",U"V$C!92;#8,6S<U
M]Z'$*\J$G'P*X_@5CZE> -S@^*]8,@%6>AG 42;38[L]+>!" &$<(%,.$"\'
MR*-N<S75&S(+@LV'4[AO3DJA:IFP_X<9#<U<9JZX%+UD+H@%@$D8 .6+5?UQ
M?KDTEL:*=5BQG8,8<:*5P_/1.-'<3B=:54-F\&3$0(:K+@@F0URAV@M7EU_.
MEZK<D#AJJM'6HCC*_9=B/@0#6S\;OV]P^?7,P&/#Z:23U#2Z;<OX9\,X1_%V
MPWB=@O=7'P74%(E8]-C<M\3MO*+%\Z3LDT=O97,N*%V3ZQ0AO#F%\[[5HP9]
M6?2]\SP\)[P)O#RSS/!@>UY$B@FA*X=LKGPH2D!QP[B*KV?7YU)W$*!17=@$
MLFVPS<1#-1=PKA >*9ZV.-_6:@ =NV+P$15..+IKFP<&M58@@?(@G6 K&R"3
M \/AIL1QSM'Y<2!W%9G>0#/<OWL&;_@9XZF98'ZX8LO;ILE(B<X?>63^2%OG
MC^C\$9T_LJ5]()B.C*X\QD!LJ:F"BYY/5:MZD);?4NL*WJ_EX[A8;@J> >7/
M&-L.=PK=86:_D_)T:N.:S1*J/,63(#!\"6<A0D=J+@CL/TQO)H7TPIH)J$=B
MQO;*04&57<:+1U80[1;3^,N/%Y5& WZPV_\K05%1W8O[2XZ2SL4UEZ=8 ZI'
M1[COUQ;7V<0/A*&[]MU'K)%[!HI;!74!PP=QUK&8K'9NFCAV/#$FS"?N ",S
MO!84_6 \RH;Q#6_L.>(FF\M(LP:FP"-(620N&YA,L"!,6*Q<M:N9/'DHT?%;
M_\='<85J!T\A-VM#M&R1OD)U4E*O.N21W^Q3,E>)YEB-5A?OYA=F62F.;S#+
M-R!/VDUD!^J%4B6S<NOJR$MQ@GHATM,BV\+Y_]W^62^H;!7R2.R?F>K*"UE8
M*^(-6YHY"\1DT^BS#-B\2$!K&WUVF686%[J4_2;(2;B_MURQF'6[C'':8%X1
MG&I]UTPX/1)G5O8YV(9!;X$QK>VR=)^,,=MD,&ETV5L#D\]A0+5-0CAI$&]2
M"3VJ,,2&-L5!$3Q28XY%LY*.<O/C@4R[8%[T'YNZW.L]+ V!+HR+F(>(N>1[
M$E%F3X8^^$)Q+3=9H"8KAP,GG:1H,=B8EDBI@"Y/X*/TH*_G-:.Y?:%0:U6>
MP38\_#$9NRL0:/ P1R;>W!/XLW3PYC+Z +Y@[#G#H8AA 8X8CC'RG 2&E=T_
M5F"+Y_[UQ?W><JO=?+$"QQ3\P;A(,?S1S1%J3<^NAPYS<+Q<P_GI##ZFGHLW
MZ![B""S+OG;D^,/*0C&1I&G$Z0B5 ZIS=#HJE.B;AB[SJ0O,'59 XJ7Z,$$9
MK4<88@8/8LXETH,7BU Q+Z0B8,RICSIVR$'Y)1@$+#Q\(3,OWC%XDF4"UT1#
M""]\;KS[8)Q@+:)6\^W%N\OO[\_H@_7VU0;#LC((O,.#+I[%1-P<93SG]CT8
M].1*;UN2DV).>RSJ\<7;5>,[M0:SI-@KLM^Z5Y)5] 0 R7HE<9UO6FJQ<R=(
M1(+ME:3?(E%B&AA+[K .%RA12M2&^YQZ?>4K4Z-$/5%"Z8FFXH/5;"[B@V4U
M-3[4'A^X5"WB0G>)-UB]8I/*8+OFGQH?RK?4>_ AU]J6$:._A!=#A44\-NA>
MT>-^F([V#7LR2@_>"VF=&-\8V,D.%0H53DC%;P5/BT,HJM/TW4$1S=H.2"_*
M3PTO?B/@OOB#^P8^@WGT\>SLJ_$A:[EYQ>P8"R%H@.\*X&BB*,66O8#*W232
M&P,6H@.K']$U/2S/&Q&I)!,[D15C^25"[*/J^Z*X+*\O#P<&=NH$IL.^D9$!
MU@V2W<0FQWO,1-U>47' R*@2#5VT;M-8!@->? BC.SMR3S^%X0\THJZSUJLO
MR(-#OGPPH_Z1VA',#--^HX*\F*L [TX-JWGZ#UUS[K$YPQV=,ZQSAO>6,UP@
MA8VZB-7F*,!]VQ*<800+1E#Z]BQF;^0?;X&'S'Q[_L8+:-/TTMM;S$UR;%_,
M"O,(_!L.&_UFGU PB>#_KAQ?H&>#H^?KQ%W^L==K--O=];]O?+G9L#;]V&VW
M'_GNQEFM=J/5&59NR=U-OZLOOZ9#Y <)&(%8^-<75O=%SJVXYHV(UIK]S#1Q
MR6S@JRWI5,%A5.,7,8P/N*#I*X98Q$EQF;?=XVS?FB$4Q<1#-K6.E3U&8SY;
M,&5.2&2'*2S4C5]E;$*<:W9B[>S )#4'(6>GY7AT)9KE[QP A3;LH RK&9:<
M BNAIZT)MOT?AADN*,RP('<U 91F-0<@ %1RA)8D%:E98H"]XKF&1,OZ4\=2
MX*TL-)(M$_:Q!+1?QO2_YZ*0PZ]EN(^U".RG;)Y'HGZ)>.@O#IA<SX<3AY[_
M,7QRQ1(%EZJ%>O[BMT_AW19*LSZZ$A[=[S!3X>SNH?]' 7$/K)K$9"DD_)(C
MJZG$@4KE=E_219H+Z9K9:M/9<R^V1^'&>^&Z0IE\\=N)A39[.MM">WI6->)
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MK *4']C#S83;JP&]Q)T-: J.87>@Q\#0\CN.5OGK9*3RHR?]!M6P"&P&4*O
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M%QU:K]F:LLC20J!*U#/A<9R%V(MP!K3N 1GHNTO+SRPKY!_+L,L-^3;NY1&
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MWYF*,6L>OGTE/>2)_9,5%1J$FLA.XFUF!0(I3>=57P0/^,* LMFU#^*+?!S
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M()=FX4H&L&3>D31;$>K+^8D4SCQ-4DQ@DH3)90H9 T1F>4!2?J>BF'II(;,
M,&9,D5T!DCP]=_&N#MBLC#!5,D)W51HK1=6X_2W!L !!)!OD:'# ]HU@%<"^
MX.AP.4)AE_J@XA*E,'<&'1*C\BM^FV84DHS"?"FF$!Q]PY/ /5 V*1R=CT7I
MI)3Y3TD2=)"9TH9^ 08B+W,B<![/^4#AQ\)!+5/9QG;DAZ:BA]Z*>R^5T ]9
M<Y'S0G.1K7:]EO&4GZMLNOC&\R(HV"&@M-""A:Y[]!K=3*W-$KCSK"CI+U+(
M1]YI0\434U>Y/H2NX&Q&(@)N>7&[JF"6V%%$FE_QHHB<G)0/8&:C;!*V?@<R
MFSMO,X/^<"Z"O/&ZE1MI+ 4=SU9$(BHFXTT9J GNBFR!6M'/1;;[2[G[;[![
MG2+QR!2)@4Z1T"D2NTR1. R^;]D+8>%B?M7%Z?<5)IXMHJOKQ$3(+V@G69]6
MPTVC+/"RJL9R,9S*<\])=//L[F&;IT9W&GUK*;L[8](B UCJ>H70,!C>"<OR
M*#SN,A<.(5<*2COOHRB=E[CX3.)SZ2IO&/ +BI1%_: MH7[1;+0+UQ]?-HN[
M,L6WC?[&QZH=)5XKE_NK4?$3&D#$(KCB0OAHO36^"1WIJQTE\WI"9 UQ8JSW
MG30,/ZG]RX_ ?? E4.C,ZM =YP&_TT]94XQ;]6"43X&"0[ J _(6*=>4P!XN
MEF?(KODL0795E0%NEQ;NC7/KG%^Y6[J(KCK+>:H8A@^Y7\X5#O-\2ZT69QT-
MXTO UGG;1B'>WIB2M4.WLXGS36R,\W.><7[Q!5\N[I,;$!LV28P7'2+LSQ0^
M^O,,IBMN2TO0HX7$IGAW,_+H"CM/'\I]7P7 D!>["!2"4E_Y0O):$92C5W+K
M3DR,G#A,;R;&W^P@1>^!O/!.&?L\:P-3O(7KYXN3A'FV4?8HWGKEEI#P(1<L
M/3LHN'4+=WR4*SYRO2,6L+%'5MSYU36'=E%&+E[?^2>Z$J\3 ']B_"U,(YQ&
MX.(LPN@,W=B2%5?H,D^S8;6ZOY*CO]OHP9\BE4E>_"_L<, 7X<LK4TK9"PQ]
MS3"\9%S!)C#$^7OHN[Q"!MZ S!WS,I>!;$IX#1$DP0 Y9=CG*38R-@"? ,=$
M+$9<(%2]X/;*?"HI)+LJN6!OK)3G\=-]H767]JWA4?E0ORR!H:LRPH5:*QC!
MR2^!4ZD:Y7K:)L:X'V:W<NE#X4)9NJ.^@2.= 8WX @WZ$H<0;?^6^G/!3H<*
MI?.P]L,8D]53OB!W)3U7^)IVWFCEN17+%Q'WR0;:C78_8P.KTA2Y$CWH;^85
MHE+( GYX>V,:"]P"$9='?BGR#(,LK$0I4# +T5BD.SG*!9B&<8%)/6YDW[E8
M1(I.*EFY); 2L$)<3B-Y*9N\&@;A+VGXL.*EPB*QN%R9G6QVHNIH!1M#]@L\
M6EYE6+G@W:R)F :WX!:1.M?XY!5:TOQ65-Q"ORMG%7DIJD\"$9;CRNILZUCK
M0V:D@BB;8S*DLQ7+;"VF _,%G(NHT/+=XCP?=4&AS2-EZ[:\M$)^?5",N*GH
MU?ITZ,VQ;NX9H 0!I8!/=C;253\!,&*J6BM_(JMED2]K?5$3$E%+<?:C,A Q
M94<;B$5V07E/CS40'ZP'68\U^G:I V5 4*V=K<PS:U$+ZC07M"!N6M$@Q7U)
MJVR5BL&M6N,LO0'44JU(L>1%U;Z9"XLU4)&6G@2(NL%UF^LL;:Z=LR.^$'D%
M9OT8RBM\C(:U7OVCVA-B1+EBRKD1EQBR1,&Q*(6A7 ;F+&^)HHM7L!?MUK75
M*$3^BIL%)O-L.,KT)5?MAHL42#E";Y.W,$0*)3PSIAH)7)\3Z[97)0F[\LX4
M)K>-, %IE8+ E\'O4>=E892\?]AW-I$IJW%F=8.4M I9K^M<26Y0DA06UB4U
M#B S6(LU' Y5R?Y\VORBSKY.L5^MRR\B8:7EWSW2;@UX-D*'4LR(A01AD<"E
MCK%D@-1,:W^H'YX"+HY0TJCF2[W@<4]V@+@N<G;UNVE<77TTC7=GOY^9TAH^
MQ]38<Z[@PY=_O\KLXX^PB9DPCD]>P"\O^,VPZ_/?STG7+3IK F,)SH426Z!)
MG&7<E2LE9W0O3C RMYBDJKA]<*0\.Y;R=7%//,M:YLR) B4BB3//\ 6.CSI/
M,J&J5OC>AF4*.WS31C)%BJ>87UVMX/#YM1_,UG-O4;C!+E.L T>UW7TE_9=,
M>G[%)LGN[TYR T?)N5&$P(+2ETP*A>X6H3)?R-:]#PX+NY0)Z-G=(7$)293M
MB)5;''0O"?.',L]JOJJODWGL.1Y,M/K>!R: 8Q;>BMWK7)9'YK(,=2Z+SF71
MY3Y6T<;3.*IR[RN^Y^+71H%SYOO"=%(>\JDP'>4.C]!OQ]#F4MUQ(E&$JI!3
M^DB8 BS<^-5Z54\Y'23=(H4*]DB].++SXBU'R"$^B]D;^<=;UXMGOCU_XP4$
M57IIL6T)3".XPW#8Z/8L8A"B[9$87S"/!F<>"RU5Q(_#1K_=VO#[II?!,MGT
M8[?=>>2[FY?<;+0WC5S")0\;[6:O4BNVK$:[5SF\L ;]:BVY>E &5+;:6[Y[
M3R>V+<75,W6RTZO1JZGJ:EK6D]H;WKMB88H]0TO7_C,T2KOV?AI7/#GW(DO.
M-:1K<&VSU_S(I7H6A-QZJ?.C>^BFN7\"J81#88TO]8*,GP7;L-SL1Z/#_M!!
MWL73"%%7<21OJ]!52;I6B'_,T'$;!.ET"WET!$>^W[[156805[QLYS9!W&IL
MZ)WM8SBG/AMZ3[D*]=G/5[IZ<1B!M*LF\9IUE0"1+B@;M#Z$L9)S:<K0E/%P
M%IO=*/AJ>VY]*(2+0IYPI<5(B7939:3*#*C:D$D=B;X^^UG+N/;@*_W%<1@;
MC^]C!)@,L!LN4!+0K\OGO?K]\0)C2U@^R@]2QB/>WLW5>08WU\M%1]9N04:G
M\FB8\3/EH>L2P<QJFO#\0OV@TH*O?#BW&G*'YA5YV';7HN%II[AF]26D"DT1
MCX7=KV4C!BTXM>#</<QZIC5L:RY1+[FI685F%9I5E Q\FE5H5G$LK((NHK;>
M:F:AF85F%B5#=LTLCH!9E"49'6%;EXC*<I&*2J4:/\V'>N^"UY)6Y9RF>XDD
M/!U^%>(^F@@J3P2: O8<*M#(7U[D-UN#W3NZZHO_6@)H(M!$H(F@?D2P+]>$
M)@--!IH,CHL,#IOS7!,GW-75QW*F-1\@5;%J7*1]\!3="G(-C=I50.T#)]J6
M':]+ETNK47H+;MWM6QJK-;?6J*U16Z-V15"[#+DT&KDU<FOD+@]RZURPW>>"
M_?U*YW[5D,-T=>Z7CO8<.Q'HW"^=^W6TR*]#G5H&:#+09*#)0).!)@--!IH,
M-!F4U@UW?/E?V/!;)X!5E(WLQ[M6<^^]1NTJH+9. -,)8#5#Z8XY[&BLUMQ:
MH[9&;8W:54%MG2.CD5LCMT9NG0"V5S_4N[/?SW0&6 U93*NKLU]TM.>H24#G
M?^G\KZ-%_H[9[/4T_FL)H(E $X$F@B,F IWTHLE DX$F@V?PP!W&SWR\343$
MCV*J-OSNANG(9[K+R&;*VPU02\KH6AUS'\Z_0\&W?%A;\K#;D<ZOV;%FQZ5D
MQTVSV2UQNTG-CC4[TNQ(LZ-JPK=\6*O9D69'I267TK&C,F3":7ZD^9'F1YH?
M:7YTR*C"Z\2&;<@L5/C'\-R_OO <I^OV^H.V8W6&'=L:#P8]I]EVAFW6'@X
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MSYAL\(C=@,* LV8GIJ1>[<)?>W!NMRXU+_>5DU48\+P,I"OC"WHF<JKDN E
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M5Z$W6)_.]'H4NG/XSR29^K_]?U!+ P04    " #<1 I1%^(]A+<?   =;0$
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ME;6VSK:>#\)PD-SK" ?D$4UG46[3Z<IGQ5G8ES(F1"[7(:6<W!9M!67R(S<
M^5[U(V2S*^23.ZFTY\'81^+==685N=1;?4)4Y4X'DQ']&DY$;ID8]F B=_JO
M"QS<(!;'$L]XT,8PBD2OCW"!2;G&MT'*G@R/!,B  =1^AH/)>HF"SS%@0@;A
M9[K&@JOE9F7>D@FL@\K^!%!#R<4QH<8X M, TQ[<44RFD"Q[D.W.=[Y&$U5
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MY#@J &R[RX4WG)4I?RJ(YN3];>5_K[G?XB5P\6D_[KZB._M7/E(R;P-JN;^
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M<$C]D-HP:+,F=/LJJUT_F\_T1M;5_,5L7M/AO][;J7DGEV[Q"$[SI E##MF
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MZO%AJ'=>B]62$ A1@:Q,;4XD!02AZ%O+O38.E?5=+FGO G9(28D/0[1=M/:
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M:Z2QGJP!G:LUH(N#8(0D'42AA-(9^Z2^;(ES7\/UEN&NC?-36(S3")5%IIV
M:,BB5@XUA!(Y.&\E<\89ZPXIE)M1#LF!ZLFZJT9M/U4V<Y-NA'B;,+Y>OQN9
M$DQFSH+0G-5:20&"3Q)X-";&E+7@70I<[8AW2*G;#\[ QNKMZWG](\S'U;Y]
M.5TBP5V>M\C\Q\OG.VW2=SZOR;:[.>(&%L]=@^WNO6SPU.ZBZN35W#7D'K;?
M)H_M+K*^E^BN%>236M(R$!D$C0BT%'GPH5B0F8D@HY.Y4\)[[X+U=Y8AK"6Q
M0W$)7-*<MNDDP'O-@.LDHD_.)-W%XMJY?O]#7Y/;BS?W5+!OIJDV5<Q?C/-I
M&H?YEUL*[7LFK K,@6.I@ IH:.8Q ,^)ZX")LZ+O6VDV&6A(YDXC C27;Y>"
M3??6JXC6!"VB!><2<=*C(G-?9-#"%\D4%JN[U W:!N2PKI\U73ZZZ:H9FU8Q
M_2NTQF@83R6"C()HK9,'9[D#1($B,RS.=*F;<P.685T;:\J-?27?MK#]42DT
MM["\@%(*"B:-A"0=0>'&0PC(R2M4&&B#,T%VN<!Z(YIAW>QJ2H/]I=^.".//
MXTS&^U56)AT%YKK-%57O*\H 3EOZ"IW-QJ#H5$CU%CQ#*D[?F@P---",#I>;
MC%XK7FYX"%D[ R4;2Z9/EA"B1]#19HW69IF[])N^"]20*LTW)D8S731CQYL3
MG(>:-7PS)G)W>(P\0$%%QHR1M>-&0$ ;=*WT%J/MXK;>#6L3AKC'R9"&^FC7
M;VG5!?GU;)TW65UDE8(S5@./*,E%Y@*<EPR,0IY8MC[Q+JO&52#[3NS6WLPU
M_TSK9&U("+QX0W:\21 9TY -=\Q[*TFO/29Y%Z@AA6CV8L7&7;*WU40STK^<
M+L/TX[A&B]831?+PZADXO9M_F\WR[^/)9,0$&?2!/#P>1"V\:C/$3%K5P6KO
M='&Q=+&N-P$WI&A.4ZXTUTPSSGP=79(]QPRMT$$H4)%9<.@X$&&%TUJP++NL
M'=OH_F#]"5OJ?B<)MS.6:F+K>26/E]//N([\+$;"RL2S0<C.!/+S9(*0:)?V
M06+P(FF,KHN9= N@(<5;FNJ_B0;:M89;7Z'%=%;.Y<7GUV/:O&J*\^QT^0Y#
M'D_JO73"2H8_+5@OPGC^CS YK4G*7A-S,UEN7A!_R=CW*FH((2;EBK&=>@WN
M#GE(P9NFG#J0%ANS[F<D>/GR*^!2(7\@,W"QO@*U%;,+R=9N*86$0^Z![-.&
M\&8\0XKO=.#+?O)O1H9W-/Q\G):8GX;%ITLSC(YS6<,'$0L90"*PVJ>;U?L0
MF1=7%/>Q!QMN S2DJ$Y3.C310*=XSKLJS#?EE\7:5!X%J[(T+$(ILH!27H%W
M$L$6X8J,-G+1)01\)ZHA17/:&BO-=-'6@KTVR2B3D4(K**HV8E99U<;MLN*)
MVHJ00^H2S[D1S29T\(^2#GO+OF_.Y(JE.Z6QG?UEDTRUFU T2.!;/W;WW,9O
M_K[A1#OE*ZX?_O6FTKC)W:L-GMI0-)NC;R:P>HEE-JW6W*RL/CE+ZMA;9O<]
MN*'8MII#JS3/.L[3V6(Y4M(Z*R,'+6OVBU4</"L!I,A*^*PL9UTB(1<(VAI0
MJSFQD$MTS $OM<,S)@&Q. DIT@H=LF<"NYC2UZ$,*?Z_F\[OMI&V%G>74_(K
MEMK1\6R^'/]S)9,1XQBU,PJRCAD49PE\D@IT0?+S+ 8KNO![0WQ#"OJW(4@/
MQ71AS45J_7D>H#0Q9@+$I"= 3!APCFN0T<6<=':YB-Y,N8)I2,<"[=FQCP(:
M=D4D>VX%II9:&&E9/0/,8%GPH!*M:C%87WO!&BY4%IEW*1WR+8PMCP/Z%@UI
MH_@]Y'P(+VKEZUTJ#W!6\60Y6_]X;WMRP^<W-"MWF5$SN_S%Z?)TCC^/I^/C
MT^/S;M"KNK'5DZXKP*3Z48V$N]-H#46]_VP;F?4WIJN= WIV2DML"%PJQR"J
M4 .;2H'+9+1Q(>J+K3GS78X<[@/6)6?R_/DWM]/*P7#+:?7R4=-ND[R'B'7S
MB09=DMR8U"6TNCW4(3D131FV4;9E.RWVS="])(3K_;.<R])Z"3I$!<HX!T&+
MFF\8@J']+I J'N*U&W+KLX=CVKX:/!C/SMMG%<^]3\9"E$&0) SA4N2%<\>=
M%,$PAEW*3&Z(;TA>S(.R:A=]'99,JSY9G*&/SDC@QB?B.OEAP7M;3SA<$!AC
MT/G!Z#2TIF8/3ZBM=7902JW:8IDBM<V1 5JBN?))@>>66$^0$P]>T.[]4(P:
M6@>S!R?4UAIK=:G^!F@?9C_AVS#.1V6)\PMPI1#+F620)6,U#I$(7!;@8L[)
M!6V9NM=SW'+,(25'=6%(3QWTOOPT\O4*M_:T@^J:86PU@9&"@_<F*Q%R]J9+
M6O\M>#K?\2K:%RDL!U>$!Q7)AO"!"S 1<[2!Q=QG?][_CM>AO-06/-GRHM<V
M2NG]/ES.?[$B.&<B))$=*-0.7%(2@C#1<Q.=ZE-3X%YD0W(U#TB7'573KHH)
M+A:(MX"[O(<$VNYCJ;U32PF@5"1;4EH)N2!7RMGB7)<S]$T!=A7$+],\7JQ*
MSV!^_D>B7STZKM^-<B3WK!@/%EDAL\B1620\0B;%6155DKE/79==T YI1>["
MNVME7[KKM+LE$] 'I4HM/<)-G3X)@HD"":4.AM?,]"X7T3:R9!XZ/>$ %&JA
ME[[^]2@%E$X6FI2O-4JJTQ\-:IJ>9,X5[3+K8NS>B*9KL0O/K+,^2' L(B@M
M::8Y!$"RL5Q(,98RR&(7#WH8LQ4_MJIWL8TZ^KX#EZPH*U,VRN4:CJ]9^83,
MHQ*01?&^6.&DZ;)@WH-K2 OG@6BRHU(.D=VQRP']Z,JFWSLA@<9[X)2$JS,^
M5%("AI!EK'70DTBUZ)8A)SI[>N.\-)&(:-6#G#=T6;IN-4.-8M86Z^M-%4_N
M8/3@T!0('AT/TG->#K>0/0:7HBFO-EKAFNBNLW6(W)<H"8 (@HS?%#CX6DRC
M9..D1,6+/=Q1R^!WP:YTV4H7AX_P1..],*[6SJV;M-0>(E>FINW3UQZE9%V8
M,H@(S]U913+D0IY_A%R-&$43J1WI C'#9&XBB^X!PCR/)D>L"P.WBO6TT^[!
M7\MKF4="%.8D9U#+(]'>4A2$D!0X%9U-PA:\VA3UL*_ID'/(AL/$?35[<!Z>
MYRHYXYVG%P9$#+4Z-FUDOG"R=,CFX=6X29VZ/VR'<T@Y9H-BW2YZ?!BRK?*8
M<E)(8$S-*% $L]"R'!@#K\AB,HE)E;H$-[=&.J0<M.$1;FM=/@CE5HDL/G,;
MO!3 ,4DRTLF+"U:0B(2U+%<K/7?)S=X6Z)!RU 9'N*TUV29G[4Z(-^=-*>9E
M\=Y 9#G5=5A!E+0LVU1+S*,Q?,/>,-N//:0<MJX,.H1N-@Q;GWU>_XD$X*__
M\O\!4$L#!!0    ( -Q$"E'P1W3!9[P  !+D!P 5    86UE:"TR,#(P,#8S
M,%]D968N>&UL[+U;=ULYDB;ZWK\B3\[K02;NEUI=/4MI.S,]Q[8\MK-Z9EZX
M D# YA1%JDG*:=6O/P%>="4E4MR@)#J[:SDE6>;^$/%M("(0EW__[]].!C]\
MQ?&D/QK^_4?Q$__Q!QRF4>X//__]QS\^_<K\C__]/_[MW_[]_V'L?_WRX<T/
M+T?I[ 2'TQ]>C!&FF'_XLS_]\L-_9IS\\X<R'IW\\)^C\3_[7X&Q_YC]HQ>C
MT_-Q__.7Z0^22W[S;\=_B]XGYT"PQ*5C6NC(0O:<H1;&JYP<%_#_?OZ;"C$:
MJ35+)7*F@1<6>78,C$S::VF#X+,/'?2'__Q;_2/"!'^@Q0TGLV___N.7Z?3T
M;S___.>??_[T+8X'/XW&GW^6G*N?E[_]X^+7O]WZ_3_5[+=%".'GV=]>_.JD
MO^H7Z6/%S__K[9N/Z0N> .L/)U,8ILL'T./S].(?7D5C?I[_)?WJI/^WR>S?
MOQDEF,[4<^\2?EC[&_4[MOPU5G_$A&1*_/1MDG_\CW_[X8>YY&"<QJ,!?L#R
MP^++/SZ\OHVT/YS^G/LG/R]^YV<8# CQ[!.FYZ?X]Q\G_9/3 2Y_]F6,92WZ
MY9(K*%/A_+?Z:3_OC.D+ 1FGLXB,?HK#2O .,:[Z]-TQ7WP6RUC@;##M$/'M
MS^X4[^@$^ET*^-9'=X!V]D'L!$\BCKN$>NUSK^!<@KR)L'XDG(X&@]$)YI^&
M./UYAF^YM\(POQI.^]/SU\,R&I_,7O[[X<()?F%UD^56\1FN.S_O"DSB0W_8
MKS]]0]\N/K0BZ@XP?IOB,&/^\8=^_ON/?6YL*(0S29=T$@:\32E#B,4+Y:SI
M;0I]2PF_.'[W\?C-ZY='GUZ]_.7HS=&[%Z\^_O[JU:>/?[P[^N/E:_KI0^2\
MP:=V(>UMP=^0>?:@$5!)]$4;--%Y9XRA[XOP(JO>!I]?5[%<QV"4KCUN4(^I
MT<5[-8"(@]E/>V<3]AG@M/=Q2A9#U2HM'%_3EY.>YMYQ99!!HB-=!X',U\/=
MAYB-]ZHX2"O?RMD;66 29Z_EX@D_5[7\C(/I9/F3F:(8%XN3[K^MAS)7T<,7
M=S29X'1R%"?3,:1I3PH=0-+Q8%P)9+"0>>*C#LPYAR4+:03:%@N[#N/ZHBZ9
M=S1>+F^Q-SYP\ZP67Z<ZGHXZD^I<<03_QQ]&XXSCO__(N]'QB[/QF!9X":HX
MEWD6S(4"3)NH&4#FK 2NA429 'P[5=] LW^-[Z*BE=K>1;ZWE2YV5?H+F'PY
M&N;ZGU?_=4;.RX# 38ZF+V \/B<WZ1\P.,,><L6SDIG9"(EI9X! !L5BH:]Y
M 8NER?N^$;K'(L5.FARU5D,#KGQ 6FD_D5]<<2Z6WTLA19FDI!W/$BCI'0O*
M>:;("^->:(4NMN#&2C2'P(7=Q7Q;]W)7W;^%\3]Q"G& 'S&=C4FHN%QT3WHK
MM.>1D0D6F8ZIL.!5#7ID):+B2JDF1\0=F Z!!UV)_#8;U,ZF0DJC,]J@/F!"
MVJP(XCN<+K&!)+L[B\"$022+"#PCI)8)KGT&HT-RH8G%< >H0^!#9T*_30C=
M/2$^X*!&4-_#^"IO47 O98HL<D_KSX)V,9LL2RJBE6A)-DT.BPWQ'29-=E?%
M;<:871ES//V"XTN,DRM<1@A:%MK<D$M/7+:%G*LH&(@2O;)2%R=:D&0]I$/@
M14<"OTT%NRL5WH_Q%/KYU;=3'$Z0S. 9U&L2Z!5C?>#%L^SK_H9!,N @& H$
MQSER;9O8&!M@.P1R=*V"VRQQN[+DW6B*$T+V9@3#U6>@-%H$J32C_V2FM5=D
M%%G#C.$^!"NAZ":&Q[W(#H$AW8K_-C]\)_RX[]#3R1H")AGW50(QT:&'G+8[
MR55T(AD7H1E%O@/CHW,EW"9*Z#3.V4N&D!A(M*O17J:+]73L.4G\+<+F9,A$
MDLWCFX>@^H>+=46HJJ-@]KO1,-U<HBM9DLG+='*&@'')O N:%3J]1.2 6;EV
M^KX-Z !"VCM*N4&TZGH([1)?ST9)NT_)+"3KJJ6;&.C F>485,+H=5Q]3]YI
ML/(2T&-I?U>5W1FR?*"\&T2LWX]'ISB>GK\? *UTF&ML_;3>W]'7O_:'-6WI
M#<($/]0<KN/R!YF^53Q'94K&;TIG)V>S\^LEGHXQ]6?W\_0OCTY&=)[]:_9M
MSSGP.4I+!K%*](<AMRDF3::/YV!CE&A,&\>D]=(.A)M/C ,-=KO7-9/D<Y_L
MK84 <?KJ6QJ<U33'WT:C_&=_,.CI:(M2RC&9"IGH*AD2(486R/=7O"CI0I/(
MVR;@#H1IG>NA0>3^ @</:+23FBD'BM5-FNSOX)F(6"Q@4;8T\80.3.</DF>#
M 'S=U:;G;W'Z991?#[_2>5RWN$DOH0P(8%GBENC&A65!*<\4J2>266]!E19J
M7H/G0+3>A;0[C*G7I+W>)8[7P_=C\K^G.#C_'0>+%,-/7V#Z<H0DB>D'/*7#
MBW:GF6SFJ07>>1MU2DSX:JA)3Z>71<6XBR)PI3)Q^;Y,P=UA/'-Z[%D/#4+Q
MQV0JD4TS_+S*).IEVL0X0F11.+)S+ _, SF-V?CDA,G<M0G"WXGJF7.F>\DW
MB+U?N0VXXMP)H006H9GUN=X@HF=!*L5RBEYJR%'D)O'VE6@.A08[2[I!:/TV
M'@#@/&?F<ZXQO6P9V!P8@G1@HM)*-<S_/3BE[R3?9A'RGE$E0-&2Q5DTF"M@
M=2E,>H.F%*<1>#LM'T!@="L)-G#VWO0A]@>SQ+&C8?XX':5_?AD-Z+,G<P/V
M8JG&JI0P(_,J$LX0R&X57K+D4>=84C0FM]#TI@"??:9_$TTT")A>P7GS;BB8
MXH76AF5NR 11R&LJ:F#!""$Y<M"A23'+>DC[9T4;-:[GRBXZ:,".96K9>SBO
MM[LU#)K2^ SS;<B]Z*/@S@-S/M.A*.N+(HMGT5BR5T'$A$T"#UM@?%3^[*3:
M-2E_7>NE0PK-7.-?^_DL]6%\?@/P!;;$7?$E,8FHZ:VI8=%B-'.TV1J-,3J\
ML<6L"4+<\Z!GK_C.I=G@5F*YY/-?1^,7 ^B?U"US\47^OV?S$,DBX:R7)7'2
MD(,C)-G,L^@I&4Z>80X!'/D^@$U,S6U /GO6--=,FTJ#NI&]'J;1"7Z";Y<;
MF0V!T[GJF!.EED#PFF$"D0SL8"+&8,#H1@?,:D0'PX]N9-[@DN-E_VL_XS#?
MW.D"!J\KK)*0W&4.G$6K+9, V7,7G<4F.5QK\!P,$;J0=X/2@:NW]A=[V1*;
MLJB*%;96-!!%!1U]T6*-IX>4D\^B<-6""W>!.AA"=";YYE<7M]"YX&GSBF3^
ME$#HO!7,.Z68 Y6L\TZ";>*^W@WK8)C1H?0;W%^\&0T_?\+QR4N,%^GJ)B2+
MQ2,I;)::)C,+BG:R4H.KFNOLL$D"Q HL!\."7>7<X.YBA0M<@O<%G&8H%*_Q
M>L%B3HYQRW/(UJ'7;31_N!&(':7<X [C"J(5MS5&V.A]5DRH')@NQM2,/46&
MK#$R"I J-[G NA/5X<<S=]1$@RC%2RQ(@"Z=G:MH<=J+]<9-.\>,3^3^2E L
M.$V6C?.\6)MD@"9$N0?7HU)E5RW>]#(Z5$&#H/=*F_?J76VJ)?96L2AK6:0,
M@;[2R%Q(/)<2N&]S+W(/KD-B2)<J:+"'K+%]KP(LFB/0:FU2GH[60(O'*%G(
M*5LIR3K*36)5]R([))9TJX86U_%7K.,KJ)SE-3N43E2>:_=?J1AH7E@!\,ZC
MC<(TJ4A;#>>0&-&!P!M$,5>NMZ>"SU'3]B41"M."CCI0&A@F*VW)&(QK?;U^
MH"386=P-0IA70/4XJJ!TB0Q"(;_+@V8U4YQ)';1V,2*=;(TU?_B>QU92;K#W
MOQB=G/3G50+ULFTTK <5#E.%ED+R.83,W*Q[ H\5)#BR8;)1 I&+V*2$\ Y,
M!TJ(KK30X:DPN\I_B__Z%PS[0[RQ5ANRXXI :)<$83+ //=$WQ*#C-K2OGC#
M;ER3$+'F 0>FYLYDV6#'_X0GIZ,QC,_GL):-/8].:NH&N;[S,L'WM:J4Y#^=
MCOOQ;-;\[].H'EM$51(S??CGU\,ICG$RG?0*B")-2(P<8#)G=<KU(C:QPE6.
M26CO<I.LS>Z7LC\>=D>1T9/2;X/ Q^V7\R'+N'RADPTV9L%$E))IZSSS( *S
M5CAP1JJ8FD32NEW&@>V83T#7;1K*S4.*LV7-"^M4RL5RQ5G"1)!R*HS>H<R$
MS!&*YUK*)O1;@>4QLMD?3[VW.\WMI)L6/=#)*AP-K^*)9/FEXABX1&^2\IIY
MS27+8(2,'J(W32X(;P+YKHFRDU8:1'F/<IX)'P;OH9]?#U_ :7\*@UX2"@0G
M6#FBJLT_,@M12\:#-<[PH(UJ4R6U&L]WS9DN=-3 ^?^ 4Q(DYE<P)JOS\^1:
M6YG23_UIC]S+@A8X4[X6^'*/+"05F42=HH@V:=DD_'<_M.^:4!UKKD$T^;:P
M>DF"%]Y81BX+^0U6:18].32Q>&6PMBEIDPY[&\IWS9T=-=,@!O&V/QR-9R*9
M+[,7R+V,F0 (@82'E\) %\F\01]L=MJ*)D5:-X%\USS922L-O*=N1-,+0ODB
MI:$%R%([F= "LLTL*4Z[I4Z099,N[MW _ZX9^0@,:)'T>T_@I*=C#EF$P(K(
MCAR*6*W"'%ETT:M8C*3_;WSQMA+8@<:8.M5' [Y<E/Q_JJSN65>\-*2](L$R
MVG\Y@V (G ])!Z _1)/N-M=A=,B%*V.,F_<[V$&6JP(\/\R'TOXM#483S'__
M<3H^P\L?TM:#WZ:O!K,'_OW'"7X^N97#L ,=7@Q@,CDN,\(>?>M/>D(D+&C(
MFW2>DS<9337@:J,N"\1:B"DW:2*\%E&')+ECKO0=I'F EM<19B=IMP@.7L'S
M<K:;;H2H=V/$=:=APEN0NCPQU@WIOD/]N^GL9MRO&X'OAPHR>'+G F>&UR,K
MDD/G30)2FG!. _?@FES![HL"U^:>/R(#MI%SBZM0'%>KY?K=Q=N94=5SL80Z
M'X&5D.F8C+6T31G%?(D&2[0JR#9VPGI,^S<@=U79S=.@(WDWF)(\A_;+2F@&
M8BF$CQSWVJ;/A-KX"S6C5R EH5"5T.:*>SVF Z'"[O)>NRO\^\\W1$,6\#\O
M!]K7I7_ \D/][Q\?7N\^QOX]U 34+SCM)QA<1S?IGYP.;IB.MQ.ZMGW$SY>+
MN;[(Q7.N:;_%LL@XQV%&4G&?;/=^<M$%$&!SM-I)'I/5="!(3?\GO/:];1_6
MD9U_Z?EPZ[6)1;-4S5<MBR)#MD[=A2(->J-=:!(8N VEVTP($MOQ>/:0/+M2
M?8_CCU](E#T@CT[)K)@4-2[MR:V/-@5&'EZV4D7TI=$0BTW@/8GN?]MPXNZ<
MATZTT.!DNXYR!FER=#;],AKW_X6Y5W(0@D=@!JPDBPX$"XX[%D*]^ ).[W"3
M&\J[81T8-W:2>I,!.K?1O9Y,S@B9!Y,UD@F6C"8+7R(MNEZL1T\G/4<T-C6)
M[Z^'=)!<>("T&R2_K$)V?#:=3&%8;P5Z7&1CK:^#+[(@FM;:'$T^7RJBKKXH
M,M/W188KN Z2$0^5>Z.JED6.UMI3+>J,B@O/%-0&<C:J:OQ[EI1)J'-)B3?Q
MCS? ]NSIT;7\&^2G7(%XZW"S5B27I&<RAUJ3E3T+*.NF5@"]$]K()H'T.S =
M$B5VDG>#])-;T*[N9#&9B+2=U=;Y=,!E55O>^\!XX#%JJX0234KD[P)U>&1X
MJ,0;I)E\&B-,SL;G,W0+H#.,O6(<MR(GAL+#_.(Q@/:,%VD%%Z&V(VU2U[0.
MT;/G03>R;G_G7@JYN(B>E6QD;1/'*R6!@4BER!"DUTURJ9_,G?LN2MY!ED__
MSEUAC%Y7%SA$1X:N1P91.R8@>B&BPY#;,N.)WKEOI>6-[]RWD?9^+EHW0?1]
MW[EOI;/[;UP?(O ]W;FCM HAL:(R.31:%Q9U*LQ(K8W@$I5MDK3\Y._<.V;
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MQ!"]%]FSIT.WLF]@%5S2M$9;YNTZWN+TRRB_'G[%^<#H28\#"AX2H<(<Z]4
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M.HJ8P)7@2^0 .VG^D1DP\X;VKO_%4Q];^ZL6?T/W(EKEE:"3-SN=L@L1I/"
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M50J2D3% 2R[.L)AU':'G=#+<>\E-"_M[#9Z#-I^ZU$7#2/Q56/,H""X;O6\
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M?,#3LW'Z A,\^DSDKC'XFQ 7A-\$9-=#$39&M_\A";LK<K0O+70\-F%SL$4
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MXR2]DDS7<%VCL=UGB->3>3G-[T-<^_4,=Z0TO/C^%F8PN1R.2L.76R/FR72
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M\>-"F>'C0IGR].&H=.7[/^ GTT'2Z$GBVDG@I6.NEF4DC\4_2LJHLL+:CI=
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MK#,$:RT$'7RC@8&/P;Q:XJM)N')-RVFY](#)E9_,OM]69(1@F$&WA BC$(]
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MN[CO0:./D_@_U\/I7( E1E>27#]<+'M_A&"8X@D(D[9$ZH(F(5%-&"[6.5P
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M4O-,@G>X 4;&,\\Y9'BVD]OFQQ_ZSF97T8^KRJWV+-Y??_GEOK6Q"DT%"4R
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M-?Z1#;M8Z>TR'L8&4TC&2Z&(H@EMDB@M<0(""5)1@3]SW)JJF]1V^%Z]GKT
MVM:H8N]KMB\3\-/KR?>YF'!EE^/137[:(*9HF/.<<%[:*TD9B76F=+V@+D',
M3/@F0=B-B%ZS"M45]QI%Z'V=]0#9,D*D9?2%)%[:"&=EB==.$NV]"$IRCHY/
M<PTXFLA?3P&OX;SWA<[;X;=A@E&:#CQUI1Z-$F4B1X^6EA8(" P\A\2D\=Z;
M%E3?(C@&AG<3YQIB^U]:Q*^0KB]@L;PWW^>+O:EO=@XMXFP8T6 5&C]0;E9
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MGX<B8B[SO[PADB<?*&C*5ELXO>8)VK6=Q;X2K=A7Z=%\N"XXCG:2]E8D;!K
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MM8T4$A@;&7*E>%9*ZLT!%(T<TG44E\#S\6+M\$T_G]VS%FO^4C8-HE]^;'_
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MY!XKDQ@DI._$!\]]EU%/0\!=B(XTYZ'#_O& (Z#Q4@7%ZJ0@.A"S8]Z8PK*
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M(G../GK!8O2UUZL*-8$)F1/!)RX<F#+D)F,0?3^]^;PW\D?+?MI"< WO&Q9
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M PW3F-LLX>9#9R(2$#%"E**A3'#@9P:>S_JH!F$%]U"NNQW^>R7=3??W1N3
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M#8S5=?[9=OS^A\I%5F9($6K]QZ+^:X%FC"5:Q8A"DD3:&/&*09J* *8Z2)C
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MS+^S7,ZXE"J@+(882?,_& MCL84:JB@@V'P'*D6)N\5VK)NI3?8*J(^9<)1
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M_/F=,AT]F)[Y7&V%DWY3E=E3F(UC78YW\\M9R&G*TH :"]%F[N 1@BPTF[M
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MTW,.M^L>FAO0&'DKNP#AY*BYP/(-KIKC$2=SUEQ@I>NNN?3(L//YPV;]U51
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MBHB'$4YBI^2:FZB9V^'\BQ2Y"<OJ]-0 OW[:K%9 <V?<QJZVQ4U+96EY3+4
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MK"\O/F]IL1T/K.-)QH/L#5V9CW$!_HNN7VCQ X0+8+;A0 B1XCBE 8-Q;"H
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M8F@$6T.D:4ADJ'03)R[@V\F7D0 =7<6MJ04_M73_V:A-#< 5T>#Q"L#.HF<
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MDU*?8D)%$(4H@5E,4X@)BE&2I#&3S-J]TC_7W,Z?7^2__TW7QG"LR76PVZ^
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M'D,6A@&6D#%3;D1H@X)(DL$DI7&4AI1SDEKORN[(<]N.FC:@B7/8AP<X66S
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MMH.7\%4A9SA- A@PCB&*H\ST85,P52G61C:306@?/^4/W0F;KQUCNP":8G\
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M,CZ_;5;ZC;(.V-Z%DSUN"C/EW79;Y.QE6U6RVICR@)OU5B.RJBYHZ[-LB9)
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MS:UDYERN9CP( R*23!^A10J1"!-(<":@(C&+%<ED$B8N6N,LI:EIC)K1JE!
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M2"S"D&04!DG*];D;8XB%""'C:9I()4DJE8OMVX^-J9FW#<_@N6*ZC*>F%=M
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MPWECA:=CAJ4E/MW)EI<&&3'OTE*>_11,VY?Z7L4O9-/BI#YA!C$)0I/VQ,.
M0)0( ;&(,QA$"F&"<(:94R3H,8FIJ5?#H?E2N[0PZ@#0]B[P&E@&O_%K(S+
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M(QRK"%.W:RR_#$[OWJLMW[_^"X["[#^ +.5T#,CW.Y%VFO3U)F=@/=L6[/^
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M ?6T&8& D0C<+ZM\*9,#M2=4F>E4BS7N3#GDN8T[8R.EL8TR<VX9:OYP[DQ
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M.*:(16&DL).^:P\^-5UVOS0%/85DCHTP]@ +LH1$8::@$-P47=!?6L*R#+)
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M<9+*F&M3-$RB3)^_D824IR&DA.(D2@A!.'(QM.Q)3\T,TYP#KED'SS7O@+V
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M2Y&F2D91!DD82!,F&T*B/X$:6(DD8AB%5H'L/6A/S9BH6(<E[V#'?)/.PEY
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MQ[$KD#IJ1G;-6/TTW870J^]RL2E#)QX6^3^DF,6Q/K;K?012K@A$3&H=QWD
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MB A-(0O2%"J&1,Q%@A&R+X6S/_;4C->&.X<4C0.PNA7'E1 ,K!T:QOK4YCJ
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MS=\^;GL:Q%3@1*8<4A%CB)*80Q;&,:1!DC(N,QHG5LFI_EF;FAJK);L!6]E
M2SBPDZ[E1J\$-'EP;1%[-*D88.;M3+W7F<^!5?384^EL+/I'W:?EZ)&[4<U(
M_Z@>VI0#4.BW0S2UGTO'8W5WPO]WDQ?F8J6Z2_DDUX]+,<-9*@-)$BAY%$-$
M4W.)GDE(8D(441%-HJCIR6JW ]B2MM('^]U8A[[/T ,]FB1:O<C7^\6SW;2T
M-?IV.M@KHN-HV&WM\?KRHN3R!C1\5[<9U1U&Q;L_W>F*ED_-:$U[5+WGBLBA
M5G-^O^_]ZU+E:]/8=29(@#,54X@X81#%1$(6X="4)$22"!8CA5S2Q79#.UF5
M(^1]_>N_A&GP'Y]EOR#F-F11G,4A13"0BD,D VW#RUAH:SYD<8!D%"FG)DX]
M(1NC+^/U8-G>&?>!8&#-:J2O HG!+X:U7\LTM+KRU9>JR@:X7:^+G&W697WZ
M];(L9K!<K#5_<_.8_S#P8ZC\W@QO1Q_Y]O=0JN,;WJ,G>B9U<6[Z,:V^2B[S
M[V;>OLJYL7FTBC5^R3=-P1/]=VVN(1CC)(,(<PEQ&F90()D1G*0BL6M&[4AW
M:CI@QVY=:N9?_P5'8?@?H*BX-Z$H[C50;"<A#5%&*(EAHJUDB!!/($%4:]U8
MQ!%2F:0,.>;:^9^&<6* K";B99AIL-/B T [L(IO. 8[EHVKHL*SYGJ;U^<Q
MF<\-**_I?9:DQTWX<\/C* 70\?4>-TEUD.2=JOT.Y=W4_*7N.BF#)(YD2B&6
M0D'$4@X9"224B4(!Y2@*C1%M>;O426IJNT.3SJ"5D,'>G#>?*GX=+F2ZP;6X
MG/(&V<#JIHD-OU-@ZQBM>;W4R=,5-8>K+6_HC73==06*;I=@5L!T7HQUCS#>
M99F5)'L7:'9O]+/ W^8K^O!0R(>Z+FQ-XMYH[GOY<_V;YOOO,RHRP3 2,.%<
MV]\9"B 52FA+7,4*11CIO[F9?E9TIV?X?>./4FSFI;.T)8*V4&H!3 K*.\H?
M3>[)L@#WF@,W,]!N0NR,0.\@#ZR3]_DU&#>H_EGR# S3H.3:X[63$TH^[3\[
MPJ-:?TY8'-I^;B]?W5JJT/2>ERLZ/^H8\V4YS_E+2WVA)-&'4VT$ABHU_1UB
MR&B(H.("A5FJ59F4;NJK#QO3TV:'Y?2JTD]'O9-Z-Z&RGR$[?38TZ@.KMW:+
MJ@(T IQL5W4#*C' G_5_!]%\U^ Y4#,K>SY>J[>5,U(=K:[<Q[K.SWJ[$'?K
M1UFT_%>?Y;KQ+&6ID#(. QA1K&T[I! D(4$P8U31*$6(8=G'R]I)=6JGZ,JJ
M-HMRM6$:XWQ1FG>+Y5K6!^O2$MEVN.WGY.N>"#<7GS=XQW+PF4VFY!CL^5$_
MFWJN@_GWK% :PKO73?A5?'M66)SS[-F]W,.O=\L?<_F=?C(U7OE?ZK#@(&(9
MHBR /#17#6F40L)# B,D21AK4RY35E6^SE*8G/[9\EA><?[%I=GY*0 M7';7
MPC*XWMA'I$^<^4EH7!J\7PG12.XX=Z@<^YMWP-#=N/S4BR-V)._@>[_5>->#
M_6RO=_^[R=<ON[[E[[]_SK4._2-?/RXWZZ^2BGS^\E::;A;:UM#J=%OX898I
MFF#*4QC21)];34M"2A,%N0A9&B.,3(=DIW-K?V:F>'K=5OK+%^"YT)O16LY?
MP*.<"R!-?QSGJ_ KYLK.9AL'_X$5<B4$V$EQ ][_)_S\H33L?E2B@%H6T!:F
M58''GX%W/:0^K;XKN!G5%+P>M4/[T,.(_1.QUW5*H_&WOUV:./09YBJ2).!0
MZTJM/%4<0I+2#":<*<9PAI!T*@!YFLS4S,==9Z0JN==P"OZL>'7,NCF#JYVB
MNQZM@958/Z!Z)4"?Q\%W9O,)2J.G+)^7]E0N<L?3/BLPSF@<A3*,,21)9!H6
M(0*9BCA,<"H%(4A&/'0SI4X3FIZ9U"Z(QUN<^BAY. N4Y!@+!@D+0XA"DD 6
M\!AF,0\C3$62!N+Z:I134[*#0FJG7Z\':F#]>K(.XZ[J7=5JCJX>F[XB0Y=;
M'$+EGJ$T@<*&YU3NA:=[>.W*1L*+U;HH_1NWS\_%\KL4II;NZG$Y%[^OY)UZ
MOUF(U4S13*M<)F!,50 190IBK96U'@Y5C-(X3I55$+<;V:GICH95L*E2[I1A
M$ORR6*Y-RH+\:>H"698,=,3?PA,X"*H#*YJJS_F6Z1NP17C+-]",FQ"UDO5!
ML'5J73\ QJ/UI?>$M6O#>4?(_C]UW]8<MXVM^U=0M:OVR50)<W@!">+,DRS'
M&>VR(Q]'F:E=>>C"5>))JZG=;-EQ?OT!>.EN]15@ Q3S$,>62&*M#^2'A85U
M.=--WO9I8[:*=]1PIP^\Z]T#B/[?LGQX7$E!M=E*'^2RS_9N4JPH7[W0N3'F
MOTNZK-=-A7 FBHC%$524ZDTXB0DD2:(@BC"G.96:[*RJE0^68&KTW^L KELE
MMHHQW&S4 $UYKA],/:[:93$8-$<6ZT)HY ,O$2Z@-YA[;1MU,8(GV6S0@\<C
MMDOT?L5Q%SUHF"OAW4M=+F1=:U.9F3 0O;1^D;QZ6)1_2G$KS!&#*NFF$VF7
M'GZ]$!\W_<B;ZMW:W&[/Q[=_T9VGZ\V1><:,X8QQ11#,L2I,CF,,"U8(&/.<
ML1R)1*2%6TV*4>6W^MQ'+6RQCC=Y;B5TVYV/._EVF_[I3>@X_-WK#;84-[F!
MO>I@6_<^E+77OHUIW:@).@ V/0*W?FF*=71OS><S;XVS7^)-9L^GNV-<!4;U
MHKS)W.PZ9]Y&"+>U4<AR]J,Y6__>'0<AC/.<Y E449)!)#*J+7S)8"3BA'.<
M)RI-;2S\W0=/S7!O97,\2MM#ZS3/7X)!Z#-_2_6M6?&8KAO"JGO&JB7_^T/U
M]7_K6[3",3%_,8U'R!9'[3UN%/HXID3_91_]_3"#].=J)<_6!Q"218@*"CF)
M4_U!I@06*58:L$CDE*A8_\[E2,9FT*E]K!\KNJBWP[6]%,JP@M_.DO,-:N"O
MOQ%WY,(,+A#YM'*LQAW5.'%!8M>F<+IW:%U>O=LN36W'&UH_FG[P^G\F&N@K
MG9MZ!(=_VL?@:F[B,4\@(41!A*(,$B4Q5/J/-,XS)'GF5HEWN#!38S$C9+-[
M:?ZR)>[ @)Z+)LJ.U\:"/S#?78#\@*JWET/FM\[M!?*,7-GV<N3V:]EZ>.;E
M#65F,:&Q2#($%4&FIQ4FD&G+#G*>18I(G,C$:EMUZ.%3X[E[4W%R>+^7&<]I
M7N0$PR0WD9Y9(:#&B^DEA=$L4TPP7+C%=@U%:YR(+F/=@N=E94(%'$W85[C9
M4?I0+ )3].OXS3 =:T+0ZZOGOUD_F6/T=_":@70FZUK*NV>YI*MR\="TWJXW
M&?^(*!(SF4"&<[U-9075!)?FL(B2.%.)9!@Y10Z>'FYJE->*Y_CMG@;4\FOV
M!E/H[[L1] JL106MK."W(*40['#Q2@2G1QR7&JRTWR,+N[N&T<>-D=P<[39N
M\++^_=WW=W+!'Y_H\O?K/\IZQHE$I"@0Q+C0.T?"8TA9$4,LHQ@K*A.,B0N!
MG!MP:A3R2EY@! 9K><%O1F+'[>%9Q.T8QB>.H;=Y%T#HS#"VN/CDF+-CCLHR
MM@CL\HSU?4.9IE[=J9^J2IC:!K_(Y=>2R_J7:BYF68Z+#+$8QD(3#8JP@I2B
M!&*2D 3G4N:9DR_]^%#38Y>Z+8+2R>A*)4<AM241'T %IX\6HT;,QEW4"PJ,
MI#ZIXQP:?DGCZ&@CT\4YK?>)XNP=PRG"/+++5:EG..,<$9E#'F52$T."(24D
MAD1%!4L2J?]D+JTZ=@=PHH,1&G8T+AH@.^G<R> 5>%*(/$]Y A-!-:O*HDD$
MR:!(E;;E(IK$U-%RNP"\,4('_,!FSYQ#P1B!+UN>/(O(((H\I+9O8GPUQNAT
M>$C#0R1X\+J!^;0KNFHR]MK\?I,V5BV,S[O9$A"I1*:$A,S4C4.<Y'H3EB0P
M)D622Z52BJVJK5N--KGONJV#L1%RT+;K-,!V'[TWV (S@#-B[LF?-DAXS0$]
M.>"XJ: VNN]EA%K=-+"X^*N\I)_UB]&%P;$HCG#$$FT^&=\-1@J2)*6P0!F-
M%!=",:=]U;&!IL88>_ES1M2!I_E'P;6C#!^0!6:+@6BY%P _ X77FM_'QAJW
MS/<9C?<J>Y^[?FCDT+J$Y#H;#9%<<P.+8187IC5W1F 1HP@FB".6B%AB:94Q
M>&*,J;'"EH@VB6?64-H1P84 !>8 1VP&1-\<U=YO4,W^,"/'RAS5<S\$YOBE
M;M]YO5S-/I6+\NGEJ8LB0R*)2,$B**+8.%15#&F>,K/ZIXE,HDP5S.;KWGOR
MU+[I3CB[CW@?I].?[D7:!_Y@.[D\5AX]JNV)#U3?L_5QZG_M?IC[#QWE<SRJ
M2_\1'K]@8 XKG9L^[+\\2KGZ:" NJT6?N:.D3'":0,QDUB:<TC3/89J3+*(%
M*YC,75;:XT--[>/L) 6-J*"7=: =?@)ANP78#VZ!/^NAD+EG29Y%PVM*X_'1
MQLT_/*OU7K+@^3N&]5:LEN^[18ACGJBB()!@3B!*%3&'' KFBB<2,1)EV*JY
M]MZ3I\8';:^N]VX-_S8XG?[,+](^\%?=*>Z[3/@A;<_UYMO<,&HKOCTY=SOO
M[5\P;"'^O*R>Y7+U_;.>@)5QS__/2_G<E.M9B _EPGS+30#5%U/FXD[]6K=9
MOM=*?P#7G+\\O329.^_E\U+RLOG<]9W73Z;W^9]MV:F4R#Q*"@9%(DS_%AKK
M+U>O[RD6"E/%XT19?:_CB3PU(OA(%^+*A%8W>C='5;)7NFGT[&8:C##G>2YR
M9?RG&3+9GK')G\HQ@BS%&5)4T"1.W&+?IS7KXT34?_X+S;B=43FM60R]C'7*
M7H%&W:OVC+G7N/E7IW,;1 P:K6&EH"E6URBN[S&J@RW=P;;RS4.VU?=G\8XW
M53XMYQ&D'M4"'V\6=BWY$4<>V,'DZ7E>?9>R"Z@Z7$/VYZIIQR'%]3>Z%'43
M,+3]>Q.6\'.U^F^YVM0TV3RIO:GI*W7_2!=WS^:6>I8E18((RZ&*B5[=9*07
M-E-HFDN4424S3IB31?-FFDS-T/EUL=Q43]HN8=W'>#GV37FS-\1N-?Q+S'O@
M1=*F('>K/VATN0(__L'G+\*DWK3:7($FXE5C +[+U5;]K2MOO=XG,V%>>\*\
MF3+CMI1YZSG;ZTCSY@(-\,#]NBCUGJ?60N@QFA)?=6D>:DIV+/0O/LYYYW;*
M>%ZD*<EAG@@31%.8Y$F:0X$H1GE6(,&YM7O.>MCIK62=X,!(#K9$![WL5^#C
MQQL'YY[]%%AX_H( &WBIL,74M]_0&:N33D7[IXWG<736\)4[TOWN 03T\XMY
MPIWZ(/4-=#[__G]?Z+Q4I13_E'2^>C3;E'I6<$&B2!%S6H@@2@B#-%84)@7&
M<5JPB*56O:+MAYP:\;1" ]7+#/ZG%QH\-E*#9R.V ^_8(6_!.=[Q#,PW'92F
M:\ :S;7(H)6Y<>WX1].A<8-W5$=JVN !73<:=P+J)(7;/6D\^G;2[!5UN]TY
ML#RD7-TN]&9>?JSJ^GJU6I;L967BN.XKTVS)%$JOYOK^A]N%)DAM],Y(2C")
M4P:C3,00Y3B%!5,()D2R@@A%LXRXG1XXRS"]PP"M B@;'0#=4L"TYUF\4D%?
MU>K@6D?2>9[LO!Q!L0^]!$@3ZMV _H,1_V_@>@?[URJ 7@>/!2>'PN>U^J2S
M$..6HAR*T5Y=RL$/NJ0+]R>Y>JS$IG&TR9/[KTI_QO_2_WA9;L5.XU2FF> *
M2I(F>G.=II"*A,$B*?2V6R).W8+C',>?FK';)6ZU\H,M!9ISL48%T.LP.(;=
M=8XL?;_AD _,B;Y!']A:VQDZ__VT[45X@R;:SO@<[ISM_AB?#7*W3@+J=]\W
MUW0G!8V?L_-N_OB'7/*REO7MXK-<EI7H6_-TW97ZWW]>EES.!,YCA(B 228)
M1#S)89%%$10DH2Q/"(NQNKQ#;"CQI\;#G0Y =D(*\$.Y $(OE:9KU;/>YM5&
M=\N>86_T2MCQ]G0G>L2#NFW5MT_K:L"^@X,G>NW170>!.</K0-";%=#"< 7V
M^J'U5X$&B]"M>$//8?@6O\$TF$#KX-"S8]>2.+@40S-6O\K%RY8-&J&(R@(Q
M*%*]QNEM 89%C@1DF,1)QI*8%X[QE[M#3,]!TDGHFJ"Z@YS=*G )&H%YNA<M
M4%[J8;W])J7NC#%R1NIA#??348]<-]A):HJW?UY67TLAQ;OOOVI6N5VLJYA>
M\U7YM6V8U;^I!&58I8S!--&?-Q(HA225"911G"9<B#B)E;.7U%&(Z;% TQI!
MS:MO-3"3"ZIUH5ZZEM[9+^HZ-=:.T8!PC^ 9;;#NQ3>FWP]& VW2_6VK/O)&
MBR",-!Q$S_Y15RG&=I .1.F AW3HDX96^JKX[Z9?N-['MBX)TSSH?5GS>56_
M+.6FU'C"&:*F?(],3-))@J@V>N($8BRIE"15M+"*/'(>>6K;\4_RSS_IHES(
MMOKGEAK_"[2*N-8"LYT"RSUT"&!#;W\/H&AB3B78R!VH"+PS7'X+B=D./G)1
M,4=,]@N,N3Y@('WQ1RE>YO).'=Y1-G)T6\:..[_?-R=.FYX4"!>QRF/(35@E
M4B2"!<LX3 632<I)IB*W:H87BS0UPFLD[KQ+X%YOT6MC[!F/Y*\+/57@U>\=
M(G8\3J(E,XXZ-2-Z# ^&]O?Q^[TFFC^;8_4P+.H-6J_T>KE4X_*N-Q3W"-G?
MDP>$E_Z;FA=S]<HI]\6\J?=ZMF475UW$F*"B2"%'"&DBEGK'S3*]]\YCQ(G2
MOU:QW8[;>LSI;; [J7><\Z 1'#22.T1#6L%^FCJ#0!F8&<]CZ#N&W06@D[&/
M5@\:+_311:]7D8].-PYL-:9W8'?J9BE%N?I N6EX;PK9/I7-0?H'*3_KL4V@
M[8.<(1XI046N"852B%"209)$$DI)<9%''*G8*;#'8>RI&7-?3*4#+;C>O"Y>
MZ!RH3GR@;*EER 38V6>!8 U,-T9JTQ&DE1OT@IO$R5YTH&4'&^$]=C!S1\QK
M.S.'X<?M;>:.RUZCLP&/&& :W<QI7=^ICC#OEDW"_VU=OQB_7WNT.5,T3U$1
M"9BG3-M#6/]!&$L@X8K$"4G3O,@=+".+(2=K&-7@[F55K^BB25$V<3!-[$MM
M&?QB#;F%5>09QL LU4AK\D%ZZ^ANV59$ :W(X+8/%?&,I$.RC6=$1TJU:9&M
M-LA6';)7/;3E66C=S$T'G$Y:FS;/&<_8=-#JE:WI<M\P4_-#N2A7\F/YU3Q1
M<\]#J3?&33V6>KOB2M=\Y8LT!1E%D_A3UIS._UM2O;L5<9'(&$&A#2V(4HHA
MY2J!-%.1B%B>%=RI]:T'F:9FFIH7%/P@UP4H5H\2U.4?X*E:K!YK(!?F'/2_
M7K2UE497P%SM&/+H8Q[M+-F19R?PVM%J QMUP$:?OHB6T8(WD85;JEV!M5:&
M&UN]@%',G_7K$66?5K$/L4:UECWBN&M%^WRTS]#WUM5YO=!2&2->R]<<7'RN
MYB7_/L-$YC$N8LBB7!O<1<$A10G2_XPIB].89#1S"_X9(,7T;/#VR.'=7I"R
MC\#STQ-B>;X3%N2W/= !O[42!SJ_&0Y=^,CKTV),('S:"B>[&&B[1PUTF3:]
MVU^5%Y0+^8W.[^7R*9YE-,Z3#&NN2YJ3<)%#S7P4"B$ISRC7K.?F)3TYW-2L
MS[Y8Z+PI%EJUI]FK"NBO35N>X(>79_TO1X/S#."67E%O,(9VA#:"7KTNNVKL
MP$9:8,3UZ/FT0L6KL_/TB./Z-ZVTWW-IVMUU8<_0.[4?_;..W15Y1(3$.8R+
MG)L4ZPA2P27,<QKE7#(B7*,(+4:=&M6LA38[HX.A;T.SJ>TFP=*:\@UM:/O)
M!ZK#>X_:H!2D!^G)@=^F%ZD-%D=[DEK=/(RC/M$%;:WI#U)V>\Y97J@<QR:P
MF44((J+1)A%-8)0229(DC4A"9@OY8.HMVY'2H6&L/A32?BC;@X7[7C92FK-?
MQYB]@TC:\<I@=$;J9;:!Q9S:_GBF-+(S89Q2WR<_'!QG5#HXI>GNUW_RVF$?
M^ZZ_Z:=E5=?K\L8_597X5L[G,\$QPAE&$&=(0$25WO7(C,,\S7G!I8@+R68K
M4R'6[N.W&];))%D/'NZMW_7JUE>@$=R-%2PAM^,)_T &9HYC&((?-D6U>[&/
M;R2="<4-)Y\48SGRJ*3CAL8N#3G>/3 ;M2L+^$4^5\NF_M4O\J%)>I_EJ6:C
M""N8XRB!".D]$A.2P@SG" D5QY%,7;9'QX>:VIZH*UBI3??E6E90=\(ZII0>
MQ]>.>?R@%IAM-H!MQ 2_G /,/0/T+!9>,SV/CS9N1N=9K?<R-\_?X?/\JOEI
M??VR>JR6ICI]DXFS%<3?.(W??=\/P+W^HZQG/,]3IC($(W/(A5A2P()@H5DG
M8UF:8<QQ=GE]IHMDG!H_'0PF_\U(ZNJB"3"?EQR/C39+@?EPR 1Y.B;S F'X
M8[3+Q)S ,9L7G.V.X?P,=6E2ZY$B@4UBU@Q)%BFE""21.:Y#N8)%FC)(&<UB
MSM.896ZN=*MAI\;+O=3&$#I>.[--?71E:KMYL"1?[^B&=J=[ ?:"1%(;G,(D
MBYX<^8T20FW0.)[T:77W@.R%YA!QI_2:R?(WC<&^T)5<'SG1F%'-51F,""(0
MD51"P@L!,R)3H3>\62ZQ0PJ#[;C3BZ':*\/8BPV,W ZQ]];0G^:G8' &#S8P
M81JGT?1ZX#<(J)/A]]8/&R\&WU6_5X'XSC</,X]Z+]SMTS,MEX;'3#GY64IP
M% DFH>(FLB!1%!888;VG98(R;1$1[M0V]/ P4S-_-M*9=?JAD]G-SCD"J)U=
M<SE,@8FB%_ *;&'U\=31AK/-<AH#GS;*D9%&M4E.:[MK@YRY>A@%7/.&5.HO
MDLORJS%B3.&TE^52/WZ6I<C4(R,P2T0"D<Q36- <01H5"A.5)$0Z5F<]-=ST
M+(R-E/6 9O8GH;6C!%]P!2:&7DRPD7/=$'X^K[XU,8RJ6O:)W>:]O0*='O[(
MPP8MGQ1R<KQ1B<1&\UTZL;KGDNCH=:G%QIKY6%+69'YW ?GU^Q<Y0WJ[PB*9
MPXRQ"**""[V7$1+F<933*$M3&14N$0.V T\M9J!IFPO4BVE4 9[*1?GT\M2%
M3S]W4@\)E[:8 3L>"H%K\%U-&T*]*?#:!5&OY;XR,>E,@L^T])!./!0J_W'5
M%F._082U/2*'8ZT=[A\8T5@NJJ5^8M\QZ^Z;Z0G[6#YOJE.\T\,UJS?G@G&6
M9I 7M( (\PS2E"!M)Z$THH31-&(N.R2'L:>V;5J+NF[GYQC^Z "['5D% C-T
M$,+A_GR:P-8 ;^0W-:Q;#3Q&4[K#YC7(TF'X<6,OW7'9"\D<\(AA)/9>LM7M
MHEXMFW(=7Z203^TA6U.\X7UEDH)GG.4D9Y)#ED891#R.S4F7A%F&\R))"X$I
M=6$OFT&G1EM&9K 1VN16]6)?=25&P&^MZ(YG75938,=DOH$-3&%>,'7F+1>0
M?!*6U;BC,I4+$KL4Y73O@..MLVV*CG4I,D7\Y]H"/-:M:(82Q1&7,228F#VD
M1)#&101ED10,1XQ3CFW8+*R84^._PYWPW"N A9M7B\.V2<Q6Z. !HP XW<X.
MO.NZV8$#W>Q KVS?U6ZKJ=V02F7A9MRAOMDD9GZDJFAO_ :X'>L&GYB3Y\#A
M1A_OX#@X@J].FL./-L!8^)$N%WH37.LG-8-_+!?R=B6?ZAE5*4))D4*<%@JB
MU!0BS@C7MID0"<ICAB6Q7NR/#C.UQ;H7U'RJW6?^FQ$6--):[D_.(&NQW'K!
M*_!R.094#NN4%\A&6F>V<6I.ZPYAZ2M(T0Z=DV1__.[QR/JL!J_(]OS5EX8Y
M=]T>WWW_1/]?M;QYJ5?5DR:H=]_;9!H]>)]+L]/V!:=1H526P3PVC5CS/(>,
M<@332"I!69REG#C6:;M8J.D%!&Q'\MX8;VW)7EJ+:E6!3LVFE]E6Y$#KJ_U>
M':_6&&I.[9Q,X\Y3Z-W2U@3U\Z'Q;Q0":XW,C]8ZK3/]1NKJ<RG*80*U!TOU
M1D'<EZ)X/,#[XB</]-R_R/OJ6JER7M*5[,.$<J0-6R0+F,B4090E I)$"1AE
MG""1X20KK)Q;)T>9FKE[_=3$'0O][6I:I;VTCF[X@WA:^MTO12FTH[U%9BUA
M@%BJDQ!X=:,?'&A<O_DI7?<<Y2<O#G%JU^2E9BIE*2YRF*0F4HI)"AE."IAQ
M3K19G.8\<8HX.#_DU%C!ZG1I0!:Q!?@^3NLFEN/K 4W/)W6A,G@M1IW0*=VI
M_%J'.P<EH)T(L[JOWDD3)W=M@GI-*?$/^DV<Q44:9077I)2;3@Q%0DSXIH ,
MI3E*:"8+9=6)8>#X4V.H^T>YE$W8LU/RF3/L%JZZL& &YB:;T,W["KQK0S>O
M0*-'TQ !&$W"@N_@_ L["2-Y!4--AFNVX% HS^0-.C]VS S"H3KOY!(.?HS;
M*E(O5[/[<F7VT+<+47XMQ0N=-_93Q'&:DRR'<6).;3+&(8D2"8LLQWK50!G.
MK>HK'!UA<BN!$=+XH#9B.MFFQZ$\S?U>  K,[@.PL>:*L_J?,"SUO5M&I?[7
MKD%Y_.&C<,)9W?JO_OR%0_I.5\O?-7O<T.=R1>?;ON]9&@F2L(A"E1 &$<[T
MAZU0!DT'!$%EI*B0UE;@\7&F]HUWD@+>B@KXEJPNG:6/ VMAY_F!*_ 7WR/5
M2?GJY,0/4@Y&F1_$1C*^[A_+&I0K^61*.>H'-\<4IIG;MQ,OGVF2*-LR,T]M
MF9FRJ5,BY=]]->D^B^'IUMS';Q^Q(?=9'5ZWX3Y_^< 2IM6BZFVSVP6OGOJ:
MS>NJ(UD>*QK1#!921A 1(2&1>0Y3K#@K\DQE"#E5,CTWXM28]DZ_\4O]$AM1
M35?#1EC'_C'G8;9S\GD%+S#O;LL*;COX.G'_%J2%@S4Z7BN=GAUTW(*GMACL
MU3VUOG%@[U5:+O]%YR_R=O'\LJH_RJ]RGGR2IMCJC*M$Y!G*H>83 9$I+T41
M9Q G.)%8)$66.:4$G1AK:NS2R 82Q_ZG)["T(Q)/" 6F$",E:,2\ JV@5Z #
M#/S62NN1/BPP\=I=],1PXW8-/:_W7C=0BUL&%F_H?4,?JN6OBV=:BILY+9_J
MZT7_%_'_7MJJ=QT_M3\V;J3/R[)JW$AU/$LY47F<8I@3B2 25,!"1/J/C"F%
M98$EQ6[-8#Q)9O5YC=H_IA$./#?'.*Z%'CS-EAUIC3D#(YTU]!HU$:^M3J 5
MN@GDZ_ZZT:MO8W/5_ZIU>[=3V*CGL9:$7[B]EIKP)-JXE2C\XKE7J,+SXX?Q
M=Q>_]EDN]1O]9$HOW;%Y^=!X*M[+FB_+YM#X3MV73]K2G,5Z+TFBN("4:?L/
MI51!PD0,DQR+B,8Y$\RI@KWC^%,S!YNMO3:VP>I4DTTOR-MQ;D \ W-K)WD3
M3]++#C;"7X$M\<V!0*N /_H<B)Q/FG05850Z'(C/+NT-?<Q0?]E*&D;]6-'%
MX=)ZBD=<Q#F'A:*I)K280);@&-(BCTF1YC(OK*)2K$><&H4U@H+E6E)73]DY
M@"7B)#'ECDAFJA^E&F7&90)SFK$"1S%3/'7+%?$*\3BI($;4@!C;>B,]XA;:
ME= T2S:NR+>M$FF-F5\?Y;E!1_916F*P[Z.TO7%(VN_!TOJ_T+DT1IE^<_2_
M]-_J4C1>TFIA<I!G D<T0ES!-.',U)"DD- $:7,6,\0%CWE<V*<$#Q%A:OR_
M$=6<"VYDO0)<2PL>Y5PT9X1Z::Z^N63$#IH?BU/LX*@'IK9C33VN@-'A"FQ-
MR,WK"3&*!)\!EWSET#,QTL%YH!EQ3&^^!,S3J<^#GCQB6O0EFK].F;[H2<.V
M&*W]\8'RQIG356Q+%!)QEJ>0(F+:KF"]J^"Q@)E@:9[P+*?8JO+$J4$FMY"T
MAE@OY,""> ?AM+-O+P4I,.\[X^-LK)X"P*=]>G"<44W24YKN6J$GKQWVS>^6
M9GA'ZY+/N$A20:2$BIF.YDC%D,5Y#B.2%5)*KJ2,W7:Z!\>9WNYV7?KC6>_.
MFJIPX#__HTCB^!^FP%3)FVIQHIK/Z7+K&L>8G,.8VS'#Q3B&-@GW:J=<@49&
M?]QP$@*?Y'!XH%'9X:2NN_1P^N(+>@>S\W6RV&Z=K/5!_75=OSSUQ;*>)5])
M<2^73_$LE3&C2%(H(OT'0I*;!BL$R@3)2&:Q+"+'+BOAA)T@4W7B#3BO"3BG
M=B0VC7D*S(2-!O!,^4+6E2^$!\H77H%-%!+84O@*K.?^_M3<#VM-''1:O'<H
M#B/M^(V*@Z)^L%]QV!&'+3:OD_5V^@!^D<;<[7_9THW@(HJ2A,,<JP2BF E(
M*4GTBI)$".5%GKHN(:XB3&]AV"2L-HUT'..JG*? CO%#PAJ8Q_<2@/<ZAJ[E
M;Z_PS,I#H?/)M<XRC,J@0Q':Y<7!S_'4]GA_B'621I*K1+(DA5)Q A$C'!8Q
M3R%'6&2FBSO)L@N;'Q\??7H<=]DG>/%L6!SMA$,X,-T=Z8I\".!QFB.?1\VY
M1?*)1[YMH^3SNIYMEVSQB&'&V;N7NES(NM8V(RL7C<GX1?+J85'^*<6MT#9B
MJ4IS**Z-0[FJK_G_O)1++=9"]/&AI:P;PU'_L+VD_YY42O2&/\N@)K,(HA0S
M2*4VZ!2G/)8)*3*[>CKA19W:244K':"=!FZV7L 9M;,*IS%/@0FU5Q)L:6G*
MCO5Z@FU%03>AO:I-+/Z6LJ#3]JJ_,$0V8_AI\6F;!I1V5"LV/.J[]NX((PZP
MC'^6?ZQ^DHON6/OZYNY3)>3\,UVN2EX^MS]\6,K&4=%E'C*:TQS'"=26,(.(
M$@5IBBAD41'%M(A9DEF%\@\<?VJ+@M$ ;%0 6@?0* %>:0'6:CA8R@-FQ\):
M#HMY8()WAOM\!JD7W!W"G\+B/U+L4X!Y<-N]#$?QY YFP&/'V\4,U_G53N:"
MQPQ88CJ?=EL_]%Z#+[M/)E(B3V-4P)@41&]$4@H)+U)8*)*E'!6FWK#U0G)L
ME*DM%Q\J$X5NMO:-D.!#67,Z!__W1:-OF@8,*N]Y%&*+U< '<($YOS^HZRH&
MM\ -H/6C,#F0MP^X1J+H8;"YL? Y.$YR[=&;QV/4<_*_XLVS%P]CQVKYKGL/
M$4=(R83"@B?:M%9I9H(T&%1YG,2B0'DJ[4WK[2=/C04;V< [MV]W@Y,=K0W2
M/CR5&<4'LM<& 3?&&H3$>"QEAX@S,>UI?8Z,-C>,2D![<NZ2SOX% YW*=&[2
MWWYYE'+UT<!G##U3[Y5PF3*BD-[28VI*K&L&R@2!D> I+42<QCAQ<@D?&6AJ
M--3)"1I!02_IH 8/1[&U=,YZ0"RT:W406.[^T#-(>/5F'AMK7%_D&8WW/(GG
MKA_2.7U5\=]OZ_I%BO<O2[T]T?N0ULYI0I#N5-]Z]4ZUO5BO%^+?U 0QK>I9
M7O L141!D1OZR$QS=(42R&*..)5Q2G++ /:+99G>Z7D3W%6#LM&GR3SNNZ&;
M:A15URO9G#Q\ZW1P:9-]R;196%%C345@ZFK4Z*= -(HT!6[;8EC@:Q/TJ6=C
M?V;>9&)<6I2/-$$C&8.WJ^T:Q.MYJ4_.GZ^FXAZ@/-TW_)(!1FP-[@&'U]V_
M?3QPR-G6B[&9[U3_K'X8,5,%+D@L!.0RCB$RJQ;+XPP*IDQO;Y$HQ.RJ!IX>
MR.H+&[4(8"_BFNI$DV35)%;5EIE59\"U.8&Z"+"1#IH:&<&= FO,UF)ZP<GE
MQ,@'7F,=#+6X:=;^MO>N^3KZ.0?'Z1.>HW>/>)!S3H/7YS5GKQ[F#_BIJL2W
M<C[7?'NKWXO%0[D./WA?UGQ>U2_+3>GRM*!)4[@9-QTX:)1!)G()641HI$B:
M"NQ4PL]I]*EY#GKA&_MP(WX?*+11P"9FR,/DV'D9@D$>F(N]HNWLD1B$FD\W
MA9L H_HN!F&SZ] 8]I!AG'?[]$S+I5D'3>.BUX-]*!?E2L[+KWIU9G%48(0+
M&'&"((IC372",<BR0@J4I8A2IY[8EN-.C><V8IL5736"PD924&Z^0]JHX<9O
MMA-AQVP!X W,::^1W2.U*_!A"VQ_9.8(E$\:LQUZ5 )SQ&.7NEQO'[DNP%V?
M-MH8C":Z]-;T%%K4)6_VWO$LS2A'.<I@DL4I1,@4T$_3 F9"%%S$7(C(Z>@G
MG*A3H\9.X'YWXUZ?,^"LVI'F-.8JM._W\LH =YM2 &N%3:>23N6V:, $*@-8
M3\LD*@.<E_:O41G &G5OE0'L1QR2*ULNY)UZ7?SJQS^>RS98M/7;MG_>J9\K
MD[30GD#."I2D:91**&62022E_IJD**!DA,8R2WE:V'?H'"K%U!:)+O9.6WB+
M+2G-OTTEF2X/Q"5W=NCL6'AEQ\ \,-D;%8S+=J=F7E/$I=.C"X>\ZL,B]=7;
MRHPQ%R[=W4>8D[%ZO(>;&\>\YPLQ/9T!/?3A(^9"7ZC_ZZSH2Q\VL,U@4^==
MONXSWZV1]?L7V7>9G^$TUHL0(S!..(<HH0@R@06,,LQXC&B!8B<_CNW 4UN(
M])N*'+L/VD)LM]D( 5S@U:03N2]%LY;Z"JPJP&37E,L(#HSD'EL4.F+EM5^A
M[=CC-B]T1&2ODZ'K_<-HZ;UDJ]M%O5HV"ZJVRJ5^'U=?Z$JVD0\M$\YXEG.&
M6 :3!#.(1"0A$0F'' F1D3RB)(I=2,ENV*E14E_M1"HE^:K\*HU+N9$<Z-7#
MT9EBB;P=5_G',S!3&8'!1N+&.=$B:80&K=2=5>6/IMQ@\DE2EB./2E%N:.P2
ME./=0[NNGC?69KA >20H@81AK,E)$5AD.(<8XT+F(I%YI%S(R6;0J5%34W#)
M''AU\KJV2[6 V8Z)?(,WQOZ[LMGC^>Q?:@^1W^:D%N..W'G4'HG]MJ(.]PYP
M*]ZM'N5RT\NI[G/ $9<I%P)2C#39X)1 9OI?$)6@1!4IPH552_@38TR-6QHI
MM]J3N825'T'1PKEW.3:!J6,/%M\9@:<1..G4.7+K>"Z;T[*_<LB<N71HN]_^
M>??Z 7VSFDP;[HCE$%&3]I/*7)L,-(<13>.8<5:P KGU]-T?9&H?[T;&@7UJ
M#B)I9PM<BD_@#]@%F@%==H_K[K>5[H%Q1NZ7>US3_::X)ZX=D@7X+'E)YZOO
M-_2Y;,\#/M/OYOE]QU"4%4DL,8$YTW^@1.K-@<S,<5]&)(D)EW'ADNIW;D"7
M]WN<?+Z-I."Y%=4E+>PLP!9+N5?0 I/"6E:PA5LG[=FNJT/P<\F=\XGC2(=H
M7S;9<28!CCY5+VT 8;T&FN^]H("W^OS=5Z:<+7"GT^'./F7$G#=;C5XGMEG?
M-3#L;S=QKMV&M1G%?=.AU]$CLRRA65)D)BW#-!.+6 (I*U(8)Q$C*4O23&+'
M/C_N4DR/M;>CN_AV%)AS]MLEDV-GYP4&/#3CM_GNK?Q7;5A=?74XO&X3ZM3W
MZ/Y0+94L5R]+G_%TP_'T&B@W0(QQ(^"&X[07VG;!HWR<O-T;$IZE:9%(RABD
M6.A=JB@R6' BH>"*I2B/8IXX9:P=&&-J^]-?^*,4+_/&"?NQ6CQ $V8&=HZ'
M:O!;([SCUO40Q$/.TYR!"\U8?C"[\/CL%2KASLK:8=[P8.R5GJ=/P5Y?ZN_(
MZZ-<Z =TOA?!"U5$.8,I-3O:7 A(J% P(Y'@PM0&B*VJD-H..#7&.'IDTPH]
MT,UU%O;AQU]#P7RKHR];'+T<?!T")_2AUZLQW_S ZQ "-H==!^\;QCF?RD6U
MU(_L3_%G&4W2%.-<DTICB.0"TBSE4._(\IRF$<F5U2G7L0&FQBD_Z^FK%BL]
MWMS$G?1A/6X4LH>B'65<@DUH0\-8Q8_57+])]?\"/_[/BVGG?KU:+4OVLFH<
M-:L*[&!W>PX[9]HX!I!/FM@;8U1:.*;A+@T<O>Z"+,V]?<U^/L^[W7R>]DW8
MLC6;,[S[1[KH,GU^:LI^W';'\#L]J)I?OJ<KN6X8.F,<QQ(G"<0DH9IO8@Y)
M$4MH>JO3 D6%HTTS&<VF1G3KSFVTBV5\,"(#88+NE.DGW)8P\]''?C)SX))<
M.@5YI[0 7)Z+VJT:VQO3-G)BI0':9*JV&.F5=YU2L]=DL+D$&*BV6E][SF*=
MTOQ[3WJ=A'+CY\A.0NUC?L?)"3C,E/A9KFYH_?AY67TMA13OOO^JY;U=W"Z^
M:C-%FX77)EZ^[0C65X#"<1XEG.4PE2:GH(ARR$RUKBPGE"HB<Q$YK?GN(DQM
M<3;B S6OOM7 O,J:##O1 5W+[K8&#Y@6N\4R+-B!5S4M/&BP[L4W2]@/1@,-
M^=_ 6@FPT2)(G:[A(/I<&@9(,2J'#T=IEVPO>-(P5KR73\_5DBZ_MVQ]0Y?+
M[V:<)@CB=L'G+\(<-57+AO2W]M7WU>M==;_AJV<$RP2C-(.21!(B'BM($4Y@
MJA52K$!YD3G%,/H7<6JL>L2W8TS-:_TC8[$^?J]+7M)%W?A#Z;Q4U7)1TBM
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MPQNU^=I6588KL)".\9!64-NYK[W!-U*KC$Y<\$,O\-^:XX9.YJVB(1[[9#A
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M-:;I&*R*LAQ%,8-9FB.S(F!8Q#F%<<*B2$2RR-/,+9#, [ CM3MK!0/F@PF
MK!W->T K,*6W$@(M(NAD!#]T4AYWK3ES]QD<?/+TL:%&Y>0S^N[R[[G+![BM
M?WYZ>O=2EPM9UX;'KQ^6LMEC]QTLDD+&B!8P2TS/,24$I#AC,"$YEDC3K4CL
M"^6<'FMJG/OSIT^@%[<Q6\!:8 =_XQE\+?S"_E +3!$G /-=@<<.DY.>N#./
M&,^K9J?+*P^9Y2W#O5T[F]8OLEXM2ZZMNVY3^_H'6U?.,*8%YG$$,T(41)FV
M*8J$Z4UG7*3*I,K0*)L]-UZY7U;:5+3WA0V6R>43V94LK)OG"G#CXY$;61O'
MSW*M2?/[*\#D0[E8F)"!2H%GAR,//W.J"HZ8B$VERRS3UB$BIAJ[@$PE"69<
MQ@7/NSG]46\+ICBCO5S3F$^3*O4F,\DP)VFL$L@8,LMYIB!%#,-$99)1%$<*
MZ>6\6M'YQ&9Q(U.X&;ROFNHS!^?QZM!$@OJQ^K8P20Y-),]*;W^;Q<[T'S6_
M5O/JVP#']_#IM7>(CS)I(SC*KPYXR3>R@[4O??=G-B<3@USG%P/KVZ4^7*#1
M7>T78W?(!7_Y0P=V2N&/4KS,Y9WZ1%==B.>=,CZS>[E\,@T*[XV#>7.:57">
M*[VG@E&>:6[.)84DRPI8()P1RN,DXTYIQJX"3&W_U<O?Q..]F(K\34' LHU_
M-3^]64I1KL 'RD_GD/F9'SMR#8EZ8#[=!GPCO/G7QGW?M$C]K5$AS/'C4/R\
MMNIPE6'<5AL#$=IKE3'T.9<>55YS3;)+^8DN?Y<K,\0F!GZ6I33''$=090F#
MB"0Y+*C,(8OR"$F.*2JRBPXI3PP^T>/)/JB_^1*?UG*#>BWXT$/*4Q/A>CQY
M*:[C'TQV$H.-R%OY0R&.(RT@"G,0>6K@-SJ"M,#B^.&CS<T^RX=]D71>_BG%
M3[1<?*SJ^F[QOJR?JYK.9RK+",8%AR0UA>1SRB!)> J1Q"3-$)<)DI>7L#HN
MP-2,-B.AB:/0HC5VA&P3\Y[:JDSE6B,?]:U.3 N5B/*(,Q@QSO5D9 PRFBB(
M<9XK%N<DC=F 923([(R_HMA.DN/"XCQ+=FM,R$\B\')SO"99+SYHYN('H\'?
MS)3T2H2N3W8>OO!ERD[(,(%J9><1LBM:9O$<]]YQ]^7*&.ZWBZ;RU@N=F^31
M)@#')(4^EL_WU8^+E9;F?672G&8JBA$F',$D$QE$,6:PR#)SELN4$DR(%%GY
M%@:,/;45JA'?L-Y& ?!;*ZI#+SK7"3A-=8%A#<QR@Q!UZFTW$)M+N]^Y#CM:
M?[R!>&QWT!OZ"(_IXUTQM5E*)14L(S#1-AM$VHB&#&<*,B%%0>,BH\@IIN_4
M8%-CHSXWN2E0!N:=M,Y[^I/XYH1P&LD"II3EIK4HA1I6 7FJ4LF+E*9,N07W
M^4)XG B_,3!.E.*2,PDCI+<92*((4J1W'5DA4HFSB*N$Z V'9;C#Q?BN]Q2A
MHQ@^RKK^/Z"KA-@T\-#TX1%7NRV"K_<Q\$)YO!!!)VO@6@,WX<I^GASO[>L'
MW)PN\VEUCR>W=Q^X)>N?EGH[,"MBE6*N04519&IXQ@DDFI9A(7):()93CIS*
MI)P;<&HKX+9+EG8N6=:)?*%C>Q?J@3[M"P!\ W?V1MHKT,@;T)5]!)F@7NS=
M,=_6@7T$@;.^ZV/W#8G@;GINW:D^^_DG\Z<4LR(I>,JHWN2G*FE-$D:P@CGG
M*,Z2',7",J?CU##3,_?6Q0,>6@D'%@$Y!NMI$O$%56#BZ/JTW:E-J85.2 \(
M.=3#\(#42$4M!B#F&-)^&HK3L>Q'[ATQB/VT]*^CU\]<.S#>:FC5B*Z2WE[1
MB"8<]':Q6I:+NN1-_;U9$J5<2)G"G)F.-1%.("6B@-I6RQC-21QE3JZ*,82>
MFL'7%]E<5VERC-L:8Y[M+,6IS5[@1:/1!9ZIZ\.ZNC[P0%V?=8'5JZW"/F5?
MV.<*K#5O:[-Z#"H;<:*\!J*-(?>XP6LCSL1>P-N88P\PY/60U?*??>(E26*>
M% I&BB.(BCR!!!481HQ)*BA'4<ZL$R^WGSRUY:"1#?S3P>Y\A9.%.3Y4^_";
M=Z/X^=3(,P@XF-M#D1C)QC[W*K@9U(>4/6E%O[IA/-/YD)RO[.6#%PQL-K2I
MT?']7O->3;F9TNZ0.DDC1E&60IS&!43<E!KE.88X$=JT+9(L9H6+=7MRM*GQ
MT'8]FN]@2US'Z  [J.T,3&\ !J:R"[!S[^]C@XG7#CXG!QRW1X^-[GM=>*QN
M&ERF9VD.3=[+]O^WB[O5H]PT]6GZ_M0S25(A<*Z-F0+%$.$$0R)( 6F<(912
M5<@\'A".:3>ZVX'I:$&8C:B -B(ZEYJQ =V.8CQB.%HAFD90\$,O\M_,'K*%
M<]-?[/HTL$,JTSC@Y+E0C<W(8]>M<4#C0!D;E[L'^@-7%?^];8_Q_D7OT![:
M/5NS2VM^M[.K$S.6)#Q#BD*N<@H12Q2D^M$0TR0N4B12D:9.SCU7":9F$GU>
M5EQ*T20>51=Z[9QGP](%%Q+CT/XT(U_7:PBTTJ]=88T"5Z"]I/>8_G@6>W?/
MV%#\O+JYG(48UV<U%*,]!]3@!PW=[7V5BQ?9MKIHAU/5\LF$NMRQ>?G0;.=-
M*3&3_7Y?/NE+[M0O^J>U:FW$)@%T%B74T&(*"T4D1$FA_Q9)":,<*Y*G"4L%
M=ML6^A!K:F39:=4WDND^YEXQL-'L"O2Z@58Y0Z_;ZG7YU<[[32^3;;LQ'7L*
M@^]@1YN] 3M>GV#[W1I[D6SD/;1/-/<WVUZ??FGID0]:B)7\6'XU77=7^H4O
M]=-;\[K]W&44,YIR M.4:)LWD@DD#%&89S*+*!)%%EDUKW4?>FK\_:K<2",[
M;(0'&^F[3>4P?G:8%$O3-PC4H6U>?RA?4%K$%K P147.COY&Y41L43E>2,3Z
M"<-X[6.YT(.T57_ZHC^?Z!_ET\O3NVJYK+YI-KVA^LW3/Y_AB.<H)Q@F6&IF
M(X70]FN40<P227F2XB1W:L?B,OC4N*V3L^EN .A76LZ[&'<W"G/"WX[$0J$:
MF,:,V <J4%V!'NFU\*"7WA^/#<',)Y,YC3\JEPU!9I?-!CUC&)\UP27W^M[K
M/\IZIN*H2"G'D"N:ZVUV2F!1J +RE!&)<\8B[D18KYX^-49J^[P9Z<!O1CY'
M8^HU<G94,QB/P%QB#X4S4QQ4V2<5O!Y@U&_]H&Z['_/ABP;$9AVW;/K-W/63
M27[\LXTI4_H;,@UE/^BW9)8QP:20$N(HCB#B)I2+\0(JD:5$("5H(:Q#N2X0
M9&H<</\HEY(:"1U"GRZ9B-,\,2:\@2GEY,YJRX.UK<L5:+1I>EX#H\](D^(0
MOC;2Y(P4[19VDMQBY3P@>S*T[I+GCQ>)YP&%5X%[/IXWT++<>FZS+:<+;NS6
MJE[5,\X9132F,(ZS&"(11;"0(H98VYQ(9504E#@9FB<&F]J:LRVKV< )4\^V
MK.N7QLW/C<B.EN@II"T-4T_XA;93=Z!K2@'?]M#=G(3.W7*UP,2K(7MJO''M
M6@O-]\Q<FWN&GB&OJ-X1BQ_ITIQGU%W0N5*Y4$PH*&B,(2(I@TQ3!S1M^%21
M)UISYE93YO! +N__..G%O9R@%]3UF/8@GK;'KI=B%/P8=0<<CXV?[$#P>[QY
M<*21CRM/:;M__'CRZH$E3#2D<KF4HHE1:5*DZKN75:TM&J$'F>49Y3F5!$;$
MI W$.8>4\PAF#/&,"&U;<"=[XLQX4S,IUN*"VLA[U=4: -5&9/<2!+;8V_&&
M1T0#$\@&S%]:,%MAP9:T'NN9V,'BM9S)F2''K69BI_]>,1/+VP:XV=H2JIMR
MWJ8HH?Z.OD@JROGW]]+TH-#6C=Y&?:#EL@F<VU1:K:\?'I9- +\Q?&89CP5&
ME,.<*@I14<2P(,CD(.0YS@61&;)WNWD4;&K\M9$3T*?JQ:F[I<_YLO#.O=$L
M!.:\KDKT1BW0Z04ZQ<"V9L"HUL8';U64KJ_ 6KUF+_9&D^C@S7NCR1S)NS?N
MI+IY^P(@?]+[YW.\\;R! 5!ZY1T,\7Q/-0JWQID5B*M4+YPP07I_CU240$(I
MAAP7*HM1E)#<*2GXU&!36QH/U28<W![A),J6=KPG[$(;\0?*$MY:P'9Y0<(#
M> 0M1K@]WML6(CR@^=DBA(?N&<8@/\N5Z9[X>5E]+844[[[_6ILSCW8 D]''
M5^77MK$4YI(EN4P@QH9/3/=9DA,*)1,93TE21)BXM*"U']J)74;H-ZLE;_O$
M/G>RF^))/[R8LDGEXF\=T1CO 5VKX,8X#K-BQS]AL [,1@;FIN?KYVV8?^UA
M7@L/KL_#[,Q0[HCYY"N'T4=E+W=4=KELP!,N*"O(SA>-8D>*1FTY1OXMRX='
M<^C[52[IPR9'Y*9:K);Z&W^A<]-Y,9EEN6 ,XQQBALT!+9>0\KS0C(D++%DF
MI5W T!OJ,#5+KD^AK2S\B)-Y#^Q(>>*S&YC=?18EW$+B"O18@ Z,K<S +3B
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M.A-IG.1$YTO0&LO5X^9RZ>XVEQZ=00Z9-3-T_+ UL7[9<P.YG,<'9("-B1Q
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M.#D12S#:Q9SQ R:R',0,&#49T@LO)T&U^O;I0W=%?>B=ST\?_@=02P,$%
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MXAQ#;]D%F@AW.NF4):,#IJSN/+P?+II/81XBTK&/R#=9^&NK=WE'B@L%/L=
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MMLX8^@9&/,O!"LUE-CM:'AP.L(=)&J<]9#U,#23\)LS6NP6<^VEZ^>4<YDO
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M8W4*^N^3,FXFJ"'<':BE!A+5;Z;S;K$6X48L$X>A?TA(,&. ]-.<B9>9$ZO
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M!\M8,.!27?#<I:@1'.VAYH<0<Y#,&P#/3?I?=&=^.I]PX%J CR2+)(F4,F,
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M[$8+M-$C,"&#U?1#\7!P53_L/D74>,_F]\#&0R/=FQ8&'Q;^O^>+Z_26Y?K
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MMU+@R5<TDV]WQ@:I#W"9>:DC16L\5(L1,S@M$:0O*?$ZRS:J%KOK2>L#[D8
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M'+EH:TYD)'=3A%!(?)U"Q8XO[ 0<_T*!TTSR(]J(/L_73206N&N#+0*C4TX
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M 2$R(\]!<H@^!Q"Y:"9DM,YUJ2!L.V9\N!NEX\S8T1)_,6/&T15DM4Q-<.9
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MP,YCL;R;I?.+.FKQX]68B%<K"HWCQ:J>IWR>7UW-KX@*>N*7FV&USGB;4'I
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MQ7G=21Q+Z<KIO*]&ZAL9,*]GT65OC"ZU=$+1>C7UHH($!U;4S'@E63TK: S
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M]?&L=L;Z>/;^TZ_7'&BE2*\J@<NU(82T"%Z5^IF2O& VR%,W/#Q^^#!1;8\
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M%#P'STH!U"DGHXU6IDG4\S19P^9^-#1)?:EB%-!Z?8&?Y_<G]%SSPHD1E[&
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MI4F^24_T#^C=CAG;AVIX%-"^(]CW\^5RT\UFN2VFQ1+)ID40H9!X63+@A;?
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ME>?@<JJ'5>32%-I6OJ]A"4,Y.]&FIAT:XX-Q<[*EF]ND<=?=X=J[<R)X\N?
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M8$PYQ"R5RG&0U7EB@:G+/D;#QFA2G+X2]C$7=V. (A<E)NY UXDF2MHJ&,Y
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MS8L7Y*U5./VI?=L':W;35N>/!WVP;##%Y#H,(NE<Y9G .:VAH+1%\L2%EX,
M^<)"78_UV-OPC2G=OFS<ZL<+_B=:JIV1TZ!L[?J'Z^=I1 E12[F^%',V!LMP
MV"/_OA1,:,-&!<#+?MS(VNCY8O+!E=53S#*=-?FJCIBU$6B?>@C,6$A(1I@)
MD2,>$E8,H6'"J\<C@V]TC4Q_.FYG](>NIT\Q2ZZ(4T$@I"0M[3 =P2NO08;
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MR<=%!\I% RZA!UV8K#-JHDA-XHG=R.P+:?L 8]#ERBA:ZA:#=[?Y64C4%-^
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M%0I9N%<0)/=@@A7_?W?7UMM6;H3?^U\&X/WR4B#=W0!]:!-LLRCZ) S)8=:
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M;!6]XC]L:%HM1YB ;+X$LWQ6?PEV"D"9<L GZK&G>L^YJX.PT+QJ;^(SS!P
M _)PA0GC7P,;.D>8G!+@/Z//RSH)5S)UKQ0NP6;?#K;X"ZT,'$GXX;X/"2YC
M$L,]#=4^Z*_%[NN2U$,SB0R,38HSQ))'[2*NMFN$VW>V@R?8:]3^J5C:402S
MJ@!)C8,D12"@"('F4^3O*^N\&FPA;AVZ)I'+*<,O:PFUDKAKQ%LVA?BXZN[U
M<"=A3I7I]QY9'QU9.JYVHCGPE^^+^]ZH.6T/\'M0J$Z/TYRP9XJ;3@L-JEE4
M)&H6 +O2^TTT,:;H$U+:Q,;Y5]K9(_'A9E*N0 B8YQ3AIMH@6,>?<7?5GN-S
M<R>45%('+@I^6D,&L@7I#%9SFO;L?$8_ &&1%2!=U8FD[DR)2DCL7>)F:8'*
M2H_! (>"]1ZS26(0QO33QCIK6D^6CT+[>=AJ=BS.U_9/ [V5[1_ERL46T+GV
MSP+%WL;6\>8\_KD@\BMW;2L*(H^>"R);51"Y6N,Z>?.U&M=)FQ6N@]>D</6-
MOG49.X5&P/H6J@2<32/Z#)N\:'&[H*',IQR.@!_)V"<=!CYD0>B4%1!4.E#9
M#A7V?C(]-ZOJ$FLEH1OMI+LUL_LTCH#I!3Y%P:]F43#*4^==[D]4YMR G(D\
MLO)1@>ISX^2#MV^.,9H!:@^Y8;MA..+&K$Z6OGIWT_+(!A.7MAA)/_R^9E+C
MH27O=?=LHG>[G.-_AV>O<O1*71* G?J<2D=]-#F4AVC#W-T!7?_P?2!-8;B[
MF6T(66#'E=>XNM-=D#C4%&[C#3WYIAO:YMT[.*+=.Y7=N]:L=?DJ\V9Z%+IQ
MC>/+ /5@6 !1,IL1>YZZ2**T^@?'^\T5-!U,23R0#2D)*$J2=\(XFL#>*)@/
M=6CD3'M?"RQQ6%+H[Y[2Y#=<O8.C;5D]DCV%V":!KK1;S2+G_F.8_N99LYL1
M9<O7<.?0HD#.OF8/3ZHH+2R;F@0-<JMB844!9UUC&[T-B^SLBK<_6%!W</1V
M"3=>K1)WKLA.-NQ5R2E9+A4OL1'>L!$H;OA^PT<PFAJ10YF")^P G"HWS%C=
M+1JE\BV,608[/7)31C6KE@>Y^BL,B&SLA-X8''*#W5YF ;5]+X_,7I:SJ)(*
M<+L%:T]1A_EZ^<UN5&DW2#OM!UA500YB[(5N;WG5O+D&31^W]SJ),TFD0]'3
M1ZQPGV*2I]A+6$R;P_V#_9YEVVQ:G_!U!/!F2?ULV_<:48"8U0Y<ZI\.,PQ\
M#!#HDA%8REJ0:9M@ ?[0">_8 3\X7K,FG8!(P%DP/K5O8I%6/]KV#_X1:!7=
MV(LFN(IJ*P/I<ZAA$DS>DFR>!E@HX9_@#EMU> B^(&U,[C Q.0>!<4/Y%+1B
M)KMZ#V/=+P]Q 0]WB<5]WP:%CU,'.N1N$8\HHH7Q/Q(:J"@4<L,Q/E+\$[9*
M=$+X5\@1^-<A4;+6WZ@IS^D&Q@QO8\\1=S0S47O;MG)3NK,K=&BJ_%3PVI)2
MJU?AH5$<O<2L#NZ5X:NQ2I)*];%I>K<='O[+_WMVVOXI6"EA=>B?0D)2_$CR
M ]%TIMB.KG3C)H5T4J.8X(3%TVFAEL4);SJYL.W$E<;N?':7#D-)Z,>;XTOK
M\!D/8-RE,;? 4]RK!;WF:/ME62.J$2>55OJ0N8R/#'/! O@T!GN-C#]5)+>5
M(-J:+VR<]HYN:CA2BSCRBYRDD!/<C->(<S=YF8PP*I)\Z(CY,3W*RKE&8L/A
M@)FI.'<;IV+2;2U+*7._ /'XN2IZNBX9DNEL8W*%]&/*^;>F<E\G(&6P*QD'
M+G!<>\YM/OJ7H YP@BD!3O.,D)/8&T,X;\W3Q]4L@X)LEQ@X;CTD/'.,AK3I
M(+4K",I.F&JQ,U!!E7*MC&W3%*>@/V7EZZ& 6 97]@W\GJW5<]DYP@<FTUB*
ME4S+F?M9U?DM)=U2.$JJ)8OX%$:EI'/$EUW+>5W*I#6UAFGPQ=EYK9,8*\G$
M&V//[:P$G]NM RE1E>_.8M=RXX[KKZ,N%$]M4VWF4.N0M20NMGMQL#4B>QKN
MM"WXCC9]M7\J56#'/\SK#M[LO6H_39*.)C'R(68U1F"XWV#]8XY91+Z2W*#7
MM@.='6Y%#0OG2&2FP?V3@1 ^IX?^^<F-[4X//7Y.#^U0>NAVQ$ZT-#?E-W\-
M>;ZT;*S]\ZJA-C_$5KDWYN-RN?=..Z9"+_XQR. \>)M,[DL[AKUZD+O-]HK+
M>*8E1$,+BL%S0U YW$2J"3&=S/0(L.N!*Z5E10J(U0J\':OTV,U=M&/8FVRN
MZR/OKH)=LIN+;4[2* O#X&#'W=TY.-E%3X8:C]%WI5UI2S;WFYJ:W3<T&>C\
M];8 G4?C #6) !C$,$+8&(&"NN3R!B_(Y L\WZ=Q/)=V'.V?^(N?-Z3DKTLZ
M/#K8$E(&!K$5M'R&KC<R.%N.??QMB'--G7Z=6K<"X4@G210(1TX_=0A,O=:^
MO"-6PMH@2U\#R+1_'A6KH">5.^C)OU8)=;O"O<//#'K(W^K@H  (< ^!J, 3
M$!Q#A," 7V9QH@C,,D$0 P+:Z5&-1!*' BT@CXVI=X%G5^Z14]Z^)N">S8E/
M\3H&2N[WKWM2>?3T(^41X6!#QM/E4;(V!VK>#-XB%]1&RQ&$H'%DINU<:04>
M<!?,^$JC[3GC8)PM,-A,&#\[Q_O_L6N&+8JB#"C-8N\S@<'].P_NT8(@M##*
M$\?YJ31+]\Q1Y+!ZSVB:^B#*M,J6(]CX8.2GI'0L&Z@,9AX_<!2.?Z%B,P;%
MQ( *?6?!MP QNQJS'0P=TF[8F^":Y7R8*@'?+* R8<W@UVDPQTOOXPR-HU1Y
M8$%E='_"Z_X0I&HY4_\*&)7#>;=; A48*JQ?=)TQKW7?,!&U?Q)57PU5?.B<
MPAYBK,3)7&:('^=NDLD1P(]D;<(^@@R2TA T1JFA'0+@I&GL!>;>+ &EPI$<
M%^9/C(Q&YR:9N%'P^S<Q.Q_?56EUTZ\N:$-;U^6@9)_:!FK[YX5H^B@ '69Z
MF+:K$PT=F_5M">^S=ZK]4^E^4XF.G04M<$3B!,7H*4TPFA3HBT7N#RI]6>H8
M>R<M,G90$W/#O-I7)S&29ER]5<H:O!@S[A@;+?)SC[0YO'24IUA=ESH[6@><
MN@03J[X$J0#1/O 'ZIG+P+)4<G$/,YAS6J<G"8/B7U_51P,T?3WJ71/MQ]S+
M,$[SQ&H;[=7J^,CY"T)4NINQ6(5;7?_>C3*LA%Z[E'O.,M^?P^"G:)KH9AXD
M\46DD\[N8@HDX8[BP#$_-.4H0*0FH""[&4,\^.9JTIDSO' 2Z&O'000V%KX]
ML#V/B4+81<&7QR;%G@O&!-\21(A-C2X>L)MFE$'+N9=X+2\#FA\AUH%375V"
M#LMLP7?#)]QQ*GA,I<,<1A3]\B]\,0S61YQJ3(65KV!-$-F>FC)Y&-&BA^#0
M\] 5V+DT'F</;B*?=+X?+!MH$_&,VT-1965/9QUS37^:8^<G&K]9"SWG8FLH
MWTP>H"'[$   S-7:HH)]Z^HG $&1.5M..9T!G<<^L( )&:+%_M"(YK1OGMXM
MO40T6,EXFR<!@7D\ZD&:)%*V9N?310I/<65=:46L/X&BLH<X^9Q2=X*8?M)W
MT!2Q)CDMT9H\>!JG<XP!R6LECP;K7NEB8%*T>L#;<G,1_F(8 1$#C80ZC0F1
MS9$Z\XAMOQW&I66CE6JK70^L8,Y[(>J 4ZGS8(AKZ:<+[;B($H2/VN4L9.I,
M-E(J(DZ0IZDR$"J2.U[-0:V=[)YCT(N;3W#5%A[_<591(M*"(5;;3M5X\+I>
M0Y7)DO_H 8XWX9'(<2]>#$ROH0C>-'S#9/:4! $L9R2^@6I29M,P5BP 4$Y<
MK )/SKK4'AW"+..0A3QK(VV2=PAC[184R?E70 M@B:UMZKYTS :P5L9=&J5L
MT3P?A8$'E\[<@-I9$J*6SP(7,V%@[,OVS\_I;'0AH7WC#,O7K4]HUU"<LE7&
M):4WK;9-Y5V,8;\GDF;8X* !TBS3P'T0AX:NW<CV/)HWV,]<K]N5 =S3*6D]
M=' S]S,P1"Z0H>3Z&=6C*GKJ/.%^%5@"4GZ$'S#R.][^;9LVESMZ+W$P'.V]
MZ2A&A=>) .&C3-0@ZT321ZE22V )B=]+*P$\H&E1O[1*E+)E@N+$EB)B"-&Z
M>(K-$/+8C4#M4M5B#&VEE/M(6IU8L59CF=S9<_H974!I83UG%".L29&']+@>
MU-Q)H=+FK!D'FY3F2JN[HN*N5YX1UYM\5FHNBD)]:? "TON69T^0DFRP\/)4
M];1EI]AR!'4\+=40+I766H/#43XD6 1(PTH;6\\6%8.H]8!Q"FH.,&U$P+=*
M^U,/M+/F6A,6W;3<I:66.\'.@%5-%I8*!_85#G;I+LHCF^QT6TIM8;/!UQUI
M$[FWEL%("YY481<YT NII[D=]\)&YV$<9$3/8BF2@6-:IPN>U&P4^XOF6PET
M"NM/*=9'00=ZW-*3@9%)8&D)?)]:<RAUA6GBDJD;PBF<!2G5X((-*X>6=!RK
MC;STSK5<,CA$C/JQ_X<:-G!S70*>2V*P*$V@FP>OP?J?:RN>:RL:1O?ZN;:B
M5;45VZK"+^>A(VQ]Q*Z:PG!BI8SY<).OI)#^*S5.4QJ-SH"Q&R2%XQK5P8)C
M,X-F7V$,C+D0.2J:H#L;QE%_0D5-:7"$J8 ]XSR?8FC$ZVT.385U1'[?M;#N
M\3'J;A9W@R*T+1%IP4.$$W.#=[0\U50K>%57(1 ^6@,FY,:N\V1A7#_MG]9F
M*GC[YX$^NSH$!;MG3;_6BD79HS @,"^0E,@RJ;UP3\I 2LHU)>.!H:E6.+KG
MAJ2)RVC/[5CYV+T9PSF"_Q+&&# )W0<:D39,I:%XQ<#CQ$[,%LPQSL(/ ,Z,
MJ'3>%%BIC,AU)HC>'-'$38R&HS&4<8EV0. %<WP$S9J"@,#V)L8*H' <%RU)
M4)<%VJIGF[Q)#9^-J4L/;N(S]OS2N[D2D8Q5BAQ;_HT_/X&I^_G<(B_4ULB+
ML]C+*43=HZX@B8]J2>:U?U8H-OJ(E%),(-$3P+AK#R&LL% UQQG].P_F=%"*
M0#R'::T@?)%="T<(&5RY\>9R;QI9[@C&-LZ3*$BG#'!9<MNMC8J2QI<H<4XT
MQR8?&1:$BQC9BW(@%$;*V+^ 3@P]Z5IXE;QIE?CJ7=T#F:@,)EMSFQG?H_%\
M:+69W^8*CN>4 B8$7U:/&>_!\I+XH,A)HP-47K_N=<&,$MDS[*9##3PJ1:+K
M5K#LBFU<"&XFCG12.$OU:'0.!R\T/\J+YX$2J P,39&/F&&^[/:>0Q*S@LSD
MD2N'S!!?J V>9%&^AX(!I5=*_:C5*(X_<VH =48D>R(%Z8O-9H-,S3BE7VA;
MIW[0:"5WPPZY(EE2S'5SDD%Y!$/B2-\8]_=A&L_P+OA+)=P_&X:[ HC[D<+C
M\1#]J^57O1!TPWJDMUU+@Y?&*V.K1*G=W!\'O%JF%1[1:XZ^MCX+D3>APF"(
M?V<$+48LS\27L0C>S4W@6H>8\5 " _%!*\RDBL3UO$ ZIJHO<Y.XMS0&MO%Q
M7',6OL=Q[%Q+!<;'WIET17E<"T]^HV;Q/8JYL7,A(J_],VH^9BS&83IJ=5"'
M@K6V]"NR22HJ7;F+,OH,)?J)2D6>FFRSVH-T.A4;U7$4+CB_+LV:0LW-P=&2
M.O7$W4X>?U*[YA64JMUI=T3BVB:(\7P!.]+^6=1.IQT=]7@6=H8"><Z7GM8=
M])/ <::@YZ[5AH *7O%D@4$2@5;-@7VPWU O=Z5[E"1XKSRL-=UWR3'^8R>X
MO"0RS.K22+'HTL4PL]>HP>8]U.G<5_@X.^%&$I$T>',,QSF(*EFCA=\/'IP6
MZ,.LL5C]$[G&=D->]%1]+1^C-M2T^/:RIZ,:J$#;^=,ZE?T4[,$\8TA:+%QN
M>?9;H[JNCV-,UFVXJ)_C0B70Q=WBK?"43_FBV)97)6R5ZQ614N[%GR_&.Z=P
MB[?V7]TY*&O]M8.7%V[0<BV[,3>TE/94S0A-Q(7&@H;HC5N'W@<P&I3@E"@%
M,L7.9(*%L"(X)&6H>P*=.]WOK\C<4W0#@F?DY#2;NHF/I5 ]4Q1%?K*BH(>>
M ]^4(TFEW*GO&U3Y:G'6B:#*YZ[8Q6L/:3_%0CSTS;9_(AL<5/O\V16.F'F(
M(4@JJC/%AU)>)9YI+KW#/V*?/-ER;ZE\T:I8M ^CKES4 1VI1,?AO9S&#SU=
MM&O*[.!HAA-04[,I^KPSY4VC &,,''/ 0TUJ/:504G9Y->#CHH).+C;VW&/<
MF3Z.R'&_8,[$YH<9?D]ZMB0LOH-[+,9E./]$<3"'G'1<94@\)E1N$M6#/"8C
MR T%D>=?<1!E6I7@\JR>G91^AV@UM$D[%"L.,0R-G:\YF@26RS@/M?%BZK36
MEM1IW)Y=W6-(3TO/%!>36ZT*(U=?YIQU.Z:<U!5I\W@K9S5IH,=2OP$<HVF_
M'N>)Q[&Q(L"S\>!I])AD@+R;^K&D0  NG<T-0G0[63QAZM@.!(1KRB4&,9LL
MP"S4I[C]D[+Z)NF YOHH9D.1Z#HF!X\FTI2"@:80;$H$K^F!KD8:G@:)Z9@"
M?"A(ZX4H:/VB+X*(CX.]QEK@+VNAU.;8).Q:(AH2<+@@"Y74/S"HE2/=H03$
M3'/MYKV7P'#H<D_RAKITR;A9:NC@T-.*)H?<A[(V>\]9Y<]9Y4VC.WG.*F]O
M5OE6VQB8 R.I&F /HAO34RLY'_'W)=Q3,CXTCR6S$G7AJGYF>J5("C=GE:0.
MPLK@?RGY8^4@"-7ER5VGE;X,1WLGM:UO.6+PR:-!>"^O[H:G ^?NRCGMGP_?
M7]U<#OO.X.+Z_.JWP>#V.^,QOWJ[!9AN'+2YSI,T=R/RVJ"0 !*/ M<Y=T>Q
M0+YCB?;)3X=O3O89AL]D$W./0GU@-"*-I1AAPO!X+,T6^2N!4,*T9-2_T'_$
M)T7.I+%2\1[K*N,4,A@3[AP]M:0N67=Q-:#NH@I<(,<$+-T_4ZI!4XV9LFK"
M#L^8'RBN*#1"I(E;2DW@-J.[XR<*BC13XK*$CM82GGB-W,)KU.?B3MX92<:V
MDOD*DJOLAC@Y"MKC@!;36J^!_GIK"' ]_16Y@\T$:!RD9DP%:@W; %C;&=G/
MCA\B-JNUNY(M:>LA1?S!Y,/V-+ 36,T%V$^OZN(HA?RL- 9X$<5&C4RD<;,3
MXQ&4_?II"/ND+L"6L]C6TK4D'QP8NKYAKXX0A*[8):?,7)<8D*-)$YQV-6FK
MN$2-C?10Q*HI9XR4$&JH.\,:N<0=8:0\TG4.!/:FW,2;\D7&WZ=?6#R?2QF>
MFK^5-9>#5\UZ2VMW6#C7H<"6W#!R'F464=%,HQ?", +M-=.+O*%>>/)-I4?G
M0H,20[>@:._D;'RA) UW,TE"/;^2+.5H%35;+DD26V6QSJ&-+D 85SYO_T@A
MRY8'^0+@:#R6K'^D^0BQD&ED(/UZ#@W;'F[JP @QFI;)3PR614'G!7>4I^]O
MJ7"*/ELJ#!HK#/ N!A(ZP+]O\/DQQ4.MI3 YY>$6!9\K37?:/YL2>(A5QHUA
MJ\A%8$Y46,IH&!M HS;#_9!9CXP[B'V2A \JO%?.SL&AZ=QLUZ.4NSA7"E-J
M;R^!(M7?7\4,TH&M:@B;V@_T&FI83.@)WE][.:J6(P674G G+CZ,:VT=I*EU
ML.L(I;"S7L.L5/STE<55'.M!)HF(1@_N8GF+A:)'A[[9YWNQ(%_WJ:CB]W!K
M!!G+6LBW8AEK$L!SYZ M9Y67[%"A;,&)C96I:V"7%+C&:?:R1 $(!3G/=!YB
MKD\=S O-!9/M@+M>#&K7KAS=E<(!-(;#4$U<S'S0VF*!6H"_"W)!@2MJ(I5K
M@#HIL[("4U/-'Z30KO&>K3(K-HCKN0P/1NJ2@1\V)Z,9$ZSI,>BQBW30"$$;
MI (**ZG"@ /7&O"6X]Q9$HSR+$Z*=AH8TF8,JV V=TE<XSFC(<TX3&SH@E"8
MX1$SKL00PC,+;CJ2L"8_S[,-5^1/+^GMO/=*A/1L=TLD]-TT2/R7URXZCTW!
M/LN\+N%!W#7$3HFK(*1W#4Y0 Q*,< K:7F+X;Y%0ENN'BOK)4:3N@SA/"Y^,
M02J?T_)I[L(YS,:UB) &C5R\#L>%(.]E/+ E,=V)QCJ6=QC.4.#E%:OAIF;L
MX:+(;M/8>P7<04DY(:3>+',]4YUL0SI45AQX$%KX4587DBNP'+\H+R_X5AF?
M=7VI<I-&1:Y6-H2U+%R&$,$XZ9) 7TTL*4I\&!:6Y6()_K41D5FBZ.M(A>J5
ME^>ZU--<2F\S8],(C(Z4'+ CNP1]7$&UM0@[-:J>."+E @HNK9N B5 UC&J4
M2/U[I9:"W>!2V52O"#:%SN9-H,Y,"(*<0/8"'C3<&,712VVB+NV[@$_14%#&
M4=(T-]T^R]Z>/]]V[:;I&FU-0N9Y8/!8V+]Q4Z#MVUUC]]H_SQ<_.\X9FZ@\
M%8XILT>GQH!*H&)-0 J>3%Y)C*O.B"5YT%=C#:N)'0<L7D^'/72#62K>8^*H
MV(W$PDI]3@%Z3@&R1O?F.06HO2E VR/"N#<2J8ZBNHK-/J+VF9EF;N,\0X5=
M>\VK3JZZ!EQD6A/T JLYGI<G";Y-VRA8HSHGUP 8$Z&J:%AN6GBN:@@X=TWJ
M)+)HP[%%):R" I%25&?'S.VEHT:/NA&0=J=,NT3$3./X@WOO!B&EO</\9DJ)
M>HX)3JD*!7%B3H!'8O!@%8!X=[#J5&>@>AF[;.!VSCM?NJBX,SF&';G8'=:4
M8&@(BGU/R[LUF.JVJ"NM-#5!>82XJRZISB@I@;I);9+(OS(87:] H[/;^C!T
MLT9!6NC$K^8',X6EWX?$$@.K)/V7RL\I>Y>Y/H)SZN>Q]QGH0[+_T4BF ?H;
MPU55S#O;)IM;.45;!/K8_EF@!T9RW-]7.(Y.<R_R5T:*@723G!T+EIND"(@N
MRI8K0C0*265(_+,8_T)ZAET>PW'E;M1!&BH7I="&%MQ3)4AMC_S;B;?&A!MP
M,!K9.\<YAM&_\LCKCM6VO/ZDJ0E "3M!P-J:>E-3@9;%E_%915,-$M54Q5:.
M.-@E(TW>FRJ>6\_Q8SKMW*5%PD;8:@F+:"DF6?%R*>U3DM!JZ?S7)EB?U@.U
M5RJZI:\"FTOS$2('<T>SA%036HL *"19[#E]SZ/&(!.,&Y8U VO5,;(T4_X"
M=1%D4%KHZ3Y4U'0=9T^%>Z7F5$4XV7B>*OVJVD^AVX-77/<_"S6-&!X-I!+3
ML%^O0V?D8F#].EVNB&\3=1!F@U:/>P7R"?4,#UD"LJ,2=614K:D=#<$\*%1S
MV,O/G.L>3T$8J#$W+_'0!-&(CU7%B-5Z0V>B86OD-]>B4F06J/11HMYRJBVO
MC]7$A[E'P$5U%%Y U9MS GUWAH%C*J==>DM,'6B=41SYW&*%\2MZ3<T/07$$
M1H"!C <7U@-T_8LX46A.-'G))=A180AL%DE=/\$#C:D@0V"7#<C&&-F&P"G7
MB_LJL>7FY@*NM83M/PK;?*3WG(_<[T^G5O"6 N/NE<F#CRB'<\K8$@:SU9T1
M(H2=+>(N=-EWM;:Q1#1X;F%MT_'"2BAHR)^QA$&%SFP)\TQ3?S9--<6=BVI7
M-!AF43!F?CZ-J?]C,B,R7*>C2-#*-SXF0O E=FI9S>MAHEVJ8%?4>)= X+'7
M2<99-]AY!+DY:#U!ZK-N]4QO[9A'HUI2D4%,?RC30<% 0<:)"(U*!F*=WRLF
M#UO]S[(XB=0B%=[CC(N41U3U ^P[KU]1E#":T@%=$]G^!=UFPM#PWP*LD>@D
ML<@VH*CQA&TRVE+F^6S_V6>;3VV:)_>!J!Z/PYY? 8/)W-OLMK89MJLY9?OG
MT;CM"/X!)@]UGM#0'+Z:*_(U&@..][%,(NP-K9!(V=5C6ZQ6>480BNE5Z* S
MRT.+:.'41YW82>%&*Z=O%[;E,Q']Z>S_,L8F1-&DBCM;@XJ-I>-<E%8P7DL^
M>7<\AA5!=*S,ROTB2R=1(6@/U7B/!KDNB.)1\*U?6<GWF)X+K76\<_GFR5Y7
MBG[60D??YAYZ=^*DY;G#!7IT@QS&D'_ O>6H#PPS9G2XZ61\%:EQ0#R1&G]K
M[4H2(X-$MQ%'5IV:)3&>/4R^]36^DU4Y(:F06"5H(KRDQTOLF7UBY&V"D=0\
M9(E.6)BI9%(J,7 7/ R)NF5L%[(+NBCG;?^6K:0]G=W<_FE@F[SVCW+E8D_C
M!P4F9?MGP2T)00]:[6A+*'D<+>/0@BF7F+4IJK4:RU94;NEBGTH9;JFZH P
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M)B=Q"%26_OUO)V]^WHXTCI[,T.^O,/1+7.+529O9!--&_\ I_K5?4JP5=G?
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MPOM$T=]2EWL6V+4-/-HA@7T=IV(ZX,4]R[OBP#F N29:P.#-ZY7-'!8A;-X
MEW'AQPBEE?JLO)RD9(S:+]H[DY+]PRRM,@[(>A!B<Y+*)6.)G$2T:8X'Y P+
M2V"Q\,8T]@**AY+_;ZQPJFLFD<U RB*3))T])2%,3R[C'+^/R@9H&>S?3S^!
M 9>*#@^2EX6Y3,/%0 #I+# )N&;,;^LF9@;'07_!_XY+1FB"'*+_^N?4^35V
M$Q]WZ Q,5B^+@9/OD!N,5M?^-=C>RE5D8M%A!(1*BJ00+1  '6^<*OV1OC=)
M'"IC><:HX57HDQRA:0!K JT,7A;@&QIOB*_NXTPQ/6(PB5X!F] #]1&G21:H
ML2=[-@VK"7HL;,I-U+_R0#2%21Y.X*LE"C;T*4M&;8(.MH>#)*"L@L8\ABWP
M%:N+>@\44W3C"L:T/7/4B.G%^LXC#X$[FO+0,C%Z&PWX/DX70082#;:/[&,O
M6+!V>LL/%NH^>V/:3W!K+XU6N-N_C!]^Z75]LR=Y@KR]_:L @X!X4TG.X&U>
MF"LA<GBNYN-"ZHZU@/&-@$'#U[\/TAA,6_-G%G&: ]$] O,!:'$"1B[;QW$R
M=:/@WVZAS7@!W#_^:09R.2.G6/EK:>R$,8KFE(P68E^+0B4"3NL'J1<"[S1B
ME&4BCNK'9"B#Z0Y[1BP7S><$K!Q5"_O5>!8.D*AT@8Q\'(2\KK*D;M9%@$^-
MW90MWD$X<^?CQ.U9\?EOKM=OXZWO@EK_<H?4^M-XOE!1*FX2(+4;%9(Z>H'B
M..F(BG]GJ]JBB;/X*3,:<]F\ZK+'*E*3(+,#(T'$7KCV;\%6WJ*7[5\'" >_
M;*P=.(,<-%+@R4OB>>XGD Z\'JU9/9_0MSTAND,HD,3?VBB[5M\OT=Q]%:HI
M,1I;W\;Q@JSR.#K.4=E6'0DXOVZS!.N_HC1,=[\C @SGN]XV!Q7'N77![ERV
M?R6K9)5;C>VC;BMN*3(I$X5+AMOBDD[GI+1@5'@OX1W.>U@?_O5=, %&>3>+
M\Y2\='$8HE-][W^^/3GLP<KVT5CET$EWW#.[1@)%3B:<.YD:&.#P8&V^BYZ[
M6B*@X:KP_21FW<93("E5VK,C7]JQN*0A9G&(K$M<)S04A1(S][-VS5@;5]@,
MBM("D#.[491S7--FT4B;0815'"FFF(3+9[;\9&QYO+\C7'E I ,4$^4M-R$:
MV+*BQ">Z"T!. =Y0BG%[BI(^([D8CN>F,V>,2]PE;MJUHS,^;V1,E/,P"5)/
M9PA4[(FU26LZRLQ\3KNKQ3&,3!I54W3S)$H4T[IOG<>MA(H, Q]CT1MF6RQ"
M-VH!WUQ5 ]4YE\R>M]\%OKG1%#Q''R,1ZBC"<C]D.(,'(,>67\4&1XSEAK39
MJ.WGI;3$)3M6*2<D,(O&"\*>8AVDO'>#T)5!)-*$L2OQP8*Z4@2C1+NA:XR/
M%Y<8GITF+NP@OO-%Y9TN;32E7")G)SW'P4 .Z-3RMU1E6<@N55A=HE9?=5#%
MO$^8O^F%.24XC7-.EPIA[A(YHN\X\8*X3P^-ZBP)//PC_P79DT272#/D5QX
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MZ!Z8[P8F7!=A=@@\2*D<J]+%:W !O+[BU3YO\&2M6[ON]M:Y!:;C%37RT4V
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M_\V*HM:VGS5"[C#G'+K4K!Q6&/CHR=>U';"5M6C0+M7@_Y4N>/]DPYYT H\
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MSPY_9W1"_E0'!Z72G\'^HZ+P7P '$:L"_C*/$T6HDPFB#1 B3H_J&Y(X% P
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M1>U<&X.276L;MNU?%\+EH^!TF.EANJ].4'1LUK<CO,\^J?8OI?M=(SIV%[3
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M%^Y&YU);8J;,Q ;[<0NKOA[=/$I1?/U,>#;A'6O"*RB/Z6STVR6J\_:QH8$
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MR5\U6O/C./:7\)]9-@]_^7]02P,$%     @ W$0*4:<:_7&K60  P*D" !L
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MU&4P@C!06-L-7R2#MRBVIBDSFL^6\SYTKO5$JRM87Z-B(\$TK:A01Y 1+S"
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M8TKL3-;MZ\.N8$ENOEZYA_Z>..E,?FV#9,8L@(#;OE&'%F;5Z(+32>LJ4M.
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M!N+A*SA YTRMEQNVI.4IN#C_+4K!IGE"3A==$L90+G^H2MU71D7R6"#6;,?
M=,VE<"<Z7:?[]V(3$70D'WLM,6RG"1Q_>Y=+ARPS<<*<=$4YV)QN0RU5#5&T
M?SD-J<]4%1!D>::U %Z4:R4'%B:73G@FY5MRG;4'!\0\*N)H\V3"%TF5]A%-
M7"6IHJ9G-IHL;"HEM6AO;ME_W0/F. /6J7\SF+SZ SH*3*G!>R)=BPHT6&O:
M"_:AVWW$'\I]*8+^<00J3S!U4D7YFMF<W$=FOG[LY?QH*0.@T(:PMM?Q\] 2
M#[XXGZLJT'?W]5!OI XQ#W'KO#SL0H>5C4Z= ="-WWZ>L:9<0I*-75P$1W[X
M;E%?=Z!V2K;3MR2@JJ/Z/?E3A-MR,BVQ -J-*A>PN=E=%=A[6V;P=<W2UFH7
M+=_4_JO=N/N_895^A#ZJ<_>^_6LQ]Y_J6*U>89A)GQ"BIZF;*%49LIU"-T Y
M,UHTAY'9Z4?*0ZJ%9NC>&]2QAL9D17AGQNEU+*2+XH'"64<C+9,@\H)ER$Y!
M\BS2J/6+]>CK\Y7]GMHN7T4Y?[TKROE5&?J@*P6*#1'3PD]>@&>:XD)G3[=I
MXNY0=J>H'EZN99YX<Q<# %0=F/3HAL9AX)LHA2G]W:< 1$A*N86@AY(+/^3;
M:1 #J3LY5Q-6 9%C"\4+OI-+L);4<PJQ<+9KK5(^*B(;L(F1[H(1%Q]+SGD-
MI:W <[/[)NKW!%,3G)"=HVQ?UZ=&49&S#%WO@3Z'3Z&!U]E&US3P/F5K]M]T
M0@KW-_4X/#>]O#"(=JWKP( $3U5".&!# EE^\OKVI\/K[Q#MU#MUMYM\MD#P
M;R*?]B^*"R RU*:TZP0%"C#BHI21%3N*9G?]F+2;^47[U_'#+R3LVC_1K3;\
M9?O7T>37I[);3F$WG91,!T0"1*M%4%GQT$D,-8CZ0KLI=\L4./7V;]/#>8CN
MJBM>+ &JWY<#0UE4^+[!LI4#09@F;XX?"0EH@'MDF:*@8@<P0975]'[\YN@W
MK0>?QK[:Y^I+S/G!4G?.2L*Z3BQ^BC#Y>%*XS#/==-Q#TLC<+]A6,Q8\1_V&
MD[=OW]IOP(:KRMD-,AKRRL?NE_8OI* DJUZX"C+ (.6Q-#\EW /E]W025PEA
MED]4+A(#4KB!7TV5UU#)\O6B?S(!.$7L141;AT;4W(M)?>%^ 6WECS6IM)3#
M=8!$I]&1BS;&>AR@>T)4EK?K&!$MH;J"/7='B)(Z7720P?5,%V0CQ*;LEW<I
M@%<]L#1ND&HBSP1>, 1+ RN^]2/ G%)J9:B]<MPFJ,+/BEN].T1QH_S< \;<
M2;H@%J*D..ZY8OBY8KAA=OVCYY+A]I8,[[1[B!6;1,UB4FQ80>JABQ9_)^P[
M:>E@XZ^@&"HW6^/"(&JV%D1>O""56EFI[+9<(DBHQ3+/"NRK.4P*I1UO(+9L
M(T"F2!G121I5O@ I"=) ]]V3293?R5J;IYW3E1Z^H!SJ 728JKH"&F:_)WCM
MZ5KT3Q+82P2$P HG2ZN;N&F V3$\\QEU_DB:=;<>YBJ67$/<!D<B K@JC21C
M*Q"2#K!6^F^;+/<-/:@[<D/0G-3_,$)D PE;I;C23-KJ?X*-XZ7/>KVE !JG
M,Q41\;JYCVCP>8+V)_46$!+QW549VLRG=I=X98/$4@T#QF=C.XC*0O ';01)
M0,Z.T2!N):*J6 AN[=>JMO*!]=]THPW9B$_X<<24QFOIB=P<"3<)2O6#+GO
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M\:C!_8$GP):FAT>,!@TJ;)X@J*EYY^L3>X9@%I^[$Z"_6U3UW<1/BZ$952G
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M'.O6#->C&TS?'?P^&)W#3;SX=#L\?X?7ZO;#Z7N:QBG-  >B!.&Q'OYL.+R
M)RZ'I\/;V\$-C7TQ^$\8RU#1)WK!Z!+FB%\]?7\EH_%\AR4MZV&:^E/]9)^>
MEY^TJU_3.CJ[LUFY(0I@UKCC<+,_PGE^<JXNA\[><7_?.1M\NG4(+?CD)?\"
MMQV(Y5+J%IC\G-]NKH#!HPS0C/GJ!K._,?G[%$8<P7NNSP>7!";LO+LZ/[_Z
MJ+.]SP9CR@$O/?T.Z,[F[$+Q(Q8%VY+(=V0[ZRBDM?0@S/[.\/K3]X/+WX:W
M?+5M4^?C^^&8$NXES1[/=G2A?^LY9U<DNL$8@@O.>?TW'R[)9L)CA5^/^P=
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MLGYZ&':G-,C2E!N.9#2X*!N[^VM$+CA@E9<"THV*@OS+662I7I@-X>PTX ;
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MIF!)(U*NQ_B+A-29U5KTZF;2V*G'=)KV\MSS9QA][CT<T/#S+!R#63'H_CJ
M$LE2L8,B^[ODB;AF6NS^*EJLXWLXC.6S)%;.WO%1M9J8&KPOK!1KN$KRLZS8
MV:-B>NDMA96ANDWUBY<R5B53!9$:B.$LJN5+*=:)$K@K0O[>*6VA[M?A\.X2
MW9Y6S\!R#6;XDF?P5OJB5/*;K,YM>SQ^:7DF>]"KC1]?'KQMQF9VR=<>EJ;O
M"I]K%7Q7-_-UU.\%=ZX RGL&1!A-P'C<._KG/UZ\_O'H>']ECOT\R7(B3!BC
MTOF=UH6/Q,5\S#"9DP+FL%32J%P']0CS1>7H)A8M17WV*5L/9H&DBZ]O/+6'
M'E4+'6P!5)7JYFB>+T@B=TETA]18F1EF9['(M4 W+;5XIUAA/76J^\LI>>)!
M2;\PPSBYCU0PU:V,FKA!2$,,V&*00FP2:J>^O1+OI24,S=^95/5T"U/:8[P4
MX)'8E1 5GC (O121)<C[;V#T]UWFDB8UL'XN>#=U0T.S-%M1KWD16UIHRQ4F
MV)O/X;R8-U^"70E0LASQC7KHK3YP;IN0+;2NQIOX#C,'P.@\?,/$]*^ #9TA
MJ$ZEN0 CW<L^"5<R1;(4-,'6XPXV&XRL5$')3.3V-REN8YK ,RV%0>BUQ5[P
MDGU(*XD-Z$V&*\3Z2.THKC>.A,?W=H,GV'O4_:58.E(,JZK!3DW"-$/8H!A!
M[3/D[VM+PEHL(FYBNB'CU*FB-6L)M9:X&\1;-8CXNC*A9TC&A%!5I=\[9'UT
M9>FZVA4QP%^VTY^>/U)\H*5K]@.@XSNO.)6:T\,4)VS/XF6S4H%JEQ2IFH?
MK?1Q$TE,* 2%A#:U6PHH[?&1('$[)=?@!LPX9<RI,0E6].?<YM5U FYQAX)*
M:L9%R\\:,$*V')W#;LXRU\Z[#D*0%7F)Z%5?2.;-E6B$Q-TE>):5&*XT# 8Y
M%.SWA.T2 T>F1YOHZ@Z]6+X)W6=AZ[FQ>&"[OPQT679_EFLW6Q#JNK\*E'I;
MF\B/Q>*/GA^W\?AMK./77>;Q1Z^(QP\,B[](G)(),8M'+L11?&&AK&2CCN\!
M4US,V T*'Y)Y06P3?LG#R*GR/.1S*-XCA9UM3+/3.H=F1AAY\5ZVWU#T3\ P
M3:(PH.C;Y3P.QT7F_%R ]9.#D0IC^F17(,\><,_8H[=O7J(7%3@MN7_ZH:KB
MP:Q/T[S\^;KC'E4F+JVCDDCJPJT];DTX[NP5%37LYWW.+K[%NU>[>A48]U1Y
M :?P4 -3#B$@&BK#SZ/+$?X>2M<*[MUDZUX6&&OM-9[NXQ6F#K6\VOI 7W]]
M-MS9\SMZ0>=W(N=WI9GKZGWFX_3):>P98]O@B* K$G'\V@%%'C\5_^&)_L>'
M+]H'[^PAR24[DD.JB"U*V76B))[">2D0]-25CO-^ RW&Q'%"@8@[2MK=;JN.
M7KWIY5:1^"DE-\ETI6UYBYX'#^'[VR?L/55/?N'Y[D3UY(NGZLE^5D_V5C <
M6X*!4[39 Y0IRAW+9R:+@[RN6'U18F,W)+S;V.Q'$;$[A*G[O.)SK")65(0S
M[_<8C"1\OY'.&"N-R5U,H1'V[\V4%^5L6I8M5_D1!B^#@QI[&<.;U4N //TG
M#'=L[6+>&B=RB\/M9Y_PO1?F**N)4FD-P]U"N*>0PF*SHLQ.4FD]2 <=A%@X
M0>[?)%U63KSN2;@"O0%/]RI-<LF50WUN@+#A 04<3[ IL7@1C@^/#EW+C;!M
M"<*7G?^+9L5!+]@D8I$QHQQZU(@=5A@&Z/[752&PE8T(TBZ!D_R=+OC1RPU[
MT@N@%EP%(U4')M!H]:;M_N0?@)G3C[-H0^*N=S60GH<:$,$D)<GA:2B%"@H3
MGK!5:H<P"]+1Y!9SCPL0&->4+$$[9A*H#S"0_>P8-_!XGUC<7]NL\$',HD>J
MGL0>$+*0_Y',0#VA%!N.B4;@CW!2HA'"OU*,P+\>29*-GGU->/W N>)3=!V)
M^S +M4]MM\ZD+XS4G K=F3HW%<S(M-+T53AHG,3/,&.#>V8$:J+2M%9>;+K?
M[48H[>+_GIYT?PE6ME<3XJ>4CQ2HE=0_M)LIB*I+V;A;(=W4."%080DH6,B)
M2<J'3K$B.RFEM4V?W:W#4!*ZQA?XTB8^QCV8=EG"O? 4]VS!\!1:?GG>BE[$
M^:*UAF0>HR3#6K#"/4O 6B/33Y5Y:Q68R/8OMBY[3W<W'*ME$@=EOE'$N6O&
MX\-IF;Q-1A:5"3QTQ8*$AK+2J9'8<#I@9"I.R\:EF$Q:RT[*O<] /$&ARN:N
M*Z9D.MR8/" ]3#6UUI3FZ^2B'$XEYP@ASNO N2G&_Q98 <X=)=AI7A%R$OM@
M"&NR??FXFU74C]T2 R\[#PS/'*,E(SK,[.* J@NF7LT,5%"G7"L9VS3'*>E/
M6;EX*"!6P9+]*2NYGV![?&-R#>A:2Z.<>Y]4D^%20BV%?:4>LHP#8_17&DA\
MWK<\SY4L65--F(6?G;U7.D.QEBB\-<C<WEJ4N?TF5!+5\>XM]RTG[J3Y.FI&
M\=@FU7;^M!Y92^)ANQ/_6BN\L&%/NP+D:--7]Y=21W#\T\SNZ,W!\^[3)"EI
MDHLRPB!X#(;[-58X%IBO%RC)PGME^\_9WU;6IW V4FY:W?_%0(.[X9#5/,)D
M[/\]N,3*0I/NKZL!^GJ?6 6BF$_+!:)[W5@*O?B',(?[X&^SN,_=F/;Z2>ZW
M:T$>XR!6D-"L$F[?BX"1>:G4'V'BEVE_8%<0UJI1RK"RU6JX&[OTT,-==F/:
MVQRN%R#OKH/DL?7,FBS)J5+=.-KS]O>.7N^C@:0F$S2)M86^XG"_J@+;@D#7
M-_V5,9)?[0I&<CP)494(@4.,8L2;$ R9"ZY/\,-<_H 7_$3ZUG<>AYP/:4M2
M_C(0\)9BR7Z2,G"(G:#E4[3H*2NVXZ"I7X<XOZ"T=P= 473LM01%<0:90RC,
MC?;(/3$3-CIO!QISHOOKJ)D%KI3>H(/P2J74R0O/#G^7MN;T5QUTD*)C!A^/
MRQID 4##JGGX9)ZDBE#P4BQ\)FP.E\H9TB22<F09-B'0<]\NO2-?G_V=D#O"
MI@'% 1AA=3"X<J5TZ/%GRC/"R48,Q,FS9'4.6\?#6^0+C=FR8S)LG9EIJ5?9
M@7L\!3._RFQ=9Q).\B4&L0@69._EX7_LFVF+IB@3RO+$_T0H4K\7X1V:$ 0P
M1,FGN#Z5(7:^OHH<KG.-JJDOHBRK:CJ"D0]6?D9*QZJ)RF06R3U[]_D3JA9C
M-#WTT]+?+,0'(&9/@SV#I4/:#;L3/+.=]S,EJ'TEQA[L&7PZ"Q?XU;LD1^LH
M4SZ84#D]G_*^WX>96M.AY*G0XV]<Z/'RJ="C-X4>JQVECZZ M5?P]JIE4 FN
MPD9$W[6OC4Y:EA3=7T3=(TNU(CH?T47PE21=R KQUX67YB+G\%?R*<$Y@J(I
M127H<J*.G(B,DV6)'YIG\Q0NBB,),JR$,&(:"<=TZL7A'U_%N?0%79?ZGV^Z
M<ST0*EXHVPW5_74AV#ZJN0YS/<SYU6F*CLW[=H3YV2?5_:7TO^=$S^Z"EC@B
M<L)R]I1D&$]+6,8R<0A-NSQSC%<C*]-]T-[RHJ+>=B<UHF92?U1*(OP$\_48
M-2T."I]L-OSJN,BP,B]S]K2E-_,(/U9]#C-!J+WG7ZCK-R/.4KG&':Q@P4FA
MOJ0;2AAM79L-L.?UK/=-J@!F;D9)5J16XWN_40-(,1Z0HM+\C.4J/.H%=UZ<
M(UK!QJT\<%9Y^!U&144'A.[U02)?9#I9YAXF4!(@*4X<LTLS#O;%:@IFL)<S
M$DM@ODV6<8Y?G(;ZNY,P]F(?WQ[:\854(1ZCP,]CFW7?RW)Y)(P1NAH=N:X3
MSBG_EC,W\;N\#>ADB!"K@6KR4@Q+Y$M^&G[#$Z=BR4P:T&'B0%#]A+\,DPT0
MQAH3:>5/L"<(?$\]FWP,7-,@./4B\@20+DLF^;V7RF\Z6Q"V#;2)9,[=HZ@J
MT]4YRPRRD178&(KF;_9"K[D\&DI6DP$TF!\B<B1IT-C4P,L]/0(0%#FMJ@FK
M<Z#S)  6,"5W4WD^-*,%G9NO3TMO$4U6TN46:4B8.P\:2)-$QCZKQ6R9P2B>
M["OMB/4C4%1^GZ2?,FI>D-!'^@E:(I8S9Q5:DX%G2;; 4*^\5I)PL&:6O@Q,
MBG8/>%MAOH2?&$9 Q$ SH49D0F0+I,XB9@_/'@/6LFN*RK(]__<B9,\,40?<
M2NVI(:ZE1Q?:\1#,"X?:YQQF:EPV5BHF3E!DF3)(1Y)Y7L]@;=QLUS&PQNTW
MN.[QFOQY5E$ATI(AUKM2-7CPIE9$M<62E_@>KC>!!LEU+U\,3*^E?M[T@\-4
M^(P$ 6QG+![ >D9GVS36; !03E+N B_.^JH].\1?QBD+>39FVB;O$-_:*RF2
M/81 "V"*'3@728XC(:RLR<M ?CE-Z.A7SMD@V<J\*[.4(UH4XRCTX:MS+Z1N
MEP1\%[# 15\-S'W5^04%W8T^I,-OG9[YJO/I\!JD4X[*.)[UH36.J7J*"9SW
M5'(46SPT0)I5&K@+D\C0M1?;\07S!GO,S;I=%=D]FY'60Q<W]SX!0^3R&DK-
MGU,MJZ)1%RFWL\ "DNH00<B0\/AXT[WP8"?"FX-&3XD6-\*+@S?]S-[?\WL1
M['^0(1KFO<C@JE1S"48H<77I)(#7,"MKG-8)3+8_4&C8LD+,'=H77[&Q08ZY
M,2A7JEZOH6V1:C-)JQTKEG.LDBX'SB"G+U".I^N,$P0^*9,*']:(FALIU'J=
MM>-@DVI<ZW=75N6YU15Q2<HGI1:B#C2W!K] VMWJ3"A2A0TP99$I5]MOBNU#
M4+JS2IWA2IFL]32<Y7V*A8(TK:RU_VQ958BZ#9B@H,P :T8 ?*OX/_-!!VLO
M1V$!3=M=V6IY$JP)V-5T:2EJ8$7A9%>>H@S99HW;LF@'.PZ^ZDFOR(.-#$8Z
M\&0*6\F!]D>-S>T8-G8[CY(P)WH6>Y#,&-,_70"GYN,D6+8_2JA46*-*<7N*
M+=!P*V\&9AD 2TOA[YFUADI3F#8NF7D1W,)YF%&=+EBJ<FE)D[%ZR4L#7<OQ
M@E/$"#Y[>:A? W?8)0C(- &[T22M\.0U6/_J18RQ]0A;1*5^PER1-Z+-)"FO
MWUJ6;^H74>>>>&%:^H>0'Y=;QCO$)GD".U.>N8JGZ#6">31'J/&)%GM3A>R
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MCUF+U=X!5ERM04IWG\D =34P""BI)5B$6[<H*BYV*VP(+Z)8A)&)-&^V&1Y
MV:\>A["/GA\_@,=VEK EV'=D"/N:K2BA"%T,1D;00J?5DV&G*4Z;=EH+K9!C
M*T&4P2%*TB MA/HYSK'Z*P63$Q4=G=M/:$%@,?HS_I*QK_4+R_$Y??^Q&5SU
MV%^]:5=<.GO"PKJ.I2+^FJ&7*)1/A2*M6K_A!-I*U9N\I6+X^JN*C]Y%U%_4
MH0QOY6I\IJ"HMYTDH=90:9ZQ<YA:?58DB:VR6-?0KELEC)2 3W^LD&7+0*9%
MNW80L/Z1%6,$TZ29@?1SI9VW-=W,@1FB\SJ7CQALA6(\2^YG3'^_H5HA^MU2
M8:@)-<& BX&$_J8G>.FG#..VV;U^RC#N38;Q7Q>5[:DI$>U06+;61:G[JZD@
M2%A0 AC0B3W$8$3;H@J)L 4*9COF"WG@4,4*DX!TUGL5W2EG[^C8=/BUBZ6J
MW7YK55.-MU>0<9KOKP/'Z)!//;A+_23<E@(K$Y2!]S=>CE;@6,%7*>R1E+],
M&GTZI/EQN.\(I; ;6V-MU#S8M<U5' 5!?09A;8#CK>Z9439=T0\'_"R"0NC&
M(W40%^YU(7/9B.Y5;F-#6?.]!1BV>>TE>U3&72I-QB&D*[17E%\G6?ZL0@&(
M^K?(=8I>H6\=MH1'PUKG >"IEY/:M^N:]R6G'OU64:2F'N8$:+NN1,[ SP4]
MHX20-#&\#9B,E'18PRJII]91T-,XNM=Y +:(>'F,$46&C4&:-3>C'1BJ;1AT
MKL<ZG(+ (5*>AV5^4<@A78UMRA'@/ W'19ZD97\4#/8RD%$X7WBD6>,]HRG-
M.8!JZ(( =V&(.1<I".&9#3<M9MCF7A3YECOR[?,R>N]I%BD]W]\1$7T["]/@
MV96'@1Z#)\%"KT]P);<M845B*PC?W "5TW@98UR"=FTPU+.(*,M-2Y@3Y-15
M=V%29*7_U*!2+VC[-'OA_%X3!D#$C58VW@1E0D#O*BK4BG#G5./:RCL,:RA1
MT\K=\#(S]VA9)GYI!+82C:.BG1 J:YY[OJF=MQ%':CL.3 B=<7'>E))K$/T^
M*[\H&5<5BW-S(7V;2D5A$?99:6&X"L"$,;$EN;R><U&6OS $* O&"M1G*_JN
M!)@WD0I5TZ]. VEF@%3>9N:F<?@<2<?GH%,%YK:&8&H1=F9T/0D:R!<H$+QI
M 67;]^:LQJF@,]3J##AD)54_S7IU4X9OW@3ZS)3@I@EJ+>1)PX-Q$C_3[J25
M&/LXBL8C,S[-MK7IAFCV\3SE%'^A6(QW)EGQ+#1X0>R,O"ZAU?O3"-CT:#EE
M(Y67P@D@['YM<* *M%T;SH<OBU<2D&YR8DFL"]1$HRLBO+S%[.FV1UXXSR32
M0RP56T]@GVYJ14'<6Z2'Z,UCZDF8Z^$G18XR4SN9ZX9F4PB5>8!4&<R<QO>+
M-,6W:34!2Z@6I)Z#/(]4C<EY66D]-B!2;MLX.FZ2V3/ARG74&.)+S0WA_18
M<Y? GXG!*M.>"E&UV%WOW7EA1$F9L+ZY4B(A,1\H4Y$41"\($4=T#LQ1%0L+
MBZ)T?I2?L]D$CW-6Y,I-Q9,I,$C'M9BPIX130IBX!YKB-H#;VL16V6G"G'\
MP=6W5"=@5&"_)'->*+ *5^:6>&5V%P7&T-0P.4N=)]4^,%-8]M>06&IP=Z3=
M176<JH>'LW<YXW.1^)^ /B0W%?54FF"P-9Y13<.RU:*%E8*S0[" W5\%<GG)
MP'Q7XS@Z";-,]Q@K!E1-"];M+4NEC!\NJ\HC@O@)2>5(_/,$?T)ZAE.>P'7E
M%K]A%BD/59DME:C'RB?:WMG0=1TJV1D=:LBA6^3N[&H<Q?\NXAY=J-7)T6U@
MS)7*7@'S:FL%2M4#%EO&L4IP<Y+45&)1=?K9^<QM]E,=[\MU@H0N.Z/EB^<6
M&UM@A1>%!6IVIM)6G40W*M>_L<#FLNZIF479@7H=&%E6C!%:EOO'I*29T%Z$
M0"$IV,<#ZD$.=QE=]U7%P-IU=.[.5;!$503YDY9YNNL'-;+&U5-52:452!G1
M,;9?K3M(]TET=P!MFQX@H:8Q@_> 4&(:#II%D@QM"XQ?YY:5(2:B#BHHUMJQ
M6];E4XO6B 4@NPI014;-FMH"4 VR0BV'_6S,N>[P%D2AFC"(O(\6B$8$K.M%
MK-4;.A,%6^,2>1:5(K- G8^RVE93;75_K&8*S#U"KO@@!Q]JWIQ %WASC-U0
MK=?*1Q+J]^>,DSA@J'LNKG;;6DV!W@B, %V)]Q[L!ZCZYTFJT)IH\U.)N['&
M$-@JDJ)3 J^84/F"X/*:"O )L@W!VVU6GM3".^T8\YZUA=V_"KM\I0^<#]Q=
M24<W^4B!<;M5\N KR@[5:N&SP?3TYE2N; =LO:6N2:P7WE2(!N\M[&TV65HQ
MO980MB4,:G1F2Y@GFOK6--46^2E+L=!>F,?AA/GY+*%N6^F<R'"3CB)NX\"X
MF CAE=BI931OAA'VJ+Q249M#0@G'EA<Y![ZQ 05R<]!ZPBQ@W>J)WKJQCE:U
MI":#F/Y0IH."@8*,0X&M2@9B8=\I)@];_<_S)(W5,A/>XTS*K"-4]4/L\JM?
M41;\F3Q[74'8_0W=9<+0\-!2]9WJ/(W8-J"H,X%M,MI2YNEN?^N[S;<V*]*[
M4%2/AV&3KP%I8^YM3EO;#+O5)*S[ZV@]=JQ,!Y.'.A/HNO% +12Y&HT!Q^=8
M)1%VAM9(I.KJL2U6JY@AC,3T*G70N>6@12Q;ZEI+[*1TH^DGG@HAG@HA6F;W
MYJD0HC>%$+L9O6"_6^GT>I)NWUPOO4BP?58\K<.U-A!6$^F(&&<U:-1*K-";
M3&!'$%,JM]+"R 4#,@?,FGH<6F-#ET3Q(-33+ZS'W8$;Q278KP_Z4@ZT$6_Y
MIO#1Z9RD'4\J+B&76\P#3$0*N2<BM2]B?1'C #I-7\5J$I*J1GVAM=$G&9-A
MJKM,HP:9F2TQ 0?,R@TT)I)54R$YDECJ:_).R+T@&3'LJB<G.,RDX;A/=1K5
M7*732O&!M^1I2"Y SNXJCHR5)?G=/[*UM*?3GKN_#&SOV/U9KMWL67*O[E3:
M_55P*TTPS];[_U/**D>'761A>TLFC:F,M]H>USP!TN0\DUKZ2ME!%<6G9C[J
M"+W%4S8XF^GJ8TXXNR6:>>H$=2XP\6I53%!,UJKGDQ( >*DU%!#NE2:CFN1V
MCG.N<IL$RL/HG$D-/*6.GQ,"*]/V-&8\+M(P,5$<@I!6_%G=[RX11&_)B>*8
MZ5"/_6CLI)6E!JE).<2P9*$D8UR/61NO!"ZAX_%#C!LSXJ> Q^D>VXVJB,JJ
M5NS-WIIO*,E9#"<U;8M\Q)@"BM5\-'L](=BT_:\+W[:C0+S,*-X<[(H:-JPX
MH;J_&%3%1NSW0IB3T+3PE:K958Y<2041+!6JJ?0CCQ)=I<(5ZV9L@)&MPG/$
M,&))B$(LQX"Y3YVM".NV"G -JVQ=!N8NA*E?S#,JY,UT%0S8;@Y#7'G"WE%K
M"[D99;)Y46Y-7)']I@0+<BRE/.2?UM.2Y(L-VPMCW<&=#FP82YV SOGY,*$L
MU_M?JK8<\__KS;_>%=4P\;_='0/P(R8,]4(M)+<)Y3>EVN=>W@CI$UL&>>E*
MH3E7<((+X4%;TI]T1J,DXN7 H4VXF+5%%-U2!$JOHT"RA>C44MNHXP]<[6:"
M2ZN9D:Q("O/X%8T,@_JSE; $YZY1(<0XPV[!\&LM0&$ZY]:GE3(3QJ0\+#"I
M[*XU',_D257Y8B_@T>%!/QC&%@ R6)O<<7>1:7T.9,S%U-3XG#II$_(_#"XI
MC=H]7NG.82JRT=HC_M N;;-B@D8&A2PG=?82J BO$UL=;*QR)B?GK*1JBE5U
M@CKA*Q#T%'W&YA\NY7]BDBB5B(6!VS"<Q-Z+/,R""@+*;I@8#U+EJUQNOK+&
MO)JYV[!PJ*H,35IJC9[@@I69CI=;^13O"]A6YUJCX7>*1!J0T$(BCUQ7O'L:
MC_"OHUWA7U=4I=YY*VL=BL8T]=IA':S$W%K%1^FFB+&''K*G*/RDV(^L'4XZ
M8]^+N U@(-5JP!1B5P/VMU4D4O\2'^LVX=9\4IH#_O,?+U[_6(73*+MC$%I
M-C,X3PV\!_V'H$B-#K41?L*49?[UJLI67;>[K:NPHGUTW).[OD4WT7@2H8L
MZ/'2]A[W!$IG;:/11) VFCY7S$5=8&$YY4KQ%K1":VT .:%]0B#UK9%6"'(F
ME4R]>GM.FAJI6Q70%PTL5H/9L?KHI [B\5+E-..B5-XO1?KB6K(PQ]$3'R@/
M5PXC*POWG/J()JO:&E-I_8%SJ8/H-7<TKA<QMB49S$,$ %U8Q'O-> DMS55,
M^J%I^:'=PF8(7$P%I7=#H3G5X8A7V;#93+@T;;^OG%6-71-J@XH50W0X=TEH
M135E+;5J<NK$(N@TQINFO-2V?^UG=7WDMKZEQ^/'?4.>%D7K>4^8[U:&XL1R
ML^(K-?EV?VGDX;:#9DW$LDAY=TK2RSFR5XL%NLY=$A4Q<+=0@U]:?UA11&O8
M>MVC8W'XC>51'%7K_BX_!.CA;\("UFY);S/>*AJ,[@NN2\,8T.4/5:O_RJE8
M'@O%V@T9F*ZY%-Y81\S_-O>BM^F/CXQX^DB-U+MMF8ER\&)7E(,AMP<T1-']
MY;1D'U(2;I@7N=8">%&>E9]3FEPZYY"4;TDWU"X<$/.HB*/-DPM?)%4Z0 AC
ME6:*>H/9*):PJ116UM[<JO_:!>8X!=:I?S-8H/H/=!08U,9[(LU]2A1*:]KS
MC0C2)<^E)9>[$U#"S2E8*/,Q+.KXT(7_';URS? -R\O3.5.N,U@@M+ISK@+T
M*SGG7BSPJBYH9?Z!ZWAV:Q(K!9-CYR5\"KO#R[QIM%.BB'WRZ-3F,\NY&)F0
M+(UXXAI.3.FD8")'$^SNP.OB\&4 ,HE!^0LG3J8H>2R?D2?-G%R0^ 4_6HE&
MEGHA5CL[01%9@C(0-WQ=&5SC]EJM!OTY[MKQ3I"K&.G+ VZQU'V^L[Y_-U!.
MT%O^*;F/'BZ"HV!\NZA?,] [I?[H>Q)2P4/SIOPYRNTLG1X=XY95N !M1YT1
MV*S]KHZNO(8?/%4E?N'1[415XMNGJL3>5"4^0H_A';>*7NV*5?0+@I'$Z((_
M\^Z[OQ8CTJE<OZ*/Q\2KK<J,2LTBNV%(IBEG2HMFC9QC&F0;95H3CKQ[ Z[(
MG0DKK95+JV3*^7NL>9?E"64L@D9:I&#0A(N(8QX4.*%1OT7R:]_ZH4E\^'5/
M[MO&^/!E%>NE?\60+0'!$BO8%#(Z>[H)%O?>LOMPN7C-%D7JSSR,=%(E8NK2
M74VB,##A6%-2O$^1UHB\#Q9D*&JE^$>^IP8B%1T+4KE8QW]/+-A"^$XA:2GD
MAZ!8,B?6-J!!XC*$"YL8ZS8C2?EG26]OP%*6 )9V)U7]GG!BHK"R<Y18[ 74
MABMV%I'G;\LE'B^OI&_V]1'I;D=O>F%?XV0WM)S0CBY,%[C216= @R<J)>3#
M(8'*;YM&^!61M7<F51H33OHA7[;H6-)&/MU?%!=;Y*A8:2<Q2A3@Q&7=).MX
ME+?3]V/2 ;7GW5\'F,4H[;H_T:TV_&7WU]$6P:0:7Z[6,;VJ3(-)@H!LY(JP
MYJ'3M1HM.4KUIMJ,5-I'='^;UJ=<\S9U?Q7?_22-.?;EP% 6E5$^,'+E0!"8
MSI_AGX0$=$,/9)FBH6*/-<'1UO1^_.;P%ZT(GR2!VN=H%68W8ET]YU]B#2FZ
M0F,LLQB7P4'AN^JSCZ21>Y^Q:VDB"+;Z#2_>OGUKOP'[V2IG-\AHR"N_]3YW
M?R$E)5FUR75$ V[+D$AO60)94(&KTU4KF-I\HG*1&/W""X-Z49 .=\K7R_;4
MA P5<X@ C1T:47,O)O6Y]QFTE3]65 V0B_09$IW&@R^[1.MQ@.X)0U[>KJ/A
MM(3Z"O:\'2%*ZNS30P;GFB;31HA-..KF4:I"_<"RI$6JB3P30-4(+ VL+M>/
M '/*J%FD=M!Q6[0:/RMO]>X0Q;4*"A\8<R_I@EB(NBN3"Y ;31-B(\R.7/2(
MX.\$:R4M(VQD!3ST:BLWKCBB5FYA["=S$F#*2I&WJ8#07N:+(B]A;68P5Z0M
MMF:Q(1REB<3*$"KQKV(.- E[K[OZR22J[V0>Z6M?4*TG*;!B/8#V#]=70,/L
MNX('GZT$\:/KL<!2;^H]7_+0L9>%F'7#,Y]29Y&TG5.ZF -9,<2XS8XXX'!5
M&B/"OJX26E]YUQ[=C_5W=EB,2X<%NF1MJ&*KR%?:XUH=5K 5MG2.;C8M0&5P
MJF(B7Z\($&^^2%'?H^X%0B2!MZSB%@743A,O;9A:K#AD\"76.ZC@!'_02H=X
MP&VG*(+2(6*"!<_4?2ZVE<UY]$T1>1]0?, G_#!BRI*5]$1F1<IMB#+]H,<6
M)]&758.)P8&[,"B0?>.N+"Q@0TELDTHJ0ACS_'HJH-%Q02" Y,#62DQE%"C
MK@O3F-)7'K8\72U%E+Z">#%YDLZ]-3XR5EY*M&]:;;;E8];&'IL>HP^9;-MU
M*B?W[5LQ,F_M4_A1V*V_S[&%+^>U:^C(G) 0C&Z6A;FB(/O](M(YM'DRY: :
M45" C9 PKS0K%B20X9TZM5-GRM9A%1KE@;D M2"&GY=IP(KVCC;VDU_(+8S1
MF9DZ1DL/ X:A&SC5[XA7:B<JI#T0FQ5YB8$/K,%LX9]JBK&+F%F\SY,BC<-L
MMF&'I(^PDRS"&(<U/5NP^XJO%KF-=E7VEVHNCAJA82<[<:'45TCG(+/DQ-]I
MD@0(",1G;9.,K*V^N]4+7Z9!3%!_=0UBK=1F^E&1$5S1PFARE"_^!%"Q91+0
MVYXD)6Q45$X8F12I\/]8&'?<KO5=DH*-<Z.B/C5!'K"]0EW(F\GM91D .92\
M?>H^>I?X=*W!@IF'MO-3[DFE.Y?<P+,D@ZLZ59C;<X.%$Z@8GQ!T(+[H0TS]
M[2C;)W-.0^Z<*E_0JL^)PK!65'Y<3S8RUK&I>R\Q"6MU'%6(PFJ7*,891$\:
M,0'X(OF*"]TVD=-R=;BM&GT@& YKCR1E0MN%4A ?QH:A&4 O8&JM[Q=S<0;:
M42#81=H?B>-(=3OL$U,A6CSF1%JA!-W*!/V2I"E) _70LER<LCYTI\G,M--:
M/5N1AG/I[T6PD(O02NC2(VE&SJAJXDK08$F5>HQ:%&:O$H8A08/-;YM][O=E
M0_P';P@KM-3 IMP./7&A@W+?,W,,DO-BQ(F MY%Y)P.1#+$6KFG;&)!ZZ+;=
ME04%#UL0]QTE=S"#1?Q;S*W*=8<756 4-&P$I_DMY3#O%,+\;J19(9/J-I5N
M30(B(#2%IM^R?1ZZR?+J5\X(3$+%SACX*P+MT!S(NX2P$Z'@0Q=SWD2*[:B'
M;62UES+I"J"ZQ 2R0.UR@:L$4^UO7S]=._-2\TV<D]QVP0BD&\XH:#;#$K,'
M$:[Y%,U[OXE&TCNO$+>^+1L?R[TU.&P"N8IY%C,AYUURLW1_&=_]I'T4DC!L
MX+,J<)^HP>,%3AQ&MF%$WYJLTH>[-:#N4_G-%Y[M3I3?'!T^U=_TL_[F,5$)
M=B3\<;PST+8GZ+]1*?+]GB1IMA?4JL_*+Z3;!4JGN* *?+*3RA6ZCD:7YH#H
M/::I8 !!/UW%L#7*)&?#LU,;77% SZBELLJ+:4Q:'3=O,N#_XC"U,JJ26!DO
M'^7N:Y]I4W0^X*KS77W[17?U^/F;@^.7C?MZ].9-];Z*O.SXY?SG/]X>=22;
M@E[\0YC#]OG;3/V&6J0@:.@5 B&_HV2F7MQ+V/3G/VZC<ST(B6&UK-A2LCV-
M]336TUA/8SV-]336TUA/8SV-]336TU@[.=:3>_EO[5X^>G(O]\:]_.@LY"%)
MH,=O5@17UTRAJUZ7T87S<71[,;RY<3Z^'UX/+]^Y];0.$[\O?9R(7)0ICQ%!
M#<)@/=\2?@^I@7$K"J>KX?FJM7AVFGZN,_*]<7*G-*CA7YW<URG(PQ4=N8;G
M5V>7OPVO*1ULXTJ;("E?("PW7I*7G(A=.93#+H5FZGMY_)SV\F)X^_'R^C^=
M\^'IZ&1PYIP/+@:_#,^'%[>N,[HX.?B68F+CM98U<%K@=H=7X7GMA]</CB8B
M4O_[><F[L/6_3A\LK6YM((X:AV7T_[<S>%7FG'GS[5?_Z/^V8]-O'I5-]R@.
MS)A/5RGV^@F<"V^NB%QW @&JI#_7.3\X/7"JJUI/$8=_<QBP49[M#B6<),].
M9J&:.$-2'C&9\E)0V%?0Q(,CUMOC@_6<7M;K?L/UNM]7PN/LE'*\XD+=$/*Y
M=:?L_^^^X-]XQRS!/PC2T(N=7[T_?B_4'Z4L+M?:!9G_=^?PNRGTJ[3W503_
M+GS6GC]U*,#&_2#OE5E)*T04)525J4GH9L1<N+8...UI0']VL[_8S?'TX-.#
M3P]VY\&G&-W?.D9W_!2CZTV,[J]C#@]1M\3!?714+R7I6&IZ0Y-BXAK^U_O1
MSZ-;9_ U@V#'+U^P5Z66S?_V+0W8HTW;:+1<JTAY&7='(02 [?;UR\)D;YN1
MEJYJ^!M<E"[;=83/@(4I(2(&:E0);L%9P="3=A'4[WZ\A'GD]TGZJ:U3Y9^H
M#7N^N3?3(5>I='9[)2B_MEGG+J$3GR3SA1<ON[\*"^0:*!S3&IH=LE<U=76E
MJRNG-ORW\]]_ALC[!C3$;7>.#YT]S!J1II4$&DJ 7<@?X+\,@]<+FM[8'ZDG
M[9GY8$H$VR#1K>53D8G(QQ&@[(YZ(&7^#*&*ZPDZ\/-\*:E!=G=?/<@>_;8;
M)RO*0O=787$KQK0G+NL2WS+]HKE6E>QH^)F *D.5R9>XNC1,-1H2-6!(%>P,
M]_IRRT99_&TOPP:SZQY7&DAFK&(U06C6"%;(5!8&A1]Z:06."#]U39VK7Z0I
MH;@S4<ZI-)<"B? E[LK%TP(J5;,D"N@#_4X<"*R)-%9+_-'@>,K<ITKPXG5Q
M;Q7!F:&*0WECB-BR\!3V&$=L3L?W%IY/F^?LP0%'O-YHN4M,34@_T A[W5^.
M?0>J4$(&3$9%R1JTD4? ='[6S"=]^XK'VCU@ ^ES*#W,1DP^!,!=HD0M=#.P
M)-5L(..F# C<G'H4%D.@40VBW'TZVZYGS]YXO_M+T6U[E)7]:UIEDZV'R 1N
MS>)#H#3D_8QN#,+^VM(?L.E&G,!ZO<A+@2/> Z^MGCZ<-D,IC.!#X,=1JKQ@
MR?(H4L$!-IB<E83#_4_E60(DQ>&E42I.2@6,+1AGY?1L##<DPU91Y")G !J<
MPP])%/I+ F9-@2BG&B@BC 7U'CY!98EA6U6&"*IA-BLQ9T7B4L](6^9NBTSZ
MQ0D:;<REVSD:@H<B;$-HY^LBN+;X87K85[;9^&_D?(JI=4W$^)!W281J3@JO
M=?;@*HS5S(LFK+)G*IJXJ+IGBZ2@)J:(VA62TD3*/&E37C /8P3U].3WJ;F$
M1N%;>!FK9<(H]JFAS;)B/M@F16E*V#=%ZWF,^U97-Z3-A(5[R7B=+H'M92XW
MUL.>R!GIL(SLAW_'=D%\[P51U$^3+#./"^**_C50<"(!_3#&8:-0Q7IT&(!^
MO%.Q1_T\Y-5$0(BA6#H$7(.4[AH$0'I6^%*2+L%ZFB,OQ'?\7H  -+\OBC@D
MA1GAXS\CJ_+LK_,&F5\%MQ2YG)]D^FRTKBM=-9P)J<!)BA*9>W*$WAA84BX:
M]ST(:#JH3Z"YX!\X4D\\/_+N&3PU=A"</5]JKQ]WJT9W""+;H& 8P^0:]( F
M("$_VKT60$S\(GT:M+@8*VPWDFFL?(%=%+Q%!''<IS_HKKQ(ZH3=6,3TH^O<
M,>PW[01!2I/4R@JR0+!'%'Z"VX4_>U,/2U?JW%K ,1EVNT:#(J8JMZ9\9(O[
M(XU]^=IH"$W=?@K1;%4=RY8<)',ML+CQ5)C/Z+TX"X4]U32(I86O3??%K2RN
M6%3:7:RRV_5I[(6(?HD<TB5\(I2R$7;F) 7-Y;L8(:Z?7"M"#44@TC!AM'>#
MSTL*$>?BWZ),=WX=C4R[M? N!!*@*^0,F)R.WKYZ085 XBYBD*35WWY[5'YC
M &SE%!A,&IJMP'ZSEE?.O..U_0YKO33.)1J0SL<D_80WYF=1$Z[2)!>-#L;9
ME^8-OQ<>=;.RQG[>/O\!F*VACU8O8>+"1,M;6"[GL'S@'<D,HGOM*S]3B+M:
M?OMY^6V>KC,(4';1:J\5D%X8:\CTBP1$FD:7AR'*1PW**SP!QC0]/.+^/Z##
M%BDVL3#O?/W"GB'8Q6?>&.CO!G5]+PVR<FC&T TQ>$E$ETHS(!OHRGQ3-[C7
MX)^U9DCEPT0%J((5P*V%_S(H;,LH_(P90C<WHJ^#@2^M":B%9 K'CR&*EAE)
M,P!6#-T*]V/69[X->S9/B&N:82H7@8?#<4A2+7"8T&>EF  R V"\QL<FM[<<
MR@#T(L>_3Y-X"M*VE*EP65/;B6&WWXPG40G]K>8)MQ;A)IS2=CQ0H*5X)7)Z
MXXTD8UPC3V2/2VE7WJ)6&82?HR,G$)]*I@3V.]OOK>]D<Y"C$ECL[B)*C\F6
MVO?1EUDI#U*_>^0 :3:VZI;[HC4Y<[W[8GAR.[J\<(Y>OCAV/@Y&OPZO.[6B
ME1"/9:\$&QD<S 81%@2$+Q#FS)5-IRM<JF:^9?R5-0]J#HLN#8F4$( [NBCL
MA\6_F'W]>HRCY\=M8?!NV['-'(W267OXX\#Y97@QO!Z<.=?#L^'@9NB<7@YO
MG(O+6V?X7[?#BU/G]M(Y.1N,SK%@?73RWKE]/W1.KH>GH]O+Z_++_WEQ^=&!
M/]Q\N+D"(L:GAO\UNKEU1A?.^]$-?O1^>.V\&_P*/PUN:93;T?G0N7P'7QR>
M?+@=7?Q"?Y5YN/*ZT3L:^\+Y^3<8Z%P/=/X!QGX_^'7HG ]NA]>CP=G9;\[@
MW3MX]_#4?N/-\/;VC*J)L?">IW\Z_!DF?R#<]]%)YBEE\N^<,OG\*66R-RF3
M6ZA)W6;N*P3R1:,;JV(QF>E>8+8$=;7KT.Z_0GXFD.IDS)!]P7VSN1,8?I K
M[69TV^5_#=<D1&LD9^L_3\1R417G8DCA I<?-V,:S:'%AZ0#ULW7P:'!M L,
M$^!\<$G\FJY$((^[KUL_-\%%$Y;BO1[Q@5#WN#@1)YMNT$WM-B>,Y8W6+"U8
M/%;:Y2N>8MM1;*Q;:4R%GM^40SS=5X*WBDI^TVSZK?N-$/C/EI?D[=>^)(>[
M8J:^T%<I;@W>NG"E8,9Q<A^I8*HD (#<DB^<:4&)R/FEPQZ!H<8>-58F+Q1Y
M\.':+ FS7LRJ6K"%67@M3D,6%B+Q$_(3\?Q$ J\H!4*TND;H=T+/E=TLS7!>
M[<@VTYS"#&,6&A12X,EQ&QO,"$H#Z1QG9D[]PCG;4]Y$/O9,HAM:?ME>+V;L
M=A\Z"4_0,T5LHA$Z</,PMWPIDF"K[Q7*OZSEG:7W4]["NUG;S(.6,[:ZXM%[
MR<*E/LA>[, &X+.2_S3'_NOX"^Y)(WY@Q" *_D0W.)#A[+C$/;64Q_""R%28
M0*#WA+>[[LO$B4^*E!9H35@ZR@.]H?,:#IZ;U:>L+; /,U/J$W69Y?A9NPAO
MH1]N8T3T;;2-0$W0ZVD:YLE>>YD$;<37P%$LRF:@.."*V<-9S&D;O'OT,.AV
M2HHU)HF8D@<6(X)AV?,^7RYP+ACS&+-CM?ML?=?$T[99L4)475+Y-@FSUUV6
M9>P[>FG40NL^Q=)DN<H^8[$JI'.R-$\DJ=1(:JH^6>\=F4A+EK0@=BX);CJI
MG=N\8/@WRR2\9+%:&R[1,AR6U9CSDJ.\F*FAV0'(OC19<"_K(HZ\>PS^P#0"
MF,17[8Z^/5'US$!E"GI5HR 2A99H--TP;:F/^QY*O@<^$*MI M+1ZF]MR\-4
M<0/3P!*A_#)D^D R&,.+$A*=2PS68;U4SOVZIUYJ[&82B?;+-[Y;J%Y;0130
M2Q;+QA1%<>"\9LH^0:FUU"DGL <Q<K5P#N0?$CAG&9TFVO<^N]+IS]A.&.@%
M B;Z#V#GX+\CW0 8E*$(KTYU?7/ED3:*[V?E#)47SHF0]NZAF&'2*QW[>U(X
M%R<RXJ3 4&[FBHSN^I:;3DJ\!Z ==>0V]34M[;5<J+KG!S;7ZMRI;-H3)@QT
MBHFB<:W#9T.=%S:,!T9DXB)S],(4H_HPH=_1TX*5 92 PQDSTMGKWEOJ]I7&
M'9"9Y"#3GM)J;*\[]$J&4?F$A+\M[4XK<Z63Z$&:@55*9D+_%#Y?79CZ9]++
M.TM%1R_)2#T\VONT3]FYTF%9-RGFC?_+SF-ETK!D;7#:,!".3F7&S);0#Q>>
M=)2#=TB9R)*LB+@<KBW3 ]8)"RUMB)(J+* <2=#8"^_:O_HP9?-+\9+[FG'\
M9F6APDCR!PNMR8UQUBAPM&7RJFF2/O(F/[)[JN-G\5;.XN,,KA8Z"!8)J,T@
MUZ7=HM&Z&M?3B(.0\LE2)?>-^WOK%L-LDE==59@?#9L4Z!M>TR4PYS$4&[P2
MJ6AH=3,5!3)\&-.0P DBHP<5L97"6I<M)7>IOI\20(OR^W:/<9<7)^_B?%Q^
M7<@F@_7&D/[&FT2^A5+L,:NT=M9.FJN^#_>B?==31;5X@:MM(:DJM+NDTVSM
M ?$XPDEE%6MVS-K]F8>*+M('X='C+>5R#'9O=>0.'O?S#AX=RB6\;?>>8O0C
M%KV;8F[ZO)%$R7U*Z Z4V(JL$:C82-J;7$1MF5'C&L?@-+Q#14^4_5(1I&Q%
M?(A&6J1A#/(T4NL&W59I?ZRTM:,7KP]>=]G9?_S\",_VY]^<F]$O%YS2,KHI
M<UI&\./5]? &TU$&%Z?.X)?KX1"^,[CE?&U0?+64I.26Z^'@U!G=.B>#Z^&[
M#V=GOY$6\J4WZ$'Y2RO-KLYMNDX$1!6N+,WY<'$ZO+ZYI5T^.\,\H]'MC7,[
MO#Z_H:VGC"7<>?CNX-SY9?0K'M>'*V=T?G5Y#<_=.M>C7][?WE 7@K,/I_CQ
MSQ]N*=WI;'0^PD2CVTM7OL7OH_2BP2]#YW1T<W(-7[H84$+?Z,)AV&!*1!J<
MW.)\."=^ -.!OYX.3]>?[=>IPSIZ=7SPII\,E'5V<]Z_7IY]N+@=7(_.?G-.
M+B_HBF$6VJ_#Z]_@$L+AP2&,;M=O\E/NUM\Z=^O%4^Y6;W*WOHY;L)<IOBN<
M[.2HD'^4M7MY?C6X^,T!A01;3X&2,CC]=72#K/%\2'F^P#8_G$FB[.#"&=S>
M7EY?#']S?AZ^N[P>6HFZ(^S-PRK*>]!0</3+*Q2;'RY&M[_A6#=F.)?$+7UW
M\.M@= 9B\_RWF^'9.Y2!-Q].WM,T3F@&.!#E'=_JX4^'PW-XXF)X,KRY&5S3
MV.>#_X2Q#,?_C5XPNH YXE=/WE_*:#S?844'^R8*%$?U'J5CVJ//JNM$?&<K
M=8;B0&W#XP01_Q&(Y3?G\F+H[!T?[3NG@]]N',*_?O&2?P&Q#Y1X(:453-O.
M+]>7H.JA-JA5M,MKS%C'A/43&'$$[[DZ&UP0/+;S[O+L[/*CSE _'=Q2WGKE
MZ7= U+:.)]=IQ$KAMO3WQ-0V:GUW1ND[>3^X^&5XPWS#MK(^OA_>4I& E ;@
MV8[.]6^N<WI)2CS88< ]N!;A^L,%F6MXK/#K\=$SH!VF(WB828EI09\JG_L5
M#'GY$,W]*Q]J[\)7^I8;7;YBN8E]1M?^!E3Y"V?OM=SQP;M;L;=$+/$MM"D!
M*>-Z^.LE2 L46"1K\/<3/COX]&<TL4^&<-M1@#@?KT<DWD TV@)3?L5J&*$/
MF@LP$B22<B+$&'171S/]RHQNWJ,QBM3W\Q"&AT&I9@79#3(@E&$GP\'/9T/8
MA=O1F53$F"DSN<%^W,"JKT;7#S(:7S^17I7T7FC2*VF/*6WTRP4:]_;!H;L
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M .O441%<((^7X@K>78 )%MS:B8LH @KW>%E#G;0]NYXNK=%+\!4_)S.R5K2
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M2;D" V#&*<)-M4FPCC_G'JD]Q^<&32BII)9;%/RTANYC"](Y[.8L[=DYB7X
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ML\/?&;*0/]7!02G_YPX 48$&("B$"& !?YG'B2(HR@0A" @FIT=%#TD<"C"
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M1>U<;X.276L;MNU?%V+HH^!TF.EANJ].4'1LUK<CO,\^J?8OI?NM)#IV%[3
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M>& 9IL[)]#+V8L#CG(F]<E/Q9'*,Q''Q-^PIH:T0WOBAIK@-P.$VL95VFIJ
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MW/&2.$W-XU(HK7_U%9R(3S^,<=@P4)$>'0:@'^]5Y!+:K;R:" A11@I_0,\
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MG7BSAWPBU#TABL6'IOME4K.9"2-LHK%**Q:'E/;HBB/8]@,;XU60V=&QFW
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MDF VSYR3XY-CYV.<? KN7/Y[%F2A^EF/\X\?^/=__$ O^<<D]E<__\,/[IS
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MT9G3U^4BK/YAT4@1#< 81NYEM;HA\G($6<[N6(..A?@N!/8>A.$TA\&"5(_
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MW'9X#/MSAW&0$3V+H4CVC>GX+7!2BTGLKYH?)<PI+#FED"#%'&BXM3<# YC
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M!$P?7][NJIL2)S[-$UJ@-6'I.@GTAGYI.'AN:)FPEL#NR50I:M0IH;%FT=U
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M<F^%-,\S<<6QVA=;:53\_]-Q_V/H]#]02P,$%     @ W$0*4687+MK6"
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M@<Z@M]'@N#_HX"5>K1I\O5MVY,%3]N;H;#PYZPQ<<(=;H)XE8/L5G!D3HVO
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M-C,P+FAT;5!+ 0(4 Q0    ( -Q$"E$7XCV$MQ\  !UM 0 1
M  "  ;", P!A;65H+3(P,C P-C,P+GAS9%!+ 0(4 Q0    ( -Q$"E%#J!T'
M)C8  ,]2 @ 5              "  9:L P!A;65H+3(P,C P-C,P7V-A;"YX
M;6Q02P$"% ,4    " #<1 I1\$=TP6>\   2Y < %0              @ 'O
MX@, 86UE:"TR,#(P,#8S,%]D968N>&UL4$L! A0#%     @ W$0*451)ST9H
M>@$ SG / !4              ( !B9\$ &%M96@M,C R,# V,S!?;&%B+GAM
M;%!+ 0(4 Q0    ( -Q$"E$C?:D_9?8  .'R"@ 5              "  20:
M!@!A;65H+3(P,C P-C,P7W!R92YX;6Q02P$"% ,4    " #<1 I13LRF821:
M  "=H0( &P              @ &\$ < 97@Q,#$R,#(P,#8S,#$P+7%N9VMS
M:6TN:'1M4$L! A0#%     @ W$0*490 OB,^6@  XZ<" !H
M ( !&6L' &5X,3 R,C R,# V,S Q,'%N9W1L86TN:'1M4$L! A0#%     @
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M<VEM+FAT;5!+ 0(4 Q0    ( -Q$"E&A#,PI\ @  (PT   7
M  "  4@N"0!E>#,Q,3(P,C P-C,P,3 M<6YG+FAT;5!+ 0(4 Q0    ( -Q$
M"E%F%R[:U@@  "@T   7              "  6TW"0!E>#,Q,C(P,C P-C,P
M,3 M<6YG+FAT;5!+ 0(4 Q0    ( -Q$"E&ER!M2P@@  %XS   7
M      "  7A "0!E>#,Q,S(P,C P-C,P,3 M<6YG+FAT;5!+ 0(4 Q0    (
M -Q$"E&"@<RAO04  *<T   6              "  6])"0!E>#,R,C R,# V
B,S Q,"UQ;F<N:'1M4$L%!@     0 !  3P0  &!/"0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
